PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Droplet discovery	SCIENCE			English	Editorial Material									Medsite Commun Corp, Boston, MA USA		Sikorski, R (corresponding author), Medsite Commun Corp, Boston, MA USA.							Borchardt A, 1997, CHEM BIOL, V4, P961, DOI 10.1016/S1074-5521(97)90304-5; Huang J, 1997, P NATL ACAD SCI USA, V94, P13396, DOI 10.1073/pnas.94.25.13396; You AJ, 1997, CHEM BIOL, V4, P969, DOI 10.1016/S1074-5521(97)90305-7	3	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					412	413						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454333				2022-12-01	WOS:000071570800056
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Cell shocked	SCIENCE			English	Article																		Suzue K, 1997, P NATL ACAD SCI USA, V94, P13146, DOI 10.1073/pnas.94.24.13146; UDONO H, 1994, P NATL ACAD SCI USA, V91, P3077, DOI 10.1073/pnas.91.8.3077	2	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2143	&						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432724				2022-12-01	WOS:A1997YM23500060
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Lactamase live!	SCIENCE			English	Editorial Material																		NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; Zlokarnik G, 1998, SCIENCE, V279, P84, DOI 10.1126/science.279.5347.84	2	2	2	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					412	412						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454333				2022-12-01	WOS:000071570800055
J	Sikorski, R; Peters, R				Sikorski, R; Peters, R			Capturing genes	SCIENCE			English	Article																		Roberts RW, 1997, P NATL ACAD SCI USA, V94, P12297, DOI 10.1073/pnas.94.23.12297	1	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2143	2143						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432724				2022-12-01	WOS:A1997YM23500059
J	Wang, SY; Miura, M; Jung, YK; Zhu, H; Li, E; Yuan, JY				Wang, SY; Miura, M; Jung, YK; Zhu, H; Li, E; Yuan, JY			Murine caspase-11, an ICE-interacting protease, is essential for the activation of ICE	CELL			English	Article							INTERLEUKIN-1-BETA CONVERTING-ENZYME; DEATH GENE CED-3; CELL-DEATH; IL-1-BETA-CONVERTING ENZYME; MAMMALIAN HOMOLOG; CYSTEINE PROTEASE; MOLECULAR-CLONING; MICE DEFICIENT; APOPTOSIS; INDUCTION	We report here the inactivation of a member of the Ice/Ced-3 (caspase) family of cell death genes, casp-11, by gene targeting. Like Ice-deficient mice, casp-11 mutant mice are resistant to endotoxic shock induced by lipopolysaccharide. Production of both IL-1 alpha and IL-1 beta after lipopolysaccharide stimulation, a crucial event during septic shock and an indication of ICE activation, is blocked in casp-11 mutant mice. casp-11 mutant embryonic fibroblast cells are resistant to apoptosis induced by overexpression of ICE. Furthermore, we found that pro-caspase-11 physically interacts with pro-ICE in cells, and the expression of casp-11 is essential for activation of ICE. Our data suggest that caspase-11 is a component of ICE complex and is required for the activation of ICE.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Osaka Univ, Sch Med, Biomed Res Ctr, Dept Neuroanat, Osaka 5650871, Japan	Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Osaka University	Yuan, JY (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Jung, Yong-Keun/0000-0002-9686-3120; Zhu, Hong/0000-0002-2575-4031				AREND WP, 1986, CLIN EXP IMMUNOL, V64, P656; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; DINARELLO CA, 1993, JAMA-J AM MED ASSOC, V269, P1829, DOI 10.1001/jama.269.14.1829; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; Friedlander RM, 1997, NATURE, V388, P31, DOI 10.1038/40299; Friedlander RM, 1997, J EXP MED, V185, P933, DOI 10.1084/jem.185.5.933; Ghayur T, 1997, NATURE, V386, P619, DOI 10.1038/386619a0; GU Y, 1995, EMBO J, V14, P1923, DOI 10.1002/j.1460-2075.1995.tb07184.x; Gu Y, 1997, SCIENCE, V275, P206, DOI 10.1126/science.275.5297.206; Hugunin M, 1996, J BIOL CHEM, V271, P3517, DOI 10.1074/jbc.271.7.3517; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NEWTON RC, 1986, J LEUKOCYTE BIOL, V39, P299, DOI 10.1002/jlb.39.3.299; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; Van de Craen M, 1997, FEBS LETT, V403, P61, DOI 10.1016/S0014-5793(97)00026-4; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; Wang SY, 1996, J BIOL CHEM, V271, P20580, DOI 10.1074/jbc.271.34.20580; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; Yamin TT, 1996, J BIOL CHEM, V271, P13273, DOI 10.1074/jbc.271.22.13273	36	554	571	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					501	509		10.1016/S0092-8674(00)80943-5	http://dx.doi.org/10.1016/S0092-8674(00)80943-5			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491891	Bronze			2022-12-01	WOS:000072251500010
J	Pincus, HA; Tanielian, TL; Marcus, SC; Olfson, M; Zarin, DA; Thompson, J; Zito, JM				Pincus, HA; Tanielian, TL; Marcus, SC; Olfson, M; Zarin, DA; Thompson, J; Zito, JM			Prescribing trends in psychotropic medications - Primary care, psychiatry, and other medical specialties	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DEFICIT-HYPERACTIVITY DISORDER; DEPRESSION; PRESCRIPTION; HALOPERIDOL; PHYSICIANS; OUTCOMES	Context.-Psychotropic medications are widely prescribed, but how new classes of psychotropic medications have affected prescribing patterns has not been well documented. Objective.-To examine changes between 1985 and 1994 (data from 1993 and 1994 were combined) in the prescribing patterns of psychotropic: medications by office-based primary care physicians, psychiatrists, and other medical specialists. Design.-National estimates for the number of visits during which a physician prescribed a psychotropic medication based on the National Ambulatory Medical Care Surveys conducted in 1985, 1993, and 1994. Setting.-Office-based physician practices in the United Stales. Participants.-A systematically sampled group of office-based physicians. Main Outcome Measures.-National estimates of visits that included a psychotropic medication. Results.-The number of visits during which a psychotropic medication was prescribed increased from 32.73 million to 45.64 million; the proportion of such visits, as a proportion of all visits, increased from 5.1% to 6.5% (P less than or equal to.01). Antianxiety or hypnotic drug visits, previously the largest category, decreased as a proportion of psychotropic drug visits (P less than or equal to.01) and are now surpassed by antidepressant visits, Visits for depression increased from 10.99 million in 1988 to 20.43 million in 1993 and 1994 (P less than or equal to.01). Stimulant drug visits increased from 0.57 million to 2.86 million (P less than or equal to.01). Although visits for depression doubled for both primary care physicians and psychiatrists, the proportion of visits for depression during which an antidepressant was prescribed increased for psychiatrists but not for primary care physicians. Conclusions.-The patterns of psychotropic medication use in outpatient medical practice changed dramatically during the study period, especially in psychiatric practice.	Amer Psychiat Assoc, Res Off, Washington, DC 20005 USA; Univ Pittsburgh, Med Ctr, Western Psychiat Inst & Clin, Pittsburgh, PA USA; Columbia Univ, Dept Psychiat, New York, NY USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Univ Maryland, Dept Psychiat, Baltimore, MD 21201 USA; Univ Maryland, Dept Phrm Practice & Sci, Baltimore, MD 21201 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Western Psychiatric Institute & Clinic of UPMC; Columbia University; New York State Psychiatry Institute; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Pincus, HA (corresponding author), Amer Psychiat Assoc, Res Off, 1400 K St NW, Washington, DC 20005 USA.	hpincus@psych.org	Olfson, Mark/AAA-8547-2021					AANA GW, 1991, HDB PSYCHIAT DRUG TH; *AM MED ASS, 1994, DRUG EV ANN 1994; American Psychiatric Association, 1996, PRACT GUID; American Psychiatric Association (Washington), 2000, DSM 4 T DIAGN STAT M; AMSTERDAM JD, 1994, J CLIN PSYCHIAT, V55, P394; [Anonymous], 1994, Am J Psychiatry, V151, P1; BEARDSLEY RS, 1988, ARCH GEN PSYCHIAT, V45, P1117; GLASER M, 1995, DRUG TOPICS, V139, P43; GLASS RM, 1991, JAMA-J AM MED ASSOC, V266, P2431, DOI 10.1001/jama.266.17.2431; GREENHILL LL, 1992, PSYCHIAT CLIN N AM, V15, P1; Herz MI, 1997, AM J PSYCHIAT, V154, P1; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kramer P. D., 1993, LISTENING PROZAC; Kroenke K, 1997, ANN INTERN MED, V126, P463, DOI 10.7326/0003-4819-126-6-199703150-00008; LENOX RH, 1992, J CLIN PSYCHIAT, V53, P47; MCLEMORE T, 1987, NATL AMBULATORY MED; *MED EC CO INC, 1994, PHYS DESK REF; *MED EC CO INC, 1997, PHYS DESK REF; OLFSON M, 1992, J FAM PRACTICE, V35, P627; OLFSON M, 1993, MED CARE, V31, P559, DOI 10.1097/00005650-199306000-00010; PINCUS HA, 1990, GEN HOSP PSYCHIAT, V12, P23, DOI 10.1016/0163-8343(90)90034-A; Pincus HA, 1996, ARCH GEN PSYCHIAT, V53, P870; REGIER DA, 1988, AM J PSYCHIAT, V145, P1351; ROGERS WH, 1993, ARCH GEN PSYCHIAT, V50, P517; SAFER DJ, 1988, JAMA-J AM MED ASSOC, V260, P2256, DOI 10.1001/jama.260.15.2256; SCHAPPERT S, 1995, NATL AMBULATORY MED; SHOPSIN B, 1975, ARCH GEN PSYCHIAT, V32, P34; SWANSON JM, 1995, NEW ENGL J MED, V333, P944, DOI 10.1056/NEJM199510053331419; SWANSON JM, 1995, ADV CLIN CHILD PSYCH, V17, P265; *US DHHS, 1988, INT CLASS DIS 9 REV; *US DHHS, 1993, DEPR PRIM CAR; WALLIS C, 1994, TIME            0718, V144, P42; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; WOLKOWITZ OM, 1991, AM J PSYCHIAT, V148, P714; WOODWELL DW, 1995, NATL AMBULATORY MED; ZARIN DA, 1993, AM J PSYCHIAT, V150, P175	37	312	317	0	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					526	531		10.1001/jama.279.7.526	http://dx.doi.org/10.1001/jama.279.7.526			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YW470	9480363				2022-12-01	WOS:000071938900034
J	Katz, MH; Gerberding, JL				Katz, MH; Gerberding, JL			The care of persons with recent sexual exposure to HIV	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; RISK-REDUCTION INTERVENTION; PRIMARY INFECTION; CONTROLLED TRIAL; HOMOSEXUAL MEN; VACCINE TRIALS; AIDS; PREVENTION; ANTIBODY; TYPE-1	Until recently, patients had little motivation to seek medical care soon after sexual exposure to HIV. However, evidence that antiretroviral treatment prevents HIV infection after occupational exposure has led to the recommendation that prophylaxis be considered after sexual exposure. This recommendation will result in an increased number of recently exposed patients presenting for care. Clinicians should seize this opportunity to reach persons who are at high risk for HIV seroconversion and provide them with evaluation, treatment, and counseling. A comprehensive approach to the care of persons recently exposed to HIV is proposed. Candidates for postexposure prophylaxis should be identified and given appropriate antiretroviral treatment. Physicians must perform HIV antibody testing to determine which persons are already infected with HIV and must do baseline laboratory studies. Follow-up care includes assessment of side effects from postexposure treatment and surveillance for development of primary HIV infection. Most important, clinicians must provide risk-reduction counseling to decrease the chance of future exposures. Public health messages must emphasize that postexposure treatment should be used only as a backup for failure of primary prevention methods, such as avoidance of high-risk sexual exposures or use of condoms.	Univ Calif San Francisco, San Francisco, CA 94143 USA; San Francisco Dept Publ Hlth, San Francisco, CA USA	University of California System; University of California San Francisco; San Francisco Department of Public Health	Katz, MH (corresponding author), 101 Grove St,Room 308, San Francisco, CA 94102 USA.							ALBERT J, 1994, J VIROL, V68, P5918, DOI 10.1128/JVI.68.9.5918-5924.1994; *AM MED ASS, 1996, PHYS GUID HIV PREV; BERRIOS DC, 1993, JAMA-J AM MED ASSOC, V270, P1576, DOI 10.1001/jama.270.13.1576; BLAUVELT A, 1995, J INVEST DERMATOL, V105, pS122, DOI 10.1111/1523-1747.ep12316662; Buchbinder SP, 1996, J INFECT DIS, V174, P954, DOI 10.1093/infdis/174.5.954; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; Cates W, 1995, NEW ENGL J MED, V333, P1783; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P574; CHESNEY MA, 1995, J ACQ IMMUN DEF SYND, V9, P30; CHMIEL JS, 1987, AM J EPIDEMIOL, V126, P568, DOI 10.1093/oxfordjournals.aje.a114696; CHOI KH, 1994, AIDS, V8, P1371, DOI 10.1097/00002030-199410000-00003; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; Claydon E, 1991, Int J STD AIDS, V2, P200; CONWAY B, 1995, P INT WORKSH HIV DRU, V4, P8; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; Deeks SG, 1997, JAMA-J AM MED ASSOC, V277, P145, DOI 10.1001/jama.277.2.145; DEGRUTTOLA V, 1989, J CLIN EPIDEMIOL, V42, P849, DOI 10.1016/0895-4356(89)90098-X; DESJARLAIS DC, 1995, JAMA-J AM MED ASSOC, V274, P1226, DOI 10.1001/jama.274.15.1226; DIAZ T, 1994, AM J PUBLIC HEALTH, V84, P1015, DOI 10.2105/AJPH.84.6.1015; DICLEMENTE RJ, 1995, JAMA-J AM MED ASSOC, V274, P1271, DOI 10.1001/jama.274.16.1271; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; ENG TR, 1996, HIDEN EPIDEMIC CONFR; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; Feder HM, 1997, NEW ENGL J MED, V336, P959; FLEISHMAN JA, 1993, INQUIRY-J HEALTH CAR, V30, P180; Fleming MF, 1997, JAMA-J AM MED ASSOC, V277, P1039, DOI 10.1001/jama.277.13.1039; Gerberding JL, 1996, ANN INTERN MED, V125, P497, DOI 10.7326/0003-4819-125-6-199609150-00011; GOSTIN LO, 1994, JAMA-J AM MED ASSOC, V271, P1436, DOI 10.1001/jama.271.18.1436; Hearst N, 1994, J Am Board Fam Pract, V7, P44; HO DD, 1995, NEW ENGL J MED, V333, P450, DOI 10.1056/NEJM199508173330710; Holmberg SD, 1996, AM J PUBLIC HEALTH, V86, P642, DOI 10.2105/AJPH.86.5.642; HORSBURGH CR, 1989, LANCET, V2, P637; Irwin K, 1996, ANN INTERN MED, V125, P471, DOI 10.7326/0003-4819-125-6-199609150-00007; JACQUEZ JA, 1994, J ACQ IMMUN DEF SYND, V7, P1169; Janz NK, 1996, HEALTH EDUC QUART, V23, P80, DOI 10.1177/109019819602300106; KAMB ML, 1996, P 1996 NAT STD PREV; Katz MH, 1997, NEW ENGL J MED, V336, P1097, DOI 10.1056/NEJM199704103361512; KELLY JA, 1993, AM PSYCHOL, V48, P1023, DOI 10.1037/0003-066X.48.10.1023; KELLY JA, 1994, AM J PUBLIC HEALTH, V84, P1918, DOI 10.2105/AJPH.84.12.1918; KINLOCHDELOES S, 1995, NEW ENGL J MED, V333, P408, DOI 10.1056/NEJM199508173330702; Kopp JB, 1997, ANN INTERN MED, V127, P119, DOI 10.7326/0003-4819-127-2-199707150-00004; Li RW, 1997, NEW ENGL J MED, V337, P499, DOI 10.1056/NEJM199708143370714; LIFSON AR, 1990, AM J PUBLIC HEALTH, V80, P1509, DOI 10.2105/AJPH.80.12.1509; Liuzzi G, 1996, AIDS, V10, pF51, DOI 10.1097/00002030-199612000-00001; MAKADON HJ, 1995, ANN INTERN MED, V123, P715, DOI 10.7326/0003-4819-123-9-199511010-00010; MANLEY M, 1991, JAMA-J AM MED ASSOC, V266, P3172, DOI 10.1001/jama.266.22.3172; Mayers Douglas L., 1997, American Journal of Medicine, V102, P70, DOI 10.1016/S0002-9343(97)00067-3; MCCUSKER J, 1992, AIDS, V6, P861, DOI 10.1097/00002030-199208000-00015; Messiah A, 1997, AM J PUBLIC HEALTH, V87, P421, DOI 10.2105/AJPH.87.3.421; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; Peterson JL, 1996, AIDS, V10, P319, DOI 10.1097/00002030-199603000-00011; *PHS, IN PRESS MMWR MORB M; Pinkerton SD, 1997, ARCH INTERN MED, V157, P1972, DOI 10.1001/archinte.157.17.1972; Pinkerton SD, 1997, NEW ENGL J MED, V337, P500; Pinto Ligia A., 1997, American Journal of Medicine, V102, P21, DOI 10.1016/S0002-9343(97)00056-9; Rasheed S, 1996, AM J OBSTET GYNECOL, V175, P122, DOI 10.1016/S0002-9378(96)70261-2; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Rubio A, 1997, AIDS, V11, P1184, DOI 10.1097/00002030-199709000-00016; SAMUEL MC, 1994, MODELING THE AIDS EPIDEMIC: PLANNING, POLICY, AND PREDICTION, P423; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; Spielberg F, 1996, ANN INTERN MED, V125, P509, DOI 10.7326/0003-4819-125-6-199609150-00014; Spira AI, 1996, J EXP MED, V183, P215, DOI 10.1084/jem.183.1.215; STALL R, 1990, J ACQ IMMUN DEF SYND, V3, P1181; STCLAIR MH, 1991, SCIENCE, V253, P1557, DOI 10.1126/science.1716788; THOMPSON JLP, 1993, AM J PUBLIC HEALTH, V83, P1409, DOI 10.2105/AJPH.83.10.1409; TRUSSELL J, 1995, FERTILITY CONTROL RE, V4, P8; Vernazza PL, 1997, AIDS, V11, P987, DOI 10.1097/00002030-199708000-00006; Voelker R, 1996, JAMA-J AM MED ASSOC, V276, P585, DOI 10.1001/jama.276.8.585; WILEY JA, 1989, STAT MED, V8, P93, DOI 10.1002/sim.4780080110; WORTLEY PM, 1995, AIDS, V9, P487, DOI 10.1097/00002030-199509050-00011; 1998, IN PRESS MMWR MORB M; 1995, MMWR MORB MORTAL WKL, V44, P929; 1993, MMWR MORB MORTAL WKL, V42, P97; 1996, MMWR MORB MORTAL WKL, V45, P468; 1993, MMWR MORB MORTAL WKL, V42, P11	77	72	72	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					306	312		10.7326/0003-4819-128-4-199802150-00012	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX170	9471935				2022-12-01	WOS:000072013400009
J	Gazelle, G				Gazelle, G			The slow code - Should anyone rush to its defense?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ADVANCE DIRECTIVES; CARDIOPULMONARY-RESUSCITATION; PHYSICIANS ATTITUDES; CARE; FUTILITY; PATIENT		Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Vanguard Medical Associates	Gazelle, G (corresponding author), Brigham & Womens Hosp, Harvard Vanguard Med Associates Div Med, 75 Francis St, Boston, MA 02115 USA.							[Anonymous], 1992, ANN INTERN MED, V117, P947; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FOWLER MDM, 1989, HEART LUNG, V18, P533; GOLDENRING J, 1979, NEW ENGL J MED, V300, P1058; Jonsen A., 1986, CLIN ETHICS PRACTICA; LANDRY FJ, 1992, ARCH INTERN MED, V152, P2305, DOI 10.1001/archinte.152.11.2305; MARKSON LJ, 1994, ARCH INTERN MED, V154, P2321, DOI 10.1001/archinte.154.20.2321; MCCUE JD, 1995, JAMA-J AM MED ASSOC, V273, P1039, DOI 10.1001/jama.273.13.1039; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; MULLER JH, 1992, SOC SCI MED, V34, P885, DOI 10.1016/0277-9536(92)90257-Q; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; NEHER JO, 1988, J FAM PRACTICE, V27, P429; Nuland S.B., 1994, WE DIE REFLECTIONS L; *PC STUD ETH PROBL, 1983, DEC FOR LIF SUST TRE; REILLY BM, 1994, ARCH INTERN MED, V154, P2299, DOI 10.1001/archinte.154.20.2299; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SAKLAYEN M, 1995, MEDICINE, V74, P163, DOI 10.1097/00005792-199507000-00001; Schneider A P 2nd, 1993, J Am Board Fam Pract, V6, P91; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; THOMASMA DC, 1983, ANN INTERN MED, V98, P243, DOI 10.7326/0003-4819-98-2-243; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; ZUGER A, 1989, JAMA-J AM MED ASSOC, V262, P2988	25	33	33	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					467	469		10.1056/NEJM199802123380712	http://dx.doi.org/10.1056/NEJM199802123380712			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459653				2022-12-01	WOS:000071900100011
J	Avins, AL; Browner, WS				Avins, AL; Browner, WS			Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels - What a difference a decade makes	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK; HEALTH; PRAVASTATIN; ADULTS; MEN	Context.-A patients coronary heart disease (CHD) risk must be correctly classified to successfully apply risk-based guidelines for treatment of hypercholesterolemia. Objective.-To determine the classification accuracy of the National Cholesterol Education Program (NCEP) CHD risk-stratification system and compare it with a simple revised system that gives greater weight to age as a CHD risk factor. Design.-Modeling of 10-year CHD risk, using equations from the Framingham Heart Study applied to a cross-sectional survey of the US population. Subjects.-The 3284 subjects aged 20 to 74 years surveyed in the Second National Health and Nutrition Examination Survey (1978-1982) who had fasting lipid levels measured. Main Outcome Measures.-The area under the receiver operating characteristic curve (AUC) for 10-year CHD risk for the NCEP and revised scales. Results.-Among all adults with a low-density lipoprotein cholesterol value of at least 4.1 mmol/L (160 mg/dL), the NCEP system showed fairly good discrimination (AUC=0.90), though there was a substantial decline among men 35 to 74 years old and women 55 to 74 years old (AUC=0.81). By contrast, the revised system showed superior performance in all hypercholesterolemic adults (AUC=0.94-0.97) as well as in the subgroup of men 35 to 74 years old and women 55 to 74 years old (AUC=0.94-0.96). Conclusions.-Simple modifications of the NCEP treatment criteria result in a substantially improved ability to discriminate between higher and lower CHD risk groups. Unlike the NCEP system, this revised system retains its classification ability in all age groups studied.	Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Avins, AL (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect 111A1, 4150 Clement St, San Francisco, CA 94121 USA.	andy_avins@quickmail.ucsf.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL051024] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL51024] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Avins AL, 1996, ANN INTERN MED, V125, P502, DOI 10.7326/0003-4819-125-6-199609150-00012; DAVEYSMITH G, 1994, BRIT MED J, V308, P72; Forrester JS, 1997, AM J CARDIOL, V79, P790; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; Glick H, 1992, Int J Technol Assess Health Care, V8, P719; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MCDOWELL A, 1981, PLAN OPERATION 2 NAT; MCISAAC WJ, 1991, J GEN INTERN MED, V6, P518, DOI 10.1007/BF02598220; MOSSMAN D, 1995, MED DECIS MAKING, V15, P358, DOI 10.1177/0272989X9501500406; PEDERSEN TR, 1994, LANCET, V344, P1765; PERKINS KA, 1986, AM J EPIDEMIOL, V124, P182, DOI 10.1093/oxfordjournals.aje.a114377; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; *STAT, 1996, STAT STAT SOFTW REL; SWETS JA, 1988, SCIENCE, V240, P1285, DOI 10.1126/science.3287615; *US BUR CENS, 1996, US POP EST AG SEX RA; ZWEIG MH, 1993, CLIN CHEM, V39, P561	23	28	29	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					445	449		10.1001/jama.279.6.445	http://dx.doi.org/10.1001/jama.279.6.445			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466637				2022-12-01	WOS:000071839800032
J	Polat, U; Mizobe, K; Pettet, MW; Kasamatsu, T; Norcia, AM				Polat, U; Mizobe, K; Pettet, MW; Kasamatsu, T; Norcia, AM			Collinear stimuli regulate visual responses depending on cell's contrast threshold	NATURE			English	Article							CAT STRIATE CORTEX; SPATIAL INTERACTIONS; LATERAL INTERACTIONS; APPARENT CONTRAST; FACILITATION; SUPPRESSION; NEURONS; CONNECTIONS; PHYSIOLOGY; POTENTIALS	Neurons in the primary visual cortex are selective for the size, orientation and direction of motion of patterns falling within a restricted region of visual space known as the receptive field(1). The response to stimuli presented within the receptive field can be facilitated or suppressed by other stimuli falling outside the receptive field which, when presented in isolation, fail to activate the cell(2-8). Whether this interaction is facilitative(3,4,7,9-12) or suppressive(2,3,5,6,8-14) depends on the relative orientation of pattern elements inside and outside the receptive field. Here we show that neuronal facilitation preferentially occurs when a near-threshold stimulus inside the receptive field is flanked by higher-contrast, collinear elements located in surrounding regions of visual space. Collinear flanks and orthogonally oriented flanks, however, both act to reduce the response to high-contrast stimuli presented within the receptive field. The observed pattern of facilitation and suppression may be the cellular basis for the observation in humans that the detectability of an oriented pattern is enhanced by collinear flanking elements(15-17). Modulation of neuronal responses by stimuli falling outside their receptive fields may thus represent an early neural mechanism for encoding objects and enhancing-their perceptual saliency.	Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Kasamatsu, T (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							ALBRECHT DG, 1982, J NEUROPHYSIOL, V48, P217, DOI 10.1152/jn.1982.48.1.217; BLAKEMORE C, 1972, EXP BRAIN RES, V15, P439; CANNON MW, 1993, VISION RES, V33, P1685, DOI 10.1016/0042-6989(93)90034-T; CANNON MW, 1991, VISION RES, V31, P1985, DOI 10.1016/0042-6989(91)90193-9; DOUGLAS RJ, 1991, J PHYSIOL-LONDON, V440, P659, DOI 10.1113/jphysiol.1991.sp018730; Douglas RJ, 1989, NEURAL COMPUT, V1, P480, DOI 10.1162/neco.1989.1.4.480; Fitzpatrick D, 1996, CEREB CORTEX, V6, P329, DOI 10.1093/cercor/6.3.329; GILBERT CD, 1989, J NEUROSCI, V9, P2432; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; HIRSCH JA, 1991, J NEUROSCI, V11, P1800; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KAPADIA MK, 1995, NEURON, V15, P843, DOI 10.1016/0896-6273(95)90175-2; KITANO M, 1994, VISUAL NEUROSCI, V11, P953, DOI 10.1017/S0952523800003904; KNIERIM JJ, 1992, J NEUROPHYSIOL, V67, P961, DOI 10.1152/jn.1992.67.4.961; Levitt JB, 1997, NATURE, V387, P73, DOI 10.1038/387073a0; LI CY, 1994, VISION RES, V34, P2337, DOI 10.1016/0042-6989(94)90280-1; MAFFEI L, 1976, VISION RES, V16, P1131, DOI 10.1016/0042-6989(76)90253-4; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MIZOBE K, 1996, ASS RES OPHTH ABSTR, V37, pS493; NELSON JI, 1985, EXP BRAIN RES, V61, P54; NORCIA AM, 1985, IEEE ENG MED BIOL, V4, P26, DOI 10.1109/MEMB.1985.5006224; Polat U, 1996, VISION RES, V36, P2099, DOI 10.1016/0042-6989(95)00281-2; POLAT U, 1993, VISION RES, V33, P993, DOI 10.1016/0042-6989(93)90081-7; POLAT U, 1994, VISION RES, V34, P73, DOI 10.1016/0042-6989(94)90258-5; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; Somers D., 1994, Society for Neuroscience Abstracts, V20, P1577; SOMERS DC, IN PRESS CEREBR CORT; STEMMLER M, 1995, SCIENCE, V269, P1877, DOI 10.1126/science.7569930; Toth LJ, 1996, P NATL ACAD SCI USA, V93, P9869, DOI 10.1073/pnas.93.18.9869; VICTOR JD, 1991, ELECTROEN CLIN NEURO, V78, P378, DOI 10.1016/0013-4694(91)90099-P	30	465	472	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					580	584		10.1038/35372	http://dx.doi.org/10.1038/35372			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468134				2022-12-01	WOS:000071842300050
J	Trapp, BD; Peterson, J; Ransohoff, RM; Rudick, R; Mork, S; Bo, L				Trapp, BD; Peterson, J; Ransohoff, RM; Rudick, R; Mork, S; Bo, L			Axonal transection in the lesions of multiple sclerosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; AMYLOID PRECURSOR PROTEIN; MONOCLONAL-ANTIBODIES DISTINGUISH; MYELIN-ASSOCIATED GLYCOPROTEIN; DISEASE PROGRESSION; N-ACETYLASPARTATE; NERVOUS-SYSTEM; CALIBER; BRAIN; NEUROFILAMENTS	Background Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system and is the most common cause of neurologic disability in young adults. Despite antiinflammatory or immunosuppressive therapy, most patients have progressive neurologic deterioration that may reflect axonal loss. We conducted pathological studies of brain tissues to define the changes in axons in patients with multiple sclerosis. Methods Brain tissue was obtained at autopsy from 11 patients with multiple sclerosis and 4 subjects without brain disease. Fourteen active multiple-sclerosis lesions, 33 chronic active lesions, and samples of normal-appearing white matter were examined for demyelination, inflammation, and axonal pathologic changes by immunohistochemistry and confocal microscopy. Axonal transection, identified by the presence of terminal axonal ovoids, was detected in all 47 lesions and quantified in 18 lesions. Results Transected axons were a consistent feature of the lesions of multiple sclerosis, and their frequency was related to the degree of inflammation within the lesion. The number of transected axons per cubic millimeter of tissue averaged 11,236 in active lesions, 3138 at the hypocellular edges of chronic active lesions, 875 in the hypocellular centers of chronic active lesions, and less than 1 in normal-appearing white matter from the control brains. Conclusions Transected axons are common in the; lesions of multiple sclerosis, and axonal transection may be the pathologic correlate of the irreversible neurologic impairment in this disease. (C) 1998, Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Neurosci, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Neurol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Mellen Ctr Multiple Sclerosis Res, Cleveland, OH 44195 USA; Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Bergen; Haukeland University Hospital	Trapp, BD (corresponding author), Cleveland Clin Fdn, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.		Peterson, John Stuart/GSE-4645-2022; Mörk, Sverre Jarl/AAW-1330-2020	Peterson, John Stuart/0000-0001-6516-5779; 	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035058] Funding Source: NIH RePORTER; NINDS NIH HHS [R01NS35058] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARBUTHNOTT ER, 1980, J PHYSIOL-LONDON, V308, P125, DOI 10.1113/jphysiol.1980.sp013465; ARNOLD DL, 1994, ANN NEUROL, V36, P76, DOI 10.1002/ana.410360115; Bo L, 1996, J NEUROPATH EXP NEUR, V55, P1060, DOI 10.1097/00005072-199655100-00006; BO L, 1994, J NEUROIMMUNOL, V51, P135, DOI 10.1016/0165-5728(94)90075-2; BO L, 1994, ANN NEUROL, V36, P778, DOI 10.1002/ana.410360515; BORNSTEI.MB, 1965, SCIENCE, V148, P1242, DOI 10.1126/science.148.3674.1242; Charcot J, 1868, GAZ HOSP, V41, P554; CHARCOT M, 1868, GAZ HOSP, P557; CHARCOT M, 1868, GAZ HOSP, P141; COCHRAN E, 1991, AM J PATHOL, V139, P485; Davie CA, 1995, BRAIN, V118, P1583, DOI 10.1093/brain/118.6.1583; DAVIE CA, 1994, BRAIN, V117, P49, DOI 10.1093/brain/117.1.49; DESTEFANO N, 1995, MAGN RESON MED, V34, P721; DeStefano N, 1995, ANN NEUROL, V38, P901, DOI 10.1002/ana.410380610; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; Ebers GC, 1996, NAT GENET, V13, P472, DOI 10.1038/ng0896-472; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; FRUTTIGER M, 1995, EUR J NEUROSCI, V7, P511, DOI 10.1111/j.1460-9568.1995.tb00347.x; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Haines JL, 1996, NAT GENET, V13, P469, DOI 10.1038/ng0896-469; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HOFFMAN PN, 1975, J CELL BIOL, V66, P351, DOI 10.1083/jcb.66.2.351; Hohlfeld R, 1997, BRAIN, V120, P865, DOI 10.1093/brain/120.5.865; Hsieh S-T, 1993, BRAIN PATHOL, V3, P307; Jacobs LD, 1996, ANN NEUROL, V39, P285, DOI 10.1002/ana.410390304; LEE VMY, 1986, J NEUROSCI, V6, P850; LEE VMY, 1987, J NEUROSCI, V7, P3474; Losseff NA, 1996, BRAIN, V119, P701, DOI 10.1093/brain/119.3.701; Losseff NA, 1996, BRAIN, V119, P2009, DOI 10.1093/brain/119.6.2009; Matthews PM, 1996, BRAIN, V119, P715, DOI 10.1093/brain/119.3.715; MCDONALD WI, 1994, J NEUROPATH EXP NEUR, V53, P338, DOI 10.1097/00005072-199407000-00003; MCFARLAND HF, 1992, ANN NEUROL, V32, P758, DOI 10.1002/ana.410320609; MEHTA V, 1995, MOL BRAIN RES, V31, P151, DOI 10.1016/0169-328X(95)00044-S; MILLIGAN NM, 1987, J NEUROL NEUROSUR PS, V50, P511, DOI 10.1136/jnnp.50.5.511; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; Narayanan S, 1997, ANN NEUROL, V41, P385, DOI 10.1002/ana.410410314; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; OHGAMI T, 1992, NEUROSCI LETT, V136, P75, DOI 10.1016/0304-3940(92)90651-M; PRINEAS JW, 1981, ANN NEUROL, V10, P149, DOI 10.1002/ana.410100205; PRINEAS JW, 1984, ANN NY ACAD SCI, V436, P11, DOI 10.1111/j.1749-6632.1984.tb14773.x; PRINEAS JW, 1985, HDB CLIN NEUROLOGY, V47, P213; RAINE CS, 1989, LAB INVEST, V60, P714; RUDICK RA, 1996, ANN NEUROL, V40, P516; Sanchez I, 1996, J NEUROSCI, V16, P5095; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; SELMAJ K, 1991, J CLIN INVEST, V87, P949, DOI 10.1172/JCI115102; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TRAPP BD, 1989, J CELL BIOL, V109, P2417, DOI 10.1083/jcb.109.5.2417; Trapp BD, 1997, J CELL BIOL, V137, P459, DOI 10.1083/jcb.137.2.459; Weinshenker BG, 1996, NEUROL CLIN, V14, P291, DOI 10.1016/S0733-8619(05)70257-7; WEINSHENKER BG, 1989, BRAIN, V112, P133, DOI 10.1093/brain/112.1.133; WINDEBANK AJ, 1985, J NEUROSCI, V5, P1563	54	3165	3241	4	161	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 29	1998	338	5					278	285		10.1056/NEJM199801293380502	http://dx.doi.org/10.1056/NEJM199801293380502			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT963	9445407				2022-12-01	WOS:000071665200002
J	Mons, B; Klasen, E; van Kessel, R; Nchinda, T				Mons, B; Klasen, E; van Kessel, R; Nchinda, T			Policy: Biomedicine - Partnership between south and north crystallizes around malaria	SCIENCE			English	Article									Netherlands Org Sci Res, NL-2593 BM The Hague, Netherlands; WHO, TDR, Geneva, Switzerland	World Health Organization	Mons, B (corresponding author), Netherlands Org Sci Res, NL-2593 BM The Hague, Netherlands.			Mons, Barend/0000-0003-3934-0072				Butler D, 1997, NATURE, V386, P535, DOI 10.1038/42306; *WELC TRUST, 1996, 7 PRISM WELC TRUST; 1997, COUNCIL RESOLUTION R	3	13	13	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					498	499		10.1126/science.279.5350.498	http://dx.doi.org/10.1126/science.279.5350.498			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9454348				2022-12-01	WOS:000071616000026
J	New, JH; Sugiyama, T; Zaitseva, E; Kowalczykowski, SC				New, JH; Sugiyama, T; Zaitseva, E; Kowalczykowski, SC			Rad52 protein stimulates DNA strand exchange by Rad51 and replication protein A	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; HOMOLOGOUS RECOMBINATION; MITOTIC RECOMBINATION; ESCHERICHIA-COLI; REPAIR; GENES; RECA; FILAMENT; BINDING; REPEAT	The generation of a double-strand break in the Saccharomyces cerevisiae genome is a potentially catastrophic event that can induce cell-cycle arrest or ultimately result in loss of cell viability. The repair of such lesions is strongly dependent on proteins encoded by the RAD52 epistasis group of genes (RAD50-55, RAD57, MRE11, XRS2)(1,2), as well as the RFA1(3,4) and RAD59 genes(5). rad52 mutants exhibit the most severe phenotypic defects in double-strand break repair(2), but almost nothing is known about the biochemical role of Rad52 protein. Rad51 protein promotes DNA strand exchange(6-8) and acts similarly to RecA protein(9). Yeast Rad52 protein interacts with Rad51 protein(10,11), binds single-stranded DNA and stimulates annealing of complementary single-stranded DNA(12). We find that Rad52 protein stimulates DNA strand exchange by targeting Rad51 protein to a complex of replication protein A (RPA) with single-stranded DNA. Rad52 protein affects an early step in the reaction, presynaptic filament formation, by overcoming the inhibitory effects of the competitor, RPA. Furthermore, stimulation is dependent on the concerted action of both Rad51 protein and RPA, implying that specific protein-protein interactions between Rad52 protein, Rad51 protein and RPA are required.	Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Kowalczykowski, SC (corresponding author), Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA.			Sugiyama, Tomohiko/0000-0003-2942-3667				Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; GAME JC, 1993, SEMIN CANCER BIOL, V4, P73; JIANG H, 1993, J BIOL CHEM, V268, P7904; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.bi.63.070194.005015; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RATTRAY AJ, 1994, GENETICS, V138, P587; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, 1992, CELL, V71, P180; SMITH J, 1995, MOL CELL BIOL, V15, P1632; SUGAWARA N, 1995, NATURE, V373, P84, DOI 10.1038/373084a0; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sung P, 1996, J BIOL CHEM, V271, P27983, DOI 10.1074/jbc.271.45.27983; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; WLD MS, 1997, ANN REV BIOCH, V66, P61; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	24	483	505	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					407	410		10.1038/34950	http://dx.doi.org/10.1038/34950			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450760				2022-12-01	WOS:000071604200060
J	Nielsen, LLW; Nielsen, NM; Melbye, M; Sodermann, M; Jacobsen, M; Aaby, P				Nielsen, LLW; Nielsen, NM; Melbye, M; Sodermann, M; Jacobsen, M; Aaby, P			Exposure to measles in utero and Crohn's disease: Danish register study	BRITISH MEDICAL JOURNAL			English	Article							VIRUS INFECTION		Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark; Danish Epidemiol Sci Ctr, Inst Epidemiol & Social Med, Aarhus, Denmark	Aarhus University; Statens Serum Institut; Aarhus University	Nielsen, LLW (corresponding author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, DK-2300 Copenhagen, Denmark.			melbye, mads/0000-0001-8264-6785; Aaby, Peter/0000-0001-8331-1389				Ekbom A, 1996, LANCET, V348, P515, DOI 10.1016/S0140-6736(96)04429-7; EKBOM A, 1994, LANCET, V344, P508, DOI 10.1016/S0140-6736(94)91898-8; Jones P, 1997, LANCET, V349, P473, DOI 10.1016/S0140-6736(05)61184-1; WAKEFIELD AJ, 1993, J MED VIROL, V39, P345, DOI 10.1002/jmv.1890390415; WAKEFIELD AJ, 1995, GASTROENTEROLOGY, V108, P911, DOI 10.1016/0016-5085(95)90467-0	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					196	197						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468686	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071616400027
J	Biervert, C; Schroeder, BC; Kubisch, C; Berkovic, SF; Propping, P; Jentsch, TJ; Steinlein, OK				Biervert, C; Schroeder, BC; Kubisch, C; Berkovic, SF; Propping, P; Jentsch, TJ; Steinlein, OK			A potassium channel mutation in neonatal human epilepsy	SCIENCE			English	Article							CONVULSIONS; GENE; CHROMOSOME-20; K(V)LQT1; PROTEINS; MYOKYMIA; SUBUNIT; CLONING; ATAXIA; FORM	Benign familial neonatal convulsions (BFNC) is an autosomal dominant epilepsy of infancy, with loci mapped to human chromosomes 20q13.3 and 8q24. By positional cloning, a potassium channel gene (KCNQ2) located on 20q13.3 was isolated and found to be expressed in brain. Expression of KCNQ2 in frog (Xenopus laevis) oocytes led to potassium-selective currents that activated slowly with depolarization. In a large pedigree with BFNC, a five-base pair insertion would delete more than 300 amino acids from the KCNQ2 carboxyl terminus. Expression of the mutant channel did not yield measurable currents. Thus, impairment of potassium-dependent repolarization is likely to cause this age-specific epileptic syndrome.	Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany; Univ Bonn, Inst Human Genet, D-5300 Bonn, Germany; Univ Melbourne, Dept Med Neurol, Melbourne, Vic, Australia	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Bonn; University of Melbourne	Jentsch, TJ (corresponding author), Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany.	Jentsch@plexus.uke.uni-hamburg.de; steinlein@snphysio2.wilhelm.uni-bonn.de	Kubisch, Christian/F-1893-2011	Kubisch, Christian/0000-0003-4220-0978; Jentsch, Thomas/0000-0002-3509-2553; Berkovic, Samuel/0000-0003-4580-841X				Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BERKOVIC SF, 1994, ARCH NEUROL-CHICAGO, V51, P1125, DOI 10.1001/archneur.1994.00540230063014; Berkovic SF, 1997, BRAIN DEV-JPN, V19, P13, DOI 10.1016/S0387-7604(96)00060-5; BROWNE DL, 1994, NAT GENET, V8, P136, DOI 10.1038/ng1094-136; BRUNT ERP, 1990, BRAIN, V113, P1361, DOI 10.1093/brain/113.5.1361; Burgess DL, 1997, CELL, V88, P385, DOI 10.1016/S0092-8674(00)81877-2; Chouabe C, 1997, EMBO J, V16, P5472, DOI 10.1093/emboj/16.17.5472; Fletcher CF, 1996, CELL, V87, P607, DOI 10.1016/S0092-8674(00)81381-1; JAN LY, 1994, NATURE, V371, P119, DOI 10.1038/371119a0; Lee MP, 1997, NAT GENET, V15, P181, DOI 10.1038/ng0297-181; LEPPERT M, 1989, NATURE, V337, P647, DOI 10.1038/337647a0; LEWIS TB, 1993, AM J HUM GENET, V53, P670; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; Neyroud N, 1997, NAT GENET, V15, P186, DOI 10.1038/ng0297-186; Ptacek LJ, 1997, NEUROMUSCULAR DISORD, V7, P250, DOI 10.1016/S0960-8966(97)00046-1; RONEN GM, 1993, NEUROLOGY, V43, P1355, DOI 10.1212/WNL.43.7.1355; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SCHROEDER BC, UNPUB; SchulzeBahr E, 1997, NAT GENET, V17, P267, DOI 10.1038/ng1197-267; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; STEINLEIN O, 1994, GENOMICS, V22, P493, DOI 10.1006/geno.1994.1420; STEINLEIN OK, 1995, NAT GENET, V11, P201, DOI 10.1038/ng1095-201; Steinlein OK, 1997, HUM MOL GENET, V6, P943, DOI 10.1093/hmg/6.6.943; TAKUMI T, 1988, SCIENCE, V242, P1042, DOI 10.1126/science.3194754; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Wollnik B, 1997, HUM MOL GENET, V6, P1943, DOI 10.1093/hmg/6.11.1943; Yokoyama M, 1996, DNA Res, V3, P311, DOI 10.1093/dnares/3.5.311	27	858	909	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					403	406		10.1126/science.279.5349.403	http://dx.doi.org/10.1126/science.279.5349.403			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430594				2022-12-01	WOS:000071570800052
J	Zhang, HM; Forde, BG				Zhang, HM; Forde, BG			An Arabidopsis MADS box gene that controls nutrient-induced changes in root architecture	SCIENCE			English	Article							NITRATE; PLANTS; GROWTH; PRODUCTIVITY; EXPRESSION; RESPONSES; THALIANA; ROLES	The development of plant root systems is sensitive to the availability and distribution of nutrients within the soil. For example, lateral roots proliferate preferentially within nitrate (NO3-)-rich soil patches. A NO3--inducible Arabidopsis gene (ANR1), was identified that encodes a member of the MADS box family of transcription factors. Transgenic plants in which ANR1 was repressed had an altered sensitivity to NO3- and no longer responded to NO3--rich zones by lateral root proliferation, indicating that ANR1 is a key determinant of developmental plasticity in Arabidopsis roots.	IACR Rothamsted, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research	Forde, BG (corresponding author), IACR Rothamsted, Dept Biochem & Physiol, Harpenden AL5 2JQ, Herts, England.		Forde, Brian G/C-6554-2009	Forde, Brian G/0000-0001-7973-7280				AGREN GI, 1987, PLANT CELL ENVIRON, V10, P579, DOI 10.1111/j.1365-3040.1987.tb01838.x; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; DREW MC, 1973, J EXP BOT, V24, P1189, DOI 10.1093/jxb/24.6.1189; FITTER AH, 1991, NEW PHYTOL, V118, P383, DOI 10.1111/j.1469-8137.1991.tb00019.x; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GRANATO TC, 1989, J EXP BOT, V40, P263, DOI 10.1093/jxb/40.2.263; GUERINEAU F, 1992, PLANT MOL BIOL, V18, P815, DOI 10.1007/BF00020027; HACKETT C, 1972, AUST J BIOL SCI, V25, P1169, DOI 10.1071/BI9721169; HUTCHINGS MJ, 1994, ADV ECOL RES, V25, P159, DOI 10.1016/S0065-2504(08)60215-9; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; LYNCH J, 1995, PLANT PHYSIOL, V109, P7, DOI 10.1104/pp.109.1.7; REDINBAUGH MG, 1991, PHYSIOL PLANTARUM, V82, P640, DOI 10.1111/j.1399-3054.1991.tb02958.x; ROBINSON D, 1994, NEW PHYTOL, V127, P635, DOI 10.1111/j.1469-8137.1994.tb02969.x; ROUNSLEY SD, 1995, PLANT CELL, V7, P1259, DOI 10.1105/tpc.7.8.1259; SATTELMACHER B, 1988, PLANT ROOTS THEIR EN, P149; Scheible WR, 1997, PLANT J, V11, P671, DOI 10.1046/j.1365-313X.1997.11040671.x; SCHIEFELBEIN JW, 1991, PLANT CELL, V3, P1147, DOI 10.1105/tpc.3.11.1147; Theissen G, 1996, J MOL EVOL, V43, P484, DOI 10.1007/BF02337521; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; TREWAVAS AJ, 1983, INTERACTIONS NITROGE, P97; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WEIGEL DA, 1995, REV GENET, V29, P19; WIERSUM L. K., 1958, ACTA BOT NEERLANDICA, V7, P174; WILKINSON JQ, 1993, MOL GEN GENET, V239, P289, DOI 10.1007/BF00281630; Zachgo S, 1997, PLANT J, V11, P1043, DOI 10.1046/j.1365-313X.1997.11051043.x; ZHANG HY, UNPUB	26	889	1013	11	207	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					407	409		10.1126/science.279.5349.407	http://dx.doi.org/10.1126/science.279.5349.407			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430595				2022-12-01	WOS:000071570800053
J	Kuehn, MJ; Herrmann, JM; Schekman, R				Kuehn, MJ; Herrmann, JM; Schekman, R			COPII-cargo interactions direct protein sorting into ER-derived transport vesicles	NATURE			English	Article							AMINO-ACID PERMEASES; ENDOPLASMIC-RETICULUM; SECRETORY PATHWAY; COATED VESICLES; YEAST; COMPONENT; COMPLEX; TRANSLOCATION; COATOMER; FAMILY	Vesicles coated with coat protein complex II (COPII) selectively transport molecules (cargo) and vesicle fusion proteins from the endoplasmic reticulum (ER) to the Golgi complex(1-3). We have investigated the role of coat proteins in cargo selection and recruitment. We isolated integral membrane and soluble cargo proteins destined for transport from the ER in complexes formed in the presence of Sar1 and Sec23/24, a subset of the COPII components, and GTP or GMP-PNP. Vesicle fusion proteins of the vSNARE family and Emp24, a member of a putative cargo carrier family(4), were also found in COPII complexes. The inclusion of amino-acid permease molecules into the complex depended on the presence of Shr3, a protein required for the permease to leave the ER3,5. Resident ER proteins Sec61, BiP (Kar2) and Shr3 were not included in the complexes, indicating that the COPII components bound specifically to vesicle cargo. COPII-cargo complexes and putative cargo adaptor-cargo complexes were also isolated from COPII vesicles. Our results indicate that cargo packaging signals and soluble cargo adaptors are recognized by a recruitment complex comprising Sar1-GTP and Sec23/24.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley	Schekman, R (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Barker Hall, Berkeley, CA 94720 USA.		Kuehn, Meta/AAL-2950-2021	Kuehn, Meta/0000-0003-0519-3019				BARLOWE C, 1993, J BIOL CHEM, V268, P873; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BRODSKY JL, 1993, J CELL BIOL, V123, P1355, DOI 10.1083/jcb.123.6.1355; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Fiedler K, 1996, SCIENCE, V273, P1396, DOI 10.1126/science.273.5280.1396; HICKE L, 1992, MOL BIOL CELL, V3, P667, DOI 10.1091/mbc.3.6.667; Kuehn MJ, 1996, J CELL BIOL, V135, P585, DOI 10.1083/jcb.135.3.585; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SIKORSKI RS, 1989, GENETICS, V122, P19; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; Yeung T, 1995, J BIOL CHEM, V270, P30567, DOI 10.1074/jbc.270.51.30567; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	19	319	326	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					187	190		10.1038/34438	http://dx.doi.org/10.1038/34438			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428766				2022-12-01	WOS:000071380900054
J	Picciotto, MR; Zoli, M; Rimondini, R; Lena, C; Marubio, LM; Pich, EM; Fuxe, K; Changeux, JP				Picciotto, MR; Zoli, M; Rimondini, R; Lena, C; Marubio, LM; Pich, EM; Fuxe, K; Changeux, JP			Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine	NATURE			English	Article							VENTRAL TEGMENTAL AREA; H-3 DOPAMINE RELEASE; NUCLEUS-ACCUMBENS; AUTORADIOGRAPHIC ANALYSIS; RAT-BRAIN; INVITRO; MODULATION; PITUITARY; STRIATUM; SYSTEM	Release of the neurotransmitter dopamine in the mesolimbic system of the brain mediates the reinforcing properties of several drugs of abuse, including nicotine(1). Here we investigate the contribution of the high-affinity neuronal nicotinic acetylcholine receptor(2) to the effects of nicotine on the mesolimbic dopamine system in mice lacking the beta 2 subunit of this receptor(3). We found that nicotine stimulates dopamine release in the ventral striatum of wild-type mice but not in the ventral striatum of beta 2-mutant mice. Using patch-clamp recording, we show that mesencephalic dopaminergic neurons from mice without the beta 2 subunit no longer respond to nicotine, and that self-administration of nicotine is attenuated in these mutant mice. Our results strongly support the idea that the beta 2-containing neuronal nicotinic acetycholine receptor is involv ed in mediating the reinforcing properties of nicotine.	Inst Pasteur, CNRS, UA D128, F-75724 Paris, France; Karolinska Inst, Dept Histol, S-10401 Stockholm, Sweden; Glaxo Wellcome Res & Dev Ltd, Geneva Biomed Res Inst, CH-1228 Geneva, Switzerland	Centre National de la Recherche Scientifique (CNRS); Karolinska Institutet; GlaxoSmithKline	Changeux, JP (corresponding author), Inst Pasteur, CNRS, UA D128, 28 Rue Dr Roux, F-75724 Paris, France.		Léna, Clément/P-6929-2019; Rimondini, Roberto/B-2500-2010; Léna, Clément/ABE-4862-2021; Picciotto, Marina R./F-8747-2012; Zoli, Michele/C-8899-2016; , clement/ADN-8076-2022	Léna, Clément/0000-0002-1431-7717; Rimondini, Roberto/0000-0003-4099-513X; Léna, Clément/0000-0002-1431-7717; Picciotto, Marina R./0000-0002-4404-1280; Zoli, Michele/0000-0002-8034-2849; Fuxe, Kjell/0000-0001-8491-4288				Blaha CD, 1996, J NEUROSCI, V16, P714; CALABRESI P, 1989, BRIT J PHARMACOL, V98, P135, DOI 10.1111/j.1476-5381.1989.tb16873.x; CLARKE PBS, 1988, J PHARMACOL EXP THER, V246, P701; CORRIGALL WA, 1992, PSYCHOPHARMACOLOGY, V107, P285, DOI 10.1007/BF02245149; Dani JA, 1996, NEURON, V16, P905, DOI 10.1016/S0896-6273(00)80112-9; DAWSON TM, 1986, J NEUROSCI, V6, P2352; GRACE AA, 1989, J NEUROSCI, V9, P3463; GRADY S, 1992, J NEUROCHEM, V59, P848, DOI 10.1111/j.1471-4159.1992.tb08322.x; GRAHAME NJ, 1995, PHARMACOL BIOCHEM BE, V51, P827, DOI 10.1016/0091-3057(95)00047-Z; HENNINGFIELD JE, 1983, PHARMACOL BIOCHEM BE, V19, P887, DOI 10.1016/0091-3057(83)90099-0; IZENWASSER S, 1991, J NEUROCHEM, V56, P603, DOI 10.1111/j.1471-4159.1991.tb08192.x; KAUFMAN MJ, 1991, SYNAPSE, V9, P177, DOI 10.1002/syn.890090304; KOOB GF, 1992, TRENDS PHARMACOL SCI, V13, P177, DOI 10.1016/0165-6147(92)90060-J; LeNovere N, 1996, EUR J NEUROSCI, V8, P2428; LUETJE CW, 1991, J NEUROSCI, V11, P837; MANSOUR A, 1990, J NEUROSCI, V10, P2587; MCGEHEE DS, 1995, SCIENCE, V269, P1692, DOI 10.1126/science.7569895; MEMO M, 1986, J NEUROCHEM, V47, P1689, DOI 10.1111/j.1471-4159.1986.tb13075.x; NISELL M, 1994, SYNAPSE, V16, P36, DOI 10.1002/syn.890160105; PICCIOTTO MR, 1995, NATURE, V374, P65, DOI 10.1038/374065a0; Pich EM, 1997, SCIENCE, V275, P83; Pontieri FE, 1996, NATURE, V382, P255, DOI 10.1038/382255a0; REAVILL C, 1990, NEUROPHARMACOLOGY, V29, P619, DOI 10.1016/0028-3908(90)90022-J; RHEINLAND JE, 1986, LIFE SCI, V39, P2185; RIMONDINI R, 1994, NEUROSCI LETT, V177, P53, DOI 10.1016/0304-3940(94)90043-4; RISINGER FO, 1995, PHARMACOL BIOCHEM BE, V51, P457, DOI 10.1016/0091-3057(95)00007-J; Role LW, 1996, NEURON, V16, P1077, DOI 10.1016/S0896-6273(00)80134-8; STOLERMAN IP, 1995, MED RES REV, V15, P47, DOI 10.1002/med.2610150105; TESSARI M, 1995, PSYCHOPHARMACOLOGY, V121, P282, DOI 10.1007/BF02245640	29	1030	1052	3	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					173	177		10.1038/34413	http://dx.doi.org/10.1038/34413			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428762				2022-12-01	WOS:000071380900050
J	Bonneux, L; Barendregt, JJ; Nusselder, WJ; Van der Maas, PJ				Bonneux, L; Barendregt, JJ; Nusselder, WJ; Van der Maas, PJ			Preventing fatal diseases increases healthcare costs: cause elimination life table approach	BRITISH MEDICAL JOURNAL			English	Article							COMPRESSION; MORBIDITY	Objectives: To examine whether elimination of fatal diseases will increase healthcare costs. Design: Mortality data from vital statistics combined with healthcare spending in a cause elimination life table. Costs were allocated to specific diseases through the various healthcare registers. Setting and subjects: The population of the Netherlands, 1988. Main outcome measures: Healthcare costs of a synthetic life table cohort, expressed as life time expected costs. Results: The life time expected healthcare costs for 1988 in the Netherlands were pound 56 600 for men and pound 80 900 for women. Elimination of fatal diseases-such as coronary heart disease, cancer, or chronic obstructive lung disease-increases healthcare costs. Major savings will be achieved only by elimination of non-fatal disease-such as musculoskeletal diseases and mental disorders. Conclusion: The aim of prevention is to spare people from avoidable misery and death not to save money on the healthcare system. Ln countries with low mortality, elimination of fatal diseases by successful prevention increases healthcare spending because of the medical expenses during added life years.	Erasmus Univ, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Bonneux, L (corresponding author), Erasmus Univ, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Barendregt, Jan J/F-6895-2010					DOLL R, 1981, J NATL CANCER I, V66, P1270; FRIES JF, 1980, NEW ENGL J MED, V303, P130, DOI 10.1056/NEJM198007173030304; FRIES JF, 1993, NEW ENGL J MED, V329, P321, DOI 10.1056/NEJM199307293290506; Koopmanschap M, 1994, EUR J PUBLIC HEALTH, V4, P258, DOI [10.1093/eurpub/4.4.258, DOI 10.1093/EURPUB/4.4.258]; KOOPMANSCHAP MA, 1991, COST ILLNESS NETHERL; LUBITZ J, 1995, NEW ENGL J MED, V332, P999, DOI 10.1056/NEJM199504133321506; NAMBOODIRI K, 1987, LIFE TABLE TECHNIQUE, P92; Nusselder WJ, 1996, AM J PUBLIC HEALTH, V86, P187, DOI 10.2105/AJPH.86.2.187; ROSE G, 1992, STRATEGY PREVENTIVE, P4; RUSSELL L, 1986, IS PREVENTION BETTER, P116; SHRYOCK HS, 1976, LIFE TABLE METHODS M, P249; *STAT NETH, DEATHS CAUSES DEATHS; van Roijen L, 1992, Ned Tijdschr Geneeskd, V136, P74; *WHO, 1977, INT STAT CLASS DIS I	14	57	57	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					26	29		10.1136/bmj.316.7124.26	http://dx.doi.org/10.1136/bmj.316.7124.26			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451262	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071377900019
J	Quillent, C; Oberlin, E; Braun, J; Rousset, D; Gonzalez-Canali, G; Metais, P; Montagnier, L; Virelizier, JL; Arenzana-Seisdedos, F; Beretta, A				Quillent, C; Oberlin, E; Braun, J; Rousset, D; Gonzalez-Canali, G; Metais, P; Montagnier, L; Virelizier, JL; Arenzana-Seisdedos, F; Beretta, A			HIV-1-resistance phenotype conferred by combination of two separate inherited mutations of CCR5 gene	LANCET			English	Article							CHEMOKINE RECEPTOR GENE; HIV-1 INFECTION; INDIVIDUALS; PROGRESSION; MIP-1-ALPHA; RESISTANCE; MIP-1-BETA; COFACTOR; CLONING; ALLELE	Background Despite multiple exposures to HIV-1, some individuals remain uninfected, and their peripheral-blood mononuclear cells (PBMC) are resistant to in-vitro infection by primary HIV-1 isolates. Such resistance has been associated with a homozygous 32-base-pair deletion (Delta 32) in the C-C chemokine receptor gene CCR5. We examined other mutations of the CCR5 gene that could be associated with resistance to HIV-1 infection. Methods We assessed the susceptibility of PBMC to in-vitro infection by HIV-1 isolates that use the CCR5 as the major coreceptor for Viral entry in 18 men who had frequent unprotected sexual intercourse with a seropositive partner. We also did genotypic analysis of CCR5 alleles. One of the 18 exposed bur uninfected men (who we refer to as ExU2) showed total resistance to in-vitro infection by CCR5-dependent viruses, and was found to carry a CCR5 Delta 32 allele and a single point mutation (T-->A) at position 303 on the other allele, To find out whether the CCR5 mutation was restricted to ExU2's family or existed in the general population, we did genetic analyses of the CCR5 genotype in ExU2's father and sister and also in 209 healthy blood donors who were not exposed to HIV-1. Findings The m303 mutation found in ExU2 introduced a premature stop codon and prevented the expression of a functional coreceptor. The family studies revealed that the m303 mutant allele was inherited as a single mendelian trait. Genotype analysis showed that three of the 209 healthy blood donors were heterozygous for the mutant allele. Interpretation We characterise a new CCR5 gene mutation, present in the general population, that prevents expression of functional coreceptors from the abnormal allele and confers resistance to HIV-1 infection when associated to the Delta 32 CCR5 mutant gene.	Hop St Joseph, Ctr Integre Rech Bioclin SIDA, F-75014 Paris, France; Inst Pasteur, Unite Immunol Virale, Paris, France; Inst Pasteur, Unite Oncol Virale, F-75724 Paris, France	Hopital Paris Saint-Joseph; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Beretta, A (corresponding author), Hop St Joseph, Ctr Integre Rech Bioclin SIDA, F-75014 Paris, France.		Rousset, Dominique/S-5400-2019; Rousset, Dominique/A-4209-2009; Oberlin, Estelle/M-4915-2018; Arenzana-Seisdedos, Fernando/E-5835-2016	Rousset, Dominique/0000-0002-1473-3147; Oberlin, Estelle/0000-0002-8200-9548; 				Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DORANZ BJ, 1996, CELL, V85, P1159; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; DRAGIC T, 1992, J VIROL, V66, P4794, DOI 10.1128/JVI.66.8.4794-4802.1992; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; LI YX, 1992, J VIROL, V66, P6587, DOI 10.1128/JVI.66.11.6587-6600.1992; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Michael NL, 1997, NAT MED, V3, P338, DOI 10.1038/nm0397-338; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; OBrien TR, 1997, LANCET, V349, P1219, DOI 10.1016/S0140-6736(97)24017-1; Pleskoff O, 1997, SCIENCE, V276, P1874, DOI 10.1126/science.276.5320.1874; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; Theodorou I, 1997, LANCET, V349, P1219; Zhang LQ, 1996, NATURE, V383, P768, DOI 10.1038/383768a0; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	25	218	226	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					14	18		10.1016/S0140-6736(97)09185-X	http://dx.doi.org/10.1016/S0140-6736(97)09185-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433423				2022-12-01	WOS:000071253100010
J	Koehler, JE; Sanchez, MA; Garrido, CS; Whitfeld, MJ; Chen, FM; Berger, TG; Rodriguez-Barradas, MC; LeBoit, PE; Tappero, JW				Koehler, JE; Sanchez, MA; Garrido, CS; Whitfeld, MJ; Chen, FM; Berger, TG; Rodriguez-Barradas, MC; LeBoit, PE; Tappero, JW			Molecular epidemiology of Bartonella infections in patients with bacillary angiomatosis-peliosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Joint Session on Emerging Pathogens, Infectious-Diseases-Society-of-America National Meeting / 36th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-20, 1996	NEW ORLEANS, LOUISIANA	Infectious Dis Soc Amer			CAT-SCRATCH DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; HENSELAE SP-NOV; ROCHALIMAEA-HENSELAE; EPITHELIOID ANGIOMATOSIS; IDENTIFICATION; BACTEREMIA; FEVER; SEPTICEMIA; QUINTANA	Background Bacillary angiomatosis and bacillary peliosis are vascular proliferative manifestations of infection with species of the genus bartonella that occur predominantly in patients infected with the human immunodeficiency virus, Two species, Bartonella henselae and B. quintana, have been associated with bacillary angiomatosis, but culture and speciation are difficult, and there has been little systematic evaluation ol the species-specific disease characteristics. We studied 49 patients seen over eight years who were infected with bartonella species identified by molecular techniques and who had clinical lesions consistent with bacillary angiomatosis-peliosis. Methods In this case-control study, a standardized questionnaire about exposures was administered to patients with bacillary angiomatosis-peliosis and to 96 marched controls. The infecting bartonella species were determined by molecular techniques. Results Of the 49 patients with bacillary angiomatosis-peliosis, 26 (53 percent) were infected with B. henselae and 23 (47 percent) with B. quintana. Subcutaneous and lytic bone lesions were strongly associated with B. quintana, whereas peliosis hepatis was associated exclusively with B. henselae, Patients with B, henselae infection were identified throughout the study period and were epidemiologically linked to cat and flea exposure (P less than or equal to 0.004), whereas those with B, quintana were clustered and were characterized by low income (P=0.003), homelessness (P=0.004), and exposure to lice (P=0.03), Prior treatment with macrolide antibiotics appeared to be protective against infection with either species. Conclusions B. henselae and B, quintana, the organisms that cause bacillary angiomatosis-peliosis, are associated with different epidemiologic risk factors and with predilections for involvement of different organs. (C) 1997, Massachusetts Medical Society.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif Berkeley, Sch Publ Hlth, Program Epidemiol, Berkeley, CA 94720 USA; Vet Affairs Med Ctr, Med Serv, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Atlanta, GA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California Berkeley; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Baylor College of Medicine; Centers for Disease Control & Prevention - USA	Koehler, JE (corresponding author), Univ Calif San Francisco, Dept Med, Box 0654,521 Parnassus Ave,Rm C-443, San Francisco, CA 94143 USA.			Whitfeld, Margot/0000-0003-4509-4461	FIC NIH HHS [D43-TW00003] Funding Source: Medline; NIAID NIH HHS [R29 AI36075] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI036075] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAL KA, 1994, NEW ENGL J MED, V330, P1509, DOI 10.1056/NEJM199405263302108; [Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BAKER JA, 1946, J EXP MED, V84, P37, DOI 10.1084/jem.84.1.37; BIRTLES RJ, 1995, INT J SYST BACTERIOL, V45, P1, DOI 10.1099/00207713-45-1-1; CARITHERS HA, 1985, AM J DIS CHILD, V139, P1124, DOI 10.1001/archpedi.1985.02140130062031; Chomel BB, 1996, J CLIN MICROBIOL, V34, P1952, DOI 10.1128/JCM.34.8.1952-1956.1996; COCKERELL CJ, 1987, LANCET, V2, P654; Dean A. G., 1990, EPI INFO VERSION 5 W; DOLAN MJ, 1993, ANN INTERN MED, V118, P331, DOI 10.7326/0003-4819-118-5-199303010-00002; KOEHLER JE, 1994, JAMA-J AM MED ASSOC, V271, P531, DOI 10.1001/jama.271.7.531; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; Lawson PA, 1996, MED MICROBIOL LETT, V5, P64; LEBOIT PE, 1989, AM J SURG PATHOL, V13, P909, DOI 10.1097/00000478-198911000-00001; Margileth A M, 1993, Adv Pediatr Infect Dis, V8, P1; MARULLO S, 1992, J INFECT DIS, V166, P1462, DOI 10.1093/infdis/166.6.1462-a; MAURIN M, 1995, ANTIMICROB AGENTS CH, V39, P2387, DOI 10.1128/AAC.39.11.2387; MohleBoetani JC, 1996, CLIN INFECT DIS, V22, P794, DOI 10.1093/clinids/22.5.794; MYERS WF, 1984, ANTIMICROB AGENTS CH, V25, P690, DOI 10.1128/AAC.25.6.690; PERKOCHA LA, 1990, NEW ENGL J MED, V323, P1581, DOI 10.1056/NEJM199012063232302; REED JA, 1992, AM J SURG PATHOL, V16, P650, DOI 10.1097/00000478-199207000-00003; REGNERY RL, 1992, LANCET, V339, P1443, DOI 10.1016/0140-6736(92)92032-B; REGNERY RL, 1992, J CLIN MICROBIOL, V30, P265, DOI 10.1128/JCM.30.2.265-274.1992; RELMAN DA, 1990, NEW ENGL J MED, V323, P1573, DOI 10.1056/NEJM199012063232301; RODRIGUEZBARRADAS MC, 1995, J CLIN MICROBIOL, V33, P1089, DOI 10.1128/JCM.33.5.1089-1093.1995; SLATER LN, 1990, NEW ENGL J MED, V323, P1587, DOI 10.1056/NEJM199012063232303; SPACH DH, 1995, NEW ENGL J MED, V332, P424, DOI 10.1056/NEJM199502163320703; STOLER MH, 1983, AM J CLIN PATHOL, V80, P714, DOI 10.1093/ajcp/80.5.714; STRONG RP, 1918, TRENCH FEVER REPORT; TAPPERO JW, 1993, ANN INTERN MED, V118, P363, DOI 10.7326/0003-4819-118-5-199303010-00007; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; WELCH DF, 1992, J CLIN MICROBIOL, V30, P275, DOI 10.1128/JCM.30.2.275-280.1992; Whitfeld MJ, 1997, CLIN INFECT DIS, V24, P562, DOI 10.1093/clind/24.4.562; ZANGWILL KM, 1993, NEW ENGL J MED, V329, P8, DOI 10.1056/NEJM199307013290102	33	210	214	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1876	1883		10.1056/NEJM199712253372603	http://dx.doi.org/10.1056/NEJM199712253372603			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407154				2022-12-01	WOS:000071128200003
J	Tesmer, JJG; Sunahara, RK; Gilman, AG; Sprang, SR				Tesmer, JJG; Sunahara, RK; Gilman, AG; Sprang, SR			Crystal structure of the catalytic domains of adenylyl cyclase in a complex with G(s alpha).GTP gamma S	SCIENCE			English	Article							GUANYLATE-CYCLASE; GS-ALPHA; STEREOCHEMICAL COURSE; MOLECULAR-CLONING; ESCHERICHIA-COLI; GTP HYDROLYSIS; G-PROTEIN; MECHANISM; EXPRESSION; DIVERSITY	The crystal structure of a soluble, catalytically active form of adenylyl cyclase in a complex with its stimulatory heterotrimeric G protein alpha subunit (G(S alpha)) and forskolin was determined to a resolution of 2.3 angstroms. When P-site inhibitors were soaked into native crystals of the complex, the active site of adenylyl cyclase was located and structural elements important for substrate recognition and catalysis were identified. On the basis of these and other structures, a molecular mechanism is proposed for the activation of adenylyl cyclase by G(S alpha).	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas			Sunahara, Roger/AAJ-8667-2020	Tesmer, John/0000-0003-1125-3727	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038828, R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38828, DK46371] Funding Source: Medline; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AN SZ, 1997, J BIOL CHEM, V272, P18849; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; Chen YB, 1997, P NATL ACAD SCI USA, V94, P2711, DOI 10.1073/pnas.94.6.2711; CHINKERS M, 1991, ANN REV BIOCH, V60, P563; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Desaubry L, 1996, J BIOL CHEM, V271, P2380, DOI 10.1074/jbc.271.5.2380; Dessauer CW, 1997, J BIOL CHEM, V272, P22272, DOI 10.1074/jbc.272.35.22272; Dessauer CW, 1997, J BIOL CHEM, V272, P27787, DOI 10.1074/jbc.272.44.27787; Dessauer CW, 1996, J BIOL CHEM, V271, P16967, DOI 10.1074/jbc.271.28.16967; ECKSTEIN F, 1981, J BIOL CHEM, V256, P9118; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; GERLT JA, 1980, J BIOL CHEM, V255, P331; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; ITOH H, 1991, J BIOL CHEM, V266, P16226; IYENGAR R, 1993, FASEB J, V7, P768, DOI 10.1096/fasebj.7.9.8330684; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KOCH KW, 1990, J BIOL CHEM, V265, P9659; KRUPINSKI J, 1989, SCIENCE, V244, P1558, DOI 10.1126/science.2472670; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; Lichtarge O, 1996, P NATL ACAD SCI USA, V93, P7507, DOI 10.1073/pnas.93.15.7507; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKANE M, 1990, J BIOL CHEM, V265, P16841; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SENTER PD, 1983, J BIOL CHEM, V258, P6741; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; SRTYMIUK PJ, 1997, NATURE, V388, P33; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Sunahara RK, 1997, J BIOL CHEM, V272, P22265, DOI 10.1074/jbc.272.35.22265; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; TANG WJ, 1995, BIOCHEMISTRY-US, V34, P14563, DOI 10.1021/bi00044a035; TANG WJ, 1995, SCIENCE, V268, P1769, DOI 10.1126/science.7792604; TAUSSIG R, 1994, J BIOL CHEM, V269, P6093; Whisnant RE, 1996, P NATL ACAD SCI USA, V93, P6621, DOI 10.1073/pnas.93.13.6621; Xia ZG, 1997, CURR OPIN NEUROBIOL, V7, P391, DOI 10.1016/S0959-4388(97)80068-2; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941; Yan SZ, 1997, J BIOL CHEM, V272, P12342, DOI 10.1074/jbc.272.19.12342; Zhang GY, 1997, PROTEIN SCI, V6, P903; Zhang GY, 1997, NATURE, V386, P247, DOI 10.1038/386247a0	52	635	649	0	52	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1907	1916		10.1126/science.278.5345.1907	http://dx.doi.org/10.1126/science.278.5345.1907			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417641				2022-12-01	WOS:A1997YL00200024
J	Guo, HW; Yang, WY; Mockler, TC; Lin, CT				Guo, HW; Yang, WY; Mockler, TC; Lin, CT			Regulations of flowering time by Arabidopsis photoreceptors	SCIENCE			English	Article							THALIANA L HEYNH; PHYTOCHROME-B; BLUE; MUTANTS; GENE; RED; INDUCTION; RESPONSES; PHOTOMORPHOGENESIS; PERCEPTION	The shift in plants from vegetative growth to floral development is regulated by red-far-red light receptors (phytochromes) and blue-ultraviolet A light receptors (cryptochromes). A mutation in the Arabidopsis thaliana CRY2 gene encoding a blue-light receptor apoprotein (CRY2) is allelic to the late-flowering mutant, fha. Flowering in cry2/fha mutant plants is only incompletely responsive to photoperiod. Cryptochrome 2 (cry2) is a positive regulator of the flowering-time gene CO, the expression of which is regulated by photoperiod. Analysis of flowering in cry2 and phyB mutants in response to different wavelengths of light indicated that flowering is regulated by the antagonistic actions of phyB and cry2.	Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Lin, CT (corresponding author), Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.	clin@mcdb.ucla.edu	Mockler, Todd C/L-2609-2013; Ecker, Joseph R/B-9144-2008	Mockler, Todd C/0000-0002-0462-5775; Ecker, Joseph R/0000-0001-5799-5895	NIGMS NIH HHS [GM56265, GM08375, R01 GM056265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008375, R29GM056265, R01GM056265] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad M, 1996, PLANT MOL BIOL, V30, P851, DOI 10.1007/BF00020798; AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Aitchitt M., 1993, Plant Molecular Biology Reporter, V11, P317, DOI 10.1007/BF02905332; ARAKI T, 1993, PLANT J, V3, P231, DOI 10.1046/j.1365-313X.1993.t01-15-00999.x; Aukerman MJ, 1996, SEMIN CELL DEV BIOL, V7, P427, DOI 10.1006/scdb.1996.0053; BAGNALL DJ, 1995, PLANT PHYSIOL, V108, P1495, DOI 10.1104/pp.108.4.1495; Bagnall DJ, 1996, PLANTA, V200, P278, DOI 10.1007/BF00208319; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; BRIGGS W, 1996, CURRENT TOPICS PLANT, V17; BROWN JAM, 1971, PLANT PHYSIOL, V47, P393, DOI 10.1104/pp.47.3.393; Chory J, 1997, PLANT CELL, V9, P1225, DOI 10.1105/tpc.9.7.1225; COUPLAND G, 1995, TRENDS GENET, V11, P393, DOI 10.1016/S0168-9525(00)89122-2; ESKINS K, 1992, PHYSIOL PLANTARUM, V86, P439, DOI 10.1111/j.1399-3054.1992.tb01341.x; Furuya M, 1996, TRENDS PLANT SCI, V1, P301; GOTO N, 1991, PHYSIOL PLANTARUM, V83, P209, DOI 10.1111/j.1399-3054.1991.tb02144.x; HALLIDAY KJ, 1994, PLANT PHYSIOL, V104, P1311, DOI 10.1104/pp.104.4.1311; Hicks KA, 1996, SEMIN CELL DEV BIOL, V7, P409, DOI 10.1006/scdb.1996.0051; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; JOHNSON E, 1994, PLANT PHYSIOL, V105, P141, DOI 10.1104/pp.105.1.141; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; King R, 1996, SEMIN CELL DEV BIOL, V7, P449, DOI 10.1006/scdb.1996.0056; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; KOORNNEEF M, IN PRESS ANN REV PLA; LIN C, 1996, CURRENT TOPICS PLANT, V17; Lin CT, 1998, P NATL ACAD SCI USA, V95, P2686, DOI 10.1073/pnas.95.5.2686; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; LISCUM E, 1994, PLANT CELL ENVIRON, V17, P639, DOI 10.1111/j.1365-3040.1994.tb00155.x; Ma H, 1997, CELL, V89, P821, DOI 10.1016/S0092-8674(00)80265-2; Martinez-Zapater JM, 1994, ARABIDOPSIS, P403; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; MOCKLER T, UNPUB; Mohr Hans, 1994, P353; PARK HW, 1995, SCIENCE, V268, P1866, DOI 10.1126/science.7604260; Peeters AJM, 1996, SEMIN CELL DEV BIOL, V7, P381, DOI 10.1006/scdb.1996.0048; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; REDEI GP, 1962, GENETICS, V47, P443; REED JW, 1993, PLANT CELL, V5, P147, DOI 10.1105/tpc.5.2.147; Simon R, 1996, SEMIN CELL DEV BIOL, V7, P419, DOI 10.1006/scdb.1996.0052; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; vonArnim A, 1996, ANNU REV PLANT PHYS, V47, P215, DOI 10.1146/annurev.arplant.47.1.215; Weller JL, 1997, PLANT PHYSIOL, V114, P1225, DOI 10.1104/pp.114.4.1225; Weller JL, 1997, TRENDS PLANT SCI, V2, P412, DOI 10.1016/S1360-1385(97)85580-X; Zagotta MT, 1996, PLANT J, V10, P691, DOI 10.1046/j.1365-313X.1996.10040691.x	46	567	636	6	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1360	1363		10.1126/science.279.5355.1360	http://dx.doi.org/10.1126/science.279.5355.1360			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478898				2022-12-01	WOS:000072251800053
J	Clandinin, TR; DeModena, JA; Sternberg, PW				Clandinin, TR; DeModena, JA; Sternberg, PW			Inositol trisphosphate mediates a RAS-independent response to LET-23 receptor tyrosine kinase activation in C-elegans	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; LIGAND-BINDING SITE; CAENORHABDITIS-ELEGANS; PHOSPHOLIPASE-C; 1,4,5-TRISPHOSPHATE 3-KINASE; VULVAR INDUCTION; SMOOTH-MUSCLE; EGF RECEPTOR; NEURONAL DIFFERENTIATION; POINT MUTATION	Activity of LET-23, the C. elegans homolog of the epidermal growth factor receptor, is required in multiple tissues. RAS activation is necessary and sufficient for certain LET-23 functions. We show that an inositol trisphosphate receptor can act as a PAS-independent, tissue-specific positive effector of LET-23. Moreover, an inositol trisphosphate kinase negatively regulates this transduction pathway. Signals transduced by LET-23 control ovulation through changes in spermathecal dilation, possibly dependent upon calcium release regulated by both IP3 and IP4. Our results demonstrate that one mechanism by which receptor tyrosine kinases can evoke tissue-specific responses is through activation of distinct signal transduction cascades in different tissues.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology	Sternberg, PW (corresponding author), CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA.							AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1994, EMBO J, V13, P360, DOI 10.1002/j.1460-2075.1994.tb06269.x; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Beitel GJ, 1995, GENE DEV, V9, P3149, DOI 10.1101/gad.9.24.3149; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRENNER S, 1974, GENETICS, V77, P71; CHAMBERLIN HM, 1994, DEVELOPMENT, V120, P2713; Chen P, 1996, MOL BIOL CELL, V7, P871, DOI 10.1091/mbc.7.6.871; CHOI KY, 1990, SCIENCE, V248, P64, DOI 10.1126/science.2157285; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLARK SG, 1992, COLD SPRING HARB SYM, V57, P363, DOI 10.1101/SQB.1992.057.01.041; COMMUNI D, 1993, BIOCHEM J, V291, P811, DOI 10.1042/bj2910811; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DIKIC I, 1994, CURR BIOL, V4, P702, DOI 10.1016/S0960-9822(00)00155-X; Dufour JF, 1997, J BIOL CHEM, V272, P2675, DOI 10.1074/jbc.272.5.2675; ERNEUX C, 1993, EUR J BIOCHEM, V214, P497, DOI 10.1111/j.1432-1033.1993.tb17947.x; FERGUSON EL, 1985, GENETICS, V110, P17; Fleming JT, 1996, PARASITOLOGY, V113, pS175, DOI 10.1017/S0031182000077969; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hajnal A, 1997, GENE DEV, V11, P2715, DOI 10.1101/gad.11.20.2715; HAN M, 1990, GENETICS, V126, P899; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; IRVINE RF, 1991, BIOESSAYS, V13, P419, DOI 10.1002/bies.950130810; JONGEWARD GD, 1995, GENETICS, V139, P1553; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; Kornfeld K, 1997, TRENDS GENET, V13, P55, DOI 10.1016/S0168-9525(97)01005-6; Lesa GM, 1997, MOL BIOL CELL, V8, P779, DOI 10.1091/mbc.8.5.779; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; McCarter J, 1997, DEV BIOL, V181, P121, DOI 10.1006/dbio.1996.8429; Mello C, 1995, CAENORHABDITIS ELEGA, P451; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MIGNERY GA, 1990, EMBO J, V9, P3893, DOI 10.1002/j.1460-2075.1990.tb07609.x; MIGNERY GA, 1990, J BIOL CHEM, V265, P12679; MIYAWAKI A, 1991, P NATL ACAD SCI USA, V88, P4911, DOI 10.1073/pnas.88.11.4911; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MOOLENAAR WH, 1986, J BIOL CHEM, V261, P279; NELSON MT, 1995, SCIENCE, V270, P633, DOI 10.1126/science.270.5236.633; Obermeier A, 1996, EMBO J, V15, P73, DOI 10.1002/j.1460-2075.1996.tb00335.x; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RONNSTRAND L, 1992, EMBO J, V11, P3911, DOI 10.1002/j.1460-2075.1992.tb05484.x; Sambrook J., 1989, MOL CLONING LAB MANU; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STEHNOBITTEL L, 1995, NEURON, V14, P163, DOI 10.1016/0896-6273(95)90250-3; TAKAZAWA K, 1990, BIOCHEM J, V272, P107, DOI 10.1042/bj2720107; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TRAVERSE S, 1994, CURR BIOL, V4, P694, DOI 10.1016/S0960-9822(00)00154-8; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Yoshikawa F, 1996, J BIOL CHEM, V271, P18277, DOI 10.1074/jbc.271.30.18277	57	160	172	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					523	533		10.1016/S0092-8674(00)80945-9	http://dx.doi.org/10.1016/S0092-8674(00)80945-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491893	Bronze			2022-12-01	WOS:000072251500012
J	Luo, RX; Postigo, AA; Dean, DC				Luo, RX; Postigo, AA; Dean, DC			Rb interacts with histone deacetylase to repress transcription	CELL			English	Article							CELL-CYCLE ARREST; RETINOBLASTOMA PROTEIN; BINDING PROTEIN; E2F; NUCLEOSOME; COMPLEX; DOMAIN; FAMILY; YEAST; REGULATOR	Previously, we found that Rb can actively repress transcription of cell cycle genes by binding and inactivating transcription factors at the promoter. Here, we demonstrate that Rb can also repress transcription of endogenous cell cycle genes containing E2F sites through recruitment of histone deacetylase, which deacetylates histones on the promoter, thereby promoting formation of nucleosomes that inhibit transcription. These two mechanisms of repression by Rb are selective-some promoters and transcription factors are blocked by this recruitment of histone deacetylase, whereas others are resistant to histone deacetylase activity and are repressed directly by inhibition of transcription factors.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Dean, DC (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.			Postigo, Antonio/0000-0003-4605-2634				Adams PD, 1996, CURR TOP MICROBIOL, V208, P79; Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; AYER DE, 1993, GENE DEV, V7, P211; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; BRAUNSTEIN M, 1993, GENE DEV, V7, P4592; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DEDON PC, 1991, ANAL BIOCHEM, V197, P83, DOI 10.1016/0003-2697(91)90359-2; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; EWEN ME, 1994, CANCER METAST REV, V13, P45, DOI 10.1007/BF00690418; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; Hartzog GA, 1997, CURR OPIN GENET DEV, V7, P192, DOI 10.1016/S0959-437X(97)80128-1; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KODOSH D, 1997, CELL, V89, P365; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NEVINS JR, 1992, SCIENCE, V258, P424; NGY L, 1997, CELL, V89, P373; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; POSTIGO AP, 1997, EMBO J, V16, P3835; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; SHAO ZH, 1995, P NATL ACAD SCI USA, V92, P3115, DOI 10.1073/pnas.92.8.3115; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; Trouche D, 1996, P NATL ACAD SCI USA, V93, P1439, DOI 10.1073/pnas.93.4.1439; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yang WM, 1997, J BIOL CHEM, V272, P28001, DOI 10.1074/jbc.272.44.28001; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	58	809	823	0	15	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					463	473		10.1016/S0092-8674(00)80940-X	http://dx.doi.org/10.1016/S0092-8674(00)80940-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491888	Bronze			2022-12-01	WOS:000072251500007
J	Krebs, JR; Anderson, RM; Clutton-Brock, T; Donnelly, CA; Frost, S; Morrison, WI; Woodroffe, R; Young, D				Krebs, JR; Anderson, RM; Clutton-Brock, T; Donnelly, CA; Frost, S; Morrison, WI; Woodroffe, R; Young, D			Policy: Biomedicine - Badgers and bovine TB: Conflicts between conservation and health	SCIENCE			English	Editorial Material							MYCOBACTERIUM-BOVIS; EPIDEMIOLOGY; TUBERCULOSIS; DYNAMICS; VARIANT		NERC, Swindon SN2 1EU, Wilts, England; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England; Ctr HIV Res, Edinburgh EH9 3JN, Midlothian, Scotland; Univ Cambridge, Dept Zool, Cambridge CB2 3EJ, England; Inst Anim Hlth, Compton RG20 7NN, England; Univ London, St Marys Hosp, Sch Med, London W2 1PG, England	UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); University of Oxford; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Imperial College London; University of London	Krebs, JR (corresponding author), NERC, Polaris House,N Star Ave, Swindon SN2 1EU, Wilts, England.	hqpo@wpo.nerc.ac.uk	Frost, Simon/F-3648-2010	Frost, Simon/0000-0002-5207-9879; Donnelly, Christl/0000-0002-0195-2463; Anderson, Roy/0000-0002-9528-3175				Anderson RM, 1996, NATURE, V382, P779, DOI 10.1038/382779a0; ANDERSON RM, 1985, PHILOS T R SOC B, V310, P327, DOI 10.1098/rstb.1985.0123; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; Collinge J, 1996, NATURE, V383, P685, DOI 10.1038/383685a0; Guerrero A, 1997, LANCET, V350, P1738, DOI 10.1016/S0140-6736(97)07567-3; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; Krebs J., 1997, PB3423 HMSO; LITTLE TWA, 1982, VET REC, V111, P550; Swinton J, 1997, PHILOS T R SOC B, V352, P619, DOI 10.1098/rstb.1997.0042; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406, DOI 10.1128/JCM.31.2.406-409.1993; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9; ZUCKERMAN, 1980, BADGERS CATTLE TUBER; [No title captured]	13	41	41	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					817	818		10.1126/science.279.5352.817	http://dx.doi.org/10.1126/science.279.5352.817			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9480550				2022-12-01	WOS:000071923500026
J	Adler, MW				Adler, MW			Antiretrovirals for developing world	LANCET			English	Editorial Material									UCL, Sch Med, Dept Sexually Transmitted Dis, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Adler, MW (corresponding author), UCL, Sch Med, Dept Sexually Transmitted Dis, Mortimer St, London WC1E 6AU, England.							FEINMANN J, 1997, LANCET, V250, P1759; *UNAIDS WHO, 1997, UNAIDS WHO REP GLOB; VANPRAAG E, 1997, IMPLICATIONS ANTIRET; *WORLD BANK POL RE, 1997, CONF AIDS PUBL PRIOR	4	7	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					232	232		10.1016/S0140-6736(05)78276-3	http://dx.doi.org/10.1016/S0140-6736(05)78276-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457091				2022-12-01	WOS:000071702200007
J	Weinmaster, G				Weinmaster, G			Reprolysins and astacins ... Alive, alive-O	SCIENCE			English	Article									Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Weinmaster, G (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.							Blader P, 1997, SCIENCE, V278, P1937, DOI 10.1126/science.278.5345.1937; Blaumueller CM, 1997, CELL, V90, P281, DOI 10.1016/S0092-8674(00)80336-0; BOND JS, 1995, PROTEIN SCI, V4, P1247, DOI 10.1002/pro.5560040701; Holley SA, 1997, BIOESSAYS, V19, P281, DOI 10.1002/bies.950190404; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Marques G, 1997, CELL, V91, P417, DOI 10.1016/S0092-8674(00)80425-0; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; Piccolo S, 1997, CELL, V91, P407, DOI 10.1016/S0092-8674(00)80424-9; Sotillos S, 1997, DEVELOPMENT, V124, P4769; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313	11	10	11	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					336	337		10.1126/science.279.5349.336	http://dx.doi.org/10.1126/science.279.5349.336			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454330				2022-12-01	WOS:000071570800033
J	Rao, PM; Rhea, JT; Novelline, RA; Mostafavi, AA; McCabe, CJ				Rao, PM; Rhea, JT; Novelline, RA; Mostafavi, AA; McCabe, CJ			Effect of computed tomography of the appendix on treatment of patients and use of hospital resources	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIAGNOSIS; EMERGENCY; CT; APPENDECTOMY; ACCURACY	Background In patients with clinically suspected appendicitis, computed tomography (CT) is diagnostically accurate. However, the effect of routine CT of the appendix on the treatment of such patients and the use of hospital resources is unknown. Method's We performed appendiceal CT on 100 consecutive patients in the emergency department who, on the basis of history, physical examination, and laboratory results, were to be hospitalized for observation for suspected appendicitis or for urgent appendectomy. Outcomes were determined at surgery and by pathological examination in 59 patients, and by clinical follow-up two months later in 41 patients. Treatment plans made before CT were compared with the patients' actual treatment, We also determined the costs of surgery that revealed no appendicitis (from data on 61 patients), one day of observation in the hospital (from data on 350 patient-days in patients with suspected appendicitis), and appendiceal CT (from data on all pelvic CT examinations in 1996). Results Fifty-three patients had appendicitis, and 47 did not. The interpretations of the appendiceal CT scans were 98 percent accurate. The results of CT led to changes in the treatment of 59 patients. These changes resulted in the prevention of unnecessary appendectomy in 13 patients, admission to the hospital for observation in 18 patients, admission to the hospital for observation before necessary appendectomy in 21 patients, and admission to the hospital for observation before the diagnosis of other conditions by CT in 11 patients. The effects of performing appendiceal CT on the use of hospital resources included the prevention of unnecessary appendectomy in 13 patients (for a savings of $47,281) and the prevention of unnecessary hospital admission for 50 patient-days (for a savings of $20,250). After the cost of 100 appendiceal CT studies ($22,800) was subtracted, the overall savings was $447 per patient. Conclusions Routine appendiceal CT performed in patients who present with suspected appendicitis improves patient care and reduces the use of hospital resources. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital	Rao, PM (corresponding author), Massachusetts Gen Hosp, Dept Radiol, 32 Fruit St, Boston, MA 02114 USA.							ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; BALTHAZAR EJ, 1994, RADIOLOGY, V190, P31, DOI 10.1148/radiology.190.1.8259423; BALTHAZAR EJ, 1991, RADIOLOGY, V180, P21, DOI 10.1148/radiology.180.1.2052696; CALDER JDF, 1995, BRIT J HOSP MED, V54, P129; Cohen M M, 1993, J Laparoendosc Surg, V3, P93, DOI 10.1089/lps.1993.3.93; IZBICKI JR, 1992, EUR J SURG, V158, P227; JESS P, 1981, AM J SURG, V141, P232, DOI 10.1016/0002-9610(81)90164-1; Lane MJ, 1997, AM J ROENTGENOL, V168, P405, DOI 10.2214/ajr.168.2.9016216; LEWIS FR, 1975, ARCH SURG-CHICAGO, V110, P677; MALONE AJ, 1993, AM J ROENTGENOL, V160, P763, DOI 10.2214/ajr.160.4.8456661; MCCALLION J, 1987, AGE AGEING, V16, P256, DOI 10.1093/ageing/16.4.256; OHMANN C, 1995, EUR J SURG, V161, P273; Rao PM, 1997, RADIOLOGY, V202, P139, DOI 10.1148/radiology.202.1.8988203; Rao PM, 1997, AM J ROENTGENOL, V169, P1275, DOI 10.2214/ajr.169.5.9353441; Rao PM, 1997, J COMPUT ASSIST TOMO, V21, P686, DOI 10.1097/00004728-199709000-00002; REYNOLDS SL, 1993, PEDIATR EMERG CARE, V9, P1, DOI 10.1097/00006565-199302000-00002; Rhea JT, 1997, AM J ROENTGENOL, V169, P113, DOI 10.2214/ajr.169.1.9207509; ROTHROCK SG, 1991, ANN EMERG MED, V20, P45, DOI 10.1016/S0196-0644(05)81117-5; Rothrock Steven G., 1995, Journal of Emergency Medicine, V13, P1, DOI 10.1016/0736-4679(94)00104-9; SHUST N, 1993, PEDIATR RADIOL, V23, P289, DOI 10.1007/BF02010917; SIMMEN HP, 1991, HEPATO-GASTROENTEROL, V38, P279; TRAUTLEIN JJ, 1984, ANN EMERG MED, V13, P709, DOI 10.1016/S0196-0644(84)80733-7; VELANOVICH V, 1992, AM SURGEON, V58, P264; WADE DS, 1993, ARCH SURG-CHICAGO, V128, P1039	24	498	511	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					141	146		10.1056/NEJM199801153380301	http://dx.doi.org/10.1056/NEJM199801153380301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428814				2022-12-01	WOS:000071384500001
J	Lebwohl, M; Tan, MH				Lebwohl, M; Tan, MH			Psoriasis and stress	LANCET			English	Editorial Material									Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Lebwohl, M (corresponding author), Mt Sinai Med Ctr, Dept Dermatol, New York, NY 10029 USA.							FINLAY AY, 1990, BRIT J DERMATOL, V123, P751, DOI 10.1111/j.1365-2133.1990.tb04192.x; Fortune DG, 1997, BRIT J DERMATOL, V137, P755; Fortune DG, 1997, J PSYCHOSOM RES, V42, P467, DOI 10.1016/S0022-3999(97)00036-6; GINSBURG IH, 1993, INT J DERMATOL, V32, P587, DOI 10.1111/j.1365-4362.1993.tb05031.x; Savin J A, 1970, Trans St Johns Hosp Dermatol Soc, V56, P139; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	6	8	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					82	82		10.1016/S0140-6736(05)78153-8	http://dx.doi.org/10.1016/S0140-6736(05)78153-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YT341	9439490				2022-12-01	WOS:000071591900007
J	Kisker, C; Schindelin, H; Pacheco, A; Wehbi, WA; Garrett, RM; Rajagopalan, KV; Enemark, JH; Rees, DC				Kisker, C; Schindelin, H; Pacheco, A; Wehbi, WA; Garrett, RM; Rajagopalan, KV; Enemark, JH; Rees, DC			Molecular basis of sulfite oxidase deficiency from the structure of sulfite oxidase	CELL			English	Article							CRYSTAL-STRUCTURE; PROTEIN CRYSTALLOGRAPHY; NITRATE REDUCTASE; CHICKEN LIVER; MOLYBDENUM; DOMAINS; OXIDOREDUCTASE; CYSTEINE-207; PURIFICATION; RESOLUTION	The molybdenum-containing enzyme sulfite oxidase catalyzes the conversion of sulfite to sulfate, the terminal step in the oxidative degradation of cysteine and methionine. Deficiency of this enzyme in humans usually leads to major neurological abnormalities and early death. The crystal structure of chicken liver sulfite oxidase at 1.9 Angstrom resolution reveals that each monomer of the dimeric enzyme consists of three domains. At the active site, the Mo is penta-coordinated by three sulfur ligands, one oxo group, and one water/hydroxo. A sulfate molecule adjacent to the Mo identifies the substrate binding pocket. Four variants associated with sulfite oxidase deficiency have been identified: two mutations are near the sulfate binding site, while the other mutations occur within the domain mediating dimerization.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Univ Arizona, Dept Chem, Tucson, AZ 85721 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA	California Institute of Technology; Howard Hughes Medical Institute; California Institute of Technology; University of Arizona; Duke University	Kisker, C (corresponding author), CALTECH, Howard Hughes Med Inst, 147-75CH, Pasadena, CA 91125 USA.		Enemark, John/AAQ-4395-2020; Schindelin, Hermann/Q-2697-2019; Kisker, Caroline/T-1724-2019	Kisker, Caroline/0000-0002-0216-6026	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050775, R01GM037773] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM00091, GM37773, GM50775] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Boyington JC, 1997, SCIENCE, V275, P1305, DOI 10.1126/science.275.5304.1305; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAN MK, 1995, SCIENCE, V267, P1463, DOI 10.1126/science.7878465; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAWFORD NM, 1988, P NATL ACAD SCI USA, V85, P5006, DOI 10.1073/pnas.85.14.5006; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GARRETT RM, 1994, J BIOL CHEM, V269, P272; GARRETT RM, 1995, BBA-GENE STRUCT EXPR, V1262, P147, DOI 10.1016/0167-4781(95)00068-R; Garrett RM, 1996, J BIOL CHEM, V271, P7387, DOI 10.1074/jbc.271.13.7387; Garton SD, 1997, J AM CHEM SOC, V119, P2590, DOI 10.1021/ja963931c; George GN, 1996, J AM CHEM SOC, V118, P8588, DOI 10.1021/ja961218h; GEORGE GN, 1909, BIOCHEMISTRY-US, V28, P5075; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; HILLE R, 1994, BBA-BIOENERGETICS, V1184, P143, DOI 10.1016/0005-2728(94)90220-8; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; JOHNSON JL, 1977, J BIOL CHEM, V252, P2017; Johnson JL, 1989, METABOLIC BASIS INHE, P1463; JONES EY, 1995, NATURE, V373, P539, DOI 10.1038/373539a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KESSLER DL, 1972, J BIOL CHEM, V247, P6566; KIPKE CA, 1989, ARCH BIOCHEM BIOPHYS, V270, P383, DOI 10.1016/0003-9861(89)90041-6; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KLEYWEGT GJ, 1994, CCP4 P, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBO Y, 1988, J BIOL CHEM, V263, P19684; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1991, CCP4 STUDY WEEKEND, P80; MATHEWS FS, 1971, COLD SPRING HARB SYM, V36, P387, DOI 10.1101/SQB.1972.036.01.050; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVE C, 1995, RADIAT PHYS CHEM, V45, P483, DOI 10.1016/0969-806X(95)92800-E; Naylor CE, 1996, BLOOD, V87, P2974, DOI 10.1182/blood.V87.7.2974.bloodjournal8772974; NEAME PJ, 1989, J BIOL CHEM, V264, P20894; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1996, METHOD ENZYMOL, P307; RAPPE AK, 1982, J AM CHEM SOC, V104, P448, DOI 10.1021/ja00366a013; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; ROWLAND P, 1994, STRUCTURE, V2, P1073, DOI 10.1016/S0969-2126(94)00110-3; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SOUTHERLAND WM, 1978, J BIOL CHEM, V253, P8747; SULLIVAN EP, 1993, BIOCHEMISTRY-US, V32, P12465, DOI 10.1021/bi00097a026; Vaughn DE, 1996, NEURON, V16, P261, DOI 10.1016/S0896-6273(00)80045-8; WOOTTON JC, 1991, BIOCHIM BIOPHYS ACTA, V1057, P157, DOI 10.1016/S0005-2728(05)80100-8	50	440	445	0	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					973	983		10.1016/S0092-8674(00)80488-2	http://dx.doi.org/10.1016/S0092-8674(00)80488-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428520	Bronze			2022-12-01	WOS:000071281400014
J	Kozielski, F; Sack, S; Marx, A; Thormahlen, M; Schonbrunn, E; Biou, V; Thompson, A; Mandelkow, EM; Mandelkow, E				Kozielski, F; Sack, S; Marx, A; Thormahlen, M; Schonbrunn, E; Biou, V; Thompson, A; Mandelkow, EM; Mandelkow, E			Phe crystal structure of dimeric kinesin and implications for microtubule-dependent motility	CELL			English	Article							3-DIMENSIONAL STRUCTURE; MOTOR DOMAIN; BETA-TUBULIN; PROTEIN; COMPLEX; ACTIN; MYOSIN; HEAD; NCD; IDENTIFICATION	The dimeric form of the kinesin motor and neck domain from rat brain with bound ADP has been solved by X-ray crystallography. The two heads of the dimer are connected via a coiled-coil alpha-helical interaction of their necks. They are broadly similar to one another; differences are most apparent in the head-neck junction and in a moderate reorientation of the neck helices in order to adopt to the coiled-coil conformation. The heads show a rotational symmetry (similar to 120 degrees) about an axis close to that of the coiled-coil. This arrangement is unexpected since it is not compatible with the microtubule lattice. In this arrangement, the two heads of a kinesin dimer could not have equivalent interactions with microtubules.	DESY, Max Planck Unit Struct Mol Biol, D-22607 Hamburg, Germany; European Synchrotron Radiat Facil, F-38042 Grenoble, France	Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; European Synchrotron Radiation Facility (ESRF)	Kozielski, F (corresponding author), Inst Biol Struct, 41 Av Martyrs, F-38027 Grenoble, France.			Schonbrunn, Ernst/0000-0002-3589-3510				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; Arnal I, 1996, CURR BIOL, V6, P1265, DOI 10.1016/S0960-9822(02)70712-4; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1995, TRENDS CELL BIOL, V5, P169; BRADY ST, 1985, NATURE, V317, P73, DOI 10.1038/317073a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Crevel IMTC, 1996, J MOL BIOL, V257, P66, DOI 10.1006/jmbi.1996.0147; CROSS RA, 1995, J MUSCLE RES CELL M, V16, P91, DOI 10.1007/BF00122526; Doublie S., 1992, CRYSTALLIZATION NUCL, P311; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HARRISON BC, 1993, NATURE, V362, P73, DOI 10.1038/362073a0; Hilgenfeld R, 1995, CURR OPIN STRUC BIOL, V5, P810, DOI 10.1016/0959-440X(95)80015-8; Hirose K, 1996, P NATL ACAD SCI USA, V93, P9539, DOI 10.1073/pnas.93.18.9539; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; HOENGER A, 1995, NATURE, V376, P271, DOI 10.1038/376271a0; Holmes KC, 1997, CURR BIOL, V7, pR112, DOI 10.1016/S0960-9822(06)00051-0; Howard J, 1996, ANNU REV PHYSIOL, V58, P703, DOI 10.1146/annurev.ph.58.030196.003415; HUNT AJ, 1993, P NATL ACAD SCI USA, V90, P11653, DOI 10.1073/pnas.90.24.11653; Inoue Y, 1997, P NATL ACAD SCI USA, V94, P7275, DOI 10.1073/pnas.94.14.7275; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KIKKAWA M, 1995, NATURE, V376, P274, DOI 10.1038/376274a0; Kozielski F, 1997, J STRUCT BIOL, V119, P28, DOI 10.1006/jsbi.1997.3872; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LORENZ M, 1993, J MOL BIOL, V234, P826, DOI 10.1006/jmbi.1993.1628; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; Moyer ML, 1996, BIOCHEMISTRY-US, V35, P6321, DOI 10.1021/bi960017n; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RAMENT I, 1996, STRUCTURE, V4, P501; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SONG YH, 1993, P NATL ACAD SCI USA, V90, P1671, DOI 10.1073/pnas.90.5.1671; STUDIER WF, 1990, METHOD ENZYMOL, V185, P60, DOI DOI 10.1016/0076-6879(90)85008-C; Tripet B, 1997, J BIOL CHEM, V272, P8946; TTHORMAHLEN M, 1998, IN PRESS J MOL BIOL; TTUCKER C, 1997, J BIOL CHEM, V272, P9481; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; WALKER RA, 1995, P NATL ACAD SCI USA, V92, P5960, DOI 10.1073/pnas.92.13.5960; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0	48	341	350	1	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					985	994		10.1016/S0092-8674(00)80489-4	http://dx.doi.org/10.1016/S0092-8674(00)80489-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428521	Bronze			2022-12-01	WOS:000071281400015
J	Sun, XP; Wahlstrom, J; Karpen, G				Sun, XP; Wahlstrom, J; Karpen, G			Molecular structure of a functional Drosophila centromere	CELL			English	Article							HUMAN Y-CHROMOSOME; ALPHA-SATELLITE DNA; TRANSPOSABLE ELEMENTS; MELANOGASTER HETEROCHROMATIN; SCHIZOSACCHAROMYCES-POMBE; INSITU HYBRIDIZATION; MARKER CHROMOSOME; FISSION YEAST; CENP-C; SEQUENCES	Centromeres play a critical role in chromosome inheritance but are among the most difficult genomic components to analyze in multicellular eukaryotes. Here, we present a highly detailed molecular structure of a functional centromere in a multicellular organism. The centromere of the Drosophila minichromosome Dp1187 is contained within a 420 kb region of centric heterochromatin. We have used a new approach to characterize the detailed structure of this centromere and found that it is primarily composed of satellites and single, complete transposable elements. In the rest of the Drosophila genome, these satellites and transposable elements are neither unique to the centromeres nor present at all centromeres. We discuss the impact of these results on our understanding of heterochromatin structure and on the determinants of centromere identity and function.	Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	Salk Institute	Karpen, G (corresponding author), Salk Inst Biol Studies, Mol Biol & Virol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054549] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABAD JP, 1992, P NATL ACAD SCI USA, V89, P4663, DOI 10.1073/pnas.89.10.4663; ALFENITO MR, 1993, GENETICS, V135, P589; AULT JG, 1988, CHROMOSOMA, V97, P71, DOI 10.1007/BF00331796; BONACCORSI S, 1990, CHROMOSOMA, V99, P260, DOI 10.1007/BF01731701; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; CARMENA M, 1995, CHROMOSOMA, V103, P676; CHARLESWORTH B, 1994, GENET RES, V64, P183, DOI 10.1017/S0016672300032845; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CHOO KH, 1991, NUCLEIC ACIDS RES, V19, P1179, DOI 10.1093/nar/19.6.1179; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKE L, 1985, ANNU REV GENET, V19, P29, DOI 10.1146/annurev.genet.19.1.29; CLARKE L, 1990, TRENDS GENET, V6, P150, DOI 10.1016/0168-9525(90)90149-Z; CLARKE L, 1993, COLD SPRING HARB SYM, V58, P687, DOI 10.1101/SQB.1993.058.01.076; Cook KR, 1997, GENETICS, V145, P737; DANILEVSKAYA O, 1994, CHROMOSOMA, V103, P215, DOI 10.1007/s004120050027; Davis PS, 1995, DROSOPH INF SERV, V76, P134; Dernburg AF, 1996, GENETICS, V143, P1629; DEVLIN RH, 1990, GENETICS, V125, P129; DINOCERA PP, 1988, NUCLEIC ACIDS RES, V16, P4041; DINOCERA PP, 1983, J MOL BIOL, V168, P715; DINOCERA PP, 1987, P NATL ACAD SCI USA, V84, P5843; DUSART D, 1997, DNA CELL BIOL, V16, P144; EARNSHAW WC, 1985, CHROMOSOMA, V92, P290, DOI 10.1007/BF00329812; Ekwall K, 1997, CELL, V91, P1021, DOI 10.1016/S0092-8674(00)80492-4; FINNEGAN DJ, 1985, INT REV CYTOL, V93, P281, DOI 10.1016/S0074-7696(08)61376-5; FISHEL B, 1988, MOL CELL BIOL, V8, P754, DOI 10.1128/MCB.8.2.754; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GATTI M, 1994, METHOD CELL BIOL, V44, P371, DOI 10.1016/S0091-679X(08)60924-3; GATTI M, 1992, ANNU REV GENET, V26, P239, DOI 10.1146/annurev.ge.26.120192.001323; HAAF T, 1992, CELL, V70, P681, DOI 10.1016/0092-8674(92)90436-G; Harrington JJ, 1997, NAT GENET, V15, P345, DOI 10.1038/ng0497-345; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; Heller R, 1996, P NATL ACAD SCI USA, V93, P7125, DOI 10.1073/pnas.93.14.7125; HOCHSTENBACH R, 1993, CHROMOSOMA, V102, P526, DOI 10.1007/BF00368346; HSU TC, 1975, CYTOGENET CELL GENET, V15, P41, DOI 10.1159/000130497; KARPEN GH, 1992, GENETICS, V132, P737; KARPEN GH, 1990, CELL, V63, P97; Kurek R, 1996, CHROMOSOME RES, V4, P87, DOI 10.1007/BF02259701; KURENOVA EV, 1990, GENETIKA+, V26, P1701; LARIN Z, 1994, HUM MOL GENET, V3, P689, DOI 10.1093/hmg/3.5.689; LE MH, 1995, GENETICS, V141, P283; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; LOHE AR, 1993, GENETICS, V134, P1149; MITCHELL AR, 1985, CHROMOSOMA, V92, P369, DOI 10.1007/BF00327469; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; MURPHY TD, 1995, CELL, V81, P139, DOI 10.1016/0092-8674(95)90378-X; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; OHARE K, 1991, MOL GEN GENET, V225, P17, DOI 10.1007/BF00282637; OHASHI H, 1994, AM J HUM GENET, V55, P1202; PAGE SL, 1995, HUM MOL GENET, V4, P289, DOI 10.1093/hmg/4.2.289; PARDUE ML, 1986, IN SITU HYBRIDIZATIO; PIMPINELLI S, 1995, P NATL ACAD SCI USA, V92, P3804, DOI 10.1073/pnas.92.9.3804; PLUTA AF, 1995, SCIENCE, V270, P1591, DOI 10.1126/science.270.5242.1591; RATTNER JB, 1991, BIOESSAYS, V13, P51, DOI 10.1002/bies.950130202; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; RUSSO VEA, 1996, COLD SPRING HARBOR M, V32; Sacchi N, 1996, CYTOGENET CELL GENET, V73, P123, DOI 10.1159/000134322; SANDMEYER SB, 1990, ANNU REV GENET, V24, P491; SCHULMAN I, 1991, ANNU REV CELL BIOL, V7, P311, DOI 10.1146/annurev.cb.07.110191.001523; SHEVELYOV YY, 1993, MOL GEN GENET, V239, P205, DOI 10.1007/BF00281619; SNYDER MP, 1982, P NATL ACAD SCI-BIOL, V79, P7430, DOI 10.1073/pnas.79.23.7430; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; SUNKEL CE, 1995, CURR OPIN GENET DEV, V5, P756, DOI 10.1016/0959-437X(95)80008-S; TOWER J, 1993, GENETICS, V133, P347; TTALOR SS, 1996, CHROMOSOMA, V105, P70; TYLERSMITH C, 1993, NAT GENET, V5, P368, DOI 10.1038/ng1293-368; VIG BK, 1994, MUTAT RES-FUND MOL M, V309, P1, DOI 10.1016/0027-5107(94)90036-1; VOULLAIRE LE, 1993, AM J HUM GENET, V52, P1153; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; WILLIAMS B, 1998, IN PRESS NAT GENET; YUKI S, 1986, EUR J BIOCHEM, V158, P403, DOI 10.1111/j.1432-1033.1986.tb09767.x; ZINKOWSKI RP, 1991, J CELL BIOL, V113, P1091, DOI 10.1083/jcb.113.5.1091	75	209	223	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1007	1019		10.1016/S0092-8674(00)80491-2	http://dx.doi.org/10.1016/S0092-8674(00)80491-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428523	Bronze, Green Accepted			2022-12-01	WOS:000071281400017
J	Ramos, PC; Hockendorff, J; Johnson, ES; Varshavsky, A; Dohmen, RJ				Ramos, PC; Hockendorff, J; Johnson, ES; Varshavsky, A; Dohmen, RJ			Ump1p is required for proper maturation of the 20S proteasome and becomes its substrate upon completion of the assembly	CELL			English	Article							N-END RULE; YEAST SACCHAROMYCES-CEREVISIAE; PROTEIN-DEGRADATION; SHUTTLE VECTORS; UBIQUITIN; PATHWAY; SUBUNIT; ENZYME; GENE; CONSTRUCTION	We report the discovery of a short-lived chaperone that is required for the correct maturation of the eukaryotic 20S proteasome and is destroyed at a specific stage of the assembly process. The S. cerevisiae Ump1p protein is a component of proteasome precursor complexes containing unprocessed beta subunits but is not detected in the mature 20S proteasome. Upon the association of two precursor complexes, Ump1p is encased and is rapidly degraded after the proteolytic sites in the interior of the nascent proteasome are activated. Cells lacking Ump1p exhibit a lack of coordination between the processing of beta subunits and proteasome assembly, resulting in functionally impaired proteasomes. We also show that the propeptide of the PreSp/Doa3p beta subunit is required for Ump1p's function in proteasome maturation.	Univ Dusseldorf, Biotechnol Zentrallabor Inst Mikrobiol, D-40225 Dusseldorf, Germany; CALTECH, Div Biol, Pasadena, CA 91125 USA; Rockefeller Univ, Cell Biol Lab, New York, NY 10021 USA	Heinrich Heine University Dusseldorf; California Institute of Technology; Rockefeller University	Dohmen, RJ (corresponding author), Univ Dusseldorf, Biotechnol Zentrallabor Inst Mikrobiol, Univ Str 1,Geb 25-02, D-40225 Dusseldorf, Germany.		Dohmen, R. Jürgen/AAD-6649-2022	Dohmen, R. Jürgen/0000-0002-5756-6780	NIGMS NIH HHS [GM31530] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031530] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Arendt CS, 1997, P NATL ACAD SCI USA, V94, P7156, DOI 10.1073/pnas.94.14.7156; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER RT, 1995, J BIOL CHEM, V270, P12065, DOI 10.1074/jbc.270.20.12065; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; DOHMEN RJ, 1995, J BIOL CHEM, V270, P18099, DOI 10.1074/jbc.270.30.18099; DOHMEN RJ, 1994, SCIENCE, V263, P1273, DOI 10.1126/science.8122109; FISCHER M, 1994, FEBS LETT, V355, P69, DOI 10.1016/0014-5793(94)01177-X; FRENTZEL S, 1994, J MOL BIOL, V236, P975, DOI 10.1016/0022-2836(94)90003-5; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Heinemeyer W, 1997, J BIOL CHEM, V272, P25200, DOI 10.1074/jbc.272.40.25200; Hochstrasser M, 1995, COLD SPRING HARB SYM, V60, P503, DOI 10.1101/SQB.1995.060.01.054; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; HOUGH R, 1987, J BIOL CHEM, V262, P8303; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JUNGMANN J, 1993, NATURE, V361, P369, DOI 10.1038/361369a0; LIU HP, 1992, GENETICS, V132, P665; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Ramos PCR, 1995, AUST J PLANT PHYSIOL, V22, P893, DOI 10.1071/PP9950893; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; Seemuller E, 1996, NATURE, V382, P468, DOI 10.1038/382468a0; SIKORSKI RS, 1989, GENETICS, V122, P19; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687	40	241	252	0	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					489	499		10.1016/S0092-8674(00)80942-3	http://dx.doi.org/10.1016/S0092-8674(00)80942-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491890	Bronze			2022-12-01	WOS:000072251500009
J	Horton, B				Horton, B			Light in the gloom for cell biologists	NATURE			English	Article																			0	0	0	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					819	820		10.1038/35912	http://dx.doi.org/10.1038/35912			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486656				2022-12-01	WOS:000072089500062
J	den Haan, JMM; Meadows, LM; Wang, W; Pool, J; Blokland, E; Bishop, TL; Reinhardus, C; Shabanowitz, J; Offringa, R; Hunt, DF; Engelhard, VH; Goulmy, E				den Haan, JMM; Meadows, LM; Wang, W; Pool, J; Blokland, E; Bishop, TL; Reinhardus, C; Shabanowitz, J; Offringa, R; Hunt, DF; Engelhard, VH; Goulmy, E			The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism	SCIENCE			English	Article							VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; UNRELATED DONORS; LYMPHOCYTES-T; PEPTIDE; HLA; IDENTIFICATION; PROTEIN	The minor histocompatibility antigen (mHag) HA-1 is the only known mHag for which mismatching is correlated with the development of severe graft versus host disease (GVHD) after human leukocyte antigen-identical bone marrow transplantation. HA-1 was found to be a nonapeptide derived from an allele of the KIAA0223 gene. The HA-1-negative allelic counterpart encoded by KIAA0223 had one amino acid difference from HA-1. Family analysis with HA-1 allele-specific polymerase chain reaction showed an exact correlation between this allelic polymorphism and the HA-1 phenotype. HA-1 allele typing of donor and recipient should improve donor selection and allow the determination of bone marrow transplantation recipients with high risk for HA-1-induced GVHD development.	Leiden Univ, Med Ctr, Dept Immunohaematol, NL-2333 ZA Leiden, Netherlands; Leiden Univ, Med Ctr, Blood Bank, NL-2333 ZA Leiden, Netherlands; Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; Univ Virginia, Dept Microbiol, Charlottesville, VA 22901 USA; Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22901 USA; Univ Virginia, Dept Pathol, Charlottesville, VA 22901 USA	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; University of Virginia; University of Virginia; University of Virginia; University of Virginia	Goulmy, E (corresponding author), Leiden Univ, Med Ctr, Dept Immunohaematol, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.		Hunt, Donald F/I-6936-2012; den Haan, Joke MM/A-4281-2010	Hunt, Donald F/0000-0003-2815-6368; den Haan, Joke MM/0000-0002-4421-6917; Engelhard, Victor/0000-0002-1741-0925	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021393] Funding Source: NIH RePORTER; NIAID NIH HHS [AI07496, AI3393, AI21393] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEATTY PG, 1991, TRANSPLANTATION, V51, P443, DOI 10.1097/00007890-199102000-00034; COX AL, 1994, SCIENCE, V264, P716, DOI 10.1126/science.7513441; DEBUEGER M, 1992, J IMMUNOL, V149, P1788; DEBUEGER M, 1993, EUR J IMMUNOL, V23, P614, DOI 10.1002/eji.1830230305; DENHAAN JMM, 1995, SCIENCE, V268, P1476, DOI 10.1126/science.7539551; Goulmy E, 1996, NEW ENGL J MED, V334, P281, DOI 10.1056/NEJM199602013340501; GOULMY E, 1983, NATURE, V302, P159, DOI 10.1038/302159a0; LINDAHL KF, 1991, TRENDS GENET, V7, P219, DOI 10.1016/0168-9525(91)90368-Z; LOVELAND B, 1990, CELL, V60, P971, DOI 10.1016/0092-8674(90)90345-F; LOVELAND BE, 1991, ANTIGEN PROCESSING R, P173; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; MARTIN PJ, 1991, BONE MARROW TRANSPL, V8, P217; Meadows L, 1997, IMMUNITY, V6, P273, DOI 10.1016/S1074-7613(00)80330-1; Mendoza LM, 1997, IMMUNITY, V7, P461, DOI 10.1016/S1074-7613(00)80368-4; Morse MC, 1996, J IMMUNOL, V156, P3301; Ossendorp F, 1996, IMMUNITY, V5, P115, DOI 10.1016/S1074-7613(00)80488-4; Ottenhoff THM, 1997, J IMMUNOL METHODS, V200, P89, DOI 10.1016/S0022-1759(96)00190-1; RUFER N, 1997, BONE MARROW TRANS S1, V19, pS184; SCHREUDER GMT, 1993, IMMUNOGENETICS, V38, P98, DOI 10.1007/BF00190897; Tan TLR, 1997, J IMMUNOL METHODS, V205, P201, DOI 10.1016/S0022-1759(97)00086-0; TRAVERSARI C, 1992, IMMUNOGENETICS, V35, P145, DOI 10.1007/BF00185107; van Lochem E, 1996, Transpl Immunol, V4, P151, DOI 10.1016/S0966-3274(96)80009-8; VANDERHARST D, 1994, BLOOD, V83, P1060; VANELS CACM, 1992, IMMUNOGENETICS, V35, P161, DOI 10.1007/BF00185109; WANG W, 1995, SCIENCE, V269, P1588, DOI 10.1126/science.7667640	25	322	336	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1054	1057		10.1126/science.279.5353.1054	http://dx.doi.org/10.1126/science.279.5353.1054			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461441				2022-12-01	WOS:000072006400053
J	Webber, AL; Ingram, RS; Levorse, JM; Tilghman, SM				Webber, AL; Ingram, RS; Levorse, JM; Tilghman, SM			Location of enhancers is essential for the imprinting of H19 and Igf2 genes	NATURE			English	Article							BETA-GLOBIN; MOUSE; METHYLATION; MICE; EXPRESSION; BOUNDARIES; DELETION; DOMAINS; ALLELE; ASSAY	Genomic imprinting is the process in mammals by which gamete-specific epigenetic modifications establish the differential expression of the two alleles of a gene, The tightly linked H19 and Igf2 genes are expressed in tissues of endodermal and mesodermal origin, with H19 expressed from the maternal chromosome and Igf2 expressed from the paternal chromosome, A model has been proposed to explain the reciprocal imprinting of these genes(1); in this model, expression of the genes is governed by competition between their promoters for a common set of enhancers. An extra set of enhancers might be predicted to relieve the competition, thereby eliminating imprinting, Here we tested this prediction by generating mice with a duplication of the endoderm-specific enhancers, The normally silent Igf2 gene on the maternal chromosome was expressed in liver, consistent with relief from competition. We then generated a maternal chromosome containing a single set of enhancers located equidistant from Igf2 and H19; the direction of the imprint was reversed, Thus, the location of the enhancers determines the outcome of competition in liver, and the strength of the H19 promoter is not sufficient to silence Igf2.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bartolomei M.S., 1992, SEMIN DEV BIOL, V3, P107; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; BRUNKOW ME, 1991, GENE DEV, V5, P1092, DOI 10.1101/gad.5.6.1092; CHOI ORB, 1988, CELL, V55, P17, DOI 10.1016/0092-8674(88)90005-0; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; FEIL R, 1994, DEVELOPMENT, V120, P2933; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; JOHNSON KA, 1995, NUCLEIC ACIDS RES, V23, P1273, DOI 10.1093/nar/23.7.1273; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KELLUM R, 1992, MOL CELL BIOL, V12, P2424, DOI 10.1128/MCB.12.5.2424; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Lyko F, 1997, NAT GENET, V16, P171, DOI 10.1038/ng0697-171; MCCARRICK JW, 1993, TRANSGENIC RES, V2, P183, DOI 10.1007/BF01977348; NICKOL JM, 1988, P NATL ACAD SCI USA, V85, P2548, DOI 10.1073/pnas.85.8.2548; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SAUER B, 1990, New Biologist, V2, P441; Walter J., 1996, Epigenetic mechanisms of gene regulation., P195; YOOWARREN H, 1988, MOL CELL BIOL, V8, P4707, DOI 10.1128/MCB.8.11.4707	28	110	116	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	1998	391	6668					711	715		10.1038/35655	http://dx.doi.org/10.1038/35655			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490417				2022-12-01	WOS:000071982500057
J	Kim, JJ; Krupa, DJ; Thompson, RF				Kim, JJ; Krupa, DJ; Thompson, RF			Inhibitory cerebello-olivary projections and blocking effect in classical conditioning	SCIENCE			English	Article							NICTITATING-MEMBRANE RESPONSE; INFERIOR OLIVE; US LOCUS; LESIONS; RABBIT; RAT; ACQUISITION; EYEBLINK; STIMULI; CAT	The behavioral phenomenon of blocking indicates that the informational relationship between the conditioned stimulus and the unconditioned stimulus is essential in classical conditioning. The eyeblink conditioning paradigm is used to describe a neural mechanism that mediates blocking, Disrupting inhibition of the inferior olive, a structure that conveys unconditioned stimulus information (airpuff) to the cerebellum prevented blocking in rabbits. Recordings of cerebellar neuronal activity show that the inferior olive input to the cerebellum becomes suppressed as learning occurs. These results suggest that the inferior olive becomes functionally inhibited by the cerebellum during conditioning, and that this negative feedback process might be the neural mechanism mediating blocking.	Univ So Calif, Neurosci Program, Los Angeles, CA 90089 USA	University of Southern California	Kim, JJ (corresponding author), Yale Univ, Dept Psychol, 2 Hillhouse Ave, New Haven, CT 06520 USA.	jeansok.kim@yale.edu			ACF HHS [AF05142] Funding Source: Medline	ACF HHS		ANDERSON G, 1988, BRAIN RES, V472, P450; ANGAUT P, 1987, NEUROSCI LETT, V83, P227, DOI 10.1016/0304-3940(87)90090-5; ANGAUT P, 1989, BRAIN RES, V479, P361, DOI 10.1016/0006-8993(89)91641-7; Angaut P, 1996, NEUROSCI RES, V26, P345, DOI 10.1016/S0168-0102(96)01116-9; Betts SL, 1996, ANIM LEARN BEHAV, V24, P459, DOI 10.3758/BF03199017; DICKINSON A, 1979, J EXP PSYCHOL ANIM B, V5, P162, DOI 10.1037/0097-7403.5.2.162; DONEGAN NH, 1989, COMPUTATIONAL MODELS, P108; FREDETTE BJ, 1991, ANAT EMBRYOL, V184, P225, DOI 10.1007/BF01673258; GIBSON AR, 1987, J COMP NEUROL, V260, P362, DOI 10.1002/cne.902600304; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; HAWKINS RD, 1984, PSYCHOL REV, V91, P375, DOI 10.1037/0033-295X.91.3.375; Hesslow G, 1996, EXP BRAIN RES, V110, P36; Kamin L.J., 1968, MIAMI S PREDICTION B, P9; Katz DB, 1997, LEARN MEMORY, V4, P88, DOI 10.1101/lm.4.1.88; Kim JJ, 1997, TRENDS NEUROSCI, V20, P177, DOI 10.1016/S0166-2236(96)10081-3; MACKINTOSH NJ, 1975, PSYCHOL REV, V82, P276, DOI 10.1037/h0076778; MARCHANT HG, 1973, J EXP PSYCHOL, V101, P155; MAUK MD, 1986, P NATL ACAD SCI USA, V83, P5349, DOI 10.1073/pnas.83.14.5349; MCCORMICK DA, 1985, BRAIN RES, V359, P120, DOI 10.1016/0006-8993(85)91419-2; MOORE JW, 1997, LEARN MEM COLD SPRIN, V3, P116; Rescorla R.A., 1972, CLASSICAL CONDITION, P64, DOI [10.1177/0269881120954052, DOI 10.1177/0269881120954052, DOI 10.1101/GR.110528.110]; RESCORLA RA, 1988, ANNU REV NEUROSCI, V11, P329, DOI 10.1146/annurev.ne.11.030188.001553; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHULTZ W, 1993, J NEUROSCI, V13, P900; SEARS LL, 1991, BRAIN RES, V545, P114, DOI 10.1016/0006-8993(91)91276-7; STICKNEY KJ, 1983, ANIM LEARN BEHAV, V11, P60, DOI 10.3758/BF03212308; THOMPSON RF, 1986, SCIENCE, V233, P941, DOI 10.1126/science.3738519; TURKER KS, 1984, BRAIN RES BULL, V13, P229, DOI 10.1016/0361-9230(84)90121-7; TURKER KS, 1986, BRAIN RES, V363, P376; VONEIDA TJ, 1990, J NEUROSCI, V10, P3583; Wagner A.R., 1981, P5; WAGNER AR, 1989, PSYCHOL LEARN MOTIV, V23, P157; YEO CH, 1991, ANN NY ACAD SCI, V627, P292; YEO CH, 1986, EXP BRAIN RES, V63, P81	34	154	156	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					570	573		10.1126/science.279.5350.570	http://dx.doi.org/10.1126/science.279.5350.570			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YT527	9438852				2022-12-01	WOS:000071616000049
J	Maley, LE; Marshall, CR				Maley, LE; Marshall, CR			Evolution - The coming of age of molecular systematics	SCIENCE			English	Article							RIBOSOMAL-RNA; PHYLOGENY; PARSIMONY		Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Maley, LE (corresponding author), Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA.							Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Balavoine G, 1997, CR ACAD SCI III-VIE, V320, P83, DOI 10.1016/S0764-4469(99)80090-0; Carranza S, 1997, MOL BIOL EVOL, V14, P485, DOI 10.1093/oxfordjournals.molbev.a025785; DEQUEIROZ A, 1995, ANNU REV ECOL SYST, V26, P657, DOI 10.1146/annurev.es.26.110195.003301; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Felsenstein J, 1996, MOL BIOL EVOL, V13, P93, DOI 10.1093/oxfordjournals.molbev.a025575; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; HENDY MD, 1989, SYST ZOOL, V38, P297, DOI 10.2307/2992396; Huelsenbeck JP, 1997, SCIENCE, V276, P227, DOI 10.1126/science.276.5310.227; Kim JH, 1996, SYST BIOL, V45, P363, DOI 10.2307/2413570; LECOINTRE G, 1993, MOL PHYLOGENET EVOL, V2, P205, DOI 10.1006/mpev.1993.1021; Mackey LY, 1996, J MOL EVOL, V42, P552, DOI 10.1007/BF02352285; MALANYCH KM, 1995, SCIENCE, V267, P1641; MARSHALL CR, 1997, COMP SCI STAT, V29, P218; Morris SC, 1997, CURR BIOL, V7, pR71, DOI 10.1016/S0960-9822(06)00039-X; PHILIPPE H, 1994, DEVELOPMENT, P15; Siddall ME, 1995, J PARASITOL, V81, P961, DOI 10.2307/3284049; SULLIVAN J, 1995, MOL BIOL EVOL, V12, P988; TELFORD MJ, 1993, MOL BIOL EVOL, V10, P660; TURBEVILLE JM, 1994, MOL BIOL EVOL, V11, P648; VANDEPEER Y, 1993, J MOL EVOL, V37, P221, DOI 10.1007/BF02407359	21	56	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					505	506		10.1126/science.279.5350.505	http://dx.doi.org/10.1126/science.279.5350.505			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9454349				2022-12-01	WOS:000071616000031
J	Iacoviello, L; Di Castelnuovo, A; de Knijff, P; D'Orazio, A; Amore, C; Arboretti, R; Kluft, C; Donati, MB				Iacoviello, L; Di Castelnuovo, A; de Knijff, P; D'Orazio, A; Amore, C; Arboretti, R; Kluft, C; Donati, MB			Polymorphism in the coagulation factor VII gene and the risk of myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; REPEAT POLYMORPHISM; HEMOSTATIC FUNCTION; HEALTHY-MEN; F7; IDENTIFICATION; FIBRINOGEN; MUTATION; ANTIGEN; REGION	Background High blood levels of coagulation factor VII are associated with a risk of ischemic vascular disease. Although factor VI levels may be genetically determined, the relation between genetic polymorphisms of factor VII, factor VII blood levels, and the risk of myocardial infarction has not been established. Methods We performed a case-control study of 165 patients with familiar myocardial infarction (mean [+/-SD] age, 55+/-9 years) and 225 controls without a personal or family history of cardiovascular disease (mean age, 56+/-8 years). The polymorphisms involving R353Q and hypervariable region 4 of the factor VI gene were studied. Factor VII clotting activity and antigen levels were also measured. Results Patients with the QQ or H7H7 genotype had a decreased risk of myocardia[ infarction (odds ratios, 0.08 [95 percent confidence interval, 0.01 to 0.9] and 0.22 [95 percent confidence interval, 0.08 to 0.63], respectively). For the R353Q polymorphism, the RR genotype was associated with the highest risk, followed by the RQ genotype and then by the QQ genotype (P<0.001). For the polymorphism involving hypervariable region 4, the combined H7H5 and H6H5 genotypes were associated with the highest risk, followed in descending order by the H6H6, H6H7, and H7H7 genotypes (P<0.001). Patients with the OQ or H7H7 genotype had lower levels of both factor VI[ antigen and factor VII clotting activity than those with the RR or H6H6 genotype. Patients with the fewest level of factor VII clotting activity had a lower risk of myocardial infarction than those with the highest level (odds ratio, 0.13; 95 percent confidence interval, 0.05 to 0.34). Conclusions Our findings suggest that certain polymorphisms of the factor VII gene may influence the risk of myocardial infarction. It is possible that this effect may be mediated by alterations in factor VII levels. (C) 1998. Massachusetts Medical Society.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud,Dept Vasc Med & Pharm, Angela Valenti Lab Thrombosis Pharmacol, Unit Genet Vasc Risk Factors, I-66030 Santa Maria Imbaro, Italy; Ist Ric Farmacol Mario Negri, Dept Clin Pharmacol & Epidemiol, Lab Drug Epidemiol, I-66030 Santa Maria Imbaro, Italy; Leiden Univ, Gaubius Lab, Leiden, Netherlands; Leiden Univ, Dept Human Genet, Ctr Genet Med, NL-2300 RA Leiden, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC	Iacoviello, L (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud,Dept Vasc Med & Pharm, Angela Valenti Lab Thrombosis Pharmacol, Unit Genet Vasc Risk Factors, I-66030 Santa Maria Imbaro, Italy.		Arboretti, Rosa/AAY-6499-2020; Donati, Maria Benedetta/K-6606-2016; Siani, Alfonso/B-7925-2015; Iacoviello, Licia/K-4676-2016; Di Castelnuovo, Augusto Filippo/AAC-2436-2022; de Knijff, Peter/Y-2519-2018; Iacoviello, Licia/AGX-7071-2022	Donati, Maria Benedetta/0000-0003-1747-5443; Iacoviello, Licia/0000-0003-0514-5885; Di Castelnuovo, Augusto Filippo/0000-0001-9767-7998; de Knijff, Peter/0000-0002-0899-771X; Iacoviello, Licia/0000-0003-0514-5885; ARBORETTI GIANCRISTOFARO, ROSA/0000-0003-1263-0440				[Anonymous], 1990, LANCET, V336, P65; BALLEISEN L, 1985, THROMB HAEMOSTASIS, V54, P475; BERNARDI F, 1993, HUM GENET, V92, P446, DOI 10.1007/BF00216448; Bernardi F, 1996, ARTERIOSCL THROM VAS, V16, P72; CORTELLARO M, 1992, ARTERIOSCLER THROMB, V12, P1063, DOI 10.1161/01.ATV.12.9.1063; DEKNIJFF P, 1994, HUM MOL GENET, V3, P384; deMaat MPM, 1997, ARTERIOSCL THROM VAS, V17, P1918, DOI 10.1161/01.ATV.17.10.1918; DICASTELNUOVO A, 1997, THROMB HAEMOST S, V77, P390; GREEN F, 1991, ARTERIOSCLER THROMB, V11, P540, DOI 10.1161/01.ATV.11.3.540; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P1392; Heywood DM, 1997, STROKE, V28, P816, DOI 10.1161/01.STR.28.4.816; HOFFMAN CJ, 1992, ARTERIOSCLER THROMB, V12, P267, DOI 10.1161/01.ATV.12.3.267; HUMPHRIES SE, 1994, ARTERIOSCLER THROMB, V14, P193, DOI 10.1161/01.ATV.14.2.193; Lane A, 1996, ATHEROSCLEROSIS, V119, P119, DOI 10.1016/0021-9150(95)05638-6; MARCHETTI G, 1992, HUM GENET, V89, P497; MARCHETTI G, 1991, NUCLEIC ACIDS RES, V19, P4570, DOI 10.1093/nar/19.16.4570-a; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; RONCAGLIONI MC, 1992, CIRCULATION, V85, P2065, DOI 10.1161/01.CIR.85.6.2065; *SAS I, 1989, SAS STAT US GUID VER; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; TERWILLINGER JD, 1994, HDB HUMAN GENETIC LI, P278; VAZIRI ND, 1992, AM J MED, V93, P651, DOI 10.1016/0002-9343(92)90198-K; Wang XL, 1997, ARTERIOSCL THROM VAS, V17, P246, DOI 10.1161/01.ATV.17.2.246; ZOLLER B, 1994, J CLIN INVEST, V94, P2521, DOI 10.1172/JCI117623; 1989, INT J EPIDEMIOL S1, V18, pS1	28	264	277	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					79	85		10.1056/NEJM199801083380202	http://dx.doi.org/10.1056/NEJM199801083380202			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420338				2022-12-01	WOS:000071341300002
J	Leeuw, T; Wu, CL; Schrag, JD; Whiteway, M; Thomas, DY; Leberer, E				Leeuw, T; Wu, CL; Schrag, JD; Whiteway, M; Thomas, DY; Leberer, E			Interaction of a G-protein beta-subunit with a conserved sequence in Ste20/PAK family protein kinases	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PHEROMONE RESPONSE; GAMMA-SUBUNITS; YEAST; PHOSPHORYLATION; ASSOCIATION; FAR1	Serine/threonine protein kinases of the Ste20/PAK family have been implicated in the signalling from heterotrimeric G proteins to mitogen-activated protein (MAP) kinase cascades(1,2). in the yeast Saccharomyces cerevisiae, Ste20 is involved in transmitting the mating-pheromone signal from the beta gamma-subunits (encoded by the STE4 and STE18 genes, respectively) of a heterotrimeric G protein to a downstream MAP kinase cascade(1). We have identified a binding site for the G-protein beta-subunit (G beta) in the non-catalytic carboxy-terminal regions of Ste20 and its mammalian homologues, the p21-activated protein kinases (PAKs). Association of G beta with this site in Ste20 was regulated by binding of pheromone to the receptor. Mutations in G beta and Ste20 that prevented this association blocked activation of the MAP kinase cascade. Considering the high degree of structural and functional conservation of Ste20/PAK family members and G-protein subunits, our results provide a possible model for a role of these kinases in G beta gamma-mediated signal transduction in organisms ranging from yeast to mammals.	Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, Montreal, PQ H4P 2R2, Canada; Natl Res Council Canada, Biotechnol Res Inst, Macromol Struct Grp, Montreal, PQ H4P 2R2, Canada; McGill Univ, Dept Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 2B2, Canada	National Research Council Canada; National Research Council Canada; McGill University; McGill University; McGill University	Leberer, E (corresponding author), Natl Res Council Canada, Biotechnol Res Inst, Eukaryot Genet Grp, 6100 Royalmount Ave, Montreal, PQ H4P 2R2, Canada.	Ekkehard.Leberer@nrc.ca	Thomas, David/M-7661-2017	Thomas, David/0000-0002-8854-762X				BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; CHANG F, 1992, MOL BIOL CELL, V3, P445, DOI 10.1091/mbc.3.4.445; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEBERER E, 1993, MOL GEN GENET, V241, P241, DOI 10.1007/BF00284675; LEBERER E, 1992, EMBO J, V11, P4805, DOI 10.1002/j.1460-2075.1992.tb05586.x; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LEEUW T, 1995, SCIENCE, V270, P1210, DOI 10.1126/science.270.5239.1210; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; SIKORSKI RS, 1989, GENETICS, V122, P19; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WHITEWAY MS, 1995, SCIENCE, V269, P1572, DOI 10.1126/science.7667635; WU CL, 1995, J BIOL CHEM, V270, P15984, DOI 10.1074/jbc.270.27.15984; Wu CL, 1996, J BIOL CHEM, V271, P31787, DOI 10.1074/jbc.271.50.31787	20	179	180	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					191	195		10.1038/34448	http://dx.doi.org/10.1038/34448			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428767				2022-12-01	WOS:000071380900055
J	McDonagh, TA; Robb, SD; Murdoch, DR; Morton, JJ; Ford, I; Morrison, CE; Tunstall-Pedoe, H; McMurray, JJV; Dargie, HJ				McDonagh, TA; Robb, SD; Murdoch, DR; Morton, JJ; Ford, I; Morrison, CE; Tunstall-Pedoe, H; McMurray, JJV; Dargie, HJ			Biochemical detection of left-ventricular systolic dysfunction	LANCET			English	Article							BRAIN NATRIURETIC PEPTIDE; ACUTE MYOCARDIAL-INFARCTION; HEART-FAILURE; IN-VITRO; ECHOCARDIOGRAPHY; COMMUNITY; INDICATOR; ACCURACY	Background In previous studies on the use of natriuretic peptides to detect left-ventricular systolic dysfunction, a higher rate of cardiac disorders in the control groups than in the study groups could have led to bias. We investigated the effectiveness of plasma N-terminal atrial natriuretic peptide (NT-ANP) and brain natriuretic peptide (BNP) concentrations to show left-ventricular systolic dysfunction in a random sample of the general population. Methods We randomly selected 2000 participants aged 25-74 years from family physicians' lists in Glasgow, UK. We sent all participants questionnaires, 1653 respondents underwent echocardiography and electrocardiography. We took a left-ventricular ejection fraction of 30% or less to show left-ventricular systolic dysfunction. NT-ANP and BNP were measured in plasma by RIAs. Findings 1252 participants had analysable electrocardiograms and echocardiograms, completed available blood samples. Median and BNP were significantly higher in participants with left-ventricular systolic dysfunction (2.8 ng/mL [IQR 1.8-4.6] and 24.0 pg/mL [18.0-33.0]) than in those without (1.3 ng/mL [0.9-1.8] and 7.7 pg/mL [3.4-13.0]; each p<0.001). Among participants with left-ventricular systolic dysfunction, both symptomatic and asymptomatic subgroups had raised NT-ANP and BNP concentrations, A BNP concentration of 17.9 pg/mL or more gave a sensitivity of 77% and specificity of 87% in all participants, and 92% and 72% in participants aged 55 years or older, NT-ANP Interpretation Measurement of BNP could be a cost-effective method of screening for left-ventricular systolic dysfunction in the general population, especially if its use were targeted to individuals at high risk.	Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, MRC, Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland; Glasgow Royal Infirm, Scottish Monica Project, Glasgow, Lanark, Scotland; Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; University of Glasgow; University of Glasgow; University of Glasgow	McDonagh, TA (corresponding author), Univ Glasgow, Western Infirm, Dept Cardiol, Glasgow G11 6NT, Lanark, Scotland.		mcmurray, John/B-2467-2013; Ford, Ian/ABE-6145-2020	mcmurray, John/0000-0002-6317-3975; 				CHOY AMJ, 1994, BRIT HEART J, V72, P16; DAVIDSON NC, 1995, CIRCULATION, V91, P1276; DAVIS M, 1994, LANCET, V343, P40; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; FRANCIS GS, 1990, CIRCULATION, V82, P1724, DOI 10.1161/01.CIR.82.5.1724; GLENBOTSKI CC, 1988, J BIOL CHEM, V263, P16073; HALL C, 1995, CIRCULATION, V91, P911; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HEUBLEIN D M, 1989, Journal of the American College of Cardiology, V13, p9A; Jacobsen SJ, 1996, ARCH INTERN MED, V156, P2462, DOI 10.1001/archinte.156.21.2462; LAND CC, 1991, J HYPERTENS, V9, P779; LERMAN A, 1993, LANCET, V341, P1105, DOI 10.1016/0140-6736(93)93125-K; McDonagh TA, 1997, LANCET, V350, P829, DOI 10.1016/S0140-6736(97)03033-X; MCKEE PA, 1971, NEW ENGL J MED, V285, P781; MOTWANI JG, 1993, LANCET, V341, P1109, DOI 10.1016/0140-6736(93)93126-L; NICKLAS JM, 1992, NEW ENGL J MED, V327, P685; Omland T, 1996, CIRCULATION, V93, P1963, DOI 10.1161/01.CIR.93.11.1963; Omland T, 1996, HEART, V76, P232, DOI 10.1136/hrt.76.3.232; ROSE GA, WHO MONOGRAPH SERIES, V56; SCHILLER NB, 1979, CIRCULATION, V60, P547, DOI 10.1161/01.CIR.60.3.547; SUNDSFJORD JA, 1988, J CLIN ENDOCR METAB, V66, P605, DOI 10.1210/jcem-66-3-605; SWEDBERG K, 1987, NEW ENGL J MED, V316, P1429; SWETS JA, 1991, MED DECIS MAKING, V11, P9, DOI 10.1177/0272989X9101100102; WEI CM, 1993, CIRCULATION, V88, P1004, DOI 10.1161/01.CIR.88.3.1004; WHEELDON NM, 1993, Q J MED, V86, P17; YAMAMOTO K, 1996, J AM COLL CARDIOL A, V69, P723; YUSUF S, 1991, NEW ENGL J MED, V325, P293, DOI 10.1056/NEJM199108013250501	27	801	862	2	18	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					9	13		10.1016/S0140-6736(97)03034-1	http://dx.doi.org/10.1016/S0140-6736(97)03034-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433422				2022-12-01	WOS:000071253100009
J	Majeti, R; Bilwes, AM; Noel, JP; Hunter, T; Weiss, A				Majeti, R; Bilwes, AM; Noel, JP; Hunter, T; Weiss, A			Dimerization-induced inhibition of receptor protein tyrosine phosphatase function through an inhibitory wedge	SCIENCE			English	Article							CELL ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; CD45; PHOSPHORYLATION; KINASES; MATURATION; ACTIVATION; EXPRESSION; MICE	The function and regulation of the receptorlike transmembrane protein tyrosine phosphatases (RPTPs) are not well understood. Ligand-induced dimerization inhibited the function of the epidermal growth factor receptor (EGFR)-RPTP CD45 chimera (EGFR-CD45) in T cell signal transduction. Properties of mutated EGFR-CD45 chimeras supported a general model for the regulation of RPTPs, derived from the crystal structure of the RPTP alpha membrane-proximal phosphatase domain, The phosphatase domain apparently forms a symmetrical dimer in which the catalytic site of one molecule is blocked by specific contacts with a wedge from the other.	Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, Biomed Sci Grad Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Mol Biol & Virol Lab, La Jolla, CA 92037 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Salk Institute; Salk Institute	Weiss, A (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, Biomed Sci Grad Program, San Francisco, CA 94143 USA.		Noel, Joseph P/A-9459-2009	Bilwes Crane, Alexandrine/0000-0001-9922-0692				Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; DESAI DM, 1994, EMBO J, V13, P4002, DOI 10.1002/j.1460-2075.1994.tb06716.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; KISHIHARA K, 1993, CELL, V74, P143, DOI 10.1016/0092-8674(93)90302-7; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LEDBETTER JA, 1991, J IMMUNOL, V146, P1577; MARVEL J, 1991, EUR J IMMUNOL, V21, P195, DOI 10.1002/eji.1830210129; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MITTLER RS, 1994, J IMMUNOL, V153, P84; MOUREY RJ, 1994, CURR OPIN GENET DEV, V4, P31, DOI 10.1016/0959-437X(94)90088-4; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; TAKEDA A, 1992, J BIOL CHEM, V267, P16651; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4	23	211	220	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					88	91		10.1126/science.279.5347.88	http://dx.doi.org/10.1126/science.279.5347.88			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417031				2022-12-01	WOS:000071323900046
J	Harlow, T				Harlow, T			Do overweight people remove their shoes before being weighed by a doctor? Consecutive study of patients in general practice	BRITISH MEDICAL JOURNAL			English	Article									Coll Surg, Cullompton EX15 1TG, Devon, England		Harlow, T (corresponding author), Coll Surg, Cullompton EX15 1TG, Devon, England.								0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1663	1663		10.1136/bmj.315.7123.1663	http://dx.doi.org/10.1136/bmj.315.7123.1663			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448534	Green Published			2022-12-01	WOS:000071149400018
J	IkeshimaKataoka, H; Skeath, JB; Nabeshima, Y; Doe, CQ; Matsuzaki, F				IkeshimaKataoka, H; Skeath, JB; Nabeshima, Y; Doe, CQ; Matsuzaki, F			Miranda directs Prospero to a daughter cell during Drosophila asymmetric divisions	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; GANGLION MOTHER CELLS; GENE; PROTEIN; NUMB; EXPRESSION; FATES; SEGREGATION; MARKERS	Asymmetric cell division is a general process used in many developmental contexts to create two differently fated cells from a single progenitor cell. Intrinsic mechanisms like the asymmetric transmission of tell-fate determinants during cell division, and extrinsic cell-interaction mechanisms, can mediate asymmetric divisions(1-3). During embryonic development of the Drosophila central nervous system, neural stem cells called neuroblasts divide asymmetrically to produce another multipotent neuroblast and a ganglion mother cell (GMC) of more restricted developmental potential. Intrinsic mechanisms promote asymmetric division of neuroblasts: for example, the transcription factor Prospero localizes to the basal cell cortex of mitotic neuroblasts and then segregates exclusively into the GMC, which buds off from the basal side of the neuroblast(4-6). In the GMC, Prospero translocates to the nucleus, where it establishes differential gene expression between sibling cells. Here we report the identification of a gene, miranda, which encodes a new protein that co-localizes with Prospero in mitotic neuroblasts, tethers Prospero to the basal cortex of mitotic neuroblasts, directing Prospero into the GMC, and releases Prospero from the cell cortex within GMCs. miranda thus creates intrinsic differences between sibling cells by mediating the asymmetric segregation of a transcription factor into only one daughter cell during neural stem-cell division.	NATL CTR NEUROL & PSYCHIAT,NATL INST NEUROSCI,DEPT MOL GENET,KODAIRA,TOKYO 187,JAPAN; WASHINGTON UNIV,SCH MED,DEPT GENET,ST LOUIS,MO 63110; UNIV ILLINOIS,HOWARD HUGHES MED INST,URBANA,IL 61801; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	National Center for Neurology & Psychiatry - Japan; Washington University (WUSTL); Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign								BRAND AH, 1993, DEVELOPMENT, V118, P401; BROADUS J, 1995, MECH DEVELOP, V53, P393, DOI 10.1016/0925-4773(95)00454-8; CamposOrtega JA, 1996, NEURON, V17, P1, DOI 10.1016/S0896-6273(00)80274-3; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; DOE CQ, 1988, NATURE, V333, P376, DOI 10.1038/333376a0; DOE CQ, 1988, SCIENCE, V239, P170, DOI 10.1126/science.2892267; DOE CQ, 1992, DEVELOPMENT, V116, P855; EATON S, 1995, CELL, V82, P5, DOI 10.1016/0092-8674(95)90045-4; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JAN YN, 1995, NEURON, V14, P1; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; OTOUSA JE, 1989, J NEUROGENET, V6, P41, DOI 10.3109/01677068909107099; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; UEMERA T, 1989, CELL, V5, P349; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; VINCENT JP, 1994, DEV BIOL, V164, P328, DOI 10.1006/dbio.1994.1203	23	258	262	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					625	629		10.1038/37641	http://dx.doi.org/10.1038/37641			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403694				2022-12-01	WOS:A1997YK85300054
J	Welch, HG; Black, WC				Welch, HG; Black, WC			Using autopsy series to estimate the disease ''reservoir'' for ductal carcinoma in situ of the breast: How much more breast cancer can we find?	ANNALS OF INTERNAL MEDICINE			English	Review							IN-SITU; EPIDEMIOLOGIC NECROPSY; LESIONS; MAMMOGRAPHY; PREVALENCE; WOMEN; RADIOLOGISTS; VARIABILITY; THERAPY; BENIGN	Purpose: To determine how many cases of breast cancer might be found if women not known to have the disease were thoroughly examined (the disease ''reservoir''). Data Sources: MEDLINE search from 1966 to the present. Study Selection: Hospital-based and forensic autopsy series examining women not known to have had breast cancer during life. Data Extraction: Observed prevalence of occult invasive breast cancer or ductal carcinoma in situ (DCIS) in which the number of women who were given a diagnosis was the numerator and the number of women examined was the denominator. For each autopsy series, we attempted to ascertain the level of scrutiny (sampling method, number of slides examined) given to the pathologic specimens. Data Synthesis: Among seven autopsy series of women not known to have had breast cancer during life, the median prevalence of invasive breast cancer was 1.3% (range, 0% to 1.8%) and the median prevalence of DCIS was 8.9% (range, 0% to 14.7%). Prevalences were higher among women likely to have been screened (that is, women 40 to 70 years of age). The mean number of slides examined per breast ranged from 9 to 275; series that reported higher levels of scrutiny tended to discover more cases of cancer. Conclusions: A substantial reservoir of DCIS is undetected during life. How hard pathologists look for the disease and, perhaps, their threshold for making the diagnosis are potentially important factors in determining how many cases of DCIS are diagnosed. The latter has important implications for what it means to have the disease.	DARTMOUTH COLL SCH MED, CTR EVALUAT CLIN SCI, HANOVER, NH 03755 USA; DARTMOUTH HITCHCOCK MED CTR, LEBANON, NH 03766 USA	Dartmouth College; Dartmouth College	Welch, HG (corresponding author), DEPT VET AFFAIRS MED CTR, VA OUTCOMES GRP 111B, WHITE RIVER JCT, VT 05009 USA.							ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Beam CA, 1996, ARCH INTERN MED, V156, P209, DOI 10.1001/archinte.156.2.209; BHATHAL PS, 1985, BRIT J CANCER, V51, P271, DOI 10.1038/bjc.1985.39; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; CHAN CK, 1989, INT J EPIDEMIOL, V18, P315, DOI 10.1093/ije/18.2.315; ELMORE JG, 1994, NEW ENGL J MED, V331, P1493, DOI 10.1056/NEJM199412013312206; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; FISHER B, 1993, NEW ENGL J MED, V328, P1581, DOI 10.1056/NEJM199306033282201; Foucar E, 1996, LANCET, V347, P707, DOI 10.1016/S0140-6736(96)90073-2; HARRIS JR, 1992, NEW ENGL J MED, V327, P390, DOI 10.1056/NEJM199208063270606; JATOI I, 1995, SURGERY, V118, P118, DOI 10.1016/S0039-6060(05)80019-4; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KETCHAM AS, 1990, CANCER, V65, P387, DOI 10.1002/1097-0142(19900201)65:3<387::AID-CNCR2820650302>3.0.CO;2-Y; KRAMER WM, 1973, CANCER, V31, P130, DOI 10.1002/1097-0142(197301)31:1<130::AID-CNCR2820310117>3.0.CO;2-N; MCFARLANE MJ, 1987, JAMA-J AM MED ASSOC, V258, P331, DOI 10.1001/jama.258.3.331; NIELSEN M, 1984, CANCER-AM CANCER SOC, V54, P612, DOI 10.1002/1097-0142(1984)54:4<612::AID-CNCR2820540403>3.0.CO;2-B; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; PAGE DL, 1982, CANCER, V49, P751, DOI 10.1002/1097-0142(19820215)49:4<751::AID-CNCR2820490426>3.0.CO;2-Y; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; POLLEI SR, 1987, RADIOLOGY, V163, P459, DOI 10.1148/radiology.163.2.3562827; ROSAI J, 1991, AM J SURG PATHOL, V15, P209, DOI 10.1097/00000478-199103000-00001; SCHNITT SJ, 1992, AM J SURG PATHOL, V16, P1133, DOI 10.1097/00000478-199212000-00001; Schwartz G F, 1994, Oncology (Williston Park), V8, P21; SEIDMAN H, 1985, CA-CANCER J CLIN, V35, P36, DOI 10.3322/canjclin.35.1.36; SHAPIRO S, 1991, J NATL CANCER I, V83, P1522, DOI 10.1093/jnci/83.21.1522; SIMONOVIS NJ, 1991, AM J EPIDEMIOL, V133, P922, DOI 10.1093/oxfordjournals.aje.a115971; STACEYCLEAR A, 1992, LANCET, V340, P991; WELLINGS SR, 1975, J NATL CANCER I, V55, P231; WHITE E, 1990, J NATL CANCER I, V82, P1546, DOI 10.1093/jnci/82.19.1546	31	230	232	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1023	1028		10.7326/0003-4819-127-11-199712010-00014	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00014			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412284				2022-12-01	WOS:A1997YJ08000010
J	Berga, SL				Berga, SL			Understanding premenstrual syndrome	LANCET			English	Editorial Material							PROGESTERONE		Univ Pittsburgh, Magee Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Sci, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Magee Womens Hosp, Dept Psychiat, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Berga, SL (corresponding author), Univ Pittsburgh, Magee Womens Hosp, Sch Med,Dept Obstet Gynecol & Reprod Sci, Div Reprod Endocrinol, Pittsburgh, PA 15213 USA.							FREEMAN E, 1990, JAMA-J AM MED ASSOC, V264, P349; FREEMAN EW, 1995, JAMA-J AM MED ASSOC, V274, P51, DOI 10.1001/jama.274.1.51; Rapkin AJ, 1997, OBSTET GYNECOL, V90, P709, DOI 10.1016/S0029-7844(97)00417-1; Reddy DS, 1997, BRAIN RES, V752, P61, DOI 10.1016/S0006-8993(96)01447-3; Rupprecht R, 1997, J PSYCHIATR RES, V31, P297, DOI 10.1016/S0022-3956(96)00060-X; Schmidt PJ, 1998, NEW ENGL J MED, V338, P209, DOI 10.1056/NEJM199801223380401; STEINER M, 1995, NEW ENGL J MED, V332, P1529, DOI 10.1056/NEJM199506083322301; YONKERS KA, 1997, JAMA-J AM MED ASSOC, V278, P1024	8	13	14	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					465	466		10.1016/S0140-6736(05)78679-7	http://dx.doi.org/10.1016/S0140-6736(05)78679-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482435				2022-12-01	WOS:000072097700006
J	Yuen, KY; Chan, PKS; Peiris, M; Tsang, DNC; Que, TL; Shortridge, KF; Cheung, PT; To, WK; Ho, ETF; Sung, R; Cheng, AFB				Yuen, KY; Chan, PKS; Peiris, M; Tsang, DNC; Que, TL; Shortridge, KF; Cheung, PT; To, WK; Ho, ETF; Sung, R; Cheng, AFB		H5N1 study grp	Clinical features and rapid viral diagnosis of human disease associated with avian influenza A H5N1 virus	LANCET			English	Article							IMMUNOGLOBULIN	Background Human infection with an avian influenza A virus (subtype H5N1) was reported recently in Hong Kong. We describe the clinical presentation of the first 12 patients and options for rapid viral diagnosis. Methods Case notes of 12 patients with virus-culture-confirmed influenza A H5N1 infection were analysed. The clinical presentation and risk factors associated with severe disease were defined and the results of methods for rapid virus diagnosis were compared. Findings Patients ranged from 1 to 60 years of age. Clinical presentation was that of an influenza-like illness with evidence of pneumonia in seven patients. All seven patients older than 13 years had severe disease (four deaths), whereas children 5 years or younger had mild symptoms with the exception of one who died with Reye's syndrome associated with intake of aspirin. Gastrointestinal manifestations, raised liver enzymes, renal failure unrelated to rhabdomyolysis, and pancytopenia were unusually prominent. Factors associated with severe disease included older age, delay in hospitalisation, lower-respiratory-tract involvement, and a low total peripheral white blood cell count or lymphopenia at admission. An H5-specific reverse-transcription PCR assay (RT-PCR) was useful for rapid detection of virus directly in respiratory specimens. A commercially available enzyme immunoassay was more sensitive than direct immunofluorescence for rapid viral diagnosis. Direct immunofluorescence with an H5-specific monoclonal antibody pool was useful for rapid exclusion of H5-subtype infection. Interpretation Avian Influenza A H5N1 virus causes human influenza-like illness with a high rate of complications in adults admitted to hospital. Rapid H5-subtype-specific laboratory diagnosis can be made by RT-PCR applied directly to clinical specimens.	Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Microbiol, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Microbiol, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Paediat, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Queen Elizabeth Hosp, Dept Intens Care, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Microbiol, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Paediat, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Yan Chai Hosp, Dept Intens Care, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Microbiol, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Paediat, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Anaesthesia, Hong Kong, Peoples R China; Tuen Mun Hosp, Dept Intens Care, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; Tuen Mun Hospital; Tuen Mun Hospital; Tuen Mun Hospital; Tuen Mun Hospital	Peiris, M (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Microbiol, Pokfulam Rd, Hong Kong, Peoples R China.	malik@hkuce-htcu.hk	Yuen, Kwok Yung/C-4465-2009; Chan, Paul KS/J-9360-2013; Peiris, Joseph Sriyal Malik/C-4380-2009	Chan, Paul KS/0000-0002-6360-4608; Yuen, Kwok-yung/0000-0002-2083-1552; Peiris, Joseph Sriyal Malik/0000-0001-8217-5995				ALEXANDER DJ, 1993, VET REC, V132, P535, DOI 10.1136/vr.132.21.535; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; deJong JC, 1997, NATURE, V389, P554, DOI 10.1038/39218; DOUGLAS RG, 1995, INFLUENZA VIRUSES IN, P395; Easterday B. C., 1991, Diseases of poultry., P532; GAMMELIN M, 1990, MOL BIOL EVOL, V7, P194; GORMAN OT, 1991, J VIROL, V65, P3704, DOI 10.1128/JVI.65.7.3704-3714.1991; ITO T, 1996, OPTIONS CONTROL INFL, V3, P516; KAPILA CC, 1958, BRIT MED J, V4, P1311; KILBOURNE ED, 1995, INFLUENZA VIRUSES IN, P483; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; Madeley C. R., 1992, P33; PALLADINO G, 1995, J VIROL, V69, P2075, DOI 10.1128/JVI.69.4.2075-2081.1995; PORTERFIELD JS, 1986, ADV VIRUS RES, V31, P335, DOI 10.1016/S0065-3527(08)60268-7; Senne DA, 1996, AVIAN DIS, V40, P425, DOI 10.2307/1592241; SHENOUDA A, 1976, AM J MED, V61, P697, DOI 10.1016/0002-9343(76)90148-0; Shortridge K F, 1992, Semin Respir Infect, V7, P11; SHORTRIDGE KF, 1995, LANCET, V346, P1210, DOI 10.1016/S0140-6736(95)92906-1; Webster Robert G., 1997, Journal of Infectious Diseases, V176, pS14, DOI 10.1086/514168; WHIMBEY E, 1995, BONE MARROW TRANSPL, V16, P393; Woo PCY, 1997, J CLIN MICROBIOL, V35, P1579, DOI 10.1128/JCM.35.6.1579-1581.1997; Ziegler Thedi, 1995, P918	23	781	873	0	109	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 14	1998	351	9101					467	471		10.1016/S0140-6736(98)01182-9	http://dx.doi.org/10.1016/S0140-6736(98)01182-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482437				2022-12-01	WOS:000072097700009
J	Logmans, A; Verhoeff, A; Raap, RB; Creighton, F; van Lent, M				Logmans, A; Verhoeff, A; Raap, RB; Creighton, F; van Lent, M			Who wants the procedure and why	BRITISH MEDICAL JOURNAL			English	Article							MUTILATION FEMALE CIRCUMCISION		Dr Daniel den Hoed Klin, Dept Gynaecol, NL-3075 EA Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute	Logmans, A (corresponding author), Zuiderziekenhuis, Gr Hilledijik 315, NL-3075 EA Rotterdam, Netherlands.							BAKER CA, 1993, AM J OBSTET GYNECOL, V169, P1616, DOI 10.1016/0002-9378(93)90448-R; BOLANDE RP, 1969, NEW ENGL J MED, V280, P591, DOI 10.1056/NEJM196903132801105; DESANTIS L, 1995, ARCH PSYCHIAT NURS, V9, P354, DOI 10.1016/S0883-9417(95)80059-X; DESILVA S, 1989, EUR J OBSTET GYN R B, V32, P233, DOI 10.1016/0028-2243(89)90041-5; JORDAN JA, 1994, BRIT J OBSTET GYNAEC, V101, P94, DOI 10.1111/j.1471-0528.1994.tb13070.x; KLUGE EH, 1993, CAN MED ASSOC J, V148, P288; Lipson J G, 1995, Health Care Women Int, V16, P279; MENIRU GI, 1994, BRIT J OBSTET GYNAEC, V101, P832, DOI 10.1111/j.1471-0528.1994.tb11967.x; Wall LL, 1996, OBSTET GYNECOL, V88, P633, DOI 10.1016/0029-7844(96)00177-9	9	34	34	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					459	460		10.1136/bmj.316.7129.459	http://dx.doi.org/10.1136/bmj.316.7129.459			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492678	Green Published, Green Submitted			2022-12-01	WOS:000071982700042
J	van Steensel, B; Smogorzewska, A; de Lange, T				van Steensel, B; Smogorzewska, A; de Lange, T			TRF2 protects human telomeres from end-to-end fusions	CELL			English	Article							DNA-BINDING PROTEIN; HUMAN FIBROBLASTS; MAMMALIAN-CELLS; IMMORTAL CELLS; IN-VIVO; SENESCENCE; LENGTH	The mechanism by which telomeres prevent end-to-end fusion has remained elusive. Here, we show that the human telomeric protein TRF2 plays a key role in the protective activity of telomeres. A dominant negative allele of TRF2 induced end-to-end chromosome fusions detectable in metaphase and anaphase cells. Telomeric DNA persisted at the fusions, demonstrating that TTAGGG repeats per se are not sufficient for telomere integrity. Molecular analysis suggested that the fusions represented ligation of telomeres that have lost their single-stranded G-tails. Therefore, TRF2 may protect chromosome ends by maintaining the correct structure at telomere termini. In addition, expression of mutant forms of TRF2 induced a growth arrest with characteristics of senescence. The results raise the possibility that chromosome end fusions and senescence in primary human cells may be caused by loss by TRF2 from shortened telomeres.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	de Lange, T (corresponding author), Rockefeller Univ, New York, NY 10021 USA.		Smogorzewska, Agata/B-8891-2011; de Lange, Titia/B-8263-2011	de Lange, Titia/0000-0002-9267-367X	NIGMS NIH HHS [GM07739] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bianchi A, 1997, EMBO J, V16, P1785, DOI 10.1093/emboj/16.7.1785; Bilaud T, 1997, NAT GENET, V17, P236, DOI 10.1038/ng1097-236; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BODMAR AG, 1998, IN PRESS SCIENCE; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; CARDENAS ME, 1993, GENE DEV, V7, P883, DOI 10.1101/gad.7.5.883; CHONG L, 1995, SCIENCE, V270, P1663, DOI 10.1126/science.270.5242.1663; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; de Lange T, 1998, SCIENCE, V279, P334, DOI 10.1126/science.279.5349.334; DELANGE T, 1995, TELOMERES, P265; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dionne I, 1996, P NATL ACAD SCI USA, V93, P13902, DOI 10.1073/pnas.93.24.13902; FARR C, 1991, P NATL ACAD SCI USA, V88, P7006, DOI 10.1073/pnas.88.16.7006; GARVIK B, 1995, MOL CELL BIOL, V15, P6128; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTSCHLING DE, 1986, CELL, V47, P195, DOI 10.1016/0092-8674(86)90442-3; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1995, TELOMERES, P247; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; HENDERSON E, 1995, TELOMERES, P11; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kirk KE, 1997, SCIENCE, V275, P1478, DOI 10.1126/science.275.5305.1478; Konig P, 1997, TRENDS BIOCHEM SCI, V22, P43, DOI 10.1016/S0968-0004(97)01008-6; Lansdorp PM, 1996, HUM MOL GENET, V5, P685, DOI 10.1093/hmg/5.5.685; Lin JJ, 1996, P NATL ACAD SCI USA, V93, P13760, DOI 10.1073/pnas.93.24.13760; Linn S.M., 1982, NUCLEASES; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Marusic L, 1997, MOL CELL BIOL, V17, P6394, DOI 10.1128/MCB.17.11.6394; McClintock B, 1942, P NATL ACAD SCI USA, V28, P458, DOI 10.1073/pnas.28.11.458; McClintock B, 1941, GENETICS, V26, P234; McElligott R, 1997, EMBO J, V16, P3705, DOI 10.1093/emboj/16.12.3705; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Morin GB, 1996, SEMIN CELL DEV BIOL, V7, P5, DOI 10.1006/scdb.1996.0003; Muller HJ., 1938, COLLECT NET, V13, P181; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; PRICE CM, 1990, MOL CELL BIOL, V10, P3241; SALTMAN D, 1993, CHROMOSOMA, V102, P121, DOI 10.1007/BF00356029; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Smith S, 1997, TRENDS GENET, V13, P21, DOI 10.1016/S0168-9525(96)10052-4; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Wellinger RJ, 1997, EUR J CANCER, V33, P735, DOI 10.1016/S0959-8049(97)00067-1; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	51	1378	1411	3	73	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					401	413		10.1016/S0092-8674(00)80932-0	http://dx.doi.org/10.1016/S0092-8674(00)80932-0			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476899	Bronze			2022-12-01	WOS:000072024700011
J	Aris, RM; Renner, JB; Winders, AD; Buell, HE; Riggs, DB; Lester, GE; Ontjes, DA				Aris, RM; Renner, JB; Winders, AD; Buell, HE; Riggs, DB; Lester, GE; Ontjes, DA			Increased rate of fractures and severe kyphosis: Sequelae of living into adulthood with cystic fibrosis	ANNALS OF INTERNAL MEDICINE			English	Article							BONE-MINERAL DENSITY; LUNG TRANSPLANTATION; BODY-COMPOSITION; OSTEOPOROSIS; ABSORPTIOMETRY; EPIDEMIOLOGY; OSTEOPENIA; CHILDREN; WOMEN	Background: Osteoporosis occurs in patients with cystic fibrosis as they age, but its clinical implications are not well defined. Objective: To determine the clinical effect of decreased bone mineral density in adults with cystic fibrosis and to assess possible clinical predictors of osteoporosis. Design: Retrospective cohort study. Setting: Academic cystic fibrosis center. Patients: 70 adults with late-stage cystic fibrosis who were referred for lung transplantation. Measurements: Bone mineral density was measured with dual-energy x-ray absorptiometry, patient-reported fracture events were confirmed by radiography, and kyphosis angles were measured by using the Cobb method. Results: Mean bone mineral densities for the spine, femur, and total body were severely depressed in patients with cystic fibrosis, averaging 2 SDs below those of age-matched normal controls (P < 0.001). Patient interviews showed that 54 fractures had occurred over 1410 patient-years, and chest radiographs showed evidence of 14 additional rib and 62 additional vertebral compression fractures. The database (which covered 1410 patient-years) showed that fracture rates were approximately twofold greater in women with cystic fibrosis aged 16 to 34 years (P = 0.015) and men with cystic fibrosis aged 25 to 45 years (P = 0.04) than in the general population. Vertebral compression and rib fractures were 100- and 10-fold more common than expected, respectively (P < 0.001 for both comparisons). The mean kyphosis angle (+/-SD) for this group was markedly abnormal (44 +/- 14 degrees; 62% greater than or equal to 40 degrees) and probably contributed to diminished stature (mean height loss, 5.8 cm in men with cystic fibrosis and 5.9 cm in women with cystic fibrosis). Cumulative prednisone dose, body mass index, and age at puberty were the strongest predictors of bone mineral density. Conclusions: Osteoporosis is universal in adults with late-stage cystic fibrosis, and its complications include increased fracture rates and severe kyphosis.	Univ N Carolina, Div Pulm Med, Chapel Hill, NC 27599 USA; Duke Univ, Duke Res Inst, Med Ctr, Durham, NC 27710 USA; Univ N Carolina, Dept Orthopaed, Chapel Hill, NC 27599 USA; Univ N Carolina, Div Endocrinol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Aris, RM (corresponding author), Univ N Carolina, Div Pulm Med, CB 7020,724 Burnett Womack Bldg, Chapel Hill, NC 27599 USA.				NCRR NIH HHS [RR00046] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Aris RM, 1996, CHEST, V109, P1176, DOI 10.1378/chest.109.5.1176; BACHRACH LK, 1994, AM J MED, V96, P27, DOI 10.1016/0002-9343(94)90112-0; Bhudhikanok GS, 1996, PEDIATRICS, V97, P103; Boat TF., 1989, CYSTIC FIBROSIS META, V6th, P2649; Cobb J., 1948, AM ACADEMY ORTHOPAED, V5, P261; *CYST FIBR FDN, 1996, REP PAT REG, P1; DENTON JR, 1981, CLIN ORTHOP RELAT R, P71; DESCHEPPER J, 1993, HORM RES, V39, P197, DOI 10.1159/000182735; ERKKILA JC, 1978, CLIN ORTHOP RELAT R, V131, P146; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; FLUME PA, 1994, AM J RESP CRIT CARE, V149, P1601, DOI 10.1164/ajrccm.149.6.7516251; FON GT, 1980, AM J ROENTGENOL, V134, P979, DOI 10.2214/ajr.134.5.979; FULWOOD R, 1981, SERIES US DEP HHS PU, V11, P31; GIBBENS DT, 1988, J PEDIATR-US, V113, P295, DOI 10.1016/S0022-3476(88)80268-3; GRAZIER KL, 1984, FREQUENCY OCCURRENCE, P72; GREY AB, 1993, THORAX, V48, P589, DOI 10.1136/thx.48.6.589; HAHN TJ, 1979, J PEDIATR-US, V94, P38, DOI 10.1016/S0022-3476(79)80346-7; HENDERSON RC, 1994, J PEDIATR-US, V125, P208, DOI 10.1016/S0022-3476(94)70194-6; Henderson RC, 1996, J PEDIATR-US, V128, P28, DOI 10.1016/S0022-3476(96)70424-9; HIGHSMITH WE, 1993, MOL BIOL PATHOLOGY G, P159; Hollander M., 1973, NONPARAMETRIC STAT, P68; JOHNSTON CC, 1991, NEW ENGL J MED, V324, P1105; KANIS JA, 1994, J BONE MINER RES, V9, P1137, DOI 10.1002/jbmr.5650090802; KOCH G, 1995, CATEGORICAL DATA ANA, P472; LOGVINOFF MM, 1984, CLIN PEDIATR, V23, P389, DOI 10.1177/000992288402300705; MELTON LJ, 1995, J BONE MINER RES, V10, P175; MELTON LJ, 1989, AM J EPIDEMIOL, V129, P1000, DOI 10.1093/oxfordjournals.aje.a115204; MISCHLER EH, 1979, AM J DIS CHILD, V133, P632, DOI 10.1001/archpedi.1979.02130060072016; NETER J, 1990, APPL LINEAR STAT MOD, P13; ROBBINS MK, IN PRESS CYSTIC FIBR; ROCHAT T, 1994, CHEST, V106, P800, DOI 10.1378/chest.106.3.800; ROSE J, 1987, AM J DIS CHILD, V141, P1313, DOI 10.1001/archpedi.1987.04460120079039; Salamoni F, 1996, ARCH DIS CHILD, V74, P314, DOI 10.1136/adc.74.4.314; Shane E, 1996, AM J MED, V101, P262, DOI 10.1016/S0002-9343(96)00155-6; SHAW N, 1995, AM J MED, V99, P690, DOI 10.1016/S0002-9343(99)80262-9; STAMP TCB, 1993, THORAX, V48, P585, DOI 10.1136/thx.48.6.585; VAANANEN HK, 1993, ANN MED, V25, P353, DOI 10.3109/07853899309147297	37	217	222	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					186	193		10.7326/0003-4819-128-3-199802010-00004	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454526				2022-12-01	WOS:000071703200003
J	Jones, S; Sadler, T; Low, N; Blott, M; Welch, J				Jones, S; Sadler, T; Low, N; Blott, M; Welch, J			Does uptake of antenatal HIV testing depend on the individual midwife? Cross sectional study	BRITISH MEDICAL JOURNAL			English	Article									Kings Healthcare, Dept Sexual Hlth, London SE5 9RS, England; Univ London Kings Coll, Sch Med & Dent, Dept Genitourinary Med, Acad Univ, London SE5 9RS, England; Kings Healthcare, Dept Womens Hlth, London SE5 9RS, England	University of London; King's College London	Welch, J (corresponding author), Kings Healthcare, Dept Sexual Hlth, London SE5 9RS, England.							*DEP HLTH, 1994, GUID OFF VOL HIV ANT; Gibb DM, 1998, BRIT MED J, V316, P259, DOI 10.1136/bmj.316.7127.259; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; *UNL AN SURV STEER, 1996, UNL AN PREV MON PROG	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					272	273		10.1136/bmj.316.7127.272	http://dx.doi.org/10.1136/bmj.316.7127.272			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472510	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000071702100024
J	Acharya, U; Mallabiabarrena, A; Acharya, JK; Malhotra, V				Acharya, U; Mallabiabarrena, A; Acharya, JK; Malhotra, V			Signaling via mitogen-activated protein kinase kinase (MEK1) is required for Golgi fragmentation during mitosis	CELL			English	Article							MAP KINASE; CELL-CYCLE; NUCLEAR LAMINA; A431 CELLS; HELA-CELLS; M-PHASE; INVITRO; PHOSPHORYLATION; APPARATUS; CASCADE	We have developed an assay using permeabilized cells to monitor fragmentation of the Golgi complex that occurs during mitosis. Golgi stacks, in permeabilized interphase normal rat kidney (NRK) cells, upon incubation with mitotic extracts undergo extensive fragmentation, and the fragmented Golgi membranes are dispersed throughout the cytoplasm. We find that the continued presence of p34(cdc2), the mitosis initiation kinase, is not necessary for Golgi fragmentation. Instead, fragmentation depends on cytosolic mitogen-activated protein kinase kinase 1 (MEK1 or MAPKK1). However, the known cytoplasmic substrates for MEK1, ERK1, and ERK2 are not required for this process. Interestingly, we find a Golgi-associated ERK, which we propose as the likely target for MEK1 in Golgi fragmentation.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Acharya, U (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Malhotra, Vivek/O-9811-2014	Malhotra, Vivek/0000-0001-6198-7943; Acharya, Jairaj/0000-0001-7366-4228	NIGMS NIH HHS [GM46224] Funding Source: Medline; CSR NIH HHS [NA66RG0477] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); CSR NIH HHS		ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ACHARYA U, 1995, J CELL BIOL, V129, P577, DOI 10.1083/jcb.129.3.577; AHN NG, 1993, P NATL ACAD SCI USA, V90, P5143, DOI 10.1073/pnas.90.11.5143; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; EILENBERG H, 1989, J LIPID RES, V30, P1127; FAURE M, 1994, J BIOL CHEM, V269, P7851; GOTOH Y, 1991, EMBO J, V10, P2261; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; HIROSE S, 1989, NEW PHYTOL, V111, P599, DOI 10.1111/j.1469-8137.1989.tb02353.x; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; MINSHULL J, 1994, CELL, V79, P475, DOI 10.1016/0092-8674(94)90256-9; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; NAKAGAWA J, 1989, J CELL SCI, V94, P449; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; RESZKA AA, 1995, P NATL ACAD SCI USA, V92, P881; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIBUYA EK, 1992, EMBO J, V11, P3963, DOI 10.1002/j.1460-2075.1992.tb05490.x; Stanley H, 1997, P NATL ACAD SCI USA, V94, P14467, DOI 10.1073/pnas.94.26.14467; STUART RA, 1993, J BIOL CHEM, V268, P4050; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; TUOMIKOSKI T, 1989, NATURE, V342, P942, DOI 10.1038/342942a0; Wang XM, 1997, J CELL BIOL, V137, P433, DOI 10.1083/jcb.137.2.433; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	41	163	165	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					183	192		10.1016/S0092-8674(00)80913-7	http://dx.doi.org/10.1016/S0092-8674(00)80913-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458043	Bronze			2022-12-01	WOS:000071672600008
J	Davis, KD; Kiss, ZHT; Luo, L; Tasker, RR; Lozano, AM; Dostrovsky, JO				Davis, KD; Kiss, ZHT; Luo, L; Tasker, RR; Lozano, AM; Dostrovsky, JO			Phantom sensations generated by thalamic microstimulation	NATURE			English	Article							ADULT HUMAN BRAIN; CORTICAL REORGANIZATION; SOMATOSENSORY CORTEX; NERVOUS-SYSTEM; MONKEYS; DEAFFERENTATION; AMPUTATION; PLASTICITY; DIGIT; PAIN	Many amputees have a sense of their missing 'phantom' limb(1-3) Amputation can alter the representation of the body's surface in the cerebral cortex(4-14) and thalamus(15,16), but it is unclear how these changes relate to such phantom sensations, One possibility is that, in amputees who experience phantom sensations, the region of the thalamus that originally represented the missing limb remains functional and can give rise to phantom sensations even when some thalamic 'limb' neurons begin to respond to stimulation of other body regions, Here we use microelectrode recording and microstimulation during functional stereotactic mapping of the ventrocaudal thalamus in amputees to determine both the responses of the neurons to stimulation of the skin and the perceptual effects of electrical activation of these neurons. Thalamic mapping revealed an unusually large thalamic stump representation, consistent with the findings from animal experiments. We also found that thalamic stimulation in amputees with a phantom limb could evoke phantom sensations, including pain, even in regions containing neurons responsive to tactile stimulation of the stump, These findings support the hypothesis that the thalamic representation of the amputated limb remains functional. in amputees with phantoms.	Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Playfair Neurosci Unit, Toronto, ON M5T 2S8, Canada	University of Toronto; University of Toronto; University of Toronto	Davis, KD (corresponding author), Univ Toronto, Dept Surg, Toronto, ON M5T 2S8, Canada.		Kiss, Zelma/D-2342-2016; Lozano, Andres M/A-5058-2012	Kiss, Zelma/0000-0002-8656-2690; Lozano, Andres M./0000-0001-8257-3694				AGLIOTI S, 1994, NEUROREPORT, V5, P473, DOI 10.1097/00001756-199401120-00026; CALFORD MB, 1991, SOMATOSENS MOT RES, V8, P249, DOI 10.3109/08990229109144748; CARLEN PL, 1978, NEUROLOGY, V28, P211, DOI 10.1212/WNL.28.3.211; Clarke S, 1996, NEUROREPORT, V7, P2853, DOI 10.1097/00001756-199611250-00009; Davis KD, 1996, J NEUROPHYSIOL, V75, P1026, DOI 10.1152/jn.1996.75.3.1026; Doetsch GS, 1997, SOMATOSENS MOT RES, V14, P6, DOI 10.1080/08990229771178; ELBERT T, 1994, NEUROREPORT, V5, P2593, DOI 10.1097/00001756-199412000-00047; FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; Florence SL, 1995, J NEUROSCI, V15, P8083; HALLIGAN PW, 1993, NEUROREPORT, V4, P233, DOI 10.1097/00001756-199303000-00001; Kew JJM, 1997, J NEUROPHYSIOL, V77, P2753, DOI 10.1152/jn.1997.77.5.2753; KISS ZHT, 1994, STEREOT FUNCT NEUROS, V62, P153, DOI 10.1159/000098612; Knecht S, 1995, NEUROSCI LETT, V201, P262, DOI 10.1016/0304-3940(95)12186-2; LENZ FA, 1988, J NEUROSURG, V68, P630, DOI 10.3171/jns.1988.68.4.0630; LENZ FA, 1988, J NEUROPHYSIOL, V59, P299, DOI 10.1152/jn.1988.59.2.299; LENZ FA, 1994, J NEUROPHYSIOL, V72, P1570, DOI 10.1152/jn.1994.72.4.1570; MELZACK R, 1990, TRENDS NEUROSCI, V13, P88, DOI 10.1016/0166-2236(90)90179-E; MERZENICH MM, 1984, J COMP NEUROL, V224, P591, DOI 10.1002/cne.902240408; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; PONS TP, 1991, SCIENCE, V252, P1857, DOI 10.1126/science.1843843; RAMACHANDRAN VS, 1993, P NATL ACAD SCI USA, V90, P10413, DOI 10.1073/pnas.90.22.10413; Rasmusson D, 1996, J COMP NEUROL, V364, P92; RASMUSSON DD, 1982, J COMP NEUROL, V205, P313, DOI 10.1002/cne.902050402; SHERMAN RA, 1984, PAIN, V18, P83, DOI 10.1016/0304-3959(84)90128-3; TASKER RR, 1995, NEUROSURG CLIN N AM, V6, P73; Tsoukatos J., 1996, Society for Neuroscience Abstracts, V22, P98; WALL JT, 1992, J NEUROSCI, V12, P3445; WALL PD, 1971, NATURE, V232, P542, DOI 10.1038/232542a0; YANG TT, 1994, NEUROREPORT, V5, P701, DOI 10.1097/00001756-199402000-00010	29	167	172	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					385	387		10.1038/34905	http://dx.doi.org/10.1038/34905			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450753				2022-12-01	WOS:000071604200053
J	Pappalardo, RT; Head, JW; Greeley, R; Sullivan, RJ; Pilcher, C; Schubert, G; Moore, WB; Carr, MH; Moore, JM; Belton, MJS; Goldsby, DL				Pappalardo, RT; Head, JW; Greeley, R; Sullivan, RJ; Pilcher, C; Schubert, G; Moore, WB; Carr, MH; Moore, JM; Belton, MJS; Goldsby, DL			Geological evidence for solid-state convection in Europa's ice shell	NATURE			English	Article							SATELLITES; WATER	The ice-rich surface of the jovian satellite Europa is sparsely cratered, suggesting that this moon might be geologically active today(1). Moreover, models of the satellite's interior indicate that tidal interactions with Jupiter might produce enough heat to maintain a subsurface liquid water layer(2-5). But the mechanisms of interior heat loss and resurfacing are currently unclear, as is the question of whether Europa has (or had at one time) a liquid water ocean(6,7). Here we report on the morphology and geological interpretation of distinct surface features-pits, domes and spots-discovered in high-resolution images of Europa obtained by the Galileo spacecraft. The features are interpreted as the surface manifestation of diapirs, relatively warm localized ice masses that have risen buoyantly through the subsurface. We find that the formation of the features can be explained by thermally induced solid-state convection within an ice shell, possibly overlying a liquid water layer. Our results are consistent with the possibility that Europa has a liquid water ocean beneath a surface layer of ice, but further tests and observations are needed to demonstrate this conclusively.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; NASA Headquarters, Washington, DC 20546 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; US Geol Survey, Menlo Park, CA 94025 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA	Brown University; Arizona State University; Arizona State University-Tempe; National Aeronautics & Space Administration (NASA); University of California System; University of California Los Angeles; United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; National Optical Astronomy Observatory	Pappalardo, RT (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Pappalardo, Robert/AAP-8953-2021	Pappalardo, Robert/0000-0003-2571-4627; Goldsby, David/0000-0002-9004-0086				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CARR MH, 1995, J GEOPHYS RES-PLANET, V100, P18935, DOI 10.1029/95JE00971; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; CASSEN PM, 1982, SATELLITES JUPITER, P93; DURHAM WB, 1992, J GEOPHYS RES-PLANET, V97, P20883, DOI 10.1029/92JE02326; GEISSLER P, 1997, P WORKSH REM SENS PL; Geissler PE, 1998, NATURE, V391, P368, DOI 10.1038/34869; Goldsby DL, 1997, SCRIPTA MATER, V37, P1399, DOI 10.1016/S1359-6462(97)00246-7; GOLDSBY DL, 1997, LUNAR PLANET SCI, V28, P429; GREELEY R, 1997, LUN PLAN SCI C ABSTR, V28, P455; GREENBERG R, 1997, LUN PLAN SCI C ABSTR, V28, P457; HOBBS PV, 1974, ICE PHYSICS; Jenyon M.K., 1986, SALT TECTONICS; KARGEL JS, 1991, ICARUS, V94, P368, DOI 10.1016/0019-1035(91)90235-L; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MCKINNON WB, 1997, B AM ASTRON SOC, V29, P984; MUELLER S, 1988, ICARUS, V76, P437, DOI 10.1016/0019-1035(88)90014-0; OBRIEN GD, 1968, AAPG BULL, V8, P1; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; OJAKANGAS GW, 1989, ICARUS, V81, P242, DOI 10.1016/0019-1035(89)90053-5; PAPPALARDO R, 1996, EOS, V78, pS203; REYNOLDS RT, 1979, GEOPHYS RES LETT, V6, P121, DOI 10.1029/GL006i002p00121; ROSS MN, 1987, NATURE, V325, P133, DOI 10.1038/325133a0; SCHENK P, 1993, GEOLOGY, V21, P299, DOI 10.1130/0091-7613(1993)021<0299:DOTARO>2.3.CO;2; Schubert G., 1986, SATELLITES, P224; Squyres S. W., 1986, SATELLITES, P293; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; STENGEL KC, 1982, J FLUID MECH, V120, P411, DOI 10.1017/S0022112082002821; WILLIAMS KK, 1997, EOS, V78, pF415	29	257	259	1	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					365	368		10.1038/34862	http://dx.doi.org/10.1038/34862			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450750				2022-12-01	WOS:000071604200046
J	Goldfeld, AE; Delgado, JC; Thim, S; Bozon, MV; Uglialoro, AM; Turbay, D; Cohen, C; Yunis, EJ				Goldfeld, AE; Delgado, JC; Thim, S; Bozon, MV; Uglialoro, AM; Turbay, D; Cohen, C; Yunis, EJ			Association of an HLA-DQ allele with clinical tuberculosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NECROSIS-FACTOR-ALPHA; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; DNA; AMPLIFICATION; POLYMORPHISM; INFECTION; RELEVANCE; HLA-DR1; VIRUS	Context.-Although tuberculosis (TB) is the leading worldwide cause of death due to an infectious disease, the extent to which progressive clinical disease is associated with genetic host factors remains undefined. Objective.-To determine the distribution of HLA antigens and the frequency of 2 alleles of the tumor necrosis factor alpha (TNF-alpha) gene in unrelated individuals with clinical TB (cases) compared with individuals with no history of clinical TB (controls) in a population with a high prevalence of TB exposure. Design.-A 2-stage, case-control molecular typing study conducted in 1995-1996. Setting.-Three district hospitals in Svay Rieng Province in rural Cambodia. Patients.-A total of 78 patients with clinical TB and 49 controls were included in the first stage and 48 patients with TB and 39 controls from the same area and socioeconomic status were included in the second stage. Main Outcome Measures.-Presence of HLA class I and class II alleles determined by sequence-specific oligonucleotide probe hybridization and presence of 2 TNF-alpha alleles determined by restriction fragment length polymorphism analysis. Results.-In the first stage, 7 DQB1*0503 alleles were detected among 156 alleles derived from patients with TB, whereas no DQB1*0503 alleles were found among the 98 alleles derived from controls (P=.04), There was no detectable difference in the distribution of the 2 TNF-alpha alleles in patients with TB compared with controls, In the second stage, we tested for the presence of a single variable, the DQB1*0503 allele, and found 9 DQB1*0503 alleles among 96 alleles derived from patients with TB and no DQB1*0503 alleles among 78 alleles in controls (P=.005), Conclusions.-The HLA-DQB1*0503 allele is significantly associated with susceptibility to TB in Cambodian patients and, to our knowledge, is the first identified gene associated with development of clinical TB.	Dana Farber Canc Inst, Div Adult Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Immunogenet, Boston, MA 02115 USA; Dana Farber Canc Inst, Blood Bank, Boston, MA 02115 USA; Phnom Penh, Cambodian Hlth Comm, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Goldfeld, AE (corresponding author), Dana Farber Canc Inst, Div Adult Oncol, 44 Binney St, Boston, MA 02115 USA.	anne_goldfeld@macmailgw.dfci.harvard.edu	Goldfeld, Anne/AAF-1818-2019		NHLBI NIH HHS [HL29583] Funding Source: Medline; NIMH NIH HHS [MH 40279] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL029583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH040279, P30MH040279] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BLOOM BR, 1992, SCIENCE, V257, P1055, DOI 10.1126/science.257.5073.1055; BLOOM BR, 1994, TUBERCULOSIS PATHOGE; BODMER JG, 1995, TISSUE ANTIGENS, V46, P1; BOTHAMLEY GH, 1989, J INFECT DIS, V159, P549, DOI 10.1093/infdis/159.3.549; Bozon MV, 1996, TISSUE ANTIGENS, V47, P512, DOI 10.1111/j.1399-0039.1996.tb02593.x; BRAHMAJOTHI V, 1991, TUBERCLE, V72, P123, DOI 10.1016/0041-3879(91)90039-U; Brinkman BMN, 1996, J INFLAMM, V46, P32; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P745, DOI 10.1164/ajrccm/144.4.745; CEREB N, 1995, TISSUE ANTIGENS, V45, P1, DOI 10.1111/j.1399-0039.1995.tb02408.x; COHN DL, 1993, AIDS, V7, pS195, DOI 10.1097/00002030-199301001-00025; dCruzGrote D, 1996, LANCET, V348, P1071, DOI 10.1016/S0140-6736(95)11031-3; Farmer P, 1991, Semin Respir Infect, V6, P254; FLYNN JL, 1995, IMMUNITY, V2, P561, DOI 10.1016/1074-7613(95)90001-2; GOLDFEL AE, 1994, COMMUNICATION   0210; Jouanguy E, 1996, NEW ENGL J MED, V335, P1956, DOI 10.1056/NEJM199612263352604; KHOMENKO AG, 1990, TUBERCLE, V71, P187, DOI 10.1016/0041-3879(90)90074-I; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; MILES SH, 1984, AM REV RESPIR DIS, V130, P827; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; OPELZ G, 1991, LANCET, V338, P461, DOI 10.1016/0140-6736(91)90540-6; PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303; Rajalingam R, 1996, J INFECT DIS, V173, P669, DOI 10.1093/infdis/173.3.669; RITH DN, 1996, P C ANT ACT CAMB PHN; Rom WN, 1996, TUBERCULOSIS, Vxxv; ROOK GAW, 1990, PATHOL BIOL, V38, P276; SALAZAR M, 1992, TISSUE ANTIGENS, V40, P116, DOI 10.1111/j.1399-0039.1992.tb02102.x; SKAMENE E, 1994, IMMUNOBIOLOGY, V191, P451, DOI 10.1016/S0171-2985(11)80451-1; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; *UN CHILDR FUND, 1990, CAMB SIT WOM CHILDR; *WHO, 1994, WHO REP TB EP; WILSON AG, 1993, J EXP MED, V177, P557, DOI 10.1084/jem.177.2.557; YUNIS JJ, 1993, TISSUE ANTIGENS, V41, P37, DOI 10.1111/j.1399-0039.1993.tb01975.x; YUNIS JJ, 1992, TISSUE ANTIGENS, V40, P41, DOI 10.1111/j.1399-0039.1992.tb01956.x	36	180	186	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					226	228		10.1001/jama.279.3.226	http://dx.doi.org/10.1001/jama.279.3.226			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438744				2022-12-01	WOS:000071460700034
J	Howard, G; Wagenknecht, LE; Burke, GL; Diez-Roux, A; Evans, GW; McGovern, P; Nieto, J; Tell, GS				Howard, G; Wagenknecht, LE; Burke, GL; Diez-Roux, A; Evans, GW; McGovern, P; Nieto, J; Tell, GS			Cigarette smoking and progression of atherosclerosis - The atherosclerosis risk in communities (ARIC) study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTIMA-MEDIA THICKNESS; POPULATION-BASED ULTRASONOGRAPHY; CORONARY HEART-DISEASE; CAROTID ATHEROSCLEROSIS; PASSIVE SMOKING; WALL THICKNESS; CARDIOVASCULAR HEALTH; ARTERY; DETERMINANTS; MORTALITY	Context.-Cigarette smoking is a powerful risk factor for incident heart disease and stroke, but the relationship of active and passive smoking with the progression of atherosclerosis has not been described. Objective.-To examine the impact of active smoking and exposure to environmental tobacco smoke (ETS) on the progression of atherosclerosis. Design.-A longitudinal assessment of the relationship between smoking exposure evaluated at the initial visit and the 3-year change in atherosclerosis. Setting.-A population-based cohort of middle-aged adults from 4 communities in the United States. Participants.-A total of 10914 participants from the Atherosclerosis Risk in Communities (ARIC) study enrolled between 1987 and 1989. Main Outcome Measure.-Change in atherosclerosis from baseline to the 5-year follow-up as indexed by intimal-medial thickness of the carotid artery assessed by ultrasound and adjusted for demographic characteristics, cardiovascular risk factors, and lifestyle variables. Results.-Exposure to cigarette smoke was associated with progression of atherosclerosis. Relative to never smokers and after adjustment for demographic characteristics, cardiovascular risk factors, and lifestyle variables, current cigarette smoking was associated with a 50% increase in the progression of atherosclerosis (mean progression rate over 3 years, 43.0 mu m for current and 28.7 mu m for never smokers, regardless of ETS exposure), and past smoking was associated with a 25% increase (mean progression rate over 3 years, 35.8 mu m for past smokers and 28.7 mu m for never smokers). Relative to those not exposed to ETS, exposure to ETS was associated with a 20% increase (35.2 mu m for those exposed to ETS vs 29.3 mu m for those not exposed). The impact of smoking on atherosclerosis progression was greater for subjects with diabetes and hypertension. Although more pack-years of exposure was independently associated with faster progression (P<.001), after controlling for the number of pack-years, the progression rates of current and past smokers did not differ (P=.11). Conclusions.-Both active smoking and ETS exposure are associated with the progression of an index of atherosclerosis. Smoking is of particular concern for patients with diabetes and hypertension. The fact that pack-years of smoking but not current vs past smoking was associated with progression of atherosclerosis suggests that some adverse effects of smoking may be cumulative and irreversible.	Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA; Univ Minnesota, Dept Epidemiol, Minneapolis, MN USA; Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway	Wake Forest University; Johns Hopkins University; University of Minnesota System; University of Minnesota Twin Cities; University of Bergen	Howard, G (corresponding author), Wake Forest Univ, Dept Publ Hlth Sci, Winston Salem, NC 27157 USA.		Tell, Grethe/G-5639-2015	Tell, Grethe/0000-0003-1386-1638; Howard, George/0000-0002-3068-5720	NHLBI NIH HHS [N01-HC-55018, N01-HC-55015, N01-HC-55016] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC055015, N01HC055016, N01HC055018] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		[Anonymous], 1991, J Neuroimaging, V1, P68; BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; BELCARO G, 1995, VASA-J VASCULAR DIS, V24, P227; BOTS ML, 1993, ARTERIOSCLER THROMB, V13, P64, DOI 10.1161/01.ATV.13.1.64; BYINGTON RP, 1994, CIRCULATION, V90, P1; Chambless LE, 1997, AM J EPIDEMIOL, V146, P483, DOI 10.1093/oxfordjournals.aje.a009302; CROUSE JR, 1992, CONTROL CLIN TRIALS, V13, P495, DOI 10.1016/0197-2456(92)90206-F; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; DELCKER A, 1995, STROKE, V26, P2016, DOI 10.1161/01.STR.26.11.2016; DIEZROUX AV, 1995, PREV MED, V24, P48, DOI 10.1006/pmed.1995.1007; EVANS GW, 1996, CIRCULATION, V93, P624; FORD ES, 1991, AM J EPIDEMIOL, V133, P1220, DOI 10.1093/oxfordjournals.aje.a115834; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAY EC, 1992, DIABETES CARE, V15, P947, DOI 10.2337/diacare.15.8.947; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; HOWARD G, 1994, ARCH INTERN MED, V154, P1277; KEYS A, 1957, LANCET, V2, P959; MACK WJ, 1993, STROKE, V24, P1779, DOI 10.1161/01.STR.24.12.1779; MARGITIC SE, 1992, CONTROL CLIN TRIALS, V13, P293; OLEARY DH, 1991, STROKE, V22, P1155, DOI 10.1161/01.STR.22.9.1155; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; RILEY WA, 1991, J NEUROIMAGING, V1, P168; SALONEN R, 1990, ATHEROSCLEROSIS, V81, P33, DOI 10.1016/0021-9150(90)90056-O; SALONEN R, 1991, J INTERN MED, V229, P225, DOI 10.1111/j.1365-2796.1991.tb00336.x; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEENLAND K, 1992, JAMA-J AM MED ASSOC, V38, P113; SUAREZ L, 1984, AM J EPIDEMIOL, V120, P670, DOI 10.1093/oxfordjournals.aje.a113933; TELL GS, 1989, JAMA-J AM MED ASSOC, V261, P1178; TELL GS, 1994, CIRCULATION, V90, P2905, DOI 10.1161/01.CIR.90.6.2905; *US OFF SMOK HLTH, 1989, HLTH CONS SMOK CARD, P179; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WELLS AJ, 1994, J AM COLL CARDIOL, V24, P546, DOI 10.1016/0735-1097(94)90315-8; WILLARD JC, 1995, VITAL HTLH STAT, V263, P1; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; 1995, CONSUMER REPORTS, V20, P27	35	504	545	2	31	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					119	124		10.1001/jama.279.2.119	http://dx.doi.org/10.1001/jama.279.2.119			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440661	Bronze			2022-12-01	WOS:000071338900028
J	Zhao, HQ; Ivic, L; Otaki, JM; Hashimoto, M; Mikoshiba, K; Firestein, S				Zhao, HQ; Ivic, L; Otaki, JM; Hashimoto, M; Mikoshiba, K; Firestein, S			Functional expression of a mammalian odorant receptor	SCIENCE			English	Article							MEDIATED GENE-TRANSFER; RECOMBINANT ADENOVIRUS; OLFACTORY EPITHELIUM; CYSTIC-FIBROSIS; CELLS; NEURONS; MOUSE; RECOGNITION; FAMILY; VECTOR	Candidate mammalian odorant receptors were first cloned some 6 years ago. The physiological function of these receptors in initiating transduction in olfactory receptor neurons remains to be established. Here, a recombinant adenovirus was used to drive expression of a particular receptor gene in an increased number of sensory neurons in the rat olfactory epithelium. Electrophysiological recording showed that increased expression of a single gene led to greater sensitivity to a small subset of odorants.	Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Yale Univ, Interdept Neurosci Program, New Haven, CT 06510 USA; RIKEN, Tsukuba Life Sci Ctr, Mol Neurobiol Lab, Tsukuba, Ibaraki 305, Japan	Columbia University; Yale University; RIKEN	Firestein, S (corresponding author), Columbia Univ, Dept Biol Sci, New York, NY 10027 USA.		Hashimoto, Mitsuhiro/G-1981-2010; Mikoshiba, Katsuhiko/N-7943-2015; Oka, Yoshitaka/C-9670-2010	Hashimoto, Mitsuhiro/0000-0002-8751-4068; Oka, Yoshitaka/0000-0002-3482-3051				BECKER TC, 1994, PROTEIN EXPRESSION A, P162; Breer Heinz, 1994, Seminars in Cell Biology, V5, P25, DOI 10.1006/scel.1994.1004; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Hashimoto M, 1996, HUM GENE THER, V7, P149, DOI 10.1089/hum.1996.7.2-149; Holtmaat AJGD, 1996, MOL BRAIN RES, V41, P148, DOI 10.1016/0169-328X(96)00085-X; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KANEGAE Y, 1994, JPN J MED SCI BIOL, V47, P157, DOI 10.7883/yoken1952.47.157; KIM DG, 1992, MOL CELL BIOL, V12, P3636, DOI 10.1128/MCB.12.8.3636; LANCET D, 1993, CURR BIOL, V3, P668, DOI 10.1016/0960-9822(93)90064-U; LESALLE GL, 1993, SCIENCE, V259, P988; LOWE G, 1993, NATURE, V366, P283, DOI 10.1038/366283a0; MACKAYSIM A, 1994, J NEUROPHYSIOL, V71, pC15; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; MORI K, 1995, PROG NEUROBIOL, V45, P585, DOI 10.1016/0301-0082(94)00058-P; Moriyoshi K, 1996, NEURON, V16, P255, DOI 10.1016/S0896-6273(00)80044-6; NGAI J, 1993, CELL, V72, P657, DOI 10.1016/0092-8674(93)90396-8; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OSTROWSKI J, 1992, ANNU REV PHARMACOL, V32, P167, DOI 10.1146/annurev.pharmtox.32.1.167; OTTOSON D, 1956, ACTA PHYSIOL SC S122, V35, P1; Ottoson D, 1971, HDB SENSORY PHYSIO 1, V4, P95; RAMING K, 1993, NATURE, V361, P353, DOI 10.1038/361353a0; RESSLER KJ, 1993, CELL, V73, P597, DOI 10.1016/0092-8674(93)90145-G; RESTREPO D, 1995, EXPT CELL BIOL TASTE, P387; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Sambrook J., 1989, MOL CLONING LAB MANU; SATO T, 1994, J NEUROPHYSIOL, V72, P2980, DOI 10.1152/jn.1994.72.6.2980; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Shenk T., 1996, FIELDS VIROLOGY, V2, P2111; SHEPHERD GM, 1994, NEURON, V13, P771, DOI 10.1016/0896-6273(94)90245-3; SHIRLEY SG, 1987, BIOCHEM J, V245, P185, DOI 10.1042/bj2450185; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; WELERDIECK C, 1997, CHEM SENSES, V22, P467; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1996, J NEUROBIOL, V30, P521, DOI 10.1002/(SICI)1097-4695(199608)30:4<521::AID-NEU7>3.0.CO;2-5	36	487	501	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					237	242		10.1126/science.279.5348.237	http://dx.doi.org/10.1126/science.279.5348.237			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422698				2022-12-01	WOS:000071408100045
J	Chesebro, B				Chesebro, B			Prion diseases - BSE and prions: Uncertainties about the agent	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; TRANSGENIC MICE; NEURODEGENERATION; PROTEIN		NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Chesebro, B (corresponding author), NIAID, Rocky Mt Labs, Persistent Viral Dis Lab, Hamilton, MT 59840 USA.							Aguzzi A, 1997, NATURE, V389, P795, DOI 10.1038/39758; BESSEN RA, 1995, NATURE, V375, P698, DOI 10.1038/375698a0; BROWN P, 1994, ANN NEUROL, V35, P513, DOI 10.1002/ana.410350504; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BRUCE ME, 1997, COMMUNICATION; Chesebro B, 1997, NAT MED, V3, P491, DOI 10.1038/nm0597-491; Cousens SN, 1997, BRIT MED J, V315, P389, DOI 10.1136/bmj.315.7105.389; CUGHEY B, 1997, TRENDS CELL BIOL, V7, P56; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; Raymond GJ, 1997, NATURE, V388, P285, DOI 10.1038/40876; Tateishi J, 1996, NEUROLOGY, V46, P532, DOI 10.1212/WNL.46.2.532; Telling GC, 1996, GENE DEV, V10, P1736, DOI 10.1101/gad.10.14.1736; Will RG, 1996, LANCET, V347, P921, DOI 10.1016/S0140-6736(96)91412-9	14	145	149	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					42	43		10.1126/science.279.5347.42	http://dx.doi.org/10.1126/science.279.5347.42			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9441410				2022-12-01	WOS:000071323900032
J	Schwartz, LB				Schwartz, LB			Understanding human parturition	LANCET			English	Editorial Material							PROGESTERONE RECEPTORS; LABOR; ESTRADIOL; PREGNANCY; TERM		NYU, Med Ctr, Dept Obstet & Gynaecol, New York, NY 10016 USA	New York University	Schwartz, LB (corresponding author), NYU, Med Ctr, Dept Obstet & Gynaecol, New York, NY 10016 USA.							AMBRUS G, 1994, ENDOCRINOLOGY, V135, P2772, DOI 10.1210/en.135.6.2772; BECK P, 1978, OBSTET GYNECOL, V51, P686; CHWALISZ K, 1994, HUM REPROD, V9, P131, DOI 10.1093/humrep/9.suppl_1.131; Faber BM, 1996, OBSTET GYNECOL, V88, P174, DOI 10.1016/0029-7844(96)00136-6; FLINT APF, 1975, BIOCHEM SOC T, V3, P1189, DOI 10.1042/bst0031189; GIANNOPOULOS G, 1979, J CLIN ENDOCR METAB, V49, P100, DOI 10.1210/jcem-49-1-100; HOW H, 1995, OBSTET GYNECOL, V86, P936, DOI 10.1016/0029-7844(95)00306-C; JOHNSTON TA, 1993, BRIT J OBSTET GYNAEC, V100, P483, DOI 10.1111/j.1471-0528.1993.tb15277.x; Karalis K, 1996, NAT MED, V2, P556, DOI 10.1038/nm0596-556; KHANDAWOOD FS, 1984, AM J OBSTET GYNECOL, V150, P510; PADAYACHI T, 1990, J STEROID BIOCHEM, V37, P509, DOI 10.1016/0960-0760(90)90394-Z; PERROTAPPLANAT M, 1994, J CLIN ENDOCR METAB, V78, P216, DOI 10.1210/jc.78.1.216; Rezapour M, 1997, OBSTET GYNECOL, V89, P918, DOI 10.1016/S0029-7844(97)00116-6; Rezapour M, 1996, STEROIDS, V61, P338, DOI 10.1016/0039-128X(96)00035-9; WILSON L, 1996, REPROD ENDOCRINOLOGY, P452	15	14	15	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1792	1793		10.1016/S0140-6736(05)63632-X	http://dx.doi.org/10.1016/S0140-6736(05)63632-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428247	hybrid			2022-12-01	WOS:000071102500004
J	Huala, E; Oeller, PW; Liscum, E; Han, IS; Larsen, E; Briggs, WR				Huala, E; Oeller, PW; Liscum, E; Han, IS; Larsen, E; Briggs, WR			Arabidopsis NPH1: A protein kinase with a putative redox-sensing domain	SCIENCE			English	Article							LIGHT-INDUCED PHOSPHORYLATION; AZOTOBACTER-VINELANDII NIFL; NUCLEOTIDE-SEQUENCE; POTASSIUM CHANNEL; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; GENE-EXPRESSION; HIGHER-PLANTS; THALIANA; DROSOPHILA	The NPH1 (nonphototropic hypocotyl 1) gene encodes an essential component acting very early in the signal-transduction chain for phototropism. Arabidopsis NPH? contains a serine-threonine kinase domain and LOV1 and LOV2 repeats that share similarity (36 to 56 percent) with Halobacterium salinarium Bat, Azotobacter vinelandii NIFL, Neurospora crassa White Collar-1, Escherichia call Aer, and the fag family of potassium-channel proteins from Drosophila and mammals. Sequence similarity with a known (NIFL) and a suspected (Aer) flavoprotein suggests that NPH1 LOV1 and LOV2 may be flavin-binding domains that regulate kinase activity in response to blue light-induced redox changes.	CARNEGIE INST WASHINGTON, DEPT PLANT BIOL, STANFORD, CA 94305 USA	Carnegie Institution for Science			Huala, Eva L/B-1377-2009	Liscum, Emmanuel/0000-0002-8672-9315; Huala, Eva/0000-0003-4631-7241				AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; ALLMEIER H, 1992, GENE, V111, P11, DOI 10.1016/0378-1119(92)90597-I; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Ballario P, 1996, EMBO J, V15, P1650, DOI 10.1002/j.1460-2075.1996.tb00510.x; BAUR B, 1994, PLANT PHYSIOL, V106, P1225, DOI 10.1104/pp.106.3.1225; Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BLANCO G, 1993, MOL MICROBIOL, V9, P869, DOI 10.1111/j.1365-2958.1993.tb01745.x; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DRUMMOND MH, 1987, MOL MICROBIOL, V1, P37, DOI 10.1111/j.1365-2958.1987.tb00524.x; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; GROPP F, 1994, P NATL ACAD SCI USA, V91, P5475, DOI 10.1073/pnas.91.12.5475; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Kaneko T, 1996, DNA Res, V3, P185, DOI 10.1093/dnares/3.3.185; KHURANA J P, 1989, Planta (Heidelberg), V178, P400, DOI 10.1007/BF00391868; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LEONG D, 1988, J BACTERIOL, V170, P4903, DOI 10.1128/jb.170.10.4903-4909.1988; Li XD, 1997, J BIOL CHEM, V272, P705, DOI 10.1074/jbc.272.2.705; Lin C., 1996, PLANT PHYSIOL, V110, P1047; LIN X, 1991, P NATL ACAD SCI USA, V88, P6951, DOI 10.1073/pnas.88.16.6951; LISCUM E, 1995, PLANT CELL, V7, P473, DOI 10.1105/tpc.7.4.473; LISCUM E, ANAL BIOTECHNOLOGY G; LUDWIG J, 1994, EMBO J, V13, P4451, DOI 10.1002/j.1460-2075.1994.tb06767.x; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; NARBERHAUS F, 1995, J BACTERIOL, V177, P5078, DOI 10.1128/jb.177.17.5078-5087.1995; PALMER JM, 1993, PLANT PHYSIOL, V102, P1211, DOI 10.1104/pp.102.4.1211; RAINA R, 1993, MOL GEN GENET, V237, P400, DOI 10.1007/BF00279444; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; REYMOND P, 1992, PLANT PHYSIOL, V100, P655, DOI 10.1104/pp.100.2.655; REYMOND P, 1992, P NATL ACAD SCI USA, V89, P4718, DOI 10.1073/pnas.89.10.4718; SHORT TW, 1994, PLANT PHYSIOL, V104, P1317, DOI 10.1104/pp.104.4.1317; SHORT TW, 1994, ANNU REV PLANT PHYS, V45, P143, DOI 10.1146/annurev.pp.45.060194.001043; Siddavattam D, 1995, MOL GEN GENET, V249, P629, DOI 10.1007/BF00418032; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; TYTGAT J, 1993, J BIOL CHEM, V268, P23777; VOS P, 1995, NUCLEIC ACIDS RES, V23, P4407, DOI 10.1093/nar/23.21.4407; WADA M, COMMUNICATION; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; ZABEAU M, 1993, Patent No. 4026297; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	45	585	622	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2120	2123		10.1126/science.278.5346.2120	http://dx.doi.org/10.1126/science.278.5346.2120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405347				2022-12-01	WOS:A1997YM23500052
J	McKernan, MG; ShinnickGallagher, P				McKernan, MG; ShinnickGallagher, P			Fear conditioning induces a lasting potentiation of synaptic currents in vitro	NATURE			English	Article							PAIRED-PULSE FACILITATION; LONG-TERM POTENTIATION; MEDIAL GENICULATE-BODY; LATERAL NUCLEUS; RAT HIPPOCAMPUS; NMDA RECEPTORS; PATCH-CLAMP; CA1 REGION; AMYGDALA; TRANSMISSION	The amygdala plays a critical role in the mediation of emotional responses, particularly fear, in both humans and animals(1-4). Fear conditioning, a conditioned learning paradigm, has served as a model for emotional learning in animals, and the neuroanatomical circuitry underlying the auditory fear-conditioning paradigm is well characterized(5). Synaptic transmission in the medial geniculate nucleus (MGN) to lateral nucleus of the amygdala (LA) pathway, a key segment of the auditory fear conditioning circuit, is mediated largely through N-methyl-D-aspartate (NMDA) and non-NMDA (such as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)) glutamate receptors(6); the potential for neural plasticity in this pathway is suggested by its capacity to support long-term potentiation (LTP)(7,8). Here we report a long-lasting increase in the synaptic efficacy of the MGN-LA pathway attributable to fear-conditioning itself, rather than an electrically induced model of learning. Fear-conditioned animals show a presynaptic facilitation of AMPA-receptor-mediated transmission, directly measured in vitro with whole-cell recordings in lateral amygdala neurons. These findings represent one of the first in vitro measures of synaptic plasticity resulting from emotional learning by whole animals.	UNIV TEXAS,MED BRANCH,DEPT PHARMACOL & TOXICOL,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston								ALDOLPHS R, 1994, NATURE, V372, P669; ANDREASEN M, 1994, J NEUROPHYSIOL, V72, P326, DOI 10.1152/jn.1994.72.1.326; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; CLARK KA, 1994, EXP BRAIN RES, V101, P272, DOI 10.1007/BF00228747; CLUGNET MC, 1990, J NEUROSCI, V10, P2818; CREAGER R, 1980, J PHYSIOL-LONDON, V299, P409, DOI 10.1113/jphysiol.1980.sp013133; DAVIS M, 1994, TRENDS NEUROSCI, V17, P208, DOI 10.1016/0166-2236(94)90106-6; DAVIS M, 1993, BEHAV BRAIN RES, V58, P175, DOI 10.1016/0166-4328(93)90102-V; KATZ B, 1968, J PHYSIOL-LONDON, V195, P481, DOI 10.1113/jphysiol.1968.sp008469; KAUER JA, 1988, NEURON, V1, P911, DOI 10.1016/0896-6273(88)90148-1; KIM M, 1993, BEHAV NEURAL BIOL, V59, P5, DOI 10.1016/0163-1047(93)91075-X; KUHNT U, 1994, NEUROSCIENCE, V62, P391, DOI 10.1016/0306-4522(94)90374-3; KULLMANN DM, 1994, NEURON, V12, P1111, DOI 10.1016/0896-6273(94)90318-2; LEDOUX JE, 1985, J COMP NEUROL, V242, P182, DOI 10.1002/cne.902420204; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LI XF, 1995, EXP BRAIN RES, V105, P87; LIN JW, 1988, J NEUROSCI, V8, P1313; MANABE T, 1993, J NEUROPHYSIOL, V70, P1451, DOI 10.1152/jn.1993.70.4.1451; Maren S, 1996, MOL NEUROBIOL, V13, P1, DOI 10.1007/BF02740749; McKernan M. G., 1996, Society for Neuroscience Abstracts, V22, P1536; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MULLER D, 1990, SYNAPSE, V5, P94, DOI 10.1002/syn.890050203; MULLER D, 1988, SCIENCE, V242, P1694, DOI 10.1126/science.2904701; Neugebauer V, 1997, J NEUROSCI, V17, P983; PARSONS CG, 1994, NEUROPHARMACOLOGY, V33, P589, DOI 10.1016/0028-3908(94)90163-5; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Scott SK, 1997, NATURE, V385, P254, DOI 10.1038/385254a0; SHULZ P, 1994, J NEUROSCI, V14, P5325	29	610	619	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					607	611		10.1038/37605	http://dx.doi.org/10.1038/37605			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403689				2022-12-01	WOS:A1997YK85300049
J	Uozumi, N; Kume, K; Nagase, T; Nakatani, N; Ishii, S; Tashiro, F; Komagata, Y; Maki, K; Ikuta, K; Ouchi, Y; Miyazaki, J; Shimizu, T				Uozumi, N; Kume, K; Nagase, T; Nakatani, N; Ishii, S; Tashiro, F; Komagata, Y; Maki, K; Ikuta, K; Ouchi, Y; Miyazaki, J; Shimizu, T			Role of cytosolic phospholipase A(2) in allergic response and parturition	NATURE			English	Article							PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID; MAST-CELLS; GENE DISRUPTION; DEFICIENT MICE; RECEPTOR; MOUSE; PHOSPHORYLATION; TRANSLOCATION; KINASE	Phospholipase A(2) (PLA(2)) comprises a superfamily of enzymes that hydrolyse the ester bond of phospholipids at the sn-2 position(1-3). Among the members of this superfamily, cytosolic PLA(2) has attracted attention because it preferentially hydrolyses arachidonoyl phospholipids and is activated by submicromolar concentrations of Ca2+ ions and by phosphorylation by mitogen-activated protein kinases (MAP kinases)(4-8). Here we investigate the function of cytosolic PLA(2) in vivo by using homologous recombination to generate mice deficient in this enzyme. These mice showed a marked decrease in their production of eicosanoids and platelet-activating factor in peritoneal macrophages. Their ovalbumin-induced anaphylactic responses were significantly reduced, as was their bronchial reactivity to methacholine. Female mutant mice failed to deliver offspring, but these could be rescued by administration of a progesterone-receptor antagonist to the mother at term. Considered together with previous findings(9-15), our results indicate that cytosolic PLA(2) plays a non-redundant role in allergic responses and reproductive physiology.	UNIV TOKYO,FAC MED,DEPT BIOCHEM & MOL BIOL,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DEPT GERIATR,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,FAC MED,DIS RELATED GENE REGULAT RES SANDOZ,BUNKYO KU,TOKYO 113,JAPAN; TOHOKU UNIV,INST DEV AGING & CANC,AOBA KU,SENDAI,MIYAGI 98077,JAPAN	University of Tokyo; University of Tokyo; University of Tokyo; Tohoku University			Miyazaki, Jun-ichi/N-1976-2015; Uozumi, Nobuyuki/AAG-3252-2019	Miyazaki, Jun-ichi/0000-0003-2475-589X; Ikuta, Koichi/0000-0003-1319-1021; Kume, Kazuhiko/0000-0003-4232-1657				AOKI Y, 1995, J IMMUNOL METHODS, V186, P225, DOI 10.1016/0022-1759(95)00147-3; Bingham CO, 1996, J BIOL CHEM, V271, P25936, DOI 10.1074/jbc.271.42.25936; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CURRIE S, 1994, BIOCHEM J, V304, P923, DOI 10.1042/bj3040923; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dudley DJ, 1996, BIOL REPROD, V55, P992, DOI 10.1095/biolreprod55.5.992; GLOVER S, 1995, J BIOL CHEM, V270, P15359, DOI 10.1074/jbc.270.25.15359; GOLDBERG VJ, 1975, PHYSIOL REV, V55, P325, DOI 10.1152/physrev.1975.55.3.325; GOULET JL, 1994, P NATL ACAD SCI USA, V91, P12852, DOI 10.1073/pnas.91.26.12852; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053, DOI 10.1152/ajplung.1997.272.6.L1053; Ishii S, 1997, EMBO J, V16, P133, DOI 10.1093/emboj/16.1.133; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Nagase T, 1996, AM J RESP CRIT CARE, V154, P504, DOI 10.1164/ajrccm.154.2.8756829; NAKATANI Y, 1994, J IMMUNOL, V153, P796; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; ONEILL C, 1989, LANCET, V2, P769; Prescott SM, 1997, J BIOL CHEM, V272, P15043, DOI 10.1074/jbc.272.24.15043; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHARP JD, 1994, J BIOL CHEM, V269, P23250; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; TAKAYAMA K, 1991, FEBS LETT, V282, P326, DOI 10.1016/0014-5793(91)80506-X	30	582	602	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					618	622		10.1038/37622	http://dx.doi.org/10.1038/37622			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403692				2022-12-01	WOS:A1997YK85300052
J	OBrien, E				OBrien, E			Walk in peace: banish landmines from our globe	BRITISH MEDICAL JOURNAL			English	Article											OBrien, E (corresponding author), ROYAL COLL SURGEONS IRELAND,SCH MED,ST STEPHENS GREEN,DUBLIN 2,IRELAND.								0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1456	1458		10.1136/bmj.315.7120.1456	http://dx.doi.org/10.1136/bmj.315.7120.1456			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418101	Green Published			2022-12-01	WOS:A1997YJ67200038
J	Moliterno, AR; Hankins, WD; Spivak, JL				Moliterno, AR; Hankins, WD; Spivak, JL			Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-MPL LIGAND; COLONY-STIMULATING FACTOR; MULTIPOTENT STEM-CELL; HUMAN BLOOD-PLATELETS; TYROSINE PHOSPHORYLATION; ERYTHROPOIETIN RECEPTOR; MYELOPROLIFERATIVE DISORDERS; HEMATOPOIETIC PROGENITORS; ESSENTIAL THROMBOCYTHEMIA; GRANULOCYTE-MACROPHAGE	Background The cause of polycythemia vera, which originates from a multipotent hematopoietic progenitor cell, is unknown, Thrombopoietin is a hematopoietic growth factor that regulates the production of multipotent hematopoietic progenitor cells and platelets. To evaluate the possibility that an abnormality in thrombopoietin-mediated signal transduction might be involved in the pathogenesis of polycythemia vera, we examined thrombopoietin-induced tyrosine phosphorylation of proteins and the expression of the thrombopoietin receptor in platelets from patients with the disease. Methods Platelets were isolated from the blood of patients with polycythemia vera or other chronic myeloproliferative disorders and control subjects, The platelets were exposed to either thrombopoietin or thrombin and then lysed for analysis of tyrosine phosphorylation of platelet proteins and the expression of the proteins by means of immunoblotting, Expression of the thrombopoietin receptor (Mpl) by platelets and megakaryocytes was also assessed. Results Thrombopoietin-mediated tyrosine phosphorylation of proteins was impaired in platelets from 20 patients with polycythemia vera and 3 with idiopathic myelofibrosis, but not in 4 patients with essential thrombocytosis, 3 with chronic myelogenous leukemia, 6 with secondary erythrocytosis, 2 with iron-deficiency anemia, 4 with hemochromatosis, or 5 normal subjects. Thrombin-mediated tyrosine phosphorylation of proteins was intact in platelets from patients with polycythemia vera, and the tyrosine kinases and substrates involved in the process were present in normal amounts. However, expression of the platelet thrombopoietin receptor Mpl was markedly reduced or absent in 34 of 34 patients with polycythemia vera and in 13 of 14 patients with idiopathic myelofibrosis. Impaired thrombopoietin-induced tyrosine phosphorylation of proteins in patients with these two diseases was uniformly associated with markedly reduced expression of Mpl or the lack of its expression. In patients with polycythemia vera, reduced expression of Mpl by platelets was associated with reduced expression of Mpl by megakaryocytes. Conclusions Reduced expression of the thrombopoietin receptor Mpl is characteristic of polycythemia vera and idiopathic myelofibrosis, The abnormality appears to distinguish polycythemia vera from other forms of erythrocytosis. (C) 1998, Massachusetts Medical Society.	Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Baltimore, MD 21205 USA	Johns Hopkins University	Spivak, JL (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Hematol, Traylor 924,720 Rutland Ave, Baltimore, MD 21205 USA.				PHS HHS [R01-H158589] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; BERGER S, 1973, CANCER RES, V33, P2683; BERK PD, 1986, SEMIN HEMATOL, V23, P132; CarverMoore K, 1996, BLOOD, V88, P803; CASHMAN J, 1983, BLOOD, V61, P876; Cocault L, 1996, BLOOD, V88, P1656; COOPER B, 1979, J CLIN INVEST, V64, P586, DOI 10.1172/JCI109497; CORREA PN, 1994, BLOOD, V83, P99; DAI CH, 1994, BRIT J HAEMATOL, V86, P12, DOI 10.1111/j.1365-2141.1994.tb03246.x; DAI CH, 1992, BLOOD, V80, P891; Damen JE, 1996, EXP HEMATOL, V24, P1455; DEBILI N, 1995, BLOOD, V85, P391, DOI 10.1182/blood.V85.2.391.bloodjournal852391; DELACHAPELLE A, 1993, P NATL ACAD SCI USA, V90, P4495, DOI 10.1073/pnas.90.10.4495; DEWOLF JTM, 1989, EXP HEMATOL, V17, P981; DRACHMAN JG, 1995, J BIOL CHEM, V270, P4979, DOI 10.1074/jbc.270.10.4979; EMANUEL PD, 1992, BLOOD, V79, P3019; Emmons RVB, 1996, BLOOD, V87, P4068, DOI 10.1182/blood.V87.10.4068.bloodjournal87104068; EZUMI Y, 1995, FEBS LETT, V374, P48, DOI 10.1016/0014-5793(95)01072-M; FIALKOW PJ, 1980, BLOOD, V56, P70; FIALKOW PJ, 1981, BLOOD, V58, P916; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; HOFFMAN R, 1995, HEMATOLOGY BASIC PRI; JACOBSON RJ, 1978, BLOOD, V51, P189; KAUSHANSKY K, 1995, BLOOD, V86, P419, DOI 10.1182/blood.V86.2.419.bloodjournal862419; KAYWIN P, 1978, NEW ENGL J MED, V299, P505, DOI 10.1056/NEJM197809072991002; Ku H, 1996, BLOOD, V87, P4544, DOI 10.1182/blood.V87.11.4544.bloodjournal87114544; KUTER DJ, 1995, BLOOD, V85, P2720, DOI 10.1182/blood.V85.10.2720.bloodjournal85102720; LeCouedic JP, 1996, BLOOD, V87, P1502, DOI 10.1182/blood.V87.4.1502.bloodjournal8741502; Marsh JCW, 1996, BRIT J HAEMATOL, V95, P605, DOI 10.1046/j.1365-2141.1996.d01-1966.x; MEANS RT, 1989, J CLIN INVEST, V84, P1340, DOI 10.1172/JCI114303; MIYAKAWA Y, 1995, BLOOD, V86, P23, DOI 10.1182/blood.V86.1.23.bloodjournal86123; Miyakawa Y, 1996, BLOOD, V87, P439, DOI 10.1182/blood.V87.2.439.bloodjournal872439; Oda A, 1996, BLOOD, V88, P4304; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; RAMAN BKS, 1989, AM J CLIN PATHOL, V91, P647, DOI 10.1093/ajcp/91.6.647; SCHAFER AI, 1982, NEW ENGL J MED, V306, P381, DOI 10.1056/NEJM198202183060701; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SOKOL L, 1995, BLOOD, V86, P15, DOI 10.1182/blood.V86.1.15.bloodjournal86115; SOUYRI M, 1990, CELL, V63, P1137, DOI 10.1016/0092-8674(90)90410-G; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TORTOLANI PJ, 1995, BLOOD, V85, P3444, DOI 10.1182/blood.V85.12.3444.bloodjournal85123444; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; WENDLING F, 1986, VIROLOGY, V149, P242, DOI 10.1016/0042-6822(86)90125-X; YAN XQ, 1995, BLOOD, V86, P4025, DOI 10.1182/blood.V86.11.4025.bloodjournal86114025	44	237	249	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					572	580		10.1056/NEJM199802263380903	http://dx.doi.org/10.1056/NEJM199802263380903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475764				2022-12-01	WOS:000072175700003
J	Vinkemeier, U; Moarefi, I; Darnell, JE; Kuriyan, J				Vinkemeier, U; Moarefi, I; Darnell, JE; Kuriyan, J			Structure of the amino-terminal protein interaction domain of STAT-4	SCIENCE			English	Article							DNA-BINDING; SIGNAL TRANSDUCERS; HORMONE INDUCTION; TRANSCRIPTION; INTERFERON; PROMOTER; SITES; ALPHA; GENE; ACTIVATORS	STATs (signal transducers and activators of transcription) are a family of transcription factors that are specifically activated to regulate gene transcription when cells encounter cytokines and growth factors, The crystal structure of an NH2-terminal conserved domain (N-domain) comprising the first 123 residues of STAT-4 was determined at 1.45 angstroms, The domain consists of eight helices that are assembled into a hook-like structure, The N-domain has been implicated in several protein-protein interactions affecting transcription, and it enables dimerized STAT molecules to polymerize and to bind DNA cooperatively, The structure shows that N-domains can interact through an extensive interface formed by polar interactions across one face of the hook. Mutagenesis of an invariant tryptophan residue at the heart of this interface abolished cooperative DNA binding by the full-length protein in vitro and reduced the transcriptional response after cytokine stimulation in vivo.	Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA; Rockefeller Univ, Labs Mol Biophys, New York, NY 10021 USA; Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University; Rockefeller University; Rockefeller University	Kuriyan, J (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10021 USA.	kuriyan@rockvax.rockefeller.edu		Vinkemeier, Uwe/0000-0001-6924-1783	NIAID NIH HHS [AI34420, AI32489] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032489, R37AI034420, R01AI034420] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BERGAD PL, 1995, J BIOL CHEM, V270, P24903, DOI 10.1074/jbc.270.42.24903; Brunger AT, 1992, XPLOR VERSION 3 1 MA; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Dajee M, 1996, MOL ENDOCRINOL, V10, P171, DOI 10.1210/me.10.2.171; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; John S, 1996, EMBO J, V15, P5627, DOI 10.1002/j.1460-2075.1996.tb00947.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawata T, 1997, CELL, V89, P909, DOI 10.1016/S0092-8674(00)80276-7; Leaman DW, 1996, FASEB J, V10, P1578, DOI 10.1096/fasebj.10.14.9002549; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Leung S, 1996, SCIENCE, V273, P750, DOI 10.1126/science.273.5276.750; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/S0968-0004(96)10052-9; McKnight SL, 1996, GENE DEV, V10, P367, DOI 10.1101/gad.10.4.367; MEIER VS, 1994, MOL CELL BIOL, V14, P128, DOI 10.1128/MCB.14.1.128; Mikita T, 1996, MOL CELL BIOL, V16, P5811; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SYMES A, 1994, MOL ENDOCRINOL, V8, P1750, DOI 10.1210/me.8.12.1750; TIJAN R, 1994, CELL, V77, P5; Vinkemeier U, 1996, EMBO J, V15, P5616, DOI 10.1002/j.1460-2075.1996.tb00946.x; VINKEMEIER U, UNPUB; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Xu D, 1997, J MOL BIOL, V265, P68, DOI 10.1006/jmbi.1996.0712; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yan RQ, 1996, P NATL ACAD SCI USA, V93, P5842, DOI 10.1073/pnas.93.12.5842; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	37	208	218	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1048	1052		10.1126/science.279.5353.1048	http://dx.doi.org/10.1126/science.279.5353.1048			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461439				2022-12-01	WOS:000072006400051
J	Witte, W				Witte, W			Medical consequences of antibiotic use in agriculture	SCIENCE			English	Article							RESISTANCE		Robert Koch Inst, Wernigerode Branch, D-38855 Wernigerode, Germany	Robert Koch Institute	Witte, W (corresponding author), Robert Koch Inst, Wernigerode Branch, D-38855 Wernigerode, Germany.		Ha, Dat Thinh/D-4995-2015	Ha, Dat Thinh/0000-0003-4260-4876				Arthur M, 1996, TRENDS MICROBIOL, V4, P401, DOI 10.1016/0966-842X(96)10063-9; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Gaunt PN, 1996, J ANTIMICROB CHEMOTH, V37, P747, DOI 10.1093/jac/37.4.747; Levy S B, 1994, Trends Microbiol, V2, P341, DOI 10.1016/0966-842X(94)90607-6; LEVY SB, 1976, NEW ENGL J MED, V295, P583, DOI 10.1056/NEJM197609092951103; Tenover FC, 1996, AM J MED SCI, V311, P9, DOI 10.1097/00000441-199601000-00003; THOMKE S, 1997, REPORT COMMISSION AN; TRELFALL J, 1996, LANCET, V347, P1053; TSCHAPE H, 1994, FEMS MICROBIOL ECOL, V15, P23, DOI 10.1016/0168-6496(94)90022-1; *WHO SCI WORK GROU, 1994, WHOCDSBVI957; Witte W, 1995, MICROB DRUG RESIST, V1, P259, DOI 10.1089/mdr.1995.1.259; 1997, WHO M MED IMP US ANT; 1969, REPORT JOINT COMMITT	13	628	657	1	196	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					996	997		10.1126/science.279.5353.996	http://dx.doi.org/10.1126/science.279.5353.996			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9490487				2022-12-01	WOS:000072006400032
J	Chen, CT; Wagner, H; Still, WC				Chen, CT; Wagner, H; Still, WC			Fluorescent, sequence-selective peptide detection by synthetic small molecules	SCIENCE			English	Article							2-ARMED RECEPTORS; BINDING; DESIGN; CHEMOSENSOR; LIBRARIES; WATER; ZINC; ACID	Small organic sensor molecules were prepared that bind and signal the presence of unlabeled tripeptides in a sequence-selective manner. Sequence-selective peptide binding is a difficult problem because small peptides are highly flexible acid there are no clear rules for designing peptide-binding molecules as there are for the nucleic acids. The signaling system involved the application of fluorescence energy transfer and provided large, real-time fluorescence increases (300 to 500 percent) upon peptide binding. With it, these sensors were sensitive enough to detect unlabeled cognate peptides both in organic solution and in the solid state at low micromolar concentrations.	Columbia Univ, Dept Chem, New York, NY 10027 USA	Columbia University	Still, WC (corresponding author), Columbia Univ, Dept Chem, New York, NY 10027 USA.							ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERT JS, 1995, J AM CHEM SOC, V117, P1143, DOI 10.1021/ja00108a037; AOKI I, 1992, J CHEM SOC CHEM COMM, P730, DOI 10.1039/c39920000730; BELL TW, 1995, SCIENCE, V269, P671, DOI 10.1126/science.7624796; BOYCE R, 1994, J AM CHEM SOC, V116, P7955, DOI 10.1021/ja00096a086; Cheng YA, 1996, J AM CHEM SOC, V118, P1813, DOI 10.1021/ja952976v; CZARNIK AW, 1995, CHEM BIOL, V2, P423, DOI 10.1016/1074-5521(95)90257-0; CZARNIK AW, 1992, ACS S SER, V538; DESVERGNE JP, 1997, NATO ASI SER C; FABBRIZZI L, 1995, CHEM SOC REV, P197; Godwin HA, 1996, J AM CHEM SOC, V118, P6514, DOI 10.1021/ja961184d; GOODMAN MS, 1995, J AM CHEM SOC, V117, P11610, DOI 10.1021/ja00151a039; HEALEY BG, 1995, SCIENCE, V269, P1078, DOI 10.1126/science.7652555; Ikeda H, 1997, J ORG CHEM, V62, P1411, DOI 10.1021/jo960425x; Iorio EJ, 1996, BIOORG MED CHEM LETT, V6, P2673, DOI 10.1016/S0960-894X(96)00500-8; JAMES TD, 1995, NATURE, V374, P345, DOI 10.1038/374345a0; KUHN MA, 1993, ACS SYM SER, V538, P147; LABRENZ SR, 1995, J AM CHEM SOC, V117, P3887; Mortellaro MA, 1996, J AM CHEM SOC, V118, P7414, DOI 10.1021/ja961323r; Nestler HP, 1996, MOL DIVERS, V2, P35, DOI 10.1007/BF01718698; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Pan ZY, 1996, TETRAHEDRON LETT, V37, P8699, DOI 10.1016/S0040-4039(96)02040-0; Peczuh MW, 1997, J AM CHEM SOC, V119, P9327, DOI 10.1021/ja970951l; Shao YF, 1996, J ORG CHEM, V61, P6086, DOI 10.1021/jo960775j; Still WC, 1996, ACCOUNTS CHEM RES, V29, P155, DOI 10.1021/ar950166i; TORNEIRO M, 1995, J AM CHEM SOC, V117, P5887, DOI 10.1021/ja00126a043; Torneiro M, 1997, TETRAHEDRON, V53, P8739, DOI 10.1016/S0040-4020(97)90388-4; TSIEN RY, 1980, BIOCHEMISTRY-US, V19, P2396, DOI 10.1021/bi00552a018; Walkup GK, 1996, J AM CHEM SOC, V118, P3053, DOI 10.1021/ja9538501; WENNEMERS H, 1995, J ORG CHEM, V60, P1108, DOI 10.1021/jo00110a007; YOON J, 1992, J AM CHEM SOC, V114, P5874, DOI 10.1021/ja00040a067	31	121	127	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					851	853		10.1126/science.279.5352.851	http://dx.doi.org/10.1126/science.279.5352.851			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452382				2022-12-01	WOS:000071923500040
J	Kurokawa, R; Kalafus, D; Ogliastro, MH; Kioussi, C; Xu, L; Torchia, J; Rosenfeld, MG; Glass, CK				Kurokawa, R; Kalafus, D; Ogliastro, MH; Kioussi, C; Xu, L; Torchia, J; Rosenfeld, MG; Glass, CK			Differential use of CREB binding protein coactivator complexes	SCIENCE			English	Article							TRANSCRIPTIONAL COACTIVATOR; NUCLEAR RECEPTORS; P300; CBP; ACTIVATION; E1A	CREB binding protein (CBP) functions as an essential coactivator of transcription factors that are inhibited by the adenovirus early gene product E1A. Transcriptional activation by the signal transducer and activator of transcription-1 (STAT1) protein requires the C/H3 domain in CBP, which is the primary target of E1A inhibition, Here it was found that the C/H3 domain is not required for retinoid acid receptor (RAR) function, nor is it involved in E1A inhibition, Instead, E1A inhibits RAR function by preventing the assembly of CBP-nuclear receptor coactivator complexes, revealing differences in required CBP domains for transcriptional activation by RAR and STAT1.	Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Biomed Sci Grad Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, Div Cellular & Mol Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; Kioussi, Chrissa/0000-0001-8226-9908				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BANNISTER AJ, 1995, EMBO J, V14, P4758, DOI 10.1002/j.1460-2075.1995.tb00157.x; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; KUROKAWA R, UNPUB; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; NEVINS JR, 1992, SCIENCE, V258, P442; ONATE SA, 1995, SCIENCE, V270, P1354; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092	32	189	190	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					700	703		10.1126/science.279.5351.700	http://dx.doi.org/10.1126/science.279.5351.700			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445474				2022-12-01	WOS:000071731500035
J	Gill, N				Gill, N			Promoting testing is no substitute for recognising risk - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England	Public Health England	Gill, N (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England.							*DEP HLTH, 1997, ANN REP UNL AN PREV; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; Nicoll A, 1998, BRIT MED J, V316, P253, DOI 10.1136/bmj.316.7127.253	3	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					295	296		10.1136/bmj.316.7127.295	http://dx.doi.org/10.1136/bmj.316.7127.295			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472519	Green Published			2022-12-01	WOS:000071702100035
J	Han, JW; Luby-Phelps, K; Das, B; Shu, XD; Xia, Y; Mosteller, RD; Krishna, UM; Falck, JR; White, MA; Broek, D				Han, JW; Luby-Phelps, K; Das, B; Shu, XD; Xia, Y; Mosteller, RD; Krishna, UM; Falck, JR; White, MA; Broek, D			Role of substrates and products of PI3-kinase in regulating activation of Rac-related guanosine triphosphatases by Vav	SCIENCE			English	Article							PROTEIN; TRANSFORMATION; EFFECTORS; EXCHANGE; DISTINCT; DOMAIN; DBL	Mitogen stimulation of cytoskeletal changes and c-jun amino-terminal kinases is mediated by Rac small guanine nucleotide-binding proteins, Vav, a guanosine diphosphate (GDP)-guanosine triphosphate (GTP) exchange factor for Rac that stimulates the exchange of bound GDP for GTP, bound to and was directly controlled by substrates and products of phosphoinositide (PI) 3-kinase, The PI 3-kinase substrate phosphatidylinositol-4,5-bisphosphate inhibited activation of Vav by the tyrosine kinase Lck, whereas the product phosphatidylinositol-3,4,5-trisphosphate enhanced phosphorylation and activation of Vav by Lck. Control of Vav in response to mitogens by the products of PI 3-kinase suggests a mechanism for Ras-dependent activation of Rac.	Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA	University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Broek, D (corresponding author), Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.	broek@zygote.hsc.usc.edu		Luby-Phelps, Katherine/0000-0002-8378-1409; Falck, John/0000-0002-9219-7845	NATIONAL CANCER INSTITUTE [R01CA071443, R01CA050261] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER; NCI NIH HHS [CA50261, CA71443] Funding Source: Medline; NIGMS NIH HHS [GM31278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSTELO XR, 1994, ONCOGENE, V9, P2405; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Han J., UNPUB; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; RAAB M, 1994, MOL CELL BIOL, V14, P2862, DOI 10.1128/MCB.14.5.2862; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; REDDY KK, 1995, J ORG CHEM, V60, P3385, DOI 10.1021/jo00116a023; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	23	687	697	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					558	560		10.1126/science.279.5350.558	http://dx.doi.org/10.1126/science.279.5350.558			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438848				2022-12-01	WOS:000071616000045
J	Glinka, A; Wu, W; Delius, H; Monaghan, AP; Blumenstock, C; Niehrs, C				Glinka, A; Wu, W; Delius, H; Monaghan, AP; Blumenstock, C; Niehrs, C			Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction	NATURE			English	Article							HOMEOBOX GENE; XENOPUS-EMBRYOS; SPEMANN ORGANIZER; WNT GENES; EXPRESSION; MESODERM; HOMOLOG; LAEVIS; RECEPTOR; SEQUENCE	The Spemann organizer in amphibian embryos is a tissue with potent head-inducing activity, the molecular nature of which is unresolved. Here we describe dickkopf-1 (dkk-1), which encodes Dkk-1, a secreted inducer of Spemann's organizer in Xenopus and a member of a new protein family. Injections of mRNA and antibody Indicate that dkk-1 is sufficient and necessary to cause head induction. dkk-1 is a potent antagonist of Wnt signalling, suggesting that dkk genes encode a family of secreted Wnt inhibitors.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Appl Tumorvirol, D-69120 Heidelberg, Germany; Deutsch Krebsforschungszentrum, Div Mol Biol Cell 1, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.							BallyCuif L, 1997, BIOESSAYS, V19, P127, DOI 10.1002/bies.950190207; BANVILLE D, 1985, NUCLEIC ACIDS RES, V13, P5407, DOI 10.1093/nar/13.15.5407; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BLITZ IL, 1995, DEVELOPMENT, V121, P993; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Carnac G, 1996, DEVELOPMENT, V122, P3055; CHO KWY, 1991, CELL, V67, P1111, DOI 10.1016/0092-8674(91)90288-A; CHRISTIAN JL, 1993, GENE DEV, V7, P13, DOI 10.1101/gad.7.1.13; CUI YZ, 1995, DEVELOPMENT, V121, P2177; Devoto SH, 1996, DEVELOPMENT, V122, P3371; Fagotto F, 1997, DEVELOPMENT, V124, P453; GAMMIL LS, 1996, DEVELOPMENT, V124, P471; GANS C, 1983, SCIENCE, V220, P268, DOI 10.1126/science.220.4594.268; Gawantka V, 1995, EMBO J, V14, P6268, DOI 10.1002/j.1460-2075.1995.tb00317.x; GERHART J, 1991, BOD MAR LAB, P57; Glinka A, 1996, MECH DEVELOP, V60, P221, DOI 10.1016/S0925-4773(96)00624-7; Glinka A, 1997, NATURE, V389, P517, DOI 10.1038/39092; GOOD PJ, 1989, NUCLEIC ACIDS RES, V17, P8000, DOI 10.1093/nar/17.19.8000; HARDY S, 1991, EUR J BIOCHEM, V202, P431, DOI 10.1111/j.1432-1033.1991.tb16392.x; Harlow E LD, 1988, ANTIBODIES LAB MANUA, V1st; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HEMMATIBRIVANLOU A, 1994, CELL, V77, P273, DOI 10.1016/0092-8674(94)90319-0; Itoh K, 1995, DEVELOPMENT, V121, P3979; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; Lecuit T, 1997, NATURE, V388, P139, DOI 10.1038/40563; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; Leyns L, 1997, CELL, V88, P747, DOI 10.1016/S0092-8674(00)81921-2; MEIER VS, 1989, NUCLEIC ACIDS RES, V17, P795, DOI 10.1093/nar/17.2.795; MONAGHAN AP, 1995, DEVELOPMENT, V121, P839; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; PANNESE M, 1995, DEVELOPMENT, V121, P707; PARR BA, 1994, CURR OPIN GENET DEV, V4, P523, DOI 10.1016/0959-437X(94)90067-D; PIERCE SB, 1995, DEVELOPMENT, V121, P755; RUPP RAW, 1994, GENE DEV, V8, P1311, DOI 10.1101/gad.8.11.1311; Ryan K, 1996, CELL, V87, P989, DOI 10.1016/S0092-8674(00)81794-8; SASAI Y, 1995, NATURE, V376, P333, DOI 10.1038/376333a0; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; SASAI Y, 1994, CELL, V79, P779, DOI 10.1016/0092-8674(94)90068-X; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL SY, 1995, DEVELOPMENT, V121, P1637; SUZUKI A, 1994, P NATL ACAD SCI USA, V91, P10255, DOI 10.1073/pnas.91.22.10255; Wang SW, 1997, CELL, V88, P757, DOI 10.1016/S0092-8674(00)81922-4; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4	46	1297	1404	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					357	362		10.1038/34848	http://dx.doi.org/10.1038/34848			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450748				2022-12-01	WOS:000071604200044
J	Xu, L; Eu, JP; Meissner, G; Stamler, JS				Xu, L; Eu, JP; Meissner, G; Stamler, JS			Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation	SCIENCE			English	Article							FROG SKELETAL-MUSCLE; PROTEIN-KINASE-C; NITRIC-OXIDE; SARCOPLASMIC-RETICULUM; FUNCTIONAL CONSEQUENCES; CA-2+ RELEASE; CA2+ RELEASE; OXIDATION; SULFHYDRYLS; MECHANISM	Several ion channels are reportedly redox responsive, but the molecular basis for the changes in activity is not known. The mechanism of nitric oxide action on the cardiac calcium release channel (ryanodine receptor) (CRC) in canines was explored. This tetrameric channel contains similar to 84 free thiols and is S-nitrosylated in vivo. S-Nitrosylation of up to 12 sites (3 per CRC subunit) led to progressive channel activation that was reversed by denitrosylation. In contrast, oxidation of 20 to 24 thiols per CRC (5 or 6 per subunit) had no effect on channel function. Oxidation of additional thiols (or of another class of thiols) produced irreversible activation. The CRC thus appears to be regulated by poly-S-nitrosylation (multiple covalent attachments), whereas oxidation can lead to loss of control. These results reveal that ion channels can differentiate nitrosative from oxidative signals and indicate that: the CRC is regulated by posttranslational chemical modification(s) of sulfurs.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Physiol, Chapel Hill, NC 27599 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Pulm, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Med,Div Cardiovasc Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Dept Cell Biol, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute	Meissner, G (corresponding author), Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA.			Stamler, Jonathan/0000-0002-6866-1572	NHLBI NIH HHS [HL59130, HL-27430, HL52529] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052529, R01HL059130, P01HL027430] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMSON JJ, 1983, P NATL ACAD SCI-BIOL, V80, P1526, DOI 10.1073/pnas.80.6.1526; ABRAMSON JJ, 1988, MOL CELL BIOCHEM, V82, P81; ABRAMSON JJ, 1989, J BIOENERG BIOMEMBR, V21, P283, DOI 10.1007/BF00812073; Aghdasi B, 1997, J BIOL CHEM, V272, P25462, DOI 10.1074/jbc.272.41.25462; ALLISON WS, 1976, ACCOUNTS CHEM RES, V9, P293, DOI 10.1021/ar50104a003; AOKI T, 1985, CAN J PHYSIOL PHARM, V63, P1070, DOI 10.1139/y85-175; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; CHIAMVIMONVAT N, 1995, CIRC RES, V76, P325, DOI 10.1161/01.RES.76.3.325; DOU YM, 1994, J BIOL CHEM, V269, P20410; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; FEELISCH M, 1996, METHODS NITRIC OXIDE, P71; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; GATH I, IN PRESS NITRIC OXID; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; JOCELYN PC, 1987, METHOD ENZYMOL, V143, P246; KAPLAN RS, 1985, ANAL BIOCHEM, V150, P97, DOI 10.1016/0003-2697(85)90445-2; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; LEE HB, 1994, J BIOL CHEM, V269, P13305; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Meszaros LG, 1996, FEBS LETT, V380, P49, DOI 10.1016/0014-5793(96)00003-8; MOHR S, 1994, FEBS LETT, V348, P223, DOI 10.1016/0014-5793(94)00596-6; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; OBA T, 1985, PFLUG ARCH EUR J PHY, V405, P354, DOI 10.1007/BF00595688; OBA T, 1992, BIOPHYS J, V63, P1416, DOI 10.1016/S0006-3495(92)81704-6; OTSU K, 1990, J BIOL CHEM, V265, P13472; Pinsky DJ, 1997, CIRC RES, V81, P372, DOI 10.1161/01.RES.81.3.372; PRABHU SD, 1990, ARCH BIOCHEM BIOPHYS, V282, P275, DOI 10.1016/0003-9861(90)90117-H; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699, DOI 10.1152/ajplung.1995.268.5.L699; RADI R, 1991, J BIOL CHEM, V266, P4244; Reid MB, 1996, NEWS PHYSIOL SCI, V11, P114, DOI 10.1152/physiologyonline.1996.11.3.114; RUPPERSBERG JP, 1991, NATURE, V352, P711, DOI 10.1038/352711a0; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STAMLER JS, 1996, METHODS NITRIC OXIDE, P521; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467; XU L, 1993, CARDIOVASC RES, V27, P1815, DOI 10.1093/cvr/27.10.1815; Xu L, 1996, CIRC RES, V79, P1100, DOI 10.1161/01.RES.79.6.1100	55	810	832	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	1998	279	5348					234	237		10.1126/science.279.5348.234	http://dx.doi.org/10.1126/science.279.5348.234			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422697				2022-12-01	WOS:000071408100044
J	Nightingale, SL				Nightingale, SL			Irradiation of meat approved for pathogen control	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-01	WOS:000071295100005
J	Banner, AS				Banner, AS			Non-steroidal anti-inflammatory therapy for bronchial asthma	LANCET			English	Editorial Material									Vet Affairs Med Ctr, Manchester, NH 03104 USA; Harvard Univ, Sch Med, Cambridge, MA 02138 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University	Banner, AS (corresponding author), Vet Affairs Med Ctr, Manchester, NH 03104 USA.							ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.me.44.020193.001305; ERZURUM SC, 1991, ANN INTERN MED, V114, P353, DOI 10.7326/0003-4819-114-5-353; FISH JE, 1997, AM J RESP CARE MED, V156; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390, DOI 10.1038/clpt.1990.167; KANE GC, 1994, CLIN PULM MED, V1, P69; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Spahn JD, 1996, ALLERGY ASTHMA PROC, V17, P341, DOI 10.2500/108854196778606365; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709, DOI 10.1164/ajrccm.151.6.7767511; Spahn JD, 1997, J ASTHMA, V34, P177, DOI 10.3109/02770909709068188	10	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					5	7		10.1016/S0140-6736(05)78098-3	http://dx.doi.org/10.1016/S0140-6736(05)78098-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433419				2022-12-01	WOS:000071253100005
J	Bielinsky, AK; Gerbi, SA				Bielinsky, AK; Gerbi, SA			Discrete start sites for DNA synthesis in the yeast ARS1 origin	SCIENCE			English	Article							REPLICATION ORIGINS; RECOGNITION COMPLEX; S-PHASE; SIMIAN VIRUS-40; CELL-CYCLE; INITIATION; ORC; CHROMOSOMES; CEREVISIAE; SEQUENCE	Sites of DNA synthesis initiation have been detected at the nucleotide level in a yeast origin of bidirectional replication with the use of replication initiation point mapping. The ARS1 origin of Saccharomyces cerevisiae showed a transition from discontinuous to continuous DNA synthesis in an 18-base pair region (nucleotides 828 to 845) from within element B1 toward B2, adjacent to the binding site for the origin recognition complex, the putative initiator protein.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, Providence, RI 02912 USA	Brown University	Gerbi, SA (corresponding author), Brown Univ, Dept Mol Biol Cell Biol & Biochem, Div Biol & Med, Providence, RI 02912 USA.			Bielinsky, Anja/0000-0003-1783-619X	NIGMS NIH HHS [GM 35929] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035929] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON S, 1977, BIOCHEMISTRY-US, V16, P4990, DOI 10.1021/bi00642a009; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BLUMENTHAL AB, 1977, CELL, V12, P183, DOI 10.1016/0092-8674(77)90196-9; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1991, BIOESSAYS, V13, P317, DOI 10.1002/bies.950130702; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; DIFFLEY JFX, 1988, P NATL ACAD SCI USA, V85, P2120, DOI 10.1073/pnas.85.7.2120; FANGMAN WL, 1983, CELL, V32, P831, DOI 10.1016/0092-8674(83)90069-7; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; HAY RT, 1982, CELL, V28, P767, DOI 10.1016/0092-8674(82)90056-3; HENDRICKSON EA, 1987, EMBO J, V6, P2011, DOI 10.1002/j.1460-2075.1987.tb02465.x; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; LASKEY RA, 1989, SCIENCE, V246, P609, DOI 10.1126/science.2683076; LIANG C, 1995, CELL, V81, P667, DOI 10.1016/0092-8674(95)90528-6; Lin S, 1997, MOL CELL BIOL, V17, P5473, DOI 10.1128/MCB.17.9.5473; LOO S, 1995, MOL BIOL CELL, V6, P741, DOI 10.1091/mbc.6.6.741; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MICKLEM G, 1993, NATURE, V366, P87, DOI 10.1038/366087a0; NETHANEL T, 1988, J VIROL, V62, P2867, DOI 10.1128/JVI.62.8.2867-2873.1988; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; RADDING CM, 1966, J MOL BIOL, V18, P235, DOI 10.1016/S0022-2836(66)80243-7; ROWLEY A, 1995, EMBO J, V14, P2631, DOI 10.1002/j.1460-2075.1995.tb07261.x; Santocanale C, 1996, EMBO J, V15, P6671, DOI 10.1002/j.1460-2075.1996.tb01057.x; YAMAGUCHI M, 1985, MOL CELL BIOL, V5, P1170, DOI 10.1128/MCB.5.5.1170; ZAKIAN VA, 1979, CELL, V17, P923, DOI 10.1016/0092-8674(79)90332-5	30	124	126	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					95	98		10.1126/science.279.5347.95	http://dx.doi.org/10.1126/science.279.5347.95			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417033				2022-12-01	WOS:000071323900048
J	Beasley, BW				Beasley, BW			Whispering through the keyhole	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material													Beasley, Brent/AAE-9466-2021	Beasley, Brent/0000-0002-0997-9636					0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2061	2061		10.1001/jama.278.23.2061	http://dx.doi.org/10.1001/jama.278.23.2061			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403410				2022-12-01	WOS:A1997YK98700019
J	Gerasimova, TI; Corces, VG				Gerasimova, TI; Corces, VG			Polycomb and trithorax group proteins mediate the function of a chromatin insulator	CELL			English	Article							POSITION-EFFECT VARIEGATION; DROSOPHILA-MELANOGASTER; CHROMOSOMAL DOMAINS; GENES; ENHANCER; EXPRESSION; PROMOTER; SITES; GYPSY	Chromatin boundaries or insulator elements affect the interaction between enhancers and promoters. The gypsy insulator contains two proteins, Su(Hw) and Mod(mdg4). Both proteins colocalize on several hundred sites on polytene chromosomes and are distributed in a punctated pattern in the nuclear matrix. Mutations in mod(mdg4) have properties characteristic of a trxG gene. In addition, mutations in trxG genes enhance insulator effects on adjacent enhancers, whereas mutations in Pc have the opposite result. These alterations correlate with changes in the pattern of nuclear localization of insulator components. The results suggest a model in which PcG and TrxG proteins regulate insulator function by establishing higher order domains of chromatin organization required for the assembly of functional insulators at the nuclear matrix.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Corces, VG (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.			Corces, Victor/0000-0001-5140-4337	NIGMS NIH HHS [GM35463] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035463] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CAI H, 1995, NATURE, V376, P533, DOI 10.1038/376533a0; Cai HN, 1997, EMBO J, V16, P1732, DOI 10.1093/emboj/16.7.1732; CHANG YL, 1995, MOL CELL BIOL, V15, P6601; CHINWALLA V, 1995, EMBO J, V14, P2056, DOI 10.1002/j.1460-2075.1995.tb07197.x; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; Gdula DA, 1996, P NATL ACAD SCI USA, V93, P9378, DOI 10.1073/pnas.93.18.9378; GEORGIEV PG, 1989, MOL GEN GENET, V220, P121, DOI 10.1007/BF00260865; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; Hagstrom K, 1996, GENE DEV, V10, P3202, DOI 10.1101/gad.10.24.3202; HARRISON DA, 1993, GENE DEV, V7, P1966, DOI 10.1101/gad.7.10.1966; KALOS M, 1995, MOL CELL BIOL, V15, P198, DOI 10.1128/MCB.15.1.198; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; Laemmli UK, 1992, CURR OPIN GENET DEV, V2, P275, DOI 10.1016/S0959-437X(05)80285-0; LAJEUNESSE D, 1995, MECH DEVELOP, V53, P123, DOI 10.1016/0925-4773(95)00430-0; MESSMER S, 1992, GENE DEV, V6, P1241, DOI 10.1101/gad.6.7.1241; PalBhadra M, 1997, CELL, V90, P479, DOI 10.1016/S0092-8674(00)80508-5; Paro R., 1996, EPIGENETIC MECH GENE, P507; PIRROTTA V, 1997, TRENDS GENET, V13, P3314; Scott KS, 1995, EMBO J, V14, P6258, DOI 10.1002/j.1460-2075.1995.tb00316.x; SHEARN A, 1989, GENETICS, V121, P517; Tripoulas N, 1996, GENETICS, V143, P913; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; ZHAO K, 1995, CELL, V81, P879, DOI 10.1016/0092-8674(95)90008-X	25	184	190	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					511	521		10.1016/S0092-8674(00)80944-7	http://dx.doi.org/10.1016/S0092-8674(00)80944-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491892	hybrid			2022-12-01	WOS:000072251500011
J	Houde, JF; Jordan, MI				Houde, JF; Jordan, MI			Sensorimotor adaptation in speech production	SCIENCE			English	Article							LANGUAGE PRODUCTION; IMPLICIT SPEECH	Human subjects are known to adapt their motor behavior to a shift of the visual field brought about by wearing prism glasses over their eyes. The analog of this phenomenon was studied in the speech domain. By use of a device that can feed back transformed speech signals in real time, subjects were exposed to phonetically sensible, online perturbations of their own speech patterns. It was found that speakers learn to adjust their production of a vowel to compensate for feedback alterations that change the vowel's perceived phonetic identity; moreover, the effect generalizes across phonetic contexts and to different vowels.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Houde, JF (corresponding author), Univ Calif San Francisco, Keck Ctr, 513 Parnassus Ave,S-877, San Francisco, CA 94143 USA.		Jordan, Michael I/C-5253-2013; Galantucci, Bruno/E-5770-2010					Chomsky N., 1968, SOUND PATTERN ENGLIS; Clements G.N., 1985, PHONOLOGY YB, V2, P225, DOI [10.1017/S0952675700000440, DOI 10.1017/S0952675700000440]; Cooper W, 1979, SPEECH PERCEPTION PR; DELL GS, 1992, COGNITION, V42, P287, DOI 10.1016/0010-0277(92)90046-K; ERIKSEN CW, 1970, J EXP PSYCHOL, V84, P502, DOI 10.1037/h0029274; FERREIRA F, 1991, J MEM LANG, V30, P210, DOI 10.1016/0749-596X(91)90004-4; Gracco VL, 1994, J ACOUST SOC AM, V95, P2821; HELD R, 1961, J NERV MENT DIS, V132, P26; Helmholtz H., 1925, TREATISE PHYSL OPTIC, V3; HOUDE JF, 1997, THESIS MIT CAMBRIDGE; Kawahara H., 1993, J ACOUST SOC AM, V94, P1883; KLAPP ST, 1973, J EXP PSYCHOL, V100, P368, DOI 10.1037/h0035471; Kohler I, 1955, ACTA PSYCHOL, V11, P176; LANE H, 1971, J SPEECH HEAR RES, V14, P677, DOI 10.1044/jshr.1404.677; LEE BS, 1950, J ACOUST SOC AM, V22, P639, DOI 10.1121/1.1906665; LEVELT WJM, 1989, SPEAKING INTENTION A; Lombard E., 1911, ANN MALADIES OREILLE, V37, P101; MEYER AS, 1991, J MEM LANG, V30, P69, DOI 10.1016/0749-596X(91)90011-8; MEYER AS, 1992, COGNITION, V42, P181, DOI 10.1016/0010-0277(92)90043-H; MOWREY RA, 1990, J ACOUST SOC AM, V88, P1299, DOI 10.1121/1.399706; Shattuck-Hufnagel Stephanie, 1979, SENTENCE PROCESSING, P295; Sternberg S., 1978, INFORMATION PROCESSI, P117, DOI DOI 10.1016/B978-0-12-665960-3.50011-6; Stratton GM, 1896, PSYCHOL REV, V3, P611, DOI DOI 10.1037/H0072918; Welch R. B., 1978, PERCEPTUAL MODIFICAT; Wells Rulon, 1951, YALE SCI MAGAZINE, V26, P9; YATES AJ, 1963, PSYCHOL BULL, V60, P213, DOI 10.1037/h0044155	26	468	472	2	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1213	1216		10.1126/science.279.5354.1213	http://dx.doi.org/10.1126/science.279.5354.1213			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YY119	9469813	Green Submitted			2022-12-01	WOS:000072115200045
J	Krezel, W; Ghyselinck, N; Samad, TA; Dupe, V; Kastner, P; Borrelli, E; Chambon, P				Krezel, W; Ghyselinck, N; Samad, TA; Dupe, V; Kastner, P; Borrelli, E; Chambon, P			Impaired locomotion and dopamine signaling in retinoid receptor mutant mice	SCIENCE			English	Article							ACID RECEPTORS; MOLECULAR-BIOLOGY; BINDING-PROTEINS; COCAINE; D2-RECEPTORS; AMPHETAMINE; LACKING; SYSTEM	In the adult mouse, single and compound null mutations in the genes for retinoic acid receptor beta and retinoid X receptors beta and gamma resulted in locomotor defects related to dysfunction of the mesolimbic dopamine signaling pathway. Expression of the D1 and D2 receptors for dopamine was reduced in the ventral striatum of mutant mice, and the response of double null mutant mice to cocaine, which affects dopamine signaling in the mesolimbic system, was blunted. Thus, retinoid receptors are involved in the regulation of brain functions, and retinoic acid signaling defects may contribute to pathologies such as Parkinson's disease and schizophrenia.	Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, F-67404 Illkirch, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chambon, P (corresponding author), Univ Strasbourg 1, Coll France, Inst Genet & Biol Mol & Cellulaire, CNRS,INSERM, Boite Postal 163, F-67404 Illkirch, France.	igbmc@igbmc.u-strasbg.fr	Krezel, Wojciech/H-9080-2017; Borrelli, Emiliana/M-8994-2018; KREZEL, Wojciech/S-8331-2019; Dupe, Valerie/P-2140-2018; Dupe, Valerie/CJQ-0939-2022; Krezel, Wojciech/I-7886-2016; GHYSELINCK, Norbert/I-6999-2015	Krezel, Wojciech/0000-0003-1605-3185; Dupe, Valerie/0000-0003-4859-0612; Dupe, Valerie/0000-0003-4859-0612; Krezel, Wojciech/0000-0003-1605-3185; GHYSELINCK, Norbert/0000-0003-4042-6818				Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BAIK JH, 1995, NATURE, V377, P424, DOI 10.1038/377424a0; CALLAHAN PM, 1991, PSYCHOPHARMACOLOGY, V103, P50, DOI 10.1007/BF02244073; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Dixon W. J., 1988, BMDP STAT SOFTWARE M; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DOLLE P, 1994, MECH DEVELOP, V45, P91, DOI 10.1016/0925-4773(94)90023-X; EVERITT BJ, 1990, NEUROSCI BIOBEHAV R, V14, P217, DOI 10.1016/S0149-7634(05)80222-2; FAROOQUI SM, 1994, LIFE SCI, V55, P1887, DOI 10.1016/0024-3205(94)00520-6; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Ghyselinck NB, 1997, INT J DEV BIOL, V41, P425; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JANSSEN PAJ, 1960, PSYCHOPHARMACOLOGIA, V1, P389, DOI 10.1007/BF00441186; Kastner P, 1997, DEVELOPMENT, V124, P313; Kastner P, 1996, GENE DEV, V10, P80, DOI 10.1101/gad.10.1.80; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOOB GF, 1978, J COMP PHYSIOL PSYCH, V92, P917, DOI 10.1037/h0077542; Krezel W, 1996, P NATL ACAD SCI USA, V93, P9010, DOI 10.1073/pnas.93.17.9010; KREZEL W, UNPUB; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MCCAFFERY P, 1994, P NATL ACAD SCI USA, V91, P7772, DOI 10.1073/pnas.91.16.7772; NESTLER EJ, 1994, CELL, V79, P923, DOI 10.1016/0092-8674(94)90022-1; PEDERSEN WA, 1995, J NEUROCHEM, V65, P50; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; RUBERTE E, 1993, DEVELOPMENT, V118, P267; SARNAD A, 1997, P NATL ACAD SCI USA, V94, P14349; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; WOLFFGRAMM J, 1990, PHARMACOL BIOCHEM BE, V36, P907, DOI 10.1016/0091-3057(90)90099-4; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	31	281	287	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					863	867						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452386				2022-12-01	WOS:000071923500044
J	Raghunathan, PL; Guthrie, C				Raghunathan, PL; Guthrie, C			A spliceosomal recycling factor that reanneals U4 and U6 small nuclear ribonucleoprotein particles	SCIENCE			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; PREMESSENGER RNA; SPLICING MUTANTS; SNRNP PROTEIN; TRI-SNRNP; YEAST; BINDING; STEP; U2	The spliceosome removes introns from pre-messenger RNAs by a mechanism that entails extensive remodeling of RNA structure, The most conspicuous rearrangement involves disruption of 24 base pairs between U4 and U6 small nuclear RNAs (snRNAs). Here, the yeast RNA binding protein Prp24 is shown to reanneal these snRNAs, When Prp24 is absent, unpaired U4 and U6 small nuclear ribonucleoprotein particles (snRNPs) accumulate; with time, splicing becomes inhibited. Addition of purified Prp24 protein regenerates duplex U4/U6 snRNPs for new rounds of splicing. The reannealing reaction catalyzed by Prp24 proceeds more efficiently with snRNPs than with deproteinized snRNAs.	Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Guthrie, C (corresponding author), Univ Calif San Francisco, Sch Med, Dept Biochem & Biophys, San Francisco, CA 94143 USA.	guthrie@cgl.ucsf.edu			NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTMANN M, 1995, EMBO J, V14, P3820, DOI 10.1002/j.1460-2075.1995.tb00051.x; ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; ARES M, 1995, PROG NUCLEIC ACID RE, V50, P131, DOI 10.1016/S0079-6603(08)60813-2; BANROQUES J, 1989, MOL CELL BIOL, V9, P3710, DOI 10.1128/MCB.9.9.3710; BEHRENS SE, 1991, GENE DEV, V5, P1439, DOI 10.1101/gad.5.8.1439; BORDONNE R, 1990, GENE DEV, V4, P1185, DOI 10.1101/gad.4.7.1185; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROWN JD, 1992, EMBO J, V11, P3721, DOI 10.1002/j.1460-2075.1992.tb05457.x; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; ELLEDGE SJ, GENE, V70, P303; FORTNER DM, 1994, GENE DEV, V8, P221, DOI 10.1101/gad.8.2.221; GALISSON F, 1993, NUCLEIC ACIDS RES, V21, P1555, DOI 10.1093/nar/21.7.1555; GHETTI A, 1995, RNA, V1, P132; Guthrie C, 1991, GUIDE YEAST GENETICS; HOROWITZ DS, 1993, GENE DEV, V7, P320, DOI 10.1101/gad.7.2.320; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Lauber J, 1996, EMBO J, V15, P4001, DOI 10.1002/j.1460-2075.1996.tb00774.x; LI ZR, 1993, NUCLEIC ACIDS RES, V21, P4645, DOI 10.1093/nar/21.19.4645; LIN RJ, 1985, J BIOL CHEM, V260, P4780; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1994, ANNU REV GENET, V28, P1; Moore M., 1993, RNA WORLD, P303; Noble SM, 1996, EMBO J, V15, P4368, DOI 10.1002/j.1460-2075.1996.tb00810.x; Noble SM, 1996, GENETICS, V143, P67; PONTIUS BW, 1990, P NATL ACAD SCI USA, V87, P8403, DOI 10.1073/pnas.87.21.8403; PORTMAN DS, 1994, EMBO J, V13, P213, DOI 10.1002/j.1460-2075.1994.tb06251.x; RAGHUNATHAN PL, UNPUB; RAGHUNATHAN PL, 1997, THESIS U SAN FRANCIS; RUBY SW, 1993, GENE DEV, V7, P1909, DOI 10.1101/gad.7.10.1909; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHNEIDER KR, 1994, SCIENCE, V266, P122, DOI 10.1126/science.7939631; SHANNON KW, 1991, GENE DEV, V5, P773, DOI 10.1101/gad.5.5.773; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571	40	119	120	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					857	860		10.1126/science.279.5352.857	http://dx.doi.org/10.1126/science.279.5352.857			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452384				2022-12-01	WOS:000071923500042
J	Nightingale, SL				Nightingale, SL			Health advisory for low-molecular weight heparins and heparinoids	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-01	WOS:000071731300007
J	Korzus, E; Torchia, J; Rose, DW; Xu, L; Kurokawa, R; McInerney, EM; Mullen, TM; Glass, CK; Rosenfeld, MG				Korzus, E; Torchia, J; Rose, DW; Xu, L; Kurokawa, R; McInerney, EM; Mullen, TM; Glass, CK; Rosenfeld, MG			Transcription factor-specific requirements for coactivators and their acetyltransferase functions	SCIENCE			English	Article							YEAST PUTATIVE ADAPTERS; CREB-BINDING PROTEIN; HISTONE ACETYLTRANSFERASE; NUCLEAR RECEPTORS; CO-REPRESSOR; ACTIVATION; CBP; P300; IDENTIFICATION; COMPLEX	Different classes of mammalian transcription factors-nuclear receptors, cyclic adenosine 3',5'-monophosphate-regulated enhancer binding protein (CREB), and signal transducer and activator of transcription-1 (STAT-1)-functionally require distinct com ponents of the coactivator complex, including CREB-binding protein (CBP/p300), nuclear receptor coactivators (NCoAs), and p300/CBP-associated factor (p/CAF), based on their platform or assembly properties. Retinoic acid receptor, CREB, and STAT-1 also require different histone acetyltransferase (HAT) activities to activate transcription. Thus, transcription factor-specific differences in configuration and content of the coactivator complex dictate requirements for specific acetyltransferase activities, providing an explanation, at least in part, for the presence of multiple HAT components of the complex.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Rosenfeld, MG (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, 9500 Gilman Dr, La Jolla, CA 92093 USA.		Glass, Christopher/AAI-3933-2021	Glass, Christopher/0000-0003-4344-3592; MULLEN, Tina-Marie/0000-0001-6150-8084				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Ausubel F.M., 1995, CURRENT PROTOCOLS MO; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Bisotto S, 1996, J BIOL CHEM, V271, P17746, DOI 10.1074/jbc.271.30.17746; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; Candau R, 1996, MOL CELL BIOL, V16, P593; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HONG M, 1997, MOL CELL BIOL, V17, P2735; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KORZUS E, UNPUB; Kurokawa R, 1998, SCIENCE, V279, P700, DOI 10.1126/science.279.5351.700; KUROKAWA R, 1995, NATURE, V377, P451, DOI 10.1038/377451a0; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAHERTY OD, 1997, CELL, V89, P349; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONATE SA, 1995, SCIENCE, V270, P1354; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	54	541	550	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					703	707		10.1126/science.279.5351.703	http://dx.doi.org/10.1126/science.279.5351.703			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445475				2022-12-01	WOS:000071731500036
J	Jiang, J; Struhl, G				Jiang, J; Struhl, G			Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb	NATURE			English	Article							LONG-RANGE ACTION; MORPHOGEN GRADIENT; BETA-CATENIN; DROSOPHILA; TRANSDUCTION	Members of the Hedgehog (Hh) and Wnt/Wingless (Wg) families of secreted proteins control many aspects of growth and patterning during animal development(1,2). Hh signal transduction leads to increased stability of a transcription factor, Cubitus interruptus (Ci)(3,4), whereas Wg signal transduction causes increased stability of Armadillo (Arm/beta-catenin)(5), a possible co-factor for the transcriptional regulator Lef1/TCF6. Here we describe a new gene, slimb (for supernumerary limbs), which negatively regulates both of these signal transduction pathways. Loss of function of slimb results in a cell-autonomous accumulation of high levels of both Ci and Arm, and the ectopic expression of both Hh(-) and Wg(-) responsive genes. The slimb gene encodes a conserved F-box. WD40-repeat protein related to Cdc4p, a protein in budding yeast that targets cell-cycle regulators for degradation by the ubiquitin/proteasome pathway(7-9). We propose that Slimb protein normally targets Ci and Arm for processing or degradation by the ubiquitin/proteasome pathway, and that Hh and Wg regulate gene expression at least in part by inducing changes in Ci and Arm, which protect them from Slimb-mediated proteolysis.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Dev, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University; Columbia University	Jiang, J (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, 701 W 168th St, New York, NY 10032 USA.							Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Altaba ARI, 1997, CELL, V90, P193, DOI 10.1016/S0092-8674(00)80325-6; AzaBlanc P, 1997, CELL, V89, P1043, DOI 10.1016/S0092-8674(00)80292-5; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; INGHAM PW, 1995, CURR OPIN GENET DEV, V5, P492, DOI 10.1016/0959-437X(95)90054-K; Irvine KD, 1997, CURR OPIN CELL BIOL, V9, P867, DOI 10.1016/S0955-0674(97)80090-7; Jiang J, 1996, CELL, V86, P401, DOI 10.1016/S0092-8674(00)80113-0; JIANG J, 1995, CELL, V80, P563, DOI 10.1016/0092-8674(95)90510-3; KALDERON D, 1995, CURR BIOL, V5, P580, DOI 10.1016/S0960-9822(95)00114-X; Kominami K, 1997, GENE DEV, V11, P1548, DOI 10.1101/gad.11.12.1548; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOTZNY CK, 1995, MECH DEVELOP, V52, P137, DOI 10.1016/0925-4773(95)00397-J; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann CJ, 1997, DEVELOPMENT, V124, P871; Nusse R, 1997, CELL, V89, P321, DOI 10.1016/S0092-8674(00)80210-X; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Nusse R, 1996, NATURE, V384, P119, DOI 10.1038/384119a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Peifer M, 1997, SCIENCE, V275, P1752, DOI 10.1126/science.275.5307.1752; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; TABATA T, 1994, CELL, V76, P89, DOI 10.1016/0092-8674(94)90175-9; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Zecca M, 1996, CELL, V87, P833, DOI 10.1016/S0092-8674(00)81991-1; ZECCA M, 1995, DEVELOPMENT, V121, P2265	30	528	550	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					493	496		10.1038/35154	http://dx.doi.org/10.1038/35154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461217				2022-12-01	WOS:000071701800052
J	Chan, JM; Stampfer, MJ; Giovannucci, E; Gann, PH; Ma, J; Wilkinson, P; Hennekens, CH; Pollak, M				Chan, JM; Stampfer, MJ; Giovannucci, E; Gann, PH; Ma, J; Wilkinson, P; Hennekens, CH; Pollak, M			Plasma insulin-like growth factor I and prostate cancer risk: A prospective study	SCIENCE			English	Article							BODY-MASS INDEX; BINDING-PROTEINS; HORMONE; SEX; ADOLESCENTS; CHILDREN; ANTIGEN; CELLS; STAGE; AGE	Insulin-like growth factor-I (IGF-I) is a mitogen for prostate epithelial cells. To investigate associations between plasma IGF levels and prostate cancer risk, a nested case-control study within the Physicians' Health Study was conducted on prospectively collected plasma from 152 cases and 152 controls. A strong positive association was observed between IGF-I levels and prostate cancer risk. Men in the highest quartile of IGF-I levels had a relative risk of 4.3 (95 percent confidence interval 1.8 to 10.6) compared with men in the lowest quartile. This association was independent of baseline prostate-specific antigen levels. Identification of plasma IGF-I as a predictor of prostate cancer risk may have implications for risk reduction and treatment.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA; Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Med,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada; McGill Univ, Jewish Gen Hosp, Lady Davis Inst Med Res, Dept Oncol,Canc Prevent Res Unit, Montreal, PQ H3T 1E2, Canada; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Northwestern University; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Chan, JM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, 677 Huntington Ave, Boston, MA 02115 USA.	jmlchan@hsph.harvard.edu	Wilkinson, Peter/AAK-6426-2020; Pollak, Michael/G-9094-2011	Wilkinson, Peter/0000-0002-1365-0470; Pollak, Michael/0000-0003-3047-0604; Chan, June/0000-0002-7620-569X	NATIONAL CANCER INSTITUTE [R01CA058684, T32CA009001, R01CA042182] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42182, CA-58684, T32 CA 09001-20] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andersson SO, 1997, JNCI-J NATL CANCER I, V89, P385, DOI 10.1093/jnci/89.5.385; COHEN P, 1994, HORM METAB RES, V26, P81, DOI 10.1055/s-2007-1000777; COHEN P, 1991, J CLIN ENDOCR METAB, V73, P401, DOI 10.1210/jcem-73-2-401; COHEN P, 1992, J CLIN ENDOCR METAB, V75, P1046, DOI 10.1210/jc.75.4.1046; COHEN SM, 1990, SCIENCE, V249, P1007, DOI 10.1126/science.2204108; GANN PH, 1995, JAMA-J AM MED ASSOC, V273, P289, DOI 10.1001/jama.273.4.289; Gann PH, 1996, J NATL CANCER I, V88, P1118, DOI 10.1093/jnci/88.16.1118; Giovannucci E, 1997, P NATL ACAD SCI USA, V94, P3320, DOI 10.1073/pnas.94.7.3320; Giovannucci E, 1997, CANCER EPIDEM BIOMAR, V6, P557; GoodmanGruen D, 1997, AM J EPIDEMIOL, V145, P970, DOI 10.1093/oxfordjournals.aje.a009065; Hebert PR, 1997, CANCER CAUSE CONTROL, V8, P591, DOI 10.1023/A:1018442329319; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; Huynh H, 1996, J BIOL CHEM, V271, P1016, DOI 10.1074/jbc.271.2.1016; Huynh H, 1996, CELL GROWTH DIFFER, V7, P1501; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; JUUL A, 1995, J CLIN ENDOCR METAB, V80, P2534, DOI 10.1210/jc.80.8.2534; JUUL A, 1994, J CLIN ENDOCR METAB, V78, P744, DOI 10.1210/jc.78.3.744; LASSARRE C, 1991, PEDIATR RES, V29, P219, DOI 10.1203/00006450-199103000-00001; LAVECCHIA C, 1990, INT J CANCER, V45, P275, DOI 10.1002/ijc.2910450212; Mantzoros CS, 1997, BRIT J CANCER, V76, P1115, DOI 10.1038/bjc.1997.520; POLLAK M, 1990, J NATL CANCER I, V82, P1693, DOI 10.1093/jnci/82.21.1693; Pollak MN, 1998, P SOC EXP BIOL MED, V217, P143; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Rechler MM, 1997, ENDOCRINOLOGY, V138, P2645, DOI 10.1210/en.138.7.2645; Rothman KJ, 1986, MODERN EPIDEMIOLOGY, P82; RUDMAN D, 1990, NEW ENGL J MED, V323, P1, DOI 10.1056/NEJM199007053230101; TIBLJIN G, 1995, EPIDEMIOLOGY, V6, P423; ZARANDI M, 1994, P NATL ACAD SCI USA, V91, P12298, DOI 10.1073/pnas.91.25.12298	28	1640	1729	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					563	566		10.1126/science.279.5350.563	http://dx.doi.org/10.1126/science.279.5350.563			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438850				2022-12-01	WOS:000071616000047
J	Kodish, E; Wiesner, GL; Mehlman, M; Murray, T				Kodish, E; Wiesner, GL; Mehlman, M; Murray, T			Genetic testing for cancer risk - How to reconcile the conflicts	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVARIAN-CANCER; BREAST-CANCER; BRCA1; MUTATIONS		Case Western Reserve Univ, Sch Med, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Human Genet, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Law Med Ctr, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Ctr Biomed Eth, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Dept Pediat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Ctr Human Genet, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Law Med Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Law, Ctr Biomed Eth, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Kodish, E (corresponding author), Rainbow Babies & Childrens Hosp, 11100 Euclid Ave,RBC 310, Cleveland, OH 44106 USA.							BAKER SG, 1995, J NATL CANCER I, V87, P1137, DOI 10.1093/jnci/87.15.1137; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; COLLINS FS, 1994, JAMA-J AM MED ASSOC, V271, P785, DOI 10.1001/jama.1994.03510340075038; Geller G, 1997, JAMA-J AM MED ASSOC, V277, P1467, DOI 10.1001/jama.277.18.1467; Giardiello FM, 1997, NEW ENGL J MED, V336, P823, DOI 10.1056/NEJM199703203361202; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Khoury MJ, 1996, AM J PUBLIC HEALTH, V86, P1717, DOI 10.2105/AJPH.86.12.1717; KING MC, 1992, NAT GENET, V2, P89, DOI 10.1038/ng1092-89; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1996, Oncology (Williston Park), V10, P191; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Mehlman MJ, 1996, AM J HUM GENET, V58, P393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Peters J A, 1996, Oncology (Williston Park), V10, P159; RICCARDI VA, 1996, HUMAN GENOME PROJECT, P21; Rimer Barbara K., 1997, P619; ROTHSTEIN MA, 1995, MONOGRAPH NCI, V17, P87; Rubin SC, 1996, NEW ENGL J MED, V335, P1413, DOI 10.1056/NEJM199611073351901; Schrag D, 1997, NEW ENGL J MED, V336, P1465, DOI 10.1056/NEJM199705153362022; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; *US DEP HHS, 1997, UND GEN TEST	25	26	26	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					179	181		10.1001/jama.279.3.179	http://dx.doi.org/10.1001/jama.279.3.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438721				2022-12-01	WOS:000071460700001
J	McCall, K; Steller, H				McCall, K; Steller, H			Requirement for DCP-1 caspase during Drosophila oogenesis	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; NUCLEAR LAMIN ISOFORMS; NONMUSCLE MYOSIN-II; DNA FRAGMENTATION; EGG CHAMBER; APOPTOSIS; GENE; INTERCONVERSION; EMBRYOGENESIS; DEGRADATION	Caspases, a class of cysteine proteases, are an essential component of the apoptotic cell death program. During Drosophila oogenesis, nurse cells transfer their cytoplasmic contents to developing oocytes and then die. Loss of function for the dcp-l gene, which encodes a caspase, caused female sterility by inhibiting this transfer. dcp-1(-) nurse cells were defective in the cytoskeletal reorganization and nuclear breakdown that normally accompany this process. The dcp-1(-) phenotype suggests that the cytoskeletal and nuclear events in the nurse cells make use of the machinery normally associated with apoptosis and that apoptosis of the nurse cells is a necessary event for oocyte development.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Dept Biol, 31 Ames St,68-430, Cambridge, MA 02139 USA.							ABRAMS JM, 1993, DEVELOPMENT, V117, P29; ADACHI M, 1995, NAT GENET, V11, P294, DOI 10.1038/ng1195-294; Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; CANT K, 1994, J CELL BIOL, V125, P369, DOI 10.1083/jcb.125.2.369; Chinnaiyan AM, 1996, CURR BIOL, V6, P555; Chou TB, 1996, GENETICS, V144, P1673; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COOLEY L, 1994, SCIENCE, V266, P590, DOI 10.1126/science.7939713; COTTER TG, 1992, CANCER RES, V52, P997; DeFelici M, 1997, CELL DEATH DIFFER, V4, P169, DOI 10.1038/sj.cdd.4400237; Edwards KA, 1996, DEVELOPMENT, V122, P1499; FOLEY KM, UNPUB; Fraser AG, 1997, EMBO J, V16, P2805, DOI 10.1093/emboj/16.10.2805; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GIORGI F, 1976, J EMBRYOL EXP MORPH, V35, P521; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; GUTZEIT HO, 1986, J CELL SCI, V80, P159; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JEWELL SA, 1982, SCIENCE, V217, P1257, DOI 10.1126/science.7112127; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; King RC., 1970, OVARIAN DEV DROSOPHI; KNOWLES BA, 1994, TRENDS GENET, V10, P235, DOI 10.1016/0168-9525(94)90170-8; Kroemer G, 1997, CELL DEATH DIFFER, V4, P443, DOI 10.1038/sj.cdd.4400266; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Mahowald A.P., 1980, Genetics and Biology of Drosophila, V2d, P141; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Moir RD, 1995, INT REV CYTOL, V162B, P141; NEAMATI N, 1995, J IMMUNOL, V154, P3788; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; OKADA E, 1959, J EMBRYOL EXP MORPH, V7, P583; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Porter AG, 1997, BIOESSAYS, V19, P501, DOI 10.1002/bies.950190609; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; RIEMER D, 1995, J CELL SCI, V108, P3189; RUBY JR, 1969, J MORPHOL, V127, P307, DOI 10.1002/jmor.1051270304; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; SAUNDERS JW, 1966, SCIENCE, V154, P604, DOI 10.1126/science.154.3749.604; SMITH DE, 1989, J CELL BIOL, V108, P255, DOI 10.1083/jcb.108.2.255; SMITH DE, 1987, J CELL BIOL, V105, P771, DOI 10.1083/jcb.105.2.771; Song Z., UNPUB; Song ZW, 1997, SCIENCE, V275, P536, DOI 10.1126/science.275.5299.536; Spradling A.C., 1993, DEV DROSOPHILA MELAN, VI, P1; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TOURMENTE S, 1990, BIOL CELL, V68, P119, DOI 10.1016/0248-4900(90)90296-F; VERHEYEN E, 1994, METHOD CELL BIOL, V44, P545, DOI 10.1016/S0091-679X(08)60931-0; WHEATLEY S, 1995, DEVELOPMENT, V121, P1937; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; ZAMBONI L, 1968, J CELL BIOL, V36, P276, DOI 10.1083/jcb.36.1.276; [No title captured]	53	142	145	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					230	234		10.1126/science.279.5348.230	http://dx.doi.org/10.1126/science.279.5348.230			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422696				2022-12-01	WOS:000071408100043
J	Stelfox, HT; Chua, G; O'Rourke, K; Detsky, AS				Stelfox, HT; Chua, G; O'Rourke, K; Detsky, AS			Conflict of interest in the debate over calcium-channel antagonists	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; GASTROINTESTINAL HEMORRHAGE; ARTERY DISEASE; BLOCKERS; NIFEDIPINE; HYPERTENSION; MORTALITY; RISK; SAFE	Background Physicians' financial relationships with the pharmaceutical industry are controversial because such relationships may pose a conflict of interest. It is unknown to what extent industry support of medical education and research influences the opinions and behavior of clinicians and researchers. The recent debate over the safety of calcium-channel antagonists provided an opportunity to examine the effect of financial conflicts of interest. Methods We searched the English-language medical literature published from March 1995 through September 1996 for articles examining the controversy about the safety of calcium-channel antagonists. Articles were reviewed and classified as being supportive, neutral, or critical with respect to the use of calcium-channel antagonists. The authors of the articles were asked about their financial relationships with bath manufacturers of calcium-channel antagonists and manufacturers of competing products (i.e., beta-blockers, angiotensin-converting-enzyme inhibitors, diuretics, and nitrates). We examined the authors' published positions on the safety of calcium-channel antagonists according to their financial relationships with pharmaceutical companies. Results Authors who supported the use of calcium-channel antagonists were significantly more likely than neutral or critical authors to have financial relationships with manufacturers of calcium-channel antagonists (96 percent, vs. 60 percent and 37 percent, respectively; P<0.001). Supportive authors were also more likely than neutral or critical authors to have financial relationships with any pharmaceutical manufacturer, irrespective of the product (100 percent, vs. 67 percent and 43 percent, respectively; P<0.001). Conclusions Our results demonstrate a strong association between authors' published positions on the safety of calcium-channel antagonists and their financial relationships with pharmaceutical manufacturers. The medical profession needs to develop a more effective policy on conflict of interest. We support complete disclosure of relationships with pharmaceutical manufacturers for clinicians and researchers who write articles examining pharmaceutical products. (C) 1998, Massachusetts Medical Society.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Univ Toronto, Dept Med, Toronto, ON, Canada; Univ Toronto, Dept Hlth Adm, Toronto, ON M5S 1A1, Canada; Univ Toronto, Dept Publ Hlth Sci, Toronto, ON, Canada; Toronto Hosp, Dept Med, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Detsky, AS (corresponding author), Mt Sinai Hosp, Dept Med, Rm 427,600 Univ Ave, Toronto, ON M5G 1X5, Canada.			Stelfox, Henry/0000-0003-1231-1490				Agresti A., 1990, CATEGORICAL DATA ANA, pXV; Angeli M, 1996, NEW ENGL J MED, V335, P1055, DOI 10.1056/NEJM199610033351410; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; Barlow RE., 1972, STAT INFERENCE ORDER; Barnett AA, 1996, LANCET, V347, P313; Blandino DA, 1996, JAMA-J AM MED ASSOC, V275, P516; BROWN MJ, 1995, LANCET, V346, P768; Buring JE, 1996, JAMA-J AM MED ASSOC, V275, P517, DOI 10.1001/jama.1996.03530310021017; BURING JE, 1995, JAMA-J AM MED ASSOC, V274, P654, DOI 10.1001/jama.274.8.654; CHREN MM, 1994, JAMA-J AM MED ASSOC, V271, P684, DOI 10.1001/jama.271.9.684; Cooper RS, 1996, JAMA-J AM MED ASSOC, V275, P515, DOI 10.1001/jama.1996.03530310021014; COOPER RS, 1995, LANCET, V346, P961; Cox D.R., 1989, MONOGRAPHS STAT APPL, V2nd ed.; Dargie HJ, 1996, LANCET, V348, P488, DOI 10.1016/S0140-6736(05)64663-6; DARGIE HJ, 1996, LANCET, V348, P694; ELLIOTT HL, 1995, LANCET, V346, P1421, DOI 10.1016/S0140-6736(95)92433-7; EPSTEIN M, 1995, ARCH INTERN MED, V155, P2150, DOI 10.1001/archinte.155.20.2150; FAGAN TC, 1995, ARCH INTERN MED, V155, P2145, DOI 10.1001/archinte.155.20.2145; Feeman WE, 1996, JAMA-J AM MED ASSOC, V275, P515, DOI 10.1001/jama.1996.03530310021013; FERRARI D, 1996, AM J CARDIOL, V77, pD22; Frohlich E D, 1995, J La State Med Soc, V147, P343; Frohlich ED, 1996, HYPERTENSION, V27, P317, DOI 10.1161/01.HYP.27.3.317; Furberg CD, 1996, CIRCULATION, V93, P1475; FURBERG CD, 1995, J AM GERIATR SOC, V43, P1309, DOI 10.1111/j.1532-5415.1995.tb07411.x; FURBERG CD, 1995, ARCH INTERN MED, V155, P2157, DOI 10.1001/archinte.155.20.2157; Furberg CD, 1996, EUR HEART J, V17, P1142; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; Furberg CD, 1996, CIRCULATION, V93, P1473; Furberg CD, 1996, CIRCULATION, V93, P1474; Ghali WA, 1996, ANN INTERN MED, V125, P518, DOI 10.7326/0003-4819-125-6-199609150-00029; GIFFORD RW, 1995, CLEV CLIN J MED, V62, P348, DOI 10.3949/ccjm.62.6.348; GOODMAN S, 1996, UPDATE CALCIUM ANTAG; Gordon RD, 1996, LANCET, V347, P1056, DOI 10.1016/S0140-6736(96)90269-X; HABIB GB, 1995, CHEST, V108, P3, DOI 10.1378/chest.108.1.3; Hardell L, 1996, LANCET, V348, P542, DOI 10.1016/S0140-6736(05)64695-8; HORTON R, 1995, LANCET, V346, P891, DOI 10.1016/S0140-6736(95)92717-4; HORTON R, 1995, LANCET, V346, P770; HORTON R, 1995, LANCET, V346, P586, DOI 10.1016/S0140-6736(95)91429-3; Kaplan NM, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023019; Kaplan NM, 1996, LANCET, V348, P541, DOI 10.1016/S0140-6736(96)24034-6; Kaplan NM, 1996, AM J CARDIOL, V77, P81, DOI 10.1016/S0002-9149(97)89139-4; KLONER RA, 1995, CIRCULATION, V92, P1074, DOI 10.1161/01.CIR.92.5.1074; LICHTLEN PR, 1995, LANCET, V346, P962; Lichtlen PR, 1996, CIRCULATION, V93, P1472; Lip GYH, 1996, LANCET, V347, P1761; LUCAS BD, 1995, ANN PHARMACOTHER, V29, P629, DOI 10.1177/106002809502900615; MacCarthy EP, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023020; MACDONALD G, 1995, LANCET, V346, P768; Mancia G, 1996, J HYPERTENS, V14, P13; Marwick C, 1996, JAMA-J AM MED ASSOC, V275, P423, DOI 10.1001/jama.275.6.423; MARWICK C, 1996, JAMA-J AM MED ASSOC, V275, P1638; MCKINNEY WP, 1990, JAMA-J AM MED ASSOC, V264, P1693, DOI 10.1001/jama.264.13.1693; Mehta JL, 1996, CIRCULATION, V93, P1472; MESSERLI FH, 1995, ANN INTERN MED, V123, P888, DOI 10.7326/0003-4819-123-11-199512010-00015; MESSERLI FH, 1995, LANCET, V346, P767, DOI 10.1016/S0140-6736(95)91526-5; Messerli FH, 1996, ANN INTERN MED, V125, P519, DOI 10.7326/0003-4819-125-6-199609150-00031; Messerli FH, 1996, J AM COLL CARDIOL, V28, P12, DOI 10.1016/0735-1097(96)00171-4; Messerli Franz H., 1996, Journal of the American College of Cardiology, V27, p319A; MONGE JC, 1996, SAFETY ANTIHYPERTENS; OPIE LH, 1995, CIRCULATION, V92, P1068, DOI 10.1161/01.CIR.92.5.1068; OPIE LH, 1995, LANCET, V346, P961; ORLOWSKI JP, 1992, CHEST, V102, P270, DOI 10.1378/chest.102.1.270; Pahor M, 1996, LANCET, V348, P493, DOI 10.1016/S0140-6736(96)04277-8; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; Pahor M, 1996, LANCET, V347, P1061, DOI 10.1016/S0140-6736(96)90276-7; Pahor M, 1996, LANCET, V348, P541, DOI 10.1016/S0140-6736(05)64694-6; Parmley WW, 1996, J AM COLL CARDIOL, V27, P1820; Parmley WW, 1996, J AM COLL CARDIOL, V27, P510, DOI 10.1016/0735-1097(95)00601-X; PHILLIPS BG, 1995, AM J HEALTH-SYST PH, V52, P1460, DOI 10.1093/ajhp/52.13.1460; Pilotto A, 1996, LANCET, V347, P1761; PooleWilson PA, 1996, EUR HEART J, V17, P1131; POOLEWILSON PA, 1995, LANCET, V346, P769; PSATY BM, 1995, JAMA-J AM MED ASSOC, V274, P620, DOI 10.1001/jama.274.8.620; Psaty BM, 1996, LANCET, V347, P1761, DOI 10.1016/S0140-6736(96)90837-5; Psaty BM, 1996, JAMA-J AM MED ASSOC, V275, P516, DOI 10.1001/jama.1996.03530310021016; Psaty BM, 1996, JAMA-J AM MED ASSOC, V275, P518, DOI 10.1001/jama.1996.03530310023021; Rafflenbeul W, 1996, EUR HEART J, V17, P1147; RAFFLENBEUL W, 1996, CIRCULATION, V493, P1473; Ryden L, 1996, EUR HEART J, V17, P1; SCHUBERT T, 1995, LANCET, V346, P961, DOI 10.1016/S0140-6736(95)91580-X; Smith G N, 1996, J Fam Pract, V42, P30; *STAT SCI, 1995, S PLUS GUID STAT MAT; Stryer DB, 1996, JAMA-J AM MED ASSOC, V275, P517, DOI 10.1001/jama.275.7.517; Tierney WM, 1996, ANN INTERN MED, V125, P519, DOI 10.7326/0003-4819-125-6-199609150-00030; Tijssen JGP, 1996, EUR HEART J, V17, P1152; Walker AM, 1996, LANCET, V348, P489, DOI 10.1016/S0140-6736(05)64664-8; Walker AM, 1996, AM J CARDIOL, V78, P380; YUSUF S, 1995, CIRCULATION, V92, P1079, DOI 10.1161/01.CIR.92.5.1079; 1996, LANCET, V348, P487	89	441	457	1	13	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					101	106		10.1056/NEJM199801083380206	http://dx.doi.org/10.1056/NEJM199801083380206			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420342	Bronze			2022-12-01	WOS:000071341300006
J	Weiss, HB; Friedman, DI; Coben, JH				Weiss, HB; Friedman, DI; Coben, JH			Incidence of dog bite injuries treated in emergency departments	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Pennsylvania-Public-Health-Association Annual Meeting	OCT   01, 1996	PITTSBURGH, PENNSYLVANIA	Penn Public Hlth Assoc			CHILDREN	Context.-Dog bites that result in injuries occur frequently, but how frequently dog bite injuries necessitate medical attention at a hospital or hospital admission is unknown. Objective.-To describe the incidence and characteristics of dog bite injuries treated in US emergency departments (EDs). Design.-Emergency department survey from the National Center for Health Statistics National Hospital Ambulatory Medical Care Survey for 1992 to 1994. Patients.-National probability sample of patients visiting EDs. Main Outcome Measure.-Incidence of dog bites treated in EDs, defined as a cause of injury recorded as the E-code E906.0. Results.-The 3-year annualized, adjusted, and weighted estimate of new dog bite-related injury visits to US EDs was 333 687, a rate of 12.9 per 10 000 persons (95% confidence interval [CI], 10.5-15.4). This represents approximately 914 new dog bite injuries requiring ED visits per day. The median age of patients bitten was 15 years, with children, especially boys aged 5 to 9 years, having the highest incidence rate (60.7 per 10 000 persons for boys aged 5 to 9 years). Children seen in EDs were more likely than older persons to be bitten on the face, neck, and head (73% vs 30%). We estimated that for each US dog bite fatality there are about 670 hospitalizations and 16000 ED visits. Conclusions.-Dog bite injuries are an important source of injury in the US population, especially among children. Improved surveillance and prevention of dog bite-related injuries, particularly among children, are needed.	Univ Pittsburgh, Ctr Injury Res & Control, Dept Emergency Med, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Weiss, HB (corresponding author), Allegheny Univ Hlth Sci, Ctr Violence & Injury Control, Dept Emergency Med, 1 Allegheny Ctr,Suite 510,320 E North Ave, Pittsburgh, PA 15212 USA.		Weiss, Hank/D-1052-2010		PHS HHS [MCH-424002-01-0] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGHABABIAN RV, 1980, ANN EMERG MED, V9, P79, DOI 10.1016/S0196-0644(80)80335-0; AVNER JR, 1991, PEDIATRICS, V88, P55; BECK AM, 1975, PUBLIC HEALTH REP, V90, P262; BECK AM, 1985, PUBLIC HEALTH REP, V100, P315; BROGAN TV, 1995, PEDIATRICS, V96, P947; BURT CW, 1995, ADV DATA VITAL HLTH, V261; CHIN Y, 1982, PEDIATRICS, V69, P119; DAVIS SJM, 1978, NATURE, V276, P608, DOI 10.1038/276608a0; GERSHMAN KA, 1994, PEDIATRICS, V93, P913; KIZER KW, 1979, JACEP-J AM COLL EMER, V8, P134, DOI 10.1016/S0361-1124(79)80339-1; LANGLEY J, 1992, NEW ZEAL MED J, V105, P33; MCCAIG LF, 1994, ADV DATA VITAL HLTH, V245; PEEL MM, 1993, PATHOLOGY, V25, P379, DOI 10.3109/00313029309090863; Pickney LE, 1982, PEDIATRICS, V69, P193; Sacks J J, 1996, Inj Prev, V2, P52, DOI 10.1136/ip.2.1.52; SACKS JJ, 1989, JAMA-J AM MED ASSOC, V262, P1489, DOI 10.1001/jama.262.11.1489; Sacks JJ, 1996, PEDIATRICS, V97, P891; Scarcella J V, 1969, Ohio State Med J, V65, P25; SOKOL AB, 1971, CLIN PEDIATR, V10, P336, DOI 10.1177/000992287101000616; STUSSMAN BJ, 1996, ADV DATA VITAL HLTH, V271; *US CONS PROD SAF, 1992, 009207 US CONS PROD; WISE JK, 1994, J AM VET MED ASSOC, V204, P1166; 1996, CONSUMER PRODUCT SUM, V1, P5	23	274	285	0	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					51	53		10.1001/jama.279.1.51	http://dx.doi.org/10.1001/jama.279.1.51			3	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424044	Bronze			2022-12-01	WOS:000071295100035
J	Gradia, S; Acharya, S; Fishel, R				Gradia, S; Acharya, S; Fishel, R			The human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch	CELL			English	Article							NONPOLYPOSIS COLON-CANCER; HUMAN MSH2 PROTEIN; HETERODUPLEX REPAIR; SIGNAL-TRANSDUCTION; BINDING-PROTEINS; NUCLEAR EXTRACTS; RAS SUPERFAMILY; TUMOR-CELLS; DNA; HETERODIMER	The mechanism of DNA mismatch repair has been modeled upon biochemical studies of the E. coli DNA adenine methylation-instructed pathway where the initial recognition of mismatched nucleotides is performed by the MutS protein. MutS homologs (MSH) have been identified based on a highly conserved region containing a Walker-A adenine nucleotide binding motif. Here we show that adenine nucleotide binding and hydrolysis by the human mismatch recognition complex hMSH2-hMSH6 functions as a novel molecular switch. The hMSH2-hMSH6 complex is ON (binds mismatched nucleotides) in the ADP-bound form and OFF in the ATP-bound form. These results suggest a new model for the function of MutS proteins during mismatch repair in which the switch determines the timing of downstream events.	Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	Jefferson University	Fishel, R (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Genet & Mol Biol Program, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.				NATIONAL CANCER INSTITUTE [R01CA056542, R01CA067007] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA067007, CA67007, CA56542] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Alani E, 1997, MOL CELL BIOL, V17, P2436, DOI 10.1128/MCB.17.5.2436; Allen DJ, 1997, EMBO J, V16, P4467, DOI 10.1093/emboj/16.14.4467; Ausubel F. M., 1994, CURRENT PROTOCOLS MO; Biswas I, 1997, J BIOL CHEM, V272, P13355, DOI 10.1074/jbc.272.20.13355; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CHI NW, 1994, J BIOL CHEM, V269, P29984; Dixon M., 1979, ENZYMES, Vthird; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; FISHEL R, 1994, CANCER RES, V54, P5539; FISHEL R, 1994, SCIENCE, V266, P1403, DOI 10.1126/science.7973733; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Fishel R, 1997, CURR OPIN GENET DEV, V7, P105, DOI 10.1016/S0959-437X(97)80117-7; FISHEL RA, 1988, P NATL ACAD SCI USA, V85, P36, DOI 10.1073/pnas.85.1.36; GLAZER PM, 1987, MOL CELL BIOL, V7, P218, DOI 10.1128/MCB.7.1.218; GRILLEY M, 1989, J BIOL CHEM, V264, P1000; HABER LT, 1991, EMBO J, V10, P2707, DOI 10.1002/j.1460-2075.1991.tb07815.x; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; HUGHES MJ, 1992, J BIOL CHEM, V267, P23876; Jiang W, 1997, J BIOL CHEM, V272, P7626, DOI 10.1074/jbc.272.12.7626; Laalami S, 1996, BIOCHIMIE, V78, P577, DOI 10.1016/S0300-9084(96)80004-6; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Maegley KA, 1996, P NATL ACAD SCI USA, V93, P8160, DOI 10.1073/pnas.93.16.8160; Marsischky GT, 1996, GENE DEV, V10, P407, DOI 10.1101/gad.10.4.407; Mello JA, 1996, CHEM BIOL, V3, P579, DOI 10.1016/S1074-5521(96)90149-0; Meyers M, 1997, CANCER RES, V57, P206; MILLER LK, 1976, P NATL ACAD SCI USA, V73, P3073, DOI 10.1073/pnas.73.9.3073; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; MODRICH P, 1989, J BIOL CHEM, V264, P6597; Modrich P, 1997, J BIOL CHEM, V272, P24727, DOI 10.1074/jbc.272.40.24727; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; PROLLA TA, 1994, SCIENCE, V265, P1091, DOI 10.1126/science.8066446; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Risinger JI, 1996, NAT GENET, V14, P102, DOI 10.1038/ng0996-102; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Tocque B, 1997, CELL SIGNAL, V9, P153, DOI 10.1016/S0898-6568(96)00135-0; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WILSON TM, 1995, CANCER RES, V55, P5146; WOODWARDGRAVES KL, 1996, J BIOL CHEM, V271, P13629; WU TH, 1994, J BACTERIOL, V176, P5393, DOI 10.1128/JB.176.17.5393-5400.1994; YU X, 1992, J MOL BIOL, V225, P193, DOI 10.1016/0022-2836(92)91036-O	49	300	307	0	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					995	1005		10.1016/S0092-8674(00)80490-0	http://dx.doi.org/10.1016/S0092-8674(00)80490-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428522	Bronze			2022-12-01	WOS:000071281400016
J	Martin, KC; Casadio, A; Zhu, HX; E, YP; Rose, JC; Chen, M; Bailey, CH; Kandel, ER				Martin, KC; Casadio, A; Zhu, HX; E, YP; Rose, JC; Chen, M; Bailey, CH; Kandel, ER			Synapse-specific, long-form facilitation of Aplysia sensory to motor synapses: A function for local protein synthesis in memory storage	CELL			English	Article							TERM FACILITATION; HETEROSYNAPTIC FACILITATION; STRUCTURAL-CHANGES; MESSENGER-RNA; CELL-CULTURE; NEURONS; DENDRITES; SENSITIZATION; LOCALIZATION; HABITUATION	The requirement for transcription during long-lasting synaptic plasticity has raised the question of whether the cellular unit of synaptic plasticity is the soma and its nucleus or the synapse. To address this question, we cultured a single bifurcated Apylsia sensory neuron making synapses with two spatially separated motor neurons. By perfusing serotonin onto the synapses made onto one motor neuron, we found that a single axonal branch can undergo long-term branch-specific facilitation. This branch-specific facilitation depends on CREB-mediated transcription and involves the growth of new synaptic connections exclusively at the treated branch. Branch-specific long-term facilitation requires local protein synthesis in the presynaptic but not the postsynaptic cell. In fact, presynaptic sensory neuron axons deprived of their cell bodies are capable of protein synthesis, and this protein synthesis is stimulated 3-fold by exposure to serotonin.	Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, Ctr Neurobiol & Behav, Howard Hughes Med Inst, 722 W 168th St, New York, NY 10032 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32099] Funding Source: Medline; NIMH NIH HHS [MH37134] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; BAILEY CH, 1992, NEURON, V9, P749, DOI 10.1016/0896-6273(92)90037-E; BAILEY CH, 1983, SCIENCE, V220, P91, DOI 10.1126/science.6828885; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; BAILEY CH, 1988, P NATL ACAD SCI USA, V85, P2373, DOI 10.1073/pnas.85.7.2373; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRUNET JF, 1991, SCIENCE, V252, P856, DOI 10.1126/science.1840700; CLARK GA, 1993, P NATL ACAD SCI USA, V90, P11411, DOI 10.1073/pnas.90.23.11411; CLARK GA, 1984, P NATL ACAD SCI-BIOL, V81, P2577, DOI 10.1073/pnas.81.8.2577; Crino PB, 1996, NEURON, V17, P1173, DOI 10.1016/S0896-6273(00)80248-2; Crispino M, 1997, J NEUROSCI, V17, P7694; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; EMPTAGE NJ, 1993, SCIENCE, V262, P253, DOI 10.1126/science.8211146; FATT P, 1951, J PHYSIOL-LONDON, V115, P320, DOI 10.1113/jphysiol.1951.sp004675; FEIG S, 1993, J NEUROSCI, V13, P1010; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GARNER CC, 1988, NATURE, V336, P674, DOI 10.1038/336674a0; GHIRARDI M, 1995, NEURON, V14, P413, DOI 10.1016/0896-6273(95)90297-X; GLANZMAN DL, 1989, NEURON, V3, P441, DOI 10.1016/0896-6273(89)90203-1; GLANZMAN DL, 1990, SCIENCE, V249, P799, DOI 10.1126/science.2389145; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Martin KC, 1996, NEURON, V17, P567, DOI 10.1016/S0896-6273(00)80188-9; Mayford M, 1996, P NATL ACAD SCI USA, V93, P13250, DOI 10.1073/pnas.93.23.13250; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; Nestler E. J., 1984, PROTEIN PHOSPHORYLAT; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; RAYPORT SG, 1986, J NEUROSCI, V6, P759; ROBISON GA, 1968, ANNU REV BIOCHEM, V37, P149, DOI 10.1146/annurev.bi.37.070168.001053; SCHACHER S, 1983, J NEUROSCI, V3, P2403; SCHELLER RH, 1982, CELL, V28, P707, DOI 10.1016/0092-8674(82)90050-2; Schuman EM, 1997, NEURON, V18, P339, DOI 10.1016/S0896-6273(00)81234-9; Sossin WS, 1996, TRENDS NEUROSCI, V19, P215; Steward O, 1997, NEURON, V18, P9, DOI 10.1016/S0896-6273(01)80041-6; STIRPE F, 1980, J BIOL CHEM, V255, P6947; TRUDEAU LE, 1995, J NEUROSCI, V15, P1275; VanMinnen J, 1997, NEUROSCIENCE, V80, P1; WEILER IJ, 1993, P NATL ACAD SCI USA, V90, P7168, DOI 10.1073/pnas.90.15.7168; ZINCK R, 1995, MOL CELL BIOL, V15, P4930	42	580	594	0	26	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					927	938		10.1016/S0092-8674(00)80484-5	http://dx.doi.org/10.1016/S0092-8674(00)80484-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428516	hybrid			2022-12-01	WOS:000071281400010
J	Ozaki, M; Sasner, M; Yano, R; Lu, HS; Buonanno, A				Ozaki, M; Sasner, M; Yano, R; Lu, HS; Buonanno, A			Neuregulin-beta induces expression of an NMDA-receptor subunit	NATURE			English	Article							NEU DIFFERENTIATION FACTOR; ACETYLCHOLINE-RECEPTOR; DEVELOPING CEREBELLUM; GENE-EXPRESSION; MESSENGER-RNAS; SINGLE-CHANNEL; GRANULE CELLS; MUSCLE; ERBB3; SYNAPSES	Neuregulins (also known as ARLA, NDF, heregulin, GGF) are a family of widely expressed growth and differentiation factors. Neuregulins secreted from motor neurons accumulate at maturing neuromuscular junctions, where they stimulate transcription of genes encoding specific acetylcholine receptors. How these factors function at central synapses, however, is unknown. In the maturing cerebellum, neuregulins are concentrated in glutamatergic messy fibres that innervate granule cells in the internal granule-cell layer(1). We have analysed the effects of neuregulins on the expression of genes encoding NMDA (N-methyl-D-aspartate) receptors in the cerebellum, because receptor composition changes dramatically as expression of the receptor NR2C subunit is specifically induced in neurons in the internal granule-cell layer during synaptogenesis. Here we report that addition of a neuregulin-beta isoform to cultured cerebellar slices specifically increases the expression of NR2C messenger RNAs by at least 100-fold; effects are only minor with a neuregulin-alpha isoform. This stimulation of NR2C expression requires synaptic activity by NMDA receptors, as well as neuregulin-beta. Addition of the NMDA-receptor-channel blocker AP-5 prevents upregulation of the NR2C subunit by neuregulin, whereas an AMPA/kainate-receptor antagonist does not. Consistent with these effects of neuregulin, we find that granule cells express its receptors ErbB2 and ErbB4 before the NR2C subunit of the NMDA receptor. Our results indicate that neuregulins regulate the composition of neurotransmitter receptors in maturing synapses in the brain, in a manner analogous to the neuromuscular junction.	NIH,MOL NEUROBIOL UNIT,LDN,BETHESDA,MD 20892; RIKEN,FRONTIER RES PROGRAM,LAB CELLULAR INFORMAT PROC,WAKO,SAITAMA 35101,JAPAN; AMGEN INC,DEPT PROT STRUCT,THOUSAND OAKS,CA 91320	National Institutes of Health (NIH) - USA; RIKEN; Amgen				Sasner, Michael/0000-0002-6612-6111				AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; ALTIOK N, 1995, EMBO J, V14, P4258, DOI 10.1002/j.1460-2075.1995.tb00100.x; ANGERER LM, 1981, NUCLEIC ACIDS RES, V9, P2819, DOI 10.1093/nar/9.12.2819; AUDINAT E, 1994, EUR J NEUROSCI, V6, P1792, DOI 10.1111/j.1460-9568.1994.tb00572.x; BUONANNO A, 1995, SOC NEUR ABSTR, V21; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHU GC, 1995, NEURON, V14, P329, DOI 10.1016/0896-6273(95)90289-9; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; FARRANT M, 1994, NATURE, V368, P335, DOI 10.1038/368335a0; Feldmeyer D, 1996, J NEUROCYTOL, V25, P857, DOI 10.1007/BF02284847; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; Kadotani H, 1996, J NEUROSCI, V16, P7859; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; Lemke G, 1996, MOL CELL NEUROSCI, V7, P247, DOI 10.1006/mcne.1996.0019; LEVI G, 1982, BRAIN RES, V239, P425, DOI 10.1016/0006-8993(82)90520-0; LU HS, 1995, J BIOL CHEM, V270, P4784, DOI 10.1074/jbc.270.9.4784; LU HS, 1995, J BIOL CHEM, V270, P4775, DOI 10.1074/jbc.270.9.4775; MEYER D, 1994, P NATL ACAD SCI USA, V91, P1064, DOI 10.1073/pnas.91.3.1064; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MOSCOSO LM, 1995, DEV BIOL, V172, P158, DOI 10.1006/dbio.1995.0012; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; Sandrock AW, 1997, SCIENCE, V276, P599, DOI 10.1126/science.276.5312.599; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; Shahar A, 1989, DISSECTION TISSUE CU, V1, P203; STERN P, 1992, P ROY SOC B-BIOL SCI, V250, P271, DOI 10.1098/rspb.1992.0159; Takahashi T, 1996, J NEUROSCI, V16, P4376; TANAKA M, 1994, BRAIN RES, V641, P319, DOI 10.1016/0006-8993(94)90161-9; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027	30	218	225	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					691	694		10.1038/37795	http://dx.doi.org/10.1038/37795			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414162				2022-12-01	WOS:A1997YM50800033
J	Fetz, EE				Fetz, EE			Neuroscience - Temporal coding in neural populations?	SCIENCE			English	Editorial Material							COOPERATIVE FIRING ACTIVITY; PRIMATE MOTOR CORTEX; MOVEMENT; NEURONS; DIRECTION; DYNAMICS				Fetz, EE (corresponding author), UNIV WASHINGTON,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98195, USA.							ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; ABELES M, 1993, BRAIN THEORY, P149; Abeles M., 1991, CORTICONICS; Aertsen A, 1996, J PHYSIOLOGY-PARIS, V90, P243, DOI 10.1016/S0928-4257(97)81432-5; AERTSEN AMHJ, 1989, J NEUROPHYSIOL, V61, P900, DOI 10.1152/jn.1989.61.5.900; Buszaki G, 1994, TEMPORAL CODING BRAI; Davis J., 1994, LARGE SCALE NEURONAL; FERSTER D, 1995, SCIENCE, V270, P756, DOI 10.1126/science.270.5237.756; FETZ EE, 1992, BEHAV BRAIN SCI, V15, P679; GEORGOPOULOS AP, 1988, J NEUROSCI, V8, P2928; GERSTEIN GL, 1985, J NEUROSCI, V5, P881; GERSTEIN GL, 1985, J NEUROPHYSIOL, V54, P1513, DOI 10.1152/jn.1985.54.6.1513; Lindsey BG, 1997, J NEUROPHYSIOL, V78, P1714, DOI 10.1152/jn.1997.78.3.1714; Murthy VN, 1996, J NEUROPHYSIOL, V76, P3968, DOI 10.1152/jn.1996.76.6.3968; RIECKE F, 1997, SPIKES; RIEHLE A, 1950, SCIENCE, V278; Roelfsema PR, 1996, J COGNITIVE NEUROSCI, V8, P603, DOI 10.1162/jocn.1996.8.6.603; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; SANES JN, 1993, P NATL ACAD SCI USA, V90, P4470, DOI 10.1073/pnas.90.10.4470; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.ph.55.030193.002025; SINGER W, 1993, ANN REV PHYSL, V55, P201; Taira M, 1996, EXP BRAIN RES, V109, P367; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; ZHANG K, IN PRESS J NEUROPHYS	25	47	50	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1901	1902		10.1126/science.278.5345.1901	http://dx.doi.org/10.1126/science.278.5345.1901			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417639				2022-12-01	WOS:A1997YL00200021
J	Hess, RF; Dakin, SC				Hess, RF; Dakin, SC			Absence of contour linking in peripheral vision	NATURE			English	Article							VISUAL-CORTEX; INTEGRATION; SYSTEM	Human foveal vision is subserved initially by groups of spatial, temporal and orientational 'filters', the outputs of which are combined to define perceptual objects, Although a great deal is known about the filtering properties of individual cortical cells, relatively little is known about the nature of this 'linking' process. One recent approach(1) has shown that the process can be thought of in terms of an association field whose strength is determined conjointly by the orientation and distance of the object. Here we describe a fundamental difference in this feature-linking process in central and peripheral parts of the visual field, which provides insight into the ways that foveal and peripheral visual perception differ(2,3). In the fovea, performance can be explained only by intercellular Linking operations whereas in the periphery intracellular filtering will suffice. This difference represents a substantial economy in cortical neuronal processing of peripheral visual information and may allow a recent theory of intercellular binding to be tested(4-7).			Hess, RF (corresponding author), MCGILL UNIV,DEPT OPHTHALMOL,MONTREAL,PQ H3A 1A1,CANADA.		Dakin, Steven C/B-7610-2008; Hess, Robert F/A-5624-2008	Dakin, Steven C/0000-0002-3548-9104; 				Aubert H., 1857, ARCHIV F UR OPHTHALM, V3, P1; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; FIELD DJ, 1993, VISION RES, V33, P173, DOI 10.1016/0042-6989(93)90156-Q; GILBERT CD, 1989, J NEUROSCI, V9, P2432; KREITER AK, 1994, EUROPEAN J NEUROSC S, V7, P153; PHILLIPS G, 1983, J OPT SOC AM, V62, P226; SCHNEIDER GE, 1969, SCIENCE, V163, P895, DOI 10.1126/science.163.3870.895; TSO DY, 1988, J NEUROSCI, V8, P1712; von der Malsburg Ch., 1983, SYNERGETICS BRAIN, P238; VONDERMALSBURG C, 1988, NEUROBIOLOGY NEOCORT, P69; Wang YZ, 1996, VISION RES, V36, P1737, DOI 10.1016/0042-6989(95)00249-9; Watt R., 1991, UNDERSTANDING VISION; WATT RJ, 1985, VISION RES, V25, P1661, DOI 10.1016/0042-6989(85)90138-5	13	125	125	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					602	604		10.1038/37593	http://dx.doi.org/10.1038/37593			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403687				2022-12-01	WOS:A1997YK85300047
J	Ferrari, G; Cusella-De Angelis, G; Coletta, M; Paolucci, E; Stornaiuolo, A; Cossu, G; Mavilio, F				Ferrari, G; Cusella-De Angelis, G; Coletta, M; Paolucci, E; Stornaiuolo, A; Cossu, G; Mavilio, F			Muscle regeneration by bone marrow derived myogenic progenitors	SCIENCE			English	Article							IMMUNE-DEFICIENCY; PRECURSOR CELLS; MICE; EXPRESSION; THERAPY	Growth and repair of skeletal muscle are normally mediated by the satellite cells that surround muscle fibers, In regenerating muscle, however, the number of myogenic precursors exceeds that of resident satellite cells, implying migration or recruitment of undifferentiated progenitors from other sources. Transplantation of genetically marked bone marrow into Immunodeficient mice revealed that marrow-derived cells migrate into areas of induced muscle degeneration, undergo myogenic differentiation, and participate in the regeneration of the damaged fibers, Genetically modified, marrow-derived myogenic progenitors could potentially be used to target therapeutic genes to muscle tissue, providing an alternative strategy for treatment of muscular dystrophies.	Univ Rome La Sapienza, Dipartimento Istol & Embriol Med, I-00161 Rome, Italy; Hosp San Raffaele, Telethon Inst Gene Therapy, I-20132 Milan, Italy; Univ Pavia, Ist Anat Umana Normale, I-27100 Pavia, Italy	Sapienza University Rome; Fondazione Telethon; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; University of Pavia	Cossu, G (corresponding author), Univ Rome La Sapienza, Dipartimento Istol & Embriol Med, Piazzale Aldo Moro 5, I-00161 Rome, Italy.		Ferrari, Giuliana/AAB-5546-2019	Ferrari, Giuliana/0000-0003-0790-3133; Cusella De Angelis, Maria Gabriella/0000-0003-2642-3346; Mavilio, Fulvio/0000-0003-0459-4320	Telethon [TGT06S01, A.067] Funding Source: Medline	Telethon(Fondazione Telethon)		BLAU HM, 1993, TRENDS GENET, V9, P269, DOI 10.1016/0168-9525(93)90012-7; CAMPION DR, 1984, INT REV CYTOL, V87, P225, DOI 10.1016/S0074-7696(08)62444-4; Cossu G, 1997, HISTOL HISTOPATHOL, V12, P755; EMERY A, 1993, DUCHENNE MUSCULAR DY, V1; FULOP GM, 1986, J IMMUNOL, V136, P4438; GROUNDS MD, 1992, CELL TISSUE RES, V267, P99, DOI 10.1007/BF00318695; KELLY R, 1995, J CELL BIOL, V129, P383, DOI 10.1083/jcb.129.2.383; Krensky AM, 1997, NAT BIOTECHNOL, V15, P720, DOI 10.1038/nbt0897-720; Miller AD, 1997, NAT MED, V3, P278, DOI 10.1038/nm0397-278; MURPHY WJ, 1987, J EXP MED, V165, P1212, DOI 10.1084/jem.165.4.1212; PARTRIDGE TA, 1991, MUSCLE NERVE, V14, P197, DOI 10.1002/mus.880140302; PARTRIDGE TA, 1995, BRIT MED BULL, V51, P123, DOI 10.1093/oxfordjournals.bmb.a072942; PEREIRA RF, 1995, P NATL ACAD SCI USA, V92, P4857, DOI 10.1073/pnas.92.11.4857; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; SALVATORI G, 1995, J CELL SCI, V108, P2733; SALVATORI G, 1993, HUM GENE THER, V4, P713, DOI 10.1089/hum.1993.4.6-713; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHULTZ E, 1980, MECH AGEING DEV, V13, P105; TAJBAKHSH S, 1994, NEURON, V13, P813, DOI 10.1016/0896-6273(94)90248-8; WAKITANI S, 1995, MUSCLE NERVE, V18, P1417, DOI 10.1002/mus.880181212	20	2134	2387	2	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1528	1530		10.1126/science.279.5356.1528	http://dx.doi.org/10.1126/science.279.5356.1528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488650				2022-12-01	WOS:000072372900063
J	Reid, MC; Schoen, RT; Evans, J; Rosenberg, JC; Horwitz, RI				Reid, MC; Schoen, RT; Evans, J; Rosenberg, JC; Horwitz, RI			The consequences of overdiagnosis and overtreatment of Lyme disease: An observational study	ANNALS OF INTERNAL MEDICINE			English	Article						Lyme disease; health services misuse; health services needs and demands; antibiotics; depression	DIAGNOSIS; CHILDREN; FIBROMYALGIA; STRESS	Background: The adverse consequences associated with overdiagnosis and overtreatment of Lyme disease, although previously recognized, have received inadequate attention. Objective: To determine the use of health services and occurrence of treatment-related illness, disability, and distress among patients in whom Lyme disease is inappropriately diagnosed or treated. Design: Observational cohort study. Setting: University-based Lyme disease clinic. Participants: 209 patients with a presumptive diagnosis of Lyme disease previously assigned by referring physicians, the patients themselves, or both. Measurements: Self-reported data, review of medical records, and standardized instruments were used to determine 1) use of health services in terms of number of outpatient visits, number of physicians seen, types of serologic tests, and days of antibiotic treatment; 2) occurrence of antibiotic-related adverse events; and 3) levels of disability, depression, and stress. Results: Of the 209 patients, 44 (21%) met criteria for active Lyme disease, 40 (19%) had previous but not active Lyme disease, and 125 (60%) had no evidence of current or previous infection. In general, patients with active Lyme disease (who were not the focus of this study) had good outcomes. Patients with previous Lyme disease and patients with no evidence of Lyme disease used considerable health resources (median number of office visits, 11 and 7; median number of serologic tests, 4 and 4; and median days of antibiotic treatment, 75 and 42), had frequent minor adverse drug events (53% and 55%), reported significant disability (proportion of symptomatic days during which normal activities could not be performed, 16% and 18%), and had high rates of depression (38% and 42%) and stress (52% and 45%). Conclusions: Overdiagnosis and overtreatment of Lyme disease are associated with inappropriate use of health services, avoidable treatment-related illness, and substantial disability and distress.	Vet Affairs Connecticut Healthcare Syst, Sect Gen Med 111GIM, West Haven, CT 06516 USA; Yale Univ, Sch Med, Dept Med, New Haven, CT 06510 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Yale University	Reid, MC (corresponding author), Vet Affairs Connecticut Healthcare Syst, Sect Gen Med 111GIM, 950 Campbell Ave, West Haven, CT 06516 USA.			Reid, Cary/0000-0001-8117-662X	NIA NIH HHS [P30 AG022845] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P30AG022845] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		*AM HOSP FORM SERV, 1996, DRUG INF; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; [Anonymous], 1997, PHYS DESK REF, P1723; ASCH ES, 1994, J RHEUMATOL, V21, P454; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; *CDCP, 1996, JAMA-J AM MED ASSOC, V275, P274; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S., 1995, MEASURING STRESS GUI, P3; CRAFT JE, 1984, J INFECT DIS, V149, P789, DOI 10.1093/infdis/149.5.789; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; FEDER HM, 1995, JAMA-J AM MED ASSOC, V274, P66, DOI 10.1001/jama.274.1.66; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; MIROWSKY J, 1992, J HEALTH SOC BEHAV, V33, P187, DOI 10.2307/2137349; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSE CD, 1994, CLIN PEDIATR, V33, P663, DOI 10.1177/000992289403301105; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P2431; Sigal LH, 1996, ARCH INTERN MED, V156, P1493, DOI 10.1001/archinte.156.14.1493; SIGAL LH, 1990, AM J MED, V88, P577, DOI 10.1016/0002-9343(90)90520-N; SIGAL LH, 1995, AM J MED, V98, pS74, DOI 10.1016/S0002-9343(99)80048-5; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; *VIT HLTH STAT, 1993, DHHS PUBL	27	126	127	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					354	+		10.7326/0003-4819-128-5-199803010-00003	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490595				2022-12-01	WOS:000072155600003
J	Coustan-Smith, E; Behm, FG; Sanchez, J; Boyett, JM; Hancock, ML; Raimondi, SC; Rubnitz, JE; Rivera, GK; Sandlund, JT; Pui, CH; Campana, D				Coustan-Smith, E; Behm, FG; Sanchez, J; Boyett, JM; Hancock, ML; Raimondi, SC; Rubnitz, JE; Rivera, GK; Sandlund, JT; Pui, CH; Campana, D			Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia	LANCET			English	Article							POLYMERASE CHAIN-REACTION; CELL RECEPTOR GENES; T-CELL; COMPLETE REMISSION; FOLLOW-UP; LEUKEMIA; RELAPSE; REARRANGEMENTS; PREDICTION; INDUCTION	Background The clinical significance of submicroscopic levels of leukaemic cells in bone-marrow aspirates from children with acute lymphoblastic leukaemia (ALL) remains controversial. We prospectively determined the frequency and prognostic importance of minimal residual disease detected by a rapid immunological assay in bone-marrow aspirates of children with ALL. Methods 1.58 children with newly diagnosed ALL received 6 weeks of remission-induction chemotherapy. Once complete clinical remission was attained the patients received 2 weeks of consolidation therapy followed by continuation therapy. Bone-marrow aspirates were collected after induction therapy and during weeks 14, 32, and 56 of continuation therapy, and then at 120 weeks (end of therapy). Cells with leukaemia-associated immuno-phenotypes were investigated by multiparameter flow-cytometry capable of detecting one leukaemic cell among 10 000 normal cells. Findings The proportion of patients with detectable leukaemic cells was 23% at remission induction and 17% at week 14 of continuation therapy, decreasing to 5% and 4% at weeks 32 and 56. None of the 65 samples examined at completion of therapy (week 120) showed evidence of Detectable residual disease at the end of induction correlated with adverse genetic abnormalities-the Philadelphia chromosome and MLL gene rearrangements-but not with other presenting features. Detectable leukaemia was associated with subsequent relapse regardless of the time at which bone-marrow samples were examined (p<0.002 for all comparisons). For example, 3-year cumulative incidence (SE) of relapse in patients with and without detectable leukaemia at remission induction was 32.5% (10.6) and 7.5% (4.0), respectively (p<0.001); for tests done at week 14, it was 42.1% (14.6) and 6.6% (3.5), p<0.001. These correlations remained significant after adjusting for adverse presenting features. A higher degree of marrow infiltration by leukaemic cells (greater than or equal to 0.1%) in week 14 samples identified a subset of patients with an especially poor prognosis. Interpretation Immunological detection of residual leukaemic cells at any point in the treatment course is a powerful predictor of relapse in children with ALL. Alternative treatment should be considered for cases with persistent disease beyond the first 3 months of continuation therapy.	St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Pathol & Lab Med, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biostat & Epidemiol, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Campana, D (corresponding author), St Jude Childrens Res Hosp, Dept Hematol Oncol, 332 N Lauderdale St, Memphis, TN 38105 USA.	dario.campana@stjude.org	Pui, Ching-Hon/N-8076-2018; Rubnitz, Jeffrey E/N-2619-2018; Raimondi, Susana C/N-8166-2018	Pui, Ching-Hon/0000-0003-0303-5658; Rubnitz, Jeffrey E/0000-0001-9885-3527; 	NCI NIH HHS [CA20180, CA21765, CA60419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA020180, P30CA021765, U01CA060419, R01CA060419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Behm FG, 1996, BLOOD, V87, P1134, DOI 10.1182/blood.V87.3.1134.bloodjournal8731134; BEISHUIZEN A, 1994, BLOOD, V83, P2238, DOI 10.1182/blood.V83.8.2238.bloodjournal8382238; BIONDI A, 1992, LEUKEMIA, V6, P282; BRISCO MJ, 1994, LANCET, V343, P196, DOI 10.1016/S0140-6736(94)90988-1; CAMPANA D, 1995, BLOOD, V85, P1416, DOI 10.1182/blood.V85.6.1416.bloodjournal8561416; CAMPANA D, 1990, BLOOD, V76, P163, DOI 10.1182/blood.V76.1.163.163; CAVE H, 1994, BLOOD, V83, P1892; CoustanSmith E, 1996, BLOOD, V87, P1140, DOI 10.1182/blood.V87.3.1140.bloodjournal8731140; COUSTANSMITH E, 1993, LEUKEMIA, V7, P853; CROSS NCP, 1995, BRIT J HAEMATOL, V89, P693; ITO Y, 1993, J CLIN ONCOL, V11, P546, DOI 10.1200/JCO.1993.11.3.546; Jacquy C, 1997, BRIT J HAEMATOL, V98, P140, DOI 10.1046/j.1365-2141.1997.1792996.x; KITCHINGMAN GR, 1994, LEUKEMIA, V8, P395; MENSSEN HD, 1995, LEUKEMIA, V9, P1060; NEALE GAM, 1991, BLOOD, V78, P739, DOI 10.1182/blood.V78.3.739.bloodjournal783739; NIZET Y, 1993, BLOOD, V82, P1618; ORFAO A, 1994, LEUKEMIA LYMPHOMA, V13, P87, DOI 10.3109/10428199409052682; Pui CH, 1997, NEW ENGL J MED, V336, P1781, DOI 10.1056/NEJM199706193362503; PUI CH, 1997, ACUTE LEUKEMIA, V6, P629; Roberts WM, 1997, NEW ENGL J MED, V336, P317, DOI 10.1056/NEJM199701303360501; Sang BC, 1997, BLOOD, V89, P2909, DOI 10.1182/blood.V89.8.2909; SERIU T, 1995, LEUKEMIA, V9, P615; STEENBERGEN EJ, 1995, BLOOD, V86, P692, DOI 10.1182/blood.V86.2.692.bloodjournal862692; STEWARD CG, 1994, BLOOD, V83, P1355; Vervoordeldonk SF, 1996, BRIT J HAEMATOL, V92, P922, DOI 10.1046/j.1365-2141.1996.440979.x; WASSERMAN R, 1992, J CLIN ONCOL, V10, P1879, DOI 10.1200/JCO.1992.10.12.1879	26	345	356	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					550	554		10.1016/S0140-6736(97)10295-1	http://dx.doi.org/10.1016/S0140-6736(97)10295-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492773				2022-12-01	WOS:000072231900009
J	Donnelly, R; Millar-Craig, MW				Donnelly, R; Millar-Craig, MW			Cardiac troponins: IT upgrade for the heart	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PROGNOSTIC VALUE; MB MASS; RISK		Univ Nottingham, Derbyshire Royal Infirm, Dept Med & Surg Sci, Derby DE1 2QY, England	University of Nottingham	Donnelly, R (corresponding author), Univ Nottingham, Derbyshire Royal Infirm, Dept Med & Surg Sci, Derby DE1 2QY, England.							Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 1996, AM J CLIN PATHOL, V105, P6; deWinter RJ, 1996, HEART, V75, P235, DOI 10.1136/hrt.75.3.235; Genser N, 1996, AM J CARDIOL, V78, P127, DOI 10.1016/S0002-9149(97)89225-9; Haft JI, 1997, NEW ENGL J MED, V336, P1257; Lindahl B, 1997, EUR HEART J, V18, P762; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; LINDAHL B, 1996, CIRCULATION, V93, P151; Luscher MS, 1997, CIRCULATION, V96, P2578, DOI 10.1161/01.CIR.96.8.2578; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Pettijohn TL, 1997, AM J CARDIOL, V80, P510, DOI 10.1016/S0002-9149(97)00405-0; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; Stubbs P, 1996, BRIT MED J, V313, P262, DOI 10.1136/bmj.313.7052.262; WU AHB, 1994, CLIN CHEM, V40, P900	14	37	42	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					537	539		10.1016/S0140-6736(05)78549-4	http://dx.doi.org/10.1016/S0140-6736(05)78549-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492767				2022-12-01	WOS:000072231900003
J	Chiu, DT; Lillard, SJ; Scheller, RH; Zare, RN; Rodriguez-Cruz, SE; Williams, ER; Orwar, O; Sandberg, M; Lundqvist, JA				Chiu, DT; Lillard, SJ; Scheller, RH; Zare, RN; Rodriguez-Cruz, SE; Williams, ER; Orwar, O; Sandberg, M; Lundqvist, JA			Probing single secretory vesicles with capillary electrophoresis	SCIENCE			English	Article							TRANSFORM MASS-SPECTROMETRY; ELECTROSPRAY-IONIZATION; FLUORESCENCE DETECTION; APLYSIA-CALIFORNICA; ATRIAL GLAND; CELLS; DERIVATIZATION; ION; LOCALIZATION	Secretory vesicles obtained from the atrial gland of the gastropod mollusk Aplysia californica were chemically analyzed individually with a combination of optical trapping, capillary electrophoresis separation, and a laser-induced fluorescence detection. With the use of optical trapping, a single Vesicle that had attoliters (10(-18) liters) of volume was introduced into the tapered inlet of a separation capillary, Once the vesicle was injected, it was lysed, and its components were fluorescently labeled with naphthalene-2,3-dicarboxaldehyde before separation, The resultant electropherograms indicated distinct variations in the contents of single vesicles.	Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Gothenburg Univ, Dept Chem, SE-41296 Gothenburg, Sweden; Gothenburg Univ, Dept Anat & Cell Biol, SE-41390 Gothenburg, Sweden	Stanford University; Howard Hughes Medical Institute; Stanford University; University of California System; University of California Berkeley; University of Gothenburg; University of Gothenburg	Zare, RN (corresponding author), Stanford Univ, Dept Chem, Stanford, CA 94305 USA.		Zare, Richard N./A-8410-2009; Williams, Evan/I-3924-2013	Zare, Richard/0000-0001-5266-4253	NIDA NIH HHS [DA09873] Funding Source: Medline; NIGMS NIH HHS [GM18386, 1R29GM50336-01A2] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018386, R29GM050336, R01GM018386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA009873] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		CASTRO A, 1995, ANAL CHEM, V67, P3181, DOI 10.1021/ac00114a013; Chiu DT, 1997, ANAL CHEM, V69, P1801, DOI 10.1021/ac961226g; DEMONTIGNY P, 1987, ANAL CHEM, V59, P1096, DOI 10.1021/ac00135a007; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; GILMAN SD, 1995, ANAL CHEM, V67, P58, DOI 10.1021/ac00097a010; GROSS DS, 1995, J AM CHEM SOC, V117, P883, DOI 10.1021/ja00108a004; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; JANKOWSKI JA, 1995, TRAC-TREND ANAL CHEM, V14, P170, DOI 10.1016/0165-9936(95)98315-Y; KALDANY RRJ, 1985, ANNU REV NEUROSCI, V8, P431; LI X, 1996, BRAIN RES, V706, P86; LILIARD SJ, 1996, HDB CAPILLARY ELECTR, P523; Lillard SJ, 1996, ANAL CHEM, V68, P2897, DOI 10.1021/ac960412j; LINDROTH P, 1979, ANAL CHEM, V51, P1667, DOI 10.1021/ac50047a019; MCCAMAN R, 1977, J NEUROCHEM, V29, P739; NAGLE GT, 1988, J BIOL CHEM, V263, P9223; OLEFIROWICZ TM, 1990, ANAL CHEM, V62, P1872, DOI 10.1021/ac00216a026; ORWAR O, 1995, ANAL CHEM, V67, P4261, DOI 10.1021/ac00119a010; PIHEL K, 1995, ANAL CHEM, V67, P4514, DOI 10.1021/ac00120a014; RodriguezCruz SE, 1997, J AM SOC MASS SPECTR, V8, P565, DOI 10.1016/S1044-0305(97)00020-2; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; VANHEUMEN WRA, 1995, CELL TISSUE RES, V279, P13, DOI 10.1007/BF00300687; WILLIAMS ER, 1994, TRAC-TREND ANAL CHEM, V13, P247, DOI 10.1016/0165-9936(94)87050-0	22	100	103	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1190	1193		10.1126/science.279.5354.1190	http://dx.doi.org/10.1126/science.279.5354.1190			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469805				2022-12-01	WOS:000072115200037
J	Henn, V; Slupsky, JR; Grafe, M; Anagnostopoulos, I; Forster, R; Muller-Berghaus, G; Kroczek, RA				Henn, V; Slupsky, JR; Grafe, M; Anagnostopoulos, I; Forster, R; Muller-Berghaus, G; Kroczek, RA			CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells	NATURE			English	Article							ADHESION MOLECULE EXPRESSION; X-LINKED IMMUNODEFICIENCY; T-CELLS; DEFECTIVE EXPRESSION; HYPER-IGM; CYTOKINES; INTERLEUKIN-8; ESTABLISHMENT; SURFACE; PROTEIN	CD40 ligand (CD40L, CD154), a transmembrane protein structurally related to the cytokine TNF-alpha, was originally identified on stimulated CD4(+) T cells(1-3), and later on stimulated mast cells and basophils(4). Interaction of CD40L on T cells with CD40 on B cells is of paramount importance for the development and function of the humoral immune system(5). CD40 is not only constitutively present on B cells, but it is also found on monocytes, macrophages and endothelial cells, suggesting that CD40L has a broader function in vivo. We now report that platelets express CD40L within seconds of activation in vitro and in the process of thrombus formation in vivo. Like TNF-alpha and interleukin-1, CD40L on platelets induces endothelial cells to secrete chemokines and to express adhesion molecules, thereby generating signals for the recruitment and extravasation of leukocytes at the site of injury. Our results indicate that platelets are not only involved in haemostasis but that they also directly initiate an inflammatory response of the vessel wall.	Robert Koch Inst, D-13353 Berlin, Germany; Max Planck Inst Physiol & Klin Forsch, Haemostasis Res Unit, D-61231 Bad Nauheim, Germany; Deutsch Herrzzentrum, D-13353 Berlin, Germany; Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pathol, D-12200 Berlin, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany	Robert Koch Institute; Max Planck Society; German Heart Center Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kroczek, RA (corresponding author), Robert Koch Inst, D-13353 Berlin, Germany.	Kroczek@rki.de	Slupsky, Joseph/H-2843-2019; Förster, Reinhold/D-6770-2011	Slupsky, Joseph/0000-0002-7410-9004; Forster, Reinhold/0000-0001-6190-7923				ALDERSON MR, 1993, J EXP MED, V178, P669, DOI 10.1084/jem.178.2.669; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.immunol.11.1.767; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Clark R., 1996, Mezhdunarodnyi Sel'skokhozyaistvennyi Zhurnal, P3; CORDELL JL, 1984, J HISTOCHEM CYTOCHEM, V32, P219, DOI 10.1177/32.2.6198355; Davies MJ, 1996, THROMB RES, V82, P1, DOI 10.1016/0049-3848(96)00035-7; Ebnet K, 1996, ANNU REV IMMUNOL, V14, P155, DOI 10.1146/annurev.immunol.14.1.155; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GRAF D, 1992, EUR J IMMUNOL, V22, P3191, DOI 10.1002/eji.1830221226; GRAF D, 1995, EUR J IMMUNOL, V25, P1749, DOI 10.1002/eji.1830250639; HAWRYLOWICZ CM, 1991, J EXP MED, V174, P785, DOI 10.1084/jem.174.4.785; HOLLENBAUGH D, 1995, J EXP MED, V182, P33, DOI 10.1084/jem.182.1.33; Holmsen H., 1994, HEMOSTASIS THROMBOSI, P524; KAPLANSKI G, 1993, BLOOD, V81, P2492; KARMANN K, 1995, P NATL ACAD SCI USA, V92, P4342, DOI 10.1073/pnas.92.10.4342; Kenny D, 1997, BLOOD, V90, P2626, DOI 10.1182/blood.V90.7.2626.2626_2626_2633; KIENER PA, 1995, J IMMUNOL, V155, P4917; KOMATSU N, 1991, CANCER RES, V51, P341; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; KROCZEK RA, 1994, IMMUNOL REV, V138, P39, DOI 10.1111/j.1600-065X.1994.tb00846.x; LAUFFER L, 1995, BEHRING I MITT, V96, P21; LEDERMAN S, 1992, J EXP MED, V175, P1091, DOI 10.1084/jem.175.4.1091; NIEUWENHUIS HK, 1987, BLOOD, V70, P838; OGURA M, 1985, BLOOD, V66, P1384; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; WARE JA, 1993, NEW ENGL J MED, V328, P628; YELLIN MJ, 1995, J EXP MED, V182, P1857, DOI 10.1084/jem.182.6.1857	29	1589	1660	3	52	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					591	594		10.1038/35393	http://dx.doi.org/10.1038/35393			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468137				2022-12-01	WOS:000071842300053
J	Echard, A; Jollivet, F; Martinez, O; Lacapere, JJ; Rousselet, A; Janoueix-Lerosey, I; Goud, B				Echard, A; Jollivet, F; Martinez, O; Lacapere, JJ; Rousselet, A; Janoueix-Lerosey, I; Goud, B			Interaction of a Golgi-associated kinesin-like protein with Rab6	SCIENCE			English	Article							HEAVY-CHAIN; BINDING; TRANSPORT; MOTOR; MICROTUBULES; EFFECTOR; DOMAINS; BRAIN; NCD	Rab guanosine triphosphatases regulate vesicular transport and membrane traffic within eukaryotic cells. Here, a kinesin-like protein that interacts with guanosine triphosphate (GTP)-bound forms of Rab6 was identified. This protein, termed Rabkinesin-6, was localized to the Golgi apparatus and shown to play a role in the dynamics of this organelle. The carboxyl-terminal domain of Rabkinesin-6, which contains the Rab6-interacting domain, inhibited the effects of Rab6-GTP on intracellular transport, Thus, a molecular motor is a potential effector of a Rab protein, and coordinated action between members of these two families of proteins could control membrane dynamics and directional vesicular traffic.	Inst Curie, CNRS, Unite Mixte Rech 144 & 168, F-75248 Paris 05, France; Inst Curie, INSERM, U248, F-75248 Paris 05, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Goud, B (corresponding author), Inst Curie, CNRS, Unite Mixte Rech 144 & 168, 26 Rue Ulm, F-75248 Paris 05, France.	bgoud@curie.fr	Goud, Bruno/GWC-4807-2022; Janoueix-Lerosey, Isabelle/G-1758-2018	Janoueix-Lerosey, Isabelle/0000-0003-0434-3003; Echard, Arnaud/0000-0001-7402-1398				ANDREWS SB, 1993, P NATL ACAD SCI USA, V90, P6503, DOI 10.1073/pnas.90.14.6503; BLOOM GS, 1995, PROTEIN PROFILE, V2, P1109; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRONDYK WH, 1995, MOL CELL BIOL, V15, P1137; CHANDRA R, 1993, J BIOL CHEM, V268, P9005; DERETIC D, 1995, J CELL SCI, V108, P215; Diaz E, 1997, J CELL BIOL, V138, P283, DOI 10.1083/jcb.138.2.283; ECHARD A, UNPUB; FEIGUIN F, 1994, J CELL BIOL, V127, P1021, DOI 10.1083/jcb.127.4.1021; Goodson HV, 1997, CURR OPIN CELL BIOL, V9, P18, DOI 10.1016/S0955-0674(97)80147-0; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; JASMIN BJ, 1989, P NATL ACAD SCI USA, V86, P7218, DOI 10.1073/pnas.86.18.7218; Johannes L, 1996, J CELL SCI, V109, P2875; JOHANNES L, UNPUB; KURIYAMA R, 1994, J CELL SCI, V107, P3485; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; LIPPINCOTTSCHWARTZ J, 1995, J CELL BIOL, V128, P293, DOI 10.1083/jcb.128.3.293; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Martinez O, 1997, P NATL ACAD SCI USA, V94, P1828, DOI 10.1073/pnas.94.5.1828; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MARTINEZ O, 1997, THESIS U PARIS; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; Peranen J, 1996, J CELL BIOL, V135, P153, DOI 10.1083/jcb.135.1.153; PFEFFER SR, 1994, CURR OPIN CELL BIOL, V6, P522, DOI 10.1016/0955-0674(94)90071-X; Ren MD, 1996, P NATL ACAD SCI USA, V93, P5151, DOI 10.1073/pnas.93.10.5151; ROA M, 1993, J CELL SCI, V106, P789; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; SKOUFIAS DA, 1994, J BIOL CHEM, V269, P1477; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; STENMARK H, 1995, CELL, V83, P423, DOI 10.1016/0092-8674(95)90120-5; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; WILLIAMS RC, 1982, METHOD ENZYMOL, V85, P376; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	37	406	418	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 23	1998	279	5350					580	585		10.1126/science.279.5350.580	http://dx.doi.org/10.1126/science.279.5350.580			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438855				2022-12-01	WOS:000071616000052
J	Weiskopf, RB; Viele, MK; Feiner, J; Kelley, S; Lieberman, J; Noorani, M; Leung, JM; Fisher, DM; Murray, WR; Toy, P; Moore, MA				Weiskopf, RB; Viele, MK; Feiner, J; Kelley, S; Lieberman, J; Noorani, M; Leung, JM; Fisher, DM; Murray, WR; Toy, P; Moore, MA			Human cardiovascular and metabolic response to acute, severe isovolemic anemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Society-of-Anesthesiologists	OCT 17-25, 1996	NEW ORLEANS, LA	Amer Soc Anesthesiologists			OXYGEN DELIVERY; HEMODYNAMICS; HEMODILUTION; TRANSFUSION	Context.-Although concern over the risks of red blood cell transfusion has resulted in several practice guidelines for transfusion, lack of data regarding the physiological effects of anemia in humans has caused uncertainty regarding the blood hemoglobin (Hb) concentration requiring treatment. Objective.-To test the hypothesis that acute isovolemic reduction of blood Hb concentration to 50 g/L in healthy resting humans would produce inadequate cardiovascular compensation and result in tissue hypoxia secondary to inadequate oxygen transport. Design.-Before and after interventional study. Setting.-Academic tertiary care medical center. Participants.-Conscious healthy patients (n=11) prior to anesthesia and surgery and volunteers not undergoing surgery (n=21). Interventions.-Aliquots of blood (450-900 mL) were removed to reduce blood Hb concentration from 131 (2) g/L to 50 (1) g/L [mean (SE)]. Isovolemia was maintained with 5% human albumin and/or autologous plasma. Cardiovascular parameters, arterial and mixed venous oxygen content, oxyhemoglobin saturation, and arterial blood lactate were measured before and after removal of each aliquot of blood, Electrocardiogram and, in a subset, Holter monitor were monitored continuously. Main Outcome Measures.-"Critical" oxygen delivery (TO2) as assessed by oxygen consumption ((V)over dot O-2), plasma lactate concentration, and ST changes on electrocardiogram. Results.-Acute, isovolemic reduction of Hb concentration decreased systemic vascular resistance and TO2 and increased heart rate, stroke volume, and cardiac index (each P<.001). We did not find evidence of inadequate oxygenation: (V)over dot O-2 increased slightly from a mean (SD) of 3.07 (0.44) mL of oxygen per kilogram per minute (mL O-2.kg(-1).min(-1)) to 3.42 (0.54) mL O-2.kg(-1).min(-1) (P<.001) and plasma lactate concentration did not change (0.81 [0.11] mmol/L to 0.62 [0.19] mmol/L; P=.09). Two subjects developed significant ST changes on Holter monitor: one apparently related to body position or activity, the other to an increase in heart rate (at an Hb concentration of 46-53 g/L); both occurred in young women and resolved without sequelae. Conclusions.-Acute isovolemic reduction of blood Hb concentration to 50 g/L in conscious healthy resting humans does not produce evidence of inadequate systemic TO2, as assessed by lack of change of (V)over dot O-2 and plasma lactate concentration. Analysis of Hotter readings suggests that at this Hb concentration in this resting healthy population, myocardial ischemia would occur infrequently.	Univ Calif San Francisco, Dept Anesthesia, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Weiskopf, RB (corresponding author), Univ Calif San Francisco, Dept Anesthesia, 521 Parnassus Ave,C450, San Francisco, CA 94143 USA.	weiskopf@jemo.ucsf.edu			NHLBI NIH HHS [1 P50HL54476] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054476] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS RP, 1982, J APPL PHYSIOL, V53, P660, DOI 10.1152/jappl.1982.53.3.660; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Beal B., 1992, NONMEM USERS GUIDE; BEAL SL, 1985, DRUG FATE METABOLISM; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; CAIN SM, 1977, J APPL PHYSIOL, V42, P228, DOI 10.1152/jappl.1977.42.2.228; CAIN SM, 1965, AM J PHYSIOL, V209, P604, DOI 10.1152/ajplegacy.1965.209.3.604; CHAITMAN BR, 1981, AM J CARDIOL, V47, P1335, DOI 10.1016/0002-9149(81)90267-8; CHAMORRO G, 1973, CIRC RES, V33, P530; COHN PF, 1985, AM J MED, V79, P2, DOI 10.1016/0002-9343(85)90486-3; FAITHFULL NS, 1992, ADV EXP MED BIOL, V317, P55; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; JAN KM, 1977, AM J PHYSIOL, V233, pH106, DOI 10.1152/ajpheart.1977.233.1.H106; LEVINE E, 1990, TRANSFUSION, V30, P11, DOI 10.1046/j.1537-2995.1990.30190117621.x; LOWENSTEIN E, 1987, CARDIAC ANESTHESIA; MICHENFELDERJD, 1988, ANESTHESIA BRAIN; MURRAY JF, 1969, AM J PHYSIOL, V216, P638, DOI 10.1152/ajplegacy.1969.216.3.638; NOLDGE GFE, 1992, ANESTH ANALG, V75, P660; RESTORFF WV, 1975, PFLUG ARCH EUR J PHY, V357, P25, DOI 10.1007/BF00584542; RESTORFF WV, 1975, PFLUG ARCH EUR J PHY, V357, P15, DOI 10.1007/BF00584541; Royal College of Physicians of Edinburgh, 1994, TRANSFUSION MED, V4, P177; VANWOERKENS ECSM, 1992, ANESTH ANALG, V75, P818; VIELE MK, 1994, TRANSFUSION, V34, P396, DOI 10.1046/j.1537-2995.1994.34594249050.x; WOHLGELERNTER D, 1986, J AM COLL CARDIOL, V7, P1245, DOI 10.1016/S0735-1097(86)80143-7	24	428	449	0	11	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					217	221		10.1001/jama.279.3.217	http://dx.doi.org/10.1001/jama.279.3.217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YR124	9438742	Bronze			2022-12-01	WOS:000071460700032
J	Gray, RH; Wawer, MJ; Serwadda, D; Sewankambo, N; Li, CJ; Wabwire-Mangen, F; Paxton, L; Kiwanuka, N; Kigozi, G; Konde-Lule, J; Quinn, TC; Gaydos, CA; McNairn, D				Gray, RH; Wawer, MJ; Serwadda, D; Sewankambo, N; Li, CJ; Wabwire-Mangen, F; Paxton, L; Kiwanuka, N; Kigozi, G; Konde-Lule, J; Quinn, TC; Gaydos, CA; McNairn, D			Population-based study of fertility in women with HIV-1 infection in Uganda	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LIGASE CHAIN-REACTION; PREGNANCY; MORTALITY; DISTRICT; DISEASE; COHORT; IMPACT; RATES; URINE	Background To assess the effects of HIV-1 and other sexually transmitted infections on pregnancy, we undertook cross-sectional and prospective-studies of a rural population in Rakai district, Uganda. Methods 4813 sexually active women aged 15-49 years were surveyed to find out the prevalence of pregnancy by interview and selective urinary human chorionic gonadotropin tests. The incidence of recognised conception and frequency of pregnancy loss were assessed by follow-up. Samples were taken to test for HIV-1 infection, syphilis, and other sexually transmitted diseases. Findings At time of survey, 757 (21.4%) of 3544 women without HIV-1 infection or syphilis were pregnant, compared with 46 (14.6%) of 316 HIV-1-negative women with active syphilis, 117 (14.2%) of 823 HIV-1-positive women with no concurrent syphilis, and 11 (8.5%) of 130 women with both syphilis and HIV-1 infection. The multivariate adjusted odds ratio of pregnancy in HIV-1-infected women was 0.45 (95% CI 0.35-0.57); the odds of pregnancy were low both in HIV-1-infected women without symptoms (0.49 [0.39-0.62]) and in women with symptoms of HIV-1-associated disease (0.23 [0.11-0.48]). In women with concurrent HIV-1 infection and syphilis the odds ratio was 0.28 (0.14-0.55). The incidence rate of recognised pregnancy during the prospective followup study was lower in HIV-1-positive than in HIV-1-negative women (23.5 vs 30.1 per 100 woman-years; adjusted risk ratio 0.73 [0.57-0.93]). Rates of pregnancy loss were higher among HIV-1-infected than uninfected women (18.5 vs 12.2%; odds ratio 1.50 [1.01-2.27]). The prevalence of HIV-1 infection was significantly lower in pregnant than in non-pregnant women (13.9 vs 21.3%). Interpretation Pregnancy prevalence is greatly reduced in HIV-1-infected women, owing to lower rates of conception and increased rates of pregnancy loss. HIV-1 surveillance confined to pregnant women underestimates the magnitude of the HIV-1 epidemic in the general population.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Populat Dynam, Baltimore, MD 21205 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21205 USA; Columbia Univ, Sch Publ Hlth, Ctr Populat & Family Hlth, New York, NY USA; Makerere Univ, Inst Publ Hlth, Kampala, Uganda; Makerere Univ, Dept Med, Kampala, Uganda; Rakai Project, Entebbe, Uganda; NIAID, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Columbia University; Makerere University; Makerere University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gray, RH (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Populat Dynam, Room 4030,615 N Wolfe St, Baltimore, MD 21205 USA.		Gaydos, Charlotte A./E-9937-2010; Quinn, Thomas/A-2494-2010	Sewankambo, Nelson/0000-0001-9362-053X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD006268] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034826] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34826-03] Funding Source: Medline; NICHD NIH HHS [5P30HD06268] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN S, 1993, AM J PUBLIC HEALTH, V83, P705, DOI 10.2105/AJPH.83.5.705; ASSIMWEOKIROR G, 1995, 9 INT C AIDS STDS AF, P14; BACKE E, 1993, AIDS, V7, P896, DOI 10.1097/00002030-199306000-00025; Bongaarts J, 1996, POPUL DEV REV, V22, P21, DOI 10.2307/2137685; BRETTLE RP, 1995, AIDS, V9, P1177, DOI 10.1097/00002030-199510000-00010; Carpenter LM, 1997, HLTH TRANSITION R S2, V7, P113; CHENG CY, 1997, J INFECT DIS, V174, P1390; Chu SY, 1996, OBSTET GYNECOL, V87, P195, DOI 10.1016/0029-7844(95)00399-1; DAVIS SF, 1995, JAMA-J AM MED ASSOC, V274, P952, DOI 10.1001/jama.274.12.952; HILLIER SL, 1993, AM J OBSTET GYNECOL, V169, P455, DOI 10.1016/0002-9378(93)90340-O; HOCKE C, 1995, OBSTET GYNECOL, V86, P886, DOI 10.1016/0029-7844(95)00257-R; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; KAMENGA MC, 1995, AM J OBSTET GYNECOL, V172, P919, DOI 10.1016/0002-9378(95)90022-5; KIGADYE RM, 1993, AIDS, V7, P849, DOI 10.1097/00002030-199306000-00014; KORN A, 1994, J ACQ IMMUN DEF SYND, V9, P361; KRIEGER JN, 1991, J INFECT DIS, V164, P464, DOI 10.1093/infdis/164.3.464; LANGSTON C, 1995, J INFECT DIS, V172, P1451, DOI 10.1093/infdis/172.6.1451; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; PAPE JW, 1989, PAHO B, V23, P50; PECKHAM C, 1995, NEW ENGL J MED, V333, P298, DOI 10.1056/NEJM199508033330507; RYDER RW, 1991, AIDS, V5, P1521, DOI 10.1097/00002030-199112000-00016; Schulz K, 1990, HOMES SEXUALLY TRANS, P821; SEWANKAMBO NK, 1994, AIDS, V8, P1707, DOI 10.1097/00002030-199412000-00011; SMITH KR, 1995, J CLIN MICROBIOL, V33, P455, DOI 10.1128/JCM.33.2.455-457.1995; Steinberg Shari, 1995, pS16; TAHA TE, 1995, INT J EPIDEMIOL, V24, P1022, DOI 10.1093/ije/24.5.1022; TEMMERMAN M, 1994, INT J GYNECOL OBSTET, V44, P107, DOI 10.1016/0020-7292(94)90062-0; TEMMERMAN M, 1995, AIDS, V9, P1057, DOI 10.1097/00002030-199509000-00011; TEMMERMAN M, 1994, OBSTET GYNECOL, V83, P495, DOI 10.1097/00006250-199404000-00002; *US BUR CENS, 1995, 9 INT C AIDS STDS AF, P1; WASSERHEIT JN, 1992, REPROD BIOL, P7; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303; WOODS JW, 1994, BIOL BIOMETRY DEMOGR, P305	33	223	225	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					98	103		10.1016/S0140-6736(97)09381-1	http://dx.doi.org/10.1016/S0140-6736(97)09381-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439494	hybrid			2022-12-01	WOS:000071591900011
J	Friend, SH; Oliff, A				Friend, SH; Oliff, A			Emerging uses for genomic information in drug discovery	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HUMAN HOMOLOG; GENE		Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Merck Res Labs, W Point, PA 19486 USA	Fred Hutchinson Cancer Center; Merck & Company	Friend, SH (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.							DOYE V, 1995, TRENDS GENET, V11, P235, DOI 10.1016/S0168-9525(00)89057-5; DOYE V, 1995, TRENDS GENET, V11, P293; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Mizuta R, 1997, P NATL ACAD SCI USA, V94, P6927, DOI 10.1073/pnas.94.13.6927; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SEKELSKY JJ, 1995, GENETICS, V139, P1347	9	24	24	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					125	126		10.1056/NEJM199801083380211	http://dx.doi.org/10.1056/NEJM199801083380211			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ039	9420347				2022-12-01	WOS:000071341300011
J	Lowe, J; Amos, LA				Lowe, J; Amos, LA			Crystal structure of the bacterial cell-division protein FtsZ	NATURE			English	Article							NUCLEOTIDE-BINDING-PROTEIN; ESCHERICHIA-COLI; SECONDARY STRUCTURE; TUBULIN; MECHANISM; GTPASE	Bacterial cell division ends with septation, the constriction of the cell wall and cell membranes that leads to the formation of two daughter cells(1,2). During septation, FtsZ, a protein of relative molecular mass 40,000 which is ubiquitous in eubacteria and is also found in archaea and chloroplasts(3), localizes early at the division site to form a ring-shaped septum. This septum is required for the mechanochemical process of membrane constriction(4). FtsZ is a GTPase(5,6) with weak sequence homology to tubulins(7). The nature of FtsZ polymers in vivo is unknown, but FtsZ can form tubules, sheets and minirings in vitro(8,9). Here we report the crystal structure at 2.8 Angstrom resolution of recombinant FtsZ from the hyperthermophilic methanogen Methanococcus jannaschii. FtsZ has two domains, one of which is a GTPase domain with a fold related to one found in the proteins p21(ras) and elongation factor EF-Tu. The carboxy-terminal domain, whose function is unknown, is a four-stranded beta-sheet tilted by 90 degrees against the beta-sheet of the GTPase domain. The two domains are arranged around a central helix GDP binding is different from that typically found in GTPases and involves four phosphate-binding loops and a sugar-binding loop in the first domain, with guanine being recognized by residues in the central connecting helix The three-dimensional structure of FtsZ is similar to the structure of alpha- and beta-tubulin(10).	MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Lowe, J (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.		Löwe, Jan/X-6998-2019; Löwe, Jan/B-3882-2011	Lowe, Jan/0000-0002-5218-6615; Amos, Linda/0000-0001-8305-5346				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRAMHILL D, 1994, P NATL ACAD SCI USA, V91, P5813, DOI 10.1073/pnas.91.13.5813; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BULT CJ, 1996, NATURE, V269, P496; CHOOK YM, 1994, J MOL BIOL, V240, P476, DOI 10.1006/jmbi.1994.1462; DEBOER P, 1992, NATURE, V359, P254, DOI 10.1038/359254a0; dePereda JM, 1996, BIOCHEMISTRY-US, V35, P14203, DOI 10.1021/bi961357b; DONACHIE WD, 1993, ANNU REV MICROBIOL, V47, P199, DOI 10.1146/annurev.mi.47.100193.001215; ERICKSON HP, 1995, CELL, V80, P367, DOI 10.1016/0092-8674(95)90486-7; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE AGW, 1991, RECENT CHANGES MOSFL; LINSE K, 1988, J BIOL CHEM, V263, P15205; LUTKENHAUS J, 1993, MOL MICROBIOL, V9, P403, DOI 10.1111/j.1365-2958.1993.tb01701.x; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; MUKHERJEE A, 1993, P NATL ACAD SCI USA, V90, P1053, DOI 10.1073/pnas.90.3.1053; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; Park J. T., 1992, NATURE, V359, P251; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; Rothfield LI, 1997, CELL, V88, P581, DOI 10.1016/S0092-8674(00)81899-1; Sackett D L, 1995, Subcell Biochem, V24, P255; Sage CR, 1995, BIOCHEMISTRY-US, V34, P16870; SHELDRICK GM, 1991, ISOMORPHOUS REPLACEM, P23; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S	30	697	729	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					203	206		10.1038/34472	http://dx.doi.org/10.1038/34472			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428770				2022-12-01	WOS:000071380900058
J	Feig, AL; Scott, WG; Uhlenbeck, OC				Feig, AL; Scott, WG; Uhlenbeck, OC			Inhibition of the hammerhead ribozyme cleavage reaction by site-specific binding of Tb(III)	SCIENCE			English	Article							SELF-CLEAVAGE; TRANSFER-RNA; CRYSTAL-STRUCTURE; METAL-BINDING; OLIGORIBONUCLEOTIDES; MECHANISM; PHOSPHOROTHIOATE; REQUIREMENTS; EUROPIUM; DOMAIN	Terbium(III) [Tb(III)] was shown to inhibit the hammerhead ribozyme by competing with a single magnesium(II) ion, X-ray crystallography revealed that the Tb(III) ion binds to a site adjacent to an essential guanosine in the catalytic core of the ribozyme, approximately 10 angstroms from the cleavage site. Synthetic modifications near this binding site yielded an RNA substrate that was resistant to Tb(III) binding and capable of being cleaved, even in the presence of up to 20 micromolar Tb(III). it is suggested that the magnesium(II) ion thought to bind at this site may act as a switch, affecting the conformational changes required to achieve the transition state.	Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	University of Colorado System; University of Colorado Boulder; Indiana University System; Indiana University Bloomington	Uhlenbeck, OC (corresponding author), Univ Colorado, Dept Chem & Biochem, Campus Box 215, Boulder, CO 80309 USA.		Feig, Andrew/B-7414-2011	Scott, William/0000-0002-9273-3564; Feig, Andrew/0000-0002-5783-1097	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036944, R37GM036944] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM087721, GM-36944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; Bassi GS, 1996, RNA, V2, P756; BASSI GS, 1995, NAT STRUCT BIOL, V2, P45, DOI 10.1038/nsb0195-45; BRUNGER AT, 1987, XPLOR VERSION 3 1; Cate JH, 1996, STRUCTURE, V4, P1221, DOI 10.1016/S0969-2126(96)00129-3; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; ClouetDOrval B, 1996, RNA, V2, P483; DRAPER DE, 1985, BIOPHYS CHEM, V21, P91, DOI 10.1016/0301-4622(85)85011-0; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FEIG AL, UNPUB; FORSTER AC, 1987, COLD SPRING HARB SYM, V52, P249, DOI 10.1101/SQB.1987.052.01.030; HENDRIX C, 1995, BIOCHEM BIOPH RES CO, V210, P67, DOI 10.1006/bbrc.1995.1628; HENDRIX C, 1995, NUCLEIC ACIDS RES, V23, P51, DOI 10.1093/nar/23.1.51; HERTEL KJ, 1992, NUCLEIC ACIDS RES, V20, P3252, DOI 10.1093/nar/20.12.3252; HERTEL KJ, 1994, BIOCHEMISTRY-US, V33, P3374, DOI 10.1021/bi00177a031; Holbrook SR, 1997, BIOPOLYMERS, V44, P3; HORROCKS WDW, 1993, METHOD ENZYMOL, V226, P495, DOI 10.1016/0076-6879(93)26023-3; JACK A, 1977, J MOL BIOL, V111, P315, DOI 10.1016/S0022-2836(77)80054-5; JONES TA, 1992, O MANUAL MANUAL O VE; KOIZUMI M, 1991, BIOCHEMISTRY-US, V30, P5145, DOI 10.1021/bi00235a005; KUIMELIS RG, 1995, J AM CHEM SOC, V117, P11019, DOI 10.1021/ja00149a030; Maniatis T., 1982, MOL CLONING LAB MANU; McKay DB, 1996, RNA, V2, P395; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORET E, 1991, J LESS-COMMON MET, V171, P273, DOI 10.1016/0022-5088(91)90151-S; Peracchi A, 1996, P NATL ACAD SCI USA, V93, P11522, DOI 10.1073/pnas.93.21.11522; Peracchi A, 1997, J BIOL CHEM, V272, P26822, DOI 10.1074/jbc.272.43.26822; PICCIRILLI JA, 1993, NATURE, V361, P85, DOI 10.1038/361085a0; PLEY HW, 1994, NATURE, V372, P68, DOI 10.1038/372068a0; RINGER DP, 1980, ANAL BIOCHEM, V103, P337, DOI 10.1016/0003-2697(80)90620-X; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; Scott WG, 1996, SCIENCE, V274, P2065, DOI 10.1126/science.274.5295.2065; SCOTT WG, 1995, CELL, V81, P991, DOI 10.1016/S0092-8674(05)80004-2; Segel I.H, 1993, ENZYME KINETICS; SHELDON CC, 1990, NUCLEIC ACIDS MOL BI, V4, P227; SLIM G, 1991, NUCLEIC ACIDS RES, V19, P1183, DOI 10.1093/nar/19.6.1183; SYMONS RH, 1989, TRENDS BIOCHEM SCI, V14, P445, DOI 10.1016/0968-0004(89)90103-5; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; Weinstein LB, 1997, NATURE, V388, P805, DOI 10.1038/42076; WOLFSON JM, 1975, BIOCHEMISTRY-US, V14, P1436, DOI 10.1021/bi00678a014	41	115	116	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					81	84		10.1126/science.279.5347.81	http://dx.doi.org/10.1126/science.279.5347.81			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417029	Green Submitted			2022-12-01	WOS:000071323900044
J	Jaworek, T; Neher, D; Wegner, G; Wieringa, RH; Schouten, AJ				Jaworek, T; Neher, D; Wegner, G; Wieringa, RH; Schouten, AJ			Electromechanical properties of an ultrathin layer of directionally aligned helical polypeptides	SCIENCE			English	Article							BENZYL-L-GLUTAMATE; SILICON CRYSTAL-SURFACE; LANGMUIR-BLODGETT-FILM; CHEMICAL-REACTION; 2ND-HARMONIC GENERATION; THIN-FILMS; CRA FILM; POLYMERS; PIEZOELECTRICITY; MONOLAYERS	The electromechanical properties of a monomolecular film of poly-gamma-benzyl-L-glutamate (PBLG) 15 nanometers thick grafted at the carboxyl-terminal end to a flat aluminum surface were measured. The field-induced change in film thickness, dominated by a large inverse-piezoelectric effect, demonstrates that the "grafting-from" technique forces the chains into a parallel arrangement. The mechanical plate modulus of the film as determined by electrostriction agrees with the theoretical prediction for a single PBLG molecule along the chain axis. The experiments show that ultrathin polypeptide layers with large persistent polarization can be fabricated by the grafting approach.	Max Planck Inst Polymerforsch, D-55128 Mainz, Germany; Univ Groningen, Dept Polymer Chem, NL-9747 AG Groningen, Netherlands	Max Planck Society; University of Groningen	Wegner, G (corresponding author), Max Planck Inst Polymerforsch, Ackermannweg 10, D-55128 Mainz, Germany.		Colella, Stefano/A-7040-2008	Colella, Stefano/0000-0003-3139-6055				Advincula R, 1996, POLYM ADVAN TECHNOL, V7, P571; Beyer D, 1995, THIN SOLID FILMS, V271, P73, DOI 10.1016/0040-6090(96)80085-X; Block H., 1983, POLY GAMMA BENZYL L; BLOCK H, 1992, POLYMER, V33, P2489; Blum G, 1995, ADV MATER, V7, P1017, DOI 10.1002/adma.19950071210; BURLAND DM, 1994, CHEM REV, V94, P31, DOI 10.1021/cr00025a002; CRESSWELL JP, 1992, THIN SOLID FILMS, V210, P216, DOI 10.1016/0040-6090(92)90215-W; DUDA G, 1988, THIN SOLID FILMS, V159, P221, DOI 10.1016/0040-6090(88)90633-5; Eckert T, 1996, MACROMOL RAPID COMM, V17, P767, DOI 10.1002/marc.1996.030171103; FUKADA E, 1968, ULTRASONICS      OCT, P229; FURUKAWA T, 1984, JPN J APPL PHYS 2, V23, pL677, DOI 10.1143/JJAP.23.L677; HALLER I, 1978, J AM CHEM SOC, V100, P8050, DOI 10.1021/ja00494a003; Heise A, 1997, LANGMUIR, V13, P723, DOI 10.1021/la960467g; HELFRICH J, 1994, MACROMOLECULES, V27, P472, DOI 10.1021/ma00080a022; JACKSON CL, 1991, POLYMER, V32, P221, DOI 10.1016/0032-3861(91)90005-4; KURTH DG, 1995, LANGMUIR, V11, P3061, DOI 10.1021/la00008a035; LEVINE BF, 1976, J CHEM PHYS, V65, P1989, DOI 10.1063/1.433297; Lin WB, 1996, J AM CHEM SOC, V118, P8034, DOI 10.1021/ja960395f; Luo Y, 1997, CHEM PHYS LETT, V275, P145, DOI 10.1016/S0009-2614(97)00731-8; LUPO D, 1988, J OPT SOC AM B, V5, P300, DOI 10.1364/JOSAB.5.000300; MACHIDA S, 1992, J CHEM SOC CHEM COMM, P1628, DOI 10.1039/c39920001628; MACHIDA S, 1992, J CHEM SOC CHEM COMM, P1626, DOI 10.1039/c39920001626; Machida S, 1995, LANGMUIR, V11, P4838, DOI 10.1021/la00012a041; MARTIN PG, 1987, POLYMER, V28, P897, DOI 10.1016/0032-3861(87)90160-1; MCGRUM NG, 1967, ANELASTIC DIELECTRIC; MOPSIK FI, 1975, J APPL PHYS, V46, P4204, DOI 10.1063/1.321433; NACIRI J, 1995, MACROMOLECULES, V28, P5274, DOI 10.1021/ma00119a016; NIZZOLI F, 1989, PHYS REV B, V40, P3323, DOI 10.1103/PhysRevB.40.3323; OOSTERLING MLCM, 1995, POLYMER, V36, P4463, DOI 10.1016/0032-3861(95)96854-2; PALACIOS P, 1991, ANGEW MAKROMOL CHEM, V193, P77, DOI 10.1002/apmc.1991.051930108; SANO K, 1992, CHEM LETT, P1477, DOI 10.1246/cl.1992.1477; SESSLER GM, 1987, TOP APPL PHYS, P7; SINGER KD, 1987, J OPT SOC AM B, V4, P968, DOI 10.1364/JOSAB.4.000968; Stupp SI, 1997, SCIENCE, V276, P384, DOI 10.1126/science.276.5311.384; TOKARSKI Z, 1994, CHEM MATER, V6, P2063, DOI 10.1021/cm00047a028; URANO TI, 1994, J CHEM SOC CHEM COMM, P231, DOI 10.1039/c39940000231; WADA A, 1962, POLYAMINO ACIDS POLY, P131; WHITESELL JK, 1994, MOL CRYST LIQ CRYS A, V240, P251, DOI 10.1080/10587259408029736; WHITESELL JK, 1993, SCIENCE, V261, P73, DOI 10.1126/science.261.5117.73; WHITESELL JK, 1994, ANGEW CHEM, V106, P921; WIENNGA RH, UNPUB; Wieringa RH, 1996, MACROMOLECULES, V29, P3032, DOI 10.1021/ma9508358; Winkelhahn HJ, 1996, MACROMOLECULES, V29, P6865, DOI 10.1021/ma960080k; WINKELHAHN HJ, 1994, APPL PHYS LETT, V64, P1347, DOI 10.1063/1.111930	44	127	128	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					57	60		10.1126/science.279.5347.57	http://dx.doi.org/10.1126/science.279.5347.57			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417021	Green Submitted			2022-12-01	WOS:000071323900036
J	Sakahira, H; Enari, M; Nagata, S				Sakahira, H; Enari, M; Nagata, S			Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis	NATURE			English	Article							CELL-DEATH; PROTEASES; FAS; EXPRESSION; SURVIVAL; GENOME; BCL-2	Various molecules such as cytokines and anticancer drugs, as well as factor deprivation, rapidly induce apoptosis (programmed cell death)(1,2), which is morphologically characterized by cell shrinkage and the blebbing of plasma membranes and by nuclear condensation(3,4). Caspases, particularly caspase 3, are proteases that are activated during apoptosis and which cleave substrates such as poly(ADP-ribose) polymerase, actin, fodrin, and lamin(5,6). Apoptosis is also accompanied by the internucleosomal degradation of chromosomal DNA(7-9). In the accompanying Article(10), we have identified and molecularly cloned a caspase-activated deoxyribonuclease (CAD) and its inhibitor (ICAD). Here we show that caspase 3 cleaves ICAD and inactivates its CAD-inhibitory effect, We identified two caspase-3 cleavage sites in ICAD by site-directed mutagenesis. When human Jurkat cells were transformed with ICAD-expressing plasmid, occupation of the receptor Fas, which normally triggers apoptosis, did not result in DNA degradation, The ICAD transformants were also resistant to staurosporine-induced DNA degradation, although staurosporine still killed the cells by activating caspase. Our results indicate that activation of CAD downstream of the caspase cascade is responsible for internucleosomal DNA degradation during apoptosis, and that ICAD works as an inhibitor of this process.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848; Duriez, Patrick/0000-0003-1814-2552				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; EARNSHAW WC, 1995, CURR OPIN CELL BIOL, V7, P337, DOI 10.1016/0955-0674(95)80088-3; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; HIGUCHI R, 1990, PCR PROTOCOLS GUIDE, P177; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LAMARRE D, 1988, BIOCHIM BIOPHYS ACTA, V950, P147, DOI 10.1016/0167-4781(88)90007-3; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peitsch Manuel C., 1994, Trends in Cell Biology, V4, P37, DOI 10.1016/0962-8924(94)90002-7; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66	28	1359	1401	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					96	99		10.1038/34214	http://dx.doi.org/10.1038/34214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422513				2022-12-01	WOS:000071326100057
J	Kramer, A; Keitel, T; Winkler, K; Stocklein, W; Hohne, W; SchneiderMergener, J				Kramer, A; Keitel, T; Winkler, K; Stocklein, W; Hohne, W; SchneiderMergener, J			Molecular basis for the binding promiscuity of an anti-p24 (HIV-1) monoclonal antibody	CELL			English	Article							PEPTIDE COMBINATORIAL LIBRARIES; ANTIGEN INTERACTIONS; CROSS-REACTIVITY; ESCHERICHIA-COLI; HIGH-AFFINITY; B-CELLS; PROTEIN; GENERATION; EXPRESSION; SURFACE	Multiple binding capabilities utilized by specific protein-to-protein interactions in molecular recognition events are being documented increasingly but remain poorly understood at the molecular level. We identified five unrelated peptides that compete with each other for binding to the paratope region of the monoclonal anti-p24 (HIV-1) antibody CB4-1 by using a synthetic positional scanning combinatorial library XXXX[B-1,B-2,B-3,X-1,X-2,X-3]XXXX (14 mers; 68,590 peptide mixtures in total) prepared by spot synthesis. Complete sets of substitution analogs of the five peptides revealed key interacting residues, information that led to the construction of binding supertopes derived from each peptide. These supertope sequences were identified in hundreds of heterologous proteins, and those proteins that could be obtained were shown to bind CB4-1. Implications of these findings for immune escape mechanisms and autoimmunity are discussed.	HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST MED IMMUNOL,D-10098 BERLIN,GERMANY; HUMBOLDT UNIV BERLIN,KLINIKUM CHARITE,INST BIOCHEM,D-10098 BERLIN,GERMANY; MAX DELBRUCK CENTRUM,UNIV POTSDAM,INST BIOCHEM & MOL PHYSIOL,D-13122 BERLIN,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Potsdam				Kramer, Achim/0000-0001-9671-6078				Appel JR, 1996, MOL DIVERS, V2, P29, DOI 10.1007/BF01718697; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BACCALA R, 1989, P NATL ACAD SCI USA, V86, P4624, DOI 10.1073/pnas.86.12.4624; BEREK C, 1988, IMMUNOL REV, V105, P5, DOI 10.1111/j.1600-065X.1988.tb00763.x; BURASTERO SE, 1988, J EXP MED, V168, P1979, DOI 10.1084/jem.168.6.1979; CARDOZO T, 1995, PROTEINS, V23, P403, DOI 10.1002/prot.340230314; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHRISTIAN RB, 1992, J MOL BIOL, V227, P711, DOI 10.1016/0022-2836(92)90219-A; Cornall RJ, 1995, CURR OPIN IMMUNOL, V7, P804, DOI 10.1016/0952-7915(95)80052-2; CUMANO A, 1986, EMBO J, V5, P2459, DOI 10.1002/j.1460-2075.1986.tb04522.x; DECIECHI PA, 1995, MOL DIV, V1, P79; Demangel C, 1996, MOL IMMUNOL, V33, P909, DOI 10.1016/S0161-5890(96)00058-2; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ehrhard B, 1996, BIOCHEMISTRY-US, V35, P9097, DOI 10.1021/bi9603534; Forster T. H., 1946, NATURWISSENSCHAFTEN, V6, P166; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; FRIGUET B, 1985, J IMMUNOL METHODS, V77, P305, DOI 10.1016/0022-1759(85)90044-4; Geysen H M, 1988, J Mol Recognit, V1, P32, DOI 10.1002/jmr.300010107; GEYSEN HM, 1986, MOL IMMUNOL, V23, P709, DOI 10.1016/0161-5890(86)90081-7; GUILBERT B, 1982, J IMMUNOL, V128, P2779; HAUSDORF G, 1994, J VIROL METHODS, V50, P1, DOI 10.1016/0166-0934(94)90158-9; Hohne W E, 1993, Mol Immunol, V30, P1213, DOI 10.1016/0161-5890(93)90140-7; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; HOUGHTEN RA, 1991, NATURE, V354, P84, DOI 10.1038/354084a0; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; JAHN S, 1995, IMMUNOBIOLOGY, V193, P400, DOI 10.1016/S0171-2985(11)80427-4; KAPLAN MH, 1962, LANCET, V1, P706; KARLSSON R, 1995, ANAL BIOCHEM, V228, P274, DOI 10.1006/abio.1995.1350; Keitel T, 1997, CELL, V91, P811, DOI 10.1016/S0092-8674(00)80469-9; KRAMER A, 1995, MOL IMMUNOL, V32, P459, DOI 10.1016/0161-5890(95)00006-Z; KRAMER A, 1997, IN PRESS METH MOL BI, V87; Kramer Achim, 1994, Methods (Orlando), V6, P388, DOI 10.1006/meth.1994.1039; MALIN R, 1995, J AM CHEM SOC, V117, P11821, DOI 10.1021/ja00152a031; MARIUZZA RA, 1993, CURR OPIN IMMUNOL, V5, P50, DOI 10.1016/0952-7915(93)90080-C; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; OSHANNESSY DJ, 1990, ANAL BIOCHEM, V191, P1, DOI 10.1016/0003-2697(90)90377-L; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; PINILLA C, 1995, PEPTIDE RES, V8, P250; PINILLA C, 1992, BIOTECHNIQUES, V13, P901; PINILLA C, 1993, MOL IMMUNOL, V30, P577, DOI 10.1016/0161-5890(93)90032-7; ROGGENBUCK D, 1994, SCAND J IMMUNOL, V40, P64, DOI 10.1111/j.1365-3083.1994.tb03434.x; ROSSLER D, 1995, MED MICROBIOL IMMUN, V184, P23, DOI 10.1007/BF00216786; SCHNEIDERMERGEN.J, 1996, COMBINATORIAL LIB, P53; SHARON J, 1990, P NATL ACAD SCI USA, V87, P4814, DOI 10.1073/pnas.87.12.4814; STIGLER RD, 1995, PROTEIN ENG, V8, P471, DOI 10.1093/protein/8.5.471; Valadon P, 1996, J MOL BIOL, V261, P11, DOI 10.1006/jmbi.1996.0438; VANREGENMORTEL MHV, 1994, IMMUNOCHEMISTRY, P277; VOLKMERENGERT R, 1994, LETT PEPT SCI, V1, P243; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WING MG, 1995, CLIN EXP IMMUNOL, V99, P313, DOI 10.1111/j.1365-2249.1995.tb05551.x; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZHANG ZX, 1994, CLIN EXP IMMUNOL, V96, P403	55	159	172	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					799	809		10.1016/S0092-8674(00)80468-7	http://dx.doi.org/10.1016/S0092-8674(00)80468-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413989	Bronze			2022-12-01	WOS:A1997YL43900011
J	Lee, MJ; Van Brocklyn, JR; Thangada, S; Liu, CH; Hand, AR; Menzeleev, R; Spiegel, S; Hla, T				Lee, MJ; Van Brocklyn, JR; Thangada, S; Liu, CH; Hand, AR; Menzeleev, R; Spiegel, S; Hla, T			Sphingosine-1-phosphate as a ligand for the G protein coupled receptor EDG-1	SCIENCE			English	Article							CELL-ADHESION; MAP KINASE; TYROSINE PHOSPHORYLATION; LYSOPHOSPHATIDIC ACID; SIGNALING PATHWAY; MOLECULAR-CLONING; GROWTH-FACTOR; MORPHOGENESIS; FIBROBLASTS; ACTIVATION	The sphingolipid metabolite sphingosine-1-phosphate (SPP) has been implicated as a second messenger in cell proliferation and survival. However, many of its biological effects are due to binding to unidentified receptors on the cell surface, SPP activated the heterotrimeric guanine nucleotide binding protein (G protein)-coupled orphan receptor EDG-1, originally cloned as Endothelial Differentiation Gene-1, EDG-1 bound SPP with high affinity (dissociation constant = 8.1 nM) and high specificity, Overexpression of EDG-1 induced exaggerated cell-cell aggregation, enhanced expression of cadherins, and formation of well-developed adherens junctions in a manner dependent on SPP and the small guanine nucleotide binding protein Rho.	Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Connecticut, Ctr Hlth, Dept Pediat Dent, Farmington, CT 06030 USA	University of Connecticut; Georgetown University; University of Connecticut	Hla, T (corresponding author), Univ Connecticut, Sch Med, Dept Physiol, Farmington, CT 06030 USA.		Hla, Timothy/G-5873-2012; Van Brocklyn, Jim/A-9733-2010	Hla, Timothy/0000-0001-8355-4065; 	NHLBI NIH HHS [HL49094] Funding Source: Medline; NIDDK NIH HHS [DK45659] Funding Source: Medline; NIGMS NIH HHS [GM43880] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049094] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R01GM043880] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Bohm SK, 1997, BIOCHEM J, V322, P1; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; DESAI NN, 1993, J CELL BIOL, V121, P1385, DOI 10.1083/jcb.121.6.1385; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HLA T, 1990, J BIOL CHEM, V265, P9308; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Lee M., UNPUB; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Masana MI, 1995, RECEPTOR CHANNEL, V3, P255; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; MURAYAMA T, 1983, J BIOL CHEM, V258, P3319; OKAZAKI H, 1993, BIOCHEM BIOPH RES CO, V190, P1104, DOI 10.1006/bbrc.1993.1163; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pyne S, 1996, EUR J BIOCHEM, V237, P819, DOI 10.1111/j.1432-1033.1996.0819p.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SEUFFERLEIN T, 1995, J BIOL CHEM, V270, P24343, DOI 10.1074/jbc.270.41.24343; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeda H, 1995, J CELL BIOL, V131, P1839, DOI 10.1083/jcb.131.6.1839; TAKEICHI M, 1992, COLD SPRING HARB SYM, V57, P327, DOI 10.1101/SQB.1992.057.01.037; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yatomi Y, 1997, J BIOCHEM, V121, P969; YATOMI Y, 1995, BLOOD, V86, P193, DOI 10.1182/blood.V86.1.193.bloodjournal861193	45	846	875	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1552	1555		10.1126/science.279.5356.1552	http://dx.doi.org/10.1126/science.279.5356.1552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488656				2022-12-01	WOS:000072372900069
J	Silva, M; Richard, C; Benito, A; Sanz, C; Olalla, I; Fernandez-Luna, JL				Silva, M; Richard, C; Benito, A; Sanz, C; Olalla, I; Fernandez-Luna, JL			Expression of Bcl-x in erythroid precursors from patients with polycythemia vera	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH FACTOR-I; CELL-DEATH; ERYTHROPOIETIN; APOPTOSIS; MARROW; DIFFERENTIATION; ERYTHROCYTOSIS; PROGENITORS; MECHANISM; SURVIVAL	Background Deregulating the expression of Bcl-x(L), an inhibitor of apoptosis, in an erythropoietin-dependent erythroblast cell line averts apoptosis induced by the withdrawal of erythropoietin. Since in polycythemia vera an abnormal clone of erythroid progenitors is independent of erythropoietin, we investigated whether the endogenous expression of Bcl-x(L) was deregulated in these cells. Methods Erythroid colonies from patients with polycythemia vera and normal subjects were cultured in the presence and absence of erythropoietin and assessed by immunocytochemical and flow-cytometric analysis with anti-Bcl-x antibodies that recognize the two species of Bcl-x (Bcl-x(L) and Bcl-x(S)). Reverse-transcriptase-polymerase-chain-reaction analysis was used to determine which one of the two species was responsible for anti-Bcl-x staining. Bone marrow mononuclear cells from 8 healthy bone marrow donors, 14 patients with polycythemia vera, 19 patients with other myeloproliferative syndromes, and 12 patients with secondary erythrocytosis were analyzed by flow cytometry with antibodies against Bcl-x and glycophorin A, an erythroid marker. Results Erythroid cells from patients with polycythemia vera survived in vitro without erythropoietin, and this finding correlated with the expression of Bcl-x protein (Bcl-x(L) messenger RNA was the main species of Bcl-x found), even in mature erythroblasts that normally do not express Bcl-x. The mean (+/-SD) percentage of cells positive for both glycophorin A and Bcl-x in the 14 patients with polycythemia vera (21.8+/-3.6 percent) was significantly higher than that in 8 normal donors (6.62+/-1.58 percent), 12 patients with secondary erythrocytosis (6.87+/-1.95 percent), 9 patients with essential thrombocythemia (3.81+/-0.97 percent), and 10 patients with chronic myeloid leukemia (2.7+/-0.41 percent). Conclusions Deregulated expression of Bcl-x may contribute to the erythropoietin-independent survival of erythroid-lineage cells in polycythemia vera and thereby contribute to the pathogenesis of this disease. (C) 1998, Massachusetts Medical Society.	Hosp Univ Marques de Valdecilla, Serv Immunol, INSALUD, Santander 39008, Spain; Hosp Univ Marques Valdecilla, Serv Hematol, Santander 39008, Spain	Hospital Universitario Marques de Valdecilla (HUMV); Hospital Universitario Marques de Valdecilla (HUMV)	Fernandez-Luna, JL (corresponding author), Hosp Univ Marques de Valdecilla, Serv Immunol, INSALUD, Santander 39008, Spain.							BENITO A, 1995, AM J PATHOL, V146, P481; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; BERLIN NI, 1975, SEMIN HEMATOL, V12, P339; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; CORREA PN, 1994, BLOOD, V83, P99; COTES PM, 1986, NEW ENGL J MED, V315, P283, DOI 10.1056/NEJM198607313150503; ERIDANI S, 1984, BRIT J HAEMATOL, V56, P157, DOI 10.1111/j.1365-2141.1984.tb01282.x; FISHER MJ, 1994, BLOOD, V84, P1982; GREENBERG BR, 1977, NEW ENGL J MED, V296, P1080, DOI 10.1056/NEJM197705122961902; HESS G, 1994, BRIT J HAEMATOL, V88, P794, DOI 10.1111/j.1365-2141.1994.tb05119.x; Hoffman Ronald, 1995, P1121; Hughes Timothy P., 1995, P1142; KELLEY LL, 1993, BLOOD, V82, P2340; KOEFFLER HP, 1981, ANN INTERN MED, V94, P44, DOI 10.7326/0003-4819-94-1-44; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KRANTZ SB, 1991, BLOOD, V77, P419; LEMOINE F, 1986, BLOOD, V68, P996; Liu Q, 1997, J IMMUNOL, V159, P829; Mirza AM, 1997, BLOOD, V89, P1862, DOI 10.1182/blood.V89.6.1862; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; PRCHAL JF, 1974, NEW ENGL J MED, V290, P1382; Sanz C, 1997, BLOOD, V89, P3199, DOI 10.1182/blood.V89.9.3199; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SOKOL L, 1993, LANCET, V342, P115, DOI 10.1016/0140-6736(93)91317-F; TEPPERMAN AD, 1974, BLOOD, V44, P659, DOI 10.1182/blood.V44.5.659.659; YARBRO JW, 1992, SEMIN ONCOL, V19, P1	27	173	182	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					564	571		10.1056/NEJM199802263380902	http://dx.doi.org/10.1056/NEJM199802263380902			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475763				2022-12-01	WOS:000072175700002
J	Cascalho, M; Wong, J; Steinberg, C; Wabl, M				Cascalho, M; Wong, J; Steinberg, C; Wabl, M			Mismatch repair co-opted by hypermutation	SCIENCE			English	Article							NONPOLYPOSIS COLON-CANCER; ESCHERICHIA-COLI; HOMOLOG; MICE; MOUSE; METHYLATION; MUTATIONS; ANTIBODY; EXTRACTS; MSH2	Mice homozygous for a disrupted allele of the mismatch repair gene Pms2 have a mutator phenotype. When this allele is crossed into quasi-monoclonal (QM) mice, which have a very limited B cell repertoire, homozygotes have fewer somatic mutations at the immunoglobulin heavy chain acid lambda chain loci than do heterozygotes or wild-type QM mice, That is, mismatch repair seems to contribute to somatic hypermutation rather than stifling it. It is suggested that at immunoglobulin loci in hypermutable B cells, mismatched base pairs are "corrected" according to the newly synthesized DNA strand, thereby fixing incipient mutations instead of eliminating them.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Wabl, M (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	mutator@itsa.ucsf.edu		Cascalho, Marilia/0000-0002-2695-3921	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037699] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM37699] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BRENNER S, 1966, NATURE, V211, P242, DOI 10.1038/211242a0; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; Cascalho M, 1997, J IMMUNOL, V159, P5795; Cascalho M, 1996, SCIENCE, V272, P1649, DOI 10.1126/science.272.5268.1649; CASCALHO M, UNPUB; CHEN JZ, 1993, EMBO J, V12, P821, DOI 10.1002/j.1460-2075.1993.tb05722.x; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IMANISHIKARI T, UNPUB; Kim N, 1997, J EXP MED, V186, P413, DOI 10.1084/jem.186.3.413; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Loeb LA, 1997, SCIENCE, V277, P1449, DOI 10.1126/science.277.5331.1449; LU AL, 1983, P NATL ACAD SCI-BIOL, V80, P4639, DOI 10.1073/pnas.80.15.4639; MCKEAN D, 1984, P NATL ACAD SCI-BIOL, V81, P3180, DOI 10.1073/pnas.81.10.3180; MESELSON M, 1988, RECOMBINATION GENETI, P91; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; NEVERS P, 1975, MOL GEN GENET, V139, P233, DOI 10.1007/BF00268974; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PUKKILA PJ, 1983, GENETICS, V104, P571; Reynaud C A, 1996, Semin Immunol, V8, P125, DOI 10.1006/smim.1996.0016; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; Wabl M, 1996, CURR OPIN IMMUNOL, V8, P89, DOI 10.1016/S0952-7915(96)80110-5; WABL M, 1987, IMMUNOL REV, V96, P90, DOI 10.1111/j.1600-065X.1987.tb00511.x; WEIGERT MG, 1970, NATURE, V228, P1045, DOI 10.1038/2281045a0	30	138	150	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1207	1210		10.1126/science.279.5354.1207	http://dx.doi.org/10.1126/science.279.5354.1207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469811				2022-12-01	WOS:000072115200043
J	Bosco, D; Meda, P				Bosco, D; Meda, P			Cellular aggregation in the pancreas	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Geneva, Sch Med, CH-1211 Geneva 4, Switzerland	University of Geneva	Bosco, D (corresponding author), Univ Geneva, Sch Med, CH-1211 Geneva 4, Switzerland.			Bosco, Domenico/0000-0003-3453-9613					0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					435	435		10.1056/NEJM199802123380705	http://dx.doi.org/10.1056/NEJM199802123380705			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459647				2022-12-01	WOS:000071900100005
J	Chen, FE; Huang, DB; Chen, YQ; Ghosh, G				Chen, FE; Huang, DB; Chen, YQ; Ghosh, G			Crystal structure of p50/p65 heterodimer of transcription factor NF-kappa B bound to DNA	NATURE			English	Article							IFN-BETA GENE; BINDING SUBUNIT; 65-KD SUBUNIT; P65 SUBUNIT; P50; SITE; REL; SPECIFICITY; RECOGNITION; PARAMETERS	The NF-kappa B p50/p65 heterodimer is the classical member of the Rel family of transcription factors which regulate diverse cellular functions such as immune response, cell growth, and development(1-3). Other mammalian Rel family members, including the proteins p52, proto-oncoprotein c-Rel, and RelB, all have amino-terminal Rel-homology regions (RHRs)(4-7). The RHR is responsible for the dimerization, DNA binding and cytosolic localization of these proteins by virtue of complex formation with inhibitor kappa B proteins(8), Signal-induced removal of kappa B inhibitors allows translocation of dimers to the cell nucleus and transcriptional regulation of kappa B DNA-containing genes(9), NF-kappa B specifically recognizes kappa B DNA elements(1,10,11) with a consensus sequence of 5'-GGGRNYYYCC-3' (R is an unspecified purine; Y is an unspecified pyrimidine; and N is any nucleotide), Here we report the crystal structure at 2.9 Angstrom resolution of the p50/p65 heterodimer bound to the kappa B DNA of the intronic enhancer of the immunoglobulin light-chain gene, Our structure reveals a 5-base-pair 5' subsite for p50, and a 4-base-pair 3' subsite for p65, This structure indicates why the p50/p65 heterodimer interface is stronger than that of either homodimer, A comparison of this structure with those of other Rel dimers reveals that both subunits adopt variable conformations in a DNA-sequence-dependent manner. Our results explain the different behaviour of the p50/p65 heterodimer with heterologous promoters.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Ghosh, G (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	gghosh@chem.ucsd.edu						BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRUNGER AT, 1992, XPLOR VERSION 3 1 SY, P1; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CHEN YQ, IN PRESS NATURE STRU; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CROSS SL, 1989, SCIENCE, V244, P466, DOI 10.1126/science.2497520; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HANSEN SK, 1994, J BIOL CHEM, V269, P22230; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; Laskowski R.A., 1993, J APPL CRYSTALLOGR A, V42, P140; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cellbio.10.1.405; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; WHITLEY MZ, 1994, MOL CELL BIOL, V14, P6464, DOI 10.1128/MCB.14.10.6464; ZABEL U, 1991, J BIOL CHEM, V266, P252	31	478	509	2	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					410	413		10.1038/34956	http://dx.doi.org/10.1038/34956			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450761				2022-12-01	WOS:000071604200061
J	Fix, AD; Strickland, GT; Grant, J				Fix, AD; Strickland, GT; Grant, J			Tick bites and Lyme disease in an endemic setting - Problematic use of serologic testing and prophylactic antibiotic therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BORRELIA-BURGDORFERI; ERYTHEMA MIGRANS; PREVENTION; AREA; MANIFESTATIONS; SERODIAGNOSIS; DIAGNOSIS; MARYLAND; CHILDREN	Context.-The use of serologic testing to diagnose Lyme disease (LD) is a source of controversy. Expert recommendations also discourage the routine use of antibiotic therapy for prophylaxis of LD following tick bites, but the extent to which physicians in endemic areas have adopted these recommendations is not known. Objective.-To assess the pattern of use of serologic testing and antibiotic therapy for tick bites and LD and associated charges for management in an endemic area. Design.-Active surveillance of patient-physician encounters for tick bites and LD. Setting.-Primary care practices on the Eastern Shore of Maryland. Patients.-Consecutive sample of 232 patients with tick bites, LD (defined by physician diagnosis in medical record), and suspected LD (physician notation of possible, but not definite LD) seen in 1995. Main Outcome Measures.-Serologic testing for LD, test results, antibiotic therapy, and direct costs of management. Results.-Surveillance identified 142 patients (61.2%) with diagnoses of tick bites, 40 patients (17.2%) with LD, and 50 patients (21.6%) with suspected LD. Of the 142 patients seen for tick bites, 95 (67%) underwent serologic testing for LD. Of these, 93 patients had initial negative or equivocal results; 24 (26%) of the 93 had convalescent testing, with 1 seroconversion. Seventy-eight patients (55%) with a diagnosis of tick bite received antibiotic therapy. No patients with tick bite developed clinical LD. Serologic testing for LD was performed for 36 patients (90%) with a diagnosis of LD and 46 patients (92%) with suspected LD. In most cases, antibiotics were prescribed before serologic test results became available. Convalescent testing was not performed for 37 (86%) of the 43 patients with suspected LD who had initial negative or equivocal results. Of these 37 patients, 25 (68%) did not receive antibiotic therapy. Direct charges for treatment of these 232 patients totaled $47 595, one third of which was attributable to serologic testing. A total of 32% of direct charges were for patients with tick bites, 48% were for patients with LD, and 20% were for patients with suspected LD. Conclusions.-In this setting, most patients consulting physicians for tick bites received prophylactic antibiotic therapy of unproven efficacy and underwent unnecessary, costly serologic testing. Despite almost universal use in this study, serologic testing for LD did not appear to influence treatment of patients diagnosed as having LD.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Kent Cty Hlth Dept, Chestertown, MD USA	University System of Maryland; University of Maryland Baltimore	Fix, AD (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, 660 Redwood St, Baltimore, MD 21201 USA.				PHS HHS [R01MS07813-04] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGRE F, 1993, AM J DIS CHILD, V147, P945, DOI 10.1001/archpedi.1993.02160330035013; AgueroRosenfeld ME, 1996, J CLIN MICROBIOL, V34, P1; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BINGHAM PM, 1995, PEDIATRICS, V96, P1053; *CDC, 1991, CONN MED, V55, P691; COSTELLO CM, 1989, J INFECT DIS, V159, P136, DOI 10.1093/infdis/159.1.136; Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; Craven RB, 1996, EMERG INFECT DIS, V2, P136, DOI 10.3201/eid0202.960211; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; Dean A.G., 1994, EPI INFO VERSION 6 W; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EPPES SC, 1994, CLIN PEDIATR, V33, P130, DOI 10.1177/000992289403300301; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; FALCO RC, 1988, AM J EPIDEMIOL, V128, P1146; FEDER HM, 1992, CLIN INFECT DIS, V15, P788, DOI 10.1093/clind/15.5.788; Gerber M A, 1995, Conn Med, V59, P195; Gerber MA, 1996, NEW ENGL J MED, V335, P1270, DOI 10.1056/NEJM199610243351703; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; LEY C, 1994, JAMA-J AM MED ASSOC, V271, P460, DOI 10.1001/jama.271.6.460; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; *MAR DEP HLTH MENT, 1996, MED MED J, V45, P715; Nachamkin I, 1996, CLIN DIAGN LAB IMMUN, V3, P287, DOI 10.1128/CDLI.3.3.287-289.1996; NADELMAN RD, 1993, LANCET, V342, P1052, DOI 10.1016/0140-6736(93)92907-B; Nocton J J, 1995, Adv Intern Med, V40, P69; SHAPIRO ED, 1992, NEW ENGL J MED, V327, P1769, DOI 10.1056/NEJM199212173272501; Sood SK, 1997, J INFECT DIS, V175, P996, DOI 10.1086/514009; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1983, ANN INTERN MED, V99, P22, DOI 10.7326/0003-4819-99-1-22; Steinberg SH, 1996, ANN EPIDEMIOL, V6, P24, DOI 10.1016/1047-2797(95)00096-8; Warshafsky S, 1996, J GEN INTERN MED, V11, P329, DOI 10.1007/BF02600042; WORMSER GP, 1995, MT SINAI J MED, V62, P188; Ziska MH, 1996, INFECTION, V24, P182, DOI 10.1007/BF01713336; 1993, MMWR MORB MORTAL WKL, V42, P345	36	48	52	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					206	210		10.1001/jama.279.3.206	http://dx.doi.org/10.1001/jama.279.3.206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438740	Bronze			2022-12-01	WOS:000071460700030
J	Bodnar, AG; Ouellette, M; Frolkis, M; Holt, SE; Chiu, CP; Morin, GB; Harley, CB; Shay, JW; Lichtsteiner, S; Wright, WE				Bodnar, AG; Ouellette, M; Frolkis, M; Holt, SE; Chiu, CP; Morin, GB; Harley, CB; Shay, JW; Lichtsteiner, S; Wright, WE			Extension of life-span by introduction of telomerase into normal human cells	SCIENCE			English	Article							MAMMARY EPITHELIAL-CELLS; HUMAN FIBROBLASTS; CELLULAR SENESCENCE; REPLICATIVE SENESCENCE; PIGMENT EPITHELIUM; IMMORTAL CELLS; AGE; LENGTH; EXPRESSION; INVITRO	Normal human cells undergo a finite number of cell divisions and ultimately enter a nondividing state called replicative senescence. It has been proposed that telomere shortening is the molecular clock that triggers senescence, To test this hypothesis, two telomerase-negative normal human cell types, retinal pigment epithelial cells and foreskin fibroblasts, were transfected with vectors encoding the human telomerase catalytic subunit. In contrast to telomerase-negative control clones, which exhibited telomere shortening and senescence, telomerase-expressing clones had elongated telomeres, divided vigorously, and showed reduced staining for beta-galactosidase, a biomarker for senescence, Notably, the telomerase-expressing clones have a normal karyotype and have already exceeded their normal life-span by at least 20 doublings, thus establishing a causal relationship between telomere shortening and in vitro cellular senescence. The ability to maintain normal human cells in a phenotypically youthful state could have important applications in research and medicine.	Geron Corp, Menlo Park, CA 94025 USA; Univ Texas, SW Med Ctr, Dept Cell Biol & Neurosci, Dallas, TX 75235 USA	Geron Corporation; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wright, WE (corresponding author), Geron Corp, 230 Constitut Dr, Menlo Park, CA 94025 USA.	slichtste@geron.com; wright@utsw.swmed.edu	Wilson, Matthew H/K-3193-2013; Morin, Gregg B/E-9123-2012; Shay, Jerry W/F-7878-2011	Morin, Gregg B/0000-0001-8949-4374; 	NIA NIH HHS [AG07992, AG05747] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG007992, F32AG005747] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALLSOPP RC, 1992, P NATL ACAD SCI USA, V89, P10114, DOI 10.1073/pnas.89.21.10114; Bodnar AG, 1996, EXP CELL RES, V228, P58, DOI 10.1006/excr.1996.0299; BODNAR AG, UNPUB; BOULTON M, 1990, VISION RES, V30, P1291, DOI 10.1016/0042-6989(90)90003-4; Broccoli D, 1997, NAT GENET, V17, P231, DOI 10.1038/ng1097-231; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; CHANG E, 1995, P NATL ACAD SCI USA, V92, P11190, DOI 10.1073/pnas.92.24.11190; Chiu CP, 1996, STEM CELLS, V14, P239, DOI 10.1002/stem.140239; COOKE HJ, 1986, COLD SPRING HARB SYM, V51, P213, DOI 10.1101/SQB.1986.051.01.026; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DELLORCO RT, 1973, EXP CELL RES, V77, P356, DOI 10.1016/0014-4827(73)90588-0; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Effros RB, 1996, AIDS, V10, pF17, DOI 10.1097/00002030-199607000-00001; ELMORE E, 1976, J CELL PHYSIOL, V87, P229, DOI 10.1002/jcp.1040870211; Engelhardt M, 1997, BLOOD, V90, P182; Faragher RGA, 1997, DRUG DISCOV TODAY, V2, P64, DOI 10.1016/S1359-6446(97)83293-X; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GREENWELL PW, 1995, CELL, V82, P823, DOI 10.1016/0092-8674(95)90479-4; GREIDER CW, 1989, NATURE, V337, P331, DOI 10.1038/337331a0; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HARLEY CB, 1978, J CELL PHYSIOL, V97, P509, DOI 10.1002/jcp.1040970326; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; HAYFLICK L, 1961, EXP CELL RES, V25, P585, DOI 10.1016/0014-4827(61)90192-6; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; KONKEL LMC, 1995, P NATL ACAD SCI USA, V92, P5558, DOI 10.1073/pnas.92.12.5558; Kumazaki Tsutomu, 1993, Hiroshima Journal of Medical Sciences, V42, P97; Lendvay TS, 1996, GENETICS, V144, P1399; LEVY MZ, 1992, J MOL BIOL, V225, P951, DOI 10.1016/0022-2836(92)90096-3; LICHTSTEINER S, UNPUB; Lingner J, 1997, SCIENCE, V276, P561, DOI 10.1126/science.276.5312.561; Marcand S, 1997, SCIENCE, V275, P986, DOI 10.1126/science.275.5302.986; MARTIN GM, 1970, LAB INVEST, V23, P86; MEYERSON M, 1997, CELL, V90, P78; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OHNO T, 1979, MECH AGEING DEV, V11, P179, DOI 10.1016/0047-6374(79)90053-8; SCHNEIDER EL, 1972, P SOC EXP BIOL MED, V141, P1092; SCHNEIDER EL, 1976, P NATL ACAD SCI USA, V73, P3584, DOI 10.1073/pnas.73.10.3584; SHAY JW, 1993, EXP CELL RES, V209, P45, DOI 10.1006/excr.1993.1283; SHAY JW, 1993, ONCOGENE, V8, P1407; SHAY JW, 1993, INT J ONCOL, V3, P559; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1997, EUR J CANCER, V33, P777; SMITH JR, 1979, J CELL PHYSIOL, V98, P597, DOI 10.1002/jcp.1040980317; STANULISPRAEGER BM, 1987, MECH AGEING DEV, V38, P1, DOI 10.1016/0047-6374(87)90109-6; TAKEDA K, 1992, J CELL PHYSIOL, V153, P450, DOI 10.1002/jcp.1041530303; TOMBRANTINK J, 1995, J NEUROSCI, V15, P4992; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; VAZIRI H, 1993, AM J HUM GENET, V52, P661; Weinrich SL, 1997, NAT GENET, V17, P498, DOI 10.1038/ng1297-498; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; WEST MD, 1994, ARCH DERMATOL, V130, P87, DOI 10.1001/archderm.130.1.87; Wotton D, 1997, GENE DEV, V11, P748, DOI 10.1101/gad.11.6.748; WRIGHT WE, 1992, EXP GERONTOL, V27, P383, DOI 10.1016/0531-5565(92)90069-C; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; Wright WE, 1996, DEV GENET, V18, P173; WRIGHT WE, 1995, TRENDS CELL BIOL, V5, P293, DOI 10.1016/S0962-8924(00)89044-3; WynfordThomas D, 1996, ONCOL RES, V8, P387	62	3786	4092	13	486	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					349	352		10.1126/science.279.5349.349	http://dx.doi.org/10.1126/science.279.5349.349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9454332				2022-12-01	WOS:000071570800037
J	des Portes, V; Pinard, JM; Billuart, P; Vinet, MC; Koulakoff, A; Carrie, A; Gelot, A; Dupuis, E; Motte, J; Berwald-Netter, Y; Catala, M; Kahn, A; Beldjord, C; Chelly, J				des Portes, V; Pinard, JM; Billuart, P; Vinet, MC; Koulakoff, A; Carrie, A; Gelot, A; Dupuis, E; Motte, J; Berwald-Netter, Y; Catala, M; Kahn, A; Beldjord, C; Chelly, J			A novel CNS gene required for neuronal migration and involved in X-linked subcortical laminar heterotopia and lissencephaly syndrome	CELL			English	Article							CORTICAL DYSPLASIA; CEREBRAL-CORTEX; CELL-MIGRATION; PROTEIN; SEQUENCE; EXPRESSION; BINDING; IDENTIFICATION; MALFORMATIONS; TRANSCRIPTION	X-SCLH/LIS syndrome is a neuronal migration disorder with disruption of the six-layered neocortex. It consists of subcortical laminar heterotopia (SCLH, band heterotopia, or double cortex) in females and lissencephaly (LIS) in males, leading to epilepsy and cognitive impairment. We report the characterization of a novel CNS gene encoding a 40 kDa predicted protein that we named Doublecortin and the identification of mutations in four unrelated X-SCLH/LIS cases. The predicted protein shares significant homology with the N-terminal segment of a protein containing a protein kinase domain at its C-terminal part. This novel gene is highly expressed during brain development, mainly in fetal neurons including precursors. The complete disorganization observed in lissencephaly and heterotopia thus seems to reflect a failure of early events associated with neuron dispersion.	Fac Med Cochin, ICGM, INSERM, U129, F-75014 Paris, France; Hop Raymond Poincare, Serv Neuropediat, Garches, France; Coll France, F-75231 Paris 05, France; Hop St Vincent de Paul, Lab Histoembryol Cytogenet, F-75014 Paris, France; Amer Mem Hosp, Serv Neuropediat, F-51092 Reims, France; Hop La Pitie Salpetriere, Lab Histoembryol Cytogenet, F-75651 Paris 13, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Montpellier; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP; UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; CHU de Reims; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Chelly, J (corresponding author), Fac Med Cochin, ICGM, INSERM, U129, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		Billuart, Pierre/K-3832-2017; Chelly, Jamel/J-7528-2015	Billuart, Pierre/0000-0003-1913-1687; Chelly, Jamel/0000-0002-0939-8719; Gelot, Antoinette/0000-0002-3032-014X; Catala, Martin/0000-0003-1554-9007				AICARDI J, 1991, BRAIN DEV-JPN, V13, P1; ALLENDOERFER KL, 1994, ANNU REV NEUROSCI, V17, P185, DOI 10.1146/annurev.neuro.17.1.185; [Anonymous], 1982, MOL CLONING LAB MANU; BACHNER D, 1995, HUM MOL GENET, V4, P701, DOI 10.1093/hmg/4.4.701; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bienvenu T, 1997, EUR J HUM GENET, V5, P105, DOI 10.1159/000484743; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; desPortes V, 1997, J MED GENET, V34, P177, DOI 10.1136/jmg.34.3.177; Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; HOUDOU S, 1990, PEDIATR NEUROL, V6, P402, DOI 10.1016/0887-8994(90)90009-P; Howell BW, 1997, NATURE, V389, P733, DOI 10.1038/39607; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; KEMP BE, 1990, TRENDS BIOCHEM SCI, V15, P342, DOI 10.1016/0968-0004(90)90073-K; KOMECKI E, 1988, SCIENCE, V240, P1792; KOMURO H, 1992, SCIENCE, V257, P806, DOI 10.1126/science.1323145; KOMURO H, 1993, SCIENCE, V260, P95, DOI 10.1126/science.8096653; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUZNIECKY R, 1993, NEUROLOGY, V43, P681, DOI 10.1212/WNL.43.4.681; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEHRACH H., 1990, GENOME ANAL, P39; LI P, 1993, GENE DEV, V7, P2483, DOI 10.1101/gad.7.12b.2483; LoNigro C, 1997, HUM MOL GENET, V6, P157, DOI 10.1093/hmg/6.2.157; LUSKIN MB, 1988, NEURON, V1, P653; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; OROURKE NA, 1995, DEVELOPMENT, V121, P2165; PALMINI A, 1991, NEUROLOGY, V41, P1656, DOI 10.1212/WNL.41.10.1656; PINARD JM, 1994, J NEUROL NEUROSUR PS, V57, P914, DOI 10.1136/jnnp.57.8.914; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAYMOND AA, 1995, BRAIN, V118, P629, DOI 10.1093/brain/118.3.629; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; ROSS E, 1997, HUM MOL GENET, V6, P555; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SCHREIBER E, 1993, NUCLEIC ACIDS RES, V21, P253, DOI 10.1093/nar/21.2.253; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; Sheldon M, 1997, NATURE, V389, P730, DOI 10.1038/39601; SHISHEVA A, 1994, MOL CELL BIOL, V14, P3459, DOI 10.1128/MCB.14.5.3459; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; TAN SS, 1993, NATURE, V362, P638, DOI 10.1038/362638a0; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; Ware ML, 1997, NEURON, V19, P239, DOI 10.1016/S0896-6273(00)80936-8	53	611	623	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					51	61						11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489699				2022-12-01	WOS:000071473700007
J	Sablowski, RWM; Meyerowitz, EM				Sablowski, RWM; Meyerowitz, EM			A homolog of NO APICAL MERISTEM is an immediate target of the floral homeotic genes APETALA3/PISTILLATA	CELL			English	Article							ARABIDOPSIS-THALIANA; FLOWER DEVELOPMENT; ORGAN-IDENTITY; DIFFERENTIAL DISPLAY; PROTEINS APETALA1; PATTERN-FORMATION; MESSENGER-RNA; PISTILLATA; DOMAIN; MUTATIONS	To understand how homeotic genes affect morphogenesis and differentiation, their target genes must be identified. In Arabidopsis flowers, the homeotic protein heterodimer APETALA3/PISTILLATA is necessary for petal and stamen formation. Here, AP3/PI function was put under posttranslational control to analyze its immediate effect on the floral mRNA population, with indirect effects blocked by cycloheximide. Using differential display, a target gene of AP3/PI was identified (NAP: NAC-LIKE, ACTIVATED BY AP3/PI), which is homologous to genes required for meristem establishment and separation of floral organs. The expression pattern of NAP and the phenotypes caused by its mis-expression suggest that it functions in the transition between growth by cell division and cell expansion in stamens and petals.	CALTECH, Div Biol 15629, Pasadena, CA 91125 USA	California Institute of Technology	Meyerowitz, EM (corresponding author), CALTECH, Div Biol 15629, Pasadena, CA 91125 USA.		Meyerowitz, Elliot M/A-7118-2009	Sablowski, Robert/0000-0002-1732-2909				Aida M, 1997, PLANT CELL, V9, P841, DOI 10.1105/tpc.9.6.841; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ANDREW DJ, 1992, NEW BIOL, V4, P5; Aoyama T, 1997, PLANT J, V11, P605, DOI 10.1046/j.1365-313X.1997.11030605.x; BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BENNETT SRM, 1995, PLANT J, V8, P505, DOI 10.1046/j.1365-313X.1995.8040505.x; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; COMELISSEN M, 1989, NUCLEIC ACIDS RES, V17, P833; DALMAN FC, 1991, J BIOL CHEM, V266, P3482; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Fryxell KJ, 1996, TRENDS GENET, V12, P364, DOI 10.1016/S0168-9525(96)80020-5; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GOTO K, 1994, GENE DEV, V8, P1548, DOI 10.1101/gad.8.13.1548; Graba Y, 1997, BIOESSAYS, V19, P379, DOI 10.1002/bies.950190505; HILL JP, 1989, CAN J BOT, V67, P2922, DOI 10.1139/b89-375; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; Jacobs T, 1997, PLANT CELL, V9, P1021, DOI 10.1105/tpc.9.7.1021; Jacobson D R, 1991, PCR Methods Appl, V1, P146; John I, 1997, PLANT MOL BIOL, V33, P641, DOI 10.1023/A:1005746831643; KLIMYUK VI, 1993, PLANT J, V3, P493, DOI 10.1046/j.1365-313X.1993.t01-26-00999.x; KONAT GW, 1994, PCR TECHNOLOGY CURRE; Krizek BA, 1996, DEVELOPMENT, V122, P11; Krizek BA, 1996, P NATL ACAD SCI USA, V93, P4063, DOI 10.1073/pnas.93.9.4063; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; LAWRENCE PA, 1994, CELL, V78, P181, DOI 10.1016/0092-8674(94)90289-5; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LLOYD AM, 1994, SCIENCE, V266, P436, DOI 10.1126/science.7939683; MARTIN C, 1993, PLANT CELL, V5, P1253, DOI 10.1105/tpc.5.10.1253; MCKINNEY EC, 1995, PLANT J, V8, P613, DOI 10.1046/j.1365-313X.1995.8040613.x; Meyerowitz EM, 1997, CELL, V88, P299, DOI 10.1016/S0092-8674(00)81868-1; Munster T, 1997, P NATL ACAD SCI USA, V94, P2415, DOI 10.1073/pnas.94.6.2415; Reuber TL, 1995, METHOD CELL BIOL, V49, P431, DOI 10.1016/S0091-679X(08)61471-5; Riechmann JL, 1996, NUCLEIC ACIDS RES, V24, P3134, DOI 10.1093/nar/24.16.3134; Riechmann JL, 1997, MOL BIOL CELL, V8, P1243, DOI 10.1091/mbc.8.7.1243; Riechmann JL, 1996, P NATL ACAD SCI USA, V93, P4793, DOI 10.1073/pnas.93.10.4793; Riechmann JL, 1997, BIOL CHEM, V378, P1079; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Souer E, 1996, CELL, V85, P159, DOI 10.1016/S0092-8674(00)81093-4; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; YANOFSKY MF, 1995, ANNU REV PLANT PHYS, V46, P167, DOI 10.1146/annurev.pp.46.060195.001123; ZACHGO S, 1995, DEVELOPMENT, V121, P2861; ZHAO S, 1995, BIOTECHNIQUES, V18, P842	52	446	509	4	50	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					93	103		10.1016/S0092-8674(00)80902-2	http://dx.doi.org/10.1016/S0092-8674(00)80902-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489703	Bronze			2022-12-01	WOS:000071473700011
J	Wu, GY; Cline, HT				Wu, GY; Cline, HT			Stabilization of dendritic arbor structure in vivo by CaMKII	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; POSTSYNAPTIC DENSITY PROTEIN; GROWTH CONE MOTILITY; NEURITE OUTGROWTH; SYNAPTIC TRANSMISSION; FUNCTIONAL COMPONENTS; ELECTRICAL-ACTIVITY; GENETIC DISSECTION; EXPRESSION	Calcium-calmodulin-dependent protein kinase II (CaMKII) promotes the maturation of retinotectal glutamatergic synapses in Xenopus. Whether CaMKII activity also controls morphological maturation of optic tectal neurons was tested using in vivo time-lapse imaging of single neurons over periods of up to 5 days. Dendritic arbor elaboration slows with maturation, in correlation with the onset of CaMKII expression. Elevating CaMKII activity in young neurons by viral expression of constitutively active CaMKII slowed dendritic growth to a rate comparable to that of mature neurons. CaMKII overexpression stabilized dendritic structure in more mature neurons, whereas CaMKII inhibition increased their dendritic growth. Thus, endogenous CaMKII activity limits dendritic growth and stabilizes dendrites, and it may act as an activity-dependent mediator of neuronal maturation.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Cline, HT (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	cline@cshl.org						ALFORD S, 1993, J PHYSIOL-LONDON, V469, P693, DOI 10.1113/jphysiol.1993.sp019838; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BALICEGORDON RJ, 1994, NATURE, V372, P519, DOI 10.1038/372519a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; COHAN CS, 1986, SCIENCE, V232, P1638, DOI 10.1126/science.3715470; Colman H, 1997, SCIENCE, V275, P356, DOI 10.1126/science.275.5298.356; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; FIELDS RD, 1990, J NEUROSCI, V10, P2950; GOSHIMA Y, 1993, J NEUROSCI, V13, P559; HAYDON PG, 1994, J NEUROBIOL, V25, P694, DOI 10.1002/neu.480250609; ISAAC JTR, 1997, NEURON, V18, P1; KELLY PT, 1984, P NATL ACAD SCI-BIOL, V81, P945, DOI 10.1073/pnas.81.3.945; KELLY PT, 1985, DEV BRAIN RES, V18, P211, DOI 10.1016/0165-3806(85)90265-2; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; LANKFORD KL, 1989, J CELL BIOL, V109, P1229, DOI 10.1083/jcb.109.3.1229; LAZAR G, 1973, J ANAT, V116, P347; Liao DZ, 1996, LEARN MEMORY, V3, P138, DOI 10.1101/lm.3.2-3.138; Litersky JM, 1996, BIOCHEM J, V316, P655, DOI 10.1042/bj3160655; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1994, P NATL ACAD SCI USA, V91, P8170, DOI 10.1073/pnas.91.17.8170; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Masse T, 1997, J NEUROSCI, V17, P924; MATTSON MP, 1988, J NEUROSCI, V8, P2087; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MCGLADEMCCULLOH E, 1993, NATURE, V362, P640, DOI 10.1038/362640a0; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MURRAY KD, 1994, NEUROSCIENCE, V60, P37, DOI 10.1016/0306-4522(94)90202-X; Nieuwkoop PD., 1956, DEVELOPMENT, DOI [DOI 10.1242/DEV.200356, 10.1242/dev.200356]; Otmakhov N, 1997, J NEUROSCI, V17, P5357; PERKEL DJ, 1993, J PHYSIOL-LONDON, V471, P481, DOI 10.1113/jphysiol.1993.sp019911; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; REGEHR WG, 1992, J NEUROSCI, V12, P4202; Scheetz AJ, 1996, EUR J NEUROSCI, V8, P1322, DOI 10.1111/j.1460-9568.1996.tb01594.x; Schulman H, 1993, CURR OPIN CELL BIOL, V5, P247, DOI 10.1016/0955-0674(93)90111-3; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; Stewart BA, 1996, J NEUROSCI, V16, P3877; Tashima K, 1996, J NEUROCHEM, V66, P57; TSUJIMOTO T, 1990, J NEUROSCI, V10, P2059; WANG J, 1994, NEURON, V13, P1373, DOI 10.1016/0896-6273(94)90422-7; WANG JH, 1995, NEURON, V15, P443, DOI 10.1016/0896-6273(95)90048-9; Witte S, 1996, J NEUROBIOL, V31, P219, DOI 10.1002/(SICI)1097-4695(199610)31:2<219::AID-NEU7>3.0.CO;2-E; Wu G., UNPUB; Wu GY, 1996, SCIENCE, V274, P972, DOI 10.1126/science.274.5289.972; WU GY, 1995, NEURON, V14, P681, DOI 10.1016/0896-6273(95)90211-2; ZHONG Y, 1995, J NEUROSCI, V15, P6679; Zou DJ, 1996, NEURON, V16, P529, DOI 10.1016/S0896-6273(00)80072-0	50	305	313	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					222	226		10.1126/science.279.5348.222	http://dx.doi.org/10.1126/science.279.5348.222			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422694				2022-12-01	WOS:000071408100041
J	Nern, A; Arkowitz, RA				Nern, A; Arkowitz, RA			A GTP-exchange factor required for cell orientation	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; MATING FACTOR; GENE-PRODUCT; YEAST-CELLS; POLARIZATION; PROTEIN; CDC42; CDC24; GRADIENTS; PATHWAY	The Rho-family of GTPases and their regulators are essential for cytoskeletal reorganization and transcriptional activation in response to extracellular signals(1,2). Little is known about what Links these molecules to membrane receptors. In the budding yeast Saccharomyces cerevisiae, haploid cells respond to mating pheromone through a G-protein-coupled receptor and the beta gamma subunit of the G protein(3), resulting in arrest of the cell cycle, transcriptional activation, and polarized growth towards a mating partner(4,5). The Rho-family GTPase Cdc42 and its exchange factor Cdc24 have been implicated in the mating process(6,7), but their specific role is unknown. Here we report the identification of cdc24 alleles that do not affect vegetative growth but drastically reduce the ability of yeast cells to mate, When exposed to mating pheromone, these mutants arrest growth, activate transcription, and undergo characteristic morphological and actin-cytoskeleton polarization, However, the mutants are unable to orient towards a pheromone gradient, and instead position their mating projection adjacent to their previous bud site. The mutants are specifically defective in the binding of Cdc24 to the G-protein beta gamma subunit, Our results demonstrate that the association of an exchange factor and the beta gamma subunit of a hetero-trimeric G protein links receptor-mediated activation to oriented cell growth.	MRC, Mol Biol Lab, Div Cell Biol, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Arkowitz, RA (corresponding author), MRC, Mol Biol Lab, Div Cell Biol, Hills Rd, Cambridge CB2 2QH, England.	ra2@mrc-lmb.cam.ac.uk	arkowitz, robert/ABC-1860-2021	arkowitz, robert/0000-0002-5216-5013				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHENEVERT J, 1992, NATURE, V356, P77, DOI 10.1038/356077a0; CHENEVERT J, 1994, GENETICS, V136, P1287; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; FROMANT M, 1995, ANAL BIOCHEM, V224, P347, DOI 10.1006/abio.1995.1050; Hirschman JE, 1997, J BIOL CHEM, V272, P240; James P, 1996, GENETICS, V144, P1425; LANGLEROUAULT F, 1995, NUCLEIC ACIDS RES, V23, P3079, DOI 10.1093/nar/23.15.3079; Leberer E, 1997, EMBO J, V16, P83, DOI 10.1093/emboj/16.1.83; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; Machesky LM, 1996, TRENDS CELL BIOL, V6, P304, DOI 10.1016/0962-8924(96)10026-X; MITCHELL DA, 1993, YEAST, V9, P715, DOI 10.1002/yea.320090705; MIYAMOTO S, 1991, BIOCHEM BIOPH RES CO, V181, P604, DOI 10.1016/0006-291X(91)91233-3; Peter M, 1996, EMBO J, V15, P7046, DOI 10.1002/j.1460-2075.1996.tb01096.x; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P732; Rose M. D., 1991, METHODS YEAST GENETI; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SLOAT BF, 1981, J CELL BIOL, V89, P395, DOI 10.1083/jcb.89.3.395; SPRAGUE GF, 1991, METHOD ENZYMOL, V194, P77; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.0.CO;2-K; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	30	116	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					195	198		10.1038/34458	http://dx.doi.org/10.1038/34458			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428768				2022-12-01	WOS:000071380900056
J	Nightingale, SL				Nightingale, SL			Rezulin labeling updated to recommend more frequent patient monitoring	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.							1997, JAMA, V278, P1728	1	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-01	WOS:000071295100003
J	Lewis, JE; Kristan, WB				Lewis, JE; Kristan, WB			A neuronal network for computing population vectors in the leech	NATURE			English	Article							LOCAL BENDING REFLEX; SENSORY INFORMATION; NEURAL NETWORKS; INTERNEURONS	The correlation of neuronal activity with sensory input and behavioural output has revealed that information is often encoded in the activity of many neurons across a population, that is, a neural population code is used(1,2). The possible algorithms that downstream networks use to read out this population code have been studied by manipulating the activity of a few neurons in a population(3,4). We have used this approach to study population coding in a small network underlying the leech local bend, a body bend directed away from a touch stimulus(5), Because of the small size of this network we are able to monitor and manipulate the complete set of sensory inputs to the network. We show here that the population vector(6) formed by the spike counts of the active mechanosensory neurons is well correlated with bend direction, A model based on the known connectivity of the identified neurons in the local bend network can account for our experimental results, and is suitable for reading out the neural population vector, Thus, for the first time to our knowledge, it is possible to link a proposed algorithm for neural population coding with synaptic and network mechanisms in an experimental system.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Kristan, WB (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.							ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; BATSCHELET E., 1981, CIRCULAR STAT BIOL M; CARLTON T, 1995, J COMP PHYSIOL A, V177, P781, DOI 10.1007/BF00187637; GEOGOPOULOS A, 1994, NEURON, V13, P257; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; Groh JM, 1997, J NEUROSCI, V17, P4312; Gur M, 1997, J NEUROSCI, V17, P2914; KRISTAN WB, 1982, J EXP BIOL, V96, P143; KRISTAN WB, 1982, J EXP BIOL, V96, P161; LEE CK, 1988, NATURE, V332, P357, DOI 10.1038/332357a0; LEWIS JE, 1997, THESIS U CALIFORNIA; LOCKERY SR, 1990, J NEUROSCI, V10, P1816; LOCKERY SR, 1990, J NEUROSCI, V10, P1811; LOCKERY SR, 1989, NATURE, V340, P468, DOI 10.1038/340468a0; LOCKERY SR, 1992, J NEUROSCI, V12, P3877; MILLER JP, 1991, J NEUROPHYSIOL, V66, P1680, DOI 10.1152/jn.1991.66.5.1680; MULLER KJ, 1981, NEUROBIOLOGY LEECH; Salinas E, 1994, J Comput Neurosci, V1, P89, DOI 10.1007/BF00962720; SALINAS E, 1995, J NEUROSCI, V15, P6461; SALZMAN CD, 1994, SCIENCE, V264, P231, DOI 10.1126/science.8146653; Shaw BK, 1997, J NEUROSCI, V17, P786; SPARKS DL, 1997, NEURONS NETWORKS MOT, P21	22	95	95	1	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					76	79		10.1038/34172	http://dx.doi.org/10.1038/34172			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422507				2022-12-01	WOS:000071326100051
J	Nichol, G; Dennis, DT; Steere, AC; Lightfoot, R; Wells, G; Shea, B; Tugwell, P				Nichol, G; Dennis, DT; Steere, AC; Lightfoot, R; Wells, G; Shea, B; Tugwell, P			Test-treatment strategies for patients suspected of having Lyme disease: A cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							BORRELIA-BURGDORFERI; DECISION-MAKING; HEART-BLOCK; MYOSITIS; DERMATOMYOSITIS; MANIFESTATIONS; FIBROMYALGIA; POPULATION; ARTHRITIS; DIAGNOSIS	Purpose: To examine the cost-effectiveness of test-treatment strategies for patients suspected of having Lyme disease. Data Sources: The medical literature was searched for information on outcomes and costs. Expert opinion was sought for information on utilities. Study Selection: Articles that described patient population, diagnostic criteria, dose and duration of therapy, and criteria for assessment of outcomes. Data Extraction: The decision analysis evaluated the following strategies: 1) no testing-no treatment; 2) testing with enzyme-linked immunosorbent assay (ELISA) followed by antibiotic treatment of patients with positive results; 3) two-step testing with ELISA followed by Western blot and antibiotic treatment for patients with positive results on either test; and 4) empirical antibiotic therapy. Three patient scenarios were considered: myalgic symptoms, rash resembling erythema migrans, and recurrent oligoarticular inflammatory arthritis. Results were calculated as costs per quality-adjusted life-year and were subjected to sensitivity analysis. Adjustment was made for the diagnostic value of common clinical features of Lyme disease. Data Synthesis: For myalgic symptoms without other features suggestive of Lyme disease, the no testing-no treatment strategy was most economically attractive (that is, had the most favorable cost-effectiveness ratio). For rash, empirical antibiotic therapy was less costly and more effective than other strategies. For oligoarticular arthritis with a history of rash and tick bite, two-step testing was associated with the lowest cost-effectiveness ratio. Testing with ELISA and empirical antibiotic therapy cost an additional $880 000 and $34 000 per quality-adjusted life-year, respectively. For oligoarticular arthritis with one or no other features suggestive of Lyme disease, two-step testing was most economically attractive. Conclusions: Neither testing nor antibiotic treatment is cost-effective if the pretest probability of Lyme disease is low. Empirical antibiotic therapy is recommended if the pretest probability is high, and two-step testing is recommended if the pretest probability is intermediate.	Ottawa Gen Hosp, Dept Med, Ottawa, ON K1H 8L6, Canada; Ottawa Civic Hosp, Clin Epidemiol Unit, Ottawa, ON K1Y 4E9, Canada; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Ft Collins, CO 80521 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Univ Kentucky, Kentucky Clin J511, Div Rheumatol, Lexington, KY 40536 USA; Tufts Univ, Med Ctr, Boston, MA 02111 USA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Centers for Disease Control & Prevention - USA; Tufts Medical Center; University of Kentucky; Tufts University	Tugwell, P (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Tugwell, Peter/AFD-8076-2022	Tugwell, Peter/0000-0001-5062-0556; Steere, Allen/0000-0002-5268-9853				*AM MED ASS CTR HL, 1993, PHYS MARK STAT PROF; [Anonymous], 1995, MMWR MORB MORTAL WKL, V44, P590; ATLAS E, 1988, ANN INTERN MED, V109, P245, DOI 10.7326/0003-4819-109-3-245; BECK JR, 1982, AM J MED, V73, P889, DOI 10.1016/0002-9343(82)90787-2; BERGER BW, 1989, REV INFECT DIS, V11, pS1475; BLAAUW I, 1992, J CLIN EPIDEMIOL, V45, P1229, DOI 10.1016/0895-4356(92)90163-H; BURDGE DR, 1993, CLIN INFECT DIS, V16, P558, DOI 10.1093/clind/16.4.558; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; COCKBURN J, 1987, BRIT MED J, V295, P814, DOI 10.1136/bmj.295.6602.814; DATTWYLER RJ, 1988, LANCET, V1, P1191; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; EPPES SC, 1994, CLIN PEDIATR, V33, P130, DOI 10.1177/000992289403300301; ETTESTAD PJ, 1995, J INFECT DIS, V171, P356, DOI 10.1093/infdis/171.2.356; FRASER DD, 1992, CLIN EXP RHEUMATOL, V10, P387; GEISLER WO, 1977, PARAPLEGIA, V14, P262, DOI 10.1038/sc.1976.44; Gold MR., 1996, COST EFFECTIVENESS H; GUSTAFSON R, 1992, EUR J CLIN MICROBIOL, V11, P894, DOI 10.1007/BF01962369; HOFFMANN JC, 1995, ARTHRITIS RHEUM-US, V38, P1157, DOI 10.1002/art.1780380820; HOROWITZ HW, 1994, CLIN INFECT DIS, V18, P166, DOI 10.1093/clinids/18.2.166; HSU VM, 1993, ARTHRITIS RHEUM, V36, P1493, DOI 10.1002/art.1780361103; JACOBS P, 1995, PHARMACOECONOMICS, V8, P182, DOI 10.2165/00019053-199508030-00002; Jung P I, 1994, Md Med J, V43, P447; KARLSSON M, 1994, NEUROLOGY, V44, P1203, DOI 10.1212/WNL.44.7.1203; KARMA A, 1995, AM J OPHTHALMOL, V119, P127, DOI 10.1016/S0002-9394(14)73864-4; KENGEN RAM, 1989, CLIN NUCL MED, V14, P728, DOI 10.1097/00003072-198910000-00002; Lew EA, 1990, MED RISKS TRENDS MOR; LEY C, 1994, JAMA-J AM MED ASSOC, V271, P460, DOI 10.1001/jama.271.6.460; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LOGIGIAN EL, 1992, NEUROLOGY, V42, P303, DOI 10.1212/WNL.42.2.303; LUI NY, 1989, ARTHRITIS RHEUM, V32, pS46; MAGID D, 1992, NEW ENGL J MED, V327, P534, DOI 10.1056/NEJM199208203270806; MALANE MS, 1991, ANN INTERN MED, V114, P490, DOI 10.7326/0003-4819-114-6-490; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; *MED EC, 1993, DRUG TOP RED BOOK; MELSKI JW, 1993, ARCH DERMATOL, V129, P709, DOI 10.1001/archderm.129.6.709; *NAT CTR HLTH STAT, 1994, ANN SUMM BIRTHS MARR; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PAUKER SG, 1980, NEW ENGL J MED, V302, P1109, DOI 10.1056/NEJM198005153022003; REIK L, 1979, MEDICINE, V58, P281, DOI 10.1097/00005792-197907000-00001; REIMERS CD, 1993, J NEUROL, V240, P278, DOI 10.1007/BF00838161; RUBIN DA, 1992, PACE, V15, P252, DOI 10.1111/j.1540-8159.1992.tb06492.x; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SCHMUTZHARD E, 1986, KLIN WOCHENSCHR, V64, P1204, DOI 10.1007/BF01728463; SCHOEN RT, 1991, ARTHRITIS RHEUM, V34, P1056, DOI 10.1002/art.1780340817; SCHOENEN J, 1989, J NEUROL NEUROSUR PS, V52, P1002, DOI 10.1136/jnnp.52.8.1002; SEIDENBERG KB, 1990, AM J OPHTHALMOL, V109, P13, DOI 10.1016/S0002-9394(14)75571-0; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SMITH JL, 1991, J CLIN NEURO-OPHTHAL, V11, P7; Sox HC, 1988, MED DECISION MAKING; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P1, DOI 10.7326/0003-4819-93-1-1; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1993, JAMA-J AM MED ASSOC, V269, P1812, DOI 10.1001/jama.269.14.1812; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1994, ARTHRITIS RHEUM-US, V37, P878, DOI 10.1002/art.1780370616; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Tugwell P, 1997, ANN INTERN MED, V127, P1109, DOI 10.7326/0003-4819-127-12-199712150-00011; Wharton M, 1990, MMWR Recomm Rep, V39, P1; 1993, MMWR MORB MORTAL WKL, V42, P39; 1995, MMWR MORB MORTAL WKL, V44, P459; 1996, MMWR MORB MORTAL WKL, V45, P481; 1994, MMWR MORB MORTAL WKL, V43, P564	66	45	46	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					37	48		10.7326/0003-4819-128-1-199801010-00007	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00007			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424980				2022-12-01	WOS:000071158000007
J	Klein, MA; Frigg, R; Flechsig, E; Raeber, AJ; Kalinke, U; Bluethmann, H; Bootz, F; Suter, M; Zinkernagel, RM; Aguzzi, A				Klein, MA; Frigg, R; Flechsig, E; Raeber, AJ; Kalinke, U; Bluethmann, H; Bootz, F; Suter, M; Zinkernagel, RM; Aguzzi, A			A crucial role for B cells in neuroinvasive scrapie	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; NECROSIS-FACTOR RECEPTOR-1; MICE LACKING; DEFICIENT MICE; T-CELLS; PROTEIN; MOUSE; PRP; REPLICATION; RESISTANT	Although prion proteins are most efficiently propagated through intracerebral inoculation, peripheral administration has caused the diseases kuru, iatrogenic Creutzfeldt-Jakob disease (CJD), bovine spongiform encephalopathy (BSE) and new-variant CJD(1,2). The development of neurological disease after peripheral inoculation depends on prion expansion within cells of the lymphoreticular system(3,4). Here we investigate the identity of these cells by using a panel of immune-deficient mice inoculated with prions intraperitoneally: we found that defects affecting only T lymphocytes had no apparent effect, but that all mutations that disrupted the differentiation and response of B lymphocytes prevented the development of clinical scrapie. As an absence of B cells and of antibodies correlates with severe defects in follicular dendritic cells, a lack of any of these three components may prevent the development of clinical scrapie. However, we found that scrapie developed after peripheral inoculation in mice expressing immunoglobulins that were exclusively of the M subclass and without detectable specificity for the normal form of the prion PrPc, and in mice which had differentiated B cells but no functional follicular dendritic cells. We conclude that differentiated B cells are crucial for neuroinvasion by scrapie, regardless of the specificity of their receptors.	UNIV ZURICH,INST NEUROPATHOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST MOL BIOL,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,INST EXPT IMMUNOL,CH-8091 ZURICH,SWITZERLAND; HOFFMANN LA ROCHE AG,CH-4070 BASEL,SWITZERLAND; UNIV ZURICH,INST LAB ANIM SCI,CH-8057 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University of Zurich; Roche Holding; University of Zurich				Aguzzi, Adriano/0000-0002-0344-6708; Kalinke, Ulrich/0000-0003-0503-9564				Blattler T, 1997, NATURE, V389, P69, DOI 10.1038/37981; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Brandner S, 1996, P NATL ACAD SCI USA, V93, P13148, DOI 10.1073/pnas.93.23.13148; Bruce ME, 1997, NATURE, V389, P498, DOI 10.1038/39057; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; Eigen M, 1996, BIOPHYS CHEM, V63, pA1, DOI 10.1016/S0301-4622(96)02250-8; FARQUHAR CF, 1989, J VIROL METHODS, V24, P215, DOI 10.1016/0166-0934(89)90023-2; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Fraser H, 1996, J GEN VIROL, V77, P1935, DOI 10.1099/0022-1317-77-8-1935; Hill AF, 1997, LANCET, V349, P99, DOI 10.1016/S0140-6736(97)24002-X; Hill AF, 1997, NATURE, V389, P448, DOI 10.1038/38925; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUMPHREY JH, 1984, EUR J IMMUNOL, V14, P859, DOI 10.1002/eji.1830140916; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kalinke U, 1996, IMMUNITY, V5, P639, DOI 10.1016/S1074-7613(00)80277-0; KITAMOTO T, 1991, J VIROL, V65, P6292, DOI 10.1128/JVI.65.11.6292-6295.1991; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Lasmezas CI, 1996, J VIROL, V70, P1292; LeHir M, 1996, J EXP MED, V183, P2367, DOI 10.1084/jem.183.5.2367; LEUNG WPF, 1991, CELL, V65, P443; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; NONOYAMA S, 1993, J IMMUNOL, V150, P3817; PRUSINER SB, 1982, ANN NEUROL, V11, P353, DOI 10.1002/ana.410110406; RAHEMTULLA A, 1991, NATURE, V353, P180, DOI 10.1038/353180a0; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; SHINKAI Y, 1992, CELL, V68, P855, DOI 10.1016/0092-8674(92)90029-C; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	29	417	425	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					687	690		10.1038/37789	http://dx.doi.org/10.1038/37789			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414161				2022-12-01	WOS:A1997YM50800032
J	Gillman, MW; Cupples, LA; Millen, BE; Ellison, RC; Wolf, PA				Gillman, MW; Cupples, LA; Millen, BE; Ellison, RC; Wolf, PA			Inverse association of dietary fat with development of ischemic stroke in men	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; SPONTANEOUSLY HYPERTENSIVE RATS; JAPANESE MEN; BLOOD-PRESSURE; FOLLOW-UP; MORTALITY; RISK; POPULATIONS; CALIFORNIA; PROGRAM	Context.-A few ecological and cohort studies in Asian populations suggest an inverse association of the intake of both fat and saturated fat with risk of stroke. However, data among western populations are scant. Objective.-To examine the association of stroke incidence with intake of fat and type of fat among middle-aged US men during 20 years of follow-up. Design and Setting.-The Framingham Heart Study, a population-based cohort study. Participants.-A total of 832 men, aged 45 through 65 years, who were free of cardiovascular disease at baseline (1966-1969). Measurements and Data Analysis.-The diet of each subject was assessed at baseline by a single 24-hour dietary recall, from which intakes of energy and macronutrients were estimated. In Kaplan-Meier analyses, we calculated age-adjusted cumulative incidence rates of stroke. Using Cox regression, we estimated stroke incidence relative risks during 20 years of follow-up. Main Outcome Measure.-Incidence of ischemic stroke, which occurred in 61 subjects during the follow-up period. Results.-Mean intakes were 10 975 kJ for energy; 114g (39% of energy) for total fat; 44g (15%) for saturated fat; 46 g (16%) for monounsaturated fat; and 16 g (5%) for polyunsaturated fat. Risk of ischemic stroke declined across the increasing quintile of total fat (log-rank trend P=.008), saturated fat (P=.002), and monounsaturated fat (P=.008) but not polyunsaturated fat (P=.33). The age-and energy-adjusted relative risk for each increment of 3% of energy from total fat was 0.85 (95% confidence interval [CI], 0.78-0.94); for an increment of 1% from saturated fat, 0.91 (95% CI, 0.85-0.98); and for 1% from monounsaturated fat, 0.89 (95% CI, 0.83-0.96). Adjustment for cigarette smoking, glucose intolerance, body mass index, blood pressure, blood cholesterol level, physical activity, and intake of vegetables and fruits and alcohol did not materially change the results. Too few cases of hemorrhagic stroke (n=14) occurred to draw inferences. Conclusion.-Intakes of fat, saturated fat, and monounsaturated fat were associated with reduced risk of ischemic stroke in men.	Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Boston Univ, Sch Publ Hlth, Boston, MA USA; Boston Univ, Sch Med, Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA	Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Boston University; Boston University; Boston University	Gillman, MW (corresponding author), Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Suite 200, Boston, MA 02215 USA.			Ellison, Robert Curtis/0000-0002-0582-7467; Wolf, Philip/0000-0002-3628-301X	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC038038] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01HC 38038] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; BENFANTE R, 1994, STROKE, V25, P814, DOI 10.1161/01.STR.25.4.814; BRONNER LL, 1995, NEW ENGL J MED, V333, P1392, DOI 10.1056/NEJM199511233332106; CUPPLES LA, 1995, STAT MED, V14, P1731, DOI 10.1002/sim.4780141603; CUPPLES LA, 1987, NIH PUBLICATION; DONAHUE RP, 1986, JAMA-J AM MED ASSOC, V255, P2311, DOI 10.1001/jama.255.17.2311; GARCIAPALMIERI MR, 1980, AM J CLIN NUTR, V33, P1818, DOI 10.1093/ajcn/33.8.1818; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Gillman MW, 1997, EPIDEMIOLOGY, V8, P144, DOI 10.1097/00001648-199703000-00004; GORDON T, 1981, CIRCULATION, V63, P500, DOI 10.1161/01.CIR.63.3.500; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; IKEDA K, 1987, J NUTR SCI VITAMINOL, V33, P31, DOI 10.3177/jnsv.33.31; KANNEL WB, 1987, AM HEART J, V113, P1489, DOI 10.1016/0002-8703(87)90666-1; Katan MB, 1997, NEW ENGL J MED, V337, P563; Key TJA, 1996, BMJ-BRIT MED J, V313, P775, DOI 10.1136/bmj.313.7060.775; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KIMURA N, 1983, PREV MED, V12, P222, DOI 10.1016/0091-7435(83)90198-6; KLATSKY AL, 1987, J AM COLL CARDIOL, V9, pA78; KULLER L, 1971, AM J EPIDEMIOL, V93, P1; LAPIDUS L, 1986, AM J CLIN NUTR, V44, P444, DOI 10.1093/ajcn/44.4.444; MANN GV, 1962, AM J CLIN NUTR, V11, P200, DOI 10.1093/ajcn/11.3.200; MANSON JE, 1994, CIRCULATION, V89, P932; MCGEE D, 1985, INT J EPIDEMIOL, V14, P97, DOI 10.1093/ije/14.1.97; OMURA T, 1987, SOC SCI MED, V24, P401, DOI 10.1016/0277-9536(87)90212-7; POSNER BM, 1991, ARCH INTERN MED, V151, P1181, DOI 10.1001/archinte.151.6.1181; Qizilbash N, 1995, LANCET, V346, P1647; REED D, 1985, HYPERTENSION, V7, P405, DOI 10.1161/01.HYP.7.3_Pt_1.405; REED DM, 1990, AM J EPIDEMIOL, V131, P579, DOI 10.1093/oxfordjournals.aje.a115542; SACCO RL, 1989, ANN NEUROL, V25, P382, DOI 10.1002/ana.410250410; SHIMOKAWA T, 1988, LIFE SCI, V43, P2067, DOI 10.1016/0024-3205(88)90356-6; SIMON JA, 1995, STROKE, V26, P778, DOI 10.1161/01.STR.26.5.778; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SYME SL, 1975, AM J EPIDEMIOL, V102, P477, DOI 10.1093/oxfordjournals.aje.a112185; TAKEYA Y, 1984, STROKE, V15, P15, DOI 10.1161/01.STR.15.1.15; TANAKA H, 1982, STROKE, V13, P62, DOI 10.1161/01.STR.13.1.62; TILLOTSON JL, 1973, AM J CLIN NUTR, V26, P177, DOI 10.1093/ajcn/26.2.177; Willett W., 1990, NUTR EPIDEMIOLOGY; YAMORI Y, 1977, JPN HEART J, V18, P551; YAMORI Y, 1987, PREVENTION CARDIOVAS, P163	41	149	152	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2145	2150		10.1001/jama.278.24.2145	http://dx.doi.org/10.1001/jama.278.24.2145			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417007				2022-12-01	WOS:000071022200029
J	Barbas, CF; Heine, A; Zhong, GF; Hoffmann, T; Gramatikova, S; Bjornestedt, R; List, B; Anderson, J; Stura, EA; Wilson, IA; Lerner, RA				Barbas, CF; Heine, A; Zhong, GF; Hoffmann, T; Gramatikova, S; Bjornestedt, R; List, B; Anderson, J; Stura, EA; Wilson, IA; Lerner, RA			Immune versus natural selection: Antibody aldolases with enzymic rates but broader scope	SCIENCE			English	Article							RABBIT MUSCLE ALDOLASE; AMINO-ACID SEQUENCE; ACTIVE-SITE; ACETOACETATE DECARBOXYLASE; CRYSTAL-STRUCTURE; CONFORMATIONAL-CHANGES; REACTIVE IMMUNIZATION; CATALYTIC ANTIBODIES; IONIZATION CONSTANT; REPORTER GROUP	Structural and mechanistic studies show that when the selection criteria of the immune system are changed, catalytic antibodies that have the efficiency of natural enzymes evolve, but the catalytic antibodies are much more accepting of a wide range of substrates. The catalytic antibodies were prepared by reactive immunization, a process whereby the selection criteria of the immune system are changed from simple binding to chemical reactivity. This process yielded aldolase catalytic antibodies that approximated the rate acceleration of the natural enzyme used in glycolysis. Unlike the natural enzyme, however, the antibody aldolases catalyzed a variety of aldol reactions and decarboxylations. The crystal structure of one of these antibodies identified the reactive lysine residue that was selected in the immunization process. This lysine is deeply buried in a hydrophobic pocket at the base of the binding site, thereby accounting for its perturbed pK(a).			Barbas, CF (corresponding author), Scripps Res Inst, SKAGGS INST CHEM BIOL, 10550 N TORREY PINES RD, LA JOLLA, CA 92037 USA.		Stura, Enrico A./A-2793-2010; List, Benjamin/A-2121-2014	Stura, Enrico A./0000-0001-6718-2118; 	NCI NIH HHS [CA27489] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA027489] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERY WJ, 1977, ANGEW CHEM INT EDIT, V16, P285, DOI 10.1002/anie.197702851; AREVALO JH, 1993, J MOL BIOL, V231, P103, DOI 10.1006/jmbi.1993.1260; BALDWIN JE, 1982, TETRAHEDRON, V38, P2939, DOI 10.1016/0040-4020(82)85023-0; BALDWIN JE, UNPUB; Bjornestedt R, 1996, J AM CHEM SOC, V118, P11720, DOI 10.1021/ja9620797; BRADY RL, 1992, J MOL BIOL, V227, P253, DOI 10.1016/0022-2836(92)90695-G; BRUICE PY, 1990, J AM CHEM SOC, V112, P7361, DOI 10.1021/ja00176a041; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Castellano J.A., 1992, HDB DISPLAY TECHNOLO; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P11521, DOI 10.1021/bi00113a006; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; FASTREZ J, 1973, BIOCHEMISTRY-US, V12, P1067, DOI 10.1021/bi00730a008; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FREY PA, 1971, J AM CHEM SOC, V93, P7266, DOI 10.1021/ja00755a024; GUDDAT LW, 1994, J MOL BIOL, V236, P247, DOI 10.1006/jmbi.1994.1133; HANSCH C, 1970, J PHARM SCI, V59, P731, DOI 10.1002/jps.2600590602; HESTER G, 1991, FEBS LETT, V292, P237, DOI 10.1016/0014-5793(91)80875-4; Highbarger LA, 1996, BIOCHEMISTRY-US, V35, P41, DOI 10.1021/bi9518306; HINE J, 1972, J AM CHEM SOC, V94, P190, DOI 10.1021/ja00756a033; HsiehWilson LC, 1996, P NATL ACAD SCI USA, V93, P5363, DOI 10.1073/pnas.93.11.5363; Jencks W. P., 1975, CATALYSIS CHEM ENZYM; JOHN RA, 1995, BBA-PROTEIN STRUCT M, V1248, P81, DOI 10.1016/0167-4838(95)00025-P; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KNOWLES JR, 1991, NATURE, V350, P121, DOI 10.1038/350121a0; KOKESH FC, 1971, J AM CHEM SOC, V93, P7270, DOI 10.1021/ja00755a025; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lee JK, 1997, SCIENCE, V276, P942, DOI 10.1126/science.276.5314.942; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MARSH JJ, 1992, TRENDS BIOCHEM SCI, V17, P110, DOI 10.1016/0968-0004(92)90247-7; MORRIS AJ, 1994, BIOCHEMISTRY-US, V33, P12291, DOI 10.1021/bi00206a036; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; REYMOND JL, 1995, J ORG CHEM, V60, P6970, DOI 10.1021/jo00126a057; Richardson J.S., 1990, PREDICTION PROTEIN S, P1; RUTTER WJ, 1964, FED PROC, V23, P1248; SCHMIDT DE, 1971, BIOCHEMISTRY-US, V10, P1249; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; SHELDRICK GM, 1996, SHELXL 96 PROGRAM CR; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VLAHOS CJ, 1986, J BIOL CHEM, V261, P1049; WADA H, 1962, J BIOL CHEM, V237, P133; WAGNER J, 1995, SCIENCE, V270, P1797, DOI 10.1126/science.270.5243.1797; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WIRSCHING P, 1995, SCIENCE, V270, P1775, DOI 10.1126/science.270.5243.1775; WONG CH, 1995, ANGEW CHEM INT EDIT, V34, P412, DOI 10.1002/anie.199504121; Zhong GF, 1997, J AM CHEM SOC, V119, P8131, DOI 10.1021/ja970944x; ZHOU GW, 1994, SCIENCE, V265, P1059, DOI 10.1126/science.8066444	51	339	354	0	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2085	2092		10.1126/science.278.5346.2085	http://dx.doi.org/10.1126/science.278.5346.2085			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405338				2022-12-01	WOS:A1997YM23500043
J	Lee, SJ; Kuntz, KM; Horowitz, MM; McGlave, PB; Goldman, JM; Sobocinski, KA; Hegland, J; Kollman, C; Parsons, SK; Weinstein, MC; Weeks, JC; Antin, JH				Lee, SJ; Kuntz, KM; Horowitz, MM; McGlave, PB; Goldman, JM; Sobocinski, KA; Hegland, J; Kollman, C; Parsons, SK; Weinstein, MC; Weeks, JC; Antin, JH			Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: A decision analysis	ANNALS OF INTERNAL MEDICINE			English	Article							CHRONIC MYELOID-LEUKEMIA; CHRONIC GRANULOCYTIC-LEUKEMIA; GRAFT-VERSUS-LEUKEMIA; INTERFERON-ALPHA THERAPY; CHRONIC-PHASE; MULTIVARIATE-ANALYSIS; HOST DISEASE; PROGNOSTIC DISCRIMINATION; PATIENT CHARACTERISTICS; CYTOGENETIC RESPONSE	Background: Chronic myelogenous leukemia (CML) is an indolent but ultimately fatal disease. Because the natural history of CML varies and quality of life with CML may be excellent until shortly before death, deciding whether and when to pursue unrelated donor bone marrow transplantation is often difficult. Objective: To compare early transplantation, delayed transplantation, and no transplantation ?or patients with chronic-phase CML on the basis of discounted, quality-adjusted life expectancy. Design: A Markov model comparing different strategies was constructed. This model considers patient age, quality of life, risk aversion, and the competing risks for CML progression and transplant toxicity. Setting: Therapeutic decision at the time of diagnosis of CML. Patients: The base case is a 35-year-old patient with intermediate-prognosis CML. Younger and older patients with better and worse prognoses are also evaluated. Intervention: Early transplantation, delayed transplantation, and no transplantation. Measurements: Quality-adjusted, discounted life expectancy. Results: For patients with newly diagnosed CML, transplantation within the first year provides the greatest quality-adjusted expected survival, although this benefit decreases with increasing patient age. For a 35-year-old patient with intermediate-prognosis CML, transplantation within the first year results in 5.3 more discounted, quality-adjusted years of life expectancy than does no transplantation. This finding is robust even with varying baseline assumptions. Conclusions: These results support the use of early unrelated donor bone marrow transplantation for most patients with CML.	Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Natl Marrow Donor Program, Minneapolis, MN 55413 USA; Royal Postgrad Med Sch, Dept Haematol, London W12 0NN, England; Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Ctr Stat, Milwaukee, WI 53226 USA	Harvard University; Brigham & Women's Hospital; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Minnesota System; University of Minnesota Twin Cities; National Marrow Donor Program; Imperial College London; Medical College of Wisconsin	Lee, SJ (corresponding author), Dana Farber Canc Inst, Ctr Outcomes & Policy Res, 454 Brookline Ave,Suite 23, Boston, MA 02115 USA.		horowitz, Mary/ABH-2173-2021		NATIONAL CANCER INSTITUTE [P01CA040053] Funding Source: NIH RePORTER; NCI NIH HHS [CP-21161, P01-CA-40053] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLAN NC, 1995, LANCET, V345, P1392, DOI 10.1016/S0140-6736(95)92596-1; ANTIN JH, 1993, BLOOD, V82, P2273; BACIGALUPO A, 1993, BONE MARROW TRANSPL, V12, P443; BEATTY PG, 1988, TRANSPLANTATION, V45, P714, DOI 10.1097/00007890-198804000-00010; Bhatia R, 1997, BLOOD, V89, P2623, DOI 10.1182/blood.V89.8.2623; BIGGS JC, 1992, BLOOD, V80, P1352; BORTIN MM, 1993, BONE MARROW TRANSPL, V12, P97; CERVANTES F, 1982, BLOOD, V60, P1298; CHAMPLIN RE, 1988, SEMIN HEMATOL, V25, P74; CHAPMAN GB, 1995, MED DECIS MAKING, V15, P373, DOI 10.1177/0272989X9501500408; DEVERGIE A, 1990, BONE MARROW TRANSPL, V5, P379; DROBYSKI WR, 1993, BLOOD, V82, P2310; Duell T, 1997, ANN INTERN MED, V126, P184, DOI 10.7326/0003-4819-126-3-199702010-00002; Enright H, 1996, BLOOD, V88, P714, DOI 10.1182/blood.V88.2.714.bloodjournal882714; Enright H, 1996, BONE MARROW TRANSPL, V17, P537; GALIMBERTI M, 1994, BONE MARROW TRANSPL, V13, P197; GIRALT S, 1995, BLOOD, V86, P4337, DOI 10.1182/blood.V86.11.4337.bloodjournal86114337; Gluckman E, 1996, BLOOD, V88, P2436; GOLDMAN JM, 1993, BLOOD, V82, P2235; GRATWOHL A, 1993, BONE MARROW TRANSPL, V12, P509; Gratwohl A, 1996, BRIT J HAEMATOL, V92, P35, DOI 10.1046/j.1365-2141.1996.00292.x; Guilhot F, 1997, NEW ENGL J MED, V337, P223, DOI 10.1056/NEJM199707243370402; Hasford J, 1996, BLOOD, V87, P5384, DOI 10.1182/blood.V87.12.5384.bloodjournal87125384; HEHLMANN R, 1993, BLOOD, V82, P398, DOI 10.1182/blood.V82.2.398.bloodjournal822398; HEHLMANN R, 1994, BLOOD, V84, P4064, DOI 10.1182/blood.V84.12.4064.bloodjournal84124064; KANTARJIAN HM, 1995, ANN INTERN MED, V122, P254, DOI 10.7326/0003-4819-122-4-199502150-00003; Kantarjian HM, 1996, BLOOD, V87, P3069, DOI 10.1182/blood.V87.8.3069.bloodjournal8783069; KANTARJIAN HM, 1990, AM J MED, V88, P1, DOI 10.1016/0002-9343(90)90119-X; KANTARJIAN HM, 1985, BLOOD, V66, P1326; KARANAS A, 1968, BLOOD, V32, P445, DOI 10.1182/blood.V32.3.445.445; KOLB HJ, 1995, BLOOD, V86, P2041, DOI 10.1182/blood.V86.5.2041.bloodjournal8652041; MACKINNON S, 1995, BLOOD, V86, P1261, DOI 10.1182/blood.V86.4.1261.bloodjournal8641261; MARKS DI, 1993, ANN INTERN MED, V119, P207, DOI 10.7326/0003-4819-119-3-199308010-00005; MARTIN PJ, 1988, BLOOD, V72, P1978; MCGLAVE P, 1993, BLOOD, V81, P543; MCGLAVE PB, 1994, LANCET, V343, P1486, DOI 10.1016/S0140-6736(94)92589-5; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; Morgenstern O., 1953, THEORY GAMES EC BEHA; OHNISHI K, 1995, BLOOD, V86, P906; OZER H, 1993, BLOOD, V82, P2975; Parker SL, 1997, CA-CANCER J CLIN, V47, P5, DOI 10.3322/canjclin.47.1.5; PORTER DL, 1994, NEW ENGL J MED, V330, P100, DOI 10.1056/NEJM199401133300204; REDELMEIER DA, 1993, MED DECIS MAKING, V13, P212, DOI 10.1177/0272989X9301300306; SACCHI S, 1995, J CLIN ONCOL, V13, P2401, DOI 10.1200/JCO.1995.13.9.2401; SEGEL GB, 1986, BLOOD, V68, P1055; SIMON W, 1988, BRIT J HAEMATOL, V70, P31, DOI 10.1111/j.1365-2141.1988.tb02430.x; SOKAL JE, 1984, BLOOD, V63, P789, DOI 10.1182/blood.V63.4.789.789; SOKAL JE, 1985, BLOOD, V66, P1352; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SPIERS ASD, 1979, BRIT J HAEMATOL, V41, P1, DOI 10.1111/j.1365-2141.1979.tb03675.x; THOMAS ED, 1986, ANN INTERN MED, V104, P155, DOI 10.7326/0003-4819-104-2-155; TURA S, 1994, NEW ENGL J MED, V330, P820; TURA S, 1981, BRIT J HAEMATOL, V47, P105, DOI 10.1111/j.1365-2141.1981.tb02765.x; TURA S, 1992, HAEMATOLOGICA, V77, P204; WAGNER JE, 1992, J CLIN ONCOL, V10, P779, DOI 10.1200/JCO.1992.10.5.779; WETZLER M, 1995, AM J MED, V99, P402, DOI 10.1016/S0002-9343(99)80189-2	56	60	60	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1080	1088		10.7326/0003-4819-127-12-199712150-00005	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412310				2022-12-01	WOS:000070936600004
J	Powell, RJ; Holbrook, MR; Stevens, A				Powell, RJ; Holbrook, MR; Stevens, A			Pyoderma gangrenosum and its treatment	LANCET			English	Editorial Material									QUEENS MED CTR,DEPT HISTOPATHOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham	Powell, RJ (corresponding author), QUEENS MED CTR,DEPT CLIN IMMUNOL,NOTTINGHAM NG7 2UH,ENGLAND.							ABUELMAGD K, 1991, TRANSPLANT P, V23, P3328; BECHSTEIN WO, 1993, TRANSPLANT P, V25, P702; Bulvik S, 1997, BRIT J DERMATOL, V136, P637, DOI 10.1111/j.1365-2133.1997.tb02169.x; CHAMPION RH, 1992, TXB DERMATOLOGY, P1922; Chow RKP, 1996, J AM ACAD DERMATOL, V34, P1047, DOI 10.1016/S0190-9622(96)90285-6; Enk AH, 1997, LANCET, V350, P494, DOI 10.1016/S0140-6736(05)63084-X; MARTIS WL, 1992, ARCH DERMATOL, V128, P1060; NORWACK R, 1997, LANCET, V349, P774; Ostraat O, 1995, TRANSPLANT P, V27, P3540; Tamir A, 1996, DERMATOLOGY, V192, P252, DOI 10.1159/000246377	10	28	28	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 13	1997	350	9093					1720	1721		10.1016/S0140-6736(05)63568-4	http://dx.doi.org/10.1016/S0140-6736(05)63568-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL554	9413459				2022-12-01	WOS:A1997YL55400004
J	Stewart, L; Redinbo, MR; Qiu, XY; Hol, WGJ; Champoux, JJ				Stewart, L; Redinbo, MR; Qiu, XY; Hol, WGJ; Champoux, JJ			A model for the mechanism of human topoisomerase I	SCIENCE			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; DNA; SEQUENCE; PROGRAM; ERRORS; MAPS	The three-dimensional structure of a 70-kilodalton amino terminally truncated form of human topoisomerase I in complex with a 22-base pair duplex oligonucleotide, determined to a resolution of 2.8 angstroms, reveals all of the structural elements of the enzyme that contact DNA. The linker region that connects the central core of the enzyme to the carboxyl-terminal domain assumes a coiled-coil configuration and protrudes away from the remainder of the enzyme, The positively charged DNA-proximal surface of the linker makes only a few contacts with the DNA downstream of the cleavage site. In combination with the crystal structures of the reconstituted human topoisomerase before and after DNA cleavage, this information suggests which amino acid residues are involved in catalyzing phosphodiester bond breakage and religation. The structures also lead to the proposal that the topoisomerization step occurs by a mechanism termed "controlled rotation."	Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Sch Med, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Champoux, JJ (corresponding author), Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA.	emerald_biostructures@rocketmail.com; champoux@u.washington.edu			NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156, F32GM016713] Funding Source: NIH RePORTER; NCI NIH HHS [CA65656] Funding Source: Medline; NIGMS NIH HHS [GM16713, GM49156] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Brunger AT, 1993, X PLOR VERSION 3 1 S; CHAMPOUX JJ, IN PRESS PROG NUCL A; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Jensen AD, 1996, EUR J BIOCHEM, V236, P389, DOI 10.1111/j.1432-1033.1996.00389.x; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LEVIN NA, 1993, GENETICS, V133, P799; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; MADDEN KR, 1992, CANCER RES, V52, P525; MCCOUBREY WK, 1986, J BIOL CHEM, V261, P5130; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE JM, 1988, BIOCHEMISTRY-US, V27, P7806, DOI 10.1021/bi00420a033; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; Stivers JT, 1997, BIOCHEMISTRY-US, V36, P5212, DOI 10.1021/bi962880t; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; VLASSI M, 1994, NAT STRUCT BIOL, V1, P706, DOI 10.1038/nsb1094-706; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001	39	599	619	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 6	1998	279	5356					1534	1541		10.1126/science.279.5356.1534	http://dx.doi.org/10.1126/science.279.5356.1534			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488652				2022-12-01	WOS:000072372900065
J	Rinzel, J; Terman, D; Wang, XJ; Ermentrout, B				Rinzel, J; Terman, D; Wang, XJ; Ermentrout, B			Propagating activity patterns in large-scale inhibitory neuronal networks	SCIENCE			English	Article							SYNCHRONIZED OSCILLATIONS; IONIC MECHANISMS; SPINDLE WAVES; IN-VITRO; MODEL; NUCLEUS; GENERATION; NEOCORTEX; THALAMUS; CIRCUITS	The propagation of activity is studied in a spatially structured network model of gamma-aminobutyric acid-containing (GABAergic) neurons exhibiting postinhibitory rebound. In contrast to excitatory-coupled networks, recruitment spreads very slowly because cells fire only after the postsynaptic conductance decays, and with two possible propagation modes. If the connection strength decreases monotonically with distance (on-center), then propagation occurs in a discontinuous manner. If the self-and nearby connections are absent (off-center), propagation can proceed smoothly. Modest changes in the synaptic reversal potential can result in depolarization-mediated waves that are 25 times faster. Functional and developmental roles for these behaviors and implications for thalamic circuitry are suggested.	NIDDKD, Math Res Branch, NIH, Bethesda, MD 20892 USA; Ohio State Univ, Dept Math, Columbus, OH 43210 USA; Brandeis Univ, Ctr Complex Syst, Waltham, MA 02254 USA; Brandeis Univ, Dept Phys, Waltham, MA 02254 USA; Univ Pittsburgh, Dept Math, Pittsburgh, PA 15260 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University System of Ohio; Ohio State University; Brandeis University; Brandeis University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rinzel, J (corresponding author), NYU, Ctr Neural Sci, 4 Washington Pl,Room 809, New York, NY 10003 USA.	rinzel@cns.nyu.edu	Wang, Xiao-Jing/D-2722-2009		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH047150] Funding Source: NIH RePORTER; NIMH NIH HHS [MH53717-01, MH 47150] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BAL T, 1995, J PHYSIOL-LONDON, V483, P665, DOI 10.1113/jphysiol.1995.sp020613; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHERVIN RD, 1988, J NEUROPHYSIOL, V60, P1695, DOI 10.1152/jn.1988.60.5.1695; Destexhe A, 1996, J NEUROPHYSIOL, V76, P2049, DOI 10.1152/jn.1996.76.3.2049; FREUND TF, 1996, HIPPOCAMPUS, V6, P345; Golomb D, 1997, J NEUROPHYSIOL, V78, P1199, DOI 10.1152/jn.1997.78.3.1199; Golomb D, 1996, J NEUROPHYSIOL, V75, P750, DOI 10.1152/jn.1996.75.2.750; KIM U, 1995, J NEUROPHYSIOL, V74, P1301, DOI 10.1152/jn.1995.74.3.1301; Kim U, 1997, SCIENCE, V278, P130, DOI 10.1126/science.278.5335.130; KISVARDAY ZF, 1993, J COMP NEUROL, V327, P398, DOI 10.1002/cne.903270307; LO FS, 1994, EXP BRAIN RES, V100, P365; Marder E, 1996, PHYSIOL REV, V76, P687, DOI 10.1152/physrev.1996.76.3.687; MILES R, 1988, J NEUROPHYSIOL, V60, P1481, DOI 10.1152/jn.1988.60.4.1481; PERKEL DH, 1974, SCIENCE, V185, P181, DOI 10.1126/science.185.4146.181; RINZEL J, UNPUB; Rinzel J., 1989, METHODS NEURONAL MOD, P135; SanchezVives MV, 1997, J NEUROSCI, V17, P8894; SATTERLIE RA, 1985, SCIENCE, V229, P402, DOI 10.1126/science.229.4711.402; Sharp AA, 1996, J NEUROPHYSIOL, V76, P867, DOI 10.1152/jn.1996.76.2.867; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; STALEY KJ, 1995, SCIENCE, V269, P977, DOI 10.1126/science.7638623; STERIADE M, 1984, BRAIN RES REV, V8, P1, DOI 10.1016/0165-0173(84)90017-1; Tamas G, 1997, J NEUROSCI, V17, P6352; TERMAN D, IN PRESS PHYSICA D; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Ulrich D, 1997, J NEUROPHYSIOL, V78, P1748, DOI 10.1152/jn.1997.78.3.1748; Van Vreeswijk C, 1994, J Comput Neurosci, V1, P313; VONKROSIGK M, 1993, SCIENCE, V261, P361, DOI 10.1126/science.8392750; Wagner S, 1997, NATURE, V387, P598, DOI 10.1038/42468; WANG XJ, 1993, NEUROSCIENCE, V53, P899, DOI 10.1016/0306-4522(93)90474-T; WANG XJ, 1992, NEURAL COMPUT, V4, P84, DOI 10.1162/neco.1992.4.1.84; Wang XJ, 1996, J NEUROSCI, V16, P6402; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0	33	110	113	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1351	1355		10.1126/science.279.5355.1351	http://dx.doi.org/10.1126/science.279.5355.1351			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478895				2022-12-01	WOS:000072251800050
J	Broadus, J; Fuerstenberg, S; Doe, CQ				Broadus, J; Fuerstenberg, S; Doe, CQ			Staufen-dependent localization of prospero mRNA contributes to neuroblast daughter-cell fate	NATURE			English	Article							ASYMMETRIC SEGREGATION; NERVOUS-SYSTEM; MOTHER CELLS; DROSOPHILA; PROTEIN; NEUROGENESIS; GENE; EXPRESSION; CORTEX	The generation of cellular diversity is essential in embryogenesis, especially in the central nervous system, During neurogenesis, cell interactions or asymmetric protein localization during mitosis can generate daughter cells with different fates(1-4). Were we describe the asymmetric localization of a messenger RNA and an RNA-binding protein that creates molecular and developmental differences between Drosophila neural precursors (neuroblasts) and their daughter cells, ganglion mother cells (GMCs). The prospero (pros) mRNA and the RNA-binding protein Staufen (Stau) are asymmetrically localized in mitotic neuroblasts and are specifically partitioned into the GMC, as is Pros protein(5-7). Stau is required for localization of pros RNA but not of Pros protein. Loss of localization of Stau or of pros RNA alters GMC development, but only in embryos with reduced levels of Pros protein, suggesting that pros RNA and Pros protein act redundantly to specify GMC fate. We also find that GMCs do not transcribe the pros gene, showing that inheritance of pros RNA and/or Pros protein from the neuroblast is essential for GMC specification.	Univ Illinois, Howard Hughes Med Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA	Howard Hughes Medical Institute; University of Illinois System; University of Illinois Urbana-Champaign	Doe, CQ (corresponding author), Univ Illinois, Howard Hughes Med Inst, Dept Cell & Struct Biol, Urbana, IL 61801 USA.							Bobola N, 1996, CELL, V84, P699, DOI 10.1016/S0092-8674(00)81048-X; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; Broadus J, 1997, CURR BIOL, V7, P827, DOI 10.1016/S0960-9822(06)00370-8; Broadus J, 1995, DEVELOPMENT, V121, P3989; DOE CQ, 1991, CELL, V65, P451, DOI 10.1016/0092-8674(91)90463-9; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Guenther C, 1996, DEVELOPMENT, V122, P3509; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; JAN YN, 1995, NEURON, V14, P1; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Lin HF, 1997, TRENDS GENET, V13, P33, DOI 10.1016/S0168-9525(96)10050-0; Long RM, 1997, SCIENCE, V277, P383, DOI 10.1126/science.277.5324.383; LUNDELL MJ, 1994, BIOTECHNIQUES, V16, P434; MATSUZAKI F, 1992, BIOCHEM BIOPH RES CO, V182, P1326, DOI 10.1016/0006-291X(92)91878-T; MCCONNELL SK, 1995, NEURON, V15, P761, DOI 10.1016/0896-6273(95)90168-X; PATEL NH, 1989, GENE DEV, V3, P890, DOI 10.1101/gad.3.6.890; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Takizawa PA, 1997, NATURE, V389, P90, DOI 10.1038/38015; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8	23	214	222	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					792	795		10.1038/35861	http://dx.doi.org/10.1038/35861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486649				2022-12-01	WOS:000072089500053
J	Tan, S; Richmond, TJ				Tan, S; Richmond, TJ			Crystal structure of the yeast MAT alpha 2/MCM1/DNA ternary complex	NATURE			English	Article							HOMEO DOMAIN PROTEIN; HOMEODOMAIN PROTEINS; REPRESSOR ALPHA-2; DNA-BINDING; SACCHAROMYCES-CEREVISIAE; SECONDARY STRUCTURE; MCM1 PROTEIN; EF-TU; TRANSCRIPTION; OPERATOR	The structure of a complex containing the homeodomain repressor protein MAT alpha 2 and the MADS-box transcription factor MCM1 bound to DNA has been determined by X-ray crystallography at 2.25 Angstrom resolution. It reveals the protein-protein interactions responsible for cooperative binding of MAT alpha 2 and MCM1 to DNA. The otherwise flexible amino-terminal extension of the MAT alpha 2 homeodomain forms a beta-hairpin that grips the MCM1 surface through parallel beta-strand hydrogen bonds and dose-packed, predominantly hydrophobic, side chains. DNA bending induced by MCM1 brings the two proteins closer together, facilitating their interaction. An unusual feature of the complex is that an eight-amino-acid sequence adopts an alpha-helical conformation in one of two copies of the MAT alpha 2 monomer and a beta-strand conformation in the other. This 'chameleon' sequence of MAT alpha 2 may be important for recognizing natural operator sites.	ETH Zurich, Inst Mol Biol & Biophys, ETH Honggerberg, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Richmond, TJ (corresponding author), ETH Zurich, Inst Mol Biol & Biophys, ETH Honggerberg, CH-8093 Zurich, Switzerland.							Abel K, 1996, STRUCTURE, V4, P1153, DOI 10.1016/S0969-2126(96)00123-2; ACTON TB, 1997, MOL CELL BIOL, V17, P1778; ALTHOEFER H, 1995, MOL CELL BIOL, V15, P5917; BRUHN L, 1994, MOL CELL BIOL, V14, P2534, DOI 10.1128/MCB.14.4.2534; BRUNGER AT, 1992, XPLOR 3 1 MANUAL; CHRIST C, 1991, GENE DEV, V5, P751, DOI 10.1101/gad.5.5.751; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HALL MN, 1987, SCIENCE, V237, P1007, DOI 10.1126/science.2887035; JOHNSON AD, 1995, CURR OPIN GENET DEV, V5, P552, DOI 10.1016/0959-437X(95)80022-0; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; KELEHER CA, 1989, MOL CELL BIOL, V9, P5228, DOI 10.1128/MCB.9.11.5228; KOMACHI K, 1994, GENE DEV, V8, P2857, DOI 10.1101/gad.8.23.2857; Kuo MH, 1997, MOL CELL BIOL, V17, P819, DOI 10.1128/MCB.17.2.819; Labeots LA, 1997, J MOL BIOL, V269, P113, DOI 10.1006/jmbi.1997.1026; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LYDALL D, 1991, GENE DEV, V5, P2405, DOI 10.1101/gad.5.12b.2405; MAHER M, 1995, MOL CELL BIOL, V15, P3129; MAK A, 1993, GENE DEV, V7, P1862, DOI 10.1101/gad.7.10.1862; Mead J, 1996, MOL CELL BIOL, V16, P2135; Minor DL, 1996, NATURE, V380, P730, DOI 10.1038/380730a0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PASSMORE S, 1988, J MOL BIOL, V204, P593, DOI 10.1016/0022-2836(88)90358-0; PELLEGRINI L, 1995, NATURE, V376, P490, DOI 10.1038/376490a0; Perutz MF, 1997, NATURE, V385, P773, DOI 10.1038/385773a0; PHILLIPS CL, 1991, GENE DEV, V5, P764, DOI 10.1101/gad.5.5.764; Polekhina G, 1996, STRUCTURE, V4, P1141, DOI 10.1016/S0969-2126(96)00122-0; PRIMIG M, 1991, EMBO J, V10, P4209, DOI 10.1002/j.1460-2075.1991.tb04999.x; SAUER RT, 1988, GENE DEV, V2, P807, DOI 10.1101/gad.2.7.807; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; SMITH DL, 1992, CELL, V68, P133, DOI 10.1016/0092-8674(92)90212-U; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; VERSHON AK, 1993, CELL, V72, P105, DOI 10.1016/0092-8674(93)90054-T; Vershon AK, 1996, CURR OPIN BIOTECH, V7, P392, DOI 10.1016/S0958-1669(96)80113-3; WILSON DS, 1995, CURR BIOL, V5, P32, DOI 10.1016/S0960-9822(95)00010-8; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Wolberger C, 1996, CURR OPIN STRUC BIOL, V6, P62, DOI 10.1016/S0959-440X(96)80096-0; Wright HT, 1996, BIOESSAYS, V18, P453, DOI 10.1002/bies.950180607; WYNNE J, 1992, NUCLEIC ACIDS RES, V20, P3297, DOI 10.1093/nar/20.13.3297; Zhong HL, 1997, J BIOL CHEM, V272, P8402, DOI 10.1074/jbc.272.13.8402	42	191	196	1	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					660	666		10.1038/35563	http://dx.doi.org/10.1038/35563			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490409				2022-12-01	WOS:000071982500042
J	Cohen, AT				Cohen, AT			Prevention of perioperative myocardial ischaemia and its complications	LANCET			English	Editorial Material							NONCARDIAC SURGERY; MORBIDITY		Univ London Kings Coll, Sch Med & Dent, Dept Med, London SE5 9DP, England	University of London; King's College London	Cohen, AT (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Med, London SE5 9DP, England.							*ACC AHA, 1996, CIRCULATION, V93, P1280; Bodenheimer MM, 1996, ANN INTERN MED, V124, P763, DOI 10.7326/0003-4819-124-8-199604150-00010; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1389, DOI 10.1016/0895-4356(94)90083-3; Eagle KA, 1996, NEW ENGL J MED, V335, P1761, DOI 10.1056/NEJM199612053352309; HOLLENBERG M, 1994, AM J CARDIOL, V73, pB30, DOI 10.1016/0002-9149(94)90263-1; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; Mangano DT, 1997, JAMA-J AM MED ASSOC, V277, P325, DOI 10.1001/jama.277.4.325; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Martin E, 1997, ANESTHESIOLOGY, V86, P346; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; Palda VA, 1997, ANN INTERN MED, V127, P309, DOI 10.7326/0003-4819-127-4-199708150-00012	11	5	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					385	386		10.1016/S0140-6736(05)78348-3	http://dx.doi.org/10.1016/S0140-6736(05)78348-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482286				2022-12-01	WOS:000071982600004
J	Cassel, CK; Nelson, EA; Smith, TW; Schwab, CW; Barlow, B; Gary, NE				Cassel, CK; Nelson, EA; Smith, TW; Schwab, CW; Barlow, B; Gary, NE			Internists' and surgeons' attitudes toward guns and firearm injury prevention	ANNALS OF INTERNAL MEDICINE			English	Article							PUBLIC-HEALTH; VIOLENCE PREVENTION; TRAUMA SURGEONS; PEDIATRICIANS; OWNERSHIP; CHILDREN; HANDGUNS; HOMICIDE; AMERICA; SUICIDE	Background: The high rates of death, injury, and longterm disability related to firearms in the United States have led to growing concern in the health care community. Medical organizations and journals are devoting increasing attention to firearm violence as a public health problem; however, few reports discuss physician attitudes toward guns and prevention of firearm-related injury. Objective: To determine internists' and surgeons' attitudes toward guns and firearm injury prevention. Design: Analysis of results of a structured telephone interview. Setting: Internal medicine and surgical offices. Participants: 457 internists and 458 surgeons. Measures: 55 questions that covered six domains: experience with firearms, knowledge about clinical sequelae of firearm injury, knowledge about public policies on firearm violence, attitudes toward public policies on firearm violence, clinical practice behavior, and education and training. Results: The interview response rate was 45.3%, with a compliance rate of 82.5% and a 95% probability (error rate, +/- 5%). Ninety-four percent of internists and 87% of surgeons believe firearm violence is a major public health issue. A majority of internists and surgeons also support community efforts to enact legislation to restrict the possession or sale of handguns (84% and 64%, respectively). Furthermore, although 84% of internists and 72% of surgeons believe that physicians should be involved with firearm injury prevention, less than 20% of respondents usually engage in some form of firearm injury prevention practice in patient care. Conclusion: Many internists and surgeons think that firearm injuries are a public health issue of growing importance, that physicians should incorporate firearm safety screening and counseling into their practice, that physicians should join community efforts to regulate handguns, and that specific gun regulation measures should be adopted as public policy.	Amer Coll Physicians, Res Ctr, Philadelphia, PA 19106 USA; Mt Sinai Med Ctr, Henry L Schwartz Dept Geriatr & Adult Dev, New York, NY 10029 USA; Harlem Hosp Med Ctr, New York, NY 10037 USA; Columbia Univ, Coll Phys & Surg, New York, NY USA; Univ Chicago, Natl Opin Res Ctr, Chicago, IL 60637 USA; Educ Commiss Foreign Med Graduates, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Div Traumatol & Surg Crit Care, Philadelphia, PA 19104 USA	American College of Physicians; Icahn School of Medicine at Mount Sinai; Columbia University; University of Chicago; University of Pennsylvania	Nelson, EA (corresponding author), Amer Coll Physicians, Res Ctr, 6th St & Race, Philadelphia, PA 19106 USA.							ADELSON L, 1992, ARCH SURG-CHICAGO, V127, P171; ADLER KP, 1994, JAMA-J AM MED ASSOC, V271, P1281, DOI 10.1001/jama.271.16.1281; *AM AC PED DEP RES, 1994, ATT COUNS PRACT REG; *AM COLL PHYS, 1991, MED KNOWL SELF ASS P; *AM COLL PHYS, 1994, MED KNOWL SELF ASS P; Ash P, 1996, JAMA-J AM MED ASSOC, V275, P1754, DOI 10.1001/jama.275.22.1754; BARONDESS JA, 1994, JAMA-J AM MED ASSOC, V272, P1409, DOI 10.1001/jama.1994.03520180030025; BATOK GR, 1993, AM J EMERG MED, V11, P678, DOI 10.1016/0735-6757(93)90038-D; BECKMANN CRB, 1994, JAMA-J AM MED ASSOC, V272, P1407, DOI 10.1001/jama.1994.03520180030020; BLACKMAN PH, 1994, JAMA-J AM MED ASSOC, V272, P1406, DOI 10.1001/jama.272.18.1406; Blackman PH, 1996, JAMA-J AM MED ASSOC, V275, P1723, DOI 10.1001/jama.1996.03530460027014; Blumstein A, 1995, J CRIM LAW CRIM, V86, P10, DOI 10.2307/1143998; BROWNING CH, 1976, JAMA-J AM MED ASSOC, V236, P2198, DOI 10.1001/jama.236.19.2198; CHENG TL, 1993, AM J EMERG MED, V11, P183, DOI 10.1016/0735-6757(93)90116-S; CHENG TL, 1993, AM J EMERG MED, V11, P680, DOI 10.1016/0735-6757(93)90039-E; CHING ESH, 1994, JAMA-J AM MED ASSOC, V272, P1407, DOI 10.1001/jama.1994.03520180030021; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; Cook PJ, 1996, JAMA-J AM MED ASSOC, V275, P1765, DOI 10.1001/jama.275.22.1765; CORNWELL EE, 1995, JAMA-J AM MED ASSOC, V273, P1788, DOI 10.1001/jama.273.22.1788; Cummings P, 1997, AM J PUBLIC HEALTH, V87, P974, DOI 10.2105/AJPH.87.6.974; DAVIS JH, 1995, J TRAUMA, V38, P162, DOI 10.1097/00005373-199502000-00002; Eilers R, 1994, N J Med, V91, P859; Eilers R, 1989, N J Med, V86, P875; FARGASON CA, 1995, ARCH PEDIAT ADOL MED, V149, P442, DOI 10.1001/archpedi.1995.02170160096014; Ferguson JS, 1996, JAMA-J AM MED ASSOC, V275, P1724; Giesecke A H, 1993, Tex Med, V89, P7; Hannon E, 1992, Iowa Med, V82, P364; Hargarten SW, 1996, JAMA-J AM MED ASSOC, V275, P1724, DOI 10.1001/jama.1996.03530460027017; Hein H A, 1993, Tex Med, V89, P7; KASSIRER JP, 1991, NEW ENGL J MED, V325, P1647, DOI 10.1056/NEJM199112053252311; KELLERMANN AL, 1992, NEW ENGL J MED, V327, P467, DOI 10.1056/NEJM199208133270705; KELLERMANN AL, 1986, NEW ENGL J MED, V314, P1557, DOI 10.1056/NEJM198606123142406; Kellermann AL, 1997, AM J PUBLIC HEALTH, V87, P910, DOI 10.2105/AJPH.87.6.910; KOOP CE, 1992, JAMA-J AM MED ASSOC, V267, P3075, DOI 10.1001/jama.267.22.3075; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; Mainous AG, 1996, JAMA-J AM MED ASSOC, V275, P1723, DOI 10.1001/jama.1996.03530460027015; Mattix H, 1994, Indiana Med, V87, P8; McFaul R B, 1993, Tex Med, V89, P8; MCGINTY JB, 1996, ORTHOPEDICS TODAY, V16, P3; MCGONIGAL MD, 1993, J TRAUMA, V35, P532, DOI 10.1097/00005373-199310000-00006; MCKAY RD, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030022; MERCY JA, 1988, NEW ENGL J MED, V319, P1283, DOI 10.1056/NEJM198811103191911; NELLSCH V, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030023; ORGAN CH, 1992, ARCH SURG-CHICAGO, V127, P651; OVERMYER M, 1994, PHYSICIANS MANAGEMEN, V34, P20; OVERMYER M, 1994, PHYSICIANS MANAGEMEN, V34, P48; Pratt L, 1995, Wis Med J, V94, P572; REED B, 1994, JAMA-J AM MED ASSOC, V272, P1408, DOI 10.1001/jama.1994.03520180030024; SCHWAB CW, 1995, J TRAUMA, V38, P163; Schwab CW, 1996, J TRAUMA, V40, P671, DOI 10.1097/00005373-199604000-00032; SCHWAB CW, 1993, J TRAUMA, V35, P657, DOI 10.1097/00005373-199311000-00001; SCHWAB CW, 1996, TXB INTERNAL MED, P281; SENTURIA YD, 1994, PEDIATRICS, V93, P469; Senturia YD, 1996, ARCH PEDIAT ADOL MED, V150, P265, DOI 10.1001/archpedi.1996.02170280035006; Sinauer N, 1996, JAMA-J AM MED ASSOC, V275, P1740; SINGH GK, 1996, MONTHLY VITAL STAT S, V45; SLOAN JH, 1988, NEW ENGL J MED, V319, P1256, DOI 10.1056/NEJM198811103191905; Tellez ML, 1996, J TRAUMA, V40, P602, DOI 10.1097/00005373-199604000-00014; TEPAS JJ, 1994, J PEDIATR SURG, V29, P369, DOI 10.1016/0022-3468(94)90352-2; TRUNKEY D, 1995, J TRAUMA, V38, P161, DOI 10.1097/00005373-199502000-00001; Vassar MJ, 1996, JAMA-J AM MED ASSOC, V275, P1734, DOI 10.1001/jama.275.22.1734; WEBSTER DW, 1992, PEDIATRICS, V89, P902; WHITE LJ, 1995, ANN INTERN MED, V122, P311; WIKTOR SZ, 1994, WESTERN J MED, V161, P137; Wintemute GJ, 1996, JAMA-J AM MED ASSOC, V275, P1749, DOI 10.1001/jama.275.22.1749; Zimring FE, 1995, J CRIM LAW CRIM, V86, P1, DOI 10.2307/1143997	66	55	55	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					224	230		10.7326/0003-4819-128-3-199802010-00009	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454531				2022-12-01	WOS:000071703200008
J	Arioli, T; Peng, LC; Betzner, AS; Burn, J; Wittke, W; Herth, W; Camilleri, C; Hofte, H; Plazinski, J; Birch, R; Cork, A; Glover, J; Redmond, J; Williamson, RE				Arioli, T; Peng, LC; Betzner, AS; Burn, J; Wittke, W; Herth, W; Camilleri, C; Hofte, H; Plazinski, J; Birch, R; Cork, A; Glover, J; Redmond, J; Williamson, RE			Molecular analysis of cellulose biosynthesis in Arabidopsis	SCIENCE			English	Article							PLASMA-MEMBRANE ROSETTES; PLANT TRANSFORMATION; ACETOBACTER-XYLINUM; CATALYTIC SUBUNIT; THALIANA; SEQUENCE; SYNTHASE; GENE; GENOME; MAP	Cellulose, an abundant, crystalline polysaccharide, is central to plant morphogenesis and to many industries. Chemical and ultrastructural analyses together with map-based cloning indicate that the RSW1 locus of Arabidopsis encodes the catalytic subunit of cellulose synthase. The cloned gene complements the rsw1 mutant whose temperature-sensitive allele is changed in one amino acid. The mutant allele causes a specific reduction in cellulose synthesis, accumulation of noncrystalline beta-1,4-glucan, disassembly of cellulose synthase, and widespread morphological abnormalities. Microfibril crystallization may require proper assembly of the RSW1 gene product into synthase complexes whereas glucan biosynthesis per se does not.	Australian Natl Univ, Res Sch Biol Sci, Plant Cell Biol Grp, Glycobiol Unit, Canberra, ACT 2601, Australia; Australian Natl Univ, Cooperat Res Ctr Plant Sci, Res Sch Biol Sci, Canberra, ACT 2601, Australia; Grp Limagrain Pacific, Canberra, ACT 2601, Australia; Zellenlehre, D-69120 Heidelberg, Germany; INRA, Biol Cellulaire Lab, F-78026 Versailles, France	Australian National University; Australian National University; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Williamson, RE (corresponding author), Australian Natl Univ, Res Sch Biol Sci, Plant Cell Biol Grp, Glycobiol Unit, POB 475, Canberra, ACT 2601, Australia.	richard@rsbs.anu.edu.au						BASKIN TI, 1992, AUST J PLANT PHYSIOL, V19, P427, DOI 10.1071/PP9920427; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BEVAN M, 1984, NUCLEIC ACIDS RES, V12, P8711, DOI 10.1093/nar/12.22.8711; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; CARPITA NC, 1989, ANAL CARBOHYDRATES G, P157; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; Cutler S, 1997, CURR BIOL, V7, pR108, DOI 10.1016/S0960-9822(06)00050-9; DELMER DP, 1995, PLANT CELL, V7, P987, DOI 10.1105/tpc.7.7.987; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOARES SH, 1991, CARBOHYD RES, V210, P311, DOI 10.1016/0008-6215(91)80131-6; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; HELM DR, 1991, PESTIC BIOCH PHYSL, V39, P93; HERTH W, 1985, PLANTA, V164, P12, DOI 10.1007/BF00391020; HERTH W, 1985, BOTANICAL MICROSCOPY, P285; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; Kawagoe Yasushi, 1997, Plant Physiology (Rockville), V114, P85; KONCZ C, 1992, METHODS ARABIDOPSISR; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Kutish GF, 1996, VIROLOGY, V223, P303, DOI 10.1006/viro.1996.0482; MATTHYSSE AG, 1995, J BACTERIOL, V177, P1069, DOI 10.1128/jb.177.4.1069-1075.1995; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; NEEDS PW, 1993, PHYTOCHEM ANALYSIS, V4, P210, DOI 10.1002/pca.2800040504; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; Saxena IM, 1997, CELLULOSE, V4, P33, DOI 10.1023/A:1018411101036; SAXENA IM, 1990, PLANT MOL BIOL, V15, P673, DOI 10.1007/BF00016118; SAXENA IM, 1995, J BACTERIOL, V177, P1419, DOI 10.1128/jb.177.6.1419-1424.1995; Schmidt R, 1996, PLANT J, V9, P755, DOI 10.1046/j.1365-313X.1996.9050755.x; SCHNEIDER B, 1986, PROTOPLASMA, V131, P142, DOI 10.1007/BF01285036; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; UPDEGRAFF DM, 1969, ANAL BIOCHEM, V32, P420, DOI 10.1016/S0003-2697(69)80009-6; WONG HC, 1990, P NATL ACAD SCI USA, V87, P8130, DOI 10.1073/pnas.87.20.8130	32	624	689	13	151	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					717	720		10.1126/science.279.5351.717	http://dx.doi.org/10.1126/science.279.5351.717			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445479				2022-12-01	WOS:000071731500040
J	Danziger, R				Danziger, R			HIV testing and HIV prevention in Sweden	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Danziger, R (corresponding author), Univ London London Sch Hyg & Trop Med, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.							BLAXHULT A, 1993, AIDS, V7, P1625, DOI 10.1097/00002030-199312000-00013; BLAXHULT A, 1993, HIV ADIS SWEDEN EPID; Faxelid EA, 1997, SOC SCI MED, V44, P1239, DOI 10.1016/S0277-9536(96)00312-7; GIESECKE J, 1991, LANCET, V338, P1096, DOI 10.1016/0140-6736(91)91962-T; Hart GJ, 1996, AIDS, V10, P337, DOI 10.1097/00002030-199603000-00014; HENRIKKSON B, 1992, AIDS IND DEMOCRACIES; *MIN HLTH SOC AFF, 1989, COMM DIS ACT OTH LEG; *NAT I PUBL HLTH, 1996, GET SUR TEST HIV WHY; *STOCKH COUNT COUN, 1995, HIV AIDS PROGR PREV, P34; *SWED I INF DIS CO, 1995, EP ENH ARSR	10	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					293	295		10.1136/bmj.316.7127.293	http://dx.doi.org/10.1136/bmj.316.7127.293			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472518	Green Published			2022-12-01	WOS:000071702100034
J	Lyall, EGH; Stainsby, C; Taylor, GP; Ait-Khaled, M; Bingham, S; Evans, JA; Wright, A; Weber, JN; McClure, MO; Walters, S; Tudor-Williams, G				Lyall, EGH; Stainsby, C; Taylor, GP; Ait-Khaled, M; Bingham, S; Evans, JA; Wright, A; Weber, JN; McClure, MO; Walters, S; Tudor-Williams, G			Review of uptake of interventions to reduce mother to child transmission of HIV by women aware of their HIV status	BRITISH MEDICAL JOURNAL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; ZIDOVUDINE TREATMENT; INFANT	Objectives: To examine the change in uptake of interventions to reduce transmission of HIV from mothers to infants from January 1994 to July 1997. Design: Review of mother-infant pairs who presented for infant diagnosis of HIV infection. Setting: Central London hospital with facilities for diagnosis of infant HIV infection. Subjects: 57 consecutive mother-infant pairs, mainly from central London but also referred from surrounding hospitals. Interventions: Data were collected on mother's country of origin; CD4 count at delivery; plasma HIV RNA copies/ml; made of delivery; antiretroviral therapy; infant feeding; and HIV infection in infants. Main outcome measures: HIV infection of infants. Results: The vertical transmission rate was 12% (7 pairs; 95% confidence interval 3% to 22%). All mothers chose not to breast feed, The caesarean section rate was 53% (30/57). Antiretroviral therapy was taken by 68.5% (39/57) of mother-infant pairs. With antiretroviral therapy or caesarean section, or both, transmission occurred in 6% (0% to 13%) of pairs (3/50), During the 24 months of 1994 and 1995, 21% (4/19) of infants were infected with HIV; 7.9% (3/38) were infected over the 19 months January 1996 to July 1997. The caesarean section rate did not change over these periods. Use of antiretroviral therapy increased from 31.5% (6/19) to 86.8% (33/38) (P < 0.0001). Conclusion: Women with a diagnosis of HIV infection acted to reduce the risk of transmission to their infants. Uptake of antiretroviral therapy increased significantly over time, and the caesarean section rate was persistently high.	St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, London W2 1PG, England; St Marys Hosp, Imperial Coll Sch Med, Dept Genitourinary Med & Communicable Dis, Jefferiss Res Trust Labs, London W2 1PG, England	Imperial College London; Imperial College London	Lyall, EGH (corresponding author), St Marys Hosp, Imperial Coll Sch Med, Dept Paediat, Praed St, London W2 1PG, England.			Stainsby, Chris/0000-0002-8890-9918				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; BLANCHE S, 1997, 4 INT C RETR OPP INF; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1996, UNL AN HIV PREV MON; Fiscus SA, 1996, JAMA-J AM MED ASSOC, V275, P1483, DOI 10.1001/jama.275.19.1483; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; MCCLURE MO, 1995, NATURE, V375, P637, DOI 10.1038/375637a0; *NAT I CHILD HLTH, 1997, PED ACTG PROT 185 EX; Sperling RS, 1996, NEW ENGL J MED, V335, P1621, DOI 10.1056/NEJM199611283352201	9	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					268	270		10.1136/bmj.316.7127.268	http://dx.doi.org/10.1136/bmj.316.7127.268			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472507	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000071702100021
J	Nimnual, AS; Yatsula, BA; Bar-Sagi, D				Nimnual, AS; Yatsula, BA; Bar-Sagi, D			Coupling of Ras and Rac guanosine triphosphatases through the Ras exchanger Sos	SCIENCE			English	Article							TRANSFORMATION; ACTIVATION; PROTEIN; PATHWAY; KINASE; DBL; PLECKSTRIN; EFFECTORS; SEVENLESS; DISTINCT	The Son of Sevenless (Sos) proteins control receptor-mediated activation of Ras by catalyzing the exchange of guanosine diphosphate for guanosine triphosphate on Ras. The NH2-terminal region of Sos contains a Dbl homology (DH) domain in tandem with a pleckstrin homology (PH) domain. In COS-1 cells, the DH domain of Sos stimulated guanine nucleotide exchange on Rac but not Cdc42 in vitro and in vivo. The tandem DH-PH domain of Sos (DH-PH-Sos) was defective in Rac activation but regained Rac stimulating activity when it was coexpressed with activated Ras, Ras-mediated activation of DH-PH-Sos did not require activation of mitogen-activated protein kinase but it was dependent on activation of phosphoinositide 3-kinase. These results reveal a potential mechanism for coupling of Ras and Rac signaling pathways.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Bar-Sagi, D (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NCI NIH HHS [CA09176, CA28146, CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA028146, R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1994, TRENDS ENDOCRIN MET, V5, P165, DOI 10.1016/1043-2760(94)90014-0; BROEK D, COMMUNICATION; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; Michiels F, 1997, J CELL BIOL, V137, P387, DOI 10.1083/jcb.137.2.387; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NIMNUAL A, UNPUB; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RAMEH LE, 1997, J BIOL CHEM, V272, P21999; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YATSULA B, UNPUB; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	30	381	385	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					560	563		10.1126/science.279.5350.560	http://dx.doi.org/10.1126/science.279.5350.560			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438849				2022-12-01	WOS:000071616000046
J	Sullivan, R; Greeley, R; Homan, K; Klemaszewski, J; Belton, MJS; Carr, MH; Chapman, CR; Tufts, R; Head, JW; Pappalardo, R; Moore, J; Thomas, P				Sullivan, R; Greeley, R; Homan, K; Klemaszewski, J; Belton, MJS; Carr, MH; Chapman, CR; Tufts, R; Head, JW; Pappalardo, R; Moore, J; Thomas, P		Galileo Imaging Team	Episodic plate separation and fracture infill on the surface of Europa	NATURE			English	Article								Images obtained by the Voyager spacecraft revealed dark, wedge-shaped bands on Europa that were interpreted as evidence that surface plates, 50-100 km across, moved and rotated relative to each other(1). This implied that they may be mechanically decoupled from the interior by a layer of warm ice or Liquid water(2,3). Here we report similar features seen in higher resolution images (420 metres per pixel) obtained by the Galileo spacecraft that reveal new details of wedge-band formation. In particular, the interior of one dark band shows bilateral symmetry of parallel lineaments and pit complexes which indicates that plate separation occurred in discrete episodes from a central axis. The images also show that this style of tectonic activity involved plates < 10 km across. Although this tectonic style superficially resembles aspects of similar activity on Earth, such as sea-floor spreading and the formation of ice leads in polar seas, there are significant differences in the underlying physical mechanisms: the wedge-shaped bands on Europa most probably formed when lower material (ice or water) rose to fill the fractures that widened in response to regional surface stresses.	Cornell Univ, Ithaca, NY 14853 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA; US Geol Survey, Menlo Pk, CA 94025 USA; SW Res Inst, Boulder, CO 80302 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA	Cornell University; National Optical Astronomy Observatory; United States Department of the Interior; United States Geological Survey; University of Arizona; Brown University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Arizona State University; Arizona State University-Tempe	Sullivan, R (corresponding author), Cornell Univ, 308 Space Sci, Ithaca, NY 14853 USA.		Sullivan, Robert/AAR-8193-2020; Pappalardo, Robert/AAP-8953-2021	Pappalardo, Robert/0000-0003-2571-4627				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; FANALE FP, 1977, PLANETARY SATELLITES, P379; GOLOMBEK MP, 1990, ICARUS, V83, P441, DOI 10.1016/0019-1035(90)90078-N; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SCHENK PM, 1980, EOS T AM GEOPHYS UN, V61, P286; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; TUFTS BR, 1996, LUNAR PLANET SCI, V27, P1343; TUFTS BR, 1993, LUN PLANET SCI C, V24, P1445; TUFTS BR, 1997, LUNAR PLANET SCI C, V28, P1455	13	87	88	0	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					371	373		10.1038/34874	http://dx.doi.org/10.1038/34874			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450752				2022-12-01	WOS:000071604200048
J	Arap, W; Pasqualini, R; Ruoslahti, E				Arap, W; Pasqualini, R; Ruoslahti, E			Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model	SCIENCE			English	Article							PHAGE DISPLAY LIBRARY; INTEGRIN ALPHA(V)BETA(3); SOLID TUMORS; ANGIOGENESIS; PEPTIDE; THERAPY; ANTIBODIES; RECEPTOR; BINDING; LIGAND	In vivo selection of phage display libraries was used to isolate peptides that home specifically to tumor blood vessels. When coupled to the anticancer drug doxorubicin, two of these peptides-one containing an alpha(v) integrin-binding Arg-Gly-Asp motif and the other an Asn-Gly-Arg motif-enhanced the efficacy of the drug against human breast cancer xenografts in nude mice and also reduced its toxicity. These results indicate that it may be possible to develop targeted chemotherapy strategies that are based on selective expression of receptors in tumor vasculature.	Burnham Inst, Ctr Canc Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Ruoslahti, E (corresponding author), Burnham Inst, Ctr Canc Res, N Torrey Pines Rd, La Jolla, CA 92037 USA.	ruoslahti@burnham-inst.org			NATIONAL CANCER INSTITUTE [R01CA062042, P30CA030199, R01CA074238] Funding Source: NIH RePORTER; NCI NIH HHS [CA74238-01, CA62042, CA30199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARAP W, UNPUB; Bauminger S, 1980, Methods Enzymol, V70, P151; Berger DP, 1991, NUDE MOUSE ONCOLOGY, P165; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; BURROWS FJ, 1994, PHARMACOL THERAPEUT, V64, P155, DOI 10.1016/0163-7258(94)90037-X; DENEKAMP J, 1993, BRIT J RADIOL, V66, P181, DOI 10.1259/0007-1285-66-783-181; DVORAK HF, 1991, CANCER CELL-MON REV, V3, P77; Folkman J, 1997, NAT BIOTECHNOL, V15, P510, DOI 10.1038/nbt0697-510; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman Judah, 1997, P3075; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GETTER MR, 1973, NATURE, V246, P221; Hammes HP, 1996, NAT MED, V2, P529, DOI 10.1038/nm0596-529; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; HART SL, 1994, J BIOL CHEM, V269, P12468; HEALY JM, 1995, BIOCHEMISTRY-US, V34, P3948, DOI 10.1021/bi00012a012; JAIN RK, 1996, CANCER METAST REV, V9, P253; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; KOIVUNEN E, 1995, BIO-TECHNOL, V13, P265, DOI 10.1038/nbt0395-265; MARTINYBARON G, 1995, CURR OPIN BIOTECH, V6, P675, DOI 10.1016/0958-1669(95)80111-1; Max R, 1997, INT J CANCER, V71, P320, DOI 10.1002/(SICI)1097-0215(19970502)71:3<320::AID-IJC2>3.3.CO;2-3; Max R, 1997, INT J CANCER, V72, P706, DOI 10.1002/(SICI)1097-0215(19970807)72:4<706::AID-IJC25>3.3.CO;2-T; Nagy A, 1996, P NATL ACAD SCI USA, V93, P7269, DOI 10.1073/pnas.93.14.7269; Pasqualini R, 1997, NAT BIOTECHNOL, V15, P542, DOI 10.1038/nbt0697-542; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; RAJOTTE D, UNPUB; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; SAKAMOTO M, UNPUB; SHOCKLEY TR, 1991, ANN NY ACAD SCI, V618, P367, DOI 10.1111/j.1749-6632.1991.tb27257.x; Steiner R, 1992, EXS, V61, P449	37	1731	1986	8	422	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					377	380		10.1126/science.279.5349.377	http://dx.doi.org/10.1126/science.279.5349.377			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430587				2022-12-01	WOS:000071570800045
J	Bada, JL; Glavin, DP; McDonald, GD; Becker, L				Bada, JL; Glavin, DP; McDonald, GD; Becker, L			A search for endogenous amino acids in martian meteorite ALH84001	SCIENCE			English	Article							MURCHISON METEORITE; GENERATION; HYDROLYSIS; MARS	Trace amounts of glycine, serine, and alanine were detected in the carbonate component of the martian meteorite ALH84001 by high-performance liquid chromatography. The detected amino acids were not uniformly distributed in the carbonate component and ranged in concentration from 0.1 to 7 parts per million. Although the detected alanine consists primarily of the L enantiomer, low concentrations (<0.1 parts per million) of endogenous D-alanine may be present in the ALH84001 carbonates. The amino acids present in this sample of ALH84001 appear to be terrestrial in origin and similar to those in Allan Hills ice, although the possibility cannot be ruled out that minute amounts of some amino acids such as D-alanine are preserved in the meteorite.	Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Univ Hawaii, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); University of Hawaii System	Bada, JL (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	jbada@ucsd.edu	Glavin, Daniel P/D-6194-2012	Glavin, Daniel P/0000-0001-7779-7765				ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; BADA JL, 1995, NATURE, V374, P594, DOI 10.1038/374594a0; Bada JL, 1996, ANAL CHEM, V68, pA668, DOI 10.1021/ac9621231; BADA JL, 1983, NATURE, V301, P494, DOI 10.1038/301494a0; Bada JL, 1997, SCIENCE, V275, P942, DOI 10.1126/science.275.5302.942; Becker L, 1997, GEOCHIM COSMOCHIM AC, V61, P475, DOI 10.1016/S0016-7037(96)00400-0; Brinton KLF, 1996, GEOCHIM COSMOCHIM AC, V60, P349, DOI 10.1016/0016-7037(95)00404-1; BRINTON KLF, IN PRESS ORIGINS LIF; CLEMETT SJ, 1993, SCIENCE, V262, P721, DOI 10.1126/science.262.5134.721; Cronin J R, 1983, Adv Space Res, V3, P5, DOI 10.1016/0273-1177(83)90036-4; Cronin JR, 1997, SCIENCE, V275, P951, DOI 10.1126/science.275.5302.951; D'Hendecourt L., 1997, Astronomical Society of the Pacific Conference Series, V122, P129; ENGEL MH, 1982, NATURE, V296, P837, DOI 10.1038/296837a0; EVANS JCE, 1996, NATURE, V381, P644; GIBSON EK, 1980, P LUNAR PLANET SCI C, V12, P1223; GRADY MM, 1994, METEORITICS, V29, P469; HAHN JH, 1988, SCIENCE, V239, P1523, DOI 10.1126/science.239.4847.1523; Jull AJT, 1998, SCIENCE, V279, P366, DOI 10.1126/science.279.5349.366; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; Kapitsa AP, 1996, NATURE, V381, P684, DOI 10.1038/381684a0; KEIL RG, 1991, MAR CHEM, V33, P243, DOI 10.1016/0304-4203(91)90070-D; KVENVOLDEN K, 1970, NATURE, V228, P923, DOI 10.1038/228923a0; KVENVOLDEN KA, 1971, P NATL ACAD SCI USA, V68, P486, DOI 10.1073/pnas.68.2.486; MACKENZIE AS, 1982, SCIENCE, V217, P491, DOI 10.1126/science.217.4559.491; MCDONALD GD, 1995, GEOCHIM COSMOCHIM AC, V59, P1179, DOI 10.1016/0016-7037(95)00033-V; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MITTLEFEHLDT DW, 1991, GEOCHIM COSMOCHIM AC, V55, P77, DOI 10.1016/0016-7037(91)90401-P; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; OSWALD GKA, 1973, NATURE, V245, P251, DOI 10.1038/245251a0; POLLOCK GE, 1975, GEOCHIM COSMOCHIM AC, V39, P1571, DOI 10.1016/0016-7037(75)90159-3; RAMDAHL T, 1983, NATURE, V306, P580, DOI 10.1038/306580a0; Scott ERD, 1997, NATURE, V387, P377, DOI 10.1038/387377a0; SIMONEIT BRT, 1990, APPL GEOCHEM, V5, P3, DOI 10.1016/0883-2927(90)90031-Y; TREIMAN AH, 1995, METEORITICS, V30, P294, DOI 10.1111/j.1945-5100.1995.tb01127.x; TSUGITA A, 1987, J BIOCHEM-TOKYO, V102, P1593, DOI 10.1093/oxfordjournals.jbchem.a122209; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; ZHAO MX, 1995, J CHROMATOGR A, V690, P55, DOI 10.1016/0021-9673(94)00927-2; ZHAO MX, 1989, NATURE, V339, P463, DOI 10.1038/339463a0	38	137	140	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					362	365		10.1126/science.279.5349.362	http://dx.doi.org/10.1126/science.279.5349.362			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430583				2022-12-01	WOS:000071570800041
J	Lledo, PM; Zhang, XY; Sudhof, TC; Malenka, RC; Nicoll, RA				Lledo, PM; Zhang, XY; Sudhof, TC; Malenka, RC; Nicoll, RA			Postsynaptic membrane fusion and long-term potentiation	SCIENCE			English	Article							CULTURED HIPPOCAMPAL-NEURONS; PROTEIN-PROTEIN INTERACTIONS; SYNAPTIC TRANSMISSION; NEUROMUSCULAR SYNAPSES; SILENT SYNAPSES; LTP; EXPRESSION; MECHANISM; ENDOSOMES; GLUTAMATE	The possibility that membrane fusion events in the postsynaptic cell may be required for the change in synaptic strength resulting from long-term potentiation (LTP) was examined. Introducing substances into the postsynaptic cell that block membrane fusion at a number of different steps reduced LTP. Introducing SNAP, a protein that promotes membrane fusion, into cells enhanced synaptic transmission, and this enhancement was significantly less when generated in synapses that expressed LTP. Thus, postsynaptic fusion events, which could be involved either in retrograde signaling or in regulating postsynaptic receptor function or both, contribute to LTP.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco	Nicoll, RA (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.							BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Calakos N, 1996, PHYSIOL REV, V76, P1; Cash S, 1996, NEURON, V16, P745, DOI 10.1016/S0896-6273(00)80095-1; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Dan Yang, 1994, Current Opinion in Neurobiology, V4, P95, DOI 10.1016/0959-4388(94)90037-X; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; Durand GM, 1996, NATURE, V381, P71, DOI 10.1038/381071a0; ESHHAR N, 1993, NEUROSCIENCE, V57, P943, DOI 10.1016/0306-4522(93)90040-M; FRANKI N, 1995, AM J PHYSIOL-CELL PH, V269, pC797, DOI 10.1152/ajpcell.1995.269.3.C797; GIROD R, 1995, J NEUROSCI, V15, P2826; Glitsch M, 1996, J PHYSIOL-LONDON, V497, P531, DOI 10.1113/jphysiol.1996.sp021786; Goda Y, 1997, P NATL ACAD SCI USA, V94, P769, DOI 10.1073/pnas.94.3.769; HENLEY JW, COMMUNICATION; HUTTNER WB, 1993, NATURE, V365, P104, DOI 10.1038/365104a0; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; JO IH, 1995, P NATL ACAD SCI USA, V92, P1876, DOI 10.1073/pnas.92.6.1876; Kandror KV, 1996, AM J PHYSIOL-ENDOC M, V271, pE1, DOI 10.1152/ajpendo.1996.271.1.E1; LARKMAN AU, 1995, CURR OPIN NEUROBIOL, V5, P324, DOI 10.1016/0959-4388(95)80045-X; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; Maletic-Savatic M. M., 1995, Society for Neuroscience Abstracts, V21, P1743; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MCWILLIAMS JR, 1981, BRAIN RES, V211, P158; MUNDIGL O, 1993, J CELL BIOL, V122, P1207, DOI 10.1083/jcb.122.6.1207; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIAVO G, 1994, ANN NY ACAD SCI, V710, P65, DOI 10.1111/j.1749-6632.1994.tb26614.x; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1993, CELL, V75, P1; TARRANT SB, 1977, TISSUE CELL, V9, P461, DOI 10.1016/0040-8166(77)90006-4; Wan Q, 1997, NATURE, V388, P686, DOI 10.1038/41792; WESTRUM LE, 1962, J COMP NEUROL, V119, P281, DOI 10.1002/cne.901190303; ZIFF EB, COMMUNICATION	38	310	322	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					399	403		10.1126/science.279.5349.399	http://dx.doi.org/10.1126/science.279.5349.399			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430593				2022-12-01	WOS:000071570800051
J	Zhang, WG; Sloan-Lancaster, J; Kitchen, J; Trible, RP; Samelson, LE				Zhang, WG; Sloan-Lancaster, J; Kitchen, J; Trible, RP; Samelson, LE			LAT: The ZAP-70 tyrosine kinase substrate that links T cell receptor to cellular activation	CELL			English	Article							ANTIGEN RECEPTOR; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; ADAPTER PROTEIN; SH2 DOMAINS; GRB2; PHOSPHORYLATION; SLP-76; PHOSPHOPROTEIN; ASSOCIATION	Despite extensive study, several of the major components involved in T cell receptor-mediated signaling remain unidentified. Here we report the cloning of the cDNA for a highly tyrosine-phosphorylated 36-38 kDa protein, previously characterized by its association with Grb2, phospholipase C-gamma 1, and the p85 subunit of phosphoinositide 3-kinase. Deduced amino acid sequence identifies a novel integral membrane protein containing multiple potential tyrosine phosphorylation sites. We show that this protein is phosphorylated by ZAP-70/Syk protein tyrosine kinases leading to recruitment of multiple signaling molecules. Its function is demonstrated by inhibition of T cell activation following overexpression of a mutant form lacking critical tyrosine residues. Therefore, we propose to name the molecule LAT-linker for activation of T cells.	NICHHD, Sect Lymphocyte Signalling, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Zhang, WG (corresponding author), NICHHD, Sect Lymphocyte Signalling, Cell Biol & Metab Branch, NIH, Bethesda, MD 20892 USA.							BUDAY L, 1994, J BIOL CHEM, V269, P9019; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; Chu DH, 1996, EMBO J, V15, P6251, DOI 10.1002/j.1460-2075.1996.tb01015.x; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; GILLILAND LK, 1992, J BIOL CHEM, V267, P13610; HUANG XM, 1995, P NATL ACAD SCI USA, V92, P11618, DOI 10.1073/pnas.92.25.11618; Isakov N, 1996, J BIOL CHEM, V271, P15753, DOI 10.1074/jbc.271.26.15753; JUNE CH, 1990, J IMMUNOL, V144, P1591; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MOTTO DG, 1994, J BIOL CHEM, V269, P21608; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Pao LI, 1997, J IMMUNOL, V158, P2663; PAWSON T, 1993, CURR BIOL, V3, P434, DOI 10.1016/0960-9822(93)90350-W; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; SloanLancaster J, 1997, J EXP MED, V186, P1713, DOI 10.1084/jem.186.10.1713; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Takaki S, 1997, J BIOL CHEM, V272, P14562, DOI 10.1074/jbc.272.23.14562; Trub T, 1997, J BIOL CHEM, V272, P894, DOI 10.1074/jbc.272.2.894; VONHEIJNE G, 1994, MEMBRANE PROTEIN STR, P27; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wu J, 1996, IMMUNITY, V4, P593, DOI 10.1016/S1074-7613(00)80485-9; Zoller KE, 1997, J IMMUNOL, V158, P1650	33	1026	1061	4	39	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					83	92		10.1016/S0092-8674(00)80901-0	http://dx.doi.org/10.1016/S0092-8674(00)80901-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489702	Bronze			2022-12-01	WOS:000071473700010
J	Nogales, E; Wolf, SG; Downing, KH				Nogales, E; Wolf, SG; Downing, KH			Structure of the alpha beta tubulin dimer by electron crystallography	NATURE			English	Article							TAXOL-BINDING-SITE; COLCHICINE-BINDING; EXCHANGEABLE GTP; GUANOSINE TRIPHOSPHATE; BRAIN BETA-1-TUBULIN; AMINO-ACIDS; MICROTUBULE; HYDROLYSIS; LOCALIZATION; PHOTOLABELS	The alpha beta tubulin heterodimer is the structural subunit of microtubules, which are cytoskeletal elements that are essential for intracellular transport and cell division in all eukaryotes. Each tubulin monomer binds a guanine nucleotide, which is non-exchangeable when it is bound in the alpha subunit, or N site, and exchangeable when bound in the beta subunit, or E site. The alpha- and beta-tubulins share 40% amino-acid sequence identity, both exist in several isotype forms, and both undergo a variety of posttranslational modifications'. Limited sequence homology has been found with the proteins FtsZ(2) and Misato(3), which are involved in cell division in bacteria and Drosophila, respectively. Here we present an atomic model of the alpha beta tubulin dimer fitted to a 3.7-Angstrom density map obtained by electron crystallography of zinc-induced tubulin sheets. The structures of alpha- and beta-tubulin are basically identical: each monomer is formed by a core of two beta-sheets surrounded by alpha-helices. The monomer structure is very compact, but can be divided into three functional domains: the amino-terminal domain containing the nucleotide-binding region, an intermediate domain containing the Taxol-binding site, and the carboxy-terminal domain, which probably constitutes the binding surface for motor proteins.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Nogales, E (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA.		WOLF, SHARON G/K-1768-2012	WOLF, SHARON G/0000-0002-5337-5063				ANDREU JM, 1993, CELL MOTIL CYTOSKEL, V26, P1, DOI 10.1002/cm.970260102; Bai RL, 1996, J BIOL CHEM, V271, P12639, DOI 10.1074/jbc.271.21.12639; BURNS RG, 1993, MICROTUBULES, P3; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; DAVIS A, 1994, SCIENCE, V264, P839, DOI 10.1126/science.8171338; DIAZ JF, 1994, J MOL BIOL, V238, P214, DOI 10.1006/jmbi.1994.1282; Fan J, 1996, J MOL BIOL, V259, P325, DOI 10.1006/jmbi.1996.0322; GUERITTEVOEGELEIN F, 1990, ACTA CRYSTALLOGR C, V46, P781, DOI 10.1107/S0108270189009376; HESSE J, 1987, J BIOL CHEM, V262, P15472; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; LINSE K, 1988, J BIOL CHEM, V263, P15205; LITTLE M, 1987, BIOCHIM BIOPHYS ACTA, V912, P28, DOI 10.1016/0167-4838(87)90243-3; LITTLE M, 1985, EMBO J, V4, P51, DOI 10.1002/j.1460-2075.1985.tb02316.x; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Ludvena R. F., 1998, INT REV CYTOL, V178, P207; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; Miklos GLG, 1997, P NATL ACAD SCI USA, V94, P5189, DOI 10.1073/pnas.94.10.5189; MITCHISON TJ, 1993, SCIENCE, V261, P1044, DOI 10.1126/science.8102497; MUKHERJEE A, 1994, J BACTERIOL, V176, P2754, DOI 10.1128/JB.176.9.2754-2758.1994; Nogales E, 1997, J STRUCT BIOL, V118, P119, DOI 10.1006/jsbi.1997.3841; NOGALES E, 1995, NATURE, V375, P424, DOI 10.1038/375424a0; NOGALES E, 1995, J STRUCT BIOL, V115, P199, DOI 10.1006/jsbi.1995.1044; Ponstingl H, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 1, P191; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SHEARWIN KE, 1994, BIOCHEMISTRY-US, V33, P894, DOI 10.1021/bi00170a007; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; VALE RD, 1994, J BIOL CHEM, V269, P23769; Wolf SG, 1996, J MOL BIOL, V262, P485, DOI 10.1006/jmbi.1996.0530	30	1725	1791	4	228	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					199	203		10.1038/34465	http://dx.doi.org/10.1038/34465			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428769				2022-12-01	WOS:000071380900057
J	Miki, H; Sasaki, T; Takai, Y; Takenawa, T				Miki, H; Sasaki, T; Takai, Y; Takenawa, T			Induction of filopodium formation by a WASP-related actin-depolymerizing protein N-WASP	NATURE			English	Article							CDC42; KINASE; RAC; POLYMERIZATION; GTPASES; COFILIN; BRAIN	Cdc42 is a small GTPase of the Rho family which regulates the formation of actin filaments to generate filopodia(1,2). Although there are several proteins such as PAK(3), ACK(4) and WASP (Wiskott-Aldrich syndrome protein)(5) that bind Cdc42 directly, none of these can account for the filopodium formation induced by Cdc42. Here we demonstrate that before it can induce filopodium formation, Cdc42 must bind a WASP-related protein, N-WASP, that is richest in neural tissues(6) but is expressed ubiquitously. N-WASP induces extremely long actin microspikes only when coexpressed with active Cdc42, whereas WASP, which is expressed in haematopoietic cells, does not, despite the structural similarities between WASP and N-WASP. In a cell-free system, addition of active Cdc42 significantly stimulates the actin-depolymerizing activity of N-WASP, creating free barbed ends from which actin polymerization can then take place. This activation seems to be caused by exposure of N-WASP's actin-depolymerizing region induced by Cdc42 binding.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan; Osaka Univ, Sch Med, Dept Mol Biol & Biochem, Osaka 565, Japan	University of Tokyo; Osaka University	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Shirokanedai 4-6-1, Tokyo 108, Japan.							AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; ASPENSTROM P, 1996, CURR BIOL, V15, P5725; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; FUKUOKAM, 1997, GENE, V196, P43; Komuro R, 1996, GENES CELLS, V1, P943, DOI 10.1046/j.1365-2443.1996.760276.x; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; NISHIDA E, 1984, BIOCHEMISTRY-US, V23, P5307, DOI 10.1021/bi00317a032; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8	15	553	560	1	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					93	96		10.1038/34208	http://dx.doi.org/10.1038/34208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422512				2022-12-01	WOS:000071326100056
J	Albrecht, U; Sun, ZS; Eichele, G; Lee, CC				Albrecht, U; Sun, ZS; Eichele, G; Lee, CC			A differential response of two putative mammalian circadian regulators, mper1 and mper2, to light	CELL			English	Article							SUPRACHIASMATIC NUCLEUS; DROSOPHILA PERIOD; BEHAVIORAL RHYTHMS; MESSENGER-RNA; CLOCK; PROTEIN; GENE; RAT; TIMELESS; DOMAIN	A mouse gene, mper1, having all the properties expected of a circadian clock gene, was reported recently. This gene is expressed in a circadian pattern in the suprachiasmatic nucleus (SCN). mper1 maintains this pattern of circadian expression in constant darkness and can be entrained to a new light/dark cycle. Here we report the isolation of a second mammalian gene, mper2, which also has these properties and greater homology to Drosophila period. Expression of mper1 and mper2 is overlapping but asynchronous by 4 hr. mper1, unlike period and mper2, is expressed rapidly after exposure to light at CT22. It appears that mper1 is the pacemaker component which responds to light and thus mediates photic entrainment.	Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Verna & Marrs Mclean Dept Biochem, Houston, TX 77030 USA; Max Planck Inst Expt Endocrinol, D-30625 Hannover, Germany	Baylor College of Medicine; Baylor College of Medicine; Max Planck Society	Lee, CC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.		Jansen, Heiko T./A-5770-2008; Sun, Zhongsheng/AAS-4883-2020; Albrecht, Urs/A-9831-2011	Jansen, Heiko T./0000-0003-0178-396X; Sun, Zhongsheng/0000-0002-7640-5026; Albrecht, Urs/0000-0002-0663-8676				Albrecht U, 1997, MOL CELLULAR METHODS, P23; Albrecht U., 1998, HUMAN GENOME METHODS, P93; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; ASCHOFF J, 1969, AEROSPACE MED, V40, P844; BARGIELLO TA, 1984, NATURE, V312, P752, DOI 10.1038/312752a0; CARD JP, 1991, SUPRACHIASMATIC NUCL, P51; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DING JM, 1994, SCIENCE, V266, P1713, DOI 10.1126/science.7527589; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; HALL JC, 1993, P NATL ACAD SCI USA, V90, P5382, DOI 10.1073/pnas.90.12.5382; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; HALL JC, 1990, ANNU REV GENET, V24, P659; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HASTINGS MH, 1995, CIBA F SYMP, V183, P175; HENDRICKSON AE, 1972, Z ZELLFORSCH MIK ANA, V135, P1, DOI 10.1007/BF00307084; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; JOHNSON RF, 1988, BRAIN RES, V462, P301, DOI 10.1016/0006-8993(88)90558-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; LINDEBRO MC, 1995, EMBO J, V14, P3528, DOI 10.1002/j.1460-2075.1995.tb07359.x; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MOORE RY, 1972, J COMP NEUROL, V146, P1, DOI 10.1002/cne.901460102; MOORE RY, 1995, CIBA F SYMP, V183, P88; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REPPERT SM, 1995, NEURON, V15, P983, DOI 10.1016/0896-6273(95)90086-1; Sambrook J., 1989, MOL CLONING LAB MANU; SAUNDERS DS, 1994, J INSECT PHYSIOL, V40, P957, DOI 10.1016/0022-1910(94)90134-1; SCHWARTZ WJ, 1995, SEMIN NEUROSCI, V7, P53, DOI 10.1016/1044-5765(95)90017-9; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIWICKI KK, 1992, J NEUROGENET, V8, P33, DOI 10.3109/01677069209167270; SMITH RF, 1992, PROTEIN ENG, V5, P35, DOI 10.1093/protein/5.1.35; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	44	707	721	1	30	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1055	1064		10.1016/S0092-8674(00)80495-X	http://dx.doi.org/10.1016/S0092-8674(00)80495-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428527	Bronze			2022-12-01	WOS:000071281400021
J	McNagny, SE; Wenger, NK; Frank, E				McNagny, SE; Wenger, NK; Frank, E			Personal use of postmenopausal hormone replacement therapy by women physicians in the United States	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENT OSTEOPOROSIS; ESTROGEN REPLACEMENT; ATTITUDES; DISEASE	Background: Women physicians' use of postmenopausal hormone replacement therapy (HRT) is unknown. Objective: To study use of HRT by women physicians in the United States. Design: Stratified random-sample mail survey. Setting: United States. Participants: 1466 postmenopausal women U.S. physicians in the Women Physicians' Health Study. Measurements: Self-reported personal use of HRT and information on demographic, professional, and behavioral characteristics and medical history. Results: Overall, 47.4% of participants currently use HRT; the prevalence of use is 59.8% in women 40 to 49 years of age, 49.4% in women 50 to 59 years of age, and 36.4% in women 60 to 70 years of age (P < 0.001). In an adjusted logistic regression model, current users were significantly more likely to be gynecologists, to be younger, to be white, to be sexually active, to be previous users of oral contraceptives, to live in Pacific or Mountain states, to have had a hysterectomy, and to have no personal or family history of breast cancer. Conclusions: Women physicians have a higher rate of HRT use than that reported in cross-sectional U.S. surveys. This may presage greater use of HRT for U.S. women in the future.	Emory Univ, Sch Med, Div Gen Med, Atlanta, GA 30303 USA	Emory University	McNagny, SE (corresponding author), Emory Univ, Sch Med, Div Gen Med, 69 Butler St, Atlanta, GA 30303 USA.			Frank, Erica/0000-0001-7159-5417	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007034] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32-HL-07034] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barrett-Connor E., 1995, J WOMENS HEALTH, V4, P143; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; *COMM TECHN B AM C, 1992, ACOG TECHN B, V166, P1; Frank E, 1995, J Am Med Womens Assoc (1972), V50, P64; Frank E, 1997, WESTERN J MED, V166, P179; FRANK E, 1995, PREV MED, V24, P543, DOI 10.1006/pmed.1995.1086; FRANK E, IN PRESS ARCH INTERN; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENDALE GA, 1990, J GEN INTERN MED, V5, P464, DOI 10.1007/BF02600870; GRISSO JA, 1990, J BONE MINER RES, V5, P213, DOI 10.1002/jbmr.5650050303; Handa VL, 1996, J AM GERIATR SOC, V44, P1; HEMMINKI E, 1991, DICP ANN PHARMAC, V25, P418, DOI 10.1177/106002809102500416; ISAACS AJ, 1995, BRIT MED J, V311, P1399, DOI 10.1136/bmj.311.7017.1399; NELSON DE, 1994, JAMA-J AM MED ASSOC, V271, P1273, DOI 10.1001/jama.271.16.1273; ODDENS BJ, 1992, MATURITAS, V15, P171, DOI 10.1016/0378-5122(92)90200-N; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; *RES TRIANGL I, 1996, SUDAAN US MAN VERS 6; WYSOWSKI DK, 1995, OBSTET GYNECOL, V85, P6, DOI 10.1016/0029-7844(94)00339-F; [No title captured]	19	48	48	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1093	1096		10.7326/0003-4819-127-12-199712150-00007	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412312				2022-12-01	WOS:000070936600006
J	Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA				Mayne, S; Parker, JH; Harden, TA; Dodds, SD; Beale, JA			Rate of RhD sensitisation before and after implementation of a community based antenatal prophylaxis programme	BRITISH MEDICAL JOURNAL			English	Article									Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England	University of Nottingham	Mayne, S (corresponding author), Derby City Gen Hosp, Blood Bank, Derby DE22 3NE, England.							[Anonymous], 1991, PRESCRIBERS J, V1, P137; HUCHET J, 1987, Journal de Gynecologie Obstetrique et biologie de la Reproduction, V16, P101; LETSKY EA, 1994, BRIT MED J, V309, P213, DOI 10.1136/bmj.309.6949.213; RAAFAT A, 1996, TRANSFUSION MED S2, V6, P26; TOVEY LAD, 1983, LANCET, V2, P244	5	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1588	1588		10.1136/bmj.315.7122.1588	http://dx.doi.org/10.1136/bmj.315.7122.1588			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437277	Green Published			2022-12-01	WOS:000071021900024
J	Rogan, MT; Staubli, UV; LeDoux, JE				Rogan, MT; Staubli, UV; LeDoux, JE			Fear conditioning induces associative long-term potentiation in the amygdala	NATURE			English	Article							NEURONAL TRANSMISSION; BRAIN TEMPERATURE; EVOKED-POTENTIALS; HIPPOCAMPUS; BEHAVIOR; NMDA; RAT; RECORDINGS; RESPONSES; RECEPTORS	Long-term potentiation (LTP) is an experience-dependent form of neural plasticity believed to involve mechanisms that underlie memory formation(1-3). Lip has been studied most extensively in the hippocampus, but the relation between hippocampal Lip and memory has been difficult to establish(4-6). Here we explore the relation between LTP and memory in fear conditioning, an amygdala-dependent form of learning in which an innocuous conditioned stimulus (CS) elicits fear responses after being associatively paired with an aversive unconditioned stimulus (US). We have previously shown that Lip induction in pathways that transmit auditory CS information to the lateral nucleus of the amygdala (LA) increases auditory-evoked field potentials in this nucleus(7). Now we show that fear conditioning alters auditory CS-evoked responses in LA in the same way as Lip induction, The changes parallel the acquisition of CS-elicited fear behaviour, are enduring, and do not occur if the CS and US remain unpaired. LTP-like associative processes thus occur during fear conditioning, and these may underlie the long-term associative plasticity that constitutes memory of the conditioning experience.			Rogan, MT (corresponding author), NYU,CTR NEURAL SCI,6 WASHINGTON PL,NEW YORK,NY 10003, USA.							BARNES CA, 1995, NEURON, V15, P751, DOI 10.1016/0896-6273(95)90166-3; BLANCHAR.RJ, 1969, J COMP PHYSIOL PSYCH, V68, P129, DOI 10.1037/h0027676; BLANCHARD RJ, 1969, J COMP PHYSIOL PSYCH, V67, P370, DOI 10.1037/h0026779; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLLES RC, 1980, BEHAV BRAIN SCI, V3, P291, DOI 10.1017/S0140525X0000491X; BOUTON ME, 1980, ANIM LEARN BEHAV, V8, P429, DOI 10.3758/BF03199629; BROWN TH, 1994, MODELS NEURAL NETWOR, V2, P287; BUZSAKI G, 1981, BRAIN RES, V225, P235, DOI 10.1016/0006-8993(81)90833-7; DEADWYLER SA, 1985, BEHAV NEURAL BIOL, V44, P201, DOI 10.1016/S0163-1047(85)90198-0; EICHENBAUM H, 1995, NATURE, V378, P131, DOI 10.1038/378131a0; Farb CR, 1997, SYNAPSE, V27, P106, DOI 10.1002/(SICI)1098-2396(199710)27:2<106::AID-SYN2>3.3.CO;2-F; Gewirtz JC, 1997, NATURE, V388, P471, DOI 10.1038/41325; Jeffery KJ, 1997, HIPPOCAMPUS, V7, P95; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; LEUNG LS, 1980, BRAIN RES, V198, P95; LI XF, 1995, EXP BRAIN RES, V105, P87; Li XF, 1996, LEARN MEMORY, V3, P229, DOI 10.1101/lm.3.2-3.229; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; Maren S, 1996, BEHAV NEUROSCI, V110, P1365, DOI 10.1037/0735-7044.110.6.1365; MISERENDINO MJD, 1990, NATURE, V345, P716, DOI 10.1038/345716a0; MOSER E, 1993, SCIENCE, V259, P1324, DOI 10.1126/science.8446900; MOSER EI, 1994, LEARN MEMORY, V1, P55; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; QUIRK GJ, 1995, NEURON, V15, P1029, DOI 10.1016/0896-6273(95)90092-6; Rogan M. T., 1995, Society for Neuroscience Abstracts, V21, P1930; ROGAN MT, 1995, NEURON, V15, P127, DOI 10.1016/0896-6273(95)90070-5; Rogan MT, 1997, J NEUROSCI, V17, P5928; SKELTON RW, 1987, J NEUROSCI, V7, P3081; STAUBLI UV, 1995, BRAIN MEMORY MODULAT, P303; WINSON J, 1978, J NEUROPHYSIOL, V41, P716, DOI 10.1152/jn.1978.41.3.716	30	952	969	3	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					604	607		10.1038/37601	http://dx.doi.org/10.1038/37601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403688				2022-12-01	WOS:A1997YK85300048
J	Magnaghi-Jaulin, L; Groisman, R; Naguibneva, I; Robin, P; Lorain, S; Le Villain, JP; Troalen, F; Trouche, D; Harel-Bellan, A				Magnaghi-Jaulin, L; Groisman, R; Naguibneva, I; Robin, P; Lorain, S; Le Villain, JP; Troalen, F; Trouche, D; Harel-Bellan, A			Retinoblastoma protein represses transcription by recruiting a histone deacetylase	NATURE			English	Article							GENE-PRODUCT; E2F; INTERACT; BINDING; MOTIF; PRB	The retinoblastoma tumour-suppressor protein Rb-1 inhibits cell proliferation by repressing a subset of genes that are controlled by the E2F family of transcription factors(2) and which are involved in progression from the G1 to the S phase of the cell cycle, Rb, which is recruited to target promoters by E2F1 (ref. 3), represses transcription by masking the E2F1 transactivation domain(4) and by inhibiting surrounding enhancer elements(5-8), an active repression that could be crucial for the proper control of progression through the cell cycle(9). Some transcriptional regulators act by acetylating or deacetylating the tails protruding from the core histones(10), thereby modulating the local structure of chromatin: for example, some transcriptional repressors function through the recruitment of histone deacetylases(11). We show here that the histone deacetylase HDAC1 physically interacts and cooperates with Rb, In HDAC1, the sequence involved is an LXCXE motif, similar to that used by viral transforming proteins to contact Rb, Our results strongly suggest that the Rb/HDAC1 complex is a key element in the control of cell proliferation and differentiation and that it is a likely target for transforming viruses.	CNRS UPR 9079, Lab Oncogenese Differciat & Transduct Signal, IFC 1, F-94801 Villejuif, France; Inst Gustave Roussy, CNRS URA 1156, F-94805 Villejuif, France; Inst Gustave Roussy, Unite Marqueurs Biol & Mol, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; UNICANCER; Gustave Roussy	Harel-Bellan, A (corresponding author), CNRS UPR 9079, Lab Oncogenese Differciat & Transduct Signal, IFC 1, F-94801 Villejuif, France.	ahbellan@vjf.cnrs.fr	Trouche, Didier/B-2854-2008; Harel-Bellan, Annick/M-9795-2015	Lorain, Stephanie/0000-0001-5266-9994; Naguibneva, Irina/0000-0001-9566-6152; Harel-Bellan, Annick/0000-0002-2339-153X; Trouche, Didier/0000-0003-1398-6481; Groisman, Sonia/0000-0003-1153-3841; Groisman, Regina/0000-0003-3990-7622				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Chow KNB, 1996, MOL CELL BIOL, V16, P4862; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Groisman R, 1996, J BIOL CHEM, V271, P5258; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NEVINS JR, 1992, SCIENCE, V258, P424; PAZINMJ, 1997, CELL, V89, P325; Tauton J, 1996, SCIENCE, V272, P408; Taya Y, 1997, TRENDS BIOCHEM SCI, V22, P14, DOI 10.1016/S0968-0004(96)10070-0; TROUCHE D, 1997, P NATL ACAD SCI USA, V94, P11295; TURNER BM, 1991, J CELL SCI, V99, P13; WEINBERG RA, 1992, CANCER SURV, V12, P43; Weinberg RA, 1996, CELL, V85, P457, DOI 10.1016/S0092-8674(00)81244-1; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Wolffe AP, 1996, CELL, V84, P817, DOI 10.1016/S0092-8674(00)81059-4; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zacksenhaus E, 1996, EMBO J, V15, P5917, DOI 10.1002/j.1460-2075.1996.tb00978.x; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	30	770	789	2	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	1998	391	6667					601	605		10.1038/35410	http://dx.doi.org/10.1038/35410			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468140				2022-12-01	WOS:000071842300056
J	Grotewiel, MS; Beck, CDO; Wu, KH; Zhu, XR; Davis, RL				Grotewiel, MS; Beck, CDO; Wu, KH; Zhu, XR; Davis, RL			Integrin-mediated short-term memory in Drosophila	NATURE			English	Article							APLYSIA SENSORY NEURONS; MUSHROOM BODIES; TRANSMITTER RELEASE; PREFERENTIAL EXPRESSION; PROTEIN-SYNTHESIS; GENE; FACILITATION; MODULATION; POTENTIATION; INDUCTION	Volado is a new memory mutant of Drosophila. the locus encodes two isoforms of a new a-integrin, a molecule that dynamically mediates cell adhesion and signal transduction. The Volado gene is expressed preferentially in mushroom body cells, which are neurons known to mediate olfactory learning in insects. Volado proteins are concentrated in the mushroom body neuropil, brain areas that contain mushroom body processes in synaptic contact with other neurons. Volado mutants display impaired olfactory memories within 3 min of training, indicating that the integrin is required for short-term memory processes. Conditional expression of a Volado transgene during adulthood rescues the memory impairment. This rescue of memory is reversible, fading over time along with expression of the transgene. Thus the Volado integrin is essential for the physiological processes underlying memory. We propose a model in which integrins act as dynamic regulators of synapse structure or the signalling events underlying short-term memory formation.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Davis, RL (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	rdavis@bcm.tmc.edu	Grotewiel, Mike/AAX-4094-2020; Davis, Ronald/J-4998-2013	Grotewiel, Mike/0000-0001-7302-3252; Davis, Ronald/0000-0002-5986-7608				ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; Bahr BA, 1997, J NEUROSCI, V17, P1320; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BAUSENWEIN B, 1994, J COMP NEUROL, V340, P255, DOI 10.1002/cne.903400210; Byrne John H., 1993, V27, P47; CHEN BM, 1995, SCIENCE, V269, P1578, DOI 10.1126/science.7667637; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Davis RL, 1996, PHYSIOL REV, V76, P299, DOI 10.1152/physrev.1996.76.2.299; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; Davis RL, 1996, CURR BIOL, V6, P146, DOI 10.1016/S0960-9822(02)00447-5; DEDHAR S, 1994, TRENDS BIOCHEM SCI, V19, P269, DOI 10.1016/0968-0004(94)90001-9; DIAMOND MS, 1994, CURR BIOL, V4, P506, DOI 10.1016/S0960-9822(00)00111-1; FEANY MB, 1995, SCIENCE, V268, P869, DOI 10.1126/science.7754370; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; GRANT SGN, 1994, TRENDS NEUROSCI, V17, P71, DOI 10.1016/0166-2236(94)90077-9; Han KA, 1996, NEURON, V16, P1127, DOI 10.1016/S0896-6273(00)80139-7; Han PL, 1996, J NEUROBIOL, V31, P88, DOI 10.1002/(SICI)1097-4695(199609)31:1<88::AID-NEU8>3.0.CO;2-B; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; Hing ALY, 1996, J NEUROBIOL, V30, P454; HUSTON JP, 1995, BEHAV BRAIN RES, V66, P117, DOI 10.1016/0166-4328(94)00132-Y; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jones LS, 1996, TRENDS NEUROSCI, V19, P68; KRETSINGER RH, 1980, CRC CR REV BIOCH MOL, V8, P119, DOI 10.3109/10409238009105467; Lindman H. R., 1992, ANAL VARIANCE EXPT D; MELLO CV, 1995, J NEUROBIOL, V26, P145, DOI 10.1002/neu.480260112; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHACHER S, 1988, SCIENCE, V240, P1667, DOI 10.1126/science.2454509; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; SKOULAKIS EMC, 1996, NEURON, V17, P951; STAUBLI U, 1990, BEHAV NEURAL BIOL, V53, P1, DOI 10.1016/0163-1047(90)90712-F; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZHANG SD, 1995, P NATL ACAD SCI USA, V92, P5525, DOI 10.1073/pnas.92.12.5525; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; ZHUO M, 1994, NATURE, V368, P635, DOI 10.1038/368635a0	42	232	243	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					455	460		10.1038/35079	http://dx.doi.org/10.1038/35079			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461212				2022-12-01	WOS:000071701800040
J	Beitel, A				Beitel, A			A moment of clarity	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					256	256		10.1001/jama.279.4.256	http://dx.doi.org/10.1001/jama.279.4.256			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450692				2022-12-01	WOS:000071607000001
J	Jones, SM; Howell, KE; Henley, JR; Cao, H; McNiven, MA				Jones, SM; Howell, KE; Henley, JR; Cao, H; McNiven, MA			Role of dynamin in the formation of transport vesicles from the trans-Golgi network	SCIENCE			English	Article							TEMPERATURE-SENSITIVE MUTANT; GTP-BINDING PROTEINS; DROSOPHILA-MELANOGASTER; REVERSIBLE BLOCKAGE; MEMBRANE RETRIEVAL; ENDOCYTOSIS; SHIBIRE; MUTATIONS; FAMILY; FORMS	Dynamin guanosine triphosphatases support the scission of clathrin-coated vesicles from the plasmalemma during endocytosis. By fluorescence microscopy of cultured rat hepatocytes, a green fluorescent protein-dynamin II fusion protein localized with clathrin-coated vesicles at the Golgi complex. A cell-free assay was utilized to demonstrate the role of dynamin in vesicle formation at the trans-Golgi. Addition of peptide-specific anti-dynamin antibodies to the assay mixture inhibited both constitutive exocytic and clathrin-coated vesicle formation. Immunodepletion of dynamin proteins also inhibited vesicle formation, and budding efficiency was restored upon readdition of purified dynamin. These data suggest that dynamin participates in the formation of distinct transport vesicles from the trans-Golgi network.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Rochester, MN 55905 USA; Univ Colorado, Sch Med, Dept Cellular & Struct Biol, Denver, CO 80262 USA	Mayo Clinic; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McNiven, MA (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, 200 1st St SW, Rochester, MN 55905 USA.		Henley, John/D-7171-2011		NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK034914] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-46934] Funding Source: Medline; NIDDK NIH HHS [P30 DK-34914] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CAO H, UNPUB; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; Cook T, 1996, J NEUROCHEM, V67, P927; COOK TA, 1994, P NATL ACAD SCI USA, V91, P644, DOI 10.1073/pnas.91.2.644; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; DAMKE H, 1995, J CELL BIOL, V131, P69, DOI 10.1083/jcb.131.1.69; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; Henley JR, 1996, J CELL BIOL, V133, P761, DOI 10.1083/jcb.133.4.761; HENLEY JR, IN PRESS J CELL BIOL; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; JONES M, 1997, J CELL BIOL, V139, P339; JONES SM, 1997, CELL BIOL LAB HDB, V2, P12; JONES SM, UNPUB; KELLY RB, 1995, NATURE, V374, P116, DOI 10.1038/374116a0; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; KOSAKA T, 1983, J CELL BIOL, V97, P499, DOI 10.1083/jcb.97.2.499; Maier O, 1996, BIOCHEM BIOPH RES CO, V223, P229, DOI 10.1006/bbrc.1996.0876; NAKATA T, 1993, J CELL SCI, V105, P1; OBAR RA, 1990, NATURE, V347, P256, DOI 10.1038/347256a0; POODRY CA, 1990, DEV BIOL, V138, P464, DOI 10.1016/0012-1606(90)90212-2; Roos J, 1997, TRENDS CELL BIOL, V7, P257, DOI 10.1016/S0962-8924(97)01068-4; SALAMERO J, 1990, P NATL ACAD SCI USA, V87, P7717, DOI 10.1073/pnas.87.19.7717; SCAIFE R, 1994, EMBO J, V13, P2574, DOI 10.1002/j.1460-2075.1994.tb06547.x; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SZTUL ES, 1985, J CELL BIOL, V100, P1255, DOI 10.1083/jcb.100.4.1255; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Urrutia R, 1997, P NATL ACAD SCI USA, V94, P377, DOI 10.1073/pnas.94.2.377; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553	31	262	264	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					573	577		10.1126/science.279.5350.573	http://dx.doi.org/10.1126/science.279.5350.573			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438853				2022-12-01	WOS:000071616000050
J	Kidd, T; Brose, K; Mitchell, KJ; Fetter, RD; Tessier-Lavigne, M; Goodman, CS; Tear, G				Kidd, T; Brose, K; Mitchell, KJ; Fetter, RD; Tessier-Lavigne, M; Goodman, CS; Tear, G			Roundabout controls axon crossing of the CNS midline and defines a novel subfamily of evolutionarily conserved guidance receptors	CELL			English	Article							GROWTH CONE GUIDANCE; C-ELEGANS; GENETIC-ANALYSIS; FASCICLIN-I; COLORECTAL-CANCER; COMMISSURAL AXONS; TYROSINE KINASE; SPINAL-CORD; NETRIN CUES; DROSOPHILA	The robe gene in Drosophila was identified in a large-scale mutant screen for genes that control the decision by axons to cross the CNS midline. In robe mutants, too many axons cross and recross the midline. Here we show that robe encodes an axon guidance receptor that defines a novel subfamily of immunoglobulin superfamily proteins that is highly conserved from fruit flies to mammals. For those axons that never cross the midline, Robe is expressed on their growth cones from the outset; for the majority of axons that do cross the midline, Robe is expressed at high levels on their growth cones only after they cross the midline. Transgenic rescue experiments reveal that Robe can function in a cell-autonomous fashion. Robe appears to function as the gatekeeper controlling midline crossing.	Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Anat, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biochem, London SW7 2AZ, England	Howard Hughes Medical Institute; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Imperial College London	Kidd, T (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.		Kidd, Thomas/AAT-9993-2020; Tear, Guy/C-5444-2009	Kidd, Thomas/0000-0001-7190-4208; Mitchell, Kevin/0000-0002-3433-4530	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018366] Funding Source: NIH RePORTER; NINDS NIH HHS [NS18366] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTMAN J, 1984, ADV ANAT EMBRYOL CEL, V85, P1; BASTIANI MJ, 1987, CELL, V48, P745, DOI 10.1016/0092-8674(87)90072-9; BRAND AH, 1993, DEVELOPMENT, V118, P401; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; ELKINS T, 1990, CELL, V60, P565, DOI 10.1016/0092-8674(90)90660-7; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; GERTLER FB, 1995, GENE DEV, V9, P521, DOI 10.1101/gad.9.5.521; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Kang JS, 1997, J CELL BIOL, V138, P203, DOI 10.1083/jcb.138.1.203; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MYERS PZ, 1993, J NEUROSCI, V13, P127; NIEKBUHR K, 1997, EMBO J, V16, P5433; Patel N, 1994, METHODS CELL BIOL, V44; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; TAMKUN JW, 1992, CELL, V68, P561, DOI 10.1016/0092-8674(92)90191-E; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Tear G, 1993, Perspect Dev Neurobiol, V1, P183; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZINN K, 1988, CELL, V53, P577, DOI 10.1016/0092-8674(88)90574-0	32	704	733	0	20	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					205	215		10.1016/S0092-8674(00)80915-0	http://dx.doi.org/10.1016/S0092-8674(00)80915-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458045	Bronze			2022-12-01	WOS:000071672600010
J	Carr, MH; Belton, MJS; Chapman, CR; Davies, AS; Geissler, P; Greenberg, R; McEwen, AS; Tufts, BR; Greeley, R; Sullivan, R; Head, JW; Pappalardo, RT; Klaasen, KP; Johnson, TV; Kaufman, J; Senske, D; Moore, J; Neukum, G; Schubert, G; Burns, JA; Thomas, P; Veverka, J				Carr, MH; Belton, MJS; Chapman, CR; Davies, AS; Geissler, P; Greenberg, R; McEwen, AS; Tufts, BR; Greeley, R; Sullivan, R; Head, JW; Pappalardo, RT; Klaasen, KP; Johnson, TV; Kaufman, J; Senske, D; Moore, J; Neukum, G; Schubert, G; Burns, JA; Thomas, P; Veverka, J			Evidence for a subsurface ocean on Europa	NATURE			English	Article							GALILEAN SATELLITES; ICE SHELL	Ground-based spectroscopy of Jupiter's moon Europa, combined with gravity data, suggests that the satellite has an icy crust roughly 150 km thick and a rocky interior(1-4). In addition, images obtained by the voyager spacecraft revealed that Europa's surface is crossed by numerous intersecting ridges and dark bands (called lineae) and is sparsely cratered, indicating that the terrain is probably significantly younger than that of Ganymede and Callisto(5). It has been suggested that Europa's thin outer ice shell might be separated from the moon's silicate interior by a liquid water layer, delayed or prevented from freezing by tidal heating(6-10); in this model, the lineae could be explained by repetitive tidal deformation of the outer ice shell(11-13). However, observational confirmation of a subsurface ocean was largely frustrated by the low resolution (>2 km per pixel) of the Voyager images(14). Here we present high-resolution (54 m per pixel) Galileo spacecraft images of Europa, in which we find evidence for mobile 'icebergs'. The detailed morphology of the terrain strongly supports the presence of liquid water at shallow depths below the surface, either today or at some time in the past. Moreover, lower-resolution observations of much larger regions suggest that the phenomena reported here are widespread.	US Geol Survey, Menlo Pk, CA 94025 USA; Natl Opt Astron Observ, Tucson, AZ 85719 USA; SW Res Inst, Boulder, CO 80302 USA; Rand Corp, Santa Monica, CA 90406 USA; Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; Cornell Univ, Ithaca, NY 14853 USA; Brown Univ, Dept Geol, Providence, RI 02912 USA; Jet Prop Lab, Pasadena, CA 91909 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; DLR, Inst Planetenerkundung, D-12489 Berlin, Germany; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA	United States Department of the Interior; United States Geological Survey; National Optical Astronomy Observatory; RAND Corporation; University of Arizona; Arizona State University; Arizona State University-Tempe; Cornell University; Brown University; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Helmholtz Association; German Aerospace Centre (DLR); University of California System; University of California Los Angeles	Carr, MH (corresponding author), US Geol Survey, 345 Middlefield Rd, Menlo Pk, CA 94025 USA.	carr@astmnl.wr.usgs.gov	Pappalardo, Robert/AAP-8953-2021; Sullivan, Robert/AAR-8193-2020	Pappalardo, Robert/0000-0003-2571-4627; 				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; CASSEN P, 1980, GEOPHYS RES LETT, V7, P987, DOI 10.1029/GL007i011p00987; CASSEN P, 1979, GEOPHYS RES LETT, V6, P731, DOI 10.1029/GL006i009p00731; CHAPMAN C, 1997, LUNAR PLANET SCI C, V28, P217; GREELEY R, UNPUB; GREENBERG R, 1984, ICARUS, V58, P186, DOI 10.1016/0019-1035(84)90038-1; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; KUIPER GP, 1961, PLANETS SATELLITES; Lucchitta B.K., 1982, SATELLITES JUPITER, P521; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; MOROZ VI, OSV ASTRON A J, V9, P999; MORRISON D, 1974, SPACE SCI REV, V15, P641, DOI 10.1007/BF00175241; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; Pappalardo R. T, 1996, P EUR OC C, P59; Pappalardo RT, 1996, ICARUS, V123, P557, DOI 10.1006/icar.1996.0178; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PAPPALARDO RT, 1996, LUNAR PLANET SCI C, V27, P997; ROSS M, 1986, NATURE, V325, P13; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SHOEMAKER EM, 1996, P EUR OC C, P65; SMITH BA, 1979, SCIENCE, V206, P927, DOI 10.1126/science.206.4421.927; SQUYRES SW, 1983, NATURE, V301, P225, DOI 10.1038/301225a0; SULLIVAN R, 1997, LUNAR PLANET SCI, V28, P1395; TUFTS RB, 1997, LUNAR PLANET SCI C, V28, P1455	24	378	386	2	162	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					363	365		10.1038/34857	http://dx.doi.org/10.1038/34857			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450749				2022-12-01	WOS:000071604200045
J	Collins, KL; Chen, BK; Kalams, SA; Walker, BD; Baltimore, D				Collins, KL; Chen, BK; Kalams, SA; Walker, BD; Baltimore, D			HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes	NATURE			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; FINE SPECIFICITY; DOWN-MODULATION; ANTIGENS; RNA	Cytotoxic T lymphocytes (CTLs) lyse virally infected cells that display viral peptide epitopes in association with major histocompatibility complex (MHC) class I molecules on the cell surface. However, despite a strong CTL response directed against viral epitopes, untreated people infected with the human immunodeficiency virus (HIV-1) develop AIDS. To resolve this enigma, we have examined the ability of CTLs to recognize and kill infected primary T lymphocytes, We found that CTLs inefficiently lysed primary cells infected with HIV-1 if the viral nef gene product was expressed. Resistance of infected cells to CTL killing correlated with nef-mediated downregulation of MHC class I (ref. 1) and could be overcome by adding an excess of the relevant HIV-1 epitope as soluble peptide. Thus, Nef protected infected cells by reducing the epitope density on their surface. This effect of nef may allow evasion of CTL lysis by HN-1-infected cells.	MIT, Dept Biol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Combined Infect Dis Training Program, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Massachusetts Gen Hosp, AIDS Res Ctr, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Infect Dis Unit, Charlestown, MA 02129 USA; Rockefeller Univ, New York, NY 10021 USA	Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Rockefeller University	Baltimore, D (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	baltimo@caltech.edu		Chen, Benjamin K/0000-0002-5404-1997				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; Borrow P, 1997, NAT MED, V3, P205, DOI 10.1038/nm0297-205; Chen BK, 1996, J VIROL, V70, P6044, DOI 10.1128/JVI.70.9.6044-6053.1996; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; Goulder PJR, 1997, NAT MED, V3, P212, DOI 10.1038/nm0297-212; HILL AB, 1995, J EXP MED, V181, P2221, DOI 10.1084/jem.181.6.2221; HOWCROFT TK, 1993, SCIENCE, V260, P1320, DOI 10.1126/science.8493575; JOHNSON RP, 1991, J IMMUNOL, V147, P1512; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; KERKAU T, 1989, AIDS RES HUM RETROV, V5, P613, DOI 10.1089/aid.1989.5.613; Kerkau T, 1997, J EXP MED, V185, P1295, DOI 10.1084/jem.185.7.1295; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; OBRIEN MC, 1995, CYTOMETRY, V19, P243, DOI 10.1002/cyto.990190308; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; Pantaleo G, 1997, P NATL ACAD SCI USA, V94, P254, DOI 10.1073/pnas.94.1.254; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; SCHEPPLER JA, 1989, J IMMUNOL, V143, P2858; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; TSOMIDES TJ, 1994, J EXP MED, V180, P1283, DOI 10.1084/jem.180.4.1283; TSOMIDES TJ, 1991, P NATL ACAD SCI USA, V88, P11276, DOI 10.1073/pnas.88.24.11276; WALKER BD, 1989, P NATL ACAD SCI USA, V86, P9514, DOI 10.1073/pnas.86.23.9514; Walter JB, 1997, INT IMMUNOL, V9, P451, DOI 10.1093/intimm/9.3.451; XU X, 1997, J EXP MED, V186, P1; Yang OO, 1996, J VIROL, V70, P5799, DOI 10.1128/JVI.70.9.5799-5806.1996	27	829	848	0	32	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					397	401		10.1038/34929	http://dx.doi.org/10.1038/34929			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450757				2022-12-01	WOS:000071604200057
J	Keitel, T; Kramer, A; Wessner, H; Scholz, C; SchneiderMergener, J; Hohne, W				Keitel, T; Kramer, A; Wessner, H; Scholz, C; SchneiderMergener, J; Hohne, W			Crystallographic analysis of anti-p24 (HIV-1) monoclonal antibody cross-reactivity and polyspecificity	CELL			English	Article							ELECTRON-DENSITY MAPS; 3-DIMENSIONAL STRUCTURE; CAPSID PROTEIN; ANTIGEN INTERACTIONS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; COMPLEX; BINDING; REARRANGEMENTS; CONFORMATIONS	The X-ray crystal structures of an anti-p24 (HIV-1) monoclonal antibody Fab fragment alone and in complexes with the epitope peptide GATPQDLNTnL (n = norleucine), an epitope-homologous peptide GATPED LNQKLAGN, as well as two unrelated peptides GLYEW GGARITNTD and efslkGpIIqwrsG (D-peptide), are presented to a maximum resolution of 2.6 Angstrom. The latter three peptides were identified from screening synthetic combinatorial peptide libraries. Although all peptides bind to the same antigen combining site, the nonhomologous peptides adopt different binding conformations and also form their critical contacts with different antibody residues. Only small readjustments are observed within the framework of the Fab fragment upon binding.	HUMBOLDT UNIV BERLIN, KLINIKUM CHARITE, INST BIOCHEM, D-10098 BERLIN, GERMANY; HUMBOLDT UNIV BERLIN, KLINIKUM CHARITE, INST MED IMMUNOL, D-10098 BERLIN, GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin				Kramer, Achim/0000-0001-9671-6078				ABAGYAN R, 1994, J COMPUT CHEM, V15, P488, DOI 10.1002/jcc.540150503; Abu-Shakra Mahmoud, 1996, P408, DOI 10.1016/B978-044482383-0/50063-7; AREVALO JH, 1993, NATURE, V365, P859, DOI 10.1038/365859a0; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1992, X PLOR VERSION 3 0 S; Chacko S, 1996, PROTEINS, V26, P55, DOI 10.1002/(SICI)1097-0134(199609)26:1<55::AID-PROT5>3.0.CO;2-F; CHITARRA V, 1993, P NATL ACAD SCI USA, V90, P7711, DOI 10.1073/pnas.90.16.7711; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; *COLL COMP PROJ NU, 1994, CCP4 SUIT PROGR PROT; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; DallAcqua W, 1996, BIOCHEMISTRY-US, V35, P9667, DOI 10.1021/bi960819i; Ehrhard B, 1996, BIOCHEMISTRY-US, V35, P9097, DOI 10.1021/bi9603534; FIELDS BA, 1995, NATURE, V374, P739, DOI 10.1038/374739a0; GELIN BR, 1979, BIOCHEMISTRY-US, V18, P1256, DOI 10.1021/bi00574a022; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; Glaser RW, 1996, J IMMUNOL METHODS, V189, P1, DOI 10.1016/0022-1759(95)00221-9; GRUNOW R, 1990, Z KLIN MED, V45, P367; Hohne W E, 1993, Mol Immunol, V30, P1213, DOI 10.1016/0161-5890(93)90140-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kabat E. A., 1987, SEQUENCES PROTEINS I, DOI 10.1016/0003-2697(84)90805-4; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kramer A, 1997, CELL, V91, P799, DOI 10.1016/S0092-8674(00)80468-7; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1990, CRYSTALLOGRAPHIC COM, P110; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; Rullmann J, 1996, AQUA COMPUTER PROGRA; SCHNEIDERMERGEN.J, 1996, COMBINATORIAL LIB, P53; SCHULZEGAHMEN U, 1993, J MOL BIOL, V234, P1098, DOI 10.1006/jmbi.1993.1663; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; Shirai H, 1996, FEBS LETT, V399, P1, DOI 10.1016/S0014-5793(96)01252-5; SHOHAM M, 1993, J MOL BIOL, V232, P1169, DOI 10.1006/jmbi.1993.1469; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; TORMO J, 1994, EMBO J, V13, P2247, DOI 10.1002/j.1460-2075.1994.tb06506.x; Wade H, 1997, ANNU REV BIOPH BIOM, V26, P461, DOI 10.1146/annurev.biophys.26.1.461; WEBSTER DM, 1994, CURR OPIN STRUC BIOL, V4, P123, DOI 10.1016/S0959-440X(94)90070-1; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; WINKLER K, 1996, THESIS HUMBOLDT U BE	49	106	115	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					811	820		10.1016/S0092-8674(00)80469-9	http://dx.doi.org/10.1016/S0092-8674(00)80469-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413990	Bronze			2022-12-01	WOS:A1997YL43900012
J	Nichol, G; Walls, R; Goldman, L; Pearson, S; Hartley, LH; Antman, E; Stockman, M; Teich, JM; Cannon, CP; Johnson, PA; Kuntz, KM; Lee, TH				Nichol, G; Walls, R; Goldman, L; Pearson, S; Hartley, LH; Antman, E; Stockman, M; Teich, JM; Cannon, CP; Johnson, PA; Kuntz, KM; Lee, TH			A critical pathway for management of patients with acute chest pain who are at low risk for myocardial ischemia: Recommendations and potential impact	ANNALS OF INTERNAL MEDICINE			English	Article							CONTROLLED INTERVENTIONAL TRIAL; CORONARY-ARTERY DISEASE; CREATINE-KINASE MB; PRACTICE GUIDELINES; EMERGENCY ROOM; PREDICTIVE INSTRUMENT; MEDICAL-PRACTICE; OPINION LEADERS; EXERCISE TEST; INFARCTION	Background: Use of resources for patients with acute chest pain may be improved with clinical strategies that integrate research, Bayesian analysis, and expert opinion, Objectives: To 1) develop a critical pathway for management of patients with acute chest pain who are at low risk for complications of ischemic heart disease and 2) assess the potential effects of implementation of the pathway on patient safety and resource use. Design: Evidence-based consensus and prospective cohort study. Setting: Urban teaching hospital. Patients: Patients at least 30 years of age who were seen in the emergency department for chest pain and who did not have a history of trauma or abnormalities on radiologic study. Intervention: Physician-opinion leaders defined criteria for patient inclusion in the pathway and for remaining on the pathway after 6 or 12 hours of observation. Criteria were defined for appropriateness of direct admission, direct discharge, or 6 hours of observation followed by exercise treadmill testing. Measurements: Number of patients admitted to the hospital, number of days that patients were hospitalized, and clinical outcome. Results: 2898 of 4585 patients (63%) were admitted to the hospital; of the 2898, 1152 (40%) were classified as potentially eligible for the pathway and 1068 (93%) had a benign clinical course during the initial observation period. The 1068 patients had a mean length of stay of 2.8 +/- 4.8 days. If 47% of these patients had been discharged after observation and exercise testing, implementation of the pathway would have reduced the number of admissions by 505 (17%) and days of hospitalization by 1407 (11%). Conclusions: Retrospective analysis suggests that a critical pathway for patients with acute chest pain may substantially reduce resource use, Prospective study is needed to ensure increased efficiency without increased adverse outcomes.	HARVARD COMMUNITY HLTH PLAN, BOSTON, MA 02215 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT MED, BOSTON, MA 02115 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SCH MED, SAN FRANCISCO, CA 94143 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT EMERGENCY MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of California System; University of California San Francisco; Harvard University; Brigham & Women's Hospital; Harvard Medical School					AHRQ HHS [R01 HS06452] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ADAMS JE, 1993, CIRCULATION, V88, P101, DOI 10.1161/01.CIR.88.1.101; CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; Coffey R J, 1992, Qual Manag Health Care, V1, P45; *COLL PHYS SURG ON, 1988, POL DEEP VEIN THROMB; ELLRODT AG, 1995, ANN INTERN MED, V122, P277, DOI 10.7326/0003-4819-122-4-199502150-00007; Falconer J A, 1993, QRB Qual Rev Bull, V19, P8; FIELD D L, 1988, Journal of Emergency Medicine, V6, P363, DOI 10.1016/0736-4679(88)90002-9; FLEISCHMANN KE, 1994, J AM COLL CARDIOL, V23, P1390, DOI 10.1016/0735-1097(94)90382-4; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GIBLER WB, 1995, ANN EMERG MED, V25, P1, DOI 10.1016/S0196-0644(95)70347-0; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GRAFF L, 1992, ANN EMERG MED, V21, P967, DOI 10.1016/S0196-0644(05)82937-3; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HIGGINS GL, 1993, AM J EMERG MED, V11, P576, DOI 10.1016/0735-6757(93)90004-U; HILTON TC, 1994, J AM COLL CARDIOL, V23, P1016, DOI 10.1016/0735-1097(94)90584-3; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; JONES J, 1995, BRIT MED J, V311, P376, DOI 10.1136/bmj.311.7001.376; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KERNS JR, 1993, ANN EMERG MED, V22, P794, DOI 10.1016/S0196-0644(05)80793-0; LEE TH, 1992, AM J CARDIOL, V69, P145, DOI 10.1016/0002-9149(92)91294-E; LEE TH, 1995, ANN INTERN MED, V122, P434, DOI 10.7326/0003-4819-122-6-199503150-00006; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LEE TH, 1987, AM J CARDIOL, V60, P219, DOI 10.1016/0002-9149(87)90217-7; LEWIS LM, 1995, ANN EMERG MED, V25, P9, DOI 10.1016/S0196-0644(95)70348-9; LEWIS WR, 1994, AM J CARDIOL, V74, P987, DOI 10.1016/0002-9149(94)90845-1; LIM R, 1994, BRIT HEART J, V71, P334; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; MARIN MM, 1992, AM HEART J, V123, P354, DOI 10.1016/0002-8703(92)90646-D; ODDERSON IR, 1993, STROKE, V24, P1823, DOI 10.1161/01.STR.24.12.1823; OGILVIEHARRIS DJ, 1993, J ORTHOP TRAUMA, V7, P428, DOI 10.1097/00005131-199310000-00005; Patton M D, 1995, Cancer Pract, V3, P286; PEARSON SD, 1995, ANN INTERN MED, V123, P941, DOI 10.7326/0003-4819-123-12-199512150-00008; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; RATNAIKE S, 1993, MED J AUSTRALIA, V159, P666, DOI 10.5694/j.1326-5377.1993.tb138081.x; RIBISL PM, 1992, ARCH INTERN MED, V152, P1618, DOI 10.1001/archinte.152.8.1618; RICHARDS JS, 1994, CLIN PATHS TOOLS OUT, P265; Schriefer J, 1995, Qual Manag Health Care, V3, P30; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SHESSER R, 1994, ANN EMERG MED, V23, P334, DOI 10.1016/S0196-0644(94)70047-8; SOX HC, 1988, MED DECIS MAKING, P406; SPATH PL, 1994, CLIN PATHS TOOLS OUT, P265; STRATMANN HG, 1994, AM J CARDIOL, V73, P647, DOI 10.1016/0002-9149(94)90927-X; TUCKER JF, 1994, ANN EMERG MED, V24, P704, DOI 10.1016/S0196-0644(94)70282-9; TURLEY K, 1994, ANN THORAC SURG, V58, P57, DOI 10.1016/0003-4975(94)91072-3; *US DHHS, 1994, AHCPR PUBL; VARETTO T, 1993, J AM COLL CARDIOL, V22, P1804, DOI 10.1016/0735-1097(93)90761-O; WACHTEL T, 1986, MED DECIS MAKING, V6, P101, DOI 10.1177/0272989X8600600208; WEINER DA, 1984, J AM COLL CARDIOL, V3, P772, DOI 10.1016/S0735-1097(84)80254-5; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; YOUNG GP, 1993, AM J EMERG MED, V11, P444, DOI 10.1016/0735-6757(93)90079-Q	56	72	73	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					996	1005		10.7326/0003-4819-127-11-199712010-00009	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412306				2022-12-01	WOS:A1997YJ08000007
J	Redinbo, MR; Stewart, L; Kuhn, P; Champoux, JJ; Hol, WGJ				Redinbo, MR; Stewart, L; Kuhn, P; Champoux, JJ; Hol, WGJ			Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA	SCIENCE			English	Article							CAMPTOTHECIN RESISTANCE; CATALYTIC ACTIVITY; ANTITUMOR-ACTIVITY; TERMINAL FRAGMENT; EUKARYOTIC TOPOISOMERASE; CLEAVABLE COMPLEXES; POINT MUTATION; BINDING-SITE; WHEAT-GERM; IDENTIFICATION	Topoisomerases I promote the relaxation of DNA superhelical tension by introducing a transient Single-stranded break in duplex DNA and are vital for the processes of replication, transcription, and recombination, The crystal structures at 2.1 and 2.5 angstrom resolution of reconstituted human topoisomerase I comprising the core and carboxyl-terminal domains in covalent and noncovalent complexes with 22-base pair DNA duplexes reveal an enzyme that "clamps" around essentially B-form DNA, The core domain and the first eight residues of the carboxyl-terminal domain of the enzyme, including the active-site nuleophile tyrosine-723, share significant structural similarity with the bacteriophage family of DNA integrases. A binding mode for the anticancer drug camptothecin is proposed on the basis of chemical and biochemical information combined with these three-dimensional structures of topoisomerase I-DNA complexes.	Univ Washington, Sch Med, Biomol Struct Ctr, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA; Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Univ Washington, Sch Med, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biochem, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Hol, WGJ (corresponding author), Univ Washington, Sch Med, Biomol Struct Ctr, Box 357742, Seattle, WA 98195 USA.				NATIONAL CANCER INSTITUTE [R01CA065656] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049156] Funding Source: NIH RePORTER; NCI NIH HHS [CA65656] Funding Source: Medline; NIGMS NIH HHS [GM49156] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ALSNER J, 1992, J BIOL CHEM, V267, P12408; ANDERSEN AH, 1985, NUCLEIC ACIDS RES, V13, P1543, DOI 10.1093/nar/13.5.1543; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; BEEN MD, 1984, NUCLEIC ACIDS RES, V12, P3097, DOI 10.1093/nar/12.7.3097; BENDIXEN C, 1990, BIOCHEMISTRY-US, V29, P5613, DOI 10.1021/bi00475a028; BENEDETTI P, 1993, CANCER RES, V53, P4343; Berger JM, 1996, NATURE, V380, P179, DOI 10.1038/380179a0; Bharti AK, 1996, J BIOL CHEM, V271, P1993, DOI 10.1074/jbc.271.4.1993; BJORNSTI MA, 1989, CANCER RES, V49, P6318; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; Brunger AT, 1993, X PLOR VERSION 3 1 S; BURGIN AB, 1985, NUCLEIC ACIDS RES, V23, P2973; Caron P R, 1994, Adv Pharmacol, V29B, P271; CHAMPOUX JJ, IN PRESS PROG NUCL A; Champoux JJ, 1990, DNA TOPOLOGY ITS BIO, P217; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; CROW RT, 1992, J MED CHEM, V35, P4160, DOI 10.1021/jm00100a022; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038; HERTZBERG RP, 1990, J BIOL CHEM, V265, P19287; HERTZBERG RP, 1989, BIOCHEMISTRY-US, V28, P4629, DOI 10.1021/bi00437a018; Hickman AB, 1997, CELL, V89, P227, DOI 10.1016/S0092-8674(00)80202-0; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; HORWITZ SB, 1971, MOL PHARMACOL, V7, P632; HSIANG YH, 1989, CANCER RES, V49, P5077; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; JAXEL C, 1989, CANCER RES, V49, P1465; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JOSHUATOR L, 1992, J MOL BIOL, V225, P397, DOI 10.1016/0022-2836(92)90929-E; KINGSBURY WD, 1991, J MED CHEM, V34, P98, DOI 10.1021/jm00105a017; KJELDSEN E, 1988, J MOL BIOL, V202, P333, DOI 10.1016/0022-2836(88)90462-7; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; KNAB AM, 1993, J BIOL CHEM, V268, P22322; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBOTA N, 1992, BIOCHEM BIOPH RES CO, V188, P571, DOI 10.1016/0006-291X(92)91094-7; LACKEY K, 1995, J MED CHEM, V38, P906, DOI 10.1021/jm00006a008; LETEURTRE F, 1994, J BIOL CHEM, V269, P28702; Li XG, 1997, BIOCHEM PHARMACOL, V53, P1019, DOI 10.1016/S0006-2952(96)00899-4; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; Lue N, 1995, STRUCTURE, V3, P1315, DOI 10.1016/S0969-2126(01)00269-6; MADDEN KR, 1992, CANCER RES, V52, P525; MCPHAIL AT, 1968, J CHEM SOC B, P923, DOI 10.1039/j29680000923; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOORE JM, 1988, BIOCHEMISTRY-US, V27, P7806, DOI 10.1021/bi00420a033; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEIN-STRUCT FUNCT, V11, P282; OTWINOWSKI Z, 1993, DATA COLLECTION PROC; POMMIER Y, 1995, P NATL ACAD SCI USA, V92, P8861, DOI 10.1073/pnas.92.19.8861; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUBIN E, 1994, J BIOL CHEM, V269, P2433; SAWADA S, 1991, CHEM PHARM BULL, V39, P3183; SHAFFER R, 1987, J BIOL CHEM, V262, P9309; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHUMAN S, 1987, P NATL ACAD SCI USA, V84, P7478, DOI 10.1073/pnas.84.21.7478; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1998, SCIENCE, V279, P1534, DOI 10.1126/science.279.5356.1534; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; TAMURA H, 1991, NUCLEIC ACIDS RES, V19, P69, DOI 10.1093/nar/19.1.69; TANIZAWA A, 1993, J BIOL CHEM, V268, P25463; TANIZAWA A, 1995, BIOCHEMISTRY-US, V34, P7200, DOI 10.1021/bi00021a035; TANIZAWA A, 1993, NUCLEIC ACIDS RES, V21, P5157, DOI 10.1093/nar/21.22.5157; WALL ME, 1966, J AM CHEM SOC, V88, P3888, DOI 10.1021/ja00968a057; WALL ME, 1993, J MED CHEM, V36, P2689, DOI 10.1021/jm00070a013; Wang HK, 1997, MED RES REV, V17, P367, DOI 10.1002/(SICI)1098-1128(199707)17:4<367::AID-MED3>3.0.CO;2-U; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang LF, 1997, CANCER RES, V57, P1516	75	742	771	6	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1504	1513		10.1126/science.279.5356.1504	http://dx.doi.org/10.1126/science.279.5356.1504			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488644				2022-12-01	WOS:000072372900057
J	Shahab, N; Evans, ML				Shahab, N; Evans, ML			Platelet satellitism	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Univ Hosp & Clin, Columbia, MO 65203 USA	University of Missouri System; University of Missouri Columbia	Shahab, N (corresponding author), Univ Hosp & Clin, Columbia, MO 65203 USA.								0	11	11	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					591	591		10.1056/NEJM199802263380906	http://dx.doi.org/10.1056/NEJM199802263380906			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475767				2022-12-01	WOS:000072175700006
J	Birchall, M				Birchall, M			Human laryngeal allograft: shift of emphasis in transplantation	LANCET			English	Editorial Material									Univ Bristol, Dept Otorhinolaryngol & Head & Neck Surg, Bristol BS10 5ND, Avon, England	University of Bristol	Birchall, M (corresponding author), Univ Bristol, Dept Otorhinolaryngol & Head & Neck Surg, Bristol BS10 5ND, Avon, England.							AFFLECK J, 1998, PHILADELPHIA DA 0110; Birchall MA, 1997, BRIT J SURG, V84, P739, DOI 10.1002/bjs.1800840603; DICK D, 1987, LIVER TRANSPLANTATIO, P145; LEOPOLD DA, 1983, ARCH OTOLARYNGOL, V109, P106; SINGER MI, 1980, ANN OTO RHINOL LARYN, V89, P529, DOI 10.1177/000348948008900608; STROME S, 1992, ANN OTO RHINOL LARYN, V101, P156, DOI 10.1177/000348949210100209; VanLithBijl JT, 1997, ARCH OTOLARYNGOL, V123, P406	7	28	30	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					539	540		10.1016/S0140-6736(05)78550-0	http://dx.doi.org/10.1016/S0140-6736(05)78550-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492768				2022-12-01	WOS:000072231900004
J	Garcia, KC; Degano, M; Pease, LR; Huang, MD; Peterson, PA; Teyton, L; Wilson, IA				Garcia, KC; Degano, M; Pease, LR; Huang, MD; Peterson, PA; Teyton, L; Wilson, IA			Structural basis of plasticity in T cell receptor recognition of a self peptide MHC antigen	SCIENCE			English	Article							ELECTRON-DENSITY MAPS; POSITIVE SELECTION; CRYSTAL-STRUCTURE; LYMPHOCYTES-T; V-ALPHA; TRANSGENIC MICE; VIRAL PEPTIDES; BETA-CHAIN; COMPLEX; ANTIBODY	The T cell receptor (TCR) inherently has dual specificity, T cells must recognize self-antigens in the thymus during maturation and then discriminate between foreign pathogens in the periphery, A molecular basis for this cross-reactivity is elucidated by the crystal structure of the alloreactive 2C TCR bound to self peptide-major histocompatibility complex (pMHC) antigen H-2K(b)-dEV8 refined against anisotropic 3.0 angstrom resolution x-ray data, The interface between peptide and TCR exhibits extremely poor shape complementarity, and the TCR beta chain complementarity-determining region 3 (CDR3) has minimal interaction with the dEV8 peptide, Large conformational changes in three of the TCR CDR loops are induced upon binding, providing a mechanism of structural plasticity to accommodate a variety of different peptide antigens, Extensive TCR interaction with the pMHC alpha helices suggests a generalized orientation that is mediated by the V-alpha domain of the TCR and rationalizes how TCRs can effectively "scan" different peptides bound within a large, low-affinity MHC structural framework for those that provide the slight additional kinetic stabilization required for signaling.	Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; RW Johnson Pharmaceut Res Inst, San Diego, CA 92121 USA; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Mayo Clinic; Johnson & Johnson; Johnson & Johnson USA; Scripps Research Institute	Wilson, IA (corresponding author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	wilson@scripps.edu	Degano, Massimo/K-4669-2018; Huang, Mary/I-6216-2013	Degano, Massimo/0000-0002-0787-1883; Huang, Mary/0000-0001-8547-5328	NCI NIH HHS [R01 CA58896] Funding Source: Medline; NIAID NIH HHS [AI42266, AI42267] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042267, R21AI142267, R01AI042266, R37AI042266] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ALLISON JP, 1984, IMMUNOL REV, V81, P145, DOI 10.1111/j.1600-065X.1984.tb01108.x; Ausubel LJ, 1996, P NATL ACAD SCI USA, V93, P15317, DOI 10.1073/pnas.93.26.15317; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; Bevan MJ, 1997, IMMUNITY, V7, P175, DOI 10.1016/S1074-7613(00)80520-8; BHAT TN, 1990, NATURE, V347, P483, DOI 10.1038/347483a0; BRANDLE D, 1991, EUR J IMMUNOL, V21, P2195, DOI 10.1002/eji.1830210930; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Clark Stephen P., 1995, Immunogenetics, V42, P531; Collaborative Computational Project, 1994, ACTA CRYST D, V50, P760; CONNOLLY ML, 1993, J MOL GRAPH MODEL, V11, P139, DOI 10.1016/0263-7855(93)87010-3; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P439; COSE SC, 1995, J VIROL, V69, P5849, DOI 10.1128/JVI.69.9.5849-5852.1995; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMBIC Z, 1986, NATURE, V320, P232, DOI 10.1038/320232a0; Fields BA, 1996, IMMUNOL TODAY, V17, P330, DOI 10.1016/0167-5699(96)10020-7; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; FREMONT DH, 1995, P NATL ACAD SCI USA, V92, P2479, DOI 10.1073/pnas.92.7.2479; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1997, P NATL ACAD SCI USA, V94, P13838, DOI 10.1073/pnas.94.25.13838; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Germain RN, 1997, CURR BIOL, V7, pR640, DOI 10.1016/S0960-9822(06)00323-X; GERMAIN RN, 1990, NATURE, V344, P19, DOI 10.1038/344019a0; HASKINS K, 1984, ANNU REV IMMUNOL, V2, P51, DOI 10.1146/annurev.iy.02.040184.000411; HERRON JN, 1991, PROTEINS, V11, P159, DOI 10.1002/prot.340110302; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.immunol.13.1.93; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1992, MOL REPLACEMENT, P91; JORGENSEN JL, 1992, ANNU REV IMMUNOL, V10, P835, DOI 10.1146/annurev.iy.10.040192.004155; KATZ DH, 1973, P NATL ACAD SCI USA, V70, P2624, DOI 10.1073/pnas.70.9.2624; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; KLEIN J, 1996, NATURAL HIST MAJOR H; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P826, DOI 10.1107/S0907444995014983; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; KUZUSHIMA K, 1995, J IMMUNOL, V155, P594; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; Madrenas J, 1996, Semin Immunol, V8, P83, DOI 10.1006/smim.1996.0011; Madrenas J, 1997, J EXP MED, V185, P219, DOI 10.1084/jem.185.2.219; MARTIN ACR, 1992, SCITECH SOFTWARE; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MCDONALD IK, 1994, J MOL BIOL, V238, P777, DOI 10.1006/jmbi.1994.1334; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; MEUER SC, 1984, ANNU REV IMMUNOL, V2, P23, DOI 10.1146/annurev.immunol.2.1.23; NANDA NK, 1995, J EXP MED, V182, P531, DOI 10.1084/jem.182.2.531; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAWLOWSKI TJ, 1996, EUR J IMMUNOL, V26, P85; PULLEN JK, 1989, J IMMUNOL, V143, P1674; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SAITO T, 1987, NATURE, V329, P256, DOI 10.1038/329256a0; SHA WC, 1988, NATURE, V336, P73, DOI 10.1038/336073a0; SHA WC, 1988, NATURE, V335, P271, DOI 10.1038/335271a0; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; SPEIR JP, UNPUB; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; Tallquist MD, 1998, J IMMUNOL, V160, P802; TALLQUIST MD, 1995, J IMMUNOL, V155, P2419; Tallquist MD, 1996, J EXP MED, V184, P1017, DOI 10.1084/jem.184.3.1017; TERHORST O, 1995, T CELL RECEPTORS, P369; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; UDAKA K, 1992, CELL, V69, P989, DOI 10.1016/0092-8674(92)90617-L; Udaka K, 1996, J IMMUNOL, V157, P670; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; Utz U, 1996, J VIROL, V70, P843, DOI 10.1128/JVI.70.2.843-851.1996; Vergelli M, 1997, J IMMUNOL, V158, P3746; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WEDEMAYER GJ, 1997, SCIENCE, V276, P16665; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	90	577	587	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1166	1172		10.1126/science.279.5354.1166	http://dx.doi.org/10.1126/science.279.5354.1166			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469799				2022-12-01	WOS:000072115200031
J	Braud, VM; Allan, DSJ; O'Callaghan, CA; Soderstrom, K; D'Andrea, A; Ogg, GS; Lazetic, S; Young, NT; Bell, JI; Phillips, JH; Lanier, LL; McMichael, AJ				Braud, VM; Allan, DSJ; O'Callaghan, CA; Soderstrom, K; D'Andrea, A; Ogg, GS; Lazetic, S; Young, NT; Bell, JI; Phillips, JH; Lanier, LL; McMichael, AJ			HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C	NATURE			English	Article							MONOCLONAL-ANTIBODY; CD94; ANTIGEN; RECOGNITION; PEPTIDE; IDENTIFICATION; LYMPHOCYTES; ALLELES; FORM	The protein HLA-E is a non-classical major histocompatibility complex (MHC) molecule of limited sequence variability. Its expression on the cell surface is regulated by the binding of peptides derived from the signal sequence of some other MHC class I molecules(1,2). Here we report the identification of ligands for HLA-E. We constructed tetramers(3) in which recombinant HLA-E and beta 2-microglobulin were refolded with an MHC leader-sequence peptide, biotinylated, and conjugated to phycoerythrin-labelled Extravidin. This HLA-E tetramer bound to natural killer (NK) cells and a small subset of T cells from peripheral blood. On transfectants, the tetramer bound to the CD94/NKG2A, CD94/NKGK2B and CD94/NKG2C NK cell receptors, but did not bind to the immunoglobulin family of NK cell receptors (KIR). Surface expression of HLA-E was enough to protect target cells from lysis by CD94/NKG2A(+) NK-cell clones. A subset of HLA class I alleles has been shown to inhibit killing by CD94/NKG2A(+) NK-cell clones(4-6). Only the HLA alleles that possess a leader peptide capable of upregulating HLA-E surface expression confer resistance to NK-cell-mediated lysis, implying that their action is mediated by HLA-E, the predominant ligand for the NK cell inhibitory receptor CD94/NKG2A.	John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; John Radcliffe Hosp, Nuffield Dept Surg, Oxford OX3 9DU, England	University of Oxford; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; University of Oxford	Braud, VM (corresponding author), John Radcliffe Hosp, Inst Mol Med, Oxford OX3 9DS, England.		braud, veronique M/I-4597-2013; Soderstrom, Kalle/G-5788-2011; D'Andrea, Annalisa/F-9836-2011; Lanier, Lewis L/E-2139-2014	braud, veronique M/0000-0001-8213-3947; Lanier, Lewis L/0000-0003-1308-3952; Ogg, Graham/0000-0002-3097-045X				ALDRICH CJ, 1994, CELL, V79, P649, DOI 10.1016/0092-8674(94)90550-9; Altman JD, 1996, SCIENCE, V274, P94, DOI 10.1126/science.274.5284.94; ARAMBURU J, 1990, J IMMUNOL, V144, P3238; Braud V, 1997, EUR J IMMUNOL, V27, P1164, DOI 10.1002/eji.1830270517; Braud VM, 1998, CURR BIOL, V8, P1, DOI 10.1016/S0960-9822(98)70014-4; Brooks AG, 1997, J EXP MED, V185, P795, DOI 10.1084/jem.185.4.795; Carretero M, 1997, EUR J IMMUNOL, V27, P563, DOI 10.1002/eji.1830270230; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; CONNOLLY DJ, 1993, J IMMUNOL, V151, P6089; Cotterill LA, 1997, EUR J IMMUNOL, V27, P2123, DOI 10.1002/eji.1830270902; DeCloux A, 1997, J IMMUNOL, V158, P2183; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Houchins JP, 1997, J IMMUNOL, V158, P3603; Lanier LL, 1997, IMMUNOL REV, V155, P145, DOI 10.1111/j.1600-065X.1997.tb00947.x; Lazetic S, 1996, J IMMUNOL, V157, P4741; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; OGG GS, IN PRESS SCIENCE; Pende D, 1997, EUR J IMMUNOL, V27, P1875, DOI 10.1002/eji.1830270809; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; Reyburn HT, 1997, NATURE, V386, P514, DOI 10.1038/386514a0; Robertson MJ, 1996, EXP HEMATOL, V24, P406; Sivori S, 1996, EUR J IMMUNOL, V26, P2487, DOI 10.1002/eji.1830261032; Sivori S, 1996, TRANSPLANT P, V28, P3199; Soderstrom K, 1997, J IMMUNOL, V159, P1072; Steven NM, 1997, J EXP MED, V185, P1605, DOI 10.1084/jem.185.9.1605; VILLAR JJP, 1997, J IMMUNOL, V158, P5736; WEI XH, 1990, HUM IMMUNOL, V29, P131, DOI 10.1016/0198-8859(90)90076-2	27	1672	1728	2	56	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					795	799		10.1038/35869	http://dx.doi.org/10.1038/35869			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486650				2022-12-01	WOS:000072089500054
J	Clynes, R; Dumitru, C; Ravetch, JV				Clynes, R; Dumitru, C; Ravetch, JV			Uncoupling of immune complex formation and kidney damage in autoimmune glomerulonephritis	SCIENCE			English	Article							SYSTEMIC LUPUS-ERYTHEMATOSUS; GLOMERULAR MESANGIAL CELLS; MURINE LUPUS; FC-RECEPTORS; GAMMA-CHAIN; MICE; NEPHRITIS; DISEASE; F1-MICE; INJURY	The generation of autoantibody and subsequent tissue deposition of immune complexes (IC) is thought to trigger the pathogenic consequences of systemic autoimmune disease. Modulation of the autoantibody response disrupts pathogenesis by preventing the formation of ICs; however, uncoupling IC formation from subsequent inflammatory responses seems unlikely because of the apparent complexity of the IC-triggered inflammatory cascade. However, the disruption of a single gene, which encodes the gamma chain of the Fc receptor, was found to achieve this uncoupling in a spontaneous model of lupus nephritis, the New Zealand Black/New Zealand White (NZB/NZW) mouse. Gamma chain-deficient NZB/NZW mice generated and deposited IC and activated complement, but were protected from severe nephritis, thus defining another potential pathway for therapeutic intervention in autoimmune disease.	Rockefeller Univ, Mol Genet & Immunol Lab, New York, NY 10021 USA	Rockefeller University	Ravetch, JV (corresponding author), Rockefeller Univ, Mol Genet & Immunol Lab, New York, NY 10021 USA.		Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				Ahearn JM, 1996, IMMUNITY, V4, P251, DOI 10.1016/S1074-7613(00)80433-1; BELMONT HM, 1997, DUBOISS LUPUS ERYTHE, P263; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; CLYNES R, 1995, IMMUNITY, V3, P21, DOI 10.1016/1074-7613(95)90155-8; CLYNES R, UNPUB; COUSER WG, 1990, J AM SOC NEPHROL, V1, P13; DAVIES KA, 1996, BR J RHEUMATOL, V35, P3; Early GS, 1996, J IMMUNOL, V157, P3159; FINCK BK, 1994, J CLIN INVEST, V94, P585, DOI 10.1172/JCI117373; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; FISCHER MB, 1997, NATURE, V159, P976; FRANK MM, 1987, NEW ENGL J MED, V316, P1525, DOI 10.1056/NEJM198706113162407; GAUTHIER VJ, 1997, DUBOIS LUPUS ERYTHEM, P207; Hahn BH, 1997, DUBOIS LUPUS ERYTHEM, P69; Hazenbos WLW, 1996, IMMUNITY, V5, P181, DOI 10.1016/S1074-7613(00)80494-X; HEBERT LA, 1992, SEMIN NEPHROL, V12, P408; ISHIDA H, 1994, J EXP MED, V179, P305, DOI 10.1084/jem.179.1.305; Janeway CA., 2021, IMMUNOBIOLOGY IMMUNE; JANKOVIC D, IN PRESS J EXP MED; MADAIO MP, 1987, J IMMUNOL, V138, P2883; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOHAN C, 1995, J IMMUNOL, V154, P1470; MORCOS M, 1994, KIDNEY INT, V46, P1627, DOI 10.1038/ki.1994.462; MOREL L, 1994, IMMUNITY, V1, P219, DOI 10.1016/1074-7613(94)90100-7; Nakajima A, 1997, J IMMUNOL, V158, P1466; RADEKE HH, 1994, J IMMUNOL, V153, P1281; RAVETCH JV, IN PRESS ANN REV IMM; REININGER L, 1992, J EXP MED, V176, P1343, DOI 10.1084/jem.176.5.1343; SCHUR PH, 1997, DUBOIS LUPUS ERYTHEM, P245; Suzuki Y., UNPUB; Sylvestre D, 1996, J EXP MED, V184, P2385, DOI 10.1084/jem.184.6.2385; SYLVESTRE DL, 1994, SCIENCE, V265, P1095, DOI 10.1126/science.8066448; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; THEOFILOPOULOS AN, 1985, ADV IMMUNOL, V37, P269, DOI 10.1016/S0065-2776(08)60342-9; TSAO BP, 1992, J IMMUNOL, V149, P350; UNANUE E, 1964, J EXP MED, V119, P965, DOI 10.1084/jem.119.6.965; Vora KA, 1997, J IMMUNOL, V159, P2116; Vyse TJ, 1996, CURR OPIN IMMUNOL, V8, P843, DOI 10.1016/S0952-7915(96)80014-8; WANG Y, 1996, P NATL ACAD SCI USA, V93, P8653; WESSELS MR, 1995, P NATL ACAD SCI USA, V92, P11490, DOI 10.1073/pnas.92.25.11490; WOLPERT MJ, 1997, ANN NY ACAD SCI, V815, P267; YUAN R, IN PRESS J EXP MED	42	492	540	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1052	1054		10.1126/science.279.5353.1052	http://dx.doi.org/10.1126/science.279.5353.1052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461440				2022-12-01	WOS:000072006400052
J	Yin, YX; Terauchi, Y; Solomon, GG; Aizawa, S; Rangarajan, PN; Yazaki, Y; Kadowaki, T; Barrett, JC				Yin, YX; Terauchi, Y; Solomon, GG; Aizawa, S; Rangarajan, PN; Yazaki, Y; Kadowaki, T; Barrett, JC			Involvement of p85 in p53-dependent apoptotic response to oxidative stress	NATURE			English	Article							PHOSPHATIDYLINOSITOL 3-KINASE; GROWTH-FACTOR; KINASE; P53; PROTEIN; REQUIREMENT; SUPPRESSION; ASSOCIATION; GENERATION; ACTIVATION	Reactive oxygen species have damaging effects on cellular components and so trigger defensive responses by the cell(1,2) and even programmed cell death(3,4), although the mechanisms by which mammalian cells transmit signals in response to oxidative damage are unknown. We report here that the protein p85, a regulator of the signalling protein phosphatidyl-3-OH kinase (PI(3)K), participates in the cell death process that is induced in response to oxidative stress and that this role of p85 in apoptosis does not involve PI(S)K. We show that disruption of p85 by homologous recombination impairs the cellular apoptotic response to oxidative stress. Because the protein p53 is required for cell death induced by oxidative damage, we examined the relation between p85 and p53. Using a chimaeric p53 fusion protein with the oestrogen receptor (p53ER) to supply p53 (p53 is induced upon binding of p53ER to oestradiol) in a p53-deficient cell line, we found that p85 is upregulated by p53 and that its involvement in p53-mediated apoptosis is independent of PI(3)K. We propose that p85 acts as a signal transducer in the cellular response to oxidative stress, mediating cell death regulated by p53.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ N Carolina, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ Tokyo, Dept Internal Med 3, Tokyo 113, Japan; Kumamoto Univ, Sch Med, Lab Morphogenesis, Kumamoto 860, Japan; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Tokyo; Kumamoto University; Indian Institute of Science (IISC) - Bangalore	Barrett, JC (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA.		Terauchi, Yasuo/AAO-4347-2020; Rangarajan, Pundi/A-7365-2009	Rangarajan, Pundi/0000-0002-6536-9891				ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bagchi D, 1995, TOXICOLOGY, V104, P129, DOI 10.1016/0300-483X(95)03156-A; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Carpenter CL, 1996, CURR OPIN CELL BIOL, V8, P153, DOI 10.1016/S0955-0674(96)80060-3; CARPENTER CL, 1996, BIOCH BIOPHYS ACTA R, V1288, P11; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ferby IM, 1996, J BIOL CHEM, V271, P11684, DOI 10.1074/jbc.271.20.11684; HARTLEY D, 1995, J BIOL CHEM, V270, P18260, DOI 10.1074/jbc.270.31.18260; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; KOTANI K, 1995, BIOCHEM BIOPH RES CO, V208, P985, DOI 10.1006/bbrc.1995.1431; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Preston GA, 1996, MOL CELL BIOL, V16, P211; Sambrook J., 1989, MOL CLONING LAB MANU; STORZ G, 1990, TRENDS GENET, V6, P363, DOI 10.1016/0168-9525(90)90278-E; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	27	149	157	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					707	710		10.1038/35648	http://dx.doi.org/10.1038/35648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490416				2022-12-01	WOS:000071982500056
J	Alberts, B				Alberts, B			The cell as a collection of protein machines: Preparing the next generation of molecular biologists	CELL			English	Editorial Material							DNA		Natl Acad Sci, Washington, DC 20418 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	National Academies of Sciences, Engineering & Medicine; University of California System; University of California San Francisco	Alberts, B (corresponding author), Natl Acad Sci, 2101 Constitut Ave Nw, Washington, DC 20418 USA.							ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ALBERTS BM, 1984, COLD SPRING HARB SYM, V49, P1; ALBERTS BM, 1986, AM ZOOL, V26, P781; ALBERTS BM, 1987, PHILOS T ROY SOC B, V317, P395, DOI 10.1098/rstb.1987.0068; Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Greenblatt J, 1997, CURR OPIN CELL BIOL, V9, P310, DOI 10.1016/S0955-0674(97)80002-6; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Meirovitch L., 1970, METHODS ANAL DYNAMIC; National Research Council Committee on Undergraduate Science Education, 1997, SCI TEACH REC; National Research Council (NRC), 1996, NAT SCI ED STAND; OGATA K, 1992, SYSTEM DYNAMICS; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Tjian R, 1996, PHILOS T R SOC B, V351, P491, DOI 10.1098/rstb.1996.0047; Wilson KS, 1998, CELL, V92, P337, DOI 10.1016/S0092-8674(00)80927-7; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	22	934	960	1	93	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 6	1998	92	3					291	294		10.1016/S0092-8674(00)80922-8	http://dx.doi.org/10.1016/S0092-8674(00)80922-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476889	Bronze			2022-12-01	WOS:000072024700001
J	Hegde, RS; Mastrianni, JA; Scott, MR; DeFea, KA; Tremblay, P; Torchia, M; DeArmond, SJ; Prusiner, SB; Lingappa, VR				Hegde, RS; Mastrianni, JA; Scott, MR; DeFea, KA; Tremblay, P; Torchia, M; DeArmond, SJ; Prusiner, SB; Lingappa, VR			A transmembrane form of the prion protein in neurodegenerative disease	SCIENCE			English	Article							STRAUSSLER-SCHEINKER SYNDROME; CREUTZFELDT-JAKOB-DISEASE; FATAL FAMILIAL INSOMNIA; TRANSGENIC MICE; PRP GENE; ENDOPLASMIC-RETICULUM; SECRETORY PROTEINS; SCRAPIE; TRANSMISSION; BIOGENESIS	At the endoplasmic reticulum membrane, the prion protein (PrP) can be synthesized in several topological forms. The role of these different forms was explored with transgenic mice expressing PrP mutations that alter the relative ratios of the topological forms, Expression of a particular transmembrane form (termed (Ctm)PrP) produced neurodegenerative changes in mice similar to those of some genetic prion diseases, Brains from these mice contained (Cim)PrP but not PrP(Sc), the PrP isoform responsible for transmission of prion diseases, Furthermore, in one heritable prion disease of humans, brain tissue contained (Ctm)PrP but not PrP(Sc), Thus, aberrant regulation of protein biogenesis and topology at the endoplasmic reticulum can result in neurodegeneration.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Lingappa, VR (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.	vrl@itsa.ucsf.edu		Hegde, Ramanujan/0000-0001-8338-852X; Lingappa, Vishwanath R./0000-0003-0962-6571	NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLOBEL G, 1975, J CELL BIOL, V67, P852, DOI 10.1083/jcb.67.3.852; BONIFACINO JS, 1990, NATURE, V344, P247, DOI 10.1038/344247a0; Brandner S, 1996, NATURE, V379, P339, DOI 10.1038/379339a0; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; COLLINGE J, 1995, LANCET, V346, P569, DOI 10.1016/S0140-6736(95)91405-6; DEFEA KA, 1994, J BIOL CHEM, V269, P16810; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; HAYWARD PAR, 1994, NEUROPATH APPL NEURO, V20, P375, DOI 10.1111/j.1365-2990.1994.tb00983.x; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HEGDE RI, UNPUB; Hegde RS, 1996, CELL, V85, P217, DOI 10.1016/S0092-8674(00)81098-3; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1994, P NATL ACAD SCI USA, V91, P9126, DOI 10.1073/pnas.91.19.9126; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HSIAO KK, 1991, NEUROLOGY, V41, P681, DOI 10.1212/WNL.41.5.681; James TL, 1997, P NATL ACAD SCI USA, V94, P10086, DOI 10.1073/pnas.94.19.10086; KATZ FN, 1977, P NATL ACAD SCI USA, V74, P3278, DOI 10.1073/pnas.74.8.3278; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MASTRIANNI JA, 1995, NEUROLOGY, V45, P2042, DOI 10.1212/WNL.45.11.2042; MASTRIANNI JA, UNPUB; Mathieu ME, 1996, BIOCHEMISTRY-US, V35, P4084, DOI 10.1021/bi952924i; Muramoto T, 1997, NAT MED, V3, P750, DOI 10.1038/nm0797-750; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; ROGERS M, 1991, J IMMUNOL, V147, P3568; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCOTT M, 1993, CELL, V73, P979, DOI 10.1016/0092-8674(93)90275-U; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; SCOTT MR, 1997, PROTEIN SCI S1, V6, P84; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SHIELDS D, 1978, J BIOL CHEM, V253, P3753; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; TATEISHI J, 1995, BRAIN PATHOL, V5, P53, DOI 10.1111/j.1750-3639.1995.tb00577.x; TATEISHI J, 1995, NATURE, V376, P434, DOI 10.1038/376434a0; TATEISHI J, 1990, NEUROLOGY, V40, P1578, DOI 10.1212/WNL.40.10.1578; TATEISHI J, 1992, E H S NEURO, P129; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; TRANCHANT C, 1992, J NEUROL NEUROSUR PS, V55, P185, DOI 10.1136/jnnp.55.3.185; Wang S, 1996, J BIOL CHEM, V271, P14124, DOI 10.1074/jbc.271.24.14124; Weissmann C, 1995, PROG BRAIN RES, V105, P15; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WESTAWAY D, 1994, CELL, V76, P117, DOI 10.1016/0092-8674(94)90177-5; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0	52	594	613	2	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					827	834		10.1126/science.279.5352.827	http://dx.doi.org/10.1126/science.279.5352.827			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452375				2022-12-01	WOS:000071923500033
J	Oakeshott, P; Kerry, S; Hay, S; Hay, P				Oakeshott, P; Kerry, S; Hay, S; Hay, P			Opportunistic screening for chlamydial infection at time of cervical smear testing in general practice: prevalence study	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Sch Med, Dept Gen Practice & Primary Care, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Genitourinary Med, London, England	St Georges University London; St Georges University London	Oakeshott, P (corresponding author), St George Hosp, Sch Med, Dept Gen Practice & Primary Care, Cranmer Terrace, London SW17 0RE, England.			Oakeshott, Pippa/0000-0003-2568-8211				[Anonymous], 1993, MMWR Recomm Rep, V42, P1; Johnson AM, 1996, BRIT MED J, V313, P1160, DOI 10.1136/bmj.313.7066.1160; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; *PUBL HLTH LAB SER, 1995, GEN CHLAM TRACH INF; Scholes D, 1996, NEW ENGL J MED, V334, P1362, DOI 10.1056/NEJM199605233342103	5	23	23	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 31	1998	316	7128					351	352		10.1136/bmj.316.7128.351	http://dx.doi.org/10.1136/bmj.316.7128.351			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487170	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071863900025
J	Bevan, M; Bancroft, I; Bent, E; Love, K; Goodman, H; Dean, C; Bergkamp, R; Dirkse, W; Van Staveren, M; Stiekema, W; Drost, L; Ridley, P; Hudson, SA; Patel, K; Murphy, G; Piffanelli, P; Wedler, H; Wedler, E; Wambutt, R; Weitzenegger, T; Pohl, TM; Terryn, N; Gielen, J; Villarroel, R; De Clerck, R; Van Montagu, M; Lecharny, A; Auborg, S; Gy, I; Kreis, M; Lao, N; Kavanagh, T; Hempel, S; Kotter, P; Entian, KD; Rieger, M; Schaeffer, M; Funk, B; Mueller-Auer, S; Silvey, M; James, R; Montfort, A; Pons, A; Puigdomenech, P; Douka, A; Voukelatou, E; Milioni, D; Hatzopoulos, P; Piravandi, E; Obermaier, B; Hilbert, H; Dusterhoft, A; Moores, T; Jones, JDG; Eneva, T; Palme, K; Benes, V; Rechman, S; Ansorge, W; Cooke, R; Berger, C; Delseny, M; Voet, M; Volckaert, G; Mewes, HW; Klosterman, S; Schueller, C; Chalwatzis, N				Bevan, M; Bancroft, I; Bent, E; Love, K; Goodman, H; Dean, C; Bergkamp, R; Dirkse, W; Van Staveren, M; Stiekema, W; Drost, L; Ridley, P; Hudson, SA; Patel, K; Murphy, G; Piffanelli, P; Wedler, H; Wedler, E; Wambutt, R; Weitzenegger, T; Pohl, TM; Terryn, N; Gielen, J; Villarroel, R; De Clerck, R; Van Montagu, M; Lecharny, A; Auborg, S; Gy, I; Kreis, M; Lao, N; Kavanagh, T; Hempel, S; Kotter, P; Entian, KD; Rieger, M; Schaeffer, M; Funk, B; Mueller-Auer, S; Silvey, M; James, R; Montfort, A; Pons, A; Puigdomenech, P; Douka, A; Voukelatou, E; Milioni, D; Hatzopoulos, P; Piravandi, E; Obermaier, B; Hilbert, H; Dusterhoft, A; Moores, T; Jones, JDG; Eneva, T; Palme, K; Benes, V; Rechman, S; Ansorge, W; Cooke, R; Berger, C; Delseny, M; Voet, M; Volckaert, G; Mewes, HW; Klosterman, S; Schueller, C; Chalwatzis, N		EU Arabidopsis Genome Project	Analysis of 1.9 Mb of contiguous sequence from chromosome 4 of Arabidopsis thaliana	NATURE			English	Article							PHYSICAL MAP; RETROTRANSPOSONS; ASSOCIATION; EXPRESSION; EVOLUTION; REGIONS; PROTEIN; GENOME; GENES	The plant Arabidopsis thaliana (Arabidopsis) has become an important model species for the study of many aspects of plant biology(1). The relatively small size of the nuclear genome and the availability of extensive physical maps of the five chromosomes(2-4) provide a feasible basis for initiating sequencing of the five chromosomes. The YAC (yeast artificial chromosome)-based physical map of chromosome 4 was used to construct a sequence-ready map of cosmid and BAC (bacterial artificial chromosome) clones covering a 1,9-megabase (Mb) contiguous region(5), and the sequence of this region is reported here. Analysis of the sequence revealed an average gene density of one gene every 4.8 kilobases (kb), and 54% of the predicted genes had significant similarity to known genes. Other interesting features were found, such as the sequence of a disease-resistance gene locus, the distribution of retroelements, the frequent occurrence of clustered gene families, and the sequence of several classes of genes not previously encountered in plants.	John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UJ, Norfolk, England; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02144 USA; DLO, Ctr Plant Breeding & Reprod Res, Dept Mol Biol, NL-6700 AA Wageningen, Netherlands; AGOWA GmbH, D-12489 Berlin, Germany; GATC GmbH, D-78467 Constance, Germany; Vlaams Interuniv Inst Biotechnol, Dept Genet, B-9000 Ghent, Belgium; Univ Paris 11, Inst Biotechnol Plantes, CNRS, ERS 569, F-91405 Orsay, France; Univ Dublin Trinity Coll, Dept Genet, Dublin 2, Ireland; SRD GmbH, D-61440 Oberursel, Germany; Genotype GmbH, D-69259 Wilhelmsfeld, Germany; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; CSIC, CID, E-08034 Barcelona, Spain; Agr Univ Athens, GR-11855 Athens, Greece; Medigene AG, D-82152 Planegg Martinsried, Germany; QIAGEN GmbH, D-4072 Hilden, Germany; John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UJ, Norfolk, England; Max Planck Gesell, Max Delbruck Lab, D-50829 Cologne, Germany; European Mol Biol Lab, D-69012 Heidelberg, Germany; Univ Perpignan, CNRS, UMR 5545, F-66860 Perpignan, France; Katholieke Univ Leuven, Lab Gene Technol, B-3001 Louvain, Belgium; Max Planck Inst Biochem, Martinsrieder Inst Prot Sequenzen, D-82152 Martinsried, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Harvard University; Harvard Medical School; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Trinity College Dublin; University of East Anglia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion y Desarrollo Pascual Vila (CID-CSIC); Agricultural University of Athens; QIAGEN GmbH; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Max Planck Society; European Molecular Biology Laboratory (EMBL); Centre National de la Recherche Scientifique (CNRS); Universite Perpignan Via Domitia; KU Leuven; Max Planck Society	Bevan, M (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Genet, Norwich NR4 7UJ, Norfolk, England.	bevan@bbsrc.ac.uk	James, Richard/B-2252-2009; Ding, Cheng-Qiang/B-6287-2011; Palme, Klaus/A-9524-2013; Entian, Karl-Dieter/D-3080-2011; Monfort, Amparo/K-1356-2015; Bancroft, Ian/AAH-3831-2020; Jones, Jonathan DG/J-5129-2012; Ansorge, Wilhelm/AAN-8780-2020; Mewes, Hans-Werner/A-8204-2019	Palme, Klaus/0000-0002-2728-3835; Monfort, Amparo/0000-0001-7106-7745; Jones, Jonathan DG/0000-0002-4953-261X; Silvey, Mark/0000-0002-9096-3139; Mewes, Hans-Werner/0000-0002-9713-6398; Benes, Vladimir/0000-0002-0352-2547; Cooke, Richard/0000-0001-6335-1092; Bancroft, Ian/0000-0001-7707-1171				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BACK K, 1995, J BIOL CHEM, V270, P7375, DOI 10.1074/jbc.270.13.7375; Bancroft I., 1997, WEEDS WORLD, V4, P1; BENT E, IN PRESS PLANT J; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; GAVIN KA, 1995, SCIENCE, V270, P1667, DOI 10.1126/science.270.5242.1667; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; KONIECZNY A, 1991, GENETICS, V127, P801; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Meyerowitz EM, 1997, GENETICS, V145, P5; MEYEROWITZ EM, 1994, ARABIDOPSIS; Miklos GLG, 1996, CELL, V86, P521, DOI 10.1016/S0092-8674(00)80126-9; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Oppenheimer DG, 1997, P NATL ACAD SCI USA, V94, P6261, DOI 10.1073/pnas.94.12.6261; Parker JE, 1997, PLANT CELL, V9, P879, DOI 10.1105/tpc.9.6.879; Pear JR, 1996, P NATL ACAD SCI USA, V93, P12637, DOI 10.1073/pnas.93.22.12637; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SanMiguel P, 1996, SCIENCE, V274, P765, DOI 10.1126/science.274.5288.765; Sato S, 1997, DNA Res, V4, P215, DOI 10.1093/dnares/4.3.215; Schmidt R, 1997, PLANT J, V11, P563, DOI 10.1046/j.1365-313X.1997.11030563.x; SCHMIDT R, 1995, SCIENCE, V270, P480, DOI 10.1126/science.270.5235.480; WESSLER SR, 1995, CURR OPIN GENET DEV, V5, P814, DOI 10.1016/0959-437X(95)80016-X; WHITE SE, 1994, P NATL ACAD SCI USA, V91, P11792, DOI 10.1073/pnas.91.25.11792; Zachgo EA, 1996, GENOME RES, V6, P19, DOI 10.1101/gr.6.1.19	29	458	877	1	4	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					485	488		10.1038/35140	http://dx.doi.org/10.1038/35140			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461215				2022-12-01	WOS:000071701800050
J	Li, HM; Lebedeva, MI; Llera, AS; Fields, BA; Brenner, MB; Mariuzza, RA				Li, HM; Lebedeva, MI; Llera, AS; Fields, BA; Brenner, MB; Mariuzza, RA			Structure of the V delta domain of a human gamma delta T-cell antigen receptor	NATURE			English	Article							CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; BETA-CHAIN; RECOGNITION; COMPLEX; ORIENTATION; HLA-A2	Antigen recognition by T lymphocytes is mediated by cell-surface glycoproteins known as T-cell antigen receptors (TCRs). These are composed of alpha and beta, or gamma and delta, polypeptide chains with variable (V) and constant (C) regions, In contrast to alpha beta TCRs, which recognize antigen only as peptide fragments bound to molecules of the major histocompatibility complex (MHC), gamma delta TCRs appear to recognize proteins directly, without antigen processing, and to recognize MHC molecules independently of the bound peptide(1-4). Moreover, small phosphate-containing non-peptide compounds have also been identified as ligands far certain gamma delta T cells(5,6). These studies indicate that antigen recognition by gamma delta TCRs may be fundamentally different from that by alpha beta TCRs. The three-dimensional structures of several ap TCRs and TCR fragments(7-10), and their complexes with peptide-MHC or superantigens(9-11), have been determined. Here we report the crystal structure of the V delta domain of a human gamma delta TCR at 1.9 Angstrom resolution. A comparison with antibody and alpha beta TCR V domains reveals that the framework structure of V delta more closely resembles that of VH than of V alpha; V beta or VL (where H and L refer to heavy and light chains), whereas the relative positions and conformations of its complementarity-determining regions (CDRs) share features of both V alpha and VH. These results provide the first direct evidence that gamma delta TCRs are structurally distinct from alpha beta TCRs and, together with the observation that thr CDR3 length distribution of TCR delta chains is similar to that of immunoglobulin heavy chains(12), are consistent with functional studies suggesting that recognition of certain antigens by gamma delta TCRs may resemble antigen recognition by antibodies(1-3).	Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, Rockville, MD 20850 USA; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Rheumatol & Immunol,Lymphocyte Biol Sect, Boston, MA 02115 USA	University of Sydney; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Mariuzza, RA (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Adv Res Biotechnol, 9600 Gudelsky Dr, Rockville, MD 20850 USA.	mariuzza@indigo2.carb.nist.gov	Li, Hongmin/ABI-2439-2020; Llera, Andrea S/AAW-8116-2021	Li, Hongmin/0000-0002-8684-5308; Fields, Barry/0000-0003-0628-1328; Llera, Andrea/0000-0002-0089-0061				Arden Bernhard, 1995, Immunogenetics, V42, P455; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; BHAT TN, 1994, P NATL ACAD SCI USA, V91, P1089, DOI 10.1073/pnas.91.3.1089; BIGBY M, 1993, J IMMUNOL, V151, P4465; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1006/jmbi.1994.1582; Chien YH, 1996, ANNU REV IMMUNOL, V14, P511, DOI 10.1146/annurev.immunol.14.1.511; CHOTHIA C, 1989, NATURE, V342, P877, DOI 10.1038/342877a0; CONSTANT P, 1994, SCIENCE, V264, P267, DOI 10.1126/science.8146660; CORREA I, 1992, P NATL ACAD SCI USA, V89, P653, DOI 10.1073/pnas.89.2.653; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; Crowley MP, 1997, J EXP MED, V185, P1223, DOI 10.1084/jem.185.7.1223; FAN ZC, 1992, J MOL BIOL, V228, P188, DOI 10.1016/0022-2836(92)90500-J; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fields BA, 1996, NATURE, V384, P188, DOI 10.1038/384188a0; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.iy.11.040193.003225; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; Kabat EA, 1991, SEQUENCES PROTEINS I, V5th; KRANGEL MS, 1990, J EXP MED, V172, P847, DOI 10.1084/jem.172.3.847; Lebedeva MI, 1996, PROTEIN SCI, V5, P2638, DOI 10.1002/pro.5560051226; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROCK EP, 1994, J EXP MED, V179, P323, DOI 10.1084/jem.179.1.323; SCHILD H, 1994, CELL, V76, P29, DOI 10.1016/0092-8674(94)90170-8; SCIAMMAS R, 1994, J IMMUNOL, V152, P5392; SPITS H, 1990, J IMMUNOL, V144, P4156; TANAKA Y, 1995, NATURE, V375, P155, DOI 10.1038/375155a0	30	110	114	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					502	506		10.1038/35172	http://dx.doi.org/10.1038/35172			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461220				2022-12-01	WOS:000071701800055
J	De Strooper, B; Saftig, P; Craessaerts, K; Vanderstichele, H; Guhde, G; Annaert, W; Von Figura, K; Van Leuven, F				De Strooper, B; Saftig, P; Craessaerts, K; Vanderstichele, H; Guhde, G; Annaert, W; Von Figura, K; Van Leuven, F			Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein	NATURE			English	Article							FAMILIAL ALZHEIMERS-DISEASE; HIPPOCAMPAL-NEURONS; BETA-PROTEIN; MUTATIONS; PEPTIDE; CELLS	Point mutations in the presenilin-1 gene (PS1) are a major cause of familial Alzheimer's disease, They result in a selective increase in the production of the amyloidogenic peptide amyloid-beta(1-42) by proteolytic processing of the amyloid precursor protein (APP)(1-4). Here we investigate whether PS1 is also involved in normal APP processing in neuronal cultures derived from PS1-deficient mouse embryos. Cleavage by alpha- and beta-secretase(5) of the extracellular domain of APP was not affected by the absence of PS1, whereas cleavage by gamma-secretase of the transmembrane domain of APP was prevented, causing carboxyl-terminal fragments of APP to accumulate and a fivefold drop in the production of amyloid peptide. Pulse-chase experiments indicated that PS1 deficiency specifically decreased the turnover of the membrane-associated fragments of APP. As in the regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor(6), PS1 appears to facilitate a proteolytic activity that cleaves the integral membrane domain of APP. Our results indicate that mutations in PS1 that manifest clinically cause a gain of function and that inhibition of PS1 activity is a potential target for anti-amyloidogenic therapy in Alzheimer's disease.	Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Louvain, Belgium; Innogenet NV, B-9057 Ghent, Belgium; Univ Gottingen, Zentrum Biochem & Mol Zellbiol, Biochem Abt 2, D-37073 Gottingen, Germany	Flanders Institute for Biotechnology (VIB); KU Leuven; Innogenetics NV; University of Gottingen	Saftig, P (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Expt Genet Grp, Louvain, Belgium.	Saftig@uni-bc2.gwdg.de	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019; Saftig, Paul/A-7966-2010; Vanderstichele, Hugo/AAD-2601-2019	De Strooper, Bart/0000-0001-5455-5819; 				Barelli HL, 1997, MOL MED, V3, P695, DOI 10.1007/BF03401708; Baumeister R, 1997, Genes Funct, V1, P149; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; DESTROOPER B, 1995, EMBO J, V14, P4932, DOI 10.1002/j.1460-2075.1995.tb00176.x; DeStrooper B, 1997, J BIOL CHEM, V272, P3590, DOI 10.1074/jbc.272.6.3590; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; Doan A, 1996, NEURON, V17, P1023, DOI 10.1016/S0896-6273(00)80232-9; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1992, NATURE, V359, P322, DOI 10.1038/359322a0; Haass C, 1997, NEURON, V18, P687, DOI 10.1016/S0896-6273(00)80309-8; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Lehmann S, 1997, J BIOL CHEM, V272, P12047, DOI 10.1074/jbc.272.18.12047; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LI X, 1996, NEURON, V17, P1017; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Simons M, 1996, J NEUROSCI, V16, P899; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; VANDERSTICHELE H, IN PRESS PROGR ALZHE; Weidemann A, 1997, NAT MED, V3, P328, DOI 10.1038/nm0397-328; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Xia WM, 1997, P NATL ACAD SCI USA, V94, P8208, DOI 10.1073/pnas.94.15.8208	29	1516	1560	1	115	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					387	390		10.1038/34910	http://dx.doi.org/10.1038/34910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450754				2022-12-01	WOS:000071604200054
J	Davies, SW; Beardsall, K; Turmaine, M; DiFiglia, M; Aronin, N; Bates, GP				Davies, SW; Beardsall, K; Turmaine, M; DiFiglia, M; Aronin, N; Bates, GP			Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?	LANCET			English	Article							SPINOCEREBELLAR ATAXIA TYPE-2; BULBAR MUSCULAR-ATROPHY; ANDROGEN RECEPTOR GENE; CAG REPEAT; HYALINE INCLUSIONS; DISEASE; DEGENERATION; CLONING	Neuronal intranuclear inclusions have been found in the brain of a transgenic mouse model of Huntington's disease and in necropsy brain tissue of patients with Huntington's disease, We suggest that neuronal intranuclear inclusions are the common neuropathology for all inherited diseases caused by expansion of polyglutamine repeats, We also suggest that patients with a pathological diagnosis of neuronal intranuclear hyaline inclusion disease may also have polyglutamine repeat expansions.	UCL, Dept Anat & Dev Biol, London WC1E 6JJ, England; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA; Univ Med & Dent New Jersey, Guys Hosp, Div Med & Mol Genet, London, England	University of London; University College London; Harvard University; Harvard Medical School; Massachusetts General Hospital; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Davies, SW (corresponding author), UCL, Dept Anat & Dev Biol, Rockefeller Bldg, London WC1E 6JJ, England.		Bates, Gillian P/E-1146-2012	Bates, Gillian P/0000-0002-4041-6305				[Anonymous], ADV NEUROL; BANFI S, 1994, NAT GENET, V7, P513, DOI 10.1038/ng0894-513; Bates GP, 1997, HUM MOL GENET, V6, P1633, DOI 10.1093/hmg/6.10.1633; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; GILLES D, 1997, NAT GENET, V17, P65; Heintz N, 1997, NAT GENET, V16, P325, DOI 10.1038/ng0897-325; Imbert G, 1996, NAT GENET, V14, P285, DOI 10.1038/ng1196-285; JANOTA I, 1979, NEUROPATH APPL NEURO, V5, P311, DOI 10.1111/j.1365-2990.1979.tb00630.x; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LINDENBERG R, 1968, ACTA NEUROPATHOL, V10, P54, DOI 10.1007/BF00690510; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; MUNOZGARCIA D, 1986, NEUROLOGY, V36, P785, DOI 10.1212/WNL.36.6.785; NAKAMURA M, 1993, ANN NEUROL, V34, P261; NAKAMURA Y, 1994, RHODIUM EX, V6, P14; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PARKER JC, 1983, J NEUROPATH EXP NEUR, V42, P352, DOI 10.1097/00005072-198305000-00149; PATEL H, 1985, J NEUROL SCI, V67, P57, DOI 10.1016/0022-510X(85)90022-X; Paulson HL, 1997, ANN NEUROL, V41, P453, DOI 10.1002/ana.410410408; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Pulst SM, 1996, NAT GENET, V14, P269, DOI 10.1038/ng1196-269; ROBITAILLE Y, 1997, BRAIN PATHOL, V7, P877; Ross CA, 1997, BRAIN PATHOL, V7, P1003, DOI 10.1111/j.1750-3639.1997.tb00898.x; Sanpei K, 1996, NAT GENET, V14, P277, DOI 10.1038/ng1196-277; Sathasivam K, 1997, HUM GENET, V99, P692, DOI 10.1007/s004390050432; SCHALLING M, 1993, NAT GENET, V4, P136; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SCHUFFLER MD, 1978, GASTROENTEROLOGY, V75, P889; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; SLOANE AE, 1994, PEDIATR NEUROL, V10, P61, DOI 10.1016/0887-8994(94)90070-1; SOFFER D, 1985, ACTA NEUROPATHOL, V65, P322, DOI 10.1007/BF00687016; SUNG JH, 1980, J NEUROPATH EXP NEUR, V39, P107, DOI 10.1097/00005072-198003000-00001; SUNG JH, 1980, ACTA NEUROPATHOL, V50, P115, DOI 10.1007/BF00692861; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; YOUNG AB, 1977, HUNTINGTONS DIS OTHE; ZHUCHENKO S, 1997, NAT GENET, V15, P622	39	145	147	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					131	133		10.1016/S0140-6736(97)08360-8	http://dx.doi.org/10.1016/S0140-6736(97)08360-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439509				2022-12-01	WOS:000071591900045
J	Salisbury, DM				Salisbury, DM			Association between oral poliovaccine and Guillain-Barre syndrome?	LANCET			English	Editorial Material							CAMPAIGN		Dept Hlth, London SE1 8UG, England		Salisbury, DM (corresponding author), Dept Hlth, London SE1 8UG, England.							daSilveira CM, 1997, LANCET, V349, P14, DOI 10.1016/S0140-6736(96)07408-9; Howson CP, 1991, ADVERSE EFFECTS PERT; Hughes R, 1996, BRIT MED J, V312, P1475; KINNUNEN E, 1989, NEUROLOGY, V39, P1034, DOI 10.1212/WNL.39.8.1034; Kinnunen E, 1998, AM J EPIDEMIOL, V147, P69; Olive JA, 1997, J INFECT DIS, V175, pS160, DOI 10.1093/infdis/175.Supplement_1.S160; Stratton K.R., 1994, ADVERSE EVENTS ASS C; UHARI M, 1989, LANCET, V2, P440	8	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					79	80		10.1016/S0140-6736(05)78156-3	http://dx.doi.org/10.1016/S0140-6736(05)78156-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439487				2022-12-01	WOS:000071591900004
J	Gow, AJ; Stamler, JS				Gow, AJ; Stamler, JS			Reactions between nitric oxide and haemoglobin under physiological conditions	NATURE			English	Article							HEMOGLOBIN; NO; BLOOD; NITROSYLATION; BINDING; CELLS	The tenet of high-affinity nitric oxide (NO) binding to a haemoglobin (Hb) has shaped our view of haem proteins and of small diffusible signaling molecules. Specifically, NO binds rapidly to haem iron in Hb (k approximate to 10(7) M-1 s(-1)) (refs 1, 2) and once bound, the NO activity is largely irretrievable (K-d approximate to 10(-5) s(-1)) (refs 3-10); the binding is purportedly so tight as to be unaffected by O-2 or CO. However, these general principles do not consider the allosteric state of Hb or the nature of the allosteric effector,and they mostly derive from the functional behaviour of fully nitrosylated Hb, whereas Hb is only partially nitrosylated in vivo(11-16). Here we show that oxygen drives the conversion of nitrosylhaemoglobin in the 'tense' T (or partially nitrosylated, deoxy) structure to S-nitrosohaemoglobin in the 'relaxed' R (or ligand-bound, oxy) structure. In the absence of oxygen, nitroxyl anion(NO-) is liberated in a reaction producing methaemoglobin. The yields of both S-nitrosohaemoglobin and methaemoeglobin are dependent on the NO/Hb ratio. These newly discovered reactions elucidate mechanisms underlying NO function in the respiratory cycle, and provide insight into the aetiology of S-nitrosothiols, methaemoglobin and its related valency hybrids. Mechanistic re-examination of NO interactions with other haem proteins containing allosteric-site thiols may be warranted.	Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Howard Hughes Med Inst, Durham, NC 27710 USA; Univ Penn, Inst Environm Med, Philadelphia, PA 19104 USA	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute; University of Pennsylvania	Stamler, JS (corresponding author), Duke Univ, Med Ctr, Dept Med, Howard Hughes Med Inst, Durham, NC 27710 USA.		Gow, Andrew/AAR-2309-2020; Gow, Andrew/N-8566-2013	Gow, Andrew/0000-0003-0876-5158; Gow, Andrew/0000-0003-0876-5158; Stamler, Jonathan/0000-0002-6866-1572				ADDISON AW, 1986, BIOCHEMISTRY-US, V25, P4104, DOI 10.1021/bi00362a018; ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, V32, P272; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; CASSOLY R, 1975, J MOL BIOL, V91, P301, DOI 10.1016/0022-2836(75)90382-4; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507, DOI 10.1113/jphysiol.1957.sp005777; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; HENRY Y, 1993, FASEB J, V7, P1124, DOI 10.1096/fasebj.7.12.8397130; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kagan VE, 1996, NATURE, V383, P30, DOI 10.1038/383030b0; KHARITONOV VG, 1996, METHODS NITRIC OXIDE, P39; KOSAKA H, 1994, AM J PHYSIOL, V266, pC1400, DOI 10.1152/ajpcell.1994.266.5.C1400; KRUSZYNA R, 1988, TOXICOL APPL PHARM, V94, P458, DOI 10.1016/0041-008X(88)90286-4; KRUSZYNA R, 1987, J PHARMACOL EXP THER, V241, P307; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; MARLETTA M A, 1990, Biofactors, V2, P219; MOORE EG, 1976, J BIOL CHEM, V251, P2788; Motterlini R, 1996, TRANSFUS MED REV, V10, P77, DOI 10.1016/S0887-7963(96)80084-8; Perutz MF, 1996, NATURE, V380, P205, DOI 10.1038/380205b0; PERUTZ MF, 1987, MOL BASIS BLOOD DISE, P127; RIGGS A, 1961, J BIOL CHEM, V236, P1948; RIGGS AF, 1956, J GEN PHYSIOL, V39, P585, DOI 10.1085/jgp.39.4.585; SHARMA VS, 1978, J BIOL CHEM, V253, P6467; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TAKETA F, 1978, J BIOL CHEM, V253, P5448; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; WESTENBERGER U, 1990, FREE RADICAL RES COM, V11, P167, DOI 10.3109/10715769009109680	30	490	508	0	40	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					169	173		10.1038/34402	http://dx.doi.org/10.1038/34402			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428761				2022-12-01	WOS:000071380900049
J	Hosenpud, JD; Bennett, LE; Keck, BM; Edwards, EB; Novick, RJ				Hosenpud, JD; Bennett, LE; Keck, BM; Edwards, EB; Novick, RJ			Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease	LANCET			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; REDUCTION SURGERY APPROPRIATE; QUALITY-OF-LIFE; EMPHYSEMA; RECIPIENTS; PROGNOSIS	Background Although certain forms of end-stage lung disease are debilitating, whether the associated mortality rate exceeds that of transplantation is unclear. We undertook analysis to clarify the survival benefit of lung transplantation for various types of end-stage lung disease. Methods We analysed data for all patients listed for transplantation in the USA for emphysema, cystic fibrosis, or interstitial pulmonary fibrosis in the years 1992-94. The numbers of patients entered on the waiting list, posttransplantation, died waiting, and currently waiting were: emphysema group 1274, 843, 143, and 165; cystic fibrosis group 664, 318, 193, and 59; interstitial pulmonary fibrosis group 481, 230, 160, and 48, A time-dependent non-proportional hazard analysis was used to assess the risk of mortality after transplantation relative to that for patients an the waiting list. Findings The dearest survival benefit from lung transplantation occurred in the cystic fibrosis group, The relative risks of transplantation compared with waiting were 0.87, 0.61, and 0.61 at 1 month, 6 months, and 1 year (p=0.008), respectively. For interstitial pulmonary fibrosis, the corresponding relative risks were 2.09, 0.71, and 0.67 (p=0.09). No survival benefit was apparent in the emphysema group, The risks of transplantation relative to waiting were 2.76, 1.12, and 1.10 at 1 month, 6 months, and 1 year, respectively, and the relative risk did not decrease to below 1.0 during 2 years of follow-up. Interpretation These findings suggest that lung transplantation does not confer a survival benefit in patients with end-stage emphysema by 2 years of follow-up, Other benefits not accounted for in this analysis such as improved quality of life, however, may justify lung transplantation for these patients.	Int Soc Heart & Lung Transplantat Thorac Registry, Joint United Network Organ Sharing, Richmond, VA USA	United Network for Organ Sharing	Hosenpud, JD (corresponding author), Med Coll Wisconsin, Div Cardiovasc Med, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA.		Bennett, Louise/AAA-8266-2020	Bennett, Louise/0000-0001-9421-4410				[Anonymous], 1980, Ann Intern Med, V93, P391; [Anonymous], 1983, ANN INTERN MED, V99, P612, DOI 10.7326/0003-4819-99-5-612; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14, DOI 10.1164/arrd.1986.133.1.14; ANTHONISEN NR, 1989, AM REV RESPIR DIS, V140, pS95, DOI 10.1164/ajrccm/140.3_Pt_2.S95; COOPER JD, 1995, J THORAC CARDIOV SUR, V109, P106, DOI 10.1016/S0022-5223(95)70426-4; Cooper JD, 1996, AM J RESP CRIT CARE, V153, P1201, DOI 10.1164/ajrccm.153.4.8616541; COX DR, 1984, ANAL SURVIVAL DATA, P137; GROSS CR, 1995, CHEST, V108, P1587, DOI 10.1378/chest.108.6.1587; Hosenpud JD, 1996, J HEART LUNG TRANSPL, V15, P655; Lynch JP, 1996, MED CLIN N AM, V80, P657, DOI 10.1016/S0025-7125(05)70459-4; Make BJ, 1996, AM J RESP CRIT CARE, V153, P1205, DOI 10.1164/ajrccm.153.4.8616542; Naunheim KS, 1996, ANN THORAC SURG, V62, P601, DOI 10.1016/0003-4975(96)00428-6; ONOFRIO JM, 1992, MED CLIN N AM, V76, P1207, DOI 10.1016/S0025-7125(16)30319-4; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; RAMSEY SD, 1995, J HEART LUNG TRANSPL, V14, P870; RAMSEY SD, 1995, CHEST, V108, P1594, DOI 10.1378/chest.108.6.1594; SUNDARESAN S, 1995, ANN THORAC SURG, V60, P1341, DOI 10.1016/0003-4975(95)00751-6; ZENATI M, 1995, ANN THORAC SURG, V59, P1581, DOI 10.1016/0003-4975(95)00082-V	18	351	352	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 3	1998	351	9095					24	27		10.1016/S0140-6736(97)06405-2	http://dx.doi.org/10.1016/S0140-6736(97)06405-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433425				2022-12-01	WOS:000071253100012
J	Chen, R; Amoui, M; Zhang, ZH; Mardon, G				Chen, R; Amoui, M; Zhang, ZH; Mardon, G			Dachshund and eyes absent proteins form a complex and function synergistically to induce ectopic eye development in Drosophila	CELL			English	Article							HOMEOBOX-CONTAINING GENE; VISUAL-SYSTEM; EYELESS GENE; ENCODES; DIFFERENTIATION; MORPHOGENESIS; ANIRIDIA; DPP; MELANOGASTER; PROPAGATION	The eyeless, dachshund, and eyes absent genes encode conserved, nuclear proteins that are essential for eye development in Drosophila. Misexpression of eyeless or dachshund is also sufficient to induce the formation of ectopic compound eyes. Here we show that the dachshund and eyes absent genes act synergistically to induce ectopic retinal development and positively regulate the expression of each other. Moreover, we show that the Dachshund and Eyes Absent proteins can physically interact through conserved domains, suggesting a molecular basis for the genetic synergy observed and that a similar complex may function in mammals. We propose that a conserved regulatory network, rather than a linear hierarchy, controls retinal specification and involves multiple protein complexes that function during distinct steps of eye development.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA; Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Mardon, G (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD024064] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011232] Funding Source: NIH RePORTER; NEI NIH HHS [EY07001, R01 EY11232-01] Funding Source: Medline; NICHD NIH HHS [P30 HD24064] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BEVERLEY SM, 1984, J MOL EVOL, V21, P1, DOI 10.1007/BF02100622; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BONINI NM, 1995, CURR OPIN GENET DEV, V5, P507, DOI 10.1016/0959-437X(95)90056-M; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chanut F, 1997, DEVELOPMENT, V124, P559; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Freund C, 1996, HUM MOL GENET, V5, P1471, DOI 10.1093/hmg/5.Supplement_1.1471; Glardon S, 1997, DEVELOPMENT, V124, P817; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HARPER JW, 1993, CELL, V75, P805; HEBERLEIN U, 1995, CELL, V81, P987, DOI 10.1016/S0092-8674(05)80003-0; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HILL RE, 1992, NATURE, V355, P750, DOI 10.1038/355750a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HORTSCH M, 1990, DEVELOPMENT, V110, P1327; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MOSES K, 1991, GENE DEV, V5, P583, DOI 10.1101/gad.5.4.583; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Oliver G, 1995, DEVELOPMENT, V121, P4045; Pignoni F, 1997, CELL, V91, P881, DOI 10.1016/S0092-8674(00)80480-8; Pignoni F, 1997, DEVELOPMENT, V124, P271; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; READY DF, 1976, DEV BIOL, V53, P217, DOI 10.1016/0012-1606(76)90225-6; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; Shen WP, 1997, DEVELOPMENT, V124, P45; STAEHLINGHAMPTON K, 1994, DEV BIOL, V164, P502, DOI 10.1006/dbio.1994.1219; THAKER HM, 1992, GENETICS, V131, P883; Tomarev SI, 1997, P NATL ACAD SCI USA, V94, P2421, DOI 10.1073/pnas.94.6.2421; TOMLINSON A, 1987, DEV BIOL, V120, P366, DOI 10.1016/0012-1606(87)90239-9; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; TREISMAN JE, 1995, DEVELOPMENT, V121, P3519; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; Wolff Tanya, 1993, P1277; Xu PX, 1997, DEVELOPMENT, V124, P219; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	44	314	323	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					893	903		10.1016/S0092-8674(00)80481-X	http://dx.doi.org/10.1016/S0092-8674(00)80481-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428513	Bronze			2022-12-01	WOS:000071281400007
J	Yaffe, MB; Rittinger, K; Volinia, S; Caron, PR; Aitken, A; Leffers, H; Gamblin, SJ; Smerdon, SJ; Cantley, LC				Yaffe, MB; Rittinger, K; Volinia, S; Caron, PR; Aitken, A; Leffers, H; Gamblin, SJ; Smerdon, SJ; Cantley, LC			The structural basis for 14-3-3 : phosphopeptide binding specificity	CELL			English	Article							PROTEIN-KINASE-C; BIOSPECIFIC INTERACTION ANALYSIS; MULTIPLE SIGNALING PATHWAYS; MIDDLE TUMOR-ANTIGEN; 14-3-3 PROTEIN; T-CELLS; 14-3-3-PROTEINS; ASSOCIATION; INHIBITION; ACTIVATION	The 14-3-3 family of proteins mediates signal transduction by binding to phosphoserine-containing proteins. Using phosphoserine-oriented peptide libraries to probe all mammalian and yeast 14-3-3s, we identified two different binding motifs, RSXpSXP and RXY/FXpSXP, present in nearly all known 14-3-3 binding proteins. The crystal structure of 14-3-3 zeta complexed with the phosphoserine motif in polyoma middle-T was determined to 2.6 Angstrom resolution. The bound peptide is in an extended conformation, with a tight turn created by the pS +2 Pro in a cia conformation. Sites of peptide-protein interaction in the complex rationalize the peptide library results. Finally, we show that the 14-3-3 dimer binds tightly to single molecules containing tandem repeats of phosphoserine motifs, implicating bidentate association as a signaling mechanism with molecules such as Raf, BAD, and CbI.	Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Surg, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Vertex Pharmaceut, Cambridge, MA 02139 USA; Natl Inst Med Res, Div Prot Struct, London NW7 1AA, England; Rigshosp, Dept Growth, DK-2100 Copenhagen, Denmark; Rigshosp, Reprod Sect GR5064, DK-2100 Copenhagen, Denmark	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Vertex Pharmaceuticals; MRC National Institute for Medical Research; Rigshospitalet; University of Copenhagen; Rigshospitalet; University of Copenhagen	Yaffe, MB (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Signal Transduct, HIM 1018,330 Brookline Ave, Boston, MA 02215 USA.		Volinia, Stefano/AAA-9264-2019; Cantley, Lewis C/D-1800-2014; Rittinger, Katrin/N-3344-2019; Rittinger, Katrin/D-2586-2014; Volinia, Stefano/A-3029-2010	Volinia, Stefano/0000-0003-0910-3893; Cantley, Lewis C/0000-0002-1298-7653; Rittinger, Katrin/0000-0002-7698-4435; Rittinger, Katrin/0000-0002-7698-4435; Volinia, Stefano/0000-0003-0910-3893; Smerdon, Stephen/0000-0001-5688-8465; Gamblin, Steve/0000-0001-5331-639X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56203, R01 GM056203] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITKEN A, 1995, MOL CELL BIOCHEM, V149, P41, DOI 10.1007/BF01076562; AITKEN A, 1995, J BIOL CHEM, V270, P5706, DOI 10.1074/jbc.270.11.5706; Aitken A, 1996, TRENDS CELL BIOL, V6, P341, DOI 10.1016/0962-8924(96)10029-5; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BONNEFOYBERARD N, 1995, P NATL ACAD SCI USA, V92, P10142, DOI 10.1073/pnas.92.22.10142; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COURTNEIDGE SA, 1984, EMBO J, V3, P585, DOI 10.1002/j.1460-2075.1984.tb01852.x; Craparo A, 1997, J BIOL CHEM, V272, P11663; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Dubois T, 1997, J BIOL CHEM, V272, P28882, DOI 10.1074/jbc.272.46.28882; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; JONES DHA, 1995, J MOL BIOL, V245, P375, DOI 10.1006/jmbi.1994.0031; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONSSON U, 1993, ANN BIOL CLIN-PARIS, V51, P19; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LIU D, 1995, NATURE, V376, P191, DOI 10.1038/376191a0; Liu YC, 1996, J BIOL CHEM, V271, P14591, DOI 10.1074/jbc.271.24.14591; Liu YC, 1997, J BIOL CHEM, V272, P9979, DOI 10.1074/jbc.272.15.9979; Meller N, 1996, MOL CELL BIOL, V16, P5782; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PALLAS DC, 1994, SCIENCE, V265, P535, DOI 10.1126/science.8036498; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peng CY, 1997, SCIENCE, V277, P1501, DOI 10.1126/science.277.5331.1501; Rommel C, 1996, ONCOGENE, V12, P609; Schulz G.E., 1979, PRINCIPLES PROTEIN S; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; TOKER A, 1990, EUR J BIOCHEM, V191, P421, DOI 10.1111/j.1432-1033.1990.tb19138.x; Vincenz C, 1996, J BIOL CHEM, V271, P20029, DOI 10.1074/jbc.271.33.20029; Wakui H, 1997, J BIOL CHEM, V272, P8153, DOI 10.1074/jbc.272.13.8153; WheelerJones CPD, 1996, BIOCHEM J, V315, P41, DOI 10.1042/bj3150041; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	51	1319	1377	10	101	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					961	971		10.1016/S0092-8674(00)80487-0	http://dx.doi.org/10.1016/S0092-8674(00)80487-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428519	Bronze			2022-12-01	WOS:000071281400013
J	Tappero, JW; Koehler, JE				Tappero, JW; Koehler, JE			Bacillary angiomatosis or Kaposi's sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Centers for Disease Control & Prevention - USA; University of California System; University of California San Francisco	Tappero, JW (corresponding author), Ctr Dis Control & Prevent, Atlanta, GA 30333 USA.								0	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 25	1997	337	26					1888	1888		10.1056/NEJM199712253372605	http://dx.doi.org/10.1056/NEJM199712253372605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN051	9407156				2022-12-01	WOS:000071128200005
J	Hanlon, VM				Hanlon, VM			Damascus Road	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2137	2138						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9416996				2022-12-01	WOS:000071022200013
J	Debbie, JG; Trimarchi, CV				Debbie, JG; Trimarchi, CV			Prophylaxis for suspected exposure to bat rabies	LANCET			English	Editorial Material							EPIDEMIOLOGY		New York State Dept Hlth, Albany, NY 12201 USA	State University of New York (SUNY) System	Debbie, JG (corresponding author), New York State Dept Hlth, Albany, NY 12201 USA.							*CDC, 1997, MMWR-MORBID MORTAL W, V46, P770; CHILDS JE, 1994, EPIDEMIOL INFECT, V113, P501, DOI 10.1017/S0950268800068515; Feder HM, 1997, LANCET, V350, P1300, DOI 10.1016/S0140-6736(05)62479-8; LAFON M, 1986, LANCET, V2, P515; SCATTERDAY JE, 1954, VET MED, V49, P133; Smith JS, 1996, CLIN MICROBIOL REV, V9, P166, DOI 10.1128/CMR.9.2.166; Whitby JE, 1996, VET REC, V139, P491, DOI 10.1136/vr.139.20.491; *WHO, 1992, WHO TECH REP SER, V824, P21	8	5	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1790	1791		10.1016/S0140-6736(97)22051-9	http://dx.doi.org/10.1016/S0140-6736(97)22051-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428245				2022-12-01	WOS:000071102500002
J	Sundar, S; Reed, SG; Singh, VP; Kumar, PCK; Murray, HW				Sundar, S; Reed, SG; Singh, VP; Kumar, PCK; Murray, HW			Rapid accurate field diagnosis of Indian visceral leishmaniasis	LANCET			English	Article							KALA-AZAR; RECOMBINANT ANTIGEN; INTERFERON-GAMMA; INFECTION; IMMUNOCHEMOTHERAPY; SPECTRUM; KINESIN; FOCUS	Background A firm diagnosis of visceral leishmaniasis (kalaazar) requires demonstration of the parasite in organ aspirates or tissue biopsy samples. The aim of this prospective study was to assess the diagnostic usefulness of non-invasive testing for antibody to the leishmanial antigen K39 by means of antigen-impregnated nitrocellulose paper strips adapted for use under field conditions. Methods One drop of peripheral blood is applied to the nitrocellulose strip. Three drops of test buffer (phosphate-buffered saline plus bovine serum albumin) are added to the dried blood. The development of two visible bands indicates presence of IgG anti-K39. 323 consecutive patients with suspected kala-azar referred to two specialist units in India, and 25 healthy controls, provided fingerstick blood samples for the test. Spleen aspirates were taken from 250 patients. Findings Kala-azar was confirmed by microscopy of spleen-aspirate smears in 127 patients. The K39 strip test was positive in all 127; the estimated sensitivity was therefore 100% (95% CI 98-100). Four patients had positive strip tests but negative aspirate smears; all four responded to treatment for leishmaniasis. 217 individuals, including the 25 healthy controls, 73 patients with malaria or tuberculosis, and 119 spleen-aspirate-negative patients who had presumed malaria or cirrhosis (79) or no final diagnosis (40), had negative strip-test results. None of the 119 aspirate-negative patients developed evidence of kala-azar during 3-6 months of follow-up. The estimated specificity of the strip test was 98% (95-100; 217/221). Interpretation Detection of anti-K39 by immunochromatographic strip testing is a rapid and non-invasive method of diagnosing kala-azar, which has good sensitivity and specificity and is well suited for use in field conditions.	Banaras Hindu Univ, Inst Med Sci, Kala Azar Med Res Ctr, Varanasi 221005, Uttar Pradesh, India; Corixa Corp, Seattle, WA USA; Cornell Univ, Coll Med, Dept Med, New York, NY USA	Banaras Hindu University (BHU); Corixa; Cornell University	Murray, HW (corresponding author), Box 130,525 E 68th St, New York, NY 10021 USA.		Murray, Heather/GQY-8016-2022					ACHORD D, 1991, PRINCIPLES PRACTICE, P584; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BARDARO R, 1996, J INFECT DIS, V173, P758; BURNS JM, 1993, P NATL ACAD SCI USA, V90, P775, DOI 10.1073/pnas.90.2.775; GALVIN JP, 1987, RAPID METHODS AUTOMA, P558; HO M, 1982, T ROY SOC TROP MED H, V76, P741, DOI 10.1016/0035-9203(82)90095-5; MARTY P, 1994, T ROY SOC TROP MED H, V88, P658, DOI 10.1016/0035-9203(94)90214-3; NUZUM E, 1995, J INFECT DIS, V171, P751, DOI 10.1093/infdis/171.3.751; Pearson RD, 1996, CLIN INFECT DIS, V22, P1, DOI 10.1093/clinids/22.1.1; PETERS BS, 1990, Q J MED, V77, P1101, DOI 10.1093/qjmed/77.2.1101; PIARROUX R, 1994, J CLIN MICROBIOL, V32, P746, DOI 10.1128/JCM.32.3.746-749.1994; QU JQ, 1994, T ROY SOC TROP MED H, V88, P543, DOI 10.1016/0035-9203(94)90154-6; SACKS DL, 1987, J IMMUNOL, V138, P908; Saran R., 1992, Journal of Communicable Diseases, V24, P242; SCOTT JM, 1991, AM J TROP MED HYG, V44, P272, DOI 10.4269/ajtmh.1991.44.272; Singh S, 1995, J PARASITOL, V81, P1000, DOI 10.2307/3284056; SINHA R, 1994, J TROP MED HYG, V97, P333; SQUIRES KE, 1993, AM J TROP MED HYG, V48, P666, DOI 10.4269/ajtmh.1993.48.666; SUNDAR S, 1995, J INFECT DIS, V171, P992, DOI 10.1093/infdis/171.4.992; Sundar S, 1997, ANN INTERN MED, V127, P133, DOI 10.7326/0003-4819-127-2-199707150-00007; ZIJLSTRA EE, 1992, T ROY SOC TROP MED H, V86, P505, DOI 10.1016/0035-9203(92)90086-R	22	196	201	0	12	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					563	565		10.1016/S0140-6736(97)04350-X	http://dx.doi.org/10.1016/S0140-6736(97)04350-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492776	hybrid			2022-12-01	WOS:000072231900012
J	Houart, C; Westerfield, M; Wilson, SW				Houart, C; Westerfield, M; Wilson, SW			A small population of anterior cells patterns for forebrain during zebrafish gastrulation	NATURE			English	Article							NEURONAL DIFFERENTIATION; EXPRESSION; ENDODERM; BRAIN; GENES; HEAD	During gastrulation in vertebrates, dorsal ectoderm is induced to form neural tissue that later gives rise to the brain and spinal card. This induction depends on signals arising from a group of cells on the dorsal side of the gastrula, This group of cells constitutes the organizer(1,2). It is thought that the organizer initially induces neural tissue with anterior, or forebrain, character, and that other signals subsequently posteriorize neural tissue in the trunk(2,3). Here we show that development of the anterior central nervous system of the zebrafish embryo also depends on a small group of ectodermal cells located in the prospective head region. Removal of these ectodermal cells during gastrulation perturbs subsequent neural patterning and results in widespread cell death, Transplantation of these cells shows that they can induce forebrain-specific gene expression in more posterior regions of the neural plate. Our results indicate that an early step in neural patterning is the establishment of a small population of signalling cells within the most anterior region of the embryo. These cells are required for patterning and survival of the anterior brain.	Univ London Kings Coll, Randall Inst, Dev Biol Res Ctr, London WC2 5RL, England; Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA	University of London; King's College London; University of Oregon	Houart, C (corresponding author), Univ London Kings Coll, Randall Inst, Dev Biol Res Ctr, 26-29 Drury Lane, London WC2 5RL, England.		Wilson, Stephen W/B-9404-2008; Zebrafish, UCL/A-3125-2009; Houart, Corinne/B-5128-2009	Wilson, Stephen W/0000-0002-8557-5940; Houart, Corinne/0000-0002-2062-3964	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		AKIMENKO MA, 1994, J NEUROSCI, V14, P3475; ALLENDE ML, 1994, DEV BIOL, V166, P509, DOI 10.1006/dbio.1994.1334; BARTH KA, 1995, DEVELOPMENT, V121, P1755; Bouwmeester T, 1996, NATURE, V382, P595, DOI 10.1038/382595a0; Bradley L, 1996, DEVELOPMENT, V122, P2739; Brand M, 1996, DEVELOPMENT, V123, P129; Furthauer M, 1997, DEVELOPMENT, V124, P4253; Heisenberg CP, 1996, DEVELOPMENT, V123, P191; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; Lemaire P, 1996, TRENDS GENET, V12, P525, DOI 10.1016/S0168-9525(97)81401-1; LI YB, 1994, MECH DEVELOP, V48, P229, DOI 10.1016/0925-4773(94)90062-0; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; Mizuno T, 1996, NATURE, V383, P131, DOI 10.1038/383131a0; MORITA T, 1995, NEUROSCI LETT, V198, P131, DOI 10.1016/0304-3940(95)11988-9; NEAVE B, 1995, MECH DEVELOP, V51, P169, DOI 10.1016/0925-4773(95)00351-7; Sasai Y, 1997, DEV BIOL, V182, P5, DOI 10.1006/dbio.1996.8445; Shimamura K, 1997, DEVELOPMENT, V124, P2709; THISSE C, 1994, DEV BIOL, V164, P420, DOI 10.1006/dbio.1994.1212; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Varlet I, 1997, DEVELOPMENT, V124, P1033; WESTERFIELD M, 1996, ZEBRAFISH BOOK; Woo K, 1997, SCIENCE, V277, P254, DOI 10.1126/science.277.5323.254	22	182	184	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					788	792		10.1038/35853	http://dx.doi.org/10.1038/35853			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486648				2022-12-01	WOS:000072089500052
J	Fellman, V; Rapola, J; Pihko, H; Varilo, T; Raivio, KO				Fellman, V; Rapola, J; Pihko, H; Varilo, T; Raivio, KO			Iron-overload disease in infants involving fetal growth retardation, lactic acidosis, liver haemosiderosis, and aminoaciduria	LANCET			English	Article							RESPIRATORY-CHAIN; PERINATAL HEMOCHROMATOSIS; COMPLEX-III; DEFICIENCY; PATHOLOGY	Background Several cases of a distinctive lethal neonatal disorder have been found in the Children's Hospital, Helsinki, Finland. However, the combination of presenting features is not typical of any known metabolic disease. We have analysed all known cases of this disorder in the hospital since 1965 and in Finland since 1990 to define clinical features of the disease. Methods We studied 17 newborn infants with severe growth retardation from 12 Finnish families and traced their genealogy. In addition to routine clinical studies, diagnostic workup included analysis of respiratory-chain function in isolated muscle mitochondria and necropsy specimens, pyruvate dehydrogenase complex activities in fibroblasts, analysis of aminoacids and organic acids in urine, staining of tissue samples for iron, and assay of liver iron content. Findings The infants were born near term (mean 37.8 [SD 3] gestational weeks) but were severely growth retarded (birthweight 1690 [460] g-ie, -3.8 [SD 0.6] SD score for gestational age). By age 24 h, mean pH was 7.00 (0.12), lactate 12.2 (7.5) mmol/L, and pyruvate 121 (57) mu mol/L. All had aminoaciduria and failed to thrive; nine died neonatally (age 2-12 days), and eight died in infancy (1-4 months). The liver of four infants showed microscopic haemosiderosis and increased iron content (2.8-55 mg iron/g dry weight). In those four infants serum ferritin concentration (1260-2700 mu g/L) and transferrin saturation (61-100%) were high, transferrin concentration (0.54-0.76 g/L) was low. Interpretation We describe a previously unrecognised clinical picture of a genetic disease, which presents with fetal growth retardation and lactic acidosis after birth. Genealogical studies indicate an autosomal-recessive mode of inheritance for this disease, which is distinct from other lactic acidoses, neonatal haemochromatosis, and hepatitis. The diagnostic criteria are: fetal growth retardation; severe lactic acidosis; aminoaciduria; iron overload with haemosiderosis of the liver, increased serum ferritin concentration, hypotransferrinaemia, and increased transferrin iron saturation. Organ dysfunction may be partly due to the toxic effects of free iron.	Univ Helsinki, Childrens Hosp, FIN-00290 Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland	University of Helsinki; Finland National Institute for Health & Welfare	Fellman, V (corresponding author), Univ Helsinki, Childrens Hosp, Stenbackinkatu 11, FIN-00290 Helsinki, Finland.							BACON BR, 1990, HEPATOLOGY, V11, P127, DOI 10.1002/hep.1840110122; BALE PM, 1994, PEDIATR PATHOL, V14, P479, DOI 10.3109/15513819409024277; Baynes RD, 1996, CLIN BIOCHEM, V29, P209, DOI 10.1016/0009-9120(96)00010-K; BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025; BRITTON RS, 1991, GASTROENTEROLOGY, V101, P806, DOI 10.1016/0016-5085(91)90543-T; BROWN GK, 1992, J INHERIT METAB DIS, V15, P625, DOI 10.1007/BF01799619; COCKALINGAM U, 1987, J PEDIATR, V111, P283; DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602; HAYASHI A, 1993, AM J HUM GENET, V53, P201; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; Knisely A S, 1992, Adv Pediatr, V39, P383; MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5; MORAES CT, 1991, AM J HUM GENET, V48, P492; MORRIS AAM, 1995, PEDIATR NEPHROL, V9, P407, DOI 10.1007/BF00866711; MUIESAN P, 1995, ARCH DIS CHILD-FETAL, V73, pF178, DOI 10.1136/fn.73.3.F178; NORIO R, 1973, ANN CLIN RES, V5, P109; Robinson B.H., 1995, METABOLIC MOL BASES, P1479; SILVER MM, 1993, AM J PATHOL, V143, P1312; SILVER MM, 1987, AM J PATHOL, V128, P538; SIMPSON RJ, 1993, J PATHOL, V171, P237, DOI 10.1002/path.1711710313; Varilo T, 1996, GENOME RES, V6, P870, DOI 10.1101/gr.6.9.870; Verloes A, 1997, AM J MED GENET, V68, P391, DOI 10.1002/(SICI)1096-8628(19970211)68:4<391::AID-AJMG3>3.0.CO;2-P; Villeneuve JP, 1996, J HEPATOL, V25, P172, DOI 10.1016/S0168-8278(96)80070-5	23	74	75	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					490	493		10.1016/S0140-6736(97)09272-6	http://dx.doi.org/10.1016/S0140-6736(97)09272-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482441				2022-12-01	WOS:000072097700013
J	Halligan, PW				Halligan, PW			Inability to recognise disgust in Huntington's disease	LANCET			English	Editorial Material							FACIAL EXPRESSIONS; HUMAN AMYGDALA; EMOTION; DAMAGE		Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England	University of Oxford	Halligan, PW (corresponding author), Univ Oxford, Dept Expt Psychol, S Parks Rd, Oxford OX1 3UD, England.		Halligan, Peter W/A-1669-2010	Halligan, Peter W/0000-0003-2784-6690				ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; BRUCE V, 1986, BRIT J PSYCHOL, V77, P305, DOI 10.1111/j.2044-8295.1986.tb02199.x; Calder AJ, 1996, COGNITIVE NEUROPSYCH, V13, P699, DOI 10.1080/026432996381890; Gray JM, 1997, BRAIN, V120, P2029, DOI 10.1093/brain/120.11.2029; Morris JS, 1996, NATURE, V383, P812, DOI 10.1038/383812a0; Phillips ML, 1997, NATURE, V389, P495, DOI 10.1038/39051; Sprengelmeyer R, 1996, BRAIN, V119, P1647, DOI 10.1093/brain/119.5.1647; Young AW, 1997, COGNITION, V63, P271, DOI 10.1016/S0010-0277(97)00003-6; YOUNG AW, 1997, PSYCHOL          OCT, P447	9	9	9	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					464	464		10.1016/S0140-6736(05)78678-5	http://dx.doi.org/10.1016/S0140-6736(05)78678-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YX958	9482434				2022-12-01	WOS:000072097700005
J	Ho, GYF; Bierman, R; Beardsley, L; Chang, CJ; Burk, RD				Ho, GYF; Bierman, R; Beardsley, L; Chang, CJ; Burk, RD			Natural history of cervicovaginal papillomavirus infection in young women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	14th International Papillomavirus Conference	JUL 21-28, 1995	QUEBEC CITY, CANADA				GENITAL HUMAN PAPILLOMAVIRUS; CYTOLOGICALLY NORMAL WOMEN; TERM FOLLOW-UP; CERVICAL-CANCER; RISK-FACTORS; LONGITUDINAL DATA; PREVALENCE; DYSPLASIA; BEHAVIOR; DNA	Background Genital human papillomavirus (HPV) infection is highly prevalent in sexually active young women. However, precise risk factors for HPV infection and its incidence and duration are not well known. Methods We followed 608 college women at six-month intervals for three years. At each visit, we collected information about lifestyle and sexual behavior and obtained cervicovaginal-lavage samples for the detection of HPV DNA by polymerase chain reaction and Southern blot hybridization. Pap smears were obtained annually. Results The cumulative 36-month incidence of HPV infection was 43 percent (95 percent confidence interval, 36 to 49 percent). An increased risk of HPV infection was significantly associated with younger age, Hispanic ethnicity, black race, an increased number of vaginal-sex partners, high frequencies of vaginal sex and alcohol consumption, anal sex, and certain characteristics of partners (regular partners having an increased number of lifetime partners and not being in school). The median duration of new infections was 8 months (95 percent confidence interval, 7 to 10 months). The persistence of HPV for greater than or equal to 6 months was related to older age, types of HPV associated with cervical cancer, and infection with multiple types of HPV but not with smoking. The risk of an abnormal Pap smear increased with persistent HPV infection, particularly with high-risk types (relative risk, 37.2; 95 percent confidence interval, 14.6 to 94.8). Conclusions The incidence of HPV infection in sexually active young college women is high. The short duration of most HPV infections in these women suggests that the associated cervical dysplasia should be managed conservatively. (C) 1998, Massachusetts Medical Society.	Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Rutgers State Univ, Student Hlth Serv, New Brunswick, NJ 08903 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Rutgers State University New Brunswick	Burk, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Ctr, 1300 Morris Pk Ave,Ullmann Bldg,Rm 515, Bronx, NY 10461 USA.		Fahimifar, Sepideh/M-5303-2019		NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031055] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13330] Funding Source: Medline; NIAID NIH HHS [AI-31055] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; BOSCH FX, 1992, INT J CANCER, V52, P750, DOI 10.1002/ijc.2910520514; BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; Brisson J, 1996, J INFECT DIS, V173, P794, DOI 10.1093/infdis/173.4.794; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BURK RD, 1986, AM J OBSTET GYNECOL, V154, P982, DOI 10.1016/0002-9378(86)90733-7; Burk RD, 1996, J INFECT DIS, V174, P679, DOI 10.1093/infdis/174.4.679; Burk RD, 1996, SEX TRANSM DIS, V23, P333, DOI 10.1097/00007435-199607000-00013; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; DEVILLIERS EM, 1992, GYNECOL ONCOL, V44, P33, DOI 10.1016/0090-8258(92)90008-7; EVANDER M, 1995, J INFECT DIS, V171, P1026, DOI 10.1093/infdis/171.4.1026; FAIRLEY CK, 1994, OBSTET GYNECOL, V84, P755; GOLDBERG GL, 1989, AM J OBSTET GYNECOL, V161, P1669, DOI 10.1016/0002-9378(89)90947-2; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HINCHLIFFE SA, 1995, BRIT J CANCER, V72, P943, DOI 10.1038/bjc.1995.438; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; HSING AW, 1994, J INFECT DIS, V170, P498, DOI 10.1093/infdis/170.2.498; KARLSSON R, 1995, SEX TRANSM DIS, V22, P119, DOI 10.1097/00007435-199503000-00008; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; LEY C, 1991, JNCI-J NATL CANCER I, V83, P997, DOI 10.1093/jnci/83.14.997; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Maiman Mitchell, 1996, P405; MOSCICKI AB, 1992, J INFECT DIS, V166, P951, DOI 10.1093/infdis/166.5.951; MOSCICKI AB, 1990, PEDIATR RES, V28, P507, DOI 10.1203/00006450-199011000-00018; NASIELL K, 1983, OBSTET GYNECOL, V61, P609; NASIELL K, 1986, OBSTET GYNECOL, V67, P665, DOI 10.1097/00006250-198605000-00012; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; Romney SL, 1997, GYNECOL ONCOL, V65, P483, DOI 10.1006/gyno.1997.4697; ROSENFELD WD, 1992, J PEDIATR-US, V121, P307, DOI 10.1016/S0022-3476(05)81212-0; *SAS I, 1989, SAS STAT US GUID VER, V2; THOMPSON WD, 1994, EPIDEMIOL REV, V16, P33, DOI 10.1093/oxfordjournals.epirev.a036143; VERMUND SH, 1991, AM J OBSTET GYNECOL, V165, P392, DOI 10.1016/0002-9378(91)90101-V; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	35	1786	1889	1	103	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					423	428		10.1056/NEJM199802123380703	http://dx.doi.org/10.1056/NEJM199802123380703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YW122	9459645				2022-12-01	WOS:000071900100003
J	Hathaway, WR; Peterson, ED; Wagner, GS; Granger, CB; Zabel, KM; Pieper, KS; Clark, KA; Woodlief, LH; Califf, RM				Hathaway, WR; Peterson, ED; Wagner, GS; Granger, CB; Zabel, KM; Pieper, KS; Clark, KA; Woodlief, LH; Califf, RM		GUSTO-I Investigators	Prognostic significance of the initial electrocardiogram in patients with acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ST-SEGMENT DEPRESSION; THROMBOLYTIC THERAPY; TRIAL; MORTALITY; ANGIOPLASTY; PREDICTORS; SIZE; ERA	Context.-Early risk stratification of patients with myocardial infarction is critical to determine optimum treatment strategies and enhance outcomes, but knowledge of the prognostic importance of the initial electrocardiogram (ECG) is limited. Objective.-To assess the independent value of the initial ECG for short-term risk stratification after acute myocardial infarction. Design.-Retrospective analysis of the Global Utilization of Streptokinase and t-PA (alteplase) for Occluded Coronary Arteries (GUSTO-I) clinical trial database. Setting.-A total of 1081 hospitals in 15 countries. Patients.-From the 41 021 patients enrolled in the overall study, we selected those who presented within 6 hours of chest pain onset with ST-segment elevation and no confounding factors (paced rhythms, ventricular rhythms, or left bundle-branch block) on the ECG performed before thrombolysis was administered (n=34 166). Main Outcome Measure.-Ability of initial ECG to predict all-cause mortality at 30 days. Results.-Most ECG variables were associated with 30-day mortality in a univariable analysis, In a multivariable analysis combining the initial ECG variables and clinical predictors of mortality, the sum of the absolute ST-segment deviation (both ST elevation and ST depression: odds ratio [OR], 1.53; 95% confidence interval [CI], 1.38-1.69), ECG, heart rate (OR, 1.49; 95% CI, 1.41-1.59), QRS duration (for anterior infarct: OR, 1.55; 95% CI, 1.43-1.68), and ECG evidence of prior infarction (for new inferior infarct: OR, 2.47; 95% CI, 2.02-3.00) were the strongest ECG predictors of mortality, A nomogram based on the multivariable model produced excellent discrimination of 30-day mortality (C-index, 0.830). Conclusions.-In patients presenting with myocardial infarction accompanied by ST-segment elevation, components of the initial ECG help predict 30-day mortality, This information should be valuable in early risk stratification, when the opportunity to reduce mortality is greatest, and may help in assessing outcomes adjusted for patient risk.	Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA	Duke University	Hathaway, WR (corresponding author), Care of Williams P, Duke Clin Res Inst, 2024 W Main St,Bay A-2, Durham, NC 27705 USA.		Peterson, Eric David/ABF-5033-2021; Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291				ALDRICH HR, 1988, AM J CARDIOL, V61, P749, DOI 10.1016/0002-9149(88)91060-0; BATES ER, 1989, J AM COLL CARDIOL, V13, P12, DOI 10.1016/0735-1097(89)90542-1; CALIFF RM, 1991, CIRCULATION, V83, P1543, DOI 10.1161/01.CIR.83.5.1543; CAPONE RJ, 1991, J AM COLL CARDIOL, V18, P1434, DOI 10.1016/0735-1097(91)90671-U; CRIMM A, 1984, AM J MED, V76, P983, DOI 10.1016/0002-9343(84)90846-5; DESANCTIS RW, 1972, CIRCULATION, V45, P681, DOI 10.1161/01.CIR.45.3.681; Devlin TF., 1986, P 11 ANN SAS US GROU, P646; EDMUNDS JJ, 1994, AM J CARDIOL, V73, P143, DOI 10.1016/0002-9149(94)90205-4; Efron B., 1993, MONOGRAPHS STAT APPL, DOI 10.1007/978-1-4899-4541-9; FLETCHER WO, 1993, AM HEART J, V126, P526, DOI 10.1016/0002-8703(93)90400-4; GRANGER C, 1994, CIRCULATION, V90, P324; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HINDMAN NB, 1985, AM J CARDIOL, V55, P1485, DOI 10.1016/0002-9149(85)90958-0; HLATKY MA, 1985, AM J CARDIOL, V55, P325, DOI 10.1016/0002-9149(85)90369-8; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MAURI F, 1989, AM J CARDIOL, V63, P1291, DOI 10.1016/0002-9149(89)91037-0; MIRVIS DM, 1988, AM HEART J, V116, P1308, DOI 10.1016/0002-8703(88)90456-5; Peterson ED, 1996, J AM COLL CARDIOL, V28, P305, DOI 10.1016/0735-1097(96)00133-7; SEVILLA DC, 1990, AM J CARDIOL, V66, P792, DOI 10.1016/0002-9149(90)90353-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001	20	127	130	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					387	391		10.1001/jama.279.5.387	http://dx.doi.org/10.1001/jama.279.5.387			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459474	Bronze			2022-12-01	WOS:000071731300031
J	Kurtz, Z; Tookey, P; Ross, E				Kurtz, Z; Tookey, P; Ross, E			Epilepsy in young people: 23 year follow up of the British national child development study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; PROGNOSIS	Objective: To estimate the incidence and prevalence of epilepsy during childhood and early adult life in England, Scotland, and Wales. Design: Prospective study of 17 414 children born in England, Scotland, and Wales between 3 and 9 March 1958, followed up at 7, 11, 16, and 23 years of age, with a review of those with epilepsy at age 28. Subjects: People with epilepsy developing at or before age 23. Main outcome measures: The age specific incidence, cumulative incidence, and prevalence of epilepsy. Results: 124 young people had a confirmed diagnosis of epilepsy during their first 23 years (cumulative incidence 8.4 per 1000; 95% confidence interval 6.8 to 10.0). 6 had died by age 23. 46 (37%) had neurological impairment or another major health problem in addition to epilepsy. The prevalence of active epilepsy at age 23 was 6.3 per 1000 (4.9 to 7.7). Conclusions: A wide variety of seizure disorders is included under the term epilepsy. A third of cases had generalised seizures. In only a quarter was the onset of seizures attributed to a specific cause. Children with additional health problems were more likely to continue to have seizures in early adult life than those with epilepsy alone. 1 in 8 were prescribed drug treatment for 6 years or more after their last seizure. All deaths occurred in young adults over the age of 16.	UCL, Sch Med, Dept Epidemiol & Publ Hlth, Inst Child Hlth, London WC1N 1EH, England; Kings Coll London, Sch Med, Dept Community Paediat, London SE11 4QW, England	University of London; University College London; UCL Medical School; University of London; King's College London	Tookey, P (corresponding author), UCL, Sch Med, Dept Epidemiol & Publ Hlth, Inst Child Hlth, Mortimer St, London WC1N 1EH, England.	p.tookey@ich.ucl.ac.uk	Tookey, Pat A/G-2732-2010	Tookey, Pat A/0000-0001-6258-0387				[Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; Breslow NE, 1987, STAT METHODS CANC RE, VII; BRITTEN N, 1986, DEV MED CHILD NEUROL, V28, P719; BRORSON LO, 1987, EPILEPSIA, V28, P324, DOI 10.1111/j.1528-1157.1987.tb03651.x; BUTLER NR, 1965, PERINATAL MORTALITY; COWAN LD, 1989, EPILEPSIA, V30, P94, DOI 10.1111/j.1528-1157.1989.tb05289.x; FOGELMAN K, 1993, GROWING UP GREAT BRI; HARRISON RM, 1976, LANCET, V1, P948; HAUSER WA, 1980, EPILEPSIA, V21, P399, DOI 10.1111/j.1528-1157.1980.tb04088.x; HOLDSWORTH L, 1974, DEV MED CHILD NEUROL, V16, P746; LIP GYH, 1992, J ROY SOC MED, V85, P609; OKUMA T, 1981, EPILEPSIA, V22, P35, DOI 10.1111/j.1528-1157.1981.tb04331.x; Power C, 1992, Paediatr Perinat Epidemiol, V6, P81, DOI 10.1111/j.1365-3016.1992.tb00748.x; REYNOLDS EH, 1990, BRIT MED J, V301, P1112, DOI 10.1136/bmj.301.6761.1112; Roger J, 1992, EPILEPTIC SYNDROMES; ROSS EM, 1980, BRIT MED J, V280, P207, DOI 10.1136/bmj.280.6209.207; ROSS EM, 1983, RES PROGR EPILEPSY, P46; SANDER JWAS, 1987, J NEUROL NEUROSUR PS, V50, P829, DOI 10.1136/jnnp.50.7.829; SCAMBLER G, 1987, EPILEPSY, P497; STORES G, 1978, DEV MED CHILD NEUROL, V20, P502; VERITY CM, 1992, BMJ-BRIT MED J, V305, P857, DOI 10.1136/bmj.305.6858.857	21	95	97	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					339	342		10.1136/bmj.316.7128.339	http://dx.doi.org/10.1136/bmj.316.7128.339			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487166	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000071863900021
J	Shou, WN; Aghdasi, B; Armstrong, DL; Guo, QX; Bao, SD; Charng, MJ; Mathews, LM; Schneider, MD; Hamilton, SL; Matzuk, MM				Shou, WN; Aghdasi, B; Armstrong, DL; Guo, QX; Bao, SD; Charng, MJ; Mathews, LM; Schneider, MD; Hamilton, SL; Matzuk, MM			Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12	NATURE			English	Article							FK506 BINDING-PROTEIN; CALCIUM-RELEASE; MOUSE; GENE	FKBP12, a cis-trans prolyl isomerase that binds the immunosuppressants FK506 and rapamycin, is ubiquitously expressed and interacts with proteins in several intracellular signal transduction systems(1). Although FKBP12 interacts with the cytoplasmic domains of type I receptors of the transforming growth factor-beta (TGF-beta) superfamily in vitro, the function of FKBP12 in TGF-beta superfamily signalling is controversial(2-6). FKBP12 also physically interacts stoichiometrically with multiple intracellular calcium release channels including the tetrameric skeletal muscle ryanodine dine receptor (RyR1)(7,8). In contrast, the cardiac ryanodine receptor, RyR2, appears to bind selectively the FKBP12 homologue, FKBP12.6 (refs 9, 10). To define the functions of FKBP12 in vivo, we generated mutant mice deficient in FKBP12 using embryonic stem (ES) cell technology. FKBP12-deficient mice have normal skeletal muscle but have severe dilated cardiomyopathy and ventricular septal defects that mimic a human congenital heart disorder, noncompaction of left ventricular myocardium(11,12). About 9% of the mutants exhibit exencephaly secondary to a defect in neural tube closure. Physiological studies demonstrate that FKBP12 is dispensable for TGF-beta-mediated signalling, but modulates the calcium release activity of both skeletal and cardiac ryanodine receptors.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Geneet, Houston, TX 77030 USA; Baylor Coll Med, Dept Physiol & Mol Biophys, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Michigan System; University of Michigan	Matzuk, MM (corresponding author), Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA.	mmatzuk@bcm.tmc.edu		Hamilton, Susan/0000-0003-0241-9369				Aghdasi B, 1997, J BIOL CHEM, V272, P3739, DOI 10.1074/jbc.272.6.3739; Albrecht U, 1997, MOL CELLULAR METHODS, P23; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; ATKISON P, 1995, LANCET, V345, P894, DOI 10.1016/S0140-6736(95)90011-X; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Charng MJ, 1996, J BIOL CHEM, V271, P22941, DOI 10.1074/jbc.271.38.22941; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; CHIN TK, 1990, CIRCULATION, V82, P507, DOI 10.1161/01.CIR.82.2.507; DILELLA AG, 1992, BIOCHEM BIOPH RES CO, V189, P819, DOI 10.1016/0006-291X(92)92276-4; JAYARAMAN T, 1992, J BIOL CHEM, V267, P9474; LAM E, 1995, J BIOL CHEM, V270, P26511, DOI 10.1074/jbc.270.44.26511; Lamb GD, 1996, J PHYSIOL-LONDON, V494, P569, DOI 10.1113/jphysiol.1996.sp021514; LAU AL, 1997, INHIBIN ACTIVIN FOLL, P220; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; Okadome T, 1996, J BIOL CHEM, V271, P21687, DOI 10.1074/jbc.271.36.21687; OKATA K, 1996, CIRCULATION S1, V94, P1; Olson EN, 1996, SCIENCE, V272, P671, DOI 10.1126/science.272.5262.671; Ritter M, 1997, MAYO CLIN PROC, V72, P26, DOI 10.4065/72.1.26; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; ROWE LB, 1994, MAMM GENOME, V5, P253, DOI 10.1007/BF00389540; SNYDER SH, 1995, NAT MED, V1, P32, DOI 10.1038/nm0195-32; TAKESHIMA H, 1994, NATURE, V369, P556, DOI 10.1038/369556a0; Tanaka N, 1996, CIRCULATION, V94, P1109, DOI 10.1161/01.CIR.94.5.1109; Timerman AP, 1996, J BIOL CHEM, V271, P20385, DOI 10.1074/jbc.271.34.20385; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; Wang TW, 1996, CELL, V86, P435, DOI 10.1016/S0092-8674(00)80116-6; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275; Zimmerman CM, 1996, BIOCHEM SOC SYMP, P25	30	350	370	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					489	492		10.1038/35146	http://dx.doi.org/10.1038/35146			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461216	Green Submitted			2022-12-01	WOS:000071701800051
J	Ishijima, A; Kojima, H; Funatsu, T; Tokunaga, M; Higuchi, H; Tanaka, H; Yanagida, T				Ishijima, A; Kojima, H; Funatsu, T; Tokunaga, M; Higuchi, H; Tanaka, H; Yanagida, T			Simultaneous observation of individual ATPase and mechanical events by a single myosin molecule during interaction with actin	CELL			English	Article							ADENOSINE-TRIPHOSPHATE HYDROLYSIS; MUSCLE-CONTRACTION; NANO-MANIPULATION; KINESIN MOLECULES; SLIDING DISTANCE; ACTOMYOSIN MOTOR; SKELETAL-MUSCLE; IN-VITRO; FILAMENTS; FORCE	We have developed a technique that allows mechanical and ligand-binding events in a single myosin molecule to be monitored simultaneously. We describe how steps in the ATPase reaction are temporally related to mechanical events at the single molecule level. The results show that the force generation does not always coincide with the release of bound nucleotide, presumably ADP. Instead the myosin head produces force several hundreds of milliseconds after bound nucleotide is released. This finding does not support the widely accepted view that force generation is directly coupled to the release of bound ligands. It suggests that myosin has a hysteresis or memory state, which stores chemical energy from ATP hydrolysis.	ERATO, Biomotron Project, JST, Osaka 562, Japan; HONDA R&D Co, Wako Res Ctr, Wako, Saitama, Japan; Osaka Univ, Sch Med, Dept Physiol, Suita, Osaka 565, Japan	Honda Motor Company; Osaka University	Ishijima, A (corresponding author), ERATO, Biomotron Project, JST, Osaka 562, Japan.		Funatsu, Takashi/Q-1404-2015; Yanagida, Toshio/D-1919-2009; Ishijima, Akihiko/F-4603-2012	Funatsu, Takashi/0000-0002-9656-8308; Ishijima, Akihiko/0000-0002-8919-9268				BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; Conibear PB, 1996, BIOCHEMISTRY-US, V35, P2299, DOI 10.1021/bi951824+; Dickson RM, 1997, NATURE, V388, P355, DOI 10.1038/41048; Eccleston J. F., 1996, Biophysical Journal, V70, pA159; EISENBERG E, 1980, BIOPHYS J, V29, P195, DOI 10.1016/S0006-3495(80)85126-5; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GEEVES MA, 1984, J MUSCLE RES CELL M, V5, P351, DOI 10.1007/BF00818255; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P629; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOODNO CC, 1979, P NATL ACAD SCI USA, V76, P2620, DOI 10.1073/pnas.76.6.2620; Guilford WH, 1997, BIOPHYS J, V72, P1006, DOI 10.1016/S0006-3495(97)78753-8; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HARADA Y, 1987, NATURE, V326, P805, DOI 10.1038/326805a0; Harada Y, 1998, METHOD CELL BIOL, V55, P117; HIGUCHI H, 1991, NATURE, V352, P352, DOI 10.1038/352352a0; Higuchi H, 1997, P NATL ACAD SCI USA, V94, P4395, DOI 10.1073/pnas.94.9.4395; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; HUXLEY HE, 1990, J BIOL CHEM, V265, P8347; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; Ishii Y., 1997, Biophysical Journal, V72, pA283; ISHIJIMA A, 1991, NATURE, V352, P301, DOI 10.1038/352301a0; Ishijima A, 1996, BIOPHYS J, V70, P383, DOI 10.1016/S0006-3495(96)79582-6; ISHIJIMA A, 1994, BIOCHEM BIOPH RES CO, V199, P1057, DOI 10.1006/bbrc.1994.1336; Iwane AH, 1997, FEBS LETT, V407, P235, DOI 10.1016/S0014-5793(97)00359-1; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KODAMA T, 1985, PHYSIOL REV, V65, P467, DOI 10.1152/physrev.1985.65.2.467; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LANDAOU L, 1969, STAT PHYSICS, P111; LOMBARDI V, 1992, NATURE, V355, P638, DOI 10.1038/355638a0; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MIYATA H, 1994, J BIOCHEM, V115, P644, DOI 10.1093/oxfordjournals.jbchem.a124389; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; OHNO T, 1991, J PHYSIOL-LONDON, V441, P685, DOI 10.1113/jphysiol.1991.sp018773; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; SIMMONS RM, 1993, ADV EXP MED BIOL, V332, P331; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Tanaka H., 1997, Biophysical Journal, V72, pA55; Tokunaga M, 1997, BIOCHEM BIOPH RES CO, V235, P47, DOI 10.1006/bbrc.1997.6732; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRENTHAM DR, 1976, Q REV BIOPHYS, V9, P217, DOI 10.1017/S0033583500002419; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WOLEDGE RC, 1985, MONOGR PHYSL SOC, V41, P119; YANAGIDA T, 1985, NATURE, V316, P366, DOI 10.1038/316366a0; YANAGIDA T, 1984, NATURE, V307, P58, DOI 10.1038/307058a0; YANAGIDA T, 1993, TRENDS BIOCHEM SCI, V18, P319, DOI 10.1016/0968-0004(93)90064-T; YOUNT RG, 1995, BIOPHYS J, V68, pS44; [No title captured]	60	399	427	0	37	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					161	171		10.1016/S0092-8674(00)80911-3	http://dx.doi.org/10.1016/S0092-8674(00)80911-3			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458041	Bronze			2022-12-01	WOS:000071672600006
J	Lieb, JD; Albrecht, MR; Chuang, PT; Meyer, BJ				Lieb, JD; Albrecht, MR; Chuang, PT; Meyer, BJ			MIX-1: An essential component of the C-elegans mitotic machinery executes x chromosome dosage compensation	CELL			English	Article							CAENORHABDITIS-ELEGANS; SEX DETERMINATION; GENE; SEGREGATION; MUTATIONS; NEMATODE; PROTEIN; XOL-1	We show that a functional component of the C. elegans mitotic machinery regulates X chromosome gene expression. This protein, MIX-1, is a member of the dosage compensation complex that associates specifically with hermaphrodite X chromosomes to reduce their gene expression during interphase. MIX-1 also associates with all mitotic chromosomes to ensure their proper segregation. Both dosage compensation and mitosis are severely disrupted by mix-1 mutations. MIX-1 belongs to the SMC protein family required for mitotic chromosome condensation and segregation in yeast and frogs. Thus, an essential, conserved component of mitotic chromosomes has been recruited to the dosage compensation process. Rather than dosage compensation and mitosis being achieved by two separate sets of related genes, these two processes share an identical component, indicating a common mechanism for establishing higher order chromosome structure and proper X chromosome gene expression.	Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Cell & Mol Biol, Berkeley, CA 94720 USA	Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Meyer, BJ (corresponding author), Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA.			Lieb, Jason/0000-0001-7601-8061; Meyer, Barbara/0000-0002-6530-4588	NIGMS NIH HHS [T32 GM07127, R01 GM030702, R37 GM30702] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007127, R01GM030702, R37GM030702] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; Charlesworth B, 1996, CURR BIOL, V6, P149, DOI 10.1016/S0960-9822(02)00448-7; CHUANG PT, 1994, CELL, V79, P459, DOI 10.1016/0092-8674(94)90255-0; Chuang PT, 1996, SCIENCE, V274, P1736, DOI 10.1126/science.274.5293.1736; Cline TW, 1996, ANNU REV GENET, V30, P637, DOI 10.1146/annurev.genet.30.1.637; Davis TL, 1997, DEVELOPMENT, V124, P1019; DELONG L, 1993, GENETICS, V133, P875; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Harlow E., 1988, ANTIBODIES LABORATOR, P353; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; HERMAN RK, 1978, GENETICS, V88, P49; Hirano T, 1997, CELL, V89, P511, DOI 10.1016/S0092-8674(00)80233-0; KEMPHUES KJ, 1988, GENETICS, V120, P977; Kimura K, 1997, CELL, V90, P625, DOI 10.1016/S0092-8674(00)80524-3; Koshland D, 1996, ANNU REV CELL DEV BI, V12, P305, DOI 10.1146/annurev.cellbio.12.1.305; Kuroda MI, 1997, CELL, V91, P9, DOI 10.1016/S0092-8674(01)80003-9; Lieb JD, 1996, SCIENCE, V274, P1732, DOI 10.1126/science.274.5293.1732; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MEYER BJ, 1986, CELL, V47, P871, DOI 10.1016/0092-8674(86)90802-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MILLER LM, 1988, CELL, V55, P167, DOI 10.1016/0092-8674(88)90019-0; NUSBAUM C, 1989, GENETICS, V122, P579; PLENEFISCH JD, 1989, GENETICS, V121, P57; RHIND NR, 1995, CELL, V80, P71, DOI 10.1016/0092-8674(95)90452-2; Willard HF, 1996, CELL, V86, P5, DOI 10.1016/S0092-8674(00)80071-9	25	142	150	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					265	277		10.1016/S0092-8674(00)80920-4	http://dx.doi.org/10.1016/S0092-8674(00)80920-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458050	Bronze			2022-12-01	WOS:000071672600015
J	McKinney, PA; Juszczak, E; Findlay, E; Smith, K				McKinney, PA; Juszczak, E; Findlay, E; Smith, K			Case-control study of childhood leukaemia and cancer in Scotland: findings for neonatal intramuscular vitamin K	BRITISH MEDICAL JOURNAL			English	Article							LEUKEMIA; RISK	Objective: To test the hypothesis of an association between neonatal intramuscular vitamin K and childhood leukaemia and other cancers. Design: Population based case-control study with data abstracted from hospital records. Setting: Scotland. Subjects: Children aged 0-14 years resident in Scotland from 1991-4 and diagnosed with leukaemia (150), lymphomas (46), central nervous system tumours (79), a range of other solid tumours (142), and a subset of acute lymphoblastic leukaemia (129). Controls were 777 children matched for age and sex, providing 417 matched sets (360 triplets and 57 pairs) for analysis. Main outcome measure: Odds ratios for the risk of childhood leukaemia and cancer and intramuscular vitamin K versus a combined group of oral doses, none, and no record. Results are given for information recorded in medical notes and data supplemented by hospital policy. Results: Odds ratios based on medical record abstractions showed no significant positive association for leukaemias (odds ratio 1.30; 95% confidence interval 0.83 to 2.03), acute lymphoblastic leukaemia (1.21; 0.74 to 1.97), lymphomas (1.06; 0.46 to 2.42), central nervous system tumours (0.74; 0.40 to 1.34), and other solid tumours (0.59; 0.37 to 0.96). There was no association with acute lymphoblastic leukaemia in children aged 1 to 6 years. Imputation of exposure from hospital policy gave similar results. Adjustment for deprivation and type of delivery moved risk estimates closer to unity for all major diagnostic groups. Conclusions: The observation of an increased risk of childhood leukaemia and cancer associated with intramuscular vitamin K is not confirmed by this independent population based study.	Common Serv Agcy Natl Hlth Serv Scotland, Informat & Stat Div, Edinburgh EH5 3SQ, Midlothian, Scotland		McKinney, PA (corresponding author), Common Serv Agcy Natl Hlth Serv Scotland, Informat & Stat Div, Trin Pk House, Edinburgh EH5 3SQ, Midlothian, Scotland.	p.a.mckinney@leeds.ac.uk						Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; BIRCH JM, 1987, INT J CANCER, V40, P620, DOI 10.1002/ijc.2910400508; Breslow NE., 1980, IARC SCI PUBLICATION, V32; Carstairs V., 1991, DEPRIVATION HLTH SCO; DOLL R, 1989, J ROY STAT SOC A STA, V152, P341, DOI 10.2307/2983131; DRAPER G, 1994, BRIT MED J, V308, P867, DOI 10.1136/bmj.308.6933.867; EKLUND H, 1993, BRIT MED J, V307, P89; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; McKinney P A, 1995, Health Bull (Edinb), V53, P222; MCKINNEY PA, 1994, BRIT J CANCER, V70, P973, DOI 10.1038/bjc.1994.432; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; *STAT, 1997, STAT STAT SOFTW REL; STILLER CA, 1995, EUR J CANCER, V202, P8; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199; Zipursky A, 1996, BMJ-BRIT MED J, V313, P179, DOI 10.1136/bmj.313.7051.179	17	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					173	177						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468680	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071616400019
J	Zlokarnik, G; Negulescu, PA; Knapp, TE; Mere, L; Burres, N; Feng, LX; Whitney, M; Roemer, K; Tsien, RY				Zlokarnik, G; Negulescu, PA; Knapp, TE; Mere, L; Burres, N; Feng, LX; Whitney, M; Roemer, K; Tsien, RY			Quantitation of transcription and clonal selection of single living cells with beta-lactamase as reporter	SCIENCE			English	Article							ESCHERICHIA-COLI; T-LYMPHOCYTES; GENE; PROTEINS; CEPHALOSPORIN; SECRETION; SEQUENCE; RECEPTOR; REAGENT; REVEALS	Gene expression was visualized in single living mammalian cells with beta-lactamase as a reporter that hydrolyzes a substrate loaded intracellularly as a membrane-permeant ester. Each enzyme molecule changed the fluorescence of many substrate molecules from green to blue by disrupting resonance energy transfer. This wavelength shift was detectable by eye or color film in individual cells containing less than 100 beta-lactamase molecules. The robust change in emission ratio reveals quantitative heterogeneity in real-time gene expression, enables clonal selection by flow cytometry, and forms a basis for high-throughput screening of pharmaceutical candidate drugs in living mammalian cells.	Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Saarland, D-66421 Homburg, Germany; Aurora Biosci, San Diego, CA 92121 USA	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; Saarland University	Tsien, RY (corresponding author), Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA.				NINDS NIH HHS [NS27177] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027177, R37NS027177] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALAM J, 1990, ANAL BIOCHEM, V188, P245, DOI 10.1016/0003-2697(90)90601-5; AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; CHRISTENSEN H, 1990, BIOCHEM J, V266, P853; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; DIVIRGILIO F, 1988, J IMMUNOL, V140, P915; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; JONES RN, 1982, J CLIN MICROBIOL, V15, P677, DOI 10.1128/JCM.15.4.677-683.1982; JONES RN, 1982, J CLIN MICROBIOL, V15, P954, DOI 10.1128/JCM.15.5.954-958.1982; KADONAGA JT, 1984, J BIOL CHEM, V259, P2149; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; Lakowicz J. R., 2006, PRINCIPLES FLUORESCE, DOI 10.1007/978-0-387-46312-4; MATAGNE A, 1990, BIOCHEM J, V265, P131, DOI 10.1042/bj2650131; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Moore JT, 1997, ANAL BIOCHEM, V247, P203, DOI 10.1006/abio.1997.2092; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NISWENDER KD, 1995, J MICROSC-OXFORD, V180, P109, DOI 10.1111/j.1365-2818.1995.tb03665.x; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; PAGE MI, 1987, ADV PHYS ORG CHEM, V23, P165, DOI 10.1016/S0065-3160(08)60204-X; RAZ E, COMMUNICATION; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SUTCLIFFE JG, 1978, P NATL ACAD SCI USA, V75, P3737, DOI 10.1073/pnas.75.8.3737; THOMPSON JF, 1991, GENE, V103, P171, DOI 10.1016/0378-1119(91)90270-L; TSIEN RY, 1996, Patent No. 30540; WEINTRAUB H, 1988, P NATL ACAD SCI USA, V85, P5819, DOI 10.1073/pnas.85.16.5819; WINGENDER E, 1982, ANAL BIOCHEM, V127, P351, DOI 10.1016/0003-2697(82)90186-5	26	538	632	3	91	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					84	88		10.1126/science.279.5347.84	http://dx.doi.org/10.1126/science.279.5347.84			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417030				2022-12-01	WOS:000071323900045
J	Pignoni, F; Hu, BR; Zavitz, KH; Xiao, JA; Garrity, PA; Zipursky, SL				Pignoni, F; Hu, BR; Zavitz, KH; Xiao, JA; Garrity, PA; Zipursky, SL			The eye-specification proteins so and eya form a complex and regulate multiple steps in Drosophila eye development	CELL			English	Article							HOMEOBOX-CONTAINING GENE; SINE OCULIS GENE; 2-HYBRID SYSTEM; NERVOUS-SYSTEM; VISUAL-SYSTEM; EYELESS GENE; EXPRESSION; FAMILY; ANIRIDIA; HOMOLOG	sine oculis (so) and eyes absent (eya) are required for Drosophila eye development and are founding members of the mammalian Six and Eya gene families. These genes have been proposed to act with eyeless (Pax6) to regulate eye development in vertebrates and invertebrates. so encodes a highly diverged homeobox transcription factor and eya encodes a novel nuclear protein. We demonstrate that So and Eya (1) regulate common steps in eye development including cell proliferation, patterning, and neuronal development; (2) synergize in inducing ectopic eyes; and (3) interact in yeast and in vitro through evolutionarily conserved domains. We propose that an So/Eya complex regulates multiple steps in eye development and functions within the context of a network of genes to specify eye tissue identity.	Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zipursky, SL (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA.			Garrity, Paul/0000-0002-8274-6564; Zipursky, Stephen/0000-0001-5630-7181				BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; BLACKMAN RK, 1991, DEVELOPMENT, V111, P657; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; CHANG HC, 1995, CELL, V80, P463, DOI 10.1016/0092-8674(95)90497-2; Chanut F, 1997, DEVELOPMENT, V124, P559; Chen R, 1997, CELL, V91, P893, DOI 10.1016/S0092-8674(00)80481-X; CHEYETTE BNR, 1994, NEURON, V12, P977, DOI 10.1016/0896-6273(94)90308-5; DICKSON BJ, 1995, CELL, V80, P453, DOI 10.1016/0092-8674(95)90496-4; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; HAY BA, 1994, DEVELOPMENT, V120, P2121; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEBERLEIN U, 1995, NATURE, V373, P709, DOI 10.1038/373709a0; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Kawakami K, 1996, NUCLEIC ACIDS RES, V24, P303, DOI 10.1093/nar/24.2.303; Kawakami K, 1996, FEBS LETT, V393, P259, DOI 10.1016/0014-5793(96)00899-X; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARDON G, 1994, DEVELOPMENT, V120, P3473; Oliver G, 1995, DEVELOPMENT, V121, P4045; OLIVER G, 1995, DEVELOPMENT, V121, P693; Pignoni F, 1997, DEVELOPMENT, V124, P271; QUIRING R, 1994, SCIENCE, V265, P785, DOI 10.1126/science.7914031; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; ROBINOW S, 1991, J NEUROBIOL, V22, P443, DOI 10.1002/neu.480220503; SERIKAKU MA, 1994, GENETICS, V138, P1137; Shen WP, 1997, DEVELOPMENT, V124, P45; Smith Donald B., 1993, Methods in Molecular and Cellular Biology, V4, P220; Tio M, 1997, DEVELOPMENT, V124, P343; TON CCT, 1991, CELL, V67, P1059, DOI 10.1016/0092-8674(91)90284-6; Wiersdorff V, 1996, DEVELOPMENT, V122, P2153; Wolff Tanya, 1993, P1277; Xu PX, 1997, P NATL ACAD SCI USA, V94, P11974, DOI 10.1073/pnas.94.22.11974; Xu PX, 1997, DEVELOPMENT, V124, P219; XU T, 1993, DEVELOPMENT, V117, P1223; Zimmerman JE, 1997, GENOME RES, V7, P128, DOI 10.1101/gr.7.2.128	40	471	479	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					881	891		10.1016/S0092-8674(00)80480-8	http://dx.doi.org/10.1016/S0092-8674(00)80480-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428512	Bronze			2022-12-01	WOS:000071281400006
J	Beckmann, R; Bubeck, D; Grassucci, R; Penczek, P; Verschoor, A; Blobel, G; Frank, J				Beckmann, R; Bubeck, D; Grassucci, R; Penczek, P; Verschoor, A; Blobel, G; Frank, J			Alignment of conduits for the nascent polypeptide chain in the Ribosome-Sec61 complex	SCIENCE			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; ESCHERICHIA-COLI; PROTEIN TRANSLOCATION; CRYOELECTRON MICROSCOPY; ELECTRON-MICROSCOPY; SECRETORY PROTEINS; ENVIRONMENT; RESOLUTION; HOMOLOG; SEC61P	An oligomer of the Sec61 trimeric complex is thought to form the protein-conducting channel for protein transport across the endoplasmic reticulum. A purified yeast Sec61 complex bound to monomeric yeast ribosomes as an oligomer in a saturable fashion. Cryo-electron microscopy of the ribosome-Sec61 complex and a three-dimensional reconstruction showed that the Sec61 oligomer is attached to the large ribosomal subunit by a single connection. Moreover, a funnel-shaped pore in the Sec61 oligomer aligned with the exit of a tunnel traversing the large ribosomal subunit, strongly suggesting that both structures function together in the translocation of proteins across the endoplasmic reticulum membrane.	NEW YORK STATE DEPT HLTH,WADSWORTH CTR,ALBANY,NY 12201; SUNY ALBANY,DEPT BIOMED SCI,ALBANY,NY 12201	State University of New York (SUNY) System; Wadsworth Center; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Beckmann, R (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,CELL BIOL LAB,1230 YORK AVE,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029169] Funding Source: NIH RePORTER; NIGMS NIH HHS [1R01 GM29169] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AITCHISON JD, 1995, J CELL BIOL, V131, P1133, DOI 10.1083/jcb.131.5.1133; BERNABEU C, 1983, J CELL BIOL, V96, P1471, DOI 10.1083/jcb.96.5.1471; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; Bottcher B, 1997, NATURE, V386, P88, DOI 10.1038/386088a0; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; DESHAIES RJ, 1987, J CELL BIOL, V105, P633, DOI 10.1083/jcb.105.2.633; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; FRANK J, 1995, NATURE, V376, P441, DOI 10.1038/376441a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Hamman BD, 1997, CELL, V89, P535, DOI 10.1016/S0092-8674(00)80235-4; Hanein D, 1996, CELL, V87, P721, DOI 10.1016/S0092-8674(00)81391-4; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; LATA KR, 1995, ULTRAMICROSCOPY, V58, P381, DOI 10.1016/0304-3991(95)00002-I; PANZNER S, 1995, CELL, V81, P561, DOI 10.1016/0092-8674(95)90077-2; Penczek PA, 1996, ULTRAMICROSCOPY, V63, P205, DOI 10.1016/0304-3991(96)00037-X; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; SIMON SM, 1992, CELL, V69, P677, DOI 10.1016/0092-8674(92)90231-Z; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; STARK H, 1995, STRUCTURE, V3, P815, DOI 10.1016/S0969-2126(01)00216-7; STIRLING CJ, 1992, MOL BIOL CELL, V3, P129, DOI 10.1091/mbc.3.2.129; STRAMBIODECASTILLIA C, 1995, J CELL BIOL, V131, P19, DOI 10.1083/jcb.131.1.19; Verschoor A, 1996, J CELL BIOL, V133, P495, DOI 10.1083/jcb.133.3.495; VERSCHOOR A, IN PRESS NUCL ACIDS; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1	28	292	298	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2123	2126		10.1126/science.278.5346.2123	http://dx.doi.org/10.1126/science.278.5346.2123			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405348				2022-12-01	WOS:A1997YM23500053
J	Bollinger, RC; Brookmeyer, RS; Mehendale, SM; Paranjape, RS; Shepherd, ME; Gadkari, DA; Quinn, TC				Bollinger, RC; Brookmeyer, RS; Mehendale, SM; Paranjape, RS; Shepherd, ME; Gadkari, DA; Quinn, TC			Risk factors and clinical preservation of acute primary HIV infection in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; EPIDEMIC; VIREMIA	Context.-Most previous studies of clinical presentation and risk factors in early human immunodeficiency virus (HIV) infection have relied on retrospective analyses and referred seroconverters, and thus were subject to possible bias. Objectives.-To apply a method based on measurement of prevalent HIV-1 p24 antigenemia for identification of risk factors for newly acquired HIV infection and to describe the signs and symptoms of acute HIV infection. Design and Setting.-Nested case-control study in Pune, India. Participants.-HIV antibody-negative persons attending 2 sexually transmitted disease (STD) clinics between May 1993 and June 1996. Outcome Measures.-Prevalent p24 antigenemia, risk factors for HIV infection, and clinical symptoms of acute primary HIV infection. Results.-Of 3874 HIV antibody-negative persons tested, 58 (1.5%) were p24 antigen positive at initial presentation to the clinics. Unprotected sexual contact with a commercial sex worker (CSW) was reported by 39 (77%) of the 51 p24 antigenemic men, compared with 131 (51%) of 255 control men (adjusted odds ratio [AOR], 3.4; 95% confidence interval [CI], 1.2-9.6; P=.02). The presence of an active genital ulcer at the time of screening was found in 46 (79%) of the 58 p24 antigenemic men and women, compared with 137 (47%) of the 290 control subjects (AOR, 4.2; 95% CI, 2.0-9.0; P<.001). Signs and symptoms independently associated with p24 antigenemia in HIV antibody-seronegative persons included fever, which was reported by 28 (48%) of the 58 p24 antigenemic subjects, but only 52 (18%) of the 290 control subjects (AOR, 4.7; 95% CI, 2.4-9.0; P<.001). Joint pain was reported by 10% of subjects recently HIV infected, compared with 2% of the control subjects (AOR, 6.5; 95% CI, 1.7-24.8; P=.006), Night sweats were reported by 9% of the p24 antigenemic, but only 1% of the control subjects (AOR, 9.1; 95% CI, 1.7-47.6; P=.009), Overall, fever, joint pain, and/or night sweats were reported in 27 (47%) of the 58 subjects with recent HIV infection. Conclusions.-This systematic case-control study of p24 antigen screening in HIV-seronegative patients attending STD clinics in India identified unprotected sex with a CSW and a genital ulcer as independent risk factors associated with newly acquired HIV infection. In addition, p24 antigen positivity identified recent fever, night sweats, and arthralgias as symptoms that may be predictive of recent HIV infection, In a study of patients attending STD clinics in India, screening for p24 antigen in HIV antibody-negative persons was found to be a reliable and effective research method for determining recent risk behavior and identifying clinical signs of acute primary HIV infection.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DIV INFECT DIS,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT BIOSTAT,BALTIMORE,MD 21205; NATL AIDS RES INST,PUNE,MAHARASHTRA,INDIA; NIAID,NIH,BETHESDA,MD 20892	Johns Hopkins University; Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)				Bollinger, Robert/0000-0002-6798-6834; Paranjape, Ramesh/0000-0003-2948-9148	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER; FIC NIH HHS [D43TW0000] Funding Source: Medline; NIAID NIH HHS [AI 33879-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; BROOKMEYER R, 1995, AM J EPIDEMIOL, V142, P709, DOI 10.1093/oxfordjournals.aje.a117700; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P19; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; FOX R, 1987, AIDS, V1, P35; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Mehendale SM, 1996, INDIAN J MED RES, V104, P327; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; Schacker T, 1996, ANN INTERN MED, V125, P257, DOI 10.7326/0003-4819-125-4-199608150-00001; SINICCO A, 1990, J ACQ IMMUN DEF SYND, V3, P260; VONSYDOW M, 1988, BMJ-BRIT MED J, V296, P238, DOI 10.1136/bmj.296.6617.238; 1996, 11 INT C AIDS JUL	15	87	88	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2085	2089		10.1001/jama.278.23.2085	http://dx.doi.org/10.1001/jama.278.23.2085			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403423				2022-12-01	WOS:A1997YK98700038
J	Brown, KE; Guest, SS; Smale, ST; Hahm, K; Merkenschlager, M; Fisher, AG				Brown, KE; Guest, SS; Smale, ST; Hahm, K; Merkenschlager, M; Fisher, AG			Association of transcriptionally silent genes with Ikaros complexes at centromeric heterochromatin	CELL			English	Article							TERMINAL TRANSFERASE GENE; CELL-CYCLE; INTERPHASE NUCLEI; TRANSGENIC MICE; GAGA FACTOR; HUNCHBACK; PROMOTER; DNA; ULTRABITHORAX; CHROMOSOME	Ikaros proteins are required for normal T, B, and NK cell development and are postulated to activate lymphocyte-specific gene expression. Here we examined Ikaros distribution in the nucleus of B lymphocytes using confocal microscopy and a novel immunofluorescence in situ hybridization (immune-FISH) approach. Unexpectedly, Ikaros localized to discrete heterochromatin-containing foci in interphase nuclei, which comprise clusters of centromeric DNA as defined by gamma-satellite sequences and the abundance of heterochromatin protein-1 (HP-1). Using locus-specific probes for CD2, CD4, CD8 alpha, CD19, CD45, and lambda 5 genes, we show that transcriptionally inactive but not transcriptionally active genes associate with Ikaros-heterochromatin foci. These findings support a model of organization of the nucleus in which repressed genes are selectively recruited into centromeric domains.	HAMMERSMITH HOSP, UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED, SCH MED,MRC, CLIN SCI CTR, LONDON W12 0NN, ENGLAND; UNIV CALIF LOS ANGELES, SCH MED, DEPT MICROBIOL & IMMUNOL, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Imperial College London; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA				Merkenschlager, Matthias/0000-0003-2889-3288	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043726, R01DK043726] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43726] Funding Source: Medline; NIGMS NIH HHS [GM-07104] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axcrona K, 1996, EUR J IMMUNOL, V26, P2203, DOI 10.1002/eji.1830260936; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Boveri T., 1909, ARCH ZELLFORSCH, V3, P181; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; BROWN KE, 1994, HUM MOL GENET, V3, P1227, DOI 10.1093/hmg/3.8.1227; BROWN KE, 1995, THESIS U OXFORD OXFO; Buckle VJ, 1993, HUMAN GENETIC DISEAS, P59; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; CARMOFONSECA M, 1991, EMBO J, V10, P195, DOI 10.1002/j.1460-2075.1991.tb07936.x; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; COMINGS DE, 1968, AM J HUM GENET, V20, P440; Dernburg AF, 1996, CELL, V85, P745, DOI 10.1016/S0092-8674(00)81240-4; EARNSHAW WC, 1994, FASEB J, V8, P947, DOI 10.1096/fasebj.8.12.8088460; Ernst P, 1996, MOL CELL BIOL, V16, P6121; ERNST P, 1993, MOL CELL BIOL, V13, P2982, DOI 10.1128/MCB.13.5.2982; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; FISHER AG, 1995, INT IMMUNOL, V7, P415, DOI 10.1093/intimm/7.3.415; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GRANOK H, 1995, CURR BIOL, V5, P238, DOI 10.1016/S0960-9822(95)00048-0; HAAF T, 1989, HUM GENET, V81, P137, DOI 10.1007/BF00293889; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HADLACZKY G, 1986, EXP CELL RES, V167, P1, DOI 10.1016/0014-4827(86)90199-0; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HENIKOFF S, 1996, GENOMES; Hostert A, 1997, J IMMUNOL, V158, P4270; HUANG S, 1992, P NATL ACAD SCI USA, V89, P305, DOI 10.1073/pnas.89.1.305; JIANG J, 1993, EMBO J, V12, P3201, DOI 10.1002/j.1460-2075.1993.tb05989.x; KIM KJ, 1979, J IMMUNOL, V122, P549; KLUG CA, 1997, IN PRESS P NATL ACAD; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAWRENCE JB, 1989, CELL, V57, P493, DOI 10.1016/0092-8674(89)90924-0; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; Marshall WF, 1997, CURR OPIN GENET DEV, V7, P259, DOI 10.1016/S0959-437X(97)80136-0; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; Merkenschlager M, 1997, J EXP MED, V186, P1149, DOI 10.1084/jem.186.7.1149; MOLNAR A, 1994, MOL CELL BIOL, V14, P8292, DOI 10.1128/MCB.14.12.8292; MOORTHIBHAT K, 1996, DEVELOPMENT, V122, P1113; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; Poux S, 1996, EMBO J, V15, P4713, DOI 10.1002/j.1460-2075.1996.tb00848.x; Rabl C., 1885, MORPHOL JB, V10, P214; RAFF JW, 1994, EMBO J, V13, P5977, DOI 10.1002/j.1460-2075.1994.tb06943.x; RALPH P, 1975, J IMMUNOL, V114, P898; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; Robb L, 1996, EMBO J, V15, P4123, DOI 10.1002/j.1460-2075.1996.tb00787.x; RODERICK TH, 1996, GENETIC VARIANTS STR, P926; ROLINK A, 1993, ADV IMMUNOL, V53, P123, DOI 10.1016/S0065-2776(08)60499-X; SAGA Y, 1988, MOL CELL BIOL, V8, P4889, DOI 10.1128/MCB.8.11.4889; SCHMID I, 1991, CYTOMETRY, V12, P279, DOI 10.1002/cyto.990120312; SPECTOR DL, 1986, EXP CELL RES, V163, P87, DOI 10.1016/0014-4827(86)90560-4; Strouboulis J, 1996, J CELL SCI, V109, P1991; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; Strutt H, 1997, EMBO J, V16, P3621, DOI 10.1093/emboj/16.12.3621; Sun L, 1996, EMBO J, V15, P5358, DOI 10.1002/j.1460-2075.1996.tb00920.x; Wang JH, 1996, IMMUNITY, V5, P537, DOI 10.1016/S1074-7613(00)80269-1; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WHITE RAH, 1986, CELL, V47, P311, DOI 10.1016/0092-8674(86)90453-8; WINANDY S, 1995, CELL, V83, P289, DOI 10.1016/0092-8674(95)90170-1; WREGGETT KA, 1994, CYTOGENET CELL GENET, V66, P99, DOI 10.1159/000133676; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; ZHANG CC, 1992, P NATL ACAD SCI USA, V89, P7511, DOI 10.1073/pnas.89.16.7511; ZHOU LJ, 1992, IMMUNOGENETICS, V35, P102, DOI 10.1007/BF00189519; Zirbel RM, 1993, CHROMOSOME RES, V1, P93, DOI 10.1007/BF00710032	67	644	661	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					845	854		10.1016/S0092-8674(00)80472-9	http://dx.doi.org/10.1016/S0092-8674(00)80472-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413993	Bronze			2022-12-01	WOS:A1997YL43900015
J	Chang, HJ; Miller, HL; Watkins, N; Arduino, MJ; Ashford, DA; Midgley, G; Aguero, SM; Pinto-Powell, R; von Reyn, F; Edwards, W; McNeil, MM; Jarvis, WR				Chang, HJ; Miller, HL; Watkins, N; Arduino, MJ; Ashford, DA; Midgley, G; Aguero, SM; Pinto-Powell, R; von Reyn, F; Edwards, W; McNeil, MM; Jarvis, WR			An epidemic of Malassezia pachydermatis in an intensive care nursery associated with colonization of health care workers pet dogs	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INFANTS; INFECTIONS; SEVERITY; FURFUR; UNIT; DNA	Background Malassezia species are lipophilic yeasts that are emerging as nosocomial pathogens, particularly in low-birth-weight neonates who receive lipid emulsions. When a cluster of patients with Malassezia pachydermatis infection was identified in an intensive care nursery, we initiated an investigation. Methods A case patient was defined as any infant in the intensive care nursery who had a positive culture for M. pachydermatis between October 17, 1993, and January 18, 1995. We conducted a cohort study to identify risk factors for colonization and infection with M. pachydermatis. We collected cultures from the infants and the health care workers and from the health care workers' pets, since this organism has been associated with otitis externa in dogs. Results Fifteen infants met the case definition: eight with bloodstream infections, two with urinary tract infections, one with meningitis, and four with asymptomatic colonization. The case patients were significantly more likely than the other infants to weigh 1300 g or less (15 of 65 vs. 0 of 419, P<0.001). In a multivariate analysis of infants weighing 1300 g or less, the independent risk factors for colonization or infection with M. pachydermatis were a greater severity of concomitant illness (odds ratio, 19.7; P=0.001), arterial catheterization for nine or more days (odds ratio, 29.5; P=0.02), and exposure to Nurse A (odds ratio, 74.7; P=0.01). In a point-prevalence survey, 9 additional infants, 1 health care worker, and 12 of the health care workers' pet dogs had positive cultures for M. pachydermatis. The isolates from all 15 case patients, the 9 additional colonized infants, 1 health care worker, and 3 of the 12 dogs had identical patterns of restriction-fragment-length polymorphisms. Conclusions In this outbreak, it is likely that M. pachydermatis was introduced into the intensive care nursery on health care workers' hands after being colonized from pet dogs at home. The organism persisted in the nursery through patient-to-patient transmission. (C)1998, Massachusetts Medical Society.	Ctr Dis Control, Hosp Infect Program, Atlanta, GA 30333 USA; Ctr Dis Control, Div Bacterial & Mycot Dis, Atlanta, GA 30333 USA; Ctr Dis Control, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Univ Chicago, Robert Wood Johnson Clin Scholars Program, Chicago, IL 60637 USA; Univ Illinois, Chicago, IL USA; Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA; St Thomas Hosp, London, England	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Dartmouth College; Guy's & St Thomas' NHS Foundation Trust	Jarvis, WR (corresponding author), Ctr Dis Control, Hosp Infect Program, Mailstop E-69, Atlanta, GA 30333 USA.		Arduino, Matthew/C-1461-2012	Arduino, Matthew/0000-0001-7072-538X; McNeil, Michael/0000-0003-0713-8312				ABOUGABAL M, 1979, MYKOSEN, V22, P192; Bandhaya Mayouree, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P343; DANKNER WM, 1987, REV INFECT DIS, V9, P743; Dean AG, 1994, EPI INFO VERSION 6 0; GRAY JE, 1995, PEDIATRICS, V95, P225; GUEHO E, 1987, J CLIN MICROBIOL, V25, P1789, DOI 10.1128/JCM.25.9.1789-1790.1987; Gueho E, 1996, ANTON LEEUW INT J G, V69, P337, DOI 10.1007/BF00399623; LAROCCO M, 1988, PEDIATR INFECT DIS J, V7, P398, DOI 10.1097/00006454-198806000-00006; LEEMING JP, 1995, PEDIATR INFECT DIS J, V14, P719, DOI 10.1097/00006454-199508000-00018; LONG JG, 1985, PEDIATRICS, V76, P896; PETERSEN NJ, 1973, HEALTH LAB SCI, V10, P18; RICHARDSON DK, 1993, PEDIATRICS, V91, P617; RICHET HM, 1989, J CLIN MICROBIOL, V27, P1197, DOI 10.1128/JCM.27.6.1197-1200.1989; *SAS I, 1990, SAS PROC GUID PC SAS; SCHERER S, 1987, J CLIN MICROBIOL, V25, P675, DOI 10.1128/JCM.25.4.675-679.1987; VARMA A, 1989, J GEN MICROBIOL, V135, P3353; WEIDMAN FD, 1925, REP LAB MUS COMP PAT, V53, P36; WELBEL SF, 1994, PEDIATR INFECT DIS J, V13, P104, DOI 10.1097/00006454-199402000-00005	18	177	189	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 12	1998	338	11					706	711		10.1056/NEJM199803123381102	http://dx.doi.org/10.1056/NEJM199803123381102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ZB546	9494146	Bronze			2022-12-01	WOS:000072483400002
J	Sangha, O; Phillips, CB; Fleischmann, KE; Wang, TJ; Fossel, AH; Lew, R; Liang, MH; Shadick, NA				Sangha, O; Phillips, CB; Fleischmann, KE; Wang, TJ; Fossel, AH; Lew, R; Liang, MH; Shadick, NA			Lack of cardiac manifestations among patients with previously treated Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article						Lyme disease; heart disease; electrocardiography; antibiotics; heart block	BORRELIA-BURGDORFERI INFECTION; NEUROLOGIC MANIFESTATIONS; MYOCARDITIS; CARDIOMYOPATHY; ARTHRITIS	Background: Cardiac involvement is common in acute Lyme disease, and case reports suggest that cardiac abnormalities might also occur years after the primary infection. Objective: To determine the prevalence of cardiac abnormalities in persons with previously treated Lyme disease. Design: Population-based, retrospective cohort study with controls. Setting: Nantucket Island, Massachusetts. Participants: From among 3703 adult respondents to a total-population (n = 6046) mail survey, 336 (176 case-patients and 160 controls) were randomly selected for clinical evaluation. Measurements: Current cardiac symptoms and major or minor abnormal electrocardiographic features, including heart rate; rhythm; axis; PR, QRS, and QT intervals; QRS structure; atrioventricular blocks; and ST-segment and T-wave changes. Results: Persons with Lyme disease (case-patients, n = 176) (mean duration from disease onset to study evaluation, 5.2 years) and persons without evidence of previous Lyme disease (controls, n = 160) did not differ significantly in their patterns of current cardiac symptoms and electrocardiographic findings, including heart rate (P > 0.2), PR interval (P = 0.15), QRS interval (P > 0.2), QT interval (P > 0.2), axis (P > 0.2), presence of arrhythmias (P > O.Z), first-degree heart block (P = 0.12), bundle-branch block (P > 0.2), and ST-segment abnormalities (P > 0.2). In multivariate analyses that adjusted for age, sex, and previous heart disease, a history of previously treated Lyme disease was not associated with either major (odds ratio, 0.78; P > O.Z) or minor (odds ratio, 1.09; P > O.Z) electrocardiographic abnormalities. Conclusion: Persons with a history of previously treated Lyme disease do not have a higher prevalence of cardiac abnormalities than persons without a history of Lyme disease.	Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Shadick, NA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 75 Francis St, Boston, MA 02115 USA.				NIAMS NIH HHS [AR02033, AR36308] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308, K08AR002033] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALPERT LI, 1985, CLIN NUCL MED, V10, P617, DOI 10.1097/00003072-198509000-00002; ASBRINK E, 1988, ANN NY ACAD SCI, V539, P4, DOI 10.1111/j.1749-6632.1988.tb31833.x; ASCH ES, 1994, J RHEUMATOL, V21, P454; BERARDI VP, 1988, J INFECT DIS, V158, P754, DOI 10.1093/infdis/158.4.754; Breslow NE., 1980, IARC SCI PUBL, P5; CASANS I, 1989, EUR J NUCL MED, V15, P330, DOI 10.1007/BF00435476; CIESIELSKI CA, 1989, REV INFECT DIS, V11, pS1435; COX J, 1991, AM HEART J, V122, P1449, DOI 10.1016/0002-8703(91)90589-A; CRAFT JE, 1986, J CLIN INVEST, V78, P934, DOI 10.1172/JCI112683; DEKONING J, 1989, J INFECT DIS, V160, P150, DOI 10.1093/infdis/160.1.150; Dillman DA, 1978, MAIL TELEPHONE SURVE; GASSER R, 1992, LANCET, V339, P1174, DOI 10.1016/0140-6736(92)90777-Z; GOLDINGS EA, 1986, CLIN RHEUM DIS, V12, P343; GOODMAN JL, 1991, J CLIN MICROBIOL, V29, P894, DOI 10.1128/JCM.29.5.894-896.1991; Heinisch O., 1963, SAMPLING TECHNIQUES, V7, P203, DOI [10.1002/bimj.19650070312, DOI 10.1002/BIMJ.19650070312]; JACOBS JC, 1984, J PEDIATR-US, V105, P950, DOI 10.1016/S0022-3476(84)80086-4; KLEIN J, 1991, EUR HEART J, V12, P73, DOI 10.1093/eurheartj/12.suppl_D.73; LOGIGIAN EL, 1990, NEW ENGL J MED, V323, P1438, DOI 10.1056/NEJM199011223232102; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MCALISTER HF, 1989, ANN INTERN MED, V110, P339, DOI 10.7326/0003-4819-110-5-339; MCNEMAR Q, 1969, PSYCHOL STAT, P322; NOKOA K, 1990, GEN SOCIAL SURVEY ME, V70, P1; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; PEETERS AJ, 1990, P 5 INT C LYM BORR S; RIENZO RJ, 1987, CLIN NUCL MED, V12, P475, DOI 10.1097/00003072-198706000-00017; SAS/STAT, 1990, US GUID; SHADICK NA, 1994, ANN INTERN MED, V121, P560, DOI 10.7326/0003-4819-121-8-199410150-00002; SONNESYN SW, 1995, AM J CARDIOL, V76, P97, DOI 10.1016/S0002-9149(99)80814-5; STANEK G, 1991, SCAND J INFECT DIS, P85; STANEK G, 1990, NEW ENGL J MED, V322, P249, DOI 10.1056/NEJM199001253220407; *STAT CONN DEP HLT, 1990, CONNECTICUT EPIDEMIO, V10, P9; STEERE AC, 1983, ANN INTERN MED, V99, P76, DOI 10.7326/0003-4819-99-1-76; STEERE AC, 1980, ANN INTERN MED, V93, P8, DOI 10.7326/0003-4819-93-1-8; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; VANDERLINDE MR, 1990, BRIT HEART J, V63, P162, DOI 10.1136/hrt.63.3.162; VANDERLINDE MR, 1991, SCAND J INFECT DIS, P81; VEGSUNDVAG J, 1993, BRIT MED J, V307, P173, DOI 10.1136/bmj.307.6897.173; VIDAILLET HJ, 1993, AM J CARDIOL, V71, P1249, DOI 10.1016/0002-9149(93)90663-W; VLAY SC, 1986, NEW ENGL J MED, V315, P1418; VLAY SC, 1991, AM HEART J, V121, P1558, DOI 10.1016/0002-8703(91)90173-F; 1996, MMWR MORB MORTAL WKL, V45, P481	43	22	23	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					346	+		10.7326/0003-4819-128-5-199803010-00002	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490594				2022-12-01	WOS:000072155600002
J	Gupta, AK; Scher, RK				Gupta, AK; Scher, RK			Oral antifungal agents for onychomycosis	LANCET			English	Editorial Material							STRATUM-CORNEUM; ITRACONAZOLE; KINETICS		Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, Toronto, ON, Canada; Columbia Univ Coll Phys & Surg, Dept Dermatol, New York, NY 10032 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Columbia University	Scher, RK (corresponding author), Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Med, Div Dermatol, 2075 Bayview Ave, Toronto, ON, Canada.		Gupta, Aditya/AAE-5797-2020	Gupta, Aditya K./0000-0002-8664-7723				CAUWENBERGH G, 1988, J AM ACAD DERMATOL, V18, P263, DOI 10.1016/S0190-9622(88)70037-7; De Doncker P, 1997, J AM ACAD DERMATOL, V37, P969, DOI 10.1016/S0190-9622(97)70074-4; DeDoncker P, 1996, ARCH DERMATOL, V132, P34, DOI 10.1001/archderm.132.1.34; EPSTEIN WL, 1972, ARCH DERMATOL, V106, P344, DOI 10.1001/archderm.106.3.344; Gupta A. K., 1997, Dermatologic Therapy, V3, P58; Gupta AK, 1997, INT J DERMATOL, V36, P783, DOI 10.1046/j.1365-4362.1997.00349.x; Gupta AK, 1998, PHARMACOECONOMICS, V13, P243, DOI 10.2165/00019053-199813020-00007; Gupta AK, 1997, J AM ACAD DERMATOL, V37, P979, DOI 10.1016/S0190-9622(97)70076-8; GUPTA AK, 1994, J AM ACAD DERMATOL, V30, P677, DOI 10.1016/S0190-9622(08)81495-8; HARRIS R, 1983, ANTIMICROB AGENTS CH, V24, P876, DOI 10.1128/AAC.24.6.876; Havu V, 1997, BRIT J DERMATOL, V136, P230, DOI 10.1111/j.1365-2133.1997.tb14902.x; MEINHOF W, 1993, J AM ACAD DERMATOL, V29, pS37, DOI 10.1016/S0190-9622(08)81835-X; Schatz F, 1995, CLIN EXP DERMATOL, V20, P377, DOI 10.1111/j.1365-2230.1995.tb01353.x; SCHER RK, 1994, BRIT J DERMATOL, V130, P15, DOI 10.1111/j.1365-2133.1994.tb06087.x; SCHER RK, 1997, 37 INT C ANT AG CHEM; Tausch I, 1997, BRIT J DERMATOL, V136, P737, DOI 10.1111/j.1365-2133.1997.tb03662.x	16	26	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	1998	351	9102					541	542		10.1016/S0140-6736(05)78552-4	http://dx.doi.org/10.1016/S0140-6736(05)78552-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492770	hybrid			2022-12-01	WOS:000072231900006
J	Grignani, F; De Matteis, S; Nervi, C; Tomassoni, L; Gelmetti, V; Cioce, M; Fanelli, M; Ruthardt, M; Ferrara, FF; Zamir, I; Seiser, C; Grignani, F; Lazar, MA; Minucci, S; Pelicci, PG				Grignani, F; De Matteis, S; Nervi, C; Tomassoni, L; Gelmetti, V; Cioce, M; Fanelli, M; Ruthardt, M; Ferrara, FF; Zamir, I; Seiser, C; Grignani, F; Lazar, MA; Minucci, S; Pelicci, PG			Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia	NATURE			English	Article							RAR-ALPHA; LEUKEMIA FUSES; TRANSLOCATION; PML; DIFFERENTIATION; TRANSGLUTAMINASE; REPRESSION; T(15-17); DOMAINS; GENE	The transforming proteins of acute promyelocytic leukaemias (APL) are fusions of the promyelocytic leukaemia (PML) and the promyelocytic leukaemia zinc-finger (PLZF) proteins with retinoic acid receptor-alpha (RAR alpha)(1,2). These proteins retain the RAR alpha DNA- and retinoic acid (RA)-binding domains, and their ability to block haematopoietic differentiation depends on the RAR alpha DNA-binding domain(3-6), Thus RA-target genes are downstream effectors(7,8). However, treatment with RA induces differentiation of leukaemic blast cells and disease remission in PML-RAR alpha APLs, whereas PLZF-RAR alpha APLs are resistant to RA(1,2), Transcriptional regulation by RARs involves modifications of chromatin by histone deacetylases, which are recruited to RA-target genes by nuclear co-repressors(9,10), Here we show that both PML-RAR alpha and PLZF-RAR alpha fusion proteins recruit the nuclear co-repressor (N-CoR)-histone deacetylase complex through the RAR alpha CoR box, PLZF-RAR alpha contains a second, RA-resistant binding site in the PLZF amino-terminal region, High doses of RA release histone deacetylase activity from PML-RAR alpha, but not from PLZF-RAR alpha. Mutation of the N-CoR binding site abolishes the ability of PML-RAR alpha to block differentiation, whereas inhibition of histone deacetylase activity switches the transcriptional and biological effects of PLZF-RAR alpha from being an inhibitor to an activator of the RA signalling pathway, Therefore, recruitment of histone deacetylase is crucial to the transforming potential of APL fusion proteins, and the different effects of RA on the stability of the PML-RAR alpha and PLZF-RAR alpha co-repressor complexes determines the differential response of APLs to RA.	Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy; Ist Super Sanita, Dept Haematol & Oncol, I-00161 Rome, Italy; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Vienna, Vienna Bioctr, Inst Mol Biol, Vienna, Austria; Univ Frankfurt, Dept Haematol, D-6000 Frankfurt, Germany	University of Perugia; Istituto Superiore di Sanita (ISS); IRCCS European Institute of Oncology (IEO); University of Pennsylvania; University of Pennsylvania; University of Vienna; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA); Goethe University Frankfurt	Pelicci, PG (corresponding author), Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy.		Fanelli, Mirco/F-2665-2011; Lazar, Mitchell A/AAF-3738-2019; Minucci, Saverio/J-9669-2012; Grignani, Francesco/AAC-2565-2022; Cioce, Mario/R-9734-2017; Pelicci, Pier Giuseppe/AAL-6572-2020	Fanelli, Mirco/0000-0002-9649-8661; Cioce, Mario/0000-0001-8129-6664; Ruthardt, Martin/0000-0003-1021-3811; Seiser, Christian/0000-0002-7046-9352; Grignani, Francesco/0000-0003-0563-5673; NERVI, Clara/0000-0001-9341-0188				Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Benedetti L, 1996, BLOOD, V87, P1939; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DHORDAIN P, 1997, P NATL ACAD SCI USA, V94, P10727; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grignani F, 1996, EMBO J, V15, P4949, DOI 10.1002/j.1460-2075.1996.tb00875.x; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; Minucci S, 1996, CURR OPIN GENET DEV, V6, P567, DOI 10.1016/S0959-437X(96)80085-2; Nagy L, 1996, J BIOL CHEM, V271, P4355; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; NERVI C, 1992, CANCER RES, V52, P3687; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; WARRELL RPJ, 1993, NEW ENGL J MED, V324, P177; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Zamir I, 1996, MOL CELL BIOL, V16, P5458	29	883	924	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					815	818		10.1038/35901	http://dx.doi.org/10.1038/35901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486655				2022-12-01	WOS:000072089500059
J	Batchelor, AH; Piper, DE; de la Brousse, FC; McKnight, SL; Wolberger, C				Batchelor, AH; Piper, DE; de la Brousse, FC; McKnight, SL; Wolberger, C			The structure of GABP alpha/beta: An ETS domain ankyrin repeat heterodimer bound to DNA	SCIENCE			English	Article							CRYSTAL-STRUCTURE; MURINE ETS-1; PROTEIN; BINDING; COMPLEX; IDENTIFICATION; EXPRESSION; ACTIVATOR; ENHANCER; SUBUNITS	GA-binding protein (GABP) is a transcriptional regulator composed of two structurally dissimilar subunits. The alpha subunit contains a DNA-binding domain that is a member of the ETS family, whereas the beta subunit contains a series of ankyrin repeats. The crystal structure of a ternary complex containing a GABP alpha/beta ETS domain-ankyrin repeat heterodimer bound to DNA was determined at 2.15 angstrom resolution. The structure shows how an ETS domain protein can recruit a partner protein using both the ETS domain and a carboxyl-terminal extension and provides a view of an,extensive protein-protein interface formed by a set of ankyrin repeats. The structure also reveals how the GABP alpha ETS domain binds to its core GGA DNA-recognition motif.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Tularik, S San Francisco, CA 94080 USA; Univ Texas, SW Med Sch, Dept Biochem, Dallas, TX 75235 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.	cynthia@groucho.med.jhmi.edu		Wolberger, Cynthia/0000-0001-8578-2969				BENNETT V, 1992, J BIOL CHEM, V267, P8703; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; DELABROUSSE FC, 1994, GENE DEV, V8, P1853, DOI 10.1101/gad.8.15.1853; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; GRAVES BJ, IN PRESS ADV CANC RE; GUNTHER CV, 1994, MOL CELL BIOL, V14, P7569, DOI 10.1128/MCB.14.11.7569; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELEHER CA, 1988, CELL, V53, P927, DOI 10.1016/S0092-8674(88)90449-7; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; PETERSEN JM, 1995, SCIENCE, V269, P1866, DOI 10.1126/science.7569926; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON CC, 1992, TRENDS GENET, V8, P232, DOI 10.1016/0168-9525(92)90121-J; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WERNER MH, 1995, CELL, V83, P761, DOI 10.1016/0092-8674(95)90189-2; WERNER MH, 1996, CELL, V87, P355	34	261	267	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	1998	279	5353					1037	1041		10.1126/science.279.5353.1037	http://dx.doi.org/10.1126/science.279.5353.1037			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461436				2022-12-01	WOS:000072006400048
J	Skoczenski, AM; Norcia, AM				Skoczenski, AM; Norcia, AM			Neural noise limitations on infant visual sensitivity	NATURE			English	Article							CONTRAST GAIN-CONTROL; EVOKED-POTENTIALS; VISION; SYSTEM; EXISTENCE; CELLS	Visual contrast sensitivity is poor in newborn human infants, but improves rapidly to approach adult levels by 8 months of age(1-5). During this period, infant sensitivity can be limited by physical factors affecting photon capture, such as eye size and photoreceptor density(6,7). Here we show that infant visual sensitivity is also limited by high levels of noise in the neural transduction process. Using a non-invasive electrophysiological measurements(8-10) and a visual noise titration technique(11), we have found that intrinsic neural noise in neonates is approximately nine times higher than in adults. As intrinsic neural noise decreases during infancy, contrast sensitivity improves proportionally, suggesting that neural noise places critical limits on contrast sensitivity throughout development. Moreover, contrast gain control(12), an inhibitory process that adjusts visual responses to changing stimulation, is in place and operating in infants as young as 6 weeks of age, in spite of high levels of neural noise and significant immaturities in contrast sensitivity, The contrast gain control that we observed in human neonates may serve as a building block for more complex forms of visual inhibition, which develop later in infancy(13).	Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA	The Smith-Kettlewell Eye Research Institute	Skoczenski, AM (corresponding author), Smith Kettlewell Eye Res Inst, 2232 Webster St, San Francisco, CA 94115 USA.							ATKINSON J, 1974, NATURE, V247, P403, DOI 10.1038/247403a0; BANKS MS, 1988, J OPT SOC AM A, V5, P2059, DOI 10.1364/JOSAA.5.002059; BONDS AB, 1991, VISUAL NEUROSCI, V6, P239, DOI 10.1017/S0952523800006258; BURR DC, 1987, J PHYSIOL-LONDON, V389, P1; CAMPBELL FW, 1970, J PHYSIOL-LONDON, V207, P635, DOI 10.1113/jphysiol.1970.sp009085; GEISLER WS, 1992, VISION RES, V32, P1409, DOI 10.1016/0042-6989(92)90196-P; HARRIS L, 1976, NATURE, V264, P570, DOI 10.1038/264570a0; MORRONE MC, 1986, NATURE, V321, P235, DOI 10.1038/321235a0; NORCIA AM, 1989, VISION RES, V29, P627, DOI 10.1016/0042-6989(89)90048-5; NORCIA AM, 1985, IEEE ENG MED BIOL, V4, P26, DOI 10.1109/MEMB.1985.5006224; NORCIA AM, 1990, VISION RES, V30, P1475, DOI 10.1016/0042-6989(90)90028-J; NORCIA AM, 1988, INVEST OPHTH VIS SCI, V29, P44; OHZAWA I, 1985, J NEUROPHYSIOL, V54, P651, DOI 10.1152/jn.1985.54.3.651; Pelli D. G., 1990, VISION CODING EFFICI, P1; PELLI DG, 1991, VISION RES, V31, P1337, DOI 10.1016/0042-6989(91)90055-A; PIRCHIO M, 1978, BRAIN RES, V141, P179, DOI 10.1016/0006-8993(78)90628-5; Shannon E, 1996, VISION RES, V36, P67, DOI 10.1016/0042-6989(95)00053-3; SHAPLEY RM, 1978, J PHYSIOL-LONDON, V285, P275, DOI 10.1113/jphysiol.1978.sp012571; SKOCZENSKI AM, 1994, NEUR ABSTR, V20, P7; TANG Y, 1994, ELECTROENCEPHALOGR C, V96, P268; TYLER CW, 1979, INVEST OPHTH VIS SCI, V18, P703; VANNES FL, 1967, J OPT SOC AM, V57, P401, DOI 10.1364/JOSA.57.000401; VICTOR JD, 1991, ELECTROEN CLIN NEURO, V78, P378, DOI 10.1016/0013-4694(91)90099-P; WILSON HR, 1988, VISION RES, V28, P611; YUODELIS C, 1986, VISION RES, V26, P847, DOI 10.1016/0042-6989(86)90143-4	25	35	35	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					697	700		10.1038/35630	http://dx.doi.org/10.1038/35630			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490413				2022-12-01	WOS:000071982500053
J	Elston, T; Wang, HY; Oster, G				Elston, T; Wang, HY; Oster, G			Energy transduction in ATP synthase	NATURE			English	Article							SUBUNIT-C; MECHANISM; ROTATION; F-0; F1-ATPASE	Mitochondria, bacteria and chloroplasts use the free energy stored in transmembrane ion gradients to manufacture ATP by the action of ATP synthase. This enzyme consists of two principal domains. The asymmetric membrane-spanning F-0 portion contains the proton channel, and the soluble F-1 portion contains three catalytic sites which cooperate in the synthetic reactions(1). The Bow of protons through F-0 is thought to generate a torque which is transmitted to F-1 by an asymmetric shaft, the coiled-coil gamma-subunit. This acts as a rotating 'cam' within F-1, sequentially releasing ATPs from the three active sites(1-5). The free-energy difference across the inner membrane of mitochondria and bacteria is sufficient to produce three ATPs per twelve protons passing through the motor. It has been suggested that this protonmotive force biases the rotor's diffusion so that F-0 constitutes a rotary motor turning the gamma shaft(6). Here we show that biased diffusion, augmented by electrostatic forces, does indeed generate sufficient torque to account for ATP production. Moreover, the motor's reversibility-supplying torque from ATP hydrolysis in F-1 converts the motor into an efficient proton pump(7)-can also be explained by our model.	Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Oster, G (corresponding author), Univ Calif Berkeley, Dept Mol & Cellular Biol, Berkeley, CA 94720 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; BERG HC, 1983, MOBILITY RECOGNITION, P485; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Cross RL, 1996, J BIOENERG BIOMEMBR, V28, P403, DOI 10.1007/BF02113981; Dimroth P, 1997, BBA-BIOENERGETICS, V1318, P11, DOI 10.1016/S0005-2728(96)00127-2; DMITRIEV OY, 1995, EUR J BIOCHEM, V233, P478, DOI 10.1111/j.1432-1033.1995.478_2.x; Elston TC, 1997, BIOPHYS J, V73, P703, DOI 10.1016/S0006-3495(97)78104-9; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; Fillingame RH, 1995, BIOCHEM SOC T, V23, P760, DOI 10.1042/bst0230760; Fillingame RH, 1997, J EXP BIOL, V200, P217; FILLINGAME RH, 1990, BACTERIA, P345; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; HARRISON M, 1997, J MEMBRANE BIOL, V14, P1; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; KHAN S, 1983, CELL, V32, P913, DOI 10.1016/0092-8674(83)90076-4; MEISTER M, 1989, BIOPHYS J, V55, P905, DOI 10.1016/S0006-3495(89)82889-9; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Risken H., 1989, FOKKERPLANCK EQUATIO; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; VALIYAVEETIL F, IN PRESS J BIOL CHEM; VIK SB, 1994, J BIOL CHEM, V269, P30364; Yasuda R, 1997, J BIOENERG BIOMEMBR, V29, P207, DOI 10.1023/A:1022449708449	25	430	439	4	89	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					510	513		10.1038/35185	http://dx.doi.org/10.1038/35185			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461222				2022-12-01	WOS:000071701800057
J	Richardson, MP; Sharland, M				Richardson, MP; Sharland, M			Late diagnosis of paediatric HIV infection in south west London	BRITISH MEDICAL JOURNAL			English	Article									St George Hosp, Paediat Infect Dis Unit, London SW17 0QT, England	St Georges University London	Richardson, MP (corresponding author), St George Hosp, Paediat Infect Dis Unit, London SW17 0QT, England.			sharland, mike/0000-0001-8626-8291				[Anonymous], 1994, MMWR Recomm Rep, V43, P1; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1996, UNL AN HIV PREV MON; *DEP HLTH, 1997, GUID OFF VOL NAM HIV; GALLI L, 1995, AIDS, V9, P455, DOI 10.1097/00002030-199509050-00007	5	13	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					271	272		10.1136/bmj.316.7127.271	http://dx.doi.org/10.1136/bmj.316.7127.271			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472509	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000071702100023
J	Carson, JL; Duff, A; Berlin, JA; Lawrence, VA; Poses, RM; Huber, EC; O'Hara, DA; Noveck, H; Strom, BL				Carson, JL; Duff, A; Berlin, JA; Lawrence, VA; Poses, RM; Huber, EC; O'Hara, DA; Noveck, H; Strom, BL			Perioperative blood transfusion and postoperative mortality	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MORBIDITY; DISEASE; SYSTEM; RISK	Context.-The risks of blood transfusion have been studied extensively but the benefits and the hemoglobin concentration at which patients should receive a transfusion have not. Objective.-To determine the effect of perioperative transfusion on 30- and 90-day postoperative mortality. Design.-Retrospective cohort study. Setting.-A total of 20 US hospitals between 1983 and 1993. Participants.-A total of 8787 consecutive hip fracture patients, aged 60 years or older, who underwent surgical repair. Main Outcome Measures.-Primary outcome was 30-day postoperative mortality; secondary outcome was 90-day postoperative mortality. The "trigger" hemoglobin level was defined as the lowest hemoglobin level prior to the first transfusion during the time period or, for patients in the nontranfused group, as the lowest hemoglobin level during the time period. Results.-Overall 30-day mortality was 4.6% (n=402; 95% confidence interval [CI], 4.1%-5.0%); overall 90-day mortality was 9.0% (n=788; 95% CI, 8.4%-9.6%). A total of 42% of patients (n=3699) received a postoperative transfusion. Among patients with trigger hemoglobin levels between 80 and 100 g/L (8.0 and 10.0 g/dL), 55.6% received a transfusion, while 90.5% of patients with hemoglobin levels less than 80 g/L (8.0 g/dL) received postoperative transfusions. Postoperative transfusion did not influence 30- or 90-day mortality after adjusting for trigger hemoglobin level, cardiovascular disease, and other risk factors for death: for 30-day mortality, the adjusted odds ratio (OR) was 0.96 (95% CI, 0.74-1.26); for 90-day mortality, the adjusted hazard ratio was 1.08 (95% CI, 0.90-1.29). Similarly, 30-day mortality after surgery did not differ between those who received a preoperative transfusion and those who did not (adjusted OR, 1.23; 95% CI, 0.81-1.89). Conclusions.-Perioperative transfusion in patients with hemoglobin levels 80 g/L (8.0 g/dL) or higher did not appear to influence the risk of 30- or 90-day mortality in this elderly population, At hemoglobin concentrations of less than 80 g/L (8.0 g/dL), 90.5% of patients received a transfusion, precluding further analysis of the association of transfusion and mortality.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Anesthesia, New Brunswick, NJ 08903 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Med, Div Gen Internal Med, Philadelphia, PA 19104 USA; S Texas Vet Hlth Care Syst, Audie Murphy Div, Div Gen Med, San Antonio, TX USA; Univ Texas, Dept Med, San Antonio, TX 78285 USA; Brown Univ, Sch Med, Dept Med, Div Gen Internal Med, Providence, RI 02912 USA; Brown Univ, Mem Hosp Rhode Isl, Pawtucket, RI 02860 USA; Virginia Commonwealth Univ, Med Coll Virginia, Div Gen Internal Med, Richmond, VA 23298 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; Brown University; Brown University; Virginia Commonwealth University	Carson, JL (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Gen Internal Med, Dept Med, 125 Paterson St, New Brunswick, NJ 08903 USA.	carson@umdnj.edu			AHRQ HHS [1R01HS07322] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON HT, 1978, SURGERY, V84, P8; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BLAIR SD, 1986, BRIT J SURG, V73, P783, DOI 10.1002/bjs.1800731007; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P142; Carson JL, 1996, LANCET, V348, P1055, DOI 10.1016/S0140-6736(96)04330-9; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; FEINBERG SE, 1977, ANAL CROSS CLASSIFIE, P9; Geha A S, 1978, World J Surg, V2, P645; GOODNOUGH LT, 1991, JAMA-J AM MED ASSOC, V265, P86, DOI 10.1001/jama.265.1.86; HAGL S, 1977, BASIC RES CARDIOL, V72, P344, DOI 10.1007/BF02023594; HERBERT PC, 1995, JAMA-J AM MED ASSOC, V273, P1439; JOHNSON RG, 1992, J THORAC CARDIOV SUR, V104, P307; KEELER EB, 1990, JAMA-J AM MED ASSOC, V264, P1962, DOI 10.1001/jama.264.15.1962; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUNN JN, 1970, BRIT MED J, V3, P71, DOI 10.1136/bmj.3.5714.71; MANTEL N, 1959, J NATL CANCER I, V22, P719; Rawstron R E, 1970, Aust N Z J Surg, V39, P425, DOI 10.1111/j.1445-2197.1970.tb05389.x; SAS Institute Inc, 1990, SAS STAT US GUID VER, V4; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; TOPLEY E, 1956, BR J CLIN PRACT, V1, P770; WEISEL RD, 1992, J THORAC CARDIOVASC, V104, P308; WILKERSON DK, 1988, SURGERY, V103, P665; YOSHIKAWA H, 1973, AM J CARDIOL, V32, P670, DOI 10.1016/S0002-9149(73)80061-X	27	297	306	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					199	205		10.1001/jama.279.3.199	http://dx.doi.org/10.1001/jama.279.3.199			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438739	Bronze			2022-12-01	WOS:000071460700029
J	De Koninck, P; Schulman, H				De Koninck, P; Schulman, H			Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; SYNAPTIC PLASTICITY; HIPPOCAMPAL SLICES; CALMODULIN KINASE; AUTOPHOSPHORYLATION; EXPRESSION; MECHANISM; MEMORY; ACTIVATION	The transduction of many cellular stimuli results in oscillations in the intracellular concentration of calcium ions (Ca2+). Although information is thought to be encoded in the frequency of such oscillations, no frequency decoder has been identified. Rapid superfusion of immobilized Ca2+ - and calmodulin-dependent protein kinase II (CaM kinase II) in vitro showed that the enzyme can decode the frequency of Ca2+ spikes into distinct amounts of kinase activity. The frequency response of CaM kinase II was modulated by several factors, including the amplitude and duration of individual spikes as well as the subunit composition and previous state of activation of the kinase. These features should provide specificity in the activation of this multifunctional enzyme by distinct cellular stimuli and may underlie its pivotal role in activity-dependent forms of synaptic plasticity.	Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University	Schulman, H (corresponding author), Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA.				NIGMS NIH HHS [GM30179, GM40600] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030179, R01GM040600, R37GM030179] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BROCKE L, 1995, J NEUROSCI, V15, P6797; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Deisseroth K, 1995, CURR BIOL, V5, P1334, DOI 10.1016/S0960-9822(95)00262-4; DEKONINCK P, UNPUB; Dosemeci A, 1996, BIOPHYS J, V70, P2493, DOI 10.1016/S0006-3495(96)79821-1; ESTEP RP, 1989, CURR TOP CELL REGUL, V31, P161; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HUERTA PT, 1993, NATURE, V364, P723, DOI 10.1038/364723a0; KANASEKI T, 1991, J CELL BIOL, V115, P1049, DOI 10.1083/jcb.115.4.1049; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN J, 1989, P NATL ACAD SCI USA, V86, P9574, DOI 10.1073/pnas.86.23.9574; LUBYPHELPS K, 1995, J BIOL CHEM, V270, P21532, DOI 10.1074/jbc.270.37.21532; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYER P, 1994, BIOCHEM J, V298, P757, DOI 10.1042/bj2980757; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; MEYER T, 1991, ANNU REV BIOPHYS BIO, V20, P153, DOI 10.1146/annurev.bb.20.060191.001101; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MICHELSON S, 1994, J THEOR BIOL, V171, P281, DOI 10.1006/jtbi.1994.1231; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MUKHERJI S, 1994, J BIOL CHEM, V269, P13744; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Skene J H, 1990, Neurosci Res Suppl, V13, pS112, DOI 10.1016/0921-8696(90)90040-A; SODERLING TR, 1995, ADV SEC MESS PHOSPH, V30, P175	37	1004	1019	4	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					227	230		10.1126/science.279.5348.227	http://dx.doi.org/10.1126/science.279.5348.227			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422695				2022-12-01	WOS:000071408100042
J	Kliewer, SA; Moore, JT; Wade, L; Staudinger, JL; Watson, MA; Jones, SA; McKee, DD; Oliver, BB; Willson, TM; Zetterstrom, RH; Perlmann, T; Lehmann, JM				Kliewer, SA; Moore, JT; Wade, L; Staudinger, JL; Watson, MA; Jones, SA; McKee, DD; Oliver, BB; Willson, TM; Zetterstrom, RH; Perlmann, T; Lehmann, JM			An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway	CELL			English	Article							HIGH-AFFINITY LIGAND; 9-CIS RETINOIC ACID; RAT-LIVER; THYROID-HORMONE; HEPATIC CYTOCHROME-P-450; MESSENGER-RNA; INDUCTION; PREGNENOLONE-16-ALPHA-CARBONITRILE; SUPERFAMILY; SEQUENCE	Steroid hormones exert profound effects on differentiation, development, and homeostasis in higher eukaryotes through interactions with nuclear receptors. We describe a novel orphan nuclear receptor, termed the pregnane X receptor (PXR), that is activated by naturally occurring steroids such as pregnenolone and progesterone, and synthetic glucocorticoids and antiglucocorticoids. PXR exists as two isoforms, PXR.1 and PXR.2, that are differentially activated by steroids. Notably, PXR.1 is efficaciously activated by pregnenolone 16 alpha-carbonitrile, a glucocorticoid receptor antagonist that induces the expression of the CYP3A family of steroid hydroxylases and modulates sterol and bile acid biosynthesis in vivo. Our results provide evidence for the existence of a novel steroid hormone signaling pathway with potential implications in the regulation of steroid hormone and sterol homeostasis.	Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Mol Sci, Res Triangle Pk, NC 27709 USA; Glaxo Wellcome Res & Dev Ltd, Dept Med Chem, Res Triangle Pk, NC 27709 USA; Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Ludwig Inst Canc Res, Stockholm Branch, S-17177 Stockholm, Sweden	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; Karolinska Institutet; Ludwig Institute for Cancer Research	Kliewer, SA (corresponding author), Glaxo Wellcome Res & Dev Ltd, Dept Mol Endocrinol, Res Triangle Pk, NC 27709 USA.		feinstein, doug/M-9414-2019	Zetterstrom, Rolf/0000-0002-3016-0019				BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Cadepond F, 1997, ANNU REV MED, V48, P129; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; DAGERLIND A, 1992, HISTOCHEMISTRY, V98, P39, DOI 10.1007/BF00716936; Debri K, 1995, BIOCHEM PHARMACOL, V50, P2047, DOI 10.1016/0006-2952(95)02107-8; ELSHOURBAGY NA, 1980, J BIOL CHEM, V255, P1279; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GONZALEZ FJ, 1985, J BIOL CHEM, V260, P7435; GREEN S, 1986, NATURE, V320, P134, DOI 10.1038/320134a0; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HEUMAN DM, 1982, MOL PHARMACOL, V21, P753; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; HUSS JM, 1996, J BIOL CHEM, V93, P4666; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; JUCHAU MR, 1990, LIFE SCI, V47, P2385, DOI 10.1016/0024-3205(90)90482-7; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Kourounakis P, 1977, Adv Steroid Biochem Pharmacol, V6, P35; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Lala DS, 1997, P NATL ACAD SCI USA, V94, P4895, DOI 10.1073/pnas.94.10.4895; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LUBAHN DB, 1988, SCIENCE, V240, P327, DOI 10.1126/science.3353727; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5790; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MASON JI, 1978, STEROIDS, V31, P849, DOI 10.1016/S0039-128X(78)80048-8; MIYATA M, 1995, ARCH BIOCHEM BIOPHYS, V318, P71, DOI 10.1006/abbi.1995.1206; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; ONATE SA, 1995, SCIENCE, V270, P1354; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PUNJABI U, 1983, J STEROID BIOCHEM, V19, P1481, DOI 10.1016/0022-4731(83)91124-X; QUATTROCHI LC, 1995, J BIOL CHEM, V270, P28917, DOI 10.1074/jbc.270.48.28917; SCHUETZ EG, 1984, J BIOL CHEM, V259, P1999; SCHUETZ EG, 1984, J BIOL CHEM, V259, P2007; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; SMITH DP, 1994, NUCLEIC ACIDS RES, V22, P66, DOI 10.1093/nar/22.1.66; STAHLBERG D, 1995, LIPIDS, V30, P361, DOI 10.1007/BF02536046; Takeshita A, 1996, ENDOCRINOLOGY, V137, P3594, DOI 10.1210/en.137.8.3594; Tietz N.M., 1995, CLIN GUIDE LAB TESTS; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TURLEY SD, 1984, GASTROENTEROLOGY, V87, P284; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; von Bergmann K, 1975, Naunyn Schmiedebergs Arch Pharmacol, V287, P33; WICHMANN U, 1984, EXP CLIN ENDOCRINOL, V83, P283, DOI 10.1055/s-0029-1210342; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	57	1251	1316	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					73	82		10.1016/S0092-8674(00)80900-9	http://dx.doi.org/10.1016/S0092-8674(00)80900-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489701	Bronze			2022-12-01	WOS:000071473700009
J	Rozwarski, DA; Grant, GA; Barton, DHR; Jacobs, WR; Sacchettini, JC				Rozwarski, DA; Grant, GA; Barton, DHR; Jacobs, WR; Sacchettini, JC			Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis	SCIENCE			English	Article							CATALASE-PEROXIDASE GENE; MYCOLIC ACID SYNTHESIS; RESISTANT STRAINS; DRUG-RESISTANCE; ENOYL REDUCTASE; OXIDATION; KATG; MUTATIONS; DNA; IDENTIFICATION	The preferred antitubercular drug isoniazid specifically targets a long-chain enoyl-acyl carrier protein reductase (InhA), an enzyme essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Despite the widespread use of this drug for more than 40 years, its precise mode of action has remained obscure. Data from x-ray crystallography and mass spectrometry reveal that the mechanism of isoniazid action against InhA is covalent attachment of the activated form of the drug to the nicotinamide ring of nicotinamide adenine dinucleotide bound within the active site of InhA.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Dept Chem, College Stn, TX 77843 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Washington University (WUSTL)	Sacchettini, JC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.			Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI036849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-36849] Funding Source: Medline; NIGMS NIH HHS [GM-45859] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1996, SCIENCE, V274, P2107, DOI 10.1126/science.274.5295.2107; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; Basso LA, 1996, J AM CHEM SOC, V118, P11301, DOI 10.1021/ja962035y; Blanchard JS, 1996, ANNU REV BIOCHEM, V65, P215, DOI 10.1146/annurev.bi.65.070196.001243; BLOOM BR, 1994, TUBERCULOSIS PATHOGE; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; BRUNGER AT, 1992, XPLOR VERSOIN 3 1 SY; COCKERILL FR, 1995, J INFECT DIS, V171, P240, DOI 10.1093/infdis/171.1.240; COLE ST, 1995, EUR RESPIR J, V8, pS701; DAVIDSON LA, 1979, ANTIMICROB AGENTS CH, V16, P104, DOI 10.1128/AAC.16.1.104; DESSEN A, 1995, SCIENCE, V267, P1638, DOI 10.1126/science.7886450; DROBNIEWSKI FA, 1995, J MED MICROBIOL, V43, P85, DOI 10.1099/00222615-43-2-85; Heym B, 1996, CURR TOP MICROBIOL, V215, P49; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1994, LANCET, V344, P293, DOI 10.1016/S0140-6736(94)91338-2; HILLAR A, 1995, ARCH BIOCHEM BIOPHYS, V323, P438, DOI 10.1006/abbi.1995.0065; ITO K, 1992, BIOCHEMISTRY-US, V31, P11606, DOI 10.1021/bi00161a046; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KAPUR V, 1995, ARCH PATHOL LAB MED, V119, P131; Lee RE, 1996, CURR TOP MICROBIOL, V215, P1; LEWIN E, 1955, AM REV TUBERC PULM, V71, P732; Magliozzo RS, 1996, J AM CHEM SOC, V118, P11303, DOI 10.1021/ja962047j; Magliozzo RS, 1997, J BIOL CHEM, V272, P8867; Mdluli K, 1996, J INFECT DIS, V174, P1085, DOI 10.1093/infdis/174.5.1085; MUSSER JH, COMMUNICATION; Musser JM, 1996, J INFECT DIS, V173, P196, DOI 10.1093/infdis/173.1.196; OBRIEN RJ, 1993, LUNG BIOL HLTH DISEA, V66, P207; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PAOLETTI F, 1990, CHEM-BIOL INTERACT, V76, P3, DOI 10.1016/0009-2797(90)90030-Q; PORTER JDH, 1994, ANNU REV PUBL HEALTH, V15, P303; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; Quemard A, 1996, J AM CHEM SOC, V118, P1561, DOI 10.1021/ja950998b; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; ROUSE DA, 1995, ANTIMICROB AGENTS CH, V39, P2472, DOI 10.1128/AAC.39.11.2472; Sacchettini JC, 1996, RES MICROBIOL, V147, P36, DOI 10.1016/0923-2508(96)80201-4; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P408, DOI 10.1128/AAC.27.3.408; SINHA BK, 1983, J BIOL CHEM, V258, P796; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; Telenti A, 1997, J CLIN MICROBIOL, V35, P719, DOI 10.1128/JCM.35.3.719-723.1997; WANG L, 1975, ANTIMICROB AGENTS CH, V16, P308; Wheeler PR, 1996, BIOCHEM J, V318, P451, DOI 10.1042/bj3180451; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1959, BIOCHEM J, V73, P500, DOI 10.1042/bj0730500; YOUNG DB, 1995, ANNU REV MICROBIOL, V49, P641, DOI 10.1146/annurev.mi.49.100195.003233; YOUNG DB, 1994, CURR BIOL, V4, P351, DOI 10.1016/S0960-9822(00)00077-4; Zabinski RF, 1997, J AM CHEM SOC, V119, P2331, DOI 10.1021/ja9639731; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1994, J ANTIMICROB CHEMOTH, V34, P313, DOI 10.1093/jac/34.3.313; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	53	572	592	3	62	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					98	102		10.1126/science.279.5347.98	http://dx.doi.org/10.1126/science.279.5347.98			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417034				2022-12-01	WOS:000071323900049
J	Jiang, CY; Ting, AT; Seed, B				Jiang, CY; Ting, AT; Seed, B			PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; PROLIFERATOR-ACTIVATED RECEPTORS; ADIPOCYTE DIFFERENTIATION; RHEUMATOID-ARTHRITIS; 3T3-L1 CELLS; FACTOR-ALPHA; EXPRESSION; LIGAND; J(2); BETA	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor family of transcription factors, a large and diverse group of proteins that mediate ligand-dependent transcriptional activation and repression(1,2). Expression of PPAR-gamma is an early and pivotal event in the differentiation of adipocytes(3-6). Several agents that promote differentiation of fibroblast lines into adipocytes have been shown to be PPAR-gamma agonists(7-10), including several prostanoids, of which 15-deoxy-Delta(12,14)-prostaglandin J(2) is the most potent(8,9), as well as members of a new class of oral antidiabetic agents, the thiazolidinediones(7), and a variety of non-steroidal anti-inflammatory drugs (NSAIDs)(10). Here we show that PPAR-gamma agonists suppress monocyte elaboration of inflammatory cytokines at agonist concentrations similar to those found to be effective for the promotion of adipogenesis. Inhibition of cytokine production may help to explain the incremental therapeutic benefit of NSAIDs observed in the treatment of rheumatoid arthritis at plasma drug concentrations substantially higher than are required to inhibit prostaglandin G/H synthase (cyclooxygenase).	Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital	Seed, B (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.							BERG M, 1994, CYTOKINE, V6, P425, DOI 10.1016/1043-4666(94)90067-1; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Brennan FM, 1996, CURR OPIN IMMUNOL, V8, P872, DOI 10.1016/S0952-7915(96)80018-5; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Firestein GS, 1997, NEW ENGL J MED, V337, P195, DOI 10.1056/NEJM199707173370310; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Greene M. E., 1995, Gene Expression, V4, P281; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LANG CH, 1992, ENDOCRINOLOGY, V130, P43, DOI 10.1210/en.130.1.43; LAU CS, 1993, BRIT J RHEUMATOL, V32, P982; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARSHALL MK, 1994, ENDOCRINOLOGY, V135, P141, DOI 10.1210/en.135.1.141; MCEVOY GK, 1997, AHFS 97 DRUG INFORMA; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; PATTON JS, 1986, P NATL ACAD SCI USA, V83, P8313, DOI 10.1073/pnas.83.21.8313; SZALKOWSKI D, 1995, ENDOCRINOLOGY, V136, P1474, DOI 10.1210/en.136.4.1474; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; TORTI FM, 1989, J CELL BIOL, V108, P1105, DOI 10.1083/jcb.108.3.1105; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	28	2549	2704	4	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					82	86		10.1038/34184	http://dx.doi.org/10.1038/34184			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422509				2022-12-01	WOS:000071326100053
J	Barrett, K; Leptin, M; Settleman, J				Barrett, K; Leptin, M; Settleman, J			The rho GTPase and a putative RhoGEF mediate a signaling pathway for the cell shape changes in Drosophila gastrulation	CELL			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; ACTIN STRESS FIBERS; BINDING PROTEIN-RHO; GENE; CDC42; RAS; ENCODES; EMBRYO; DOMAIN; TRANSFORMATION	The Rho GTPases mediate actin rearrangements that are likely to be required for the numerous cell shape changes in a developing embryo. In a genetic screen for Rho signaling pathway components in Drosophila, we identified a gene, DRhoGEF2, that encodes a predicted Rho-specific guanine nucleotide exchange factor. Embryos lacking DRhoGEF2 fail to gastrulate due to a defect in cell shape changes required for tissue invagination, and expression of a dominant-negative Rho GTPase in early embryos results in similar defects. Evidence is also presented that DRhoGEF2 mediates these specific cell shape changes in response to the extracellular ligand, Fog. Together, these results establish a Rho-mediated signaling pathway that is essential for the major morphogenetic events in Drosophila gastrulation.	Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA; Univ Cologne, Inst Genet, D-5000 Cologne, Germany	Harvard University; Massachusetts General Hospital; Harvard University; University of Cologne	Settleman, J (corresponding author), Massachusetts Gen Hosp, Ctr Canc, Bldg 149,13th St, Charlestown, MA 02129 USA.							BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CHOU TB, 1993, DEVELOPMENT, V119, P1359; COSTA M, 1994, CELL, V76, P1075, DOI 10.1016/0092-8674(94)90384-0; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dutartre H, 1996, J CELL SCI, V109, P367; Eaton S, 1996, J CELL BIOL, V135, P1277, DOI 10.1083/jcb.135.5.1277; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FISCHERVIZE JA, 1992, DEVELOPMENT, V116, P985; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GULBINS E, 1994, MOL CELL BIOL, V14, P4749, DOI 10.1128/MCB.14.7.4749; HAFEN E, 1987, SCIENCE, V236, P55, DOI 10.1126/science.2882603; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; HARDEN N, 1995, DEVELOPMENT, V121, P903; HARIHARAN IK, 1995, EMBO J, V14, P292, DOI 10.1002/j.1460-2075.1995.tb07003.x; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HAY BA, 1994, DEVELOPMENT, V120, P2121; HIROMI Y, 1985, CELL, V43, P603, DOI 10.1016/0092-8674(85)90232-6; HUANG KP, 1989, TRENDS NEUROSCI, V12, P425, DOI 10.1016/0166-2236(89)90091-X; KIMMEL BE, 1990, GENE DEV, V4, P712, DOI 10.1101/gad.4.5.712; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; LEPTIN M, 1991, GENE DEV, V5, P1568, DOI 10.1101/gad.5.9.1568; LEPTIN M, 1990, DEVELOPMENT, V110, P73; Leptin M, 1995, ANNU REV CELL DEV BI, V11, P189; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Murphy AM, 1996, J CELL BIOL, V133, P617, DOI 10.1083/jcb.133.3.617; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; NARUMIYA S, 1993, CELL SIGNAL, V5, P9, DOI 10.1016/0898-6568(93)90003-5; NOBES C, 1994, CURR OPIN GENET DEV, V4, P77, DOI 10.1016/0959-437X(94)90094-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PARKS S, 1991, CELL, V64, P447, DOI 10.1016/0092-8674(91)90652-F; PATEL NH, 1994, DROSOPHILA MELANOGAS, P445; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SCHMALZING G, 1995, J CELL BIOL, V130, P1319, DOI 10.1083/jcb.130.6.1319; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; Sone M, 1997, SCIENCE, V275, P543, DOI 10.1126/science.275.5299.543; Strutt DI, 1997, NATURE, V387, P292, DOI 10.1038/387292a0; SULLIVAN W, 1995, CURR OPIN CELL BIOL, V7, P18, DOI 10.1016/0955-0674(95)80040-9; SWEETON D, 1991, DEVELOPMENT, V112, P775; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; THOMAS GH, 1994, DEVELOPMENT, V120, P2039; TOMLINSON A, 1987, DEV BIOL, V123, P264, DOI 10.1016/0012-1606(87)90448-9; WAHL MI, 1989, MOL CELL BIOL, V9, P2934, DOI 10.1128/MCB.9.7.2934; Werner LA, 1997, GENE, V187, P107, DOI 10.1016/S0378-1119(96)00732-9; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; YOUNG PE, 1991, DEVELOPMENT, V111, P1; Zheng Y, 1996, J BIOL CHEM, V271, P19017, DOI 10.1074/jbc.271.32.19017	57	306	309	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					905	915		10.1016/S0092-8674(00)80482-1	http://dx.doi.org/10.1016/S0092-8674(00)80482-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428514	Bronze			2022-12-01	WOS:000071281400008
J	Levchenko, I; Smith, CK; Walsh, NP; Sauer, RT; Baker, TA				Levchenko, I; Smith, CK; Walsh, NP; Sauer, RT; Baker, TA			PDZ-like domains mediate binding specificity in the Clp/Hsp100 family of chaperones and protease regulatory subunits	CELL			English	Article							BACTERIOPHAGE-MU REPRESSOR; DEPENDENT CLP PROTEASE; HEAT-SHOCK PROTEIN; ESCHERICHIA-COLI; TRANSPOSASE TETRAMER; MOLECULAR CHAPERONE; SERINE-PROTEASE; MESSENGER-RNA; HSP104; COMPONENT	ClpX, a molecular chaperone and the regulatory subunit of the ClpXP protease, is shown to contain tandem modular domains that bind to the C-terminal sequences of target proteins in a manner that parallels functional specificity Nuclear magnetic resonance studies show that these C-terminal sequences are displayed as disordered peptides on the surface of otherwise folded proteins. The ClpX substrate-binding domains are homologous to sequences in other Clp/Hsp100 proteins and are related more distantly to PDZ domains, which also mediate C-terminal specific protein-protein interactions. Conservation of these binding domains indicates that the mode of substrate recognition characterized here for ClpX will be a conserved feature among Clp/Hsp100 family members and a distinguishing characteristic between this chaperone family and the Hsp70 chaperones.	MIT, Dept Biol, Cambridge, MA 02139 USA; MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Baker, TA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sauer, Robert/0000-0002-1719-5399	NIAID NIH HHS [AI-16892] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016892] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; Bochtler M, 1997, P NATL ACAD SCI USA, V94, P6070, DOI 10.1073/pnas.94.12.6070; Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; CAMPBELL ID, 1975, FEBS LETT, V57, P96, DOI 10.1016/0014-5793(75)80160-8; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Domian IJ, 1997, CELL, V90, P415, DOI 10.1016/S0092-8674(00)80502-4; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Fanning AS, 1996, CURR BIOL, V6, P1385, DOI 10.1016/S0960-9822(96)00737-3; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Frank EG, 1996, P NATL ACAD SCI USA, V93, P10291, DOI 10.1073/pnas.93.19.10291; GEUSKENS V, 1992, EMBO J, V11, P5121, DOI 10.1002/j.1460-2075.1992.tb05619.x; GEUSKENS V, 1991, J BACTERIOL, V173, P6578, DOI 10.1128/jb.173.20.6578-6585.1991; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Irie M, 1997, SCIENCE, V277, P1511, DOI 10.1126/science.277.5331.1511; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kruklitis R, 1996, EMBO J, V15, P935, DOI 10.1002/j.1460-2075.1996.tb00428.x; Laachouch JE, 1996, EMBO J, V15, P437, DOI 10.1002/j.1460-2075.1996.tb00374.x; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; Levchenko I, 1997, GENE DEV, V11, P1561, DOI 10.1101/gad.11.12.1561; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MILLA ME, 1993, PROTEIN SCI, V2, P2198, DOI 10.1002/pro.5560021219; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; PARSELL DA, 1991, NATURE, V353, P270, DOI 10.1038/353270a0; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; Ponting CP, 1997, PROTEIN SCI, V6, P464; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Saras J, 1996, TRENDS BIOCHEM SCI, V21, P455, DOI 10.1016/S0968-0004(96)30044-3; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Shieh BH, 1996, NEURON, V16, P991, DOI 10.1016/S0896-6273(00)80122-1; SKELTON NJ, 1993, J MAGN RESON SER B, V102, P253, DOI 10.1006/jmrb.1993.1095; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; TOBIAS JW, 1991, SCIENCE, V254, P1374, DOI 10.1126/science.1962196; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; TU GF, 1995, J BIOL CHEM, V270, P9322, DOI 10.1074/jbc.270.16.9322; VOGEL JL, 1995, CURR BIOL, V5, P306, DOI 10.1016/S0960-9822(95)00061-3; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; WEISS MA, 1987, BIOCHEMISTRY-US, V26, P890, DOI 10.1021/bi00377a033; Welty DJ, 1997, J MOL BIOL, V272, P31, DOI 10.1006/jmbi.1997.1193; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOJTKOWIAK D, 1993, J BIOL CHEM, V268, P22609	47	102	105	0	1	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					939	947		10.1016/S0092-8674(00)80485-7	http://dx.doi.org/10.1016/S0092-8674(00)80485-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428517	Bronze			2022-12-01	WOS:000071281400011
J	Brancati, FL; Whelton, PK; Randall, BL; Neaton, JD; Stamler, J; Klag, MJ				Brancati, FL; Whelton, PK; Randall, BL; Neaton, JD; Stamler, J; Klag, MJ			Risk of end-stage renal disease in diabetes mellitus - A prospective cohort study of men screened for MRFIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	56th Scientific Session of the American-Diabetes-Association	JUN 08-11, 1996	SAN FRANCISCO, CA	Amer Diabet Assoc			FACTOR INTERVENTION TRIAL; RACIAL-DIFFERENCES; EXCESS INCIDENCE; BLOOD-PRESSURE; AMERICANS; FAILURE; INDIANS; RACE	Context.-Diabetes is a frequent cause of end-stage renal disease (ESRD). However, the degree of risk is uncertain. Objective.-To determine the relative risk (RR) of ESRD related to diabetes in the United States. Design.-Nonconcurrent prospective cohort study. Participants.-A total of 332 544 men aged 35 to 57 years from 18 US cities screened in 1973 to 1975 for participation in the Multiple Risk Factor Intervention Trial (MRFIT). Main Exposure.-Diabetes mellitus defined by self-reported use of medication for diabetes at baseline. Main Outcome.-Incident ESRD through 1990 assessed from a national ESRD registry and by surveillance for death from renal disease. Results.-Over an average follow-up of 16 years, there were 136 cases of ESRD in 5147 diabetic men and 678 cases in 327 397 nondiabetic men. Age-adjusted incidence of all-cause ESRD in the diabetic men was 199.8 per 100 000 person-years compared with 13.7 per 100 000 person years in their nondiabetic counterparts (RR, 12.7; 95% confidence interval [CI], 10.5-15.4). Diabetic men were also at higher risk for ESRD ascribed to causes other than diabetes (RR=4.3; 95% CI, 3.2-5.9). With simultaneous adjustment for age, ethnicity, income, blood pressure, serum cholesterol level, and history of myocardial infarction, diabetic men remained at higher risk for ail-cause ESRD (RR, 9.0; 95% CI, 7.4-11.0), ESRD ascribed to diabetes (RR, 92.3; 95% CI, 64.6-131.9), and ESRD ascribed to nondiabetic causes (RR, 3.0; 95% CI, 2.2-4.1). Conclusions.-Diabetes mellitus is a strong independent risk factor for ESRD, even for ESRD ascribed to causes other than diabetes. Improvements in the prevention and control of diabetes should produce substantial reductions in ESRD incidence.	JOHNS HOPKINS MED INST,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS MED INST,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; UNIV MINNESOTA,SCH PUBL HLTH,DIV BIOSTAT,MINNEAPOLIS,MN 55455; NORTHWESTERN UNIV,SCH MED,DEPT PREVENT MED,CHICAGO,IL	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; University of Minnesota System; University of Minnesota Twin Cities; Northwestern University					NHLBI NIH HHS [R01 HL28715] Funding Source: Medline; NIDDK NIH HHS [R01 DK41837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1977, Journal of Chronic Diseases, V30, P261; BRANCATI FL, 1992, JAMA-J AM MED ASSOC, V268, P3079, DOI 10.1001/jama.268.21.3079; COWIE CC, 1989, NEW ENGL J MED, V321, P1074, DOI 10.1056/NEJM198910193211603; COX DR, 1972, J R STAT SOC B, V34, P187; DISCHINGER P, 1986, CONTROL CLIN TRIALS, V7, pS137; DYCK RF, 1994, CAN MED ASSOC J, V150, P203; Eggers P W, 1984, Health Care Financ Rev, V5, P69; FERTIG BJ, 1995, NIH PUBLICATION, P519; *HLTH CAR FIN ADM, 1987, HCFA PUBL; HUMPHREY LL, 1989, ANN INTERN MED, V111, P788, DOI 10.7326/0003-4819-111-10-788; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPPEL DF, 1986, AM J KIDNEY DIS, V8, P234, DOI 10.1016/S0272-6386(86)80031-2; Kenny S.J., 1995, NIH PUBLICATION, P47; Klag MJ, 1996, NEW ENGL J MED, V334, P13, DOI 10.1056/NEJM199601043340103; Krolewski M, 1996, KIDNEY INT, V50, P2041, DOI 10.1038/ki.1996.527; LEE ET, 1994, DIABETES, V43, P572, DOI 10.2337/diabetes.43.4.572; MEGILL DM, 1988, WESTERN J MED, V149, P178; *MULT RISK FACT IN, 1982, JAMA-J AM MED ASSOC, V248, P1465; *NAT HEART LUNG I, 1974, DHEW PUBL; NEATON JD, 1988, CONTROL CLIN TRIALS, V8, P415; NELSON RG, 1988, DIABETOLOGIA, V31, P730, DOI 10.1007/BF00274774; Nelson RG, 1995, DIABETES AM, V2, P349; NEWMAN JM, 1990, AM J PUBLIC HEALTH, V80, P318, DOI 10.2105/AJPH.80.3.318; PASINSKI R, 1987, ARCH INTERN MED, V147, P1093, DOI 10.1001/archinte.147.6.1093; PERNEGER TV, 1995, AM J KIDNEY DIS, V25, P722, DOI 10.1016/0272-6386(95)90548-0; PERNEGER TV, 1995, AM J EPIDEMIOL, V141, P10, DOI 10.1093/oxfordjournals.aje.a117338; Prevention CfDCa, 1992, MMWR-MORBID MORTAL W, V41, P845; PUGH JA, 1988, AM J EPIDEMIOL, V127, P135, DOI 10.1093/oxfordjournals.aje.a114773; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHERWIN R, 1981, PREV MED, V10, P402, DOI 10.1016/0091-7435(81)90058-X; STAMLER J, 1993, DIABETES CARE, V16, P434, DOI 10.2337/diacare.16.2.434; STEPHENS GW, 1990, AM J KIDNEY DIS, V15, P562, DOI 10.1016/S0272-6386(12)80527-0; SUGIMOTO T, 1984, AM J PUBLIC HEALTH, V74, P14, DOI 10.2105/AJPH.74.1.14; *US DEP HHS, 1988, INT CLASS DIS 9 REV; *US REN DAT SYST, 1995, USRDS 1995 ANN DAT R, P25; WELLER JM, 1985, AM J NEPHROL, V5, P84, DOI 10.1159/000166912; WENTWORTH DN, 1983, AM J PUBLIC HEALTH, V73, P1270, DOI 10.2105/AJPH.73.11.1270	37	218	222	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2069	2074		10.1001/jama.278.23.2069	http://dx.doi.org/10.1001/jama.278.23.2069			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403420				2022-12-01	WOS:A1997YK98700035
J	Gee, MA; Heuser, JE; Vallee, RB				Gee, MA; Heuser, JE; Vallee, RB			An extended microtubule-binding structure within the dynein motor domain	NATURE			English	Article							BETA-HEAVY CHAIN; CRYSTAL-STRUCTURE; RETROGRADE TRANSPORT; CYTOPLASMIC DYNEIN; DICTYOSTELIUM; PROTEINS; CLEAVAGE; SEQUENCE; MAP-1C; MYOSIN	Flagellar dynein was discovered over 30 years ago as the first motor protein capable of generating force along microtubules(1). A cytoplasmic form of dynein has also been identified which is involved in mitosis and a wide range of other intracellular movement(2) (reviewed in ref. 3). Rapid progress has been made on understanding the mechanism of force production by kinesins and myosins(4-8). In contrast, progress in understanding the dyneins has been limited by their great size (relative molecular mass 1,000K-2,000K) and subunit complexity. We now report evidence that the entire carboxy-terminal two-thirds of the 532K force-producing heavy chain subunit is required for ATP-binding activity. We further identify a microtubule-binding domain, which, surprisingly, lies well downstream of the entire ATPase region and is predicted to form a hairpin-like stalk Direct ultrastructural analysis of a recombinant fragment confirms this model, and suggests that the mechanism for dynein force production differs substantially from that of other motor proteins.	WORCESTER FDN BIOMED RES, SHREWSBURY, MA 01545 USA; UNIV MASSACHUSETTS, MED CTR, WORCESTER, MA 01655 USA; WASHINGTON UNIV, ST LOUIS, MO 63110 USA	Worcester Foundation for Biomedical Research; University of Massachusetts System; University of Massachusetts Worcester; Washington University (WUSTL)			Heuser, John/H-5940-2012					AMOS LA, 1989, J CELL SCI, V93, P19; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; GIBBONS IR, 1987, J BIOL CHEM, V262, P2780; GIBBONS IR, 1965, SCIENCE, V149, P424, DOI 10.1126/science.149.3682.424; GIBBONS IR, 1991, NATURE, V352, P640, DOI 10.1038/352640a0; GOODENOUGH U, 1984, J MOL BIOL, V180, P1083, DOI 10.1016/0022-2836(84)90272-9; GOODENOUGH UW, 1982, J CELL BIOL, V95, P798, DOI 10.1083/jcb.95.3.798; HAIMO LT, 1979, P NATL ACAD SCI USA, V76, P5759, DOI 10.1073/pnas.76.11.5759; HEUSER JE, 1983, J MOL BIOL, V169, P155, DOI 10.1016/S0022-2836(83)80179-X; HOLZBAUR ELF, 1994, ANNU REV CELL BIOL, V10, P339, DOI 10.1146/annurev.cb.10.110194.002011; KANAI Y, 1989, J CELL BIOL, V109, P1173, DOI 10.1083/jcb.109.3.1173; KOONCE MP, 1992, J CELL BIOL, V119, P1597, DOI 10.1083/jcb.119.6.1597; Koonce MP, 1996, MOL BIOL CELL, V7, P935, DOI 10.1091/mbc.7.6.935; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Mazumdar M, 1996, P NATL ACAD SCI USA, V93, P6552, DOI 10.1073/pnas.93.13.6552; MIKAMI A, 1993, NEURON, V10, P787, DOI 10.1016/0896-6273(93)90195-W; MITCHELL DR, 1994, J CELL SCI, V107, P635; OGAWA K, 1991, NATURE, V352, P643, DOI 10.1038/352643a0; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; PORTER ME, 1989, ANNU REV CELL BIOL, V5, P119; PORTER ME, 1994, J CELL BIOL, V126, P1495, DOI 10.1083/jcb.126.6.1495; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ruppel KM, 1996, ANNU REV CELL DEV BI, V12, P543, DOI 10.1146/annurev.cellbio.12.1.543; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SMITH EF, 1992, SCIENCE, V257, P1557, DOI 10.1126/science.1387971; STEBBINS CE, 1995, NATURE, V373, P636, DOI 10.1038/373636a0; STEUER ER, 1988, CELL MOTIL CYTOSKEL, V11, P200; Vallee RB, 1996, SCIENCE, V271, P1539, DOI 10.1126/science.271.5255.1539; Woehlke G, 1997, CELL, V90, P207, DOI 10.1016/S0092-8674(00)80329-3	30	256	261	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					636	639		10.1038/37663	http://dx.doi.org/10.1038/37663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403697				2022-12-01	WOS:A1997YK85300057
J	Keely, PJ; Westwick, JK; Whitehead, IP; Der, CJ; Parise, LV				Keely, PJ; Westwick, JK; Whitehead, IP; Der, CJ; Parise, LV			Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K	NATURE			English	Article							NUCLEOTIDE EXCHANGE FACTORS; ACTIVATED PROTEIN-KINASE; GTP-BINDING PROTEIN; STRUCTURAL SIMILARITIES; ACTIN POLYMERIZATION; EXPRESSION CLONING; RHO; FAMILY; PATHWAY; PHOSPHORYLATION	Transformation of mammary epithelial cells into invasive carcinoma results in alterations in their integrin-mediated responses to the extracellular matrix, including a loss of normal epithelial polarization and differentiation, and a switch to a more motile, invasive phenotype, Changes in the actin cytoskeleton associated with this switch suggest that the small GTPases Cdc42 and Rac, which regulate actin organization(1,2), might modulate motility and invasion, However, the role of Cdc42 and Rad in epithelial cells, especially with respect to integrin-mediated events, has not been well characterized, Here we show that activation of Cdc42 and Rad disrupts the normal polarization of mammary epithelial cells in a collagenous matrix, and promotes motility and invasion. This motility does not require the activationof PAK, JNK, p70 S6 kinase, or Rho, but instead requires phosphatidylinositol-3-OH kinase (PI(3)K). Further, direct PI(3)K activation is sufficient to disrupt epithelial polarization and induce cell motility and invasion. PI(3)K inhibition also disrupts actin structures, suggesting that activation of PI(3)K by Cdc42 and Rad alters actin organization, leading to increased motility and invasiveness.	UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill	Keely, PJ (corresponding author), UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,DEPT PHARMACOL,CHAPEL HILL,NC 27599, USA.			Der, Channing/0000-0002-7751-2747				ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Collard JG, 1996, INT J ONCOL, V8, P131; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; EATON S, 1995, J CELL BIOL, V131, P151, DOI 10.1083/jcb.131.1.151; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; KEELY PJ, 1995, J CELL SCI, V108, P595; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PEPPELENBOSCH MP, 1995, CELL, V81, P849, DOI 10.1016/0092-8674(95)90005-5; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SANTORO SA, 1994, METHOD ENZYMOL, V245, P147; STOWERS L, 1995, P NATL ACAD SCI USA, V92, P5027, DOI 10.1073/pnas.92.11.5027; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; vanLeeuwen FN, 1995, ONCOGENE, V11, P2215; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6; Whitehead IP, 1996, J BIOL CHEM, V271, P18643, DOI 10.1074/jbc.271.31.18643; YAN MH, 1994, NATURE, V372, P798; ZHENG Y, 1994, J BIOL CHEM, V269, P18727	29	628	639	2	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					632	636		10.1038/37656	http://dx.doi.org/10.1038/37656			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403696				2022-12-01	WOS:A1997YK85300056
J	Wang, ZG; Delva, L; Gaboli, M; Rivi, R; Giorgio, M; Cordon-Cardo, C; Grosveld, F; Pandolfi, PP				Wang, ZG; Delva, L; Gaboli, M; Rivi, R; Giorgio, M; Cordon-Cardo, C; Grosveld, F; Pandolfi, PP			Role of PML in cell growth and the retinoic acid pathway	SCIENCE			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; RECEPTOR-ALPHA GENE; RAR-ALPHA; TRANSCRIPTIONAL ACTIVATION; T(15-17) TRANSLOCATION; DIFFERENTIATION; SUPPRESSOR; EXPRESSION; TRANSFORMATION; LOCALIZATION	The PML gene is fused to the retinoic acid receptor alpha (RAR alpha) gene in chromosomal translocations associated with acute promyelocytic leukemia (APL). Ablation of murine PML protein by homologous recombination revealed that PML regulates hemopoietic differentiation and controls cell growth and tumorigenesis. PML function was essential for the tumor-growth-suppressive activity of retinoic acid (RA) and for its ability to induce terminal myeloid differentiation of precursor cells. PML was needed for the RA-dependent transactivation of the p21(WAF1/CIP1) gene, which regulates cell cycle progression and cellular differentiation, These results indicate that PML is critical component of the RA pathway and that disruption of its activity by the PML-RAR alpha fusion protein may be important in APL pathogenesis.	Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Mol Biol Program, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Erasmus Univ, Fac Med, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands	Cornell University; Memorial Sloan Kettering Cancer Center; Cornell University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Erasmus University Rotterdam	Pandolfi, PP (corresponding author), Cornell Univ, Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Dept Human Genet, 1275 York Ave, New York, NY 10021 USA.		Giorgio, Marco/I-9425-2012	Giorgio, Marco/0000-0002-5842-6042; DELVA, Laurent/0000-0002-1086-3964	NCI NIH HHS [CA 71692, CA-08748] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA071692, P30CA008748, R01CA071692] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARKA T, 1980, LAB INVEST, V42, P656; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Conzen SD, 1995, ONCOGENE, V11, P2295; DELVA L, UNPUB; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DOUER D, 1982, EXP CELL RES, V138, P193, DOI 10.1016/0014-4827(82)90105-7; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FAGIOLI M, 1992, ONCOGENE, V7, P1083; GABOLI M, UNPUB; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRATAS C, 1993, LEUKEMIA, V7, P1156; GRIGNANI F, 1994, BLOOD, V83, P10; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUDAS L, 1994, RETINOIDS CELLULAR B; He LZ, 1997, P NATL ACAD SCI USA, V94, P5302, DOI 10.1073/pnas.94.10.5302; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KOKEN MHM, 1995, ONCOGENE, V10, P1315; KOKEN MHM, 1994, EMBO J, V13, P1073, DOI 10.1002/j.1460-2075.1994.tb06356.x; LAVAU C, 1995, ONCOGENE, V11, P871; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LIU JH, 1995, J EXP MED, V181, P1965, DOI 10.1084/jem.181.6.1965; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Liu M, 1996, J BIOL CHEM, V271, P31723, DOI 10.1074/jbc.271.49.31723; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; Manshouri T, 1997, BLOOD, V89, P2507, DOI 10.1182/blood.V89.7.2507; MU ZM, 1994, MOL CELL BIOL, V14, P6858, DOI 10.1128/MCB.14.10.6858; NasonBurchenal K, 1996, BLOOD, V88, P3926, DOI 10.1182/blood.V88.10.3926.bloodjournal88103926; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pandolfi PP, 1996, HAEMATOLOGICA, V81, P472; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SMITH MA, 1992, J CLIN ONCOL, V10, P839, DOI 10.1200/JCO.1992.10.5.839; Stadler M, 1995, ONCOGENE, V11, P2565; WANG Z, UNPUB; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7	41	438	454	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1547	1551						5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488655				2022-12-01	WOS:000072372900068
J	Mohri, H; Bonhoeffer, S; Monard, S; Perelson, AS; Ho, DD				Mohri, H; Bonhoeffer, S; Monard, S; Perelson, AS; Ho, DD			Rapid turnover of T lymphocytes in SIV-infected rhesus macaques	SCIENCE			English	Article							HIV-1 INFECTION; LIFE-SPAN; IN-VIVO; CELLS; MEMORY; ACTIVATION; LENGTH; NAIVE; DEATH; CD4	Studies of lymphocyte turnover in animal models have implications for understanding the mechanism of cell killing and the extent of lymphocyte regeneration in human immunodeficiency virus infection. Quantitative analyses of the sequential changes in bromodeoxyuridine labeling of CD4 and CD8 T lymphocytes not only revealed the normal proliferation and death rates of these cell populations in uninfected macaques, but also showed a substantial increase in these rates associated with simian immunodeficiency virus (SIV) infection. Faster labeling and delabeling in memory and naive T lymphocyte subpopulations as well as in NK (natural killer) and B cells were also observed in infected macaques, suggesting a state of generalized activation induced by SIV.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	Rockefeller University; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@adarc.org	Perelson, Alan S/Z-1959-2019; Bonhoeffer, Sebastian/A-2735-2008	Perelson, Alan S/0000-0002-2455-0002; Bonhoeffer, Sebastian/0000-0001-8052-3925	NIAID NIH HHS [AI45128, AI40387, AI41534] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041534, R01AI040387] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CARAYON P, 1992, J IMMUNOL METHODS, V147, P225, DOI 10.1016/S0022-1759(12)80012-3; DIMITROV DS, 1995, NATURE, V375, P194, DOI 10.1038/375194b0; Efron B., 1986, STAT SCI, V1, P54, DOI DOI 10.1214/SS/1177013815; GIORGI JV, 1994, AIDS S1, V8, pS183; Gougeon ML, 1996, J IMMUNOL, V156, P3509; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Lafeuillade A, 1997, J INFECT DIS, V176, P1378, DOI 10.1086/517326; LANE HC, 1983, NEW ENGL J MED, V309, P453, DOI 10.1056/NEJM198308253090803; MACKALL CL, 1995, NEW ENGL J MED, V332, P143, DOI 10.1056/NEJM199501193320303; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MICHIE CA, 1992, NATURE, V360, P264, DOI 10.1038/360264a0; MOHRI H, UNPUB; MOSLER DE, 1995, NATURE, V375, P193, DOI 10.1038/375193b0; Nowak MA, 1997, J VIROL, V71, P7518, DOI 10.1128/JVI.71.10.7518-7525.1997; Palmer LD, 1997, J EXP MED, V185, P1381, DOI 10.1084/jem.185.7.1381; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; ROCHA B, 1990, EUR J IMMUNOL, V20, P1697, DOI 10.1002/eji.1830200812; SACHSENBERG N, UNPUB; SPRENT J, 1995, NATURE, V375, P194, DOI 10.1038/375194a0; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Tough DF, 1996, SCIENCE, V272, P1947, DOI 10.1126/science.272.5270.1947; TSE D, UNPUB; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENG NP, 1995, P NATL ACAD SCI USA, V92, P11091, DOI 10.1073/pnas.92.24.11091; Wolthers KC, 1996, SCIENCE, V274, P1543, DOI 10.1126/science.274.5292.1543; Zhang ZQ, 1998, P NATL ACAD SCI USA, V95, P1154, DOI 10.1073/pnas.95.3.1154	28	292	296	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1223	1227		10.1126/science.279.5354.1223	http://dx.doi.org/10.1126/science.279.5354.1223			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469816				2022-12-01	WOS:000072115200048
J	Santana, LF; Gomez, AM; Lederer, WJ				Santana, LF; Gomez, AM; Lederer, WJ			Ca2+ flux through promiscuous cardiac Na+ channels: Slip-mode conductance	SCIENCE			English	Article							SODIUM-CALCIUM EXCHANGE; RAT VENTRICULAR MYOCYTES; VOLTAGE-GATED SODIUM; SARCOPLASMIC-RETICULUM; ENDOGENOUS OUABAIN; DEPENDENT PHOSPHORYLATION; ATRIONATRIURETIC-PEPTIDE; SPATIAL NONUNIFORMITIES; RYANODINE RECEPTORS; IONIC SELECTIVITY	The tetrodotoxin-sensitive sodium ion (Na+) channel is opened by cellular depolarization and favors the passage of Na+ over other ions. Activation of the beta-adrenergic receptor or protein kinase A in rat heart cells transformed this Na+ channel into one that is promiscuous with respect to ion selectivity, permitting calcium ions (Ca2+) to permeate as readily as Na+. Similarly, nanomolar concentrations of cardiotonic steroids such as ouabain and digoxin switched the ion selectivity of the Na+ channel to this state of promiscuous permeability called slip-mode conductance. Slip-mode conductance of the Na+ channel can contribute significantly to local and global cardiac Ca2+ signaling and may be a general signaling mechanism in excitable cells.	Univ Maryland, Dept Mol Biol & Biophys, 725 W Lombard St, Baltimore, MD 21201 USA; Univ Maryland, Dept Physiol, Ctr Med Biotechnol, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Lederer, WJ (corresponding author), Univ Maryland, Dept Mol Biol & Biophys, 725 W Lombard St, Baltimore, MD 21201 USA.	jlederer@umaryland.edu	Gomez, Ana M./B-5376-2013; Santana, Luis/AAF-9298-2019; Lederer, William/B-1285-2010	Gomez, Ana M./0000-0003-0009-2884; Santana, Luis/0000-0002-4297-8029; 				Aggarwal R, 1997, J PHYSIOL-LONDON, V505, P353, DOI 10.1111/j.1469-7793.1997.353bb.x; AKAIKE N, 1992, J PHYSIOL-LONDON, V450, P529, DOI 10.1113/jphysiol.1992.sp019141; AKASU T, 1977, JPN HEART J, V18, P860; AKERA T, 1981, CARDIAC GLYCOSIDES 1, P287; ARMSTRONG CM, 1991, P NATL ACAD SCI USA, V88, P6528, DOI 10.1073/pnas.88.15.6528; BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BAKER PF, 1971, J PHYSIOL-LONDON, V218, P709, DOI 10.1113/jphysiol.1971.sp009641; BARCENASRUIZ L, 1987, CIRC RES, V61, P148, DOI 10.1161/01.RES.61.1.148; BAYLOR SM, 1990, BIOPHYS J, V57; Benitah JP, 1997, BIOPHYS J, V73, P603, DOI 10.1016/S0006-3495(97)78096-2; BERS DM, 1991, EXCITATION CONTRACTI; Blaustein MP, 1996, KIDNEY INT, V49, P1748, DOI 10.1038/ki.1996.260; CAMPBELL DL, 1988, J PHYSIOL-LONDON, V403, P267, DOI 10.1113/jphysiol.1988.sp017249; CANNELL MB, 1987, SCIENCE, V238, P1419, DOI 10.1126/science.2446391; Cannell MB, 1997, BIOPHYS J, V73, P112, DOI 10.1016/S0006-3495(97)78052-4; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANNELL MB, 1994, BIOPHYS J, V67, P1942, DOI 10.1016/S0006-3495(94)80677-0; CANNELL MB, 1994, J PHYSIOL-LONDON, V477P, pP25; Chen SF, 1997, J MEMBRANE BIOL, V155, P11, DOI 10.1007/s002329900154; CHENG H, 1995, CIRC RES, V76, P236, DOI 10.1161/01.RES.76.2.236; Cheng H, 1996, AM J PHYSIOL-CELL PH, V270, pC148; Cheng H, 1996, CELL CALCIUM, V20, P129, DOI 10.1016/S0143-4160(96)90102-5; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; CHENG HC, 1986, J BIOL CHEM, V261, P989; CHIAMVIMONVAT N, 1996, J PHYSL, P51; Cole WC, 1997, AM J PHYSIOL-HEART C, V273, pH128, DOI 10.1152/ajpheart.1997.273.1.H128; Conti F, 1996, BIOPHYS J, V71, P1295, DOI 10.1016/S0006-3495(96)79330-X; COSTA MRC, 1982, J BIOL CHEM, V257, P7918; DEITMER JW, 1978, J PHYSIOL-LONDON, V284, P241, DOI 10.1113/jphysiol.1978.sp012539; deWardener HE, 1996, J HYPERTENS, V14, pS9; DUBELL WH, 1987, CELL CALCIUM, V8, P259, DOI 10.1016/0143-4160(87)90002-9; DUBELL WH, 1989, AM J PHYSIOL, V257, pH746, DOI 10.1152/ajpheart.1989.257.3.H746; Dumaine R, 1996, AM J PHYSIOL-HEART C, V270, pH2029; Evans AM, 1997, CARDIOVASC RES, V35, P294, DOI 10.1016/S0008-6363(97)00117-X; FABIATO A, 1985, J GEN PHYSIOL, V85, P189, DOI 10.1085/jgp.85.2.189; FABIATO A, 1985, J GEN PHYSIOL, V85, P291, DOI 10.1085/jgp.85.2.291; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; Favre I, 1996, BIOPHYS J, V71, P3110, DOI 10.1016/S0006-3495(96)79505-X; FERRIER GR, 1997, BIOPHYS J, V161, pA161; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; FRELIN C, 1986, EUR J PHARMACOL, V122, P245, DOI 10.1016/0014-2999(86)90109-3; FRENCH RJ, 1994, J GEN PHYSIOL, V103, P447, DOI 10.1085/jgp.103.3.447; GADSBY DC, 1984, ANNU REV BIOPHYS BIO, V13, P373; GODFRAIND T, 1982, NATURE, V299, P824, DOI 10.1038/299824a0; Gomez AM, 1997, SCIENCE, V276, P800, DOI 10.1126/science.276.5313.800; GONOI T, 1985, J NEUROSCI, V5, P2559; GORDON D, 1988, BIOCHEMISTRY-US, V27, P7032, DOI 10.1021/bi00418a054; Grantham CJ, 1996, CIRC RES, V79, P194, DOI 10.1161/01.RES.79.2.194; GUNDERTREMY U, 1981, CARDIAC GLYCOSIDES 1, P83; Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002; HAMLYN JM, 1991, P NATL ACAD SCI USA, V88, P6259, DOI 10.1073/pnas.88.14.6259; HANCOX JC, 1995, PFLUG ARCH EUR J PHY, V430, P887, DOI 10.1007/BF01837401; HEINEMANN SH, 1994, BRAZ J MED BIOL RES, V27, P2781; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; Hille B., 1992, IONIC CHANNELS EXCIT; HOBAI A, 1997, PFLUEGERS ARCH, V435, P164; Howlett S. E., 1997, Biophysical Journal, V72, pA161; HOWLETT SE, 1998, AM J PHYSIOL, V43, pH155; HUME JR, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.251.4999.1370-a; JEWELL EA, 1992, ACTA PHYSIOL SCAND, V146, P161; JOHNSON EA, 1991, SCIENCE, V251, P1370, DOI 10.1126/science.1848371; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; KOHMOTO O, 1994, CIRC RES, V74, P550, DOI 10.1161/01.RES.74.3.550; Laredo J, 1997, HYPERTENSION, V29, P401, DOI 10.1161/01.HYP.29.1.401; LAREDO J, 1994, ENDOCRINOLOGY, V135, P794, DOI 10.1210/en.135.2.794; LEBLANC N, 1990, SCIENCE, V248, P372, DOI 10.1126/science.2158146; LEDERER WJ, 1990, SCIENCE, V248, P283, DOI 10.1126/science.2326638; LEDERER WJ, 1995, HEART VESSELS, P161; LEDERER WJ, 1991, SCIENCE, V251, P1371, DOI 10.1126/science.251.4999.1371; LEMAIRE S, 1995, RECEPTOR CHANNEL, V3, P71; LEVESQUE PC, 1994, CARDIOVASC RES, V28, P370, DOI 10.1093/cvr/28.3.370; LEVI AJ, 1994, AM J PHYSIOL, V266, pH1422, DOI 10.1152/ajpheart.1994.266.4.H1422; LEVI AJ, 1997, BIOPHYS J, V161, pA161; Levi Allan J., 1997, Biophysical Journal, V72, pA161; LIPKIND GM, 1994, BIOPHYS J, V66, P1, DOI 10.1016/S0006-3495(94)80746-5; Lipp P, 1996, J PHYSIOL-LONDON, V492, P31, DOI 10.1113/jphysiol.1996.sp021286; LIPP P, 1994, J PHYSIOL-LONDON, V474, P439, DOI 10.1113/jphysiol.1994.sp020035; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; MAKIELSKI JC, 1987, BIOPHYS J, V52, P1, DOI 10.1016/S0006-3495(87)83182-X; MATSUDA JJ, 1992, CIRC RES, V70, P199, DOI 10.1161/01.RES.70.1.199; MEVES H, 1973, J PHYSL, V235, P226; MOGUL DJ, 1989, CIRC RES, V64, P1063, DOI 10.1161/01.RES.64.6.1063; Murphy BJ, 1996, J BIOL CHEM, V271, P28837, DOI 10.1074/jbc.271.46.28837; NABAUER M, 1989, SCIENCE, V244, P800, DOI 10.1126/science.2543067; NIGGLI E, 1990, SCIENCE, V250, P565, DOI 10.1126/science.2173135; NILIUS B, 1988, J PHYSIOL-LONDON, V399, P537; OBRIEN WJ, 1994, ARCH BIOCHEM BIOPHYS, V310, P32, DOI 10.1006/abbi.1994.1136; ONO K, 1995, PFLUG ARCH EUR J PHY, V429, P561, DOI 10.1007/BF00704162; PerezGarcia MT, 1997, BIOPHYS J, V72, P989, DOI 10.1016/S0006-3495(97)78751-4; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P8170, DOI 10.1073/pnas.86.20.8170; ROSSI GP, 1995, J HYPERTENS, V13, P1181, DOI 10.1097/00004872-199510000-00013; ROSSIE S, 1987, J BIOL CHEM, V262, P12735; Santana LF, 1996, CIRC RES, V78, P166, DOI 10.1161/01.RES.78.1.166; SANTANA LF, UNPUB; SATIN J, 1994, BIOPHYS J, V67, P1007, DOI 10.1016/S0006-3495(94)80566-1; SCHILD L, 1994, BIOPHYS J, V66, P654, DOI 10.1016/S0006-3495(94)80839-2; Schlief T, 1996, EUR BIOPHYS J BIOPHY, V25, P75, DOI 10.1007/s002490050020; SCHNEIDER MF, 1973, NATURE, V242, P244, DOI 10.1038/242244a0; SCHREIBMAYER W, 1994, RECEPTOR CHANNEL, V2, P339; SHACKLOCK PS, 1995, J PHYSIOL-LONDON, V487, P601, DOI 10.1113/jphysiol.1995.sp020903; SHAM JSK, 1992, SCIENCE, V255, P850, DOI 10.1126/science.1311127; SHEETS MF, 1991, SCIENCE, V252, P449, DOI 10.1126/science.1850170; Soeller C, 1997, BIOPHYS J, V73, P97, DOI 10.1016/S0006-3495(97)78051-2; SORBERA LA, 1990, SCIENCE, V247, P969, DOI 10.1126/science.2154853; TALVENHEIMO JA, 1982, J BIOL CHEM, V257, P1868; TOMASELLI GF, 1995, BIOPHYS J, V68, P1814, DOI 10.1016/S0006-3495(95)80358-9; TSUGORKA A, 1995, SCIENCE, V269, P1723, DOI 10.1126/science.7569901; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; VALDIVIA HH, 1995, SCIENCE, V267, P1997, DOI 10.1126/science.7701323; Vites AM, 1996, ANN NY ACAD SCI, V779, P521, DOI 10.1111/j.1749-6632.1996.tb44826.x; VORHERR T, 1992, BIOCHEMISTRY-US, V31, P371, DOI 10.1021/bi00117a009; Wasserstrom JA, 1996, J PHYSIOL-LONDON, V493, P529, DOI 10.1113/jphysiol.1996.sp021401; Yamagishi T, 1997, BIOPHYS J, V73, P195, DOI 10.1016/S0006-3495(97)78060-3; YOSHIMURA N, 1996, J PHYSL, P1; ZHU JQ, 1997, BIOPHYS J, V161, pA161	117	150	155	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 13	1998	279	5353					1027	1033		10.1126/science.279.5353.1027	http://dx.doi.org/10.1126/science.279.5353.1027			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461434				2022-12-01	WOS:000072006400046
J	Schauber, C; Chen, L; Tongaonkar, P; Vega, I; Lambertson, D; Potts, W; Madura, K				Schauber, C; Chen, L; Tongaonkar, P; Vega, I; Lambertson, D; Potts, W; Madura, K			Rad23 links DNA repair to the ubiquitin/proteasome pathway	NATURE			English	Article							NUCLEOTIDE EXCISION-REPAIR; TRANSCRIPTION FACTOR TFIIH; SACCHAROMYCES-CEREVISIAE; PYRIMIDINE DIMERS; IN-VIVO; PROTEIN; MUTANTS; PURIFICATION; HOMOLOG; XPC	Rad23 is an evolutionarily conserved protein that is important for nucleotide excision repair(1-3). A regulatory role has been proposed for Rad23 because rad23 mutants are sensitive to ultraviolet light but are still capable of incising damaged DNA(4,5). Here we show that Rad23 interacts with the 26S proteasome through an aminoterminal ubiquitin-like domain (UbL(R23)). The carboxy terminus of Rad23 binds to the Rad4 DNA repair protein and creates a link between the DNA repair and proteasome pathways. The ultraviolet sensitivity caused by deletion of the UbL(R23) domain may therefore arise from its inability to interact with the proteasome. The fusion proteins glutathione S-transferase (GST)-Rad23 and Rad4-haemagglutinin (HA), and the proteasome subunits Cim3 and Cim5, cofractionate through consecutive chromatography steps. The ubiquitin-like domain of human Rad23 (UbL(HRB)) also interacts with the human proteasome. These results demonstrate that ubiquitin-like domains (UbLs) represent a new class of proteasome-interacting motifs.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Madura, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.	maduraki@umdnj.edu						BANIAHMAD C, 1994, BIOTECHNIQUES, V16, P194; CHEN P, 1993, CELL, V74, P357, DOI 10.1016/0092-8674(93)90426-Q; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; GARRETT KP, 1995, P NATL ACAD SCI USA, V92, P7172, DOI 10.1073/pnas.92.16.7172; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; GUZDER SN, 1995, J BIOL CHEM, V270, P8385, DOI 10.1074/jbc.270.15.8385; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MCCREADY S, 1994, MUTAT RES-DNA REPAIR, V315, P261, DOI 10.1016/0921-8777(94)90037-X; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MILLER RD, 1982, MOL GEN GENET, V188, P235, DOI 10.1007/BF00332681; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; Mueller JP, 1996, MOL CELL BIOL, V16, P2361; Reardon JT, 1996, J BIOL CHEM, V271, P19451, DOI 10.1074/jbc.271.32.19451; Rubin DM, 1996, NATURE, V379, P655, DOI 10.1038/379655a0; Sugasawa K, 1996, MOL CELL BIOL, V16, P4852; vanderSpek PJ, 1996, NUCLEIC ACIDS RES, V24, P2551, DOI 10.1093/nar/24.13.2551; Verhage RA, 1996, MUTAT RES-DNA REPAIR, V362, P155, DOI 10.1016/0921-8777(95)00045-3; Wang ZG, 1997, MOL CELL BIOL, V17, P635, DOI 10.1128/MCB.17.2.635; WATKINS JF, 1993, MOL CELL BIOL, V13, P7757, DOI 10.1128/MCB.13.12.7757	23	396	406	1	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					715	718		10.1038/35661	http://dx.doi.org/10.1038/35661			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490418				2022-12-01	WOS:000071982500058
J	Ahmad, W; Haque, WFU; Brancolini, V; Tsou, HC; Haque, SU; Lam, H; Aita, VM; Owen, J; deBlaquiere, M; Frank, J; Cserhalmi-Friedman, PB; Leask, A; McGrath, JA; Peacocke, M; Ahmad, M; Ott, J; Christiano, AM				Ahmad, W; Haque, WFU; Brancolini, V; Tsou, HC; Haque, SU; Lam, H; Aita, VM; Owen, J; deBlaquiere, M; Frank, J; Cserhalmi-Friedman, PB; Leask, A; McGrath, JA; Peacocke, M; Ahmad, M; Ott, J; Christiano, AM			Alopecia universalis associated with a mutation in the human hairless gene	SCIENCE			English	Article							GROWTH CYCLE; NUDE LOCUS; MOUSE; EXPRESSION; MICE; MECHANISMS; FOLLICLE; PROTEIN; RAT	There are several forms of hereditary human hair loss, known collectively as alopecias, the molecular bases of which are entirely unknown. A kindred with a rare, recessively inherited type of alopecia universalis was used to search for a locus by homozygosity mapping, and linkage was established in a B-centimorgan interval on chromosome 8p12 (the logarithm of the odds favoring linkage score was 6.19). The human homolog of a murine gene, hairless, was localized in this interval by radiation hybrid mapping, and a missense mutation was found in affected individuals. Human hairless encodes a putative single zinc finger transcription factor protein with restricted expression in the brain and skin.	Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA; Quaid I Azam Univ, Dept Biol Sci, Islamabad, Pakistan; Rockefeller Univ, Lab Stat Genet, New York, NY 10021 USA; Res Genet Inc, Huntsville, AL 35801 USA; Fibrogen Inc, San Francisco, CA 94080 USA; St Thomas Hosp, Inst Dermatol, London SE1 7EH, England	Columbia University; Columbia University; Quaid I Azam University; Rockefeller University; FibroGen; Guy's & St Thomas' NHS Foundation Trust	Christiano, AM (corresponding author), Columbia Univ, Dept Dermatol, 630 W 168 St,VC-15-526, New York, NY 10032 USA.	amc65@columbia.edu	McGrath, John/N-3529-2019; Leask, Andy/ABH-9433-2020; Ahmad, Wasim/GSD-8904-2022; Ahmad, Wasim/E-9713-2015; Leask, Andrew/G-5217-2015; McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964; Brancolini, Valeria/0000-0003-0871-537X	NHGRI NIH HHS [HG-00008] Funding Source: Medline; NIAMS NIH HHS [P30AR44535] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR044535] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BERGFELD WF, 1995, AM J MED, V98, pS95, DOI 10.1016/S0002-9343(99)80065-5; BROOKE HC, 1924, J HERED, V15, P173; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Engelkamp D, 1996, CURR OPIN GENET DEV, V6, P334, DOI 10.1016/S0959-437X(96)80011-6; GALLAGHER CH, 1984, J INVEST DERMATOL, V83, P169, DOI 10.1111/1523-1747.ep12263512; GANGULY A, 1993, P NATL ACAD SCI USA, V90, P10325, DOI 10.1073/pnas.90.21.10325; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; HEBERT JM, 1994, CELL, V78, P1017, DOI 10.1016/0092-8674(94)90276-3; HOOG C, 1991, MOL REPROD DEV, V30, P173, DOI 10.1002/mrd.1080300302; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Latchman DS, 1996, NEW ENGL J MED, V334, P28, DOI 10.1056/NEJM199601043340108; MORRISSEY PJ, 1980, J IMMUNOL, V125, P1558; MULLER HK, 1980, BRIT J DERMATOL, V102, P609, DOI 10.1111/j.1365-2133.1980.tb07664.x; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; ROOK A, 1991, DIS HAIR SCALP, P136; Rosenquist TA, 1996, DEV DYNAM, V205, P379, DOI 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F; Sambrook J., 1989, MOL CLONING LAB MANU, V3; Schaffer AA, 1996, HUM HERED, V46, P226, DOI 10.1159/000154358; Schuddekopf K, 1996, P NATL ACAD SCI USA, V93, P9661, DOI 10.1073/pnas.93.18.9661; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; SEMENZA GL, 1994, HUM MUTAT, V3, P180, DOI 10.1002/humu.1380030304; SHEFFIELD VC, 1995, CURR OPIN GENET DEV, V5, P335, DOI 10.1016/0959-437X(95)80048-4; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; Thompson CC, 1996, J NEUROSCI, V16, P7832; ZHOU PB, 1995, GENE DEV, V9, P700, DOI 10.1101/gad.9.6.700	27	322	352	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					720	724		10.1126/science.279.5351.720	http://dx.doi.org/10.1126/science.279.5351.720			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445480				2022-12-01	WOS:000071731500041
J	Bitter, W; Gerrits, H; Kieft, R; Borst, P				Bitter, W; Gerrits, H; Kieft, R; Borst, P			The role of transferrin-receptor variation in the host range of Trypanosoma brucei	NATURE			English	Article							GENE-EXPRESSION SITE; SURFACE GLYCOPROTEIN GENES; BINDING PROTEIN COMPLEX; ANTIGENIC VARIATION; AFRICAN TRYPANOSOMES; CELLS; IDENTIFICATION; INVITRO; FAMILY; GROWTH	Trypanosoma brucei(1) is a unicellular parasite transmitted between African mammals by tsetse flies. T. brucei multiplies freely in the bloodstream of many different mammals, and survives by antigenic variation of the main component of its surface coat, variant surface glycoprotein (VSG)(2,3). Trypanosomes take up transferrin through a heterodimeric transferrin receptor(4-9), the genes for which are expressed in telomeric expression sites along with the VSG gene. There are up to 20 of these expression sites per trypanosome nucleus(3,10-15), but usually only one is active at a time. Different expression sites encode transferrin receptors that are similar but not identical(16). Here we show that these small differences between transferrin receptors can have profound effects on the binding affinity for transferrins from different mammals, and an the ability of trypanosomes to grow in the sera of these mammals. Our results suggest that the ability ro switch between different transferrin-receptor genes allows T. brucei to cope with the large sequence diversity in the transferrins of its hosts(17).	Netherlands Canc Inst, Div Mol Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, P (corresponding author), Netherlands Canc Inst, Div Mol Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.		Bitter, Wilbert/AAA-6872-2019; Bitter, W/CAJ-5778-2022; Bitter, Wilbert/ABG-3726-2020	Bitter, Wilbert/0000-0001-8347-6511				BORST P, 1994, SCIENCE, V264, P1872, DOI 10.1126/science.7516579; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BORST P, 1991, TRENDS GENET, V7, P307, DOI 10.1016/0168-9525(91)90406-G; BORST P, 1997, TRYPANOSOMIASIS LEIS, V1, P109; Bruce D., 1895, PRELIMINARY REPORT T; BRUN R, 1979, ACTA TROP, V36, P387; CHAUDHRI M, 1994, P NATL ACAD SCI USA, V91, P6443, DOI 10.1073/pnas.91.14.6443; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROSS GAM, 1975, PARASITOLOGY, V71, P393, DOI 10.1017/S003118200004717X; CULLY DF, 1985, CELL, V42, P173, DOI 10.1016/S0092-8674(85)80113-6; DONELSON JE, 1995, J BIOL CHEM, V270, P7783, DOI 10.1074/jbc.270.14.7783; ENNS CA, 1981, J BIOL CHEM, V256, P2620; HIRUMI H, 1989, J PARASITOL, V75, P985, DOI 10.2307/3282883; HOBBS MR, 1990, MOL BIOCHEM PARASIT, V43, P1, DOI 10.1016/0166-6851(90)90125-6; LIGTENBERG MJL, 1994, EMBO J, V13, P2565, DOI 10.1002/j.1460-2075.1994.tb06546.x; LIPS S, 1993, MOL BIOCHEM PARASIT, V62, P135, DOI 10.1016/0166-6851(93)90189-5; LIU AYC, 1985, J MOL BIOL, V182, P383, DOI 10.1016/0022-2836(85)90198-6; PAYS E, 1989, CELL, V57, P835, DOI 10.1016/0092-8674(89)90798-8; PAYS E, 1994, ANNU REV MICROBIOL, V48, P25, DOI 10.1146/annurev.mi.48.100194.000325; Retzer MD, 1996, J BIOL CHEM, V271, P1166, DOI 10.1074/jbc.271.2.1166; REVELARD P, 1990, NUCLEIC ACIDS RES, V18, P7299, DOI 10.1093/nar/18.24.7299; RUDENKO G, 1995, CELL, V83, P547, DOI 10.1016/0092-8674(95)90094-2; SALMON D, 1994, CELL, V78, P75, DOI 10.1016/0092-8674(94)90574-6; SCHELL D, 1991, EMBO J, V10, P1061, DOI 10.1002/j.1460-2075.1991.tb08045.x; STEVERDING D, 1994, EUR J CELL BIOL, V64, P78; STEVERDING D, 1995, J CELL BIOL, V131, P1173, DOI 10.1083/jcb.131.5.1173; URIEL J, 1983, BRIT J CANCER, V48, P261, DOI 10.1038/bjc.1983.181; VOEST EE, 1993, CELL PROLIFERAT, V26, P77, DOI 10.1111/j.1365-2184.1993.tb00008.x; YOUNG SP, 1990, BIOCHEM J, V265, P587, DOI 10.1042/bj2650587; ZOMERDIJK JCBM, 1991, NUCLEIC ACIDS RES, V19, P1359, DOI 10.1093/nar/19.7.1359	30	125	126	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					499	502		10.1038/35166	http://dx.doi.org/10.1038/35166			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461219				2022-12-01	WOS:000071701800054
J	Crameri, A; Raillard, SA; Bermudez, E; Stemmer, WPC				Crameri, A; Raillard, SA; Bermudez, E; Stemmer, WPC			DNA shuffling of a family of genes from diverse species accelerates directed evolution	NATURE			English	Article							BETA-LACTAMASE; MOLECULAR EVOLUTION; IN-VITRO; SEQUENCE; RECOMBINATION; PROTEIN; PLASMID	DNA shuffling is a powerful process for directed evolution, which generates diversity by recombination(1,2), combining useful mutations from individual genes. Libraries of chimaeric genes can be generated by random frag;mentation of a pool of related genes, followed by reassembly of the fragments in a self-priming polymerase reaction. Template switching causes crossovers in areas of sequence homology. Our previous studies used single genes and random point mutations as the source of diversity(3-6). An alternative source of diversity is naturally occurring homologous genes, which provide 'functional diversity.' To evaluate whether natural diversity could accelerate the evolution process, we compared the efficiency of obtaining moxalactamase activity from four cephalosporinase genes evolved separately with that from a mixed pool of the four genes. A single cycle of shuffling yielded eightfold improvements from the four separately evolved genes, versus a 270- to 540-fold improvement from the four genes shuffled together, a 50-fold increase per cycle of shuffling. The best clone contained eight segments from three of the four genes as well as 33 amino-acid point mutations, Molecular breeding by shuffling can efficiently mix sequences from different species, unlike traditional breeding techniques, The power of family shuffling may arise from sparse sampling of a larger portion of sequence space.	Maxygen Inc, Santa Clara, CA 95051 USA		Stemmer, WPC (corresponding author), Maxygen Inc, 3410 Cent Expressway, Santa Clara, CA 95051 USA.							Crameri A, 1996, NAT BIOTECHNOL, V14, P315, DOI 10.1038/nbt0396-315; Crameri A, 1997, NAT BIOTECHNOL, V15, P436, DOI 10.1038/nbt0597-436; Eigen M, 1992, STEPS LIFE PERSPECTI; GALLENI M, 1988, BIOCHEM J, V250, P753, DOI 10.1042/bj2500753; Kauffman S.A., 1993, ORIGINS ORDER; LEIZA MG, 1994, ANTIMICROB AGENTS CH, V38, P2150; LINDBERG F, 1986, EUR J BIOCHEM, V156, P441, DOI 10.1111/j.1432-1033.1986.tb09601.x; LOBKOVSKY E, 1993, P NATL ACAD SCI USA, V90, P11257, DOI 10.1073/pnas.90.23.11257; Moore JC, 1996, NAT BIOTECHNOL, V14, P458, DOI 10.1038/nbt0496-458; SEOANE A, 1992, ANTIMICROB AGENTS CH, V36, P1049, DOI 10.1128/AAC.36.5.1049; STEMMER WPC, 1994, NATURE, V370, P389, DOI 10.1038/370389a0; STEMMER WPC, 1994, P NATL ACAD SCI USA, V91, P10747, DOI 10.1073/pnas.91.22.10747; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; STEMMER WPC, 1995, BIO-TECHNOL, V13, P549, DOI 10.1038/nbt0695-549; Zhang JH, 1997, P NATL ACAD SCI USA, V94, P4504, DOI 10.1073/pnas.94.9.4504; Zhao HM, 1997, NUCLEIC ACIDS RES, V25, P1307, DOI 10.1093/nar/25.6.1307	16	618	1129	5	132	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					288	291		10.1038/34663	http://dx.doi.org/10.1038/34663			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440693				2022-12-01	WOS:000071484400052
J	Crick, F; Koch, C				Crick, F; Koch, C			Constraints on cortical and thalamic projections: The no-strong-loops hypothesis	NATURE			English	Article							LATERAL GENICULATE NEURONS; PRIMARY VISUAL-CORTEX; INDETERMINATE ORGANIZATION; SQUIRREL-MONKEY; STRIATE CORTEX; CONNECTIONS; PULVINAR; SYSTEM; TERMINATIONS; NETWORKS	The many distinct cortical areas of the macaque monkey visual system can be arranged hierarchically, but not in a unique way, We suggest that the connections between these cortical areas never form strong, directed loops. For connections between the visual cortex and particular thalamic nuclei, we predict that certain types of connections will not be found, If strong, directed loops were to exist, we suggest that the cortex would go into uncontrolled oscillations.	Salk Inst Biol Studies, La Jolla, CA 92037 USA; CALTECH, Computat & Neural Syst Program, Pasadena, CA 91125 USA	Salk Institute; California Institute of Technology	Crick, F (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.			Koch, Christof/0000-0001-6482-8067				BAKER FH, 1977, EXP BRAIN RES, V29, P433; BOURASSA J, 1995, NEUROSCIENCE, V66, P253, DOI 10.1016/0306-4522(95)00009-8; CALLWAY EM, IN PRESS ANN REV NEU; CRICK F, 1995, NATURE, V375, P121, DOI 10.1038/375121a0; DOUGLAS RJ, 1995, SCIENCE, V269, P891; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Guillery R W, 1971, Vision Res, VSuppl 3, P211; Guillery RW, 1995, J ANAT, V187, P583; Gutierrez C, 1995, J COMP NEUROL, V363, P545, DOI 10.1002/cne.903630404; HENDRY SHC, 1994, SCIENCE, V264, P575, DOI 10.1126/science.8160015; Hilgetag CC, 1996, SCIENCE, V271, P776, DOI 10.1126/science.271.5250.776; HIRSCH MW, 1989, NEURAL NETWORKS, V2, P331, DOI 10.1016/0893-6080(89)90018-X; Jones EG., 2003, THALAMUS, V1st; KALIL RE, 1970, J NEUROPHYSIOL, V33, P459, DOI 10.1152/jn.1970.33.3.459; KUAN CM, 1994, NEURAL COMPUT, V6, P420, DOI 10.1162/neco.1994.6.3.420; LEVITT JB, 1995, EXP BRAIN RES, V104, P419; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; MATHERS LH, 1972, J COMP NEUROL, V146, P43, DOI 10.1002/cne.901460104; MATHERS LH, 1972, J COMP NEUROL, V146, P15, DOI 10.1002/cne.901460103; MIGNARD M, 1991, SCIENCE, V251, P1249, DOI 10.1126/science.1848727; OJIMA H, 1994, CEREB CORTEX, V4, P646, DOI 10.1093/cercor/4.6.646; PETERS A, 1994, CEREB CORTEX, V4, P215, DOI 10.1093/cercor/4.3.215; Robinson D. F., 1980, DIGRAPHS THEORY TECH; ROBINSON DL, IN PRESS THALAMUS, V2; ROCKLAND KS, 1994, NEUROREPORT, V5, P1865, DOI 10.1097/00001756-199410000-00006; Rockland KS, 1996, J COMP NEUROL, V368, P57, DOI 10.1002/(SICI)1096-9861(19960422)368:1<57::AID-CNE5>3.0.CO;2-J; ROCKLAND KS, 1979, BRAIN RES, V179, P3, DOI 10.1016/0006-8993(79)90485-2; ROCKLAND KS, IN PRESS J COMP NEUR; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SANDELL JH, 1982, J NEUROPHYSIOL, V48, P38, DOI 10.1152/jn.1982.48.1.38; Sherman SM, 1996, J NEUROPHYSIOL, V76, P1367, DOI 10.1152/jn.1996.76.3.1367; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; VanEssen DC, 1996, SCIENCE, V271, P777; WEBSTER MJ, 1994, CEREB CORTEX, V4, P470, DOI 10.1093/cercor/4.5.470	34	232	235	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					245	250		10.1038/34584	http://dx.doi.org/10.1038/34584			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440687				2022-12-01	WOS:000071484400039
J	Veeken, H				Veeken, H			Russia: Sex, drugs, and AIDS and MSF	BRITISH MEDICAL JOURNAL			English	Article									Med Sans Frontieres, NL-1001 EA Amsterdam, Netherlands	Doctors Without Borders	Veeken, H (corresponding author), Med Sans Frontieres, POB 10014, NL-1001 EA Amsterdam, Netherlands.								0	14	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					138	139						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462323	Green Published			2022-12-01	WOS:000071492300031
J	Huang, HJ; Liao, J; Cohen, SN				Huang, HJ; Liao, J; Cohen, SN			Poly(A)- and poly(U)-specific RNA 3 ' tail shortening by E-coli ribonuclease E	NATURE			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; ANTISENSE RNAI; DEGRADATION; REPLICATION; PROTEINS; CLEAVES; BINDING; COMPLEX; ENZYME	Ribonuclease (RNase) E is an extensively studied enzyme from Escherichia coli whose site-specific endoribonuclease activity on single-stranded RNA has a central role in the processing of ribosomal RNA, the degradation of messenger RNA and the control of replication of ColE1-type plasmids (for recent reviews, see refs 1-3). Here we report a previously undetected activity of RNase E: the ability to shorten 3' poly(A)- and poly(U)-homopolymer tails on RNA molecules. This activity, which leaves a 6-nucleotide adenylate or a 1-nucleotide uridylate remnant on primary transcripts, resides in the amino-terminal region of RNase E and does not require other protein cofactors. Addition of a 3'-terminal phosphate group prevents both removal of the poly(A) tail and endonucleolytic cleavage within primary transcripts, but has no effect on the cleavage of transcripts with tails that have already been truncated. The ability of RNase E to shorten poly(A) tails, together with the effect of tail length on endonucleolytic cleavage within primary transcripts, suggests a mechanism by which RNase E may exercise overall control over RNA decay.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Cohen, SN (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.							Caponigro G, 1996, MICROBIOL REV, V60, P233, DOI 10.1128/MMBR.60.1.233-249.1996; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; ClaverieMartin F, 1997, J BIOL CHEM, V272, P13823, DOI 10.1074/jbc.272.21.13823; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; Cohen SN, 1997, MOL MICROBIOL, V23, P1099, DOI 10.1111/j.1365-2958.1997.tb02593.x; EHRETSMANN CP, 1992, FASEB J, V6, P318; HAJNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973, DOI 10.1073/pnas.92.9.3973; HELMERCITTERICH M, 1988, EMBO J, V7, P557, DOI 10.1002/j.1460-2075.1988.tb02845.x; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JACOBSON A, 1996, COLD SPRING HARBOR M, V30, P451; Kaberdin VR, 1996, J BIOL CHEM, V271, P13103, DOI 10.1074/jbc.271.22.13103; Kido M, 1996, J BACTERIOL, V178, P3917, DOI 10.1128/jb.178.13.3917-3925.1996; KLEE CB, 1968, J BIOL CHEM, V243, P923; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; LITTAUER UZ, 1982, ENZYMES, V15, P517; McDowall KJ, 1996, J MOL BIOL, V255, P349, DOI 10.1006/jmbi.1996.0027; MELEFORS O, 1993, CONTROL MESSENGER RN, P53; Miczak A, 1996, P NATL ACAD SCI USA, V93, P3865, DOI 10.1073/pnas.93.9.3865; NOSSAL NG, 1968, J BIOL CHEM, V243, P913; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; RAZZELL WE, 1959, J BIOL CHEM, V234, P2105; Sarkar N, 1996, MICROBIOL-UK, V142, P3125, DOI 10.1099/13500872-142-11-3125; SINGER MF, 1965, BIOCHEMISTRY-US, V4, P1319, DOI 10.1021/bi00883a016; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756	28	68	70	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					99	102		10.1038/34219	http://dx.doi.org/10.1038/34219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422514				2022-12-01	WOS:000071326100058
J	Simmonds, RE; Ireland, H; Lane, DA; Zoller, B; de Frutos, PG; Dahlback, B				Simmonds, RE; Ireland, H; Lane, DA; Zoller, B; de Frutos, PG; Dahlback, B			Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect	ANNALS OF INTERNAL MEDICINE			English	Article						protein S deficiency; thrombophlebitis; heterozygote; mutation; hereditary diseases	C4B-BINDING PROTEIN; C DEFICIENCY; PLASMA-LEVELS; FACTOR-X; THROMBOPHILIA; ORGANIZATION; COMPLEX; DISEASE; OUTPATIENTS; RESISTANCE	Background: Protein S is an important regulatory protein of the coagulation cascade. The risk for venous thrombosis associated with protein S deficiency has been uncertain because all previous risk estimates used phenotypic evaluation alone, which can be ambiguous. Objective: To quantitate the risk for thrombosis associated with a characterized protein S gene mutation that causes a Gly295-->Val substitution and protein S deficiency. Design: Retrospective study of a single extended family. Setting: University hospital referral center. Participants: A 122-member protein S-deficient family, in which 44 members had a recently characterized gene defect. Measurements: Comprehensive history of thrombosis, history of exposure to acquired risk factors for thrombosis, levels of total and free protein S antigen, and genotype for the mutation causing the Gly295-->Val substitution. Results: Kaplan-Meier analysis of thrombosis-free survival showed that the probability of remaining free of thrombosis at 30 years of age is 0.5 (95% CI, 0.33 to 0.66) for carriers of the Gly295-->Val mutation compared with 0.97 (CI, 0.93 to 1.0) for normal family members (P < 0.001). In a multivariate Cox regression model that included smoking and obesity, the mutation was a strong independent risk factor for thrombosis (hazard ratio, 11.5 [CI, 4.33 to 30.6]; P < 0.001). For free (but not total) protein S antigen levels, the distributions of persons with and persons without the mutation did not overlap. Conclusions: Protein S deficiency, as defined by the presence of a causative gene mutation or a reduced level of free protein S antigen; is a strong independent risk factor for venous thrombosis in a clinically affected family.	Charing Cross Hosp, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, London W6 8RP, England; Univ Lund Hosp, Dept Internal Med, S-22185 Lund, Sweden; Lund Univ, Dept Clin Chem, S-20502 Malmo, Sweden	Imperial College London; Lund University; Skane University Hospital; Lund University	Simmonds, RE (corresponding author), Charing Cross Hosp, Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Haematol, St Dunstans Rd, London W6 8RP, England.		Zöller, Bengt/M-3217-2019; Simmonds, Rachel E/M-7122-2016; de Frutos, Pablo García/B-8594-2011; Zöller, Bengt/H-8856-2012; Ireland, Helen A/B-9868-2008	Zöller, Bengt/0000-0002-8250-5613; Simmonds, Rachel E/0000-0003-4843-8266; de Frutos, Pablo García/0000-0003-1547-1190; Zöller, Bengt/0000-0002-8250-5613; Ireland, Helen A/0000-0002-7980-548X; Dahlback, Bjorn/0000-0003-1546-0328; Lane, David/0000-0003-4283-3695				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BENTAL O, 1989, THROMB HAEMOSTASIS, V61, P50; COX DR, 1972, J R STAT SOC B, V34, P187; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1995, THROMB RES, V77, P1, DOI 10.1016/0049-3848(94)00138-4; DAHLBACK B, 1981, P NATL ACAD SCI-BIOL, V78, P2512, DOI 10.1073/pnas.78.4.2512; EDENBRANDT CM, 1990, BIOCHEMISTRY-US, V29, P7861, DOI 10.1021/bi00486a012; ENGESSER L, 1987, ANN INTERN MED, V106, P677, DOI 10.7326/0003-4819-106-5-677; FAIONI EM, 1993, THROMB HAEMOSTASIS, V70, P1067; Gandrille S, 1997, THROMB HAEMOSTASIS, V77, P1201; GLADSON CL, 1988, THROMB HAEMOSTASIS, V59, P18; GRIFFIN JH, 1992, BLOOD, V79, P3203; HACKENG TM, 1994, J BIOL CHEM, V269, P21051; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; HENKENS CMA, 1995, THROMB HAEMOSTASIS, V74, P1271; Hille ETM, 1997, BLOOD, V89, P1963, DOI 10.1182/blood.V89.6.1963; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOPPELMAN SJ, 1995, BLOOD, V86, P1062; KOSTER T, 1995, BLOOD, V85, P2756, DOI 10.1182/blood.V85.10.2756.bloodjournal85102756; MAHASANDANA C, 1990, LANCET, V335, P61, DOI 10.1016/0140-6736(90)90201-F; MALM J, 1992, THROMB HAEMOSTASIS, V68, P7; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PABINGER I, 1994, THROMB HAEMOSTASIS, V71, P441; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; Rosendaal FR, 1997, THROMB HAEMOSTASIS, V78, P1; SCHMIDEL DK, 1990, BIOCHEMISTRY-US, V29, P7845, DOI 10.1021/bi00486a010; SCHWARZ HP, 1984, BLOOD, V64, P1297; SCOTT BD, 1991, AM HEART J, V122, P76, DOI 10.1016/0002-8703(91)90761-6; Simmonds RE, 1996, BLOOD, V88, P4195; Simmonds RE, 1997, BLOOD, V89, P4364, DOI 10.1182/blood.V89.12.4364; TABERNERO MD, 1991, AM J HEMATOL, V36, P249, DOI 10.1002/ajh.2830360405; VANAMSTEL HKP, 1990, BIOCHEMISTRY-US, V29, P7853, DOI 10.1021/bi00486a011; VANBOVEN HH, 1994, BLOOD, V84, P4209, DOI 10.1182/blood.V84.12.4209.bloodjournal84124209; vanBoven HH, 1997, THROMB HAEMOSTASIS, V77, P452; ZOLLER B, 1993, THROMB HAEMOSTASIS, V69, P1256; ZOLLER B, 1995, BLOOD, V85, P3524, DOI 10.1182/blood.V85.12.3524.bloodjournal85123524; ZOLLER B, 1995, BLOOD, V85, P3518, DOI 10.1182/blood.V85.12.3518.bloodjournal85123518	38	76	77	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					8	+		10.7326/0003-4819-128-1-199801010-00002	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424998				2022-12-01	WOS:000071158000002
J	Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG				Hay, JA; Maldonado, L; Weingarten, SR; Ellrodt, AG			Prospective evaluation of a clinical guideline recommending hospital length of stay in upper gastrointestinal tract hemorrhage	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONTROLLED TRIAL; EARLY ENDOSCOPY; SCORING SYSTEM; PEPTIC-ULCERS; MORTALITY; SIGNS; POPULATION	Context.-Upper gastrointestinal tract hemorrhage (UGIH) is a common and potentially life-threatening disorder. Resource utilization can vary without adverse effect on patient outcome. Clinical practice guidelines are a potential solution to reduce variation in practice while improving patient outcomes. Objective.-To validate prospectively the safety, acceptability, and impact of a clinical practice guideline defining the medically appropriate length of stay (LOS) for patients hospitalized with UGIH. Design.-Prospective, controlled time-series study with an alternate-month design. Outcome surveyors and patients were blinded to study group allocation. Guideline.-A retrospectively validated scoring system using 4 independent variables: hemodynamics, time from bleeding, comorbidity, and esophagogastroduodenoscopy (EGD) findings to predict risk of adverse events. The quantitative risk for the low-risk subset was 0.6% (95% confidence interval [CI], 0.0%-2.0%) for subsequent complications and 0% (95% CI, 0.0%-0.9%) for life-threatening complications from this retrospective evaluation. Setting.-A 1000-bed, not-for-profit, university-affiliate teaching hospital. Patients.-Consecutive adult patients hospitalized for acute UGIH. Intervention.-Concurrent feedback of guideline recommendation (same-day hospital discharge) to physicians caring for patients at low risk for complication. No risk information was provided during control months. Results.-Seventy percent (209/299) of UGIH patients achieved low-risk status according to the guideline and were therefore potentially suitable for early discharge from the hospital. Providing real-time quantitative risk information (intervention group only) was associated with an increase in guideline compliance from 30% to 70% (P<.001) and a decrease in mean (SD) LOS from 4.6 (3.5) days to 2.9 (1.3) days (mean reduction of 1.7 days per patient; P<.001). No differences in complications, patient health status, or patient satisfaction were found when measured 1 month after discharge. An independent variable predicting decreased hospital LOS for low-risk UGIH patients was early EGD. Conclusions.-Implementation of the clinical practice guideline safely reduced hospital LOS for selected low-risk patients with acute UGIH. Further prospective validation in other settings is warranted.	Healthcare Partners Med Grp, Pasadena, CA 91105 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Med, Los Angeles, CA 90048 USA; Univ Calif Los Angeles, Cedars Sinai Med Ctr, Sch Med, Dept Hlth Serv Res, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Hay, JA (corresponding author), Healthcare Partners Med Grp, 55 E Calif Blvd, Pasadena, CA 91105 USA.							BORDLEY DR, 1985, JAMA-J AM MED ASSOC, V253, P3282, DOI 10.1001/jama.253.22.3282; BORNMAN PC, 1985, BRIT MED J, V291, P245, DOI 10.1136/bmj.291.6490.245; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CARSTENSEN HE, 1980, SCAND J GASTROENTERO, V15, P103, DOI 10.3109/00365528009181439; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; COOK DJ, 1992, GASTROENTEROLOGY, V102, P139, DOI 10.1016/0016-5085(92)91793-4; Cooper GS, 1996, GASTROENTEROLOGY, V111, P385, DOI 10.1053/gast.1996.v111.pm8690203; Dixon W.J, 1990, BMDP STAT SOFTWARE; EVERETT S, 1996, GUT               S1, V39, pA4; FLEISCHER D, 1983, GASTROENTEROLOGY, V84, P538; FLEISCHER DE, 1990, J CLIN GASTROENTE S2, V12, P41; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, P8; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; HALL WH, 1989, JAMA-J AM MED ASSOC, V262, P1369; Hay JA, 1996, AM J MED, V100, P313, DOI 10.1016/S0002-9343(97)89490-9; HAY JA, 1995, AM J GASTROENTEROL, V90, P1661; LAINE L, 1987, NEW ENGL J MED, V316, P1613, DOI 10.1056/NEJM198706253162601; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; MCMAHON LF, 1989, MED CARE, V27, P623, DOI 10.1097/00005650-198906000-00005; MORGAN AG, 1977, BRIT MED J, V2, P237, DOI 10.1136/bmj.2.6081.237; *NAT CTR HLTH STAT, 1991, VIT HLTH STAT, V13; *NIH CONS DEV PAN, 1990, GASTROINTEST ENDOS S, V36, P31; OSHITA Y, 1986, ENDOSCOPY, V18, P11, DOI 10.1055/s-2007-1018419; PANES J, 1987, LANCET, V2, P1292; PETERSON WL, 1981, NEW ENGL J MED, V304, P925, DOI 10.1056/NEJM198104163041601; PIMPL W, 1987, ENDOSCOPY, V19, P101, DOI 10.1055/s-2007-1013010; PROVENZALE D, 1987, AM J MED SCI, V294, P26, DOI 10.1097/00000441-198707000-00004; RICHTER JM, 1991, J CLIN GASTROENTEROL, V13, P268, DOI 10.1097/00004836-199106000-00005; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X; SAEED ZA, 1995, GASTROINTEST ENDOSC, V41, P561, DOI 10.1016/S0016-5107(95)70191-5; STEEL K, 1981, NEW ENGL J MED, V304, P638, DOI 10.1056/NEJM198103123041104; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706	34	136	137	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 24	1997	278	24					2151	2156		10.1001/jama.278.24.2151	http://dx.doi.org/10.1001/jama.278.24.2151			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM043	9417008				2022-12-01	WOS:000071022200030
J	Martin, LA; Vile, R; Lemoine, NR; Sikora, K; Pandha, HS				Martin, LA; Vile, R; Lemoine, NR; Sikora, K; Pandha, HS			Genetic prodrug activation therapy	LANCET			English	Editorial Material									Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, London W12 0NN, England	Cancer Research UK; Imperial College London	Martin, LA (corresponding author), Hammersmith Hosp, Imperial Coll Sch Med, Imperial Canc Res Fund, London W12 0NN, England.							Cosset FL, 1996, GENE THER, V3, P946; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; HARRIS JD, 1994, GENE THER, V1, P170; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; Martin LA, 1996, CANCER METAST REV, V15, P301, DOI 10.1007/BF00046344; Ram Z, 1997, NAT MED, V3, P1354, DOI 10.1038/nm1297-1354; Ring CJA, 1997, GENE THER, V4, P1045, DOI 10.1038/sj.gt.3300510; VILE RG, 1993, CANCER RES, V53, P3860	8	5	5	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	DEC 20	1997	350	9094					1793	1794		10.1016/S0140-6736(05)63633-1	http://dx.doi.org/10.1016/S0140-6736(05)63633-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM803	9428248				2022-12-01	WOS:000071102500005
J	Ferrer, M; Alonso, J; Morera, J; Marrades, RM; Khalaf, A; Aguar, MC; Plaza, V; Prieto, L; Anto, JM				Ferrer, M; Alonso, J; Morera, J; Marrades, RM; Khalaf, A; Aguar, MC; Plaza, V; Prieto, L; Anto, JM		Quality Life Chronic Obstructive Pulm Dis Stud	Chronic obstructive pulmonary disease stage and health-related quality of life	ANNALS OF INTERNAL MEDICINE			English	Article							GEORGE RESPIRATORY QUESTIONNAIRE; SPANISH VERSION; OF-LIFE; MANAGEMENT; ADAPTATION; VALIDITY; OUTCOMES; PROFILE	Background: The American Thoracic Society recently recommended that chronic obstructive pulmonary disease be staged on the basis of the percentage of predicted FEV1. Objective: To examine 1) the relation between the American Thoracic Society system for staging chronic obstructive pulmonary disease and health-related quality of life and 2) the effect of self-reported comorbid conditions on health-related quality of life. Design: Cross-sectional study. Setting: Outpatient clinics of respiratory departments of four hospitals and one primary health care center in Spain. Patients: 321 consecutive male patients with chronic obstructive pulmonary disease. Measurements: Functional respiratory impairment, FEV1, respiratory symptoms, and health-related quality of life. Respiratory symptoms and health-related quality of life were measured by using the Spanish version of the St. George's Respiratory Questionnaire and the Nottingham Health Profile. Results: Patient scores on the St. George's Respiratory Questionnaire were moderately to strongly associated with disease staging (r = 0.27 to 0.51). Compared with reference values, values for health-related quality of life for patients with stage I disease were substantially higher on the St. George's Respiratory Questionnaire (6 and 34; P < 0.001) and values for impairment were significantly greater in stage I patients with comorbid conditions (19 and 36; P = 0.001). At least one concomitant chronic condition was found in 84% of study patients. Comorbid conditions only partly influenced the observed pattern of deterioration of health-related quality of life with worsening stages of disease. Conclusion: Staging criteria for chronic obstructive pulmonary disease based on percentage of predicted FEV1 separated groups of patients with varying degrees of impair ment in health-related quality of life. Contrary to expectations, even patients with mild disease showed substantially compromised health-related quality of life. Comorbid conditions influenced the relation between chronic obstructive pulmonary disease and health-related quality of life.	Hosp Badalona Germans Trias & Pujol, Dept Pneumol, E-08915 Badalona, Spain; Hosp Mar, Inst Municipal Invest Med, Hosp Clin & Prov, Barcelona, Spain; Hosp Vic, Barcelona, Spain; Hosp Magdalena, Dept Pneumol, E-12004 Castellon de La Plana, Spain	Hospital Germans Trias i Pujol; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; University of Barcelona; Hospital Clinic de Barcelona	Anto, JM (corresponding author), Hosp Mar, Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Carrer Doctor Aiguader 80, E-08003 Barcelona, Spain.		MArrades, Ramón M/AFU-6757-2022; Anto, J M/H-2676-2014; Ferrer, Montse/A-5510-2010; Alonso, Jordi/A-5514-2010	Anto, J M/0000-0002-4736-8529; Ferrer, Montse/0000-0001-9867-7391; Alonso, Jordi/0000-0001-8627-9636; Plaza, Vicente/0000-0003-2567-5496				ALONSO J, 1995, MED CLIN-BARCELONA, V104, P771; ALONSO J, 1990, AM J PUBLIC HEALTH, V80, P704, DOI 10.2105/AJPH.80.6.704; ALONSO J, 1994, QUAL LIFE RES, V3, P385, DOI 10.1007/BF00435390; ALONSO J, 1992, MED CARE, V30, pMS125, DOI 10.1097/00005650-199205001-00011; [Anonymous], 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; ARINO EC, 1988, ANN MED BARCELONA, V74, P231; Brooks SM, 1982, ATS NEWS, V8, P12; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; CURTIS JR, 1994, THORAX, V49, P162, DOI 10.1136/thx.49.2.162; Domingo Salvany A, 1989, Gac Sanit, V3, P320; FEINSTEIN AR, 1970, J CHRON DIS, V23, P455, DOI 10.1016/0021-9681(70)90054-8; Ferrer M, 1996, EUR RESPIR J, V9, P1160, DOI 10.1183/09031936.96.09061160; *GRUP TRAB SEPAR P, 1985, NORM ESP FORZ; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Ketelaars CAJ, 1996, THORAX, V51, P39, DOI 10.1136/thx.51.1.39; MAHLER DA, 1987, CLIN CHEST MED, V8, P215; MCSWEENY AJ, 1982, ARCH INTERN MED, V142, P473, DOI 10.1001/archinte.142.3.473; Okubadejo AA, 1996, THORAX, V51, P44, DOI 10.1136/thx.51.1.44; PRIGATANO GP, 1984, ARCH INTERN MED, V144, P1613, DOI 10.1001/archinte.144.8.1613; ROCA J, 1986, B EUR PHYSIOPATH RES, V22, P217; *SAS I, 1989, SAS STAT US GUID VER; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Ware J.E., 1993, LINC RI QUAL METR IN	26	288	298	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1072	1079		10.7326/0003-4819-127-12-199712150-00003	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412309				2022-12-01	WOS:000070936600003
J	Burn, J; Dennis, M; Bamford, J; Sandercock, P; Wade, D; Warlow, C				Burn, J; Dennis, M; Bamford, J; Sandercock, P; Wade, D; Warlow, C			Epileptic seizures after a first stroke: the Oxfordshire community stroke project	BRITISH MEDICAL JOURNAL			English	Article							ACUTE CEREBROVASCULAR-DISEASE; CEREBRAL INFARCTION; INTRACEREBRAL HEMORRHAGE; POPULATION; CLASSIFICATION; DEMOGRAPHY; FREQUENCY; ONSET	Objective: To describe the immediate and long term risk of epileptic seizures after a first ever stroke. Design: Cohort study following up stroke survivors for 2 to 6.5 years; comparison with age specific incidence rates of epileptic seizures in the general population. Setting: Community based stroke register. Subjects: 675 patients with a first stroke, followed up for a minimum of 2 years. Main outcome measures: Occurrence of single and recurrent seizures. Results: 52 patients had one or more post stroke seizures; in 25 the seizures were recurrent The 5 year actuarial risk of a post stroke seizure in survivors (excluding 19 patients with a history of epilepsy and 3 patients in whom the seizure occurred shortly before death from another cause) was 11.5% (95% confidence interval 4.8% to 18.2%). The relative risk of seizures, in comparison with the general population, was estimated at 35.2 in the first year after stroke and 19.0 in year 2. The risk of seizures was increased in survivors of subarachnoid and intracerebral haemorrhage (hazard ratio for intracranial haemorrhage v cerebral infarction 10.2 (3.7 to 27.9)), The risk of seizures after ischaemic stroke was substantial only in patients presenting with severe strokes due to total anterior circulation infarction. Only 9 of 295 patients (3%) independent one month after stroke suffered a seizure between 1 month and 5 years (actuarial risk 4.2% (0.1% to 8.3%)). Conclusion: Stroke patients hare about an 11.5% risk of single or recurrent seizures in the first 5 years after a stroke, Patients with more severe strokes or haemorrhagic strokes are at higher risk.	Southampton Gen Hosp, Rehabil Res Unit, Southampton SO9 4XY, Hants, England; Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland; St James Univ Hosp, Dept Neurol, Leeds LS9 7TF, W Yorkshire, England; Rivermead Rehabil Ctr, Oxford OX1 4XD, England	University of Southampton; University of Edinburgh; Saint James's University Hospital	Burn, J (corresponding author), Southampton Gen Hosp, Rehabil Res Unit, Southampton SO9 4XY, Hants, England.		sandercock, peter/GQI-3167-2022; Bamford, John/ABE-6218-2021; Ritter, Stefanie L/D-9312-2012	sandercock, peter/0000-0001-8484-0135; Wade, Derick/0000-0002-1188-8442				ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; Aring CD, 1935, ARCH INTERN MED, V56, P435, DOI 10.1001/archinte.1935.00170010023002; AVRAHAMI E, 1988, J NEUROL, V235, P472, DOI 10.1007/BF00314250; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BAMFORD J, 1988, J NEUROL NEUROSUR PS, V51, P1373, DOI 10.1136/jnnp.51.11.1373; BAMFORD J, 1990, J NEUROL NEUROSUR PS, V53, P16, DOI 10.1136/jnnp.53.1.16; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; BAMFORD JM, 1988, STROKE, V19, P1074, DOI 10.1161/01.STR.19.9.1074; BAMFORD JM, 1989, STROKE, V20, P828, DOI 10.1161/01.STR.20.6.828; BAQUIS GD, 1985, STROKE, V16, P444, DOI 10.1161/01.STR.16.3.444; BAROLIN GS, 1971, FORTSCHR NEUROL P I, V39, P199; DAVALOS A, 1988, J NEUROL NEUROSUR PS, V51, P1464, DOI 10.1136/jnnp.51.11.1464; DECAROLIS P, 1984, J NEUROL NEUROSUR PS, V47, P1345, DOI 10.1136/jnnp.47.12.1345; DODGE PR, 1954, BRAIN, V77, P610, DOI 10.1093/brain/77.4.610; EVANS JH, 1963, NEUROLOGY, V13, P207, DOI 10.1212/WNL.13.3.207; FAUGHT E, 1984, EPILEPSIA, V25, P666; FRENCH JD, 1956, ARCH NEURO PSYCHIATR, V75, P260, DOI 10.1001/archneurpsyc.1956.02330210040005; Gardner M. J., 1989, STAT CONFIDENCE; GOODRIDGE DMG, 1983, BMJ-BRIT MED J, V287, P641, DOI 10.1136/bmj.287.6393.641; GUPTA SR, 1988, STROKE, V19, P1477, DOI 10.1161/01.STR.19.12.1477; HALL G C, 1988, Pharmaceutical Medicine (London), V2, P345; HAUSER WA, 1984, EPILEPSIA, V25, P666; Jennet B, 1975, EPILEPSY NONMISSILE; KASE CS, 1989, STROKE, V20, P850, DOI 10.1161/01.STR.20.7.850; KILPATRICK CJ, 1990, ARCH NEUROL-CHICAGO, V47, P157, DOI 10.1001/archneur.1990.00530020053014; MOSKOWITZ E, 1972, ARCH PHYS MED REHAB, V53, P167; OLSEN TS, 1987, NEUROLOGY, V37, P1209, DOI 10.1212/WNL.37.7.1209; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; REITH J, 1996, EUR J N EUROL S2, V3, P93; ROBERTS MA, 1982, AGE AGEING, V11, P24, DOI 10.1093/ageing/11.1.24; ROBERTS RC, 1988, EPILEPSIA, V29, P190, DOI 10.1111/j.1528-1157.1988.tb04418.x; ROPPER AH, 1988, NEUROLOGY, V38, P1500, DOI 10.1212/WNL.38.9.1500-a; SHINTON RA, 1988, J NEUROL NEUROSUR PS, V51, P273, DOI 10.1136/jnnp.51.2.273; SHINTON RA, 1987, LANCET, V1, P11; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; STARKEY IR, 1987, LANCET, V1, P742; SUNG CY, 1989, J NEUROL NEUROSUR PS, V52, P1273, DOI 10.1136/jnnp.52.11.1273; TALLIS R, 1991, AGE AGEING, V20, P442, DOI 10.1093/ageing/20.6.442; VIITANEN M, 1988, EUR NEUROL, V28, P227, DOI 10.1159/000116272	39	274	286	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1582	1587		10.1136/bmj.315.7122.1582	http://dx.doi.org/10.1136/bmj.315.7122.1582			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437276	Green Published			2022-12-01	WOS:000071021900023
J	Ordway, JM; TallaksenGreene, S; Gutekunst, CA; Bernstein, EM; Cearley, JA; Wiener, HW; Dure, LS; Lindsey, R; Hersch, SM; Jope, RS; Albin, RL; Detloff, PJ				Ordway, JM; TallaksenGreene, S; Gutekunst, CA; Bernstein, EM; Cearley, JA; Wiener, HW; Dure, LS; Lindsey, R; Hersch, SM; Jope, RS; Albin, RL; Detloff, PJ			Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse	CELL			English	Article							LESCH-NYHAN SYNDROME; HUNTINGTONS-DISEASE; IN-VITRO; MODEL; POLYGLUTAMINE; DEFICIENCY; PATHOGENESIS; EXPANSION; CELLS; MICE	The mutations responsible for several human neurodegenerative disorders are expansions of translated CAG repeats beyond a normal size range. To address the role of repeat context, we have introduced a 146-unit CAG repeat into the mouse hypoxanthine phosphoribosyltransferase gene (Hprt). Mutant mice express a form of the HPRT protein that contains a long polyglutamine repeat. These mice develop a phenotype similar to the human translated CAG repeat disorders. Repeat containing mice show a late onset neurological phenotype that progresses to premature death. Neuronal intranuclear inclusions are present in affected mice. Our results show that CAG repeats do not need to be located within one of the classic repeat disorder genes to have a neurotoxic effect.	UNIV ALABAMA,DEPT BIOCHEM & MOL GENET,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PSYCHIAT & BEHAV NEUROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT ORAL BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT PEDIAT NEUROL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT COMPARAT MED,BIRMINGHAM,AL 35294; UNIV MICHIGAN,DEPT NEUROL,ANN ARBOR,MI 48104; EMORY UNIV,DEPT NEUROL,ATLANTA,GA 30329	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Michigan System; University of Michigan; Emory University			Dure, Leon/B-3243-2008; Longo, Kenneth A/A-5631-2010		NIA NIH HHS [AG06569, AG08671] Funding Source: Medline; NINDS NIH HHS [NS34492] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG006569] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CHA JHJ, 1994, LIFE SCI, V54, P1459, DOI 10.1016/0024-3205(94)90012-4; David G, 1997, NAT GENET, V17, P65, DOI 10.1038/ng0997-65; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; DUNNETT SB, 1989, BRAIN RES, V501, P401, DOI 10.1016/0006-8993(89)90659-8; FINGER S, 1988, J NEUROL SCI, V86, P203, DOI 10.1016/0022-510X(88)90099-8; Gusella JF, 1996, COLD SPRING HARB SYM, V61, P615; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; JINNAH HA, 1993, J NEUROCHEM, V60, P2036, DOI 10.1111/j.1471-4159.1993.tb03488.x; JINNAH HA, 1994, J NEUROSCI, V14, P1164; JINNAH HA, 1991, BEHAV NEUROSCI, V105, P1004, DOI 10.1037/0735-7044.105.6.1004; KAZEMIESFARJANI P, 1995, HUM MOL GENET, V4, P523, DOI 10.1093/hmg/4.4.523; Mangiarini L, 1996, CELL, V87, P493, DOI 10.1016/S0092-8674(00)81369-0; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Nasir J, 1996, HUM MOL GENET, V5, P1431, DOI 10.1093/hmg/5.Supplement_1.1431; Ordway JM, 1996, BIOTECHNIQUES, V21, P609; Orr HT, 1996, COLD SPRING HARB SYM, V61, P649; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; QUARREL O, 1991, HUNTINGTONS DISEASE, P37; REDDY RS, 1997, CURR OPIN CELL BIOL, V9, P364; ROSS CA, 1995, NEURON, V15, P493, DOI 10.1016/0896-6273(95)90138-8; Ruppert SML, 1996, HYBRIDOMA, V15, P55, DOI 10.1089/hyb.1996.15.55; Saudou F, 1996, COLD SPRING HARB SYM, V61, P639; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; SKINNER PJ, 1997, ATAXIN 1 EXPANDED GL; STRITTMATTER WJ, 1997, COLD SPRING HARB SYM, V61, P597; TROTTIER Y, 1995, NATURE, V378, P403, DOI 10.1038/378403a0; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WILLIAMSON DJ, 1992, J INHERIT METAB DIS, V15, P665, DOI 10.1007/BF01799622; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; Zoghbi HY, 1996, NAT GENET, V14, P237, DOI 10.1038/ng1196-237	33	301	305	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					753	763		10.1016/S0092-8674(00)80464-X	http://dx.doi.org/10.1016/S0092-8674(00)80464-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413985	Bronze			2022-12-01	WOS:A1997YL43900007
J	Vaughan, CW; Ingram, SL; Connor, MA; Christie, MJ				Vaughan, CW; Ingram, SL; Connor, MA; Christie, MJ			How opioids inhibit GABA-mediated neurotransmission	NATURE			English	Article							ARACHIDONIC-ACID METABOLITES; HIPPOCAMPUS IN-VITRO; LIPOXYGENASE METABOLITES; PRESYNAPTIC INHIBITION; PROTEIN-KINASE; RAT; CELLS; CHANNELS; NOCICEPTION; ACTIVATION	The midbrain region periaqueductal grey (FAG) is rich in opioid receptors and endogenous opioids and is a major target of analgesic action in the central nervous system(1). It has been proposed that the analgesic effect of opioids on the FAG works by suppressing the inhibitory influence of the neurotransmitter GABA (gamma-aminobutyric acid) on neurons that form part of a descending antinociceptive pathway(2). Opioids inhibit GABA-mediated (GABAergic) synaptic transmission in the FAG and other brain regions by reducing the probability of presynaptic neurotransmitter release(3,4), but the mechanisms involved remain uncertain. Here we report that opioid inhibition of GABAergic synaptic currents in the FAG is controlled by a presynaptic voltage-dependent potassium conductance, Opioid receptors of the mu type in GABAergic presynaptic terminals are specifically coupled to this potassium conductance by a pathway involving phospholipase A(2), arachidonic acid and 12-lipoxygenase. Furthermore, opioid inhibition of GABAergic synaptic transmission is potentiated by inhibitors of the enzymes cyclooxygenase and 5-lipoxygenase, presumably because more arachidonic acid is available for conversion to IZ-lipoxygenase products, These mechanisms account for the analgesic action of cyclooxygenase inhibitors in the PAG(5) and their synergism with opioids(6).			Vaughan, CW (corresponding author), UNIV SYDNEY,DEPT PHARMACOL,SYDNEY,NSW 2006,AUSTRALIA.		Connor, Mark/A-4197-2008; Christie, MacDonald J/F-4724-2013	Connor, Mark/0000-0003-2538-2001; Christie, MacDonald J/0000-0002-0622-609X; Vaughan, Christopher/0000-0003-4314-7689				BASBAUM AI, 1984, ANNU REV NEUROSCI, V7, P309, DOI 10.1146/annurev.ne.07.030184.001521; BLACKWELL GJ, 1983, BRIT MED BULL, V39, P260, DOI 10.1093/oxfordjournals.bmb.a071830; CAPOGNA M, 1995, J NEUROSCI, V15, P1249; CAPOGNA M, 1993, J PHYSIOL-LONDON, V470, P539, DOI 10.1113/jphysiol.1993.sp019874; Duerson K, 1996, NEUROPHARMACOLOGY, V35, P949, DOI 10.1016/0028-3908(96)00131-1; EVANS JF, 1991, MOL PHARMACOL, V40, P22; Fukuda K, 1996, J NEUROCHEM, V67, P1309; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; KURACHI Y, 1989, PFLUG ARCH EUR J PHY, V414, P102, DOI 10.1007/BF00585635; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; MAVES TJ, 1994, ANESTHESIOLOGY, V80, P1094, DOI 10.1097/00000542-199405000-00018; NORTH RA, 1993, OPIOIDS, V1, P773; PIOMELLI D, 1990, TRENDS PHARMACOL SCI, V11, P367, DOI 10.1016/0165-6147(90)90182-8; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; SCHWEITZER P, 1990, NATURE, V346, P464, DOI 10.1038/346464a0; SHAPIRO MS, 1994, J NEUROSCI, V14, P7109; SHIMIZU T, 1990, J NEUROCHEM, V55, P1, DOI 10.1111/j.1471-4159.1990.tb08813.x; Simmons ML, 1996, MOL PHARMACOL, V50, P80; TORTORICI V, 1995, EUR J NEUROSCI, V7, P1857, DOI 10.1111/j.1460-9568.1995.tb00706.x; Vaughan CW, 1997, J PHYSIOL-LONDON, V498, P463, DOI 10.1113/jphysiol.1997.sp021872; Vaughan CW, 1997, J NEUROSCI, V17, P996; WIMPEY TL, 1991, NEURON, V6, P281, DOI 10.1016/0896-6273(91)90363-5	22	400	415	1	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					611	614		10.1038/37610	http://dx.doi.org/10.1038/37610			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403690				2022-12-01	WOS:A1997YK85300050
J	Sharp, D				Sharp, D			Another tropical-drug donation	LANCET			English	Editorial Material									Lancet, London WC1B 3SL, England		Sharp, D (corresponding author), Lancet, London WC1B 3SL, England.							Addiss DG, 1997, LANCET, V350, P480, DOI 10.1016/S0140-6736(97)02231-9; Bloland PB, 1997, LANCET, V350, P1624, DOI 10.1016/S0140-6736(97)06082-0; Brown KR, 1997, LANCET, V349, P5	3	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					388	388		10.1016/S0140-6736(05)78352-5	http://dx.doi.org/10.1016/S0140-6736(05)78352-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482290				2022-12-01	WOS:000071982600008
J	Javaheri, S; Corbett, WS				Javaheri, S; Corbett, WS			Association of low PaCO2 with central sleep apnea and ventricular arrhythmias in ambulatory patients with stable heart failure	ANNALS OF INTERNAL MEDICINE			English	Article							PATHOGENESIS; RESPIRATION	Background: Central sleep apnea frequently occurs in patients with heart failure. Because it is not practical to perform sleep studies on all patients, readily available laboratory tests that predict sleep apnea would be clinically useful. Arterial PCO2 has a profound influence on breathing during sleep: When it decreases below a certain threshold, apnea occurs. Objective: To study the value of a low PaCO2 while patients are awake in predicting central sleep apnea in patients with stable, treated heart failure. Design: Prospective study. Setting: Referral sleep laboratory of a Department of Veterans Affairs Medical Center. Participants: 59 patients with left ventricular ejection fractions of 45% or less. Measurements: Arterial blood gases and hydrogen ion concentrations were measured, and cardiac radionuclide ventriculography, Holter monitoring, and polysomnography were done. Results: Patients were classified as eucapnic (PaCO2 > 35 and < 44 mm Hg [n = 41]) or hypocapnic (PaCO2 less than or equal to 35 mm Hg [n = 18]). The mean (+/- SD) hourly episodes of apnea or hypopnea (36 +/- 25 and 20 +/- 27; P = 0.015), the prevalence of central sleep apnea (78% and 39%; P = 0.01), and the mean hourly occurrences of ventricular tachycardia (Z +/- 3 and 0.1 +/- 0.1; P = 0.003) were significantly greater in hypocapnic patients than in eucapnic patients. Conclusion: Data on patients with heart failure in this study are consistent with the physiologic notion that a low PaCO2 results in ventilatory instability and central apnea during sleep. The positive predictive value of a low PaCO2 for central sleep apnea is 78%. The prevalence of ventricular tachycardia was 20 times greater in hypocapnic patients than in eucapnic patients.	Vet Affairs Med Ctr, Pulm Sect 111F, Cincinnati, OH 45220 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati	Javaheri, S (corresponding author), Vet Affairs Med Ctr, Pulm Sect 111F, 3200 Vine St, Cincinnati, OH 45220 USA.							AYRES SM, 1969, AM J MED, V46, P495, DOI 10.1016/0002-9343(69)90069-2; CHERNIACK NS, 1984, J CLIN INVEST, V73, P1501, DOI 10.1172/JCI111355; *EEG, 1992, SLEEP, V15, P174; Gennari FJ, 1982, ACID BASE, P349; GRINER PF, 1981, ANN INTERN MED, V94, P553, DOI 10.7326/0003-4819-94-4-571; HANLY P, 1993, CHEST, V104, P1079, DOI 10.1378/chest.104.4.1079; HANLY PJ, 1989, ANN INTERN MED, V111, P777, DOI 10.7326/0003-4819-111-10-777; JAVAHERI S, 1987, AM REV RESPIR DIS, V135, P597; Javaheri S, 1996, NEW ENGL J MED, V335, P562, DOI 10.1056/NEJM199608223350805; Javaheri S, 1996, SLEEP, V19, pS229; JAVAHERI S, 1995, ANN INTERN MED, V122, P487, DOI 10.7326/0003-4819-122-7-199504010-00002; JAVAHERI S, 1994, SLEEP, V17, P416, DOI 10.1093/sleep/17.5.416; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; NAUGHTON M, 1993, AM REV RESPIR DIS, V148, P330, DOI 10.1164/ajrccm/148.2.330; *SAS I INC, 1998, SAS STAT US GUID VER; SKATRUD JB, 1983, J APPL PHYSIOL, V55, P813, DOI 10.1152/jappl.1983.55.3.813; TAKASAKI Y, 1989, AM REV RESPIR DIS, V140, P1578, DOI 10.1164/ajrccm/140.6.1578; YAMASHIRO Y, 1993, SLEEP, V16, P513, DOI 10.1093/sleep/16.6.513	18	107	112	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1998	128	3					204	207		10.7326/0003-4819-128-3-199802010-00006	http://dx.doi.org/10.7326/0003-4819-128-3-199802010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU303	9454528				2022-12-01	WOS:000071703200005
J	Benson, FE; Baumann, P; West, SC				Benson, FE; Baumann, P; West, SC			Synergistic actions of Rad51 and Rad52 in recombination and DNA repair	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN; YEAST; COMPLEX; MOUSE; RECA; GENE; UVSY; BACTERIOPHAGE-T4; HOMOLOGS	In the yeast Saccharomyces cerevisiae, mutations in the genes RAD51 or RAD52 result in severe defects in genetic recombination and the repair of double-strand DNA breaks, These genes, and others of the RAD52 epistasis group (RAD50, RAD54, RAD55 RAD57, RAD59 MRE11 and XRS2), were first identified by their sensitivity to X-rays(1). They were subsequently shown to be required for spontaneous and induced mitotic recombination, meiotic recombination, and mating-type switching (reviewed in ref, 2), Human homologues of RAD50, RAD51, RAD52 RAD54 and MRE11 have been identified(3-6). Targeted disruption of the murine RAD51 gene results in an embryonic lethal phenotype, indicating that Rad51 protein is required during cell proliferation(7,8). Biochemical studies have shown that human RAD51 encodes a protein of relative molecular mass 36,966 (hRad51) that promotes ATP-dependent homologous pairing and DNA strand exchange(9-11), As a structural and functional homologue of the RecA protein from Escherichia coli(3,9,12), hRad51 is thought to play a central role in recombination, Yeast Rad51 has been shown to interact with Rad52 protein(13-15), as does the human homologue(16), Here we show that hRad52 stimulates homologous pairing by hRad51. The DNA-binding properties of hRad52 indicate that Rad52 is involved in an early stage of Rad51-mediated recombination.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		West, SC (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.			Baumann, Peter/0000-0003-4892-1485; West, Stephen/0000-0001-8848-9418; Benson, Fiona Elizabeth/0000-0002-3918-7015				Barlow AL, 1997, EMBO J, V16, P5207, DOI 10.1093/emboj/16.17.5207; Baumann P, 1997, MUTAT RES-DNA REPAIR, V384, P65, DOI 10.1016/S0921-8777(97)00028-1; Baumann P, 1997, EMBO J, V16, P5198, DOI 10.1093/emboj/16.17.5198; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1994, CELL, V79, P1081, DOI 10.1016/0092-8674(94)90038-8; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0165-1218(74)90185-2; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; HASHIMOTO K, 1991, J BIOL CHEM, V266, P4883; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; KODADEK T, 1989, J BIOL CHEM, V264, P16451; Lim DS, 1996, MOL CELL BIOL, V16, P7133; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Moens PB, 1997, CHROMOSOMA, V106, P207, DOI 10.1007/s004120050241; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURIS DFR, 1994, MUTAT RES-DNA REPAIR, V315, P295, DOI 10.1016/0921-8777(94)90040-X; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Plug AW, 1996, P NATL ACAD SCI USA, V93, P5920, DOI 10.1073/pnas.93.12.5920; Reddy G, 1997, MUTAT RES-FUND MOL M, V377, P53, DOI 10.1016/S0027-5107(97)00057-2; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; YONESAKI T, 1989, J BIOL CHEM, V264, P7814	26	319	340	0	23	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					401	404		10.1038/34937	http://dx.doi.org/10.1038/34937			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450758				2022-12-01	WOS:000071604200058
J	Carithers, RL				Carithers, RL			Effect of interferon on hepatitis B	LANCET			English	Editorial Material							ETIOLOGY; VIRUS		Univ Washington, Med Ctr, Dept Med, Seattle, WA 98105 USA	University of Washington; University of Washington Seattle	Carithers, RL (corresponding author), Univ Washington, Med Ctr, Dept Med, Seattle, WA 98105 USA.							BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Evans AA, 1997, J INFECT DIS, V176, P845, DOI 10.1086/516538; Lau DTY, 1997, GASTROENTEROLOGY, V113, P1660, DOI 10.1053/gast.1997.v113.pm9352870; Lau G. K. K., 1997, Hepatology, V26, p259A; LOK ASF, 1990, J HEPATOL, V10, P29, DOI 10.1016/0168-8278(90)90069-4; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	7	6	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					157	157						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449867				2022-12-01	WOS:000071616300006
J	Parker, L; Cole, M; Craft, AW; Hey, EN				Parker, L; Cole, M; Craft, AW; Hey, EN			Neonatal vitamin K administration and childhood cancer in the north of England: retrospective case-control study	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN-INFANTS; PROPHYLAXIS; LEUKEMIA; DENMARK; GERMANY; DISEASE; BIRTH; RISK	Objective: To explore the possible association between intramuscular vitamin K given to neonates and the subsequent development of childhood cancer. Design: Retrospective case-control study on the basis of hospital records. Setting: The former Northern Health region of England. Subjects: 685 children who were born and lived in the region and who developed cancer before their 15th birthday, and 3442 controls also born between 1960 and 1991 and matched only for date and hospital of birth. The notes of a further 701 index cases were untraceable. Main exposure measure: Administration of intramuscular vitamin K versus no exposure to vitamin K. Results: There was no association between the administration of vitamin K and the development of all childhood cancers (unadjusted odds ratio 0.89; 95% confidence interval 0.69 to 1.15) or for all acute lymphoblastic leukaemia (1.20; 0.75 to 1.92), but there was a raised odds ratio for acute lymphoblastic leukaemia developing 1-6 years after birth (1.79; 1.02 to 3.15). No such association was seen in a separate cohort-based study not dependent on case note retrieval in which the rates of acute lymphoblastic leukaemia in children born in hospital units where all babies received vitamin K were compared with those born in units where less than a third received prophylaxis. Conclusions: It is not possible, on the basis of currently published evidence, to refute the suggestion that neonatal intramuscular vitamin K administration increases the risk of early childhood leukaemia. Any association may have been masked in earlier studies that did not use controls matched for time and locality by other unidentified factors affecting the spatiotemporal variations in incidence of leukaemia.	Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Newcastle University - UK	Parker, L (corresponding author), Univ Newcastle Upon Tyne, Royal Victoria Infirm, Sir James Spence Inst Child Hlth, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.			PARKER, LOUISE/0000-0002-5188-8113				Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Baenziger O, 1996, LANCET, V348, P1456, DOI 10.1016/S0140-6736(04)70106-3; BRESLOW NE, 1987, IARC SCI PUBL, V82, P135; Breslow NE, 1980, IARC SCI PUBL, V32, P248; CORNELISSEN M, 1994, BMJ-BRIT MED J, V309, P1441, DOI 10.1136/bmj.309.6966.1441c; Cornelissen M, 1997, EUR J PEDIATR, V156, P126, DOI 10.1007/s004310050570; CRAFT AW, 1987, BRIT J CANCER, V56, P853, DOI 10.1038/bjc.1987.305; *DEP HLTH SOC SERV, 1988, REP HLTH SOC SUBJ, V32, P35; DRAPER G, 1995, OPCS SERIES DS, V11, P140; DRAPER GJ, 1991, GEOGRAPHICAL EPIDEMI; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P241; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GREER FR, 1997, PEDIATRICS, V99, P8; Hansen KN, 1996, ACTA PAEDIATR, V85, P1137, DOI 10.1111/j.1651-2227.1996.tb18216.x; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; LAUGHNAN PM, 1996, J PAEDIAT CHILD HLTH, V32, P251; MCNINCH A, 1996, VITAMIN K DEFICIENCY; MCNINCH AW, 1985, ARCH DIS CHILD, V60, P814, DOI 10.1136/adc.60.9.814; Nishiguchi T, 1996, BRIT J OBSTET GYNAEC, V103, P1078, DOI 10.1111/j.1471-0528.1996.tb09586.x; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; SCHUBIGER G, 1993, J PEDIATR GASTR NUTR, V16, P435, DOI 10.1097/00005176-199305000-00016; VONKRIES R, 1995, BMJ-BRIT MED J, V310, P1097, DOI 10.1136/bmj.310.6987.1097; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199; Zipursky A, 1996, BMJ-BRIT MED J, V313, P179, DOI 10.1136/bmj.313.7051.179	27	34	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					189	193						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468683	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000071616400023
J	Koehler, CM; Jarosch, E; Tokatlidis, K; Schmid, K; Schweyen, RJ; Schatz, G				Koehler, CM; Jarosch, E; Tokatlidis, K; Schmid, K; Schweyen, RJ; Schatz, G			Import of mitochondrial carriers mediated by essential proteins of the intermembrane space	SCIENCE			English	Article							ADP-ATP CARRIER; SACCHAROMYCES-CEREVISIAE; YEAST MITOCHONDRIA; INNER MEMBRANE; TRANSLOCATION; MUTAGENESIS; CONTAINS; STEPS	In order to reach the inner membrane of the mitochondrion, multispanning carrier proteins must cross the aqueous intermembrane space. Two essential proteins of that space, Tim10p and Tim12p, were shown to mediate import of multispanning carriers into the inner membrane. Both proteins formed a complex with the inner membrane protein Tim22p. Tim10p readily dissociated from the complex and was required to transport carrier precursors across the outer membrane; Tim12p was firmly bound to Tim22p and mediated the insertion of carriers into the inner membrane. Neither protein was required for protein import into the other mitochondrial compartments. Both proteins may function as intermembrane space chaperones for the highly insoluble carrier proteins.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Univ Vienna, Inst Mikrobiol & Genet, A-1030 Vienna, Austria	University of Basel; University of Vienna	Schatz, G (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 70, CH-4056 Basel, Switzerland.			Tokatlidis, Kostas/0000-0001-6295-8183; Jarosch, Ernst/0000-0002-5897-3492				ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; [Anonymous], 1991, Methods Enzymol, V194, P1; Dekker PJT, 1997, EMBO J, V16, P5408, DOI 10.1093/emboj/16.17.5408; DIETMEIER K, 1993, J BIOL CHEM, V268, P25958; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GEITZ RD, 1991, YEAST, V7, P253; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; Jarosch E, 1996, J BIOL CHEM, V271, P17219, DOI 10.1074/jbc.271.29.17219; Jarosch E, 1997, MOL GEN GENET, V255, P157, DOI 10.1007/s004380050484; KOEHLER CM, UNPUB; Komiya T, 1997, EMBO J, V16, P4267, DOI 10.1093/emboj/16.14.4267; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Pfanner N, 1996, TRENDS BIOCHEM SCI, V21, P51, DOI 10.1016/0968-0004(96)80864-4; ROSPERT S, 1994, J BIOL CHEM, V269, P17279; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; SMAGULA C, 1988, J BIOL CHEM, V263, P6783; SMAGULA CS, 1988, J CELL BIOCHEM, V36, P323, DOI 10.1002/jcb.240360402; STAPLES RR, 1993, GENETICS, V135, P981; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; WACHTER C, 1994, MOL BIOL CELL, V5, P465, DOI 10.1091/mbc.5.4.465; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; WALDHERR M, 1993, CURR GENET, V24, P301, DOI 10.1007/BF00336780	32	258	261	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					369	373		10.1126/science.279.5349.369	http://dx.doi.org/10.1126/science.279.5349.369			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430585				2022-12-01	WOS:000071570800043
J	[Anonymous]				[Anonymous]			Needle exchange programmes in the USA: time to act now	LANCET			English	Editorial Material																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 10	1998	351	9096					75	75						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439484				2022-12-01	WOS:000071591900001
J	Bloom, BR				Bloom, BR			The highest attainable standard: Ethical issues in AIDS vaccines	SCIENCE			English	Article							CONTROLLED TRIAL; PERTUSSIS		Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Bloom, BR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Howard Hughes Med Inst, Bronx, NY 10461 USA.	bloom@aecom.yu.edu						Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; *CIOMS WHO, 1982, INT ETH GUID BIOM RE; CJ Murray, 1996, GLOBAL BURDEN DIS CO, VI; Council of Europe, 1997, CONV HUM RIGHTS BIOM; deWachter MAM, 1997, HASTINGS CENT REP, V27, P13, DOI 10.2307/3528021; Dommel FW, 1997, KENNEDY INST ETHIC J, V7, P259, DOI 10.1353/ken.1997.0023; Gazzard BG, 1997, LANCET, V349, P1086, DOI 10.1016/S0140-6736(96)12073-0; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Lurie P, 1997, NEW ENGL J MED, V337, P853, DOI 10.1056/NEJM199709183371212; MELLORS JW, 1997, ANN INTERN MED, V126, P12946; *NAT COMM PROT HUM, 1988, BELM REP ETH PRINC G; RIIS P, COMMUNICATION; *UNAIDS, 1997, P M HELD 23 24 SEPT; *US PHS, 1990, CONS INT COLL HUM IM; VanHeyningen WE, 1983, CHOLERA AM SCI EXPER; Varmus H, 1997, NEW ENGL J MED, V337, P1003, DOI 10.1056/NEJM199710023371411; World Bank, 1993, WORLD DEV REP 1993 I, V1; World Medical Association, 1964, DECL HELS	20	55	56	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					186	188		10.1126/science.279.5348.186	http://dx.doi.org/10.1126/science.279.5348.186			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9446225				2022-12-01	WOS:000071408100027
J	Phelan, P; Stebbings, LA; Baines, RA; Bacon, JP; Davies, JA; Ford, C				Phelan, P; Stebbings, LA; Baines, RA; Bacon, JP; Davies, JA; Ford, C			Drosophila Shaking-B protein forms gap junctions in paired Xenopus oocytes	NATURE			English	Article							GIANT FIBER SYSTEM; SYNAPTIC CONNECTIVITY; MOLECULAR-BASIS; NERVOUS-SYSTEM; VOLTAGE; EXPRESSION; MELANOGASTER; CONNEXINS; MUTATIONS; LOCUS	In most multicellular organisms direct cell-cell communication is mediated by the intercellular channels of gap junctions. These channels allow the exchange of ions and molecules that are believed to be essential for cell signalling during development and in some differentiated tissues, Proteins called connexins, which are products of a multigene family, are the structural components of vertebrate gap junctions(1,2). Surprisingly, molecular homologues of the connexins have not been described in any invertebrate. A separate gene family, which includes the Drosophila genes shaking-B and l(1)ogre, and the Caenorhabditis elegans genes unc-7 and eat-5, encodes transmembrane proteins with a predicted structure similar to that of the connexins(3-9). shaking-B and eat-5 are required for the formation of functional gap junctions(8,10). To test directly whether Shaking-B is a channel protein, we expressed it in paired Xenopus oocytes. Here we show that Shaking-B localizes to the membrane, and that its presence induces the formation of functional intercellular channels. To our knowledge, this is the first structural component of an invertebrate gap junction to be characterized.	Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Brighton BN1 9QG, E Sussex, England; Univ Sussex, Sch Biol Sci, Dept Genet & Dev, Brighton BN1 9QG, E Sussex, England	University of Sussex; University of Sussex	Phelan, P (corresponding author), Univ Sussex, Sch Biol Sci, Sussex Ctr Neurosci, Brighton BN1 9QG, E Sussex, England.	bafb5@central.sussex.ac.uk		Phelan, Pauline/0000-0002-9348-837X; Baines, Richard/0000-0001-8571-4376				BARNES TM, 1994, TRENDS GENET, V10, P303, DOI 10.1016/0168-9525(94)90023-X; BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; BRUZZONE R, 1995, FEBS LETT, V358, P301, DOI 10.1016/0014-5793(94)01457-C; BRUZZONE R, 1994, J CELL SCI, V107, P955; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CHEVALIER S, 1995, J CELL SCI, V108, P1831; COLMAN A, 1984, TRANSCRIPTION TRANSL, P271; CROMPTON D, 1995, DEV BIOL, V170, P142, DOI 10.1006/dbio.1995.1203; EBIHARA L, 1989, SCIENCE, V243, P1194, DOI 10.1126/science.2466337; GHO M, 1994, J PHYSIOL-LONDON, V481, P371, DOI 10.1113/jphysiol.1994.sp020446; HANSEN P, 1981, STAIN TECHNOL, V56, P287; HENNEMANN H, 1992, J BIOL CHEM, V267, P17225; HOMYK T, 1980, MOL GEN GENET, V177, P553; KRISHNAN SN, 1993, CELL, V73, P967, DOI 10.1016/0092-8674(93)90274-T; KRISHNAN SN, 1995, P NATL ACAD SCI USA, V92, P2021, DOI 10.1073/pnas.92.6.2021; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; Phelan P, 1996, J NEUROSCI, V16, P1101; SPRAY DC, 1981, J GEN PHYSIOL, V77, P77, DOI 10.1085/jgp.77.1.77; Starich TA, 1996, J CELL BIOL, V134, P537, DOI 10.1083/jcb.134.2.537; STARICH TA, 1993, GENETICS, V133, P527; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; THOMAS JB, 1984, J NEUROSCI, V4, P530; VERSELIS VK, 1991, BIOPHYS J, V59, P114, DOI 10.1016/S0006-3495(91)82204-4; WATANABE T, 1990, GENETICS, V126, P1033; WILDERS R, 1992, BIOPHYS J, V63, P942, DOI 10.1016/S0006-3495(92)81664-8; Willecke K, 1996, J BIOENERG BIOMEMBR, V28, P319, DOI 10.1007/BF02110108	26	132	139	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 8	1998	391	6663					181	184		10.1038/34426	http://dx.doi.org/10.1038/34426			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428764				2022-12-01	WOS:000071380900052
J	Annegers, JF; Hauser, WA; Coan, SP; Rocca, WA				Annegers, JF; Hauser, WA; Coan, SP; Rocca, WA			A population-based study of seizures after traumatic brain injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPILEPSY	Background The risk of seizures is increased after traumatic brain injury, but the extent and duration of the increase in risk are unknown. The purpose of this study was to identify the characteristics of brain injuries that are associated with the development of seizures. Methods We identified 4541 children and adults with traumatic brain injury (characterized by loss of consciousness, post-traumatic amnesia, or skull fracture) in Olmsted County, Minnesota, during the period from 1935 through 1984. Injuries were classified as mild (loss of consciousness or amnesia lasting less than 30 minutes), moderate (loss of consciousness for 30 minutes to 24 hours or a skull fracture), or severe (loss of consciousness or amnesia for more than 24 hours, subdural hematoma, or brain contusion). We compared the incidence of new unprovoked seizures in this cohort with population rates, using standardized incidence ratios and Cox proportional-hazards analysis. Results The overall standardized incidence ratio was 3.1 (95 percent confidence interval, 2.5 to 3.8). The standardized incidence ratio was 1.5 (95 percent confidence interval, 1.0 to 2.2) after mild injuries but with no increase over the expected number after five years, 2.9 (95 percent confidence interval, 1.9 to 4.1) after moderate injuries, and 17.0 (95 percent confidence interval, 12.3 to 23.6) after severe injuries, In the multivariate analysis, significant risk factors for later seizures were brain contusion with subdural hematoma, skull fracture, loss of consciousness or amnesia for more than one day, and an age of 65 years or older. Conclusions The increased risk of seizures after traumatic brain injury varies greatly according to the severity of the injury and the time since the injury. (C) 1998, Massachusetts Medical Society.	Univ Texas, Sch Publ Hlth, Houston, TX 77225 USA; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; Columbia University; Mayo Clinic	Annegers, JF (corresponding author), Univ Texas, Sch Publ Hlth, POB 20186, Houston, TX 77225 USA.		Hauser, W Allen/AAB-5277-2020; Ritter, Stefanie L/D-9312-2012; Rocca, Walter/Z-5335-2019		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR30582] Funding Source: Medline; NINDS NIH HHS [NS16308] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1988, NEUROLOGY, V38, P1407, DOI 10.1212/WNL.38.9.1407; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1976, EPILEPSIA, V17, P1, DOI 10.1111/j.1528-1157.1976.tb03375.x; HAUSER WA, 1993, EPILEPSIA, V34, P453, DOI 10.1111/j.1528-1157.1993.tb02586.x; Jennett B., 1975, EPILEPSY NONMISSILE, V2nd; KLEINBAUM DG, 1986, EPIDEMIOLOGIC RES PR, P103; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; PENFIELD W, 1945, RES PUBL ASSOC RES N, V24, P620; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; *STATACORP, 1997, STATA REF MAN REL 5, V1; WALKER AE, 1989, SURG NEUROL, V32, P235, DOI 10.1016/0090-3019(89)90185-7; WEISS GH, 1983, ARCH NEUROL-CHICAGO, V40, P7, DOI 10.1001/archneur.1983.04050010027006	12	642	668	0	33	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					20	24		10.1056/NEJM199801013380104	http://dx.doi.org/10.1056/NEJM199801013380104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414327				2022-12-01	WOS:000071209200004
J	Savchenko, A; Barnes, S; Kramer, RH				Savchenko, A; Barnes, S; Kramer, RH			Cyclic-nucleotide-gated channels mediate synaptic feedback by nitric oxide	NATURE			English	Article							EXCITATORY AMINO-ACIDS; CONE PHOTORECEPTORS; HIPPOCAMPAL-NEURONS; GUANYLYL CYCLASE; HORIZONTAL CELLS; TURTLE RETINA; RELEASE; CALCIUM; GMP; TRANSMISSION	Cyclic-nucleotide-gated (CNG) channels in outer segments of vertebrate photoreceptors generate electrical signals in response to changes in cyclic GMP concentration during phototransduction(1). CNG channels also allow the influx of Ca2+, which is essential for photoreceptor adaptation(2). In cone photoreceptors, cGMP triggers an increase in membrane capacitance indicative of exocytosis, suggesting that CNG channels are also involved in synaptic function(3), Here we examine whether CNG channels reside in cone terminals and whether they regulate neurotransmitter release, specifically in response to nitric oxide (NO), a retrograde transmitter that increases cGMP synthesis and potentiates synaptic transmission in the brain(4-6). Using intact retina, we show that endogenous NO modulates synapses between cones and horizontal cells. In experiments on isolated cones, we show directly that CNG channels occur in dusters and are indirectly activated by S-nitrosocysteine (SNC), an NO donor. Furthermore, both SNC and pCPT-cGMP, a membrane-permeant analogue of cGMP, trigger the release of transmitter from the cone terminals, The NO-induced transmitter release is suppressed by guanylate cyclase inhibitors and prevented by direct activation of CNG channels, indicating that their activation is required for NO to elicit release. These results expand our view of CNG channel function to include the regulation of synaptic transmission and mediation of the presynaptic effects of NO.	UNIV MIAMI,SCH MED,DEPT MOL & CELLULAR PHARMACOL,MIAMI,FL 33101; UNIV CALGARY,NEUROSCI RES GRP,CALGARY,AB T2N 4N1,CANADA	University of Miami; University of Calgary					NATIONAL EYE INSTITUTE [P30EY003176] Funding Source: NIH RePORTER; NEI NIH HHS [P30 EY003176] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ARANCIO O, 1995, NATURE, V376, P74, DOI 10.1038/376074a0; BARNES S, 1992, J NEUROPHYSIOL, V68, P745, DOI 10.1152/jn.1992.68.3.745; BARNES S, 1989, J GEN PHYSIOL, V94, P719, DOI 10.1085/jgp.94.4.719; BAYLOR DA, 1971, J PHYSIOL-LONDON, V214, P265, DOI 10.1113/jphysiol.1971.sp009432; Bradley J, 1997, J NEUROSCI, V17, P1993; Broillet MC, 1996, NEURON, V16, P377, DOI 10.1016/S0896-6273(00)80055-0; COPENHAGEN DR, 1989, NATURE, V341, P536, DOI 10.1038/341536a0; DIXON DB, 1997, IN PRESS J NEUROSCI; Finn JT, 1996, ANNU REV PHYSIOL, V58, P395, DOI 10.1146/annurev.ph.58.030196.002143; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; HORN R, 1991, BIOPHYS J, V60, P433, DOI 10.1016/S0006-3495(91)82069-0; Kingston PA, 1996, P NATL ACAD SCI USA, V93, P10440, DOI 10.1073/pnas.93.19.10440; KOCH KW, 1994, EMBO J, V13, P3312, DOI 10.1002/j.1460-2075.1994.tb06633.x; Koutalos Y, 1996, TRENDS NEUROSCI, V19, P73; KURENNY DR, 1995, NEURON, V13, P315; LIEPE BA, 1994, J NEUROSCI, V14, P7641; MARICQ AV, 1988, NEURON, V1, P503, DOI 10.1016/0896-6273(88)90181-X; MEFFERT MK, 1994, NEURON, V12, P1235, DOI 10.1016/0896-6273(94)90440-5; MULSCH A, 1988, J PHARMACOL EXP THER, V247, P282; NORMANN RA, 1979, J PHYSIOL-LONDON, V286, P509, DOI 10.1113/jphysiol.1979.sp012634; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; PICCOLINO M, 1981, J NEUROPHYSIOL, V45, P363, DOI 10.1152/jn.1981.45.3.363; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; TACHIBANA M, 1991, J NEUROSCI, V11, P2199; WATANABE SI, 1988, J NEUROSCI, V8, P2334; Wilkinson MF, 1996, J GEN PHYSIOL, V107, P621, DOI 10.1085/jgp.107.5.621; WU SM, 1994, ANNU REV PHYSIOL, V56, P141; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289; ZIMMERMAN AL, 1985, P NATL ACAD SCI USA, V82, P8813, DOI 10.1073/pnas.82.24.8813	31	152	159	1	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					694	698		10.1038/37803	http://dx.doi.org/10.1038/37803			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414163	Green Accepted			2022-12-01	WOS:A1997YM50800034
J	Egeland, GM; Middaugh, JP				Egeland, GM; Middaugh, JP			Balancing fish consumption benefits with mercury exposure	SCIENCE			English	Editorial Material							FETAL METHYLMERCURY; DIET				Egeland, GM (corresponding author), ALASKA DEPT HLTH & SOCIAL SERV,DIV PUBL HLTH,EPIDEMIOL SECT,ANCHORAGE,AK 99524, USA.							Anderson Paul D., 1995, P104; BAKIR F, 1973, SCIENCE, V181, P230, DOI 10.1126/science.181.4096.230; BANG HO, 1971, LANCET, V1, P1143, DOI 10.1016/S0140-6736(71)91658-8; Bauernfeind J., 1980, Vitamin E, P99; CRUMP K, 1995, RISK ANAL, V15, P523, DOI 10.1111/j.1539-6924.1995.tb00345.x; DAHL R, 1996, NEUROTOXICOL TERATOL, V18, P1; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; *EPA, 1996, EPA452R96001F; GRANDJEAN P, 1995, NEUROTOXICOLOGY, V16, P27; GRANDJEAN P, 1994, CLIN CHEM, V40, P1395; GRANDJEAN P, 1992, ARCH ENVIRON HEALTH, V47, P185, DOI 10.1080/00039896.1992.9938348; GRANDJEAN P, 1997, NEUROTOXICOL TERATOL, V20, P1; Hansen J.C., 1989, Meddelelser om Gronland Man & Society, V12, P161; HOLMAN RT, 1991, P NATL ACAD SCI USA, V88, P4835, DOI 10.1073/pnas.88.11.4835; Kinsella JE., 1987, SEAFOODS FISH OILS H; Marsh DO, 1995, NEUROTOXICOLOGY, V16, P717; MARSH DO, 1987, ARCH NEUROL-CHICAGO, V44, P1017, DOI 10.1001/archneur.1987.00520220023010; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P629; *NIH, 1995, EFF FISH OILS POL OM; Shkilnyk A., 1985, POISON STRONGER THAN; SIU KWM, 1989, OCCURRENCE DISTRIBUT, P263; SKERFVING SB, 1976, B WORLD HEALTH ORGAN, V54, P101; TOLLEFSON L, 1986, ENVIRON HEALTH PERSP, V68, P203, DOI 10.2307/3430265; UAUYDAGACH R, 1995, CLIN PERINATOL, V22, P157; USHER PJ, 1995, COMMUNICATING CONTAM; WHEATLEY B, 1994, ARCT MED RES S2, V53, P386; WHO, 1990, ENV HLTH CRIT, V101	27	117	124	2	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 12	1997	278	5345					1904	1905		10.1126/science.278.5345.1904	http://dx.doi.org/10.1126/science.278.5345.1904			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YL002	9417640				2022-12-01	WOS:A1997YL00200023
J	Lee, DH; Severin, K; Yokobayashi, Y; Ghadiri, MR				Lee, DH; Severin, K; Yokobayashi, Y; Ghadiri, MR			Emergence of symbiosis in peptide self-replication through a hypercyclic network	NATURE			English	Article							COILED-COILS; ORGANIZATION; PRINCIPLE; EVOLUTION; SYSTEM; RNA	Symbiosis is an association between different organisms that leads to a reciprocal enhancement of their ability to survive, Similar mutually beneficial relationships can operate at the molecular level in the form of a hypercycle, a collective of two or more self-replicating species interlinked through a cyclic catalytic network(1-5). The superposition of cross-catalysis onto autocatalytic replication integrates the members of the hypercycle into a single system that reproduces through a second-order (or higher) form of nonlinear autocatalysis. The hypercycle population as a whole is therefore able to compete more efficiently for existing resources than any one member on its own. In addition, the effects of beneficial mutations of any one member are spread over the entire population, The formation of hypercycles has been suggested as an important step in the transition from inanimate to living chemistry(6), and a large number of hypercycles are expected to be embedded within the complex networks of living systems(7). But only one naturally occurring hypercycle has been well documented(8), while two autocatalytic chemical systems may contain vestiges of hypercyclic organization(9,10). Here we report a chemical system that constitutes a dear example of a minimal hypercyclic network, in which two otherwise competitive self-replicating peptides symbiotically catalyse each others' production.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, SKAGGS INST CHEM BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute			Yokobayashi, Yohei/B-5898-2009	Yokobayashi, Yohei/0000-0002-2417-1934; Severin, Kay/0000-0003-2224-7234				ACHILLES T, 1993, ANGEW CHEM INT EDIT, V32, P1198, DOI 10.1002/anie.199311981; EIGEN M, 1978, NATURWISSENSCHAFTEN, V65, P341, DOI 10.1007/BF00439699; EIGEN M, 1991, BIOCHEMISTRY-US, V30, P11005, DOI 10.1021/bi00110a001; EIGEN M, 1977, NATURWISSENSCHAFTEN, V64, P541, DOI 10.1007/BF00450633; EIGEN M, 1971, NATURWISSENSCHAFTEN, V58, P465, DOI 10.1007/BF00623322; EIGEN M, 1978, NATURWISSENSCHAFTEN, V65, P7, DOI 10.1007/BF00420631; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HONG JI, 1992, SCIENCE, V255, P848, DOI 10.1126/science.255.5046.848; HU JC, 1990, SCIENCE, V250, P1400, DOI 10.1126/science.2147779; JOYCE GF, 1989, NATURE, V338, P217, DOI 10.1038/338217a0; Kauffman S.A., 1993, ORIGINS ORDER; KUPPERS BO, 1990, ORIGIN BIOL INFORMAT; Lee DH, 1996, NATURE, V382, P525, DOI 10.1038/382525a0; LEE DH, IN PRESS CURR OPIN C; MULLERHEROLD U, 1983, J THEOR BIOL, V102, P569, DOI 10.1016/0022-5193(83)90391-0; RICARD J, 1986, EUR J BIOCHEM, V155, P183, DOI 10.1111/j.1432-1033.1986.tb09475.x; Severin K, 1997, NATURE, V389, P706, DOI 10.1038/39556; Severin K, 1997, CHEM-EUR J, V3, P1017, DOI 10.1002/chem.19970030706; SEVERIN K, IN PRESS ANGEW CHEM; von Kiedrowski G., 1993, BIOORG CHEM FRONT, V3, P113	20	194	200	2	50	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					591	594		10.1038/37569	http://dx.doi.org/10.1038/37569			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403686				2022-12-01	WOS:A1997YK85300043
J	Basso, O; Olsen, J; Johansen, AMT; Christensen, K				Basso, O; Olsen, J; Johansen, AMT; Christensen, K			Change in social status and risk of low birth weight in Denmark: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							FOR-GESTATIONAL-AGE; HEALTH; SMOKING	Objective: To estimate the risk of having a low birth-weight infant associated with changes in social, environmental, and genetic factors. Design: Population based, historical cohort study using the Danish medical birth registry and Statistic Denmark's fertility database. Subjects: All women who had a low birthweight infant (<2500 g) (index birth) and a subsequent liveborn infant (outcome birth) in Denmark between 1980 and 1992 (exposed cohort, n = 11 069) and a random sample of the population who gave birth to an infant weighing greater than or equal to 2500 g and to a subsequent liveborn infant (unexposed cohort, n = 10 211), Main outcome measures: Risk of having a low birthweight infant in the outcome birth as a function of changes in male partner, area of residence, type of job, and social status between the two births. Results: Women in the exposed cohort showed a high risk (18.5%) of having a subsequent low birthweight infant while women in the unexposed cohort had a risk of 2.8%. After adjustment for initial social status, a decline in social statics increased the absolute risk of having a low birthweight infant by about 5% in both cohorts, though this was significant only in the unexposed cohort, Change of male partner did not modify the risk of low birth weight in either cohort. Conclusion: Having had a low birthweight infant and a decline in social status are strong risk factors for having a low birthweight infant subsequently.	DANISH NATL BOARD HLTH,COPENHAGEN,DENMARK; ODENSE UNIV,CTR HLTH & SOCIAL POLICY,DK-5230 ODENSE M,DENMARK	University of Southern Denmark	Basso, O (corresponding author), AARHUS UNIV,DANISH EPIDEMIOL SCI CTR,DEPT EPIDEMIOL & SOCIAL MED,GULDBERGSGADE 10,DK-8000 AARHUS C,DENMARK.		Basso, Olga/E-5384-2010; Christensen, Kaare/C-2360-2009	Basso, Olga/0000-0001-9298-4921; Christensen, Kaare/0000-0002-5429-5292				BAKKETEIG LS, 1979, AM J OBSTET GYNECOL, V135, P1086, DOI 10.1016/0002-9378(79)90742-7; BAKKETEIG LS, 1986, EARLY HUM DEV, V14, P187, DOI 10.1016/0378-3782(86)90180-5; Bartley M, 1996, BRIT MED J, V313, P445; *DANM STAT, 1996, FERT DAT; *DANM STAT, 1986, DANM STAT ERHV 1 APR; KLINE J, 1989, CONCEPTION BIRTH EPI, P231; KNUDSEN LB, 1993, VITALSTATISTIK, V1, P33; LAHELMA E, 1989, UNEMPLOYMENT POVERTY, P135; LIE RT, 1994, NEW ENGL J MED, V331, P1, DOI 10.1056/NEJM199407073310101; MacGillivray I, 1988, TWINNING TWINS; MORRISON J, 1991, AUST NZ J OBSTET GYN, V31, P114, DOI 10.1111/j.1479-828X.1991.tb01795.x; MORTON NE, 1955, ANN HUM GENET, V20, P125; MUTALE T, 1991, BRIT J OBSTET GYNAEC, V98, P166, DOI 10.1111/j.1471-0528.1991.tb13363.x; Nordentoft M, 1996, AM J PUBLIC HEALTH, V86, P347, DOI 10.2105/AJPH.86.3.347; NORDSTROM ML, 1996, SCAND J SOC MED, V1, P55; OLSEN J, 1993, SCAND J SOC MED, V21, P90, DOI 10.1177/140349489302100206; Olsen J, 1997, EPIDEMIOLOGY, V8, P6, DOI 10.1097/00001648-199701000-00001; Power C, 1996, BRIT MED J, V313, P449; RAINE T, 1994, OBSTET GYNECOL, V84, P485; Read A W, 1993, Paediatr Perinat Epidemiol, V7, P177, DOI 10.1111/j.1365-3016.1993.tb00392.x; Read A W, 1991, Paediatr Perinat Epidemiol, V5, P138, DOI 10.1111/j.1365-3016.1991.tb00695.x; RUSH D, 1983, J EPIDEMIOL COMMUN H, V37, P249, DOI 10.1136/jech.37.4.249; *SUNDH, 1995, MED FODS 1993, P2; VLIETINCK R, 1989, BEHAV GENET, V19, P151, DOI 10.1007/BF01065890; Wang XB, 1995, NEW ENGL J MED, V333, P1744, DOI 10.1056/NEJM199512283332606; WILCOX MA, 1995, ACTA OBSTET GYN SCAN, V74, P15, DOI 10.3109/00016349509009936	26	29	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1498	1502		10.1136/bmj.315.7121.1498	http://dx.doi.org/10.1136/bmj.315.7121.1498			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YK986	9420490	Green Published			2022-12-01	WOS:A1997YK98600019
J	Gilbert, SC; Plebanski, M; Gupta, S; Morris, J; Cox, M; Aidoo, M; Kwiatkowski, D; Greenwood, BM; Whittle, HC; Hill, AVS				Gilbert, SC; Plebanski, M; Gupta, S; Morris, J; Cox, M; Aidoo, M; Kwiatkowski, D; Greenwood, BM; Whittle, HC; Hill, AVS			Association of malaria parasite population structure, HLA, and immunological antagonism	SCIENCE			English	Article							T-CELL EPITOPES; PLASMODIUM-FALCIPARUM; CIRCUMSPOROZOITE PROTEIN; PEPTIDE; POLYMORPHISM; RESPONSES; VARIANTS; VACCINE; VIRUS; BLOOD	Host-parasite coevolution has been likened to a molecular arms race, with particular parasite genes evolving to evade specific host defenses, Study of the variants of an antigenic epitope of Plasmodium falciparum that induces a cytotoxic T cell response supports this view, In African children with malaria, the variants present are influenced by the presence of a human leukocyte antigen (HLA) type that restricts the immune response to this epitope. The distribution of parasite variants may be further influenced by the ability of cohabiting parasite strains to facilitate each other's survival by down-regulating cellular immune responses, using altered peptide ligand antagonism.	Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, John Radcliffe Hosp, Nuffield Dept Med, Inst Mol Med,Mol Immunol Grp, Oxford OX3 9DU, England; Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol Infect Dis, Oxford OX1 3PS, England; Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Sci, London WC1E 7HT, England; MRC Labs, Fajara, Senegal	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Hill, AVS (corresponding author), Univ Oxford, Nuffield Dept Med, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		HILL, Adrian V>S>/C-1306-2008; Plebanski, Magdalena/AAU-3144-2021; Gilbert, Sarah C./H-2857-2019	Gilbert, Sarah C./0000-0002-6823-9750; , Magdalena/0000-0001-6889-3667; Kwiatkowski, Dominic/0000-0002-5023-0176	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Aidoo M, 1997, INT IMMUNOL, V9, P731, DOI 10.1093/intimm/9.5.731; AIDOO M, 1995, LANCET, V345, P1003, DOI 10.1016/S0140-6736(95)90754-8; BABIKER HA, 1994, PARASITOLOGY, V109, P413, DOI 10.1017/S0031182000080665; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; CONWAY DJ, 1991, PARASITOLOGY, V1, P1; DAVENPORT MP, 1995, IMMUNOL TODAY, V16, P432, DOI 10.1016/0167-5699(95)80020-4; Dong T, 1996, EUR J IMMUNOL, V26, P335, DOI 10.1002/eji.1830260210; ELVIN J, 1991, EUR J IMMUNOL, V21, P2025, DOI 10.1002/eji.1830210909; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; KLENERMAN P, 1995, EUR J IMMUNOL, V25, P1927, DOI 10.1002/eji.1830250720; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; LALVANI A, 1994, RES IMMUNOL, V145, P461, DOI 10.1016/S0923-2494(94)80177-0; LOCKYER MJ, 1989, MOL BIOCHEM PARASIT, V37, P275, DOI 10.1016/0166-6851(89)90159-X; Nei M., 1987, MOL EVOLUTIONARY GEN; PAUL REL, 1995, SCIENCE, V269, P1709, DOI 10.1126/science.7569897; PLEBANSKI M, 1995, EUR J IMMUNOL, V25, P1783, DOI 10.1002/eji.1830250645; Plebanski M, 1997, J IMMUNOL, V158, P2849; PLEBANSKI M, UNPUB; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; SNOKE K, 1993, J IMMUNOL, V151, P6815; THURSZ MR, 1995, NEW ENGL J MED, V332, P1065, DOI 10.1056/NEJM199504203321604; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; YOSHIDA N, 1990, EXP PARASITOL, V71, P386, DOI 10.1016/0014-4894(90)90064-J	25	225	229	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1173	1177		10.1126/science.279.5354.1173	http://dx.doi.org/10.1126/science.279.5354.1173			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469800				2022-12-01	WOS:000072115200032
J	Swain, A; Narvaez, S; Burgoyne, P; Camerino, G; Lovell-Badge, R				Swain, A; Narvaez, S; Burgoyne, P; Camerino, G; Lovell-Badge, R			Dax1 antagonizes Sry action in mammalian sex determination	NATURE			English	Article							ADRENAL HYPOPLASIA CONGENITA; HORMONE-RECEPTOR SUPERFAMILY; DETERMINING GENE; CAMPOMELIC DYSPLASIA; DETERMINING REGION; Y-CHROMOSOME; HYPOGONADOTROPIC HYPOGONADISM; REVERSAL; EXPRESSION; MICE	DAX1, which encodes an unusual member of the nuclear hormone-receptor superfamily, is a gene that may be responsible for a sex-reversal syndrome in humans, referred to as dosage-sensitive sex reversal, in which XY individuals carrying duplications of Xp21, part of the small arm of the X chromosome, develop as females, XY mice carrying extra copies of mouse Dax1 as a transgene show delayed testis development when the gene Is expressed at high levels, but do not normally show sex reversal. Complete sex reversal occurs, however, when the transgene is tested against weak alleles of the sex-determining Y-chromosome gene Sry, These results show that DAX1 is largely, if not solely, responsible for dosage-sensitive sex reversal and provide a model for early events in mammalian sex determination, when precise levels and timing of gene expression are critical.	Natl Inst Med Res, MRC, Div Dev Genet, London NW7 1AA, England; Univ Autonoma Estad Morelos, Fac Ciencias, Cuernavaca 62210, Morelos, Mexico; Univ Pavia, I-27100 Pavia, Italy	MRC National Institute for Medical Research; Universidad Autonoma del Estado de Morelos; University of Pavia	Lovell-Badge, R (corresponding author), Natl Inst Med Res, MRC, Div Dev Genet, Ridgeway,Mill Hill, London NW7 1AA, England.			Narvaez Padilla, Veronica/0000-0002-3484-1612; Lovell-Badge, Robin/0000-0001-9364-4179; Swain, Amanda/0000-0001-8666-1608	Medical Research Council [MC_U117562207] Funding Source: Medline; Telethon [B.38] Funding Source: Medline; MRC [MC_U117562207] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Telethon(Fondazione Telethon); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BARDONI B, 1994, NAT GENET, V7, P497, DOI 10.1038/ng0894-497; CAPEL B, 1993, NAT GENET, V5, P301, DOI 10.1038/ng1193-301; CAPEL B, 1993, ADV DEV BIOL, V2, P1; CLEPET C, 1993, HUM MOL GENET, V2, P2007, DOI 10.1093/hmg/2.12.2007; COWARD P, 1994, NAT GENET, V6, P245, DOI 10.1038/ng0394-245; DABOVIC B, 1995, MAMM GENOME, V6, P571, DOI 10.1007/BF00352360; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; DUBIN RA, 1994, MOL ENDOCRINOL, V8, P1182, DOI 10.1210/me.8.9.1182; Eicher EM, 1995, PHILOS T R SOC B, V350, P263, DOI 10.1098/rstb.1995.0160; Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206; EICHER EM, 1982, SCIENCE, V217, P535, DOI 10.1126/science.7089579; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Graves JAM, 1995, PHILOS T R SOC B, V350, P305, DOI 10.1098/rstb.1995.0166; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; GUO WW, 1995, BIOCHEM MOL MED, V56, P8, DOI 10.1006/bmme.1995.1049; HACKER A, 1995, DEVELOPMENT, V121, P1603; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; HAWKINS JR, 1994, HUM MOL GENET, V3, P1463, DOI 10.1093/hmg/3.suppl_1.1463; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1993, MOL ENDOCRINOL, V7, P852, DOI 10.1210/me.7.7.852; Ikeda Y, 1996, MOL ENDOCRINOL, V10, P1261, DOI 10.1210/me.10.10.1261; Ito M, 1997, MOL CELL BIOL, V17, P1476, DOI 10.1128/MCB.17.3.1476; JESKE YWA, 1995, NAT GENET, V10, P480, DOI 10.1038/ng0895-480; Kent J, 1996, DEVELOPMENT, V122, P2813; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; KWOK C, 1995, AM J HUM GENET, V57, P1028; LovellBadge R, 1995, PHILOS T R SOC B, V350, P205, DOI 10.1098/rstb.1995.0153; LOVELLBADGE R, 1993, PHILOS T R SOC B, V339, P159, DOI 10.1098/rstb.1993.0012; LOVELLBADGE R, 1990, DEVELOPMENT, V109, P635; MCLAREN A, 1991, BIOESSAYS, V13, P151, DOI 10.1002/bies.950130402; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; NARVAEZ V, 1996, THESIS U LONDON; PALMER SJ, 1991, DEVELOPMENT, V113, P709; PALMER SJ, 1991, DEVELOPMENT, V112, P265; Pask A, 1997, GENOMICS, V41, P422, DOI 10.1006/geno.1997.4651; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Poulat F, 1997, J BIOL CHEM, V272, P7167, DOI 10.1074/jbc.272.11.7167; Renfree MB, 1995, PHILOS T R SOC B, V350, P243, DOI 10.1098/rstb.1995.0158; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SMITH RL, 1995, J VIROL, V69, P4593, DOI 10.1128/JVI.69.8.4593-4599.1995; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tamai KT, 1996, MOL ENDOCRINOL, V10, P1561, DOI 10.1210/me.10.12.1561; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0	50	417	442	2	21	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					761	767		10.1038/35799	http://dx.doi.org/10.1038/35799			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486644				2022-12-01	WOS:000072089500043
J	Katz, BA; Clark, JM; Finer-Moore, JS; Jenkins, TE; Johnson, CR; Ross, MJ; Luong, C; Moore, WR; Stroud, RM				Katz, BA; Clark, JM; Finer-Moore, JS; Jenkins, TE; Johnson, CR; Ross, MJ; Luong, C; Moore, WR; Stroud, RM			Design of potent selective zinc-mediated serine protease inhibitors	NATURE			English	Article							COMPLEX; BINDING; TRYPSIN; BIS(5-AMIDINO-2-BENZIMIDAZOLYL)METHANE; DERIVATIVES; CHEMISTRY; AMIDINES; MODEL	Many serine proteases are targets for therapeutic intervention because they often play key roles in disease(1). Small molecule inhibitors of serine proteases with high affinity are especially interesting as they could be used as scaffolds from which to develop drugs selective for protease targets. One such inhibitor is bis(5-amidino-2-benzimidazolyl)methane (BABIM), standing out as the best inhibitor of trypsin (by a factor of over 100) in a series of over 60 relatively closely related analogues(2-4). By probing the structural basis of inhibition, we discovered, using crystallographic methods, a new mode of high-affinity binding in which a Zn2+ ion is tetrahedrally coordinated between two chelating nitrogens of BABIM and two active site residues, His 57 and Ser 195. Zn2+, at subphysiological levels, enhances inhibition by over 10(3)-fold. The distinct Zn2+ coordination geometry implies a strong dependence of affinity on substituents. This unique structural paradigm has enabled development of potent, highly selective, Zn2+-dependent inhibitors of several therapeutically important serine proteases, using a physiologically ubiquitous metal ion.	Arris Pharmaceut Corp, S San Francisco, CA 94080 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Katz, BA (corresponding author), Arris Pharmaceut Corp, 385 Oyster Point Blvd,Suite 3, S San Francisco, CA 94080 USA.		Stroud, Rhonda M./C-5503-2008; Stroud, Rhonda/GQZ-0151-2022	Stroud, Rhonda M./0000-0001-5242-8015; Stroud, Rhonda/0000-0001-5242-8015				BernersPrice SJ, 1996, COORDIN CHEM REV, V151, P1; Brinen LS, 1996, BIOCHEMISTRY-US, V35, P5999, DOI 10.1021/bi9530200; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, XPLOR MANUAL VERSION; CAUGHEY GH, 1993, J PHARMACOL EXP THER, V264, P676; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; GROVES JT, 1985, INORG CHEM, V24, P2715, DOI 10.1021/ic00212a001; HAMBRIDGE KM, 1996, TRACE ELEMENTS HUMAN, V2; IPPOLITO JA, 1990, J MOL BIOL, V215, P457, DOI 10.1016/S0022-2836(05)80364-X; JENNETTE JC, 1987, AM J PATHOL, V127, P499; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KATZ BA, 1995, BIOCHEMISTRY-US, V34, P8264, DOI 10.1021/bi00026a008; Katz BA, 1997, J BIOL CHEM, V272, P13220, DOI 10.1074/jbc.272.20.13220; KIMURA E, 1990, J AM CHEM SOC, V112, P5805, DOI 10.1021/ja00171a020; KRIEGER M, 1974, J MOL BIOL, V83, P209, DOI 10.1016/0022-2836(74)90388-X; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; LENTER C, 1984, GEIGY SCI TABLES, V3; Lippard S. J., 1994, BIOINORG CHEM, P505; Lipscomb WN, 1996, CHEM REV, V96, P2375, DOI 10.1021/cr950042j; Matthews DJ, 1994, CHEM BIOL, V1, P25, DOI 10.1016/1074-5521(94)90037-X; McGrath ME, 1997, FEBS LETT, V413, P486, DOI 10.1016/S0014-5793(97)00962-9; PERONA JJ, 1995, PROTEIN SCI, V4, P337; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STROUD RM, 1974, SCI AM, V231, P74, DOI 10.1038/scientificamerican0774-74; TANAKA RD, 1995, INT ARCH ALLERGY IMM, V107, P408, DOI 10.1159/000237056; TIDWELL RR, 1983, J MED CHEM, V26, P294, DOI 10.1021/jm00356a036; TIDWELL RR, 1978, J MED CHEM, V21, P613, DOI 10.1021/jm00205a005; TIDWELL RR, 1984, ANTIMICROB AGENTS CH, V26, P591, DOI 10.1128/AAC.26.4.591; Tong L, 1996, NATURE, V383, P272, DOI 10.1038/383272a0; VEDANI A, 1990, J AM CHEM SOC, V112, P4759, DOI 10.1021/ja00168a021	30	155	167	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					608	612		10.1038/35422	http://dx.doi.org/10.1038/35422			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468142				2022-12-01	WOS:000071842300058
J	Holmberg, SD; Moorman, AC; Von Bargen, J; Palella, FJ; Loveless, MO; Ward, DJ; Navin, TR				Holmberg, SD; Moorman, AC; Von Bargen, J; Palella, FJ; Loveless, MO; Ward, DJ; Navin, TR		HOPS Investigators	Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTESTINAL CRYPTOSPORIDIOSIS; AIDS; PROPHYLAXIS	Context.-Cryptosporidium parvum infection, a common cause of diarrhea in persons infected with the human immunodeficiency virus (HIV), is difficult to treat or prevent. Objective.-To evaluate relative rates of cryptosporidiosis in HIV-infected patients who were either receiving or not receiving chemoprophylaxis or treatment for Mycobacterium avium complex. Design.-Analysis of prospectively collected data from HIV-infected patients' visits to their physicians since 1992. Setting.-Ten (8 private, 2 publicly funded) HIV clinics in 9 US cities. Patients.-A total of 1019 HIV-infected patients with CD4(+) cell counts less than 0.075 x 10(9)/L. Main Outcome Measures.-Incidence of clinical cryptosporidiosis during treatment with clarithromycin, rifabutin, and azithromycin. Results.-Five of the 312 patients reportedly taking clarithromycin developed cryptosporidiosis vs 30 of the 707 patients not taking clarithromycin (relative hazard [RH], 0.25 [95% confidence interval (CI), 0.10-0.67]; P=.004). Two of the 214 patients taking rifabutin developed cryptosporidiosis vs 33 of the 805 not taking rifabutin (RH, 0.15 [95% CI, 0.04-0.62]; P=.01). Prophylactic efficacy of either drug was 75% or greater. No protective effect was seen in the 54 patients reportedly taking azithromycin (RH, 1.48 [95% CI, 0.44-5.04]; P=.46). Conclusions.-Clarithromycin and rifabutin were highly protective against development of cryptosporidiosis in immune-suppressed HIV-infected persons in this analysis; further study is warranted.	Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Northwestern University; Oregon Health & Science University	Holmberg, SD (corresponding author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV STD & TB Prevent, Mailstop E-45,1600 Clifton Rd NE, Atlanta, GA 30333 USA.			Moorman, Anne/0000-0003-2411-2798				BLAGBURN BL, 1997, CRYPTOSPORIDIUM CRYP, P113; Blanshard C, 1997, INT J STD AIDS, V8, P124, DOI 10.1258/0956462971919543; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P669; *CDCP, 1994, MMWR-MORBID MORTAL W, V43, P661; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; DIBARI MA, 1996, 11 INT C AIDS JUL 7; FAYER R, 1993, J PARASITOL, V79, P553, DOI 10.2307/3283382; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; Flanigan T P, 1993, Prog Clin Parasitol, V3, P1; GIACOMETTI A, 1996, 36 INT C ANT AG CHEM; HOSMER DW, 1989, APPL LOGISTIC REGRES, P66; Jordan WC, 1996, J NATL MED ASSOC, V88, P425; Kalbfleisch JD., 2002, STAT ANAL FAILURE TI, V2, DOI [10.1002/9781118032985, DOI 10.1016/0197-2456(81)90009-X]; MCGOWAN I, 1993, AIDS, V7, P349, DOI 10.1097/00002030-199303000-00007; PETERSEN C, 1992, CLIN INFECT DIS, V15, P903, DOI 10.1093/clind/15.6.903; PORTNOY D, 1984, ANN INTERN MED, V101, P202, DOI 10.7326/0003-4819-101-2-202; REHG JE, 1991, J PROTOZOOL S, V38, pS147; RITCHIE DJ, 1994, ANN PHARMACOTHER, V28, P767, DOI 10.1177/106002809402800615; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	20	50	56	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					384	386		10.1001/jama.279.5.384	http://dx.doi.org/10.1001/jama.279.5.384			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459473	Bronze			2022-12-01	WOS:000071731300030
J	Prasad, N; Srikanthan, VS; Wright, A; Dunn, FG				Prasad, N; Srikanthan, VS; Wright, A; Dunn, FG			Management of suspected myocardial infarction before admission: updated audit	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Stobhill NHS Trust, Dept Cardiol, Glasgow G21 3UW, Lanark, Scotland		Dunn, FG (corresponding author), Stobhill NHS Trust, Dept Cardiol, Glasgow G21 3UW, Lanark, Scotland.							[Anonymous], 1988, LANCET, V2, P349; BURNS JMA, 1989, BRIT HEART J, V61, P322; JULIAN DG, 1989, BMJ-BRIT MED J, V299, P555; WYLLIE HR, 1994, BMJ-BRIT MED J, V308, P760, DOI 10.1136/bmj.308.6931.760a	4	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 31	1998	316	7128					353	353		10.1136/bmj.316.7128.353	http://dx.doi.org/10.1136/bmj.316.7128.353			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV793	9487171	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000071863900026
J	Alcolado, J				Alcolado, J			Genetics of diabetic complications	LANCET			English	Editorial Material							NEPHROPATHY; MELLITUS; SUSCEPTIBILITY; LOCUS		Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Alcolado, J (corresponding author), Univ Wales Hosp, Dept Med, Cardiff CF4 4XN, S Glam, Wales.		Alcolado, John/B-4999-2009	Alcolado, John/0000-0003-0666-0352				ALCOLADO JC, 1993, HUM HERED, V43, P126, DOI 10.1159/000154129; ALCOLADO JC, 1995, DIABETIC MED, V12, P102, DOI 10.1111/j.1464-5491.1995.tb00438.x; Baynes KCR, 1997, QJM-MON J ASSOC PHYS, V90, P557, DOI 10.1093/qjmed/90.9.557; BORCHJOHNSEN K, 1992, KIDNEY INT, V41, P719, DOI 10.1038/ki.1992.112; Diabet Control Complications Trial Res Grp, 1997, DIABETES, V46, P1829; Hanis CL, 1996, NAT GENET, V13, P161, DOI 10.1038/ng0696-161; Heesom AE, 1997, DIABETES, V46, P287, DOI 10.2337/diabetes.46.2.287; Horikawa Y, 1997, NAT GENET, V17, P384, DOI 10.1038/ng1297-384; NEEL JV, 1965, GENETICS EPIDEMIOLOG, P105; Quinn M, 1996, DIABETOLOGIA, V39, P940; SEAQUIST ER, 1989, NEW ENGL J MED, V320, P1161, DOI 10.1056/NEJM198905043201801; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Todd JA, 1996, HUM MOL GENET, V5, P1443, DOI 10.1093/hmg/5.Supplement_1.1443; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0	15	18	19	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 24	1998	351	9098					230	231		10.1016/S0140-6736(05)78278-7	http://dx.doi.org/10.1016/S0140-6736(05)78278-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457089				2022-12-01	WOS:000071702200005
J	Hacohen, N; Kramer, S; Sutherland, D; Hiromi, Y; Krasnow, MA				Hacohen, N; Kramer, S; Sutherland, D; Hiromi, Y; Krasnow, MA			sprouty encodes a novel antagonist of FGF signaling that patterns apical branching of the Drosophila airways	CELL			English	Article							MIDLINE GLIAL-CELLS; TRACHEAL SYSTEM; RECEPTOR HOMOLOG; GENE; TRANSCRIPTION; MIGRATION; PATHWAY; PROTEIN; DIFFERENTIATION; EXPRESSION	Antagonists of several growth factor signaling pathways play important roles in developmental patterning by limiting the range of the cognate inducer. Here, we describe an antagonist of FGF signaling that patterns apical branching of the Drosophila airways. In wild-type embryos, the Branchless FGF induces secondary branching by activating the Breathless FGF receptor near the tips of growing primary branches. In sprouty mutants, the FGF pathway is overactive and ectopic branches are induced on the stalks of primary branches. We show that FGF signaling induces sprouty expression in the nearby tip cells, and sprouty acts nonautonomously and in a competitive fashion to block signaling to the more distant stalk cells. sprouty encodes a novel cysteine-rich protein that defines a new family of putative signaling molecules that may similarly function as FGF antagonists in vertebrate development.	Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Sch Med, Stanford, CA 94305 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Stanford University; Princeton University	Krasnow, MA (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Biochem, Sch Med, Stanford, CA 94305 USA.							AFFOLTER M, 1994, DEVELOPMENT, V120, P743; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Beiman M, 1996, GENE DEV, V10, P2993, DOI 10.1101/gad.10.23.2993; BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BRAND AH, 1993, DEVELOPMENT, V118, P401; Gabay L, 1996, DEVELOPMENT, V122, P3355; GLAZER L, 1991, GENE DEV, V5, P697, DOI 10.1101/gad.5.4.697; Golembo M, 1996, DEVELOPMENT, V122, P223; Guillemin K, 1996, DEVELOPMENT, V122, P1353; HACOHEN N, 1997, THESIS STANFORD U ST; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; KLAES A, 1994, CELL, V78, P149, DOI 10.1016/0092-8674(94)90581-9; KLAMBT C, 1992, GENE DEV, V6, P1668, DOI 10.1101/gad.6.9.1668; KLAMBT C, 1993, DEVELOPMENT, V117, P163; KRAMER S, 1995, DEVELOPMENT, V121, P1361; LAI ZC, 1992, CELL, V70, P609, DOI 10.1016/0092-8674(92)90430-K; Lee T, 1996, GENE DEV, V10, P2912, DOI 10.1101/gad.10.22.2912; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; Manning Gerards, 1993, P609; ONEILL EM, 1994, CELL, V78, P137, DOI 10.1016/0092-8674(94)90580-0; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Piccolo S, 1996, CELL, V86, P589, DOI 10.1016/S0092-8674(00)80132-4; REBAY I, 1995, CELL, V81, P857, DOI 10.1016/0092-8674(95)90006-3; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; SCHOLZ H, 1993, GENETICS, V135, P455; SCHWEITZER R, 1995, NATURE, V376, P699, DOI 10.1038/376699a0; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; Sutherland D, 1996, CELL, V87, P1091, DOI 10.1016/S0092-8674(00)81803-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319; WOHLWILL AD, 1991, GENETICS, V128, P763; WOLPERT L, 1983, CIBA F SYMP, V100, P1; XU T, 1993, DEVELOPMENT, V117, P1223; Zimmerman LB, 1996, CELL, V86, P599, DOI 10.1016/S0092-8674(00)80133-6	35	628	658	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					253	263		10.1016/S0092-8674(00)80919-8	http://dx.doi.org/10.1016/S0092-8674(00)80919-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458049	Bronze			2022-12-01	WOS:000071672600014
J	Zallen, JA; Yi, BA; Bargmann, CI				Zallen, JA; Yi, BA; Bargmann, CI			The conserved immunoglobulin superfamily member SAX-3/Robo directs multiple aspects of axon guidance in C-elegans	CELL			English	Article							GROWTH CONE GUIDANCE; CAENORHABDITIS-ELEGANS; COLORECTAL-CANCER; COMMISSURAL AXONS; NERVOUS-SYSTEM; NETRIN CUES; CNS MIDLINE; GUIDES CELL; DROSOPHILA; RECEPTOR	The C. elegans sax-3 gene encodes a predicted transmembrane protein with five immunoglobulin domains and three fibronectin type III repeats that is closely related to Drosophila Robe. Mutations in sax-3 lead to repeated midline crossing by ventral cord axons that normally do not cross the midline after they join the ventral cord, a phenotype similar to that of robe mutants. sax-3 is also required for guidance of some axons to the ventral cord, implicating this gene in two different types of guidance events. A sax-3:GFP fusion gene is expressed in developing neurons during axon outgrowth, and sax-3 function is required at the time of axon guidance, suggesting that this gene mediates cell interactions during guidance decisions.	Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Program Dev Biol, San Francisco, CA 94143 USA.			Bargmann, Cornelia/0000-0002-8484-0618				BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Baum PD, 1997, NEURON, V19, P51, DOI 10.1016/S0896-6273(00)80347-5; BRENNER S, 1974, GENETICS, V77, P71; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; Drescher U, 1997, CURR OPIN NEUROBIOL, V7, P75, DOI 10.1016/S0959-4388(97)80123-7; Friedman GC, 1996, CURR OPIN NEUROBIOL, V6, P127, DOI 10.1016/S0959-4388(96)80018-3; GARRIGA G, 1993, DEVELOPMENT, V117, P1071; Goodman CS, 1996, ANNU REV NEUROSCI, V19, P341, DOI 10.1146/annurev.ne.19.030196.002013; HAMELIN M, 1993, NATURE, V364, P327, DOI 10.1038/364327a0; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; Kang JS, 1997, J CELL BIOL, V138, P203, DOI 10.1083/jcb.138.1.203; KeinoMasu K, 1996, CELL, V87, P175, DOI 10.1016/S0092-8674(00)81336-7; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; KEYNES R, 1995, CELL, V83, P161, DOI 10.1016/0092-8674(95)90157-4; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; LUSCINSKAS FW, 1994, J CELL BIOL, V125, P1417, DOI 10.1083/jcb.125.6.1417; MARICQ AV, 1995, NATURE, V378, P78, DOI 10.1038/378078a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; MYERS PZ, 1993, J NEUROSCI, V13, P127; Sambrook J., 1989, MOL CLONING LAB MANU; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Serafini T, 1996, CELL, V87, P1001, DOI 10.1016/S0092-8674(00)81795-X; SERAFINI T, 1994, CELL, V78, P409, DOI 10.1016/0092-8674(94)90420-0; STOECKLI ET, 1995, NEURON, V14, P1165, DOI 10.1016/0896-6273(95)90264-3; Stoeckli ET, 1997, NEURON, V18, P209, DOI 10.1016/S0896-6273(00)80262-7; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Wadsworth WG, 1996, NEURON, V16, P35, DOI 10.1016/S0896-6273(00)80021-5; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wightman B, 1997, DEVELOPMENT, V124, P2571; Wightman B, 1996, DEVELOPMENT, V122, P671; [No title captured]	45	239	244	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					217	227		10.1016/S0092-8674(00)80916-2	http://dx.doi.org/10.1016/S0092-8674(00)80916-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458046	Bronze			2022-12-01	WOS:000071672600011
J	Eiserich, JP; Hristova, M; Cross, CE; Jones, AD; Freeman, BA; Halliwell, B; van der Vliet, A				Eiserich, JP; Hristova, M; Cross, CE; Jones, AD; Freeman, BA; Halliwell, B; van der Vliet, A			Formation of nitric oxide derived inflammatory oxidants by myeloperoxidase in neutrophils	NATURE			English	Article							CONVERTING-ENZYME; OXIDATIVE DAMAGE; SYNOVIAL-FLUID; SYNTHASE; SERUM; PEROXYNITRITE; NITROTYROSINE; BIOACTIVITY; NITRATION; PEPTIDES	Nitric oxide ((NO)-N-.) plays a central role in the pathogenesis of diverse inflammatory and infectious disorders(1,2). The toxicity of (NO)-N-. is thought to be engendered, in part, by its reaction with superoxide (O-2(.-)), yielding the potent oxidant peroxynitrite (ONOO-)(3). However, evidence for a role of ONOO- in vivo is based largely upon detection of 3-nitrotyrosine in injured tissues(4-8). We have recently demonstrated that nitrite (NO2-), a major end-product of (NO)-N-. metabolism, readily promotes tyrosine nitration through formation of nitryl chloride (NO2Cl) and nitrogen dioxide ((NO2)-N-.) by reaction with the inflammatory mediators hypochlorous acid (HOCl) or myeloperoxidase(9,10). We now show that activated human polymorphonuclear neutrophils convert NO2- into NO2Cl and (NO2)-N-. through myeloperoxidase-dependent pathways. Polymorphonuclear neutrophil-mediated nitration and chlorination of tyrosine residues or 4-hydroxyphenylacetic acid is enhanced by addition of NO2- or by fluxes of (NO)-N-.. Addition of (NO2-)-N-15 led to N-15 enrichment of nitrated phenolic substrates, confirming its role in polymorphonuclear neutrophil-mediated nitration reactions. Polymorphonuclear neutrophil-mediated inactivation of endothelial cell angiotensin-converting enzyme was exacerbated by NO2-, illustrating the physiological significance of these reaction pathways to cellular dysfunction. Our data reveal that NO2- may regulate inflammatory processes through oxidative mechanisms, perhaps by contributing to the tyrosine nitration and chlorination observed in vivo.	Univ Calif Davis, Dept Internal Med, Div Pulm & Crit Care Med, Davis, CA 95616 USA; Univ Calif Davis, Facil Adv Instrumentat, Davis, CA 95616 USA; Univ Alabama, Dept Anesthesiol, Birmingham, AL 35233 USA; Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35233 USA; Univ Alabama, Dept Pediat, Birmingham, AL 35233 USA; Univ London, Univ London Kings Coll, Neurodegenerat Dis Res Ctr, Pharmacol Grp, London SW3 6LX, England	University of California System; University of California Davis; University of California System; University of California Davis; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of London; King's College London	Eiserich, JP (corresponding author), Univ Alabama, Ctr Free Radical Biol, Dept Anesthesiol, 619 19th St S,946 THT, Birmingham, AL 35233 USA.		Jones, Arthur D/C-2670-2013; Halliwell, Barry/C-8318-2009; Freeman, Bruce A/H-9342-2012	Jones, A. Daniel/0000-0002-7408-6690				Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; CHEN XL, 1993, AM J PHYSIOL, V265, pL243, DOI 10.1152/ajplung.1993.265.3.L243; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Eiserich JP, 1996, J BIOL CHEM, V271, P19199, DOI 10.1074/jbc.271.32.19199; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; KAUR H, 1994, FEBS LETT, V350, P9, DOI 10.1016/0014-5793(94)00722-5; KETTLE AJ, 1995, BIOCHEM J, V308, P559, DOI 10.1042/bj3080559; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MOORADIAN DL, 1995, J CARDIOVASC PHARM, V25, P674, DOI 10.1097/00005344-199504000-00023; PRUTZ WA, 1985, ARCH BIOCHEM BIOPHYS, V243, P125, DOI 10.1016/0003-9861(85)90780-5; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763, DOI 10.1164/ajrccm.155.5.9154889; Simon DI, 1996, P NATL ACAD SCI USA, V93, P4736, DOI 10.1073/pnas.93.10.4736; Singer II, 1996, GASTROENTEROLOGY, V111, P871, DOI 10.1016/S0016-5085(96)70055-0; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEISS SJ, 1983, SCIENCE, V222, P625, DOI 10.1126/science.6635660	30	1290	1314	1	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					393	397		10.1038/34923	http://dx.doi.org/10.1038/34923			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450756				2022-12-01	WOS:000071604200056
J	Kawai, A; Woodruff, J; Healey, JH; Brennan, MF; Antonescu, CR; Ladanyi, M				Kawai, A; Woodruff, J; Healey, JH; Brennan, MF; Antonescu, CR; Ladanyi, M			SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KRUPPEL-ASSOCIATED BOX; TRANSLOCATION BREAKPOINTS; X-CHROMOSOME; CLASSIFICATION; IDENTIFICATION; DIAGNOSIS; SYT-SSX2; PROTEINS; FEATURES; SURVIVAL	Background Synovial sarcomas account for up to 10 percent of soft-tissue sarcomas and include two major histologic subtypes, biphasic and monophasic, defined respectively by the presence and absence of glandular epithelial differentiation in a background of spindle tumor cells, A characteristic SYT-SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas, The translocation fuses the SYT gene from chromosome 18 to either of two highly homologous genes at Xp11, SSX1 or SSX2. SYT-SSX1 and SYT-SSX2 are thought to function as aberrant transcriptional regulators. We attempted to determine the influence of the two alternative forms of the SYT-SSX fusion gene on tumor morphology and clinical outcome in patients with this sarcoma. Methods We analyzed SYT-SSX fusion transcripts in 45 synovial sarcomas (33 monophasic and 12 biphasic) by the reverse-transcriptase polymerase chain reaction and compared the results with relevant clinical and pathological data. Results The SYT-SSX1 and SYT-SSX2 fusion transcripts were detected in 29 (64 percent) and 16 (36 percent) of the tumors, respectively. There was a significant relation (P=0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had an SYT-SSX1 fusion transcript, and all 16 tumors that were positive for SYT-SSX2 were monophasic. Kaplan-Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT-SSX2 had significantly better metastasis-free survival than the 24 patients with SYT-SSX1 (P=0.03 by multivariate analysis; relative risk, 3.0). There were no significant correlations between the type of SYT-SSX transcript and age, sex, tumor location and size, whether there were metastases at diagnosis, or whether patients underwent chemotherapy. Histologic subtype alone was not prognostically important. Conclusions The type of SYT-SSX fusion transcript correlates with both the histologic subtype and the clinical behavior of synovial sarcoma. SYT-SSX fusion transcripts are a defining diagnostic marker of synovial sarcomas and may also yield important independent prognostic information. (C) 1998, Massachusetts Medical Society.	Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Ladanyi, M (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA.		Ladanyi, Marc/AAG-8585-2019	Healey, John/0000-0002-0802-1186				ARGANI P, IN PRESS MOD PATHOL; Brett D, 1997, HUM MOL GENET, V6, P1559, DOI 10.1093/hmg/6.9.1559; BRODSKY JT, 1992, CANCER-AM CANCER SOC, V70, P484, DOI 10.1002/1097-0142(19920715)70:2<484::AID-CNCR2820700217>3.0.CO;2-7; CAGLE LA, 1987, CANCER, V59, P1810, DOI 10.1002/1097-0142(19870515)59:10<1810::AID-CNCR2820591021>3.0.CO;2-R; Chand A, 1995, GENOMICS, V30, P545, DOI 10.1006/geno.1995.1275; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Connelly EF, 1996, SEMIN ONCOL, V23, P16; CREW AJ, 1995, EMBO J, V14, P2333, DOI 10.1002/j.1460-2075.1995.tb07228.x; DEALAVA E, IN PRESS J CLIN ONCO; DELEEUW B, 1995, HUM MOL GENET, V4, P1097, DOI 10.1093/hmg/4.6.1097; deLeeuw B, 1996, CYTOGENET CELL GENET, V73, P179, DOI 10.1159/000134334; DELEEUW B, 1994, CANCER GENET CYTOGEN, V73, P89, DOI 10.1016/0165-4608(94)90191-0; dosSantos NR, 1997, HUM MOL GENET, V6, P1549, DOI 10.1093/hmg/6.9.1549; ENZINGER FM, 1995, SOFT TISSUE TUMORS, P757; FLIGMAN I, 1995, AM J PATHOL, V147, P1592; JANZ M, 1995, J PATHOL, V175, P391, DOI 10.1002/path.1711750405; KAMPE CE, 1993, CANCER-AM CANCER SOC, V72, P2161, DOI 10.1002/1097-0142(19931001)72:7<2161::AID-CNCR2820720716>3.0.CO;2-2; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kelly KM, 1997, J CLIN ONCOL, V15, P1831, DOI 10.1200/JCO.1997.15.5.1831; KRALL RA, 1981, AM J SURG PATHOL, V5, P137, DOI 10.1097/00000478-198103000-00005; LADANYI M, 1995, DIAGN MOL PATHOL, V4, P162, DOI 10.1097/00019606-199509000-00003; LIMON J, 1991, GENE CHROMOSOME CANC, V3, P338, DOI 10.1002/gcc.2870030504; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; ODA Y, 1993, AM J SURG PATHOL, V17, P35, DOI 10.1097/00000478-199301000-00004; PAPPO AS, 1994, J CLIN ONCOL, V12, P2360, DOI 10.1200/JCO.1994.12.11.2360; Pisters PWT, 1996, J CLIN ONCOL, V14, P1679, DOI 10.1200/JCO.1996.14.5.1679; RENWICK PJ, 1995, CYTOGENET CELL GENET, V70, P58, DOI 10.1159/000133992; ROOSER B, 1989, CANCER, V63, P2182, DOI 10.1002/1097-0142(19890601)63:11<2182::AID-CNCR2820631120>3.0.CO;2-Y; ROSEN G, 1994, CANCER, V73, P2506, DOI 10.1002/1097-0142(19940515)73:10<2506::AID-CNCR2820731009>3.0.CO;2-S; Shipley J, 1996, AM J PATHOL, V148, P559; SHIPLEY JM, 1994, ONCOGENE, V9, P1447; Singer S, 1996, J CLIN ONCOL, V14, P1201, DOI 10.1200/JCO.1996.14.4.1201; Sorensen PHB, 1996, SEMIN CANCER BIOL, V7, P3, DOI 10.1006/scbi.1996.0002; SREEKANTAIAH C, 1994, AM J PATHOL, V144, P1121; Zoubek A, 1996, J CLIN ONCOL, V14, P1245, DOI 10.1200/JCO.1996.14.4.1245	35	472	499	1	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					153	160		10.1056/NEJM199801153380303	http://dx.doi.org/10.1056/NEJM199801153380303			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428816				2022-12-01	WOS:000071384500003
J	Vlahov, D; Graham, N; Hoover, D; Flynn, C; Bartlett, JG; Margolick, JB; Lyles, CM; Nelson, KE; Smith, D; Holmberg, S; Farzadegan, H				Vlahov, D; Graham, N; Hoover, D; Flynn, C; Bartlett, JG; Margolick, JB; Lyles, CM; Nelson, KE; Smith, D; Holmberg, S; Farzadegan, H			Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users - Plasma viral load and CD4(+) cell count	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; PNEUMOCYSTIS-CARINII; PERIPHERAL-BLOOD; CUBIC MILLIMETER; RNA; QUANTITATION; PROGRESSION; ZIDOVUDINE; THERAPY; COHORT	Context.-Plasma human immunodeficiency virus type 1 (HIV-1) viral load and CD4(+) cell count are used to predict prognosis of persons infected with HIV. However, whether combining these markers improves prognostic accuracy and whether they predict prognosis for injection drug users (IDUs) and nonwhite persons infected with HIV has not been extensively investigated. Objective.-To evaluate plasma viral load and CD4(+) cell count as prognostic indicators for the acquired immunodeficiency syndrome (AIDS) and infectious disease deaths. Design.-Cohort study initiated in 1988 and 1989 with follow-up for up to 7.9 years. Participants.-Injection drug users infected with HIV recruited from the community in Baltimore, Md. Main Outcome Measures.-Plasma HIV-1 RNA and CD4(+) cell count measured at baseline compared with time to first clinical AIDS diagnosis and death due to an infectious disease. Results.-Of 522 subjects, 96% were African American, 80% were male, 96% injected drugs within the past 6 months, and the median age was 33 years. A total of 146 cases of AIDS and 119 infectious disease deaths were seen during a median follow-up period of 6.4 years. Time-fixed baseline levels of viral load and CD4(+) cell count were independent predictors of progression to AIDS and infectious disease deaths, but in proportional hazards models, viral load had better predictive value than CD4(+) cell count. Kaplan-Meier analysis of time to AIDS and to infectious disease deaths by Viral load (<500, 500-9999, 10 000-29 999, greater than or equal to 30 000 copies/mL) at 3 levels of CD4(+) cell count (<0.20, 0.20-0.49, and greater than or equal to 0.50X10(9)/L [<200, 200-499, and greater than or equal to 500/uL]) was reduced to a 5-stage classification scheme using a backward stepwise regression procedure. The 5-year cumulative probabilities for AIDS and infectious disease deaths ranged from 0% and 0%, respectively, for group I (viral load, <500 copies/mL; CD4(+) cell count, 0.50X10(9)/L) to 81.2% and 76.1% respectively, for group V (viral load, greater than or equal to 10000 copies/mL; CD4(+) cell count, 0.20X10(9)/L). Conclusions.-In this study, plasma HIV-1 viral load independently and in combination with CD4(+) cell count measurements provided powerful prognostic information for progression to AIDS and death caused by infectious disease in a population of predominantly African American IDUs. Combining categories of both markers provided a simple method for prognostically staging HIV disease.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Ctr Dis Control & Prevent, Div HIV AIDS, Atlanta, GA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Centers for Disease Control & Prevention - USA	Vlahov, D (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Room E-6008,615 N Wolfe St, Baltimore, MD 21205 USA.				NATIONAL INSTITUTE ON DRUG ABUSE [R37DA004334, R01DA004334] Funding Source: NIH RePORTER; NIDA NIH HHS [DA04334] Funding Source: Medline; PHS HHS [U54/CCU306802] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		CAIAFFA WT, 1994, AM J RESP CRIT CARE, V150, P1493, DOI 10.1164/ajrccm.150.6.7952605; *CDC, 1992, MMWR-MORBID MORTAL W, V41, pRR17; Centers for Disease Control (CDC), 1989, MMWR Suppl, V38, P1; CHAISSON RE, 1991, AIDS, V5, P177, DOI 10.1097/00002030-199102000-00007; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; Cox DR., 1984, ANAL SURVIVAL DATA; ESCAICH S, 1992, AIDS RES HUM RETROV, V8, P1833, DOI 10.1089/aid.1992.8.1833; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FARZADEGAN H, 1996, 11 INT C AIDS JUL 7; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; HARRISON K, 1995, J ACQ IMMUN DEF SYND, V10, P386; HOFFMAN RA, 1980, P NATL ACAD SCI-BIOL, V77, P4914, DOI 10.1073/pnas.77.8.4914; HOLODNIY M, 1995, J CLIN MICROBIOL, V33, P1562, DOI 10.1128/JCM.33.6.1562-1566.1995; HOLODNIY M, 1993, J ACQ IMMUN DEF SYND, V6, P366; HOOVER DR, 1995, DRUGS, V49, P20, DOI 10.2165/00003495-199549010-00003; Katzenstein DA, 1996, NEW ENGL J MED, V335, P1091, DOI 10.1056/NEJM199610103351502; Manoff SB, 1996, EPIDEMIOLOGY, V7, P566, DOI 10.1097/00001648-199611000-00001; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Mellors JW, 1997, ANN INTERN MED, V126, P946, DOI 10.7326/0003-4819-126-12-199706150-00003; MULDER J, 1994, J CLIN MICROBIOL, V32, P292, DOI 10.1128/JCM.32.2.292-300.1994; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; OBrien TR, 1996, JAMA-J AM MED ASSOC, V276, P105, DOI 10.1001/jama.276.2.105; OBrien WA, 1996, NEW ENGL J MED, V334, P426, DOI 10.1056/NEJM199602153340703; SAKSELA K, 1994, P NATL ACAD SCI USA, V91, P1104, DOI 10.1073/pnas.91.3.1104; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P438, DOI 10.7326/0003-4819-113-6-438; SOLOMON L, 1995, J DRUG ISSUES, V25, P225, DOI 10.1177/002204269502500115; VLAHOV D, 1991, J DRUG ISSUES, V21, P767; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; YERLY S, 1992, J INFECT DIS, V166, P269, DOI 10.1093/infdis/166.2.269	30	167	175	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					35	40		10.1001/jama.279.1.35	http://dx.doi.org/10.1001/jama.279.1.35			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424041	Bronze			2022-12-01	WOS:000071295100032
J	Chen, ZL; Strickland, S				Chen, ZL; Strickland, S			Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin	CELL			English	Article							ADULT-RAT BRAIN; EXTRACELLULAR-MATRIX; NERVOUS-SYSTEM; GRANULE NEURONS; KAINIC ACID; ACTIVATOR; GENE; EXPRESSION; SURVIVAL; SEIZURE	Excess excitatory amino acids can provoke neuronal death in the hippocampus, and the extracellular proteases tissue plasminogen activator (tPA) and plasmin (ogen) have been implicated in this death. To investigate substrates for plasmin that might influence neuronal degeneration, extracellular matrix (ECM) protein expression was examined. Laminin is expressed in the hippocampus and disappears after excitotoxin injection. Laminin disappearance precedes neuronal death, is spatially coincident with regions that exhibit neuronal loss, and is blocked by either tPA-deficiency or infusion of a plasmin inhibitor, both of which also block neuronal degeneration. Preventing neuron-laminin interaction by infusion of anti-laminin antibodies into tPA-deficient mice restores excitotoxic sensitivity to their hippocampal neurons. These results indicate that disruption of neuron-ECM interaction via tPA/plasmin catalyzed degradation of laminin sensitizes hippocampal neurons to cell death.	SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Genet Program, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook	Strickland, S (corresponding author), SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA.			Strickland, Sidney/0000-0002-3072-9244	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035704] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-35704] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; ANDERSSON PB, 1991, NEUROSCIENCE, V42, P201, DOI 10.1016/0306-4522(91)90159-L; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARROLL PM, 1994, DEVELOPMENT, V120, P3173; CHEN ZL, 1995, J NEUROSCI, V15, P5088; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; Einheber S, 1996, J COMP NEUROL, V370, P105; EMSBERGER U, 1989, DEV BIOL, V135, P250; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gualandris A, 1996, J NEUROSCI, V16, P2220; HAGG T, 1989, NEURON, V3, P721, DOI 10.1016/0896-6273(89)90241-9; JUCKER M, 1992, BRAIN RES, V586, P166, DOI 10.1016/0006-8993(92)91390-Z; KALCHEIM C, 1987, EMBO J, V6, P2871, DOI 10.1002/j.1460-2075.1987.tb02589.x; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kleiner DE, 1993, CURR OPIN CELL BIOL, V5, P891, DOI 10.1016/0955-0674(93)90040-W; LIESI P, 1989, EXP NEUROL, V105, P86, DOI 10.1016/0014-4886(89)90175-1; Liesi P, 1996, J CELL BIOL, V134, P477, DOI 10.1083/jcb.134.2.477; LIOTTA LA, 1981, CANCER RES, V41, P4629; LuckenbillEdds L, 1997, BRAIN RES REV, V23, P1, DOI 10.1016/S0165-0173(96)00013-6; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MURTOMAKI S, 1992, J NEUROSCI RES, V32, P261, DOI 10.1002/jnr.490320216; MURTOMAKI S, 1995, DEV BIOL, V168, P635, DOI 10.1006/dbio.1995.1108; Niquet J, 1996, DEV BRAIN RES, V95, P227, DOI 10.1016/S0165-3806(96)00089-2; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; PAULSSON M, 1988, EUR J BIOCHEM, V177, P477, DOI 10.1111/j.1432-1033.1988.tb14397.x; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROGERS SL, 1986, DEV BIOL, V113, P429, DOI 10.1016/0012-1606(86)90177-6; SALONEN EM, 1984, FEBS LETT, V172, P29, DOI 10.1016/0014-5793(84)80866-2; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCHNAPP LM, 1995, J BIOL CHEM, V270, P23196, DOI 10.1074/jbc.270.39.23196; Strickland S, 1996, COLD SPRING HARB SYM, V61, P739; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TIMPL R, 1979, J BIOL CHEM, V254, P9933; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Tsirka SE, 1997, P NATL ACAD SCI USA, V94, P9779, DOI 10.1073/pnas.94.18.9779; VENSTROM KA, 1993, FASEB J, V7, P996, DOI 10.1096/fasebj.7.11.8370483; YAMAMOTO T, 1988, J NEUROL SCI, V84, P1, DOI 10.1016/0022-510X(88)90169-4	46	527	544	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					917	925		10.1016/S0092-8674(00)80483-3	http://dx.doi.org/10.1016/S0092-8674(00)80483-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428515	Bronze			2022-12-01	WOS:000071281400009
J	Letrilliart, L; Desenclos, JC; Flahault, A				Letrilliart, L; Desenclos, JC; Flahault, A			Risk factors for winter outbreak of acute diarrhoea in France: case-control study	BRITISH MEDICAL JOURNAL			English	Article							ANTIBIOTIC-ASSOCIATED DIARRHEA; GASTROENTERITIS	Objectives: To assess the potential role of consumption of shellfish (particularly raw oysters) and tap water in the winter epidemic of acute diarrhoea in France. Design: Population based, case-control study during the 1995-6 winter epidemic of acute diarrhoea in France. Setting: A national network comprising 1% of general practitioners in France. Subjects: 568 pairs of cases and controls consulting in general practice and interviewed by 209 doctors from 26 December 1995 to 31 January 1996. Cases and controls were matched for age, doctor, and time of consultation. Main outcome measures: Adjusted relative risk of diarrhoea estimated from conditional logistic regression. Results: The risk of acute diarrhoea was not increased in people who had recently eaten raw oysters (odds ratio 1.1; 95% confidence interval 0.9% to 1.4%) or other shellfish such as clams, cockles, and mussels, or in those people who usually consumed tap rather than bottled water (0.8; 0.6% to 1.1%). The risk was, however, increased in people who had had recent contact with a person with diarrhoea, either within the household (adjusted odds ratio 5.0) or in the workplace (3.1), and in people who lived with a child less than or equal to 2 years of age (1.6). Recent treatment with either oral penicillin or cephalosporin was also independently associated with acute diarrhoea in winter. Conclusions: The winter epidemic of acute diarrhoea in France is probably not caused by consumption of either shellfish or tap water. A viral aetiology, however, is suggested by the speed with which the acute diarrhoea is transmitted.	Inst Fed St Antoine Rech Sante, INSERM, U444, Paris, France; Reseau Natl Sante Publ, St Maurice, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Letrilliart, L (corresponding author), Inst Fed St Antoine Rech Sante, INSERM, U444, Paris, France.							BARTLETT JG, 1992, CLIN INFECT DIS, V15, P573, DOI 10.1093/clind/15.4.573; Carrat F, 1996, BEH, P143; DAURAT G, 1994, B EPIDEMIOL HEBD, V37, P170; DUFOUR A, 1995, OPINIONS FRANCAIS EN; FLAHAULT A, 1995, LANCET, V346, P162, DOI 10.1016/S0140-6736(95)91214-2; Fourquet F, 1997, LANCET, V349, P794; GARTHRIGHT WE, 1988, PUBLIC HEALTH REP, V103, P107; GEORGE WL, 1984, REV INFECT DIS, V6, pS208; Glass RI, 1996, J INFECT DIS, V174, pS5, DOI 10.1093/infdis/174.Supplement_1.S5; Hosmer DW, 2000, APPL LOGISTIC REGRES, V2nd; LAURSEN E, 1994, J EPIDEMIOL COMMUN H, V48, P453, DOI 10.1136/jech.48.5.453; LeBaron C W, 1990, MMWR Recomm Rep, V39, P1; *MET FRANC, 1996, B CLIM ANN 1995; MORSE DL, 1986, NEW ENGL J MED, V314, P678, DOI 10.1056/NEJM198603133141103; Ryan MJ, 1996, J INFECT DIS, V174, pS12, DOI 10.1093/infdis/174.Supplement_1.S12; SURAWICZ CM, 1989, GASTROENTEROLOGY, V96, P981, DOI 10.1016/0016-5085(89)91613-2; THOMPSON SC, 1994, J PAEDIATR CHILD H, V30, P210, DOI 10.1111/j.1440-1754.1994.tb00621.x; WATSON AJM, 1992, BRIT MED J, V304, P1302, DOI 10.1136/bmj.304.6837.1302; World Health Organisation, 1993, MAN PREV DIARRH PRAC	19	24	24	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1645	1649		10.1136/bmj.315.7123.1645a	http://dx.doi.org/10.1136/bmj.315.7123.1645a			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448526	Green Published			2022-12-01	WOS:000071149400009
J	Gangakhedkar, RR; Bentley, ME; Divekar, AD; Gadkari, D; Mehendale, SM; Shepherd, ME; Bollinger, RC; Quinn, TC				Gangakhedkar, RR; Bentley, ME; Divekar, AD; Gadkari, D; Mehendale, SM; Shepherd, ME; Bollinger, RC; Quinn, TC			Spread of HIV infection in married monogamous women in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED DISEASES; IMMUNODEFICIENCY-VIRUS TYPE-1; EPIDEMIC; CLINICS	Context.-A high prevalence of human immunodeficiency virus (HIV) infection in female sex workers (FSWs) and men who attend sexually transmitted disease (STD) clinics poses al risk for spread of infection to other populations. Objective.-To examine spread of HIV to a low-risk population by comparing prevalence of, and risk factors for, HIV and STDs in FSWs and non-FSWs. Methods.-Women attending STD clinics in Pune, India, were assessed for STDs and HIV from May 13, 1993, to July 11, 1996. Demographic and behavioral information was collected, and clinical and laboratory assessment was performed. Main Outcome Measure.-Prevalence and risk determinants of HIV infection. Results.-Of 916 women enrolled, 525 were FSWs and 391 were non-FSWs. Prevalence of HIV in FSWs and non-FSWs was 49.9% and 13.6%, respectively (P<.001). In multivariate analysis, inconsistent condom use and genital ulcer disease or genital warts were associated with prevalent HIV in FSWs. History of sexual contact with a partner with an STD was associated with HIV in non-FSWs. Conclusions.-Infection with HIV is increasing in non-FSWs, previously thought to be at low risk in India. Since history of sexual contact with their only sex partner was the only risk factor significantly associated with HIV infection, it is likely that these women are being infected by their spouses. This underscores the need for strengthening partner-notification strategies and counseling facilities in India.	JOHNS HOPKINS UNIV,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21205; NATL AIDS RES INST,PUNE,MAHARASHTRA,INDIA; NIAID,BETHESDA,MD 20892; NIH,BETHESDA,MD 20892	Johns Hopkins University; Indian Council of Medical Research (ICMR); ICMR - National AIDS Research Institute (NARI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA			Quinn, Thomas/A-2494-2010	Bollinger, Robert/0000-0002-6798-6834	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI033879] Funding Source: NIH RePORTER; FIC NIH HHS [D43-TW0000] Funding Source: Medline; NCRR NIH HHS [RR-00722] Funding Source: Medline; NIAID NIH HHS [AI-33879] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOLLINGER RC, 1995, MEDICINE, V74, P97, DOI 10.1097/00005792-199503000-00005; GUPTA GR, 1996, WOMENS EXPERIENCE; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; LAGA M, 1994, LANCET, V344, P246, DOI 10.1016/S0140-6736(94)93005-8; Lalvani A, 1996, LANCET, V347, P1349, DOI 10.1016/S0140-6736(96)91007-7; MANE P, 1992, AIDS PREVENTION; MEHENDALE SM, 1995, J INFECT DIS, V172, P1486, DOI 10.1093/infdis/172.6.1486; Mehendale SM, 1996, INDIAN J MED RES, V104, P327; NAG M, 1996, SEXUAL BEHAV AIDS IN, P26; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; Quinn TC, 1996, LANCET, V348, P99, DOI 10.1016/S0140-6736(96)01029-X; RAMASUBBAN R, 1994, WOMEN HLTH DEV INDIA, P212; RODRIGUES JJ, 1995, BRIT MED J, V311, P283, DOI 10.1136/bmj.311.7000.283; STONE AB, 1994, AIDS S1, V8, pS285; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001	15	210	212	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2090	2092		10.1001/jama.278.23.2090	http://dx.doi.org/10.1001/jama.278.23.2090			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403424				2022-12-01	WOS:A1997YK98700039
J	Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH				Von Korff, M; Gruman, J; Schaefer, J; Curry, SJ; Wagner, EH			Collaborative management of chronic illness	ANNALS OF INTERNAL MEDICINE			English	Article							BEHAVIORAL MEDICINE INTERVENTIONS; ACUTE MYOCARDIAL-INFARCTION; ARTHRITIS SELF-MANAGEMENT; CONGESTIVE-HEART-FAILURE; QUALITY-OF-LIFE; PATIENT EDUCATION; PSYCHOSOCIAL INTERVENTIONS; DIABETES-MELLITUS; CONTROLLED TRIAL; CANCER-PATIENTS	In chronic illness, day-to-day care responsibilities fall most heavily on patients and their families. Effective collaborative relationships with health care providers can help patients and families better handle self-care tasks. Collaborative management is care that strengthens and supports self-care in chronic illness while assuring that effective medical, preventive, and health maintenance interventions take place. In this paper, the following essential elements of collaborative management developed in light of behavioral principles and empirical evidence about effective care in chronic illness are discussed: 1) collaborative definition of problems, in which patient-defined problems are identified along with medical problems diagnosed by physicians; 2) targeting, goal setting, and planning, in which patients and providers focus on a specific problem, set realistic objectives, and develop an action plan for attaining those objectives in the context of patient preferences and readiness; 3) creation of a continuum of selfmanagement training and support services, in which patients have access to services that teach skills needed to carry out medical regimens, guide health behavior changes, and provide emotional support; and 4) active and sustained follow-up, in which patients are contacted at specified intervals to monitor health status, identify potential complications, and check and reinforce progress in implementing the care plan. These elements make up a common core of services for chronic illness care that need not be reinvented for each disease.	Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Ctr Advancement Hlth, Washington, DC 20009 USA	Group Health Cooperative	Von Korff, M (corresponding author), Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, 1730 Minor Ave,Suite 1600, Seattle, WA 98101 USA.		Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213; VonKorff, Michael/0000-0001-5386-8477				ALARANTA H, 1994, SPINE, V19, P1339, DOI 10.1097/00007632-199406000-00007; ANDERSEN BL, 1992, J CONSULT CLIN PSYCH, V60, P552, DOI 10.1037/0022-006X.60.4.552; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BAUM D, 1986, J ASTHMA, V23, P49, DOI 10.3109/02770908609077475; BERESFORD SAA, 1992, AM J PUBLIC HEALTH, V82, P79, DOI 10.2105/AJPH.82.1.79; BOLTON MB, 1991, J GEN INTERN MED, V6, P401, DOI 10.1007/BF02598160; BROWN SA, 1992, RES NURS HEALTH, V15, P409, DOI 10.1002/nur.4770150603; Burg MM., 1994, ANN BEHAV MED, V16, P109, DOI 10.1093/abm/16.2.109; CLARK NM, 1992, GERONTOLOGIST, V32, P438, DOI 10.1093/geront/32.4.438; CLARK NM, 1992, HEALTH EDUC QUART, V19, P341, DOI 10.1177/109019819201900306; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; CLARK NM, 1994, J ASTHMA, V31, P427, DOI 10.3109/02770909409089484; CLARK NM, 1989, CHEST, V95, P1110, DOI 10.1378/chest.95.5.1110; Clark NM, 1991, J AGING HEALTH, V3, P3, DOI DOI 10.1177/089826439100300101; CURRY SJ, 1993, J CONSULT CLIN PSYCH, V61, P790, DOI 10.1037/0022-006X.61.5.790; CURRY SJ, 1994, ANNU REV PUBL HEALTH, V15, P345; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; FAWZY FI, 1995, ARCH GEN PSYCHIAT, V52, P100; FAWZY FI, 1990, ARCH GEN PSYCHIAT, V47, P720; FIATARONE MA, 1993, J AM GERIATR SOC, V41, P333, DOI 10.1111/j.1532-5415.1993.tb06714.x; Frasure-Smith N, 1995, J Cardiopulm Rehabil, V15, P103; GILOTH BE, 1990, PATIENT EDUC COUNS, V15, P29, DOI 10.1016/0738-3991(90)90005-6; GLASGOW RE, 1992, DIABETES CARE, V15, P1423, DOI 10.2337/diacare.15.10.1423; GLASGOW RE, 1989, HEALTH PSYCHOL, V8, P285, DOI 10.1037/0278-6133.8.3.285; GLASGOW RE, 1992, PATIENT EDUC COUNS, V19, P61, DOI 10.1016/0738-3991(92)90102-O; GLASGOW RE, 1995, DIABETES CARE, V18, P117, DOI 10.2337/diacare.18.1.117; Glasgow RE, 1996, DIABETES CARE, V19, P835, DOI 10.2337/diacare.19.8.835; GLYNN TJ, 1990, HEALTH EDUC QUART, V17, P329, DOI 10.1177/109019819001700308; GOODALL TA, 1991, HEALTH PSYCHOL, V10, P1, DOI 10.1037/0278-6133.10.1.1; GREENE B, 1994, J CONSULT CLIN PSYCH, V62, P576, DOI 10.1037/0022-006X.62.3.576; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; GRUESSER M, 1993, DIABETES CARE, V16, P1268, DOI 10.2337/diacare.16.9.1268; GUSTAFSON DH, 1994, J AM MED INFORM ASSN, P604; Haynes RB, 1979, COMPLIANCE HLTH CARE; HELLER RF, 1993, AM J CARDIOL, V72, P759, DOI 10.1016/0002-9149(93)91058-P; HELLMAN CJC, 1990, BEHAV MED, V16, P165, DOI 10.1080/08964289.1990.9934605; HILTON S, 1986, LANCET, V1, P26; HIRANO PC, 1994, PATIENT EDUC COUNS, V24, P9, DOI 10.1016/0738-3991(94)90024-8; Hoffman C, 1996, JAMA-J AM MED ASSOC, V276, P1473, DOI 10.1001/jama.276.18.1473; Holman H, 1988, Trans Assoc Am Physicians, V101, P173; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353, DOI 10.1164/ajrccm.151.2.7842191; INUI TS, 1985, MED CARE, V23, P521, DOI 10.1097/00005650-198505000-00013; JAMES LD, 1993, BEHAV THER, V24, P305, DOI 10.1016/S0005-7894(05)80271-0; JENKINS CD, 1995, BEHAV MED, V21, P53, DOI 10.1080/08964289.1995.9933742; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLY JA, 1993, AM J PSYCHIAT, V150, P1679; KIRKMAN MS, 1994, DIABETES CARE, V17, P840, DOI 10.2337/diacare.17.8.840; KOSTIS JB, 1994, CHEST, V106, P996, DOI 10.1378/chest.106.4.996; KOVAR PA, 1992, ANN INTERN MED, V116, P529, DOI 10.7326/0003-4819-116-7-529; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; LORIG K, 1993, HEALTH EDUC QUART, V20, P17, DOI 10.1177/109019819302000104; LORIG K, 1984, GERONTOLOGIST, V24, P455; Lorig K, 1993, GENERATIONS, V3, P11; Lorig K., 1994, LIVING HLTH LIFE CHR; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MAZZE RS, 1994, DIABETES CARE, V17, P5; MAZZE RS, 1994, DIABETES CARE, V17, P56; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; MEYER TJ, 1995, HEALTH PSYCHOL, V14, P101, DOI 10.1037/0278-6133.14.2.101; MONTGOMERY EB, 1994, AM J MED, V97, P429, DOI 10.1016/0002-9343(94)90322-0; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; Patterson J.M., 1994, ANN BEHAV MED, V16, P131, DOI 10.1093/abm/16.2.131; Payne T H, 1995, HMO Pract, V9, P101; PAYNE TJ, 1994, J PSYCHOSOM RES, V38, P409, DOI 10.1016/0022-3999(94)90102-3; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037//0022-006X.51.3.390; RENE J, 1992, ARTHRITIS RHEUM, V35, P511, DOI 10.1002/art.1780350504; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; ROBINSON TN, 1989, COMPUT METH PROG BIO, V30, P137, DOI 10.1016/0169-2607(89)90065-5; Ruggiero L., 1993, DIABETES SPECTRUM, V6, P22; RUTTAN VW, 1988, GENERATION DIFFUSION, P69; SCHAFER LC, 1986, DIABETES CARE, V9, P179, DOI 10.2337/diacare.9.2.179; Sikkema KJ, 1996, ANN BEHAV MED, V18, P40, DOI 10.1007/BF02903938; SOBEL DS, 1995, PSYCHOSOM MED, V57, P234, DOI 10.1097/00006842-199505000-00005; SPIEGEL D, 1989, LANCET, V2, P888; STEWART AL, 1994, J CLIN EPIDEMIOL, V47, P719, DOI 10.1016/0895-4356(94)90169-4; STUCK AE, 1995, NEW ENGL J MED, V333, P1184, DOI 10.1056/NEJM199511023331805; TOBIN D, 1986, HDB CLIN INTERVENTIO; Turner JA, 1996, SPINE, V21, P2851, DOI 10.1097/00007632-199612150-00010; *U CAL, 1996, CHRON CAR AM 21 CENT; VANELDERENVANKEMENADE T, 1994, BRIT J CLIN PSYCHOL, V33, P367, DOI 10.1111/j.2044-8260.1994.tb01133.x; VINICOR F, 1987, J CHRON DIS, V40, P345, DOI 10.1016/0021-9681(87)90050-6; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391; WASSON J, 1992, JAMA-J AM MED ASSOC, V267, P1788, DOI 10.1001/jama.267.13.1788; WEINBERER M, 1995, J GEN INTERN MED, V10, P59, DOI 10.1007/BF02600227	85	837	844	2	81	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1097	1102		10.7326/0003-4819-127-12-199712150-00008	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YL262	9412313				2022-12-01	WOS:000070936600007
J	Whitfield, CR; Raafat, A; Urbaniak, SJ				Whitfield, CR; Raafat, A; Urbaniak, SJ			Underreporting of mortality from RhD haemolytic disease in Scotland and its implications: retrospective review	BRITISH MEDICAL JOURNAL			English	Article							PROPHYLAXIS		UNIV ABERDEEN,REG TRANSFUS CTR,DEPT MED & THERAPEUT,ACAD TRANSFUS MED UNIT,ABERDEEN AB9 2ZW,SCOTLAND	University of Aberdeen	Whitfield, CR (corresponding author), UNIV GLASGOW,QUEEN MOTHERS MATERN HOSP,DEPT OBSTET & GYNAECOL,GLASGOW G3 8SH,LANARK,SCOTLAND.							Bowman J M, 1988, Transfus Med Rev, V2, P129, DOI 10.1016/S0887-7963(88)70039-5; CLARKE C, 1994, J ROY COLL PHYS LOND, V28, P310; MURPHY KW, 1994, CONT REV OBSTETRICS, V6, P61; THORNTON JG, 1989, BMJ-BRIT MED J, V298, P1671, DOI 10.1136/bmj.298.6689.1671; Vick S, 1996, HEALTH ECON, V5, P319, DOI 10.1002/(SICI)1099-1050(199607)5:4<319::AID-HEC211>3.0.CO;2-6	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1504	1505		10.1136/bmj.315.7121.1504	http://dx.doi.org/10.1136/bmj.315.7121.1504			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420492	Green Published			2022-12-01	WOS:A1997YK98600021
J	Hogg, RS; Heath, KV; Yip, B; Craib, KJP; O'Shaughnessy, MV; Schechter, MT; Montaner, JSG				Hogg, RS; Heath, KV; Yip, B; Craib, KJP; O'Shaughnessy, MV; Schechter, MT; Montaner, JSG			Improved survival among HIV-infected individuals following initiation of antiretroviral therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; CUBIC MILLIMETER; CONTROLLED TRIAL; CONTINUED ZIDOVUDINE; COMBINATION THERAPY; MONOTHERAPY; LAMIVUDINE; PLASMA; CELLS; AIDS	Context.-Clinical trials have established the efficacy of antiretroviral therapy with double-and triple-drug regimens for individuals infected with the human immunodeficiency virus (HIV), but the effectiveness of these regimens in the population of patients not enrolled in clinical trials is unknown. Objective.-To characterize survival following the initiation of antiretroviral therapy among HIV-infected individuals in the province of British Columbia. Design.-Prospective, population-based Cohort study of patients with antiretroviral therapy available free of charge (median follow-up, 21 months). Setting.-Province of British Columbia, Canada. Patients.-All HIV-positive men and women 18 years of age or older in the province who were first prescribed any antiretroviral therapy between October 1992 and June 1996 and whose CD4(+) cell counts were less than 0.350x10(9)/L. Main Outcome Measures.-Rates of progression from initiation of antiretroviral therapy to death or a primary acquired immunodeficiency syndrome (AIDS) diagnosis for subjects who initially received zidovudine-, didanosine-, or zalcitabine-based therapy (ERA-I) and for those who initially received therapy regimens including lamivudine or stavudine (ERA-II). Results.-A total of 1178 patients (951 ERA-I, 227 ERA-II) were eligible, A total of 390 patients died (367 ERA-I, 23 ERA-II), yielding a crude mortality rate of 33.1%, ERA-I group subjects were almost twice as likely to die as ERA-II group subjects, with a mortality risk ratio of 1.86 (95% confidence interval [CI], 1.21-2.86, P=.005). After adjusting for Pneumocystis carinii and Mycobacterium avium prophylaxis use, AIDS diagnosis, CD4(+) cell count, sex, and age, ERA-I participants were 1.93 times (95% CI, 1.25-2.97; P=.003) more likely to die than ERA-II participants, Among patients without AIDS when treatment was started, ERA-I participants were 2.50 times (95% CI, 1.59-3.93; P<.001) more likely to progress to AIDS or death than ERA-II participants. Conclusion.-The HIV-infected individuals who received initial therapy with regimens including stavudine or lamivudine had significantly fewer mortality and longer AIDS-free survival than those who received initial therapy with regimens limited to zidovudine, didanosine, and zalcitabine.	Univ British Columbia, St Pauls Hosp, AIDS Res Programme, British Columbia Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Hlth Care & Epidemiol, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Pathol, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Univ British Columbia, Dept Med, Fac Med, Vancouver, BC V6Z 1Y6, Canada; Canadian HIV Trials Network, Vancouver, BC, Canada	B.C. Centre for Excellence in HIV/AIDS; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; University of British Columbia; University of British Columbia; University of British Columbia	Montaner, JSG (corresponding author), Univ British Columbia, St Pauls Hosp, AIDS Res Programme, British Columbia Ctr Excellence HIV AIDS, 667-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		Montaner, Julio/K-7621-2012; Hogg, Robert S/B-2783-2012	Hogg, Robert S/0000-0003-3463-5488; Schechter, Martin/0000-0001-6063-2155				Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1; Centers for Disease Control (CDC), 1992, MMWR Morb Mortal Wkly Rep, V41, P1; BROOKMEYER R, 1987, AM J EPIDEMIOL, V126, P14, DOI 10.1093/oxfordjournals.aje.a114646; CAMERON DW, 1996, 11 INT C AIDS JUL 7; Carpenter CCJ, 1996, JAMA-J AM MED ASSOC, V276, P146, DOI 10.1001/jama.276.2.146; COLLIER CA, 1996, NEW ENGL J MED, V834, P1011; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COX DR, 1972, J R STAT SOC B, V34, P187; *CTR EXC HIV AIDS, 1995, THER GUID TREATM HIV; Egger M, 1997, BMJ-BRIT MED J, V315, P1194, DOI 10.1136/bmj.315.7117.1194; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; Glesby MJ, 1996, ANN INTERN MED, V124, P999, DOI 10.7326/0003-4819-124-11-199606010-00008; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; Graham NMH, 1996, ANN INTERN MED, V124, P1031, DOI 10.7326/0003-4819-124-12-199606150-00002; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; Hogg RS, 1997, LANCET, V349, P1294, DOI 10.1016/S0140-6736(05)62505-6; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KATLAMA C, 1996, 3 C RETR OPP INF JAN; MATHEZ D, 1996, 3 C RETR OPP INF JAN; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; Montaner JSG, 1996, JAMA-J AM MED ASSOC, V275, P598, DOI 10.1001/jama.275.8.598; MURRAY HW, 1995, J INFECT DIS S2, V171, P5123; MYERS M, 1996, 11 INT C AIDS JUL 7; Neave H.R., 1998, DISTRIBUTION FREE TE; OBRIEN WA, 1996, NEW ENGL J MED, V334, P425; RIDHY T, 1995, J BIOL CHEM, V270, P29621; VELLA S, 1996, AIDS, V9, P21; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; *WHO, 1990, WKLY EPIDEMIOL REC, V65, P221	33	680	689	0	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					450	454		10.1001/jama.279.6.450	http://dx.doi.org/10.1001/jama.279.6.450			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV580	9466638	Bronze			2022-12-01	WOS:000071839800033
J	Dua, HS				Dua, HS			Bacterial keratitis in the critically ill and comatose patient	LANCET			English	Editorial Material									Univ Nottingham, Queens Med Ctr, Dept Ophthalmol, Nottingham NG7 2UH, England	University of Nottingham	Dua, HS (corresponding author), Univ Nottingham, Queens Med Ctr, Dept Ophthalmol, Nottingham NG7 2UH, England.		Dua, Harminder S/F-3656-2011					HILTON E, 1983, LANCET, V1, P1318; HUTTON WL, 1972, AM J OPHTHALMOL, V73, P37, DOI 10.1016/0002-9394(72)90301-7; Kirwan JF, 1997, BRIT MED J, V314, P433, DOI 10.1136/bmj.314.7078.433; Parkin B, 1997, BRIT J OPHTHALMOL, V81, P1060, DOI 10.1136/bjo.81.12.1060	4	22	24	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					387	388		10.1016/S0140-6736(05)78351-3	http://dx.doi.org/10.1016/S0140-6736(05)78351-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482289				2022-12-01	WOS:000071982600007
J	Oakley, MJ; Wheelwright, EF; James, PJ				Oakley, MJ; Wheelwright, EF; James, PJ			Lesson of the week - Pneumatic compression boots for prophylaxis against deep vein thrombosis: beware occult arterial disease	BRITISH MEDICAL JOURNAL			English	Review							TOTAL HIP-REPLACEMENT		Glasgow Royal Infirm, Orthopaed Directorate, Glasgow G4 0SF, Lanark, Scotland; Stobhill Hosp NHS Trust, Orthopaed Directorate, Glasgow G21 3UW, Lanark, Scotland	University of Glasgow	James, PJ (corresponding author), Glasgow Royal Infirm, Orthopaed Directorate, Glasgow G4 0SF, Lanark, Scotland.							BERNSTEIN MJ, 1986, JAMA-J AM MED ASSOC, V256, P744; EVARTS CM, 1967, MED CLIN N AM, V51, P1285, DOI 10.1016/S0025-7125(16)32995-9; EVARTS CM, 1987, CLIN ORTHOP RELAT R, P98; FORDYCE MJF, 1992, J BONE JOINT SURG BR, V74, P775; Gardner A M, 1983, Bristol Med Chir J, V98, P109; HULL RD, 1990, JAMA-J AM MED ASSOC, V263, P2313, DOI 10.1001/jama.263.17.2313; IMPERIALE TF, 1994, JAMA-J AM MED ASSOC, V271, P1780, DOI 10.1001/jama.271.22.1780; KILLEWICH LA, 1995, J VASC SURG, V22, P598, DOI 10.1016/S0741-5214(95)70046-3; LOTKE PA, 1984, J BONE JOINT SURG AM, V66A, P202, DOI 10.2106/00004623-198466020-00006; LYNCH JA, 1990, CLIN ORTHOP RELAT R, P24; Murray DW, 1996, J BONE JOINT SURG BR, V78B, P863, DOI 10.1302/0301-620X78B6.6714; SALZMAN EW, 1983, NEW ENGL J MED, V16, P980; STRANKS GL, 1996, J BONE JOINT SURG BR, V74, P775; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; WILSON NV, 1992, J BONE JOINT SURG BR, V74, P50, DOI 10.1302/0301-620X.74B1.1732265	15	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					454	455		10.1136/bmj.316.7129.454	http://dx.doi.org/10.1136/bmj.316.7129.454			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492676	Green Published			2022-12-01	WOS:000071982700040
J	Giese, KP; Fedorov, NB; Filipkowski, RK; Silva, AJ				Giese, KP; Fedorov, NB; Filipkowski, RK; Silva, AJ			Autophosphorylation at Thr(286) of the alpha calcium-calmodulin kinase II in LTP and learning	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; LONG-TERM POTENTIATION; MUTANT MICE; CAM KINASE; EXPRESSION; MEMORY; TRANSMISSION; MUTAGENESIS; MECHANISM; MUTATION	The calcium-calmodulin-dependent kinase II (CaMKII) is required for hippocampal longterm potentiation (LTP) and spatial learning. In addition to its calcium-calmodulin (CaM)dependent activity, CaMKII can undergo autophosphorylation, resulting in CaM-independent activity. A point mutation was introduced into the alpha CaMKII gene that blocked the autophosphorylation of threonine at position 286 (Thr(286)) Of this kinase without affecting its CaM-dependent activity, The mutant mice had no N-methyl-D-aspartate receptor-dependent LTP in the hippocampal CAI area and showed no spatial learning in the Morris water maze. Thus, the autophosphorylation of alpha CaMII at Thr(286) appears to be required for LTP and learning.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; M Nencki Inst Expt Biol, Dept Neurophysiol, PL-02093 Warsaw, Poland	Cold Spring Harbor Laboratory; Polish Academy of Sciences; Nencki Institute of Experimental Biology of the Polish Academy of Sciences	Silva, AJ (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.		Silva, Alcino/ABD-7684-2021; Giese, Karl P/A-3112-2011	Silva, Alcino/0000-0002-1587-4558; Giese, Karl P/0000-0003-4503-7344; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE ON AGING [R01AG013622, U01AG013622] Funding Source: NIH RePORTER; NIA NIH HHS [AG13622] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; FONG YL, 1989, J BIOL CHEM, V264, P16759; FUKUNAGA K, 1993, J BIOL CHEM, V268, P7863; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1989, NEURON, V3, P59, DOI 10.1016/0896-6273(89)90115-3; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; Kirkwood A, 1997, P NATL ACAD SCI USA, V94, P3380, DOI 10.1073/pnas.94.7.3380; KOLB SJ, 1995, J NEUROCHEM, V64, P2147; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1988, P NATL ACAD SCI USA, V85, P5320, DOI 10.1073/pnas.85.14.5320; LLEDO PM, 1995, P NATL ACAD SCI USA, V92, P11175, DOI 10.1073/pnas.92.24.11175; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MAYFORD M, 1995, CELL, V81, P891, DOI 10.1016/0092-8674(95)90009-8; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MILLER SG, 1988, NEURON, V1, P593, DOI 10.1016/0896-6273(88)90109-2; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; OHASAKO S, 1991, J BIOCH, V109, P137; Olson EN, 1996, CELL, V85, P1, DOI 10.1016/S0092-8674(00)81073-9; Otmakhov N, 1997, J NEUROSCI, V17, P5357; Ouyang Y, 1997, J NEUROSCI, V17, P5416; PETTIT DL, 1994, SCIENCE, V266, P1881, DOI 10.1126/science.7997883; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; SAUER B, 1993, METHOD ENZYMOL, V225, P890; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Silva AJ, 1996, COLD SPRING HARB SYM, V61, P239; STELZER A, 1994, P NATL ACAD SCI USA, V91, P3058, DOI 10.1073/pnas.91.8.3058; STEVENS CF, 1994, CURR BIOL, V4, P687, DOI 10.1016/S0960-9822(00)00153-6; Tan SE, 1996, BRAIN RES, V711, P234, DOI 10.1016/0006-8993(95)01411-X; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; WAXHAM MN, 1990, P NATL ACAD SCI USA, V87, P1273, DOI 10.1073/pnas.87.4.1273; WOLFMAN C, 1994, BEHAV NEURAL BIOL, V61, P203, DOI 10.1016/S0163-1047(05)80001-9; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	42	813	864	0	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 6	1998	279	5352					870	873		10.1126/science.279.5352.870	http://dx.doi.org/10.1126/science.279.5352.870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452388				2022-12-01	WOS:000071923500046
J	Meier, R; Owen, TC; Matthews, HE; Jewitt, DC; Bockelee-Morvan, D; Biver, N; Crovisier, J; Gautier, D				Meier, R; Owen, TC; Matthews, HE; Jewitt, DC; Bockelee-Morvan, D; Biver, N; Crovisier, J; Gautier, D			A determination of the HDO/H2O ratio in comet C/1995 O1 (Hale-Bopp)	SCIENCE			English	Article							WATER; D/H; RATES	Deuterated water (HDO) was detected in comet C/1995 O1 (Hale-Bopp) with the use of the James Clerk Maxwell Telescope on Mauna Kea, Hawaii. The inferred D/H ratio in Hale-Bopp's water is (3.3 +/- 0.8) x 10(-4). This result is consistent with in situ measurements of comet P/Halley and the value found in C/1996 B2 (Hyakutake). This D/H ratio, higher than that in terrestrial water and more than 10 times the value for protosolar H-2,, implies that comets cannot be the only source for the oceans on Earth.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; Natl Res Council Canada, Herzberg Inst Astrophys, Victoria, BC V8X 4M6, Canada; Joint Astron Ctr, Hilo, HI 96720 USA; Observ Paris, F-92195 Meudon, France	University of Hawaii System; National Research Council Canada; UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris	Meier, R (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.							Bailey ME, 1996, MON NOT R ASTRON SOC, V281, P916, DOI 10.1093/mnras/281.3.916; BALSIGER H, 1995, J GEOPHYS RES-SPACE, V100, P5827, DOI 10.1029/94JA02936; BIVER N, 1997, B AM ASTRON SOC, V29, P1047; BIVER N, 1997, THESIS U PARIS 7; BOCKELEEMORVAN D, UNPUB; BROWN PD, 1989, MON NOT R ASTRON SOC, V237, P661, DOI 10.1093/mnras/237.3.661; CROVISIER J, 1994, J GEOPHYS RES-PLANET, V99, P3777, DOI 10.1029/93JE02088; De Wit JC., 1980, GEOSTANDARD NEWSLETT, V4, P33, DOI [DOI 10.1111/J.1751-908X.1980.TB00270.X, 10.1111/j.1751-908X.1980.tb00270.x]; DELLORUSSO N, 1997, B AM ASTRON SOC, V29, P1050; EBERHARDT P, 1995, ASTRON ASTROPHYS, V302, P301; Gensheimer PD, 1996, ASTRON ASTROPHYS, V314, P281; HAGEMANN R, 1970, TELLUS, V22, P712, DOI 10.1111/j.2153-3490.1970.tb00540.x; Haser L., 1957, B SOC R SCI 51 GE, V43, P740; Irvine WM, 1989, ORIGIN EVOLUTION PLA, P3; LECLUSE C, 1994, GEOCHIM COSMOCHIM AC, V58, P2927, DOI 10.1016/0016-7037(94)90126-0; LEVISON HF, 1994, ICARUS, V108, P18, DOI 10.1006/icar.1994.1039; LUNINE JI, 1991, ICARUS, V94, P333, DOI 10.1016/0019-1035(91)90232-I; MEHRINGER D, 1997, 6614 IAU; MEIER R, 1997, 6615 IAU; MILLAR TJ, 1989, ASTROPHYS J, V340, P906, DOI 10.1086/167444; Oort J., 1950, BAIN, V11, P91; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Owen T. C., 1997, Astronomical Society of the Pacific Conference Series, V122, P435; SCHLEICHER DG, 1997, B AM ASTRON SOC, V29, P1033; WEISSMAN PR, 1991, COMETS POST HALLEY E, V1, P463	25	203	205	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					842	844		10.1126/science.279.5352.842	http://dx.doi.org/10.1126/science.279.5352.842			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452379				2022-12-01	WOS:000071923500037
J	Pullen, N; Dennis, PB; Andjelkovic, M; Dufner, A; Kozma, SC; Hemmings, BA; Thomas, G				Pullen, N; Dennis, PB; Andjelkovic, M; Dufner, A; Kozma, SC; Hemmings, BA; Thomas, G			Phosphorylation and activation of p70(s6k) by PDK1	SCIENCE			English	Article							S6 KINASE; DOMAIN; SITE	Activation of the protein p70(s6k) by mitogens leads to increased translation of a family of messenger RNAs that encode essential components of the protein synthetic apparatus. Activation of the kinase requires hierarchical phosphorylation at multiple sites, culminating in the phosphorylation of the threonine in position 229 (Thr(229)), in the catalytic domain. The homologous site in protein kinase B (PKB), Thr(308), has been shown to be phosphorylated by the phosphoinositide-dependent protein kinase PDK1.A regulatory link between p70(s6k) and PKB was demonstrated, as PDK1 was found to selectively phosphorylate p70(s6k) at Thr(229). More importantly, PDK1 activated p70(s6k) in vitro and in vivo, whereas the catalytically inactive PDK1 blocked insulin-induced activation of p70(s6k).	Friedrich Miescher Inst, CH-4058 Basel, Switzerland	Friedrich Miescher Institute for Biomedical Research	Hemmings, BA (corresponding author), Friedrich Miescher Inst, Maulbeerstr 66, CH-4058 Basel, Switzerland.		Thomas, George/K-9235-2014	Thomas, George/0000-0003-3518-8149; Pullen, Nicholas/0000-0002-4014-9278				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dennis P.B., UNPUB; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; HANKS SK, 1995, PROTEIN KINASE FACTS; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Meyuhas Oded, 1996, V30, P363; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; Moser BA, 1997, MOL CELL BIOL, V17, P5648, DOI 10.1128/MCB.17.9.5648; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	17	718	732	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					707	710		10.1126/science.279.5351.707	http://dx.doi.org/10.1126/science.279.5351.707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445476				2022-12-01	WOS:000071731500037
J	Melamed, D; Benschop, RJ; Cambier, JC; Nemazee, D				Melamed, D; Benschop, RJ; Cambier, JC; Nemazee, D			Developmental regulation of B lymphocyte immune tolerance compartmentalizes clonal selection from receptor selection	CELL			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; ANTIGEN-RECEPTOR; CELL DIFFERENTIATION; BONE-MARROW; NEGATIVE SELECTION; STROMAL CELLS; CROSS-LINKING; EXPRESSION; MOUSE; SELF	B lymphocyte development is a highly ordered process that involves immunoglobulin gene rearrangements, antigen receptor expression, and a learning process that minimizes the development of cells with reactivity to self tissue. Two distinct mechanisms for immune tolerance have been defined that operate during early bone marrow stages of B cell development: apoptosis, which eliminates clones of cells, and receptor editing, which spares the cells but genetically reprograms their autoreactive antigen receptors through nested immunoglobulin L chain gene rearrangements. We show here that sensitivity to antigen-induced apoptosis arises relatively late in B cell development and is preceded by a functionally distinct developmental stage capable of receptor editing. This regulation compartmentalizes clonal selection from receptor selection.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Immunol, Denver, CO 80220 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Melamed, D (corresponding author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA.			Cambier, John/0000-0002-7803-242X	NIAID NIH HHS [R01 AI033608, R01 AI 33608, K04 AI01161, P01 AI22295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033608, P01AI022295, K04AI001161] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BILLIPS LG, 1992, BLOOD, V79, P1185; BOEKEL ET, 1995, INT IMMUNOL, V7, P1013; BRETSCHER P, 1970, SCIENCE, V169, P1042, DOI 10.1126/science.169.3950.1042; BRINES RD, 1992, INT IMMUNOL, V4, P765, DOI 10.1093/intimm/4.7.765; Burrows PD, 1997, CURR OPIN IMMUNOL, V9, P239, DOI 10.1016/S0952-7915(97)80142-2; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Chen C, 1997, IMMUNITY, V6, P97, DOI 10.1016/S1074-7613(00)80673-1; Choi MSK, 1996, EUR J IMMUNOL, V26, P676, DOI 10.1002/eji.1830260325; Constantinescu A, 1997, J EXP MED, V185, P609, DOI 10.1084/jem.185.4.609; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; FINKELMAN FD, 1995, J EXP MED, V181, P515, DOI 10.1084/jem.181.2.515; GAY D, 1993, J EXP MED, V177, P999, DOI 10.1084/jem.177.4.999; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Hardy RR, 1995, ANN NY ACAD SCI, V764, P19; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1993, CELL, V72, P325, DOI 10.1016/0092-8674(93)90111-3; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; Hertz M, 1997, IMMUNITY, V6, P429, DOI 10.1016/S1074-7613(00)80286-1; KINOSHITA T, 1988, J IMMUNOL, V140, P3066; Klinman NR, 1996, IMMUNITY, V5, P189, DOI 10.1016/S1074-7613(00)80314-3; Lang J, 1997, J EXP MED, V186, P1513, DOI 10.1084/jem.186.9.1513; Lang J, 1996, J EXP MED, V184, P1685, DOI 10.1084/jem.184.5.1685; LEDERBERG J, 1959, SCIENCE, V129, P1649, DOI 10.1126/science.129.3364.1649; LI YS, 1993, J EXP MED, V178, P951, DOI 10.1084/jem.178.3.951; Li Z, 1996, IMMUNITY, V5, P575, DOI 10.1016/S1074-7613(00)80272-1; Lu LW, 1997, J IMMUNOL, V158, P5136; Melamed D, 1997, J IMMUNOL, V159, P1233; Melamed D, 1997, P NATL ACAD SCI USA, V94, P9267, DOI 10.1073/pnas.94.17.9267; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; MELCHERS F, 1995, CURR OPIN IMMUNOL, V7, P214, DOI 10.1016/0952-7915(95)80006-9; METCALF ES, 1977, J IMMUNOL, V118, P2111; Monroe JG, 1996, J IMMUNOL, V156, P2657; NAKAYAMA K, 1993, SCIENCE, V261, P1584, DOI 10.1126/science.8372353; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NORVELL A, 1995, J IMMUNOL, V154, P4404; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; NOSSAL GJV, 1994, CELL, V76, P229, DOI 10.1016/0092-8674(94)90331-X; OJCIUS DM, 1991, EXP CELL RES, V197, P43, DOI 10.1016/0014-4827(91)90477-C; PARRY SL, 1994, J IMMUNOL, V152, P2821; Pelanda R, 1997, IMMUNITY, V7, P765, DOI 10.1016/S1074-7613(00)80395-7; PIKE BL, 1980, J EXP MED, V152, P1407, DOI 10.1084/jem.152.5.1407; Radic MZ, 1995, ANN NY ACAD SCI, V764, P384; Radic MZ, 1996, IMMUNITY, V5, P505, DOI 10.1016/S1074-7613(00)80266-6; RAFF MC, 1975, J EXP MED, V142, P1052, DOI 10.1084/jem.142.5.1052; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RETH M, 1995, IMMUNOL TODAY, V16, P310; ROLINK A, 1991, EUR J IMMUNOL, V21, P2895, DOI 10.1002/eji.1830211137; ROLINK A, 1993, J EXP MED, V178, P1263, DOI 10.1084/jem.178.4.1263; ROLINK A, 1994, INT IMMUNOL, V6, P1257, DOI 10.1093/intimm/6.8.1257; RUSSELL DM, 1991, NATURE, V354, P308, DOI 10.1038/354308a0; Shaffer AL, 1997, J IMMUNOL, V159, P1265; SIDMAN CL, 1975, NATURE, V257, P149, DOI 10.1038/257149a0; Sleckman BP, 1996, ANNU REV IMMUNOL, V14, P459, DOI 10.1146/annurev.immunol.14.1.459; SMITHSON G, 1995, J IMMUNOL, V155, P3409; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; STORB U, 1994, IMMUNOL RES, V13, P291, DOI 10.1007/BF02935620; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; TSUBATA T, 1994, CURR BIOL, V4, P8, DOI 10.1016/S0960-9822(00)00003-8; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; VILAN BJ, 1997, J IMMUNOL, V159, P231; WINKLER TH, 1995, BLOOD, V85, P2045, DOI 10.1182/blood.V85.8.2045.bloodjournal8582045; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043	65	201	203	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					173	182		10.1016/S0092-8674(00)80912-5	http://dx.doi.org/10.1016/S0092-8674(00)80912-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458042	Bronze			2022-12-01	WOS:000071672600007
J	Krentz, AJ; Evans, AJ				Krentz, AJ; Evans, AJ			Selective imidazoline receptor agonists for metabolic syndrome	LANCET			English	Editorial Material							INSULIN-RESISTANCE; HYPERTENSION; ABNORMALITIES; DISEASE; SYSTEM		Southampton Gen Hosp, Dept Endocrinol & Diabet, Southampton SO16 6YD, Hants, England	University of Southampton	Krentz, AJ (corresponding author), Southampton Gen Hosp, Dept Endocrinol & Diabet, Southampton SO16 6YD, Hants, England.		Krentz, Andrew/AAD-2493-2019					CHRISP P, 1992, DRUGS, V44, P993, DOI 10.2165/00003495-199244060-00008; Curb JD, 1996, JAMA-J AM MED ASSOC, V276, P1886, DOI 10.1001/jama.276.23.1886; Davis BR, 1996, AM J HYPERTENS, V9, P342, DOI 10.1016/0895-7061(96)00037-4; Ernsberger P, 1996, CARDIOVASC DRUG THER, V10, P275, DOI 10.1007/BF00120497; JULIUS S, 1991, J HYPERTENS, V9, P983, DOI 10.1097/00004872-199111000-00001; KAAN EC, 1995, CARDIOVASC RISK F S1, V5, P19; Landsberg Lewis, 1996, Blood Pressure, V5, P25; LITHELL H, 1997, EUR CARD SOC STOCKH; OGHIHARA T, 1995, AM J HYPERTENS, V8, P316; Reaven Gerald M., 1996, New England Journal of Medicine, V334, P374; Rosen P, 1997, J HYPERTENS, V15, pS31	11	18	20	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					152	153		10.1016/S0140-6736(98)22003-4	http://dx.doi.org/10.1016/S0140-6736(98)22003-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449863				2022-12-01	WOS:000071616300002
J	Quemeneur, E; Moutiez, M; Charbonnier, JB; Menez, A				Quemeneur, E; Moutiez, M; Charbonnier, JB; Menez, A			Engineering cyclophilin into a proline-specific endopeptidase	NATURE			English	Article							CIS-TRANS-ISOMERASE; ESCHERICHIA-COLI; ENZYME; ISOMERIZATION; HYDROLYSIS; MECHANISM; PROGRAM	Designing an enzyme requires, among a number of parameters, the appropriate positioning of catalytic machinery within a substrate-binding cleft. Using the structures of cyclophilin-peptide complexes(1-4), we have engineered a new catalytic activity into an Escherichia coli cyclophilin by mutating three amino acids, close to the peptide binding deft, to form a catalytic triad similar to that found in serine proteases. In conjunction with cyclophilin's specificity for proline-bearing peptides, this creates a unique endopeptidase, cyproase 1, which cleaves peptides on the amino-side of proline residues. When acting on an Ala-Pro dipeptide, cyproase 1 has an efficiency (k(cat)/K-m) of 0.7 x 10(4) M-1 s(-1) and enhances the rate of reaction (k(cat)/k(uncat)) 8 x 10(8)-fold. This activity depends upon a deprotonated histidine and is inhibited by nucleophile-specific reagents, as occurs in natural serine proteases. Cyproase 1 can hydrolyse a protein substrate with a proline-specific endoprotease activity.	CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Quemeneur, E (corresponding author), CEA Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France.		Moutiez, Mireille/T-7788-2019; Charbonnier, Jean-Baptiste/A-3868-2009	Moutiez, Mireille/0000-0002-0064-8291; Charbonnier, Jean-Baptiste/0000-0002-5219-1983				BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CLUBB RT, 1994, BIOCHEMISTRY-US, V33, P2761, DOI 10.1021/bi00176a004; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; Fersht A., 1985, ENZYME STRUCTURE MEC; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; GALAT A, 1995, PROG BIOPHYS MOL BIO, V63, P69; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; KAHNE D, 1988, J AM CHEM SOC, V110, P7529, DOI 10.1021/ja00230a041; Kirby AJ, 1996, ANGEW CHEM INT EDIT, V35, P707; Konno M, 1996, J MOL BIOL, V256, P897, DOI 10.1006/jmbi.1996.0136; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIU J, 1990, P NATL ACAD SCI USA, V87, P4028, DOI 10.1073/pnas.87.11.4028; MAILLERE B, 1995, TOXICON, V33, P475, DOI 10.1016/0041-0101(94)00186-C; MATTHEWS BW, 1994, P NATL ACAD SCI USA, V91, P4103, DOI 10.1073/pnas.91.10.4103; MENEZ A, 1980, BIOCHEMISTRY-US, V19, P5202, DOI 10.1021/bi00564a008; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; PLUMMER TH, 1980, ANAL BIOCHEM, V108, P348, DOI 10.1016/0003-2697(80)90598-9; RADZICKA A, 1995, SCIENCE, V267, P90, DOI 10.1126/science.7809611; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Segel IH., 1993, ENZYME KINETICS BEHA; STEIN RL, 1993, ADV PROTEIN CHEM, V44, P1, DOI 10.1016/S0065-3233(08)60562-8; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7356, DOI 10.1021/bi9602775; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7362, DOI 10.1021/bi960278x	25	55	60	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					301	304		10.1038/34687	http://dx.doi.org/10.1038/34687			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440697				2022-12-01	WOS:000071484400056
J	Marsden, AFA; Wilkinson, B; Cortes, J; Dunster, NJ; Staunton, J; Leadlay, PF				Marsden, AFA; Wilkinson, B; Cortes, J; Dunster, NJ; Staunton, J; Leadlay, PF			Engineering broader specificity into an antibiotic-producing polyketide synthase	SCIENCE			English	Article							BIOSYNTHETIC GENE-CLUSTER; SACCHAROPOLYSPORA-ERYTHRAEA; STREPTOMYCES-HYGROSCOPICUS; ORGANIZATION; AVERMECTINS; RAPAMYCIN; DOMAIN; ACID; BACTERIA; SEQUENCE	The wide-specificity loading module for the avermectin-producing polyketide synthase was grafted onto the first multienzyme component (DEBS1) of the erythromycin-producing polyketide synthase in place of the normal loading module. Expression of this hybrid enzyme in the erythromycin producer Saccharopolyspora erythraea produced several novel antibiotic erythromycins derived from endogenous branched-chain acid starter units typical of natural avermectins. Because the avermectin polyketide synthase is known to accept more than 40 alternative carboxylic acids as starter units, this approach opens the way to facile production of novel analogs of antibiotic macrolides.	Univ Cambridge, Cambridge Ctr Mol Recognit, Cambridge CB2 1QW, England; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; Univ Cambridge, Chem Lab, Cambridge CB2 1EW, England; Univ Cambridge, Cambridge Ctr Mol Recognit, Cambridge CB2 1EW, England	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge	Leadlay, PF (corresponding author), Univ Cambridge, Cambridge Ctr Mol Recognit, Tennis Court Rd, Cambridge CB2 1QW, England.			Cortes, Jesus/0000-0002-2475-6983; Leadlay, Peter/0000-0002-3247-509X				Aparicio JF, 1996, GENE, V169, P9, DOI 10.1016/0378-1119(95)00800-4; Bax RP, 1997, CLIN INFECT DIS, V24, pS151, DOI 10.1093/clinids/24.Supplement_1.S151; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BROWN MJB, 1995, J CHEM SOC CHEM COMM, P1517, DOI 10.1039/c39950001517; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1983, J AM CHEM SOC, V105, P4110, DOI 10.1021/ja00350a070; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; CUTTER A, UNPUB; Davies J, 1996, NATURE, V383, P219, DOI 10.1038/383219a0; DHILLON N, 1989, MOL MICROBIOL, V3, P1405, DOI 10.1111/j.1365-2958.1989.tb00123.x; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; DUTTON CJ, 1991, J ANTIBIOT, V44, P357, DOI 10.7164/antibiotics.44.357; GRAMAJO HC, 1993, MOL MICROBIOL, V7, P837, DOI 10.1111/j.1365-2958.1993.tb01174.x; Hopwood D. A., 1985, GENETIC MANIPULATION; HUTCHINSON CR, 1995, ANNU REV MICROBIOL, V49, P201; Jack DB, 1996, MOL MED TODAY, V2, P499, DOI 10.1016/S1357-4310(97)81453-0; Jacobsen JR, 1997, SCIENCE, V277, P367, DOI 10.1126/science.277.5324.367; KAO CM, 1994, SCIENCE, V265, P509, DOI 10.1126/science.8036492; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Kim CG, 1996, J AM CHEM SOC, V118, P7486, DOI 10.1021/ja9601292; Kuhstoss S, 1996, GENE, V183, P231, DOI 10.1016/S0378-1119(96)00565-3; LAMBALOT RH, 1995, BIOCHEMISTRY-US, V34, P1858, DOI 10.1021/bi00006a006; Leadlay PF, 1997, CURR OPIN CHEM BIOL, V1, P162, DOI 10.1016/S1367-5931(97)80005-1; Lowden PAS, 1996, ANGEW CHEM INT EDIT, V35, P2249, DOI 10.1002/anie.199622491; MACNEIL DJ, 1992, GENE, V115, P119, DOI 10.1016/0378-1119(92)90549-5; MACNEIL DJ, 1994, ANN NY ACAD SCI, V721, P123, DOI 10.1111/j.1749-6632.1994.tb47384.x; MCARTHUR HAI, IN PRESS DEV IND MIC; MCDANIEL R, 1993, SCIENCE, V262, P1546, DOI 10.1126/science.8248802; MCDANIEL R, 1995, NATURE, V375, P549, DOI 10.1038/375549a0; Oliynyk M, 1996, CHEM BIOL, V3, P833, DOI 10.1016/S1074-5521(96)90069-1; PAIVA NL, 1993, J IND MICROBIOL, V12, P423, DOI 10.1007/BF01569676; PIEPER R, 1995, J AM CHEM SOC, V117, P11373, DOI 10.1021/ja00150a049; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Staunton J, 1996, NAT STRUCT BIOL, V3, P188, DOI 10.1038/nsb0296-188; SWAN DG, 1994, MOL GEN GENET, V242, P358, DOI 10.1007/BF00280426; TRAEDER W, 1994, TIERARZTL UMSCHAU, V49, P465; Wallace KK, 1997, J BACTERIOL, V179, P3884, DOI 10.1128/jb.179.12.3884-3891.1997; WEBER JM, 1990, J BACTERIOL, V172, P2372, DOI 10.1128/jb.172.5.2372-2383.1990; WIESMANN KEH, 1995, CHEM BIOL, V2, P583, DOI 10.1016/1074-5521(95)90122-1; Williams DH, 1996, CHEMTECH, V26, P17	42	191	224	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					199	202		10.1126/science.279.5348.199	http://dx.doi.org/10.1126/science.279.5348.199			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422686				2022-12-01	WOS:000071408100033
J	Dickson, N; Paul, C; Herbison, P; Silva, P				Dickson, N; Paul, C; Herbison, P; Silva, P			First sexual intercourse: age, coercion, and later regrets reported by a birth cohort	BRITISH MEDICAL JOURNAL			English	Article							BEHAVIOR; ADOLESCENTS; SAMPLE	Objectives: To investigate how age at first sexual intercourse is related to the reported circumstances and to determine how these corresponded to views in early adulthood about its timing, Design: Cross sectional study within a birth cohort using a questionnaire presented by computer. Setting: Dunedin, New Zealand in 1993-4. Subjects: 477 men and 458 women enrolled in the Dunedin Multidisciplinary Health and Development Study, comprising 92% of survivors of the cohort. Results: The median age at first intercourse was 17 years for men and 16 years for women. Only one man (0.2%) but 30 (7%) women reported being forced to have intercourse on the first occasion. For women, there were increasing races of coercion with younger age at first intercourse. More men than women reported that they and their partner were equally willing (77% (316/413) v 53% (222/419)). Mutual willingness of both partners was greater for those who reported that it was also the first time for their partner, Timing of first intercourse was consider ed about right by 49% (200/411) of men and 38% (148/388) of women, Many women (54% (211/388) reported that they should have waited longer; and this rose to 70% (90/129) for women reporting intercourse before age 16. Conclusions: Most women regretted having sexual intercourse before age 16, First intercourse at younger ages is associated with risks that are shared unequally between men and women. This information is important to young people themselves.	Univ Otago, Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Sch Med, Dunedin Multidisciplinary Hlth & Dev Unit, Dunedin, New Zealand	University of Otago; University of Otago	Dickson, N (corresponding author), Univ Otago, Sch Med, Dept Prevent & Social Med, POB 913, Dunedin, New Zealand.	ndickson@gandalf.otago.ac.nz		Herbison, Graham Peter/0000-0002-5684-024X				CURTIS HA, 1988, ARCH DIS CHILD, V63, P373, DOI 10.1136/adc.63.4.373; Dean A.G., 1994, EPI INFO VERSION 6 W; DICKSON N, 1993, GENITOURIN MED, V69, P133; Dickson N, 1996, NEW ZEAL MED J, V109, P308; *FAC PUBL HLTH MED, 1995, GUID HLTH PROM, V42; Giddens A., 1992, TRANSFORMATION INTIM; HAYES CD, 1987, RISKING FUTURE; JOHNSON AM, 1989, AIDS, V3, P135, DOI 10.1097/00002030-198903000-00003; Johnson AM, 1994, SEXUAL ATTITUDES LIF; KRAFT P, 1991, SOC SCI MED, V33, P207, DOI 10.1016/0277-9536(91)90182-C; Laumann E.O., 2000, SOCIAL ORG SEXUALITY; LEWIN B, 1982, ARCH SEX BEHAV, V11, P417, DOI 10.1007/BF01541574; MILLSTEIN SG, 1983, J PEDIATR-US, V103, P815, DOI 10.1016/S0022-3476(83)80493-4; PAUL C, 1995, AUST J PUBLIC HEALTH, V19, P13; Silva, 1996, CHILD ADULT DUNEDIN; StuartSmith S, 1996, BRIT MED J, V312, P390; THOMPSON S, 1989, PLEASURE DANGER EXPL, P350; USA Centers of Disease Control, 1991, Morbidity and Mortality Weekly Report, V40, P885; WADSWORTH J, 1991, J ROY STAT SOC A STA, V154, P367; Wellings K, 1994, SEXUAL BEHAV BRITAIN	20	133	136	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 3	1998	316	7124					29	33		10.1136/bmj.316.7124.29	http://dx.doi.org/10.1136/bmj.316.7124.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ353	9451263	Green Published, Bronze, Green Submitted			2022-12-01	WOS:000071377900020
J	Ekwall, K; Olsson, T; Turner, BM; Cranston, G; Allshire, RC				Ekwall, K; Olsson, T; Turner, BM; Cranston, G; Allshire, RC			Transient inhibition of histone deacetylation alters the structural and functional imprint at fission yeast centromeres	CELL			English	Article							POSITION-EFFECT VARIEGATION; INACTIVE X-CHROMOSOME; MATING-TYPE LOCI; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN STRUCTURE; CPG ISLANDS; ACETYLATION; HETEROCHROMATIN; MUTATIONS; GENE	Histone acetylation may act to mark and maintain transcriptionally active or inactive chromosomal domains through the cell cycle and in different lineages. A novel role for histone acetylation in centromere regulation has been identified. Exposure of fission yeast cells to TSA, a specific inhibitor of histone deacetylase, interferes with repression of marker genes in centromeric heterochromatin, causes chromosome loss, and disrupts the localization of Swi6p, a component of centromeric heterochromatin. Transient TSA treatment induces a heritable hyperacetylated state in centromeric chromatin that is propagated in lineages in the absence of drug. This state is linked in cis to the treated centromere locus and correlates with inheritance of functionally defective centromeres and persistent chromosome segregation problems. Thus, assembly of fully functional centromeres is partly imprinted in the underacetylated or transcriptionally silent state of centromeric chromatin.	Western Gen Hosp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Gothenburg Univ, Dept Mol Biol, Lundberg Lab, S-41390 Gothenburg, Sweden; Univ Birmingham, Sch Med, Dept Anat, Chromatin & Gene Express Grp, Birmingham B15 2TT, W Midlands, England	University of Edinburgh; University of Gothenburg; University of Birmingham	Allshire, RC (corresponding author), Western Gen Hosp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.			Ekwall, Karl/0000-0002-3029-4041; Allshire, Robin/0000-0002-8005-3625	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSHIRE RC, 1994, CELL, V76, P157, DOI 10.1016/0092-8674(94)90180-5; ALLSHIRE RC, 1995, GENE DEV, V9, P218, DOI 10.1101/gad.9.2.218; ALLSHIRE RC, 1996, EPIGENETIC MECH GENE; Belyaev ND, 1996, HUM GENET, V97, P573; BICKMORE WA, 1995, J CELL SCI, V108, P2801; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; DORN R, 1986, CHROMOSOMA, V93, P398, DOI 10.1007/BF00285820; duSart D, 1997, NAT GENET, V16, P144; EKWALL K, 1994, GENETICS, V136, P53; EKWALL K, 1995, SCIENCE, V269, P1429, DOI 10.1126/science.7660126; Ekwall K, 1996, J CELL SCI, V109, P2637; Grewal SIS, 1996, CELL, V86, P95, DOI 10.1016/S0092-8674(00)80080-X; Grewal SIS, 1997, GENETICS, V146, P1221; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; HEGEMANN JH, 1993, BIOESSAYS, V15, P451, DOI 10.1002/bies.950150704; HOFFMAN CS, 1991, GENE DEV, V5, P561, DOI 10.1101/gad.5.4.561; Javerzat JP, 1996, NUCLEIC ACIDS RES, V24, P4676, DOI 10.1093/nar/24.23.4676; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KARPEN G, 1998, IN PRESS TRENDS GENE; KELLUM R, 1995, J CELL SCI, V108, P1419; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MURPHY TD, 1995, CELL, V82, P599, DOI 10.1016/0092-8674(95)90032-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; Roth SY, 1996, CELL, V87, P5, DOI 10.1016/S0092-8674(00)81316-1; Shelby RD, 1997, J CELL BIOL, V136, P501, DOI 10.1083/jcb.136.3.501; STEINER NC, 1994, CELL, V79, P865, DOI 10.1016/0092-8674(94)90075-2; STEINER NC, 1993, MOL CELL BIOL, V13, P4578, DOI 10.1128/MCB.13.8.4578; SULLIVAN BA, 1995, HUM MOL GENET, V4, P2189, DOI 10.1093/hmg/4.12.2189; Sun XP, 1997, CELL, V91, P1007, DOI 10.1016/S0092-8674(00)80491-2; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; THON G, 1992, GENETICS, V131, P287; Thon G, 1997, GENETICS, V145, P685; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1995, SEMIN CELL BIOL, V6, P229, DOI 10.1006/scel.1995.0031; Warburton PE, 1997, CURR BIOL, V7, P901, DOI 10.1016/S0960-9822(06)00382-4; WOLFFE AP, 1997, J BIOL CHEM, V387, P16	41	317	325	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 26	1997	91	7					1021	1032		10.1016/S0092-8674(00)80492-4	http://dx.doi.org/10.1016/S0092-8674(00)80492-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428524	Bronze			2022-12-01	WOS:000071281400018
J	Salpeter, SR; Sanders, GD; Salpeter, EE; Owens, DK				Salpeter, SR; Sanders, GD; Salpeter, EE; Owens, DK			Monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age: A risk-benefit and cost-effectiveness analysis	ANNALS OF INTERNAL MEDICINE			English	Article							PREVENTIVE THERAPY; DECISION-ANALYSIS; UNITED-STATES; YOUNG-ADULTS; SKIN-TEST; CHEMOPROPHYLAXIS; HEPATITIS; LIVER; INFECTION; CHILDREN	Background: Isoniazid chemoprophylaxis effectively prevents the development of active infectious tuberculosis. Current guidelines recommend withholding this prophylaxis for low-risk tuberculin reactors older than 35 years of age because of the risk for fatal isoniazid-induced hepatitis. However, recent studies have shown that monitoring for hepatotoxicity can significantly reduce the risk for isoniazid-related death. Objective: To evaluate the effectiveness and cost-effectiveness of monitored isoniazid prophylaxis for low-risk tuberculin reactors older than 35 years of age. Design: A Markov model was used to compare the health and economic outcomes of prescribing or withholding a course of prophylaxis for low-risk reactors 35, 50, or 70 years of age. Subsequent analyses evaluated costs and benefits when the effect of transmission of Mycobacterium tuberculosis to contacts was included. Measurements: Probability of survival at 1 year, number needed to treat, life expectancy, and cost per year of life gained for individual persons and total population. Results: Isoniazid prophylaxis increased the probability of survival at 1 year and for all subsequent years. For 35-year-old, 50-year-old, and 70-year-old tuberculin reactors, life expectancy increased by 4.9 days, 4.7 days, and 3.1 days, respectively, and costs per person decreased by $101, $69, and $11, respectively. When the effect of secondary transmission to contacts was included, the gains in life expectancy per person receiving prophylaxis were 10.0 days for 35-year-old reactors, 9.0 days for 50-year-old reactors, and 6.0 days for 70-year-old reactors. Costs per person for these cohorts decreased by $259, $203, and $100, respectively. The magnitude of the benefit of isoniazid prophylaxis is moderately sensitive to the effect of isoniazid on quality of life. The hypothetical provision of isoniazid prophylaxis for all low-risk reactors older than 35 years of age in the U.S. population could prevent 35 176 deaths and save $2.11 billion. Conclusions: Monitored isoniazid prophylaxis reduces mortality rates and health care costs for low-risk tuberculin reactors older than 35 years of age, although reductions for individual patients are small. For the U.S. population, however, the potential health benefits and economic savings resulting from wider use of monitored isoniazid prophylaxis are substantial. We should consider expanding current recommendations to include prophylaxis for tuberculin reactors of all ages with no contraindications.	Santa Clara Valley Med Ctr, San Jose, CA 95128 USA; Stanford Univ, Sch Med, Sect Med Informat, Stanford, CA 94305 USA; Cornell Univ, Ctr Radiophys & Space Res, Ithaca, NY USA; Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA	Santa Clara Valley Medical Center; Stanford University; Cornell University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System	Salpeter, EE (corresponding author), Santa Clara Valley Med Ctr, 2400 Moorpark Ave,Suite 118, San Jose, CA 95128 USA.							ALCABES P, 1989, AM REV RESPIR DIS, V140, P1194, DOI 10.1164/ajrccm/140.5.1194; *AM MED ASS, 1995, PHYS CURR PROC TERM; *AM MED ASS, 1996, MED RBRVS PHYS GUID; BAILEY TC, 1995, ANN INTERN MED, V122, P580, DOI 10.7326/0003-4819-122-8-199504150-00004; BAILEY WC, 1983, AM REV RESPIR DIS, V127, P790; BAILEY WC, 1974, ANN INTERN MED, V81, P200, DOI 10.7326/0003-4819-81-2-200; BAILEY WC, 1973, AM REV RESPIR DIS, V107, P523, DOI 10.1164/arrd.1973.107.4.523; BAILEY WC, 1985, CHEST, V87, pS128; BARLOW PB, 1974, AM REV RESPIR DIS, V110, P371; BARNES PF, 1991, NEW ENGL J MED, V324, P1644, DOI 10.1056/NEJM199106063242307; BARNES PF, 1993, ANN INTERN MED, V119, P400, DOI 10.7326/0003-4819-119-5-199309010-00009; BEAUDRY PH, 1974, AM REV RESPIR DIS, V110, P581; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK M, 1975, GASTROENTEROLOGY, V69, P289; BLUM RN, 1993, CHEST, V103, P1670, DOI 10.1378/chest.103.6.1670; BROWN RE, 1995, ARCH INTERN MED, V155, P1595, DOI 10.1001/archinte.155.15.1595; BURRILL D, 1985, CAN MED ASSOC J, V132, P137; BYRD RB, 1979, JAMA-J AM MED ASSOC, V241, P1239, DOI 10.1001/jama.241.12.1239; BYRD RB, 1972, J AMER MED ASSOC, V220, P1471, DOI 10.1001/jama.1972.03200110051009; *CDC, 1994, COR CURR TUB, P13; *CDC, 1992, TUB US, P67; *CDC, 1991, TUB US, P14; *CDC PREV, 1996, REP TUB US 1995, P5; COLICE GL, 1990, ARCH INTERN MED, V150, P2517, DOI 10.1001/archinte.150.12.2517; COMSTOCK GW, 1976, PUBLIC HEALTH REP, V91, P276; COMSTOCK GW, 1967, AM REV RESPIR DIS, V95, P935; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; COMSTOCK GW, 1974, AM REV RESPIR DIS, V110, P195; COMSTOCK GW, 1981, ANN INTERN MED, V94, P817, DOI 10.7326/0003-4819-94-6-817; COOPER JK, 1986, J AM GERIATR SOC, V34, P814, DOI 10.1111/j.1532-5415.1986.tb03988.x; CULLINAN P, 1991, THORAX, V46, P347, DOI 10.1136/thx.46.5.347; DASH LA, 1980, AM REV RESPIR DIS, V121, P1039; DICKINSON DS, 1981, J CLIN GASTROENTEROL, V3, P271, DOI 10.1097/00004836-198109000-00012; DOLAN JG, 1994, MED DECIS MAKING, V14, P1, DOI 10.1177/0272989X9401400101; FEREBEE SH, 1963, AM REV RESPIR DIS, V88, P161; FEREBEE SH, 1970, ADV TUBERC RES, V17, P28; FITZGERALD JM, 1990, AM REV RESPIR DIS, V142, P848, DOI 10.1164/ajrccm/142.4.848; FITZGERALD JM, 1990, AM REV RESPIR DIS, V1415, pA438; FRANKS AL, 1989, PUBLIC HEALTH REP, V104, P151; Gage BF, 1996, ARCH INTERN MED, V156, P1829, DOI 10.1001/archinte.156.16.1829; GARIBALDI RA, 1972, AM REV RESPIR DIS, V106, P357, DOI 10.1164/arrd.1972.106.3.357; GIRLING DJ, 1992, AM REV RESPIR DIS, V145, P36; GLASSROTH J, 1990, AM REV RESPIR DIS, V141, P1236, DOI 10.1164/ajrccm/141.5_Pt_1.1236; GOLD MR, 1996, COST EFFECTIVENESS H, P214; GRZYBOWSKI S, 1976, CAN MED ASSOC J, V114, P607; GRZYBOWSKI S, 1969, CAN MED ASSOC J, V101, P555; GURUMURTHY P, 1984, AM REV RESPIR DIS, V129, P58; HANSON ML, 1967, PUBLIC HEALTH REP, V82, P1045, DOI 10.2307/4593193; *HLTH CAR INV AN I, 1996, MED DRG HDB; HORWITZ O, 1969, B WORLD HEALTH ORGAN, V41, P95; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P46, DOI 10.1080/00039896.1968.10665013; HSU KHK, 1974, JAMA-J AM MED ASSOC, V229, P528, DOI 10.1001/jama.229.5.528; Jordan T J, 1990, Bull Int Union Tuberc Lung Dis, V66 Suppl, P21; JORDAN TJ, 1991, AM REV RESPIR DIS, V144, P1357, DOI 10.1164/ajrccm/144.6.1357; KOPANOFF DE, 1978, AM REV RESPIR DIS, V117, P991; KULLER LH, 1974, PREV MED, V3, P61, DOI 10.1016/0091-7435(74)90063-2; LEVIN ML, 1974, MARYLAND STATE MED J, V23, P64; LITT IF, 1976, J PEDIATR-US, V89, P133, DOI 10.1016/S0022-3476(76)80949-3; MACKAY AD, 1984, Q J MED, V53, P497; MADDREY WC, 1973, ANN INTERN MED, V79, P1, DOI 10.7326/0003-4819-79-1-1; *MED, 1997, FEE COD STAND; MEHTA JB, 1988, CHEST, V94, P138, DOI 10.1378/chest.94.1.138; Millard PS, 1996, WESTERN J MED, V164, P486; MITCHELL JR, 1975, CHEST, V68, P181, DOI 10.1378/chest.68.2.181; MOHLEBOETANI JC, 1995, JAMA-J AM MED ASSOC, V274, P613, DOI 10.1001/jama.274.8.613; MORI MA, 1992, ARCH INTERN MED, V152, P547, DOI 10.1001/archinte.152.3.547; NAKAJO MM, 1989, PEDIATR INFECT DIS J, V8, P649, DOI 10.1097/00006454-198909000-00019; *NAT CTR HLTH STAT, 1995, MONTHL VIT STAT REP; *NAT CTR HLTH STAT, 1991, VIT STAT US 1988 A, V2; NAZAR V, 1990, American Review of Respiratory Disease, V141, pA438; NOLAN CM, 1986, AM REV RESPIR DIS, V133, P431; OBRIEN RJ, 1990, AM REV RESPIR DIS, V141, P821, DOI 10.1164/ajrccm/141.4_Pt_1.821; Protection against viral hepatitis, 1990, MMWR RECOMM REP, V39, P1; Quillan S, 1990, J Am Coll Health, V38, P165; Rabindran E, 1991, Md Med J, V40, P793; RAPP RS, 1978, AM REV RESPIR DIS, V118, P794, DOI 10.1164/arrd.1978.118.4.794; ROSE DN, 1986, JAMA-J AM MED ASSOC, V256, P2709, DOI 10.1001/jama.256.19.2709; ROSENBERG T, 1993, AM REV RESPIR DIS, V148, P1537, DOI 10.1164/ajrccm/148.6_Pt_1.1537; SALPETER EE, IN PRESS AM J EPIDEM; SALPETER S, 1992, WESTERN J MED, V157, P421; SALPETER SR, 1993, WESTERN J MED, V159, P560; SCHARER L, 1969, ANN INTERN MED, V71, P1113, DOI 10.7326/0003-4819-71-6-1113; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SPYRIDIS P, 1979, ARCH DIS CHILD, V54, P65, DOI 10.1136/adc.54.1.65; STEAD WW, 1987, ANN INTERN MED, V107, P843, DOI 10.7326/0003-4819-107-6-843; STERLING TR, 1995, ARCH INTERN MED, V155, P1622, DOI 10.1001/archinte.155.15.1622; TAYLOR WC, 1981, ANN INTERN MED, V94, P808, DOI 10.7326/0003-4819-94-6-808; THOMAS PA, 1979, ARCH SURG-CHICAGO, V114, P597; THOMPSON JE, 1978, MED J AUSTRALIA, V1, P165, DOI 10.5694/j.1326-5377.1978.tb107815.x; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; TRUMP DH, 1993, ARCH INTERN MED, V153, P211, DOI 10.1001/archinte.153.2.211; TSEVAT J, 1988, AM REV RESPIR DIS, V137, P215, DOI 10.1164/ajrccm/137.1.215; VADASZ I, 1974, Bulletin of the International Union Against Tuberculosis, V49, P294; WADHAWAN D, 1990, P ABSTR 6 INT C AIDS, V1, pA249; 1980, MMWR MORB MORTAL WKL, V29, P589; 1997, EC REPORT PRESIDENT; [No title captured]	97	86	87	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1051	1061		10.7326/0003-4819-127-12-199712150-00001	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412307				2022-12-01	WOS:000070936600001
J	Livesey, FJ; OBrien, JA; Li, M; Smith, AG; Murphy, LJ; Hunt, SP				Livesey, FJ; OBrien, JA; Li, M; Smith, AG; Murphy, LJ; Hunt, SP			A Schwann cell mitogen accompanying regeneration of motor neurons	NATURE			English	Article							PANCREATITIS-ASSOCIATED PROTEIN; SPINAL MOTONEURONS; SENSORY NEURONS; MESSENGER-RNA; EXPRESSION; RECEPTOR; RAT; IDENTIFICATION; SURVIVAL; AXOTOMY	Motor neurons are the only adult mammalian neurons of the central nervous system to regenerate following injury(1). This ability is dependent on the environment of the peripheral nerve and an intrinsic capacity of motor neurons for regrowth(2). We report here the identification, using a technique known as messenger RNA differential display(3), of an extracellular signalling molecule, previously described as the pancreatic secreted protein Reg-2 (ref. 4), that is expressed solely in regenerating and developing rat motor and sensory neurons. Axon-stimulated Schwann cell proliferation is necessary for successful regeneration(5,6), and we show that Reg-2 is a potent Schwann cell mitogen in vitro. In vivo, Reg-2 protein is transported along regrowing axons and inhibition of Reg-2 signalling significantly retards the regeneration of Reg-2-containing axons. During development, Reg-2 production by motor and sensory neurons is regulated by contact with peripheral targets. Strong candidates for peripheral factors regulating Reg-2 production are cytokines of the LIF/CNTF family, because Reg-2 is not exp,ressed in developing motor or sensory neurons of mice carrying a targeted disruption of the LIF receptor gene, a common component of the receptor complexes for all of the LIF/CNTF family(7).	MRC,MOL BIOL LAB,CAMBRIDGE CB2 2QH,ENGLAND; UNIV EDINBURGH,CTR GENOME RES,EDINBURGH EH9 3JQ,MIDLOTHIAN,SCOTLAND; UNIV MANITOBA,DEPT INTERNAL MED,WINNIPEG,MB R3E 3J7,CANADA; UNIV MANITOBA,DEPT PHYSIOL,WINNIPEG,MB R3E 3J7,CANADA	MRC Laboratory Molecular Biology; University of Edinburgh; University of Manitoba; University of Manitoba			HUNT, STEPHEN P/C-1646-2008; Li, Meng/I-6941-2013	Hunt, Stephen/0000-0001-9453-5505; Livesey, Rick/0000-0001-6128-3372; Smith, Austin/0000-0002-3029-4682				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; Carroll SL, 1997, J NEUROSCI, V17, P1642; CHAKRABORTY C, 1995, J ENDOCRINOL, V145, P461, DOI 10.1677/joe.0.1450461; DEFELIPE C, 1994, J NEUROSCI, V14, P2911; DELAMONTE SM, 1990, J CLIN INVEST, V86, P1004, DOI 10.1172/JCI114762; DUMOULIN FL, 1991, EUR J NEUROSCI, V3, P338, DOI 10.1111/j.1460-9568.1991.tb00820.x; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; ECCLESTON PA, 1992, EXP CELL RES, V199, P1, DOI 10.1016/0014-4827(92)90455-H; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; FRIGERIO JM, 1993, BIOCHIM BIOPHYS ACTA, V1216, P329, DOI 10.1016/0167-4781(93)90167-C; FRIGERIO JM, 1993, BIOCHEMISTRY-US, V32, P9236, DOI 10.1021/bi00086a032; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; Greensmith L, 1996, TRENDS NEUROSCI, V19, P450, DOI 10.1016/S0166-2236(96)20034-7; HALL SM, 1986, NEUROPATH APPL NEURO, V12, P401, DOI 10.1111/j.1365-2990.1986.tb00151.x; IOVANNA J, 1991, J BIOL CHEM, V266, P25664; JENKINS R, 1991, NEUROSCI LETT, V129, P107, DOI 10.1016/0304-3940(91)90731-8; LI M, 1995, NATURE, V378, P724, DOI 10.1038/378724a0; LIANG P, 1994, NUCLEIC ACIDS RES, V22, P5763, DOI 10.1093/nar/22.25.5763; Pennica D, 1996, NEURON, V17, P63, DOI 10.1016/S0896-6273(00)80281-0; Reynolds M L, 1993, Curr Opin Neurobiol, V3, P683, DOI 10.1016/0959-4388(93)90139-P; Scherer S.S., 1996, GLIAL CELL DEV, P165; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHMALBRUCH H, 1995, BRAIN RES, V700, P254, DOI 10.1016/0006-8993(95)00982-V; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; WEINMASTER G, 1990, EMBO J, V9, P915, DOI 10.1002/j.1460-2075.1990.tb08189.x; WISDEN W, 1991, MOL NEUROBIOLOGY PRA, P205; YAN Q, 1992, NATURE, V360, P753, DOI 10.1038/360753a0	30	155	157	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					614	618		10.1038/37615	http://dx.doi.org/10.1038/37615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403691				2022-12-01	WOS:A1997YK85300051
J	McFadzean, J; Monson, JP; Watson, JD; Coakley, JH				McFadzean, J; Monson, JP; Watson, JD; Coakley, JH			Ethical debate - The dilemma of the incapacitated patient who has previously refused consent for surgery	BRITISH MEDICAL JOURNAL			English	Article								What should doctors do if a patient is critically ill and unable to give consent to a procedure that he or she has previously refused to consent to? Such a case is described below and discussed by a medicolegal specialist and by an ethicist.	ST BARTHOLOMEWS HOSP,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London									0	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1530	1531		10.1136/bmj.315.7121.1530	http://dx.doi.org/10.1136/bmj.315.7121.1530			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420500	Green Published			2022-12-01	WOS:A1997YK98600032
J	Valway, SE; Sanchez, MPC; Shinnick, TF; Orme, I; Agerton, T; Hoy, D; Jones, JS; Westmoreland, H; Onorato, IM				Valway, SE; Sanchez, MPC; Shinnick, TF; Orme, I; Agerton, T; Hoy, D; Jones, JS; Westmoreland, H; Onorato, IM			An outbreak involving extensive transmission of a virulent strain of Mycobacterium tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	35th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 07-16, 1997	SAN FRANCISCO, CALIFORNIA	Infect Dis Soc Amer			COMMUNITY; INFECTION; EPIDEMIC; CHILDREN	Background and Methods From 1994 to 1996, there was a large outbreak of tuberculosis in a small, rural community with a population at low risk for tuberculosis. Twenty-one patients with tuberculosis (15 with positive cultures) were identified; the DNA fingerprints of the 13 isolates available for testing were identical. To determine the extent of transmission, we investigated both the close and casual contacts of the patients. Using a mouse model, we also studied the virulence of the strain of Mycobacterium tuberculosis that caused the outbreak. Results The index patient, in whom tuberculosis was diagnosed in 1995; the source patient, in whom the disease was diagnosed in 1994; and a patient in whom the disease was diagnosed in 1996 infected the other 18 persons. In five, active disease developed after only brief, casual exposure. There was extensive transmission from the three patients to both close and casual contacts. Of the 429 contacts, 311 (72 percent) had positive skin tests, including 86 with documented skin-test conversions. Mice infected with the virulent Erdman strain of M. tuberculosis had approximately 1000 bacilli per lung after 10 days and about 10,000 bacilli per lung after 20 days. In contrast, mice infected with the strain involved in the outbreak had about 10,000 bacilli per lung after 10 days and about 10 million bacilli per lung after 20 days. Conclusions In this outbreak of tuberculosis, the growth characteristics of the strain involved greatly exceeded those of other clinical isolates of M. tuberculosia. The extensive transmission of tuberculosis may have been due to the increased virulence of the strain rather than to environmental factors or patient characteristics. (C) 1998, Massachusetts Medical Society.	Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div TB Eliminat, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Epidemiol Intelligence Serv, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div AIDS STD & TB Lab Res, Atlanta, GA 30333 USA; Colorado State Univ, Dept Microbiol & Immunol, Ft Collins, CO 80523 USA; Tennessee Dept Hlth, Upper Cumberland Reg, Cookeville, TN 38501 USA; Kentucky Dept Hlth Serv, Frankfort, KY 40601 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Colorado State University; Tennessee Department Health	Valway, SE (corresponding author), Ctr Dis Control & Prevent, Natl Ctr HIV STD & TB Prevent, Div TB Eliminat, Mailstop E-10,1600 Clifton Rd, Atlanta, GA 30333 USA.							Allos BM, 1996, ANN INTERN MED, V125, P114, DOI 10.7326/0003-4819-125-2-199607150-00007; BOSLEY ARJ, 1986, LANCET, V1, P1141; BRADEN CR, 1995, CLIN INFECT DIS, V21, P565, DOI 10.1093/clinids/21.3.565; CAVE MD, 1991, MOL CELL PROBE, V5, P73, DOI 10.1016/0890-8508(91)90040-Q; Chaves F, 1996, J CLIN MICROBIOL, V34, P1118, DOI 10.1128/JCM.34.5.1118-1123.1996; Decker J., 1995, APPL OCCUPATIONAL EN, V10, P887; Frieden TR, 1996, JAMA-J AM MED ASSOC, V276, P1229, DOI 10.1001/jama.276.15.1229; GRIFFITH DE, 1995, AM J RESP CRIT CARE, V152, P808, DOI 10.1164/ajrccm.152.2.7633747; HALEY CE, 1989, INFECT CONT HOSP EP, V10, P204, DOI 10.1086/646003; HILL JD, 1983, BRIT MED J, V286, P1471, DOI 10.1136/bmj.286.6376.1471; HOGE CW, 1994, AM J EPIDEMIOL, V139, P520, DOI 10.1093/oxfordjournals.aje.a117035; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; Jacobs H, 1996, SCIENCE, V274, P17; KLINE SE, 1995, NEW ENGL J MED, V333, P222, DOI 10.1056/NEJM199507273330404; Lincoln E M, 1965, Bibl Tuberc, V21, P157; Moreira AL, 1997, TUBERCLE LUNG DIS, V78, P47, DOI 10.1016/S0962-8479(97)90015-0; NORTH RJ, 1993, J EXP MED, V177, P1723, DOI 10.1084/jem.177.6.1723; ORDWAY DJ, 1995, INFECT IMMUN, V63, P741, DOI 10.1128/IAI.63.2.741-743.1995; RAO VR, 1980, BRIT MED J, V281, P187, DOI 10.1136/bmj.281.6234.187; SACKS JJ, 1985, AM J PUBLIC HEALTH, V75, P361, DOI 10.2105/AJPH.75.4.361	20	320	325	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					633	639		10.1056/NEJM199803053381001	http://dx.doi.org/10.1056/NEJM199803053381001			7	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486991				2022-12-01	WOS:000072299700001
J	Herold, BC; Immergluck, LC; Maranan, MC; Lauderdale, DS; Gaskin, RE; Boyle-Vavra, S; Leitch, CD; Daum, RS				Herold, BC; Immergluck, LC; Maranan, MC; Lauderdale, DS; Gaskin, RE; Boyle-Vavra, S; Leitch, CD; Daum, RS			Community-acquired methicillin-resistant Staphylococcus aureus in children with no identified predisposing risk	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTRAVENOUS DRUG-ABUSERS; UNITED-STATES HOSPITALS; INFECTIONS; OUTBREAK; COLONIZATION; EPIDEMIOLOGY; EVOLUTION; STRAINS; MRSA	Context.-Community-acquired methicillin-resistant Staphylococcus aureus (MRSA) infections in children have occurred primarily in individuals with recognized predisposing risks. Community-acquired MRSA infections in the absence of identified risk factors have been reported infrequently. Objectives.-To determine whether community-acquired MRSA infections in children with no identified predisposing risks are increasing and to define the spectrum of disease associated with MRSA isolation. Design.-Retrospective review of medical records. Patients.-Hospitalized children with S aureus isolated between August 1988 and July 1990 (1988-1990) and between August 1993 and July 1995 (1993-1995). Setting.-The University of Chicago Children's Hospital. Main Outcome Measures.-Prevalence of community-acquired MRSA over time, infecting vs colonizing isolates, and risk factors for disease. Results.-The number of children hospitalized with community-acquired MRSA disease increased from 8 in 1988-1990 to 35 in 1993-1995. Moreover, the prevalence of community-acquired MRSA without identified risk increased from 10 per 100 000 admissions in 1988-1990 to 259 per 100 000 admissions in 1993-1995 (P<.001), and a greater proportion of isolates produced clinical infection. The clinical syndromes associated with MRSA in children without identified risk were similar to those associated with community-acquired methicillin-susceptible S aureus. Notably, 7 (70%) of 10 community-acquired MRSA isolates obtained from children with an identified risk were nonsusceptible to at least 2 drugs, compared with only 6 (24%) of 25 isolates obtained from children without an identified risk (P=.02). Conclusions.-These findings demonstrate that the prevalence of community-acquired MRSA among children without identified risk factors is increasing.	Univ Chicago Hosp, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago Hosp, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago Hosp, Clin Microbiol Labs, Chicago, IL 60637 USA; Vet Affairs Med Ctr, Res Serv, Boston, MA USA	University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; University of Chicago; University of Illinois System; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Herold, BC (corresponding author), Univ Chicago Hosp, Dept Pediat, 5841 S Maryland Ave,MC6054, Chicago, IL 60637 USA.			Herold, Betsy/0000-0001-9974-0786				BERMAN DS, 1993, NEW ENGL J MED, V329, P1896, DOI 10.1056/NEJM199312163292517; BERMAN DS, 1987, J INFECT DIS, V155, P829, DOI 10.1093/infdis/155.4.829-a; BOXERBAUM B, 1988, PEDIATR PULM, V4, P159, DOI 10.1002/ppul.1950040307; BOYCE JM, 1981, INFECT CONT HOSP EP, V2, P110, DOI 10.1017/S0195941700053881; BOYCE JM, 1982, INFECT CONTROL, V3, P337; *CDC, 1981, MMWR-MORBID MORTAL W, V30, P557; CRAVEN DE, 1986, AM J MED, V80, P770, DOI 10.1016/0002-9343(86)90614-5; CROSSLEY K, 1979, J INFECT DIS, V139, P273, DOI 10.1093/infdis/139.3.273; DUNKLE LM, 1981, AM J MED, V70, P455, DOI 10.1016/0002-9343(81)90787-7; EMBIL J, 1994, INFECT CONT HOSP EP, V15, P646; HALEY RW, 1982, ANN INTERN MED, V97, P297, DOI 10.7326/0003-4819-97-3-297; HIRAMATSU K, 1992, MICROBIOL IMMUNOL, V36, P445, DOI 10.1111/j.1348-0421.1992.tb02043.x; HIRAMATSU K, 1995, MICROBIOL IMMUNOL, V39, P531, DOI 10.1111/j.1348-0421.1995.tb02239.x; Immergluck LC, 1996, PEDIATR INFECT DIS J, V15, P96, DOI 10.1097/00006454-199601000-00025; KALLEN AJ, 1997, 35 ANN M INF DIS SOC; KLINE MW, 1987, J INFECT DIS, V156, P205, DOI 10.1093/infdis/156.1.205; LAYTON MC, 1995, INFECT CONT HOSP EP, V16, P12; LEVINE DP, 1982, ANN INTERN MED, V97, P330, DOI 10.7326/0003-4819-97-3-330; LOCKSLEY RM, 1982, ANN INTERN MED, V97, P317, DOI 10.7326/0003-4819-97-3-317; Maranan MC, 1997, INFECT DIS CLIN N AM, V11, P813, DOI 10.1016/S0891-5520(05)70392-5; MARANAN MC, 1997, 35 ANN M INF DIS SOC; MARCINAK JF, 1997, 35 ANN M INF DIS SOC; Maslow Joel N., 1993, P563; MORENO F, 1995, CLIN INFECT DIS, V21, P1308, DOI 10.1093/clinids/21.5.1308; MURPHY S, 1992, J AM GERIATR SOC, V40, P213, DOI 10.1111/j.1532-5415.1992.tb02070.x; *NAT COMM CLIN LAB, 1993, M7A3 NCCLS, P13; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PATE KR, 1995, LANCET, V346, P132; RIBNER BS, 1989, AM J INFECT CONTROL, V17, P244, DOI 10.1016/0196-6553(89)90170-3; ROSENBERG J, 1995, LANCET, V346, P132, DOI 10.1016/S0140-6736(95)91203-7; RYFFEL C, 1990, GENE, V94, P137, DOI 10.1016/0378-1119(90)90481-6; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SARAVOLATZ LD, 1982, ANN INTERN MED, V97, P325, DOI 10.7326/0003-4819-97-3-325; TENOVER FC, 1995, J CLIN MICROBIOL, V33, P2233, DOI 10.1128/JCM.33.9.2233-2239.1995; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; WENZEL RP, 1976, AM J EPIDEMIOL, V103, P251, DOI 10.1093/oxfordjournals.aje.a112223	36	1115	1167	0	38	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					593	598		10.1001/jama.279.8.593	http://dx.doi.org/10.1001/jama.279.8.593			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486753	Bronze			2022-12-01	WOS:000072041900034
J	Schweizer, FE; Dresbach, T; DeBello, WM; O'Connor, V; Augustine, GJ; Betz, H				Schweizer, FE; Dresbach, T; DeBello, WM; O'Connor, V; Augustine, GJ; Betz, H			Regulation of neurotransmitter release kinetics by NSF	SCIENCE			English	Article							SENSITIVE FUSION PROTEIN; SYNAPTIC VESICLE FUSION; SQUID GIANT SYNAPSE; N-TYPE; TRANSMITTER RELEASE; CA2+ CHANNELS; ALPHA-SNAP; IN-VITRO; EXOCYTOSIS; ACTIVATION	NSF (N-ethylmaleimide-sensitive factor) is an adenosine triphosphatase (ATPase) that contributes to a protein complex essential for membrane fusion. The synaptic function of this protein was investigated by injecting, into the giant presynaptic terminal of squid, peptides that inhibit the ATPase activity of NSF stimulated by the soluble NSF attachment protein (SNAP). These peptides reduced the amount and slowed the kinetics of neurotransmitter release as a result of actions that required vesicle turnover and occurred at a step subsequent to vesicle docking. These results define NSF as an essential participant in synaptic vesicle exocytosis that regulates the kinetics of neurotransmitter release and, thereby, the integrative properties of synapses.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Marine Biol Lab, Woods Hole, MA 02543 USA; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	Duke University; Marine Biological Laboratory - Woods Hole; Max Planck Society	Augustine, GJ (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.		Augustine, George James/J-9228-2013					Augustine GJ, 1996, ANNU REV PHARMACOL, V36, P659, DOI 10.1146/annurev.pa.36.040196.003303; AUGUSTINE GJ, 1984, J PHYSIOL-LONDON, V346, P257, DOI 10.1113/jphysiol.1984.sp015020; AUGUSTINE GJ, 1987, ANNU REV NEUROSCI, V10, P633, DOI 10.1146/annurev.ne.10.030187.003221; BAMARD RJO, 1997, J CELL BIOL, V139, P875; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; BOMMERT K, 1993, NATURE, V363, P163, DOI 10.1038/363163a0; Byrne JH, 1996, J NEUROSCI, V16, P425; Colombo MI, 1996, J BIOL CHEM, V271, P18810, DOI 10.1074/jbc.271.31.18810; CORRIE JET, 1993, J PHYSIOL-LONDON, V465, P1; DEBELLO WM, 1995, NATURE, V373, P626, DOI 10.1038/373626a0; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; Diamond JS, 1997, J NEUROSCI, V17, P4672; Fasshauer D, 1997, J BIOL CHEM, V272, P28036, DOI 10.1074/jbc.272.44.28036; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; ISAACSON JS, 1993, J NEUROPHYSIOL, V70, P2187, DOI 10.1152/jn.1993.70.5.2187; KATZ B, 1965, PROC R SOC SER B-BIO, V161, P483, DOI 10.1098/rspb.1965.0016; MANN DW, 1978, J NEUROBIOL, V9, P329, DOI 10.1002/neu.480090410; Martin TFJ, 1995, COLD SPRING HARB SYM, V60, P197, DOI 10.1101/SQB.1995.060.01.022; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; MORGAN A, 1994, J BIOL CHEM, V269, P29347; NAGIEC EE, 1995, J BIOL CHEM, V270, P29182, DOI 10.1074/jbc.270.49.29182; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; OConnor V, 1997, P NATL ACAD SCI USA, V94, P12186, DOI 10.1073/pnas.94.22.12186; OConnor V, 1996, BIOCHEM SOC T, V24, P666, DOI 10.1042/bst0240666; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PARNAS H, 1994, J MEMBRANE BIOL, V142, P267; PARSONS TD, 1995, NEURON, V15, P1085, DOI 10.1016/0896-6273(95)90097-7; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; Rahamimoff R, 1997, NEURON, V18, P17, DOI 10.1016/S0896-6273(01)80043-X; Rothman JE, 1997, SCIENCE, V276, P1212, DOI 10.1126/science.276.5316.1212; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SIDDIQI O, 1976, P NATL ACAD SCI USA, V73, P3253, DOI 10.1073/pnas.73.9.3253; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TONG G, 1994, NEURON, V13, P1195, DOI 10.1016/0896-6273(94)90057-4; Vogel SS, 1996, J CELL BIOL, V134, P329, DOI 10.1083/jcb.134.2.329; Vyshedskiy A, 1997, J NEUROPHYSIOL, V78, P1791, DOI 10.1152/jn.1997.78.4.1791; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Young JZ, 1939, PHILOS T ROY SOC B, V229, P465, DOI 10.1098/rstb.1939.0003	48	86	89	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1203	1206		10.1126/science.279.5354.1203	http://dx.doi.org/10.1126/science.279.5354.1203			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469810				2022-12-01	WOS:000072115200042
J	Jones, CG; Ostfeld, RS; Richard, MP; Schauber, EM; Wolff, JO				Jones, CG; Ostfeld, RS; Richard, MP; Schauber, EM; Wolff, JO			Chain reactions linking acorns to gypsy moth outbreaks and Lyme disease risk	SCIENCE			English	Article							LEPIDOPTERA-LYMANTRIIDAE POPULATIONS; IXODES-DAMMINI ACARI; BORRELIA-BURGDORFERI; PEROMYSCUS-LEUCOPUS; DISPAR LEPIDOPTERA; NATURAL ENEMIES; NORTH-AMERICA; MAST; CONSEQUENCES; DYNAMICS	In eastern U.S. oak forests, defoliation by gypsy moths and the risk of Lyme disease are determined by interactions among acorns, white-footed mice, moths, deer, and ticks. Experimental removal of mice, which eat moth pupae, demonstrated that moth outbreaks are caused by reductions in mouse density that occur when there are no acorns. Experimental acorn addition increased mouse density. Acorn addition also increased densities of black-legged ticks, evidently by attracting deer, which are key tick hosts. Mice are primarily responsible for infecting ticks with the Lyme disease agent. The results have important implications for predicting and managing forest health and human health.	Inst Ecosyst Studies, Millbrook, NY 12545 USA; Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA; Oregon State Univ, Dept Fisheries & Wildlife, Corvallis, OR 97331 USA	Cary Institute of Ecosystem Studies; University of Connecticut; Oregon State University	Jones, CG (corresponding author), Inst Ecosyst Studies, POB AB, Millbrook, NY 12545 USA.		Schauber, Eric/K-4043-2019; Jones, Clive G/I-4603-2014	Schauber, Eric/0000-0002-0667-2604; Jones, Clive G/0000-0001-7630-7285; Ostfeld, Richard/0000-0002-3707-9301				BARBOUR AG, 1993, SCIENCE, V260, P1610, DOI 10.1126/science.8503006; BATZLI GO, 1977, AM MIDL NAT, V97, P18, DOI 10.2307/2424681; Bess Henry A., 1947, HARVARD FOREST BULL, V22, P1; CAMPBELL ROBERT W., 1967, FOREST SCI MONOGR, V15, P1; CAMPBELL RW, 1977, ENVIRON ENTOMOL, V6, P323, DOI 10.1093/ee/6.2.323; CAMPBELL RW, 1977, ENVIRON ENTOMOL, V6, P315, DOI 10.1093/ee/6.2.315; CAMPBELL RW, 1972, NE236 USDA FOR SERV; CAMPBELL RW, 1977, FOR SCI MONOGR, V19; DESY EA, 1989, ECOLOGY, V70, P411, DOI 10.2307/1937546; DOANE CC, 1970, J INVERTEBR PATHOL, V15, P21, DOI 10.1016/0022-2011(70)90094-7; ELKINTON JS, 1990, ANNU REV ENTOMOL, V35, P571, DOI 10.1146/annurev.en.35.010190.003035; Elkinton JS, 1996, ECOLOGY, V77, P2332, DOI 10.2307/2265735; FALCO RC, 1992, EXP APPL ACAROL, V14, P165, DOI 10.1007/BF01219108; Fish Durland, 1993, P25; Forbush E. H., 1896, GYPSY MOTH; Gottschalk K.W., 1990, P WORKSH SO APP MAST, P42; GOULD JR, 1990, J ANIM ECOL, V59, P213, DOI 10.2307/5169; HAJEK AE, 1990, P NATL ACAD SCI USA, V87, P6979, DOI 10.1073/pnas.87.18.6979; HANSEN LP, 1978, CAN J ZOOL, V56, P230; HOLT RD, 1994, ANNU REV ECOL SYST, V25, P495, DOI 10.1146/annurev.es.25.110194.002431; KROHNE DT, 1988, CAN J ZOOL, V66, P2170, DOI 10.1139/z88-324; LALONDE RG, 1992, AM NAT, V139, P1293, DOI 10.1086/285387; LANE RS, 1991, ANNU REV ENTOMOL, V36, P587, DOI 10.1146/annurev.en.36.010191.003103; LEVINE JF, 1985, AM J TROP MED HYG, V34, P355, DOI 10.4269/ajtmh.1985.34.355; MATHER TN, 1989, AM J EPIDEMIOL, V130, P143, DOI 10.1093/oxfordjournals.aje.a115306; MCSHEA W J, 1992, Virginia Journal of Science, V43, P177; MCSHEA WJ, 1993, J MAMMAL, V74, P999, DOI 10.2307/1382439; Ostfeld RS, 1996, J MAMMAL, V77, P266, DOI 10.2307/1382727; Ostfeld RS, 1996, J MED ENTOMOL, V33, P90, DOI 10.1093/jmedent/33.1.90; Ostfeld RS, 1997, AM SCI, V85, P338; Ostfeld RS, 1996, BIOSCIENCE, V46, P323, DOI 10.2307/1312946; PIESMAN J, 1986, J MED ENTOMOL, V23, P219, DOI 10.1093/jmedent/23.2.219; Piesman Joseph, 1994, P327; Pimm S.L., 1991, BALANCE NATURE ECOLO; Price M.V., 1986, P191; SKALLER PM, 1985, ENVIRON ENTOMOL, V14, P106, DOI 10.1093/ee/14.2.106; SMITH HR, 1985, WILDLIFE SOC B, V13, P166; SORK VL, 1993, ECOLOGY, V74, P528, DOI 10.2307/1939313; WILSON ML, 1988, J MED ENTOMOL, V25, P224, DOI 10.1093/jmedent/25.4.224; WOLFF JO, 1986, J MAMMAL, V67, P409, DOI 10.2307/1380900; Wolff JO, 1996, J MAMMAL, V77, P850, DOI 10.2307/1382690; WOOTTON JT, 1994, ANNU REV ECOL SYST, V25, P443, DOI 10.1146/annurev.es.25.110194.002303	42	313	326	3	288	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1023	1026		10.1126/science.279.5353.1023	http://dx.doi.org/10.1126/science.279.5353.1023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461433				2022-12-01	WOS:000072006400045
J	Paterson-Brown, S				Paterson-Brown, S			Education about the hymen is needed - Commentary	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Queen Charlottes & Chelsea Hosp, London W6 0XG, England	Imperial College London	Paterson-Brown, S (corresponding author), Queen Charlottes & Chelsea Hosp, London W6 0XG, England.	s.paterson-brown@rpms.ac.uk						Adler MW, 1997, BRIT MED J, V314, P1743, DOI 10.1136/bmj.314.7096.1743; DeCock KM, 1997, BRIT MED J, V314, P1747, DOI 10.1136/bmj.314.7096.1747; EMANS SJ, 1994, J PEDIATR-US, V125, P153, DOI 10.1016/S0022-3476(94)70144-X; Fenton K, 1997, BRIT MED J, V314, P1703, DOI 10.1136/bmj.314.7096.1703; Kandela P, 1996, LANCET, V347, P1615, DOI 10.1016/S0140-6736(96)91096-X; Lacey CJN, 1997, BRIT MED J, V314, P1715, DOI 10.1136/bmj.314.7096.1715; Low N, 1997, BRIT MED J, V314, P1719, DOI 10.1136/bmj.314.7096.1719; UNDERHILL RA, 1978, LANCET, V1, P375, DOI 10.1016/S0140-6736(78)91094-2	8	18	17	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 7	1998	316	7129					461	461		10.1136/bmj.316.7129.461	http://dx.doi.org/10.1136/bmj.316.7129.461			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492680	Green Published			2022-12-01	WOS:000071982700046
J	Mukhopadhyay, CK; Attieh, ZK; Fox, PL				Mukhopadhyay, CK; Attieh, ZK; Fox, PL			Role of ceruloplasmin in cellular iron uptake	SCIENCE			English	Article							K562 CELLS; SERUM IRON; FET3 GENE; TRANSFERRIN; METABOLISM; YEAST; HEMOCHROMATOSIS; FERROXIDASE; DEFICIENCY; TRANSPORT	Individuals with hereditary ceruloplasmin (Cp) deficiency have profound iron accumulation in most tissues, which suggests that Cp is important for normal release of cellular iron. Here, in contrast to expectations, Cp was shown to increase iron uptake by HepG2 cells, increasing the apparent affinity for the substrate by three times. Consistent with its role in iron uptake, Cp synthesis was regulated by iron supply and was increased four- to fivefold after iron depletion. Unlike other iron controllers that are posttranscriptionally regulated, Cp synthesis was transcriptionally regulated. Thus, iron-deficient cells could increase Cp synthesis to maintain intracellular iron homeostasis, so that defects would lead to global accumulation of iron in tissues.	Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fox, PL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	foxp@cesmtp.ccf.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052692, P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL29582, HL52692] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Askwith C, 1997, J BIOL CHEM, V272, P401; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BACON BR, 1988, ANN NY ACAD SCI, V526, P155, DOI 10.1111/j.1749-6632.1988.tb55502.x; BATEY RG, 1980, DIGEST DIS SCI, V25, P340, DOI 10.1007/BF01308057; BOUMA ME, 1989, IN VITRO CELL DEV B, V25, P267; BREUER W, 1995, J BIOL CHEM, V270, P24209, DOI 10.1074/jbc.270.41.24209; BRITTON RS, 1994, IRON METABOLISM HLTH, P311; BROCK JH, 1994, IRON METABOLISM HLTH, P353; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hart EB, 1928, J BIOL CHEM, V77, P796; HERSHKO C, 1978, BRIT J HAEMATOL, V40, P255, DOI 10.1111/j.1365-2141.1978.tb03662.x; Kaplan J, 1996, J CLIN INVEST, V98, P3, DOI 10.1172/JCI118772; Kaplan J, 1996, SCIENCE, V271, P1510, DOI 10.1126/science.271.5255.1510; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LOGAN JI, 1994, Q J MED, V87, P663; MORITA H, 1995, ANN NEUROL, V37, P646, DOI 10.1002/ana.410370515; MUKHOPADHYAY C, UNPUB; OSAKI S, 1969, J BIOL CHEM, V244, P5757; OSAKI S, 1971, J BIOL CHEM, V246, P3018; OSAKI S, 1966, J BIOL CHEM, V241, P2746; PARKES JG, 1995, BBA-GEN SUBJECTS, V1243, P373, DOI 10.1016/0304-4165(94)00162-Q; RAGAN HA, 1969, AM J PHYSIOL, V217, P1320, DOI 10.1152/ajplegacy.1969.217.5.1320; ROESER HP, 1970, J CLIN INVEST, V49, P2408, DOI 10.1172/JCI106460; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; STEIN BS, 1986, J BIOL CHEM, V261, P319; WHITE S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P28, DOI 10.1016/0167-4889(92)90081-L; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	30	170	176	1	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 30	1998	279	5351					714	717		10.1126/science.279.5351.714	http://dx.doi.org/10.1126/science.279.5351.714			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445478				2022-12-01	WOS:000071731500039
J	Hirota, S; Isozaki, K; Moriyama, Y; Hashimoto, K; Nishida, T; Ishiguro, S; Kawano, K; Hanada, M; Kurata, A; Takeda, M; Tunio, GM; Matsuzawa, Y; Kanakura, Y; Shinomura, Y; Kitamura, Y				Hirota, S; Isozaki, K; Moriyama, Y; Hashimoto, K; Nishida, T; Ishiguro, S; Kawano, K; Hanada, M; Kurata, A; Takeda, M; Tunio, GM; Matsuzawa, Y; Kanakura, Y; Shinomura, Y; Kitamura, Y			Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors	SCIENCE			English	Article							RECEPTOR TYROSINE KINASE; LIGAND-INDEPENDENT ACTIVATION; HUMAN SMALL-INTESTINE; INTERSTITIAL-CELLS; BONE-MARROW; MAST-CELLS; W-LOCUS; CONSTITUTIVE ACTIVATION; POSSIBLE INVOLVEMENT; SUBMUCOSAL BORDER	Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors in the human digestive tract, but their molecular etiology and cellular origin are unknown. Sequencing of c-kit complementary DNA, which encodes a proto-oncogenic receptor tyrosine kinase (KIT), from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains. All of the corresponding mutant KIT proteins were constitutively activated without the KIT ligand, stem cell factor (SCF). Stable transfection of the mutant c-kit complementary DNAs induced malignant transformation of Ba/F3 murine lymphoid cells, suggesting that the mutations contribute to tumor development. GISTs may originate from the interstitial cells of Cajal (ICCs) because the development of ICCs is dependent on the SCF-KIT interaction and because, like GISTs, these cells express both KIT and CD34.	Osaka Univ, Sch Med, Dept Pathol, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Internal Med 2, Suita, Osaka 565, Japan; Osaka Univ, Sch Med, Dept Surg 1, Suita, Osaka 565, Japan; Osaka Med Ctr Canc & Cardiovasc Dis, Div Pathol, Osaka, Japan; Osaka Rosai Hosp, Div Pathol, Sakai, Osaka, Japan; Toyonaka Municipal Hosp, Div Pathol, Toyonaka, Osaka, Japan; Osaka Natl Hosp, Div Pathol, Osaka, Japan; Osaka Univ, Sch Med, Dept Hematol Oncol, Suita, Osaka 565, Japan	Osaka University; Osaka University; Osaka University; Osaka Medical Center for Cancer & Cardiovascular Diseases; Osaka Rosai Hospital; Osaka National Hospital; Osaka University	Kitamura, Y (corresponding author), Osaka Univ, Sch Med, Dept Pathol, Yamada Oka 2-2, Suita, Osaka 565, Japan.	kitamura@patho.med.osaka-u.ac.jp						ASHMAN LK, 1991, BLOOD, V78, P30; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; CATLETT JP, 1991, BLOOD, V78, P3186; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; FAUSSONEPELLEGRINI MS, 1990, CAN J PHYSIOL PHARM, V68, P1437, DOI 10.1139/y90-218; FAUSSONEPELLEGRINI MS, 1989, J SUBMICR CYTOL PATH, V21, P439; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; HIROTA S, 1995, LAB INVEST, V72, P64; HIROTA S, 1993, ARCH PATHOL LAB MED, V117, P996; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; ISOZAKI K, 1995, GASTROENTEROLOGY, V109, P456, DOI 10.1016/0016-5085(95)90333-X; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; MAEDA H, 1992, DEVELOPMENT, V116, P369; MATSUDA R, 1993, AM J PATHOL, V142, P339; MIETTINEN M, 1995, AM J SURG PATHOL, V19, P207, DOI 10.1097/00000478-199502000-00009; MONIHAN JM, 1994, HISTOPATHOLOGY, V25, P469, DOI 10.1111/j.1365-2559.1994.tb00009.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; RUMESSEN JJ, 1993, GASTROENTEROLOGY, V104, P343, DOI 10.1016/0016-5085(93)90400-7; RUMESSEN JJ, 1993, LAB INVEST, V68, P481; RUMESSEN JJ, 1992, GASTROENTEROLOGY, V102, P56, DOI 10.1016/0016-5085(92)91784-2; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; TSUJIMURA T, 1995, INT ARCH ALLERGY IMM, V106, P377, DOI 10.1159/000236870; TSUJIMURA T, 1994, BLOOD, V83, P2619; Tsujimura T, 1996, BLOOD, V87, P273; VANDERIJN M, 1994, HUM PATHOL, V25, P776; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P901, DOI 10.1016/S0016-5085(96)70057-4; Vanderwinden JM, 1996, GASTROENTEROLOGY, V111, P279, DOI 10.1053/gast.1996.v111.pm8690192; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	35	3240	3540	5	128	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					577	580		10.1126/science.279.5350.577	http://dx.doi.org/10.1126/science.279.5350.577			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438854				2022-12-01	WOS:000071616000051
J	Geissler, PE; Greenberg, R; Hoppa, G; Helfenstein, P; McEwen, A; Pappalardo, R; Tufts, R; Ockert-Bell, M; Sullivan, R; Greeley, R; Belton, MJS; Denk, T; Clark, B; Burns, J; Veverka, J				Geissler, PE; Greenberg, R; Hoppa, G; Helfenstein, P; McEwen, A; Pappalardo, R; Tufts, R; Ockert-Bell, M; Sullivan, R; Greeley, R; Belton, MJS; Denk, T; Clark, B; Burns, J; Veverka, J		Galileo Imaging Team	Evidence for non-synchronous rotation of Europa	NATURE			English	Article							ICE SHELL; GALILEAN SATELLITES; POLAR WANDER	Non-synchronous rotation of Europa was predicted on theoretical grounds(1), by considering the orbitally averaged torque exerted by Jupiter on the satellite's tidal bulges, If Europa's orbit were circular, or the satellite were comprised of a frictionless fluid without tidal dissipation, this torque would average to zero. However, Europa has a small forced eccentricity e approximate to 0.01 (ref. 2), generated by its dynamical interaction with Io and Ganymede, which should cause the equilibrium spin rate of the satellite to be slightly faster than synchronous, Recent gravity data(3) suggest that there may be a permanent asymmetry in Europa's interior mass distribution which is large enough to offset the tidal torque; hence, if non-synchronous rotation is observed, the surface is probably decoupled from the interior by a subsurface layer of liquid(4) or ductile ice(1), Non-synchronous rotation was invoked to explain Europa's global system of lineaments and an equatorial region of rifting seen in Voyager images(5,6). Here we report an analysis of the orientation and distribution of these surface features, based on initial observations made by the Galileo spacecraft. We find evidence that Europa spins faster than the synchronous rate (or did so in the past), consistent with the possibility of a global subsurface ocean.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85712 USA; Cornell Univ, Lab Planetary Sci, Ithaca, NY 14853 USA; Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Natl Opt Astron Observ, Tucson, AZ 85726 USA; Arizona State Univ, Dept Geol, Tempe, AZ 85287 USA; DLR, Inst Planetary Explorat, D-12489 Berlin, Germany	University of Arizona; Cornell University; Brown University; National Optical Astronomy Observatory; Arizona State University; Arizona State University-Tempe; Helmholtz Association; German Aerospace Centre (DLR)	Geissler, PE (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85712 USA.	geissler@pirl.lpl.arizona.edu	Pappalardo, Robert/AAP-8953-2021; Sullivan, Robert/AAR-8193-2020	Pappalardo, Robert/0000-0003-2571-4627; 				Anderson JD, 1997, SCIENCE, V276, P1236, DOI 10.1126/science.276.5316.1236; Belton MJS, 1996, SCIENCE, V274, P377, DOI 10.1126/science.274.5286.377; BURNS JA, 1986, SATELLITES, pCH1; Carr MH, 1998, NATURE, V391, P363, DOI 10.1038/34857; GREENBERG R, 1984, ICARUS, V58, P186, DOI 10.1016/0019-1035(84)90038-1; GREENBERG R, 1997, LUN PLAN SCI C ABSTR, V28, P457; HELFENSTEIN P, 1985, ICARUS, V61, P175, DOI 10.1016/0019-1035(85)90099-5; HOPPA GV, 1997, LUNAR PLANET SCI, V28, P597; Leith AC, 1996, ICARUS, V120, P387, DOI 10.1006/icar.1996.0058; LUCCHITTA BK, 1982, SATELLITES JUPITER, pCH14; MCEWEN AS, 1986, NATURE, V321, P49, DOI 10.1038/321049a0; OJAKANGAS GW, 1989, ICARUS, V81, P220, DOI 10.1016/0019-1035(89)90052-3; OJAKANGAS GW, 1989, ICARUS, V81, P242, DOI 10.1016/0019-1035(89)90053-5; Pappalardo RT, 1998, NATURE, V391, P365, DOI 10.1038/34862; PIERI DC, 1981, NATURE, V289, P17, DOI 10.1038/289017a0; SCHENK PM, 1989, ICARUS, V79, P75, DOI 10.1016/0019-1035(89)90109-7; SULLIVAN R, 1997, LUNAR PLANET SCI, V28, P1395	17	88	92	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					368	370		10.1038/34869	http://dx.doi.org/10.1038/34869			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450751				2022-12-01	WOS:000071604200047
J	Jull, AJT; Courtney, C; Jeffrey, DA; Beck, JW				Jull, AJT; Courtney, C; Jeffrey, DA; Beck, JW			Isotopic evidence for a terrestrial source of organic compounds found in martian meteorites Allan Hills 84001 and Elephant Moraine 79001	SCIENCE			English	Article							ACCELERATOR MASS-SPECTROMETRY; SNC METEORITES; WEATHERING PRODUCTS; ALH 84001; CARBON; EETA-79001; MARS; ALH84001; NITROGEN; OXYGEN	Stepped-heating experiments on martian meteorites Allan Hills 84001 (ALH84001) and Elephant Moraine 79001 (EETA79001) revealed low-temperature (200 to 430 degrees Celsius) fractions with a carbon isotopic composition delta(13)C between -22 and -33 per mil and a carbon-14 content that is 40 to 60 percent of that of modern terrestrial carbon, consistent with a terrestrial origin for most of the organic material. Intermediate-temperature (400 to 600 degrees Celsius) carbonate-rich fractions of ALH84001 have delta(13)C of +32 to 140 per mil with a low carbon-14 content, consistent with an extraterrestrial origin, whereas some of the carbonate fraction of EETA79001 is terrestrial, In addition, ALH84001 contains a small preterrestrial carbon component of unknown origin that combusts at intermediate temperatures. This component is likely a residual acid-insoluble carbonate or a more refractory organic phase.	Univ Arizona, Natl Sci Fdn, Arizona Accelerator Mass Spect Facil, Tucson, AZ 85721 USA	National Science Foundation (NSF); University of Arizona	Jull, AJT (corresponding author), Univ Arizona, Natl Sci Fdn, Arizona Accelerator Mass Spect Facil, Tucson, AZ 85721 USA.							Ash RD, 1996, NATURE, V380, P57, DOI 10.1038/380057a0; Bada JL, 1998, SCIENCE, V279, P362, DOI 10.1126/science.279.5349.362; Becker L, 1997, GEOCHIM COSMOCHIM AC, V61, P475, DOI 10.1016/S0016-7037(96)00400-0; CARR RH, 1985, NATURE, V314, P248, DOI 10.1038/314248a0; CLAYTON RN, 1988, GEOCHIM COSMOCHIM AC, V52, P925, DOI 10.1016/0016-7037(88)90363-8; DONAHUE DJ, 1990, RADIOCARBON, V32, P135, DOI 10.1017/S0033822200040121; DONAHUE DJ, 1995, INT J MASS SPECTROM, V143, P235, DOI 10.1016/0168-1176(94)04132-Q; Friedman I., 1977, 440KK US GEOL SURV; Garrison DH, 1997, METEORIT PLANET SCI, V32, pA45; GOODING JL, 1988, GEOCHIM COSMOCHIM AC, V52, P909, DOI 10.1016/0016-7037(88)90361-4; GRADY MM, 1994, METEORITICS, V29, P469; GRADY MM, 1988, GEOCHIM COSMOCHIM AC, V52, P2855, DOI 10.1016/0016-7037(88)90152-4; Harvey RP, 1996, NATURE, V382, P49, DOI 10.1038/382049a0; HUTCHINS KS, 1997, THESIS U COLORADO; JAGOUTZ E, 1994, METEORITICS, V29, P478; JULL AJT, 1989, GEOCHIM COSMOCHIM AC, V53, P2095, DOI 10.1016/0016-7037(89)90327-X; JULL AJT, 1995, METEORITICS, V30, P311, DOI 10.1111/j.1945-5100.1995.tb01129.x; Jull AJT, 1997, J GEOPHYS RES-PLANET, V102, P1663, DOI 10.1029/96JE03111; JULL AJT, 1988, GEOCHIM COSMOCHIM AC, V52, P1309, DOI 10.1016/0016-7037(88)90285-2; LEVIN I, 1985, RADIOCARBON, V27, P1, DOI 10.1017/S0033822200006895; McKay DS, 1996, SCIENCE, V273, P924, DOI 10.1126/science.273.5277.924; MCSWEEN HY, 1994, METEORITICS, V29, P757, DOI 10.1111/j.1945-5100.1994.tb01092.x; MITTLEFEHLDT DW, 1994, METEORITICS, V29, P214, DOI 10.1111/j.1945-5100.1994.tb00673.x; Neupert U, 1997, METEORIT PLANET SCI, V32, pA98; ROMANEK CS, 1994, NATURE, V372, P655, DOI 10.1038/372655a0; SLOTA PJ, 1987, RADIOCARBON, V29, P303; SPERGEL MS, 1986, J GEOPHYS RES-SOLID, V91, pD483, DOI 10.1029/JB091iB04p0D483; Taylor R.E., 1987, RADIOCARBON DATING A; Turner G, 1997, GEOCHIM COSMOCHIM AC, V61, P3835, DOI 10.1016/S0016-7037(97)00285-8; Valley JW, 1997, SCIENCE, V275, P1633, DOI 10.1126/science.275.5306.1633; WRIGHT IP, 1989, NATURE, V340, P220, DOI 10.1038/340220a0; WRIGHT IP, 1988, GEOCHIM COSMOCHIM AC, V52, P917, DOI 10.1016/0016-7037(88)90362-6; WRIGHT IP, 1992, GEOCHIM COSMOCHIM AC, V56, P817, DOI 10.1016/0016-7037(92)90100-W; WRIGHT IP, 1997, LUNAR PLANET SCI, V28, P1591; [No title captured]	35	119	125	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					366	369		10.1126/science.279.5349.366	http://dx.doi.org/10.1126/science.279.5349.366			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430584				2022-12-01	WOS:000071570800042
J	Cnattingius, S; Bergstrom, R; Lipworth, L; Kramer, MS				Cnattingius, S; Bergstrom, R; Lipworth, L; Kramer, MS			Prepregnancy weight and the risk of adverse pregnancy outcomes	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BODY-MASS INDEX; PRETERM BIRTH; WOMEN; PREECLAMPSIA; GAIN; STILLBIRTH; PREVALENCE; NUTRITION; INFANTS	Background Obesity before pregnancy is associated with an increased risk of several adverse outcomes of pregnancy. The risk profiles among lean, normal, or mildly overweight women are not, however, well established. Methods We studied the associations between prepregnancy body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and the frequency of late fetal death, early neonatal death, preterm delivery, and delivery of a small-for-gestational-age infant in a population-based cohort of 167,750 women in Sweden in 1992 and 1993. The women were categorized as follows, according to body-mass index: lean, less than 20.0; normal, 20.0 through 24.9; overweight, 25.0 through 29.9; and obese, 30.0 or more. The estimates were adjusted for maternal age, parity, smoking, educa tion, whether the mother was living with the father, and maternal height. Results Among nulliparous women, the odds ratios for late fetal death were increased among women with higher body-mass indexes as compared with lean women, as follows: normal women, 2.2 (95 percent confidence interval, 1.2 to 4.1); overweight women, 3.2 (95 percent confidence interval, 1.6 to 6.2); and obese women, 4.3 (95 percent confidence interval, 2.0 to 9.3). Among parous women, only obese women had a significant increase in the risk of late fetal death (odds ratio, 2.0; 95 percent confidence interval, 1.2 to 3.3). Among nulliparous women, the risk of very preterm delivery (at less than or equal to 32 weeks' gestation) was significantly increased among obese as compared with lean women (odds ratio, 1.6; 95 percent confidence interval, 1.1 to 2.3), whereas among parous women, the risk was highest among those who were lean. The risk of delivering a small-for-gestational-age infant decreased more with increasing body-mass index among parous than among nulliparous women. Conclusions Higher maternal weight before pregnancy increases the risk of late fetal death, although it protects against the delivery of a small-for-gestational-age infant. (C) 1998, Massachusetts Medical Society.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Uppsala Univ, Dept Stat, S-75105 Uppsala, Sweden; Mt Sinai Sch Med, Dept Community Med, New York, NY USA; McGill Univ, Fac Med, Dept Pediat, Montreal, PQ, Canada; McGill Univ, Fac Med, Dept Biostat & Epidemiol, Montreal, PQ, Canada	Karolinska Institutet; Uppsala University; Icahn School of Medicine at Mount Sinai; McGill University; McGill University	Cnattingius, S (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.							[Anonymous], 1985, ANN INTERN MED, V103, P1073, DOI 10.7326/0003-4819-103-6-1073; BERKOWITZ GS, 1993, EPIDEMIOL REV, V15, P414, DOI 10.1093/oxfordjournals.epirev.a036128; ESKENAZI, 1995, AM J OBSTET GYNECOL, V173, P950; ESKENAZI B, 1993, AM J OBSTET GYNECOL, V169, P1112, DOI 10.1016/0002-9378(93)90265-K; ESKENAZI B, 1991, JAMA-J AM MED ASSOC, V266, P237; Galuska DA, 1996, AM J PUBLIC HEALTH, V86, P1729, DOI 10.2105/AJPH.86.12.1729; GLEICHER N, 1986, AM J OBSTET GYNECOL, V154, P1044, DOI 10.1016/0002-9378(86)90747-7; *I MED, 1992, NUTR PREGN LACT IMPL; Institute of Medicine (Subcommittees on Nutritional Status and Weight Gain During Pregnancy and Dietary Intake and Nutrient Supplements During Pregnancy Committee on Nutritional Status During Pregnancy and Lactation Food and Nutrition Board), 1990, NUTR PREGN 1; KAMINSKI M, 1973, INT J EPIDEMIOL, V2, P195, DOI 10.1093/ije/2.2.195; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KRAMER MS, 1992, AM J EPIDEMIOL, V136, P574, DOI 10.1093/oxfordjournals.aje.a116535; KRASOVEC K, 1991, B WORLD HEALTH ORGAN, V69, P523; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; KUSKOWSKAWOLK A, 1993, J EPIDEMIOL COMMUN H, V47, P195, DOI 10.1136/jech.47.3.195; *LIB ALLM FORL, 1986, SWED VERS INT CLASS; LITTLE RE, 1993, AM J EPIDEMIOL, V137, P1177, DOI 10.1093/oxfordjournals.aje.a116620; LUCAS A, 1988, BRIT MED J, V296, P1495, DOI 10.1136/bmj.296.6635.1495; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; Marsal K, 1996, ACTA PAEDIATR, V85, P843, DOI 10.1111/j.1651-2227.1996.tb14164.x; MEYER MB, 1976, AM J EPIDEMIOL, V103, P464, DOI 10.1093/oxfordjournals.aje.a112248; MITCHELL MC, 1989, J AM DIET ASSOC, V89, P634; NAEYE RL, 1990, AM J CLIN NUTR, V52, P273, DOI 10.1093/ajcn/52.2.273; NAEYE RL, 1979, AM J OBSTET GYNECOL, V135, P3; RANTAKALLIO P, 1995, J CLIN EPIDEMIOL, V48, P199, DOI 10.1016/0895-4356(94)00130-I; RYDHSTROM H, 1994, ACTA OBSTET GYN SCAN, V73, P779, DOI 10.3109/00016349409072504; SKODOVA Z, 1991, Cor et Vasa, V33, P114; STEIN ZA, 1984, SEMIN PERINATOL, V8, P5; STONE JL, 1994, OBSTET GYNECOL, V83, P357; WOLFE HM, 1991, AM J OBSTET GYNECOL, V164, P1306, DOI 10.1016/0002-9378(91)90705-V; WYNN A H A, 1991, Nutrition and Health (Bicester), V7, P69	31	748	767	0	59	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 15	1998	338	3					147	152		10.1056/NEJM199801153380302	http://dx.doi.org/10.1056/NEJM199801153380302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ414	9428815				2022-12-01	WOS:000071384500002
J	Goldin-Meadow, S; Mylander, C				Goldin-Meadow, S; Mylander, C			Spontaneous sign systems created by deaf children in two cultures	NATURE			English	Article							GESTURAL COMMUNICATION; LANGUAGE-DEVELOPMENT; PARENTAL INPUT	Deaf children whose access to usable conventional linguistic input, signed or spoken, is severely limited nevertheless use gesture to communicate(1-3). These gestures resemble natural language in that they are structured at the level both of sentence(4) and of word(5). Although the inclination Ito use gesture maybe traceable to the fact that the deaf children's]tearing parents, like all speakers, gesture as they talk(6), the children themselves are responsible for introducing language-like structure into their gestures(7). We have explored the robustness of this phenomenon by observing deaf children of hearing parents in two cultures, an American and a Chinese culture, that differ in their child-rearing practices(8-12) and in the way gesture is used in relation to speech(13). The spontaneous sign systems developed in these cultures shared a number of structural similarities: patterned production and deletion of semantic elements ii the surface structure of a sentence; patterned ordering of those elements within the sentence; and concatenation of propositions within a sentence. These striking similarities offer critical empirical input towards resolving the ongoing debate about the 'innateness' of language in human infants(14-16).	Univ Chicago, Dept Psychol, Chicago, IL 60637 USA	University of Chicago	Goldin-Meadow, S (corresponding author), Univ Chicago, Dept Psychol, 5730 S Woodlawn Ave, Chicago, IL 60637 USA.		Galantucci, Bruno/E-5770-2010					CHEN CS, 1988, HUM DEV, V31, P351, DOI 10.1159/000276334; Chomsky N., 1965, ASPECTS THEORY SYNTA; Dixon R.M.W., 1994, ERGATIVITY; Fant L. J., 1972, AMESLAN; FEYEREISEN P, 1991, GESTURE SPEECH; GLEITMAN L, 1995, LANGUAGE INVITATION, V1, P1; Goldin-Meadow S., 1996, INT J PRIMATOL, V17, P145; GOLDINMEADOW S, 1994, COGNITIVE PSYCHOL, V27, P259, DOI 10.1006/cogp.1994.1018; GOLDINMEADOW S, 1995, COGNITION, V56, P195, DOI 10.1016/0010-0277(95)00662-I; GOLDINMEADOW S, 1983, SCIENCE, V221, P372, DOI 10.1126/science.6867713; GOLDINMEADOW S, 1984, MONOGR SOC RES CHILD, V49, P1, DOI 10.2307/1165838; GOLDINMEADOW S, 1977, SCIENCE, V197, P401, DOI 10.1126/science.877567; McNeill D., 1992, HAND MIND WHAT HANDS; MCNEILL D, UNPUB LANGUAGE GESTU; Miller PJ, 1997, CHILD DEV, V68, P557, DOI 10.2307/1131678; MOORES DF, 1974, LANGUAGE PERSPECTIVE, P377; PETITTO LA, 1988, DEV LANGUAGE LANGUAG, P187; Pinker S., 1995, LANGUAGE INSTINCT; Siegel S., 1956, NONPARAMETRIC STAT B; Silverstein M., 1976, GRAMMATICAL CATEGORI, P112, DOI DOI 10.1016/J.BANDL.2007.09.005; Stevenson H W, 1990, Monogr Soc Res Child Dev, V55, P1; TERVOORT BT, 1961, AM ANN DEAF, V106, P436; Wang X.-L., 1996, RES FAMILY RESOURCES, P363; Wimsatt W.C., 1986, INTEGRATING SCI DISC, P185, DOI 10.1007/978-94-010-9435-1_11; YOUNG NF, 1972, AMERASIA J, V1, P31; Zar JH., 1999, BIOSTAT ANAL, V4	26	175	176	1	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					279	281		10.1038/34646	http://dx.doi.org/10.1038/34646			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YR328	9440690				2022-12-01	WOS:000071484400049
J	Grady, TA; Chiu, AC; Snader, CE; Marwick, TH; Thomas, JD; Pashkow, FJ; Lauer, MS				Grady, TA; Chiu, AC; Snader, CE; Marwick, TH; Thomas, JD; Pashkow, FJ; Lauer, MS			Prognostic significance of exercise-induced left bundle-branch block	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; CLINICAL-SIGNIFICANCE; HEART-DISEASE	Context.-Approximately 0.5% of all patients who undergo exercise testing develop a transient left bundle-branch block (LBBB) during exercise, but its prognostic significance is unclear. Objective.-To determine whether exercise-induced LBBB is an independent predictor of mortality and cardiac morbidity. Design.-Matched control cohort study. Between September 1990 and February 10, 1994, 17 277 exercise stress tests were performed on patients. Setting.-Tertiary care, academic medical center. Patients.-From the cohort, 70 cases of exercise-induced LBBB were identified. The controls comprised 70 individuals without LBBB at rest or during exercise that matched the 70 cases based on age, test date, sex, prior history of coronary artery disease, hypertension, diabetes, smoking, and beta-blocker use. Main Outcome Measures.-All-cause mortality, percutaneous coronary intervention, open heart surgery, nonfatal myocardial infarction, documented symptomatic or sustained ventricular tachydysrhythmia, or implantation of a permanent pacemaker or an implantable cardiac defibrillator. Results.-A total of 37 events (28 events from the exercise-induced LBBB cases and 9 from the control cohort) occurred in 25 patients (17 exercise-induced LBBB patients and 8 control patients) during a mean follow-up period of 3.7 (0.9 years) (median, 3.8 years [range, 0.9-5.2 years]). There were 7 deaths, of which 5 occurred among patients with exercise-induced LBBB. Four-year Kaplan-Meier event rates were 19% among exercise-induced LBBB patients and 10% among controls (log-rank chi(2), 5.2; P=.02). After further adjusting for small differences in age, exercise-induced LBBB remained associated with a higher risk of primary events (adjusted relative risk, 2.78; 95% confidence interval, 1.16-6.65; P=.02). Conclusion.-Exercise-induced LBBB independently predicts a higher risk of death and major cardiac events.	Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, George M & Linda H Kaufman Ctr Heart Failure, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Lauer, MS (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Sect Heart Failure & Cardiac Transplant Med, George M & Linda H Kaufman Ctr Heart Failure, Desk F-25, Cleveland, OH 44195 USA.		Lauer, Michael S/L-9656-2013; Marwick, Thomas H/C-7261-2013	Lauer, Michael S/0000-0002-9217-8177; Marwick, Thomas H/0000-0001-9065-0899				[Anonymous], STRESS TESTING PRINC; BOUNHOURE J, 1991, ARCH MAL COEUR VAISS, V842, P167; BRUCE RA, 1980, AM J CARDIOL, V46, P371, DOI 10.1016/0002-9149(80)90003-X; CHAPMAN JH, 1977, CHEST, V71, P776, DOI 10.1378/chest.71.6.776; CHOU T, 1995, ELECTROCARDIOGRAPHY, P939; COX DR, 1972, J R STAT SOC B, V34, P187; *CRIT COMM NEW YOR, 1994, NOM CRIT DIAGN DIS H, P210; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; GIBBONS R, 1997, AM J CARDIOL, V30, P260; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAND M, 1988, AM HEART J, V118, P23; HEINSIMER JA, 1987, AM J CARDIOL, V60, P1065, DOI 10.1016/0002-9149(87)90353-5; HERTZEANU H, 1992, EUR HEART J, V13, P1447, DOI 10.1093/oxfordjournals.eurheartj.a060084; HINDMAN MC, 1978, CIRCULATION, V58, P679, DOI 10.1161/01.CIR.58.4.679; KAFKA H, 1984, AM J CARDIOL, V54, P676, DOI 10.1016/0002-9149(84)90276-5; MCNEER JF, 1978, CIRCULATION, V57, P64, DOI 10.1161/01.CIR.57.1.64; MORAN JF, 1992, J ELECTROCARDIOL, V3, P229; *SAS INC, 1996, SAS STAT SOFTW CHANG, P835; SCHNEIDER JF, 1979, ANN INTERN MED, V90, P303, DOI 10.7326/0003-4819-90-3-303; VASEY C, 1985, AM J CARDIOL, V56, P892, DOI 10.1016/0002-9149(85)90777-5; VIEWEG WVR, 1976, CHEST, V69, P123, DOI 10.1378/chest.69.1.123; VIRTANEN KS, 1982, CHEST, V81, P326, DOI 10.1378/chest.81.3.326; WAYNE V, 1993, AM J CARDIOLF, V52, P283; WILLIAMS MA, 1988, AM J CARDIOL, V61, P346, DOI 10.1016/0002-9149(88)90942-3	24	58	72	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					153	156		10.1001/jama.279.2.153	http://dx.doi.org/10.1001/jama.279.2.153			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440667	Bronze			2022-12-01	WOS:000071338900034
J	Shisler, JL; Senkevich, TG; Berry, MJ; Moss, B				Shisler, JL; Senkevich, TG; Berry, MJ; Moss, B			Ultraviolet-induced cell death blocked by a selenoprotein from a human dermatotropic poxvirus	SCIENCE			English	Article							MOLLUSCUM CONTAGIOSUM VIRUS; VACCINIA VIRUS; SELENOCYSTEINE INCORPORATION; GENE-EXPRESSION; MAMMALIAN-CELLS; SEQUENCE; EUKARYOTES; APOPTOSIS; BIOLOGY; ELEMENT	Selenium, an essential trace element, is a component of prokaryotic and eukaryotic antioxidant proteins, A candidate selenoprotein homologous to glutathione peroxidase was deduced from the sequence of molluscum contagiosum, a poxvirus that causes persistent skin neoplasms in children and acquired immunodeficiency syndrome (AIDS) patients. Selenium was incorporated into this protein during biosynthesis, and a characteristic stem-loop structure near the end of the messenger RNA was required for alternative selenocysteine decoding of a potential UGA stop codon within the open reading frame. The selenoprotein protected human keratinocytes against cytotoxic effects of ultraviolet irradiation and hydrogen peroxide, providing a mechanism for a virus to defend itself against environmental stress.	NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Inst Med, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University	Moss, B (corresponding author), NIAID, Viral Dis Lab, NIH, 4 Ctr Dr,MSC 0445, Bethesda, MD 20892 USA.			Shisler, Joanna/0000-0003-4833-1557; Moss, Bernard/0000-0002-2154-8564	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047320] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK47320] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertin J, 1997, P NATL ACAD SCI USA, V94, P1172, DOI 10.1073/pnas.94.4.1172; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BSL MR, 1997, P NATL ACAD SCI USA, V94, P5531; BULLER RML, 1995, VIROLOGY, V213, P655, DOI 10.1006/viro.1995.0037; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; Fife KH, 1996, VIROLOGY, V226, P95, DOI 10.1006/viro.1996.0631; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOTTLIEB SL, 1994, INT J DERMATOL, V33, P453, DOI 10.1111/j.1365-4362.1994.tb02853.x; HAAKE AR, 1993, J INVEST DERMATOL, V101, P107, DOI 10.1111/1523-1747.ep12363594; Henseleit U, 1996, ARCH DERMATOL RES, V288, P676, DOI 10.1007/BF02505277; Hu SM, 1997, J BIOL CHEM, V272, P9621; Lee BJ, 1996, MOL CELLS, V6, P509; LOW CC, 1996, TRENDS BIOCHEM SCI, V21, P203; Manji GA, 1997, J VIROL, V71, P4509, DOI 10.1128/JVI.71.6.4509-4516.1997; Martin GW, 1996, RNA, V2, P171; MASSUNG RF, 1994, VIROLOGY, V201, P215, DOI 10.1006/viro.1994.1288; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; Porter C D, 1992, Mol Cell Biol Hum Dis Ser, V1, P233; Senkevich TG, 1997, VIROLOGY, V233, P19, DOI 10.1006/viro.1997.8607; Senkevich TG, 1996, SCIENCE, V273, P813, DOI 10.1126/science.273.5276.813; Stadtman TC, 1996, ANNU REV BIOCHEM, V65, P83, DOI 10.1146/annurev.bi.65.070196.000503; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thome M, 1997, NATURE, V386, P517, DOI 10.1038/386517a0; Walczak R, 1996, RNA, V2, P367; WARD GA, 1995, P NATL ACAD SCI USA, V92, P6773, DOI 10.1073/pnas.92.15.6773; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	30	127	134	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					102	105		10.1126/science.279.5347.102	http://dx.doi.org/10.1126/science.279.5347.102			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417017				2022-12-01	WOS:000071323900050
J	Middeldorp, S; Henkens, CMA; Koopman, MMW; van Pampus, ECM; Hamulyak, K; van der Meer, J; Prins, MH; Buller, HR				Middeldorp, S; Henkens, CMA; Koopman, MMW; van Pampus, ECM; Hamulyak, K; van der Meer, J; Prins, MH; Buller, HR			The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						thrombophlebitis; thromboembolism; heterozygote; mutation; factor	ACTIVATED PROTEIN-C; DEEP-VEIN THROMBOSIS; COAGULATION-FACTOR-V; RESISTANCE; OUTPATIENTS; POPULATION; DEFICIENCY; PREGNANCY; THERAPY; WOMEN	Background: The factor V Leiden mutation is a genetic defect associated with an increased incidence of Venous thromboembolism. When the incidence of venous thromboembolism in relatives of patients known to have the mutation outweighs the disadvantages of prophylactic strategies, family screening may be necessary. Objective: To determine the incidence of venous thromboembolism in first-degree relatives of symptomatic carriers of the factor V Leiden mutation. Design: Retrospective blinded study. Setting: University hospitals. Participants: 437 first-degree relatives of 112 heterozygous propositi and 30 relatives of 6 homozygous propositi. Measurements: Before DNA testing, information on previous venous thromboembolism and concomitant risk factors was obtained. Relatives with and without the FV: Q(506) mutation were compared. Results: The annual incidence of thromboembolism in relatives of heterozygous propositi was 0.45% (95% CI, 0.28% to 0.61%) in those with the mutation and 0.10% (CI, 0.02% to 0.19%) in those without the mutation (relative risk, 4.2 [CI, 1.8 to 9.9]). Among carriers, the incidence increased from 0.25% (CI, 0.12% to 0.49%) in the 15- to 30-year-old age group to 1.1% (CI, 0.24% to 3.33%) in persons older than 60 years of age. Half of the episodes of Venous thromboembolism occurred spontaneously, 20% were related to surgery, and 30% were associated with pregnancy or use of oral contraceptives. Conclusions: The observed low annual risk for venous thromboembolism in persons carrying the factor V Leiden mutation does not seem to outweigh the risks for bleeding associated with coumarin prophylaxis or justify discouragement of the use of oral contraceptives. A general policy of screening the families of all patients with the factor V Leiden mutation does not seem to be indicated. The observations in this moderate-size, retrospective study need to be confirmed by prospective follow-up studies.	Univ Amsterdam, Acad Med Ctr, Ctr Haemostas Thrombos Atheroscl & Inflamm Res, NL-1105 AZ Amsterdam, Netherlands; Ziekenhuis Rivienland, Dept Intern Med, NL-4002 WP Tiel, Netherlands; Univ Hosp Maastricht, Dept Haematol, NL-6229 HX Maastricht, Netherlands; Univ Groningen Hosp, Dept Haematol, Div Haematostasis Thrombosis & Rheol, NL-9713 EZ Groningen, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1105 AZ Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Maastricht University; Maastricht University Medical Centre (MUMC); University of Groningen; University of Amsterdam; Academic Medical Center Amsterdam	Middeldorp, S (corresponding author), Univ Amsterdam, Acad Med Ctr, Ctr Haemostas Thrombos Atheroscl & Inflamm Res, F-4,Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.		Middeldorp, Saskia/ABI-8197-2020	Middeldorp, Saskia/0000-0002-1006-6420				ALLAART CF, 1995, BRIT MED J, V311, P910; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BRIDEY F, 1995, THROMB HAEMOSTASIS, V74, P1382; Dahlback B, 1996, LANCET, V347, P1346, DOI 10.1016/S0140-6736(96)91004-1; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Frezzato M, 1996, AM J EPIDEMIOL, V143, P1257; Friederich PW, 1996, ANN INTERN MED, V125, P955, DOI 10.7326/0003-4819-125-12-199612150-00003; GREENGARD JS, 1994, LANCET, V343, P1361, DOI 10.1016/S0140-6736(94)92497-X; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LANDEFELD CS, 1989, AM J MED, V87, P144; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; ROSENDAAL FR, 1991, LANCET, V337, P260, DOI 10.1016/0140-6736(91)90867-O; SVENSSON PJ, 1994, NEW ENGL J MED, V330, P517, DOI 10.1056/NEJM199402243300801; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VANDERMEER FJM, 1993, ARCH INTERN MED, V153, P1557, DOI 10.1001/archinte.153.13.1557; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4	21	183	185	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					15	+		10.7326/0003-4819-128-1-199801010-00003	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424976	Green Submitted			2022-12-01	WOS:000071158000003
J	Smith, GD; Frankel, S; Yarnell, J				Smith, GD; Frankel, S; Yarnell, J			Sex and death: are they related? Findings from the Caerphilly cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; MYOCARDIAL-INFARCTION; LAY EPIDEMIOLOGY; HEALTH-EDUCATION; MORTALITY; PREVENTION; WOMEN; RISK; MEN	Objective: To examine the relation between frequency of orgasm and mortality, Study design: Cohort study with a 10 year follow up. Setting: The town of Caerphilly, South Wales, and five adjacent villages. Subjects: 918 men aged 45-59 at time of recruitment between 1979 and 1983. Main outcome measures: All deaths and deaths from coronary heart disease. Result: Mortality risk was 50% lower in the group with high orgasmic frequency than in the group with low orgasmic frequency, with evidence of a dose-response relation across the groups. Age adjusted odds ratio for all cause mortality was 2.0 for the group with low frequency of orgasm (95% confidence interval 1.1 to 3.5, test for trend P = 0.02). With adjustment for risk factors this became 1.9 (1.0 to 3.4, test for trend P = 0.04). Death from coronary heart disease and from other causes showed similar associations with frequency of orgasm, although the gradient was most marked for deaths from coronary heart disease. Analysed in terms of actual frequency of orgasm, the odds ratio for total mortality associated with an increase in 100 orgasms per year was 0.64 (0.44 to 0.95). Conclusion: Sexual activity seems to have a protective effect on men's health.	Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England; Queens Univ Belfast, Dept Epidemiol & Publ Hlth, Belfast BT12 6BJ, Antrim, North Ireland	University of Bristol; Queens University Belfast	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; s, hema/0000-0002-3440-9475				ABRAMOV LA, 1976, PSYCHOSOM MED, V38, P418, DOI 10.1097/00006842-197611000-00006; ACKER K, 1984, BLOOD GUTS HIGH SCH; Alter JS, 1997, MED ANTHROPOL Q, V11, P275, DOI 10.1525/maq.1997.11.3.275; Butler SM, 1996, J GERONTOL B-PSYCHOL, V51, pS201, DOI 10.1093/geronb/51B.4.S201; COHEN KN, 1984, PALEOPATHOLOGY ORIGI; Cohen L., 1963, FAVOURITE GAME; DAVIDSON JM, 1983, J CLIN ENDOCR METAB, V57, P71, DOI 10.1210/jcem-57-1-71; DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; DEMING W, 1995, PAUL MARRIAGE CELIBA; DRORY Y, 1995, AM J CARDIOL, V75, P835, DOI 10.1016/S0002-9149(99)80425-1; EASTON EB, 1988, AM PSYCHO; Ebrahim S, 1997, BMJ-BRIT MED J, V314, P1666, DOI 10.1136/bmj.314.7095.1666; ELWOOD PC, 1984, J EPIDEMIOL COMMUN H, V38, P259, DOI 10.1136/jech.38.3.259; FRANKEL S, 1991, BRIT J GEN PRACT, V41, P428; Frankel S., 1986, HULI RESPONSE ILLNES, DOI 10.1017/CBO9780511521072; FRASER I, 1984, BRIT MED J, V288, P242, DOI 10.1136/bmj.288.6412.242-b; GREER G, 1968, FEMALE EUNUCH; HAIRE N, 1924, REJUVENATION; Joyce James, 1916, PORTRAIT ARTIST YOUN; KAPLAN SD, 1988, PREV MED, V17, P335, DOI 10.1016/0091-7435(88)90008-4; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; LOCK S, 1983, BRIT MED J, V287, P1964, DOI 10.1136/bmj.287.6409.1964; Muller JE, 1996, JAMA-J AM MED ASSOC, V275, P1405, DOI 10.1001/jama.275.18.1405; NYYSSONEN K, 1997, BMJ-BRIT MED J, V314, P6348; PALMORE EB, 1982, GERONTOLOGIST, V22, P513, DOI 10.1093/geront/22.6.513; PERSSON G, 1981, ACTA PSYCHIAT SCAND, V64, P244, DOI 10.1111/j.1600-0447.1981.tb00780.x; PHILLIPS AN, 1991, J CLIN EPIDEMIOL, V44, P1223, DOI 10.1016/0895-4356(91)90155-3; PURDY J, 1961, COLOR DARKNESS; SCHUTTE H, 1975, INVEST UROL, V12, P330; *SCUM AUX, 1983, OBSC IND CLASS; SHARP I, 1997, LEAST 5 DAY STRATEGI; SMITH GD, 1992, BRIT MED J, V305, P757, DOI 10.1136/bmj.305.6856.757; SMITH GD, 1992, LANCET, V340, P709; Solanas Valerie, 1971, SCUM MANIFESTO; Whiteman MC, 1997, LANCET, V350, P541, DOI 10.1016/S0140-6736(96)03141-8; YARNELL JWG, 1993, ARTERIOSCLER THROMB, V13, P517, DOI 10.1161/01.ATV.13.4.517; YARNELL JWG, 1994, BRIT HEART J, V71, P293	37	111	115	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 20	1997	315	7123					1641	1644		10.1136/bmj.315.7123.1641	http://dx.doi.org/10.1136/bmj.315.7123.1641			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YN263	9448525	Green Published			2022-12-01	WOS:000071149400007
J	RichEdwards, JW; Gillman, MW				RichEdwards, JW; Gillman, MW			A hypothesis challenged - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							CORONARY HEART-DISEASE; BIRTH-WEIGHT; BREAST-CANCER; RISK		HARVARD PILGRIM CARE,BOSTON,MA 02215	Harvard Pilgrim Health Care	RichEdwards, JW (corresponding author), HARVARD UNIV,SCH MED,DEPT AMBULATORY CARE & PREVENT,126 BROOKLINE AVE,SUITE 200,BOSTON,MA 02215, USA.							ANTONOV AN, 1947, J PEDIATR, V30, P250, DOI 10.1016/S0022-3476(47)80160-X; Barker D. J. P., 1994, MOTHERS BABIES DIS L; Curhan GC, 1996, CIRCULATION, V94, P1310, DOI 10.1161/01.CIR.94.6.1310; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; EKBOM A, 1992, LANCET, V340, P1015, DOI 10.1016/0140-6736(92)93019-J; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; MCCANCE DR, 1994, BRIT MED J, V308, P945; Michels KB, 1996, LANCET, V348, P1542, DOI 10.1016/S0140-6736(96)03102-9; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; Rich-Edwards J. W., 1996, American Journal of Epidemiology, V143, pS39; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; Sanderson M, 1996, EPIDEMIOLOGY, V7, P34, DOI 10.1097/00001648-199601000-00007; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P571, DOI 10.1038/bjc.1987.116; Trichopoulos D, 1990, Epidemiology, V1, P95; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/BF00403383	15	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1348	1349		10.1136/bmj.315.7119.1348	http://dx.doi.org/10.1136/bmj.315.7119.1348			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402776	Green Published			2022-12-01	WOS:A1997YJ21800023
J	Gastel, JA; Roseboom, PH; Rinaldi, PA; Weller, JL; Klein, DC				Gastel, JA; Roseboom, PH; Rinaldi, PA; Weller, JL; Klein, DC			Melatonin production: Proteasomal proteolysis in serotonin N-acetyltransferase regulation	SCIENCE			English	Article							LIGHT-INDUCED DECREASE; PINEAL-GLAND; PROTEIN; UBIQUITIN; SECRETION; PATHWAY; TURNOVER; RHYTHM; ORGAN	The nocturnal increase in circulating melatonin in vertebrates is regulated bg, 10- to 100-fold increases in pineal serotonin N-acetyltransferase (AA-NAT) activity. Changes in the amount of AA-NAT protein were shown to parallel changes in AA-NAT activity. When neural stimulation was switched off by either light exposure or L-propranalol-induced beta-adrenergic blockade, both AA-NAT activity and protein decreased rapidly. Effects of L-propranolol were blocked in vitro by dibutyryl adenosine 3',5'-monophasphate (cAMP) or inhibitors of proteasomal proteolysis. This result indicates that adrenergic-cAMP regulation of AA-NAT is mediated by rapid reversible control af selective proteasomal proteolysis. Similar proteasome-based mechanisms may function widely as selective molecular switches in vertebrate neural systems.	NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Klein, DC (corresponding author), NICHHD, Sect Neuroendocrinol, Dev Neurobiol Lab, NIH, Bethesda, MD 20892 USA.	klein@helix.nih.gov		Klein, David/0000-0002-1792-5806				Arendt J., 1995, MELATONIN MAMMALIAN, P1; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; Baler R, 1997, J BIOL CHEM, V272, P6979, DOI 10.1074/jbc.272.11.6979; Bernard M, 1997, J NEUROCHEM, V68, P213; BINKLEY S, 1975, ENDOCRINOLOGY, V96, P848, DOI 10.1210/endo-96-4-848; BITTMAN EL, 1983, ENDOCRINOLOGY, V113, P2276, DOI 10.1210/endo-113-6-2276; Bogyo M, 1997, P NATL ACAD SCI USA, V94, P6629, DOI 10.1073/pnas.94.13.6629; BROWNSTEIN M, 1974, SCIENCE, V184, P163, DOI 10.1126/science.184.4133.163; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; COSTELLI P, 1995, J CLIN INVEST, V95, P2367, DOI 10.1172/JCI117929; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; DECKER RS, 1993, AM J PHYSIOL, V265, pH329, DOI 10.1152/ajpheart.1993.265.1.H329; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2547, DOI 10.1073/pnas.69.9.2547; Dick LR, 1996, J BIOL CHEM, V271, P7273, DOI 10.1074/jbc.271.13.7273; FALCON J, 1989, J NEUROSCI, V9, P1943; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GASTEL JA, UNPUB; HAMM HE, 1983, BRAIN RES, V266, P287, DOI 10.1016/0006-8993(83)90660-1; Hegde AN, 1997, CELL, V89, P115, DOI 10.1016/S0092-8674(00)80188-9; HEGDE AN, 1993, P NATL ACAD SCI USA, V90, P7436, DOI 10.1073/pnas.90.16.7436; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; ILLNEROVA H, 1979, J NEUROCHEM, V32, P673, DOI 10.1111/j.1471-4159.1979.tb00407.x; ILLNEROVA H, 1971, LIFE SCI, V10, P955, DOI 10.1016/0024-3205(71)90360-2; KARSCH FJ, 1991, SUPRACHIASMATIC NUCL, P217; KLEIN DC, 1970, SCIENCE, V169, P1093, DOI 10.1126/science.169.3950.1093; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KLEIN DC, 1972, SCIENCE, V177, P532, DOI 10.1126/science.177.4048.532; KLEIN DC, 1992, BIOCHEM SOC T, V20, P299, DOI 10.1042/bst0200299; KLEIN DC, 1978, SCIENCE, V199, P309, DOI 10.1126/science.202027; KLEIN DC, 1970, SCIENCE, V167, P1738, DOI 10.1126/science.167.3926.1738; LERNER AB, 1960, J BIOL CHEM, V235, P1992; LEWY AJ, 1980, SCIENCE, V210, P1267, DOI 10.1126/science.7434030; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; NAMBOODIRI MAA, 1987, METHOD ENZYMOL, V142, P583; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P2107, DOI 10.1073/pnas.72.6.2107; Roseboom PH, 1996, ENDOCRINOLOGY, V137, P3033, DOI 10.1210/en.137.7.3033; TAMARKIN L, 1977, SCIENCE, V198, P953, DOI 10.1126/science.563102; WAYNE DW, 1995, BIOSTATISTICS, P210; WELLER J, 1996, BRAIN RES, V25, P713	43	244	249	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1358	1360		10.1126/science.279.5355.1358	http://dx.doi.org/10.1126/science.279.5355.1358			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478897				2022-12-01	WOS:000072251800052
J	Best, PJM; Berger, PB; Miller, VM; Lerman, A				Best, PJM; Berger, PB; Miller, VM; Lerman, A			The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women	ANNALS OF INTERNAL MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; FOLLOW-UP; CORONARY ATHEROSCLEROSIS; 17-BETA-ESTRADIOL; DISEASE; GROWTH; AORTA	Background: Estrogen replacement therapy (ERT) in postmenopausal women decreases cardiac mortality and improves endothelial function. The endothelium regulates vascular tone and growth by releasing such factors as nitric oxide and endothelin-l. Objective: To determine whether ERT alters the balance between the total oxidized products of nitric oxide and endothelin-l. Design: Single-arm, before-after clinical trial. Setting: Outpatient clinical research center of an academic medical center. Patients: 15 postmenopausal women. Intervention: Treatment with 17 beta-estradiol for 6 months and a 10-day course of methoxyprogesterone every 3 months. Measurements: Plasma nitric oxide and endothelin-l levels were measured at baseline and after 6 months of ERT. Results: The mean baseline nitric oxide level was 27.5 nmol/mL (range, 20.3 to 34.8 nmol/mL) and increased by a mean of 7.2 nmol/ml (range, 0.2 to 14.1 nmol/ml) (P = 0.04). The mean baseline plasma endothelin-l level was 16.4 pg/mL (range, 12.0 to 20.8 pg/mL) and decreased by a mean of 3.9 pg/mL (range, 0.4 to 7.8 pg/mL) (P = 0.04). The mean baseline ratio of nitric oxide to endothelin-l was 2.0 (range, 1.3 to 2.8) and increased by 1.2 (range, 0.1 to 2.2) (P = 0.03). Conclusion: ERT results in an increased ratio of nitric oxide to endothelin-l. This may be one mechanism by which ERT provides cardiovascular benefit.	Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, Rochester, MN 55905 USA	Mayo Clinic	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Dept Internal Med & Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051736] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL07111-21D, HL51736] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; BRAMAN RS, 1989, ANAL CHEM, V61, P2715, DOI 10.1021/ac00199a007; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; COLLINS P, 1995, CIRCULATION, V92, P24, DOI 10.1161/01.CIR.92.1.24; DUBEY RK, 1994, J PHARMACOL EXP THER, V269, P402; Duckles SP, 1996, J PHARMACOL EXP THER, V279, P1; GISCLARD V, 1988, J PHARMACOL EXP THER, V244, P19; GOETZ RM, 1994, BIOCHEM BIOPH RES CO, V205, P905, DOI 10.1006/bbrc.1994.2750; LERMAN A, 1995, CIRCULATION, V92, P2426, DOI 10.1161/01.CIR.92.9.2426; LOSCALZO J, 1995, PROG CARDIOVASC DIS, V38, P87, DOI 10.1016/S0033-0620(05)80001-5; Mathew V, 1996, MAYO CLIN PROC, V71, P769; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; POLDERMAN KH, 1993, ANN INTERN MED, V118, P429, DOI 10.7326/0003-4819-118-6-199303150-00006; QUYYUMI AA, 1995, J CLIN INVEST, V95, P1747, DOI 10.1172/JCI117852; RODEHEFFER RJ, 1992, MAYO CLIN PROC, V67, P719, DOI 10.1016/S0025-6196(12)60795-2; ROSSELLI M, 1995, HYPERTENSION, V25, P848, DOI 10.1161/01.HYP.25.4.848; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P756, DOI 10.1056/NEJM199109123251102; WEISSBERG PL, 1990, ATHEROSCLEROSIS, V85, P257, DOI 10.1016/0021-9150(90)90118-3; YLIKORKALA O, 1995, J CLIN ENDOCR METAB, V80, P3384, DOI 10.1210/jc.80.11.3384	20	174	178	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					285	288		10.7326/0003-4819-128-4-199802150-00006	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471931				2022-12-01	WOS:000072013400005
J	Kadir, RA; Economides, DL; Sabin, CA; Owens, D; Lee, CA				Kadir, RA; Economides, DL; Sabin, CA; Owens, D; Lee, CA			Frequency of inherited bleeding disorders in women with menorrhagia	LANCET			English	Article							FACTOR-XI DEFICIENCY; MENSTRUAL BLOOD-LOSS; VON-WILLEBRAND DISEASE; VONWILLEBRANDS DISEASE; COAGULATION DISORDERS; FACTOR-VIII; DEFINITION; PREVALENCE; DIAGNOSIS; ANTIGEN	Background Although menorrhagia is a common gynaecological symptom, a specific cause is identified in less than 50% of affected women. We investigated the frequency of inherited bleeding disorders in women with menorrhagia. Methods Women referred for investigation of menorrhagia whose pelvis was normal on clinical examination and who had an estimated menstrual blood loss of more than 80 mL were studied. A detailed menstrual history and history about other bleeding symptoms was taken. The activated partial thromboplastin time, factor VIII activity, von-Willebrand-factor antigen and activity, and factor XI (FXI) were measured in all patients; further tests were done when results were at or outside the limits of the assays. Findings 150 women were screened. An inherited bleeding disorder was diagnosed in 26 (17%) patients: the disorders were von Willebrand's disease of mild (15) or moderate severity (three), mild FXI deficiency (four), mild von Willebrand's disease and FXI deficiency (one), combined von Willebrand's disease, FXI deficiency, and factor X deficiency (one), carriage of haemophilia-A gene (one), and platelet dysfunction (one). The frequency of von Willebrand's disease and FXI deficiency were 13% (95% CI 7.9-18.8%) and 4% (1.5-8.5%), respectively. Menorrhagia since menarche was noted in 11 (8.9%) of 123 women without a bleeding disorder compared with 13 (65%) of 20 women with von Willebrand's disease (p=0.001) and four (66.7%) of six women with FXI deficiency (p<0.001). Interpretation Inherited bleeding disorders are found in a substantial proportion of women with menorrhagia and a normal pelvis examination. We suggest that such patients should be investigated for these disorders-especially von Willebrand's disease-before invasive procedures are done.	Univ London Royal Free Hosp, Sch Med, Dept Obstet & Gynaecol, London NW3 2QG, England; Royal Free Hosp, Sch Med, Dept Primary Care & Populat Sci, London NW3 2QG, England; Royal Free Hosp, Sch Med, Haemophilia Ctr, London NW3 2QG, England; Royal Free Hosp, Sch Med, Haemostasis Unit, London NW3 2QG, England	University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Economides, DL (corresponding author), Univ London Royal Free Hosp, Sch Med, Dept Obstet & Gynaecol, Pond St, London NW3 2QG, England.		Abdulkadir, Rezan/C-5589-2008; Sabin, Caroline/C-2464-2008	Sabin, Caroline/0000-0001-5173-2760				ABILDGAARD CF, 1980, BLOOD, V56, P712; BOLTONMAGGS PHB, 1995, THROMB HAEMOSTASIS, V73, P194; BOLTONMAGGS PHB, 1988, BRIT J HAEMATOL, V69, P521, DOI 10.1111/j.1365-2141.1988.tb02409.x; BRADLOW J, 1992, PATTERNS REFERRAL; CEJKA J, 1982, CLIN CHEM, V28, P1356; CHEDIAK J, 1980, AM J CLIN PATHOL, V74, P108; Edlund M, 1996, AM J HEMATOL, V53, P234, DOI 10.1002/(SICI)1096-8652(199612)53:4<234::AID-AJH4>3.0.CO;2-Z; EVANS PC, 1971, OBSTET GYNECOL, V38, P37; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; FRASER IS, 1986, OBSTET GYNECOL, V68, P630; GREER IA, 1991, BRIT J OBSTET GYNAEC, V98, P909, DOI 10.1111/j.1471-0528.1991.tb13514.x; HALLBERG L, 1966, ACTA OBSTET GYN SCAN, V45, P320, DOI 10.3109/00016346609158455; HALLBERG L, 1964, SCAND J CLIN LAB INV, V16, P244, DOI 10.3109/00365516409060511; HAYNES PJ, 1977, BRIT J OBSTET GYNAEC, V84, P763, DOI 10.1111/j.1471-0528.1977.tb12490.x; HIGHAM JM, 1990, BRIT J OBSTET GYNAEC, V97, P734, DOI 10.1111/j.1471-0528.1990.tb16249.x; LEIBA H, 1965, BRIT J HAEMATOL, V11, P654, DOI 10.1111/j.1365-2141.1965.tb00114.x; LIAN ECY, 1976, AM J HEMATOL, V1, P319, DOI 10.1002/ajh.2830010306; LUSHER JM, 1978, AM J MED, V65, P637, DOI 10.1016/0002-9343(78)90852-5; Lusher JM, 1996, AM J OBSTET GYNECOL, V175, P778, DOI 10.1016/S0002-9378(96)80084-6; Murdock PJ, 1997, THROMB HAEMOSTASIS, V78, P1272; NILSSON IM, 1977, ACTA MED SCAND, V201, P497; REES M, 1987, BRIT MED J, V294, P759, DOI 10.1136/bmj.294.6574.759; RODEGHIERO F, 1990, THROMB HAEMOSTASIS, V64, P349; RODEGHIERO F, 1987, BLOOD, V69, P454; *ROYAL COLL GEN PR, 1986, SER MBS, V1; RUGGI ZM, 1987, J CLIN LAB ANAL, V1, P535; SADLER JE, 1994, THROMB HAEMOSTASIS, V71, P520; SELIGSOHN U, 1978, BLOOD, V51, P1223; SELIGSOHN U, 1981, ISRAEL J MED SCI, V17, P413; SELIGSOHN U, 1979, GENETIC DISEASES ASH, P141; Smith JK, 1996, HAEMOPHILIA, V2, P128, DOI 10.1111/j.1365-2516.1996.tb00155.x; TAVORI S, 1990, THROMB HAEMOSTASIS, V63, P36; WERNER EJ, 1993, J PEDIATR-US, V123, P893, DOI 10.1016/S0022-3476(05)80384-1; WERNER EJ, 1992, J PEDIATR-US, V121, P34, DOI 10.1016/S0022-3476(05)82537-5; ZHANG ZP, 1995, HUM GENET, V96, P388	35	302	306	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 14	1998	351	9101					485	489		10.1016/S0140-6736(97)08248-2	http://dx.doi.org/10.1016/S0140-6736(97)08248-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX958	9482440				2022-12-01	WOS:000072097700012
J	Kim, SH; Lin, DP; Matsumoto, S; Kitazono, A; Matsumoto, T				Kim, SH; Lin, DP; Matsumoto, S; Kitazono, A; Matsumoto, T			Fission yeast Slp1: An effector of the Mad2-dependent spindle checkpoint	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; CYCLIN-B; ASSEMBLY CHECKPOINT; BUDDING YEAST; CDC20 GENE; CELL-CYCLE; MITOSIS; PROTEIN; PROTEOLYSIS	Mad2 is a component of the spindle checkpoint, which delays the onset of anaphase until all chromosomes are attached to the spindle. Mad2 formed a complex with Slp1, a WD (tryptophan-aspartic acid)-repeat protein essential for the onset of anaphase. When the physical interaction between the two proteins was disrupted, the spindle checkpoint was no longer functional. Post-anaphase events such as chromosome decondensation and the next round of DNA replication were not delayed even when the spindle assembly was incomplete. This relief of dependence appears to be a result of deregulation of ubiquitin-dependent proteolysis mediated by the anaphase-promoting complex.	Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Matsumoto, T (corresponding author), Albert Einstein Coll Med, Dept Radiat Oncol, Bronx, NY 10461 USA.			Kitazono, Ana/0000-0002-6924-1799; Kim, Sanghoon/0000-0002-4078-6269	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056305, T32GM007491] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM56305, 5T32GM07491] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chen RH, 1996, SCIENCE, V274, P242, DOI 10.1126/science.274.5285.242; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; FEILOTTER HE, 1994, NUCLEIC ACIDS RES, V22, P1502, DOI 10.1093/nar/22.8.1502; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HERSHKO A, 1991, J BIOL CHEM, V266, P4940; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Leatherwood J, 1996, NATURE, V379, P360, DOI 10.1038/379360a0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Matsumoto T, 1997, MOL CELL BIOL, V17, P742, DOI 10.1128/MCB.17.2.742; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; ROSE M, 1983, METHOD ENZYMOL, V101, P167; SAMEJIMA I, 1994, J CELL BIOL, V127, P1655, DOI 10.1083/jcb.127.6.1655; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Sigrist SJ, 1997, CELL, V90, P671, DOI 10.1016/S0092-8674(00)80528-0; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Yamashita YM, 1996, NATURE, V384, P276, DOI 10.1038/384276a0; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	31	310	317	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1045	1047		10.1126/science.279.5353.1045	http://dx.doi.org/10.1126/science.279.5353.1045			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461438				2022-12-01	WOS:000072006400050
J	Rowe, T; Dascher, C; Bannykh, S; Plutner, H; Balch, WE				Rowe, T; Dascher, C; Bannykh, S; Plutner, H; Balch, WE			Role of vesicle-associated syntaxin 5 in the assembly of pre-Golgi intermediates	SCIENCE			English	Article							STOMATITIS-VIRUS GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; PROTEIN-TRANSPORT; CELL-SURFACE; ALPHA-SNAP; FUSION; DOCKING; COPII; ACTIVATION; EXOCYTOSIS	Syntaxins are thought to function during vesicular transport as receptors on the target membrane and to contribute to the specificity of membrane docking and fusion by interacting with vesicle-associated receptors. Here, syntaxin 5 (Syn5) was shown to be an integral component of endoplasmic reticulum-derived transport vesicles. This pool, but not the target, Golgi-associated Syn5 pool, was essential for the assembly of vesicular-tubular pre-Golgi intermediates and the delivery of cargo to the Golgi. The requirement for vesicle-associated Syn5 in transport suggests a reevaluation of the basis for operation of the early secretory pathway.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute	Balch, WE (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	webalch@scripps.edu			NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042336] Funding Source: NIH RePORTER; NCI NIH HHS [CA58689] Funding Source: Medline; NIGMS NIH HHS [GM 42336] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Banerjee A, 1996, J BIOL CHEM, V271, P20223, DOI 10.1074/jbc.271.34.20223; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; Dascher C, 1996, J BIOL CHEM, V271, P15866, DOI 10.1074/jbc.271.27.15866; DASCHER C, 1994, J BIOL CHEM, V269, P29363; DAVIDSON HW, 1993, J BIOL CHEM, V268, P4216; Fleischer S, 1974, Methods Enzymol, V31, P6; Hanson PI, 1997, CELL, V90, P523, DOI 10.1016/S0092-8674(00)80512-7; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Hui N, 1997, MOL BIOL CELL, V8, P1777, DOI 10.1091/mbc.8.9.1777; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Mayer A, 1996, CELL, V85, P83, DOI 10.1016/S0092-8674(00)81084-3; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Otto H, 1997, P NATL ACAD SCI USA, V94, P6197, DOI 10.1073/pnas.94.12.6197; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; Presley JF, 1997, NATURE, V389, P81, DOI 10.1038/38001; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Rowe T, 1996, J CELL BIOL, V135, P895, DOI 10.1083/jcb.135.4.895; ROWE T, UNPUB; Sacher M, 1997, J BIOL CHEM, V272, P17134, DOI 10.1074/jbc.272.27.17134; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1991, J CELL SCI, V100, P415; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Steel GJ, 1996, EMBO J, V15, P745, DOI 10.1002/j.1460-2075.1996.tb00410.x; TANG BL, 1995, EUR J CELL BIOL, V68, P397; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WALCHSOLIMENA C, 1995, J CELL BIOL, V128, P637, DOI 10.1083/jcb.128.4.637; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531	42	98	98	1	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					696	700		10.1126/science.279.5351.696	http://dx.doi.org/10.1126/science.279.5351.696			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445473				2022-12-01	WOS:000071731500034
J	Sha, BD; Phillips, SE; Bankaitis, VA; Luo, M				Sha, BD; Phillips, SE; Bankaitis, VA; Luo, M			Crystal structure of the Saccharomyces cerevisiae phosphatidylinositol-transfer protein	NATURE			English	Article							PHOSPHOLIPID TRANSFER PROTEIN; YEAST GOLGI; GENE; SEC14; MUTATIONS; MEMBRANES; PRODUCT; PATHWAY	The yeast phosphatidylinositol-transfer protein (Sec14) catalyses exchange of phosphatidylinositol and phosphatidylcholine between membrane bilayers in vitro(1,2). In vivo, Sec14 activity is essential for vesicle budding from the Golgi complex(3). Hero we report a three-dimensional structure for Sec14 at 2.5 A resolution. Sec14 consists of twelve alpha-helices, six beta-strands, eight 3(10)-helices and has two distinct domains. The carboxy-terminal domain forms a hydrophobic pocket which, in the crystal structure, is occupied by two molecules of N-octyl-beta-D-glucopyranoside and represents the phospholipid-binding domain. This pocket is reinforced by a string motif whose disruption in a sec14 temperature-sensitive mutant results in destabilization of the phospholipid-binding domain. Finally, we have identified an unusual surface helix that may play a critical role in driving Sec14-mediated phospholipid exchange. From this structure, we derive the first molecular clues into how a phosphatidylinositol-transfer protein functions.	Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Ctr Macromol Crystallog, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Bankaitis, VA (corresponding author), Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA.	vabankaitis@tmg.bhs.uab.edu; ming@orion.cmc.vab.edu		PHILLIPS, SCOTT/0000-0002-5451-0984				Alb JG, 1996, CURR OPIN CELL BIOL, V8, P534, DOI 10.1016/S0955-0674(96)80032-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BANKAITIS VA, 1996, PHOSPHOLIPID TRANSFE; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; Chinen K, 1996, CYTOGENET CELL GENET, V73, P218, DOI 10.1159/000134342; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; CLEVES AE, 1989, J CELL BIOL, V109, P2939, DOI 10.1083/jcb.109.6.2939; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; GU MX, 1992, P NATL ACAD SCI USA, V89, P2980, DOI 10.1073/pnas.89.7.2980; HOLM L, 1994, PROTEINS, V19, P165, DOI 10.1002/prot.340190302; HUANG C, 1978, P NATL ACAD SCI USA, V75, P308, DOI 10.1073/pnas.75.1.308; JIANG JS, 1994, J MOL BIOL, V243, P100, DOI 10.1006/jmbi.1994.1633; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kearns BG, 1997, NATURE, V387, P101, DOI 10.1038/387101a0; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Minor W., 1993, XDISPLAYF PROGRAM; NICHOOS A, 1992, GRASP GRAPHICAL REPR; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; SALAMA SR, 1990, J BACTERIOL, V172, P4510, DOI 10.1128/jb.172.8.4510-4521.1990; SATO Y, 1993, J BIOL CHEM, V268, P17705; Sha BD, 1997, ACTA CRYSTALLOGR D, V53, P784, DOI 10.1107/S0907444997006872; SKINNER HB, 1993, EMBO J, V12, P4775, DOI 10.1002/j.1460-2075.1993.tb06166.x; VAZ WLC, 1984, FEBS LETT, V174, P199, DOI 10.1016/0014-5793(84)81157-6	29	222	232	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 29	1998	391	6666					506	510		10.1038/35179	http://dx.doi.org/10.1038/35179			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461221				2022-12-01	WOS:000071701800056
J	Groigno, L; Whitaker, M				Groigno, L; Whitaker, M			An anaphase calcium signal controls chromosome disjunction in early sea urchin embryos	CELL			English	Article							SISTER-CHROMATID SEPARATION; NUCLEAR-ENVELOPE BREAKDOWN; DNA TOPOISOMERASE-II; STAMEN HAIR-CELLS; INTRACELLULAR FREE CALCIUM; PROTEIN-KINASE; SPINDLE MICROTUBULES; CYCLIN DEGRADATION; BUDDING YEAST; EGG EXTRACTS	A transient increase in intracellular calcium concentration [Ca2+](i) occurs throughout the cell as sea urchin embryos enter anaphase of the first cell cycle. The transient just precedes chromatid disjunction and spindle elongation. Microinjection of calcium chelators or heparin, an InsP(3), receptor antagonist, blocks chromosome separation. Photorelease of calcium or InsP, can reverse the block. Nuclear reformation is merely delayed by calcium antagonists at concentrations that block chromatid separation. Thus, the calcium signal triggers the separation of chromatids, while calcium-independent pathways can bring about the alterations in microtubule dynamics and nuclear events associated with anaphase progression. That calcium triggers chromosome disjunction alone is unexpected. It helps explain previous conflicting results and allows the prediction that calcium plays a similar role at anaphase in other cell types.	Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Whitaker, M (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Dept Physiol Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BAITINGER C, 1990, J CELL BIOL, V111, P1763, DOI 10.1083/jcb.111.5.1763; Becchetti A, 1997, DEVELOPMENT, V124, P1099; Bhat MA, 1996, CELL, V87, P1103, DOI 10.1016/S0092-8674(00)81804-8; CIAPA B, 1994, NATURE, V368, P875, DOI 10.1038/368875a0; DINSMORE JH, 1988, CELL, V53, P769, DOI 10.1016/0092-8674(88)90094-3; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLISDAVIES GCR, 1994, P NATL ACAD SCI USA, V91, P187, DOI 10.1073/pnas.91.1.187; FELIX MA, 1990, NATURE, V346, P379, DOI 10.1038/346379a0; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GILLOT I, 1994, CELL CALCIUM, V16, P269, DOI 10.1016/0143-4160(94)90090-6; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEPLER PK, 1985, J CELL BIOL, V100, P1363, DOI 10.1083/jcb.100.5.1363; HEPLER PK, 1994, CELL CALCIUM, V16, P322, DOI 10.1016/0143-4160(94)90096-5; HEPLER PK, 1987, J CELL BIOL, V105, P2137, DOI 10.1083/jcb.105.5.2137; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HOLM C, 1989, MOL CELL BIOL, V9, P159, DOI 10.1128/MCB.9.1.159; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; IZANT JG, 1983, CHROMOSOMA, V88, P1, DOI 10.1007/BF00329497; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KAWAHARA H, 1994, DEV BIOL, V166, P623, DOI 10.1006/dbio.1994.1342; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; Khodjakov A, 1996, J CELL BIOL, V132, P1093, DOI 10.1083/jcb.132.6.1093; KIEHART DP, 1981, J CELL BIOL, V88, P604, DOI 10.1083/jcb.88.3.604; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LI XT, 1995, NATURE, V373, P630, DOI 10.1038/373630a0; LINDSAY HD, 1995, J CELL SCI, V108, P3557; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; LORCA T, 1993, NATURE, V366, P270, DOI 10.1038/366270a0; LU KP, 1993, ENDOCR REV, V14, P40, DOI 10.1210/er.14.1.40; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; MCINTOSH JR, 1991, ANNU REV CELL BIOL, V7, P403, DOI 10.1146/annurev.cellbio.7.1.403; MORIN N, 1994, EMBO J, V13, P4343, DOI 10.1002/j.1460-2075.1994.tb06754.x; Murray AW, 1996, P NATL ACAD SCI USA, V93, P12327, DOI 10.1073/pnas.93.22.12327; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; NICKLAS RB, 1995, J CELL BIOL, V130, P929, DOI 10.1083/jcb.130.4.929; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; PETZELT C, 1987, European Journal of Cell Biology, V45, P268; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RATTAN RR, 1986, P NATL ACAD SCI USA, V83, P5136; RATTAN RR, 1988, J CELL BIOL, V107, P993; RIEDER CL, 1994, J CELL BIOL, V127, P1301, DOI 10.1083/jcb.127.5.1301; RIEDER CL, 1994, J CELL BIOL, V124, P223, DOI 10.1083/jcb.124.3.223; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SHAMU CE, 1992, J CELL BIOL, V117, P921, DOI 10.1083/jcb.117.5.921; SILVER RB, 1980, CELL, V19, P505, DOI 10.1016/0092-8674(80)90525-5; SILVER RB, 1989, DEV BIOL, V131, P11; SLUDER G, 1994, J CELL BIOL, V126, P189, DOI 10.1083/jcb.126.1.189; SLUDER G, 1979, J CELL BIOL, V80, P674, DOI 10.1083/jcb.80.3.674; SLUDER G, 1988, ZOOL SCI, V5, P653; SPEKSNIJDER JE, 1989, P NATL ACAD SCI USA, V86, P6607, DOI 10.1073/pnas.86.17.6607; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; Stratmann R, 1996, CELL, V84, P25, DOI 10.1016/S0092-8674(00)80990-3; SUPRYNOWICZ FA, 1994, P NATL ACAD SCI USA, V91, P6176, DOI 10.1073/pnas.91.13.6176; SUPRYNOWICZ FA, 1985, P NATL ACAD SCI USA, V82, P2389, DOI 10.1073/pnas.82.8.2389; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; SWEET SC, 1988, J CELL BIOL, V107, P2243, DOI 10.1083/jcb.107.6.2243; TERASAKI M, 1991, J CELL BIOL, V114, P929, DOI 10.1083/jcb.114.5.929; TOMBES RM, 1989, J CELL BIOL, V109, P627, DOI 10.1083/jcb.109.2.627; TWIGG J, 1988, NATURE, V332, P366, DOI 10.1038/332366a0; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; WHITAKER M, 1993, NATURE, V366, P211, DOI 10.1038/366211a0; WHITAKER M, 1990, DEVELOPMENT, V108, P525; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; ZHANG DH, 1992, J CELL SCI, V102, P79	69	109	111	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					193	204		10.1016/S0092-8674(00)80914-9	http://dx.doi.org/10.1016/S0092-8674(00)80914-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458044	Bronze			2022-12-01	WOS:000071672600009
J	Sprengel, R; Suchanek, B; Amico, C; Brusa, R; Burnashev, N; Rozov, A; Hvalby, O; Jensen, V; Paulsen, O; Andersen, P; Kim, JJ; Thompson, RF; Sun, W; Webster, LC; Grant, SGN; Eilers, J; Konnerth, A; Li, JY; McNamara, JO; Seeburg, PH				Sprengel, R; Suchanek, B; Amico, C; Brusa, R; Burnashev, N; Rozov, A; Hvalby, O; Jensen, V; Paulsen, O; Andersen, P; Kim, JJ; Thompson, RF; Sun, W; Webster, LC; Grant, SGN; Eilers, J; Konnerth, A; Li, JY; McNamara, JO; Seeburg, PH			Importance of the intracellular domain of NR2 subunits for NMDA receptor function in vivo	CELL			English	Article							D-ASPARTATE RECEPTOR; SIGNAL-TRANSDUCTION; TARGETED DISRUPTION; EPSILON-1 SUBUNIT; HIPPOCAMPAL LTP; MESSENGER-RNAS; MUTANT MICE; RAT-BRAIN; EXPRESSION; GENE	NMDA receptors, a class of glutamate-gated cation channels with high Ca2+ conductance, mediate fast transmission and plasticity of central excitatory synapses. We show here that gene-targeted mice expressing NMDA receptors without the large intracellular C-terminal domain of any one of three NR2 subunits phenotypically resemble mice made deficient in that particular subunit. Mice expressing the NR2B subunit in a C-terminally truncated form (NR2B(Delta C/Delta C) mice) die perinatally. NR2A(Delta C Delta C) mice are viable but exhibit impaired synaptic plasticity and contextual memory. These and NR2C(Delta C Delta C) mice display deficits in motor coordination. C-terminal truncation of NR2 subunits does not interfere with the formation of gateable receptor channels that can be synaptically activated. Thus, the phenotypes of our mutants appear to reflect defective intracellular signaling.	Max Planck Inst Med Res, Dept Mol Neurosci, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany; Univ Oslo, Inst Neurophysiol, N-0317 Oslo, Norway; Univ So Calif, Los Angeles, CA 90089 USA; Univ Edinburgh, Ctr Genome Res & Neurosci, Edinburgh EH9 3JQ, Midlothian, Scotland; Univ Saarland, Inst Physiol, D-66421 Homburg, Germany; Duke Univ, Dept Med, Durham, NC 27710 USA	Max Planck Society; Max Planck Society; University of Oslo; University of Southern California; University of Edinburgh; Saarland University; Duke University	Sprengel, R (corresponding author), Max Planck Inst Med Res, Dept Mol Neurosci, Jahnstr 29, D-69120 Heidelberg, Germany.		Rozov, Andrei/C-1997-2015; Eilers, Jens/E-6251-2012; Sun, William/B-9092-2014; Burnashev, Nail/G-4056-2013; Paulsen, Ole/ABB-4843-2020	Eilers, Jens/0000-0003-0497-5625; Sun, William/0000-0003-3279-7408; Paulsen, Ole/0000-0002-2258-5455; Kim, Jeansok/0000-0001-7964-106X; Grant, Seth/0000-0001-8732-8735	NIA NIH HHS [AG0093] Funding Source: Medline; Wellcome Trust Funding Source: Medline; ACF HHS [AF05142] Funding Source: Medline; OMHHE CDC HHS [IF32MN10521-01] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Wellcome Trust(Wellcome TrustEuropean Commission); ACF HHS; OMHHE CDC HHS		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; AMMASSARITEULE M, 1991, BRAIN RES, V551, P104, DOI 10.1016/0006-8993(91)90919-M; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; BURBELO PD, 1995, CURR BIOL, V5, P95, DOI 10.1016/S0960-9822(95)00022-4; Chen C, 1995, CELL, V83, P1233, DOI 10.1016/0092-8674(95)90148-5; Chen C, 1996, BEHAV NEUROSCI, V110, P1177; COLLINGRIDGE GL, 1995, TRENDS NEUROSCI, V18, P54, DOI 10.1016/0166-2236(95)93868-X; Ebralidze AK, 1996, J NEUROSCI, V16, P5014; Ehlers MD, 1996, CELL, V84, P745, DOI 10.1016/S0092-8674(00)81052-1; Eilers Jens, 1995, P213; FORREST D, 1994, NEURON, V13, P325, DOI 10.1016/0896-6273(94)90350-6; GODDARD GV, 1969, EXP NEUROL, V25, P295, DOI 10.1016/0014-4886(69)90128-9; HARTVEIT E, 1994, J COMP NEUROL, V348, P570, DOI 10.1002/cne.903480407; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; IKEDA K, 1995, MOL BRAIN RES, V33, P61, DOI 10.1016/0169-328X(95)00107-4; Ito I, 1996, NEUROSCI LETT, V203, P69, DOI 10.1016/0304-3940(95)12258-3; Kadotani H, 1996, J NEUROSCI, V16, P7859; Klingauf J, 1997, BIOPHYS J, V72, P674, DOI 10.1016/S0006-3495(97)78704-6; KOH DS, 1995, J PHYSIOL-LONDON, V485, P383, DOI 10.1113/jphysiol.1995.sp020737; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; LAURIE DJ, 1997, IN PRESS MOL BRAIN R; LI YQ, 1994, CELL, V76, P427, DOI 10.1016/0092-8674(94)90108-2; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MCNAMARA JO, 1993, CURR OPIN NEUROL NEU, V6, P583; MCNAMARA JO, 1988, TRENDS NEUROSCI, V11, P33, DOI 10.1016/0166-2236(88)90047-1; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; Niethammer M, 1996, J NEUROSCI, V16, P2157; NITSCHKE L, 1993, BIOTECHNIQUES, V14, P914; Omkumar RV, 1996, J BIOL CHEM, V271, P31670, DOI 10.1074/jbc.271.49.31670; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; SATHER W, 1992, J PHYSIOL-LONDON, V450, P643, DOI 10.1113/jphysiol.1992.sp019148; Smart TG, 1997, CURR OPIN NEUROBIOL, V7, P358, DOI 10.1016/S0959-4388(97)80063-3; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SUTULA T, 1988, SCIENCE, V239, P1147, DOI 10.1126/science.2449733; Sutula T, 1996, J NEUROSCI, V16, P7398; Takahashi T, 1996, J NEUROSCI, V16, P4376; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WATANABE M, 1993, J COMP NEUROL, V338, P377, DOI 10.1002/cne.903380305; Watanabe Y, 1996, J NEUROSCI, V16, P3827; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	53	372	388	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 23	1998	92	2					279	289		10.1016/S0092-8674(00)80921-6	http://dx.doi.org/10.1016/S0092-8674(00)80921-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458051	hybrid			2022-12-01	WOS:000071672600016
J	Wang, YD; DuBois, JL; Hedman, B; Hodgson, KO; Stack, TDP				Wang, YD; DuBois, JL; Hedman, B; Hodgson, KO; Stack, TDP			Catalytic galactose oxidase models: Biomimetic Cu(II)-phenoxyl-radical reactivity	SCIENCE			English	Article							CRYSTAL-STRUCTURE; ACTIVE-SITE; COPPER; COMPLEXES; OXIDATION; ALCOHOLS; SYSTEM	Biomimetic functional models of the mononuclear copper enzyme galactose oxidase are presented that catalytically oxidize benzylic and allylic alcohols to aldehydes with O-2 under mild conditions, The mechanistic fidelity between the models and the natural system is pronounced. Modest structural mimicry proves sufficient to transfer an unusual ligand-based radical mechanism, previously unprecedented outside the protein matrix, to a simple chemical system.	Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA	Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory; Stanford University	Hedman, B (corresponding author), Stanford Univ, Stanford Synchrotron Radiat Lab, Stanford, CA 94309 USA.			Wang, Yadong/0000-0003-2067-382X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050730, R01GM050730] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-01209] Funding Source: Medline; NIGMS NIH HHS [GM50730] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		COLPAS GJ, 1991, INORG CHEM, V30, P920, DOI 10.1021/ic00005a010; COOKSON PG, 1975, J ORGANOMET CHEM, V99, pC31, DOI 10.1016/S0022-328X(00)88466-1; DuBois JL, 1997, J AM CHEM SOC, V119, P8578, DOI 10.1021/ja9717673; FILIPPONI A, 1991, SOLID STATE COMMUN, V78, P265, DOI 10.1016/0038-1098(91)90194-Z; Groves John T., 1995, P3; GROVES JT, 1988, STUD ORG CHEM AMSTER, V33, P541; Halfen JA, 1997, J AM CHEM SOC, V119, P8217, DOI 10.1021/ja9700663; Hamilton G., 1973, OXIDASES RELATED RED, V1, P103; HAMILTON GA, 1978, J AM CHEM SOC, V100, P1899, DOI 10.1021/ja00474a042; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; ITO N, 1991, NATURE, V350, P87, DOI 10.1038/350087a0; KARLIN KD, 1994, J AM CHEM SOC, V116, P1324, DOI 10.1021/ja00083a018; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KITAJIMA N, 1986, J CHEM SOC CHEM COMM, P1504, DOI 10.1039/c39860001504; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOWLES PF, 1995, INORG CHEM, V34, P3895, DOI 10.1021/ic00119a010; KOCH WO, 1996, ANGEW CHEM INT EDIT, V34, P2671; LEE SC, 1993, INORG CHEM, V32, P4745, DOI 10.1021/ic00074a016; MARADUFU A, 1971, CAN J CHEMISTRY, V49, P3429, DOI 10.1139/v71-575; Marko IE, 1996, SCIENCE, V274, P2044, DOI 10.1126/science.274.5295.2044; MCMILLEN DF, 1982, ANNU REV PHYS CHEM, V33, P493, DOI 10.1146/annurev.pc.33.100182.002425; REGLIER M, 1990, J CHEM SOC CHEM COMM, P1752, DOI 10.1039/c39900001752; Sokolowski A, 1997, J AM CHEM SOC, V119, P8889, DOI 10.1021/ja970417d; SOKOLOWSKI A, 1996, J CHEM SOC CHEM COMM, P1671; SOLOMON EI, 1984, COMMENTS INORG CHEM, V0003, P00227; Wachter RM, 1996, J AM CHEM SOC, V118, P2782, DOI 10.1021/ja9519896; Wang YD, 1996, J AM CHEM SOC, V118, P13097, DOI 10.1021/ja9621354; WESTRE TE, 1995, J AM CHEM SOC, V117, P1566, DOI 10.1021/ja00110a012; WHITTAKER MM, 1993, BIOPHYS J, V64, P762, DOI 10.1016/S0006-3495(93)81437-1; WHITTAKER MM, 1989, J BIOL CHEM, V264, P7104; WOLFE WC, 1962, ANAL CHEM, V34, P1328, DOI 10.1021/ac60190a040; Zondervan C, 1997, CHEM COMMUN, P419, DOI 10.1039/a607779j	32	419	421	2	106	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					537	540		10.1126/science.279.5350.537	http://dx.doi.org/10.1126/science.279.5350.537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438841				2022-12-01	WOS:000071616000038
J	O'Leary, TJ; Tellado, M; Buckner, SB; Ali, IS; Stevens, A; Ollayos, CW				O'Leary, TJ; Tellado, M; Buckner, SB; Ali, IS; Stevens, A; Ollayos, CW			PAPNET-assisted rescreening of cervical smears - Cost and accuracy compared with a 100% manual rescreening strategy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY ASSURANCE; NEGATIVE SMEARS; TESTING SYSTEM; BENEFITS; INCREASE; EFFICACY; CYTOLOGY	Context.-The Food and Drug Administration has recently approved several devices that use computerized image analysis to rescreen Papanicolaou (Pap) smears that have already been examined by cytotechnologists. Physicians and laboratories must decide whether the utility of these devices justifies the cost. Objective.-To determine the effectiveness and cost of PAPNET-assisted rescreening in identifying cervical abnormalities not identified by manual rescreening. Design.-PAPNET-assisted rescreening of 5478 Pap smears obtained in 1994 and 1995 previously identified as "within normal limits" or "benign changes" on both initial and random screening. Patients.-Female service members and dependents aged 12 to 88 years. Setting.-Air Force clinics in the United States and Japan. Intervention.-Rescreening of Pap smears by PAPNET, followed by reevaluation of abnormal smears by the consensus panel, consisting of 3 cytotechnologists and 3 pathologists. Main Outcome Measures.-Proportion of Pap smears initially screened as normal identified as abnormal by both PAPNET and consensus panel; costs of rescreening. Results.-PAPNET screening identified 1614 (29%) slides requiring additional microscopic review, On further review, 448 (8% of total) had possibly abnormal cells, Ultimately, 11 of these cases were reviewed by the consensus panel for potentially atypical cells, Of these 11 cases, 5 were reclassified as atypical squamous cells of undetermined significance (ASCUS) and 1 as atypical glandular cells of undetermined significance (AGUS). No additional squamous intraepithelial neoplasia (SIL) was identified in these smears; the patient with a diagnosis of AGUS on rescreening was diagnosed as having a low-grade SIL (LSIL) on follow-up, Costs were $5825 to $33 781 for each additional ASCUS or AGUS diagnosis, A cost of $17 475 to $101 343 is expected for each case of LSIL identified by PAPNET-assisted rescreening and not by traditional manual rescreening. Conclusions.-PAPNET-assisted rescreening identified a few more cases of ASCUS than did manual rescreening, but at a relatively high cost, The costs of rescreening should be carefully compared with the expected efficacy in reducing cervical cancer mortality.	Armed Forces Inst Pathol, Dept Cellular Pathol, Washington, DC 20306 USA	United States Department of Defense	O'Leary, TJ (corresponding author), Armed Forces Inst Pathol, Dept Cellular Pathol, 14th St & Alaska Ave NW, Washington, DC 20306 USA.	tjo@afip.mil	Oleary, Timothy/AAE-5219-2021; Oleary, Timothy/AAF-2829-2021	O'LEARY, TIMOTHY/0000-0002-2435-9136				ASHFAQ R, 1995, DIAGN CYTOPATHOL, V13, P31, DOI 10.1002/dc.2840130108; BOON ME, 1993, DIAGN CYTOPATHOL, V9, P411, DOI 10.1002/dc.2840090408; BOON ME, 1994, MODERN PATHOL, V7, P957; Boon ME, 1996, ACTA CYTOL, V40, P1109; CRANE M, 1996, MED ECON, P177; HENDEE WR, 1989, JAMA-J AM MED ASSOC, V262, P1672; HUSAIN OAN, 1994, ANAL CELL PATHOL, V6, P157; Hutchinson ML, 1996, ACTA CYTOL, V40, P4; KAMINSKY FC, 1995, ACTA CYTOL, V39, P232; Kok MR, 1996, CANCER, V78, P112, DOI 10.1002/(SICI)1097-0142(19960701)78:1<112::AID-CNCR16>3.0.CO;2-2; KOSS LG, 1994, AM J CLIN PATHOL, V101, P220, DOI 10.1093/ajcp/101.2.220; Mango LJ, 1996, ACTA CYTOL, V40, P138; NEUHAUSER D, 1975, NEW ENGL J MED, V293, P226, DOI 10.1056/NEJM197507312930504; OUWERKERKNOORDAM E, 1994, CYTOPATHOLOGY, V5, P211, DOI 10.1111/j.1365-2303.1994.tb00422.x; Patten SF, 1996, ACTA CYTOL, V40, P45; Rosenthal DL, 1996, ACTA CYTOL, V40, P120; Ryan MR, 1996, AM J CLIN PATHOL, V105, P711; SCHWARZ PJ, 1981, PUBLIC HEALTH REP, V96, P547; SHERMAN ME, 1994, MODERN PATHOL, V7, P578; SLAGEL DD, 1995, DIAGN CYTOPATHOL, V13, P26, DOI 10.1002/dc.2840130107; Vooijs GP, 1996, ACTA CYTOL, V40, P14; Vuong P. N., 1995, Archives d'Anatomie et de Cytologie Pathologiques, V43, P147; Waugh N, 1996, CYTOPATHOLOGY, V7, P249, DOI 10.1046/j.1365-2303.1996.40182401.x; Wied GL, 1996, ACTA CYTOL, V40, P1; Wilbur DC, 1996, ACTA CYTOL, V40, P127	25	60	61	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 21	1998	279	3					235	237		10.1001/jama.279.3.235	http://dx.doi.org/10.1001/jama.279.3.235			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR124	9438746	Bronze			2022-12-01	WOS:000071460700036
J	Ahsan, H; Neugut, AI				Ahsan, H; Neugut, AI			Radiation therapy for breast cancer and increased risk for esophageal carcinoma	ANNALS OF INTERNAL MEDICINE			English	Article							LUNG-CANCER; TUMORS; CHEMOTHERAPY	Background: Several case reports have suggested an association between radiation therapy for breast cancer and the subsequent occurrence of esophageal carcinomas. Objective: To examine the association between radiation therapy for breast cancer and subsequent esophageal squamous-cell carcinomas and adenocarcinomas. Design: Population-based retrospective cohort study. Setting: Population-based U.S. cancer registries. Patients: 220 806 women in whom breast cancer was diagnosed between 1 January 1973 and 31 December 1993; 1 216 853 person-years of follow-up. Measurements: Age- and period-adjusted standardized incidence ratio as a measure of relative risk for the second primary cancer. Results: In women who had received radiation therapy for breast cancer, the relative risk for esophageal squamous-cell carcinoma increased to 5.42 (95% CI, 2.33 to 10.68) and the relative risk for esophageal adenocarcinoma increased to 4.22 (CI, 0.47 to 15.25) 10 or more years after radiation therapy. No increased risk was seen for either type of carcinoma among patients with breast cancer who did not receive radiation therapy. Conclusion: The risk for esophageal carcinoma is increased in women who receive radiation therapy for breast cancer.	Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Med, Div Oncol, New York, NY 10032 USA	Columbia University; Columbia University	Ahsan, H (corresponding author), Columbia Univ, Sch Publ Hlth, Div Epidemiol, 600 W 168th St, New York, NY 10032 USA.							Ahsan H, 1997, CANCER EPIDEM BIOMAR, V6, P779; AHSAN H, 1995, J CLIN ONCOL, V13, P2931, DOI 10.1200/JCO.1995.13.12.2931; BRESLOW NE, 1987, IARC SCI PUBL, V82, P65; Cartei G, 1996, EUR J CANCER PREV, V5, P400; DAVIS FG, 1989, CANCER RES, V49, P6130; DOLL R, 1981, BRIT J RADIOL, V54, P179, DOI 10.1259/0007-1285-54-639-179; Fekete F, 1994, Dysphagia, V9, P289; GATES O, 1968, AM J PATHOL, V53, P667; GOFFMAN TE, 1983, CANCER, V52, P1808, DOI 10.1002/1097-0142(19831115)52:10<1808::AID-CNCR2820521008>3.0.CO;2-W; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; HARRIS JR, 1988, INT J RADIAT ONCOL, V15, P497, DOI 10.1016/S0360-3016(98)90034-7; INSKIP PD, 1994, J NATL CANCER I, V86, P983, DOI 10.1093/jnci/86.13.983; Kelsey J., 1996, METHODS OBSERVATIONA; *NAT AC SCI, 1980, BIOL EFF ION RAD EFF, P431; NEUGUT AI, 1993, CANCER, V71, P3054, DOI 10.1002/1097-0142(19930515)71:10<3054::AID-CNCR2820711027>3.0.CO;2-N; Neugut AI, 1997, CANCER, V79, P1600, DOI 10.1002/(SICI)1097-0142(19970415)79:8<1600::AID-CNCR24>3.0.CO;2-0; OCONNELL EW, 1984, GASTROINTEST RADIOL, V9, P287, DOI 10.1007/BF01887853; SHERRILL DJ, 1984, CANCER, V54, P726, DOI 10.1002/1097-0142(1984)54:4<726::AID-CNCR2820540422>3.0.CO;2-X; SHIMIZU T, 1990, JPN J SURG, V20, P97, DOI 10.1007/BF02470720; *SURV EP END RES S, 1996, PROGR PUBL US DAT 19; THOMPSON DE, 1994, RADIAT RES, V137, pS17, DOI 10.2307/3578892; VANAGUNAS A, 1990, AM J GASTROENTEROL, V85, P808; WANG JX, 1990, INT J CANCER, V45, P889, DOI 10.1002/ijc.2910450519	23	74	74	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					114	117		10.7326/0003-4819-128-2-199801150-00007	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441571				2022-12-01	WOS:000071470800006
J	Gill, TM; Robison, JT; Tinetti, ME				Gill, TM; Robison, JT; Tinetti, ME			Difficulty and dependence: Two components of the disability continuum among community-living older persons	ANNALS OF INTERNAL MEDICINE			English	Article						activities of daily living; aged; disabled persons; independent living; geriatric assessment	PHYSICAL-DISABILITY; FUNCTIONAL STATUS; ADULTS; PREDICTORS; ELDERS; HEALTH; POPULATIONS; IMPAIRMENT; DESIGN; FALLS	Background: Although most epidemiologic studies have defined disability in basic activities of daily living (BADLs) as dependence, some investigators have argued that BADL disability should be defined as degree of difficulty. Objective: To determine whether the responses to questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than the response to either question alone. Setting: General community. Participants: 1065 persons 72 years of age and older. Measurements: On the basis of self-reported information collected at baseline, participants were categorized into three BADL groups: independent without difficulty, independent with difficulty, and dependent. Additional baseline information was collected on several measures of higher-level function and physical performance. Follow-up information was collected on regular home care visits and BADL function at 1 and 3 years and on hospitalizations, admissions to skilled-nursing facilities, and deaths over a 4-year period. Results: In a cross-sectional analysis, the proportion of participants with poor higher-level function and physical performance increased substantially across the three BADL groups. In a longitudinal analysis, the rates of hospitalization and regular home care visits for the independent without difficulty group, the independent with difficulty group, and the dependent group were 46%, 57%, and 72% (P < 0.001) and 17%, 30%, and 49% (P < 0.001), respectively; survival curves for admission to a skilled-nursing facility and death differed significantly for each pair-wise comparison. Among persons who were BADL independent, those with difficulty were significantly more likely to develop BADL dependence over a 3-year period than those without difficulty (31% compared with 18%; P < 0.001). Conclusions: In the assessment of BADL function in older persons, questions about difficulty and dependence provide complementary information that together can depict the continuum of disability more fully than either question alone.	Yale Univ, Sch Med, Genet Program, New Haven, CT 06504 USA	Yale University	Gill, TM (corresponding author), Yale Univ, Sch Med, Genet Program, Room 17B-TMP,POB 208025, New Haven, CT 06504 USA.		Gill, Thomas M./H-7043-2019	Gill, Thomas M./0000-0002-6450-0368	NATIONAL INSTITUTE ON AGING [R01AG007449, T32AG000153, P60AG010469] Funding Source: NIH RePORTER; NIA NIH HHS [P60 AG-10469, R01 AG-07449, 5T32-AG00153] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BENVENUTI F, 1995, J AM GERIATR SOC, V43, P479, DOI 10.1111/j.1532-5415.1995.tb06092.x; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; Crawford SL, 1997, J AM GERIATR SOC, V45, P338, DOI 10.1111/j.1532-5415.1997.tb00950.x; DIPIETRO L, 1993, MED SCI SPORT EXER, V25, P628; ETTINGER WH, 1994, J AM GERIATR SOC, V42, P1035, DOI 10.1111/j.1532-5415.1994.tb06206.x; FERRUCCI L, 1991, J GERONTOL, V46, pM52, DOI 10.1093/geronj/46.2.M52; Ferrucci L, 1996, J CLIN EPIDEMIOL, V49, P1089, DOI 10.1016/0895-4356(96)00231-4; FILLENBAUM GG, 1981, J GERONTOL, V36, P428, DOI 10.1093/geronj/36.4.428; Fried LP, 1996, J GERONTOL A-BIOL, V51, pM206, DOI 10.1093/gerona/51A.5.M206; FRIED LP, 1994, J CLIN EPIDEMIOL, V47, P747, DOI 10.1016/0895-4356(94)90172-4; GILL TM, 1995, J GERONTOL A-BIOL, V50, pM235, DOI 10.1093/gerona/50A.5.M235; GILL TM, 1995, J AM GERIATR SOC, V43, P603, DOI 10.1111/j.1532-5415.1995.tb07192.x; Gill TM, 1996, J GERONTOL A-BIOL, V51, pM283, DOI 10.1093/gerona/51A.6.M283; Gill TM, 1997, J GEN INTERN MED, V12, P757, DOI 10.1046/j.1525-1497.1997.07161.x; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HARRIS T, 1989, AM J PUBLIC HEALTH, V79, P698, DOI 10.2105/AJPH.79.6.698; JETTE AM, 1994, SOC SCI MED, V38, P937, DOI 10.1016/0277-9536(94)90426-X; JETTE AM, 1985, J CHRON DIS, V38, P59, DOI 10.1016/0021-9681(85)90008-6; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KATZ S, 1983, NEW ENGL J MED, V309, P1218, DOI 10.1056/NEJM198311173092005; KEIL JE, 1989, J CLIN EPIDEMIOL, V42, P521, DOI 10.1016/0895-4356(89)90148-0; Kempen GIJM, 1996, SOC SCI MED, V43, P1601, DOI 10.1016/S0277-9536(96)00057-3; KEMPEN GIJM, 1990, GERONTOLOGIST, V30, P497, DOI 10.1093/geront/30.4.497; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINSKY JL, 1987, J CHRON DIS, V40, pS159, DOI 10.1016/S0021-9681(87)80045-0; REUBEN DB, 1995, J AM GERIATR SOC, V43, P936, DOI 10.1111/j.1532-5415.1995.tb05540.x; ROOS NP, 1991, AM J PUBLIC HEALTH, V81, P63, DOI 10.2105/AJPH.81.1.63; TINETTI ME, 1993, JAMA-J AM MED ASSOC, V269, P65, DOI 10.1001/jama.269.1.65; Tinetti ME, 1997, NEW ENGL J MED, V337, P1279, DOI 10.1056/NEJM199710303371806; TINETTI ME, 1994, J GERONTOL, V49, pM140, DOI 10.1093/geronj/49.3.M140; VERBRUGGE LM, 1994, SOC SCI MED, V38, P1, DOI 10.1016/0277-9536(94)90294-1; WIENER JM, 1990, J GERONTOL, V45, pS229, DOI 10.1093/geronj/45.6.S229	35	184	184	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					96	+		10.7326/0003-4819-128-2-199801150-00004	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YR200	9441588				2022-12-01	WOS:000071470800003
J	Fraser, CM; Casjens, S; Huang, WM; Sutton, GG; Clayton, R; Lathigra, R; White, O; Ketchum, KA; Dodson, R; Hickey, EK; Gwinn, M; Dougherty, B; Tomb, JF; Fleischmann, RD; Richardson, D; Peterson, J; Kerlavage, AR; Quackenbush, J; Salzberg, S; Hanson, M; vanVugt, R; Palmer, N; Adams, MD; Gocayne, J; Weidman, J; Utterback, T; Watthey, L; McDonald, L; Artiach, P; Bowman, C; Garland, S; Fujii, C; Cotton, MD; Horst, K; Roberts, K; Hatch, B; Smith, HO; Venter, JC				Fraser, CM; Casjens, S; Huang, WM; Sutton, GG; Clayton, R; Lathigra, R; White, O; Ketchum, KA; Dodson, R; Hickey, EK; Gwinn, M; Dougherty, B; Tomb, JF; Fleischmann, RD; Richardson, D; Peterson, J; Kerlavage, AR; Quackenbush, J; Salzberg, S; Hanson, M; vanVugt, R; Palmer, N; Adams, MD; Gocayne, J; Weidman, J; Utterback, T; Watthey, L; McDonald, L; Artiach, P; Bowman, C; Garland, S; Fujii, C; Cotton, MD; Horst, K; Roberts, K; Hatch, B; Smith, HO; Venter, JC			Genomic sequence of a Lyme disease spirochaete, Borrelia burgdorferi	NATURE			English	Article							RIBOSOMAL-RNA GENES; LINEAR CHROMOSOME; CIRCULAR-PLASMID; ESCHERICHIA-COLI; AGENT; REPLICATION; ORGANIZATION; INFECTIVITY; ORIGIN; DNA	The genome of the bacterium Borrelia burgdorferi B31, the aetiologic agent of Lyme disease, contains a linear chromosome of 910,725 base pairs and at least 17 linear and circular plasmids with a combined size of more than 533,000 base pairs. The chromosome contains 853 genes encoding a basic set of proteins for DNA replication, transcription, translation, solute transport and energy metabolism, but, like Mycoplasma genitalium, it contains no genes for cellular biosynthetic reactions. Because B. burgdorferi and M. genitalium are distantly related eubacteria, we suggest that their limited metabolic capacities reflect convergent evolution by gene loss from more metabolically competent progenitors. Of 430 genes on 11 plasmids, most have no known biological function; 39% of plasmid genes are paralogues that form 47 gene families. The biological significance of the multiple plasmid-encoded genes is not clear, although they may be involved in antigenic variation or immune evasion.	UNIV UTAH,DEPT ONCOL SCI,DIV MOL BIOL & GENET,SALT LAKE CITY,UT 84132; MEDIMMUNE INC,GAITHERSBURG,MD 20878	Utah System of Higher Education; University of Utah; AstraZeneca; Medimmune	Fraser, CM (corresponding author), INST GENOM RES,9712 MED CTR DR,ROCKVILLE,MD 20850, USA.		Salzberg, Steven/Q-6514-2019; Salzberg, Steven L/F-6162-2011	Salzberg, Steven/0000-0002-8859-7432; Salzberg, Steven L/0000-0002-8859-7432; Kerlavage, Anthony/0000-0002-3954-9653; Fraser, Claire/0000-0003-1462-2428; Quackenbush, John/0000-0002-2702-5879				BARBOUR AG, 1986, MICROBIOL REV, V50, P381, DOI 10.1128/MMBR.50.4.381-400.1986; BARBOUR AG, 1988, J CLIN MICROBIOL, V26, P475, DOI 10.1128/JCM.26.3.475-478.1988; BARBOUR AG, 1987, SCIENCE, V237, P409, DOI 10.1126/science.3603026; BARBOUR AG, 1983, CURR MICROBIOL, V8, P123, DOI 10.1007/BF01566969; BARBOUR AG, 1996, J BACTERIOL, V178, P6625; BARIL C, 1989, RES MICROBIOL, V140, P507, DOI 10.1016/0923-2508(89)90083-1; BRANDT ME, 1990, INFECT IMMUN, V58, P983, DOI 10.1128/IAI.58.4.983-991.1990; BREWER BJ, 1988, CELL, V53, P679, DOI 10.1016/0092-8674(88)90086-4; Bult CJ, 1996, SCIENCE, V273, P1058, DOI 10.1126/science.273.5278.1058; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Casjens S, 1997, MOL MICROBIOL, V26, P581, DOI 10.1046/j.1365-2958.1997.6051963.x; CASJENS S, 1993, MOL MICROBIOL, V8, P967, DOI 10.1111/j.1365-2958.1993.tb01641.x; CASJENS S, 1995, J BACTERIOL, V177, P2769, DOI 10.1128/jb.177.10.2769-2780.1995; Casjens S, 1997, J BACTERIOL, V179, P217, DOI 10.1128/jb.179.1.217-227.1997; CASJENS S, IN PRESS BACTERIAL G; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CUMOW AW, 1997, P NATL ACAD SCI USA, V94, P11819; DAVIDSON BE, 1992, J BACTERIOL, V174, P3766, DOI 10.1128/JB.174.11.3766-3774.1992; DUNN JJ, 1994, J BACTERIOL, V176, P2706, DOI 10.1128/JB.176.9.2706-2717.1994; FERDOWS MS, 1989, P NATL ACAD SCI USA, V86, P5969, DOI 10.1073/pnas.86.15.5969; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; FRENCH S, 1992, SCIENCE, V258, P1362, DOI 10.1126/science.1455232; GAZUMYAN A, 1994, GENE, V146, P57, DOI 10.1016/0378-1119(94)90833-8; Himmelreich R, 1996, NUCLEIC ACIDS RES, V24, P4420, DOI 10.1093/nar/24.22.4420; HINNEBUSCH J, 1990, MOL MICROBIOL, V4, P811, DOI 10.1111/j.1365-2958.1990.tb00651.x; HINNEBUSCH J, 1992, J BACTERIOL, V174, P5251, DOI 10.1128/JB.174.16.5251-5257.1992; IBBA M, IN PRESS P NATL ACAD; JOHNSON RC, 1984, INT J SYST BACTERIOL, V34, P496, DOI 10.1099/00207713-34-4-496; KITTEN T, 1990, P NATL ACAD SCI USA, V87, P6077, DOI 10.1073/pnas.87.16.6077; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; NORRIS SJ, 1995, INFECT IMMUN, V63, P2206, DOI 10.1128/IAI.63.6.2206-2212.1995; OGASAWARA N, 1992, MOL MICROBIOL, V6, P629, DOI 10.1111/j.1365-2958.1992.tb01510.x; OJAIMI C, 1994, MICROBIOL-SGM, V140, P2931, DOI 10.1099/13500872-140-11-2931; OLD IG, 1992, FEMS MICROBIOL LETT, V99, P245, DOI 10.1111/j.1574-6968.1992.tb05575.x; Reizer J, 1996, Microb Comp Genomics, V1, P151; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; SADZIENE A, 1992, J EXP MED, V176, P799, DOI 10.1084/jem.176.3.799; SALZBERG S, IN PRESS NUCL ACIDS; SCHWAN TG, 1988, INFECT IMMUN, V56, P1831, DOI 10.1128/IAI.56.8.1831-1836.1988; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; TAKASE K, 1994, J BIOL CHEM, V269, P11037; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TRAKTMAN P, 1996, DNA REPLICATION EUKA, P775; Xu YN, 1996, INFECT IMMUN, V64, P3870, DOI 10.1128/IAI.64.9.3870-3876.1996; Zhang JR, 1997, CELL, V89, P275, DOI 10.1016/S0092-8674(00)80206-8; Zuckert WR, 1996, J BACTERIOL, V178, P2287	49	1645	2156	3	111	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					580	586		10.1038/37551	http://dx.doi.org/10.1038/37551			23	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403685				2022-12-01	WOS:A1997YK85300040
J	Higgins, RM; West, N; Edmunds, ME; Dukes, DC; Kashi, H; Jurewicz, A; Lam, FT				Higgins, RM; West, N; Edmunds, ME; Dukes, DC; Kashi, H; Jurewicz, A; Lam, FT			Effect of a strict HLA matching policy on distribution of cadaveric kidney transplants to Indo-Asian and white European recipients: regional study	BRITISH MEDICAL JOURNAL			English	Article									WALSGRAVE GEN HOSP,TRANSPLANT UNIT,COVENTRY CV2 2DX,W MIDLANDS,ENGLAND		Higgins, RM (corresponding author), WALSGRAVE GEN HOSP,DIALYSIS UNIT,COVENTRY CV2 2DX,W MIDLANDS,ENGLAND.							GASTON RS, 1993, JAMA-J AM MED ASSOC, V270, P1352, DOI 10.1001/jama.270.11.1352; HIGGINS RM, 1995, Q J MED, V89, P522; TAKIFF H, 1988, TRANSPLANTATION, V45, P410, DOI 10.1097/00007890-198802000-00033	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 22	1997	315	7119					1354	1355		10.1136/bmj.315.7119.1354	http://dx.doi.org/10.1136/bmj.315.7119.1354			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ218	9402778	Green Published			2022-12-01	WOS:A1997YJ21800025
J	Sakurai, T; Amemiya, A; Ishii, M; Matsuzaki, I; Chemelli, RM; Tanaka, H; Williams, SC; Richardson, JA; Kozlowski, GP; Wilson, S; Arch, JRS; Buckingham, RE; Haynes, AC; Carr, SA; Annan, RS; McNulty, DE; Liu, WS; Terrett, JA; Elshourbagy, NA; Bergsma, DJ; Yanagisawa, M				Sakurai, T; Amemiya, A; Ishii, M; Matsuzaki, I; Chemelli, RM; Tanaka, H; Williams, SC; Richardson, JA; Kozlowski, GP; Wilson, S; Arch, JRS; Buckingham, RE; Haynes, AC; Carr, SA; Annan, RS; McNulty, DE; Liu, WS; Terrett, JA; Elshourbagy, NA; Bergsma, DJ; Yanagisawa, M			Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior	CELL			English	Article							GLUCAGON-LIKE PEPTIDE-1; RAT-BRAIN; LEPTIN RECEPTOR; HUMAN GENOME; FOOD-INTAKE; OBESE GENE; IDENTIFICATION; LOCALIZATION; MICE; NEUROENDOCRINE	The hypothalamus plays a central role in the integrated control of feeding and energy homeostasis. We have identified two novel neuropeptides, both derived from the same precursor by proteolytic processing, that bind and activate two closely related (previously) orphan G protein-coupled receptors. These peptides, termed orexin-A and -B, have no significant structural similarities to known families of regulatory peptides. prepro-orexin mRNA and immunoreactive orexin-A are localized in neurons within and around the lateral and posterior hypothalamus in the adult rat brain. When administered centrally to rats, these peptides stimulate food consumption. prepro-orexin mRNA level is up-regulated upon fasting, suggesting a physiological role for the peptides as mediators in the central feedback mechanism that regulates feeding behavior.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; SmithKline Beecham Pharmaceut, Harlow CM19 5AD, Essex, England; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; GlaxoSmithKline; GlaxoSmithKline	Yanagisawa, M (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dept Mol Genet, Dallas, TX 75235 USA.		Carr, Steven A./AAH-8366-2019; sheng, jian/E-9474-2012	Ishii, Makoto/0000-0003-3397-9908				AIYAR N, 1994, MOL CELL BIOCHEM, V131, P75, DOI 10.1007/BF01075727; [Anonymous], [No title captured]; ARASE K, 1988, AM J PHYSIOL, V255, pE255, DOI 10.1152/ajpendo.1988.255.3.E255; BATEMAN A, 1990, J BIOL CHEM, V265, P22130; Benjamin IJ, 1997, DEV DYNAM, V208, P75; Bernardis LL, 1996, NEUROSCI BIOBEHAV R, V20, P189, DOI 10.1016/0149-7634(95)00015-1; BERNARDIS LL, 1993, NEUROSCI BIOBEHAV R, V17, P141, DOI 10.1016/S0149-7634(05)80149-6; Bing C, 1996, BIOCHEM SOC T, V24, P559, DOI 10.1042/bst0240559; BITTENCOURT JC, 1992, J COMP NEUROL, V319, P218, DOI 10.1002/cne.903190204; BRADBURY AF, 1991, TRENDS BIOCHEM SCI, V16, P112, DOI 10.1016/0968-0004(91)90044-V; Bray George A., 1995, P1591; BUSBY WH, 1987, J BIOL CHEM, V262, P8532; CARR S, 1996, CURRENT PROTOCOLS PR; Carr SA, 1996, ANAL BIOCHEM, V239, P180, DOI 10.1006/abio.1996.0313; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Erickson JC, 1996, SCIENCE, V274, P1704, DOI 10.1126/science.274.5293.1704; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Friedman JM, 1997, NATURE, V385, P119, DOI 10.1038/385119a0; Gerald C, 1996, NATURE, V382, P168, DOI 10.1038/382168a0; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; HEPLER JR, 1994, METHOD ENZYMOL, V237, P191; HUDSON TJ, 1995, SCIENCE, V270, P1945, DOI 10.1126/science.270.5244.1945; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; IKEDA M, 1980, J NEUROSCI METH, V2, P9, DOI 10.1016/0165-0270(80)90041-2; JACOBOWITZ DM, 1978, P NATL ACAD SCI USA, V75, P6300, DOI 10.1073/pnas.75.12.6300; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OhkiHamazaki H, 1997, NATURE, V390, P165, DOI 10.1038/36568; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; OOMURA Y, 1974, NATURE, V247, P284, DOI 10.1038/247284a0; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd ed; Qu DQ, 1996, NATURE, V380, P243, DOI 10.1038/380243a0; Roden D.M., 1996, GOODMAN GILMANS PHAR, V9th, P869; Rosenbaum M, 1997, NEW ENGL J MED, V337, P396, DOI 10.1056/NEJM199708073370606; ROUILLE Y, 1995, FRONT NEUROENDOCRIN, V16, P322, DOI 10.1006/frne.1995.1012; Shughrue PJ, 1996, ENDOCRINOLOGY, V137, P5159, DOI 10.1210/en.137.11.5159; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Stadel JM, 1997, TRENDS PHARMACOL SCI, V18, P430, DOI 10.1016/S0165-6147(97)01117-6; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; TAKIGAWA M, 1995, EUR J BIOCHEM, V228, P102, DOI 10.1111/j.1432-1033.1995.0102o.x; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Turton MD, 1996, NATURE, V379, P69, DOI 10.1038/379069a0; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WAREMBOURG M, 1993, J NEUROENDOCRINOL, V5, P487, DOI 10.1111/j.1365-2826.1993.tb00512.x; Wijker M, 1996, HUM MOL GENET, V5, P151, DOI 10.1093/hmg/5.1.151; Wilhelmsen KC, 1997, ANN NEUROL, V41, P139, DOI 10.1002/ana.410410202; WILHELMSEN KC, 1994, AM J HUM GENET, V55, P1159; WILHELMSEN KC, 1997, AM J HUM GENET, V55, P85; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519; Wolf G, 1997, NUTR REV, V55, P85, DOI 10.1111/j.1753-4887.1997.tb01602.x; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; YEN TT, 1994, FASEB J, V8, P479, DOI 10.1096/fasebj.8.8.8181666; ZARJEVSKI N, 1993, ENDOCRINOLOGY, V133, P1753, DOI 10.1210/en.133.4.1753; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	3976	4241	6	220	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					573	585		10.1016/S0092-8674(00)80949-6	http://dx.doi.org/10.1016/S0092-8674(00)80949-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491897	Bronze			2022-12-01	WOS:000072251500016
J	Welte, MA; Gross, SP; Postner, M; Block, SM; Wieschaus, EF				Welte, MA; Gross, SP; Postner, M; Block, SM; Wieschaus, EF			Developmental regulation of vesicle transport in Drosophila embryos: Forces and kinetics	CELL			English	Article							FAST AXONAL-TRANSPORT; ORGANELLE TRANSPORT; NUCLEAR MIGRATION; KINESIN; MELANOGASTER; CELLS; PHOSPHORYLATION; GASTRULATION; MICROSCOPY; POLARITY	In Drosophila embryos, microtubules oriented along apical-basal directions support saltatory vesicle movement. Vesicle traffic includes lipid droplets whose distribution shifts twice during early embryogenesis. Using microscopy, optical tweezers, and a novel squashed-mount embryo preparation, we tracked single droplets and measured the forces these generated. Droplet stalling forces change developmentally, in a roughly quantized fashion, consistent with variation in the number of active motors. We characterized a mutation, klarsicht, that affects droplet transport. Klar(+) facilitates changes in force, possibly by coordinating the activity of multiple motors. Alterations in transport affected motion in both apical and basal directions, indicating tight coupling between motors of opposite polarity. Mutations in klar also affect nuclear migration during eye development, suggesting multiple roles for klar-based transport.	Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA; Princeton Univ, Howard Hughes Med Inst, Princeton Mat Inst, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Howard Hughes Medical Institute; Princeton University	Wieschaus, EF (corresponding author), Princeton Univ, Howard Hughes Med Inst, Dept Mol Biol, Princeton, NJ 08544 USA.		Welte, Michael/AAH-5589-2019	Welte, Michael/0000-0001-5741-4720	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD015587] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018329] Funding Source: NIH RePORTER; NICHD NIH HHS [5R37HD15587] Funding Source: Medline; NIGMS NIH HHS [5R01GM5143, 5F32GM18329] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALONSO LAG, 1988, ROUX ARCH DEV BIOL, V197, P328, DOI 10.1007/BF00375952; ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0; BEREITERHAHN J, 1979, J CELL BIOL, V82, P767, DOI 10.1083/jcb.82.3.767; Bevington P. R., 1969, DATA REDUCTION ERROR; BRADY ST, 1985, CELL MOTIL CYTOSKEL, V5, P81, DOI 10.1002/cm.970050203; EDGAR BA, 1987, GENE DEV, V1, P1226, DOI 10.1101/gad.1.10.1226; Fan SS, 1997, DEVELOPMENT, V124, P1497; FISCHERVIZE JA, 1994, DEVELOPMENT, V120, P2609; FOE VE, 1983, J CELL SCI, V61, P31; FULLILOVE SL, 1971, DEV BIOL, V26, P560, DOI 10.1016/0012-1606(71)90141-2; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; Gepner J, 1996, GENETICS, V142, P865; GINIGER E, 1993, ROUX ARCH DEV BIOL, V202, P112, DOI 10.1007/BF00636536; GRAFSTEIN B, 1980, PHYSIOL REV, V60, P1167, DOI 10.1152/physrev.1980.60.4.1167; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAMMALVAREZ SF, 1993, J CELL SCI, V106, P955; Hurd DD, 1996, GENETICS, V144, P1075; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; LEE KD, 1995, J BIOL CHEM, V270, P5600, DOI 10.1074/jbc.270.10.5600; MERRILL PT, 1988, DEVELOPMENT, V104, P495; MORRIS NR, 1995, TRENDS CELL BIOL, V5, P278; NUSSLEINVOLHARD C, 1987, SCIENCE, V238, P1675, DOI 10.1126/science.3686007; Parsons SF, 1997, CELL MOTIL CYTOSKEL, V36, P1; Preece A., 1972, MANUAL HISTOLOGIC TE; RAY S, 1993, J CELL BIOL, V121, P1083, DOI 10.1083/jcb.121.5.1083; RICKOLL WL, 1976, DEV BIOL, V49, P304, DOI 10.1016/0012-1606(76)90278-5; SATOYOSHITAKE R, 1992, J BIOL CHEM, V267, P23930; SAXTON WM, 1991, CELL, V64, P1093, DOI 10.1016/0092-8674(91)90264-Y; SCHLIWA M, 1991, J CELL BIOL, V112, P1199, DOI 10.1083/jcb.112.6.1199; SVOBODA K, 1994, ANNU REV BIOPH BIOM, V23, P247, DOI 10.1146/annurev.bb.23.060194.001335; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; Thaler C D, 1996, Int Rev Cytol, V164, P269; THALER CD, 1992, CELL MOTIL CYTOSKEL, V22, P175, DOI 10.1002/cm.970220305; TIFFANY JM, 1986, CURR EYE RES, V5, P887, DOI 10.3109/02713688609029242; TOMLINSON A, 1985, J EMBRYOL EXP MORPH, V89, P313; VALE RD, 1992, J CELL BIOL, V119, P1589, DOI 10.1083/jcb.119.6.1589; VALKENBURG JAC, 1984, J BACTERIOL, V160, P1151, DOI 10.1128/JB.160.3.1151-1157.1984; Visscher K, 1996, IEEE J SEL TOP QUANT, V2, P1066, DOI 10.1109/2944.577338; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; Wang ZH, 1995, BIOPHYS J, V69, P2011, DOI 10.1016/S0006-3495(95)80071-8; WEAST R, 1986, CRC HDB CHEM PHYSICS, pE374; White G, 1996, BIOPHYS J, V71, P2701, DOI 10.1016/S0006-3495(96)79461-4; Wieschaus E., 1986, P199	44	306	311	3	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					547	557		10.1016/S0092-8674(00)80947-2	http://dx.doi.org/10.1016/S0092-8674(00)80947-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491895	Bronze			2022-12-01	WOS:000072251500014
J	Gunn, MD; Ngo, VN; Ansel, KM; Ekland, EH; Cyster, JG; Williams, LT				Gunn, MD; Ngo, VN; Ansel, KM; Ekland, EH; Cyster, JG; Williams, LT			A B-cell-homing chemokine made in lymphoid follicles activates Burkitt's lymphoma receptor-1	NATURE			English	Article							FOLLICULAR DENDRITIC CELLS; MAREKS-DISEASE; CHEMOATTRACTANT; EXPRESSION; GENOME; LIGAND; SDF-1; BLR1	Secondary lymphoid organs (spleen, lymph nodes and Peyer's patches) are divided into compartments, such as B-cell zones (follicles) and T-cell zones, which provide specialized environments for specific steps of the immune response. Migration of lymphocyte subsets into these compartments is essential for normal immune function, yet the molecular cues guiding this cellular traffic are poorly defined. Chemokines constitute a family of chemotactic cytokines that have been shown to direct the migration of leukocytes during inflammation(1,2) and which may be involved in the constitutive homing of lymphocytes into follicles and T-cell zones(3-8). Here we describe a novel chemokine, B-lymphocyte chemoattractant (BLC), that is strongly expressed in the follicles of Peyer's patches, the spleen and lymph nodes. BLC strongly attracts B lymphocytes while promoting migration of only small numbers of T cells and macrophages, and therefore is the first chemokine to be identified that is selective towards B cells. An orphan chemokine receptor, Burkitt's lymphoma receptor 1 (BLR-1), has been found to be required for B-cell migration into lymphoid follicles(6). We show that BLC stimulates calcium influx into, and chemotaxis of, cells transfected with BLR-1. Our results indicate that BLC functions as a BLR-1 ligand and may guide B lymphocytes to follicles in secondary lymphoid organs.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94143 USA; Chiron Corp, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Novartis	Cyster, JG (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.			Ngo, Vu/0000-0002-9501-6990; Gunn, Michael/0000-0003-4602-0667	NATIONAL CANCER INSTITUTE [U19CA179512] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM125089] Funding Source: NIH RePORTER; NCI NIH HHS [U19 CA179512] Funding Source: Medline; NIGMS NIH HHS [R01 GM125089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bacon KB, 1996, INT ARCH ALLERGY IMM, V109, P97, DOI 10.1159/000237207; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; BARELLA L, 1995, BIOCHEM J, V309, P773, DOI 10.1042/bj3090773; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CALNEK BW, 1986, CRC CR REV MICROBIOL, V12, P293; CYSTER JG, 1995, J EXP MED, V182, P581, DOI 10.1084/jem.182.2.581; FORSTER R, 1994, BLOOD, V84, P830; FORSTER R, 1996, CELL, V87, P1; Goodnow CC, 1997, CURR BIOL, V7, pR219, DOI 10.1016/S0960-9822(06)00105-9; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Imai Y, 1996, PATHOL INT, V46, P807, DOI 10.1111/j.1440-1827.1996.tb03555.x; ISHII K, 1993, J BIOL CHEM, V268, P9780; KAISER E, 1993, EUR J IMMUNOL, V23, P2532, DOI 10.1002/eji.1830231023; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LYONS AB, 1995, EUR J IMMUNOL, V25, P3165, DOI 10.1002/eji.1830251127; MACLENNAN ICM, 1994, ANNU REV IMMUNOL, V12, P117, DOI 10.1146/annurev.immunol.12.1.117; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENG Q, 1995, VIROLOGY, V213, P590, DOI 10.1006/viro.1995.0031; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Ueda H, 1997, J BIOL CHEM, V272, P24966, DOI 10.1074/jbc.272.40.24966; YOSHIDA K, 1994, EUR J IMMUNOL, V24, P464, DOI 10.1002/eji.1830240230	28	626	654	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					799	803		10.1038/35876	http://dx.doi.org/10.1038/35876			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486651				2022-12-01	WOS:000072089500055
J	Seaman, SR; Brettle, RP; Gore, SM				Seaman, SR; Brettle, RP; Gore, SM			Mortality from overdose among injecting drug users recently released from prison: database linkage study	BRITISH MEDICAL JOURNAL			English	Article							COHORT	Objective: To assess whether injecting drug users have a higher than usual risk of death from overdose in the 2 weeks after release from prison. Design: Sounder coding of surnames and information on date of birth were used to link entry and release dates from the local prison between 1983 and 1994 with clinical data from Edinburgh City Hospital's cohort of male injecting drug users who are infected with HIV. Setting: Edinburgh City Hospital and Edinburgh Prison. Subjects: 316/332 male injecting drug users infected with HIV in the City Hospital HIV cohort; 16 were excluded because they were enrolled after developing AIDS or because their precise date of death was not available. Main outcome measure: Relative risk of dying from overdose before developing AIDS and relative risk of dying of all causes before developing AIDS during the 2 weeks after release from prison; this was compared with relative risks of death during other time at liberty. Results: 238/316 (75%) injecting drug users served time in the prison between 1983 and 1994. 33 out of 316 injecting drug users who were infected with HIV died before developing AIDS during 517 177 days at risk 20 of these men died of an overdose; 6 of these deaths occurred within 2 weeks of release during 5903 days at risk Death rates from overdose before the development of AIDS were 1.02/1000 days during the 2 weeks after release (recently released) and 0.029/1000 days during other times of liberty. The relative risk of death from overdose became 7.7 (1.5 to 39.1) after temporal matching (when the comparison was limited to the first 2 weeks after release v the next 10 weeks). The crude relative risk in an analysis combining stratified prison term and the 2 weeks after release was 4.5 (1.7 to 11.7) for death from overdose. After temporal matching these risks became 1.8 (0.4 to 9.2). Conclusion: Prisons should evaluate interventions to reduce the risk of death from overdose after release.	Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England; City Hosp Edinburgh, Reg Infect Dis Unit, Edinburgh EH11 3XA, Midlothian, Scotland	MRC Biostatistics Unit; University of Cambridge	Gore, SM (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.			Seaman, Shaun/0000-0003-3726-5937				BIRD AG, 1995, AIDS, V9, P801, DOI 10.1097/00002030-199507000-00019; Bird AG, 1997, BRIT MED J, V315, P21, DOI 10.1136/bmj.315.7099.21; BRETTLE RP, 1995, QJM-INT J MED, V88, P479; FAIRWEATHER C, 1997, HER MAJESTYS CHIEF I; GORE SM, 1995, ANSWER, V39, P1; Strang J, 1996, BRIT MED J, V312, P1435, DOI 10.1136/bmj.312.7044.1435; vanHaastrecht HJA, 1996, AM J EPIDEMIOL, V143, P380	7	183	185	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					426	428		10.1136/bmj.316.7129.426	http://dx.doi.org/10.1136/bmj.316.7129.426			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492665	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071982700023
J	Carr, A; Marriott, D; Field, A; Vasak, E; Cooper, DA				Carr, A; Marriott, D; Field, A; Vasak, E; Cooper, DA			Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; INFECTION; PARVUM; AIDS; GAMMA; INTERFERON; RITONAVIR; INHIBITOR; DIARRHEA; PROTEASE	Background Enterocytozoon bieneusi and Cryptosporidium parvum? cause chronic antimicrobial-resistant gastrointestinal infections in HIV-1-infected individuals. HIV-1 reverse transcriptase inhibitors delay the onset of opportunistic infections, but are not known to reverse: established infections. HIV-1 protease inhibitors are more effective across a broader range of HIV-l-infected immune cells. Combination antiretroviral[ therapy that includes a protease inhibitor could improve immunity to E bieneusi and C:parvum, Methods HIV-1 infected patients with chronic microsporidiosis (five), cryptosporidiosis (three), or dual infection lane), were treated with combination therapy that included at least one HIV-1 protease inhibitor, Outcome measures were symptoms weight, use of antidiarrhoeal and antimicrobial drugs, T-lymphocyte subsets, HIV-1 viraemia! stool microscopy, and biopsy by endoscopy. Findings Ail patients had complete clinical responses, gained a median 15 hg in weight, and ceased ail antidiarrhoeal and antimicrobial therapies, Biliary cryptosporidiosis responded in both affected patients, Neither pathogen was detected in follow-up stool microscopy (eight of eight patients) or in biopsy samples by endoscopy (five of five), Intestinal architecture returned to normal in three patients, There was a dense CD8 lymphocyte and macrophage infiltrate and staining of intraepithelial E bieneusi with interferon-gamma before and after treatment, but little staining for CD4 or B lymphocytes, interleukin 10, or HIV-1 gp41., Five patients remained symptom-free after a median 13 months' follow-up, Four patients had recurrent diarrhoea at 7-13 months (one with positive stool microscopy), associated with declining CD4 counts. Interpretation Combination antiretroviral therapy that includes a protease inhibitor can restore immunity to E bieneusi or C parvum in HIV-1 infected individuals, and result in complete clinical, microbiological, and histological responses, The persistent CD8 cell and macrophage infiltrate, and the rapid time to relapse in patients with declining CD4 lymphocyte counts, suggest that neither infection was eradicated.	St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia; St Vincents Hosp, Ctr Immunol, Sydney, NSW 2010, Australia; St Vincents Hosp, Dept Anat Pathol, Sydney, NSW 2010, Australia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Sydney, NSW, Australia	St Vincents Hospital Sydney; St Vincents Hospital Sydney; St Vincents Hospital Sydney; University of New South Wales Sydney; Kirby Institute	Carr, A (corresponding author), St Vincents Hosp, HIV Med Unit, Sydney, NSW 2010, Australia.	acarr@stvincents.com.au						AnwarBruni DM, 1996, AIDS, V10, P619, DOI 10.1097/00002030-199606000-00007; BIGGS BA, 1995, J IMMUNOL, V154, P6132; BISSUEL F, 1994, CLIN INFECT DIS, V18, P447, DOI 10.1093/clinids/18.3.447; CAMERON B, 1996, 11 INT C AIDS VANC C; Carr A, 1996, J ACQ IMMUN DEF SYND, V13, P320, DOI 10.1097/00042560-199612010-00004; CARR A, 1996, AIDS SA, V10, P151; Cavert W, 1997, SCIENCE, V276, P960, DOI 10.1126/science.276.5314.960; Connors M, 1997, NAT MED, V3, P533, DOI 10.1038/nm0597-533; Cooper DA, 1997, LANCET, V349, P1413, DOI 10.1016/S0140-6736(97)04441-3; COZON G, 1994, J INFECT DIS, V169, P696, DOI 10.1093/infdis/169.3.696; DANNER SA, 1995, NEW ENGL J MED, V333, P1528, DOI 10.1056/NEJM199512073332303; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; FIELD AS, 1993, AIDS S, V7, P27; FLANIGAN T, 1992, ANN INTERN MED, V116, P840, DOI 10.7326/0003-4819-116-10-840; HARP JA, 1994, J PARASITOL, V80, P67, DOI 10.2307/3283347; HARRIS M, 1994, AIDS, V8, P1109, DOI 10.1097/00002030-199408000-00011; Kelleher AD, 1996, J INFECT DIS, V173, P321, DOI 10.1093/infdis/173.2.321; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MACDONALD TT, 1988, J EXP MED, V167, P1341, DOI 10.1084/jem.167.4.1341; MCGOWAN I, 1994, AIDS, V8, P1569, DOI 10.1097/00002030-199411000-00008; MEISEL JL, 1976, GASTROENTEROLOGY, V70, P1156; MONTAGNINO G, 1994, AM J NEPHROL, V14, P121, DOI 10.1159/000168700; Orenstein JM, 1997, SCIENCE, V276, P1857, DOI 10.1126/science.276.5320.1857; POL S, 1993, NEW ENGL J MED, V328, P95, DOI 10.1056/NEJM199301143280204; Rehg JE, 1996, J INFECT DIS, V174, P229, DOI 10.1093/infdis/174.1.229; SAXON A, 1987, J PARASITOL, V73, P413, DOI 10.2307/3282099; SLOPER KS, 1982, GUT, V23, P80, DOI 10.1136/gut.23.1.80; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; UNGAR BLP, 1991, J IMMUNOL, V147, P1014; Vakil NB, 1996, NEW ENGL J MED, V334, P19, DOI 10.1056/NEJM199601043340104; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419	33	233	238	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					256	261		10.1016/S0140-6736(97)07529-6	http://dx.doi.org/10.1016/S0140-6736(97)07529-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457096				2022-12-01	WOS:000071702200012
J	Campbell, JJ; Hedrick, J; Zlotnik, A; Siani, MA; Thompson, DA; Butcher, EC				Campbell, JJ; Hedrick, J; Zlotnik, A; Siani, MA; Thompson, DA; Butcher, EC			Chemokines and the arrest of lymphocytes rolling under flow conditions	SCIENCE			English	Article							T-CELL ADHESION; ENDOTHELIAL-CELLS; CHEMOATTRACTANT; MOLECULES; PROTEINS; MIP-1-BETA; MIGRATION; INTEGRINS; RECEPTOR; MEMORY	Circulating lymphocytes are recruited from the blood to the tissue by railing along the endothelium until being stopped by a signaling event linked to the G(i) alpha subunit of a heterotrimeric GTP-binding protein; that event then triggers rapid integrin-dependent adhesion. Four chemokines are now shown to induce such adhesion tb intercellular adhesion molecule-1 and to induce arrest of rolling cells within 1 second under flow conditions similar to those of blood. SDF-1 (also called PBSF), 6-C-kine (also called Exodus-2), and MIP-3 beta (also called ELC or Exodus-3) induced adhesion of most circulating lymphocytes, including most CD4(+) T cells; and MIP-3 alpha (also called LARC or Exodus-1) triggered adhesion of memory, but not nai ve, CD4(+) T cells. Thus, chemokines can regulate the arrest of lymphocyte subsets under flawing conditions, which may allow them to control lymphocyte-endothelial cell recognition and lymphocyte recruitment in vivo.	Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Ctr Digest Dis, Stanford, CA 94305 USA; Vet Affairs Palo Alto Hlth Care Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunol, Palo Alto, CA 94304 USA; Gryphon Sci, San Francisco, CA 94080 USA	Stanford University; Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Campbell, JJ (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA.		Zlotnik, Albert/C-3791-2011	Thompson, Darren/0000-0002-3725-7112; Campbell, James/0000-0003-4252-5182	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037734, R37GM037734] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA090302] Funding Source: Medline; NIDDK NIH HHS [DK38707] Funding Source: Medline; NIGMS NIH HHS [GM37734] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Baba M, 1997, J BIOL CHEM, V272, P14893, DOI 10.1074/jbc.272.23.14893; BARGATZE R, 1994, THESIS MONTANA STATE; BARGATZE RF, 1993, J EXP MED, V178, P367, DOI 10.1084/jem.178.1.367; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1997, EUR J IMMUNOL, V27, P2571, DOI 10.1002/eji.1830271016; CARLOS TM, 1994, BLOOD, V84, P2068; Carr MW, 1996, IMMUNITY, V4, P179, DOI 10.1016/S1074-7613(00)80682-2; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; Hedrick JA, 1997, J IMMUNOL, V159, P1589; Hieshima K, 1997, J IMMUNOL, V159, P1140; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; HONDA S, 1994, J IMMUNOL, V152, P4026; Hromas R, 1997, BLOOD, V89, P3315; Imai T, 1997, J BIOL CHEM, V272, P15036, DOI 10.1074/jbc.272.23.15036; IMHOF BA, 1995, ADV IMMUNOL, V58, P345, DOI 10.1016/S0065-2776(08)60623-9; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; Lloyd AR, 1996, J IMMUNOL, V156, P932; MACKAY CR, 1993, ADV IMMUNOL, V53, P217, DOI 10.1016/S0065-2776(08)60501-5; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; Pan Y, 1997, NATURE, V387, P611, DOI 10.1038/42491; Rossi DL, 1997, J IMMUNOL, V158, P1033; SANDERS ME, 1988, J IMMUNOL, V140, P1401; SCHALL TJ, 1994, CURR OPIN IMMUNOL, V6, P865, DOI 10.1016/0952-7915(94)90006-X; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; TAUB DD, 1993, J EXP MED, V177, P1809, DOI 10.1084/jem.177.6.1809; VONANDRIAN UH, 1992, AM J PHYSIOL, V263, pH1034, DOI 10.1152/ajpheart.1992.263.4.H1034; VONANDRIAN UH, 1995, CELL, V82, P989, DOI 10.1016/0092-8674(95)90278-3; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WARNOCK RA, IN PRESS J EXP MED; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803	41	791	821	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					381	384		10.1126/science.279.5349.381	http://dx.doi.org/10.1126/science.279.5349.381			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430588				2022-12-01	WOS:000071570800046
J	Bezzi, P; Carmignoto, G; Pasti, L; Vesce, S; Rossi, D; Rizzini, BL; Pozzan, T; Volterra, A				Bezzi, P; Carmignoto, G; Pasti, L; Vesce, S; Rossi, D; Rizzini, BL; Pozzan, T; Volterra, A			Prostaglandins stimulate calcium-dependent glutamate release in astrocytes	NATURE			English	Article							ARACHIDONIC-ACID; SYNAPTIC TRANSMISSION; GLIAL-CELLS; HIPPOCAMPAL; NEURONS; CULTURES; INHIBITION; RECEPTORS; RESPONSES; TETANUS	Astrocytes in the brain form an intimately associated network with neurons. They respond to neuronal activity and synaptically released glutamate by raising intracellular calcium concentration ([Ca2+](i))(1,2), which could represent the start of back-signalling to neurons(3-5). Here we show that coactivation of the AMPA/kainate and metabotropic glutamate receptors (mGluRs) on astrocytes stimulates these cells to release glutamate through a Ca2+-dependent process mediated by prostaglandins. Pharmacological inhibition of prostaglandin synthesis prevents glutamate release, whereas application of prostaglandins (in particular PGE(2)) mimics and occludes the releasing action of GluR agonists. PGE(2) promotes Ca2+-dependent glutamate release from cultured astrocytes and also from acute brain slices under conditions that suppress neuronal exocytotic release. When applied to the CA1 hippocampal region, PGE(2) induces increases in [Ca2+](i) both in astrocytes and in neurons. The [Ca2+](i) increase in neurons is mediated by glutamate released from astrocytes, because it is abolished by GluR antagonists. Our results reveal a new pathway of regulated transmitter release from astrocytes and outline the existence of an integrated glutamatergic cross-talk between neurons and astrocytes in situ that may play critical roles in synaptic plasticity and in neurotoxicity.	Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; Univ Padua, Dept Expt Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Ctr Study Biomembranes, I-35121 Padua, Italy	University of Milan; University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua	Volterra, A (corresponding author), Univ Milan, Inst Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.		Carmignoto, Giorgio/A-8375-2018; Bezzi, Paola/AAP-2440-2020; Rossi, Daniela Maria/AAA-3401-2021	Carmignoto, Giorgio/0000-0003-3063-6774; Rossi, Daniela Maria/0000-0002-3346-1327; Volterra, Andrea/0000-0003-1069-1602	Telethon [586, 845] Funding Source: Medline	Telethon(Fondazione Telethon)		BARAN H, 1987, BRAIN RES, V404, P107, DOI 10.1016/0006-8993(87)91360-6; CALABRESI P, 1989, NEUROSCIENCE, V30, P663, DOI 10.1016/0306-4522(89)90159-0; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CollacoMoraes Y, 1996, J CEREBR BLOOD F MET, V16, P1366, DOI 10.1097/00004647-199611000-00035; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DUMUIS A, 1990, NATURE, V347, P182, DOI 10.1038/347182a0; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; ERIKSSON PS, 1992, NEUROSCI LETT, V143, P195, DOI 10.1016/0304-3940(92)90264-8; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; Jeftinija SD, 1997, BRAIN RES, V750, P41, DOI 10.1016/S0006-8993(96)00610-5; JEFTINIJA SD, 1996, J NEUROCHEM, V66, P674; KIMELBERG HK, 1990, J NEUROSCI, V10, P1583; MALMBERG AB, 1992, SCIENCE, V257, P1276, DOI 10.1126/science.1381521; Mennerick S, 1996, J NEUROSCI, V16, P55; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NICHOLLS DG, 1987, J NEUROCHEM, V49, P50, DOI 10.1111/j.1471-4159.1987.tb03393.x; OBanion MK, 1996, J NEUROCHEM, V66, P2532; OOMAGARI K, 1991, EUR J NEUROSCI, V3, P928, DOI 10.1111/j.1460-9568.1991.tb00028.x; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pasti L, 1997, J NEUROSCI, V17, P7817; PIOMELLI D, 1994, CRIT REV NEUROBIOL, V8, P65; Porter JT, 1996, J NEUROSCI, V16, P5073; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Steinhauser C, 1996, TRENDS NEUROSCI, V19, P339, DOI 10.1016/0166-2236(96)10043-6; STELLA N, 1994, J NEUROSCI, V14, P568; SZATKOWSKI M, 1990, NATURE, V348, P443, DOI 10.1038/348443a0; Vesce S, 1997, FEBS LETT, V411, P107, DOI 10.1016/S0014-5793(97)00674-1; Volterra A, 1996, EUR J NEUROSCI, V8, P2019, DOI 10.1111/j.1460-9568.1996.tb01345.x	29	928	962	1	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					281	285		10.1038/34651	http://dx.doi.org/10.1038/34651			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440691				2022-12-01	WOS:000071484400050
J	Boccaccio, C; Ando, M; Tamagnone, L; Bardelli, A; Michieli, P; Battistini, C; Comoglio, PM				Boccaccio, C; Ando, M; Tamagnone, L; Bardelli, A; Michieli, P; Battistini, C; Comoglio, PM			Induction of epithelial tubules by growth factor HGF depends on the STAT pathway	NATURE			English	Article							SCATTER FACTOR-RECEPTOR; C-FOS PROMOTER; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASE; MET RECEPTOR; PROTEIN; EXPRESSION; CELLS; TRANSFORMATION; MORPHOGENESIS	Hepatocyte growth factor (HGF) induces a three-phase response leading-to the formation of branched tubular structures in epithelial cells(1,2). The HGF receptor tyrosine kinase works through a Src homology (SH2) docking site that can activate several signalling pathways(3). The first phase of the response (scattering), which results from cytoskeletal reorganization, loss of intercellular junctions and cell migration(4), is depdent on phosphatidylinositol-3-OH kinase and Rac activation(5,6). The second phase (growth) requires stimulation of the Ras-MAP kinase cascade(7). Here we show that the third phase (tubulogenesis) is dependent on the STAT pathway. HGF stimulates recruitment of Stat-3 to the receptor, tyrosine phosphorylation, nuclear translocation and binding to the specific promoter element SIE. Electroporation of a tyrosine-phosphorylated peptide, which interferes with both the association of STAT to the receptor and STAT dimerization, inhibits tubule formation in vitro without affecting either HGF-induced 'scattering' or growth. The same result is obtained using a specific 'decoy' oligonucleotide that prevents STAT from binding to DNA and affecting the expression of genes involved in cell-cycle regulation (c-fos and waf-1). Activation of signal transducers that directly control transcription is therefore required for morphogenesis.	Univ Turin, Sch Med, Inst Canc Res, I-10060 Candiolo, Italy; Pharmacia & Upjohn Inc, Preclin Res, I-20014 Nerviano, Italy	University of Turin; Pfizer	Boccaccio, C (corresponding author), Univ Turin, Sch Med, Inst Canc Res, Str Prov 142, I-10060 Candiolo, Italy.	cboccaccio@hal.ircc.polito.it	Tamagnone, Luca/J-8948-2018; Boccaccio, Carla/AHE-7875-2022; Battistini, Carlo/AAJ-1193-2020; Michieli, Paolo/A-2588-2011; BARDELLI, Alberto/J-9721-2018	Tamagnone, Luca/0000-0002-2884-7946; Boccaccio, Carla/0000-0003-2620-9083; Michieli, Paolo/0000-0002-3093-8871; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070				BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; COMOGLIO PM, 1984, EMBO J, V3, P483, DOI 10.1002/j.1460-2075.1984.tb01834.x; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gambarotta G, 1996, ONCOGENE, V13, P1911; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; GRAZIANI A, 1993, J BIOL CHEM, V268, P9165; IHLE JN, 1996, CELL, V84, P221; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; Medico E, 1996, MOL BIOL CELL, V7, P495, DOI 10.1091/mbc.7.4.495; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; Ponzetto C, 1996, J BIOL CHEM, V271, P14119, DOI 10.1074/jbc.271.24.14119; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RAPTIS LH, 1995, BIOTECHNIQUES, V18, P104; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; STOCKER M, 1987, NATURE, V327, P239; TEKEDA K, 1997, P NATL ACAD SCI USA, V94, P3801; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	30	435	456	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					285	288		10.1038/34657	http://dx.doi.org/10.1038/34657			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440692				2022-12-01	WOS:000071484400051
J	van Veen, HW; Callaghan, R; Soceneantu, L; Sardini, A; Konings, WN; Higgins, CF				van Veen, HW; Callaghan, R; Soceneantu, L; Sardini, A; Konings, WN; Higgins, CF			A bacterial antibiotic-resistance gene that complements the human multidrug-resistance P-glycoprotein gene	NATURE			English	Article							DRUG TRANSPORT; CELLS; BINDING; MDR1; VINBLASTINE; MEMBRANE; PROTEIN	Bacteria have developed many fascinating antibiotic-resistance mechanisms(1,2). A protein in Lactococcus lactis, LmrA, mediates antibiotic resistance by extruding amphiphilic compounds from the inner leaflet of the cytoplasmic membrane(3,4). Unlike other known bacterial multidrug-resistance proteins, LmrA is an ATP-binding cassette (ABC) transporter(5). The human multidrug-resistance P-glycoprotein(6), encoded by the MDR1 gene, is also an ABC transporter, overexpression of which is one of the principal causes of resistance of human cancers to chemotherapy(7,8). We expressed ImrA in human lung fibroblast cells. Surprisingly, LmrA was targeted to the plasma membrane and conferred typical multidrug resistance on these human cells. The pharmacological characteristics of LmrA and P-glycoprotein-expressing lung fibroblasts were very similar, and the affinities of both proteins for vinblastine and magnesium-ATP were indistinguishable. Blockers of P-glycoprotein-mediated multidrug resistance also inhibited LmrA-dependent drug resistance. Kinetic analysis of drug dissociation from LmrA expressed in plasma membranes of insect cells revealed the presence of two allosterically linked drug-binding sites indistinguishable from those of P-glycoprotein. These findings have implications for the reversal of antibiotic resistance in pathogenic microorganisms. Taken together, they demonstrate that bacterial LmrA and human P-glycopiotein are functionally interchangeable and that this type of multidrug-resistance efflux pump is conserved from bacteria to man.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands; Univ Oxford, John Radcliffe Hosp, Inst Mol Med,Nuffield Dept Clin Biochem, Imperial Canc Res Fund Labs, Oxford OX3 9DS, England; Univ Oxford, John Radcliffe Hosp, Inst Mol Med,Nuffield Dept Clin Biochem, Canc Res Campaign,Drug Resistance Grp, Oxford OX3 9DS, England; Univ London Kings Coll, Dept Physiol, London WC2R 2LS, England	University of Groningen; Cancer Research UK; University of Oxford; University of Oxford; University of London; King's College London	van Veen, HW (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020; Konings, Wilhelmus N./C-7063-2013; van Veen, Hendrik W./A-4162-2008	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; van Veen, Hendrik W./0000-0002-9658-8077				Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Ferry D. R, 1994, NEW MOL TARGETS CANC, P177; FERRY DR, 1992, BIOCHEM BIOPH RES CO, V188, P440, DOI 10.1016/0006-291X(92)92404-L; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; Goodfellow HR, 1996, J BIOL CHEM, V271, P13668, DOI 10.1074/jbc.271.23.13668; Gottesman MM, 1995, ANNU REV GENET, V29, P607, DOI 10.1146/annurev.ge.29.120195.003135; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cellbio.8.1.67; Kostenis E, 1996, TRENDS PHARMACOL SCI, V17, P280, DOI 10.1016/0165-6147(96)10034-1; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LEVER JE, 1977, J BIOL CHEM, V252, P1990; MALKHANDI J, 1994, EUR J PHARM-MOLEC PH, V288, P105, DOI 10.1016/0922-4106(94)90015-9; Martin C, 1997, BRIT J PHARMACOL, V122, P765, DOI 10.1038/sj.bjp.0701429; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Ruetz S, 1997, BIOCHEMISTRY-US, V36, P8180, DOI 10.1021/bi970564o; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Shao YM, 1997, BBA-MOL BASIS DIS, V1360, P30, DOI 10.1016/S0925-4439(96)00065-8; SHAPIRO AB, 1995, J BIOL CHEM, V270, P16167, DOI 10.1074/jbc.270.27.16167; TAMAI I, 1991, J BIOL CHEM, V266, P16796; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; vanVeen HW, 1997, BIOL CHEM, V378, P769; VanVeen HW, 1996, P NATL ACAD SCI USA, V93, P10668, DOI 10.1073/pnas.93.20.10668; VAUGHN JL, 1977, IN VITRO CELL DEV B, V13, P213	29	213	217	2	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					291	295		10.1038/34669	http://dx.doi.org/10.1038/34669			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440694				2022-12-01	WOS:000071484400053
J	Gannon, PJ; Holloway, RL; Broadfield, DC; Braun, AR				Gannon, PJ; Holloway, RL; Broadfield, DC; Braun, AR			Asymmetry of chimpanzee planum temporale: Humanlike pattern of Wernicke's brain language area homolog	SCIENCE			English	Article							CEREBRAL LATERALIZATION; BIOLOGICAL MECHANISMS; RHESUS-MONKEYS; ASSOCIATIONS; HYPOTHESIS; PATHOLOGY; PROGRAM; ORGANIZATION; REGION	The anatomic pattern and left hemisphere size predominance of the planum temporale, a language area of the human brain, are also present in chimpanzees (Pan troglodytes). The left planum temperate was significantly larger in 94 percent (17 of 18) of chimpanzee brains examined. It is widely accepted that the planum temporale is a key component of Wernicke's receptive language area, which is also implicated in human communication-related disorders such as schizophrenia and in normal variations such as musical talent. However, anatomic hemispheric asymmetry of this cerebrocortical site is clearly not unique to humans, as is currently thought. The evolutionary origin of human language may have been founded on this basal anatomic substrate, which was already lateralized to the left hemisphere in the common ancestor of chimpanzees and humans 8 million years ago.	CUNY Mt Sinai Sch Med, Dept Otolaryngol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; Columbia Univ, Dept Anthropol, New York, NY 10027 USA; CUNY, Dept Anthropol, New York, NY 10036 USA; Natl Inst Deafness & Other Commun Disorders, Bethesda, MD 20892 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University; City University of New York (CUNY) System; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Gannon, PJ (corresponding author), CUNY Mt Sinai Sch Med, Dept Otolaryngol, Box 1189,5th Ave & 100th St, New York, NY 10029 USA.	P_Gannon@smtplink.mssm.edu						ANNETT M, 1992, NEUROPSYCHOLOGIA, V30, P951, DOI 10.1016/0028-3932(92)90048-Q; Bailey P, 1950, ISOCORTEX CHIMPANZEE; Binder JR, 1996, BRAIN, V119, P1239, DOI 10.1093/brain/119.4.1239; Calvert GA, 1997, SCIENCE, V276, P593, DOI 10.1126/science.276.5312.593; Crow TJ, 1997, TRENDS NEUROSCI, V20, P339; DDEWAAL F, 1997, DISCOVER, V18, P50; DEACON TW, 1992, EVOLUTION HUMAN LANG, V11, P49; FALK D, 1986, FOLIA PRIMATOL, V46, P98, DOI 10.1159/000156242; FOUNDAS AL, 1994, NEUROPSYCHOLOGIA, V32, P1225, DOI 10.1016/0028-3932(94)90104-X; FOUNDAS AL, 1995, ARCH NEUROL-CHICAGO, V52, P501, DOI 10.1001/archneur.1995.00540290091023; GALABURDA A, 1980, J COMP NEUROL, V190, P597, DOI 10.1002/cne.901900312; GALABURDA AM, 1993, ARCH NEUROL-CHICAGO, V50, P457, DOI 10.1001/archneur.1993.00540050011007; GALABURDA AM, 1978, ARCH NEUROL-CHICAGO, V35, P812, DOI 10.1001/archneur.1978.00500360036007; GALLUP GG, 1970, SCIENCE, V167, P86, DOI 10.1126/science.167.3914.86; GANNON PJ, 1995, THESIS CITY U NEW YO; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P428, DOI 10.1001/archneur.1985.04060050026008; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P521, DOI 10.1001/archneur.1985.04060060019009; GESCHWIND N, 1985, ARCH NEUROL-CHICAGO, V42, P634, DOI 10.1001/archneur.1985.04060070024012; GESCHWIND N, 1968, SCIENCE, V161, P186, DOI 10.1126/science.161.3837.186; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; GREENFIELD PM, 1993, J CHILD LANG, V20, P1, DOI 10.1017/S0305000900009090; HABIB M, 1995, BRAIN LANG, V48, P238, DOI 10.1006/brln.1995.1011; Harasty J, 1997, ARCH NEUROL-CHICAGO, V54, P171, DOI 10.1001/archneur.1997.00550140045011; HEILBRONER PL, 1988, AM J PHYS ANTHROPOL, V76, P39, DOI 10.1002/ajpa.1330760105; Hickok G, 1996, NATURE, V381, P699, DOI 10.1038/381699a0; HOLLOWAY RL, 1980, AM J PHYS ANTHROPOL, V53, P285, DOI 10.1002/ajpa.1330530213; Just MA, 1996, SCIENCE, V274, P114, DOI 10.1126/science.274.5284.114; KIOYASHI H, 1997, NATURE, V387, P767; LEMAY M, 1975, BRAIN BEHAV EVOLUT, V11, P48, DOI 10.1159/000123623; LEMAY M, 1976, ANN NY ACAD SCI, V280, P349, DOI 10.1111/j.1749-6632.1976.tb25499.x; Lynch MP, 1996, BEHAV BRAIN SCI, V19, P788, DOI 10.1017/S0140525X00044071; Ojemann G A, 1993, Adv Neurol, V63, P155; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; PETTY RG, 1995, AM J PSYCHIAT, V152, P715; PFEIFER RA, 1936, HDB NEUROLOGIE, V6, P533; Poizner H., 1987, LANGUAGE, DOI [10.2307/414579, DOI 10.2307/414579]; ROSSI A, 1994, BRAIN LANG, V47, P89, DOI 10.1006/brln.1994.1043; SAVAGERUMBAUGH ES, 1993, MONOGR SOC RES CHILD, V58, pR5; SCHLAUG G, 1995, SCIENCE, V267, P699, DOI 10.1126/science.7839149; STEINMETZ H, 1991, ANN NEUROL, V29, P315, DOI 10.1002/ana.410290314; STEINMETZ H, 1989, J COMPUT ASSIST TOMO, V13, P996, DOI 10.1097/00004728-198911000-00011; STEKIIS HD, 1979, NEUROBIOLOGY SOCIAL; STEKLIS HD, COMMUNICATION; TOBIAS PV, 1987, J HUM EVOL, V16, P741, DOI 10.1016/0047-2484(87)90022-4; Vauclair J, 1997, TRENDS COGN SCI, V1, P35, DOI 10.1016/S1364-6613(97)01004-8; von Economo C, 1930, Z GESAMTE NEUROL PSY, V130, P678; WITELSON SF, 1973, BRAIN, V96, P641, DOI 10.1093/brain/96.3.641; WITELSON SF, 1991, PSYCHONEUROENDOCRINO, V16, P131, DOI 10.1016/0306-4530(91)90075-5; YENIKOMSHIAN GH, 1976, SCIENCE, V192, P387, DOI 10.1126/science.816005; [No title captured]	50	338	342	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 9	1998	279	5348					220	222		10.1126/science.279.5348.220	http://dx.doi.org/10.1126/science.279.5348.220			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YQ636	9422693				2022-12-01	WOS:000071408100040
J	van Leeuwen, FW; de Kleijn, DPV; van den Hurk, HH; Neubauer, A; Sonnemans, MAF; Sluijs, JA; Koycu, S; Ramdjielal, RDJ; Salehi, A; Martens, GJM; Grosveld, FG; Burbach, JPH; Hol, EM				van Leeuwen, FW; de Kleijn, DPV; van den Hurk, HH; Neubauer, A; Sonnemans, MAF; Sluijs, JA; Koycu, S; Ramdjielal, RDJ; Salehi, A; Martens, GJM; Grosveld, FG; Burbach, JPH; Hol, EM			Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; HUMAN-BRAIN; DOWNS-SYNDROME; DISEASE; GENE; MUTATIONS; IDENTIFICATION; TRANSCRIPTS; DESTRUCTION; PEPTIDES	The cerebral cortex of Alzheimer's and Down syndrome patients is characterized by the presence of protein deposits in neurofibrillary tangles, neuritic plaques, and neuropil threads. These structures were shown to contain forms of beta amyloid precursor protein and ubiquitin-B that are aberrant(+1 proteins) in the carboxyl terminus. The +1 proteins were not found in young control patients, whereas the presence of ubiquitin-B+1 in elderly control patients may indicate early stages of neurodegeneration. The two species of +1 proteins displayed cellular colocalization, suggesting a common origin, operating at the transcriptional level or by posttranscriptional editing of RNA. This type of transcript mutation is likely an important factor in the widely occurring nonfamilial early- and late-onset forms of Alzheimer's disease.	Netherlands Inst Brain Res, Grad Sch Neurosci, NL-1105 AZ Amsterdam, Netherlands; Univ Nijmegen, Dept Mol Anim Physiol, NL-6525 ED Nijmegen, Netherlands; Erasmus Univ, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Rudolf Magnus Inst Neurosci, NL-3584 CG Utrecht, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Radboud University Nijmegen; Erasmus University Rotterdam; Utrecht University; Utrecht University Medical Center	van Leeuwen, FW (corresponding author), Netherlands Inst Brain Res, Grad Sch Neurosci, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.		Hol, Elly M/F-1891-2013; Salehi, Ahmad/H-2746-2019; Hol, Elly/J-2025-2019; Salehi, Ahmad/A-1148-2007; Martens, Gerard JM/D-1925-2010	Hol, Elly M/0000-0001-5604-2603; Salehi, Ahmad/0000-0001-8257-3280; Hol, Elly/0000-0001-5604-2603; Salehi, Ahmad/0000-0001-8257-3280; 				ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ALIKHAN Z, 1992, NEUROSCI LETT, V139, P24, DOI 10.1016/0304-3940(92)90849-3; BAKER RT, 1987, NUCLEIC ACIDS RES, V15, P443, DOI 10.1093/nar/15.2.443; Braak H, 1996, J NEURAL TRANSM, V103, P455, DOI 10.1007/BF01276421; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Glisic S, 1996, TRENDS GENET, V12, P391, DOI 10.1016/S0168-9525(96)90094-3; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Harrison PJ, 1996, NEURODEGENERATION, V5, P409, DOI 10.1006/neur.1996.0055; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Hilt W, 1996, TRENDS BIOCHEM SCI, V21, P96, DOI 10.1016/0968-0004(96)10012-8; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; JIN LW, 1994, J NEUROSCI, V14, P5461; Johnston JA, 1996, MOL BRAIN RES, V43, P85, DOI 10.1016/S0169-328X(96)00161-1; KWAK S, 1991, NEUROSCI LETT, V128, P21, DOI 10.1016/0304-3940(91)90751-E; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; MORISHIMAKAWASHIMA M, 1993, NEURON, V10, P1151, DOI 10.1016/0896-6273(93)90063-W; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; OYAMA F, 1994, J NEUROCHEM, V62, P1062; PERRY G, 1989, J NEUROCHEM, V52, P1523, DOI 10.1111/j.1471-4159.1989.tb09203.x; PHILIPPE B, 1993, NEUROREPORT, V5, P289, DOI 10.1097/00001756-199312000-00027; RUMBLE B, 1989, NEW ENGL J MED, V320, P1446, DOI 10.1056/NEJM198906013202203; Simpson L, 1996, ANNU REV NEUROSCI, V19, P27, DOI 10.1146/annurev.ne.19.030196.000331; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STRACHAN T, 1997, HUMAN MOL GENETICS; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Terry Robert D., 1994, P179; VANBROECKHOVEN CL, 1995, EUR NEUROL, V35, P8, DOI 10.1159/000117083; VANLEEUWEN F, 1989, P NATL ACAD SCI USA, V86, P6417, DOI 10.1073/pnas.86.16.6417; VANLEEUWEN FXR, UNPUB; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	31	465	478	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 9	1998	279	5348					242	247		10.1126/science.279.5348.242	http://dx.doi.org/10.1126/science.279.5348.242			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ636	9422699				2022-12-01	WOS:000071408100046
J	Kippelen, B; Marder, SR; Hendrickx, E; Maldonado, JL; Guillemet, G; Volodin, BL; Steele, DD; Enami, Y; Sandalphon; Yao, YJ; Wang, JF; Rockel, H; Erskine, L; Peyghambarian, N				Kippelen, B; Marder, SR; Hendrickx, E; Maldonado, JL; Guillemet, G; Volodin, BL; Steele, DD; Enami, Y; Sandalphon; Yao, YJ; Wang, JF; Rockel, H; Erskine, L; Peyghambarian, N			Infrared photorefractive polymers and their applications for imaging	SCIENCE			English	Article							STATE; GAIN	Photorefractive polymers with high diffraction efficiency in the visible and near-infrared regions of the electromagnetic spectrum have been developed, These polymers, which have a large dynamic range because of their high orientational birefringence, incorporate a dye designed to have a large dipole moment and a high linear polarizability anisotropy, Such polymers have enabled demonstrations of imaging through scattering media, using a holographic time-gating technique at a wavelength that is compatible with the transparency of biological tissues and with the emission of low-cost semiconductor laser diodes.	Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA	University of Arizona; California Institute of Technology; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL)	Kippelen, B (corresponding author), Univ Arizona, Ctr Opt Sci, Tucson, AZ 85721 USA.		Kippelen, Bernard/I-4058-2013; Maldonado, Jose-Luis/L-6884-2017; Marder, Seth/GRR-9990-2022; Enami, Yasufumi/E-4273-2016	Kippelen, Bernard/0000-0002-8417-7051; Maldonado, Jose-Luis/0000-0003-3601-7464; Enami, Yasufumi/0000-0002-0303-2695				ABRAMSON NH, 1989, APPL OPTICS, V28, P1834, DOI 10.1364/AO.28.001834; ASHKIN A, 1966, APPL PHYS LETT, V9, P72, DOI 10.1063/1.1754607; DONCKERS MCJM, 1993, OPT LETT, V18, P1044, DOI 10.1364/OL.18.001044; DUCHARME S, 1991, PHYS REV LETT, V66, P1846, DOI 10.1103/PhysRevLett.66.1846; Gayen S. K., 1996, OPT PHOTONICS NEWS, V7, P16; GrunnetJepsen A, 1997, SCIENCE, V277, P549, DOI 10.1126/science.277.5325.549; GUNTER P, 1988, PHOTOREFRACTIVE MAT, V1; GUNTER P, 1989, PHOTOREFRACTIVE MAT, V2; Hendrickx E, 1997, APPL PHYS LETT, V71, P1159, DOI 10.1063/1.119612; Huignard J. P., 1988, PHOTOREFRACTIVE MAT; HYDE SCW, 1995, OPT LETT, V20, P1331, DOI 10.1364/OL.20.001331; Kippelen B, 1997, J AM CHEM SOC, V119, P4559, DOI 10.1021/ja9643477; Kippelen B, 1996, APPL PHYS LETT, V68, P1748, DOI 10.1063/1.116653; KIPPELEN B, 1997, NONLINEAR OPTICS ORG, P465; KOGELNIK H, 1969, AT&T TECH J, V48, P2909, DOI 10.1002/j.1538-7305.1969.tb01198.x; KUZYK MG, 1990, J OPT SOC AM B, V7, P842, DOI 10.1364/JOSAB.7.000842; LIPHARDT M, 1994, SCIENCE, V263, P367, DOI 10.1126/science.263.5145.367; Lundquist PM, 1996, SCIENCE, V274, P1182, DOI 10.1126/science.274.5290.1182; MEERHOLZ K, 1994, NATURE, V371, P497, DOI 10.1038/371497a0; MOERNER WE, 1994, J OPT SOC AM B, V11, P320, DOI 10.1364/JOSAB.11.000320; MOERNER WE, 1994, CHEM REV, V94, P127, DOI 10.1021/cr00025a005; OUDAR JL, 1977, J CHEM PHYS, V66, P2664, DOI 10.1063/1.434213; SINGER KD, 1987, J OPT SOC AM B, V4, P968, DOI 10.1364/JOSAB.4.000968; STEELE DD, IN PRESS OPT LETT; Volodin BL, 1996, NATURE, V383, P58, DOI 10.1038/383058a0; WILLIAMS DJ, 1987, NONLINEAR OPTICAL PR, V1; WU JW, 1991, J OPT SOC AM B, V8, P142, DOI 10.1364/JOSAB.8.000142; Zhang Y, 1996, ADV MATER, V8, P111, DOI 10.1002/adma.19960080203	28	235	243	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 2	1998	279	5347					54	57		10.1126/science.279.5347.54	http://dx.doi.org/10.1126/science.279.5347.54			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP866	9417020				2022-12-01	WOS:000071323900035
J	Escalante, CR; Yie, JM; Thanos, D; Aggarwal, AK				Escalante, CR; Yie, JM; Thanos, D; Aggarwal, AK			Structure of IRF-1 with bound DNA reveals determinants of interferon regulation	NATURE			English	Article							CRYSTAL-STRUCTURE; TRANSCRIPTION FACTORS; PROTEINS; RECOGNITION; COMPLEX; BINDING; IFN; EXPRESSION; DOMAIN; GENES	The family of interferon regulatory factor (IRF) transcription factors is important in the regulation of interferons in response to infection by virus and in the regulation of interferon-inducible genes(1,2). The IRF family is characterized by a unique 'tryptophan cluster' DNA-binding region. Here we report the crystal structure of the IRF-1 region bound to the natural positive regulatory domain I (PRD I) DNA element from the interferon-beta promoter(1). The structure provides the first three-dimensional view of a member of the growing IRF family, revealing a new helix-turn-helix motif that latches onto DNA through three of the five conserved tryptophans. The moth selects a short GAAA core sequence through an obliquely angled recognition helix, with an accompanying bending of the DNA axis in the direction of the protein. Together, these features suggest a basis for the occurrence of GAAA repeats within IRF response elements and provide clues to the assembly of the higher-order interferon-beta enhancesome.	CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Columbia University	Aggarwal, AK (corresponding author), CUNY Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, Box 1677,1425 Madison Ave, New York, NY 10029 USA.		Thanos, Dimitris/AAE-5720-2019					AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; AU WC, 1995, P NATL ACAD SCI USA, V92, P11657, DOI 10.1073/pnas.92.25.11657; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Escalante CR, 1997, FEBS LETT, V414, P219, DOI 10.1016/S0014-5793(97)00996-4; Falvo JV, 1995, CELL, V83, P1101, DOI 10.1016/0092-8674(95)90137-X; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FUREY W, 1993, PHASES PROGRAM PACKA; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; MANIATIS T, 1992, TRANSCRIPTIONAL REGU, P1993; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; TANIGUCHI T, 1995, J CANCER RES CLIN, V121, P516, DOI 10.1007/BF01197763; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; UEGAKI K, 1995, FEBS LETT, V359, P184, DOI 10.1016/0014-5793(95)00040-G; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315	30	307	320	2	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					103	106		10.1038/34224	http://dx.doi.org/10.1038/34224			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422515				2022-12-01	WOS:000071326100059
J	Bender, M; Imam, FB; Talbot, WS; Ganetzky, B; Hogness, DS				Bender, M; Imam, FB; Talbot, WS; Ganetzky, B; Hogness, DS			Drosophila ecdysone receptor mutations reveal functional differences among receptor isoforms	CELL			English	Article							SINGLE-BASE CHANGES; INDUCIBLE GENE; EARLY PUFF; ENCODES 2; METAMORPHOSIS; SUPERFAMILY; TRANSCRIPTION; MELANOGASTER; PROTEINS; E74	The steroid hormone ecdysone directs Drosophila metamorphosis via three heterodimeric receptors that differ according to which of three ecdysone receptor isoforms encoded by the EcR gene (EcR-A, EcR-B1, or EcR-B2) is activated by the orphan nuclear receptor USP. We have identified and molecularly mapped two classes of EcR mutations: those specific to EcR-B1 that uncouple metamorphosis, and embryonic-lethal mutations that map to common sequences encoding the DNA-and ligand-binding domains. In the larval salivary gland, loss of EcR-B1 results in loss of activation of ecdysone-induced genes. Comparable transgenic expression of EcR-B1, EcR-B2, and EcR-A in these mutant glands results, respectively, in full, partial, and no repair of that loss.	STANFORD UNIV,MED CTR,DEPT DEV BIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,DEPT BIOCHEM,STANFORD,CA 94305; UNIV GEORGIA,DEPT GENET,ATHENS,GA 30602; UNIV WISCONSIN,GENET LAB,MADISON,WI 53706	Stanford University; Stanford University; University System of Georgia; University of Georgia; University of Wisconsin System; University of Wisconsin Madison				Imam, Farhad/0000-0003-2854-2568	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043100, R01GM053681] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53681, GM43100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andres A.J., 1994, DROSOPHILA MELANOGAS, P565; ANDRES AJ, 1995, DEVELOPMENT, V121, P2667; ANDRES AJ, 1993, DEV BIOL, V160, P388, DOI 10.1006/dbio.1993.1315; ASHBURNER M, 1974, DEV BIOL, V39, P141, DOI 10.1016/S0012-1606(74)80016-3; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BELYAEVA ES, 1981, CHROMOSOMA, V84, P207, DOI 10.1007/BF00399132; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; Crossgrove K, 1996, DEV BIOL, V180, P745, DOI 10.1006/dbio.1996.0343; DAI JD, 1991, DEV BIOL, V144, P309, DOI 10.1016/0012-1606(91)90424-2; DIBELLO PR, 1991, GENETICS, V129, P385; FLETCHER JC, 1995, DEVELOPMENT, V121, P1411; Fristrom Dianne, 1993, P843; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; JIANG C, 1997, IN PRESS DEVELOPMENT; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, THESIS STANFORD U ST; Lewis E., 1968, DROSOPHILA INFO SERV, V43, P193; MADHAVAN MM, 1980, J EMBRYOL EXP MORPH, V60, P1; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; MUNROE S, 1995, THESIS STANFORD U ST; MYERS RM, 1987, METHOD ENZYMOL, V155, P501; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; REFETOFF S, 1994, ENDOCR REV, V15, P336; Riddiford Lynn M., 1993, P899; ROBINOW S, 1993, DEVELOPMENT, V119, P1251; Russell S., 1996, METAMORPHOSIS CELL B, P109, DOI [10.1016/B978-012283245-1/50005-1, DOI 10.1016/B978-012283245-1/50005-1]; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1988, THESIS STANFORD U ST; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; Skaer Helen, 1993, P941; TALBOT WS, 1993, CELL, V73, P1323, DOI 10.1016/0092-8674(93)90359-X; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; THUMMEL CS, 1995, CELL, V83, P871, DOI 10.1016/0092-8674(95)90203-1; UMESS LD, 1995, EMBO J, V14, P6239; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F	38	226	232	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					777	788		10.1016/S0092-8674(00)80466-3	http://dx.doi.org/10.1016/S0092-8674(00)80466-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413987	hybrid			2022-12-01	WOS:A1997YL43900009
J	Darji, A; Guzman, CA; Gerstel, B; Wachholz, P; Timmis, KN; Wehland, J; Chakraborty, T; Weiss, S				Darji, A; Guzman, CA; Gerstel, B; Wachholz, P; Timmis, KN; Wehland, J; Chakraborty, T; Weiss, S			Oral somatic transgene vaccination using attenuated S-typhimurium	CELL			English	Article							COMPLEX CLASS-I; SALMONELLA-TYPHIMURIUM; LISTERIA-MONOCYTOGENES; ESCHERICHIA-COLI; T-CELLS; BETA-GALACTOSIDASE; IMMUNE-RESPONSES; BACTERIAL-DNA; LYMPHOCYTE-T; ANTIGEN	An attenuated strain of S. typhimurium has been used as a vehicle for oral genetic immunization. Eukaryotic expression vectors containing truncated genes of ActA and listeriolysin-two virulence factors of Listeria monocytogenes-have been used to transform S. typhimurium aroA. Multiple or even single oral immunizations with such transformants induced excellent cellular and humoral responses. In addition, protective immunity was induced with listeriolysin transformants. The quality of the responses suggested a transfer of plasmid DNA from the bacterial carrier to the host. Such transfer was unequivocally shown in vitro with primary peritoneal macrophages. We describe a highly versatile system for antigen delivery, identification of protective antigens for vaccination, and efficient generation of antibodies against the product of open reading frames present on virtually any DNA segment.	GESELL BIOTECHNOL FORSCH MBH,NATL RES CTR BIOTECHNOL,DIV MICROBIOL,D-38124 BRAUNSCHWEIG,GERMANY; UNIV GIESSEN,INST MED MICROBIOL,D-35392 GIESSEN,GERMANY	Gesellschaft fur Biotechnologische Forschung mbH; Justus Liebig University Giessen	Darji, A (corresponding author), GESELL BIOTECHNOL FORSCH MBH,NATL RES CTR BIOTECHNOL,DIV CELL BIOL & IMMUNOL,MASCHERODER WEG 1,D-38124 BRAUNSCHWEIG,GERMANY.							[Anonymous], 1982, MOL CLONING LAB MANU; BROOKS AG, 1993, J IMMUNOL, V150, P3690; BROWN A, 1987, J INFECT DIS, V155, P86, DOI 10.1093/infdis/155.1.86; CHAKRABORTY T, 1992, J BACTERIOL, V174, P568, DOI 10.1128/jb.174.2.568-574.1992; Chatfield SN, 1994, MODERN VACCINOLOGY, P55; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Condon C, 1996, NAT MED, V2, P1122, DOI 10.1038/nm1096-1122; Courvalin P, 1995, CR ACAD SCI III-VIE, V318, P1207; Darji A, 1995, J BIOTECHNOL, V43, P205, DOI 10.1016/0168-1656(95)00138-7; DARJI A, 1995, EUR J IMMUNOL, V25, P2967, DOI 10.1002/eji.1830251038; Darji A, 1997, EUR J IMMUNOL, V27, P1353, DOI 10.1002/eji.1830270609; DESOUSA CR, 1995, J EXP MED, V182, P841; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Donnelly JJ, 1997, ANNU REV IMMUNOL, V15, P617, DOI 10.1146/annurev.immunol.15.1.617; FAIRWEATHER NF, 1990, RES MICROBIOL, V141, P769, DOI 10.1016/0923-2508(90)90109-4; FLYNN JL, 1990, MOL MICROBIOL, V4, P2111, DOI 10.1111/j.1365-2958.1990.tb00572.x; Fox BC, 1997, AM J VET RES, V58, P265; Geissler M, 1997, J IMMUNOL, V158, P1231; GERMANIER R, 1975, J INFECT DIS, V131, P553, DOI 10.1093/infdis/131.5.553; GUZMAN CA, 1991, INFECT IMMUN, V59, P4391; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; Hassan JO, 1996, INFECT IMMUN, V64, P938, DOI 10.1128/IAI.64.3.938-944.1996; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; HOLTEL A, 1992, NUCLEIC ACIDS RES, V20, P1755, DOI 10.1093/nar/20.7.1755; JARAQUEMADA D, 1990, J EXP MED, V172, P947, DOI 10.1084/jem.172.3.947; Kim JJ, 1997, J IMMUNOL, V158, P816; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; MATZINGER P, 1991, J IMMUNOL METHODS, V145, P185, DOI 10.1016/0022-1759(91)90325-A; MENGAUD J, 1988, INFECT IMMUN, V56, P766, DOI 10.1128/IAI.56.4.766-772.1988; MESSINA JP, 1991, J IMMUNOL, V147, P1759; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.iy.07.040189.001045; Neutra MR, 1996, ANNU REV IMMUNOL, V14, P275, DOI 10.1146/annurev.immunol.14.1.275; NEWTON SMC, 1989, SCIENCE, V244, P70, DOI 10.1126/science.2468182; Norbury CC, 1995, IMMUNITY, V3, P783, DOI 10.1016/1074-7613(95)90067-5; OCALLAGHAN D, 1990, MOL GEN GENET, V223, P156, DOI 10.1007/BF00315809; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; RAMMENSEE HG, 1989, IMMUNOGENETICS, V30, P296, DOI 10.1007/BF02421334; ROBERTS M, 1994, NOVEL DELIVERY SYSTE, P27; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.iy.10.040192.002125; Siebers A, 1996, TRENDS MICROBIOL, V4, P22, DOI 10.1016/0966-842X(96)81501-0; SIZEMORE DR, 1995, SCIENCE, V270, P299, DOI 10.1126/science.270.5234.299; Steinbach G, 1996, VET MICROBIOL, V48, P199, DOI 10.1016/0378-1135(95)00134-4; Tian JD, 1996, NAT MED, V2, P1348, DOI 10.1038/nm1296-1348; TURNER SJ, 1993, INFECT IMMUN, V61, P5374, DOI 10.1128/IAI.61.12.5374-5380.1993; WALKER MJ, 1992, INFECT IMMUN, V60, P4260, DOI 10.1128/IAI.60.10.4260-4268.1992; WILES MV, 1993, METHOD ENZYMOL, V225, P900; XIANG ZQ, 1995, IMMUNITY, V2, P129, DOI 10.1016/S1074-7613(95)80001-8; YAMAMOTO S, 1992, J IMMUNOL, V148, P4072; ZHU N, 1993, SCIENCE, V261, P209, DOI 10.1126/science.7687073	50	346	414	0	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					765	775		10.1016/S0092-8674(00)80465-1	http://dx.doi.org/10.1016/S0092-8674(00)80465-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413986	Bronze			2022-12-01	WOS:A1997YL43900008
J	Gong, XH; Li, E; Klier, G; Huang, QL; Wu, Y; Lei, H; Kumar, NM; Horwitz, J; Gilula, NB				Gong, XH; Li, E; Klier, G; Huang, QL; Wu, Y; Lei, H; Kumar, NM; Horwitz, J; Gilula, NB			Disruption of alpha(3) connexin gene leads to proteolysis and cataractogenesis in mice	CELL			English	Article							GAP JUNCTION PROTEIN; TRANSGENIC MICE; RAT LENS; STRUCTURAL ORGANIZATION; BETA-GALACTOSIDASE; MAMMALIAN LENS; CHICK LENS; CALPAIN-II; MOUSE; CRYSTALLIN	Gap junction channels formed by alpha(3) (Cx46) and alpha(8) (Cx50) connexin provide pathways for communication between the fiber cells in the normal transparent lens. To determine the specific role of alpha(3) connexin in vivo, the alpha(3) connexin gene was disrupted in mice. Although the absence of alpha(3) connexin had no obvious influence on the early stages of lens formation and the differentiation of lens fibers, mice homozygous for the disrupted alpha(3) gene developed nuclear cataracts that were associated with the proteolysis of crystallins. This study establishes the importance of gap junctions in maintaining normal lens transparency by providing a cell-cell signaling pathway or structural component for the proper organization of lens membrane and cytoplasmic proteins.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; HARVARD UNIV, MGH, SCH MED, CARDIOVASC RES CTR, CHARLESTOWN, MA 02129 USA; UNIV CALIF LOS ANGELES, JULES STEIN EYE INST, LOS ANGELES, CA 90095 USA	Scripps Research Institute; Harvard University; University of California System; University of California Los Angeles					NATIONAL EYE INSTITUTE [R01EY011093, R37EY003897] Funding Source: NIH RePORTER; NEI NIH HHS [EY11093, R37EY3897] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AlGhoul KJ, 1996, EXP EYE RES, V62, P237, DOI 10.1006/exer.1996.0029; Bassnett S, 1997, J CELL BIOL, V137, P37, DOI 10.1083/jcb.137.1.37; BLOEMENDAL H, 1981, MOL CELLULAR BIOL EY, P85; Bond J, 1996, INVEST OPHTH VIS SCI, V37, P1557; BONNEROT C, 1987, P NATL ACAD SCI USA, V84, P6795, DOI 10.1073/pnas.84.19.6795; BONNEROT C, 1993, METHOD ENZYMOL, V225, P451; Brady JP, 1997, P NATL ACAD SCI USA, V94, P884, DOI 10.1073/pnas.94.3.884; BRAKENHOFF RH, 1994, HUM MOL GENET, V3, P279, DOI 10.1093/hmg/3.2.279; Bruzzone R, 1996, EUR J BIOCHEM, V238, P1, DOI 10.1111/j.1432-1033.1996.0001q.x; CAPUTO A, 1994, NAT STRUCT BIOL, V1, P364, DOI 10.1038/nsb0694-364; CHAUDUN E, 1994, J CELL PHYSIOL, V158, P354, DOI 10.1002/jcp.1041580218; COSTELLO MJ, 1989, INVEST OPHTH VIS SCI, V30, P975; DAVID LL, 1986, EXP EYE RES, V42, P227, DOI 10.1016/0014-4835(86)90057-6; DUNCAN G, 1994, PROG RETIN EYE RES, V13, P623, DOI 10.1016/1350-9462(94)90025-6; Dunia I, 1996, J CELL BIOL, V132, P701, DOI 10.1083/jcb.132.4.701; EVANS CW, 1993, EUR J CELL BIOL, V60, P243; Goodenough D.A., 1992, Seminars in Cell Biology, V3, P49; GORING DR, 1987, SCIENCE, V235, P456, DOI 10.1126/science.3099390; Harding JJ, 1984, EYE B, V1b, P207; JAHNGENHODGE J, 1992, EXP EYE RES, V55, P897, DOI 10.1016/0014-4835(92)90016-L; JARVIS LJ, 1993, INVEST OPHTH VIS SCI, V34, P613; JIANG JX, 1995, DEV BIOL, V168, P649, DOI 10.1006/dbio.1995.1109; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI WC, 1995, J CELL BIOL, V130, P169, DOI 10.1083/jcb.130.1.169; Lin JS, 1997, EUR J CELL BIOL, V73, P141; LO WK, 1987, CURR EYE RES, V6, P433, DOI 10.3109/02713688709025199; Mackay D, 1997, AM J HUM GENET, V60, P1474, DOI 10.1086/515468; Mathias RT, 1997, PHYSIOL REV, V77, P21, DOI 10.1152/physrev.1997.77.1.21; Mitton KP, 1996, J BIOL CHEM, V271, P31803, DOI 10.1074/jbc.271.50.31803; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; PAUL DL, 1991, J CELL BIOL, V115, P1077, DOI 10.1083/jcb.115.4.1077; Rae JL, 1996, J MEMBRANE BIOL, V150, P89, DOI 10.1007/s002329900033; Rao PV, 1995, BBA-GEN SUBJECTS, V1245, P439, DOI 10.1016/0304-4165(95)00125-5; RISEK B, 1994, DEV BIOL, V164, P183, DOI 10.1006/dbio.1994.1190; ROBINSON KR, 1983, CURR EYE RES, V2, P843, DOI 10.3109/02713688209020020; Sambrook J., 1989, MOL CLONING LAB MANU; SHEARER TR, 1992, CURR EYE RES, V11, P357, DOI 10.3109/02713689209001789; Shiels A, 1996, NAT GENET, V12, P212, DOI 10.1038/ng0296-212; SIEZEN RJ, 1988, J MOL BIOL, V199, P475, DOI 10.1016/0022-2836(88)90619-5; SPECTOR A, 1985, OCULAR LENS STRUCTUR, P405; Srivastava OP, 1996, EXP EYE RES, V62, P593, DOI 10.1006/exer.1996.0070; TAKEMOTO L, 1994, EXP EYE RES, V59, P239, DOI 10.1006/exer.1994.1103; TRUSCOTT RJW, 1990, INVEST OPHTH VIS SCI, V31, P2405; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WHITE TW, 1992, MOL BIOL CELL, V3, P711, DOI 10.1091/mbc.3.7.711; Wride MA, 1996, DIFFERENTIATION, V61, P77, DOI 10.1046/j.1432-0436.1996.6120077.x; YANCEY SB, 1992, DEVELOPMENT, V114, P203; YOSHIDA H, 1986, INVEST OPHTH VIS SCI, V27, P1269; YOSHIDA H, 1985, CURR EYE RES, V4, P983, DOI 10.3109/02713689509000005; ZAMPIGHI GA, 1989, J CELL BIOL, V108, P2255, DOI 10.1083/jcb.108.6.2255	52	343	353	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					833	843		10.1016/S0092-8674(00)80471-7	http://dx.doi.org/10.1016/S0092-8674(00)80471-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413992	Bronze			2022-12-01	WOS:A1997YL43900014
J	Liu, C; Weaver, DR; Strogatz, SH; Reppert, SM				Liu, C; Weaver, DR; Strogatz, SH; Reppert, SM			Cellular construction of a circadian clock: Period determination in the suprachiasmatic nuclei	CELL			English	Article							IN-VITRO; NEURONS; HAMSTER; OSCILLATORS; ELECTRODES; MUSCIMOL; EXPRESS; RHYTHM; SYSTEM; PHASE	The circadian clock in the suprachiasmatic nuclei is composed of multiple, single-cell circadian oscillators (clock cells). We now test the hypothesis that the circadian period in behavior is determined by the mean period that arises from the coupling of clock cells with diverse circadian periods. For these studies, we monitored firing rate rhythms of individual suprachiasmatic nuclei neurons on fixed multielectrode plates and exploited the altered circadian periods expressed by heterozygous and homozygous tau mutant hamsters. The results show that circadian period in the whole animal is determined by averaging widely dispersed periods of individual clock cells. The data also demonstrate that the tau mutation affects circadian function in a cell-autonomous manner.	MASSACHUSETTS GEN HOSP,SERV PEDIAT,LAB DEV CHRONOBIOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02114; CORNELL UNIV,DEPT THEORET & APPL MECH,CTR APPL MATH,ITHACA,NY 14853	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Cornell University			Strogatz, Steven H/A-1641-2014	Strogatz, Steven H/0000-0003-2923-3118; Weaver, David/0000-0001-7941-6719				CARD JP, 1984, NEUROSCIENCE, V13, P415, DOI 10.1016/0306-4522(84)90240-9; DAVIES IR, 1994, NEUROREPORT, V5, P2165, DOI 10.1097/00001756-199410270-00044; DAVIS FC, 1983, AM J PHYSIOL, V244, pR93, DOI 10.1152/ajpregu.1983.244.1.R93; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; ERMENTROUT GB, 1984, SIAM J MATH ANAL, V15, P215, DOI 10.1137/0515019; ERMENTROUT GB, 1991, J MATH BIOL, V29, P195, DOI 10.1007/BF00160535; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; MASON R, 1991, BRAIN RES, V552, P53, DOI 10.1016/0006-8993(91)90659-J; MEISTER M, 1994, J NEUROSCI METH, V51, P95, DOI 10.1016/0165-0270(94)90030-2; OKAMURA H, 1989, NEUROSCI LETT, V102, P131, DOI 10.1016/0304-3940(89)90067-0; PINE J, 1980, J NEUROSCI METH, V2, P19, DOI 10.1016/0165-0270(80)90042-4; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REGEHR WG, 1989, J NEUROSCI METH, V30, P91, DOI 10.1016/0165-0270(89)90055-1; Reppert SM, 1997, CELL, V89, P487, DOI 10.1016/S0092-8674(00)80229-9; REPPERT SM, 1986, J NEUROSCI, V6, P2724; SMITH RD, 1989, J COMP PHYSIOL A, V164, P805, DOI 10.1007/BF00616752; STROGAIZ SH, 1994, NONLINEAR DYNAMICS C; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; TOMINAGA K, 1994, NEUROSCI LETT, V166, P81, DOI 10.1016/0304-3940(94)90845-1; VANDENPOL AN, 1986, NEUROSCIENCE, V17, P643, DOI 10.1016/0306-4522(86)90037-0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Wagner S, 1997, NATURE, V387, P598, DOI 10.1038/42468; Welsh DK, 1996, BRAIN RES, V706, P30, DOI 10.1016/0006-8993(95)01172-2; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WELSH DK, 1995, THESIS HARVARD U CAM; WINTREE AT, 1967, J THEOR BIOL, V16, P15; Worden, 1974, NEUROSCIENCES 3RD ST, P437	32	383	388	0	28	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 12	1997	91	6					855	860		10.1016/S0092-8674(00)80473-0	http://dx.doi.org/10.1016/S0092-8674(00)80473-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413994	hybrid			2022-12-01	WOS:A1997YL43900016
J	Rouillard, SS; Bass, NM; Roberts, JP; Doherty, CA; Gee, L; Bacchetti, P; Somberg, KA				Rouillard, SS; Bass, NM; Roberts, JP; Doherty, CA; Gee, L; Bacchetti, P; Somberg, KA			Severe hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts: Natural history and predictors of outcome	ANNALS OF INTERNAL MEDICINE			English	Article							THERAPEUTIC PORTACAVAL-SHUNT; ENCEPHALOPATHY; SURVIVAL	Background: Hyperbilirubinemia after creation of transjugular intrahepatic portosystemic shunts (TIPS) has been attributed to hemolysis and portal diversion, but the causes and natural history of this condition remain unknown. Objective: To determine clinical outcomes and predictors of severe hyperbilirubinemia after TIPS creation. Design: Retrospective analysis of all patients who underwent TIPS creation from June 1990 to September 1996. Setting: Academic medical center. Patients: 19 adults who developed severe hyperbilirubinemia (bilirubin level > 171.0 mu mol/L) within 1 month after TIPS creation were compared with 213 adults who did not develop hyperbilirubinemia after TIPS creation. Intervention: TIPS creation. Measurements: Laboratory measures and clinical outcomes. Results: According to laboratory indices, hemolysis was unlikely to have occurred. By 90 days, 95% of patients with hyperbilirubinemia had died or had undergone liver transplantation compared with 17% of controls (P < 0.001). Predictors of hyperbilirubinemia included nonalcoholic causes of liver disease (P = 0.01) and a pre-TIPS prothrombin time of 17 seconds or more (P = 0.016). Conclusions: Severe hyperbilirubinemia after TIPS creation heralds a high risk for death or need for liver transplantation. Reduced hepatic reserve predicts the development of hyperbilirubinemia.	Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Transplant Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Knowledge Management, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Somberg, KA (corresponding author), Univ Calif San Francisco, Div Gastroenterol, S-357,513 Parnassus Ave,Box 0538, San Francisco, CA 94143 USA.				NIDDK NIH HHS [5 P30 DK26743-17, T32DK07007] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007007, P30DK026743] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURCHELL AR, 1976, ANN SURG, V184, P289, DOI 10.1097/00000658-197609000-00006; CONN HO, 1974, GASTROENTEROLOGY, V67, P1065; CRIPPIN JS, 1995, J VASC INTERV RADIOL, V6, P461, DOI 10.1016/S1051-0443(95)72842-1; DAWSONSAUNDERS B, 1994, BASIC CLIN BIOSTATIS, P222; FREEDMAN AM, 1993, RADIOGRAPHICS, V13, P1185, DOI 10.1148/radiographics.13.6.8290720; GIMSON AES, 1986, HEPATOLOGY, V6, P288, DOI 10.1002/hep.1840060222; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; NOELDGE G, 1992, CARDIOVASC INTER RAD, V15, P342, DOI 10.1007/BF02733960; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; RING EJ, 1992, ANN INTERN MED, V116, P304, DOI 10.7326/0003-4819-116-4-304; RUEFF B, 1976, LANCET, V1, P655; RYPINS EB, 1988, AM J SURG, V155, P152, DOI 10.1016/S0002-9610(88)80273-3; Sanyal AJ, 1996, HEPATOLOGY, V23, P32, DOI 10.1002/hep.510230105; SANYAL AJ, 1992, ANN INTERN MED, V117, P443, DOI 10.7326/0003-4819-117-5-443; SOMBERG KA, 1995, HEPATOLOGY, V21, P709, DOI 10.1002/hep.1840210317; SOMBERG KA, 1995, AM J GASTROENTEROL, V90, P549	17	25	25	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					374	377		10.7326/0003-4819-128-5-199803010-00006	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490598				2022-12-01	WOS:000072155600006
J	Courtney, SM; Petit, L; Maisog, JM; Ungerleider, LG; Haxby, JV				Courtney, SM; Petit, L; Maisog, JM; Ungerleider, LG; Haxby, JV			An area specialized for spatial working memory in human frontal cortex	SCIENCE			English	Article							POSITRON EMISSION TOMOGRAPHY; HUMAN PREFRONTAL CORTEX; EYE-MOVEMENTS; FUNCTIONAL-ANATOMY; NEURAL SYSTEMS; PET; OBJECT; FIELDS; ACTIVATION; LOCATION	Working memory is the proc!ss of maintaining an active representation of information so that it is available for use. In monkeys, a prefrontal cortical region important for spatial working memory lies in and around the principal sulcus, but in humans the location, and even the existence, of a region for spatial working memory is in dispute. By using functional magnetic resonance imaging in humans, an area in the superior frontal sulcus was identified that is specialized for spatial working memory. This area is located more superiorly and posteriorly in the human than in the monkey brain, which may explain why it was not recognized previously.	NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Courtney, SM (corresponding author), NIMH, Lab Brain & Cognit, Bldg 10,Room 4C104,10 Ctr Dr, Bethesda, MD 20892 USA.		Petit, Laurent/M-3888-2019; GINSPAN, All/B-8714-2008; Petit, Laurent/D-6583-2011	Petit, Laurent/0000-0003-2499-5367; Petit, Laurent/0000-0003-2499-5367				Baker SC, 1996, CEREB CORTEX, V6, P612, DOI 10.1093/cercor/6.4.612; BRUCE CJ, 1985, J NEUROPHYSIOL, V54, P714, DOI 10.1152/jn.1985.54.3.714; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; Cohen JD, 1997, NATURE, V386, P604, DOI 10.1038/386604a0; Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; Courtney SM, 1996, CEREB CORTEX, V6, P39, DOI 10.1093/cercor/6.1.39; Fiez JA, 1996, J NEUROSCI, V16, P808; FUNAHASHI S, 1994, NEUROSCI RES, V21, P1, DOI 10.1016/0168-0102(94)90063-9; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster J, 1989, PREFRONTAL CORTEX; Goldberg ME, 1989, NEUROBIOLOGY SACCADI, P283; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; GOTTLIEB JP, 1994, J NEUROPHYSIOL, V72, P1634, DOI 10.1152/jn.1994.72.4.1634; Haxby JV, 1995, HUM BRAIN MAPP, V3, P68, DOI 10.1002/hbm.460030204; HAXBY JV, IN PRESS MAPPING MOD; JONIDES J, 1993, NATURE, V363, P623, DOI 10.1038/363623a0; Luna B, 1998, CEREB CORTEX, V8, P40, DOI 10.1093/cercor/8.1.40; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; McCarthy G, 1996, CEREB CORTEX, V6, P600, DOI 10.1093/cercor/6.4.600; Mellet E, 1996, J NEUROSCI, V16, P6504; Owen AM, 1996, CEREB CORTEX, V6, P31, DOI 10.1093/cercor/6.1.31; Owen AM, 1997, EUR J NEUROSCI, V9, P1329, DOI 10.1111/j.1460-9568.1997.tb01487.x; Paus T, 1996, NEUROPSYCHOLOGIA, V34, P475, DOI 10.1016/0028-3932(95)00134-4; Petit L, 1996, J NEUROSCI, V16, P3714; Petit L, 1997, J NEUROPHYSIOL, V77, P3386, DOI 10.1152/jn.1997.77.6.3386; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Rencher A.C., 1995, METHODS MULTIVARIATE; SMITH EE, 1995, J COGNITIVE NEUROSCI, V7, P337, DOI 10.1162/jocn.1995.7.3.337; Smith EE, 1996, CEREB CORTEX, V6, P11, DOI 10.1093/cercor/6.1.11; STANTON GB, 1989, J COMP NEUROL, V282, P415, DOI 10.1002/cne.902820308; Stuss D.T., 1986, FRONTAL LOBES; Sweeney JA, 1996, J NEUROPHYSIOL, V75, P454, DOI 10.1152/jn.1996.75.1.454; Ungerleider Leslie G., 1994, Current Opinion in Neurobiology, V4, P157, DOI 10.1016/0959-4388(94)90066-3; UNGERLEIDER LG, 1995, SCIENCE, V270, P769, DOI 10.1126/science.270.5237.769; Walker E.A, 1940, J COMP NEUROL, V73, P59; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836	37	717	737	2	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1347	1351		10.1126/science.279.5355.1347	http://dx.doi.org/10.1126/science.279.5355.1347			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478894				2022-12-01	WOS:000072251800049
J	Leyland, AH; Boddy, FA				Leyland, AH; Boddy, FA			League tables and acute myocardial infarction	LANCET			English	Article							PERFORMANCE; HOSPITALS	Background Comparison of the outcomes of care provided by hospitals is a growing trend. Outcomes need to be distinguished into those attributable to the practice of hospitals and those that arise from differences in the characteristics of patients and the underlying morbidity of the populations for whom hospitals provide care. We explored these issues for deaths in hospital or within 30 days of discharge after acute myocardial infarction in Scotland, UK. Methods We used records from December, 1992, to November, 1993, for 14 359 episodes of acute myocardial infarction, the death records of those who died, and 9391 death records for individuals who died after acute myocardial infarction but who had not been in hospital in the 30 days before death. Hospital discharge records were taken from the Scottish Morbidity Records. The outcomes we investigated were all-cause mortality within 30 Flays of discharge from hospital, and death from acute myocardial infarction at any time during the study period. We estimated separately effects attributable to patients' characteristics, hospitals, and areas of residence with multilevel modelling. Findings We found significant differences between hospitals by age, sex, and medical history. The odds ratios for death ranged from 0.62 (95% CI 0.50-0.80) to 1.28 (1.07-1.59), relative to the average performance for Scotland as a whole. Analysis including area of residence, deaths occurring out of hospital, and more detailed information about patients showed no significant differences between hospitals for patients aged 70 years. By postcode area, there was a strong association between out-of-hospital deaths and deaths in hospital or shortly after discharge. Interpretation Hospital outcomes may vary from one subgroup of patients to another and should be assessed independently of patients' areas of residence. Measures of performance that do not provide valid comparisons could diminish public confidence in hospital services.	Univ Glasgow, Publ Hlth Res Inst, Glasgow G12 8RZ, Lanark, Scotland	University of Glasgow	Leyland, AH (corresponding author), Univ Glasgow, Publ Hlth Res Inst, Glasgow G12 8RZ, Lanark, Scotland.	a.leyland@udcf.gla.ac.uk	Leyland, Alastair/C-6069-2011	Leyland, Alastair/0000-0003-3741-7099				Blumberg M S, 1986, Med Care Rev, V43, P351, DOI 10.1177/107755878604300205; Carstairs V., 1991, DEPRIVATION HLTH SCO; CHRISTIE B, 1996, SCOTSMAN        0217; DILLNER L, 1994, BRIT MED J, V309, P1599, DOI 10.1136/bmj.309.6969.1599a; EPSTEIN A, 1995, NEW ENGL J MED, V333, P57, DOI 10.1056/NEJM199507063330114; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; Goldstein H., 2011, MULTILEVEL STAT MODE, V4th, DOI DOI 10.1002/9780470973394; GOLDSTEIN H, 1996, RES INTELLIGENCE, V57, P12; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; Leyland AH, 1997, EUR J PUBLIC HEALTH, V7, P136, DOI 10.1093/eurpub/7.2.136; Leyland AH, 1995, IMA J MATH APPL MED, V12, P175; LOVE D, 1995, HEALTH SERV RES, V29, P629; LOWRY S, 1988, BRIT MED J, V296, P992, DOI 10.1136/bmj.296.6627.992; McKee M, 1997, BRIT MED J, V315, P142, DOI 10.1136/bmj.315.7101.142; McKee M, 1995, Qual Health Care, V4, P5, DOI 10.1136/qshc.4.1.5; Morrison C, 1997, BMJ-BRIT MED J, V314, P541, DOI 10.1136/bmj.314.7080.541; Naylor CD, 1997, BRIT MED J, V315, P1462, DOI 10.1136/bmj.315.7120.1462; Normand SLT, 1997, J AM STAT ASSOC, V92, P803, DOI 10.2307/2965545; ORCHARD C, 1994, BRIT MED J, V308, P1493, DOI 10.1136/bmj.308.6942.1493; Orchard C, 1996, J Eval Clin Pract, V2, P111, DOI 10.1111/j.1365-2753.1996.tb00035.x; Rasbash J, 1995, MLN COMMAND REFERENC; Rasbash J., 1994, J EDUC BEHAV STAT, V19, P337, DOI 10.2307/1165397.; Rice N, 1996, J Health Serv Res Policy, V1, P154; *SCOTT OFF, 1994, CLIN OUTC IND; *SCOTT OFF, 1995, CLIN OUTC IND; SMITH P, 1990, J ROY STAT SOC A STA, V153, P53, DOI 10.2307/2983096; Smith P., 1995, INT J PUBLIC ADMIN, V18, P277, DOI DOI 10.1080/01900699508525011; Wise J, 1997, BRIT MED J, V315, P76; YATES JM, 1984, BRIT MED J, V288, P1935, DOI 10.1136/bmj.288.6434.1935	30	69	69	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	1998	351	9102					555	558		10.1016/S0140-6736(97)09362-8	http://dx.doi.org/10.1016/S0140-6736(97)09362-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492774				2022-12-01	WOS:000072231900010
J	Nelson, JL; Furst, DE; Maloney, S; Gooley, T; Evans, PC; Smith, A; Bean, MA; Ober, C; Bianchi, DW				Nelson, JL; Furst, DE; Maloney, S; Gooley, T; Evans, PC; Smith, A; Bean, MA; Ober, C; Bianchi, DW			Microchimerism and HLA-compatible relationships of pregnancy in scleroderma	LANCET			English	Article							MATERNAL BLOOD; CELLS; SEQUENCE; DISEASE; HYBRIDIZATION; ALLOANTIGENS; WOMEN; DNA	Background Fetal cells can be found in the maternal circulation in most pregnancies. Fetal progenitor cells have been found to persist in the circulation of women many years after childbirth. We tested the hypothesis that microchimerism is involved in the pathogenesis of scleroderma. Scleroderma is of interest because of a strong female predilection, an increased incidence in the years after childbearing, and clinical similarities between scleroderma and chronic graft-versus-host disease after allogeneic bone-marrow transplantation. We also investigated whether HLA-compatibility of a child was associated with later development of scleroderma in the mother. Methods We enrolled 40 women who had previously given birth to at least one son-16 healthy controls, 17 scleroderma and seven healthy sisters of quantitative PCR to Y-chromosome-specific sequence in blood from these women. Also 32 children, and 21 scleroderma patients with 47 children were HLA genotyped. Findings The mean number of male cell DNA equivalents among controls was 0.38 cells per 16 mL whole blood (median 0 [range 0-2]) and 11.1 (6.0 [0-61]) among scleroderma patients (p=0.0007). Controls' youngest sons were born a mean of 15.4 years previously, and scleroderma patients' sons 18.5 years previously. Some scleroderma patients had concentrations of male DNA higher than those found in most pregnant women, HLA-class II compatibility of a child from the mother's perspective was more common among scleroderma patients than among controls, but was not essential for persistence of male DNA in maternal peripheral blood. Interpretation Low concentrations of male DNA can be detected in healthy women decades after the birth of a son. Microchimerism in scleroderma patients could be secondary to the underlying disease. However, the finding that HLA class II compatibility of a child was more common for scleroderma patients than for controls, supports the possibility that microchimerism may be involved in the pathogenesis of scleroderma.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Washington, Seattle, WA 98195 USA; Virginia Mason Res Ctr, Seattle, WA 98101 USA; Pacific NW Res Fdn, Seattle, WA 98122 USA; Univ Chicago, Med Ctr, Ctr Med Genet, Chicago, IL 60637 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; Virginia Mason Medical Center; University of Chicago; University of Chicago Medical Center; Tufts Medical Center	Nelson, JL (corresponding author), Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA.			Evans, Paul/0000-0001-7975-681X	NIAID NIH HHS [AI 41721, AI 38583] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038583, R01AI041721] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		[Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; Bianchi DW, 1996, P NATL ACAD SCI USA, V93, P705, DOI 10.1073/pnas.93.2.705; BIANCHI DW, 1995, J PEDIATR-US, V127, P847, DOI 10.1016/S0022-3476(95)70018-8; Bianchi DW, 1997, AM J HUM GENET, V61, P822, DOI 10.1086/514885; Bodmer JG, 1997, TISSUE ANTIGENS, V49, P297, DOI 10.1111/j.1399-0039.1997.tb02759.x; Bonney EA, 1997, J IMMUNOL, V158, P40; Claman HN, 1993, IMMUNOLOGY HUMAN PRE; DEMOOR G, 1988, ACTA CLIN BELG, V43, P231; ENGLERT H, 1992, J RHEUMATOL, V19, P1575; FINK PJ, 1988, ANNU REV IMMUNOL, V6, P115; FURST DE, 1979, ARTHRITIS RHEUM, V22, P904, DOI 10.1002/art.1780220815; HALL JM, 1995, BLOOD, V86, P2829; HUTCHINSON DL, 1971, AM J OBSTET GYNECOL, V109, P281, DOI 10.1016/0002-9378(71)90876-3; LAWLEY TJ, 1977, ANN INTERN MED, V87, P707, DOI 10.7326/0003-4819-87-6-707; LEE TH, 1997, J ALLERGY CLIN IMMUN, V99, P468; Lo YMD, 1996, BLOOD, V88, P4390; LUCOTTE G, 1991, MOL CELL PROBE, V5, P359, DOI 10.1016/S0890-8508(06)80007-1; McMilin Kenneth D., 1993, Transfusion Medicine Reviews, V7, P37, DOI 10.1016/S0887-7963(93)70031-0; MICKELSON E, 1993, TISSUE ANTIGENS, V41, P86, DOI 10.1111/j.1399-0039.1993.tb01984.x; Nelson JL, 1996, ARTHRITIS RHEUM, V39, P191, DOI 10.1002/art.1780390203; NELSON JL, 1993, NEW ENGL J MED, V329, P466, DOI 10.1056/NEJM199308123290704; Piotrowski P, 1996, BIOL REPROD, V54, P1103, DOI 10.1095/biolreprod54.5.1103; POLLACK MS, 1982, NEW ENGL J MED, V307, P662, DOI 10.1056/NEJM198209093071106; Silman A., 1993, EPIDEMIOLOGY RHEUMAT, P192; Smith AG, 1996, TISSUE ANTIGENS, V48, P118, DOI 10.1111/j.1399-0039.1996.tb02616.x; TAFURI A, 1995, SCIENCE, V270, P630, DOI 10.1126/science.270.5236.630; THOMAS MR, 1994, LANCET, V343, P413, DOI 10.1016/S0140-6736(94)91248-3	27	456	469	1	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 21	1998	351	9102					559	562		10.1016/S0140-6736(97)08357-8	http://dx.doi.org/10.1016/S0140-6736(97)08357-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ216	9492775				2022-12-01	WOS:000072231900011
J	Hof, P; Pluskey, S; Dhe-Paganon, S; Eck, MJ; Shoelson, SE				Hof, P; Pluskey, S; Dhe-Paganon, S; Eck, MJ; Shoelson, SE			Crystal structure of the tyrosine phosphatase SHP-2	CELL			English	Article							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; INSULIN-RECEPTOR SUBSTRATE-1; CAVITY-CREATING MUTATIONS; SH2 DOMAINS; PHOSPHATIDYLINOSITOL 3'-KINASE; CHYMOTRYPSIN INHIBITOR-2; HYDROPHOBIC CORE; PROTEIN; SH-PTP2; ACTIVATION	The structure of the SHP-2 tyrosine phosphatase, determined at 2.0 Angstrom resolution, shows how its catalytic activity is regulated by its two SH2 domains. In the absence of a tyrosine-phosphorylated binding partner, the N-terminal SH2 domain binds the phosphatase domain and directly blocks its active site. This interaction alters the structure of the N-SH2 domain, disrupting its phosphopeptide-binding cleft. Conversely, interaction of the N-SH2 domain with phosphopeptide disrupts its phosphatase recognition surface. Thus, the N-SHP domain is a conformational switch; it either binds and inhibits the phosphatase, or it binds phosphoproteins and activates the enzyme. Recognition of bisphosphorylated ligands by the tandem SH2 domains is an integral element of this switch; the C-terminal SH2 domain contributes binding energy and specificity, but it does not have a direct role in activation.	Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Eck, MJ (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.							Allard JD, 1996, DEVELOPMENT, V122, P1137; Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldwin E, 1996, J MOL BIOL, V259, P542, DOI 10.1006/jmbi.1996.0338; BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Cowtan K., 1994, JT CCP4 ESF EACBM NE, V31, P34; DECHERT U, 1994, J BIOL CHEM, V269, P5602; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Hoffmann KMV, 1997, J BIOL CHEM, V272, P27505, DOI 10.1074/jbc.272.44.27505; Jackson DE, 1997, J BIOL CHEM, V272, P24868, DOI 10.1074/jbc.272.40.24868; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11270, DOI 10.1021/bi00093a002; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P11259, DOI 10.1021/bi00093a001; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; JONES TA, 1989, CRYSTALLOGRAPHIC COM; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; NAVAZA J, 1992, MOL REPLACEMENT, P87; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; PEI DH, 1994, BIOCHEMISTRY-US, V33, P15483, DOI 10.1021/bi00255a030; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RICHARDS FM, 1988, PROTEINS, V3, P71, DOI 10.1002/prot.340030202; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUGIMOTO S, 1993, J BIOL CHEM, V268, P22771; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tonks N K, 1996, Adv Pharmacol, V36, P91, DOI 10.1016/S1054-3589(08)60578-5; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; TURK D, 1996, P 1996 M INT UN CRYS; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WELHAM MJ, 1994, J BIOL CHEM, V269, P23764; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0	59	704	730	1	33	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					441	450		10.1016/S0092-8674(00)80938-1	http://dx.doi.org/10.1016/S0092-8674(00)80938-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491886	Bronze			2022-12-01	WOS:000072251500005
J	Hackley, SA; Valle-Inclan, F				Hackley, SA; Valle-Inclan, F			Automatic alerting does not speed late motoric processes in a reaction-time task	NATURE			English	Article							REFLEX; ACTIVATION	When an irrelevant 'accessory' stimulus is presented at about the same time as the imperative signal in a choice reaction time-task, the latency of the voluntary response is markedly reduced(1), The most prominent cognitive theories agree that this effect-is attributable to a brief surge in arousal ('automatic alerting'), but they disagree over whether the facilitation is localized to a late, low-level motoric process(2) or to an earlier stage, the process of orienting to and then perceptually categorizing the reaction stimulus(3,4). To lest these alternative hypotheses, we used the onset of the lateralized readiness potential (a movement-related brain potential) as a temporal landmark to partition mean reaction time into two time segments. The first segment included the time required to perceive the visual stimulus and decide which hand to react with; the second included only motoric processes. Presentation of an irrelevant acoustic stimulus shortened the first interval but had no effect on the second. We therefore rejected the motoric hypothesis.	Univ Missouri, Dept Psychol, Columbia, MO 65211 USA; Univ A Coruna, Dept Psychol, La Coruna 15071, Spain	University of Missouri System; University of Missouri Columbia; Universidade da Coruna	Hackley, SA (corresponding author), Univ Missouri, Dept Psychol, 210 Mcalester Hall, Columbia, MO 65211 USA.	shackley@showme.missouri.edu	Valle-Inclán, Fernando/Y-9218-2019	Valle-Inclán, Fernando/0000-0002-4702-0151				BERNSTEIN IH, 1970, PSYCHON SCI, V19, P113, DOI 10.3758/BF03337448; ERIKSEN CW, 1988, PERCEPT PSYCHOPHYS, V44, P191, DOI 10.3758/BF03208712; FernandezDuque D, 1997, NEUROPSYCHOLOGIA, V35, P477, DOI 10.1016/S0028-3932(96)00103-0; GRATTON G, 1988, J EXP PSYCHOL HUMAN, V14, P331, DOI 10.1037/0096-1523.14.3.331; Low KA, 1996, ELECTROEN CLIN NEURO, V98, P385, DOI 10.1016/0013-4694(96)95085-3; MILLER J, 1992, J EXP PSYCHOL GEN, V121, P195, DOI 10.1037/0096-3445.121.2.195; MILLER J, 1991, PERCEPT PSYCHOPHYS, V50, P584, DOI 10.3758/BF03207544; MILLER J, IN PRESS PSYCHOPHYSI; Posner MI., 1978, CHRONOMETRIC EXPLORA; Sanders A. F., 1980, TUTORIALS MOTOR BEHA, P331, DOI [10.1016/S0166-4115(08)61955-X, DOI 10.1016/S0166-4115(08)61955-X]; SANDERS AF, 1983, ACTA PSYCHOL, V53, P61, DOI 10.1016/0001-6918(83)90016-1; STAFFORD IL, 1990, J NEUROSCI, V10, P99; Stein BE, 1996, J COGNITIVE NEUROSCI, V8, P497, DOI 10.1162/jocn.1996.8.6.497; Sternberg S, 1969, ACTA PSYCHOL, V30, P276, DOI 10.1016/0001-6918(69)90055-9; VALLEINCLAN F, 1997, PSYCHOPHYSIOLOGY, V34, pS92; YOUNG RA, 1976, J COMP PHYSIOL PSYCH, V90, P424, DOI 10.1037/h0077219	16	111	111	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					786	788		10.1038/35849	http://dx.doi.org/10.1038/35849			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	YX884	9486647				2022-12-01	WOS:000072089500051
J	Huang, CL; Feng, SY; Hilgemann, DW				Huang, CL; Feng, SY; Hilgemann, DW			Direct activation of inward rectifier potassium channels by PIP2 and its stabilization by G beta gamma	NATURE			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; RECTIFYING K+ CHANNELS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; FUNCTIONAL EXPRESSION; MOLECULAR-PROPERTIES; I-KACH; PROTEINS; SUBUNITS; BINDING; G(BETA-GAMMA)	Inward rectifier K+ channels, which modulate electrical activity in many cell types, are regulated by protein kinases(1,2), guanine-nucleotide-binding proteins (G proteins)(3-6) and probably actin cytoskeleton(7), Generation of phosphatidylinositol 4,5-bisphosphate (PIP2) by ATP-dependent lipid kinases is known to activate inward rectifier Ki(+) channels in cardiac membrane patches(8), Here we report that several cloned inward rectifier K+ channels directly bind PIP2, and that this binding correlates with channel activity. Application of ATP or PIP2 liposomes activates the cloned channels, Stabilized by lipid phosphatase inhibitors, PIP2 antibodies(9) potently inhibit each channel with a unique rate (GIRK1/4 (refs 3-5) approximate to GIRK2 (ref, 6) much greater than IRK1 (ref, 10) approximate to ROMK (ref. 11)). Consistent with the faster dissociation of PIP, from the GIRK channels, the carboxy terminus of GIRK1 binds H-3-PIP2 liposomes more weakly than does that of IRK1 or ROMK1. Mutation of a conserved arginine to glutamine at position 188 reduces the ability of ROMK1 to bind PIP2 and increases its sensitivity to inhibition by PIP2 antibodies. Interactions between GIRK channels and PIP2 are modulated by the beta gamma subunits of the G protein (G beta gamma). When GIRK1/4 channels are allowed to run down completely, they are not activated by addition of G beta gamma alone, but application of PIP2 activates them in minutes without G beta gamma and in just seconds with G beta gamma, Finally, coexpression of G beta gamma with GIRK channels slows the inhibition of K+ currents by PIP2 antibodies by more than 10-fold, Thus G beta gamma activates GIRK channels by stabilizing interactions between PIP2 and the K+ channel.	Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Huang, CL (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Nephrol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.	chuanl@mednet.swmed.edu						CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FAKLER B, 1994, NEURON, V13, P1413, DOI 10.1016/0896-6273(94)90426-X; Fan Z, 1997, J BIOL CHEM, V272, P5388, DOI 10.1074/jbc.272.9.5388; FUKAMI K, 1994, J BIOL CHEM, V269, P1518; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; Furukawa T, 1996, PFLUG ARCH EUR J PHY, V431, P504, DOI 10.1007/s004240050028; HARLAN JE, 1995, BIOCHEMISTRY-US, V34, P9859, DOI 10.1021/bi00031a006; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; Huang CL, 1997, FEBS LETT, V405, P291, DOI 10.1016/S0014-5793(97)00197-X; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; KIM JY, 1991, BIOPHYS J, V60, P135, DOI 10.1016/S0006-3495(91)82037-9; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; MCNICHOLAS CM, 1994, P NATL ACAD SCI USA, V91, P8077, DOI 10.1073/pnas.91.17.8077; PENNISTON JT, 1982, ANN NY ACAD SCI, V402, P291; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SCHACHT J, 1976, J NEUROCHEM, V27, P1119, DOI 10.1111/j.1471-4159.1976.tb00318.x; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TAGLIALATELA M, 1994, SCIENCE, V264, P844, DOI 10.1126/science.8171340; ZHANG XL, 1995, P NATL ACAD SCI USA, V92, P4853, DOI 10.1073/pnas.92.11.4853	29	740	752	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					803	806		10.1038/35882	http://dx.doi.org/10.1038/35882			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486652				2022-12-01	WOS:000072089500056
J	Naficy, A; Rao, MR; Paquet, C; Antona, D; Sorkin, A; Clemens, JD				Naficy, A; Rao, MR; Paquet, C; Antona, D; Sorkin, A; Clemens, JD			Treatment and vaccination strategies to control cholera in sub-Saharan refugee settings - A cost-effectiveness analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FIELD TRIAL; DEVELOPING-COUNTRIES; EPIDEMIC CHOLERA; PUBLIC-HEALTH; LATIN-AMERICA; FOLLOW-UP; BANGLADESH; VACCINES; MORTALITY; TRANSMISSION	Context.-There is significant controversy about how best to control cholera epidemics in refugee settings. Specifically, there is marked disagreement about whether to use oral cholera vaccines in these settings, despite the improved safety and effectiveness profiles of these vaccines. Objective.-To determine the cost-effectiveness of alternative intervention strategies, including vaccination, to control cholera outbreaks in sub-Saharan refugee camps. Design.-A cost-effectiveness analysis based on probabilities of cholera outcomes derived from epidemiologic data compiled for refugee settings in Malawi from 1987 through 1993; data for costs were obtained from a large relief agency that provides medical care in such settings. Setting and Participants.-A hypothetical refugee camp with 50 000 persons in sub-Saharan Africa evaluated for a 2-year period. Interventions.-We compared the costs and outcomes of alternative strategies in which appropriate rehydration therapy for cholera is introduced preemptively (at the establishment of a camp) or reactively (once an epidemic is recognized) and in which mass immunization with oral B subunit killed whole-cell (BS-WC) cholera vaccine is added to a rehydration program either preemptively or reactively. Main Outcome Measures.-Cost per cholera case prevented and cost per cholera death averted. Results.-In a situation with no available rehydration therapy suitable for the management of severe cholera, a strategy of preemptive therapy ($320 per death averted) costs less and is more effective than a strategy of reactive therapy ($586 per death averted). Adding vaccination to preemptive therapy is expensive: $1745 per additional death averted for preemptive vaccination and $3833 per additional death averted for reactive vaccination. However, if the cost of vaccine falls below $0.22 per dose, strategies combining vaccination and preemptive therapy become more cost-effective than therapy alone. Conclusions.-Provision for managing cholera outbreaks at the inception of a refugee camp (preemptive therapy) is the most cost-effective strategy for controlling cholera outbreaks in sub-Saharan refugee settings. Should the price of BS-WC cholera vaccine fall below $0.22 per dose, however, supplementation of preemptive therapy with mass vaccination will become a cost-effective option.	NICHHD, Epidemiol Branch, Bethesda, MD 20892 USA; Epicentre, Paris, France; Med Sans Frontieres, Paris, France; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Univ Maryland Baltimore Cty, Dept Econ, Catonsville, MD USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Doctors Without Borders; Johns Hopkins University; University System of Maryland; University of Maryland Baltimore County	Naficy, A (corresponding author), NICHHD, Epidemiol Branch, Room 7B03,6100 Execut Blvd, Bethesda, MD 20892 USA.							[Anonymous], 1995, Lancet, V345, P339; CARPENTER CCJ, 1976, JOHNS HOPKINS MED J, V139, P153; *CDCP, 1992, MMWR-MORBID MORTAL W, V41; Clemens J, 1995, B I PASTEUR, V93, P237, DOI 10.1016/0020-2452(96)85757-5; CLEMENS JD, 1986, LANCET, V2, P124; CLEMENS JD, 1990, LANCET, V335, P270, DOI 10.1016/0140-6736(90)90080-O; CLEMENS JD, 1988, J INFECT DIS, V158, P60, DOI 10.1093/infdis/158.1.60; CLEMENS JD, 1988, J INFECT DIS, V158, P372, DOI 10.1093/infdis/158.2.372; Clemens John, 1994, P425; CVJETANOVIC B, 1974, CHOLERA, P435; DJEDDAH C, 1988, EUR J EPIDEMIOL, V4, P227, DOI 10.1007/BF00144757; GLASS RI, 1991, LANCET, V338, P791, DOI 10.1016/0140-6736(91)90673-D; ICHINOSE Y, 1986, J TROP MED HYG, V89, P269; LEVINE MM, 1988, LANCET, V2, P468, DOI 10.1016/S0140-6736(88)90120-1; MAHALANABIS D, 1973, JOHNS HOPKINS MED J, V132, P197; MANDARA M P, 1980, Medical Journal of Zambia, V15, P10; MOREN A, 1991, J TROP MED HYG, V94, P1; MORRIS JG, 1982, J INFECT DIS, V145, P131, DOI 10.1093/infdis/145.1.131; *REF HLTH UNT, 1985, 1985 ANN REP; SACK DA, 1994, LANCET, V344, P616, DOI 10.1016/S0140-6736(94)92003-6; SACK DA, 1991, J INFECT DIS, V163, P503, DOI 10.1093/infdis/163.3.503; SANCHEZ JL, 1994, LANCET, V344, P1273, DOI 10.1016/S0140-6736(94)90755-2; Swerdlow David L., 1994, P297; TACKET CO, 1992, J INFECT DIS, V166, P837, DOI 10.1093/infdis/166.4.837; TAUXE RV, 1992, JAMA-J AM MED ASSOC, V267, P1388, DOI 10.1001/jama.267.10.1388; TAUXE RV, 1988, EPIDEMIOL INFECT, V100, P279, DOI 10.1017/S0950268800067418; TOOLE MJ, 1988, B WORLD HEALTH ORGAN, V66, P237; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; Weinstein M C, 1981, Med Decis Making, V1, P309, DOI 10.1177/0272989X8100100403; *WHO, 1995, PUBL WHO	31	47	47	2	16	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 18	1998	279	7					521	525		10.1001/jama.279.7.521	http://dx.doi.org/10.1001/jama.279.7.521			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW470	9480362	Bronze			2022-12-01	WOS:000071938900033
J	Chapman, DL; Papaioannou, VE				Chapman, DL; Papaioannou, VE			Three neural tubes in mouse embryos with mutations in the T-box gene Tbx6	NATURE			English	Article							EXPRESSION; MESODERM; PROTEIN; GASTRULATION; EVOLUTION; HINDBRAIN; PATTERN; CNS	Somites, segmented mesodermal units of the vertebrate embryo, are the precursors of adult skeletal muscle, bone and cartilage(1). During embryogenesis, somite progenitor cells ingress through the primitive streak, move laterally to a paraxial position (alongside the body axis) and segment into epithelial somites(2). Little is known about how this paraxial mesoderm tissue is specified(1,2). We have previously described a mouse T-box gene, Tbx6 (ref. 3), which codes for a putative DNA-binding protein(4,5). The embryonic pattern of expression of Tbx6 in somite precursor cells suggests that this gene may be involved in the specification of paraxial mesoderm(3). We now report the creation of a mutation in Tbx6 that profoundly affects the differentiation of paraxial mesoderm. Irregular somites form in the neck region of mutant embryos, whereas more posterior paraxial tissue does not form somites but instead differentiates along a neural pathway, forming neural-tube-like structures that flank the axial neural tube. These paraxial tubes show dorsal/ventral patterning that is characteristic of the neural tube, and have differentiated motor neurons, These results indicate that Tbx6 is needed for cells to choose between a mesodermal and a neuronal differentiation pathway during gastrulation; Tbx6 is essential for the specification of posterior paraxial mesoderm, and in its absence cells destined to form posterior somites differentiate along a neuronal pathway.	Columbia Univ Coll Phys & Surg, Dept Genet & Dev, New York, NY 10032 USA	Columbia University	Chapman, DL (corresponding author), Columbia Univ Coll Phys & Surg, Dept Genet & Dev, 701 W 168th St, New York, NY 10032 USA.			Chapman, Deborah/0000-0002-8695-6243; Papaioannou, Virginia/0000-0001-7558-8601				Agulnik SI, 1996, GENETICS, V144, P249; BETTENHAUSEN B, 1995, DEVELOPMENT, V121, P2407; BURGESS R, 1995, DEV BIOL, V168, P296, DOI 10.1006/dbio.1995.1081; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Chapman DL, 1996, DEV BIOL, V180, P534, DOI 10.1006/dbio.1996.0326; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Deng CX, 1997, DEV BIOL, V185, P42, DOI 10.1006/dbio.1997.8553; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; HOGAN B, 1985, TRENDS GENET, V1, P67, DOI 10.1016/0168-9525(85)90029-0; Irving C, 1996, DEV BIOL, V173, P26, DOI 10.1006/dbio.1996.0004; JOYNER AL, 1993, GENE TARGETING; KISPERT A, 1993, EMBO J, V12, P3211, DOI 10.1002/j.1460-2075.1993.tb05990.x; LEWIS SA, 1985, J CELL BIOL, V100, P843, DOI 10.1083/jcb.100.3.843; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NIETO MA, 1992, DEVELOPMENT, V116, P1137; Pfaff SL, 1996, CELL, V84, P309, DOI 10.1016/S0092-8674(00)80985-X; SASAKI H, 1993, DEVELOPMENT, V118, P47; Smith J, 1997, CURR OPIN GENET DEV, V7, P474, DOI 10.1016/S0959-437X(97)80073-1; TAKADA S, 1994, GENE DEV, V8, P174, DOI 10.1101/gad.8.2.174; TAM PPL, 1987, DEVELOPMENT, V99, P109; TAM PPL, 1994, ANAT EMBRYOL, V189, P2275; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WILKINSON DG, 1990, NATURE, V343, P657, DOI 10.1038/343657a0; WILKINSON DG, 1992, WHOLE MOUNT IN SITU; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785; Yoshikawa Y, 1997, DEV BIOL, V183, P234, DOI 10.1006/dbio.1997.8502	26	316	325	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					695	697		10.1038/35624	http://dx.doi.org/10.1038/35624			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490412				2022-12-01	WOS:000071982500052
J	Estivill, X; Fortina, P; Surrey, S; Rabionet, R; Melchionda, S; D'Agruma, L; Mansfield, E; Rappaport, E; Govea, N; Mila, M; Zelante, L; Gasparini, P				Estivill, X; Fortina, P; Surrey, S; Rabionet, R; Melchionda, S; D'Agruma, L; Mansfield, E; Rappaport, E; Govea, N; Mila, M; Zelante, L; Gasparini, P			Connexin-26 mutations in sporadic and inherited sensorineural deafness	LANCET			English	Article							GAP-JUNCTIONS; COCHLEA; GENES	Background Hearing impairment affects one infant in 1000 and 4% of people aged younger than 45 years. Congenital deafness is inherited or apparently sporadic. We have shown previously that DFNB1 on chromosome 13 is a major locus for recessive deafness in about 80% of Mediterranean families and that the connexin-26 gene gap junction protein beta 2 (GJB2) is mutated in DFNB1 families, We investigated mutations in the GJB2 gene in familial and sporadic cases of deafness. Methods We obtained DNA samples from 82 families from Italy and Spain with recessive non-syndromic deafness and from 54 unrelated participants with apparently sporadic congenital deafness. We analysed the coding region of the GJB2 gene for mutations. We also tested 280 unrelated people from the general populations of Italy and Spain for the frameshift mutation 35delG. Findings 49% of participants with recessive deafness and 37% of sporadic cases had mutations in the GJB2 gene; The 35delG mutation accounted for 85% of GJB2 mutations, six other mutations accounted for 6% of alleles, and no changes in the coding region of GJB2 were detected in 9% of DFNB1 alleles., The carrier frequency of mutation 35delG among people from the general population was one in 31 (95% CI one in 19 to one in 87). Interpretation Mutations in the GJB2 gene are a major cause of inherited and apparently sporadic congenital deafness. Mutation 35delG is the most common mutation for sensorineural deafness. Identification of 35delG and other mutations in the GJB2 gene should facilitate diagnosis and counselling for the most common genetic form of deafness.	Hosp Duran I Reynals, Ctr Genet Med & Mol, Dept Genet, Barcelona 08907, Catalonia, Spain; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Osped Casa Solllevo Sofferenza, Serv Genet Med, Foggia, Italy; Jefferson Med Coll, Dept Pediat, Wilmington, DE USA; Du Pont Hosp Children, Wilmington, DE USA; Mol Dynam, Sunnyvale, CA USA; Hosp Clin Barcelona, Serv Genet, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Hospital Duran i Reynals; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; IRCCS Casa Sollievo Della Sofferenza; Jefferson University; Nemours Alfred I. duPont Hospital for Children; Pfizer; University of Barcelona; Hospital Clinic de Barcelona	Estivill, X (corresponding author), Hosp Duran I Reynals, Ctr Genet Med & Mol, Dept Genet, Lhospitalet, Barcelona 08907, Catalonia, Spain.	estivill@iro.es	rabionet, raquel/A-7407-2009; Rabionet, Raquel/C-8379-2009; Fortina, Paolo/ABE-8350-2020; Estivill, Xavier/E-2957-2012; Gasparini, Paolo/B-6173-2014; Estivill, Xavier/A-3125-2013; Leonardo, D'Agruma/A-4824-2015	rabionet, raquel/0000-0001-5006-8140; Rabionet, Raquel/0000-0001-5006-8140; Estivill, Xavier/0000-0002-0723-2256; Mila, Montserrat/0000-0002-7906-0916; Leonardo, D'Agruma/0000-0001-8308-8957; Fortina, Paolo/0000-0002-5898-2081	NINDS NIH HHS [1R43NS/MH34589] Funding Source: Medline; Telethon [E.0549] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R43NS034589] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Telethon(Fondazione Telethon); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; Carrasquillo MM, 1997, HUM MOL GENET, V6, P2163, DOI 10.1093/hmg/6.12.2163; Cohen M. M., 1995, HEREDITARY HEARING L, P9; Denoyelle F, 1997, HUM MOL GENET, V6, P2173, DOI 10.1093/hmg/6.12.2173; DUNN RA, 1975, P NATL ACAD SCI USA, V72, P3599, DOI 10.1073/pnas.72.9.3599; Fleiss J.L., 1981, STAT METHODS RATES P; Gasparini P, 1997, EUR J HUM GENET, V5, P83; ICHIMIYA I, 1994, ANN OTO RHINOL LARYN, V103, P457; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; KIKUCHI T, 1995, ANAT EMBRYOL, V191, P101, DOI 10.1007/BF00186783; LATHROP GM, 1988, AM J HUM GENET, V42, P498; Lench NJ, 1997, AM J HUM GENET, V61, pA22; Liu XZ, 1997, NAT GENET, V16, P188, DOI 10.1038/ng0697-188; Lynch ED, 1997, SCIENCE, V278, P1315, DOI 10.1126/science.278.5341.1315; Mignon C, 1996, CYTOGENET CELL GENET, V72, P185, DOI 10.1159/000134183; NADOL JB, 1993, NEW ENGL J MED, V329, P1092, DOI 10.1056/NEJM199310073291507; NADOL JB, 1976, AM J ANAT, V147, P281, DOI 10.1002/aja.1001470304; Petit C, 1996, NAT GENET, V14, P385, DOI 10.1038/ng1296-385; RAHMAN S, 1991, J CELL SCI, V100, P567; SOSINSKY G, 1995, P NATL ACAD SCI USA, V92, P9210, DOI 10.1073/pnas.92.20.9210; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; VanCamp G, 1997, AM J HUM GENET, V60, P758; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; Zelante L, 1997, HUM MOL GENET, V6, P1605, DOI 10.1093/hmg/6.9.1605	27	504	540	0	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 7	1998	351	9100					394	398		10.1016/S0140-6736(97)11124-2	http://dx.doi.org/10.1016/S0140-6736(97)11124-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482292	hybrid			2022-12-01	WOS:000071982600010
J	Brehm, A; Miska, EA; McCance, DJ; Reid, JL; Bannister, AJ; Kouzarides, T				Brehm, A; Miska, EA; McCance, DJ; Reid, JL; Bannister, AJ; Kouzarides, T			Retinoblastoma protein recruits histone deacetylase to repress transcription	NATURE			English	Article							GENE-PRODUCT; BINDING; REGULATOR; YEAST; SITE; CBP	The retinoblastoma protein (Rb) silences specific genes that are active in the S phase of the cell cycle and which are regulated by E2F transcription factors(1). Rb binds to the activation domain of E2F and then actively represses the promoter by a mechanism that is poorly understood(2,3). Here we show that Rb associates with a histone deacetylase, HDAC1, through the Rb 'pocket' domain. Association with the deacetylase is reduced by naturally occurring mutations in the pocket and by binding of the human papilloma virus oncoprotein E7. We find that Rb can recruit histone deacetylase to E2F and that Rb cooperates with HDAC1 to repress the E2F-regulated promoter of the gene encoding the cell-cycle protein cyclin E. Inhibition of histone deacetylase activity by trichostatin A (TSA) inhibits Rb-mediated repression of a chromosomally integrated E2F-regulated promoter. Our results indicate that histone deacetylases are important for regulating the cell cycle and that active transcriptional repression by Rb may involve the modification of chromatin structure.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England; Univ Rochester, Med Ctr, Dept Microbiol & Immunol, Rochester, NY 14642 USA	University of Cambridge; University of Cambridge; University of Rochester	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Miska, Eric/0000-0002-4450-576X; Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Botz J, 1996, MOL CELL BIOL, V16, P3401; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAGEMEIER C, 1993, NUCLEIC ACIDS RES, V21, P4998, DOI 10.1093/nar/21.22.4998; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; Tauton J, 1996, SCIENCE, V272, P408; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0	25	1034	1074	2	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					597	601		10.1038/35404	http://dx.doi.org/10.1038/35404			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468139				2022-12-01	WOS:000071842300055
J	Davidson, FF; Steller, H				Davidson, FF; Steller, H			Blocking apoptosis prevents blindness Drosophila retinal degeneration mutants	NATURE			English	Article							PROGRAMMED CELL-DEATH; DOMINANT RETINITIS-PIGMENTOSA; BACULOVIRUS P35 PROTEIN; CAENORHABDITIS-ELEGANS; PHOTORECEPTOR CELL; RHODOPSIN; MELANOGASTER; INHIBITION; EXPRESSION; MUTATION	Apoptosis is a gene-directed form of cell death that is essential for normal development and health. Yet abnormally high levels of apoptosis are linked to many degenerative diseases(1), Some important biochemical events in apoptosis have been identified(2), but the therapeutic utility of blocking cell death remains unclear. An important question in this regard is whether cells rescued from apoptosis can function. We have investigated the mechanism of cell death in two Drosophila mutant strains that exhibit age-related retinal degeneration. One of these mutations also occurs in humans, where it causes retinitis pigmentosa. We found that retinal cell death in rdgC and ninaE(RH27)/+ flies occurred by apoptosis and was blocked by eye-specific expression of the baculoviral cell survival protein p35. Most importantly, the mutant flies expressing p35 showed significant retention of visual function, The results demonstrate a therapeutic benefit of late-stage inhibition of apoptosis to flies, and suggest that similar results may be obtained in higher organisms.	MIT, Howard Hughes Med Inst, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Steller, H (corresponding author), MIT, Howard Hughes Med Inst, 31 Ames St, Cambridge, MA 02139 USA.							BEIDLER DR, 1995, J BIOL CHEM, V270, P16526, DOI 10.1074/jbc.270.28.16526; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; BYK T, 1993, P NATL ACAD SCI USA, V90, P1907, DOI 10.1073/pnas.90.5.1907; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; COHEN GM, 1995, BIOCHEM J, V326, P1; COLLEY NJ, 1995, P NATL ACAD SCI USA, V92, P3070, DOI 10.1073/pnas.92.7.3070; DRYJA TP, 1992, EYE, V6, P1; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HAY BA, 1994, DEVELOPMENT, V120, P2121; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; HUMPHRIES P, 1990, CLIN GENET, V38, P1; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KURADA P, 1995, NEURON, V14, P571, DOI 10.1016/0896-6273(95)90313-5; MARTINOU I, 1995, J CELL BIOL, V128, P201, DOI 10.1083/jcb.128.1.201; Nickells RW, 1996, OPHTHALMIC GENET, V17, P145, DOI 10.3109/13816819609057889; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RANGANATHAN R, 1995, ANNU REV NEUROSCI, V18, P283; RENDAHL KG, 1992, J NEUROSCI, V12, P390; RICHARDS JE, 1995, OPHTHALMOLOGY, V102, P669, DOI 10.1016/S0161-6420(95)30972-4; STEELE F, 1990, NEURON, V4, P883, DOI 10.1016/0896-6273(90)90141-2; STEELE FR, 1992, CELL, V69, P669, DOI 10.1016/0092-8674(92)90230-A; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; White K, 1996, SCIENCE, V271, P805, DOI 10.1126/science.271.5250.805; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0	28	144	149	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					587	591		10.1038/35385	http://dx.doi.org/10.1038/35385			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468136				2022-12-01	WOS:000071842300052
J	Nightingale, SL				Nightingale, SL			Guidance on industry-supported scientific and educational activities	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-01	WOS:000071731300006
J	Stephens, L; Anderson, K; Stokoe, D; Erdjument-Bromage, H; Painter, GF; Holmes, AB; Gaffney, PRJ; Reese, CB; McCormick, F; Tempst, P; Coadwell, J; Hawkins, PT				Stephens, L; Anderson, K; Stokoe, D; Erdjument-Bromage, H; Painter, GF; Holmes, AB; Gaffney, PRJ; Reese, CB; McCormick, F; Tempst, P; Coadwell, J; Hawkins, PT			Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B	SCIENCE			English	Article							3-KINASE; AKT; PHOSPHATIDYLINOSITOL(3,4,5)-TRISPHOSPHATE; EGF	Protein kinase B (PKB) is activated in response to phosphoinositide 3-kinases and their lipid products phosphatidylinositol 3,4,5-trisphosphate [PtdIns(3,4,5)P-3] and PtdIns(3,4)P-2 in the signaling pathways used by a wide variety of growth factors, antigens, and inflammatory stimuli. PKB is a direct target of these lipids, but this regulation is complex. The lipids can bind to the pleckstrin homologqus domain of PKB, causing its translocation to the membrane, and also enable upstream, Thr(308)-directed kinases to phosphorylate and activate PKB. Four isoforms of these PKB kinases were purified from sheep brain. They bound PtdIns(3,4,5)P-3 and associated with lipid vesicles containing ii. These kinases contain an NH2-terminal catalytic domain and a COOH-terminal pleckstrin homologous domain, and their heterologous expression augments receptor activation of PKB, which suggests they are the primary signal transducers that enable PtdIns(3,4,5)P-3 or PtdIns(3,4)P-2 to activate PKB and hence to control signaling pathways regulating cell survival, glucose uptake, and glycogen metabolism.	Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England; Univ Calif San Francisco, Canc Res Inst, San Francisco, CA 94115 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Univ London Kings Coll, Dept Chem, London WC2R 2LS, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute; University of California System; University of California San Francisco; Memorial Sloan Kettering Cancer Center; University of Cambridge; University of London; King's College London	Stephens, L (corresponding author), Babraham Inst, Inositide Lab, Cambridge CB2 4AT, England.	len.stephens@bbsrc.ac.uk		Hawkins, Phillip/0000-0002-6979-0464; stephens, len/0000-0002-2771-3487; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Anderson, Karen/0000-0002-7394-6660	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Akimoto K, 1996, EMBO J, V15, P788, DOI 10.1002/j.1460-2075.1996.tb00414.x; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDERSON K, UNPUB; BALLACOSA A, 1993, ONCOGENE, V8, P745; BUNN TC, 1996, GENOME RES, V6, P525; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; HAWKINS PT, 1995, CURR BIOL, V5, P393, DOI 10.1016/S0960-9822(95)00080-7; Hemmings BA, 1997, SCIENCE, V277, P534, DOI 10.1126/science.277.5325.534; James SR, 1996, BIOCHEM J, V315, P709, DOI 10.1042/bj3150709; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STEPHENS LR, UNPUB; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; TOKER A, 1994, J BIOL CHEM, V269, P32358	25	898	940	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 30	1998	279	5351					710	714		10.1126/science.279.5351.710	http://dx.doi.org/10.1126/science.279.5351.710			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU574	9445477				2022-12-01	WOS:000071731500038
J	Rosse, T; Olivier, R; Monney, L; Rager, M; Conus, S; Fellay, I; Jansen, B; Borner, C				Rosse, T; Olivier, R; Monney, L; Rager, M; Conus, S; Fellay, I; Jansen, B; Borner, C			Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c	NATURE			English	Article							APOPTOSIS; DEATH; INHIBITION; DOMAINS; BH1	Following exposure of cells to stimuli that trigger programmed cell death (apoptosis), cytochrome c is rapidly released from mitochondria irate the cytoplasm where it activates proteolytic molecules known as caspases that specifically cleave the amino-acid sequence DEVD and are crucial for the execution of apoptosis(1-4). The protein Bcl-2 interferes with this activation of caspases by preventing the release of cytochrome c(2-4). Here we study these molecular interactions during apoptosis induced by the protein Bax, a pro-apoptotic homologue of Bcl-2 (refs 5, 6). We show that in cells transiently transfected with bax, Bax localizes to mitochondria and induces the release of cytochrome c, activation of caspase-3, membrane blebbing, nuclear fragmentation, and cell death. Caspase inibitors do not affect Bax-induced cytochrome c release but block caspase-3 activation and nuclear fragmentation. Unexpectedly, Bcl-2 also fails to prevent Bax-induced cytochrome c release, although it co-localizes with Bax to mitochondria. Cells overexpressing both Bcl-2 and Bax show no signs of caspase activation and survive with significant amounts of cytochrome c in the cytoplasm. These findings indicate that Bcl-2 can interfere with Bax killing downstream of and independently of cytochrome c release.	Univ Fribourg, Inst Biochem, CH-1700 Fribourg, Switzerland; Univ Vienna, Vienna Gen Hosp, Dept Clin Pharmacol, Sect Expt Oncol, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Dermatol, Div Gen Dermatol, A-1090 Vienna, Austria	University of Fribourg; University of Vienna; University of Vienna	Borner, C (corresponding author), Univ Fribourg, Inst Biochem, Rue Musee 5, CH-1700 Fribourg, Switzerland.							BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; Kluck RM, 1997, EMBO J, V16, P4639, DOI 10.1093/emboj/16.15.4639; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; McCarthy NJ, 1997, J CELL BIOL, V136, P215, DOI 10.1083/jcb.136.1.215; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OTTER I, IN PRESS J BIOL CHEM; Xiang JL, 1996, P NATL ACAD SCI USA, V93, P14559, DOI 10.1073/pnas.93.25.14559; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	13	759	843	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					496	499		10.1038/35160	http://dx.doi.org/10.1038/35160			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461218				2022-12-01	WOS:000071701800053
J	Weiss, RA				Weiss, RA			Transgenic pigs and virus adaptation	NATURE			English	Editorial Material							ACCELERATING FACTOR CD55; HUMAN-SERUM; CELLS; PROTEINS; RECEPTOR; CD46		Inst Canc Res, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Weiss, RA (corresponding author), Inst Canc Res, 237 Fulham Rd, London SW3 6JB, England.							BERGELSON JM, 1995, J VIROL, V69, P1903, DOI 10.1128/JVI.69.3.1903-1906.1995; Darrieussecq Marie, 1997, PIG TALES; DORIG RE, 1993, CELL, V75, P295, DOI 10.1016/0092-8674(93)80071-L; Dorling A, 1997, LANCET, V349, P867, DOI 10.1016/S0140-6736(96)09404-4; LeTissier P, 1997, NATURE, V389, P681, DOI 10.1038/39489; McMorrow IM, 1997, TRANSPLANTATION, V64, P501, DOI 10.1097/00007890-199708150-00021; Meng XJ, 1997, P NATL ACAD SCI USA, V94, P9860, DOI 10.1073/pnas.94.18.9860; MONTEFIORI DC, 1994, VIROLOGY, V205, P82, DOI 10.1006/viro.1994.1622; Murphy FA, 1996, SCIENCE, V273, P746, DOI 10.1126/science.273.5276.746; OSullivan JD, 1997, LANCET, V349, P93, DOI 10.1016/S0140-6736(96)06162-4; Patience C, 1997, NAT MED, V3, P282, DOI 10.1038/nm0397-282; ROTHER RP, 1995, J EXP MED, V182, P1345, DOI 10.1084/jem.182.5.1345; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; Stoiber H, 1996, J EXP MED, V183, P307, DOI 10.1084/jem.183.1.307; Takeuchi Y, 1997, J VIROL, V71, P6174, DOI 10.1128/JVI.71.8.6174-6178.1997; Takeuchi Y, 1996, NATURE, V379, P85, DOI 10.1038/379085a0; VAUGHAN HA, 1994, TRANSPLANTATION, V58, P879, DOI 10.1097/00007890-199410270-00003; WARD T, 1994, EMBO J, V13, P5070, DOI 10.1002/j.1460-2075.1994.tb06836.x; WELSH RM, 1975, NATURE, V257, P612, DOI 10.1038/257612a0; White D, 1996, TRENDS BIOTECHNOL, V14, P3, DOI 10.1016/0167-7799(96)80906-1	20	139	142	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 22	1998	391	6665					327	328		10.1038/34772	http://dx.doi.org/10.1038/34772			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450739	Bronze			2022-12-01	WOS:000071604200022
J	Chaturvedi, N; Jarrett, J; Shipley, MJ; Fuller, JH				Chaturvedi, N; Jarrett, J; Shipley, MJ; Fuller, JH			Socioeconomic gradient in morbidity and mortality in people with diabetes: cohort study findings from the Whitehall study and the WHO multinational study of vascular disease in diabetes	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; BRITISH CIVIL-SERVANTS; RISK-FACTORS; SOCIAL DEPRIVATION; GLYCEMIC CONTROL; MELLITUS; HYPERGLYCEMIA; PROTEINURIA; IDDM; COMPLICATIONS	Objectives: To assess whether the inverse socioeconomic mortality gradient observed in the general population persists in diabetic people. Design: The Whitehall cohort study and the London cohort of the WHO multinational study of vascular disease in diabetes. Setting: London. Subjects: 17 264 male civil servants (17 046 without diabetes, 218 with diabetes) aged 40-64 examined in 1967-9, and 300 people with diabetes aged 35-55 from London clinics examined in 1975-7. Both cohorts were followed up until January 1995. Main outcome measures: Mortality from all causes, cardiovascular disease, and ischaemic heart disease. Results: In both cohorts people in the lower social groups were older, had higher blood pressure, and were more Likely to smoke. In the Whitehall study, the prevalence of heart disease was higher in the lowest social group compared with the highest group, by 6% among non-diabetic people (P = 0.0001) and by 14% among diabetic subjects (P = 0.02). In the WHO study proteinuria was more common in tie lowest social group compared with the highest (27% v 15%, P = 0.01), as was retinopathy (54% v 48%, P = 0.5). There was a clear socioeconomic gradient in all cause mortality in both cohorts, with death rates being about twice as high in the lowest compared with the highest social groups. In the Whitehall study this gradient was similar in both diabetic and non-diabetic subjects, and it persisted for mortality from cardiovascular disease and from ischaemic heart disease. About half of the increased risk of death in the lowest social group was accounted for by blood pressure and smoking. Conclusions: We confirm the existence of an inverse socioeconomic mortality gradient in diabetic people and suggest that this is largely due to conventional cardiovascular risk factors.	UCL, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	Chaturvedi, N (corresponding author), UCL, Dept Epidemiol & Publ Hlth, Mortimer St, London WC1E 6BT, England.	nish@public-health.ucl.ac.uk						ANDERSSON DKG, 1995, DIABETES CARE, V18, P1534, DOI 10.2337/diacare.18.12.1534; BarrettConnor E, 1996, DIABETES CARE, V19, P333, DOI 10.2337/diacare.19.4.333; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; Chaturvedi N, 1997, DIABETES CARE, V20, P1266, DOI 10.2337/diacare.20.8.1266; Chaturvedi N, 1996, DIABETES CARE, V19, P423, DOI 10.2337/diacare.19.5.423; Connolly VM, 1996, DIABETES CARE, V19, P419, DOI 10.2337/diacare.19.5.419; Diabetes Drafting Group, 1985, DIABETOLOGIA, V28, P615; DORMAN JS, 1985, DIABETES CARE, V8, P54, DOI 10.2337/diacare.8.1.S54; EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; FULLER JH, 1979, J CHRON DIS, V32, P721, DOI 10.1016/0021-9681(79)90051-1; GOLDBLATT P, 1990, LONGITUDINAL STUDY M, P164; HAFFNER SM, 1989, DIABETES CARE, V12, P128, DOI 10.2337/diacare.12.2.128; KELLY WF, 1994, DIABETIC MED, V11, P344, DOI 10.1111/j.1464-5491.1994.tb00284.x; KELLY WF, 1993, BRIT MED J, V307, P1115, DOI 10.1136/bmj.307.6912.1115; Koskinen SVP, 1996, BRIT MED J, V313, P975, DOI 10.1136/bmj.313.7063.975; KUNST AE, 1994, AM J PUBLIC HEALTH, V84, P932, DOI 10.2105/AJPH.84.6.932; LLOYD CE, 1993, DIABETES RES CLIN PR, V21, P187, DOI 10.1016/0168-8227(93)90068-G; Lowry R, 1996, JAMA-J AM MED ASSOC, V276, P792, DOI 10.1001/jama.276.10.792; MAJEED FA, 1994, BMJ-BRIT MED J, V308, P1426, DOI 10.1136/bmj.308.6941.1426; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; Matsushima M, 1996, DIABETOLOGIA, V39, P710; MORRISH NJ, 1991, DIABETOLOGIA, V34, P584, DOI 10.1007/BF00400278; MUGGEO M, 1995, DIABETOLOGIA, V38, P318, DOI 10.1007/s001250050288; *OFF POP CENS SURV, 1986, SER DS OFF POP CENS, V6, P82; Office of Population Censuses and Surveys, 1980, CLASS OCC; PRINGLE M, 1993, BRIT MED J, V306, P630, DOI 10.1136/bmj.306.6878.630; REID DD, 1974, LANCET, V1, P469; Rose G.A., 1982, CARDIOVASCULAR SURVE; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SPRAFKA JM, 1993, DIABETIC MED, V10, P627, DOI 10.1111/j.1464-5491.1993.tb00135.x; STEPHENSON JM, 1995, DIABETIC MED, V12, P149, DOI 10.1111/j.1464-5491.1995.tb00446.x; *UK PROSP DIAB STU, 1995, BMJ-BRIT MED J, V310, P83; Unwin N, 1996, DIABETIC MED, V13, P72, DOI 10.1002/(SICI)1096-9136(199601)13:1<72::AID-DIA21>3.3.CO;2-K; Wang SL, 1996, DIABETES CARE, V19, P305, DOI 10.2337/diacare.19.4.305; WILL JC, 1988, AM J PUBLIC HEALTH, V78, P831, DOI 10.2105/AJPH.78.7.831	36	136	136	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					100	105						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462313				2022-12-01	WOS:000071492300016
J	Bais, C; Santomasso, B; Coso, O; Arvanitakis, L; Raaka, EG; Gutkind, JS; Asch, AS; Cesarman, E; Gerhengorn, MC; Mesri, EA				Bais, C; Santomasso, B; Coso, O; Arvanitakis, L; Raaka, EG; Gutkind, JS; Asch, AS; Cesarman, E; Gerhengorn, MC; Mesri, EA			G-protein-coupled receptor of Kaposi's sarcoma-associated herpesvirus is a viral oncogene and angiogenesis activator	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; DNA-SEQUENCES; CELLS; EXPRESSION; VIRUS	The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV8) is a gamma-2 herpesvirus(1-5) that is implicated in the pathogenesis of Kaposi's sarcoma(1,5) and of primary effusion B-cell lymphomas (PELs)(6). KSHV infects malignant and progenitor cells of Kaposi's sarcoma(7) and PEL2,6,8, it encodes putative oncogenes(4,5,9) and genes that may cause Kaposi's sarcoma pathogenesis by stimulating angiogenesis(4,5,9,10). The G-protein-coupled receptor encoded by an open reading frame (ORF 74) of KSHV9 is expressed in Kaposi's sarcoma lesions and in PEL9,11 and stimulates signalling pathways linked to cell proliferation(12) in a constitutive (agonist-independent) way(12). Here we show that signalling by this KSHV G-protein-coupled receptor leads to cell transformation and tumorigenicity, and induces a switch to an angiogenic phenotype(13) mediated by vascular endothelial growth factor(14), an angiogenesis(13,14) and Kaposi's-spindle-cell growth factor(15-17). We find that this receptor can activate two protein kinases, JNK/SAPK and p38MAPK, by triggering signalling cascades like those induced by inflammatory cytokines(18) that are angiogenesis activators(19) and mitogens for Kaposi's sarcoma cells(10) and B cells. We conclude that the KSHV G-protein-coupled receptor is a viral oncogene that can exploit cell signalling pathways to induce transformation and angiogenesis in KSHV-mediated oncogenesis.	Cornell Univ, Coll Med, Lab Viral Oncogenesis, New York, NY 10021 USA; Cornell Univ, Coll Med, Div Hematol Oncol, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Med, Div Mol Med, New York, NY 10021 USA; Cornell Univ, Coll Med, Dept Pathol, New York, NY 10021 USA; NIDR, Mol Signaling Unit, Cellular Dev & Oncol Lab, NIH, Bethesda, MD 20892 USA	Cornell University; Cornell University; Cornell University; Cornell University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Mesri, EA (corresponding author), Cornell Univ, Coll Med, Lab Viral Oncogenesis, New York, NY 10021 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Santomasso, Bianca/0000-0001-9423-4059				Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; ARVANITAKIS L, 1996, BLOOD, V86, P2708; BOSHOFF C, 1995, NAT MED, V1, P1274, DOI 10.1038/nm1295-1274; Boshoff C, 1997, CURR OPIN INFECT DIS, V10, P26, DOI 10.1097/00001432-199702000-00007; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Cornali E, 1996, AM J PATHOL, V149, P1851; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; ENSOLI B, 1992, IMMUNOL REV, V127, P147, DOI 10.1111/j.1600-065X.1992.tb01412.x; Ferrara N, 1996, EUR J CANCER, V32A, P2413, DOI 10.1016/S0959-8049(96)00387-5; GOTO F, 1993, LAB INVEST, V69, P508; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; HANAHAN D, 1996, CELL, V86, P356; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; MESRI EA, 1995, CIRC RES, V76, P161, DOI 10.1161/01.RES.76.2.161; MONTESANO R, 1993, J CELL SCI, V105, P1013; Nakamura S, 1997, J IMMUNOL, V158, P4992; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAAKA EG, UNPUB J EXP MED; Renne R, 1996, NAT MED, V2, P342, DOI 10.1038/nm0396-342; RICKINSON AB, 1996, FIELDS VIROLOGY, P2397; RUSSO JJ, 1997, P NATL ACAD SCI USA, V93, P14862; SAMANIEGO F, 1995, J IMMUNOL, V154, P3582; VANSANDE J, 1995, J CLIN ENDOCR METAB, V80, P2577, DOI 10.1210/jc.80.9.2577	30	685	710	0	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					86	89		10.1038/34193	http://dx.doi.org/10.1038/34193			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422510				2022-12-01	WOS:000071326100054
J	Ricote, M; Li, AC; Willson, TM; Kelly, CJ; Glass, CK				Ricote, M; Li, AC; Willson, TM; Kelly, CJ; Glass, CK			The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation	NATURE			English	Article							INTERFERON-GAMMA; EXPRESSION; GENE; CELLS; METALLOPROTEINASES; LIPOPOLYSACCHARIDE; COLLAGENASE; LIGAND; J(2); AP-1	The peroxisome proliferator-activated receptor-gamma (PPAR-gamma) is a member of the nuclear receptor superfamily of ligand-dependent transcription factors that is predominantly expressed in adipose tissue, adrenal gland and spleen(1-3). PPAR-gamma has been demonstrated to regulate adipocyte differentiation and glucose homeostasis in response to several structurally distinct compounds, including thiazolidinediones and fibrates(3-6). Naturally occurring compounds such as fatty acids and the prostaglandin D-2 metabolite 15-deoxy-Delta(12,14) prostaglandin J(2) (15d-PGJ(2)) bind to PPAR-gamma and stimulate transcription of target genes(7-10). Prostaglandin D-2 metabolites have not yet been identified in adipose tissue, but are major products of arachidonic-acid metabolism in macrophages(11), raising the possibility that they might serve as endogenous PPAR-gamma ligands in this cell type, Here we show that PPAR-gamma is markedly upregulated in activated macrophages and inhibits the expression of the inducible nitric oxide synthase, gelatinase B and scavenger receptor A genes in response to 15d-PGJ(2) and synthetic PPAR-gamma ligands, PPAR-gamma inhibits gene expression in part by antagonizing the activities of the transcription factors AP-1, STAT and NF-kappa B, These observations suggest that PPAR-gamma and locally produced prostaglandin D-2 metabolites are involved in the regulation of inflammatory responses, and raise the possibility that synthetic PPAR-gamma ligands may be of therapeutic value in human diseases such as atherosclerosis and rheumatoid arthritis in which activated macrophages exert pathogenic effects.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Glaxo Wellcome Inc, Res & Dev, Dept Med Chem, Res Triangle Pk, NC 27709 USA; San Diego Vet Affairs Med Ctr, Div Cellular & Mol Med, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Endocrinol & Metab, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Cardiol, La Jolla, CA 92161 USA; San Diego Vet Affairs Med Ctr, Div Nephrol, La Jolla, CA 92161 USA	University of California System; University of California San Diego; GlaxoSmithKline	Glass, CK (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.		feinstein, doug/M-9414-2019; Ricote, Mercedes/L-4615-2014; Glass, Christopher/AAI-3933-2021	Ricote, Mercedes/0000-0002-8090-8902; Glass, Christopher/0000-0003-4344-3592				AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; FANJUL A, 1994, NATURE, V372, P107, DOI 10.1038/372107a0; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Greene M. E., 1995, Gene Expression, V4, P281; Hawke RL, 1997, J LIPID RES, V38, P1189; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; LORSBACH RB, 1993, J BIOL CHEM, V268, P1908; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P8730; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SATO H, 1993, ONCOGENE, V8, P395; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; URADE Y, 1989, J IMMUNOL, V143, P2982; WELGUS HG, 1990, J CLIN INVEST, V86, P1496, DOI 10.1172/JCI114867; Willson TM, 1996, J MED CHEM, V39, P665, DOI 10.1021/jm950395a; WU H, 1994, MOL CELL BIOL, V14, P2129, DOI 10.1128/MCB.14.3.2129; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; Zhu Y, 1996, MOL CELL BIOL, V16, P4808	27	3079	3240	7	172	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					79	82		10.1038/34178	http://dx.doi.org/10.1038/34178			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422508				2022-12-01	WOS:000071326100052
J	Lambert, ML; Francois, I; Salort, C; Slypen, V; Bertrand, F; Tonglet, R				Lambert, ML; Francois, I; Salort, C; Slypen, V; Bertrand, F; Tonglet, R			Household survey of locomotor disability caused by poliomyelitis and landmines in Afghanistan	BRITISH MEDICAL JOURNAL			English	Article									HANDICAP INT BELGIUM,B-1040 BRUSSELS,BELGIUM; HANDICAP INT AFGHANISTAN,QUETTA,PAKISTAN		Lambert, ML (corresponding author), UNIV CATHOLIQUE LOUVAIN,SCH PUBL HLTH,EPIDEMIOL UNIT,CLOS CHAPELLE AUX CHAMPS 30,UCL 30-34,B-1200 BRUSSELS,BELGIUM.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; BERNIER R, 1984, EPIGEN843 WHO; KALSBEEK W, 1995, EPI INFO VERSON 6 WO; *MIN CLEAR PLANN A, 1993, REP NAT SURV MIN SIT; *WHO, 1992, EXP PROGR IMM EPI CO	5	17	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1424	1425		10.1136/bmj.315.7120.1424	http://dx.doi.org/10.1136/bmj.315.7120.1424			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418091	Green Published			2022-12-01	WOS:A1997YJ67200027
J	Lu, YM; Roder, JC; Davidow, J; Salter, MW				Lu, YM; Roder, JC; Davidow, J; Salter, MW			Src activation in the induction of long-term potentiation in CA1 hippocampal neurons	SCIENCE			English	Article							D-ASPARTATE RECEPTOR; PROTEIN-TYROSINE KINASES; POSTSYNAPTIC CALCIUM; SYNAPTIC PLASTICITY; MUTANT MICE; SUBUNIT 2B; PHOSPHORYLATION; FYN; PHOSPHATASES; MECHANISMS	Long-term potentiation (LTP) is an activity-dependent strengthening of synaptic efficacy that is considered to be a model of learning and memory. Protein tyrosine phosphorylation is necessary io induce LTP. Here, induction of LTP in CA1 pyramidal cells of rats was prevented by blocking the tyrosine kinase Src, and Src activity was increased by stimulation producing LTP. Directly activating Sre in the postsynaptic neuron enhanced excitatory synaptic responses, occluding LTP. Src-induced enhancement of alpha-amino-3-hydroxy-5-methylisoxazolepropionic acid (AMPA) receptor-mediated synaptic responses required raised intracellular Ca2+ and N-methyl-D-aspartate (NMDA) receptors. Thus, Sre activation is necessary and sufficient for inducing LTP and may function by up-regulating NMDA receptors.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Hosp Sick Children, Div Neurosci, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Roder, JC (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5S 1A8, Canada.		Roder, John/G-6468-2013					Barria A, 1997, SCIENCE, V276, P2042, DOI 10.1126/science.276.5321.2042; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BURKHARDT AL, 1993, CURRENT PROTOCOLS IM, P1; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; Kohr G, 1996, J PHYSIOL-LONDON, V492, P445; Kojima N, 1997, P NATL ACAD SCI USA, V94, P4761, DOI 10.1073/pnas.94.9.4761; LAU LF, 1995, J BIOL CHEM, V270, P20036, DOI 10.1074/jbc.270.34.20036; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LIU XQ, 1993, ONCOGENE, V8, P1119; Lu YM, 1997, J NEUROSCI, V17, P5196; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MALENKA RC, 1992, NEURON, V9, P121, DOI 10.1016/0896-6273(92)90227-5; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOON IS, 1994, P NATL ACAD SCI USA, V91, P3954, DOI 10.1073/pnas.91.9.3954; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; ROCHE S, 1995, SCIENCE, V269, P1567, DOI 10.1126/science.7545311; Rosenblum K, 1996, P NATL ACAD SCI USA, V93, P10457, DOI 10.1073/pnas.93.19.10457; Rostas JAP, 1996, P NATL ACAD SCI USA, V93, P10452, DOI 10.1073/pnas.93.19.10452; STEIN PL, 1994, GENE DEV, V8, P1999, DOI 10.1101/gad.8.17.1999; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; WANG LY, 1991, SCIENCE, V253, P1132, DOI 10.1126/science.1653455; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; WYLLIE DJA, 1994, NEURON, V12, P127, DOI 10.1016/0896-6273(94)90158-9; Yu XM, 1997, SCIENCE, V275, P674, DOI 10.1126/science.275.5300.674	32	268	279	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1363	1367		10.1126/science.279.5355.1363	http://dx.doi.org/10.1126/science.279.5355.1363			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478899				2022-12-01	WOS:000072251800054
J	Hwang, LH; Lau, LF; Smith, DL; Mistrot, CA; Hardwick, KG; Hwang, ES; Amon, A; Murray, AW				Hwang, LH; Lau, LF; Smith, DL; Mistrot, CA; Hardwick, KG; Hwang, ES; Amon, A; Murray, AW			Budding yeast Cdc20: A target of the spindle checkpoint	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ASSEMBLY CHECKPOINT; MITOSIS; ANAPHASE; COMPLEX; UBIQUITIN; PDS1P	The spindle checkpoint regulates the cell division cycle by keeping cells with defective spindles from leaving mitosis. In the two-hybrid system, three proteins that are components of the checkpoint, Mad1, Mad2, and Mad3, were shown to interact with Cdc20, a protein required for exit from mitosis. Mad2 and Mad3 coprecipitated with Cdc20 at all stages of the cell cycle. The binding of Mad2 depended on Mad1 and that of Mad3 on Mad1 and Mad2. Overexpression of Cdc20 allowed cells with a depolymerized spindle or damaged DNA to leave mitosis but did not overcome the arrest caused by unreplicated DNA. Mutants in Cdc20 that were resistant to the spindle checkpoint no longer bound Mad proteins, suggesting that Cdc20 is the target of the spindle checkpoint.	Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem, San Francisco, CA 94143 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Massachusetts Institute of Technology (MIT); Whitehead Institute	Murray, AW (corresponding author), Univ Calif San Francisco, Dept Physiol, Box 0444, San Francisco, CA 94143 USA.		Holt, Janet E/B-2415-2013	Hardwick, Kevin/0000-0002-6462-1047; Amon, Angelika/0000-0001-9837-0314				AMON A, UNPUB; Cohen-Fix O, 1997, P NATL ACAD SCI USA, V94, P14361, DOI 10.1073/pnas.94.26.14361; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HARDWICK KG, 1995, J CELL BIOL, V131, P709, DOI 10.1083/jcb.131.3.709; Hardwick KG, 1996, SCIENCE, V273, P953, DOI 10.1126/science.273.5277.953; HARDWICK KG, UNPUB; He XW, 1997, P NATL ACAD SCI USA, V94, P7965, DOI 10.1073/pnas.94.15.7965; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; HWANG LC, UNPUB; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V77, P1037; Kim SH, 1998, SCIENCE, V279, P1045, DOI 10.1126/science.279.5353.1045; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lim HH, 1996, MOL GEN GENET, V253, P138, DOI 10.1007/s004380050306; Rudner AD, 1996, CURR OPIN CELL BIOL, V8, P773, DOI 10.1016/S0955-0674(96)80077-9; SCHOTT EJ, IN PRESS GENETICS; Schwab M, 1997, CELL, V90, P683, DOI 10.1016/S0092-8674(00)80529-2; Sherman R., 1974, METHODS YEAST GENETI; STAUDINGER J, 1993, J BIOL CHEM, V268, P4608; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wells WAE, 1996, TRENDS CELL BIOL, V6, P228, DOI 10.1016/0962-8924(96)10018-0; Yamamoto A, 1996, J CELL BIOL, V133, P99, DOI 10.1083/jcb.133.1.99; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201	29	453	466	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1041	1044		10.1126/science.279.5353.1041	http://dx.doi.org/10.1126/science.279.5353.1041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461437				2022-12-01	WOS:000072006400049
J	Raymond, CS; Shamu, CE; Shen, MM; Seifert, KJ; Hirsch, B; Hodgkin, J; Zarkower, D				Raymond, CS; Shamu, CE; Shen, MM; Seifert, KJ; Hirsch, B; Hodgkin, J; Zarkower, D			Evidence for evolutionary conservation of sex-determining genes	NATURE			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA; TRA-1; ORIENTATION; FRUITLESS; PROTEINS; REGIONS; DOMAIN; MICE	Most metazoans occur as two sexes. Surprisingly, molecular analyses have hitherto indicated that sex-determining mechanisms differ completely between phyla. Here we present evidence to the contrary, We have isolated the male sexual regulatory gene mab-3 (ref. 1) from the nematode Caenorhabditis elegans and found that it is related to the Drosophila melanogaster sexual regulatory gene doublesex (dsx)(2). Both genes encode proteins with a DNA-binding motif(3) that we have named the 'DM domain'. Both genes control sex-specific neuroblast differentiation and yolk protein gene transcription; dsx controls other sexually dimorphic features as well, The form of DSX that is found in males can direct male-specific neuroblast differentiation in C. elegans. This structural and functional similarity between phyla suggests a common evolutionary origin of at least some aspects of sexual regulation. We have identified a human gene, DMT1, that encodes a protein with a DM domain and find that DMT1 is expressed only in testis. DMT1 maps to the distal short arm of chromosome 9, a location implicated in human XY sex reversal(4). Proteins with DM domains may therefore also regulate sexual development in mammals.	Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Biochem, Minneapolis, MN 55455 USA; Univ Minnesota, Sch Med, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; MRC Laboratory Molecular Biology	Zarkower, D (corresponding author), Univ Minnesota, Sch Med, Inst Human Genet, Minneapolis, MN 55455 USA.		Shen, Michael M/C-7546-2009	Shen, Michael M/0000-0002-4042-1657; Raymond, Christopher/0000-0003-1128-8524				BAKER BS, 1980, GENETICS, V94, P383; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; deBono M, 1996, GENETICS, V144, P587; Eicher EM, 1996, NAT GENET, V14, P206, DOI 10.1038/ng1096-206; Erdman SE, 1996, GENETICS, V144, P1639; ERDMAN SE, 1993, EMBO J, V12, P527, DOI 10.1002/j.1460-2075.1993.tb05684.x; Finley KD, 1997, P NATL ACAD SCI USA, V94, P913, DOI 10.1073/pnas.94.3.913; HODGKIN J, 1987, GENE DEV, V1, P731, DOI 10.1101/gad.1.7.731; HODGKIN J, 1980, GENETICS, V96, P649; HODGKIN J, 1983, GENETICS, V103, P43; Hodgkin J., 1988, NEMATODE CAENORHABDI, P243; HODGKIN JA, 1977, GENETICS, V86, P275; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; KOOPMAN P, 1991, NATURE, V351, P117, DOI 10.1038/351117a0; Kuwabara PE, 1996, GENETICS, V144, P597; McDonald MT, 1997, AM J MED GENET, V73, P321; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; SCHEDL T, 1989, GENETICS, V123, P755; SHEN MM, 1988, CELL, V54, P1019, DOI 10.1016/0092-8674(88)90117-1; SIGURDSON DC, 1984, GENETICS, V108, P331; SPIETH J, 1985, NUCLEIC ACIDS RES, V13, P5283, DOI 10.1093/nar/13.14.5283; SPIETH J, 1991, MOL CELL BIOL, V11, P4651, DOI 10.1128/MCB.11.9.4651; Sulston J.E., 1988, NEMATODE CAENORHABDI, P587; TRASK B, GENOME ANAL LAB MANU; TUCKER PK, 1993, NATURE, V364, P715, DOI 10.1038/364715a0; Veitia R, 1997, GENOMICS, V41, P271, DOI 10.1006/geno.1997.4648; WHITFIELD LS, 1993, NATURE, V364, P713, DOI 10.1038/364713a0; WILKINS AS, 1995, BIOESSAYS, V17, P71, DOI 10.1002/bies.950170113; ZARKOWER D, 1992, CELL, V70, P237, DOI 10.1016/0092-8674(92)90099-X	30	614	682	3	131	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					691	695		10.1038/35618	http://dx.doi.org/10.1038/35618			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490411				2022-12-01	WOS:000071982500051
J	Tincello, DG; Richmond, DH				Tincello, DG; Richmond, DH			Evaluation of reagent strips in detecting asymptomatic bacteriuria in early pregnancy: prospective case series	BRITISH MEDICAL JOURNAL			English	Article							URINE; NITRITE; WOMEN	Objective: To evaluate the performance of reagent test strips in screening pregnant women for asymptomatic bacteriuria at their first visit to an antenatal clinic. Design: Prospective case series. Setting: Antenatal clinic of a large inner city maternity hospital. Subjects: All women attending for their first antenatal clinic. Patients taking antibiotics for any reason and those with urinary tract symptoms were excluded. Intervention: A midstream urine specimen was divided; half was sent for microscopy and formal bacteriological culture and the other half was tested with a commercial reagent strip test for the presence of blood, protein, nitrite, and leucocyte esterase, Main outcome measures: Sensitivity, specificity, and positive and negative predictive values of the reagent strips in diagnosing asymptomatic bacteriuria (defined as 10(5) colony forming units/ml urine). Results: Sensitivity was low, with a maximum of 33% when all four tests were used in combination, Specificity was high, with typical values of 99% or more. Positive predictive value reached a maximum of 69% and negative predictive value was typically 95% or more. Conclusion: Urine reagent strips are not sufficiently sensitive to be of use in the screening for asymptomatic bacteriuria and therefore many patients would be missed. In view of the potentially serious sequelae of this condition in pregnant women we recommend that formal bacteriological investigation remain the investigation of choice in this group of patients.	Liverpool Womens Hosp, Dept Urogynaecol, Liverpool L8 7SS, Merseyside, England	University of Liverpool	Tincello, DG (corresponding author), Liverpool Womens Hosp, Dept Urogynaecol, Liverpool L8 7SS, Merseyside, England.							ETHERINGTON IJ, 1993, BRIT J OBSTET GYNAEC, V100, P806, DOI 10.1111/j.1471-0528.1993.tb14303.x; KASS EH, 1955, AM J MED, V18, P764, DOI 10.1016/0002-9343(55)90190-X; LENKE RR, 1981, AM J OBSTET GYNECOL, V140, P427, DOI 10.1016/0002-9378(81)90039-9; MARQUETTE GP, 1988, AM J OBSTET GYNECOL, V153, P888; MCFADYEN IR, 1973, J OBSTET GYN BR COMM, V80, P385; MCFADYEN IR, 1986, KIDNEY PREGNANCY, P205; MCNEELY SG, 1987, OBSTET GYNECOL, V69, P50; MOLLER M, 1984, LANCET, V2, P69; NUNNS D, 1995, BRIT J UROL, V76, P87, DOI 10.1111/j.1464-410X.1995.tb07838.x; ROBERTSON AW, 1988, OBSTET GYNECOL, V71, P878; VANDORSTEN JP, 1986, AM J OBSTET GYNECOL, V155, P777, DOI 10.1016/S0002-9378(86)80019-9	11	32	33	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					435	437		10.1136/bmj.316.7129.435	http://dx.doi.org/10.1136/bmj.316.7129.435			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492667	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071982700026
J	De Guzman, RN; Wu, ZR; Stalling, CC; Pappalardo, L; Borer, PN; Summers, MF				De Guzman, RN; Wu, ZR; Stalling, CC; Pappalardo, L; Borer, PN; Summers, MF			Structure of the HIV-1 nucleocapsid protein bound to the SL3 Psi-RNA recognition element	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIPLE-RESONANCE NMR; ACID-BINDING-PROTEINS; MURINE LEUKEMIA-VIRUS; SIDE-CHAIN RESONANCES; GAG GENE-PRODUCTS; CYS-HIS BOX; PACKAGING SIGNAL; ZINC FINGERS; POSTTRANSLATIONAL MODIFICATIONS	The three-dimensional structure of the human immunodeficiency virus-type 1 (HIV-1) nucleocapsid protein (NC) bound to the SL3 stem-loop recognition element of the genomic Psi RNA packaging signal has been determined by heteronuclear magnetic resonance spectroscopy. Tight binding (dissociation constant, similar to 100 nM) is mediated by specific interactions between the amino-and carboxyl-terminal CCHC-type zinc knuckles of the NC protein and the G(7) and G(9) nucleotide bases, respectively, of the G(6)-G(7)-A(8)-G(9) RNA tetraloop. A(8) packs against the amino-terminal knuckle and forms a hydrogen bond with conserved Arg(32), and residues Lys(3) to Arg(10) of NC form a 3(10) helix that binds to the major groove of the RNA stem and also packs against the amino-terminal zinc knuckle. The structure provides insights into the mechanism of viral genome recognition, explains extensive amino acid conservation within NC, and serves as a basis for the development of inhibitors designed to interfere with genome encapsidation.	Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA; Univ Maryland Baltimore Cty, Howard Hughes Med Inst, Baltimore, MD 21250 USA; Univ Maryland Baltimore Cty, Dept Chem & Biochem, Baltimore, MD 21250 USA	Syracuse University; Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore County; University System of Maryland; University of Maryland Baltimore County	Summers, MF (corresponding author), Syracuse Univ, Dept Chem, Syracuse, NY 13244 USA.		Pappalardo, Lucia/ABA-9311-2020	Pappalardo, Lucia/0000-0002-4491-2082; Pinnix, Chelsea/0000-0003-3982-3664; Borer, Philip N/0000-0003-1633-5393	NIGMS NIH HHS [GM32691, GM42561] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032691, R01GM042561, R29GM042561] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; Allain FHT, 1996, NATURE, V380, P646, DOI 10.1038/380646a0; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Batey RT, 1995, METHOD ENZYMOL, V261, P300; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; BAX A, 1990, J MAGN RESON, V88, P425, DOI 10.1016/0022-2364(90)90202-K; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERKOWITZ RD, 1995, J VIROL, V69, P6445, DOI 10.1128/JVI.69.10.6445-6456.1995; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DICKSON C, 1984, RNA TUMOR VIRUSES, V1, P513; DUPRAZ P, 1990, J VIROL, V64, P4978, DOI 10.1128/JVI.64.10.4978-4987.1990; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; Foster MP, 1997, NAT STRUCT BIOL, V4, P605, DOI 10.1038/nsb0897-605; GORELICK RJ, 1993, J VIROL, V67, P4027, DOI 10.1128/JVI.67.7.4027-4036.1993; GORELICK RJ, 1988, P NATL ACAD SCI USA, V85, P8420, DOI 10.1073/pnas.85.22.8420; GORELICK RJ, 1990, J VIROL, V64, P3207, DOI 10.1128/JVI.64.7.3207-3211.1990; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; HAYASHI T, 1993, FEBS LETT, V327, P213, DOI 10.1016/0014-5793(93)80172-Q; HAYASHI T, 1992, VIROLOGY, V188, P590, DOI 10.1016/0042-6822(92)90513-O; HENDERSON LE, 1981, J BIOL CHEM, V256, P8400; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HEUS HA, 1991, SCIENCE, V253, P191, DOI 10.1126/science.1712983; IKURA M, 1990, J AM CHEM SOC, V112, P9020, DOI 10.1021/ja00180a080; IKURA M, 1991, Journal of Biomolecular NMR, V1, P299, DOI 10.1007/BF01875522; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JENTOFT JE, 1988, P NATL ACAD SCI USA, V85, P7094, DOI 10.1073/pnas.85.19.7094; Ji XD, 1996, BIOCHEMISTRY-US, V35, P132, DOI 10.1021/bi951707e; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEE W, 1994, FEBS LETT, V350, P87, DOI 10.1016/0014-5793(94)00740-3; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; MACURA S, 1980, MOL PHYS, V41, P95, DOI 10.1080/00268978000102601; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; McDonnell NB, 1997, J MED CHEM, V40, P1969, DOI 10.1021/jm970147+; MERIC C, 1989, J VIROL, V63, P1558; MERIC C, 1988, J VIROL, V62, P3328; MERVIS RJ, 1988, J VIROL, V62, P3993, DOI 10.1128/JVI.62.11.3993-4002.1988; MEYERS G, 1995, HUMAN RETROVIRUSES A; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; MORELLET N, 1992, EMBO J, V11, P3059, DOI 10.1002/j.1460-2075.1992.tb05377.x; MUHANDIRAM DR, 1993, J BIOMOL NMR, V3, P463; Nicholls A., GRASP GRAPHICAL REPR; OTTMANN M, 1995, J VIROL, V69, P1778, DOI 10.1128/JVI.69.3.1778-1784.1995; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PAPPALARDO L, UNPUB; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; PUGLISI JD, 1995, SCIENCE, V270, P1200, DOI 10.1126/science.270.5239.1200; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Ramos A, 1997, CURR OPIN STRUC BIOL, V7, P317, DOI 10.1016/S0959-440X(97)80046-2; RICE WG, 1993, P NATL ACAD SCI USA, V90, P9721, DOI 10.1073/pnas.90.20.9721; RICE WG, 1995, SCIENCE, V270, P1194, DOI 10.1126/science.270.5239.1194; RICE WG, 1993, NATURE, V361, P473, DOI 10.1038/361473a0; Rice WG, 1997, NAT MED, V3, P341, DOI 10.1038/nm0397-341; Rice WG, 1996, REV MED VIROL, V6, P187, DOI 10.1002/(SICI)1099-1654(199612)6:4&lt;187::AID-RMV176&gt;3.0.CO;2-F; SAKAGUCHI K, 1993, P NATL ACAD SCI USA, V90, P5219, DOI 10.1073/pnas.90.11.5219; Schmitz U, 1996, RNA, V2, P1213; SOUTH TL, 1993, PROTEIN SCI, V2, P3; SUMMERS MF, 1990, BIOCHEMISTRY-US, V29, P329, DOI 10.1021/bi00454a005; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; Vandevelde M, 1996, AIDS RES HUM RETROV, V12, P567, DOI 10.1089/aid.1996.12.567; VUISTER GW, 1992, J MAGN RESON, V98, P428, DOI 10.1016/0022-2364(92)90144-V; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Wuttke DS, 1997, J MOL BIOL, V273, P183, DOI 10.1006/jmbi.1997.1291; WYATT JR, 1991, BIOTECHNIQUES, V11, P764; Ye XM, 1995, CHEM BIOL, V2, P827, DOI 10.1016/1074-5521(95)90089-6; Ye XM, 1996, NAT STRUCT BIOL, V3, P1026, DOI 10.1038/nsb1296-1026; YOU JC, 1993, J BIOL CHEM, V268, P16519; YU XL, 1995, CHEM RES TOXICOL, V8, P586, DOI 10.1021/tx00046a013; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	89	589	600	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 16	1998	279	5349					384	388		10.1126/science.279.5349.384	http://dx.doi.org/10.1126/science.279.5349.384			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430589				2022-12-01	WOS:000071570800047
J	Gleeson, JG; Allen, KM; Fox, JW; Lamperti, ED; Berkovic, S; Scheffer, I; Cooper, EC; Dobyns, WB; Minnerath, SR; Ross, ME; Walsh, CA				Gleeson, JG; Allen, KM; Fox, JW; Lamperti, ED; Berkovic, S; Scheffer, I; Cooper, EC; Dobyns, WB; Minnerath, SR; Ross, ME; Walsh, CA			doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein	CELL			English	Article							CORTICAL DEVELOPMENT; KINASE; MICE; MALFORMATIONS; OUTGROWTH; SUBUNIT	X-linked lissencephaly and "double cortex" are allelic human disorders mapping to Xq22.3-Xq23 associated with arrest of migrating cerebral cortical neurons. We identified a novel 10 kb brain-specific cDNA interrupted by a balanced translocation in an XLIS patient that encodes a novel 40 kDa predicted protein named Doublecortin. Four double cortex/X-linked lissencephaly families and three sporadic double cortex patients show independent doublecortin mutations, at least one of them a de novo mutation. Doublecortin contains a consensus Abl phosphorylation site and other sites of potential phosphorylation. Although Doublecortin does not contain a kinase domain, it is homologous to the amino terminus of a predicted kinase protein, indicating a likely role in signal transduction. Doublecortin, along with the newly characterized mDab1, may define an Abl-dependent pathway regulating neuronal migration.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA; Childrens Hosp, Dept Neurol, Boston, MA 02115 USA; Austin Hosp, Heidelberg, Vic 3084, Australia; Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA; Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA; Univ Minnesota, Lab Mol Neurobiol & Dev, Minneapolis, MN 55455 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of California System; University of California San Francisco; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Walsh, CA (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Div Neurogenet, Boston, MA 02115 USA.		Scheffer, Ingrid E/G-1668-2013; Dobyns, William/AAI-2768-2020; Cooper, Edward/A-1036-2009; Dobyns, William Brian/ABC-6525-2021; Cooper, Edward/X-6659-2019	Scheffer, Ingrid E/0000-0002-2311-2174; Dobyns, William/0000-0002-7681-2844; Cooper, Edward/0000-0003-3672-8442; Berkovic, Samuel/0000-0003-4580-841X; Walsh, Christopher/0000-0002-0156-2238	NIMH NIH HHS [MH10691] Funding Source: Medline; NINDS NIH HHS [5K12NS01701-04, KO8-NS01520, R01 NS041537] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K12NS001701, R01NS041537, K08NS001520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BERG M, 1997, IN PRESS NEUROLOGY; Brunati AM, 1996, EUR J BIOCHEM, V240, P400, DOI 10.1111/j.1432-1033.1996.0400h.x; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; des Portes V, 1998, CELL, V92, P51; desPortes V, 1997, J MED GENET, V34, P177, DOI 10.1136/jmg.34.3.177; Dobyns WB, 1996, NEUROLOGY, V47, P331, DOI 10.1212/WNL.47.2.331; DOBYNS WB, 1992, NEUROLOGY, V42, P1375, DOI 10.1212/WNL.42.7.1375; DOBYNS WB, 1995, NEUROPEDIATRICS, V26, P132, DOI 10.1055/s-2007-979744; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Eksioglu YZ, 1996, NEURON, V16, P77, DOI 10.1016/S0896-6273(00)80025-2; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GERTLER FB, 1993, GENE DEV, V7, P441, DOI 10.1101/gad.7.3.441; Gonzalez JL, 1997, J NEUROSCI, V17, P9204; Harding B, 1996, DYSPLASIAS OF CEREBRAL CORTEX AND EPILEPSY, P81; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; INGEIZI MA, 1994, NEURON, V12, P873; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Nagase T, 1997, DNA Res, V4, P141, DOI 10.1093/dnares/4.2.141; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; OGILVIE DJ, 1996, YAC PROTOCOLS, V54; RAYMOND AA, 1995, BRAIN, V118, P829; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; ROSS ME, 1997, HUM MOL GENET, V6, P553; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SCHWARTZBERG PL, 1991, CELL, V65, P1165, DOI 10.1016/0092-8674(91)90012-N; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Smith RF, 1996, GENOME RES, V6, P454, DOI 10.1101/gr.6.5.454; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; SRIVASTAVA A, 1995, CYTOGENET CELL GENET, V31, P430; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WARE ML, 1997, NEURON, V19, P1	36	812	836	2	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					63	72		10.1016/S0092-8674(00)80899-5	http://dx.doi.org/10.1016/S0092-8674(00)80899-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489700	Bronze			2022-12-01	WOS:000071473700008
J	Brenner, H; Rothenbacher, D; Bode, G; Adler, G				Brenner, H; Rothenbacher, D; Bode, G; Adler, G			Relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection: cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							CAMPYLOBACTER-PYLORI; LIVING-CONDITIONS; POPULATION; CHILDHOOD; GASTRITIS; SECRETION; ETHANOL; LIFE; RISK; AGE	Objective: To assess the relation of smoking and alcohol and coffee consumption to active Helicobacter pylori infection. Design: Cross sectional study of patients attending a general practitioner Active H pylori infection was measured by the C-13-urea breath test and detailed quantitative information on smoking and on alcohol and coffee consumption was obtained by a standardised self administered questionnaire. Setting: One general practice in Germany. Subjects: 447 patients aged 15-79 who had not had peptic ulcer disease or treatment for H pylori infection. Main outcome measures: Prevalence of H pylori infection according to smoking and alcohol and coffee consumption. Results: Overall prevalence of infection was 21% (94/447). There was no significant relation between smoking and active H pylori infection. Alcohol consumption showed a negative dose-response relation and coffee consumption a positive dose-response relation with active infection. After adjustment for potential confounders, the odds ratios for patients who drank less than or equal to 75 g and >75 g of ethanol a week compared with non-drinkers were 0.90 (95% confidence interval 0.55 to 1.59) and 0.33 (0.16 to 0.68), respectively (P value for trend 0.005, assuming that 1 litre of beer and 0.5 l of nine contain on average 50 g of ethanol in south Germany). Adjusted odds ratios for patients who drank <3 cups and greater than or equal to 3 cups of coffee per day compared with those who did not drink coffee were 1.49 (0.71 to 3.12) and 2.49 (1.23 to 5.03), respectively (P value for trend 0.007). Conclusion: These results suggest a protective effect of alcohol consumption against active infection with H pyolri and an opposite effect of coffee consumption.	UNIV ULM,DEPT INTERNAL MED 1,D-89069 ULM,GERMANY	Ulm University	Brenner, H (corresponding author), UNIV ULM,DEPT EPIDEMIOL,D-89069 ULM,GERMANY.		Brenner, Hermann/B-4627-2017; Brenner, Hermann/ABE-6383-2020	Brenner, Hermann/0000-0002-6129-1572; Brenner, Hermann/0000-0002-6129-1572; Rothenbacher, Dietrich/0000-0002-3563-2791				[Anonymous], 1993, Gut, V34, P1672; BATESON MC, 1993, POSTGRAD MED J, V69, P41, DOI 10.1136/pgmj.69.807.41; BRENNER H, 1994, EPIDEMIOLOGY, V5, P510; CHODOS JE, 1988, AM J GASTROENTEROL, V83, P1226; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; ENDOH K, 1994, GASTROENTEROLOGY, V107, P864, DOI 10.1016/0016-5085(94)90138-4; FONTHAM ETH, 1995, AM J GASTROENTEROL, V90, P1094; GASBARRINI G, 1995, GUT, V36, P838, DOI 10.1136/gut.36.6.838; GILBOA S, 1995, INT J EPIDEMIOL, V24, P232, DOI 10.1093/ije/24.1.232; GRAHAM DY, 1991, GASTROENTEROLOGY, V100, P1495, DOI 10.1016/0016-5085(91)90644-Z; HOOKNIKANNE J, 1991, DIGESTION, V50, P92, DOI 10.1159/000200745; JIAN R, 1986, DIGEST DIS SCI, V31, P604, DOI 10.1007/BF01318691; MAXTON DG, 1990, POSTGRAD MED J, V66, P717, DOI 10.1136/pgmj.66.779.717; MENDALL MA, 1992, LANCET, V339, P896, DOI 10.1016/0140-6736(92)90931-R; MEYER B, 1991, GUT, V32, P347, DOI 10.1136/gut.32.4.347; *NIH CONS DEV PAN, 1994, JAMA-J AM MED ASSOC, V272, P65; PARSONNET J, 1992, GASTROENTEROLOGY, V102, P41, DOI 10.1016/0016-5085(92)91782-Y; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PAUNIO M, 1994, EUR J EPIDEMIOL, V10, P205, DOI 10.1007/BF01730371; ROBERT A, 1983, AM J PHYSIOL, V245, pG113, DOI 10.1152/ajpgi.1983.245.1.G113; ROKKAS T, 1987, AM J GASTROENTEROL, V82, P1149; *SAS I, 1990, SAS LANG REF; SINGER MV, 1987, GASTROENTEROLOGY, V93, P1247, DOI 10.1016/0016-5085(87)90252-6; WEBB PM, 1994, BRIT MED J, V308, P750, DOI 10.1136/bmj.308.6931.750; Weisse ME, 1995, BRIT MED J, V311, P1657, DOI 10.1136/bmj.311.7021.1657	25	118	121	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 6	1997	315	7121					1489	1492		10.1136/bmj.315.7121.1489	http://dx.doi.org/10.1136/bmj.315.7121.1489			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK986	9420488	Green Published			2022-12-01	WOS:A1997YK98600016
J	Ransohoff, DF; Harris, RP				Ransohoff, DF; Harris, RP			Lessons from the mammography screening controversy: Can we improve the debate?	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; DECISION; RISK	The debate about breast cancer screening for women in their 40s has become so contentious that effective communication and rational discussion on this topic have been compromised. This contentiousness might be defused by understanding the reasons for it. The debate is less about facts than it is about perceptions and values. There is disagreement about how to fairly describe facts about risk and how to avoid misperceptions that may distort assessment of risk. Other sources of disagreement concern the potential harms of screening, the relative roles of physicians and patients in decision making, and how to factor cost into screening decisions. The entire decision-making process has also been highly charged by single-issue advocacy groups and a kind of gender rivalry. Several approaches might help defuse the debate and improve discussion. First, those on both sides of the debate might agree on several things: 1) that the evidence from clinical trials is widely agreed-upon and thus that a main task now is to factor in the values of individual women who are making decisions; 2) that the values of women may differ substantially and that those differences should be respected; 3) that both individuals and the public should be fully and fairly informed about the pros and cons of screening; and 4) that cost-effectiveness should at least be considered during the decision-making process. Lessons from this debate may apply to other medical problems that have small degrees of risk and whose management is strongly debated.			Ransohoff, DF (corresponding author), UNIV N CAROLINA, SCH MED, CB 7105, CHAPEL HILL, NC 27599 USA.							*ACS, 1997, WORKSH GUID BREAST C; BARRY MJ, 1995, MED CARE, V33, P771, DOI 10.1097/00005650-199508000-00003; BERNSTEIN PL, 1997, GODS REMARKABLE STOD; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; BRODY J, 1997, NY TIMES        1007, pB9; BRODY J, 1997, NY TIMES        1007, pB14; Coley CM, 1997, ANN INTERN MED, V126, P468, DOI 10.7326/0003-4819-126-6-199703150-00010; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2493, DOI 10.1001/jama.263.18.2493; EDDY DM, 1990, ANN INTERN MED, V113, P373, DOI 10.7326/0003-4819-113-5-373; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P441, DOI 10.1001/jama.263.3.441; Elmore J. G., 1997, JGIM, V12, P107; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; ERNSTER VL, 1997, NIH CONS DEV C BREAS; Fisher R., 1991, GETTING YES NEGOTIAT; Flood AB, 1996, J GEN INTERN MED, V11, P342, DOI 10.1007/BF02600045; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; Harris R., 1996, JGIM, V11, P124; JAROFF L, 1996, TIME            0401, P58; Kasper J F, 1992, QRB Qual Rev Bull, V18, P183; LERMAN C, 1991, ANN INTERN MED, V114, P657, DOI 10.7326/0003-4819-114-8-657; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; MILLER BA, 1993, NIH PUB; Morgan M. W., 1997, JGIM, V12, P62; *NAT CANC I, 1997, NAT CANC ADV BOARD I; REDELMEIER DA, 1993, JAMA-J AM MED ASSOC, V270, P72, DOI 10.1001/jama.270.1.72; REDELMEIER DA, 1995, JAMA-J AM MED ASSOC, V273, P302, DOI 10.1001/jama.273.4.302; Roter DL, 1997, JAMA-J AM MED ASSOC, V277, P350, DOI 10.1001/jama.277.4.350; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Thune I, 1997, NEW ENGL J MED, V336, P1269, DOI 10.1056/NEJM199705013361801; TVERSKY A, 1974, SCIENCE, V185, P1124, DOI 10.1126/science.185.4157.1124; WAGNER JL, 1995, BPH146 OFF TECHN ASS; Willan AR, 1997, CONTROL CLIN TRIALS, V18, P121, DOI 10.1016/S0197-2456(96)00092-X; WILLETT WC, 1987, NEW ENGL J MED, V316, P1174, DOI 10.1056/NEJM198705073161902; Winawer SJ, 1997, GASTROENTEROLOGY, V112, P594, DOI 10.1053/gast.1997.v112.agast970594; Woolf SH, 1997, BRIT MED J, V314, P989, DOI 10.1136/bmj.314.7086.989; WOOLF SH, 1997, WASHINGTON POST 0504, pC5; WOOLF SH, 1997, WASHINGTON POST 0504, pC1; 1997, NY TIMES        0320, P10	41	51	51	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					1029	1034		10.7326/0003-4819-127-11-199712010-00016	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00016			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412285				2022-12-01	WOS:A1997YJ08000011
J	Rowe, PM				Rowe, PM			Signalling an end to transplant rejection?	LANCET			English	News Item																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 22	1997	350	9090					1526	1526		10.1016/S0140-6736(05)63956-6	http://dx.doi.org/10.1016/S0140-6736(05)63956-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YH115	9417481				2022-12-01	WOS:A1997YH11500028
J	Braun, E; Eichen, Y; Sivan, U; Ben-Yoseph, G				Braun, E; Eichen, Y; Sivan, U; Ben-Yoseph, G			DNA-templated assembly and electrode attachment of a conducting silver wire	NATURE			English	Article							TRANSPORT; MOLECULES; GOLD	Recent research in the field of nanometre-scale electronics has focused on two fundamental issues: the operating principles of small-scale devices, and schemes that lead to their realization and eventual integration into useful circuits, Experimental studies on molecular(1) to submicrometre(2) quantum dots and on the electrical transport in carbon nanotubes(3-5) have confirmed theoretical predictions(6-8) of an increasing role for charging effects as the device size diminishes. Nevertheless, the construction of nanometre-scale circuits from such devices remains problematic, largely owing to the difficulties of achieving inter-element wiring and electrical interfacing to macroscopic electrodes. The use of molecular recognition processes and the self-assembly of molecules into supramolecular structures(9,10) might help overcome these difficulties. In this context, DNA has the appropriate molecular-recognition(11) and mechanical(12-16) properties, but poor electrical characteristics prevent its direct use in electrical circuits. Here we describe a two-step procedure that may allow the application of DNA tc, the construction of functional circuits, In our scheme, hybridization of the DNA molecule with surface-bound oligonucleotides is first used to stretch it between two gold electrodes; the DNA molecule is then used as a template for the vectorial growth of a 12 mu m long, 100 nm wide conductive silver wire. The experiment confirms that the recognition capabilities of DNA can be exploited for the targeted attachment of functional wires.	Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Dept Chem, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Technion Israel Institute of Technology	Braun, E (corresponding author), Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel.	erez@physics.technion.ac.il						Alivisatos AP, 1996, NATURE, V382, P609, DOI 10.1038/382609a0; Arkin MR, 1996, SCIENCE, V273, P475, DOI 10.1126/science.273.5274.475; Atwood J. L., 1996, COMPREHENSIVE SUPRAM, DOI DOI 10.1021/jacs.6b12949; Austin RH, 1997, PHYS TODAY, V50, P32, DOI 10.1063/1.881674; Averin D. V., 1991, MESOSCOPIC PHENOMENA, P173; BARTON JK, 1994, BIOINORGANIC CHEM, pCH8; BENSIMON A, 1994, SCIENCE, V265, P2096, DOI 10.1126/science.7522347; BENSIMON D, 1995, PHYS REV LETT, V74, P4754, DOI 10.1103/PhysRevLett.74.4754; BIRRELL GB, 1986, J HISTOCHEM CYTOCHEM, V34, P339, DOI 10.1177/34.3.3950384; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; BURROUGHES JH, 1990, NATURE, V347, P539, DOI 10.1038/347539a0; Coffer JL, 1996, APPL PHYS LETT, V69, P3851, DOI 10.1063/1.117126; Eichhorn GL, 1973, INORGANIC BIOCH, V2; Grabert H., 1992, SINGLE CHARGE TUNNEL; Hall DB, 1996, NATURE, V382, P731, DOI 10.1038/382731a0; HOLGATE CS, 1983, J HISTOCHEM CYTOCHEM, V31, P938, DOI 10.1177/31.7.6189883; KASTNER MA, 1992, REV MOD PHYS, V64, P849, DOI 10.1103/RevModPhys.64.849; Langer L, 1996, PHYS REV LETT, V76, P479, DOI 10.1103/PhysRevLett.76.479; Lewis FD, 1997, SCIENCE, V277, P673, DOI 10.1126/science.277.5326.673; MARZILLI LG, 1977, J AM CHEM SOC, V99, P2797, DOI 10.1021/ja00450a066; Meirav U, 1996, SEMICOND SCI TECH, V11, P255, DOI 10.1088/0268-1242/11/3/003; Mirkin CA, 1996, NATURE, V382, P607, DOI 10.1038/382607a0; PORATH D, 1997, J APPL PHYS, V81, P1; Sanders JK, 1995, SUPRAMOLECULAR CHEM, V107, P2617; SCHWARTZ DC, 1989, NATURE, V338, P520, DOI 10.1038/338520a0; Spiro TG, 1980, NUCL ACID METAL ION; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Watson J. D., 1987, MOL BIOL GENE; WIRTZ D, 1995, PHYS REV LETT, V75, P2436, DOI 10.1103/PhysRevLett.75.2436; ZIMMERMANN RM, 1994, NUCLEIC ACIDS RES, V22, P492, DOI 10.1093/nar/22.3.492	30	2136	2259	7	608	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 19	1998	391	6669					775	778		10.1038/35826	http://dx.doi.org/10.1038/35826			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486645				2022-12-01	WOS:000072089500047
J	Ogasawara, K; Hida, S; Azimi, N; Tagaya, Y; Sato, T; Yokochi-Fukuda, T; Waldmann, TA; Taniguchi, T; Taki, S				Ogasawara, K; Hida, S; Azimi, N; Tagaya, Y; Sato, T; Yokochi-Fukuda, T; Waldmann, TA; Taniguchi, T; Taki, S			Requirement for IRF-1 in the microenvironment supporting development of natural killer cells	NATURE			English	Article							RECEPTOR-GAMMA CHAIN; REGULATORY FACTOR-I; INTERLEUKIN-2 RECEPTOR; BETA-CHAIN; TRANSCRIPTION FACTOR; IL-2 RECEPTOR; MICE; MARROW; DIFFERENTIATION; SUPPRESSION	Natural killer (NK) cells are critical for both innate and adaptive immunity(1,2). The development of NK cells requires interactions between their progenitors and the bone-marrow microenvironment(3-6); however, little is known about the molecular nature of such interactions, Mice that do not express the transcription factor interferon-regulatory factor-1 (IRF-1; such mice are IRF-1(-/-) mice) have been shown to exhibit a severe NK-cell deficiency(7,8). Here we demonstrate that the lack of IRF-1 affects the radiation-resistant cells that constitute the microenvironment required for NK-cell development, but not the NK-cell progenitors themselves. We also show that IRF-1(-/-) bone-marrow cells can generate functional NK cells when cultured with the cytokine interleukin-15 (refs 9-12) and that the interleukin-15 gene is transcriptionally regulated by IRF-1. These results reveal, for the first time, a molecular mechanism by which the bone-marrow microenvironment supports NK-cell development.	Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Tokyo 113, Japan; Univ Tokyo, Fac Med, Bunkyo Ku, Tokyo 113, Japan; NCI, Metab Branch, NIH, Bethesda, MD 20892 USA	University of Tokyo; University of Tokyo; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Taki, S (corresponding author), Univ Tokyo, Grad Sch Med, Dept Immunol, Bunkyo Ku, Hongo 7-3-1, Tokyo 113, Japan.	shin-t@m.u-tokyo.ac.jp	Ogasawara, Kouetsu/G-9892-2011; Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660; Taki, Shinsuke/0000-0001-5143-3496				ANDERSON DM, 1995, GENOMICS, V25, P701, DOI 10.1016/0888-7543(95)80013-C; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; Bendelac A, 1997, ANNU REV IMMUNOL, V15, P535, DOI 10.1146/annurev.immunol.15.1.535; CARSON WE, 1994, J EXP MED, V180, P1395, DOI 10.1084/jem.180.4.1395; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DiSanto JP, 1997, CURR BIOL, V7, pR424, DOI 10.1016/S0960-9822(06)00208-9; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GRABSTEIN KH, 1994, SCIENCE, V264, P965, DOI 10.1126/science.8178155; HACKETT J, 1985, J IMMUNOL, V134, P3731; HALLER O, 1977, J IMMUNOL, V118, P1503; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; KUMAR V, 1979, J IMMUNOL, V123, P1832; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; Mrozek E, 1996, BLOOD, V87, P2632, DOI 10.1182/blood.V87.7.2632.bloodjournal8772632; Ohbo K, 1996, BLOOD, V87, P956, DOI 10.1182/blood.V87.3.956.bloodjournal873956; Puzanov IJ, 1996, J IMMUNOL, V157, P4282; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; SCOTT P, 1995, CURR OPIN IMMUNOL, V7, P34, DOI 10.1016/0952-7915(95)80026-3; SEAMAN WE, 1979, J IMMUNOL, V122, P2541; Suzuki H, 1997, J EXP MED, V185, P499, DOI 10.1084/jem.185.3.499; Tagaya Y, 1996, IMMUNITY, V4, P329, DOI 10.1016/S1074-7613(00)80246-0; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Tan RSP, 1996, CANCER RES, V56, P2417; TANAKA N, 1993, MOL CELL BIOL, V13, P4531, DOI 10.1128/MCB.13.8.4531; TANAKA T, 1993, J EXP MED, V178, P1103, DOI 10.1084/jem.178.3.1103; Taniguchi T, 1997, BBA-REV CANCER, V1333, pM9, DOI 10.1016/S0304-419X(97)00014-0; TRINCHIERI G, 1989, ADV IMMUNOL, V47, P187, DOI 10.1016/S0065-2776(08)60664-1	30	281	284	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	1998	391	6668					700	703		10.1038/35636	http://dx.doi.org/10.1038/35636			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490414				2022-12-01	WOS:000071982500054
J	Basade, MM; Gulati, SC				Basade, MM; Gulati, SC			High-dose chemotherapy in metastatic breast cancer	LANCET			English	Editorial Material							RESCUE		Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India; New York Hosp, Cornell Med Ctr, Stem Cell Transplantat & Clin Res Div Hematol Onc, New York, NY USA	Tata Memorial Centre (TMC); Cornell University; NewYork-Presbyterian Hospital	Basade, MM (corresponding author), Tata Mem Ctr, Rural Canc Project, Dept Med & Paediat Oncol, Barshi 413401, Maharashtra, India.							BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BROUN ER, 1992, HIGH DOSE CANCER THE, P690; Dillman RO, 1996, BREAST CANCER RES TR, V37, P277, DOI 10.1007/BF01806509; GOLDSTONE AH, 1992, HIGH DOSE CANCER THE, P662; GULATI SC, 1993, PURGING BONE MARROW, P45; PETERS WP, 1995, P AN M AM SOC CLIN, V14, P317; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; ROWLINGS PA, 1997, P AM SOC CLIN ONCOL, V16, pA117; UNG O, 1995, J CLIN ONCOL, V13, P435, DOI 10.1200/JCO.1995.13.2.435	9	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	FEB 7	1998	351	9100					386	387		10.1016/S0140-6736(05)78349-5	http://dx.doi.org/10.1016/S0140-6736(05)78349-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW873	9482287				2022-12-01	WOS:000071982600005
J	Nyren, O; Yin, L; Josefsson, S; McLaughlin, JK; Blot, WJ; Engqvist, M; Hakelius, L; Boice, JD; Adami, HO				Nyren, O; Yin, L; Josefsson, S; McLaughlin, JK; Blot, WJ; Engqvist, M; Hakelius, L; Boice, JD; Adami, HO			Risk of connective tissue disease and related disorders among women with breast implants: a nation-wide retrospective cohort study in Sweden	BRITISH MEDICAL JOURNAL			English	Article							SILICONE; CONTROVERSY	Objective: To examine the relation between connective tissue disease and related conditions and breast implants. Design: Retrospective cohort study of all women in the Swedish national inpatient registry who underwent breast augmentation surgery with artificial implants during 1964-93, compared with women who underwent breast reduction surgery during the same period. Setting: Sweden. Subjects: 7442 women with implants for cosmetic reasons or for reconstruction after breast cancer surgery and 3353 women with breast reduction surgery. Main outcome measures: Subsequent hospitalisation for definite connective tissue diseases (rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, dermatomyositis, and Sjogren's syndrome) or related disorders. Results: 29 women with implants were hospitalised for definite connective tissue disease compared with 25.5 expected based on general population rates (standardised hospitalisation ratio 1.1 (95% confidence interval 0.8 to 1.6)). There were no diagnoses of systemic sclerosis, and no significant excess in risk for polymyalgia rheumatica, fibromyalgia, and several related disorders. Among women who underwent breast reduction surgery, 14 were hospitalised for definite connective tissue disease compared with 10.5 expected (standardised hospitalisation ratio 1.3 (0.7 to 2.2)). Compared with the breast reduction group, women with breast implants showed a slight reduction for all definite connective tissue disease (relative risk 0.8 (95% confidence interval 0.5 to 1.4)). Conclusions: This large nationwide cohort study shows no evidence of association between breast implants and connective tissue disease.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; Int Epidemiol Inst, Rockville, MD USA; Natl Board Hlth & Welf, Stockholm, Sweden; Univ Uppsala Hosp, Dept Plast & Hand Surg, Uppsala, Sweden; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Karolinska Institutet; National Board of Health & Welfare; Uppsala University; Uppsala University Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Nyren, O (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, S-17177 Stockholm, Sweden.	Olof.Nyren@mep.ki.se						BAILAR JC, 1964, BIOMETRICS, V20, P638; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; BRIDGES AJ, 1994, LANCET, V344, P1451, DOI 10.1016/S0140-6736(94)90284-4; Burns CJ, 1996, J RHEUMATOL, V23, P1904; Cronin TD., 1963, EXCERPTA MED, V66, P41; Hennekens CH, 1996, JAMA-J AM MED ASSOC, V275, P616, DOI 10.1001/jama.275.8.616; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; Hochberg MC, 1996, CURR TOP MICROBIOL, V210, P411; Hochberg MC, 1996, ARTHRITIS RHEUM, V39, P1125, DOI 10.1002/art.1780390708; MARTIN L, 1995, J RHEUMATOL, V22, P198; McCullagh P, 2019, GEN LINEAR MODELS; MIYOSHI K, 1964, IJISHIMPO, V2122, P9; Nilsson A C, 1994, Lakartidningen, V91, P603; Perkins LL, 1995, ANN PLAS SURG, V35, P561, DOI 10.1097/00000637-199512000-00001; Rothman KJ, 1986, MODERN EPIDEMIOLOGY; SANCHEZGUERRERO J, 1995, NEW ENGL J MED, V332, P1666, DOI 10.1056/NEJM199506223322502; *SOC EP CENTR, 1995, PAT 1992 93; SOLOMON G, 1994, SEMIN ARTHRITIS RHEU, V24, P29, DOI 10.1016/0049-0172(94)90107-4; Wong O, 1996, REGUL TOXICOL PHARM, V23, P74, DOI 10.1006/rtph.1996.0011	19	105	107	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					417	422		10.1136/bmj.316.7129.417	http://dx.doi.org/10.1136/bmj.316.7129.417			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492663	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000071982700021
J	Ryan, CM; Schoenfeld, DA; Thorpe, WP; Sheridan, RL; Cassem, EH; Tompkins, RG				Ryan, CM; Schoenfeld, DA; Thorpe, WP; Sheridan, RL; Cassem, EH; Tompkins, RG			Objective estimates of the probability of death from burn injuries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROMPT ESCHAR EXCISION; INHALATION INJURY; MORTALITY	Background Over the past 20 years, there has been remarkable improvement in the chances of survival of patients treated in burn centers. A simple, accurate system for objectively estimating the probability of death would be useful in counseling patients and making medical decisions. Methods We conducted a retrospective review of all 1665 patients with acute burn injuries admitted from 1990 to 1994 to Massachusetts General Hospital and the Shriners Burns Institute in Boston. Using logistic-regression analysis, we developed probability estimates for the prediction of mortality based on a minimal set of well-defined variables. The resulting mortality formula was used to determine whether changes in mortality have occurred since 1984, and it was tested prospectively on all 530 patients with acute burn injuries admitted in 1995 or 1996. Results Of the 1665 patients (mean [+/-SD] age, 21+/-20 years; mean burn size, 14+/-20 percent of body-surface area), 1598 (96 percent) lived to discharge. The mean length of stay was 21+/-29 days. Three risk factors for death were identified: age greater than 60 years, more than 40 percent of body-surface area burned, and inhalation injury. The mortality formula we developed predicts 0.3 percent, 3 percent, 33 percent, or approximately 90 percent mortality, depending on whether zero, one, two, or three risk factors are present. The results of the prospective test of the formula were similar. A large increase in the proportion of patients who chose not to be resuscitated complicated comparisons of mortality over time. Conclusions The probability of death after burns is low and can be predicted soon after injury on the basis of simple, objective clinical criteria. (C) 1998, Massachusetts Medical Society.	Massachusetts Gen Hosp, Shriners Burns Inst, Boston, MA 02114 USA; Massachusetts Gen Hosp, Sumner Redstone Burn Ctr, Boston, MA 02114 USA; Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA; Massachusetts Gen Hosp, Surg Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Med Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Psychiat Serv, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Tompkins, RG (corresponding author), Massachusetts Gen Hosp, Trauma Serv, Bigelow 1302, Boston, MA 02114 USA.			Ryan, Colleen/0000-0002-6455-936X	NIGMS NIH HHS [GM P50-21700, GM T32-07035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM021700, T32GM007035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURKE JF, 1974, J TRAUMA, V14, P389, DOI 10.1097/00005373-197405000-00005; KNAUS WA, 1991, SCIENCE, V254, P389, DOI 10.1126/science.1925596; MANKTELOW A, 1989, J TRAUMA, V29, P203, DOI 10.1097/00005373-198902000-00009; Monafo WW, 1996, NEW ENGL J MED, V335, P1581, DOI 10.1056/NEJM199611213352108; PECK M D, 1991, Journal of Burn Care and Rehabilitation, V12, P282, DOI 10.1097/00004630-199105000-00017; PRUITT BA, 1964, ANN SURG, V159, P396; RYAN CM, 1995, ANN SURG, V222, P163, DOI 10.1097/00000658-199508000-00008; Ryan CM, 1997, J AM GERIATR SOC, V45, P1283, DOI 10.1111/j.1532-5415.1997.tb03792.x; Saffle Jeffrey R., 1995, Journal of Burn Care and Rehabilitation, V16, P219, DOI 10.1097/00004630-199505000-00002; SCHOENFELD DA, 1982, STATISTICS MED RES, P432; SHERIDAN RL, 1997, SURG SCI PRINCIPLES, P422; SHIRANI KZ, 1987, ANN SURG, V205, P82, DOI 10.1097/00000658-198701000-00015; TOMPKINS RG, 1988, ANN SURG, V208, P577, DOI 10.1097/00000658-198811000-00006; TOMPKINS RG, 1986, ANN SURG, V204, P272, DOI 10.1097/00000658-198609000-00006; TREDGET EE, 1990, ANN SURG, V212, P720, DOI 10.1097/00000658-199012000-00011; ZAWACKI BE, 1979, ANN SURG, V189, P1, DOI 10.1097/00000658-197901000-00001	16	485	507	4	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 5	1998	338	6					362	366		10.1056/NEJM199802053380604	http://dx.doi.org/10.1056/NEJM199802053380604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YV426	9449729				2022-12-01	WOS:000071822200004
J	Tai, KK; Goldstein, SAN				Tai, KK; Goldstein, SAN			The conduction pore of a cardiac potassium channel	NATURE			English	Article							K+ CHANNEL; XENOPUS-OOCYTES; SELECTIVITY; MUTATIONS; RESIDUES; BLOCK; ISK; CHARYBDOTOXIN; K(V)LQT1; PROTEINS	Ion channels form transmembrane water-filled pores that allow ions to cross membranes in a rapid and selective fashion, The amino acid residues that line these pores have been sought to reveal the mechanisms of ion conduction and selectivity(1-7). The pore (P) loop(8) is a stretch of residues that influences single-channel-current amplitude, selectivity among ions and open-channel blockade(2,3,5) and is conserved in potassium-channel subunits previously recognized to contribute to pore formation(5,9). To date, potassium-channel pores have been shown to form by symmetrical alignment of four P loops around a central conduction pathway(10-12). Here we show that the selectivity-determining pore region of the voltage-gated potassium channel of human heart through which the I-Ks current passes includes the transmembrane segment of the non-P-loop protein minK. Two adjacent residues in this segment of minK are exposed in the pore on either side of a short barrier that restricts the movement of sodium, cadmium and zinc ions across the membrane, Thus, potassium-selective pores are not restricted to P loops or a strict P-loop geometry.	Yale Univ, Sch Med, Dept Pediat, Sect Dev Biol & Biophys, New Haven, CT 06536 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Dept Cellular & Mol Physiol, New Haven, CT 06536 USA	Yale University; Yale University	Goldstein, SAN (corresponding author), Yale Univ, Sch Med, Dept Pediat, Sect Dev Biol & Biophys, 295 Congress Ave, New Haven, CT 06536 USA.		Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061				ARMSTRON.CM, 1969, J GEN PHYSIOL, V54, P553, DOI 10.1085/jgp.54.5.553; ATTALI B, 1993, NATURE, V365, P850, DOI 10.1038/365850a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; BLUMENTHAL EM, 1994, J NEUROSCI, V14, P3097; DWYER TM, 1980, J GEN PHYSIOL, V75, P469, DOI 10.1085/jgp.75.5.469; GLOWATZKI E, 1995, P ROY SOC B-BIOL SCI, V261, P251, DOI 10.1098/rspb.1995.0145; Goldstein SAN, 1998, J MOL MED-JMM, V76, P13, DOI 10.1007/s109-1998-8100-0; Goldstein SAN, 1996, NEURON, V16, P717, DOI 10.1016/S0896-6273(00)80092-6; GOLDSTEIN SAN, 1991, NEURON, V7, P403, DOI 10.1016/0896-6273(91)90292-8; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; HARTMANN HA, 1991, SCIENCE, V251, P942, DOI 10.1126/science.2000495; HEGINBOTHAM L, 1994, BIOPHYS J, V66, P1061, DOI 10.1016/S0006-3495(94)80887-2; LATORRE R, 1983, J MEMBRANE BIOL, V71, P11, DOI 10.1007/BF01870671; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; MACKINNON R, 1995, NEURON, V14, P889, DOI 10.1016/0896-6273(95)90327-5; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Romey G, 1997, J BIOL CHEM, V272, P16713, DOI 10.1074/jbc.272.27.16713; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SHEN KZ, 1994, PFLUG ARCH EUR J PHY, V426, P440, DOI 10.1007/BF00388308; Tai KK, 1997, J BIOL CHEM, V272, P1654, DOI 10.1074/jbc.272.3.1654; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; YELLEN G, 1994, BIOPHYS J, V66, P1068, DOI 10.1016/S0006-3495(94)80888-4	30	108	109	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 5	1998	391	6667					605	608		10.1038/35416	http://dx.doi.org/10.1038/35416			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468141	Green Submitted			2022-12-01	WOS:000071842300057
J	Rimm, EB; Willett, WC; Hu, FB; Sampson, L; Colditz, GA; Manson, JE; Hennekens, C; Stampfer, MJ				Rimm, EB; Willett, WC; Hu, FB; Sampson, L; Colditz, GA; Manson, JE; Hennekens, C; Stampfer, MJ			Folate and vitamin B-6 from diet and supplements in relation to risk of coronary heart disease among women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; OCCLUSIVE ARTERIAL-DISEASE; FOLIC-ACID; PLASMA HOMOCYSTEINE; MYOCARDIAL-INFARCTION; ELDERLY POPULATION; METABOLISM; METHIONINE; HYPERHOMOCYSTEINEMIA; HOMOCYST(E)INE	Context.-Hyperhomocysteinemia is caused by genetic and lifestyle influences, including low intakes of folate and vitamin B-6. However, prospective data relating intake of these vitamins to risk of coronary heart disease (CHD) are not available, Objective.-To examine intakes of folate and vitamin B-6 in relation to the incidence of nonfatal myocardial infarction (MI) and fatal CHD. Design.-Prospective cohort study. Setting and Patients.-In 1980, a total of 80 082 women from the Nurses' Health Study with no previous history of cardiovascular disease, cancer, hypercholesterolemia, or diabetes completed a detailed food frequency questionnaire from which we derived usual intake of folate and vitamin B-6. Main Outcome Measure.-Nonfatal MI and fatal CHD confirmed by World Health Organization criteria. Results.-During 14 years of follow-up, we documented 658 incident cases of nonfatal MI and 281 cases of fatal CHD. After controlling for cardiovascular risk factors, including smoking and hypertension and intake of alcohol, fiber, vitamin E, and saturated, polyunsaturated, and trans fat, the relative risks (RRs) of CHD between extreme quintiles were 0.69 (95% confidence interval [CI], 0.55-0.87) for folate (median intake, 696 mu g/d vs 158 mu g/d) and 0.67 (95% CI, 0.53-0.85) for vitamin B-6 (median intake, 4.6 mg/d vs 1.1 mg/d). Controlling for the same variables, the RR was 0.55 (95% CI, 0.41-0.74) among women in the highest quintile of both folate and vitamin B-6 intake compared with the opposite extreme. Risk of CHD was reduced among women who regularly used multiple vitamins (RR=0.76; 95% CI, 0.65-0.90), the major source of folate and vitamin B-6, and after excluding multiple vitamin users, among those with higher dietary intakes of folate and vitamin B-6. In a subgroup analysis, compared with nondrinkers, the inverse association between a high-folate diet and CHD was strongest among women who consumed up to 1 alcoholic beverage per day (RR=0.69; 95% CI, 0.49-0.97) or more than 1 drink per day (RR=0.27; 95% CI, 0.13-0.58). Conclusion.-These results suggest that intake of folate and vitamin B-6 above the current recommended dietary allowance may be important in the primary prevention of CHD among women.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Rimm, EB (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.	eric.rimm@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1996, JAMA-J AM MED ASSOC, V275, P681, DOI 10.1001/jama.1996.03530330025013; ARNESEN E, 1995, INT J EPIDEMIOL, V24, P704, DOI 10.1093/ije/24.4.704; BENDICH A, 1994, J NUTR EDUC, V26, P294; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOSTOM AG, 1995, ATHEROSCLEROSIS, V116, P147, DOI 10.1016/0021-9150(95)05529-6; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; BRATTSTROM L, 1990, ATHEROSCLEROSIS, V81, P51, DOI 10.1016/0021-9150(90)90058-Q; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; ChasanTaber L, 1996, J AM COLL NUTR, V15, P136; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Durand P, 1996, ATHEROSCLEROSIS, V121, P231, DOI 10.1016/0021-9150(95)06724-8; Food and Nutrition Board Commission on Life Sciences National Research Council, 1989, REC DIET ALL; GIOVANNUCCI E, 1993, J NATL CANCER I, V85, P875, DOI 10.1093/jnci/85.11.875; Graham IM, 1997, JAMA-J AM MED ASSOC, V277, P1775, DOI 10.1001/jama.277.22.1775; HERBERT VD, 1988, MODERN NUTRITION HLT, P388; ISRAELSSON B, 1988, ATHEROSCLEROSIS, V71, P227, DOI 10.1016/0021-9150(88)90147-5; JACOB RA, 1994, J NUTR, V124, P1072, DOI 10.1093/jn/124.7.1072; KANG SS, 1986, J CLIN INVEST, V77, P1482, DOI 10.1172/JCI112461; MALINOW MR, 1989, CIRCULATION, V79, P1180, DOI 10.1161/01.CIR.79.6.1180; MCCULLY KS, 1969, AM J PATHOL, V56, P111; MILLER JW, 1994, AM J CLIN NUTR, V59, P1033, DOI 10.1093/ajcn/59.5.1033; Morrison HI, 1996, JAMA-J AM MED ASSOC, V275, P1893, DOI 10.1001/jama.275.24.1893; MUDD SH, 1964, SCIENCE, V143, P1443, DOI 10.1126/science.143.3613.1443; NAURATH HJ, 1995, LANCET, V346, P85, DOI 10.1016/S0140-6736(95)92113-3; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; Oakley GP, 1997, AM J CLIN NUTR, V65, P1889, DOI 10.1093/ajcn/65.6.1889; OKEEFE CA, 1995, J NUTR, V125, P2717; PANCHARUNITI N, 1994, AM J CLIN NUTR, V59, P940, DOI 10.1093/ajcn/59.4.940; RIMM EB, 1996, CIRCULATION, V93, P625; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; SHAW S, 1989, BIOCHEM J, V257, P277, DOI 10.1042/bj2570277; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V275, P1929, DOI 10.1001/jama.275.24.1929; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Tawakol A, 1997, CIRCULATION, V95, P1119; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; Tucker KL, 1996, JAMA-J AM MED ASSOC, V276, P1879, DOI 10.1001/jama.276.23.1879; UBBINK JB, 1994, J NUTR, V124, P1927, DOI 10.1093/jn/124.10.1927; Ueland PM., 1992, ATHEROSCLEROTIC CARD, P183; *USDA, 1993, USDA AGR HDB SER, V8; Verhoef P, 1996, AM J EPIDEMIOL, V143, P845, DOI 10.1093/oxfordjournals.aje.a008828; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W., 1990, NUTR EPIDEMIOLOGY; WILLETT WC, 1987, J AM DIET ASSOC, V87, P43; WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Wilson JW, 1997, DATA TABLES COMBINED	52	619	650	0	25	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					359	364		10.1001/jama.279.5.359	http://dx.doi.org/10.1001/jama.279.5.359			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459468	Green Accepted, Bronze			2022-12-01	WOS:000071731300025
J	Gottlieb, JP; Kusunoki, M; Goldberg, ME				Gottlieb, JP; Kusunoki, M; Goldberg, ME			The representation of visual salience in monkey parietal cortex	NATURE			English	Article							LATERAL INTRAPARIETAL AREA; EYE-MOVEMENTS; MACAQUE; FIELD; ORGANIZATION	When natural scenes are viewed, a multitude of objects that are stable in their environments are brought in and out of view by eye movements. The posterior parietal cortex is crucial for the analysis of space, visual attention and movement(1). Neurons in one of its subdivisions, the lateral intraparietal area (LIP), have visual responses to stimuli appearing abruptly at particular retinal locations (their receptive fields)(2). We have rested the responses of LIP neurons to stimuli that entered their receptive field by saccades. Neurons had little or no response to stimuli brought into their receptive field by saccades, unless the stimuli were behaviourally significant. We established behavioural significance in two ways: either by making a stable stimulus task-relevant, or by taking advantage of the attentional attraction of an abruptly appearing stimulus. Our results show that under ordinary circumstances the entire visual world is only weakly represented in LIP. The visual representation in LIP is sparse, with only the most salient or behaviourally relevant objects being strongly represented.	NEI, Sensorimotor Res Lab, Bethesda, MD 20892 USA; Georgetown Univ, Sch Med, Dept Neurol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); Georgetown University	Goldberg, ME (corresponding author), NEI, Sensorimotor Res Lab, Bldg 10, Bethesda, MD 20892 USA.							Andersen R A, 1989, Rev Oculomot Res, V3, P315; Andersen R A, 1992, Curr Opin Neurobiol, V2, P840, DOI 10.1016/0959-4388(92)90143-9; BAIZER JS, 1991, J NEUROSCI, V11, P168; BARASH S, 1991, J NEUROPHYSIOL, V66, P1095, DOI 10.1152/jn.1991.66.3.1095; BLATT GJ, 1990, J COMP NEUROL, V299, P421, DOI 10.1002/cne.902990404; BURMAN DD, 1994, J NEUROPHYSIOL, V71, P1266, DOI 10.1152/jn.1994.71.3.1266; Colby CL, 1996, J NEUROPHYSIOL, V76, P2841, DOI 10.1152/jn.1996.76.5.2841; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P183; DUHAMEL JR, 1992, SCIENCE, V255, P90, DOI 10.1126/science.1553535; GNADT JW, 1988, EXP BRAIN RES, V70, P216; Hays AV, 1982, WESCON C P, V2, P1; Irwin DE, 1996, CURR DIR PSYCHOL SCI, V5, P94, DOI 10.1111/1467-8721.ep10772833; KOCH C, 1985, HUM NEUROBIOL, V4, P219; Livingstone MS, 1996, COLD SPRING HARB SYM, V61, P27; LYNCH JC, 1985, J COMP NEUROL, V235, P241, DOI 10.1002/cne.902350207; RAO RPN, 1996, ADV NEURAL INFORMATI, V8; RICHMOND BJ, 1987, J NEUROPHYSIOL, V57, P147, DOI 10.1152/jn.1987.57.1.147; Snyder LH, 1997, NATURE, V386, P167, DOI 10.1038/386167a0; STANTON GB, 1995, J COMP NEUROL, V353, P291, DOI 10.1002/cne.903530210; Treisman A, 1996, CURR OPIN NEUROBIOL, V6, P171, DOI 10.1016/S0959-4388(96)80070-5; WOLFE JM, 1994, PSYCHON B REV, V1, P202, DOI 10.3758/BF03200774; Yantis S., 1996, ATTENTIONAL CAPTURE	22	800	811	1	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					481	484		10.1038/35135	http://dx.doi.org/10.1038/35135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461214				2022-12-01	WOS:000071701800049
J	Strickler, HD; Rosenberg, PS; Devesa, SS; Hertel, J; Fraumeni, JF; Goedert, JJ				Strickler, HD; Rosenberg, PS; Devesa, SS; Hertel, J; Fraumeni, JF; Goedert, JJ			Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN BRAIN-TUMORS; CHOROID-PLEXUS; DNA-SEQUENCES; SV40	Context.-Poliovirus vaccine contaminated with live simian virus 40 (SV40), a polyomavirus that is tumorigenic in rodents, was used extensively in the United States between 1955 and 1963, Simian virus 40 DNA has recently been detected in several rare human tumors, including ependymomas, osteosarcomas. mesotheliomas. Objective.-To determine the risk of ependymoma, osteosarcoma, and mesothelioma among Americans who as children received SV40-contaminated poliovirus vaccine. Design.-Retrospective cohort study using data from the Surveillance, Epidemiology, and End Results program (1973-1993) and the Connecticut Tumor Registry (1950-1969), as well as national mortality statistics (1947-1973). Setting.-United States. Participants.-Birth cohorts that were likely to have received SV40-contaminated poliovirus vaccine as infants, born 1956 through 1962 (60 811 730 person-years of observation); as children, born 1947 through 1952 (46 430 953 person-years); or that were unexposed, born 1964 through 1969 (44 959 979 peron-years). Main Outcome Measures.-Relative risk (RR) of each cancer among exposed compared with unexposed birth cohorts. Results.-Age-specific cancer rates were generally low and were not significantly elevated in birth cohorts exposed to SV40-contaminated vaccine, Specifically, compared with the unexposed, the relative risk of ependymoma was not increased in the cohorts exposed as infants (RR, 1.06; 95% confidence interval [CI], 0.69-1.63), or as children (RR, 0.98; 95% CI, 0.57-1.69) nor did the exposed have an increased risk of all brain cancers. Osteosarcoma incidence also showed no relation to exposure as infants (RR, 0.87; 95% CI, 0.71-1.06) or children (RR, 0.85; 95% CI, 0.59-1.22). Last, mesotheliomas were not significantly associated with exposure, although the cohorts studied have not. yet reached the age at which these tumors tend to occur. Conclusions.-After more than 30 years of follow-up, exposure to SV40-contaminated poliovirus vaccine was not associated with significantly increased rates of ependymomas and other brain cancers, osteosarcomas, or mesotheliomas in the United States.	NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, Rockville, MD 20852 USA; Informat Management Syst, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Strickler, HD (corresponding author), NCI, Viral Epidemiol Branch, Div Canc Epidemiol & Genet, NIH, 6130 Execut Blvd,EPN Room 434, Rockville, MD 20852 USA.			Rosenberg, Philip/0000-0001-6349-9126				BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; CARBONE M, 1994, ONCOGENE, V9, P1781; Carbone M, 1996, ONCOGENE, V13, P527; DIAMANDO.GT, 1973, JNCI-J NATL CANCER I, V50, P1347, DOI 10.1093/jnci/50.5.1347; DORFMAN HD, 1995, CANCER, V75, P203, DOI 10.1002/1097-0142(19950101)75:1+<203::AID-CNCR2820751308>3.0.CO;2-V; EDDY BE, 1961, P SOC EXP BIOL MED, V107, P191; EDDY BE, 1962, FED PROC, V21, P930; Farwell J R, 1979, Trans Am Neurol Assoc, V104, P261; FRAUMENI JF, 1963, JAMA-J AM MED ASSOC, V185, P713, DOI 10.1001/jama.1963.03060090045016; GEISSLER E, 1990, PROG MED VIROL, V37, P211; HAENSZEL W, 1962, JNCI-J NATL CANCER I, V28, P947; HEINONEN OP, 1973, INT J EPIDEMIOL, V2, P229, DOI 10.1093/ije/2.3.229; INNIS MD, 1968, NATURE, V219, P972, DOI 10.1038/219972a0; LEDNICKY JA, 1995, VIROLOGY, V212, P710, DOI 10.1006/viro.1995.1529; Martini F, 1996, CANCER RES, V56, P4820; MORTIMER EA, 1981, NEW ENGL J MED, V305, P1517, DOI 10.1056/NEJM198112173052507; POLEDNAK AP, 1995, CANCER, V75, P330, DOI 10.1002/1097-0142(19950101)75:1+<330::AID-CNCR2820751315>3.0.CO;2-5; SALONEN T, 1976, ANN CLIN RES, V8, P27; SHAH K, 1976, AM J EPIDEMIOL, V103, P1; STEWART AM, 1965, LANCET, V2, P789; ZIPPIN C, 1995, CANCER, V76, P2343, DOI 10.1002/1097-0142(19951201)76:11<2343::AID-CNCR2820761124>3.0.CO;2-#	21	130	133	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					292	295		10.1001/jama.279.4.292	http://dx.doi.org/10.1001/jama.279.4.292			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450713	Bronze			2022-12-01	WOS:000071607000036
J	Lin, RL; Hill, RJ; Priess, JR				Lin, RL; Hill, RJ; Priess, JR			POP-1 and anterior-posterior fate decisions in C-elegans embryos	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; ASYMMETRIC CELL DIVISIONS; BLASTOMERE IDENTITY; MATERNAL GENES; AB LINEAGE; HMG BOX; SPECIFICATION; ENCODES; PROTEIN; PIE-1	Blastomeres in C. elegans embryos execute lineage programs wherein the fate of a cell is correlated reproducibly with the division sequence by which that cell is born. We provide evidence that the pop-1 gene functions to link anterior-posterior cell divisions with cell fate decisions. Each anterior cell resulting from an anterior-posterior division appears to have a higher level of nuclear POP-1 protein than does its posterior sister. Genes in the C. elegans Wnt pathway are required for this inequality in POP-1 levels. We show that loss of pop-1(+) activity leads to several types of anterior cells adopting the fates of their posterior sisters. These results suggest a mechanism for the invariance of blastomere lineages.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Howard Hughes Med Inst, Seattle, WA 98104 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Priess, JR (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Howard Hughes Med Inst, 1124 Columbia St, Seattle, WA 98104 USA.							BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BRENNER S, 1974, GENETICS, V77, P71; GENDREAU SB, 1994, DEV BIOL, V166, P770, DOI 10.1006/dbio.1994.1355; GOLDSTEIN B, 1993, DEVELOPMENT, V118, P1267; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; Guedes S, 1997, DEVELOPMENT, V124, P731; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; Hunter CP, 1996, CELL, V87, P217, DOI 10.1016/S0092-8674(00)81340-9; HUTTER H, 1995, DEVELOPMENT, V121, P1559; HUTTER H, 1994, DEVELOPMENT, V120, P2051; JUNKERSDORF B, 1992, ROUX ARCH DEV BIOL, V202, P17, DOI 10.1007/BF00364593; KEMPHUES KJ, 1997, NEMATODE C; LIN RL, 1995, CELL, V83, P599, DOI 10.1016/0092-8674(95)90100-0; MANGO SE, 1994, DEVELOPMENT, V120, P2305; MCGHEE JD, 1995, DEV GENET, V17, P155, DOI 10.1002/dvg.1020170207; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; Mello CC, 1996, NATURE, V382, P710, DOI 10.1038/382710a0; MELLO CC, 1994, CELL, V77, P95, DOI 10.1016/0092-8674(94)90238-0; Moon RT, 1997, TRENDS GENET, V13, P256, DOI 10.1016/S0168-9525(97)01196-7; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Moskowitz IPG, 1996, DEVELOPMENT, V122, P4105; MOSKOWITZ IPG, 1994, DEVELOPMENT, V120, P3325; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Peifer M, 1996, SCIENCE, V272, P974, DOI 10.1126/science.272.5264.974; Rocheleau CE, 1997, CELL, V90, P707, DOI 10.1016/S0092-8674(00)80531-0; Sawa H, 1996, GENE DEV, V10, P2189, DOI 10.1101/gad.10.17.2189; Schnabel R, 1996, MECH DEVELOP, V54, P133, DOI 10.1016/0925-4773(95)00466-1; SCHNABEL R, 1997, NEMATODE C; Seydoux G, 1996, NATURE, V382, P713, DOI 10.1038/382713a0; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P542, DOI 10.1016/0012-1606(80)90352-8; Thomas C, 1996, SCIENCE, V273, P603, DOI 10.1126/science.273.5275.603; Thorpe CJ, 1997, CELL, V90, P695, DOI 10.1016/S0092-8674(00)80530-9; VANDEWETERING M, 1991, EMBO J, V10, P123, DOI 10.1002/j.1460-2075.1991.tb07928.x; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873	38	227	229	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					229	239		10.1016/S0092-8674(00)80917-4	http://dx.doi.org/10.1016/S0092-8674(00)80917-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458047	Bronze			2022-12-01	WOS:000071672600012
J	Hemesath, TJ; Price, ER; Takemoto, C; Badalian, T; Fisher, DE				Hemesath, TJ; Price, ER; Takemoto, C; Badalian, T; Fisher, DE			MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes	NATURE			English	Article							RECEPTOR TYROSINE KINASE; CULTURED MAST-CELLS; GENE-EXPRESSION; MI/MI GENOTYPE; MELANOMA-CELLS; IN-VIVO; MOUSE; ACTIVATION; MUTATIONS; PROTEIN	Germline mutations at loci encoding the transcription factor Microphthalmia (Mi), the cytokine receptor c-Kit, or its ligand Steel factor (Sl) result in strikingly similar defects in mast cell and melanocyte development(1-3). Here we describe a biochemical link between Kit signalling and the activity of Mi. Stimulation of melanoma cells with Sl results in activation of MAP kinase, which in turn phosphorylates Mi at a consensus target serine. This phosphorylation upregulates Mi transactivation of the tyrosinase pigmentation gene promoter. In addition to modulating pigment production, such signalling may regulate the expression of genes essential for melanocyte survival and development. The pathway represents a new application of the general MAP kinase machinery in transducing a signal between a tissue-specific receptor at the cell surface and a tissue-specific transcription factor in the nucleus.	Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Fisher, DE (corresponding author), Childrens Hosp, Div Pediat Hematol Oncol, 44 Binney St, Boston, MA 02115 USA.	david_fisher@dfci.harvard.edu	Takemoto, Clifford M/Y-7558-2018					Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BENTLEY NJ, 1994, MOL CELL BIOL, V14, P7996, DOI 10.1128/MCB.14.12.7996; Bertolotto C, 1996, J CELL BIOL, V134, P747, DOI 10.1083/jcb.134.3.747; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EBI Y, 1992, BLOOD, V80, P1454; ENGLARO W, 1995, J BIOL CHEM, V270, P24315, DOI 10.1074/jbc.270.41.24315; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; ISOZAKI K, 1994, AM J PATHOL, V145, P827; Lorenz U, 1996, J EXP MED, V184, P1111, DOI 10.1084/jem.184.3.1111; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MOORE KJ, 1995, TRENDS GENET, V11, P442, DOI 10.1016/S0168-9525(00)89143-X; OKUDA K, 1992, BLOOD, V79, P2880; Paulson RF, 1996, NAT GENET, V13, P309, DOI 10.1038/ng0796-309; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; TACHIBANA M, 1994, HUM MOL GENET, V3, P553, DOI 10.1093/hmg/3.4.553; TASSABEHJI M, 1994, NAT GENET, V8, P251, DOI 10.1038/ng1194-251; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Tsujimura T, 1996, BLOOD, V88, P1225, DOI 10.1182/blood.V88.4.1225.bloodjournal8841225; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; YASUMOTO KI, 1994, MOL CELL BIOL, V14, P8058, DOI 10.1128/MCB.14.12.8058	27	528	546	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	1998	391	6664					298	301		10.1038/34681	http://dx.doi.org/10.1038/34681			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440696				2022-12-01	WOS:000071484400055
J	Sarasin, FP; Bounameaux, H				Sarasin, FP; Bounameaux, H			Decision analysis model of prolonged oral anticoagulant treatment in factor V Leiden carriers with first episode of deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACTIVATED PROTEIN-C; MOLECULAR-WEIGHT HEPARIN; COAGULATION-FACTOR-V; VENOUS THROMBOEMBOLISM; PULMONARY-EMBOLISM; OPTIMAL DURATION; THERAPY; RESISTANCE; MUTATION; RISK	Objective: To assess the risks and benefits of oral anticoagulant treatment extended beyond 3 months after a first episode of deep vein thrombosis in patients who carry factor V Leiden mutation. Such patients have over twice the risk of recurrence after the recommended treatment period, but more information is required before widespread genetic screening can be recommended. Design: A decision analysis Markov model (with data extracted form literature) representing the risks of developing symptomatic venous thromboembolism, the risks of major bleeding, and the efficacy of anticoagulant treatment. Subjects: A hypothetical cohort of 1000 carriers of factor V Leiden recovering from a first episode of deep vein thrombosis in the lower limbs. Main outcome measures: Risks and benefits of, firstly, stopping oral anticoagulation 3 months after first episode of thrombosis with reinitiation of treatment only after recurrent thrombosis and, secondly, extension of oral anticoagulation up to 1 to 5 years. Results: Despite consistent biases in favour of extended oral anticoagulation, analysis revealed that among factor V carriers the number of major haemorrhages induced by oral anticoagulants would exceed that of clinical pulmonary emboli prevented over the entire range of duration of anticoagulation (1 to 5 years). On the other hand, the number of recurrent deep vein thrombi prevented would exceed that of iatrogenic major bleedings. Conclusion: The lack of evidence of a net clinical benefit of prolonged oral anticoagulation, at least beyond 1 year, among patients recovering from acute deep vein thrombosis does not support the decision to promote widespread genetic screening programmes to detect the factor V mutation.	Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, CH-1211 Geneva 14, Switzerland; Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Div Angiol & Haemostasis, CH-1211 Geneva 14, Switzerland	University of Geneva; University of Geneva	Sarasin, FP (corresponding author), Univ Geneva, Hosp Cantonal,Sch Med, Dept Internal Med, Med Clin, 24 Rue Micheli Crest, CH-1211 Geneva 14, Switzerland.	sarasin-francois@diogenes.hcuge.ch						BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BEYTH RJ, 1995, ARCH INTERN MED, V218, P279; Bounameaux H, 1996, BLOOD COAGUL FIBRIN, V7, P507, DOI 10.1097/00001721-199607000-00001; CARSON JL, 1992, NEW ENGL J MED, V326, P1240, DOI 10.1056/NEJM199205073261902; CLAGETT GP, 1995, CHEST, V108, pS312, DOI 10.1378/chest.108.4_Supplement.312S; DAHLBACK B, 1995, BLOOD, V85, P607, DOI 10.1182/blood.V85.3.607.bloodjournal853607; Desmarais S, 1996, LANCET, V347, P1374, DOI 10.1016/S0140-6736(96)91013-2; Eichinger S, 1997, THROMB HAEMOSTASIS, V77, P624; Ginsberg JS, 1996, NEW ENGL J MED, V335, P1816, DOI 10.1056/NEJM199612123352407; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; Koepke JA, 1996, AM J CLIN PATHOL, V106, P161; Koopman MMW, 1996, NEW ENGL J MED, V334, P682, DOI 10.1056/NEJM199603143341102; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LANDEFELD CS, 1993, AM J MED, V95, P315, DOI 10.1016/0002-9343(93)90285-W; LEVINE MN, 1995, THROMB HAEMOSTASIS, V74, P606; LEVINE MN, 1995, CHEST, V108, pS276, DOI 10.1378/chest.108.4_Supplement.276S; Manten B, 1996, THROMB HAEMOSTASIS, V76, P510; Marinelli I, 1997, THROMB HAEMOSTASIS, V77, P440; MONREAL M, 1992, CHEST, V102, P677, DOI 10.1378/chest.102.3.677; PARASKOS JA, 1973, NEW ENGL J MED, V289, P55, DOI 10.1056/NEJM197307122890201; PRANDONI P, 1992, LANCET, V339, P441, DOI 10.1016/0140-6736(92)91054-C; RIDKER PM, 1995, NEW ENGL J MED, V332, P912, DOI 10.1056/NEJM199504063321403; Ridker PM, 1997, ANN INTERN MED, V126, P528, DOI 10.7326/0003-4819-126-7-199704010-00005; RIDKER PM, 1995, CIRCULATION, V92, P2800, DOI 10.1161/01.CIR.92.10.2800; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; Simioni P, 1997, NEW ENGL J MED, V336, P399, DOI 10.1056/NEJM199702063360602; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; SUDLOW MF, 1992, LANCET, V340, P873; Vandenbroucke JP, 1996, BRIT MED J, V313, P1127, DOI 10.1136/bmj.313.7065.1127; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0	31	43	43	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 10	1998	316	7125					95	99						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462312				2022-12-01	WOS:000071492300014
J	Barrett, TE; Savva, R; Panayotou, G; Barlow, T; Brown, T; Jiricny, J; Pearl, LH				Barrett, TE; Savva, R; Panayotou, G; Barlow, T; Brown, T; Jiricny, J; Pearl, LH			Crystal structure of a G : T/U mismatch-specific DNA glycosylase: Mismatch recognition by complementary-strand interactions	CELL			English	Article							BASE-EXCISION-REPAIR; ESCHERICHIA-COLI; NUCLEAR EXTRACTS; G.T MISPAIRS; HUMAN-CELLS; HELA-CELLS; URACIL; THYMINE; PROTEIN; PURIFICATION	G:U mismatches resulting from deamination of cytosine are the most common promutagenic lesions occurring in DNA. Uracil is removed in a base-excision repair pathway by uracil DNA-glycosylase (UDG), which excises uracil from both single-and double-stranded DNA. Recently, a biochemically distinct family of DNA repair enzymes has been identified, which excises both uracil and thymine, but only from mispairs with guanine. Crystal structures of the mismatch-specific uracil DNA-glycosylase (MUG) from E. coli, and of a DNA complex, reveal a remarkable structural and functional homology to UDGs despite low sequence identity. Details of the MUG structure explain its thymine DNA-glycosylase activity and the specificity for G:U/T mispairs, which derives from direct recognition of guanine on the complementary strand.	Univ London Univ Coll, Dept Biochem & Mol Biol, London WC1E 6BT, England; UCL, Ludwig Inst Canc Res, London W1P 8BT, England; Univ Southampton, Dept Chem, Southampton SO17 1BJ, Hants, England; Inst Med Radiobiol, CH-8029 Zurich, Switzerland	University of London; University College London; Ludwig Institute for Cancer Research; University of London; University College London; University of Southampton	Pearl, LH (corresponding author), Univ London Univ Coll, Dept Biochem & Mol Biol, Gower St, London WC1E 6BT, England.		Brown, Tom/B-8521-2008; Brown, Tom/C-9185-2016	Brown, Tom/0000-0003-4683-1873; Brown, Tom/0000-0002-6538-3036; Pearl, Laurence/0000-0002-6910-1809; Savva, Renos/0000-0001-7375-2340				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BJELLAND S, 1994, J BIOL CHEM, V269, P30489; BOITEUX S, 1990, J BIOL CHEM, V265, P3916; BROWN T, 1989, J MOL BIOL, V207, P455, DOI 10.1016/0022-2836(89)90268-4; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CHAYEN NE, 1990, J APPL CRYSTALLOGR, V23, P297, DOI 10.1107/S0021889890003260; CONE R, 1980, J BIOL CHEM, V255, P354; DIANOV G, 1994, CURR BIOL, V4, P1069, DOI 10.1016/S0960-9822(00)00245-1; DODSON ML, 1994, J BIOL CHEM, V269, P32709; DOMENA JD, 1988, BIOCHEMISTRY-US, V27, P6742, DOI 10.1021/bi00418a015; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JIRICNY J, 1996, GENETIC INSTABILITY, V28, P47; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kavli B, 1996, EMBO J, V15, P3442, DOI 10.1002/j.1460-2075.1996.tb00710.x; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESLIE A, 1995, MOSFLM USERS GUIDE; LETTIERI T, 1997, BASE EXCISION REPAIR, P45; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Neddermann P, 1996, J BIOL CHEM, V271, P12767, DOI 10.1074/jbc.271.22.12767; NICHOLLS A, 1993, BIOPHYS J, V64, pA116; Orengo CA, 1996, METHOD ENZYMOL, V266, P617; ORNSTEIN RL, 1978, BIOPOLYMERS, V17, P2341, DOI 10.1002/bip.1978.360171005; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Panayotou G, 1998, J BIOL CHEM, V273, P45, DOI 10.1074/jbc.273.1.45; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROY R, 1994, BIOCHEMISTRY-US, V33, P15131, DOI 10.1021/bi00254a024; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; SAVVA R, 1995, NATURE, V373, P487, DOI 10.1038/373487a0; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; SHIEH HS, 1980, NUCLEIC ACIDS RES, V8, P85, DOI 10.1093/nar/8.1.85; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Spanopoulou E, 1996, CELL, V87, P263, DOI 10.1016/S0092-8674(00)81344-6; WIEBAUER K, 1990, P NATL ACAD SCI USA, V87, P5842, DOI 10.1073/pnas.87.15.5842; WIEBAUER K, 1989, NATURE, V339, P234, DOI 10.1038/339234a0	45	221	229	2	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					117	129		10.1016/S0092-8674(00)80904-6	http://dx.doi.org/10.1016/S0092-8674(00)80904-6			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489705	Bronze			2022-12-01	WOS:000071473700013
J	Mansuy, IM; Mayford, M; Jacob, B; Kandel, ER; Bach, ME				Mansuy, IM; Mayford, M; Jacob, B; Kandel, ER; Bach, ME			Restricted and regulated overexpression reveals calcineurin as a key component in the transition from short-term to long-term memory	CELL			English	Article							HIPPOCAMPAL CA1 REGION; DAY-OLD CHICKS; GENE-EXPRESSION; HUMAN AMNESIA; RATS; MONKEYS; LESIONS; MODEL; POTENTIATION; NOVELTY	To investigate the roles phosphatases play in hippocampal-dependent memory, we studied transgenic mice overexpressing a truncated form of calcineurin. These mice have normal short-term memory but defective long-term memory evident on both a spatial task and on a visual recognition task, providing genetic evidence for the role of the rodent hippocampus in spatial and nonspatial memory. The defect in longterm memory could be fully rescued by increasing the number of training trials, suggesting that the mice have the capacity for long-term memory. We next analyzed mice overexpressing calcineurin in a regulated manner and found the memory defect is reversible and not due to a developmental abnormality. Our behavioral results suggest that calcineurin has a role in the transition from short-to long-term memory, which correlates with a novel intermediate phase of LTP.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA; Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute; Howard Hughes Medical Institute	Mansuy, IM (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA.		Mansuy, Isabelle M/N-3042-2015	Mansuy, Isabelle M/0000-0001-7785-5371; Mayford, Mark/0000-0002-9001-5024				Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; AGGLETON JP, 1985, Q J EXP PSYCHOL-B, V37, P279, DOI 10.1080/14640748508401171; ALVAREZ P, 1994, P NATL ACAD SCI USA, V91, P5637, DOI 10.1073/pnas.91.12.5637; BARNES CA, 1979, J COMP PHYSIOL PSYCH, V93, P74, DOI 10.1037/h0077579; BEACH ME, 1995, CELL, V81, P905, DOI 10.1016/0092-8674(95)90010-1; Bennett PC, 1996, BRAIN RES, V730, P107; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Brindle PK, 1992, CURR OPIN GENET DEV, V2, P199, DOI 10.1016/S0959-437X(05)80274-6; CHERKIN A, 1969, P NATL ACAD SCI USA, V63, P1094, DOI 10.1073/pnas.63.4.1094; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIK FIM, 1972, J VERB LEARN VERB BE, V11, P671, DOI 10.1016/S0022-5371(72)80001-X; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Ebbinghaus H. E., 1885, MEMORY CONTRIBUTION; EICHENBAUM H, 1995, NATURE, V378, P131, DOI 10.1038/378131a0; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; FRIEDER B, 1982, PHYSIOL BEHAV, V29, P1071, DOI 10.1016/0031-9384(82)90300-6; GIBBS ME, 1977, BIOBEHAV REV, V1, P113, DOI 10.1016/0147-7552(77)90017-1; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Hogan B., 2014, MANIPULATING MOUSE E; Huang Y Y, 1994, Learn Mem, V1, P74; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; James W., 1890, PRINCIPLES PSYCHOL; KLEE CB, 1988, ADV ENZYMOL RAMB, V61, P149; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; Knight RT, 1996, NATURE, V383, P256, DOI 10.1038/383256a0; LEE KAW, 1993, BIOCHIM BIOPHYS ACTA, V1174, P221, DOI 10.1016/0167-4781(93)90191-F; MANDEL RJ, 1989, BEHAV BRAIN RES, V31, P221, DOI 10.1016/0166-4328(89)90004-1; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MCGAUGH JL, 1968, MULTITRACE VIEW MEMO; MISHKIN M, 1978, NATURE, V273, P297, DOI 10.1038/273297a0; MUMBY DG, 1995, PSYCHOBIOLOGY, V23, P26; MYHRER T, 1988, BEHAV NEUROSCI, V102, P356, DOI 10.1037/0735-7044.102.3.356; MYHRER T, 1988, PHYSIOL BEHAV, V42, P371, DOI 10.1016/0031-9384(88)90279-X; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; OVERMAN WH, 1990, EXP BRAIN RES, V79, P18; PHILLIPS RR, 1988, BEHAV BRAIN RES, V27, P99, DOI 10.1016/0166-4328(88)90035-6; REED JM, 1997, BEHAV NEUROSCI, V111, P1; ROSENZWEIG MR, 1993, BEHAV BRAIN RES, V57, P193, DOI 10.1016/0166-4328(93)90135-D; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; Squire L.R., 1987, MEMORY BRAIN; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; TULLY T, 1994, CELL, V79, P35, DOI 10.1016/0092-8674(94)90398-0; Tulving E, 1996, CEREB CORTEX, V6, P71, DOI 10.1093/cercor/6.1.71; WEISKRANTZ L, 1970, LONG TERM VIEW SHORT; WICKELGREN WA, 1973, PSYCHOL BULL, V80, P425, DOI 10.1037/h0035255; ZHAO WQ, 1995, BRAIN RES BULL, V36, P557, DOI 10.1016/0361-9230(94)00244-U; ZHAO WQ, 1995, NEUROBIOL LEARN MEM, V64, P106, DOI 10.1006/nlme.1995.1049; ZOLAMORGAN S, 1985, BEHAV NEUROSCI, V99, P22, DOI 10.1037/0735-7044.99.1.22	52	291	305	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					39	49		10.1016/S0092-8674(00)80897-1	http://dx.doi.org/10.1016/S0092-8674(00)80897-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489698	hybrid			2022-12-01	WOS:000071473700006
J	Winder, DG; Mansuy, IM; Osman, M; Moallem, TM; Kandel, ER				Winder, DG; Mansuy, IM; Osman, M; Moallem, TM; Kandel, ER			Genetic and pharmacological evidence for a novel, intermediate phase of long-term potentiation suppressed by calcineurin	CELL			English	Article							HIPPOCAMPAL CA1 REGION; PROTEIN-KINASE; RAT-BRAIN; PHOSPHATASE INHIBITOR-1; NMDA RECEPTORS; LTP; EXPRESSION; CAMP; MEMORY; BETA	To investigate the role of phosphatases in synaptic plasticity using genetic approaches, we generated transgenic mice that overexpress a truncated form of calcineurin under the control of the CaMKII alpha promoter. Mice expressing this transgene show increased calcium-dependent phosphatase activity in the hippocampus. Physiological studies of these mice and parallel pharmacological experiments in wild-type mice reveal a novel, intermediate phase of LTP (I-LTP) in the CA1 region of the hippocampus. This intermediate phase differs from E-LTP by requiring multiple trains for induction and in being dependent on PKA. It differs from L-LTP in not requiring new protein synthesis. These data suggest that calcineurin acts as an inhibitory constraint on I-LTP that is relieved by PKA. This inhibitory constraint acts as a gate to regulate the synaptic induction of L-LTP.	Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; New York State Psychiatry Institute	Kandel, ER (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Howard Hughes Med Inst, Ctr Neurobiol & Behav, New York, NY 10032 USA.		Winder, Danny G./H-4857-2013; Mansuy, Isabelle M/N-3042-2015	Mansuy, Isabelle M/0000-0001-7785-5371				ABEL T, 1997, CELL, V88, P1; BARTSCH D, 1995, CELL, V83, P979, DOI 10.1016/0092-8674(95)90213-9; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Blitzer RD, 1995, NEURON, V15, P1403, DOI 10.1016/0896-6273(95)90018-7; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FIGUROV A, 1993, EUR J NEUROSCI, V5, P1035, DOI 10.1111/j.1460-9568.1993.tb00956.x; FREY U, 1993, SCIENCE, V260, P1661, DOI 10.1126/science.8389057; GUSTAFSON EL, 1991, J COMP NEUROL, V310, P170, DOI 10.1002/cne.903100204; Helekar SA, 1997, P NATL ACAD SCI USA, V94, P5432, DOI 10.1073/pnas.94.10.5432; Hogan B., 2014, MANIPULATING MOUSE E; Huang YY, 1996, LEARN MEMORY, V3, P74, DOI 10.1101/lm.3.2-3.74; HUBBARD MJ, 1991, MOL NEUROBIOL, P135; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLEE CB, 1983, METHOD ENZYMOL, V102, P227; KUNO T, 1992, J NEUROCHEM, V58, P1643, DOI 10.1111/j.1471-4159.1992.tb10036.x; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; Lu YF, 1996, BRAIN RES, V729, P142, DOI 10.1016/0006-8993(96)00568-9; Martin KC, 1997, NEURON, V18, P899, DOI 10.1016/S0896-6273(00)80330-X; Mayford M, 1997, CURR BIOL, V7, pR580, DOI 10.1016/S0960-9822(06)00287-9; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Osten P, 1996, J NEUROSCI, V16, P2444; PARSONS JN, 1994, J BIOL CHEM, V269, P19610; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; Raman IM, 1996, NEURON, V16, P415, DOI 10.1016/S0896-6273(00)80059-8; Roberson ED, 1996, LEARN MEMORY, V3, P1, DOI 10.1101/lm.3.1.1; SAKAGAMI H, 1994, MOL BRAIN RES, V25, P7, DOI 10.1016/0169-328X(94)90273-9; SCHWANINGER M, 1995, J BIOL CHEM, V270, P8860, DOI 10.1074/jbc.270.15.8860; STANTON PK, 1984, J NEUROSCI, V4, P3080; Thomas MJ, 1996, NEURON, V17, P475, DOI 10.1016/S0896-6273(00)80179-8; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Traynelis SF, 1997, J PHYSIOL-LONDON, V503, P513, DOI 10.1111/j.1469-7793.1997.513bg.x; Wang JH, 1996, LEARN MEMORY, V3, P170, DOI 10.1101/lm.3.2-3.170; WANG JH, 1994, NEUROREPORT, V5, P2377, DOI 10.1097/00001756-199411000-00041; Wang JH, 1997, J NEUROSCI, V17, P4600; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	43	284	295	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					25	37		10.1016/S0092-8674(00)80896-X	http://dx.doi.org/10.1016/S0092-8674(00)80896-X			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489697	hybrid			2022-12-01	WOS:000071473700005
J	Hakim, AA; Petrovitch, H; Burchfiel, CM; Ross, GW; Rodriguez, BL; White, LR; Yano, K; Curb, JD; Abbott, RD				Hakim, AA; Petrovitch, H; Burchfiel, CM; Ross, GW; Rodriguez, BL; White, LR; Yano, K; Curb, JD; Abbott, RD			Effects of walking on mortality among nonsmoking retired men	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MIDDLE-AGED MEN; PHYSICAL-ACTIVITY; JAPANESE MEN; PROGRAM; RISK; DIETARY; STROKE; HAWAII; WEIGHT	Background The potential benefit of low-intensity activity in terms of longevity among older men has not been clearly documented. We examined the association between walking and mortality in a cohort of retired men who were nonsmokers and physically capable of participating in low-intensity activities on a daily basis. Methods We studied 707 nonsmoking retired men, 61 to 81 years of age, who were enrolled in the Honolulu Heart Program. The distance walked (miles per day) was recorded at a base-line examination, which took place between 1980 and 1982. Data on overall mortality (from any cause) were collected over a 12-year period of follow-up. Results During the follow-up period, there were 208 deaths. After adjustment for age, the mortality rate among the men who walked less than 1 mile (1.6 km) per day was nearly twice that among those who walked more than 2 miles (3.2 km) per day (40.5 percent vs. 23.8 percent, P=0.001). The cumulative incidence of death after 12 years for the most active walkers was reached in less than 7 years among the men who were least active. The distance walked remained inversely related to mortality after adjustment for overall measures of activity and other risk factors (P = 0.01). Conclusions Our findings in older physically capable men indicate that regular walking is associated with a lower overall mortality rate, Encouraging elderly people to walk may benefit their health. (C) 1998, Massachusetts Medical Society.	Univ Virginia, Sch Med, Div Biostat, Charlottesville, VA 22908 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA; Univ Hawaii, John A Burns Sch Med, Dept Med, Honolulu, HI 96822 USA; Kuakini Med Ctr, Honolulu Heart Program, Honolulu, HI 96817 USA; NHLBI, Honolulu Epidemiol Res Sect, Epidemiol & Biometry Program, Honolulu, HI USA; Dept Vet Affairs, Honolulu, HI USA; NIA, Honolulu, HI USA	University of Virginia; University of Minnesota System; University of Minnesota Twin Cities; University of Hawaii System; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Abbott, RD (corresponding author), Univ Virginia, Sch Med, Div Biostat, Box 600, Charlottesville, VA 22908 USA.				NCRR NIH HHS [P20 RR/AI 11091] Funding Source: Medline; NHLBI NIH HHS [N01-HC-05102] Funding Source: Medline; DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC005102] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR011091] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ABBOTT RD, 1994, AM J EPIDEMIOL, V139, P881, DOI 10.1093/oxfordjournals.aje.a117094; CASTELLI WP, 1977, J CHRON DIS, V30, P147, DOI 10.1016/0021-9681(77)90082-0; COX DR, 1972, J R STAT SOC B, V34, P187; DONAHUE RP, 1988, AM J PUBLIC HEALTH, V78, P683, DOI 10.2105/AJPH.78.6.683; GARCIAPALMIERI MR, 1982, AM J CARDIOL, V50, P749, DOI 10.1016/0002-9149(82)91229-2; GARRISON RJ, 1983, JAMA-J AM MED ASSOC, V249, P2199, DOI 10.1001/jama.249.16.2199; HARRIS T, 1988, JAMA-J AM MED ASSOC, V259, P1520; Heilbrun L K, 1985, Hawaii Med J, V44, P294; KAGAN A, 1974, J CHRON DIS, V27, P345, DOI 10.1016/0021-9681(74)90014-9; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P818; LANE PW, 1982, BIOMETRICS, V38, P613, DOI 10.2307/2530043; LEE IM, 1993, JAMA-J AM MED ASSOC, V270, P2823, DOI 10.1001/jama.270.23.2823; LINDSTED KD, 1991, J CLIN EPIDEMIOL, V44, P355, DOI 10.1016/0895-4356(91)90074-J; PAFFENBARGER RS, 1993, NEW ENGL J MED, V328, P538, DOI 10.1056/NEJM199302253280804; SHERMAN SE, 1994, AM HEART J, V128, P965, DOI 10.1016/0002-8703(94)90596-7; SIMONSICK EM, 1993, AM J PUBLIC HEALTH, V83, P1443, DOI 10.2105/AJPH.83.10.1443; YANO K, 1984, AM J EPIDEMIOL, V119, P653, DOI 10.1093/oxfordjournals.aje.a113787; YANO K, 1986, ARTERIOSCLEROSIS, V6, P422, DOI 10.1161/01.ATV.6.4.422	21	381	387	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 8	1998	338	2					94	99		10.1056/NEJM199801083380204	http://dx.doi.org/10.1056/NEJM199801083380204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	YQ039	9420340				2022-12-01	WOS:000071341300004
J	Albert, CM; Hennekens, CH; O'Donnell, CJ; Ajani, UA; Carey, VJ; Willett, WC; Ruskin, JN; Manson, JE				Albert, CM; Hennekens, CH; O'Donnell, CJ; Ajani, UA; Carey, VJ; Willett, WC; Ruskin, JN; Manson, JE			Fish consumption and risk of sudden cardiac death	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; POLYUNSATURATED FATTY-ACIDS; VENTRICULAR-FIBRILLATION; MYOCARDIAL-INFARCTION; MORTALITY; OMEGA-3-FATTY-ACIDS; REPRODUCIBILITY; POPULATION; PHYSICIANS	Context.-Dietary fish intake has been associated with a reduced risk of fatal cardiac end points, but not with nonfatal end points. Dietary fish intake may have a selective benefit on fatal arrhythmias and therefore sudden cardiac death. Objective.-To investigate prospectively the association between fish consumption and the risk of sudden cardiac death. Design.-Prospective cohort study. Setting.-The US Physicians' Health Study. Patients.-A total of 20 551 US male physicians 40 to 84 years of age and free of myocardial infarction, cerebrovascular disease, and cancer at baseline who completed an abbreviated, semiquantitative food frequency questionnaire on fish consumption and were then followed up to 11 years. Main Outcome Measure.-Incidence of sudden cardiac death (death within 1 hour of symptom onset) as ascertained by hospital records and reports of next of kin. Results.-There were 133 sudden deaths over the course of the study. After controlling for age, randomized aspirin and beta carotene assignment, and coronary risk factors, dietary fish intake was associated with a reduced risk of sudden death, with an apparent threshold effect at a consumption level of 1 fish meal per week (P for trend=.03). For men who consumed fish at least once per week, the multivariate relative risk of sudden death was 0.48 (95% confidence interval, 0.24-0.96; P=.04) compared with men who consumed fish less than monthly. Estimated dietary n-3 fatty acid intake from seafood also was associated with a reduced risk of sudden death but without a significant trend across increasing categories of intake. Neither dietary fish consumption nor n-3 fatty acid intake was associated with a reduced risk of total myocardial infarction, nonsudden cardiac death, or total cardiovascular mortality. However, fish consumption was associated with a significantly reduced risk of total mortality. Conclusion.-These prospective data suggest that consumption of fish at least once per week may reduce the risk of sudden cardiac death in men.	Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02215 USA; Massachusetts Gen Hosp, Dept Med, Cardiac Unit, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; NHLBI, Framingham Heart Study, Framingham, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Framingham Heart Study; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Albert, CM (corresponding author), Brigham & Womens Hosp, Dept Med, Div Prevent Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.			Albert, Christine/0000-0002-2081-1121	NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40360, CA-34944] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM HEART ASS, 1995, HEART STROK FACTS S; [Anonymous], 1988, NEW ENGL J MED, V318, P262; ASCHERIO A, 1995, NEW ENGL J MED, V332, P977, DOI 10.1056/NEJM199504133321501; BILLMAN GE, 1994, P NATL ACAD SCI USA, V91, P4427, DOI 10.1073/pnas.91.10.4427; Broughton KS, 1997, AM J CLIN NUTR, V65, P1011, DOI 10.1093/ajcn/65.4.1011; BURR ML, 1989, LANCET, V2, P757; Christensen JH, 1997, AM J CARDIOL, V79, P1670, DOI 10.1016/S0002-9149(97)00220-8; COX DR, 1972, J R STAT SOC B, V34, P187; CURB JD, 1985, NEW ENGL J MED, V313, P821; Daviglus ML, 1997, NEW ENGL J MED, V336, P1046, DOI 10.1056/NEJM199704103361502; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DOBSON AJ, 1983, AM J EPIDEMIOL, V117, P397, DOI 10.1093/oxfordjournals.aje.a113558; DOLECEK TA, 1992, P SOC EXP BIOL MED, V200, P177, DOI 10.3181/00379727-200-43413; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; GOLDSTEIN S, 1984, J AM COLL CARDIOL, V3, P1111, DOI 10.1016/S0735-1097(84)80167-9; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; GUALLAR E, 1995, J AM COLL CARDIOL, V25, P387, DOI 10.1016/0735-1097(94)00370-6; Hartikainen JEK, 1996, J AM COLL CARDIOL, V28, P296, DOI 10.1016/0735-1097(96)00169-6; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; HEPBURN FN, 1986, J AM DIET ASSOC, V86, P788; HINKLE LE, 1982, CIRCULATION, V65, P457, DOI 10.1161/01.CIR.65.3.457; HUNTER DJ, 1992, AM J EPIDEMIOL, V135, P418, DOI 10.1093/oxfordjournals.aje.a116302; Kang JX, 1996, CIRCULATION, V94, P1774, DOI 10.1161/01.CIR.94.7.1774; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KROMHOUT D, 1995, INT J EPIDEMIOL, V24, P340, DOI 10.1093/ije/24.2.340; KROMHOUT D, 1985, NEW ENGL J MED, V312, P1205, DOI 10.1056/NEJM198505093121901; KULLER L, 1967, MEDICINE, V46, P341, DOI 10.1097/00005792-196707000-00003; MCLENNAN PL, 1992, AM HEART J, V123, P1555, DOI 10.1016/0002-8703(92)90809-A; MISHINA T, 1985, PROSTATE, V6, P423, DOI 10.1002/pros.2990060411; MORRIS MC, 1995, AM J EPIDEMIOL, V142, P166, DOI 10.1093/oxfordjournals.aje.a117615; NORELL SE, 1986, BRIT MED J, V293, P426, DOI 10.1136/bmj.293.6544.426; SHEKELLE RB, 1985, NEW ENGL J MED, V313, P820; SIMOPOULOS AP, 1991, AM J CLIN NUTR, V54, P438, DOI 10.1093/ajcn/54.3.438; SISCOVICK DS, 1995, JAMA-J AM MED ASSOC, V274, P1363, DOI 10.1001/jama.274.17.1363; *USDA, 1963, AGR HDB SER, V8; VALENZUELA TD, 1992, JAMA-J AM MED ASSOC, V267, P272, DOI 10.1001/jama.267.2.272; VOLLSET SE, 1985, NEW ENGL J MED, V313, P820; *WHO, 1971, ISCH HEART DIS REG R; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	41	694	717	0	40	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					23	28		10.1001/jama.279.1.23	http://dx.doi.org/10.1001/jama.279.1.23			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424039				2022-12-01	WOS:000071295100030
J	Hawton, K				Hawton, K			Integration of treatments for male erectile dysfunction	LANCET			English	Editorial Material							THERAPY		Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England	University of Oxford	Hawton, K (corresponding author), Univ Oxford, Warneford Hosp, Dept Psychiat, Oxford OX3 7JX, England.							ALTHOF SE, 1989, J SEX MARITAL THER, V15, P121; BANCROFT J, 1989, HUMAN SEXUALITY ITS; Boolell M, 1996, BRIT J UROL, V78, P257, DOI 10.1046/j.1464-410X.1996.10220.x; HAWTON K, 1995, BRIT J PSYCHIAT, V167, P307, DOI 10.1192/bjp.167.3.307; Jeremy JY, 1997, BRIT J UROL, V79, P958, DOI 10.1046/j.1464-410X.1997.00206.x; PADMANATHAN H, 1997, NEW ENGL J MED, V336, P309; SPECKENS AEM, 1995, ARCH SEX BEHAV, V24, P157, DOI 10.1007/BF01541579; Stravynski A, 1997, BRIT J PSYCHIAT, V170, P338, DOI 10.1192/bjp.170.4.338	8	19	19	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 3	1998	351	9095					7	8		10.1016/S0140-6736(05)78097-1	http://dx.doi.org/10.1016/S0140-6736(05)78097-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP205	9433420				2022-12-01	WOS:000071253100006
J	Shaw, LM; Rabinovitz, I; Wang, HHF; Toker, A; Mercurio, AM				Shaw, LM; Rabinovitz, I; Wang, HHF; Toker, A; Mercurio, AM			Activation of phosphoinositide 3-OH kinase by the alpha 6 beta 4 integrin promotes carcinoma invasion	CELL			English	Article							PROTEIN-KINASE; ACTIN POLYMERIZATION; CELL-ADHESION; E-CADHERIN; S6 KINASE; RAC; EXPRESSION; CDC42; HEMIDESMOSOMES; RHO	We demonstrate that the alpha 6 beta 4 integrin promotes carcinoma invasion through a preferential and localized targeting of phosphoinositide-3 OH kinase (PI3K) activity. Stable expression of alpha 6 beta 4 increased carcinoma invasion in a PI3K-dependent manner, and transient expression of a constitutively active PI3K increased invasion in the absence of alpha 6 beta 4. Ligation of alpha 6 beta 4 stimulated significantly more PI3K activity than ligation of beta 1 integrins, establishing specificity among integrins for PI3K activation. alpha 6 beta 4-regutated PI3K activity was required for the formation of lamellae, dynamic sites of motility, in carcinoma cells. The small G protein Rac is required downstream of PI3K for invasion. These studies define a mechanism by which the alpha 6 beta 4 integrin promotes carcinoma invasion and invoke a novel function for PI3K signaling.	Beth Israel Deaconess Med Ctr, Dept Med, GI Div, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Boston Biomed Res Inst, Boston, MA 02114 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Boston Biomedical Research Institute	Shaw, LM (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, GI Div, Boston, MA 02215 USA.				NATIONAL CANCER INSTITUTE [P01CA044704] Funding Source: NIH RePORTER; NCI NIH HHS [CA44704] Funding Source: Medline; PHS HHS [A139264] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBINI A, 1987, CANCER RES, V47, P3239; BIRCHMEIER W, 1995, CIBA F SYMP, V189, P124; Borradori L, 1996, CURR OPIN CELL BIOL, V8, P647, DOI 10.1016/S0955-0674(96)80106-2; CANTLEY LC, 1994, J CELL SCI S, V18, P121; CAO C, 1996, CANCER RES, V56, P4811; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Derman MP, 1997, J BIOL CHEM, V272, P6465, DOI 10.1074/jbc.272.10.6465; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FALCIONI R, 1986, CANCER RES, V46, P5772; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Green KJ, 1996, FASEB J, V10, P871, DOI 10.1096/fasebj.10.8.8666164; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Harden N, 1996, MOL CELL BIOL, V16, P1896; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HEMLER ME, 1989, J BIOL CHEM, V264, P6529; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Joneson T, 1996, SCIENCE, V274, P1374, DOI 10.1126/science.274.5291.1374; Juliano RL, 1993, CURR OPIN CELL BIOL, V5, P812, DOI 10.1016/0955-0674(93)90030-T; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; KENNEL SJ, 1989, J BIOL CHEM, V264, P15515; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LOTZ MM, 1990, CELL REGUL, V1, P249, DOI 10.1091/mbc.1.3.249; Lu PJ, 1996, BIOCHEMISTRY-US, V35, P14027, DOI 10.1021/bi961878z; Mainiero F, 1997, EMBO J, V16, P2365, DOI 10.1093/emboj/16.9.2365; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P4385, DOI 10.1002/j.1460-2075.1995.tb00113.x; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; Rabinovitz I, 1996, BIOCHEM CELL BIOL, V74, P811, DOI 10.1139/o96-087; RABINOVITZ I, 1997, IN PRESS J CELL BIOL; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; SEFTOR REB, 1992, P NATL ACAD SCI USA, V89, P1557, DOI 10.1073/pnas.89.5.1557; Serini G, 1996, J NATL CANCER I, V88, P442, DOI 10.1093/jnci/88.7.442; Shaw LM, 1996, CANCER RES, V56, P959; Sheetz Michael P., 1994, Seminars in Cell Biology, V5, P149, DOI 10.1006/scel.1994.1019; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Tani T, 1996, AM J PATHOL, V149, P781; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VANWAES C, 1991, CANCER RES, V51, P2395; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324	62	531	542	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					949	960		10.1016/S0092-8674(00)80486-9	http://dx.doi.org/10.1016/S0092-8674(00)80486-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428518	Bronze			2022-12-01	WOS:000071281400012
J	Wu, Y; Kuzma, J; Marechal, E; Graeff, R; Lee, HC; Foster, R; Chua, NH				Wu, Y; Kuzma, J; Marechal, E; Graeff, R; Lee, HC; Foster, R; Chua, NH			Abscisic acid signaling through cyclic ADP-Ribose in plants	SCIENCE			English	Article							SEA-URCHIN EGGS; ARABIDOPSIS-THALIANA; CA2+ RELEASE; INOSITOL TRISPHOSPHATE; TRANSDUCTION PATHWAYS; PROTEIN PHOSPHATASE; TRANSGENIC PLANTS; CYTOSOLIC CA-2+; GUARD-CELLS; EXPRESSION	Abscisic acid (ABA) is the primary hormone that mediates plant responses to stresses such as cold, drought, and salinity. Single-cell microinjection experiments in tomato were used to identify possible intermediates involved in ABA signal transduction. Cyclic ADP-ribose (cADPR) was identified as a signaling molecule in the ABA response and Mras shown to exert its effects by way of calcium. Bioassay experiment is showed that the amounts of cADPR in Arabidopsis thaliana plants increased in response to ABA treatment and before ASA-induced gene expression.	ROCKEFELLER UNIV, PLANT MOL BIOL LAB, NEW YORK, NY 10021 USA; UNIV MINNESOTA, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	Rockefeller University; University of Minnesota System; University of Minnesota Twin Cities			Graeff, Richard Milton/B-3425-2011; Lee, Hon Cheung/C-4329-2009	Kuzma, Jennifer/0000-0003-4456-9613	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017484] Funding Source: NIH RePORTER; NICHD NIH HHS [HD17484] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALLEN GJ, 1995, SCIENCE, V268, P735, DOI 10.1126/science.7732384; [Anonymous], UNPUB; Barnes SA, 1996, PLANT CELL, V8, P601, DOI 10.1105/tpc.8.4.601; BENFEY PN, 1989, EMBO J, V8, P2195, DOI 10.1002/j.1460-2075.1989.tb08342.x; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOWLER C, 1994, GENE DEV, V8, P2188, DOI 10.1101/gad.8.18.2188; BOWLER C, 1994, CELL, V77, P73, DOI 10.1016/0092-8674(94)90236-4; BOWLER C, 1994, CELL, V79, P743; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; CHANDLER PM, 1994, ANNU REV PLANT PHYS, V45, P113, DOI 10.1146/annurev.pp.45.060194.000553; CHANG YC, 1991, PLANT PHYSIOL, V97, P1260, DOI 10.1104/pp.97.3.1260; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; deBruxelles GL, 1996, PLANT PHYSIOL, V111, P381, DOI 10.1104/pp.111.2.381; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GIRAUDAT J, 1994, PLANT MOL BIOL, V26, P1557, DOI 10.1007/BF00016490; Hey SJ, 1997, PLANTA, V202, P85, DOI 10.1007/s004250050106; HIRAYAMA T, 1995, P NATL ACAD SCI USA, V92, P3903, DOI 10.1073/pnas.92.9.3903; Ingram J, 1996, ANNU REV PLANT PHYS, V47, P377, DOI 10.1146/annurev.arplant.47.1.377; JEFFERSON RA, 1987, EMBO J, V6, P3901; KEARNS EV, 1993, PLANT PHYSIOL, V102, P711, DOI 10.1104/pp.102.3.711; KIM H, 1993, SCIENCE, V261, P1330, DOI 10.1126/science.8395705; Knetsch MLW, 1996, PLANT CELL, V8, P1061, DOI 10.1105/tpc.8.6.1061; Kuo AL, 1996, PLANT CELL, V8, P259, DOI 10.1105/tpc.8.2.259; KURKELA S, 1992, PLANT MOL BIOL, V19, P689, DOI 10.1007/BF00026794; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, BIOCHIM BIOPHYS ACTA, V1164, P68, DOI 10.1016/0167-4838(93)90113-6; Lee HC, 1996, BIOL SIGNAL, V5, P101; LEE HC, 1991, J BIOL CHEM, V266, P2276; LEE HC, 1995, RYANODINE RECEPTORS, P31; Lee YS, 1996, PLANT PHYSIOL, V110, P987, DOI 10.1104/pp.110.3.987; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; Merlot S, 1997, PLANT PHYSIOL, V114, P751, DOI 10.1104/pp.114.3.751; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; MILLAR AJ, 1992, PLANT CELL, V4, P1075, DOI 10.1105/tpc.4.9.1075; Muir SR, 1996, FEBS LETT, V395, P39, DOI 10.1016/0014-5793(96)01000-9; NEUHAUS G, 1993, CELL, V73, P937, DOI 10.1016/0092-8674(93)90272-R; NEUHAUS G, 1994, CELL, V79, P743; PARCY F, 1994, PLANT CELL, V6, P1567, DOI 10.1105/tpc.6.11.1567; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Prasad GS, 1996, NAT STRUCT BIOL, V3, P957, DOI 10.1038/nsb1196-957; SCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9535, DOI 10.1073/pnas.92.21.9535; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; Sheen J, 1996, SCIENCE, V274, P1900, DOI 10.1126/science.274.5294.1900; Terry MJ, 1996, J BIOL CHEM, V271, P21681, DOI 10.1074/jbc.271.35.21681; THOMASHOW MF, 1994, ARABIDOPSIS, P807, DOI DOI 10.1101/0.807-834; VASIL V, 1995, PLANT CELL, V7, P1511, DOI 10.1105/tpc.7.9.1511; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y; WALSETH TF, 1991, BIOCHIM BIOPHYS ACTA, V1094, P113, DOI 10.1016/0167-4889(91)90032-S; Wu Y, 1996, PLANT J, V10, P1149, DOI 10.1046/j.1365-313X.1996.10061149.x; YAMAGUCHISHINOZAKI K, 1993, MOL GEN GENET, V236, P331, DOI 10.1007/BF00277130	56	307	345	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2126	2130		10.1126/science.278.5346.2126	http://dx.doi.org/10.1126/science.278.5346.2126			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405349				2022-12-01	WOS:A1997YM23500054
J	Chen, WB; Kelly, MA; OpitzAraya, X; Thomas, RE; Low, MJ; Cone, RD				Chen, WB; Kelly, MA; OpitzAraya, X; Thomas, RE; Low, MJ; Cone, RD			Exocrine gland dysfunction in MC5-R-deficient mice: Evidence for coordinated regulation of exocrine gland function by melanocortin peptides	CELL			English	Article							MELANOCYTE-STIMULATING HORMONE; RAT LACRIMAL GLAND; MOLECULAR-CLONING; HARDERIAN-GLAND; ALPHA-MSH; MALE-MOUSE; RECEPTOR; EXPRESSION; SECRETION; SYSTEM	The effects of pituitary-derived melanocortin peptides are primarily attributed to ACTH-mediated adrenocortical glucocorticoid production. Identification of a widely distributed receptor for ACTH/MSH peptides, the melanocortin-5 receptor (MC5-R), suggested non-steroidally mediated systemic effects of these peptides. Targeted disruption of the MC5-R produced mice with a severe defect in water repulsion and thermoregulation due to decreased production of sebaceous lipids. High levels of MC5-R was found in multiple exocrine tissues, including Harderian, preputial, lacrimal, and sebaceous glands, and was also shown to be required for production and stress-regulated synthesis of porphyrins by the Harderian gland and ACTH/MSH-regulated protein secretion by the lacrimal gland. These data show a requirement for the MC5-R in multiple exocrine glands for the production of numerous products, indicative of a coordinated system for regulation of exocrine gland function by melanocortin peptides.	OREGON HLTH SCI UNIV, VOLLUM INST, PORTLAND, OR 97201 USA	Oregon Health & Science University			Chen, Wenbiao/ABG-1276-2020	Chen, Wenbiao/0000-0002-0750-8275; Kelly, Michele/0000-0003-1799-055X; Low, Malcolm/0000-0002-9900-3708	NIAMS NIH HHS [AR42415] Funding Source: Medline; NICHD NIH HHS [HD30236] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD030236] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042415] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABEL EL, 1994, HORM BEHAV, V28, P139, DOI 10.1006/hbeh.1994.1011; ABEL EL, 1992, PSYCHONEUROENDOCRINO, V17, P255, DOI 10.1016/0306-4530(92)90065-F; BARRETT P, 1994, J MOL ENDOCRINOL, V12, P203, DOI 10.1677/jme.0.0120203; BIJLSMA WA, 1983, EUR J PHARMACOL, V92, P231, DOI 10.1016/0014-2999(83)90291-1; BOTELHO SY, 1973, AM J PHYSIOL, V224, P1119, DOI 10.1152/ajplegacy.1973.224.5.1119; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRONSON FH, 1971, J REPROD FERTIL, V25, P279; BUCKLEY DI, 1981, P NATL ACAD SCI-BIOL, V78, P7431, DOI 10.1073/pnas.78.12.7431; CARR WJ, 1970, J COMP PHYSIOL PSYCH, V71, P223, DOI 10.1037/h0029164; CATANIA A, 1993, ENDOCR REV, V14, P564, DOI 10.1210/er.14.5.564; CHEN WB, 1995, ANAL BIOCHEM, V226, P349, DOI 10.1006/abio.1995.1235; CHHAJLANI V, 1993, BIOCHEM BIOPH RES CO, V195, P866, DOI 10.1006/bbrc.1993.2125; CHHAJLANI V, 1992, FEBS LETT, V309, P417, DOI 10.1016/0014-5793(92)80820-7; COSSU G, 1989, DEV BIOL, V131, P331, DOI 10.1016/S0012-1606(89)80006-5; DARTT DA, 1994, ADV EXP MED BIOL, V350, P1; EBLING FJ, 1969, J ENDOCRINOL, V45, P257, DOI 10.1677/joe.0.0450257; EBLING FJ, 1974, J INVEST DERMATOL, V62, P161, DOI 10.1111/1523-1747.ep12676781; EBLING FJ, 1975, J ENDOCRINOL, V66, P407, DOI 10.1677/joe.0.0660407; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; FENG JD, 1987, BRAIN RES BULL, V18, P473, DOI 10.1016/0361-9230(87)90111-0; GANTZ I, 1993, J BIOL CHEM, V268, P15174; GANTZ I, 1994, BIOCHEM BIOPH RES CO, V200, P1214, DOI 10.1006/bbrc.1994.1580; GANTZ I, 1993, J BIOL CHEM, V268, P8246; GOOLAMALI SK, 1974, J INVEST DERMATOL, V63, P253, DOI 10.1111/1523-1747.ep12680076; GRIFFON N, 1994, BIOCHEM BIOPH RES CO, V200, P1007, DOI 10.1006/bbrc.1994.1550; GRUBER KA, 1989, AM J PHYSIOL, V257, pR681, DOI 10.1152/ajpregu.1989.257.4.R681; HARLOW HJ, 1984, PHYSIOL ZOOL, V57, P349, DOI 10.1086/physzool.57.3.30163724; Huang QH, 1997, J NEUROSCI, V17, P3343; JAHN R, 1982, EUR J BIOCHEM, V126, P623, DOI 10.1111/j.1432-1033.1982.tb06826.x; LABBE O, 1994, BIOCHEMISTRY-US, V33, P4543, DOI 10.1021/bi00181a015; LEEMAN SE, 1967, ENDOCRINOLOGY, V81, P803, DOI 10.1210/endo-81-4-803; LEIBA H, 1990, EUR J PHARMACOL, V181, P71, DOI 10.1016/0014-2999(90)90246-3; Li SJ, 1996, J NEUROSCI, V16, P5182; MACALUSO A, 1994, J NEUROSCI, V14, P2377; MARGOLIS FL, 1971, ARCH BIOCHEM BIOPHYS, V145, P373, DOI 10.1016/0003-9861(71)90050-6; Mogil Jefrey S., 1996, Physiology and Behavior, V59, P123, DOI 10.1016/0031-9384(95)02073-X; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; NOWELL NW, 1980, PHYSIOL BEHAV, V24, P5, DOI 10.1016/0031-9384(80)90006-2; ORSULAK PJ, 1972, BIOL REPROD, V6, P219, DOI 10.1093/biolreprod/6.2.219; PAWELEK JM, 1976, J INVEST DERMATOL, V66, P201, DOI 10.1111/1523-1747.ep12482134; PAYNE AP, 1994, J ANAT, V185, P1; ROSELLIREHFUSS L, 1993, P NATL ACAD SCI USA, V90, P8856, DOI 10.1073/pnas.90.19.8856; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SCHAUER E, 1994, J CLIN INVEST, V93, P2258, DOI 10.1172/JCI117224; SIEGRIST W, 1989, CANCER RES, V49, P6352; SMOCK T, 1981, BRAIN RES, V212, P202, DOI 10.1016/0006-8993(81)90052-4; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Spike R.C., 1992, HARDERIAN GLANDS POR, P165; STEWART ME, 1991, ADV LIPID RES, V24, P263; Strand F L, 1993, Rev Neurosci, V4, P321; TATRO JB, 1987, ENDOCRINOLOGY, V121, P1900, DOI 10.1210/endo-121-5-1900; TATRO JB, 1990, BRAIN RES, V536, P124, DOI 10.1016/0006-8993(90)90016-5; THIESSEN DD, 1980, PHYSIOL BEHAV, V24, P417, DOI 10.1016/0031-9384(80)90229-2; THODY AJ, 1983, PHYSIOL BEHAV, V31, P67, DOI 10.1016/0031-9384(83)90097-5; THODY AJ, 1973, NATURE, V245, P207, DOI 10.1038/245207a0; THODY AJ, 1976, J ENDOCRINOL, V71, P279, DOI 10.1677/joe.0.0710279; VALENTA JG, 1968, SCIENCE, V161, P599, DOI 10.1126/science.161.3841.599; WATSON SJ, 1979, EUR J PHARMACOL, V58, P101, DOI 10.1016/0014-2999(79)90351-0; WETTERBERG L, 1970, SCIENCE, V168, P996, DOI 10.1126/science.168.3934.996; YU JH, 1983, P SOC EXP BIOL MED, V173, P467	61	396	425	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 12	1997	91	6					789	798		10.1016/S0092-8674(00)80467-5	http://dx.doi.org/10.1016/S0092-8674(00)80467-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YL439	9413988	Bronze			2022-12-01	WOS:A1997YL43900010
J	Knowlton, JR; Johnston, SC; Whitby, FG; Realini, C; Zhang, ZG; Rechsteiner, M; Hill, CP				Knowlton, JR; Johnston, SC; Whitby, FG; Realini, C; Zhang, ZG; Rechsteiner, M; Hill, CP			Structure of the proteasome activator REG alpha (PA28 alpha)	NATURE			English	Article							PROTEIN-DEGRADATION; 20S PROTEASOME; MULTICATALYTIC PROTEASE; 20-S PROTEASOME; REGULATOR PA28; PURIFICATION	The specificity of the 20S proteasome, which degrades many intracellular proteins, is regulated by protein complexes that bind to one or both ends of the cylindrical proteasome structure(1-5). One of these regulatory complexes, the 11S regulator (known as REG or PA28), stimulates proteasome peptidase activity(6,7) and enhances the production of antigenic peptides for presentation by class I molecules of the major histocompatibility complex (MHC)(8,9). The three REG subunits that have been identified REG alpha, REG beta and REG gamma (also known as the Ki antigen).	UNIV UTAH, DEPT BIOCHEM, SALT LAKE CITY, UT 84132 USA	Utah System of Higher Education; University of Utah								AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1996, XPLOR VERSION 3 843; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dick TP, 1996, CELL, V86, P253, DOI 10.1016/S0092-8674(00)80097-5; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; Groettrup M, 1996, NATURE, V381, P166, DOI 10.1038/381166a0; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hoffman L, 1996, CURR TOP CELL REGUL, V34, P1, DOI 10.1016/S0070-2137(96)80001-X; JENTSCH S, 1995, CELL, V82, P881, DOI 10.1016/0092-8674(95)90021-7; Johnston SC, 1997, PROTEIN SCI, V6, P2469; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; MA CP, 1993, J BIOL CHEM, V268, P22514; MA CP, 1992, J BIOL CHEM, V267, P10515; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; Realini C, 1997, J BIOL CHEM, V272, P25483, DOI 10.1074/jbc.272.41.25483; REALINI C, 1994, J BIOL CHEM, V269, P20727; Song XL, 1996, J BIOL CHEM, V271, P26410, DOI 10.1074/jbc.271.42.26410; USTRELL V, 1995, FEBS LETT, V376, P155, DOI 10.1016/0014-5793(95)01257-9; WENZEL T, 1995, NAT STRUCT BIOL, V2, P199, DOI 10.1038/nsb0395-199	30	147	150	3	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					639	643		10.1038/37670	http://dx.doi.org/10.1038/37670			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403698				2022-12-01	WOS:A1997YK85300058
J	Conte, D; Manachino, D; Colli, A; Guala, A; Aimo, G; Andreoletti, M; Corsetti, M; Fraquelli, M				Conte, D; Manachino, D; Colli, A; Guala, A; Aimo, G; Andreoletti, M; Corsetti, M; Fraquelli, M			Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus	ANNALS OF INTERNAL MEDICINE			English	Article							LONG-TERM SURVIVAL; HEREDITARY HEMOCHROMATOSIS; EXPRESSION	Background: Few data exist on the prevalence of genetic hemochromatosis among diabetic patients. Objective: To compare the prevalence of genetic hemochromatosis in diabetic patients and a matched control group and to evaluate the accuracy of iron-related indexes in detecting hemochromatosis. Design: Cross-sectional study. Setting: Diabetes clinics of four hospitals in northern Italy. Patients: 894 diabetic patients (117 with type 1 diabetes and 777 with type 2 diabetes) and 467 matched controls. Measurements: Transferrin saturation and serum ferritin levels were measured in all study participants. After secondary iron overload was excluded as the cause of persistently elevated transferrin saturation and serum ferritin levels, liver biopsy was performed and siderosis was estimated semiquantitatively and quantitatively. A hepatic iron index greater than 1.9 was considered diagnostic for hemochromatosis. Results: Hemochromatosis was diagnosed in 12 patients with type Z diabetes (prevalence, 1.34% [95% CI, 0.7% to 2.3%]) and 1 control (prevalence, 0.2% [CI, 0.1% to 1.4%]; P = 0.032). The odds ratio of hemochromatosis in association with diabetes was 6.3 (CI, 1.1 to 37.7). Measurement of transferrin saturation was the most sensitive test for hemochromatosis. Conclusions: Genetic hemochromatosis is frequently not diagnosed in patients with diabetes, although it is a hallmark of the disease. Screening for hemochromatosis could be beneficial for patients with diabetes.	Univ Milan, Osped Maggiore, IRCCS, Ist Sci Med,Cattedra Gastroenterol, I-20122 Milan, Italy	IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan	Conte, D (corresponding author), Univ Milan, Osped Maggiore, IRCCS, Ist Sci Med,Cattedra Gastroenterol, Padiglione Granelli 3 Piano,Via F Sforza 35, I-20122 Milan, Italy.			Corsetti, Maura/0000-0003-2957-4684				ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; BARRY M, 1971, LANCET, V1, P100; BASSETT ML, 1984, GASTROENTEROLOGY, V87, P628; BASSETT ML, 1986, HEPATOLOGY, V6, P24, DOI 10.1002/hep.1840060106; Carella M, 1997, AM J HUM GENET, V60, P828; DADONE MM, 1982, AM J CLIN PATHOL, V78, P196, DOI 10.1093/ajcp/78.2.196; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; LEGGETT BA, 1990, BRIT J HAEMATOL, V74, P525, DOI 10.1111/j.1365-2141.1990.tb06345.x; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; OBRIEN T, 1990, DIABETES CARE, V13, P532, DOI 10.2337/diacare.13.5.532; PHELPS G, 1989, LANCET, V2, P233; Piperno A, 1996, HEPATOLOGY, V24, P43, DOI 10.1002/hep.510240109; SCHEUER PJ, 1962, J PATHOL BACTERIOL, V84, P53, DOI 10.1002/path.1700840107; SIMON M, 1988, J HEPATOL, V6, P116, DOI 10.1016/S0168-8278(88)80471-9; SINGH BM, 1992, DIABETIC MED, V9, P730, DOI 10.1111/j.1464-5491.1992.tb01881.x; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105	19	64	65	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					370	373		10.7326/0003-4819-128-5-199803010-00005	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490597				2022-12-01	WOS:000072155600005
J	Alberts, AS; Geneste, O; Treisman, R				Alberts, AS; Geneste, O; Treisman, R			Activation of SRF-regulated chromosomal templates by Rho-family GTPases requires a signal that also induces H4 hyperacetylation	CELL			English	Article							CORE HISTONE HYPERACETYLATION; PROTEIN-SYNTHESIS INHIBITORS; SERUM RESPONSE ELEMENT; TUMOR VIRUS PROMOTER; C-FOS PROMOTER; TERNARY COMPLEX; TRANSCRIPTIONAL ACTIVATION; NUCLEOSOME STRUCTURE; CHROMATIN STRUCTURE; GENE-EXPRESSION	Constitutively active forms of the small GTPases RhoA (RhoA.V14) and Cdc42 (Cdc42.V12) induce expression of extrachromosomal SRF reporter genes in microinjection experiments, but only Cdc42.V12 can efficiently activate a chromosomal template. Both SAPK/JNK-dependent or -independent signals can cooperate with RhoA.V14 to activate chromosomal SRF reporters, and it is SAPK/JNK activation by Cdc42.V12 that allows it to activate chromosomal templates. Cooperating signals can be bypassed by deacetylase inhibitors. Three findings show that histone H4 hyperacetylation is one target for cooperating signals, although it alone is not sufficient: (1) Cdc42.V12, but not RhoA.V14, induces H4 hyperacetylation; (2) cooperating signals use the same SAPK/JNK-dependent or -independent pathways to induce H4 hyperacetylation; (3) growth factor and stress stimuli induce substantial H4 hyperacetylation, detectable in reporter gene chromatin. These data establish a link between signal-regulated acetylation events and gene transcription.	Imperial Canc Res Fund, Transcript Lab, London WC2A 3PX, England	Cancer Research UK	Treisman, R (corresponding author), Imperial Canc Res Fund, Transcript Lab, 44 Lincolns Inn Fields, London WC2A 3PX, England.			Treisman, Richard/0000-0002-9658-0067				ALBERTS AS, 1993, DNA CELL BIOL, V12, P935, DOI 10.1089/dna.1993.12.935; ALBERTS AS, 1994, MOL CELL BIOL, V14, P4398, DOI 10.1128/MCB.14.7.4398; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; ARCHER TK, 1992, SCIENCE, V255, P1573, DOI 10.1126/science.1347958; ARCHER TK, 1992, SCIENCE, V256, P161; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARRATT MJ, 1994, P NATL ACAD SCI USA, V91, P4781, DOI 10.1073/pnas.91.11.4781; BARRATT MJ, 1994, EMBO J, V13, P4524, DOI 10.1002/j.1460-2075.1994.tb06774.x; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; BRESNICK EH, 1990, P NATL ACAD SCI USA, V87, P3977, DOI 10.1073/pnas.87.10.3977; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHEN TA, 1990, J MOL BIOL, V212, P481, DOI 10.1016/0022-2836(90)90327-I; CHEN TA, 1987, P NATL ACAD SCI USA, V84, P5252, DOI 10.1073/pnas.84.15.5252; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HEBBES TR, 1989, MOL IMMUNOL, V26, P865, DOI 10.1016/0161-5890(89)90143-0; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; INNIS JW, 1983, MOL CELL BIOL, V3, P2203, DOI 10.1128/MCB.3.12.2203; Janknecht R, 1996, ONCOGENE, V12, P1961; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; JEONG S, 1994, J BIOL CHEM, V269, P2197; JEONG SW, 1994, NUCLEIC ACIDS RES, V22, P370, DOI 10.1093/nar/22.3.370; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; MAHADEVAN LC, 1991, CELL, V65, P775, DOI 10.1016/0092-8674(91)90385-C; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MEISTRICH ML, 1992, MOL REPROD DEV, V31, P170, DOI 10.1002/mrd.1080310303; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; NICOLAS RH, 1990, GEL ELECTROPHORESIS, P249; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; ONEILL LP, 1995, EMBO J, V14, P3946, DOI 10.1002/j.1460-2075.1995.tb00066.x; PALMER RH, 1994, FEBS LETT, V356, P5, DOI 10.1016/0014-5793(94)01202-4; Pazin MJ, 1997, CELL, V89, P325, DOI 10.1016/S0092-8674(00)80211-1; PENNIE WD, 1995, MOL CELL BIOL, V15, P2125; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13605, DOI 10.1021/bi00212a028; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; SCHLAKE T, 1994, BIOCHEMISTRY-US, V33, P4197, DOI 10.1021/bi00180a012; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; STACEY DW, 1987, MOL CELL BIOL, V7, P523, DOI 10.1128/MCB.7.1.523; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VanLint C, 1996, EMBO J, V15, P1112, DOI 10.1002/j.1460-2075.1996.tb00449.x; YAN MH, 1994, NATURE, V372, P798; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	57	193	197	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					475	487		10.1016/S0092-8674(00)80941-1	http://dx.doi.org/10.1016/S0092-8674(00)80941-1			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491889	Bronze			2022-12-01	WOS:000072251500008
J	Linzer, M				Linzer, M			Leaders or lemmings?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		MCMURRAY JE, 1993, ANN INTERN MED, V119, P812, DOI 10.7326/0003-4819-119-8-199310150-00007; SCHAEF AW, 1988, ADDICTIVE ORG, P79; TIERNEY W, 1996, SGIM FORUM, V10, P3; TIERNEY W, 1996, SGIM FORUM, V10, P12	4	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					341	341		10.1001/jama.279.5.341	http://dx.doi.org/10.1001/jama.279.5.341			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459452				2022-12-01	WOS:000071731300001
J	White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB				White, S; Szewczyk, JW; Turner, JM; Baird, EE; Dervan, PB			Recognition of the four Watson-Crick base pairs in the DNA minor groove by synthetic ligands	NATURE			English	Article							SEQUENCE-SPECIFIC RECOGNITION; DOUBLE-HELICAL DNA; HAIRPIN POLYAMIDE; BINDING; COMPLEX; MOTIF; OLIGONUCLEOTIDES; TRANSCRIPTION; DISTAMYCIN; IMIDAZOLE	The design of synthetic ligands that read the information stored in the DNA double helix has been along-standing gal at the interface of chemistry and biology(1-5). Cell-permeable small molecules that target predetermined DNA. sequences offer a potential approach for the regulation of gene expression(6). Oligodeoxy-nucleotides that recognize the major groove of double-helical DNA via triple-helix formation bind to a broad range of sequences with high affinity and specificity(3,4), Although oligonucleotides and their analogues have been shown to interfere with gene expression(7,8), the triple-helix approach is limited to recognition of purines and suffers from poor cellular uptake. The subsequent development of pairing rules for minor-groove binding polyamides containing pyrrole (Py) and imidazole (Im) amino acids offers a second code to control sequence specificity(9-11). An Im/Py pair distinguishes G.C from C.G and both of these from A.T/T.A base pairs(9-11). A Py/Py pair specifies A.T from G.C but does not distinguish A.T from T.A(9-14). To break this degeneracy, we have added a new aromatic amino acid, 3-hydroxypyrrole (Hp), to the repertoire to test for pairings that discriminate A.T from T.A. We find that replacement of a single hydrogen atom with a hydroxy group in a Hp/Py pairing regulates affinity and specificity by an order of magnitude. By incorporation of this third amino acid, hydroxy pyrrole-imidazole-pyrrole polyamides form four ring-pairings (Im/Py, Py/Im Hp/Py and Py/Hp) which distinguish all four Watson-Crick base pairs in the minor groove of DNA.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; CALTECH, Beckman Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology	Dervan, PB (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.							ADES SE, 1995, BIOCHEMISTRY-US, V34, P14601, DOI 10.1021/bi00044a040; Baird EE, 1996, J AM CHEM SOC, V118, P6141, DOI 10.1021/ja960720z; BRENOWITZ M, 1986, METHOD ENZYMOL, V130, P132; Choo Y, 1997, CURR OPIN STRUC BIOL, V7, P117, DOI 10.1016/S0959-440X(97)80015-2; DERVAN PB, 1986, SCIENCE, V232, P464, DOI 10.1126/science.2421408; DUVALVALENTIN G, 1992, P NATL ACAD SCI USA, V89, P504, DOI 10.1073/pnas.89.2.504; GARTENBERG MR, 1988, NATURE, V333, P824, DOI 10.1038/333824a0; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Kelly JJ, 1996, P NATL ACAD SCI USA, V93, P6981, DOI 10.1073/pnas.93.14.6981; KIELKOPF CL, IN PRESS NATURE STRU; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; MAHER LJ, 1992, BIOCHEMISTRY-US, V31, P70, DOI 10.1021/bi00116a012; MOSER HE, 1987, SCIENCE, V238, P645, DOI 10.1126/science.3118463; MRKSICH M, 1995, J AM CHEM SOC, V117, P3325, DOI 10.1021/ja00117a002; MRKSICH M, 1992, P NATL ACAD SCI USA, V89, P7586, DOI 10.1073/pnas.89.16.7586; Nielsen PE, 1997, CHEM-EUR J, V3, P505, DOI 10.1002/chem.19970030404; PELTON JG, 1989, P NATL ACAD SCI USA, V86, P5723, DOI 10.1073/pnas.86.15.5723; Pilch DS, 1996, P NATL ACAD SCI USA, V93, P8306, DOI 10.1073/pnas.93.16.8306; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; STEITZ TA, 1990, Q REV BIOPHYS, V23, P203; Swalley SE, 1997, J AM CHEM SOC, V119, P6953, DOI 10.1021/ja971184t; Swalley SE, 1996, J AM CHEM SOC, V118, P8198, DOI 10.1021/ja9611598; THUONG NT, 1993, ANGEW CHEM INT EDIT, V32, P666, DOI 10.1002/anie.199306661; Trauger JW, 1996, NATURE, V382, P559, DOI 10.1038/382559a0; WADE WS, 1992, J AM CHEM SOC, V114, P8783, DOI 10.1021/ja00049a006; White S, 1997, CHEM BIOL, V4, P569, DOI 10.1016/S1074-5521(97)90243-X; WHITE S, 1996, BIOCHEMISTRY-US, V35, P6147; WONG JM, 1994, NUCLEIC ACIDS RES, V22, P1890, DOI 10.1093/nar/22.10.1890; ZIMMER C, 1986, PROG BIOPHYS MOL BIO, V47, P31, DOI 10.1016/0079-6107(86)90005-2	30	487	517	1	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 29	1998	391	6666					468	471		10.1038/35106	http://dx.doi.org/10.1038/35106			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YU290	9461213				2022-12-01	WOS:000071701800044
J	Neven, P; Vergote, I				Neven, P; Vergote, I			Should tamoxifen users be screened for endometrial lesions?	LANCET			English	Editorial Material							BREAST-CANCER PATIENTS		Algemene Klin St Jan, Dept Obstet & Gynaecol, Brussels, Belgium; UZ Gasthuisberg, Dept Gynaecol Oncol, B-3000 Louvain, Belgium	Universite Libre de Bruxelles; Vrije Universiteit Brussel; KU Leuven; University Hospital Leuven	Neven, P (corresponding author), Algemene Klin St Jan, Dept Obstet & Gynaecol, Brussels, Belgium.							ANDERSSON M, 1992, ACTA ONCOL, V31, P259, DOI 10.3109/02841869209088912; Carmichael PL, 1996, CANCER RES, V56, P1475; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FORNANDER T, 1989, LANCET, V1, P117; Hemminki K, 1996, CANCER RES, V56, P4374; *INT AG RES CANC, 1996, IARC MON EV CARC RIS, V66; KAUFMANN M, 1995, BREAST, V4, P245; Langer RD, 1997, NEW ENGL J MED, V337, P1792, DOI 10.1056/NEJM199712183372502; Neven P, 1998, LANCET, V351, P36, DOI 10.1016/S0140-6736(05)78091-0; Peto R, 1996, J NATL CANCER I, V88, P1791, DOI 10.1093/jnci/88.24.1791; TIMMERMAN D, IN PRESS AM J OBSTET	12	41	41	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					155	157		10.1016/S0140-6736(05)78216-7	http://dx.doi.org/10.1016/S0140-6736(05)78216-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449866				2022-12-01	WOS:000071616300005
J	Huang, ZP; Willett, WC; Manson, JE; Rosner, B; Stampfer, MJ; Speizer, FE; Colditz, GA				Huang, ZP; Willett, WC; Manson, JE; Rosner, B; Stampfer, MJ; Speizer, FE; Colditz, GA			Body weight, weight change, and risk for hypertension in women	ANNALS OF INTERNAL MEDICINE			English	Article						body; weight; weight gain; hypertension; body index	HIGH BLOOD-PRESSURE; UNITED-STATES; NUTRITIONAL FACTORS; MILD HYPERTENSION; OBESITY; REDUCTION; INTERVENTION; OVERWEIGHT; DISEASE; PROGRAM	Background: Obesity increases the risk for hypertension, but the effects of modest long-term weight changes have not been precisely quantified. Objective: To investigate body mass index (BMI) and weight change in relation to risk for hypertension. Design: Cohort study. Setting: General community. Participants: Cohort of 82 473 U.S. female nurses 30 to 55 years of age followed every 2 years since 1976. The follow-up rate was 95%. Measurements: Primary risk factors examined were 1) BMI at age 18 years and midlife and 2) long-term and medium-term weight changes. The outcome was incident cases of hypertension. Results: By 1992, 16 395 incident cases of hypertension had been diagnosed. After adjustment for multiple covariates, BMI at 18 years of age and midlife were positively associated with occurrence of hypertension (P for trend < 0.001). Long-term weight loss after 18 years of age was related to a significantly lower risk for hypertension, and weight gain dramatically increased the risk for hypertension (compared with weight change less than or equal to 2 kg, multivariate relative risks were 0.85 for a loss of 5.0 to 9.9 kg, 0.74 for a loss greater than or equal to 10 kg, 1.74 for a gain of 5.0 to 9.9 kg, and 5.21 for a gain greater than or equal to 25.0 kg). Among women in the top tertile of baseline BMI at age 18 years, weight loss had a greater apparent benefit. The association between weight change and risk for hypertension was stronger in younger (<45 years of age) than older women (greater than or equal to 55 years of age). Medium-term weight changes after 1976 showed similar relations to risk for hypertension. Conclusions: Excess weight and even modest adult weight gain substantially increase risk for hypertension. Weight loss reduces the risk for hypertension.	Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Prevent Med, Boston, MA 02215 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huang, ZP (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40356] Funding Source: Medline; NIDDK NIH HHS [DK 46200] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA040356, R01CA040356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK046200] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Cassano Patricia A., 1990, Annals of Epidemiology, V1, P33; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; COX DR, 1972, J R STAT SOC B, V34, P187; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; DAVIS BR, 1993, ARCH INTERN MED, V153, P1773, DOI 10.1001/archinte.153.15.1773; EPSTEIN FH, 1965, AM J EPIDEMIOL, V81, P307, DOI 10.1093/oxfordjournals.aje.a120517; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; HAVLIK RJ, 1983, ANN INTERN MED, V98, P855, DOI 10.7326/0003-4819-98-5-855; Hebert Patricia R., 1995, Annals of Epidemiology, V5, P130, DOI 10.1016/1047-2797(94)00057-Z; HIGGINS MW, 1980, HYPERTENSION, V2, pI117, DOI 10.1161/01.HYP.2.4_Pt_2.I117; HSUEH WA, 1994, ENDOCRIN METAB CLIN, V23, P405, DOI 10.1016/S0889-8529(18)30105-1; HYPERTENSION DETECTION FOLLOW-UP, 1977, AM J EPIDEMIOL, V106, P351; Ikeda T, 1996, HYPERTENSION, V27, P1180, DOI 10.1161/01.HYP.27.5.1180; KANNEL WB, 1967, ANN INTERN MED, V67, P48, DOI 10.7326/0003-4819-67-1-48; KULLER LH, 1980, HYPERTENSION, V2, pI109, DOI 10.1161/01.HYP.2.4_Pt_2.I109; MACMAHON S, 1987, EUR HEART J, V8, P57, DOI 10.1093/eurheartj/8.suppl_B.57; MAKELA M, 1978, J CHRON DIS, V31, P587, DOI 10.1016/0021-9681(78)90019-X; MICOZZI MS, 1990, AM J PHYS ANTHROPOL, V81, P375, DOI 10.1002/ajpa.1330810307; REED D, 1982, HYPERTENSION, V4, P406, DOI 10.1161/01.HYP.4.3.406; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P35; SEVER PS, 1980, LANCET, V2, P60; STAMLER R, 1978, JAMA-J AM MED ASSOC, V240, P1607, DOI 10.1001/jama.240.15.1607; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; STEVENS VJ, 1993, ARCH INTERN MED, V153, P849, DOI 10.1001/archinte.153.7.849; TROY LM, 1995, INT J OBESITY, V19, P570; TUCK ML, 1981, NEW ENGL J MED, V304, P930, DOI 10.1056/NEJM198104163041602; *USDA, 1995, DIET GUID AM, P15; VANITALLIE TB, 1985, ANN INTERN MED, V103, P983, DOI 10.7326/0003-4819-103-6-983; WASSERTHEILSMOLLER S, 1992, ARCH INTERN MED, V152, P131, DOI 10.1001/archinte.152.1.131; WEINSTEIN MC, 1976, HYPERTENSION POLICY; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; Willett W., 2013, NUTR EPIDEMIOLOGY, V3rd; WITTEMAN JCM, 1989, CIRCULATION, V80, P1320, DOI 10.1161/01.CIR.80.5.1320; YONG LC, 1993, AM J EPIDEMIOL, V138, P973, DOI 10.1093/oxfordjournals.aje.a116817	39	455	470	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1998	128	2					81	+		10.7326/0003-4819-128-2-199801150-00001	http://dx.doi.org/10.7326/0003-4819-128-2-199801150-00001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR200	9441586				2022-12-01	WOS:000071470800001
J	Sinclair, DA; Guarente, L				Sinclair, DA; Guarente, L			Extrachromosomal rDNA circles - A cause of aging in yeast	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CAENORHABDITIS-ELEGANS; PODOSPORA-ANSERINA; MITOCHONDRIAL-DNA; SYNDROME GENE; LONGEVITY; TRANSCRIPTION; REPLICATION; SENESCENCE	Although many cellular and organismal changes have been described in aging individuals, a precise, molecular cause of aging has yet to be found. A prior study of aging yeast mother cells showed a progressive enlargement and fragmentation of the nucleolus. Here we show that these nucleolar changes are likely due to the accumulation of extrachromosomal rDNA circles (ERCs) in old cells and that, in fact, ERCs cause aging. Mutants for sgs1, the yeast homolog of the Werner's syndrome gene, accumulate ERCs more rapidly, leading to premature aging and a shorter life span. We speculate on the generality of this molecular cause of aging in higher species, including mammals.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sinclair, David/0000-0002-9936-436X	NATIONAL INSTITUTE ON AGING [R37AG011119, R01AG011119] Funding Source: NIH RePORTER; NIA NIH HHS [AG11119] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ausubel F. M., 1994, CURRENT PROTOCOLS MO; BREWER BJ, 1988, CELL, V55, P637, DOI 10.1016/0092-8674(88)90222-X; BRILL SJ, 1988, CELL, V54, P403, DOI 10.1016/0092-8674(88)90203-6; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; CHEN JB, 1990, MOL MICROBIOL, V4, P2081, DOI 10.1111/j.1365-2958.1990.tb00568.x; Childress AM, 1996, MICROBIOL-UK, V142, P2289, DOI 10.1099/13500872-142-8-2289; CLARKWALKER GD, 1980, NUCLEIC ACIDS RES, V8, P1009; CUMMINGS DJ, 1985, J MOL BIOL, V185, P659, DOI 10.1016/0022-2836(85)90052-X; DAMMANN R, 1993, NUCLEIC ACIDS RES, V21, P2331, DOI 10.1093/nar/21.10.2331; DMELLO NP, 1994, J BIOL CHEM, V269, P15451; DORMAN JB, 1995, GENETICS, V141, P1399; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EMILGEZ NK, 1989, J BACTERIOL, V171, P37; Ewbank JJ, 1997, SCIENCE, V275, P980, DOI 10.1126/science.275.5302.980; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GORDON CN, 1977, J CELL SCI, V24, P81; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Guarente L, 1997, GENE DEV, V11, P2449, DOI 10.1101/gad.11.19.2449; Guarente L, 1996, CELL, V86, P9, DOI 10.1016/S0092-8674(00)80072-0; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; HOLM C, 1982, CELL, V29, P585, DOI 10.1016/0092-8674(82)90174-X; HOROWITZ H, 1985, MOL CELL BIOL, V5, P2369, DOI 10.1128/MCB.5.9.2369; JAMETVIERNY C, 1980, CELL, V21, P189, DOI 10.1016/0092-8674(80)90126-9; Jazwinski SM, 1996, SCIENCE, V273, P54, DOI 10.1126/science.273.5271.54; Kennedy BK, 1997, CELL, V89, P381, DOI 10.1016/S0092-8674(00)80219-6; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; KIM RA, 1989, CELL, V57, P975, DOI 10.1016/0092-8674(89)90336-X; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; Kimura KD, 1997, SCIENCE, V277, P942, DOI 10.1126/science.277.5328.942; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; LARIONOV V, 1984, GENE, V28, P229, DOI 10.1016/0378-1119(84)90260-9; LARIONOV VL, 1980, GENE, V12, P41, DOI 10.1016/0378-1119(80)90014-1; LARSEN PL, 1995, GENETICS, V139, P1567; LISKENS M, 1988, MOL CELL BIOL, V8, P4927; Lu JA, 1996, NATURE, V383, P678, DOI 10.1038/383678a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARTIN GM, 1985, ADV EXP MED BIOL, V190, P161; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; MULLER I, 1985, A VAN LEEUW J MICROB, V51, P1, DOI 10.1007/BF00444223; MURRAY AW, 1983, CELL, V34, P961, DOI 10.1016/0092-8674(83)90553-6; Nierras CR, 1997, CHROMOSOMA, V105, P444; POHLEY HJ, 1987, MECH AGEING DEV, V38, P231, DOI 10.1016/0047-6374(87)90092-3; PRUSS GJ, 1985, J MOL BIOL, V185, P51, DOI 10.1016/0022-2836(85)90182-2; RINE J, 1987, GENETICS, V116, P9; ROBINOW CF, 1966, J CELL BIOL, V29, P129, DOI 10.1083/jcb.29.1.129; SALK D, 1981, CYTOGENET CELL GENET, V30, P108, DOI 10.1159/000131597; Shaw PJ, 1995, ANNU REV CELL DEV BI, V11, P93, DOI 10.1146/annurev.cellbio.11.1.93; SHERMAN F, 1979, METHODS YEAST GENETI; SHURE M, 1977, NUCLEIC ACIDS RES, V4, P1183, DOI 10.1093/nar/4.5.1183; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smeal T, 1996, CELL, V84, P633, DOI 10.1016/S0092-8674(00)81038-7; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Stewart E, 1997, EMBO J, V16, P2682, DOI 10.1093/emboj/16.10.2682; STREHLER BL, 1986, EXP GERONTOL, V21, P283, DOI 10.1016/0531-5565(86)90038-0; SWEENEY R, 1989, GENETICS, V122, P749; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TTSUKAMOTO Y, 1997, NATURE, V388, P900; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Warner JR, 1990, CURR OPIN CELL BIOL, V2, P521, DOI 10.1016/0955-0674(90)90137-4; Watt PM, 1996, GENETICS, V144, P935; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WRIGHT RM, 1982, CELL, V29, P505, DOI 10.1016/0092-8674(82)90167-2; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	69	1111	1140	4	61	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1033	1042		10.1016/S0092-8674(00)80493-6	http://dx.doi.org/10.1016/S0092-8674(00)80493-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428525	Bronze			2022-12-01	WOS:000071281400019
J	Cooke, F; Morse, R				Cooke, F; Morse, R			Do you know your chocolates? Recognition survey among medical staff of various grades	BRITISH MEDICAL JOURNAL			English	Article									Univ Wales Hosp, Dept Integrat Med, Cardiff CF4 4XW, S Glam, Wales; Royal Brompton Hosp, London SW3 6NP, England	Cardiff University; Royal Brompton Hospital	Morse, R (corresponding author), Univ Wales Hosp, Dept Integrat Med, Heath Pk, Cardiff CF4 4XW, S Glam, Wales.							SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P305	1	0	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1655	1656		10.1136/bmj.315.7123.1655	http://dx.doi.org/10.1136/bmj.315.7123.1655			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448530	Green Published			2022-12-01	WOS:000071149400013
J	Sawyer, LA; Hennessy, JM; Peixoto, AA; Rosato, E; Parkinson, H; Costa, R; Kyriacou, CP				Sawyer, LA; Hennessy, JM; Peixoto, AA; Rosato, E; Parkinson, H; Costa, R; Kyriacou, CP			Natural variation in a Drosophila clock gene and temperature compensation	SCIENCE			English	Article							PERIOD GENE; REPETITIVE REGION; MELANOGASTER; POLYMORPHISM; EVOLUTION; BEHAVIOR; SIMULANS; REPEAT	The threonine-glycine (Thr-Gly) encoding repeat within the clock gene period of Drosophila melanogaster is polymorphic in length. The two major variants (Thr-Gly)17 and (Thr-Gly)20 are distributed as a highly significant latitudinal dine in Europe and North Africa. Thr-Gly length variation from both wild-caught and transgenic individuals is related to the flies' ability to maintain a circadian period at different temperatures. This phenomenon provides a selective explanation for the geographical distribution of Thr-Gly lengths and gives a rare glimpse of the interplay between molecular polymorphism, behavior, population biology, and natural selection.	UNIV LEICESTER,DEPT GENET,LEICESTER LE1 7RH,LEICS,ENGLAND; UNIV PADUA,DIPARTIMENTO BIOL,I-35121 PADUA,ITALY	University of Leicester; University of Padua				Rosato, Ezio/0000-0001-7297-4697; Parkinson, Helen/0000-0003-3035-4195				AQUADRO CF, 1992, TRENDS GENET, V8, P355, DOI 10.1016/0168-9525(92)90281-8; CASTIGLIONEMORELLI MA, 1995, P ROY SOC B-BIOL SCI, V260, P155, DOI 10.1098/rspb.1995.0073; CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; COSTA R, 1991, J MOL EVOL, V32, P238, DOI 10.1007/BF02342746; COSTA R, 1992, P ROY SOC B-BIOL SCI, V250, P43, DOI 10.1098/rspb.1992.0128; DOWSE HB, 1989, J THEOR BIOL, V139, P487, DOI 10.1016/S0022-5193(89)80067-0; Hulme M, 1995, INT J CLIMATOL, V15, P1333, DOI 10.1002/joc.3370151204; KIMURA M, 1962, GENETICS, V47, P713; KLIMAN RM, 1993, GENETICS, V133, P375; KONOPKA RJ, 1997, J NEUROGENET, V11, P117; Kyriacou CP, 1996, SEMIN CELL DEV BIOL, V7, P803, DOI 10.1006/scdb.1996.0098; MINIS DH, 1972, P NATL ACAD SCI USA, V69, P1537; NIELSEN J, 1994, MOL BIOL EVOL, V11, P839; PEIXOTO AA, 1993, MOL BIOL EVOL, V10, P127; PEIXOTO AA, UNPUB; Pittendrigh C, 1993, ANNU REV PHYSIOL, V55, P17; PITTENDRIGH CS, 1954, P NATL ACAD SCI USA, V40, P1018, DOI 10.1073/pnas.40.10.1018; Rosato E, 1997, GENET RES, V69, P89, DOI 10.1017/S001667239700267X; Rosato E, 1996, J MOL EVOL, V42, P392, DOI 10.1007/BF02498633; ROSATO E, 1994, GENETICS, V138, P693; ROSATO E, IN PRESS BIOESSAYS; SAWYER L, UNPUB; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WHEELER DA, 1991, SCIENCE, V251, P1082, DOI 10.1126/science.1900131; YON J, 1989, NUCLEIC ACIDS RES, V17, P4895, DOI 10.1093/nar/17.12.4895; YU Q, 1987, NATURE, V326, P765, DOI 10.1038/326765a0	27	251	254	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2117	2120		10.1126/science.278.5346.2117	http://dx.doi.org/10.1126/science.278.5346.2117			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405346				2022-12-01	WOS:A1997YM23500051
J	Spinozzi, F; Fizzotti, M; Agea, E; Piattoni, S; Droetto, S; Russano, A; Forenza, N; Bassotti, G; Grignani, F; Bertotto, A				Spinozzi, F; Fizzotti, M; Agea, E; Piattoni, S; Droetto, S; Russano, A; Forenza, N; Bassotti, G; Grignani, F; Bertotto, A			Defective expression of Fas messenger RNA and Fas receptor on pulmonary T cells from patients with asthma	ANNALS OF INTERNAL MEDICINE			English	Article						T-lymphocytes; asthma; I gene expression; DNA fragmentation; I receptors, Fas	BRONCHOALVEOLAR LAVAGE; INDUCED APOPTOSIS; ATOPIC ASTHMA; LYMPHOCYTES; DEATH; ACTIVATION; ENGAGEMENT; EXPANSION; ETIOLOGY; DISEASE	Background: Inflammation at sites of target organs seems to be the pathologic hallmark of respiratory allergic diseases, but why this response cannot be turned off in atopic persons is not known. Programmed cell death (apoptosis) mediated by Fas/APO-1 (CD95), a 45-kD surface protein belonging to the tumor necrosis factor receptor family, is important in the resolution of all inflammatory immune responses. Objective: To test whether the expression of Fas receptor is defective in allergen-specific pulmonary T lymphocytes from persons with asthma. Design: 12-month prospective study. Setting: University allergy and immunology clinic. Patients: 12 untreated persons with newly diagnosed allergic asthma who underwent bronchoalveolar lavage. Ten normal persons served as controls. Measurements: Fas receptor expression was studied by using surface double-color cytofluorometry on pulmonary and circulating T lymphocytes. Fas messenger RNA (mRNA) was searched for in bronchoalveolar lavage cells from patients and controls by reverse transcription polymerase chain reaction (PCR). In vitro induction of DNA fragmentation, as an expression of cell death induced by an IgM anti-fas monoclonal antibody, was assessed by propidium iodide staining and agarose gel electrophoresis. In vitro modulation of surface Fas receptor was studied on pulmonary T lymphocytes stimulated with anti-CD3 monoclonal antibody and interleukin-2 or interleukin-4. Results: Pulmonary T lymphocytes from patients as opposed to controls did not undergo DNA fragmentation after in vitro exposure to IgM anti-Fas. Other activation markers (CD25, HLA-DR, and CD45R0) were displayed, but surface Fas expression was always negative. A remarkable proportion of T cells from controls showed a clear double-staining pattern. Reverse transcription PCR for Fas mRNA yielded the same results. Circulating T lymphocytes from patients and controls included similar percentages of CD3(+) Fast cells. Pulmonary T cells from both patients and controls showed upregulation of Fas receptor expression after in vitro anti-CD3 stimulation; co-culturing with interleukin-4 downmodulated surface Fas receptor expression on T cells from patients; it was less effective in controls. Conclusions: Hypoexpression of Fas mRNA and surface Fas receptor on pulmonary CD3(+) T lymphocytes may explain the persistence of inflammatory cellular infiltrates in allergic bronchial asthma.	Univ Perugia, Sez Med Interna & Sci Oncol, Dipartimento Med Clin & Sperimentale, Monteluce Policlin, I-06122 Perugia, Italy; Univ Perugia, Monteluce Policlin, Ist Clin Pediat, I-06122 Perugia, Italy	University of Perugia; University of Perugia	Spinozzi, F (corresponding author), Univ Perugia, Sez Med Interna & Sci Oncol, Dipartimento Med Clin & Sperimentale, Monteluce Policlin, I-06122 Perugia, Italy.							Abbas AK, 1996, CELL, V84, P655, DOI 10.1016/S0092-8674(00)81042-9; BARNES PJ, 1995, MOL MED TODAY, V1, P149, DOI 10.1016/S1357-4310(95)80093-X; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Chauhan AJ, 1996, MOL MED TODAY, V2, P192, DOI 10.1016/1357-4310(96)88771-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; Critchfield Jeffrey M., 1995, P55; DELPRETE G, 1992, ALLERGY, V47, P450; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KALINER MA, 1996, CLIN IMMUNOLOGY, P909; Keegan AD, 1996, IMMUNOLOGIST, V4, P194; Lenardo M J, 1995, Int Rev Immunol, V13, P115, DOI 10.3109/08830189509061742; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MIGLIORATI G, 1993, BLOOD, V81, P1352; Milik AM, 1997, J CLIN INVEST, V99, P1082, DOI 10.1172/JCI119236; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; OWENSCHAUB LB, 1992, CELL IMMUNOL, V140, P197, DOI 10.1016/0008-8749(92)90187-T; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Rovere P, 1996, J IMMUNOL, V156, P4631; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749, DOI 10.1164/ajrccm.153.6.8665031; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Simon HU, 1996, J EXP MED, V183, P1071, DOI 10.1084/jem.183.3.1071; SPINOZZI F, 1992, ARCH INTERN MED, V152, P99, DOI 10.1001/archinte.152.1.99; SPINOZZI F, 1995, MOL MED, V1, P821, DOI 10.1007/BF03401896; SPINOZZI F, 1995, SCAND J IMMUNOL, V41, P504, DOI 10.1111/j.1365-3083.1995.tb03599.x; SPINOZZI F, 1993, GASTROENTEROLOGY, V105, P1490, DOI 10.1016/0016-5085(93)90156-7; Spinozzi F, 1996, ANN INTERN MED, V124, P223, DOI 10.7326/0003-4819-124-2-199601150-00005; Spinozzi F, 1998, IMMUNOL TODAY, V19, P22, DOI 10.1016/S0167-5699(97)01182-1; SPINOZZI F, 1995, IMMUNOLOGY, V86, P379; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62, DOI 10.1164/ajrccm/137.1.62	40	31	41	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					363	+		10.7326/0003-4819-128-5-199803010-00004	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490596				2022-12-01	WOS:000072155600004
J	Yu, HT; Peters, JM; King, RW; Page, AM; Hieter, P; Kirschner, MW				Yu, HT; Peters, JM; King, RW; Page, AM; Hieter, P; Kirschner, MW			Identification of a cullin homology region in a subunit of the anaphase-promoting complex	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; UBIQUITIN LIGASE; MITOTIC CYCLINS; CELL-CYCLE; PROTEOLYSIS; DESTRUCTION; TRANSITION; YEAST; DEGRADATION	The anaphase-promoting complex is composed of eight protein subunits, including BimE (APC1), CDC27 (APC3), CDC16 (APC6), and CDC23 (APC8). The remaining four human APC subunits, APC2, APC4, APC5, and APC7, as well as human CDC23, were cloned. APC7 contains multiple copies of the tetratrico peptide repeat, similar to CDC16, CDC23, and CDC27. Whereas APC4 and APC5 share no similarity to proteins of known function, APC2 contains a region that is similar to a sequence in cullins, a family of proteins implicated in the ubiquitination of G(1) phase cyclins and cyclin-dependent kinase inhibitors. The APC2 gene is essential in Saccharomyces cerevisiae, and apc2 mutants arrest at metaphase and are defective in the degradation of Pds1p. APC2 and cullins may be distantly related members of a ubiquitin ligase family that targets cell cycle regulators for degradation.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V6R 2X8, Canada	Harvard University; Harvard Medical School; University of British Columbia	Kirschner, MW (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, 240 Longwood Ave, Boston, MA 02115 USA.	marc@hms.harvard.edu		Yu, Hongtao/0000-0002-8861-049X	NCI NIH HHS [CA16519] Funding Source: Medline; NIGMS NIH HHS [GM39023-08, GM26875-17] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA016519] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039023, R01GM026875, R37GM026875] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aristarkhov A, 1996, P NATL ACAD SCI USA, V93, P4294, DOI 10.1073/pnas.93.9.4294; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; Juang YL, 1997, SCIENCE, V275, P1311, DOI 10.1126/science.275.5304.1311; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; King RW, 1996, MOL BIOL CELL, V7, P1343, DOI 10.1091/mbc.7.9.1343; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Mathias N, 1996, MOL CELL BIOL, V16, P6634; PAGE AR, UNPUB; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; Schneider BL, 1996, SCIENCE, V272, P560, DOI 10.1126/science.272.5261.560; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Yamamoto A, 1996, J CELL BIOL, V133, P85, DOI 10.1083/jcb.133.1.85; Yew PR, 1997, SCIENCE, V277, P1672, DOI 10.1126/science.277.5332.1672; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216	28	206	223	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 20	1998	279	5354					1219	1222		10.1126/science.279.5354.1219	http://dx.doi.org/10.1126/science.279.5354.1219			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469815				2022-12-01	WOS:000072115200047
J	Rosenstein, N; Levine, O; Taylor, JP; Evans, D; Plikaytis, BD; Wenger, JD; Perkins, BA				Rosenstein, N; Levine, O; Taylor, JP; Evans, D; Plikaytis, BD; Wenger, JD; Perkins, BA			Efficacy of meningococcal vaccine and barriers to vaccination	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	26th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 15-18, 1996	NEW ORLEANS, LA	Amer Soc Microbiol			MULTILOCUS ENZYME ELECTROPHORESIS; SEROGROUP-C; GROUP-A; DISEASE; CAMPAIGN; CARRIAGE; CANADA; CAMPUS	Context.-Use of the quadrivalent meningococcal vaccine for control of outbreaks has increased in recent years, but the efficacy of meningococcal vaccine during mass vaccination campaigns in US civilian populations has not been assessed. Objectives.-To evaluate the efficacy of the quadrivalent meningococcal vaccine against serogroup C meningococcal disease in a community outbreak setting and to evaluate potentially modifiable barriers to vaccination in an area with persistent meningococcal disease following immunization. Design.-Matched case-control study of vaccine efficacy using cases of serogroup C meningococcal disease in persons eligible for vaccination during mass vaccination campaigns. Control patients were matched by neighborhood and age. The control group was used to identify possible barriers to vaccination. Setting.-Gregg County, Texas, population 106 076, from 1993 to 1995. Participants.-A total of 17 case patients with serogroup C meningococcal disease eligible for vaccine and 84 control patients. Main Outcome Measures.-Vaccine efficacy and risk factors associated with nonvaccination. Results.-Vaccine efficacy among 2- to 29-year-olds was 85% (95% confidence interval, 27%-97%) and did not change in bivariate analyses with other risk factors that were significant in univariate analysis. Among control patients, older age was strongly associated with nonvaccination; vaccination rates for 2- to 4-year-olds, 5- to 18-year-olds, and 19- to 29-year-olds were 67%, 48%, and 20%, respectively (chi(2) for linear trend, P=.01). Conclusions.-The meningococcal polysaccharide vaccine was effective against serogroup C meningococcal disease in this community outbreak. Although specific barriers to vaccination were not identified, older age was a risk factor for nonvaccination in the target population of 2- to 29-year-olds. In future outbreaks, emphasis should be placed on achieving high vaccination coverage, with special efforts to vaccinate young adults.	Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Childhood & Resp Dis Branch, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Biostat & Informat Management Branch, Atlanta, GA 30333 USA; Texas Dept Hlth, Infect Dis Epidemiol & Surveillance Div, Austin, TX 78756 USA; Texas Dept Hlth, Infect Dis Epidemiol & Surveillance Div, Tyler, TX USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Texas Department of State Health Services; Texas Department of State Health Services	Rosenstein, N (corresponding author), Ctr Dis Control & Prevent, NCID, Div Bacterial & Mycot Dis, Childhood & Resp Dis Branch, Mailstop C-23,1600 Clifton Rd NE, Atlanta, GA 30333 USA.	nar5@cdc.gov						ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; ARTENSTEIN MS, 1970, NEW ENGL J MED, V282, P417, DOI 10.1056/NEJM197002192820803; ASHTON FE, 1991, J CLIN MICROBIOL, V29, P2489, DOI 10.1128/JCM.29.11.2489-2493.1991; BISELLI R, 1993, VACCINE, V11, P578, DOI 10.1016/0264-410X(93)90236-Q; BLAKEBROUGH IS, 1983, ANN TROP MED PARASIT, V77, P175, DOI 10.1080/00034983.1983.11811694; CAUGANT DA, 1987, J BACTERIOL, V169, P2781, DOI 10.1128/jb.169.6.2781-2792.1987; *CDCP, 1993, MMWR-MORBID MORTAL W, V42, P21; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; DeWals P, 1996, B WORLD HEALTH ORGAN, V74, P407; Fischer M, 1997, PEDIATR INFECT DIS J, V16, P979, DOI 10.1097/00006454-199710000-00015; GOLD R, 1975, J CLIN INVEST, V56, P1536, DOI 10.1172/JCI108235; GOLD R, 1971, B WORLD HEALTH ORGAN, V45, P279; GOTSCHLICH EC, 1969, J EXP MED, V129, P1385, DOI 10.1084/jem.129.6.1385; HASSANKING MKA, 1988, J INFECTION, V16, P55, DOI 10.1016/S0163-4453(88)96117-8; Imrey PB, 1996, AM J EPIDEMIOL, V143, P624, DOI 10.1093/oxfordjournals.aje.a008792; JACKSON LA, 1995, JAMA-J AM MED ASSOC, V273, P383, DOI 10.1001/jama.273.5.383; Le Saux N, 1992, Can J Infect Dis, V3, P60; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; Lieberman JM, 1996, JAMA-J AM MED ASSOC, V275, P1499, DOI 10.1001/jama.275.19.1499; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; ORENSTEIN WA, 1988, EPIDEMIOL REV, V10, P212, DOI 10.1093/oxfordjournals.epirev.a036023; Roberts CL, 1996, AM J PUBLIC HEALTH, V86, P1155, DOI 10.2105/AJPH.86.8_Pt_1.1155; SELANDER RK, 1986, APPL ENVIRON MICROB, V51, P873, DOI 10.1128/AEM.51.5.873-884.1986; Tappero JW, 1996, NEW ENGL J MED, V335, P833, DOI 10.1056/NEJM199609193351201; TAUNAY A E, 1978, Revista do Instituto Adolfo Lutz, V38, P77; WHITNEY CG, 1996, 10 INT PATH NEISS C; WOODS TC, 1992, J CLIN MICROBIOL, V30, P132, DOI 10.1128/JCM.30.1.132-137.1992	27	81	83	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 11	1998	279	6					435	439		10.1001/jama.279.6.435	http://dx.doi.org/10.1001/jama.279.6.435			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YV580	9466635	Bronze			2022-12-01	WOS:000071839800030
J	Mallipeddi, R; Mathias, CJ				Mallipeddi, R; Mathias, CJ			Raynaud's phenomenon after sympathetic denervation in patients with primary autonomic failure: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article									Univ London, Natl Hosp Neurol & Neurosurg, Dept Clin Neurol, Auton Unit, London WC1N 3BG, England; UCL, Inst Neurol, London WC1N 3BG, England; St Marys Hosp, Imperial Coll Sch Med, Div Neurosci & Psychol Med, Neurovasc Med Unit, London W2 1NY, England	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; Imperial College London	Mathias, CJ (corresponding author), Univ London, Natl Hosp Neurol & Neurosurg, Dept Clin Neurol, Auton Unit, Queen Sq, London WC1N 3BG, England.	c.mathias@ic.ac.uk						BLACK C, 1994, BRIT J HOSP MED, V52, P555; DOWD PM, 1995, LANCET, V346, P286; JAMIESON GG, 1971, CIRCULATION, V44, P254, DOI 10.1161/01.CIR.44.2.254; MATHIAS CJ, 1996, NEUROLOGY CLIN PRACT, V2, P1953; POLINSKY RJ, 1992, AUTONOMIC FAILURE TX, P234	5	7	7	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					438	439		10.1136/bmj.316.7129.438	http://dx.doi.org/10.1136/bmj.316.7129.438			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492669	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071982700028
J	Freudenreich, CH; Kantrow, SM; Zakian, VA				Freudenreich, CH; Kantrow, SM; Zakian, VA			Expansion and length-dependent fragility of CTG repeats in yeast	SCIENCE			English	Article							NUCLEOTIDE EXCISION-REPAIR; SACCHAROMYCES-CEREVISIAE; MYOTONIC-DYSTROPHY; HUMAN-CHROMOSOMES; HUMAN-DISEASE; DNA-SYNTHESIS; GENE; DELETION; SITES; INSTABILITY	Expansion of DNA trinucleotide repeats (TNRs) is the causative mutation in a growing number of human genetic diseases. Large expansions of a CTG tract were obtained and shown by genetic and physical assays to be length-dependent sites of chromosome breakage in Saccharomyces cerevisiae. Deletion of RAD27, which encodes a nuclease involved in Okazaki fragment processing, caused length-dependent destabilization of CTG tracts and a substantial increase in expansion frequency. The genetic assay described here can be used to evaluate other factors that induce TNR expansion or chromosome fragility in humans.	Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Zakian, VA (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	vzakian@molecular.princeton.edu		Freudenreich, Catherine/0000-0002-1652-2917	NIA NIH HHS [F32 AG005740, AG05740-02] Funding Source: Medline; NIGMS NIH HHS [GM26938, GM43265] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM026938, R01GM043265] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashizawa T, 1996, GENOMICS, V36, P47, DOI 10.1006/geno.1996.0424; Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bierne H, 1997, EMBO J, V16, P3332, DOI 10.1093/emboj/16.11.3332; DEBRUIN D, 1992, GENOMICS, V14, P332, DOI 10.1016/S0888-7543(05)80223-X; Freudenreich CH, 1997, MOL CELL BIOL, V17, P2090, DOI 10.1128/MCB.17.4.2090; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; HIRAOKA LR, 1995, GENOMICS, V25, P220, DOI 10.1016/0888-7543(95)80129-A; JALAL SM, 1993, AM J MED GENET, V46, P441, DOI 10.1002/ajmg.1320460419; JOHNSON RE, 1995, SCIENCE, V269, P238, DOI 10.1126/science.7618086; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KANG S, 1995, NAT GENET, V10, P213, DOI 10.1038/ng0695-213; Korneluk RG, 1997, NAT GENET, V15, P119, DOI 10.1038/ng0297-119; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Maurer DJ, 1996, MOL CELL BIOL, V16, P6617; Michel B, 1997, EMBO J, V16, P430, DOI 10.1093/emboj/16.2.430; Miret JJ, 1997, MOL CELL BIOL, V17, P3382, DOI 10.1128/MCB.17.6.3382; Mitas M, 1997, NUCLEIC ACIDS RES, V25, P2245, DOI 10.1093/nar/25.12.2245; Ohshima K, 1997, J BIOL CHEM, V272, P16798, DOI 10.1074/jbc.272.27.16798; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Reddy PS, 1997, CURR OPIN CELL BIOL, V9, P364, DOI 10.1016/S0955-0674(97)80009-9; RICHARDS RI, 1994, NAT GENET, V6, P114, DOI 10.1038/ng0294-114; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; SUGAWARA N, 1995, BIOESSAYS, V17, P609; SUTHERLAND GR, 1995, CURR OPIN GENET DEV, V5, P323, DOI 10.1016/0959-437X(95)80046-8; TISHKOFF DX, 1997, CELL, V88, P263; Wenger SL, 1996, AM J MED GENET, V66, P60, DOI 10.1002/(SICI)1096-8628(19961202)66:1<60::AID-AJMG13>3.0.CO;2-O	33	340	342	1	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					853	856		10.1126/science.279.5352.853	http://dx.doi.org/10.1126/science.279.5352.853			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452383				2022-12-01	WOS:000071923500041
J	Cooper, RS; Osotimehin, B; Kaufman, JS; Forrester, T				Cooper, RS; Osotimehin, B; Kaufman, JS; Forrester, T			Disease burden in sub-Saharan Africa: what should we conclude in the absence of data?	LANCET			English	Editorial Material									Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, Maywood, IL 60153 USA; Univ Coll Ibadan Hosp, Ibadan, Nigeria; Trop Metab Res Unit, Mona, Jamaica	Loyola University Chicago	Cooper, RS (corresponding author), Loyola Univ, Stritch Sch Med, Dept Epidemiol & Prevent Med, 2160 S 1st Ave, Maywood, IL 60153 USA.		Swaibu, Ramadhani A/H-3164-2011	Kaufman, Jay/0000-0003-1606-401X				Akinkugbe OO, 1997, FINAL REPORT NATL SU; Asuzu M C, 1996, World Health Forum, V17, P373; Barker DJP, 1992, FETAL INFANT ORIGINS; Cooper R, 1997, AM J PUBLIC HEALTH, V87, P160, DOI 10.2105/AJPH.87.2.160; Cooper RS, 1996, TROP CARDIOL, V22, P69; Gwatkin DR, 1997, LANCET, V350, P141, DOI 10.1016/S0140-6736(97)26028-9; Jamison D.T., 1993, DIS CONTROL PRIORITI; Kaufman JS, 1996, J HUM HYPERTENS, V10, P461; MANTON K G, 1988, World Health Statistics Quarterly, V41, P255; MULLER AS, 1991, DIS MORTALITY SUBSAH, P267; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Murray CJL, 1992, HLTH ADULTS DEV WORL, P113; Murray CJL., 1996, GLOBAL BURDEN DIS CO; *NAT CTR HLTH STAT, 1995, HLTH US 1994; OWOAJE E, 1997, E AFR MED J, V74, P29; Patterson, 1982, SLAVERY SOCIAL DEATH; Tanner M., 1991, DIS MORTALITY SUBSAH	17	95	95	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					208	210		10.1016/S0140-6736(97)06512-4	http://dx.doi.org/10.1016/S0140-6736(97)06512-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449884				2022-12-01	WOS:000071616300043
J	Passmore, SJ; Draper, G; Brownbill, P; Kroll, M				Passmore, SJ; Draper, G; Brownbill, P; Kroll, M			Ecological studies of relation between hospital policies on neonatal vitamin K administration and subsequent occurrence of childhood cancer	BRITISH MEDICAL JOURNAL			English	Article								Objective: To investigate the possible link between neonatal administration of intramuscular vitamin K and childhood cancer. Design: Ecological studies comparing incidence of cancer in groups of children classified by the vitamin K policy in operation at their hospital of birth. Setting: Selected large maternity units in England, Scotland, and Wales. Subjects: Children born in these units in varying periods between 1966 and 1991. Main outcome measures: Cancer occurring among these children before age 15 years identified by using the National Registry of Childhood Tumours. Ratios of observed to expected numbers of these conditions calculated for hospitals where the policy was to give all babies intramuscular vitamin K (non-selective) and where the policy was to use this treatment only for a selected minority of babies at increased risk of vitamin K deficiency bleeding (selective). Results: These ratios were calculated for children horn in 94 hospitals with varying vitamin K policies. A raised fisk was occasionally associated with vitamin K, but the overall results were not significant, and there was no evidence to support the previously suggested doubling of the risk of childhood cancer. Conclusions: On the basis of the results reported here it is unlikely that there is a greatly increased risk of childhood cancer attributable to intramuscular vitamin K given to newborns, if indeed there is any.	Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Draper, G (corresponding author), Childhood Canc Res Grp, Oxford OX2 6HJ, England.							[Anonymous], BIOMETRIKA TABLES ST; Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; BRESLOW NE, 1987, IARC SCI PUBL, V82, P94; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; PASSMORE J, 1998, BRIT MED J, V316, P178	6	23	23	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					184	189						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468682	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071616400022
J	Birdwell, BG; Raskob, GE; Whitsett, TL; Durica, SS; Comp, PC; George, JN; Tytle, TL; McKee, PA				Birdwell, BG; Raskob, GE; Whitsett, TL; Durica, SS; Comp, PC; George, JN; Tytle, TL; McKee, PA			The clinical validity of normal compression ultrasonography in outpatients suspected of raving deep venous thrombosis	ANNALS OF INTERNAL MEDICINE			English	Article						ultrasonography; thrombophlebitis; thromboembolism; thrombolytic therapy; pulmonary embolism	PROXIMAL-VEIN-THROMBOSIS; SERIAL IMPEDANCE PLETHYSMOGRAPHY; PULMONARY-EMBOLISM; INITIAL TREATMENT; LOWER-EXTREMITY; DIAGNOSIS; LEG; MANAGEMENT; VENOGRAPHY; HEPARIN	Background: Ultrasonography using Vein compression accurately detects proximal deep Venous thrombosis in symptomatic outpatients. Repeated testing is required for patients with normal results at presentation, but the optimal management of such patients is uncertain. Objective: To test the safety of withholding anticoagulation in outpatients suspected of having first-episode deep venous thrombosis who have normal results on simplified compression ultrasonography at presentation and on a single repeated test done 5 to 7 days later. Design: Prospective cohort study. Setting: Noninvasive vascular laboratories at a university teaching hospital and a Veterans Administration medical center. Patients: 405 consecutive outpatients suspected of having first-episode deep Venous thrombosis. Intervention: Ultrasonography was performed at presentation. The common femoral and popliteal veins were assessed for compressibility. If the result was normal, anticoagulation was withheld and testing was repeated 5 to 7 days later. Anticoagulation was withheld from all patients whose results remained normal according to compression ultrasonography, regard less of their symptoms. The safety of this approach was tested by follow-up lasting 3 months. Measurements: Objective testing was done during follow-up in all patients with symptoms or signs of venous thromboembolism. The outcome measure was symptomatic Venous thrombosis or pulmonary embolism during follow-up, confirmed by objective testing. Results: Ultrasonography had normal results in 335 patients (83%) and abnormal results in 70 (17%). None of the patients with normal results died of pulmonary embolism. Venous thromboembolism occurred during follow-up in 2 patients with normal ultrasonographic results (0.6% [95% CI, 0.07% to 2.14%]) and in 4 patients with abnormal results (5.7% [CI, 1.58% to 13.99%]) (P = 0.009). Conclusions: It is safe to withhold anticoagulation in outpatients suspected of having first-episode deep venous thrombosis if results of simplified compression ultrasonography are normal at presentation and on a single repeated test done 5 to 7 days later.	Vet Adm Med Ctr, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biostat & Epidemiol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Radiol Sci, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Warren Med Res Inst, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Birdwell, BG (corresponding author), Vet Adm Med Ctr, 151,921 NE 13th St, Oklahoma City, OK 73104 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008883, F32HL008756] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 08883, HL 08756] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; APPELMAN PT, 1987, RADIOLOGY, V163, P743, DOI 10.1148/radiology.163.3.3554343; BRANDJES DPM, 1992, NEW ENGL J MED, V327, P1485, DOI 10.1056/NEJM199211193272103; COGO A, 1993, ARCH INTERN MED, V153, P2777, DOI 10.1001/archinte.153.24.2777; CRANLEY JJ, 1976, ARCH SURG-CHICAGO, V111, P34; CRONAN JJ, 1987, RADIOLOGY, V162, P191, DOI 10.1148/radiology.162.1.3538148; DALEN JE, 1971, AM HEART J, V81, P175, DOI 10.1016/0002-8703(71)90128-1; DARKE SG, 1991, VENOUS DISORDERS, P227; HEIJBOER H, 1993, NEW ENGL J MED, V329, P1365, DOI 10.1056/NEJM199311043291901; HILLNER BE, 1992, ARCH INTERN MED, V152, P165, DOI 10.1001/archinte.152.1.165; HUISMAN MV, 1986, NEW ENGL J MED, V314, P823, DOI 10.1056/NEJM198603273141305; HUISMAN MV, 1989, ARCH INTERN MED, V149, P511, DOI 10.1001/archinte.149.3.511; HULL R, 1977, NEW ENGL J MED, V296, P1497, DOI 10.1056/NEJM197706302962604; HULL R, 1981, CIRCULATION, V64, P622, DOI 10.1161/01.CIR.64.3.622; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1976, CIRCULATION, V53, P696, DOI 10.1161/01.CIR.53.4.696; HULL R, 1978, CIRCULATION, V58, P898, DOI 10.1161/01.CIR.58.5.898; HULL R, 1981, ANN INTERN MED, V94, P12, DOI 10.7326/0003-4819-94-1-12; HULL RD, 1985, CHEST, V88, P819, DOI 10.1378/chest.88.6.819; HULL RD, 1986, NEW ENGL J MED, V315, P1109, DOI 10.1056/NEJM198610303151801; HULL RD, 1983, CIRCULATION, V67, P901, DOI 10.1161/01.CIR.67.4.901; HULL RD, 1985, ANN INTERN MED, V102, P21, DOI 10.7326/0003-4819-102-1-21; KEARON C, 1994, THROMB HAEMOSTASIS, V72, P652; KOBAK M, 1954, AMA ARCH SURG, V68, P350, DOI 10.1001/archsurg.1954.01260050352011; Lensing Anthonie W. A., 1996, P115; LENSING AWA, 1989, NEW ENGL J MED, V320, P342, DOI 10.1056/NEJM198902093200602; MOSER KM, 1981, ANN INTERN MED, V94, P439, DOI 10.7326/0003-4819-94-4-439; ODONNELL TF, 1980, SURG GYNECOL OBSTET, V150, P69; Pezzullo JA, 1996, RADIOLOGY, V198, P67, DOI 10.1148/radiology.198.1.8539408; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; SACKETT DL, 1979, J CHRON DIS, V32, P51, DOI 10.1016/0021-9681(79)90012-2; STRANDNESS DE, 1972, ARCH SURG-CHICAGO, V104, P180; SUMNER D, 1990, J VASC SURG, V11, P60; Sumner DS, 1993, VASCULAR DIAGNOSIS, P785; VOGEL P, 1987, RADIOLOGY, V163, P747, DOI 10.1148/radiology.163.3.3554344; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WHEELER HB, 1982, ARCH SURG-CHICAGO, V117, P1206; WILLIAMS SG, 1953, VENOUS DISORDERS, V97, P769	38	205	210	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1998	128	1					1	+		10.7326/0003-4819-128-1-199801010-00001	http://dx.doi.org/10.7326/0003-4819-128-1-199801010-00001			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN342	9424975				2022-12-01	WOS:000071158000001
J	Stevens, J; Cai, JW; Pamuk, ER; Williamson, DF; Thun, MJ; Wood, JL				Stevens, J; Cai, JW; Pamuk, ER; Williamson, DF; Thun, MJ; Wood, JL			The effect of age on the association between body-mass index and mortality	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WEIGHT; WOMEN; MEN	Background The effect of age on optimal body weight is controversial, and few studies have had adequate numbers of subjects to analyze mortality as a function of body-mass index across age groups. Methods We studied mortality over 12 years among white men and women who participated in the American Cancer Society's Cancer Prevention Study I (from 1960 through 1972). The 62,116 men and 262,019 women included in this analysis had never smoked cigarettes, had no history of heart disease, stroke, or cancer (other than skin cancer) at base line in 1959-1960, and had no history of recent unintentional weight loss. The date and cause of death for subjects who died were determined from death certificates. The associations between body-mass index (defined as the weight in kilograms divided by the square of the height in meters) and mortality were examined for six age groups in analyses in which we adjusted for age, educational level, physical activity, and alcohol consumption. Results Greater body-mass index was associated with higher mortality from all causes and from cardiovascular disease in men and women up to 75 years of age. However, the relative risk associated with greater body-mass index declined with age. For example, for mortality from cardiovascular disease, the relative risk associated with an increment of 1 in the body-mass index was 1.10 (95 percent confidence interval, 1.04 to 1.16) for 30-to-44-year-old men and 1.03 (95 percent confidence interval, 1.02 to 1.05) for 65-to-74-year-old men. For women, the corresponding relative risk estimates were 1.08 (95 percent confidence interval, 1.05 to 1.11) and 1.02 (95 percent confidence interval, 1.02 to 1.03). Conclusions Excess body weight increases the risk of death from any cause and from cardiovascular disease in adults between 30 and 74 years of age. The relative risk associated with greater body weight is higher among younger subjects. (C) 1998, Massachusetts Medical Society.	Univ N Carolina, Sch Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA; Amer Canc Soc, Atlanta, GA 30329 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Centers for Disease Control & Prevention - USA; American Cancer Society	Stevens, J (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Nutr, CB 7400, Chapel Hill, NC 27599 USA.				NIDDK NIH HHS [R01 DK50776] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050776] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON DB, 1996, OBES RES S1, V4, pS12; [Anonymous], 1983, Stat Bull Metrop Life Found, V64, P3; Cox DR., 1984, ANAL SURVIVAL DATA; *DIET GUID AM, 1990, DIET GUID AM PUBL; *DIET GUID AM, 1995, DIET GUID AM PUBL; GARFINKEL L, 1984, AM HEART J, V108, P802, DOI 10.1016/0002-8703(84)90675-6; GREENLAND S, 1988, AM J EPIDEMIOL, V128, P1185, DOI 10.1093/oxfordjournals.aje.a115073; LEW EA, 1985, ANN INTERN MED, V103, P1024, DOI 10.7326/0003-4819-103-6-1024; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; Lindsted KD, 1997, AM J EPIDEMIOL, V146, P1, DOI 10.1093/oxfordjournals.aje.a009185; MANSON JE, 1987, JAMA-J AM MED ASSOC, V257, P353, DOI 10.1001/jama.257.3.353; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; PETERSON B, 1994, CONTROL CLIN TRIALS, V15, P326; PETERSON B, 1993, CONTROL CLIN TRIALS, V14, P511, DOI 10.1016/0197-2456(93)90031-8; PLANKEY MW, 1995, OBESITY RES S3, V3, pS386; RISSANEN A, 1989, J CLIN EPIDEMIOL, V42, P781, DOI 10.1016/0895-4356(89)90076-0; RISSANEN A, 1991, J CLIN EPIDEMIOL, V44, P787, DOI 10.1016/0895-4356(91)90131-R; ROWLAND ML, 1990, AM J CLIN NUTR, V52, P1125, DOI 10.1093/ajcn/52.6.1125; *SOC ACT ASS LIF I, 1980, BUILD STUD 1979; SORKIN JD, 1996, OBES RES S1, V4, pS12; Steel R. G. D., 1980, Principles and procedures of statistics, a biometrical approach.; STEVENS J, 1990, AM J EPIDEMIOL, V132, P1156, DOI 10.1093/oxfordjournals.aje.a115758; WAALER HT, 1984, ACTA MED SCAND, P1; WILLIAMSON DF, 1991, AM J CLIN NUTR, V53, pS1515, DOI 10.1093/ajcn/53.6.1515S; World Health Organization (WHO), 1957, INT CLASS DIS	25	1033	1070	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 1	1998	338	1					1	7		10.1056/NEJM199801013380101	http://dx.doi.org/10.1056/NEJM199801013380101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN801	9414324	Green Published			2022-12-01	WOS:000071209200001
J	Xie, JW; Murone, M; Luoh, SM; Ryan, A; Gu, QM; Zhang, CH; Bonifas, JM; Lam, CW; Hynes, M; Goddard, A; Rosenthal, A; Epstein, EH; de Sauvage, FJ				Xie, JW; Murone, M; Luoh, SM; Ryan, A; Gu, QM; Zhang, CH; Bonifas, JM; Lam, CW; Hynes, M; Goddard, A; Rosenthal, A; Epstein, EH; de Sauvage, FJ			Activating Smoothened mutations in sporadic basal-cell carcinoma	NATURE			English	Article							HUMAN HOMOLOG; GENE; RECEPTOR; HEDGEHOG	Basal-cell carcinomas (BCCs) are the commonest human cancer(1). Insight into their genesis came from identification of mutations in the PATCHED gene (PTCH) in patients with the basal-cell nevus syndrome, a hereditary disease characterized by multiple BCCs and by developmental abnormalities(2-7). The binding of Sonic hedgehog (SHH) to its receptor, PTCH, is thought to prevent normal inhibition by PTCH of Smoothened (SMO), a seven-span transmembrane protein(8,9). According to this model, the inhibition of SMO signalling is relieved following mutational inactivation of PTCH in basal-cell nevus syndrome, We report here the identification of activating somatic missense mutations in the SMO gene itself in sporadic BCCs from three patients. Mutant SMO, unlike wild type, can cooperate with adenovirus E1A to transform rat embryonic fibroblast cells in culture, Furthermore, skin abnormalities similar to BCCs developed in transgenic murine skin overexpressing mutant SMO. These findings support the role of SMO as a signalling component of the SHH-receptor complex and provide direct evidence that mutated SMO can function as an oncogene in BCCs.	Univ Calif San Francisco, San Francisco Gen Hosp, Dept Dermatol, San Francisco, CA 94110 USA; Genentech Inc, Dept Mol Oncol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Pathol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, S San Francisco, CA 94080 USA; Genentech Inc, Dept Neurosci, S San Francisco, CA 94080 USA; Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Chinese University of Hong Kong; Prince of Wales Hospital	de Sauvage, FJ (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Dermatol, 1001 Potrero St,Rm 269,Bldg 100, San Francisco, CA 94110 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584; Zhang, Chengfei/0000-0002-6016-9436; Hynes, Mary/0000-0001-6623-6727				BYME C, 1993, MOL CELL BIOL, V13, P3176; Chidambaram A, 1996, CANCER RES, V56, P4599; Fan H., 1997, Journal of Investigative Dermatology, V108, P544; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MILLER DL, 1994, J AM ACAD DERMATOL, V30, P774, DOI 10.1016/S0190-9622(08)81509-5; Oro AE, 1997, SCIENCE, V276, P817, DOI 10.1126/science.276.5313.817; Raffel C, 1997, CANCER RES, V57, P842; RUPPERT JM, 1991, MOL CELL BIOL, V11, P1724, DOI 10.1128/MCB.11.3.1724; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Unden AB, 1996, CANCER RES, V56, P4562; Unden Anne Birgitte, 1997, Journal of Investigative Dermatology, V108, P596; Wicking C, 1997, AM J HUM GENET, V60, P21; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Xie JW, 1997, CANCER RES, V57, P2369; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	21	1028	1090	1	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					90	92		10.1038/34201	http://dx.doi.org/10.1038/34201			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422511				2022-12-01	WOS:000071326100055
J	Morris, ME; Viswanathan, N; Kuhlman, S; Davis, FC; Weitz, CJ				Morris, ME; Viswanathan, N; Kuhlman, S; Davis, FC; Weitz, CJ			Screen for genes induced in the suprachiasmatic nucleus by light	SCIENCE			English	Article							MAMMALIAN CIRCADIAN CLOCK; IMMEDIATE-EARLY GENES; RETINOHYPOTHALAMIC TRACT; TRANSCRIPTION FACTORS; N-ACETYLTRANSFERASE; MESSENGER-RNAS; C-FOS; EXPRESSION; ENTRAINMENT; INDUCTION	The mechanism by which mammalian circadian clocks are entrained to light-dark cycles is unknown. The clock that drives behavioral rhythms is located in the suprachiasmatic nucleus (SCN) of the brain, and entrainment is thought to require induction of genes in the SCN by light. A complementary DNA subtraction method based on genomic representational difference analysis was developed to identify such genes without making assumptions about their nature. Four clones corresponded to genes induced specifically in the SCN by light, all of which showed gating of induction by the circadian clock. Among these genes are c-fos and nur77, two of the five early-response genes known to be induced in the SCN by light, and egr-3, a zinc finger transcription factor not previously identified in the SCN. In contrast to known examples, egr-3 induction by light is restricted to the ventral SCN, a structure implicated in entrainment.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA; Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Northeastern University	Weitz, CJ (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA.		Jansen, Heiko T./A-5770-2008; Kuhlman, Sandra/Q-1211-2015	Jansen, Heiko T./0000-0003-0178-396X; Kuhlman, Sandra/0000-0003-0450-7282				ABE H, 1991, NEUROSCI LETT, V127, P9, DOI 10.1016/0304-3940(91)90881-S; ABE H, 1992, BRAIN RES BULL, V28, P831, DOI 10.1016/0361-9230(92)90269-4; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARONIN N, 1990, P NATL ACAD SCI USA, V87, P5959, DOI 10.1073/pnas.87.15.5959; EDWARDS LN, 1988, CELLULAR MOL BASES B; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; Guido ME, 1996, BRAIN RES, V739, P132, DOI 10.1016/S0006-8993(96)00816-5; HONKANIEMI J, 1995, MOL BRAIN RES, V28, P157, DOI 10.1016/0169-328X(94)00200-X; HONKANIEMI J, 1994, MOL BRAIN RES, V25, P234, DOI 10.1016/0169-328X(94)90158-9; JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5; Klein D.C., 1991, SUPRACHIASMATIC NUCL; KLEIN DC, 1979, BRAIN RES, V174, P245, DOI 10.1016/0006-8993(79)90848-5; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Miller JD, 1996, SLEEP, V19, P641, DOI 10.1093/sleep/19.8.641; MOORE RY, 1974, BRAIN RES, V71, P17, DOI 10.1016/0006-8993(74)90188-7; Morris M.S., UNPUB; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLIDIS T, 1973, BIOL OSCILLATORS THE; PITTENDRIGH CS, 1976, J COMP PHYSIOL, V106, P291, DOI 10.1007/BF01417859; REA MA, 1989, BRAIN RES BULL, V23, P577, DOI 10.1016/0361-9230(89)90204-9; RUSAK B, 1992, MOL BRAIN RES, V14, P124, DOI 10.1016/0169-328X(92)90019-8; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Shigeyoshi Y, 1997, CELL, V91, P1043, DOI 10.1016/S0092-8674(00)80494-8; Silver R, 1996, NEUROREPORT, V7, P1224, DOI 10.1097/00001756-199604260-00026; SIMMONS DM, 1989, J HISTOTECHNOL, V12, P169; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; Treep JA, 1995, J BIOL RHYTHM, V10, P299, DOI 10.1177/074873049501000403; WILKINSON DG, 1987, DEVELOPMENT, V99, P493; WOLLNIK F, 1995, EUR J NEUROSCI, V7, P388, DOI 10.1111/j.1460-9568.1995.tb00334.x	31	88	88	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1544	1547		10.1126/science.279.5356.1544	http://dx.doi.org/10.1126/science.279.5356.1544			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488654				2022-12-01	WOS:000072372900067
J	Bellamy, R; Ruwende, C; Corrah, T; McAdam, KPWJ; Whittle, HC; Hill, AVS				Bellamy, R; Ruwende, C; Corrah, T; McAdam, KPWJ; Whittle, HC; Hill, AVS			Variations in the Nrampi gene and susceptibility to tuberculosis in West Africans	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NATURAL-RESISTANCE; MACROPHAGE PROTEIN; INTRACELLULAR PARASITES; GENOMIC ORGANIZATION; INFECTION; IDENTIFICATION; EXPRESSION; MICE; SEQUENCE; LOCUS	Background Genetic factors may affect the susceptibility to tuberculosis, but no specific genes governing susceptibility have been identified. in mice, natural resistance to infection with some mycobacteria is influenced by the gene for natural-resistance-associated macrophage protein 1 (Nramp1), but the role of the human homologue of this gene, NRAMP1, in tuberculosis is unknown, We typed polymorphisms in NRAMP1 in a case-control study of tuberculosis in the Gambia, West Africa. Methods Sequence-specific oligonucleotide hybridization and microsatellite analysis were used to type NRAMP1 polymorphisms in 410 adults (mean age, 34.7 years) with smear-positive pulmonary tuberculosis and 417 ethnically matched, healthy controls. Patients with human immunodeficiency virus infection were excluded. Results Four NRAMP1 polymorphisms were each significantly associated with tuberculosis, Subjects who were heterozygous for two NRAMP1 polymorphisms in intron 4 and the 3' untranslated region of the gene were particularly overrepresented among those with tuberculosis, as compared with those with the most common NRAMP1 genotype (odds ratio, 4.07; 95-percent confidence interval, 1.86 to 9.12; chi-square=14.58; P<0.001). Conclusions Genetic variation in NRAMP1 affects susceptibility to tuberculosis in West Africans. (C) 1998, Massachusetts Medical Society.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; MRC Labs, Fajara, Gambia	University of Oxford; Wellcome Centre for Human Genetics; MRC Laboratory Molecular Biology	Hill, AVS (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Windmill Rd, Oxford OX3 7BN, England.		Yang, Pan-Chyr/B-8808-2009; HILL, Adrian V>S>/C-1306-2008		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLSOPP CEM, 1992, AM J HUM GENET, V50, P411; Blackwell JM, 1996, MOL MED TODAY, V2, P205, DOI 10.1016/1357-4310(96)88773-9; BLACKWELL JM, 1995, MOL MED, V1, P194, DOI 10.1007/BF03401567; BRADLEY DJ, 1977, CLIN EXP IMMUNOL, V30, P130; CELLIER M, 1994, J EXP MED, V180, P1741, DOI 10.1084/jem.180.5.1741; COMSTOCK GW, 1978, AM REV RESPIR DIS, V117, P621; CROCKER PR, 1984, INFECT IMMUN, V43, P1033, DOI 10.1128/IAI.43.3.1033-1040.1984; DENIS M, 1990, J LEUKOCYTE BIOL, V47, P25, DOI 10.1002/jlb.47.1.25; Fleming MD, 1997, NAT GENET, V16, P383, DOI 10.1038/ng0897-383; GOTO Y, 1989, IMMUNOGENETICS, V30, P218, DOI 10.1007/BF02421210; Govoni G, 1996, INFECT IMMUN, V64, P2923, DOI 10.1128/IAI.64.8.2923-2929.1996; GROS P, 1981, J IMMUNOL, V127, P2417; Gruenheid S, 1997, J EXP MED, V185, P717, DOI 10.1084/jem.185.4.717; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; KALLMANN F. J., 1943, American Review of Tuberculosis and Pulmonary Diseases, V47, P549; Lewis LA, 1996, IMMUNOGENETICS, V44, P309, DOI 10.1007/s002510050129; LISSNER CR, 1983, J IMMUNOL, V131, P3006; LIU J, 1995, AM J HUM GENET, V56, P845; MALO D, 1994, GENOMICS, V23, P51, DOI 10.1006/geno.1994.1458; Murray C J, 1990, Bull Int Union Tuberc Lung Dis, V65, P6; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; PLANT J, 1976, J INFECT DIS, V133, P72, DOI 10.1093/infdis/133.1.72; ROOK GAW, 1988, BRIT MED BULL, V44, P611, DOI 10.1093/oxfordjournals.bmb.a072271; SKAMENE E, 1984, IMMUNOGENETICS, V19, P117, DOI 10.1007/BF00387854; SKAMENE E, 1982, NATURE, V297, P506, DOI 10.1038/297506a0; STACH JL, 1984, J IMMUNOL, V132, P888; STEAD WW, 1992, ANN INTERN MED, V116, P937, DOI 10.7326/0003-4819-116-11-937; STEAD WW, 1990, NEW ENGL J MED, V322, P422, DOI 10.1056/NEJM199002153220702; Supek F, 1996, P NATL ACAD SCI USA, V93, P5105, DOI 10.1073/pnas.93.10.5105; VIDAL S, 1995, J EXP MED, V182, P655, DOI 10.1084/jem.182.3.655; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; WHITE JK, 1994, GENOMICS, V24, P295, DOI 10.1006/geno.1994.1619; ZIEGLE JS, 1992, GENOMICS, V14, P1026, DOI 10.1016/S0888-7543(05)80126-0	33	594	635	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					640	644		10.1056/NEJM199803053381002	http://dx.doi.org/10.1056/NEJM199803053381002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486992				2022-12-01	WOS:000072299700002
J	Johnston, IDA; Strachan, DP; Anderson, HR				Johnston, IDA; Strachan, DP; Anderson, HR			Effect of pneumonia and whooping cough in childhood on adult lung function	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOWER RESPIRATORY ILLNESS; PRIMARY-SCHOOL-CHILDREN; LOW BIRTH-WEIGHT; PULMONARY-FUNCTION; MATERNAL SMOKING; PASSIVE SMOKING; SYMPTOMS; DISEASE; INFANCY; LIFE	Background Previous studies have suggested that respiratory infection during childhood is associated with respiratory disease in adulthood, but the link is unclear because of retrospective ascertainment of childhood infection, selection bias, and confounding factors. Methods We studied the effects of childhood pneumonia and whooping cough in 1392 British adults followed from their births in 1958. Of these, 193 had a history of pneumonia and 215 a history of whooping cough by the age of seven years. When the subjects were 34 or 35 years old, their forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured before and after they inhaled albuterol. Results A history of pneumonia was associated with deficits (+/-95 percent confidence limits) in both FEV1 (102+/-73 ml, P=0.006) and FVC (173+/-70 ml, P=0.001) when the analysis was adjusted for sex, height, and smoking, with no change in the ratio of FEV1 to FVC. These deficits persisted after inhalation of albuterol. In subjects with no history of wheezing, the deficit in FEV1 was 155+/-122 ml (P=0.01), in those with past wheezing it was 41+/-128 ml (P=0.53), and in those with current wheezing it was 119+/-133 ml (P=0.08). The effect was no greater for the subjects who had pneumonia at less than two years of age than for those who had it between the ages of two and seven years and was not diminished after control for multiple confounding factors. The deficits associated with whooping cough were smaller (FEV1, 41+/-70 ml; P=0.25; FVC, 81+/-76 ml; P=0.04). Conclusions Childhood pneumonia is associated with reduced ventilatory function in adults. This reduction is independent of a history of wheezing and is not explained by other confounding factors. (C) 1998, Massachusetts Medical Society.	Univ Nottingham Hosp, Queens Med Ctr, Dept Resp Med, Nottingham NG7 2UH, England; St George Hosp, Sch Med, Dept Publ Hlth Sci, London, England	University of Nottingham; St Georges University London	Johnston, IDA (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Dept Resp Med, Nottingham NG7 2UH, England.		Anderson, Hugh R/A-7417-2016		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1987, Am Rev Respir Dis, V136, P1285; BARKER DJP, 1991, BRIT MED J, V303, P671, DOI 10.1136/bmj.303.6804.671; BRITTEN N, 1987, BRIT MED J, V294, P1317, DOI 10.1136/bmj.294.6583.1317; BRITTEN N, 1986, BRIT MED J, V292, P441, DOI 10.1136/bmj.292.6518.441; Britton J, 1996, AM J RESP CRIT CARE, V154, pS240, DOI 10.1164/ajrccm/154.6_Pt_2.S240; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; CHAN KN, 1989, ARCH DIS CHILD, V64, P1294, DOI 10.1136/adc.64.9.1294; CHAN KN, 1989, ARCH DIS CHILD, V64, P1284, DOI 10.1136/adc.64.9.1284; CHEN Y, 1986, BRIT MED J, V293, P303, DOI 10.1136/bmj.293.6542.303; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358, DOI 10.1136/adc.55.5.358; GOLD DR, 1989, AM REV RESPIR DIS, V140, P877, DOI 10.1164/ajrccm/140.4.877; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; HENRY RL, 1983, ARCH DIS CHILD, V58, P60, DOI 10.1136/adc.58.1.60; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; JOHNSTON IDA, 1983, LANCET, V2, P1104; JOHNSTON IDA, 1986, AM REV RESPIR DIS, V134, P270; LEEDER SR, 1976, BRIT J PREV SOC MED, V30, P203; MANN SL, 1992, J EPIDEMIOL COMMUN H, V46, P286, DOI 10.1136/jech.46.3.286; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MELIA RJW, 1979, INT J EPIDEMIOL, V8, P333, DOI 10.1093/ije/8.4.333; MOK JYQ, 1979, ARCH DIS CHILD, V54, P506, DOI 10.1136/adc.54.7.506; MOK JYQ, 1982, BRIT MED J, V285, P333, DOI 10.1136/bmj.285.6338.333; PAOLETTI P, 1989, EUR RESPIR J, V2, P428; PULLAN CR, 1982, BRIT MED J, V284, P1665, DOI 10.1136/bmj.284.6330.1665; RONA RJ, 1993, BMJ-BRIT MED J, V306, P817, DOI 10.1136/bmj.306.6881.817; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508, DOI 10.1164/arrd.1983.127.4.508; *SAS I INC, 1988, SAS STAT US GUID, P549; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616, DOI 10.1164/ajrccm.149.3.8118627; SOMERVILLE SM, 1988, J EPIDEMIOL COMMUN H, V42, P105, DOI 10.1136/jech.42.2.105; STRACHAN DP, 1990, ARCH DIS CHILD, V65, P161, DOI 10.1136/adc.65.2.161; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629, DOI 10.1164/ajrccm.154.6.8970346; STRACHAN DP, 1994, INT J EPIDEMIOL, V23, P1060, DOI 10.1093/ije/23.5.1060; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786, DOI 10.1136/adc.62.8.786; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; WATKINS CJ, 1982, INT J EPIDEMIOL, V11, P62, DOI 10.1093/ije/11.1.62; WEISS ST, 1995, EUR RESPIR REV, V5, P303; YOUNG S, 1995, ARCH DIS CHILD, V72, P16, DOI 10.1136/adc.72.1.16	40	118	119	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 26	1998	338	9					581	587		10.1056/NEJM199802263380904	http://dx.doi.org/10.1056/NEJM199802263380904			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY708	9475765				2022-12-01	WOS:000072175700004
J	Fire, A; Xu, SQ; Montgomery, MK; Kostas, SA; Driver, SE; Mello, CC				Fire, A; Xu, SQ; Montgomery, MK; Kostas, SA; Driver, SE; Mello, CC			Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans	NATURE			English	Article							SEX-DETERMINING GENE; HEAVY-CHAIN GENE; PROTEIN; MUSCLE; EXPRESSION; MYOSIN; INHIBITION; EMBRYOS; KINASE; UNC-22	Experimental introduction of RNA into cells can be used in certain biological systems to interfere with function of an endogenous gene(1,2). Such effects have been proposed io result from a simple antisense mechanism that depends on hybridization between the injected RNA and endogenous messenger RNA transcripts, RNA interference has been used in the nematode Caenorhabditis elegans to manipulate gene expression(3,4). Here we investigate the requirements for structure and delivery of the interfering RNA. To our surprise, we found that double-stranded RNA was substantially more effective at producing interference than was either strand individually. After injection into adult animals, purified single strands had at most a modest effect, whereas double-stranded mixtures caused potent and specific interference. The effects of this interference were evident in bath the injected animals and their progeny. Only a few molecules of injected double-stranded RNA were required per affected cell, arguing against stochiometric interference with endogenous mRNA and suggesting that there could be a catalytic or amplification component in the interference process.	Carnegie Inst Washington, Dept Embryol, Baltimore, MD 21210 USA; Johns Hopkins Univ, Biol Grad Program, Baltimore, MD 21218 USA; Univ Massachusetts, Ctr Canc, Dept Cell Biol, Program Mol Med, Worcester, MA 01605 USA	Carnegie Institution for Science; Johns Hopkins University; University of Massachusetts System; University of Massachusetts Worcester	Fire, A (corresponding author), Carnegie Inst Washington, Dept Embryol, 115 W Univ Pkwy, Baltimore, MD 21210 USA.	fire@mail1.ciwemb.edu	Pillay, Nischalan/F-9536-2012	Fire, Andrew/0000-0001-6217-8312	NIGMS NIH HHS [R01 GM037706] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037706] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BENIAN GM, 1993, GENETICS, V134, P1097; BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHEN LS, 1994, DEVELOPMENT, V120, P1631; CLARK DV, 1995, MOL GEN GENET, V247, P367, DOI 10.1007/BF00293205; DIBB NJ, 1989, J MOL BIOL, V205, P603, DOI 10.1016/0022-2836(89)90229-5; DONIACH T, 1984, DEV BIOL, V106, P223, DOI 10.1016/0012-1606(84)90077-0; Draper BW, 1996, CELL, V87, P205, DOI 10.1016/S0092-8674(00)81339-2; EPSTEIN HF, 1974, J MOL BIOL, V90, P291, DOI 10.1016/0022-2836(74)90374-X; FIRE A, 1991, DEVELOPMENT, V113, P503; GUO S, 1995, CELL, V81, P611, DOI 10.1016/0092-8674(95)90082-9; IZANT JG, 1984, CELL, V36, P1007, DOI 10.1016/0092-8674(84)90050-3; KARN J, 1983, P NATL ACAD SCI-BIOL, V80, P4253, DOI 10.1073/pnas.80.14.4253; KRAUSE M, 1990, CELL, V63, P907, DOI 10.1016/0092-8674(90)90494-Y; Latham KE, 1996, TRENDS GENET, V12, P134, DOI 10.1016/0168-9525(96)10017-2; MATZKE MA, 1995, PLANT PHYSIOL, V107, P679, DOI 10.1104/pp.107.3.679; Mello C, 1995, METHOD CELL BIOL, V48, P451; MOERMAN DG, 1979, GENETICS, V91, P95; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; SEYDOUX G, 1994, DEVELOPMENT, V120, P2823; SPENCE AM, 1990, CELL, V60, P981, DOI 10.1016/0092-8674(90)90346-G; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1981, DEV BIOL, V82, P41, DOI 10.1016/0012-1606(81)90427-9	27	10578	13066	83	2167	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					806	811		10.1038/35888	http://dx.doi.org/10.1038/35888			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486653				2022-12-01	WOS:000072089500057
J	Hauser, WA; Rich, SS; Lee, JRJ; Annegers, JF; Anderson, VE				Hauser, WA; Rich, SS; Lee, JRJ; Annegers, JF; Anderson, VE			Risk of recurrent seizures after two unprovoked seizures	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXTENDED FOLLOW-UP; ADULT LIFE; EPILEPSY; POPULATION; MINNESOTA; CHILDHOOD; PROGNOSIS; ROCHESTER	Background Patients with a single unprovoked seizure have about a 35 percent risk of recurrence in the subsequent five years. We studied the risk of recurrence after two unprovoked seizures. Methods We prospectively followed 204 patients with a first unprovoked seizure from the day of the initial seizure. Information was obtained from patients (and verified by a review of their medical records) about the dates and circumstances of any subsequent seizures. The risk of a second, third, and fourth seizure was estimated by the Kaplan-Meier method. Results Of the 204 patients, 63 had a second seizure, 41 a third seizure, and 26 a fourth seizure. The mean age of the patients was 36 years, 10 percent were less than 16 years of age, 70 percent were male, 71 percent had epilepsy of unknown cause, and 66 percent had generalized seizures. The risk of a second unprovoked seizure was 33 percent. Among those with a second seizure, the risk of a third unprovoked seizure was 73 percent; among those with a third unprovoked seizure, the risk of a fourth was 76 percent. Most recurrences occurred within one year of the second or third seizure. The risk of a third seizure was higher in those with a presumed cause of epilepsy (relative risk, 1.9; 95 percent confidence interval, 1.0 to 3.4). Conclusions Although only about one third of patients with a first unprovoked seizure will have fur ther seizures within five years, about three quarters of those with two or three unprovoked seizures have further seizures within four years. (C) 1998, Massachusetts Medical Society.	Columbia Univ Coll Phys & Surg, GH Sergievsky Ctr, New York, NY 10032 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Neurol, Winston Salem, NC 27103 USA; Ischemia Res & Educ Fdn, San Francisco, CA USA; Univ Texas, Sch Publ Hlth, Houston, TX USA; Univ Minnesota, Div Epidemiol, Minneapolis, MN 55455 USA	Columbia University; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas School Public Health; University of Minnesota System; University of Minnesota Twin Cities	Hauser, WA (corresponding author), Columbia Univ Coll Phys & Surg, GH Sergievsky Ctr, 630 W 168th St, New York, NY 10032 USA.		Hauser, W Allen/AAB-5277-2020	Rich, Stephen/0000-0003-3872-7793	NINDS NIH HHS [NS16308] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS016308] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANNEGERS JF, 1995, EPILEPSIA, V36, P327, DOI 10.1111/j.1528-1157.1995.tb01005.x; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; ANNEGERS JF, 1986, EPILEPSIA, V27, P43, DOI 10.1111/j.1528-1157.1986.tb03499.x; Annegers JR, 1984, ADV EPILEPTOL, P521; [Anonymous], 1981, Epilepsia, V22, P489; [Anonymous], 1993, EPILEPSIA, V34, P592; [Anonymous], 1989, EPILEPSIA, V30, P389, DOI 10.1111/j.1528-1157.1989.tb05316.x; BENEDETTI MD, 1986, DEV MED CHILD NEUROL, V28, P36; BERAN R G, 1985, Neuroepidemiology, V4, P71, DOI 10.1159/000110217; CAMFIELD PR, 1985, NEUROLOGY, V35, P1657, DOI 10.1212/WNL.35.11.1657; CLELAND PG, 1981, BRIT MED J, V283, P1364, DOI 10.1136/bmj.283.6303.1364; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER SJ, 1958, J CHRON DIS, V8, P699; Elandt-Johnson RC, 1980, SURVIVAL MODELS DATA, P150; ELWES RDC, 1988, BRIT MED J, V297, P948, DOI 10.1136/bmj.297.6654.948; ELWES RDC, 1985, LANCET, V2, P752; Hauser W, 1990, EPILEPSY FREQUENCY C; HAUSER WA, 1991, EPILEPSIA, V32, P429, DOI 10.1111/j.1528-1157.1991.tb04675.x; HAUSER WA, 1990, NEUROLOGY, V40, P1163, DOI 10.1212/WNL.40.8.1163; HAUSER WA, 1982, NEW ENGL J MED, V307, P522, DOI 10.1056/NEJM198208263070903; HIRTZ DG, 1984, NEUROLOGY, V34, P637, DOI 10.1212/WNL.34.5.637; HOPKINS A, 1988, LANCET, V1, P721; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MATTSON RH, 1985, NEW ENGL J MED, V313, P145, DOI 10.1056/NEJM198507183130303; MUSICCO M, 1993, NEUROLOGY, V43, P478; NICOLOSI A, 1986, J INFECT DIS, V154, P399, DOI 10.1093/infdis/154.3.399; PLACENCIA M, 1994, J NEUROL NEUROSUR PS, V57, P320, DOI 10.1136/jnnp.57.3.320; SANDER JWAS, 1990, LANCET, V336, P1267, DOI 10.1016/0140-6736(90)92959-L; SHINNAR S, 1990, PEDIATRICS, V85, P1076; Shinnar S, 1996, PEDIATRICS, V98, P216; So EL, 1996, NEUROLOGY, V46, P350, DOI 10.1212/WNL.46.2.350; *STATA, 1995, STAT STAT SOFTW REL; VANDONSELAAR CA, 1992, ARCH NEUROL-CHICAGO, V49, P231, DOI 10.1001/archneur.1992.00530270045017	33	245	258	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 12	1998	338	7					429	434		10.1056/NEJM199802123380704	http://dx.doi.org/10.1056/NEJM199802123380704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW122	9459646				2022-12-01	WOS:000071900100004
J	Ross, LF				Ross, LF			Surgery is not what it seems - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA	University of Chicago	Ross, LF (corresponding author), Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA.								0	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					462	462		10.1136/bmj.316.7129.462a	http://dx.doi.org/10.1136/bmj.316.7129.462a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492682	Green Published			2022-12-01	WOS:000071982700047
J	Jennings, DE; Sada, PV				Jennings, DE; Sada, PV			Water in Betelgeuse and Antares	SCIENCE			English	Article							ALPHA-ORIONIS; STELLAR SPECTRA; SCORPII; STARS; COOL; DUST; DIAMETERS; EMISSION; SUN; IAB	Absorption lines of hot water have been identified in the infrared spectra of Betelgeuse (alpha Orionis) and Antares (alpha Scorpii) near 12.3 micrometers (811 to 819 wavenumbers). The water lines originate in the atmospheres of the stars, not in their circumstellar material. The spectra are similar in structure to umbral sunspot spectra. Pure rotation water lines of this type will occur throughout the spectra of cool stars at wavelengths greater than 10 micrometers. From the water spectra, the upper limit for the temperature in the line formation region in both stars is 2800 kelvin, The water column density in both stars is (3 +/- 2) x 10(18) molecules per square centimeter, yielding an abundance relative to atomic hydrogen of n(H-2,O)/n(H) approximate to 10(-7).	NASA, Planetary Syst Branch, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; Consultoria Astron Monterrey, Garza Garcia 66250, NL, Mexico	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Jennings, DE (corresponding author), NASA, Planetary Syst Branch, Goddard Space Flight Ctr, Code 693, Greenbelt, MD 20771 USA.		Jennings, Donald/D-7978-2012					ALLARD F, 1994, ASTROPHYS J, V426, pL39, DOI 10.1086/187334; ALLER LH, 1960, STELLAR ATMOSPHERES, P252; BASRI GS, 1981, ASTROPHYS J, V251, P162, DOI 10.1086/159451; BEER R, 1972, ASTROPHYS J, V172, P89, DOI 10.1086/151330; BERNAT AP, 1979, ASTROPHYS J, V233, pL135, DOI 10.1086/183092; Bester M, 1996, ASTROPHYS J, V463, P336, DOI 10.1086/177246; BLOEMHOF EE, 1995, ASTROPHYS J, V440, pL93, DOI 10.1086/187769; CARPENTER KG, 1994, ASTROPHYS J, V428, P329, DOI 10.1086/174244; COBB ML, 1987, ASTROPHYS J, V315, P325, DOI 10.1086/165137; DEKOTER A, 1988, ASTRON ASTROPHYS, V200, P146; DIBENEDETTO GP, 1993, ASTRON ASTROPHYS, V270, P315; *DOW CHEM, 1965, JANAF THERM TABL; GEZARI DY, 1984, NASA RES PUBL, V1119; HINKLE KH, 1979, ASTROPHYS J, V227, P923, DOI 10.1086/156801; HOFFLEIT D, 1982, BRIGHT STAR CATALOG, P422; JENNINGS DE, 1986, ASTROPHYS J, V310, pL39, DOI 10.1086/184778; JENNINGS DE, 1992, INFRARED SOLAR PHYSI, P151; KLUCKERS MG, 1997, MON NOT R ASTRON SOC, V284, P711; Lewis G.N., 1961, THERMODYNAMICS, P419; MAURON N, 1990, ASTRON ASTROPHYS, V227, P141; Polyansky OL, 1997, SCIENCE, V277, P346, DOI 10.1126/science.277.5324.346; Polyansky OL, 1996, J MOL SPECTROSC, V176, P305, DOI 10.1006/jmsp.1996.0091; RIDGWAY ST, 1984, ASTROPHYS J SUPPL S, V54, P177, DOI 10.1086/190925; ROTHMAN LS, 1987, APPL OPTICS, V26, P4058, DOI 10.1364/AO.26.004058; SLOAN GC, 1993, ASTROPHYS J, V404, P328, DOI 10.1086/172282; SNOW TP, 1987, ASTROPHYS J, V321, P921, DOI 10.1086/165685; SPINRAD H, 1965, ASTROPHYS J, V141, P965, DOI 10.1086/148190; Treffers R., 1974, Astrophysical Journal, V188, P545, DOI 10.1086/152746; Tsuji T, 1997, ASTRON ASTROPHYS, V320, pL1; Tsuji T., 1964, ANN TOKYO ASTRON OBS, V9, P1; TSUJI T, 1995, ELEMENTARY PROCESSES, P193; VANDERHUCHT KA, 1980, ASTRON ASTROPHYS, V82, P14; WALLACE L, 1995, SCIENCE, V268, P1155, DOI 10.1126/science.7761830; Wallace L, 1996, ASTROPHYS J SUPPL S, V107, P312, DOI 10.1086/192367; WALLACE L, 1994, 199401 NAT SOL OBS	35	35	35	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					844	847		10.1126/science.279.5352.844	http://dx.doi.org/10.1126/science.279.5352.844			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452380	Green Submitted			2022-12-01	WOS:000071923500038
J	Zhang, JJ; Talbot, WS; Schier, AF				Zhang, JJ; Talbot, WS; Schier, AF			Positional cloning identifies zebrafish one-eyed pinhead as a permissive EGF-related ligand required during gastrulation	CELL			English	Article							MESODERM INDUCTION; XENOPUS EMBRYOS; FGF RECEPTOR; GENE; EXPRESSION; GROWTH; MOUSE; FAMILY; CELLS; ALIGNMENT	The zebrafish one-eyed pinhead (oep) mutation disrupts embryonic development, resulting in cyclopia and defects in endoderm, prechordal plate, and ventral neuroectoderm formation. We report the molecular isolation of oep using a positional cloning approach. The oep gene encodes a novel EGF-related protein with similarity to the EGF-CFC proteins cripto, cryptic, and FRL-1. Wild-type oep protein contains a functional signal sequence and is membrane-associated. Following ubiquitous maternal and zygotic expression, highest levels of oep mRNA are found in the gastrula margin and in axial structures and forebrain. Widespread misexpression of both membrane-attached and secreted forms of oep rescues prechordal plate and forebrain development in mutant embryos but does not lead to the ectopic induction of these cell types in wild-type fish. These results establish an essential but permissive role for an EGF-related ligand during vertebrate gastrulation.	NYU, Med Ctr, Dev Genet Program, Skirball Inst Biomol Med,Dept Cell Biol, New York, NY 10016 USA	New York University	Schier, AF (corresponding author), NYU, Med Ctr, Dev Genet Program, Skirball Inst Biomol Med,Dept Cell Biol, New York, NY 10016 USA.			Schier, Alexander Franz/0000-0001-7645-5325	NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR012349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056211] Funding Source: NIH RePORTER; NCRR NIH HHS [1RO1 RR12349-01] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM56211-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelmann HB, 1936, Q REV BIOL, V11, P284, DOI 10.1086/394509; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BAXENDALE S, 1991, NUCLEIC ACIDS RES, V19, P6651, DOI 10.1093/nar/19.23.6651; BRANDT R, 1994, J BIOL CHEM, V269, P17320; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; CIARDIELLO F, 1994, ONCOGENE, V9, P291; CICCODICOLA A, 1989, EMBO J, V8, P1987, DOI 10.1002/j.1460-2075.1989.tb03605.x; Dale JK, 1997, CELL, V90, P257, DOI 10.1016/S0092-8674(00)80334-7; DONO R, 1993, DEVELOPMENT, V118, P1157; Driever W, 1996, DEVELOPMENT, V123, P37; Gabay L, 1997, SCIENCE, V277, P1103, DOI 10.1126/science.277.5329.1103; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Gupta S K, 1995, J Comput Biol, V2, P459, DOI 10.1089/cmb.1995.2.459; Haffter P, 1996, DEVELOPMENT, V123, P1; Halpern ME, 1995, DEVELOPMENT, V121, P4257; Hammerschmidt M, 1996, DEVELOPMENT, V123, P143; Heasman J, 1997, DEVELOPMENT, V124, P4179; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON SE, 1994, DEV DYNAM, V201, P216, DOI 10.1002/aja.1002010305; KANE DA, 1993, DEVELOPMENT, V119, P447; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; KIMMEL CB, 1989, NATURE, V337, P358, DOI 10.1038/337358a0; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; KINOSHITA N, 1995, CELL, V83, P621, DOI 10.1016/0092-8674(95)90102-7; Li HS, 1997, DEVELOPMENT, V124, P603; LIPMAN DJ, 1989, P NATL ACAD SCI USA, V86, P4412, DOI 10.1073/pnas.86.12.4412; Lohmeyer M, 1997, BIOCHEMISTRY-US, V36, P3837, DOI 10.1021/bi961542p; Melby AE, 1996, DEVELOPMENT, V122, P2225; MIGNATTI P, 1991, P NATL ACAD SCI USA, V88, P11007, DOI 10.1073/pnas.88.24.11007; Muenke M, 1995, CONGENITAL MALFORMAT, P187; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Postlethwait JH, 1997, TRENDS GENET, V13, P183, DOI 10.1016/S0168-9525(97)01129-3; Roessler E, 1996, NAT GENET, V14, P357, DOI 10.1038/ng1196-357; Schier AF, 1996, DEVELOPMENT, V123, P165; Schier AF, 1997, DEVELOPMENT, V124, P327; Schier AF, 1997, CURR OPIN NEUROBIOL, V7, P119, DOI 10.1016/S0959-4388(97)80129-8; SchulteMerker S, 1997, NATURE, V387, P862, DOI 10.1038/43092; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P1009; Schweitzer R, 1997, TRENDS GENET, V13, P191, DOI 10.1016/S0168-9525(97)01091-3; Shen MM, 1997, DEVELOPMENT, V124, P429; SHIH J, 1995, DEVELOPMENT, V121, P2755; SolnicaKrezel L, 1996, DEVELOPMENT, V123, P67; Spemann H., 1938, EMBRYONIC DEV INDUCT; Strahle U, 1997, Genes Funct, V1, P131; TALBOT WS, 1995, NATURE, V378, P150, DOI 10.1038/378150a0; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032	50	373	383	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 23	1998	92	2					241	251		10.1016/S0092-8674(00)80918-6	http://dx.doi.org/10.1016/S0092-8674(00)80918-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YU028	9458048	hybrid			2022-12-01	WOS:000071672600013
J	Roeper, J; Sewing, S; Zhang, Y; Sommer, T; Wanner, SG; Pongs, O				Roeper, J; Sewing, S; Zhang, Y; Sommer, T; Wanner, SG; Pongs, O			NIP domain prevents N-type inactivation in voltage-gated potassium channels	NATURE			English	Article							K+ CHANNELS; RAT-BRAIN; ALPHA-SUBUNITS; BETA-SUBUNITS; MECHANISMS; PROTEINS	Shaker-related voltage-gated K+ (K-v) channels(1,2) are assembled from ion-conducting K-v alpha subunits, which are integral membrane proteins, and auxiliary K-v beta subunits. This leads to the formation of highly diverse heteromultimeric K-v channels that mediate outward currents with a wide range of time courses for inactivation, Two principal inactivation mechanisms have been recognized(1): C-type inactivation correlated with carboxy-terminal K-v alpha-subunit structures(3), and N-type inactivation conferred by 'ball' domains in the amino termini of certain K-v alpha(4,5) and K-v beta(6) subunits, Assembly of heteromultimers with one or more K-v alpha(4,7)- and/or K-v beta(6) ball domains appears to be an essential principle of the generation of A-type K-v channel diversity, Here we show that, unexpectedly, the presence of K-v alpha- or K-v beta-ball domains does not dominate the gating phenotype in heteromultimers containing K(v)1.6 alpha subunits. These heteromultimers mediate non-inactivating currents because of the dominant-negative activity of a new type of N-type inactivation-prevention (NIP) domain present in the K(v)1.6 amino terminus. Mutations in the NIP domain lead to loss of function, and its transfer to another K-v alpha subunit leads to gain of function. Our discovery of the NIP domain, which neutralizes the activity of K-v alpha- and K-v beta-inactivation gates, establishes a new determinant for the gating behaviour of heteromultimeric K-v channels.	Zentrum Mol Neurobiol Hamburg, Inst Neurale Signalverarbeitung, D-20246 Hamburg, Germany; Univ Innsbruck, Fak Med, Inst Biochem Pharmakol, A-6020 Innsbruck, Austria	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Innsbruck	Pongs, O (corresponding author), Zentrum Mol Neurobiol Hamburg, Inst Neurale Signalverarbeitung, Martinistr 52, D-20246 Hamburg, Germany.	pointuri@uke.uni-hamburg.de		Roeper, Jochen/0000-0003-2145-8742; Sommer, Tobias/0000-0002-3504-7357				Chandy K. G., 1994, HDB RECEPTORS CHANNE, P1; CHOI KL, 1991, P NATL ACAD SCI USA, V88, P5092, DOI 10.1073/pnas.88.12.5092; GRUPE A, 1990, EMBO J, V9, P1749, DOI 10.1002/j.1460-2075.1990.tb08299.x; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; JAN YN, 1997, ANN REVNEUROSCI, V20, P91; Knaus HG, 1996, J NEUROSCI, V16, P955; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; MACKINNON R, 1993, SCIENCE, V262, P757, DOI 10.1126/science.7694359; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; PONGS O, 1992, PHYSIOL REV, V72, pS69, DOI 10.1152/physrev.1992.72.suppl_4.S69; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; Uebele VN, 1996, J BIOL CHEM, V271, P2406, DOI 10.1074/jbc.271.5.2406; VEH RW, 1995, EUR J NEUROSCI, V7, P21089; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; ZAGOTTA WN, 1990, SCIENCE, V250, P568, DOI 10.1126/science.2122520	24	59	60	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	1998	391	6665					390	393		10.1038/34916	http://dx.doi.org/10.1038/34916			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450755				2022-12-01	WOS:000071604200055
J	Shinohara, A; Ogawa, T				Shinohara, A; Ogawa, T			Stimulation by Rad52 of yeast Rad51-mediated recombination	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; STRAND-EXCHANGE; PROTEIN; RECA; MUTATIONS; FILAMENT; REPAIR; GENE	In Saccharomyces cerevisiae, the RAD51 and RAD52 genes are involved in recombination and in repair of damaged DNA(1-3). The RAD51 gene is a structural and functional homologue of the recA gene(4,5) and the gene product participates in strand exchange and single-stranded-DNA-dependent ATP hydrolysis by means of nucleoprotein filament formation(6-11). The RAD52 gene(12) is important in RAD51-mediated recombination(1-3). Binding of this protein to Rad51 (refs 4, 13) suggests that they cooperate In recombination. Homologues of both Rad51 and Rad52 are conserved from yeast to humans(14-16), suggesting that the mechanisms used for pairing homologous DNA molecules during recombination may be universal in eukaryotes. Here we show that Rad52 protein stimulates Rad51 reactions and that binding to Rad51 is necessary for this stimulatory effect. We conclude that this binding is crucial in recombination and that it facilitates the formation of Rad51 nucleoprotein filaments.	Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan; Natl Inst Genet, Shizuoka 4110801, Japan	Osaka University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Shinohara, A (corresponding author), Osaka Univ, Grad Sch Sci, Dept Biol, Osaka 5600043, Japan.	ashino@bio.sci.osaka-u.ac.jp; tomogawa@lab.nig.jp						ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Baumann P, 1996, CELL, V87, P757, DOI 10.1016/S0092-8674(00)81394-X; Benson FE, 1998, NATURE, V391, P401, DOI 10.1038/34937; BOUNDYMILLS KL, 1993, GENETICS, V133, P39; Gupta RC, 1997, P NATL ACAD SCI USA, V94, P463, DOI 10.1073/pnas.94.2.463; KOWALCZYKOWSKI SC, 1994, ANNU REV BIOCHEM, V63, P991, DOI 10.1146/annurev.bi.63.070194.005015; MILNE GT, 1993, GENE DEV, V7, P1755, DOI 10.1101/gad.7.9.1755; Mortensen UH, 1996, P NATL ACAD SCI USA, V93, P10729, DOI 10.1073/pnas.93.20.10729; MURRIS DFR, 1994, MUTAT RESDNA REPAIR, V315, P295; Namsaraev E, 1997, MOL CELL BIOL, V17, P5359, DOI 10.1128/MCB.17.9.5359; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; OGAWA T, 1995, ADV BIOPHYS, V31, P93, DOI 10.1016/0065-227X(95)99385-3; OGAWA T, 1993, COLD SPRING HARB SYM, V58, P567, DOI 10.1101/SQB.1993.058.01.063; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; RESNICK M A, 1987, P157; Shen ZY, 1996, J BIOL CHEM, V271, P148, DOI 10.1074/jbc.271.1.148; SHINOHARA A, 1993, NAT GENET, V4, P239, DOI 10.1038/ng0793-239; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SHINOHARA A, UNPUB GENES CELLS; SHINOHARA A, 1995, TRENDS BIOCHEM SCI, V20, P587; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; WEST SC, 1992, ANNU REV BIOCHEM, V61, P603, DOI 10.1146/annurev.bi.61.070192.003131	29	373	384	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 22	1998	391	6665					404	407		10.1038/34943	http://dx.doi.org/10.1038/34943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT444	9450759				2022-12-01	WOS:000071604200059
J	Enari, M; Sakahira, H; Yokoyama, H; Okawa, K; Iwamatsu, A; Nagata, S				Enari, M; Sakahira, H; Yokoyama, H; Okawa, K; Iwamatsu, A; Nagata, S			A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD	NATURE			English	Article							FAS-MEDIATED APOPTOSIS; NF-KAPPA-B; CELL-DEATH; ICE-LIKE; PROTEASE; PROTEINS; FAMILY; FRAGMENTATION; IDENTIFICATION; INVOLVEMENT	The homeostasis of animals is regulated not only by the growth and differentiation of cells, but also by cell death through a process known as apoptosis. Apoptosis is mediated by members of the caspase family of proteases, and eventually causes the degradation of chromosomal DNA. A caspase-activated deoxyribonuclease (CAD) and its inhibitor (ICAD) have now been identified in the cytoplasmic fraction of mouse lymphoma cells. CAD is a protein of 343 amino acids which carries a nuclear-localization signal; ICAD exists in a long and a short form. Recombinant ICAD specifically inhibits CAD-induced degradation of nuclear DMA and its DNase activity. When CAD is expressed with ICAD In COS cells or in a cell-free system, CAD is produced as a complex with ICAD: treatment with caspase 3 releases the DNase activity which causes DNA fragmentation in nuclei. ICAD therefore seems to function as a chaperone for CAD during its synthesis, remaining complexed with CAD to inhibit its DNase activity; caspases activated by apoptotic stimuli then cleave ICAD, allowing CAD to enter the nucleus and degrade chromosomal DNA.	Osaka Univ, Sch Med, Dept Genet, Osaka 565, Japan; Kirin Brewery Co Ltd, Cent Lab Key Technol, Kanagawa 236, Japan; Osaka Biosci Inst, Osaka 565, Japan	Osaka University; Kirin Brewery Company Limited	Nagata, S (corresponding author), Osaka Univ, Sch Med, Dept Genet, 2-2 Yamada Oka, Osaka 565, Japan.		Enari, Masato/E-5507-2014; Nagata, Shigekazu/AAG-3203-2019	Enari, Masato/0000-0003-4293-3848; Nagata, Shigekazu/0000-0001-9758-8426				Armstrong RC, 1996, J BIOL CHEM, V271, P16850, DOI 10.1074/jbc.271.28.16850; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARTL FU, 1994, TRENDS BIOCHEM SCI, V19, P20, DOI 10.1016/0968-0004(94)90169-4; Henkart PA, 1996, IMMUNITY, V4, P195, DOI 10.1016/S1074-7613(00)80428-8; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; Iwamatsu A, 1996, J BIOCHEM-TOKYO, V120, P29; IWAMATSU A, 1992, ELECTROPHORESIS, V13, P142, DOI 10.1002/elps.1150130129; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Longthorne VL, 1997, EMBO J, V16, P3805, DOI 10.1093/emboj/16.13.3805; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; Montague JW, 1997, J BIOL CHEM, V272, P6677, DOI 10.1074/jbc.272.10.6677; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; PETISCH MC, 1993, EMBO J, V12, P371; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Shiokawa D, 1997, ARCH BIOCHEM BIOPHYS, V346, P15, DOI 10.1006/abbi.1997.0275; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WALLIS R, 1992, EUR J BIOCHEM, V207, P687, DOI 10.1111/j.1432-1033.1992.tb17096.x; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; WYLLIE AH, 1984, J PATHOL, V142, P66; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0	44	2638	2806	2	137	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 1	1998	391	6662					43	50		10.1038/34112	http://dx.doi.org/10.1038/34112			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YP888	9422506				2022-12-01	WOS:000071326100042
J	Davies, SJA; Fitch, MT; Memberg, SP; Hall, AK; Raisman, G; Silver, J				Davies, SJA; Fitch, MT; Memberg, SP; Hall, AK; Raisman, G; Silver, J			Regeneration of adult axons in white matter tracts of the central nervous system	NATURE			English	Article							DORSAL-ROOT GANGLION; NEURITE OUTGROWTH; SPINAL-CORD; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; OLIGODENDROCYTES; ASTROCYTES; INVITRO; PROTEOGLYCANS; INHIBITION	It is widely accepted that the adult mammalian central nervous system (CNS) is unable to regenerate axons(1), In addition to physical or molecular barriers presented by glial scarring at the lesion site(2-4), it has been suggested that the normal myelinated CNS environment contains potent growth inhibitors(5,6) or lacks growth-promoting molecules(1,7). Here we investigate whether adult CNS white matter can support long-distance regeneration of adult axons in the absence of glial scarring, by using a microtransplantation technique(8) that minimizes scarring(9) to inject minute volumes of dissociated adult rat dorsal root ganglia directly into adult rat CNS pathways. This atraumatic injection procedure allowed considerable numbers of regenerating adult axons immediate access to the host glial terrain, where we found that they rapidly extended for long distances in white matter, eventually invading grey matter. Abortive regeneration correlated precisely with increased levels of proteoglycans within the extracellular matrix at the transplant interface, whereas successfully regenerating transplants were associated with minimal upregulation of these molecules, Our results demonstrate, to our knowledge for the first time, that reactive glial extracellular matrix at the lesion site is directly associated with failure of axon regrowth in vivo, and that adult myelinated white matter tracts beyond the glial scar can be highly permissive for regeneration.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT NEUROSCI,CLEVELAND,OH 44106; NATL INST MED RES,DIV NEUROBIOL,NORMAN & SADIE LEE RES CTR,LONDON NW7 1AA,ENGLAND	Case Western Reserve University; MRC National Institute for Medical Research			Raisman, Geoffrey/B-3215-2009	Hall, Alison/0000-0002-7237-7945				ARD MD, 1991, GLIA, V4, P70, DOI 10.1002/glia.440040109; BANDTLOW C, 1990, J NEUROSCI, V10, P3837, DOI 10.1523/JNEUROSCI.10-12-03837.1990; Berry M, 1983, Acta Neurochir Suppl (Wien), V32, P31; BRITTIS PA, 1995, MOL CELL NEUROSCI, V6, P413, DOI 10.1006/mcne.1995.1031; CARLSTEDT T, 1987, NEUROSCI LETT, V74, P14, DOI 10.1016/0304-3940(87)90043-7; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Davies SJA, 1996, EXP NEUROL, V142, P203, DOI 10.1006/exnr.1996.0192; DAVIES SJA, 1993, EUR J NEUROSCI, V5, P95, DOI 10.1111/j.1460-9568.1993.tb00474.x; DAVIES SJA, 1994, J NEUROSCI, V14, P1596, DOI 10.1523/JNEUROSCI.14-03-01596.1994; FAWCETT JW, 1995, J CELL SCI, V103; FITCH MT, IN PRESS EXP NEUROL; GIBSON SJ, 1984, J NEUROSCI, V4, P3101, DOI 10.1523/jneurosci.04-12-03101.1984; GIULIAN D, 1994, DEV NEUROSCI-BASEL, V16, P128, DOI 10.1159/000112099; Grill R, 1997, J NEUROSCI, V17, P5560; KOBAYASHI H, 1995, DEV BIOL, V168, P383, DOI 10.1006/dbio.1995.1088; Krekoski CA, 1996, J NEUROSCI RES, V43, P1, DOI 10.1002/jnr.490430102; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; MCKEON RJ, 1991, J NEUROSCI, V11, P3398; PINDZOLA RR, 1993, DEV BIOL, V156, P34, DOI 10.1006/dbio.1993.1057; Ramon y Cajal S, 1928, DEGENERATION REGENER; REIER PJ, 1983, SPINAL CORD RECONSTR, P163; ROHRER H, 1985, DEV BIOL, V111, P95, DOI 10.1016/0012-1606(85)90438-5; RUDGE JS, 1990, J NEUROSCI, V10, P3594; SCHWAB ME, 1993, ANNU REV NEUROSCI, V16, P565, DOI 10.1146/annurev.ne.16.030193.003025; SMITHTHOMAS LC, 1994, J CELL SCI, V107, P1687; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; STEINDLER DA, 1990, EXP NEUROL, V109, P35, DOI 10.1016/S0014-4886(05)80007-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; VAUDANO E, 1995, J NEUROSCI, V15, P3594; WICTORIN K, 1990, NATURE, V347, P556, DOI 10.1038/347556a0	30	628	653	0	36	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					680	683		10.1038/37776	http://dx.doi.org/10.1038/37776			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414159				2022-12-01	WOS:A1997YM50800030
J	Bonventre, JV; Huang, ZH; Taheri, MR; OLeary, E; Li, E; Moskowitz, MA; Sapirstein, A				Bonventre, JV; Huang, ZH; Taheri, MR; OLeary, E; Li, E; Moskowitz, MA; Sapirstein, A			Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A(2)	NATURE			English	Article							ARACHIDONIC-ACID; GERBIL BRAIN; ISCHEMIA; REPERFUSION; MITOCHONDRIAL; IMPLANTATION; DAMAGE; PLA(2); KIDNEY; FORMS	Phospholipase A(2) (PLA(2)) enzymes are critical regulators of prostaglandin and leukotriene synthesis and can directly modify the composition of cellular membranes(1,2). PLA(2) enzymes release fatty acids and lysophospholipids, including the precursor of platelet-activating factor, PAF, from phospholipids. Free fatty acids, eicosanoids, lysophospholipids and PAF are potent regulators of inflammation(1,3,4), reproduction(5-7) and neurotoxicity(1,8,9). The physiological roles of the various forms of PLA(2) are not well defined. The cytosolic form, cPLA(2), preferentially releases arachidonic acid from phospholipids and is regulated by changes in intracellular calcium concentration(10,11). We have now created 'knockout' (cPLA(2)(-/-)) mice that lack this enzyme, in order to evaluate its physiological importance. We find that cPLA(2)(-/-) mice develop normally, but that the females produce only small litters in which the pups are usually dead, Stimulated peritoneal macrophages from cPLA(2)(-/-) animals did not produce prostaglandin E-2 or leukotriene B-4 or C-4. After transient middle cerebral artery occlusion, cPLA(2)(-/-) mice had smaller infarcts and developed less brain oedema and fewer neurological deficits. Thus cPLA(2) is important for macrophage production of inflammatory mediators, fertility, and in the pathophysiology of neuronal death after transient focal cerebral ischaemia.	MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT MED, CHARLESTOWN, MA 02129 USA; HARVARD UNIV, SCH MED, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT NEUROSURG, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, ANESTHESIA SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, MED SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, NEUROSURG SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; MASSACHUSETTS GEN HOSP, CARDIAC SERV, DEPT ANESTHESIA, CHARLESTOWN, MA 02129 USA; HARVARD MIT DIV HLTH SCI & TECHNOL, CHARLESTOWN, MA 02129 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University	Bonventre, JV (corresponding author), MASSACHUSETTS GEN HOSP, MED SERV, DEPT MED, 149 13TH ST, CHARLESTOWN, MA 02129 USA.		Moskowitz, Michael A/D-9916-2011					ABRAHAMSOHN PA, 1993, J EXP ZOOL, V266, P603, DOI 10.1002/jez.1402660610; Ausubel F.M., 1994, CURRENT PROTOCOLS MO; BAZAN NG, 1989, ANN NY ACAD SCI, V559, P1; BONVENTRE JV, 1993, J LIPID MEDIATOR, V6, P457; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; Challis John R. G., 1994, P985; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Clemens JA, 1996, STROKE, V27, P527, DOI 10.1161/01.STR.27.3.527; Dennis EA, 1997, TRENDS BIOCHEM SCI, V22, P1, DOI 10.1016/S0968-0004(96)20031-3; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; Hara H, 1996, J CEREBR BLOOD F MET, V16, P605, DOI 10.1097/00004647-199607000-00010; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; KIM DK, 1993, BIOCHEM J, V294, P261, DOI 10.1042/bj2940261; Kol S, 1997, ENDOCRINOLOGY, V138, P314, DOI 10.1210/en.138.1.314; MALIS CD, 1986, J BIOL CHEM, V261, P14201; MOSKOWITZ MA, 1984, SCIENCE, V224, P886, DOI 10.1126/science.6719118; Novaro V, 1996, PROSTAGLANDINS, V51, P363, DOI 10.1016/0090-6980(96)00043-3; RAJABI MR, 1995, AM J PHYSIOL-ENDOC M, V269, pE940, DOI 10.1152/ajpendo.1995.269.5.E940; Rice GE, 1995, REPROD FERT DEVELOP, V7, P1471, DOI 10.1071/RD9951471; RORDORF G, 1991, J NEUROSCI, V11, P1829; ROSS BM, 1995, J NEUROCHEM, V64, P2213; Sapirstein A, 1996, J BIOL CHEM, V271, P21505, DOI 10.1074/jbc.271.35.21505; Sugimoto Y, 1997, SCIENCE, V277, P681, DOI 10.1126/science.277.5326.681; Teslenko V, 1997, BBA-LIPID LIPID MET, V1344, P189, DOI 10.1016/S0005-2760(96)00137-3; vanderWeiden RMF, 1996, J REPROD FERTIL, V107, P161; VERITY MA, 1993, ANN NY ACAD SCI, V679, P110; WINKLER JD, 1997, BIOCHIM BIOPHYS ACTA, P173; YANG GY, 1994, STROKE, V25, P165, DOI 10.1161/01.STR.25.1.165	28	717	725	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 11	1997	390	6660					622	625		10.1038/37635	http://dx.doi.org/10.1038/37635			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403693				2022-12-01	WOS:A1997YK85300053
J	Petricoin, EF; Ito, S; Williams, BL; Audet, S; Stancato, LF; Gamero, A; Clouse, K; Grimley, P; Weiss, A; Beeler, J; Finbloom, DS; Shores, EW; Abraham, R; Larner, AC				Petricoin, EF; Ito, S; Williams, BL; Audet, S; Stancato, LF; Gamero, A; Clouse, K; Grimley, P; Weiss, A; Beeler, J; Finbloom, DS; Shores, EW; Abraham, R; Larner, AC			Antiproliferative action of interferon-alpha requires components of T-cell-receptor signalling	NATURE			English	Article							ANTIGEN RECEPTOR; TYROSINE PHOSPHATASE; KINASE; TRANSDUCTION; EXPRESSION; PROTEINS; CD45	Signal transduction through both cytokine and lymphocyte antigen receptors shares some common pathways by which they initiate cellular responses, such as activation of mitogen-activated protein kinase(s)(1,2). However, other signalling components appear to be uniquely coupled to each receptor. For example, the interferon receptors transduce regulatory signals through the JAK/ STAT pathway, resulting in an inhibition of growth and of antiviral effects, whereas this pathway apparently plays no role in T-cell-receptor (TCR)-dependent gene expression(3,4). Conversely, signal transduction through the TCR requires the tyrosine kinases Lck and ZAP-70 and the tyrosine phosphatase CD45 (ref. 5). Here we show that, unexpectedly, transmission of growth-inhibitory signals by interferon-alpha (IFN-alpha) in T cells requires the expression and association of CD45, Lck and ZAP-70 with the IFN-alpha-receptor signalling complex.	US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892; MAYO CLIN & MAYO FDN,DEPT IMMUNOL & PHARMACOL,ROCHESTER,MN 55905; USUHS,DEPT PATHOL,BETHESDA,MD 20892; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	US Food & Drug Administration (FDA); Mayo Clinic; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BEADLING C, 1994, EMBO J, V13; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; LARNER AC, 1995, BBA-MOL CELL RES, V1266, P278, DOI 10.1016/0167-4889(95)00015-K; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WILLIAMS BL, UNPUB MOL CELL BIOL	10	137	140	1	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 11	1997	390	6660					629	632		10.1038/37648	http://dx.doi.org/10.1038/37648			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YK853	9403695				2022-12-01	WOS:A1997YK85300055
J	Salzmann, P; Kerlikowske, K; Phillips, K				Salzmann, P; Kerlikowske, K; Phillips, K			Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age	ANNALS OF INTERNAL MEDICINE			English	Article							BREAST-CANCER; RECOMMENDATIONS; METAANALYSIS; STRATEGIES; MEDICINE; BENEFIT; YOUNGER; PROGRAM; TRIALS; HEALTH	Background: Screening mammography is recommended for women 50 to 69 years of age because of its proven efficacy and reasonable cost-effectiveness. Extending screening recommendations to include women 40 to 49 years of age remains controversial. Objective: To compare the cost-effectiveness of screening mammography in women of different age groups. Design: Cost-effectiveness analysis done using Markov and Monte Carlo models. Patients: General population of women 40 years of age and older. Interventions: Biennial screening from 50 to 69 years of age was compared with no screening. Screening done every 18 months from ages 40 to 49 years, followed by biennial screening from ages 50 to 69 years, was compared with biennial screening from ages 50 to 69 years. Measurements: Life-expectancy, costs, and incremental cost-effectiveness. Results: Screening women from 50 to 69 years of age improved life expectancy by 12 days at a cost of $704 per woman, resulting in a cost-effectiveness ratio of $21 400 per year of life saved. Extending screening to include women 40 to 49 years of age improved life expectancy by 2.5 days at a cost of $676 per woman. The incremental cost-effectiveness of screening women 40 to 49 years of age was $105 000 per year of life saved. On the basis of a multiway sensitivity analysis, there is a 75% chance that screening mammography in women 50 to 69 years of age costs less than $50 000 per year of life saved, compared with a 7% chance in women 40 to 49 years of age. Conclusion: The cost-effectiveness of screening mammography in women 40 to 49 years of age is almost five times that in older women. When breast cancer screening policies are being set, the incremental cost-effectiveness of extending mammographic screening to younger women should be considered.	VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco					NCI NIH HHS [P50 CA58207, 1 U01 CA 63740] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA063740, P50CA058207] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		American College of Radiology, 1982, POL STAT GUID MAMM; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BLACK WC, 1995, J NATL CANCER I, V87, P720, DOI 10.1093/jnci/87.10.720; Black WC, 1996, JAMA-J AM MED ASSOC, V275, P111, DOI 10.1001/jama.1996.03530260025021; Boer R, 1996, JAMA-J AM MED ASSOC, V275, P111, DOI 10.1001/jama.1996.03530260025022; BROWN ML, 1995, AM J ROENTGENOL, V165, P1373, DOI 10.2214/ajr.165.6.7484568; BROWN ML, 1993, BREAST CANCER RES TR, V25, P113, DOI 10.1007/BF00662136; BROWN ML, 1995, RADIOLOGY, V195, P529, DOI 10.1148/radiology.195.2.7724778; DEKONING HJ, 1997, NIH CONS DEV C BREAS, P40; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; ELWOOD JM, 1993, ONLINE J CURR CLIN T, V2; FEIG SA, 1995, CANCER, V76, P2097, DOI 10.1002/1097-0142(19951115)76:10+<2097::AID-CNCR2820761332>3.0.CO;2-B; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; GLASZIOU PP, 1995, MED J AUSTRALIA, V162, P625, DOI 10.5694/j.1326-5377.1995.tb126047.x; HALL J, 1992, SOC SCI MED, V34, P993, DOI 10.1016/0277-9536(92)90130-I; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; HARRIS RP, 1991, CANCER, V67, P2010, DOI 10.1002/1097-0142(19910401)67:7<2010::AID-CNCR2820670730>3.0.CO;2-8; KATTLOVE H, 1995, JAMA-J AM MED ASSOC, V273, P142, DOI 10.1001/jama.273.2.142; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; KERLIKOWSKE K, 1997, MONOGR NATL CANC I, V22, P105; KERLIKOWSKE K, 1997, MONOGR NATL CANC I, V22, P79; KOSARY CL, 1995, NIH PUBLICATION; Lee TT, 1997, ANN INTERN MED, V126, P337, DOI 10.7326/0003-4819-126-5-199703010-00001; LINDFORS KK, 1995, JAMA-J AM MED ASSOC, V274, P881, DOI 10.1001/jama.274.11.881; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; PEER PGM, 1994, J NATL CANCER I, V86, P436, DOI 10.1093/jnci/86.6.436; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; SHAPIRO S, 1994, AM J PUBLIC HEALTH, V84, P10, DOI 10.2105/AJPH.84.1.10; Shapiro S, 1988, PERIODIC SCREENING B; SICKLES EA, 1995, ANN INTERN MED, V122, P534, DOI 10.7326/0003-4819-122-7-199504010-00010; SICKLES EA, 1993, J NATL CANCER I, V85, P1621, DOI 10.1093/jnci/85.20.1621; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; SOX HC, 1995, ANN INTERN MED, V122, P550, DOI 10.7326/0003-4819-122-7-199504010-00013; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; *TREEAG SOFTW, 1996, DATA 3 0; *US BUR CENS, 1991, STAT ABSTR US, P84; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, V2nd; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; 1997, CANC LETT, V23, P4; 1986, CAN MED ASSOC J, V134, P724	43	193	193	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					955	965		10.7326/0003-4819-127-11-199712010-00001	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00001			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412300				2022-12-01	WOS:A1997YJ08000001
J	Coupland, RM				Coupland, RM			Abhorrent weapons and ''superfluous injury or unnecessary suffering'': from field surgery to law	BRITISH MEDICAL JOURNAL			English	Article											Coupland, RM (corresponding author), RED CROSS,INT COMM,HLTH OPERAT DIV,CH-1202 GENEVA,SWITZERLAND.							*INT COMM RED CROS, 1997, SIRUS PROJ DET WHICH	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1450	1452		10.1136/bmj.315.7120.1450	http://dx.doi.org/10.1136/bmj.315.7120.1450			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418099	Green Published			2022-12-01	WOS:A1997YJ67200035
J	Joyce, S; Woods, AS; Yewdell, JW; Bennink, JR; De Silva, AD; Boesteanu, A; Balk, SP; Cotter, RJ; Brutkiewicz, RR				Joyce, S; Woods, AS; Yewdell, JW; Bennink, JR; De Silva, AD; Boesteanu, A; Balk, SP; Cotter, RJ; Brutkiewicz, RR			Natural ligand of mouse CD1d1: Cellular glycosylphosphatidylinositol	SCIENCE			English	Article							FAST ATOM BOMBARDMENT; T-CELLS; MASS-SPECTROMETRY; PEPTIDES; FAMILY	Mouse CD1d1, a member of the CD1 family of evolutionarily conserved major histocompatibility antigen-like molecules, controls the differentiation and function of a T lymphocyte subset, NK1(+) natural T cells, proposed to regulate immune responses. The CD1d1 crystal structure revealed a large hydrophobic binding site occupied by a ligand of unknown chemical nature. Mass spectrometry and metabolic radiolabeling were used to identify cellular glycosylphosphatidylinositol as a major natural ligand of CD1d1. CD1d1 bound glycosylphosphatidylinositol through its phosphatidylinositol aspect with high affinity. Glycosylphosphatidylinositol or another glycolipid could be a candidate natural ligand for CD1d1-restricted T cells.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA; Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Johns Hopkins University; Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Joyce, S (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Dept Microbiol & Immunol, Hershey, PA 17033 USA.		yewdell, jyewdell@nih.gov jonathan/A-1702-2012	Brutkiewicz, Randy/0000-0002-7396-480X; JOYCE, Sebastian/0000-0002-3183-1451				ARASE H, 1992, P NATL ACAD SCI USA, V89, P6506, DOI 10.1073/pnas.89.14.6506; Baxter AG, 1997, DIABETES, V46, P572, DOI 10.2337/diabetes.46.4.572; BENDELAC A, 1995, SCIENCE, V268, P863, DOI 10.1126/science.7538697; BROOKS EG, 1993, P NATL ACAD SCI USA, V90, P11787, DOI 10.1073/pnas.90.24.11787; BRUTKIEWICZ RR, 1995, J EXP MED, V182, P1913, DOI 10.1084/jem.182.6.1913; CASTANO AR, 1995, SCIENCE, V269, P223, DOI 10.1126/science.7542403; Chen YH, 1997, IMMUNITY, V6, P459, DOI 10.1016/S1074-7613(00)80289-7; Exley M, 1997, J EXP MED, V186, P109, DOI 10.1084/jem.186.1.109; HELLER DN, 1988, ANAL CHEM, V60, P2787, DOI 10.1021/ac00175a029; HELLER DN, 1987, ANAL CHEM, V59, P2806, DOI 10.1021/ac00150a018; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JOYCE S, 1994, J EXP MED, V179, P577; JOYCE SA, UNPUB; LANTZ O, 1994, J EXP MED, V180, P1097, DOI 10.1084/jem.180.3.1097; MARTIN LH, 1986, P NATL ACAD SCI USA, V83, P9154, DOI 10.1073/pnas.83.23.9154; Mendiratta SK, 1997, IMMUNITY, V6, P469, DOI 10.1016/S1074-7613(00)80290-3; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Sugita M, 1996, SCIENCE, V273, P349, DOI 10.1126/science.273.5273.349; SYKES M, 1990, J IMMUNOL, V145, P3209; UDENFRIEND S, 1995, ANNU REV BIOCHEM, V64, P563, DOI 10.1146/annurev.bi.64.070195.003023; VARKI A, 1994, METHOD ENZYMOL, V230, P16; Wolf PR, 1995, ANNU REV CELL DEV BI, V11, P267, DOI 10.1146/annurev.cb.11.110195.001411; WOODS AS, 1995, ANAL BIOCHEM, V226, P15, DOI 10.1006/abio.1995.1185; YOSHIMOTO T, 1995, SCIENCE, V270, P1845, DOI 10.1126/science.270.5243.1845; Zeng ZH, 1997, SCIENCE, V277, P339, DOI 10.1126/science.277.5324.339	27	353	368	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	MAR 6	1998	279	5356					1541	1544		10.1126/science.279.5356.1541	http://dx.doi.org/10.1126/science.279.5356.1541			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ZA527	9488653				2022-12-01	WOS:000072372900066
J	Niederau, C; Niederau, CM; Lange, S; Littauer, A; Abdel-Jalil, N; Maurer, M; Haussinger, D; Strohmeyer, G				Niederau, C; Niederau, CM; Lange, S; Littauer, A; Abdel-Jalil, N; Maurer, M; Haussinger, D; Strohmeyer, G			Screening for hemochromatosis and iron deficiency in employees and primary care patients in western Germany	ANNALS OF INTERNAL MEDICINE			English	Article						hemochromatosis; iron overload; anemia, iron-deficiency; ferritin; transferrin	LONG-TERM SURVIVAL; COST-EFFECTIVENESS; HEREDITARY HEMOCHROMATOSIS; BLOOD-DONORS; GENETIC HEMOCHROMATOSIS; SERUM FERRITIN; PREVALENCE; HEMOGLOBIN; POPULATION; CHILDREN	Background: Many physicians still believe that iron overload (hemochromatosis) is an uncommon disorder. Objective: To estimate the frequency of iron overload and iron deficiency in a group of employees and a group of outpatients. Design: Prospective screening study. Setting: Western Germany. Participants: 3012 asymptomatic employees and 3027 outpatients of nine practitioners. Measurements: Serum ferritin levels and transferrin saturation were measured. Participants with repeatedly abnormal results had thorough clinical evaluations to identify the cause of iron deficiency or overload. Results: Gross iron overload (elevated transferrin saturation and ferritin levels) was proven by liver biopsy and phlebotomy treatment in 28 participants (0.4% of female outpatients, 0.7% of male outpatients, 0.2% bf female employees, and 0.4% of male employees) and in six siblings of these participants. Of the 34 participants with iron overload, 30 were precirrhotic. Because 60% of an unselected group of employees with elevated transferrin saturation but normal ferritin levels were assumed to have early hemochromatosis, the prevalence of hemochromatosis was estimated to be 1.8% among patients (1.9% in women and 1.6% in men) and 1.0% among employees (1.1% in women and 1.0% in men). Iron deficiency was found in 6.8% of female patients, 2.4% of male patients, 6.0% of female employees, and 0.5% of male employees. Conclusions: Iron deficiency was more common in women, and iron overload was more common in men. Among male employees, iron overload was almost as common as iron deficiency.	Univ Dusseldorf, Dept Med, Div Gatroenterol Hepatol & Infect Dis, D-40225 Dusseldorf, Germany; Mannesmann Rohrenwerke AG, Betriebsarztzentrum, D-40472 Dusseldorf, Germany; Univ Dusseldorf, Inst Clin Chem & Lab Diagnost, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Niederau, C (corresponding author), Univ Dusseldorf, Dept Med, Div Gatroenterol Hepatol & Infect Dis, Moorenstr 5, D-40225 Dusseldorf, Germany.							Adams PC, 1995, HEPATOLOGY, V22, P1720, DOI 10.1016/0270-9139(95)90197-3; ADAMS PC, 1995, GASTROENTEROLOGY, V109, P177, DOI 10.1016/0016-5085(95)90283-X; ADAMS PC, 1991, GASTROENTEROLOGY, V101, P368, DOI 10.1016/0016-5085(91)90013-B; BALAN V, 1994, GASTROENTEROLOGY, V107, P453, DOI 10.1016/0016-5085(94)90171-6; BUFFONE GJ, 1994, CLIN CHEM, V40, P1631; Bulaj ZJ, 1996, NEW ENGL J MED, V335, P1799, DOI 10.1056/NEJM199612123352403; COOK JD, 1986, BLOOD, V68, P726; DEUGNIER YM, 1993, GASTROENTEROLOGY, V104, P228, DOI 10.1016/0016-5085(93)90856-8; EDWARDS CQ, 1993, NEW ENGL J MED, V328, P1616; EDWARDS CQ, 1988, NEW ENGL J MED, V318, P1355, DOI 10.1056/NEJM198805263182103; FARGION S, 1992, HEPATOLOGY, V15, P655, DOI 10.1002/hep.1840150417; FISHER KD, 1985, AM J CLIN NUTR, V42, P1318; GORDEUK V, 1992, NEW ENGL J MED, V326, P95, DOI 10.1056/NEJM199201093260204; JONSSON JJ, 1991, J CLIN EPIDEMIOL, V44, P1289, DOI 10.1016/0895-4356(91)90090-V; KENT G, 1968, AM J MED, V44, P837, DOI 10.1016/0002-9343(68)90083-1; KUSHNER JP, 1992, CECIL TXB MED, P839; LOREAL O, 1992, J HEPATOL, V16, P122, DOI 10.1016/S0168-8278(05)80104-7; MerryweatherClarke AT, 1997, J MED GENET, V34, P275, DOI 10.1136/jmg.34.4.275; MILMAN N, 1984, TRANSFUSION, V24, P464, DOI 10.1046/j.1537-2995.1984.24685066801.x; NELSON M, 1993, BRIT J NUTR, V70, P147, DOI 10.1079/BJN19930112; Niederau C, 1996, GASTROENTEROLOGY, V110, P1107, DOI 10.1053/gast.1996.v110.pm8613000; NIEDERAU C, 1985, NEW ENGL J MED, V313, P1256, DOI 10.1056/NEJM198511143132004; NIEDERAU C, 1994, ADV EXP MED BIOL, V356, P293; OSKI FA, 1993, NEW ENGL J MED, V329, P190, DOI 10.1056/NEJM199307153290308; PHATAK PD, 1994, ARCH INTERN MED, V154, P769, DOI 10.1001/archinte.154.7.769; PI DW, 1994, TRANSFUSION, V34, P7, DOI 10.1046/j.1537-2995.1994.34194098609.x; SUMMERS KM, 1990, HEPATOLOGY, V12, P20, DOI 10.1002/hep.1840120105; VALBERG LS, 1976, CAN MED ASSOC J, V114, P417; WEINSTEIN MC, 1985, ANNU REV PUBL HEALTH, V6, P41; WELCH HG, 1989, NEW ENGL J MED, V321, P807, DOI 10.1056/NEJM198909213211207	30	85	85	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1998	128	5					337	+		10.7326/0003-4819-128-5-199803010-00001	http://dx.doi.org/10.7326/0003-4819-128-5-199803010-00001			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YY519	9490593				2022-12-01	WOS:000072155600001
J	Gale, CA; Bendel, CM; McClellan, M; Hauser, M; Becker, JM; Berman, J; Hostetter, MK				Gale, CA; Bendel, CM; McClellan, M; Hauser, M; Becker, JM; Berman, J; Hostetter, MK			Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1	SCIENCE			English	Article							CELL-ADHESION; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; EPITHELIAL ADHESION; HYPHAL FORMATION; INTEGRIN ANALOG; PROTEIN; YEAST; MORPHOGENESIS; EXPRESSION	Adhesion and the ability to form filaments are thought to contribute to the pathogenicity of Candida albicans, the leading cause of fungal disease in immunocompromised patients. Int1p is a C. albicans surface protein with limited similarity to vertebrate integrins. INT1 expression in Saccharomyces cerevisiae was sufficient to direct the adhesion of this normally nonadherent yeast to human epithelial cells, Furthermore, disruption of INT1 in C. albicans suppressed hyphal growth, adhesion to epithelial cells, and virulence in mice, Thus, INT1 links adhesion, filamentous growth, and pathogenicity in C. albicans and Int1p may be an attractive target for the development of antifungal therapies.	Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 220, St Paul, MN 55108 USA; Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; Univ Tennessee, Dept Microbiol, Knoxville, TN 37996 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Tennessee System; University of Tennessee Knoxville	Berman, J (corresponding author), Univ Minnesota, Dept Plant Biol, Biol Sci Ctr 220, 220 Biol Sci Ctr, St Paul, MN 55108 USA.		Berman, Judith/AAS-5115-2021; Berman, Judith/ABA-8528-2021	Berman, Judith/0000-0002-8577-0084; Bendel, Catherine/0000-0001-6093-5930	NIAID NIH HHS [AI25827] Funding Source: Medline; NICHD NIH HHS [HD00850, HD33692] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025827] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; BECKER JM, 1995, INFECT IMMUN, V63, P4515, DOI 10.1128/IAI.63.11.4515-4518.1995; BENDEL C, UNPUB; BENDEL CM, 1993, J CLIN INVEST, V92, P1840, DOI 10.1172/JCI116775; BENDEL CM, 1995, J INFECT DIS, V171, P1660, DOI 10.1093/infdis/171.6.1660; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COLE MF, 1995, FEMS MICROBIOL LETT, V126, P177, DOI 10.1111/j.1574-6968.1995.tb07413.x; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; FONZI WA, 1993, GENETICS, V134, P717; Gale C, 1996, P NATL ACAD SCI USA, V93, P357, DOI 10.1073/pnas.93.1.357; Gale C., UNPUB; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUSTAFSON KS, 1991, J CLIN INVEST, V87, P1896, DOI 10.1172/JCI115214; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JITSURONG S, 1993, MYCOPATHOLOGIA, V123, P95, DOI 10.1007/BF01365086; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KLOTZ SA, 1991, J INFECT DIS, V163, P604, DOI 10.1093/infdis/163.3.604; Kohler JR, 1996, P NATL ACAD SCI USA, V93, P13223, DOI 10.1073/pnas.93.23.13223; KURTZ MB, 1986, MOL CELL BIOL, V6, P142, DOI 10.1128/MCB.6.1.142; Leberer E, 1996, P NATL ACAD SCI USA, V93, P13217, DOI 10.1073/pnas.93.23.13217; LIU HP, 1994, SCIENCE, V266, P1723, DOI 10.1126/science.7992058; Lo HJ, 1997, CELL, V90, P939, DOI 10.1016/S0092-8674(00)80358-X; MAISCH PA, 1980, INFECT IMMUN, V27, P650, DOI 10.1128/IAI.27.2.650-656.1980; ODDS FC, 1988, CANDIDA CANDIDOSIS, P46; RADFORD DR, 1994, J MED MICROBIOL, V40, P416, DOI 10.1099/00222615-40-6-416; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SAPORITOIRWIN SM, 1995, MOL CELL BIOL, V15, P601; WENZEL RP, 1991, INFECT CONT HOSP EP, V12, P523, DOI 10.1086/646403; Yan SH, 1996, INFECT IMMUN, V64, P2930, DOI 10.1128/IAI.64.8.2930-2935.1996	30	271	292	2	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1355	1358		10.1126/science.279.5355.1355	http://dx.doi.org/10.1126/science.279.5355.1355			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478896				2022-12-01	WOS:000072251800051
J	Rouse, D; Mackay, P; Stirnberg, P; Estelle, M; Leyser, O				Rouse, D; Mackay, P; Stirnberg, P; Estelle, M; Leyser, O			Changes in auxin response from mutations in an AUX/IAA gene	SCIENCE			English	Article							ARABIDOPSIS-THALIANA; REGULATED GENES; MESSENGER-RNAS; LINKAGE MAP; EXPRESSION; TISSUE; ACID	Transcription of the AUX/IAA family of genes is rapidly induced by the plant hormone auxin, but evidence that AUX/IAA genes mediate further responses to auxin has been elusive. Changes in diverse auxin responses result from mutations in the Arabidopsis AXR3 gene. AXR3 was shown to be a member of the AUX/IAA family, providing direct evidence that AUX/IAA genes are central in auxin signaling, Molecular characterization of axr3 gain-of-function and loss-of-function mutations established the functional importance of domains conserved among AUX/IAA proteins.	Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England; Indiana Univ, Dept Biol, Bloomington, IN 47405 USA	University of York - UK; Indiana University System; Indiana University Bloomington	Leyser, O (corresponding author), Univ York, Dept Biol, York YO1 5YW, N Yorkshire, England.		Leyser, Ottoline/AAC-5577-2019; Rouse, Dean/B-3636-2009	Leyser, Ottoline/0000-0003-2161-3829				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ABEL S, 1994, P NATL ACAD SCI USA, V91, P326, DOI 10.1073/pnas.91.1.326; AINLEY WM, 1988, J BIOL CHEM, V263, P10658; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; CONNER TW, 1990, PLANT MOL BIOL, V15, P3210; Dellaporta S.L., 1983, PLANT MOL BIOL REP, V1, P19, DOI [10.1007/BF02712670, DOI 10.1007/BF02712670]; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; Leyser HMO, 1996, PLANT J, V10, P403, DOI 10.1046/j.1365-313x.1996.10030403.x; LEYSER HMO, 1997, PHYSIOL PLANTARUM, V100, P407; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PUTTERILL J, 1993, MOL GEN GENET, V239, P145, DOI 10.1007/BF00281613; SIMMONS C, 1995, J EXP BOT, V46, P143, DOI 10.1093/jxb/46.1.143; STIRNBERG P, UNPUB; THEOLOGIS A, 1985, J MOL BIOL, V183, P53, DOI 10.1016/0022-2836(85)90280-3; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; WILSON AK, 1990, MOL GEN GENET, V222, P377, DOI 10.1007/BF00633843; YAMAMOTO KT, 1992, PLANT CELL PHYSIOL, V33, P93	20	281	304	10	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 27	1998	279	5355					1371	1373		10.1126/science.279.5355.1371	http://dx.doi.org/10.1126/science.279.5355.1371			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478901				2022-12-01	WOS:000072251800056
J	Finger, FP; Hughes, TE; Novick, P				Finger, FP; Hughes, TE; Novick, P			Sec3p is a spatial landmark for polarized secretion in budding yeast	CELL			English	Article							GREEN FLUORESCENT PROTEIN; BUD-SITE SELECTION; MYOSIN HEAVY-CHAIN; SACCHAROMYCES-CEREVISIAE; CELL POLARITY; PLASMA-MEMBRANE; ACTIN CYTOSKELETON; 19.5S PARTICLE; GENE; COMPONENTS	Exocytosis in yeast occurs at plasma membrane subdomains whose locations vary with the cell cycle, but the primary protein determinants of these sites are unknown. A functional fusion of Sec3 protein with green fluorescent protein (Sec3-GFP) localizes to the site of polarized exocytosis for each cell-cycle stage, where it colocalizes with Sec4p and Sec8p. Sec3-GFP localization is independent of secretory pathway function, of the actin and septin cytoskeletons, and of the polarity establishment proteins. We propose that Sec3p is a spatial landmark defining sites of exocytosis. Polarized secretion would result from the coupling of actin-dependent vesicle targeting with Sec3p-dependent establishment of the vesicle fusion site.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Ophthalmol & Visual Sci, New Haven, CT 06520 USA	Yale University; Yale University	Novick, P (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.			Hughes, Thomas/0000-0002-8430-070X; Hughes, Thomas/0000-0001-5880-9951	NATIONAL EYE INSTITUTE [R01EY008362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035370, R01GM035370] Funding Source: NIH RePORTER; NEI NIH HHS [EY08362] Funding Source: Medline; NIGMS NIH HHS [GM35370] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Bi GQ, 1997, J CELL BIOL, V138, P999, DOI 10.1083/jcb.138.5.999; BOWSER R, 1992, J CELL BIOL, V118, P1041, DOI 10.1083/jcb.118.5.1041; BOWSER R, 1991, J CELL BIOL, V112, P1117, DOI 10.1083/jcb.112.6.1117; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Drubin DG, 1996, CELL, V84, P335, DOI 10.1016/S0092-8674(00)81278-7; FARKAS V, 1974, J BACTERIOL, V117, P265; FIELD C, 1980, J CELL BIOL, V86, P123, DOI 10.1083/jcb.86.1.123; Finger FP, 1997, MOL BIOL CELL, V8, P647, DOI 10.1091/mbc.8.4.647; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; Govindan B, 1995, J EXP ZOOL, V273, P401, DOI 10.1002/jez.1402730505; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; Guo W, 1997, FEBS LETT, V404, P135, DOI 10.1016/S0014-5793(97)00109-9; GUTHRIE C, 1991, METH ENZYMOL, V194; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; Haarer BK, 1996, GENETICS, V144, P495; HARTWELL LH, 1971, EXP CELL RES, V69, P265, DOI 10.1016/0014-4827(71)90223-0; Hazuka CD, 1997, GENE, V187, P67, DOI 10.1016/S0378-1119(96)00720-2; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; Hsu SC, 1996, NEURON, V17, P1209, DOI 10.1016/S0896-6273(00)80251-2; JOHNSON DI, 1990, J CELL BIOL, V111, P143, DOI 10.1083/jcb.111.1.143; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; Kee Y, 1997, P NATL ACAD SCI USA, V94, P14438, DOI 10.1073/pnas.94.26.14438; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lew DJ, 1997, MOL CELLULAR BIOL YE, V3, P607; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8; Mondesert G, 1997, GENETICS, V147, P421; Mulholland J, 1997, MOL BIOL CELL, V8, P1481, DOI 10.1091/mbc.8.8.1481; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NOVICK P, 1993, CELL, V75, P597, DOI 10.1016/0092-8674(93)90478-9; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Pringle JR, 1995, COLD SPRING HARB SYM, V60, P729, DOI 10.1101/SQB.1995.060.01.079; RODRIGUEZ JR, 1990, CELL MOTIL CYTOSKEL, V17, P301, DOI 10.1002/cm.970170405; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; Sanders SL, 1996, J CELL BIOL, V134, P413, DOI 10.1083/jcb.134.2.413; SIKORSKI RS, 1989, GENETICS, V122, P19; Simons K, 1993, Harvey Lect, V89, P125; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TING AE, 1995, P NATL ACAD SCI USA, V92, P9613, DOI 10.1073/pnas.92.21.9613; TKACZ JS, 1972, J GEN MICROBIOL, V72, P243, DOI 10.1099/00221287-72-2-243; TKACZ JS, 1973, J BACTERIOL, V113, P1073, DOI 10.1128/JB.113.2.1073-1075.1973; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WATTS FZ, 1985, NATURE, V316, P83, DOI 10.1038/316083a0	51	303	314	1	11	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					559	571		10.1016/S0092-8674(00)80948-4	http://dx.doi.org/10.1016/S0092-8674(00)80948-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491896	hybrid			2022-12-01	WOS:000072251500015
J	Yang, ZY; Delgado, R; Xu, L; Todd, RF; Nabel, EG; Sanchez, A; Nabel, GJ				Yang, ZY; Delgado, R; Xu, L; Todd, RF; Nabel, EG; Sanchez, A; Nabel, GJ			Distinct cellular interactions of secreted and transmembrane Ebola virus glycoproteins	SCIENCE			English	Article							MARBURG VIRUS; CELLS	The mechanisms by which Ebola virus evades detection and infects cells to cause hemorrhagic fever have not been defined, though its glycoprotein, synthesized in either a secreted or transmembrane form, is likely involved. Here the secreted glycoprotein was found to interact with neutrophils through CD16b, the neutrophil-specific form of the Fc gamma receptor III, whereas the transmembrane glycoprotein was found to interact with endothelial cells but not neutrophils. A murine retroviral vector pseudotyped with the transmembrane glycoprotein preferentially infected endothelial cells. Thus, the secreted glycoprotein inhibits early neutrophil activation, which likely affects the host response to infection, whereas binding of the transmembrane glycoprotein to endothelial cells may contribute to the hemorrhagic symptoms of this disease.	Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Ctr Dis Control & Prevent, Atlanta, GA 30333 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Centers for Disease Control & Prevention - USA	Nabel, GJ (corresponding author), Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA.		Delgado, Rafael/C-4910-2016; Todd, Robert/GWM-4486-2022; DELGADO, RAFAEL/A-2938-2012	Delgado, Rafael/0000-0002-6912-4736; 				BOWEN ETW, 1977, LANCET, V1, P571; CDC, 1995, MMWR-MORBID MORTAL W, V44, P381; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; EMBRETSON JE, 1987, J VIROL, V61, P3454, DOI 10.1128/JVI.61.11.3454-3462.1987; Gallaher WR, 1996, CELL, V85, P477, DOI 10.1016/S0092-8674(00)81248-9; Kinsella TM, 1996, HUM GENE THER, V7, P1405, DOI 10.1089/hum.1996.7.12-1405; LEGUENNO B, 1995, LANCET, V345, P1271, DOI 10.1016/S0140-6736(95)90925-7; Peters C.J., 1996, FIELDS VIROLOGY, P1161; SANCHEZ A, 1993, VIRUS RES, V29, P215, DOI 10.1016/0168-1702(93)90063-S; Sanchez A, 1996, P NATL ACAD SCI USA, V93, P3602, DOI 10.1073/pnas.93.8.3602; SANCHEZ A, UNPUB; SCHNITTLER HJ, 1993, J CLIN INVEST, V91, P1301, DOI 10.1172/JCI116329; Volchkov VE, 1995, VIROLOGY, V214, P421, DOI 10.1006/viro.1995.0052; Xu L, 1998, NAT MED, V4, P37, DOI 10.1038/nm0198-037; YANG ZB, UNPUB	15	216	238	0	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1034	1037		10.1126/science.279.5353.1034	http://dx.doi.org/10.1126/science.279.5353.1034			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461435				2022-12-01	WOS:000072006400047
J	Lanier, LL; Corliss, BC; Wu, J; Leong, C; Phillips, JH				Lanier, LL; Corliss, BC; Wu, J; Leong, C; Phillips, JH			Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells	NATURE			English	Article							NATURAL-KILLER-CELLS; HLA-C; RECEPTOR; KINASES; PHOSPHATASES; SUPERFAMILY; RECOGNITION; FAMILY; CD94; TCR	Natural killer (NK) cells express cell-surface receptors of the immunoglobulin and C-type lectin superfamilies that recognize major histocompatibility complex (MHC) class I peptides and inhibit NK-cell-mediated cytotoxicity(1). These inhibitory receptors possess ITIM sequences (for immunoreceptor tyrosine-based inhibitory motifs) in their cytoplasmic domains that recruit SH2-domain-containing protein tyrosine phosphatases, resulting in inactivation of NK cells(2-4). Certain isoforms of these NK-cell receptors lack ITIM sequences and it has been proposed that these 'non-inhibitory' receptors may activate,rather than inhibit, NK cells(4-6). Here we show that DAP12, a disulphide-bonded homodimer containing an immunoreceptor tyrosine-based activation motif (ITAM) in its cytoplasmic domain, non-covalently associates with membrane glycoproteins of the killer-cell inhibitory receptor (KIR) family without an ITIM in their cytoplasmic domain. Crosslinking of KIR-DAP12 complexes results in cellular activation, as demonstrated by tyrosine phosphorylation of cellular proteins and upregulation of early-activation antigens. Phosphorylated DAP12 peptides bind ZAP-70 and Syk protein tyrosine kinases, suggesting that the activation pathway is similar to that of the T- and B-cell antigen receptors.	DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, Palo Alto, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lanier, LL (corresponding author), DNAX Res Inst Mol & Cellular Biol Inc, Dept Immunobiol, 901 Calif Ave, Palo Alto, CA 94304 USA.		Lanier, Lewis L/E-2139-2014	Lanier, Lewis L/0000-0003-1308-3952				BAKER E, 1995, CHROMOSOME RES, V3, P511; Biassoni R, 1996, J EXP MED, V183, P645, DOI 10.1084/jem.183.2.645; Blery M, 1997, J BIOL CHEM, V272, P8989; Burshtyn DN, 1996, IMMUNITY, V4, P77, DOI 10.1016/S1074-7613(00)80300-3; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1994, J IMMUNOL, V152, P4758; CHANG CW, 1995, EUR J IMMUNOL, V25, P2433, DOI 10.1002/eji.1830250904; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; COLONNA M, 1995, SCIENCE, V268, P405, DOI 10.1126/science.7716543; Hayami K, 1997, J BIOL CHEM, V272, P7320, DOI 10.1074/jbc.272.11.7320; Houchins JP, 1997, J IMMUNOL, V158, P3603; HOUCHINS JP, 1991, J EXP MED, V173, P1017, DOI 10.1084/jem.173.4.1017; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KESE L, 1997, J IMMUNOL, V158, P5083; Kubagawa H, 1997, P NATL ACAD SCI USA, V94, P5261, DOI 10.1073/pnas.94.10.5261; LANIER L L, 1991, Methods (Orlando), V2, P192, DOI 10.1016/S1046-2023(05)80061-1; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; Mason LH, 1996, J EXP MED, V184, P2119, DOI 10.1084/jem.184.6.2119; MEYAARD L, 1997, IMMUNITY, V7, P282; Olcese L, 1996, J IMMUNOL, V156, P4531; ONIHSI M, 1996, EXP HEMATOL, V24, P324; Phillips JH, 1996, IMMUNITY, V5, P163, DOI 10.1016/S1074-7613(00)80492-6; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Samaridis J, 1997, EUR J IMMUNOL, V27, P660, DOI 10.1002/eji.1830270313; Takase K, 1997, J IMMUNOL, V159, P741; Wagtmann N, 1997, CURR BIOL, V7, P615, DOI 10.1016/S0960-9822(06)00263-6; WU J, 1995, MOL CELL BIOL, V15, P4337	28	739	776	0	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 12	1998	391	6668					703	707		10.1038/35642	http://dx.doi.org/10.1038/35642			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW872	9490415				2022-12-01	WOS:000071982500055
J	Webb, E				Webb, E			Cultural complexities should not be ignored - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales	Cardiff University	Webb, E (corresponding author), Univ Wales Coll Med, Dept Child Hlth, Cardiff CF4 4XN, S Glam, Wales.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 7	1998	316	7129					462	462		10.1136/bmj.316.7129.462	http://dx.doi.org/10.1136/bmj.316.7129.462			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YW874	9492681	Green Published			2022-12-01	WOS:000071982700048
J	Mossessova, E; Gulbis, JM; Goldberg, J				Mossessova, E; Gulbis, JM; Goldberg, J			Structure of the guanine nucleotide exchange factor Sec7 domain of human Arno and analysis of the interaction with ARF GTPase	CELL			English	Article							ADP-RIBOSYLATION FACTOR-1; PROTEIN-PROTEIN RECOGNITION; HA-RAS P21; AMINO-TERMINUS; MOLECULAR MECHANISM; ESCHERICHIA-COLI; MYRISTOYLATION; IDENTIFICATION; BINDING; SURFACE	Sec7-related guanine nucleotide exchange factors (GEFs) initiate vesicle budding from the Golgi membrane surface by converting the GTPase ARF to a GTP-bound, membrane-associated form. Here we report the crystal structure of the catalytic Sec7 homology domain of Arno, a human GEF for ARF1, determined at 2.2 Angstrom resolution. The Sec7 domain is an elongated, all-helical protein with a distinctive hydrophobic groove that is phylogenetically conserved. Structure-based mutagenesis identifies the groove and an adjacent conserved loop as the ARF-interacting surface. The sites of Sec7 domain interaction on ARF1 have subsequently been mapped, by protein footprinting experiments, to the switch 1 and switch 2 GTPase regions, leading to a model for the interaction between ARF GTPases and Sec7 domain exchange factors.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Cornell Univ, Grad Sch Med Sci, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Goldberg, J (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.							ACHSTETTER T, 1988, J BIOL CHEM, V263, P11711; AMOR JC, 1994, NATURE, V372, P704, DOI 10.1038/372704a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1992, XPLOR VERSION 3 1 MA; BURTON JL, 1994, EMBO J, V13, P5547, DOI 10.1002/j.1460-2075.1994.tb06892.x; Chardin P, 1996, NATURE, V384, P481, DOI 10.1038/384481a0; Crechet JB, 1996, J BIOL CHEM, V271, P17234, DOI 10.1074/jbc.271.29.17234; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FRANCO M, 1995, J BIOL CHEM, V270, P1337, DOI 10.1074/jbc.270.3.1337; FRANCO M, 1993, J BIOL CHEM, V268, P24531; Franco M, 1996, J BIOL CHEM, V271, P1573, DOI 10.1074/jbc.271.3.1573; HEYDUK E, 1994, BIOCHEMISTRY-US, V33, P9643, DOI 10.1021/bi00198a033; Heyduk T, 1996, P NATL ACAD SCI USA, V93, P10162, DOI 10.1073/pnas.93.19.10162; Huber AH, 1997, CELL, V90, P871, DOI 10.1016/S0092-8674(00)80352-9; JANIN J, 1990, J BIOL CHEM, V265, P16027; KAHN RA, 1992, J BIOL CHEM, V267, P13039; Kawashima T, 1996, NATURE, V379, P511, DOI 10.1038/379511a0; Klarlund JK, 1997, SCIENCE, V275, P1927, DOI 10.1126/science.275.5308.1927; Kleywegt G. J., 1994, P CCP4 STUD WEEK 1 M, P59; Kleywegt GJ, 1997, METHOD ENZYMOL, V277, P525, DOI 10.1016/S0076-6879(97)77029-0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; Liemann S, 1997, CELL MOL LIFE SCI, V53, P516, DOI 10.1007/s000180050065; Mendenhall W., 1988, STAT ENG COMPUTER SC; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MISTOU MY, 1992, EMBO J, V11, P2391, DOI 10.1002/j.1460-2075.1992.tb05303.x; MOSTELLER RD, 1994, MOL CELL BIOL, V14, P1104, DOI 10.1128/MCB.14.2.1104; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Otwinowski Z., 1993, DATA COLLECTION PROC, P556; Paris S, 1997, J BIOL CHEM, V272, P22221, DOI 10.1074/jbc.272.35.22221; Peyroche A, 1996, NATURE, V384, P479, DOI 10.1038/384479a0; Quilliam LA, 1996, J BIOL CHEM, V271, P11076, DOI 10.1074/jbc.271.19.11076; RANDAZZO PA, 1994, J BIOL CHEM, V269, P29490; RANDAZZO PA, 1995, J BIOL CHEM, V270, P14809, DOI 10.1074/jbc.270.24.14809; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Rittinger K, 1997, NATURE, V389, P758, DOI 10.1038/39651; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; Wang Y, 1997, J MOL BIOL, V270, P648, DOI 10.1006/jmbi.1997.1139; YOUNG L, 1994, PROTEIN SCI, V3, P717; YU HT, 1995, NATURE, V376, P788, DOI 10.1038/376788a0	52	146	150	1	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					415	423		10.1016/S0092-8674(00)80933-2	http://dx.doi.org/10.1016/S0092-8674(00)80933-2			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476900	hybrid			2022-12-01	WOS:000072024700012
J	Eyer, J; Cleveland, DW; Wong, PC; Peterson, AC				Eyer, J; Cleveland, DW; Wong, PC; Peterson, AC			Pathogenesis of two axonopathies does not require axonal neurofilaments	NATURE			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; DYSTONIA-MUSCULORUM; MOUSE MODEL; DEGENERATION; MICE; GENE; SUBUNIT; PATHOLOGY; TRANSGENE	Neurofilaments are a major component of the axonal cytoskeleton and their abnormal accumulation is a prominent feature of the cytopathology encountered in several neurodegenerative diseases(1-8). Thus, an attractive and widely held model of pathogenesis involves the participation of disrupted neurofilaments as a common toxic intermediate(9-13). Here, in direct contrast to this hypothesis, we show that two neurodegenerative disease models in the mouse, dystonia musculorum (dt)(14,15) and a superoxide dismutase 1 (SOD1)-mediated form of human motor neuron disease (amyotrophic lateral sclerosis, ALS)(16,17), progress with little or no abatement on a transgenic background in which neurofilaments are withheld from the axonal compartment(18). By specifically excluding a necessary role for axonal neurofilaments, our observations redefine the components of the pathogenic pathway leading to axon disruption in these two degenerative diseases.	McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Dev Biol Lab, Montreal, PQ H3A 1A1, Canada; INSERM, CJF 97 08, F-49033 Angers, France; Univ Angers, CHU, F-49033 Angers, France; Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Div Neuropathol, Baltimore, MD 21205 USA	McGill University; Royal Victoria Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Johns Hopkins University	Peterson, AC (corresponding author), McGill Univ, Royal Victoria Hosp, Mol Oncol Grp, Dev Biol Lab, H-5,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	Alan@devbiol2.molonc.mcgill.ca	Eyer, Joel/K-4265-2015; Cleveland, Don/AAN-9783-2021; Eyer, Joel/V-8679-2019	Eyer, Joel/0000-0001-6301-7465; Eyer, Joel/0000-0001-6301-7465; Cleveland, Don/0000-0002-1934-3682				BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; BROWN A, 1995, NAT GENET, V10, P301, DOI 10.1038/ng0795-301; CAMPBELL RM, 1992, NEURON, V9, P693, DOI 10.1016/0896-6273(92)90032-9; CARDEN MJ, 1986, NEUROCHEM PATHOL, V5, P25, DOI 10.1007/BF03028034; CARPENTER S, 1968, NEUROLOGY, V18, P841, DOI 10.1212/WNL.18.9.841; CLEVELAND DW, 1996, NEUROLOGY, V47, P54; COLLARD JF, 1995, NATURE, V375, P61, DOI 10.1038/375061a0; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DICKSON DW, 1986, ACTA NEUROPATHOL, V71, P216, DOI 10.1007/BF00688042; Duchen L W, 1976, Adv Neurol, V14, P353; EYER J, 1989, J NEUROCHEM, V52, P1759, DOI 10.1111/j.1471-4159.1989.tb07254.x; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FIGLEWICZ DA, 1994, HUM MOL GENET, V3, P1757, DOI 10.1093/hmg/3.10.1757; GOLDMAN JE, 1986, ANN NEUROL, V19, P209, DOI 10.1002/ana.410190302; GRIFFIN JW, 1980, EXPT CLIN NEUROTOXIC, P161; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; HILL WD, 1991, J COMP NEUROL, V309, P150, DOI 10.1002/cne.903090111; KOTHARY R, 1988, NATURE, V335, P435, DOI 10.1038/335435a0; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LEE MK, 1994, NEURON, V13, P975, DOI 10.1016/0896-6273(94)90263-1; Plummer J, 1995, MOL CELL NEUROSCI, V6, P532, DOI 10.1006/mcne.1995.0005; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; SOTELO C, 1988, NEUROSCIENCE, V27, P403, DOI 10.1016/0306-4522(88)90277-1; Tu PH, 1997, J NEUROSCI, V17, P1064; Vechio JD, 1996, ANN NEUROL, V40, P603, DOI 10.1002/ana.410400410; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L; Yang YM, 1996, CELL, V86, P655, DOI 10.1016/S0092-8674(00)80138-5	30	84	87	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 5	1998	391	6667					584	587		10.1038/35378	http://dx.doi.org/10.1038/35378			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YV594	9468135				2022-12-01	WOS:000071842300051
J	Doublie, S; Tabor, S; Long, AM; Richardson, CC; Ellenberger, T				Doublie, S; Tabor, S; Long, AM; Richardson, CC; Ellenberger, T			Crystal structure of a bacteriophage T7 DNA replication complex at 2.2 angstrom resolution	NATURE			English	Article							ESCHERICHIA-COLI THIOREDOXIN; I KLENOW FRAGMENT; POLYMERASE-I; DEOXYNUCLEOSIDE TRIPHOSPHATE; DEOXYRIBONUCLEIC-ACID; EXONUCLEASE ACTIVITY; PROTEIN; MECHANISM; RESIDUES; MUTANT	DNA polymerases change their specificity for nucleotide substrates with each catalytic cycle, while achieving error frequencies in the range of 10(-5) to 10(-6). Here we present a 2.2 Angstrom crystal structure of the replicative DNA polymerase from bacteriophage T7 complexed with a primer-template and a nucleoside triphosphate in the polymerase active site. The structure illustrates how nucleotides are selected in a template-directed manner, and provides a structural basis for a metal-assisted mechanism of phosphoryl transfer by a large group of related polymerases.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Ellenberger, T (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	stabor@heckle.med.harvard.edu; tome@jeckle.med.harvard.edu		Doublie, Sylvie/0000-0002-6294-5304				ADLER S, 1983, J BIOL CHEM, V258, P6956; ASTATKE M, 1995, J BIOL CHEM, V270, P1945, DOI 10.1074/jbc.270.4.1945; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bedford E, 1997, P NATL ACAD SCI USA, V94, P479, DOI 10.1073/pnas.94.2.479; BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BEESE LS, 1993, BIOCHEMISTRY-US, V32, P14095, DOI 10.1021/bi00214a004; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; BRUNGER AT, 1992, XPLOR VERSOIN 3 1 SY; BRYANT FR, 1983, BIOCHEMISTRY-US, V22, P3537, DOI 10.1021/bi00284a001; BURGERS PMJ, 1979, J BIOL CHEM, V254, P6889; CARTER CW, 1992, CRYSTALLIZATION NUCL, P47; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DONLIN MJ, 1991, BIOCHEMISTRY-US, V30, P538, DOI 10.1021/bi00216a031; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Eom SH, 1996, NATURE, V382, P278, DOI 10.1038/382278a0; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Himawan JS, 1996, J BIOL CHEM, V271, P19999, DOI 10.1074/jbc.271.33.19999; HUBER HE, 1986, J BIOL CHEM, V261, P5006; HUNTER WN, 1986, NATURE, V320, P552, DOI 10.1038/320552a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; Kaushik N, 1996, BIOCHEMISTRY-US, V35, P7256, DOI 10.1021/bi960537i; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KIM Y, 1995, NATURE, V376, P612, DOI 10.1038/376612a0; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KOROLEV S, 1995, P NATL ACAD SCI USA, V92, P9264, DOI 10.1073/pnas.92.20.9264; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Minnick DT, 1996, J BIOL CHEM, V271, P24954, DOI 10.1074/jbc.271.40.24954; MODRICH P, 1975, J BIOL CHEM, V250, P5508; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATEL SS, 1991, BIOCHEMISTRY-US, V30, P511, DOI 10.1021/bi00216a029; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; Rould MA, 1997, METHOD ENZYMOL, V276, P461, DOI 10.1016/S0076-6879(97)76072-5; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; TABOR S, 1987, J BIOL CHEM, V262, P16212; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; TABOR S, 1989, J BIOL CHEM, V264, P6447; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030; Yang XM, 1997, J BIOL CHEM, V272, P6599, DOI 10.1074/jbc.272.10.6599	50	1072	1102	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 15	1998	391	6664					251	258		10.1038/34593	http://dx.doi.org/10.1038/34593			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440688				2022-12-01	WOS:000071484400040
J	Reed, BA; Habicht, JP				Reed, BA; Habicht, JP			Sales of food aid as sign of distress, not excess	LANCET			English	Article								In 1996 the sale and export of food aid from refugee camps near Uvira, Zaire, prompted a reduction in donated rations. However, research has revealed that the sales did not reflect an excess of food in the camps. They were provoked by the absence of important components of the food basket, by cultural aversion to the staple (maize) and oil provided, by difficulties in food preparation, and by the refugees' limited ability to diversify their diet and cover pressing non-food needs. Food sales improved the micronutrient content of diets but at the expense of energy lost from an already energy-deficient diet. At most 23% of the refugee households were eating sufficient and adequate diets; the poorest one-fifth of households were twice as likely to sell or exchange food as were other households and their diets were the worst. These findings demonstrate the perils of the gap between policy and practice in food aid distribution.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cornell University	Habicht, JP (corresponding author), Cornell Univ, Div Nutr Sci, Savage Hall, Ithaca, NY 14853 USA.							CHRISTENSEN H, 1982, 823 UN RES I SOC DEV, P1; Hansch S., 1992, Journal of Refugee Studies, V5, P300, DOI 10.1093/jrs/5.3-4.300; Harrell-Bond B., 1992, Journal of Refugee Studies, V5, P205, DOI 10.1093/jrs/5.3-4.205; Shoham J, 1996, DISASTERS, V20, P338, DOI 10.1111/j.1467-7717.1996.tb01048.x; Wilson K. B., 1992, Journal of Refugee Studies, V5, P226, DOI 10.1093/jrs/5.3-4.226; *WORLD FOOD PROGR, 1994, MEM UND JOINT WORK A	6	16	16	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					128	130		10.1016/S0140-6736(97)06329-0	http://dx.doi.org/10.1016/S0140-6736(97)06329-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439508	hybrid			2022-12-01	WOS:000071591900044
J	Orphanides, G; LeRoy, G; Chang, CH; Luse, DS; Reinberg, D				Orphanides, G; LeRoy, G; Chang, CH; Luse, DS; Reinberg, D			FACT, a factor that facilitates transcript elongation through nucleosomes	CELL			English	Article							RNA-POLYMERASE-II; REMODELING FACTOR; CHROMATIN; DNA; STIMULATION; ACTIVATION; TEMPLATES; COMPLEX; BINDING; PURIFICATION	The requirements for transcriptional activation by RNA polymerase II were examined using chromatin templates assembled in vitro and a transcription system composed of the human general transcription factors and RNA polymerase II. Activator-induced, energy-dependent chromatin remodeling promoted efficient preinitiation complex formation and transcription initiation, but was not sufficient for productive transcription. Polymerases that initiated transcription on remodeled chromatin templates encountered a block to transcription proximal to the promoter. Entry into productive transcription required an accessory factor present in HeLa cell nuclear extract, FACT (facilitates chromatin transcription), which we have purified. FACT acts subsequent to transcription initiation to release RNA polymerase II from a nucleosome-induced block to productive transcription. The biochemical properties anal polypeptide composition of FACT suggest that it is a novel protein factor that facilitates transcript elongation through nucleosomes.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Cleveland Clinic Foundation	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Div Nucle Acid Enzymol,Howard Hughes Med Inst, Piscataway, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016	NIGMS NIH HHS [GM-37120, GM-29487] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029487, R37GM037120, R01GM037120] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Brown SA, 1996, GENE DEV, V10, P1479, DOI 10.1101/gad.10.12.1479; Bulger M., 1994, METH MOL G, V5, P241; Cairns BR, 1996, CELL, V87, P1249, DOI 10.1016/S0092-8674(00)81820-6; CAIRNS BR, 1994, P NATL ACAD SCI USA, V91, P1950, DOI 10.1073/pnas.91.5.1950; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; COTE J, 1994, SCIENCE, V265, P53, DOI 10.1126/science.8016655; CROSTON GE, 1992, GENE DEV, V6, P2270, DOI 10.1101/gad.6.12a.2270; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DING HF, 1994, SCIENCE, V265, P796, DOI 10.1126/science.8047885; FLORES O, 1992, J BIOL CHEM, V267, P2786; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GRALLA JD, 1985, P NATL ACAD SCI USA, V82, P3078, DOI 10.1073/pnas.82.10.3078; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kingston RE, 1996, GENE DEV, V10, P905, DOI 10.1101/gad.10.8.905; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; LUSE DS, 1987, J BIOL CHEM, V262, P289; Ma DM, 1996, P NATL ACAD SCI USA, V93, P6583, DOI 10.1073/pnas.93.13.6583; Maldonado E, 1996, METHOD ENZYMOL, V274, P72; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; MERINO A, 1993, NATURE, V365, P227, DOI 10.1038/365227a0; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Owen-Hughes Thomas, 1994, Critical Reviews in Eukaryotic Gene Expression, V4, P403; PAZIN MJ, 1994, SCIENCE, V266, P2007, DOI 10.1126/science.7801129; Peterson CL, 1996, CURR OPIN GENET DEV, V6, P171, DOI 10.1016/S0959-437X(96)80047-5; REECE RJ, 1993, GENE, V126, P105, DOI 10.1016/0378-1119(93)90596-U; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/S0968-0004(96)10050-5; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; TSUKIYAMA T, 1995, CELL, V83, P1011, DOI 10.1016/0092-8674(95)90216-3; TSUKIYAMA T, 1995, CELL, V83, P1021, DOI 10.1016/0092-8674(95)90217-1; UCKER DS, 1984, J BIOL CHEM, V259, P7416; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wade PA, 1997, CURR BIOL, V7, pR82, DOI 10.1016/S0960-9822(06)00042-X; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; WOLFFE AP, 1994, CURR BIOL, V4, P523; WOLFFE AP, 1993, METH MOL G, V2, P314; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	47	488	500	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JAN 9	1998	92	1					105	116		10.1016/S0092-8674(00)80903-4	http://dx.doi.org/10.1016/S0092-8674(00)80903-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489704	Bronze			2022-12-01	WOS:000071473700012
J	Nightingale, SL				Nightingale, SL			List of disqualified investigators available an Internet	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 7	1998	279	1					9	9		10.1001/jama.279.1.9	http://dx.doi.org/10.1001/jama.279.1.9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YP607	9424027				2022-12-01	WOS:000071295100004
J	Wilson, AC; Forsyth, JS; Greene, SA; Irvine, L; Hau, C; Howie, PW				Wilson, AC; Forsyth, JS; Greene, SA; Irvine, L; Hau, C; Howie, PW			Relation of infant diet to childhood health: seven year follow up of cohort of children in Dundee infant feeding study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR RISK-FACTORS; BRITISH CHILDREN; BLOOD-PRESSURE; SCHOOLCHILDREN; ASTHMA; GROWTH; LIFE	Objective: To investigate the relation of infant feeding practice to childhood respiratory illness, growth, body composition, and blood pressure. Design: Follow up study of a cohort of children (mean age 7.3 years) who had detailed infant feeding and demographic data collected prospectively during the first two years of life. Setting: Dundee. Subjects: 674 infants, of whom 545 (81%) were available for study. Data on respiratory illness were available for 545 children (mean age 7.3 (range 6.1-9.9) years); height for 410 children; weight and body mass index for 412 children; body composition for 405 children; blood pressure for 301 children (mean age 7.2 (range 6.9-10.0) years). Main outcome measures: Respiratory illness, weight, height, body mass index, percentage body fat, and blood pressure in relation to duration of breast feeding and timing of introduction of solids. Results: After adjustment for the significant confounding variables the estimated probability of ever having respiratory illness in children who received breast milk exclusively for at least 15 weeks was consistently lower (17.0% (95% confidence interval 15.9% to 18.1%) for exclusive breast feeding, 31.0% (26.8% to 35.2%) for partial breast feeding, and 32.2% (30.7% to 33.7%) for bottle feeding. Solid feeding before 15 weeks was associated with an inn eased probability of wheeze during childhood (21.0% (19.9% to 22.1%) v 9.7% (8.6% to 10.8%)). It was also associated with increased percentage body fat and weight in childhood (mean body fat 18.5% (18.2% to 18.8%) v 16.5% (16.0% to 17.0%); weight standard deviation score 0.02 (-0.02 to 0.06) v -0.09 (-0.16 to 0.02). Systolic blood pressure was raised significantly in children who were exclusively bottle fed compared with children who received breast milk (mean 94.2 (93.5 to 94.9) mm Hg v 90.7 (89.9 to 91.7) mm Hg). Conclusions: The probability of respiratory illness occurring at any time during childhood is significantly reduced in the child is fed exclusively breast milk for 15 weeks and no solid foods are introduced during this time. Breast feeding and the late introduction of solids may have a beneficial effect on childhood health and subsequent adult disease.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee; University of Dundee	Forsyth, JS (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Child Hlth, Dundee DD1 9SY, Scotland.	stewart.f@dth.scot.nhs.uk		Irvine, Linda/0000-0002-8527-876X				ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BROOK CGD, 1971, ARCH DIS CHILD, V46, P182, DOI 10.1136/adc.46.246.182; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1118, DOI 10.1136/adc.64.8.1118; DAVIES PSW, 1991, ARCH DIS CHILD, V66, P1467, DOI 10.1136/adc.66.12.1467-a; *DEP HLTH SOC SEC, 1994, WEAN WEAN DIET REP W; DESWIET M, 1989, BRIT MED J, V299, P497, DOI 10.1136/bmj.299.6697.497; DHSS (Department of Health and Social Security), 1988, LANCET, V331, P975; ELLIOTT P, 1988, BRIT MED J, V297, P319; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; Forrester TE, 1996, BRIT MED J, V312, P156; FORSYTH JS, 1993, BMJ-BRIT MED J, V306, P1572, DOI 10.1136/bmj.306.6892.1572; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; LUCAS A, 1991, BRIT MED J, V302, P350, DOI 10.1136/bmj.302.6772.350-b; LUCAS A, 1988, ARCH DIS CHILD, V63, P656, DOI 10.1136/adc.63.6.656; MARTIN J, 1988, INFANT FEEDING 1985; Office of Population Censuses and Surveys, 1980, CLASS OCC; TAITZ LS, 1971, BRIT MED J, V1, P315, DOI 10.1136/bmj.1.5744.315; Whincup PH, 1996, BMJ-BRIT MED J, V313, P79, DOI 10.1136/bmj.313.7049.79; WHITE EM, 1995, ARCH DIS CHILD, V72, P38, DOI 10.1136/adc.72.1.38	23	395	404	0	27	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 3	1998	316	7124					21	25		10.1136/bmj.316.7124.21	http://dx.doi.org/10.1136/bmj.316.7124.21			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ353	9451261	Bronze, Green Submitted, Green Published			2022-12-01	WOS:000071377900018
J	Schnieke, AE; Kind, AJ; Ritchie, WA; Mycock, K; Scott, AR; Ritchie, M; Wilmut, I; Colman, A; Campbell, KHS				Schnieke, AE; Kind, AJ; Ritchie, WA; Mycock, K; Scott, AR; Ritchie, M; Wilmut, I; Colman, A; Campbell, KHS			Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts	SCIENCE			English	Article							EMBRYONIC-CELL-LINES; MOUSE GENOME; COMPENDIUM; KNOCKOUTS; CHALLENGES; EXPRESSION; CATTLE; GENE; MICE	Ovine primary fetal fibroblasts were cotransfected with a neomycin resistance marker gene (neo) and a human coagulation factor IX genomic construct designed for expression of the encoded protein in sheep milk. Two cloned transfectants and a population ol neomycin (G418)-resistant cells were used as donors for nuclear transfer to enucleated oocytes. Six transgenic lambs were liveborn: Three produced from cloned cells contained factor IX and neo transgenes, whereas three produced from the uncloned population contained the marker gene only. Somatic cells can therefore be subjected to genetic manipulation in vitro and produce viable animals by nuclear transfer. Production of transgenic sheep by nuclear transfer requires fewer than half the animals needed for pronuclear microinjection.	ROSLIN INST, ROSLIN EH25 9PS, MIDLOTHIAN, SCOTLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute	Schnieke, AE (corresponding author), PPL THERAPEUT, ROSLIN EH25 9PP, MIDLOTHIAN, SCOTLAND.			Schnieke, Angelika/0000-0002-5761-9635				BOWEN RA, 1994, BIOL REPROD, V50, P664, DOI 10.1095/biolreprod50.3.664; BRANDON EP, 1995, CURR BIOL, V5, P873, DOI 10.1016/S0960-9822(95)00177-1; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BRANDON EP, 1995, CURR BIOL, V5, P758, DOI 10.1016/S0960-9822(95)00152-7; BROWNLEE GG, 1987, BIOCHEM SOC T, V15, P1; Campbell KHS, 1996, NATURE, V380, P64, DOI 10.1038/380064a0; CARVER AS, 1993, BIO-TECHNOL, V11, P1263; Cibelli J. B., 1997, Theriogenology, V47, P241, DOI 10.1016/S0093-691X(97)82368-0; Damak S, 1996, BIO-TECHNOL, V14, P185, DOI 10.1038/nbt0296-185; EYESTONE WH, 1994, REPROD FERT DEVELOP, V6, P647, DOI 10.1071/RD9940647; Gerfen RW, 1995, ANIM BIOTECHNOL, V6, P1, DOI 10.1080/10495399509525828; GRIFFITHS R, 1993, MOL ECOL, V2, P405, DOI 10.1111/j.1365-294X.1993.tb00034.x; HAMMER RE, 1985, NATURE, V315, P680, DOI 10.1038/315680a0; JALLAT S, 1990, EMBO J, V9, P3295, DOI 10.1002/j.1460-2075.1990.tb07529.x; KILL IR, 1991, J CELL SCI, V100, P869; KIRKPATRICK BW, 1993, J REPROD FERTIL, V98, P335, DOI 10.1530/jrf.0.0980335; Kruip TAM, 1997, THERIOGENOLOGY, V47, P43, DOI 10.1016/S0093-691X(96)00338-X; NOTARIANNI E, 1991, J REPROD FERTIL, P255; Ramirez-Solis Ramiro, 1994, Current Opinion in Biotechnology, V5, P528, DOI 10.1016/0958-1669(94)90069-8; SHIM H, 1997, THERIOGENOLOGY, V47, P425; Stice SL, 1996, BIOL REPROD, V54, P100, DOI 10.1095/biolreprod54.1.100; Takada T, 1997, NAT BIOTECHNOL, V15, P458, DOI 10.1038/nbt0597-458; THOMPSON EM, 1995, P NATL ACAD SCI USA, V92, P1317, DOI 10.1073/pnas.92.5.1317; Walker SK, 1996, THERIOGENOLOGY, V45, P111, DOI 10.1016/0093-691X(95)00360-K; WALL RJ, 1992, THERIOGENOLOGY, V38, P337, DOI 10.1016/0093-691X(92)90239-N; Wells DN, 1997, BIOL REPROD, V57, P385, DOI 10.1095/biolreprod57.2.385; WHEELER MB, 1994, REPROD FERT DEVELOP, V6, P563, DOI 10.1071/RD9940563; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; YOSHITAKE S, 1985, BIOCHEMISTRY-US, V24, P3736, DOI 10.1021/bi00335a049; YULL F, 1995, P NATL ACAD SCI USA, V92, P10899, DOI 10.1073/pnas.92.24.10899	30	648	847	2	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 19	1997	278	5346					2130	2133		10.1126/science.278.5346.2130	http://dx.doi.org/10.1126/science.278.5346.2130			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405350				2022-12-01	WOS:A1997YM23500055
J	Woolf, SH; Lawrence, RS				Woolf, SH; Lawrence, RS			Preserving scientific debate and patient choice - Lessons from the consensus panel on mammography screening	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							BREAST-CANCER; DECISION-MAKING; PARTICIPATE; PHYSICIANS		JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BALTIMORE, MD USA	Johns Hopkins University	Woolf, SH (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT FAMILY PRACTICE, 3712 CHARLES STEWART DR, FAIRFAX, VA 22033 USA.							BEGLEY S, 1997, NEWSWEEK        0224, P55; Berwick DM, 1996, JAMA-J AM MED ASSOC, V275, P877, DOI 10.1001/jama.275.11.877; BJURSTAM N, 1997, MONOGR NATL CANC I, V22, P53; Budetti PP, 1997, JAMA-J AM MED ASSOC, V277, P193; Coley CM, 1997, ANN INTERN MED, V126, P480; DEBER RB, 1994, CAN MED ASSOC J, V151, P423; Ernster VL, 1997, AM J PUBLIC HEALTH, V87, P1103, DOI 10.2105/AJPH.87.7.1103; Fletcher SW, 1997, NEW ENGL J MED, V336, P1180, DOI 10.1056/NEJM199704173361612; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; Gordis L, 1997, J NATL CANCER I, V89, P1015, DOI 10.1093/jnci/89.14.1015; GRADY D, 1992, ANN INTERN MED, V117, P1038; GRIFFITH RS, 1992, PRIMARY CARE, V19, P535; HARRIS R, 1995, ANN INTERN MED, V122, P539, DOI 10.7326/0003-4819-122-7-199504010-00011; Hendrick R E, 1997, J Natl Cancer Inst Monogr, P87; HOROWITZ M, 1985, JAMA-J AM MED ASSOC, V253, P1929, DOI 10.1001/jama.253.13.1929; Kassirer JP, 1997, NEW ENGL J MED, V336, P1747, DOI 10.1056/NEJM199706123362409; KASSIRER JP, 1983, NEW ENGL J MED, V308, P898, DOI 10.1056/NEJM198304143081511; KASSIRER JP, 1981, NEW ENGL J MED, V305, P1465, DOI 10.1056/NEJM198112103052409; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P79; KOLATA G, 1997, NY TIMES        0224, pA1; Kolata G., 1997, NY TIMES        0128, pC1; KOLATA G, 1997, NY TIMES        0124, pA12; Marwick C, 1997, JAMA-J AM MED ASSOC, V277, P519, DOI 10.1001/jama.277.7.519; MCCONNELL JD, 1994, AHCPR PUBL; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; *NCAB, 1997, JNCI-J NATL CANCER I, V89, P417; Pauker SG, 1997, NEW ENGL J MED, V336, P1243, DOI 10.1056/NEJM199704243361708; SHAPIRO J, 1979, NEW ENGL J MED, V301, P211, DOI 10.1056/NEJM197907263010410; SLACK WV, 1977, LANCET, V2, P240; SNOWE OJ, 1997, WASHINGTON POST 0211, pA21; STRULL WM, 1984, JAMA-J AM MED ASSOC, V252, P2990, DOI 10.1001/jama.252.21.2990; Tabar L, 1996, INT J CANCER, V68, P693; Taubes G, 1997, SCIENCE, V276, P27, DOI 10.1126/science.276.5309.27; Taubes G, 1997, SCIENCE, V275, P1056, DOI 10.1126/science.275.5303.1056; Woolf SH, 1997, J FAM PRACTICE, V45, P205; WOOLF SH, 1993, ARCH INTERN MED, V153, P2646, DOI 10.1001/archinte.153.23.2646	36	29	29	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 17	1997	278	23					2105	2108		10.1001/jama.278.23.2105	http://dx.doi.org/10.1001/jama.278.23.2105			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YK987	9403427				2022-12-01	WOS:A1997YK98700042
J	Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR				Sellers, TA; Mink, PJ; Cerhan, JR; Zheng, W; Anderson, KE; Kushi, LH; Folsom, AR			The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer	ANNALS OF INTERNAL MEDICINE			English	Article							POSTMENOPAUSAL WOMEN; MENOPAUSAL ESTROGEN; OLDER WOMEN; FOLLOW-UP; METAANALYSIS; DISEASE	Background: The risks and benefits of hormone replacement therapy (HRT) are of considerable interest and importance, especially in terms of whether they differ among subsets of women. Objective: To determine whether HRT is associated with increased risks for breast cancer and total mortality in women with a family history of breast cancer. Design: Prospective cohort study. Setting: Population-based sample of midwestern post-menopausal women enrolled in an observational study of risk factors for cancer. Participants: Random sample of 41 837 female Iowa residents 55 to 69 years of age. Measurements: Incidence rates of and relative risks for breast cancer (n = 1085) and total mortality (n = 2035) th rough 8 years of follow-up were calculated by using data from the State Health Registry of Iowa and the National Death Index. Results: A family history of breast cancer was reported by 12.2% of the cohort at risk. Among women with a family history of breast cancer, those who currently used HRT and had done so for at least 5 years developed breast cancer at an age-adjusted annual rate of 61 cases per 10 000 person-years (95% CI, 28 to 94 cases); this rate was not statistically significantly higher than the rate in women who had never used HRT (46 cases per 10 000 person-years ICI, 36 to 55 cases]). Among women with a family history, those who used HRT had a significantly lower risk for total mortality than did women who had never used HRT (relative risk, 0.67 [CI, 0.51 to 0.89]), including total cancer-related mortality (relative risk, 0.75 [CI, 0.50 to 1.12]). The age-adjusted annual mortality rate for women using HRT for at least 5 years was 46 deaths per 10 000 person-years (CI, 19 to 74 deaths); this is roughly half the rate seen in women who had never used HRT (80 deaths per In 000 person-years [CI, 69 to 92 deaths]). Conclusions: These data suggest that HRT use in women with a family history of breast cancer is not associated with a significantly increased incidence of breast cancer but is associated with a significantly reduced total mortality rate.	UNIV IOWA, IOWA CITY, IA 52242 USA	University of Iowa	Sellers, TA (corresponding author), UNIV MINNESOTA, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.		Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022	Zheng, Wei/0000-0003-1226-070X; Kushi, Lawrence/0000-0001-9136-1175; Cerhan, James/0000-0002-7482-178X	NCI NIH HHS [R01 CA39742, T32CA09607] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA039742, T32CA009607] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1994, NIH PUBLICATION, V94-1447; ARMSTRONG BK, 1988, MED J AUSTRALIA, V148, P213, DOI 10.5694/j.1326-5377.1988.tb99424.x; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BLACKMAN JA, 1995, NEW ENGL J MED, V333, P1355; Breslow N., 1987, STATISTICAL METHODS; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; BRINTON LA, 1981, CANCER-AM CANCER SOC, V47, P2517, DOI 10.1002/1097-0142(19810515)47:10<2517::AID-CNCR2820471035>3.0.CO;2-L; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, 1995, AM J PUBLIC HEALTH, V85, P1128, DOI 10.2105/AJPH.85.8_Pt_1.1128; FOLSOM AR, 1993, JAMA-J AM MED ASSOC, V269, P483, DOI 10.1001/jama.269.4.483; GO RCP, 1983, J NATL CANCER I, V71, P455; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1997, NEW ENGL J MED, V336, P1769, DOI 10.1056/NEJM199706193362501; HEMMINKI E, 1988, AM J PUBLIC HEALTH, V78, P1478, DOI 10.2105/AJPH.78.11.1479; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; HENDERSON BE, 1996, CANC EPIDEMIOLOGY PR, P1022; HOOVER R, 1981, J NATL CANCER I, V67, P815; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KUSHI LH, 1988, AM J EPIDEMIOL, V128, P740, DOI 10.1093/oxfordjournals.aje.a115027; MILLS PK, 1989, CANCER, V64, P591, DOI 10.1002/1097-0142(19890801)64:3<591::AID-CNCR2820640305>3.0.CO;2-U; NEWCOMB PA, 1995, AM J EPIDEMIOL, V142, P788, DOI 10.1093/oxfordjournals.aje.a117717; NOMURA AMY, 1986, INT J CANCER, V37, P49, DOI 10.1002/ijc.2910370109; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; *SAS I, 1985, SAS US GUID; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SILLEROARENAS M, 1992, OBSTET GYNECOL, V79, P286; STANFORD JL, 1995, JAMA-J AM MED ASSOC, V274, P137, DOI 10.1001/jama.274.2.137; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; STURGEON SR, 1995, EPIDEMIOLOGY, V6, P227, DOI 10.1097/00001648-199505000-00006; *WHO, 1977, MAN INT STAT CLASS D; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	40	146	150	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 1	1997	127	11					973	980		10.7326/0003-4819-127-11-199712010-00004	http://dx.doi.org/10.7326/0003-4819-127-11-199712010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ080	9412302				2022-12-01	WOS:A1997YJ08000003
J	Collins, FS; Guyer, MS; Chakravarti, A				Collins, FS; Guyer, MS; Chakravarti, A			Variations on a theme: Cataloging human DNA sequence variation	SCIENCE			English	Editorial Material							DEPENDENT DIABETES-MELLITUS; POSITIONAL CLONING; HUMAN GENOME; GENE; MUTATION; CANCER; BREAST		CASE WESTERN RESERVE UNIV,CTR HUMAN GENET,DEPT GENET,CLEVELAND,OH 44106	Case Western Reserve University	Collins, FS (corresponding author), NATL HUMAN GENOME RES INST,NIH,BETHESDA,MD 20892, USA.							BALLABIO A, 1993, NAT GENET, V3, P277, DOI 10.1038/ng0493-277; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; COLLINS FS, 1991, NAT GENET, V1, P3; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; Gerhold D, 1996, BIOESSAYS, V18, P973, DOI 10.1002/bies.950181207; GRANT SFA, 1996, NAT GENET, V14, P205; KAISER J, 1996, SCIENCE, V271, P749; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Lander ES, 1996, SCIENCE, V274, P536, DOI 10.1126/science.274.5287.536; Lifton RP, 1996, SCIENCE, V272, P676, DOI 10.1126/science.272.5262.676; LIVAK KJ, 1995, PCR METH APPL, V4, P357; Marshall E, 1997, SCIENCE, V277, P1752, DOI 10.1126/science.277.5333.1752; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEPOM GT, 1991, ANNU REV IMMUNOL, V9, P493; PAPADOPOULOS N, 1994, SCIENCE, V263; Pastinen T, 1997, GENOME RES, V7, P606, DOI 10.1101/gr.7.6.606; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Schuler GD, 1996, SCIENCE, V274, P540, DOI 10.1126/science.274.5287.540; Shuber AP, 1997, HUM MOL GENET, V6, P337, DOI 10.1093/hmg/6.3.337; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; VIONNET N, 1992, NATURE, V356, P721, DOI 10.1038/356721a0; VOORBERG J, 1994, LANCET, V343, P1535, DOI 10.1016/S0140-6736(94)92939-4; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yamagata K, 1996, NATURE, V384, P455, DOI 10.1038/384455a0	29	780	831	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	NOV 28	1997	278	5343					1580	1581		10.1126/science.278.5343.1580	http://dx.doi.org/10.1126/science.278.5343.1580			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YJ874	9411782				2022-12-01	WOS:A1997YJ87400028
J	Kitanaka, S; Takeyama, K; Murayama, A; Sato, T; Okumura, K; Nogami, M; Hasegawa, Y; Niimi, H; Yanagisawa, J; Tanaka, T; Kato, S				Kitanaka, S; Takeyama, K; Murayama, A; Sato, T; Okumura, K; Nogami, M; Hasegawa, Y; Niimi, H; Yanagisawa, J; Tanaka, T; Kato, S			Inactivating mutations in the 25-hydroxyvitamin D(3) 1 alpha-hydroxylase gene in patients with pseudovitamin D-deficiency rickets	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-D DEPENDENCY; D-RECEPTOR; CDNA; EXPRESSION; CLONING; SEQUENCES; SYSTEM; ALPHA; LIVER; ACID	Background Pseudovitamin D-deficiency rickets is characterized by the early onset of rickets with hy pocalcemia and is thought to be caused by a deficit in renal 25-hydroxyvitamin D(3) 1 alpha-hydroxylase, the key enzyme for the synthesis of 1 alpha,25-dihydroxyvitamin D(3), Methods We cloned human 25-hydroxyvitamin D(3) 1 alpha-hydroxylase complementary DNA (cDNA) using a mouse 1 alpha-hydroxylase cDNA fragment as a probe. its genomic structure was determined, and its chromosomal location was mapped by fluorescence in situ hybridization. We then identified mutations in the 1 alpha-hydroxylase gene in four unrelated patients with pseudovitamin D-deficiency rickets by DNA-sequence analysis. Both the normal and the mutant 1 alpha-hydroxylase proteins were expressed in COS-1 cells and were assayed for 1 alpha-hydroxylase activity. Results The gene for 25-hydroxyvitamin D(3) 1 alpha-hydroxylase was mapped to chromosome 12q13.3, which had previously been reported to be the locus for pseudovitamin D-deficiency rickets by linkage analysis, Four different homozygous missense mutations were detected in this gene in the four patients with pseudovitamin D-deficiency rickets. The unaffected parents and one sibling tested were heterozygous for the mutations. Functional analysis of the mutant 1 alpha-hydroxylase protein revealed that all four mutations abolished 1 alpha-hydroxylase activity. Conclusions Inactivating mutations in the 25-hydroxyvitamin D(3) 1 alpha-hydroxylase gene are a cause of pseudovitamin D-deficiency rickets. (C) 1998, Massachusetts Medical Society.	Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan; Mie Univ, Fac Bioresources, Tsu, Mie, Japan; Tokyo Metropolitan Kiyose Hosp, Tokyo, Japan; Chiba Univ, Sch Med, Dept Pediat, Chiba, Japan; Natl Childrens Med Res Ctr, Dept Endocrinol & Metab, Tokyo 154, Japan	University of Tokyo; Mie University; Chiba University; National Center for Child Health & Development - Japan	Kato, S (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Yayoi, Tokyo 1130032, Japan.							BALSAN S, 1991, NESTLE NUTR WORKS SE, V21, P155; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHUA SC, 1987, P NATL ACAD SCI USA, V84, P7193, DOI 10.1073/pnas.84.20.7193; CHUNG B, 1986, P NATL ACAD SCI USA, V83, P8962, DOI 10.1073/pnas.83.23.8962; COWEN J, 1980, ARCH DIS CHILD, V55, P964, DOI 10.1136/adc.55.12.964; DELVIN EE, 1981, J PEDIATR-US, V99, P26, DOI 10.1016/S0022-3476(81)80952-3; DEMAY MB, 1995, ENDOCRINOLOGY, V2, P1173; Ebihara K, 1996, MOL CELL BIOL, V16, P3393; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; FRASER D, 1973, NEW ENGL J MED, V289, P817, DOI 10.1056/NEJM197310182891601; Fujii H, 1997, EMBO J, V16, P4163, DOI 10.1093/emboj/16.14.4163; GOTOH O, 1992, J BIOL CHEM, V267, P83; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HENRY HL, 1992, J CELL BIOCHEM, V49, P4, DOI 10.1002/jcb.240490103; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KAWAJIRI K, 1984, P NATL ACAD SCI-BIOL, V81, P1649, DOI 10.1073/pnas.81.6.1649; KAWASHIMA H, 1981, P NATL ACAD SCI-BIOL, V78, P1199, DOI 10.1073/pnas.78.2.1199; Kitanaka S, 1997, J CLIN ENDOCR METAB, V82, P4054, DOI 10.1210/jc.82.12.4054; KOBORI M, 1993, NUCLEIC ACIDS RES, V21, P2782, DOI 10.1093/nar/21.11.2782; LABUDA M, 1990, AM J HUM GENET, V47, P28; LABUDA M, 1992, J BONE MINER RES, V7, P1447; Liberman Uri A., 1995, P425; MALLOY PJ, 1990, J CLIN INVEST, V86, P2071, DOI 10.1172/JCI114944; MARX SJ, 1995, METABOLIC MOL BASES, V2, P3091; MAWER EB, 1994, J CLIN ENDOCR METAB, V79, P554, DOI 10.1210/jc.79.2.554; MORNET E, 1989, J BIOL CHEM, V264, P20961; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NONAKA Y, 1989, FEBS LETT, V255, P21, DOI 10.1016/0014-5793(89)81053-1; OKUMURA K, 1995, GENOMICS, V27, P377, DOI 10.1006/geno.1995.1062; PEDERSEN JI, 1976, J BIOL CHEM, V251, P3933; PRADER A, 1961, HELV PAEDIATR ACTA, V16, P452; SASAKI H, 1995, BIOCHEMISTRY-US, V34, P370, DOI 10.1021/bi00001a045; SASAKI T, 1961, ENDOCRINOL JAPON, V8, P272; SCRIVER CR, 1978, NEW ENGL J MED, V299, P976, DOI 10.1056/NEJM197811022991803; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; WHITE PC, 1994, HUM MUTAT, V3, P373, DOI 10.1002/humu.1380030408; YANASE T, 1991, ENDOCR REV, V12, P91, DOI 10.1210/edrv-12-1-91; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	41	234	241	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 5	1998	338	10					653	661		10.1056/NEJM199803053381004	http://dx.doi.org/10.1056/NEJM199803053381004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YZ844	9486994				2022-12-01	WOS:000072299700004
J	Morris, CD; Reller, MD; Menashe, VD				Morris, CD; Reller, MD; Menashe, VD			Thirty-year incidence of infective endocarditis after surgery for congenital heart defect	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VENTRICULAR SEPTAL-DEFECT; BACTERIAL-ENDOCARDITIS; PULMONARY STENOSIS; AORTIC-STENOSIS; PROPHYLAXIS; DISEASE; ADULTS; CHILDHOOD; KNOWLEDGE; CHILDREN	Context.-The incidence of infective endocarditis after surgical repair of congenital heart defects is unknown. Objective.-To determine the long-term incidence of endocarditis after repair of any of 12 congenital heart defects in childhood. Design.-Population-based registry started in 1982. Setting.-State of Oregon. Participants.-All Oregon residents who underwent surgical repair for 1 of 12 major congenital defects at the age of 18 years or younger from 1958 to the present. Main Outcome Measure.-Diagnosis of infective endocarditis confirmed by hospital or autopsy records. Results.-Follow-up data were obtained from 88% of this cohort of 3860 individuals through 1993. At 25 years after surgery, the cumulative incidence of infective endocarditis was 1.3% for tetralogy of Fallot, 2.7% for isolated ventricular septal defect, 3.5% for coarctation of the aorta, 13.3% for valvular aortic stenosis, and 2.8% for primum atrial septal defect. In the cohorts with shorter follow-up, at 20 years after surgery the cumulative incidence was 4.0% for dextrotransposition of the great arteries; at 10 years, the cumulative incidence was 1.1% for complete atrioventricular septal defect, 5.3% for pulmonary atresia with an intact ventricular septum, and 6.4% for pulmonary atresia with ventricular septal defect. No children with secundum atrial septal defect, patent ductus arteriosus, or pulmonic stenosis have had infective endocarditis after surgery. Conclusion.-The continuing incidence of endocarditis after surgery for congenital heart defect, particularly valvular aortic stenosis, merits education about endocarditis prophylaxis for children and adults with repaired congenital heart defects.	Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Med Informat & Outcomes Res, BICC, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Pediat Cardiol, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Morris, CD (corresponding author), Oregon Hlth Sci Univ, Congenital Heart Dis Res Ctr, Div Med Informat & Outcomes Res, BICC, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL039052, R23HL036856] Funding Source: NIH RePORTER; NHLBI NIH HHS [R29 HL39052, R23 HL36856] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AWADALLAH SM, 1991, AM J CARDIOL, V68, P90, DOI 10.1016/0002-9149(91)90717-Y; CETTA F, 1995, MAYO CLIN PROC, V70, P50; CETTA F, 1993, PEDIATR CARDIOL, V14, P220, DOI 10.1007/BF00795374; CHILD JS, 1991, J AM COLL CARDIOL, V18, P337, DOI 10.1016/0735-1097(91)90581-S; Dajani AS, 1997, JAMA-J AM MED ASSOC, V277, P1794, DOI 10.1001/jama.277.22.1794; DEGEVIGNEY G, 1995, EUR HEART J, V16, P7, DOI 10.1093/eurheartj/16.suppl_B.7; GERSONY WM, 1993, CIRCULATION, V87, P121; GERSONY WM, 1977, CIRCULATION, V56, P84; GRIFFIN MR, 1985, JAMA-J AM MED ASSOC, V254, P1199, DOI 10.1001/jama.254.9.1199; HANSEN D, 1992, PEDIATR CARDIOL, V13, P198, DOI 10.1007/BF00838776; IGA K, 1991, JPN CIRC J, V55, P437, DOI 10.1253/jcj.55.437; KARL T, 1987, BRIT HEART J, V58, P57; LEPORT C, 1995, EUR HEART J, V16, P126, DOI 10.1093/eurheartj/16.suppl_B.126; MCKINSEY DS, 1987, AM J MED, V82, P681, DOI 10.1016/0002-9343(87)90001-5; MICHEL PL, 1995, EUR HEART J, V16, P2, DOI 10.1093/eurheartj/16.suppl_B.2; MORRIS CD, 1991, JAMA-J AM MED ASSOC, V266, P3447, DOI 10.1001/jama.266.24.3447; SCOVIL JA, 1976, CIRCULATION, V53, P953, DOI 10.1161/01.CIR.53.6.953	17	94	105	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 25	1998	279	8					599	603		10.1001/jama.279.8.599	http://dx.doi.org/10.1001/jama.279.8.599			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX457	9486754	Bronze			2022-12-01	WOS:000072041900035
J	Kaiser, RI; Ochsenfeld, C; Head-Gordon, M; Lee, YT				Kaiser, RI; Ochsenfeld, C; Head-Gordon, M; Lee, YT			The formation of HCS and HCSH molecules and their role in the collision of comet Shoemaker-Levy 9 with Jupiter	SCIENCE			English	Article							GAUSSIAN-BASIS SETS; IMPACT; THIOFORMALDEHYDE; SPECTROSCOPY; ATMOSPHERE; BEAM	The reaction of hydrogen sulfide with ground-state atomic carbon was examined with crossed molecular beams experiments and ab initio calculations. The thiohydroxycarbene molecule, HCSH, was the reactive intermediate, which fragmented into atomic hydrogen and the thioformyl radical HCS. This finding may account for the unassigned HCS source and an unidentified HCSH radical needed to match observed CS abundances from the collision of comet Shoemaker-Levy 9 into Jupiter. In the shocked jovian atmosphere, HCS could further decompose to H and CS, and CS could react with SH and OH to yield the observed CS2 and COS.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Chem Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Kaiser, RI (corresponding author), Acad Sinica, Inst Atom & Mol Sci, 1,Sect 4,Roosevelt Rd, Taipei 116, Taiwan.		Ochsenfeld, Christian/E-8021-2015; Head-Gordon, Martin/AAR-4028-2020; Lee, Yuan-Tseh/F-7914-2012	Ochsenfeld, Christian/0000-0002-4189-6558; 				ATREYA S, IN PRESS 3 GALILEOS; Atreya S. K., 1986, ATMOSPHERES IONOSPHE; Atreya S.K., 1985, PLANETARY METEOROLOG; ATREYA SK, 1995, GEOPHYS RES LETT, V22, P1625, DOI 10.1029/95GL01718; Borunov S, 1997, ICARUS, V125, P121, DOI 10.1006/icar.1996.5608; Conrath B.J., 1996, COLLISION COMET SHOE, P293; CROVISIER J, 1996, COLLISION COMET SHOE, P31; DUNNING TH, 1989, J CHEM PHYS, V90, P1007, DOI 10.1063/1.456153; ENTENMANN EA, 1966, THESIS HARVARD U CAM; HACHEY MRJ, 1995, CHEM PHYS, V197, P61, DOI 10.1016/0301-0104(95)00154-G; JUDGE RH, 1980, J MOL SPECTROSC, V81, P37, DOI 10.1016/0022-2852(80)90328-8; Kaiser RI, 1996, SCIENCE, V274, P1508, DOI 10.1126/science.274.5292.1508; Kaiser RI, 1995, REV SCI INSTRUM, V66, P5405, DOI 10.1063/1.1146061; LEE YT, 1987, SCIENCE, V236, P793, DOI 10.1126/science.236.4803.793; LELLOUCH E, 1995, NATURE, V373, P592, DOI 10.1038/373592a0; LELLOUCH E, 1996, COLLISION COMET SHOE, P213; MILLER WB, 1969, THESIS HARVARD U CAM; MOSES JI, 1996, COLLISION COMET SHOE, P243; Niemann HB, 1996, SCIENCE, V272, P846, DOI 10.1126/science.272.5263.846; NOLL KS, 1995, SCIENCE, V267, P1307, DOI 10.1126/science.7871428; NOLL KS, 1996, COLLISION COMET SHOE; Ragent B, 1996, SCIENCE, V272, P854, DOI 10.1126/science.272.5263.854; RAGHAVACHARI K, 1989, CHEM PHYS LETT, V157, P479, DOI 10.1016/S0009-2614(89)87395-6; RUSCIC B, 1993, J CHEM PHYS, V98, P2568, DOI 10.1063/1.464139; SCHAFER A, 1992, J CHEM PHYS, V97, P2571, DOI 10.1063/1.463096; SHOEMAKER CS, 1993, 5725 INT ASTR UN; STANTON JF, 1992, INT J QUANTUM CHEM S, V26, P879; Yelle RV, 1996, ICARUS, V119, P90, DOI 10.1006/icar.1996.0004; ZAHNLE K, 1995, GEOPHYS RES LETT, V22, P1593, DOI 10.1029/95GL01190; ZAHNLE K, 1996, COLLISION COMET SHOE, P183	30	36	36	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1181	1184		10.1126/science.279.5354.1181	http://dx.doi.org/10.1126/science.279.5354.1181			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469802				2022-12-01	WOS:000072115200034
J	Lin, RJ; Nagy, L; Inoue, S; Shao, WL; Miller, WH; Evans, RM				Lin, RJ; Nagy, L; Inoue, S; Shao, WL; Miller, WH; Evans, RM			Role of the histone deacetylase complex in acute promyelocytic leukaemia	NATURE			English	Article							PML-RAR-ALPHA; FUSION PROTEIN; TRANSCRIPTIONAL PROPERTIES; LEUKEMIA-CELLS; CO-REPRESSOR; DNA-BINDING; TRANSLOCATION; T(15-17); TRANSACTIVATION; DIFFERENTIATION	Non-liganded retinoic acid receptors (RARs) repress transcription of target genes by recruiting the histone deacetylase complex(1-3) through a class of silencing mediators termed SMRT or N-CoR4,5. Mutant forms of RAR alpha, created by chromosomal translocations with either the PML (for promyelocytic leukaemia)(6-8) or the PLZF (for promyelocytic leukaemia zinc finger)(9,10) locus, are oncogenic and result in human acute promyelocytic leukaemia (APL). PML-RAR alpha APL patients achieve complete remission following treatments with pharmacological doses of retinoic acids (RA); in contrast, PLZF-RAR alpha patients respond very poorly, if at all(11). Here we report that the association of these two chimaeric receptors with the histone deacetylase (HDAC) complex helps to determine both the development of APL and the ability of patients to respond to retinoids. Consistent with these observations, inhibitors of histone deacetylase dramatically potentiate retinoid-induced differentiation of RA-sensitive, and restore retinoid responses of RA-resistant, APL cell lines. Our findings suggest that oncogenic RARs mediate leukaemogenesis through aberrant chromatin acetylation, and that pharmacological manipulation, of nuclear receptor co-factors may be a useful approach in the treatment of human disease.	Howard Hughes Med Inst, La Jolla, CA 92037 USA; Salk Inst Biol Studies, La Jolla, CA 92037 USA; Univ Calif San Diego, Sch Med, Grad Program Mol Pathol, La Jolla, CA 92093 USA; McGill Univ, Lady Davis Inst Med Res, Dept Oncol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Lady Davis Inst Med Res, Dept Med, Montreal, PQ H3T 1E2, Canada	Howard Hughes Medical Institute; Salk Institute; University of California System; University of California San Diego; Lady Davis Institute; McGill University; Lady Davis Institute; McGill University	Evans, RM (corresponding author), Howard Hughes Med Inst, La Jolla, CA 92037 USA.		Evans, Ronald/AAF-4001-2019; Nagy, Laszlo/A-3814-2008	Evans, Ronald/0000-0002-9986-5965; Nagy, Laszlo/0000-0001-6653-2155; Lin, Richard/0000-0002-0834-7880				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Brown D, 1997, P NATL ACAD SCI USA, V94, P2551, DOI 10.1073/pnas.94.6.2551; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEN Z, 1994, P NATL ACAD SCI USA, V91, P1178, DOI 10.1073/pnas.91.3.1178; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LANOTTE M, 1991, BLOOD, V77, P1080; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Licht JD, 1996, ONCOGENE, V12, P323; LICHT JD, 1995, BLOOD, V85, P1083, DOI 10.1182/blood.V85.4.1083.bloodjournal8541083; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Ruthardt M, 1997, MOL CELL BIOL, V17, P4859, DOI 10.1128/MCB.17.8.4859; Shao WL, 1997, BLOOD, V89, P4282, DOI 10.1182/blood.V89.12.4282; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	29	946	1001	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					811	814		10.1038/35895	http://dx.doi.org/10.1038/35895			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486654				2022-12-01	WOS:000072089500058
J	Yeo, TC; Malouf, JF; Oh, JK; Seward, JB				Yeo, TC; Malouf, JF; Oh, JK; Seward, JB			Clinical profile and outcome in 52 patients with cardiac pseudoaneurysm	ANNALS OF INTERNAL MEDICINE			English	Review							LEFT-VENTRICULAR PSEUDOANEURYSM; MITRAL-VALVE REPLACEMENT; MYOCARDIAL-INFARCTION; FALSE ANEURYSM; DOPPLER ECHOCARDIOGRAPHY; PSEUDO-ANEURYSM; RUPTURE; DIAGNOSIS; MANAGEMENT; TRUE	Background: Cardiac pseudoaneurysm, a contained cardiac rupture, predisposes patients to further rupture. However, knowledge of the clinical profile and natural history of this cardiac complication is limited. Objective: To study the clinical features and outcomes of patients with cardiac pseudoaneurysm. Design: Retrospective analysis of patients with cardiac pseudoaneurysm seen between January 1980 and September 1996. Setting: Mayo Clinic in Rochester, Minnesota; Scottsdale, Arizona; and Jacksonville, Florida. Patients: 52 patients with pseudoaneurysm. Results: Pseudoaneurysm was discovered incidentally in 25 asymptomatic patients (48%). Four patients (8%) presented acutely (3 with acute myocardial infarction and 1 with cardiac tamponade). Other clinical presentations were congestive heart failure in 8 patients (15%), chest pain in 7 (13%), syncope or arrhythmia in 5 (10%), and systemic embolism in 3 (6%). Initial diagnostic tests were echocardiography in 32 patients, cardiac catheterization in 12, magnetic resonance imaging in 4, and computed tomography in 2. Diagnosis was made intraoperatively in two patients. Pseudoaneurysm occurred after cardiac surgery in 30 patients (58%) and after myocardial infarction in 22 (42%). Location of the pseudoaneurysm was primarily related to its cause: Pseudoaneurysm was located in the inferior or posterolateral wall in 18 of 22 patients (82%) after myocardial infarction, in the right ventricular outflow tract in 13 of 15 patients (87%) after congenital heart surgery, in the posterior subannular region of the mitral valve in 4 of 4 patients (100%) after mitral valve replacement and in the subaortic region in 3 of 3 (100%) after aortic valve replacement. Forty-two patients (81%) had surgical repair (surgical mortality rate, 7%). Ten patients (19%) did not have surgery. Nineteen patients died after a median survival of 2.3 years (range, 3 days to 8.2 years): Eight died of noncardiac cause, 5 of congestive heart failure, 4 of acute myocardial infarction, and 2 of cardiac arrhythmia (ventricular tachycardia). No further cardiac ruptures were documented. Conclusions: A substantial number of patients with pseudoaneurysm are asymptomatic. Although surgical repair is the treatment of choice, conservative management in selected patients with increased surgical risk seems reasonable because no deaths were caused by further rupture.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic	Oh, JK (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW, Rochester, MN 55905 USA.							Adamick R, 1986, ECHOCARDIOGR-J CARD, V3, P237; ALAM M, 1989, CHEST, V95, P231, DOI 10.1378/chest.95.1.231; Aronstein CG, 1941, AM J CLIN PATHOL, V11, P128; BATES RJ, 1977, AM J CARDIOL, V40, P429, DOI 10.1016/0002-9149(77)90167-9; Becker RC, 1996, J AM COLL CARDIOL, V27, P1321, DOI 10.1016/0735-1097(96)00008-3; BORMAN JB, 1982, SCAND J THORAC CARD, V16, P125, DOI 10.3109/14017438209101797; BROSS W, 1967, J CARDIOVASC SURG, V8, P256; Burn CG, 1943, AM HEART J, V26, P415, DOI 10.1016/S0002-8703(43)90338-2; CATHERWOOD E, 1980, CIRCULATION, V62, P294, DOI 10.1161/01.CIR.62.2.294; CLEARKIN K P, 1955, Thorax, V10, P42, DOI 10.1136/thx.10.1.42; DAVIDSON KH, 1977, ANN INTERN MED, V86, P430, DOI 10.7326/0003-4819-86-4-430; GATEWOOD RP, 1980, AM J CARDIOL, V46, P869, DOI 10.1016/0002-9149(80)90442-7; GRUBE E, 1980, BRIT HEART J, V43, P232; GUERON M, 1975, J THORAC CARDIOV SUR, V69, P736; HURST CO, 1963, CIRCULATION, V28, P427, DOI 10.1161/01.CIR.28.3.427; KAHN J, 1991, MAGN RESON IMAGING, V9, P159, DOI 10.1016/0730-725X(91)90005-7; KERR WF, 1961, BRIT HEART J, V23, P88; KILLEN DA, 1969, CIRCULATION, V39, P101, DOI 10.1161/01.CIR.39.1.101; KOMEDA M, 1993, J THORAC CARDIOV SUR, V106, P1189, DOI 10.1016/S0022-5223(19)33997-2; KUPARI M, 1987, BRIT HEART J, V58, P52; Lanzarini L, 1987, Recenti Prog Med, V78, P402; LEE SJK, 1976, CAN MED ASSOC J, V115, P45; MACKENZIE JW, 1994, TEX HEART I J, V21, P296; Malara D, 1987, Radiol Med, V74, P577; MARCH KL, 1989, CLIN CARDIOL, V12, P531, DOI 10.1002/clc.4960120911; MARTIN RH, 1977, AM J MED, V62, P418, DOI 10.1016/0002-9343(77)90841-5; MCLIMOYLE G, 1973, CAN MED ASSOC J, V109, P388; MILGALTER E, 1987, THORAC CARDIOV SURG, V35, P20, DOI 10.1055/s-2007-1020191; NATARAJAN MK, 1994, CAN J CARDIOL, V10, P927; OLIVA PB, 1993, J AM COLL CARDIOL, V22, P720, DOI 10.1016/0735-1097(93)90182-Z; ONIK G, 1980, J NUCL MED, V21, P177; OREILLY RJ, 1970, AM J DIS CHILD, V120, P252, DOI 10.1001/archpedi.1970.02100080136016; PAPPAS G, 1972, J THORAC CARDIOV SUR, V63, P925, DOI 10.1016/S0022-5223(19)41820-5; QIZILBASH AH, 1973, AM J CARDIOL, V32, P110, DOI 10.1016/S0002-9149(73)80095-5; Rittoo D, 1994, J Am Soc Echocardiogr, V7, P429; ROELANDT J, 1975, CIRCULATION, V52, P466, DOI 10.1161/01.CIR.52.3.466; ROELANDT JRTC, 1988, J AM COLL CARDIOL, V12, P807, DOI 10.1016/0735-1097(88)90325-7; SAKAI K, 1992, AM HEART J, V124, P975, DOI 10.1016/0002-8703(92)90981-Z; SCHWARZ J, 1988, AM HEART J, V116, P1353, DOI 10.1016/0002-8703(88)90461-9; SPINDOLAFRANCO H, 1978, RADIOLOGY, V127, P29, DOI 10.1148/127.1.29; STEWART S, 1981, ANN THORAC SURG, V31, P259, DOI 10.1016/S0003-4975(10)60938-1; Stosiek M, 1986, Rofo, V145, P728, DOI 10.1055/s-2008-1049026; SUTHERLAND GR, 1989, BRIT HEART J, V61, P59; VANTASSEL RA, 1972, CHEST, V61, P104, DOI 10.1378/chest.61.2.104; VLODAVER Z, 1975, CIRCULATION, V51, P567, DOI 10.1161/01.CIR.51.3.567	45	144	152	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1998	128	4					299	305		10.7326/0003-4819-128-4-199802150-00010	http://dx.doi.org/10.7326/0003-4819-128-4-199802150-00010			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YX170	9471934				2022-12-01	WOS:000072013400008
J	Duffy, TA; Wolfe, CDA; Varden, C; Kennedy, J; Chrystie, IL; Banatvala, JE				Duffy, TA; Wolfe, CDA; Varden, C; Kennedy, J; Chrystie, IL; Banatvala, JE			Antenatal HIV testing: current problems, future solutions. Survey of uptake in one London hospital	BRITISH MEDICAL JOURNAL			English	Article									United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England; St Thomas Hosp, Guys & St Thomas NHS Trust, Dept Midwifery, London SE1 7EH, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust	Banatvala, JE (corresponding author), United Med & Dent Sch Guys & St Thomas Hosp, Dept Virol, London SE1 7EH, England.			Wolfe, Charles/0000-0001-8264-0981				BOYD KM, 1990, J MED ETHICS, V16, P173, DOI 10.1136/jme.16.4.173; CHRYSTIE IL, 1991, LANCET, V339, P364; *PUBL HLTH LAB SER, 1997, UNL AN HIV PREV MON; *UNL AN SURV STEER, 1996, UNL AN HIV SER MON P; WESTMORLAND T, 1997, INT C GLOB STRAT PRE	5	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					270	271		10.1136/bmj.316.7127.270	http://dx.doi.org/10.1136/bmj.316.7127.270			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472508	Green Submitted, Bronze, Green Published			2022-12-01	WOS:000071702100022
J	Boyers, SP; Gilbert, WM				Boyers, SP; Gilbert, WM			Elective repeat caesarean section versus trial of labour: the neonatologist's view	LANCET			English	Editorial Material							VAGINAL BIRTH		Univ Calif Davis, Sch Med, Dept Obstet & Gynecol, Sacramento, CA 95816 USA	University of California System; University of California Davis	Boyers, SP (corresponding author), Univ Calif Davis, Sch Med, Dept Obstet & Gynecol, Sacramento, CA 95816 USA.							American College of Obstetricians and Gynecologists Committee on Ethics, 1991, ACOG COMM OP; *CDC, 1993, MMWR-MORBID MORTAL W, V42, P285; *DEP HLTH HUM SERV, 1991, USDHHS PUBL, P378; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; Hook B, 1997, PEDIATRICS, V100, P348, DOI 10.1542/peds.100.3.348; MILLER DA, 1994, OBSTET GYNECOL, V84, P255; ROSEN MG, 1991, OBSTET GYNECOL, V77, P465; STAFFORD RS, 1990, JAMA-J AM MED ASSOC, V263, P683, DOI 10.1001/jama.263.5.683	8	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					155	155		10.1016/S0140-6736(05)78217-9	http://dx.doi.org/10.1016/S0140-6736(05)78217-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449865				2022-12-01	WOS:000071616300004
J	Ilver, D; Arnqvist, A; Ogren, J; Frick, IM; Kersulyte, D; Incecik, ET; Berg, DE; Covacci, A; Engstrand, L; Boren, T				Ilver, D; Arnqvist, A; Ogren, J; Frick, IM; Kersulyte, D; Incecik, ET; Berg, DE; Covacci, A; Engstrand, L; Boren, T			Helicobacter pylori adhesin binding fucosylated histo-blood group antigens revealed by retagging	SCIENCE			English	Article							HUMAN GASTRIC EPITHELIUM; NEISSERIA-GONORRHOEAE; VIRULENCE FACTORS; HUMAN STOMACH; EXPRESSION; INFECTION; CYTOTOXIN; DISEASE; STRAINS; CLONING	The bacterium Helicobacter pylori is the causative agent for peptic ulcer disease. Bacterial adherence to the human gastric epithelial lining is mediated by the fucosylated Lewis b (Le(b)) histo-blood group antigen. The Le(b)-binding adhesin, BabA, was purified by receptor activity-directed affinity tagging. The bacterial Le(b)-binding phenotype was associated with the presence of the cag pathogenicity island among clinical isolates of H. pylori. A vaccine strategy based on the BabA adhesin might serve as a means to target the virulent type I strains of H. pylori.	Umea Univ, Dept Oral Biol, SE-90187 Umea, Sweden; Umea Univ, Dept Microbiol, SE-90187 Umea, Sweden; Univ Lund, Dept Cell & Mol Biol, SE-22100 Lund, Sweden; Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Immunobiol Res Inst Siena, I-53100 Siena, Italy; Univ Hosp, Dept Clin Microbiol & Canc Epidemiol, SE-75185 Uppsala, Sweden	Umea University; Umea University; Lund University; Washington University (WUSTL); Uppsala University; Uppsala University Hospital	Boren, T (corresponding author), Umea Univ, Dept Oral Biol, SE-90187 Umea, Sweden.	thomas.boren@micro.umu.se		Ilver, Dag/0000-0002-3618-9496				Blaser M J, 1993, Trends Microbiol, V1, P255, DOI 10.1016/0966-842X(93)90047-U; Blaser MJ, 1997, LANCET, V349, P1020, DOI 10.1016/S0140-6736(96)09133-7; BLASER MJ, 1996, SCI AM, V274, P92; BLEIL JD, 1990, P NATL ACAD SCI USA, V87, P5563, DOI 10.1073/pnas.87.14.5563; BOREN T, 1993, SCIENCE, V262, P1892, DOI 10.1126/science.8018146; BOREN T, UNPUB; BOREN T, 1994, SCI MED, V1, P28; Brunner J, 1996, TRENDS CELL BIOL, V6, P154, DOI 10.1016/0962-8924(96)40001-0; BUKANOV NO, 1994, MOL MICROBIOL, V11, P509, DOI 10.1111/j.1365-2958.1994.tb00332.x; Censini S, 1996, P NATL ACAD SCI USA, V93, P14648, DOI 10.1073/pnas.93.25.14648; CLAUSEN H, 1989, VOX SANG, V56, P1, DOI 10.1111/j.1423-0410.1989.tb03040.x; COVACCI A, 1993, P NATL ACAD SCI USA, V90, P5791, DOI 10.1073/pnas.90.12.5791; DUBOIS A, 1995, EMERG INFECT DIS, V1, P79, DOI 10.3201/eid0103.950302; FALK P, 1994, METHOD ENZYMOL, V236, P353; FALK P, 1993, P NATL ACAD SCI USA, V90, P2035, DOI 10.1073/pnas.90.5.2035; FALK P, 1994, METHOD CELL BIOL, V45, P161; HAAS R, 1986, CELL, V44, P107, DOI 10.1016/0092-8674(86)90489-7; HAGBLOM P, 1985, NATURE, V315, P156, DOI 10.1038/315156a0; Jiang Q, 1996, MOL MICROBIOL, V20, P833, DOI 10.1111/j.1365-2958.1996.tb02521.x; KIRSCHNER DE, 1995, J THEOR BIOL, V176, P281, DOI 10.1006/jtbi.1995.0198; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LOGAN RPH, 1994, LANCET, V344, P1078, DOI 10.1016/S0140-6736(94)91729-9; MARCHETTI M, 1995, SCIENCE, V267, P1655, DOI 10.1126/science.7886456; MARSHALL B, 1983, LANCET, V1, P1273; Mol O, 1996, FEMS MICROBIOL REV, V19, P25, DOI 10.1016/0168-6445(96)00022-8; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P600; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TOMPKINS LS, 1995, SCIENCE, V267, P1621, DOI 10.1126/science.7886448; TUMMURU MKR, 1993, INFECT IMMUN, V61, P1799, DOI 10.1128/IAI.61.5.1799-1809.1993; WANG Y, 1990, GENE, V94, P23, DOI 10.1016/0378-1119(90)90463-2; WARREN JR, 1983, LANCET, V1, P1273; XIANG ZY, 1995, INFECT IMMUN, V63, P94, DOI 10.1128/IAI.63.1.94-98.1995	32	905	961	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 16	1998	279	5349					373	377		10.1126/science.279.5349.373	http://dx.doi.org/10.1126/science.279.5349.373			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT158	9430586				2022-12-01	WOS:000071570800044
J	Garkavtsev, I; Grigorian, IA; Ossovskaya, VS; Chernov, MV; Chumakov, PM; Gudkov, AV				Garkavtsev, I; Grigorian, IA; Ossovskaya, VS; Chernov, MV; Chumakov, PM; Gudkov, AV			The candidate tumour suppressor p33(ING1) cooperates with p53 in cell growth control	NATURE			English	Article							FIBROBLASTS	The candidate tumour-suppressor gene ING1 has been identified by using the genetic suppressor element (GSE) methodology(1). ING1 encodes a nuclear protein, p33(ING1), overexpression of which inhibits growth of different cell lines. The properties of p33(ING1) suggest its involvement in the negative regulation of cell proliferation and in the control of cellular ageing, anchorage dependence and apoptosis(1-3). These cellular functions depend largely on the activity of p53, a tumour-suppressor gene that determines the cellular response to various types of stress(4). Here we report that the biological effects of ING1 and p53 are interrelated and require the activity of both genes: neither of the two genes can, on its own, cause growth inhibition when the other one is suppressed. Furthermore, activation of transcription from the P21/WAF1 promoter, a key mechanism of p53-mediated growth control, depends on the expression of ING1. A physical association between p33(ING1) and p53 proteins has been detected by immunoprecipitation. These results indicate that p33(ING1) is a component of the p53 signalling pathway that cooperates with p53 in the negative regulation of cell proliferation by modulating p53-dependent transcriptional activation.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Calgary, Dept Med Biochem, Calgary, AB T2N 4N1, Canada; Univ Calgary, So Alberta Canc Res Ctr, Calgary, AB T2N 4N1, Canada; VA Engelhardt Mol Biol Inst, Moscow 117984, Russia; Cleveland Clin Fdn, Cleveland, OH 44195 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Calgary; University of Calgary; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS; Cleveland Clinic Foundation	Gudkov, AV (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA.			Gudkov, Andrei/0000-0003-2548-0154; Chumakov, Peter/0000-0002-8078-2908				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garkavtsev I, 1997, MOL CELL BIOL, V17, P2014, DOI 10.1128/MCB.17.4.2014; Garkavtsev I, 1997, CYTOGENET CELL GENET, V76, P176, DOI 10.1159/000134539; Garkavtsev I, 1996, NAT GENET, V14, P415, DOI 10.1038/ng1296-415; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Helbing CC, 1997, CANCER RES, V57, P1255; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kondratov R. V., 1996, Molekulyarnaya Biologiya (Moscow), V30, P613; KOPNIN BP, 1995, ONCOL RES, V7, P299; Maestro R, 1996, CANCER RES, V56, P1146; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PAUWELS R, 1988, J VIROL METHODS, V20, P309, DOI 10.1016/0166-0934(88)90134-6; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; ZEREMSKI M, 1997, CELL MOL GENET, V23, P233	18	270	326	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					295	298		10.1038/34675	http://dx.doi.org/10.1038/34675			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440695				2022-12-01	WOS:000071484400054
J	Snow, TP; Le Page, V; Keheyan, Y; Bierbaum, VM				Snow, TP; Le Page, V; Keheyan, Y; Bierbaum, VM			The interstellar chemistry of PAH cations	NATURE			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; BANDS; MOLECULES; IONS; HYDROGEN; C10H8+; DUST	Diffuse interstellar bands (DIBs) are mysterious absorption lines in the optical spectra of stars, and have been known for 75 years(1). Although it is widely believes(2-4) that they arise from gas-phase organic molecules (rather than from dust grains) in the interstellar medium, no consensus has been reached regarding their precise cause. The realization that many emission features in astronomical infrared spectra probably arise from polycyclic aromatic hydrocarbons(5-8) (PAHs), which may themselves be very abundant in the interstellar medium, has led to the suggestion that ionized PAHs might be the source of the DIBs(9-12). Laboratory investigations have revealed that small, positively charged PAHs in matrices have absorption features that bear some resemblance to DIBs(13-15), but no clear identification of any DIB with any specific PAH cation has yet been made. Here we report a laboratory study of the chemical reactivity of PAH cations (C6H6+, C10H8+ and C16H10+) in the gas phase. We find that these PAH cations are very reactive, and are therefore unlikely to survive in high abundances in the interstellar medium. Rather, such molecules will react rapidly with hydrogen, and we therefore suggest that the resulting protonated PAH cations (and species derived from them) should become the focus of future searches for a correspondence between molecular absorption features and the DIBs.	Univ Colorado, Ctr Astrophys & Space Astron, Boulder, CO 80309 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; CNR, Ist Chim Nucl, I-00016 Rome, Italy	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Consiglio Nazionale delle Ricerche (CNR)	Snow, TP (corresponding author), Univ Colorado, Ctr Astrophys & Space Astron, Campus Box 389, Boulder, CO 80309 USA.							ABOUELAZIZ H, 1993, J CHEM PHYS, V99, P237, DOI 10.1063/1.465801; ADAMSON AJ, 1991, MON NOT R ASTRON SOC, V252, P234, DOI 10.1093/mnras/252.2.234; Allain T, 1996, ASTRON ASTROPHYS, V305, P602; ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLAMANDOLA LJ, 1985, ASTROPHYS J, V290, pL25, DOI 10.1086/184435; CRAWFORD MK, 1985, ASTROPHYS J, V293, pL45, DOI 10.1086/184488; DEPETRIS G, 1994, INT J MASS SPECTROM, V136, P155, DOI 10.1016/0168-1176(94)04022-2; GILES K, 1989, INT J MASS SPECTROM, V89, P303, DOI 10.1016/0168-1176(89)83066-6; HEGER ML, 1922, LICK OBS B, V10, P146; HERBIG GH, 1995, ANNU REV ASTRON ASTR, V33, P19, DOI 10.1146/annurev.aa.33.090195.000315; HOWORKA F, 1978, J CHEM PHYS, V68, P804, DOI 10.1063/1.435866; LEGER A, 1985, ASTRON ASTROPHYS, V146, P81; LEGER A, 1995, ASTRON ASTROPHYS, V293, pL53; LEGER A, 1984, ASTRON ASTROPHYS, V137, pL5; LePage V, 1997, J AM CHEM SOC, V119, P8373, DOI 10.1021/ja971330v; LEPAGE V, UNPUB J AM CHEM SOC; OMONT A, 1986, ASTRON ASTROPHYS, V164, P159; PETRIE S, 1992, J AM CHEM SOC, V114, P9205, DOI 10.1021/ja00049a072; PUGET JL, 1989, ANNU REV ASTRON ASTR, V27, P161; SALAMA F, 1992, ASTROPHYS J, V395, P301, DOI 10.1086/171652; Salama F, 1996, ASTROPHYS J, V458, P621, DOI 10.1086/176844; SALAMA F, 1992, NATURE, V358, P42, DOI 10.1038/358042a0; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Scott GBI, 1997, J PHYS CHEM A, V101, P4973, DOI 10.1021/jp9706947; SETSER DW, 1979, REACTIVE INTERMEDIAT; SNOW TP, 1995, ASTRON ASTROPHYS, V296, pL37; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SNOW TP, 1997, STARDUST PLANETESIMA, P147; Tielens A.G.G.M., 1995, DIFFUSE INTERSTELLAR; TOSI P, 1984, J CHEM PHYS, V80, P1905, DOI 10.1063/1.446951; VANDERZWET GP, 1985, ASTRON ASTROPHYS, V146, P76; VANDOREN JM, 1987, INT J MASS SPECTROM, V81, P85, DOI 10.1016/0168-1176(87)80007-1	32	195	195	0	47	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					259	260		10.1038/34602	http://dx.doi.org/10.1038/34602			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440689				2022-12-01	WOS:000071484400041
J	Chiodini, PL				Chiodini, PL			Non-microscopic methods for diagnosis of malaria	LANCET			English	Editorial Material							PLASMODIUM-FALCIPARUM		Hosp Trop Dis, Dept Clin Parasitol, London NW1 0PE, England	University College London Hospitals NHS Foundation Trust; University of London; London School of Hygiene & Tropical Medicine	Chiodini, PL (corresponding author), Hosp Trop Dis, Dept Clin Parasitol, London NW1 0PE, England.							Banchongaksorn T, 1996, B WORLD HEALTH ORGAN, V74, P47; BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; CHIODINI PL, 1996, MDA9633; Craig MH, 1997, T ROY SOC TROP MED H, V91, P279, DOI 10.1016/S0035-9203(97)90074-2; GILLES HM, 1993, BRUCECHWATTS ESSENTI, P1; Humar A, 1997, AM J TROP MED HYG, V56, P44, DOI 10.4269/ajtmh.1997.56.44; Laferi H, 1997, NEW ENGL J MED, V337, P1635, DOI 10.1056/NEJM199711273372219; MAKLER MT, 1993, AM J TROP MED HYG, V48, P205, DOI 10.4269/ajtmh.1993.48.205; Reilly JT, 1997, CLIN LAB HAEMATOL, V19, P165, DOI 10.1111/j.1365-2257.1997.tb00001.x; Singh N, 1997, T ROY SOC TROP MED H, V91, P396, DOI 10.1016/S0035-9203(97)90254-6	10	29	29	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					80	81		10.1016/S0140-6736(05)78155-1	http://dx.doi.org/10.1016/S0140-6736(05)78155-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439488				2022-12-01	WOS:000071591900005
J	Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER				Cramer, DW; Harlow, BL; Titus-Ernstoff, L; Bohlke, K; Welch, WR; Greenberg, ER			Over-the-counter analgesics and risk of ovarian cancer	LANCET			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; COLORECTAL-CANCER; COLON-CANCER; ASPIRIN USE	Background Evidence that aspirin and other non-steroidal anti-inflammatory drugs reduce risk for colorectal cancer has prompted interest in their ability to prevent other cancers. We aimed to find out what effect over-the-counter analgesics have on risk of ovarian cancer. Methods In a case-control study we compared use of over-the-counter analgesics by 563 women from eastern Massachusetts and New Hampshire, USA, who had epithelial ovarian cancer with 523 women from the general population. We calculated exposure odds ratios to estimate the effect of over-the-counter analgesics on ovarian cancer risk. Use of over-the-counter analgesics was assessed through interviews and defined as use al least once a week continuously for at least 6 months. Findings The odds ratio for risk of ovarian cancer for aspirin use was 0.75 (95% CI 0.52-1.10), that for ibuprofen was 1.03 (0.64-1.64), and that for paracetamol was 0.52 (0.31-0.86), after adjusting for age, study centre, education, religion, parity, oral contraceptive use, and menstrual, arthritic, or headache pain. Relative to no use, the lower risk of ovarian cancer associated with paracetamol was more apparent for use on a daily basis, 0.39 (0.21-0.74), for more than 10 years of use, 0.40 (0.19-0.88), or for more than 20 tablet years defined as (tablets per dayXyears of use), 0.45 (0.20-0.99). Interpretation In our data, there was a statistically significant inverse association between paracetamol use and ovarian cancer risk. There was a modest but nonsignificant inverse association with aspirin use and ovarian cancer and no association with ibuprofen use. Experimental studies in rodents demonstrating uterine and ovarian atrophy at high doses of paracetamol and decreased ovarian-cyst formation at lower doses suggest a biological basis for our observations.	Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Dartmouth College; Norris Cotton Cancer Center	Cramer, DW (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp,Dept Obstet & Gynecol, Obstet & Gynecol Epidemiol Ctr, 221 Longwood Ave, Boston, MA 02115 USA.			Harlow, Bernard/0000-0002-6735-8862	NCI NIH HHS [R01 CA 54419] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054419] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berkel HJ, 1996, EPIDEMIOL REV, V18, P205, DOI 10.1093/oxfordjournals.epirev.a017926; GOODWIN JS, 1981, MED CLIN N AM, V65, P829, DOI 10.1016/S0025-7125(16)31500-0; GREENBERG ER, 1996, IARC SCI PUBL, V139, P91; *INT AG RES CANC W, 1990, IARC MONOGRAPHS; ISENHOWER WD, 1986, BIOL RES PREG PERIN, V7, P6; LOGAN RF, 1993, BRIT MED J, V309, P285; MARNETT LJ, 1995, PREV MED, V24, P103, DOI 10.1006/pmed.1995.1017; MUSCAT JE, 1994, CANCER-AM CANCER SOC, V74, P1847, DOI 10.1002/1097-0142(19941001)74:7<1847::AID-CNCR2820740704>3.0.CO;2-#; *NAT TOX PROGR, 1993, NIH PUBL; PASHA KV, 1989, BRAIN RES BULL, V22, P617, DOI 10.1016/0361-9230(89)90079-8; PELEG II, 1994, ARCH INTERN MED, V154, P394, DOI 10.1001/archinte.154.4.394; SANTACOLOMA TA, 1991, BIOCHEM BIOPH RES CO, V176, P1256, DOI 10.1016/0006-291X(91)90421-3; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301	15	190	192	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 10	1998	351	9096					104	107		10.1016/S0140-6736(97)08064-1	http://dx.doi.org/10.1016/S0140-6736(97)08064-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT341	9439495				2022-12-01	WOS:000071591900012
J	Shigeyoshi, Y; Taguchi, K; Yamamoto, S; Takekida, S; Yan, L; Tei, H; Moriya, T; Shibata, S; Loros, JJ; Dunlap, JC; Okamura, H				Shigeyoshi, Y; Taguchi, K; Yamamoto, S; Takekida, S; Yan, L; Tei, H; Moriya, T; Shibata, S; Loros, JJ; Dunlap, JC; Okamura, H			Light-induced resetting of a mammalian circadian clock is associated with rapid induction of the mPer1 transcript	CELL			English	Article							RAT SUPRACHIASMATIC NUCLEUS; VASOACTIVE INTESTINAL POLYPEPTIDE; MESSENGER-RNA; CEREBROSPINAL-FLUID; VASOPRESSIN RHYTHM; PHOTIC REGULATION; GENE-EXPRESSION; FEEDBACK LOOP; TIMELESS; NEURONS	To understand how light might entrain a mammalian circadian clock, we examined the effects of light on mPer1, a sequence homolog of Drosophila per, that exhibits robust rhythmic expression in the SCN.mPer1 is rapidly induced by short duration exposure to light at levels sufficient to reset the clock, and dose-response curves reveal that mPer1 induction shows both reciprocity and a strong correlation with phase shifting of the overt rhythm. Thus, in both the phasing of dark expression and the response to light mPer1 is most similar to the Neurospora clock gene fro. Within the SCN there appears to be localization of the induction phenomenon, consistent with the localization of both light-sensitive and light-insensitive oscillators in this circadian center.	Kobe Univ, Sch Med, Dept Anat & Brain Sci, Chuo Ku, Kobe, Hyogo 650, Japan; Univ Tokyo, Inst Med Sci, Ctr Human Genome, Minato Ku, Tokyo 108, Japan; Waseda Univ, Sch Human Sci, Dept Pharmacol & Brain Sci, Tokorozawa, Saitama 359, Japan; Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Kobe University; University of Tokyo; Waseda University; Dartmouth College	Okamura, H (corresponding author), Kobe Univ, Sch Med, Dept Anat & Brain Sci, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 650, Japan.		Jansen, Heiko T./A-5770-2008; Dunlap, Jay/L-6232-2013; Loros, Jennifer/B-6293-2014	Jansen, Heiko T./0000-0003-0178-396X; Dunlap, Jay/0000-0003-1577-0457; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034985, R37GM034985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH044651, K05MH001186] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34985] Funding Source: Medline; NIMH NIH HHS [MH44651, MH01186] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ARONIN N, 1991, SUPRACHIASMATIC NUCL, P445; ARONSON BD, 1994, SCIENCE, V263, P1578, DOI 10.1126/science.8128244; Aschoff J., 1981, BIOL RHYTHMS HDB BEH; Ban Y, 1997, J NEUROSCI, V17, P3920; BEST J, 1996, HOW QUICKLY DOES LIG, P105; COLWELL CS, 1992, J COMP NEUROL, V324, P135, DOI 10.1002/cne.903240202; CROSTHWAITE SK, 1995, CELL, V81, P1003, DOI 10.1016/S0092-8674(05)80005-4; Crosthwaite SK, 1997, SCIENCE, V276, P763, DOI 10.1126/science.276.5313.763; DAAN S, 1976, J COMP PHYSIOL, V106, P253, DOI 10.1007/BF01417857; Davisson M T, 1995, Trends Genet, P35; DUNLAP JC, 1993, ANNU REV PHYSIOL, V55, P683, DOI 10.1146/annurev.physiol.55.1.683; Dunlap JC, 1996, ANNU REV GENET, V30, P579, DOI 10.1146/annurev.genet.30.1.579; ELLIOT J, 1996, TIME COURSE HAMSTER, P105; FOSTER RG, 1991, J COMP PHYSIOL A, V169, P39, DOI 10.1007/BF00198171; Foulkes NS, 1996, P NATL ACAD SCI USA, V93, P14140, DOI 10.1073/pnas.93.24.14140; Garceau NY, 1997, CELL, V89, P469, DOI 10.1016/S0092-8674(00)80227-5; Gillette MU, 1996, PROG BRAIN RES, V111, P121, DOI 10.1016/S0079-6123(08)60404-5; HALL JC, 1995, TRENDS NEUROSCI, V18, P230, DOI 10.1016/0166-2236(95)93908-G; Hall JC, 1996, NEURON, V17, P799, DOI 10.1016/S0896-6273(00)80211-1; Hall JC, 1997, CELL, V90, P9, DOI 10.1016/S0092-8674(00)80308-6; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; HASTINGS JW, 1958, BIOL BULL, V115, P440, DOI 10.2307/1539108; Hastings MH, 1997, TRENDS NEUROSCI, V20, P459, DOI 10.1016/S0166-2236(97)01087-4; Hastings MH, 1996, PROG BRAIN RES, V111, P147, DOI 10.1016/S0079-6123(08)60406-9; HENDRICKSON AE, 1972, Z ZELLFORSCH MIK ANA, V135, P1, DOI 10.1007/BF00307084; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; INOUYE SIT, 1994, NEUROSCI RES, V20, P109, DOI 10.1016/0168-0102(94)90029-9; KORNHAUSER JM, 1992, SCIENCE, V255, P1581, DOI 10.1126/science.1549784; KORNHAUSER JM, 1990, NEURON, V5, P127, DOI 10.1016/0896-6273(90)90303-W; Lee CG, 1996, SCIENCE, V271, P1740, DOI 10.1126/science.271.5256.1740; LOROS J, 1995, SEMIN NEUROSCI, V7, P3, DOI 10.1016/1044-5765(95)90012-8; Millar AJ, 1997, CURR BIOL, V7, pR474, DOI 10.1016/S0960-9822(06)00240-5; MOORE RY, 1973, BRAIN RES, V49, P403, DOI 10.1016/0006-8993(73)90431-9; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; OKAMURA H, 1987, BIOMED RES-TOKYO, V8, P253, DOI 10.2220/biomedres.8.253; OKAMURA H, 1995, MOL BRAIN RES, V29, P358, DOI 10.1016/0169-328X(94)00278-M; PITTENDRIGH CS, 1960, COLD SPRING HARB SYM, V25, P159, DOI 10.1101/SQB.1960.025.01.015; PITTENDRIGH CS, 1996, ANN REV PHYSL, V16, P4182; Qiu J, 1996, MOL CELL BIOL, V16, P4182; Rosbash M, 1996, COLD SPRING HARB SYM, V61, P265; RUSAK B, 1990, SCIENCE, V248, P1237, DOI 10.1126/science.2112267; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; SCHWARTZ WJ, 1983, BRAIN RES, V263, P105, DOI 10.1016/0006-8993(83)91205-2; SCHWARTZ WJ, 1985, J NEUROSCI, V5, P2771; SEHGAL A, 1995, SEMIN NEUROSCI, V7, P27, DOI 10.1016/1044-5765(95)90014-4; SHINOHARA K, 1994, NEUROSCI LETT, V170, P183, DOI 10.1016/0304-3940(94)90269-0; SHINOHARA K, 1993, J NEUROSCI, V13, P793; SUN S, 1997, CELL, V90, P1003; SWANSON LW, 1974, J COMP NEUROL, V156, P143, DOI 10.1002/cne.901560203; TAKAHASHI JS, 1984, NATURE, V308, P186, DOI 10.1038/308186a0; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; WINFREE A, 1976, MOL BASIS CIRCADIAN, P109; WINFREE AT, 1967, J THEOR BIOL, V16, P15, DOI 10.1016/0022-5193(67)90051-3; WINFREE AT, 1971, BIOCHRONOMETRY, P81; Young MW, 1996, COLD SPRING HARB SYM, V61, P279; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0	57	703	718	0	40	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	DEC 26	1997	91	7					1043	1053		10.1016/S0092-8674(00)80494-8	http://dx.doi.org/10.1016/S0092-8674(00)80494-8			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YP484	9428526	hybrid			2022-12-01	WOS:000071281400020
J	Prendergast, BD				Prendergast, BD			La salle de garde: bastion of the French lunch hour for junior doctors	BRITISH MEDICAL JOURNAL			English	Article									Hop Lariboisiere, INSERM, Unite Rech Biol & Pathophysiol Syst Cardiovasc, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Prendergast, BD (corresponding author), Hop Lariboisiere, INSERM, Unite Rech Biol & Pathophysiol Syst Cardiovasc, 2 Rue Ambroise Pare, F-75010 Paris, France.							BALLOUL P, 1994, SALLE GARDE PLAISIR, V2, P78	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 20	1997	315	7123					1708	1709		10.1136/bmj.315.7123.1708	http://dx.doi.org/10.1136/bmj.315.7123.1708			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448548	Green Published			2022-12-01	WOS:000071149400040
J	Gaal, T; Bartlett, MS; Ross, W; Turnbough, CL; Gourse, RL				Gaal, T; Bartlett, MS; Ross, W; Turnbough, CL; Gourse, RL			Transcription regulation by initiating NTP concentration: RRNA synthesis in bacteria	SCIENCE			English	Article							RIBOSOMAL-RNA TRANSCRIPTION; ESCHERICHIA-COLI K-12; NUCLEOTIDE-SENSITIVE SELECTION; FACTOR-INDEPENDENT ACTIVATION; RATE-DEPENDENT REGULATION; PYRBI OPERON EXPRESSION; GROWTH-RATE CONTROL; FEEDBACK-REGULATION; GUANOSINE TETRAPHOSPHATE; ALPHA-SUBUNIT	The sequence of a promoter determines not only the efficiency with which it forms a complex with RNA polymerase, but also the concentration of nucleoside triphosphate (NTP) required for initiating transcription. Escherichia coli ribosomal RNA (rrn PI) promoters required high initiating NTP concentrations for efficient transcription because they form unusually short-lived complexes with RNA polymerase; high initiating NTP concentrations [adenosine or guanosine triphosphate (ATP or GTP), depending on the rrn P1 promoter] are needed lo bind to and stabilize the open complex. ATP and GTP concentrations, and therefore rrn P1 promoter activity, increase with growth rate. Because ribosomal RNA transcription determines the rate of ribosome synthesis, the control of ribosomal RNA transcription by NTP concentration provides a molecular explanation for the growth rate-dependent control and homeostatic regulation of ribosome synthesis.	UNIV WISCONSIN,DEPT BACTERIOL,MADISON,WI 53706; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294	University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037048, R01GM029466] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29466, GM37048] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALPER MD, 1978, J BACTERIOL, V133, P149, DOI 10.1128/JB.133.1.149-157.1978; Alper S, 1996, J MOL BIOL, V260, P165, DOI 10.1006/jmbi.1996.0390; APPLEMAN JA, 1983, GENE EXPRESSION, P65; APPLEMAN JA, UNPUB; Bachmann B.J., 1987, CELLULAR MOL BIOL, P1190; BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; BARTLETT MS, 1994, J BACTERIOL, V176, P5560, DOI 10.1128/JB.176.17.5560-5564.1994; BARTLETT MS, UNPUB; BECK C, 1973, J MOL BIOL, V78, P117, DOI 10.1016/0022-2836(73)90431-2; BLATTER EE, 1994, CELL, V78, P889, DOI 10.1016/S0092-8674(94)90682-3; BOCK A, 1966, J BACTERIOL, V92, P470; Bokal AJ, 1997, EMBO J, V16, P154, DOI 10.1093/emboj/16.1.154; CASHEL M, 1968, J MOL BIOL, V34, P317, DOI 10.1016/0022-2836(68)90256-8; CASHEL M, 1996, CELLULAR MOL BIOL, P1458; COLE JR, 1987, J MOL BIOL, V198, P383, DOI 10.1016/0022-2836(87)90288-9; CONDON C, 1993, EMBO J, V12, P4305, DOI 10.1002/j.1460-2075.1993.tb06115.x; CONDON C, 1995, MICROBIOL REV, V59, P623, DOI 10.1128/MMBR.59.4.623-645.1995; de Boer H, 1979, J Biol Chem, V254, P5609; DONAHUE JP, 1994, J BIOL CHEM, V269, P18185; DONAHUE JP, 1990, J BIOL CHEM, V265, P19091; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; GAAL T, 1990, P NATL ACAD SCI USA, V87, P5533, DOI 10.1073/pnas.87.14.5533; Gaal T, 1996, GENE DEV, V10, P16, DOI 10.1101/gad.10.1.16; GAAL T, UNPUB; GAFNY R, 1994, J MOL BIOL, V243, P152, DOI 10.1006/jmbi.1994.1641; GOURSE RL, 1988, NUCLEIC ACIDS RES, V16, P9789, DOI 10.1093/nar/16.20.9789; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; Gourse RL, 1996, ANNU REV MICROBIOL, V50, P645, DOI 10.1146/annurev.micro.50.1.645; GOURSE RL, 1985, P NATL ACAD SCI USA, V82, P1069, DOI 10.1073/pnas.82.4.1069; GRUMMT I, 1976, CELL, V7, P447, DOI 10.1016/0092-8674(76)90175-6; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; JENSEN KF, 1990, MICROBIOL REV, V54, P89, DOI 10.1128/MMBR.54.2.89-100.1990; JENSEN KF, 1993, J BACTERIOL, V175, P3401, DOI 10.1128/jb.175.11.3401-3407.1993; JINKSROBERTSON S, 1983, CELL, V33, P865, DOI 10.1016/0092-8674(83)90029-6; JOSAITIS CA, 1995, P NATL ACAD SCI USA, V92, P117; KEENER J, 1996, CELLULAR MOL BIOL, P1417; KUPPER H, 1976, RNA POLYMERASE, P473; LEIRMO S, 1991, J MOL BIOL, V220, P555, DOI 10.1016/0022-2836(91)90100-K; LITTLE R, 1983, ANAL BIOCHEM, V126, P381; LIU CG, 1994, GENE DEV, V8, P2904, DOI 10.1101/gad.8.23.2904; LIU J, 1994, J BACTERIOL, V176, P2938, DOI 10.1128/JB.176.10.2938-2945.1994; LUND E, 1979, P NATL ACAD SCI USA, V76, P5480, DOI 10.1073/pnas.76.11.5480; LUND E, 1972, EUR J BIOCHEM, V28, P316, DOI 10.1111/j.1432-1033.1972.tb01916.x; Maaloe O, 1966, CONTROL MACROMOLECUL; MARR AG, 1991, MICROBIOL REV, V55, P316, DOI 10.1128/MMBR.55.2.316-333.1991; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; MCQUADE KL, UNPUB; MULLIGAN ME, 1985, J BIOL CHEM, V260, P3529; NEIDHARDT F, 1961, COLD SPRING HARB SYM, V26, P63, DOI 10.1101/SQB.1961.026.01.012; Neidhardt F.C., 1990, PHYSL BACTERIAL CELL; NEIDHARDT FC, 1996, CELLULAR MOL BIOL, pR11; NEUHARD J, 1987, CELLULAR MOL BIOL, P445; NIERMAN WC, 1979, J BIOL CHEM, V254, P7921; NILSSON L, 1994, J BIOL CHEM, V269, P9460; NINFA A, 1996, CELLULAR MOL BIOL, P1246; NOMURA M, 1984, ANNU REV BIOCHEM, V53, P75, DOI 10.1146/annurev.bi.53.070184.000451; OHLSEN KL, 1992, J BIOL CHEM, V267, P19813; OHLSEN KL, 1992, J BACTERIOL, V174, P6071, DOI 10.1128/JB.174.19.6071-6075.1992; OHLSEN KL, 1992, MOL MICROBIOL, V6, P2243, DOI 10.1111/j.1365-2958.1992.tb01400.x; POULSEN P, 1987, MOL GEN GENET, V208, P152, DOI 10.1007/BF00330436; QI FX, 1995, J MOL BIOL, V254, P552, DOI 10.1006/jmbi.1995.0638; RAO L, 1994, J MOL BIOL, V235, P1421, DOI 10.1006/jmbi.1994.1098; RECORD MT, 1996, CELLULAR MOL BIOL, P792; ROSS W, 1990, EMBO J, V9, P3733, DOI 10.1002/j.1460-2075.1990.tb07586.x; ROSS W, 1993, SCIENCE, V262, P1407, DOI 10.1126/science.8248780; ROSS W, UNPUB; ROWLEY KB, 1993, J BACTERIOL, V175, P1309, DOI 10.1128/JB.175.5.1309-1315.1993; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SCHAECHTER M, 1958, J GEN MICROBIOL, V19, P592, DOI 10.1099/00221287-19-3-592; SHARROCK RA, 1985, P NATL ACAD SCI USA, V82, P5275, DOI 10.1073/pnas.82.16.5275; SHEN V, 1977, J BACTERIOL, V130, P1109, DOI 10.1128/JB.130.3.1109-1116.1977; SINGER M, 1991, J BACTERIOL, V173, P6249, DOI 10.1128/jb.173.19.6249-6257.1991; SMITH RC, 1964, BIOCHIM BIOPHYS ACTA, V86, P229, DOI 10.1016/0304-4165(64)90047-9; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; TRAVERS A, 1976, NATURE, V263, P641, DOI 10.1038/263641a0; Tu AHT, 1997, J BACTERIOL, V179, P6665, DOI 10.1128/jb.179.21.6665-6673.1997; TURNBOUGH CL, 1983, P NATL ACAD SCI-BIOL, V80, P368, DOI 10.1073/pnas.80.2.368; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358; VOGEL U, 1991, J BACTERIOL, V173, P1168, DOI 10.1128/jb.173.3.1168-1174.1991; WILSON HR, 1992, J BACTERIOL, V174, P514, DOI 10.1128/jb.174.2.514-524.1992; YAMAGISHI M, 1987, J MOL BIOL, V198, P547, DOI 10.1016/0022-2836(87)90299-3; ZENGEL JM, 1994, PROG NUCLEIC ACID RE, V47, P331, DOI 10.1016/S0079-6603(08)60256-1	84	288	291	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2092	2097		10.1126/science.278.5346.2092	http://dx.doi.org/10.1126/science.278.5346.2092			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9405339				2022-12-01	WOS:A1997YM23500044
J	Zachariae, W; Shevchenko, A; Andrews, PD; Ciosk, R; Galova, M; Stark, MJR; Mann, M; Nasmyth, K				Zachariae, W; Shevchenko, A; Andrews, PD; Ciosk, R; Galova, M; Stark, MJR; Mann, M; Nasmyth, K			Mass spectrometric analysis of the anaphase-promoting complex from yeast: Identification of a subunit related to cullins	SCIENCE			English	Article							SISTER-CHROMATID SEPARATION; SACCHAROMYCES-CEREVISIAE; POLYACRYLAMIDE GELS; CYCLIN; UBIQUITIN; PROTEINS; TRANSITION; FAMILY; PROTEOLYSIS; REPLICATION	Entry into anaphase and exit from mitosis depend on a ubiquitin-protein ligase complex called the anaphase-promoting complex (APC) or cyclosome. At least 12 different subunits were detected in the purified particle from budding yeast, including the previously identified proteins Apc1p, Cdc16p, Cdc23p, Cdc26p, and Cdc27p, Five additional subunits purified in low nanogram amounts were identified by tandem mass spectrometric sequencing, Apc2p, Apc5p, and the RING-finger protein Apc11p are conserved from yeast to humans, Apc2p is similar to the cullin Cdc53p, which is a subunit of the ubiquitin-protein ligase complex SCFCdc4 required for the initiation of DNA replication.	European Mol Biol Lab, D-69012 Heidelberg, Germany; Res Inst Mol Pathol, A-1030 Vienna, Austria; Univ Dundee, Dept Biochem, Dundee DD1 4HN, Scotland	European Molecular Biology Laboratory (EMBL); Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Dundee	Nasmyth, K (corresponding author), European Mol Biol Lab, Meyerhofstr 1, D-69012 Heidelberg, Germany.		Stark, Michael J. R./B-2815-2014; Mann, Matthias/A-3454-2013; Ciosk, Rafal/L-7327-2013	Stark, Michael J. R./0000-0001-9086-191X; Mann, Matthias/0000-0003-1292-4799; Andrews, Paul/0000-0001-7699-5604; Nasmyth, Kim/0000-0001-7030-4403; Ciosk, Rafal/0000-0003-2234-6216				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CohenFix O, 1996, GENE DEV, V10, P3081, DOI 10.1101/gad.10.24.3081; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; Funabiki H, 1996, NATURE, V381, P438, DOI 10.1038/381438a0; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hwang LH, 1997, MOL BIOL CELL, V8, P1877, DOI 10.1091/mbc.8.10.1877; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Lamond AI, 1997, TRENDS CELL BIOL, V7, P139, DOI 10.1016/S0962-8924(97)01031-3; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; MANN M, 1994, ANAL CHEM, V66, P4390, DOI 10.1021/ac00096a002; Mathias N, 1996, MOL CELL BIOL, V16, P6634; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Neubauer G, 1997, P NATL ACAD SCI USA, V94, P385, DOI 10.1073/pnas.94.2.385; Peters JM, 1996, SCIENCE, V274, P1199, DOI 10.1126/science.274.5290.1199; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SHEVCHENKO A, UNPUB; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TYERS MB, COMMUNICATION; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.0.CO;2-K; Willems AR, 1996, CELL, V86, P453, DOI 10.1016/S0092-8674(00)80118-X; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1996, SCIENCE, V274, P1201, DOI 10.1126/science.274.5290.1201; Zachariae W, 1996, MOL BIOL CELL, V7, P791, DOI 10.1091/mbc.7.5.791	33	289	302	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 20	1998	279	5354					1216	1219		10.1126/science.279.5354.1216	http://dx.doi.org/10.1126/science.279.5354.1216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YY119	9469814				2022-12-01	WOS:000072115200046
J	Davis, AJ; Jenkinson, LS; Lawton, JH; Shorrocks, B; Wood, S				Davis, AJ; Jenkinson, LS; Lawton, JH; Shorrocks, B; Wood, S			Making mistakes when predicting shifts in species range in response to global warming	NATURE			English	Article							TEMPERATURE; CLIMATE; LIMITS	Many attempts to predict the biotic responses to climate change rely on the 'climate envelope' approach(1-3), in which the current distribution of a species is mapped in climate-space and then, if the position of that climate-space changes, the distribution of the species is predicted to shift accordingly(4-6). The flaw in this approach is that distributions of species also reflect the influence of interactions with other species(7-10), so predictions based on climate envelopes may be very misleading if the interactions between species are altered by climate change(11). An additional problem is that current distributions may be the result of sources and sinks(12), in which species appear to thrive in places where they really persist only because individuals disperse into them from elsewhere(13,14). Here we use microcosm experiments on simple but realistic assemblages to show how misleading the climate envelope approach can be. We show that dispersal and interactions, which are important elements of population dynamics(15), must be included in predictions of biotic responses to climate change.	Univ Leeds, Dept Biol, Ecol & Evolut Grp, Leeds LS2 9JT, W Yorkshire, England; Univ London Imperial Coll Sci Technol & Med, NERC, Ctr Populat Biol, Ascot SL5 7PY, Berks, England	University of Leeds; Imperial College London; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC)	Davis, AJ (corresponding author), Univ Leeds, Dept Biol, Ecol & Evolut Grp, Leeds LS2 9JT, W Yorkshire, England.	a.j.davis@leeds.ac.uk	Wood, Simon N/B-3058-2010	Wood, Simon N/0000-0002-2034-7453				BEERLING DJ, 1993, J BIOGEOGR, V20, P45, DOI 10.2307/2845738; Bennetts D. A., 1995, P49; BRUSSARD PF, 1984, ANNU REV ECOL SYST, V15, P25, DOI 10.1146/annurev.es.15.110184.000325; CONNELL JH, 1970, ECOL MONOGR, V40, P49, DOI 10.2307/1942441; Coope GR, 1995, INSECTS CHANGING ENV, P30; Davis M.B., 1986, COMMUNITY ECOL, P269; Graham R.W., 1992, P76; Graham RW, 1996, SCIENCE, V272, P1601; Hanski I., 1997, METAPOPULATION BIOL; HOLT RD, 1994, ANNU REV ECOL SYST, V25, P495, DOI 10.1146/annurev.es.25.110194.002431; Jeffree CE, 1996, FUNCT ECOL, V10, P562, DOI 10.2307/2390166; KRAAIJEVELD AR, 1995, EVOL ECOL, V9, P10, DOI 10.1007/BF01237692; Lasalle John, 1993, P197; Lawton J.H., 1984, P451; NORDLANDER G, 1980, ENTOMOL SCAND, V11, P428; PACALA SW, 1993, BIOTIC INTERACTIONS AND GLOBAL CHANGE, P57; PAINE RT, 1966, AM NAT, V100, P65, DOI 10.1086/282400; Parmesan C, 1996, NATURE, V382, P765, DOI 10.1038/382765a0; Porter J., 1995, P93; PULLIAM HR, 1988, AM NAT, V132, P652, DOI 10.1086/284880; RODRIGUEZ J, 1994, J ANIM ECOL, V63, P31, DOI 10.2307/5580; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; SCOTT D, 1991, HYDROBIOLOGIA, V222, P147, DOI 10.1007/BF00006102; Sutherst R. W., 1995, P59; Valentine James W., 1993, P341; WATKINSON AR, 1985, J ECOL, V73, P569, DOI 10.2307/2260494; Wheeler M.R., 1986, GENETICS BIOL DROS E, P1	27	841	869	1	319	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	FEB 19	1998	391	6669					783	786		10.1038/35842	http://dx.doi.org/10.1038/35842			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX884	9486646				2022-12-01	WOS:000072089500050
J	McKim, KS; Green-Marroquin, BL; Sekelsky, JJ; Chin, G; Steinberg, C; Khodosh, R; Hawley, RS				McKim, KS; Green-Marroquin, BL; Sekelsky, JJ; Chin, G; Steinberg, C; Khodosh, R; Hawley, RS			Meiotic synapsis in the absence of recombination	SCIENCE			English	Article							DROSOPHILA-MELANOGASTER FEMALES; SYNAPTONEMAL COMPLEX; SACCHAROMYCES-CEREVISIAE; CAENORHABDITIS-ELEGANS; GENE CONVERSION; WILD-TYPE; MEIOSIS; YEAST; TRANSLOCATIONS; FREQUENCY	Although in Saccharomyces cerevisiae the initiation of meiotic recombination, as indicated by double-strand break formation, appears to be functionally linked to the initiation of synapsis, meiotic chromosome synapsis in Drosophila females occurs in the absence of meiotic exchange. Electron microscopy of oocytes from females homozygous for either of two meiotic mutants (mei-W68 and mei-P22), which eliminate both meiotic crossing over and gene conversion, revealed normal synaptonemal complex formation. Thus, synapsis in Drosophila is independent of meiotic recombination, consistent with a model in which synapsis is required for the initiation of meiotic recombination. Furthermore, the basic processes of early meiosis may have different functional or temporal relations, or both, in yeast and Drosophila.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA	University of California System; University of California Davis	McKim, KS (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.			Hawley, R. Scott/0000-0002-6478-0494				BAKER B, COMMUNICATION; BURNHAM CR, 1972, GENETICS, V71, P111; CARPENTER ATC, 1975, CHROMOSOMA, V51, P157, DOI 10.1007/BF00319833; CARPENTER ATC, 1994, CIBA F SYMP, V182, P223; CARPENTER ATC, 1979, CHROMOSOMA, V75, P259, DOI 10.1007/BF00293472; CARPENTER ATC, 1979, GENETICS, V92, P511; CARPENTER AW, COMMUNICATION; CRAYMER L, 1984, GENETICS, V108, P573; CRAYMER L, 1981, GENETICS, V99, P75; CURTIS D, 1991, GENETICS, V127, P739; DEMASSY B, 1994, P NATL ACAD SCI USA, V91, P11929, DOI 10.1073/pnas.91.25.11929; GILBERTSON LA, 1994, P NATL ACAD SCI USA, V91, P11934, DOI 10.1073/pnas.91.25.11934; Goldman ASH, 1996, GENETICS, V144, P43; HABER JE, 1991, P NATL ACAD SCI USA, V88, P1120, DOI 10.1073/pnas.88.4.1120; HALL J, 1977, INFORMATION SERVICE, V52, P142; HAWLEY RC, UNPUB; HAWLEY RS, 1980, GENETICS, V94, P625; HAWLEY RS, 1993, CELL, V72, P301, DOI 10.1016/0092-8674(93)90108-3; HILLIKER AJ, 1991, GENETICS, V129, P779; HINTON CW, 1960, GENETICS, V45, P87; HIPEAUJACQUOTTE R, 1989, MOL GEN GENET, V220, P140, DOI 10.1007/BF00260868; JINKSROBERTSON S, 1986, GENETICS, V114, P731; KLECKNER N, 1991, COLD SH Q B, V56, P729; Kleckner N, 1996, P NATL ACAD SCI USA, V93, P8167, DOI 10.1073/pnas.93.16.8167; LICHTEN M, 1987, GENETICS, V115, P233; LUTKEN T, 1979, MUTAT RES, V61, P221, DOI 10.1016/0027-5107(79)90129-5; MAGUIRE MP, 1984, J THEOR BIOL, V106, P605, DOI 10.1016/0022-5193(84)90010-9; MCKIM KS, 1988, GENETICS, V120, P987; MCKIM KS, 1993, GENETICS, V134, P749; MCKIM KS, UNPUB; Moens PB, 1997, GENOME, V40, P770, DOI 10.1139/g97-799; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROBERTS PA, 1970, GENETICS, V65, P429; ROBERTS PA, 1972, GENETICS, V71, P401; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1995, P NATL ACAD SCI USA, V92, P10450, DOI 10.1073/pnas.92.23.10450; ROSE AM, 1984, MOL GEN GENET, V195, P52, DOI 10.1007/BF00332723; ROSENBLUTH RE, 1981, GENETICS, V99, P415; SHERMAN F, 1978, GENETICS, V88, P689; SYM M, 1994, CELL, V79, P283, DOI 10.1016/0092-8674(94)90197-X	40	217	226	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					876	878		10.1126/science.279.5352.876	http://dx.doi.org/10.1126/science.279.5352.876			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452390	Green Submitted			2022-12-01	WOS:000071923500048
J	Vogel, JP; Andrews, HL; Wong, SK; Isberg, RR				Vogel, JP; Andrews, HL; Wong, SK; Isberg, RR			Conjugative transfer by the virulence system of Legionella pneumophila	SCIENCE			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; RANGE PLASMID RSF1010; T-DNA TRANSFER; AGROBACTERIUM-TUMEFACIENS; MOLECULAR CHARACTERIZATION; CITRATE UTILIZATION; GENE ORGANIZATION; ESCHERICHIA-COLI; HUMAN-MONOCYTES; PHAGOSOME	Legionella pneumophila, the causative agent of Legionnaires' pneumonia, replicates within alveolar macrophages by preventing phagosome-lysosome fusion. Here, a large number of mutants called dof (defective for organelle trafficking) that were unable to replicate intracellularly because of an inability of the bacteria to alter the endocytic pathway of macrophages were isolated. The dot virulence genes encoded a large putative membrane complex that functioned as a secretion system that was able to transfer plasmid DNA from one cell to another.	Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA; Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA	Tufts University; Howard Hughes Medical Institute; Tufts University	Isberg, RR (corresponding author), Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.	risberg@opal.tufts.edu						AltMorbe J, 1996, J BACTERIOL, V178, P4248, DOI 10.1128/jb.178.14.4248-4257.1996; ANDREWS HL, IN PRESS INFECT IMMU; BACHMAN BJ, 1987, SALMONELLA TYPHIMURI, P1190; BELJERSBERGEN A, 1992, SCIENCE, V256, P1324; BERGER KH, 1994, MOL MICROBIOL, V14, P809, DOI 10.1111/j.1365-2958.1994.tb01317.x; BERGER KH, 1993, MOL MICROBIOL, V7, P7, DOI 10.1111/j.1365-2958.1993.tb01092.x; BRAND BC, 1994, MOL MICROBIOL, V14, P797, DOI 10.1111/j.1365-2958.1994.tb01316.x; BUCHANANWOLLASTON V, 1987, NATURE, V328, P172, DOI 10.1038/328172a0; CATRENICH CE, 1989, INFECT IMMUN, V57, P1862, DOI 10.1128/IAI.57.6.1862-1864.1989; Christie PJ, 1997, J BACTERIOL, V179, P3085, DOI 10.1128/jb.179.10.3085-3094.1997; CLEMENS DL, 1995, J EXP MED, V181, P257, DOI 10.1084/jem.181.1.257; FREIBERG C, 1997, NATURE, V387, P3954; FREY J, 1992, GENE, V113, P101, DOI 10.1016/0378-1119(92)90675-F; Fullner KJ, 1996, SCIENCE, V273, P1107, DOI 10.1126/science.273.5278.1107; Furuya N, 1996, J BACTERIOL, V178, P1491, DOI 10.1128/jb.178.6.1491-1497.1996; HORWITZ MA, 1983, J EXP MED, V158, P1319, DOI 10.1084/jem.158.4.1319; HORWITZ MA, 1984, J CELL BIOL, V99, P1936, DOI 10.1083/jcb.99.6.1936; ISHIGURO N, 1985, J BACTERIOL, V164, P977, DOI 10.1128/JB.164.3.977-982.1985; Joiner KA, 1997, J CLIN INVEST, V99, P1814, DOI 10.1172/JCI119347; KELLEHER JE, 1991, J BACTERIOL, V173, P5220, DOI 10.1128/jb.173.16.5220-5223.1991; KULDAU GA, 1990, MOL GEN GENET, V221, P256, DOI 10.1007/BF00261729; Lee CA, 1996, INFECT AGENT DIS, V5, P1; LESSL M, 1992, J BIOL CHEM, V267, P20471; Mecsas J, 1996, EMERG INFECT DIS, V2, P271, DOI 10.3201/eid0204.960403; PEARLMAN E, 1988, MICROB PATHOG, V63, P4928; POHLMAN RF, 1994, MOL MICROBIOL, V14, P655, DOI 10.1111/j.1365-2958.1994.tb01304.x; PORTILLO FG, 1995, TRENDS MICROBIOL, V3, P373; ROGOWSKY PM, 1990, PLASMID, V23, P85, DOI 10.1016/0147-619X(90)90028-B; ROY C, UNPUB; Roy CR, 1997, INFECT IMMUN, V65, P571, DOI 10.1128/IAI.65.2.571-578.1997; SALMOND GPC, 1994, ANNU REV PHYTOPATHOL, V32, P181, DOI 10.1146/annurev.py.32.090194.001145; SASATSU M, 1985, J BACTERIOL, V164, P983, DOI 10.1128/JB.164.3.983-993.1985; SCHOLZ P, 1989, GENE, V75, P271, DOI 10.1016/0378-1119(89)90273-4; Segal G, 1997, INFECT IMMUN, V65, P5057, DOI 10.1128/IAI.65.12.5057-5066.1997; Swanson MS, 1996, INFECT IMMUN, V64, P2585, DOI 10.1128/IAI.64.7.2585-2594.1996; Vogel JP, 1996, ANN NY ACAD SCI, V797, P271, DOI 10.1111/j.1749-6632.1996.tb52975.x; WEISS AA, 1993, P NATL ACAD SCI USA, V90, P2970, DOI 10.1073/pnas.90.7.2970; Winans SC, 1996, TRENDS MICROBIOL, V4, P64, DOI 10.1016/0966-842X(96)81513-7	38	576	598	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 6	1998	279	5352					873	876		10.1126/science.279.5352.873	http://dx.doi.org/10.1126/science.279.5352.873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YW330	9452389				2022-12-01	WOS:000071923500047
J	Ray, WA; Gigante, J; Mitchel, EF; Hickson, GB				Ray, WA; Gigante, J; Mitchel, EF; Hickson, GB			Perinatal outcomes following implementation of TennCare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-CARE; MEDICAID; TENNESSEE; ELIGIBILITY	Context.-The abrupt initiation of capitated Medicaid care in Tennessee (TennCare) in 1994 prompted many questions about changes in quality of care. Objective.-To evaluate the effect on perinatal outcomes of the transition to TennCare in 1994. Design.-Before and after retrospective cohort analysis. Setting and Population.-Births to women residing in Tennessee between 1990 and 1995 with complete demographic information on birth certificates, with a focus on women enrolled in Medicaid giving birth in 1993 (before TennCare) and 1995 (after TennCare). Outcome Measures.-Late prenatal care (after the fourth month of pregnancy) or inadequate prenatal visits, low and very low birth weight, and death in the first 60 days of life. Results.-Tennessee residents had 72 014 study births in 1993 and 72 278 in 1995, of which 37 543 (52.1%) and 35 707 (49.4%) were to women enrolled in Medicaid at delivery. For these Medicaid births, there were no changes after TennCare In the proportions with late prenatal care (16.2% in 1993 vs 15.8% in 1995), inadequate prenatal visits (5.9% vs 5.6%), low birth weight (9.4% vs 9.0%), very low birth weight (1.6% vs 1.5%), and death in the first 60 days (0.6% both years). These findings were unchanged in multivariate analysis, in analysis of high-risk subgroups, and in analysis of women with demographics characteristic of Medicaid women. Conclusion.-Study perinatal outcomes did not change among Medicaid births following the transition to TennCare.	Vanderbilt Univ, Dept Prevent Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Pediat, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Ray, WA (corresponding author), Vanderbilt Univ, Dept Prevent Med, A-1124 MCN, Nashville, TN 37232 USA.				PHS HHS [18-C-90029] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; IGLEHART JK, 1995, NEW ENGL J MED, V332, P1727, DOI 10.1056/NEJM199506223322525; KOTELCHUCK M, 1994, AM J PUBLIC HEALTH, V84, P1414, DOI 10.2105/AJPH.84.9.1414; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Meyer GS, 1996, JAMA-J AM MED ASSOC, V276, P672, DOI 10.1001/jama.276.9.672; MIRVIS DM, 1995, JAMA-J AM MED ASSOC, V274, P1235, DOI 10.1001/jama.274.15.1235; PIPER JM, 1991, AM J PUBLIC HEALTH, V81, P1046, DOI 10.2105/AJPH.81.8.1046; PIPER JM, 1990, JAMA-J AM MED ASSOC, V264, P2219, DOI 10.1001/jama.264.17.2219; PIPER JM, 1990, AM J EPIDEMIOL, V132, P561, DOI 10.1093/oxfordjournals.aje.a115692; PIPER JM, 1994, AM J PUBLIC HEALTH, V84, P1626, DOI 10.2105/AJPH.84.10.1626; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; Ray WA, 1997, AM J PREV MED, V13, P292, DOI 10.1016/S0749-3797(18)30178-8; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SMITH T, 1996, TENNESSEAN      0921, pB6; *US BUR CENS, 1993, 1992 TECHN DOC PREP; *US BUR CENS, 1992, CENS POP HOUS 1990 S; *US BUR CENS, 1993, 1992 PREP BUR CENS; US Bureau of the Census, 1992, CENS POP HOUS SUMM S	18	33	33	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 28	1998	279	4					314	316		10.1001/jama.279.4.314	http://dx.doi.org/10.1001/jama.279.4.314			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT472	9450717				2022-12-01	WOS:000071607000040
J	Adar, R				Adar, R			Compensatory hyperhidrosis after thoracic sympathectomy	LANCET			English	Editorial Material							UPPER DORSAL SYMPATHECTOMY; CHAIN		Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Hashomer, Israel; Chaim Sheba Med Ctr, Dept Surg, IL-52621 Tel Hashomer, Israel	Tel Aviv University; Sackler Faculty of Medicine; Chaim Sheba Medical Center	Adar, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, IL-52621 Tel Hashomer, Israel.							ADAMS DCR, 1992, EUR J VASCULAR SURG, V6, P558, DOI 10.1016/S0950-821X(05)80633-4; ADAR R, 1979, J NEUROSURG, V51, P424; ADAR R, 1994, EUR J SURG S, V572, P9; Andrews BT, 1997, BRIT J SURG, V84, P1702, DOI 10.1046/j.1365-2168.1997.02821.x; CLAES G, 1993, SCAND J PLAST RECONS, V27, P29, DOI 10.3109/02844319309080288; DROTT C, 1993, ARCH SURG-CHICAGO, V128, P237; PAPA MZ, 1986, ANN SURG, V204, P715, DOI 10.1097/00000658-198612000-00016; SHIH CJ, 1979, J NEUROSURG, V50, P88, DOI 10.3171/jns.1979.50.1.0088	8	22	23	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 24	1998	351	9098					231	232		10.1016/S0140-6736(05)78277-5	http://dx.doi.org/10.1016/S0140-6736(05)78277-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU294	9457090				2022-12-01	WOS:000071702200006
J	Granier, S; Owen, P; Pill, R; Jacobson, L				Granier, S; Owen, P; Pill, R; Jacobson, L			Recognising meningococcal disease in primary care: Qualitative study of how general practitioners process clinical and contextual information	BRITISH MEDICAL JOURNAL			English	Article							MENINGITIS; INFECTIONS; PENICILLIN; DIAGNOSIS; FEATURES; CHILDREN	Objectives: To describe the presentation of meningococcal disease in primary care; to explore how general practitioners process clinical and contextual information in children with meningococcal disease; and to describe ho rv this information affects management. Design: Qualitative analysis of semistructured interviews. Setting: General practices in South Glamorgan. Subjects: 26 general practitioners who between January 1994 and December 1996 admitted 31 children (under 16 years of age) in whom meningococcal disease was diagnosed. Main outcome measures: Categories of clinical rules and techniques used by general practitioners in processing each case. Results: 22 children had rashes; in 16 of them the rashes were non-blanching. When present, a haemorrhagic rash was the most important factor in the doctor's decision to admit a child. 22 children had clinical features not normally expected in children with acute self limiting illnesses-for example, lethargy poor eye contact, altered mental states, pallor with a high temperature, and an abnormal cry. Contextual information such as knowledge of parents' consultation patterns and their normal degree of anxiety, played an important part in the management decisions in 15 cases. Use of penicillin was associated with the certainty of diagnosis and the presence and type of haemorrhagic rash. Conclusion: The key clinical feature of meningococcal disease-a haemorrhagic rash-was present ill only half of the study children. The general practitioners specifically hunted for the rash in some ill children, but doctors should not be deterred from diagnosing meningococcal disease and starting antibiotic treatment if the child is otherwise well, if the rash has an unusual or scanty distribution, or if the rash is non-haemorrhagic.	Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England; Llanedeyrn Hlth Ctr, Cardiff CF3 7PN, S Glam, Wales; Univ Wales Coll Med, Dept Gen Practice, Cardiff CF3 7PN, S Glam, Wales	University of London; King's College London; Cardiff University	Granier, S (corresponding author), Univ London Kings Coll, Sch Med & Dent, Dept Gen Practice & Primary Care, London SE5 9PJ, England.							CARTWRIGHT K, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774; CARTWRIGHT K, 1992, BMJ-BRIT MED J, V305, P143, DOI 10.1136/bmj.305.6846.143; CARTWRIGHT K, 1992, BRIT MED J, V304, P115; *DEP HLTH SOC SEC, 1988, CMO882 DEP HLTH SOC; DONALD PR, 1980, S AFR MED J, V60, P271; KILPI T, 1991, LANCET, V338, P406, DOI 10.1016/0140-6736(91)91032-P; Koorevaar R, 1995, EUR J GEN PRACT, V1, P21; MARZOUK O, 1991, ARCH DIS CHILD, V66, P486; MCAVOY B, 1989, BRIT MED J, V313, P732; Nielsen B, 1988, Scand J Prim Health Care, V6, P229, DOI 10.3109/02813438809009322; OLCEN P, 1979, SCAND J INFECT DIS, V11, P111, DOI 10.3109/inf.1979.11.issue-2.03; PALMER SR, 1992, J INFECTION, V25, P321, DOI 10.1016/0163-4453(92)91699-C; Riordan FAI, 1996, BRIT MED J, V313, P1255, DOI 10.1136/bmj.313.7067.1255; SORENSEN HT, 1992, BRIT MED J, V305, P774, DOI 10.1136/bmj.305.6856.774-a; STRANG JR, 1992, BRIT MED J, V305, P141, DOI 10.1136/bmj.305.6846.141; VOSS L, 1989, NEW ZEAL MED J, V102, P243; WONG VK, 1989, PEDIATR INFECT DIS J, V8, P224; Woodward C M, 1995, Commun Dis Rep CDR Rev, V5, pR135	18	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					276	279		10.1136/bmj.316.7127.276	http://dx.doi.org/10.1136/bmj.316.7127.276			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472513	Green Submitted, Green Published, Bronze			2022-12-01	WOS:000071702100027
J	Hood, S; Birnie, D; Swan, L; Hillis, WS				Hood, S; Birnie, D; Swan, L; Hillis, WS			Questionnaire survey of thrombolytic treatment in accident and emergency departments in United Kingdom	BRITISH MEDICAL JOURNAL			English	Article									Victoria Infirm, Dept Cardiol, Glasgow G42 9TY, Lanark, Scotland; Dumfries & Galloway Royal Infirm, Dept Med, Dumfries DG1 4AL, Scotland; Univ Glasgow, Western Infirm, Dept Med & Therapeut, Glasgow G11 6NT, Lanark, Scotland	University of Glasgow	Hood, S (corresponding author), Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.		Hood, Sean David/H-5058-2014	Hood, Sean David/0000-0003-2852-7923				APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BIRKHEAD JS, 1992, BMJ-BRIT MED J, V305, P445, DOI 10.1136/bmj.305.6851.445; *CMA MED DAT, 1997, UK DIR EM SPEC CAR U; Hood S, 1996, Health Bull (Edinb), V54, P131	4	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					274	274		10.1136/bmj.316.7127.274	http://dx.doi.org/10.1136/bmj.316.7127.274			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472511	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071702100025
J	Nicoll, A; McGarrigle, C; Brady, AR; Ades, AE; Tookey, P; Duong, T; Mortimer, J; Cliffe, S; Goldberg, D; Tappin, D; Hudson, C; Peckham, C				Nicoll, A; McGarrigle, C; Brady, AR; Ades, AE; Tookey, P; Duong, T; Mortimer, J; Cliffe, S; Goldberg, D; Tappin, D; Hudson, C; Peckham, C			Epidemiology and detection of HIV-1 among pregnant women in the United Kingdom: results from national surveillance 1988-96	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE; INFECTION; TRANSMISSION; TYPE-1	Objective: To describe the epidemiology of HIV-1 infection in pregnant women in the United Kingdom. Design: Serial unlinked serosurveillance for HIV-1 in neonatal specimens and surveillance through registers of diagnosed maternal and paediatric infections from reporting by obstetricians, paediatricians, and microbiologists. Setting: United Kingdom, 1988-96. Subjects: Pregnant women proceeding to live births and their children Main outcome measures: Time trends in prevalence of HIV-1 seropositivity in newborn infants (as a proxy for infection in mothers); the proportions of mothers with diagnosed HIV-1 infections, and their characteristics. Results: HIV-1 prevalence among mothers in London rose sixfold between 1988 and 1996 (0.19% of women tested; 1 in 520 in 1996). Apart from in Edinburgh and Dundee, levels remained low in Scotland (0.025%; 1 in 3970) and elsewhere in the United Kingdom (0.016%; 1 in 1930). Over a third of births to infected mothers in 1996 occurred outside London. In London the reported infections were predominantly among black African women, whereas in Scotland most were associated with drug injecting. The contribution of reported infection among African women increased over time as that of drug injecting declined. In Scotland 51% of mothers' infections were diagnosed before the birth. In England, despite a national policy initiative in 1992 to increase the antenatal detection rate of HIV, no improvement in detection was observed, and in 1996 only 15% of previously unrecognised HN infections were diagnosed during pregnancy. Conclusions: HIV-1 infection affects mothers throughout the United Kingdom but is most common in London. Levels of diagnosis in pregnant women have not improved. Surveillance data can monitor effectively the impact of initiatives to reduce preventable HIV-1 infections in children.	Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England; Inst Child Hlth, Dept Biostat & Epidemiol, London WC1N 1EH, England; Ruchill Hosp, Scottish Ctr Infect & Environm Hlth, Glasgow G20 9NB, Lanark, Scotland; St Bartholomews Hosp, Dept Obstet & Gynaecol, London EC1A 7BF, England; Royal Hosp Sick Children, Dept Child Hlth, Glasgow G3 8SJ, Lanark, Scotland	Public Health England; University of London; University College London; University of London; Queen Mary University London; University of Glasgow	Nicoll, A (corresponding author), Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, AIDS & Sexually Transmitted Dis Ctr, London NW9 5EQ, England.	anicoll@phls.co.uk	Tookey, Pat A/G-2732-2010; McGarrigle, Christine/J-8331-2017	Tookey, Pat A/0000-0001-6258-0387; McGarrigle, Christine/0000-0001-5814-5673; Brady, Tony/0000-0003-4751-7616				ADES AE, 1993, BRIT MED J, V306, P1296, DOI 10.1136/bmj.306.6888.1296; ADES AE, 1992, AIDS, V6, P1031, DOI 10.1097/00002030-199209000-00018; ADES AE, 1995, J ACQ IMMUN DEF SYND, V9, P490; ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; [Anonymous], 1994, MMWR Recomm Rep, V43, P1; Boisson E, 1996, J ACQ IMMUN DEF SYND, V13, P434, DOI 10.1097/00042560-199612150-00006; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; *DEP HLTH, 1994, GUID OFF VOL NAM HIV; *DEP HLTH, 1992, OFF VOL NAM HIV ANT; Dunn D T, 1995, J Med Screen, V2, P35; *EUR CTR EP MON AI, 1996, HIV AIDS SURV EUR 19, P7; Gibb DM, 1997, AIDS, V11, pF53, DOI 10.1097/00002030-199707000-00001; GIBB DM, 1996, COM DIS REP CDR REV, V5, pR123; GIBB DM, 1998, BMJ, V316; Holland F J, 1994, J Med Screen, V1, P176; JONES S, 1998, BMJ, V316; Lalvani A, 1996, LANCET, V347, P1349, DOI 10.1016/S0140-6736(96)91007-7; MacDonagh SE, 1996, BRIT MED J, V313, P532; MAYAUX MJ, IN PRESS J PEDIAT; MERCEY D, 1997, BRIT J OBSTET GYNAEC, V103, P1129; MILLER R, 1997, DIPLOMATE, V4, P26; Noone A, 1997, BRIT MED J, V314, P1429, DOI 10.1136/bmj.314.7092.1429; PAPPAIOANOU M, 1993, AIDS, V7, P483, DOI 10.1097/00002030-199304000-00005; *PUBL HLTH LAB SER, 1991, COM DIS REP CDR REV, V1, pR51; *PUBL HLTH LAB SER, 1995, UNPUB; ROGERS MF, 1995, MMWR-MORBID MORTAL W, V44, P1; *SCOTT CTR INF ENV, 1995, ANSWER AIDS NEWS S, pI104; *SCOTT OFF NAT HLT, 1995, OFF VOL NAM HIV ANT; Stephenson JM, 1996, AIDS, V10, P1683, DOI 10.1097/00002030-199612000-00013; Stimson GV, 1996, AIDS, V10, P657, DOI 10.1097/00002030-199606000-00012; TAPPIN DM, 1991, LANCET, V337, P1565; *UK DEP HLTH, 1995, HIV AIDS HLTH PROM E; *UNL ANN HIV SURV, 1997, UNL AN HIV PREV MON; *US DEP HHS, 1997, MMWR-MORBID MORTAL W, V46, P1086; VANHUIS M, 1997, C WOM CHILDR HIV AID; Wiznia AA, 1996, JAMA-J AM MED ASSOC, V275, P1504, DOI 10.1001/jama.275.19.1504	36	66	69	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 24	1998	316	7127					253	258		10.1136/bmj.316.7127.253	http://dx.doi.org/10.1136/bmj.316.7127.253			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU293	9472504	Bronze, Green Published, Green Submitted			2022-12-01	WOS:000071702100017
J	Crair, MC; Gillespie, DC; Stryker, MP				Crair, MC; Gillespie, DC; Stryker, MP			The role of visual experience in the development of columns in cat visual cortex	SCIENCE			English	Article							BINOCULAR IMPULSE BLOCKADE; OCULAR DOMINANCE COLUMNS; ORIENTATION SELECTIVITY; MONOCULAR DEPRIVATION; POSTNATAL-DEVELOPMENT; SENSITIVE PERIOD; CORTICAL-CELLS; KITTENS; FERRET; CONNECTIONS	The role of experience in the development of the cerebral cortex has long been controversial. Patterned visual experience in the cat begins when the eyes open about a week after birth. Cortical maps for orientation and ocular dominance in the primary visual cortex of cats were found to be present by 2 weeks. Early pattern vision appeared unimportant because these cortical maps developed identically until nearly 3 weeks of age, whether or not the eyes were open. The naive maps were powerfully dominated by the contralateral eye, and experience was needed for responses to the other eye to become strong, a process unlikely to be strictly Hebbian, With continued visual deprivation, responses to both eyes deteriorated, with a time course parallel to the well-known critical period of cortical plasticity. The basic structure of cortical maps is therefore innate, but experience is essential for specific features of these maps, as well as for maintaining the responsiveness and selectivity of cortical neurons.	Univ Calif San Francisco, Dept Physiol, WM Keck Fdn Ctr Integrat Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Stryker, MP (corresponding author), Univ Calif San Francisco, Dept Physiol, WM Keck Fdn Ctr Integrat Neurosci, Box 0444, San Francisco, CA 94143 USA.			Stryker, Michael/0000-0003-1546-5831	NATIONAL EYE INSTITUTE [R37EY002874] Funding Source: NIH RePORTER; NEI NIH HHS [EY09760, R37 EY002874, R37 EY002874-20, EY02874] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBUS K, 1984, J PHYSIOL-LONDON, V348, P153, DOI 10.1113/jphysiol.1984.sp015104; ANTONINI A, 1993, J NEUROSCI, V13, P3549; Antonini A, 1996, J COMP NEUROL, V369, P64; BARLOW HB, 1971, J PHYSIOL-LONDON, V218, P98; BLAKEMORE C, 1973, NATURE, V241, P467, DOI 10.1038/241467a0; BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; BLAKEMORE C, 1974, J PHYSIOL-LONDON, V237, P195, DOI 10.1113/jphysiol.1974.sp010478; BONHOEFFER T, 1996, BRAIN MAPPING METHOD, P75; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1996, J NEUROSCI, V16, P6443; Crair MC, 1997, NEURON, V19, P307, DOI 10.1016/S0896-6273(00)80941-1; Crair MC, 1997, J NEUROPHYSIOL, V77, P3381, DOI 10.1152/jn.1997.77.6.3381; CRAIR MC, UNPUB; FREGNAC Y, 1978, J PHYSIOL-LONDON, V278, P27, DOI 10.1113/jphysiol.1978.sp012290; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; HUBEL DH, 1970, J PHYSIOL-LONDON, V206, P419, DOI 10.1113/jphysiol.1970.sp009022; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IMBERT M, 1975, EXP BRAIN RES, V22, P25; Kohonen T., 2012, SELF ORG ASSOCIATIVE; KUHL PK, 1994, CURR OPIN NEUROBIOL, V4, P812, DOI 10.1016/0959-4388(94)90128-7; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; MCCORMICK DA, 1995, J NEUROSCI, V15, P5739; MILLER KD, 1989, SCIENCE, V245, P605, DOI 10.1126/science.2762813; Movshon J.A., 1990, P155; MOVSHON JA, 1976, J PHYSIOL-LONDON, V261, P125, DOI 10.1113/jphysiol.1976.sp011551; OLSON CR, 1980, EXP BRAIN RES, V39, P17; PETTIGREW JD, 1974, J PHYSIOL-LONDON, V237, P49, DOI 10.1113/jphysiol.1974.sp010469; PRESTON KL, 1993, EARLY VISUAL DEV NOR, P80; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; SHATZ CJ, 1988, SCIENCE, V242, P87, DOI 10.1126/science.3175636; SHERK H, 1976, J NEUROPHYSIOL, V39, P63, DOI 10.1152/jn.1976.39.1.63; STRYKER MP, 1986, J NEUROSCI, V6, P2117; TORREALBA F, 1982, J COMP NEUROL, V211, P377, DOI 10.1002/cne.902110405; von der Malsburg C, 1979, Biol Cybern, V32, P49, DOI 10.1007/BF00337452; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; WIESEL TN, 1982, NATURE, V299, P583, DOI 10.1038/299583a0; WILLSHAW DJ, 1976, PROC R SOC SER B-BIO, V194, P431, DOI 10.1098/rspb.1976.0087; WONG ROL, 1993, NEURON, V11, P923, DOI 10.1016/0896-6273(93)90122-8	40	436	447	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 23	1998	279	5350					566	570		10.1126/science.279.5350.566	http://dx.doi.org/10.1126/science.279.5350.566			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YT527	9438851	Green Accepted			2022-12-01	WOS:000071616000048
J	Passmore, SJ; Draper, G; Brownbill, P; Kroll, M				Passmore, SJ; Draper, G; Brownbill, P; Kroll, M			Case-control studies of relation between childhood cancer and neonatal vitamin K administration	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN	Objective: To investigate the possible link between neonatal administration of intramuscular vitamin K and childhood cancer. Design: Matched case-control study. Setting: Selected large maternity units in England and Wales. Subjects: Children with cancer born 1968-85, diagnosed 1969-86; controls matched for sex, month of birth, and hospital of birth. Main exposure measures: Neonatal administration of vitamin K, length of gestation, birth weight type of delivery, admission to special care baby unit. Results: After exclusion of cases with missing notes or unknown hospital vitamin K policy, 597 cases and matched controls were studied. Written records on the use of vitamin K were available for only about 40% of these, and to avoid possible bias from selective recording it tvas assumed that the stated hospital policy was followed. The association between cancer generally and intramuscular vitamin K was of borderline significance (odds ratio 1.44, P = 0.05); the association was strongest for leukaemia. There was, however, also an effect of abnormal delivery, which could explain some of the findings. Conclusions: The lack of consistency between the various studies so far published, including this one, and the low relative risks found in most of them suggest that the risk, if any, attributable to the use of vitamin K cannot be large, but the possibility that there is some risk cannot be excluded. A comparison of the predicted consequences of various policies shows that even a 10% increase would imply that prophylaxis using the commonly recommended 1 mg intramuscular dose should be restricted to babies at particularly high risk of vitamin K deficiency bleeding; alternatively a lower dose might be given to a larger proportion of those at risk.	Childhood Canc Res Grp, Oxford OX2 6HJ, England	University of Oxford	Draper, G (corresponding author), Childhood Canc Res Grp, Oxford OX2 6HJ, England.							Ansell P, 1996, BRIT MED J, V313, P204, DOI 10.1136/bmj.313.7051.204; Breslow NE., 1980, IARC SCI PUBLICATION, V32; Cornelissen M, 1997, EUR J PEDIATR, V156, P126, DOI 10.1007/s004310050570; EKELUND H, 1993, BRIT MED J, V307, P89, DOI 10.1136/bmj.307.6896.89; FRANCIS B, 1993, GLIM SYSTEM GEN LINE; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HANDEL J, 1991, BRIT MED J, V303, P1109, DOI 10.1136/bmj.303.6810.1109; KLEBANOFF MA, 1993, NEW ENGL J MED, V329, P905, DOI 10.1056/NEJM199309233291301; McKinney PA, 1998, BRIT MED J, V316, P173, DOI 10.1136/bmj.316.7126.173; OLSEN JH, 1994, BRIT MED J, V308, P895, DOI 10.1136/bmj.308.6933.895; Parker L, 1998, BRIT MED J, V316, P189, DOI 10.1136/bmj.316.7126.189; PASSMORE J, 1998, BRIT MED J, V316, P184; Stiller CA, 1995, EUR J CANCER, V31A, P2028, DOI 10.1016/0959-8049(95)00428-9; vonKries R, 1996, BRIT MED J, V313, P199, DOI 10.1136/bmj.313.7051.199	15	33	34	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					178	184						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468681	Green Published, Green Submitted, Bronze			2022-12-01	WOS:000071616400021
J	Ponsonby, AL; Dwyer, T; Couper, D; Cochrane, J				Ponsonby, AL; Dwyer, T; Couper, D; Cochrane, J			Association between use of a quilt and sudden infant death syndrome: case-control study	BRITISH MEDICAL JOURNAL			English	Article									Univ Tasmania, Menzies Ctr Populat Hlth Res, Hobart, Tas 7001, Australia	University of Tasmania	Ponsonby, AL (corresponding author), Univ Tasmania, Menzies Ctr Populat Hlth Res, GPO Box 252-23, Hobart, Tas 7001, Australia.		Ponsonby, Anne-Louise/AAE-4351-2019	Couper, David/0000-0002-4313-9235; Ponsonby, Anne-Louise/0000-0002-6581-3657				BRESLOW NE, 1980, STATISTICAL METHODS, V1, P196; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; ILLINGSWORTH RS, 1983, NORMAL CHILD SOME PR, P16; PONSONBY AL, 1993, NEW ENGL J MED, V329, P377, DOI 10.1056/NEJM199308053290601; WILSON CA, 1994, J PAEDIATR CHILD H, V30, P506, DOI 10.1111/j.1440-1754.1994.tb00722.x	5	42	43	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 17	1998	316	7126					195	196						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT531	9468685				2022-12-01	WOS:000071616400026
J	Freedberg, KA; Scharfstein, JA; Seage, GR; Losina, E; Weinstein, MC; Craven, DE; Paltiel, AD				Freedberg, KA; Scharfstein, JA; Seage, GR; Losina, E; Weinstein, MC; Craven, DE; Paltiel, AD			The cost-effectiveness of preventing AIDS-related opportunistic infections	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; MYCOBACTERIUM-AVIUM COMPLEX; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; SECONDARY PROPHYLAXIS; RANDOMIZED TRIAL; CUBIC MILLIMETER; VIRUS INFECTION; RIFABUTIN; THERAPY; DISEASE	Context-Multiple options are now available for prophylaxis of opportunistic infections related to the acquired immunodeficiency syndrome (AIDS). However, because of differences in incidence rates as well as drug efficacy, toxicity, and costs, the role of different types of prophylaxis remains uncertain. Objective.-To determine the clinical impact, cost, and cost-effectiveness of strategies for preventing opportunistic infections in patients with advanced human immunodeficiency virus (HIV) disease. Design.-We developed a Markov simulation model to compare different strategies for prophylaxis of Pneumocystis carinii pneumonia (PCP), toxoplasmosis, Mycobacterium avium complex (MAC) infection, fungal infections, and cytomegalovirus (CMV) disease in HIV-infected patients. Data for the model were derived from the Multicenter AIDS Cohort Study, randomized controlled trials, and the national AIDS Cost and Services Utilization Survey. Main Outcome Measures.-Projected life expectancy, quality-adjusted life expectancy, total lifetime direct medical costs, and cost-effectiveness in dollars per quality-adjusted life-year (QALY) saved. Results.-For patients with CD4 cell counts of 0.200 to 0.300x10(9)/L (200-300/mu L) who receive no prophylaxis, we projected a quality-adjusted life expectancy of 39.08 months and average total lifetime costs of $40 288. Prophylaxis for PCP and toxoplasmosis with trimethoprim-sulfamethoxazole for patients with CD4 cell counts of 0.200x10(9)/L (200/mu L) or less increased quality-adjusted life expectancy to 42.56 months, implying an incremental cost of $16 000 per QALY saved. Prophylaxis for MAC for patients with CD4 cell counts of 0.050x10(9)/L (50/mu L) or less produced smaller gains in quality-adjusted life expectancy; incremental cost-effectiveness ratios were $35 000 per QALY saved for azithromycin and $74 000 per QALY saved for rifabutin. Oral ganciclovir for the prevention of CMV infection was the least cost-effective prophylaxis ($314 000 per QALY saved). Results were most sensitive to the risk of developing an opportunistic infection, the impact of opportunistic infection history on long-term survival, and the cost of prophylaxis. Conclusions.-The cost-effectiveness of prophylaxis against HIV-related opportunistic infections varies widely, but prophylaxis against PCP or toxoplasmosis and against MAC delivers the greatest comparative value. In an era of limited resources, these results can be used to set priorities and explore new alternatives for improving HIV patient care.	Boston Univ, Med Ctr, Dept Med, Clin Econ Res Unit, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Gen Internal Med Sect, Boston, MA 02118 USA; Boston Univ, Med Ctr, Dept Med, Clin AIDS Program, Boston, MA 02118 USA; Boston Univ, Med Ctr, Evans Med Fdn, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Dept Biostat & Epidemiol, Boston, MA USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Yale University	Freedberg, KA (corresponding author), Boston Univ, Med Ctr, Dept Med, Clin Econ Res Unit, 91E Concord St,Suite 200, Boston, MA 02118 USA.			Paltiel, A. David/0000-0002-4861-3290; Losina, ELENA/0000-0002-3424-0892	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K24AR057827] Funding Source: NIH RePORTER; AHRQ HHS [1-RO1-HS07317-01A1] Funding Source: Medline; NIAMS NIH HHS [K24 AR057827] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1997, MMWR Recomm Rep, V46, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BERK ML, 1993, AHCPR PUBLICATION; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; BROSGART C, 1996, 11 INT C AIDS JUL 7; *BUR CENS, 1995, STAT ABSTR US; CANTOR SB, 1994, MED DECIS MAKING, V14, P259, DOI 10.1177/0272989X9401400308; Carpenter CCJ, 1997, JAMA-J AM MED ASSOC, V277, P1962, DOI 10.1001/jama.277.24.1962; CASTELLANO AR, 1991, JAMA-J AM MED ASSOC, V266, P820, DOI 10.1001/jama.266.6.820; *CDCP, 1993, HIV AIDS SURVEIL FEB, P7; DOYLE A, 1997, STATE AIDS DRUG ASSI; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; ERON JJ, 1995, NEW ENGL J MED, V333, P1662, DOI 10.1056/NEJM199512213332502; Finkelstein DM, 1996, J ACQ IMMUN DEF SYND, V12, P38, DOI 10.1097/00042560-199605010-00006; Freedberg KA, 1996, MED DECIS MAKING, V16, P29, DOI 10.1177/0272989X9601600110; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; Freedberg KA, 1997, J ACQ IMMUN DEF SYND, V15, P275, DOI 10.1097/00042560-199708010-00005; GOLD MR, 1996, GOST EFFECTIVENESS H; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Hammer SM, 1996, NEW ENGL J MED, V335, P1081, DOI 10.1056/NEJM199610103351501; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; Havlir DV, 1996, NEW ENGL J MED, V335, P392, DOI 10.1056/NEJM199608083350604; Ioannidis JPA, 1996, ARCH INTERN MED, V156, P177, DOI 10.1001/archinte.156.2.177; JACOBSON MA, 1997, 4 C RETR OPP INF JAN; KAPLAN JE, 1995, CLIN INFECT DIS    S, V21, P512; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KASPAR R, 1997, 4 C RETR OPP INF JAN; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; *MED EC, 1996, DRUG TOP RED BOOK; MIETTINEN OS, 1983, AM J EPIDEMIOL, V38, P963; MILLER DK, 1994, MED DECIS MAKING, V14, P52, DOI 10.1177/0272989X9401400107; Moore RD, 1996, ANN INTERN MED, V124, P633, DOI 10.7326/0003-4819-124-7-199604010-00003; *NAT PUBL HLTH HOS, 1991, HOSP AIDS HIV SURV; *NAT TECHN INF SER, 1994, AIDS COST SERV UT SU; *NAT TECHN INF SER, 1995, MULT AIDS COH STUD M; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PALTIEL AD, IN PRESS INTERFACES; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; Pierce M, 1996, NEW ENGL J MED, V335, P384, DOI 10.1056/NEJM199608083350603; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; ROBBINS GK, 1997, 4 C RETR OPP INF JAN; Rose DN, 1997, AIDS, V11, P883, DOI 10.1097/00002030-199707000-00007; SANDE MA, 1993, JAMA-J AM MED ASSOC, V270, P2583, DOI 10.1001/jama.270.21.2583; Scharfstein JA, 1997, MED DECIS MAKING, V17, P373, DOI 10.1177/0272989X9701700402; Spector SA, 1996, NEW ENGL J MED, V334, P1491, DOI 10.1056/NEJM199606063342302; TORRANCE GW, 1976, SOCIO ECON PLAN SCI, V10, P129, DOI 10.1016/0038-0121(76)90036-7; WALMSLEY S, 1997, 4 C RETR OPP INF JAN	48	166	168	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 14	1998	279	2					130	136		10.1001/jama.279.2.130	http://dx.doi.org/10.1001/jama.279.2.130			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YQ015	9440663	Bronze			2022-12-01	WOS:000071338900030
J	Kaur, B; Anderson, HR; Austin, J; Burr, M; Harkins, LS; Strachan, DP; Warner, JO				Kaur, B; Anderson, HR; Austin, J; Burr, M; Harkins, LS; Strachan, DP; Warner, JO			Prevalence of asthma symptoms, diagnosis, and treatment in 12-14 year old children across Great Britain (international study of asthma and allergies in childhood, ISAAC UK)	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; ABERDEEN SCHOOLCHILDREN; TRENDS; QUESTIONNAIRE; SEVERITY; ATOPY	Objective: To investigate variations in the prevalence of self reported symptoms, diagnosis, and treatment of asthma in 12-14 year old children. Design: Self completion questionnaire. Setting: Great Britain. Subjects: All pupils aged 12-14 years in a stratified cluster sample of 93 large mixed secondary schools in 1995. Main outcome measures: Self reported prevalence of symptoms, diagnosis, and treatment of asthma at four geographical levels. Results: 27 507 questionnaires were completed (85.9% response rate). The national 12 month prevalence of any wheezing, speech limiting wheeze, four or more attacks of wheeze, and frequent night waking with wheeze was 33.3% (n = 9155), 8.8% (2427), 9.6% (2634), and 3.7% (1023) respectively. The prevalence of ever having had a diagnosis of asthma was 20.9% (5736). In total, 19.8% (5438/27 507) of pupils reported treatment with anti-asthma drugs in the past year, but, of pupils reporting frequent nocturnal wheeze in the past year, 33.8% (342/1012) had no diagnosis of asthma and 38.6% (395/1023) denied receiving inhaler therapy. The 12 month prevalence of wheeze was highest in Scotland (36.7%, 1633/4444), but in England and Wales there was no discernible north-south or east-west gradient. Wheeze prevalence was slightly higher in non-metropolitan ar eas (35.0%, 6155/17 605) than in metropolitan areas (30.3%, 3000/9902). The prevalence of self reported asthma diagnosis and inhaler use showed no discernible national, regional, north-south, or east-west geographical pattern but was higher in non-metropolitan areas. Conclusion: Prevalence of self reported symptoms, diagnosis, and treatment of asthma was high among 12-14 year olds throughout Great Britain with little geographical or urban-rural variation. Underdiagnosis and undertreatment were substantial.	Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Royal No Infirm, Highland Communities NHS Trust, Dept Child Hlth, Inverness IV3 5SF, Scotland; Temple Peace & Hlth, Ctr Appl Publ Hlth Med, Cardiff CF1 3NW, S Glam, Wales; Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	St Georges University London; University of Southampton	Kaur, B (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England.		Warner, John/AAF-9587-2020; Anderson, Hugh R/A-7417-2016					ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ANDERSON HR, 1995, OPCS SER DS, V11, P111; ANDERSON HR, 1994, HLTH CARE NEEDS ASSE, P256; Asher M. I., 1996, European Respiratory Journal Supplement, V9, p410S; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; AUSTIN JB, 1994, ARCH DIS CHILD, V71, P211, DOI 10.1136/adc.71.3.211; BLAND M, 1994, CLINSTAT; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452, DOI 10.1136/adc.64.10.1452; *CENTR HLTH MON UN, 1995, EP OV SER, V1; *CYT SOFTW CORP, 1991, STATX VERS 2; DuranTauleria E, 1996, BRIT MED J, V313, P148, DOI 10.1136/bmj.313.7050.148; *I EP SOZ U, 1993, ISAAC INT STUD ASTHM, P3; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; LEWIS S, 1996, THORAX, V51, P6706; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; *OFF POP CENS SURV, 1988, SER OHS; Omran M, 1996, BRIT MED J, V312, P34, DOI 10.1136/bmj.312.7022.34; PEARCE N, 1993, EUR RESPIR J, V6, P1455; RONA RJ, 1995, THORAX, V50, P992, DOI 10.1136/thx.50.9.992; *SAS I, 1990, SAS US GUID BAS STAT; SHAW R, 1995, INT J EPIDEMIOL, V24, P597, DOI 10.1093/ije/24.3.597; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174, DOI 10.1136/adc.70.3.174; STRACHAN DP, 1990, J EPIDEMIOL COMMUN H, V44, P231, DOI 10.1136/jech.44.3.231; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729, DOI 10.1136/adc.68.6.729	25	199	201	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	JAN 10	1998	316	7125					118	124						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YR408	9462318				2022-12-01	WOS:000071492300024
J	Hemminki, A; Markie, D; Tomlinson, I; Avizienyte, E; Roth, S; Loukola, A; Bignell, G; Warren, W; Aminoff, M; Hoglund, P; Jarvinen, H; Kristo, P; Pelin, K; Ridanpaa, M; Salovaara, R; Toro, T; Bodmer, W; Olschwang, S; Olsen, AS; Stratton, MR; de la Chapelle, A; Aaltonen, LA				Hemminki, A; Markie, D; Tomlinson, I; Avizienyte, E; Roth, S; Loukola, A; Bignell, G; Warren, W; Aminoff, M; Hoglund, P; Jarvinen, H; Kristo, P; Pelin, K; Ridanpaa, M; Salovaara, R; Toro, T; Bodmer, W; Olschwang, S; Olsen, AS; Stratton, MR; de la Chapelle, A; Aaltonen, LA			A serine/threonine kinase gene defective in Peutz-Jegheus syndrome	NATURE			English	Article							MUTATIONS; CANCER	Studies of hereditary cancer syndromes have contributed greatly to our understanding of molecular events involved in tumorigenesis. Here we investigate the molecular background of the Peutz-Jeghers syndrome(1,2) (PJS), a rare hereditary disease in which there is predisposition to benign and malignant tumours of many organ systems. A locus for this condition was recently assigned to chromosome 19p (ref. 3). We have identified truncating germline mutations in a gene residing on chromosome 19p in multiple individuals affected by PJS. This previously identified but unmapped gene, LKB1 (ref. 4), has strong homology to a cytoplasmic Xenopus serine/threonine protein kinase XEEK1 (ref. 5), and weaker similarity to many other protein kinases. Peutz-Jeghers syndrome is therefore the first cancer-susceptibility syndrome to be identified that is due to inactivating mutations in a protein kinase.	Univ Helsinki, Haartman Inst, Dept Med Genet, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Dunedin Sch Med, Dept Pathol, Dunedin, New Zealand; Inst Canc Res, Haddow Labs, Sect Canc Genet, Sutton SM2 5NG, Surrey, England; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Univ Helsinki, Cent Hosp, Dept Surg 2, FIN-00290 Helsinki, Finland; Folkhalsan Inst Genet, Helsinki 00280, Finland; John Radcliffe Hosp, Inst Mol Med, Imperial Canc Res Fund, Canc & Immunogenet Lab, Oxford OX3 9DS, England; Fdn Jean Dausset CEPH, INSERM, U434, F-75010 Paris, France; Univ Calif Lawrence Livermore Natl Lab, Ctr Human Genome, Livermore, CA 94550 USA; Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University of Helsinki; University of Helsinki; University of Otago; University of London; Institute of Cancer Research - UK; University of Oxford; University of Helsinki; Helsinki University Central Hospital; University of Oxford; Foundation Jean Dausset-CEPH; Institut National de la Sante et de la Recherche Medicale (Inserm); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Aaltonen, LA (corresponding author), Univ Helsinki, Haartman Inst, Dept Med Genet, POB 21 Haartmaninkatu 3, FIN-00014 Helsinki, Finland.	Lauri.Aaltonen@Helsinki.Fi	Olschwang, Sylviane/G-2716-2013; Markie, David/I-7893-2019; Aaltonen, Lauri/A-5375-2010	Olschwang, Sylviane/0000-0001-7078-3029; Aaltonen, Lauri/0000-0001-6839-4286; Bodmer, Walter/0000-0001-6244-9792; Loukola, Anu-Maria/0000-0003-0542-5967; Markie, David/0000-0001-5452-9194; Pelin, Katarina/0000-0002-7040-7266				ASHWORTH LK, 1995, NAT GENET, V11, P422, DOI 10.1038/ng1295-422; FUTREAL PA, 1994, HUM MOL GENET, V3, P1359, DOI 10.1093/hmg/3.8.1359; GIARDIELLO FM, 1987, NEW ENGL J MED, V316, P1511, DOI 10.1056/NEJM198706113162404; Hemminki A, 1997, NAT GENET, V15, P87, DOI 10.1038/ng0197-87; JEGHERS H, 1949, NEW ENGL J MED, V241, P992; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KO MSH, SYSTEMATIC ANAL MOUS; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; NEZU J, UNPUB MOL CLONING NO; Peutz JL, 1921, NEDERL MAANDSCHR GEN, V10, P134; PHILLIPS RK, 1994, FAMILIAL ADENOMATOUS; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; Su JY, 1996, J BIOL CHEM, V271, P14430, DOI 10.1074/jbc.271.24.14430; TAGLE DA, 1993, NATURE, V361, P751, DOI 10.1038/361751a0; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	15	1165	1242	1	44	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 8	1998	391	6663					184	187		10.1038/34432	http://dx.doi.org/10.1038/34432			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YQ378	9428765				2022-12-01	WOS:000071380900053
J	Meulenberg, F				Meulenberg, F			The hidden delight of psoriasis	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Dutch Coll Gen Practitioners, NL-3511 AN Utrecht, Netherlands		Meulenberg, F (corresponding author), Dutch Coll Gen Practitioners, Oudegracht 16, NL-3511 AN Utrecht, Netherlands.							BENNETT P, 1991, PRACTITIONER, V235, P241; Boyd Brian, 1991, V NABOKOV AM YEARS; Boyd Brian, 1990, V NABOKOV RUSSIAN YE; FARBER EM, 1991, INT J DERMATOL, V30, P295, DOI 10.1111/j.1365-4362.1991.tb04644.x; Fuller Graham Fuller, 1993, POTTER POTTER; Gupta M A, 1990, Adv Dermatol, V5, P21; INGRAM JT, 1954, BMJ-BRIT MED J, V2, P823, DOI 10.1136/bmj.2.4892.823; Ishiguro Kazuo, 1995, UNCONSOLED; JOWETT S, 1985, SOC SCI MED, V20, P425, DOI 10.1016/0277-9536(85)90021-8; LANIGAN SW, 1991, BRIT J DERMATOL, V125, P340, DOI 10.1111/j.1365-2133.1991.tb14168.x; NABOKOV V, 1990, SELECTED LETT 1940 1, P25; Nabokov Vladimir, 1971, ADA ARDOR FAMILY CHR; Nabokov Vladimir, 1974, STRONG OPINIONS; PALMEN C, 1992, LAWS; Potter Dennis, 1986, SINGING DETECTIVE; POUER D, 1994, SEEING BLOSSOM 2 INT; RAMSAY B, 1988, BRIT J DERMATOL, V118, P195, DOI 10.1111/j.1365-2133.1988.tb01774.x; UPDIKE J, 1980, PROBLEMS OTHER STORI, P181; UPDIKE J, 1991, ODD JOBS ESSAYS CRIT, P865; UPDIKE J, 1963, CENTAUR; Updike John, 1989, SELF CONSCIOUSNESS M; WITTKOWER E, 1946, LANCET, V250, P566	22	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 20	1997	315	7123					1709	1711		10.1136/bmj.315.7123.1709	http://dx.doi.org/10.1136/bmj.315.7123.1709			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YN263	9448549	Green Published			2022-12-01	WOS:000071149400041
J	Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Shea, B; Nichol, G; Hayward, R; Lightfoot, R; Baker, P; Steere, AC				Tugwell, P; Dennis, DT; Weinstein, A; Wells, G; Shea, B; Nichol, G; Hayward, R; Lightfoot, R; Baker, P; Steere, AC			Laboratory evaluation in the diagnosis of Lyme disease	ANNALS OF INTERNAL MEDICINE			English	Article							BORRELIA-BURGDORFERI DNA; CENTRAL-NERVOUS-SYSTEM; LINKED IMMUNOSORBENT-ASSAY; ERYTHEMA MIGRANS; ARTHRITIS; SERODIAGNOSIS; ANTIBODY; NEUROBORRELIOSIS; FIBROMYALGIA; EPIDEMIC	Purpose: To provide a quantitative and qualitative evaluation of the predictive value of the laboratory diagnosis of Lyme disease and to use the resultant data to formulate guidelines for clinical diagnosis. Data Sources: A MEDLINE search of English-language articles or articles with English-language abstracts published from 1982 to 1996. Data Extraction: Sensitivity, specificity, and likelihood ratios were calculated, and a random-effects model was used to combine the proportions from the eligible studies. Prespecified criteria were used to determine which studies were eligible for analysis. Data Synthesis: Laboratory testing in general is not clinically useful if the pretest probability of Lyme disease is less than 0.20 or greater than 0.80. When the pretest probability is 0.20 to 0.80, sequential testing with enzyme-linked immunosorbent assay and Western blot is the most accurate method for ruling in or ruling out the possibility of Lyme disease. Conclusions: Laboratory testing is recommended only in patients whose pretest probability of Lyme disease is 0.20 to 0.80. If the pretest probability is less than 0.20, testing will result in more false-positive results than true-positive results; a negative test result in this situation effectively rules out the disease.	Univ Ottawa, Dept Med, Ottawa, ON K1H 8L6, Canada; Ctr Dis Control & Prevent, Ft Collins, CO 80521 USA; New York Med Coll, Div Rheumat Dis & Immunol, Valhalla, NY 10595 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; McMaster Univ, Med Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	University of Ottawa; Centers for Disease Control & Prevention - USA; New York Medical College; Tufts Medical Center; McMaster University	Tugwell, P (corresponding author), Ottawa Gen Hosp, Dept Med, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.		Tugwell, Peter/AFD-8076-2022; Baker, Philip R A/J-1109-2012	Tugwell, Peter/0000-0001-5062-0556; Steere, Allen/0000-0002-5268-9853				ALPERT B, 1992, NEW YORK STATE J MED, V92, P5; BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; BERGER BW, 1992, J CLIN MICROBIOL, V30, P359, DOI 10.1128/JCM.30.2.359-361.1992; BERGER BW, 1983, AM J DERMATOPATH, V5, P111, DOI 10.1097/00000372-198304000-00008; BOWEN GS, 1984, AM J EPIDEMIOL, V120, P387; BURGDORFER W, 1982, SCIENCE, V216, P1317, DOI 10.1126/science.7043737; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P590; CIESIELSKI CA, 1988, ANN NY ACAD SCI, V539, P283, DOI 10.1111/j.1749-6632.1988.tb31862.x; Coyle BS, 1996, J INFECT DIS, V173, P1260, DOI 10.1093/infdis/173.5.1260; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; Dennis D. T., 1993, Lyme disease., P27; DENNIS DT, 1991, JAMA-J AM MED ASSOC, V266, P1269, DOI 10.1001/jama.266.9.1269; DINERMAN H, 1992, ANN INTERN MED, V117, P281, DOI 10.7326/0003-4819-117-4-281; DRESSLER F, 1991, ANN INTERN MED, V115, P533, DOI 10.7326/0003-4819-115-7-533; DRESSLER F, 1993, J INFECT DIS, V167, P392, DOI 10.1093/infdis/167.2.392; FAWCETT PT, 1992, J RHEUMATOL, V19, P582; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; HALPERIN JJ, 1991, NEUROLOGY, V41, P1571, DOI 10.1212/WNL.41.10.1571; HANRAHAN JP, 1984, J INFECT DIS, V150, P489, DOI 10.1093/infdis/150.4.489; HANSEN K, 1988, J CLIN MICROBIOL, V26, P338, DOI 10.1128/JCM.26.2.338-346.1988; HEDBERG CW, 1987, J INFECT DIS, V155, P1325, DOI 10.1093/infdis/155.6.1325; HEDGES LV, 1985, STAT METHODS META AN; IRWIG L, 1994, ANN INTERN MED, V120, P667, DOI 10.7326/0003-4819-120-8-199404150-00008; Johnson BJB, 1996, J INFECT DIS, V174, P346, DOI 10.1093/infdis/174.2.346; JOHNSTON YE, 1985, AM J PATHOL, V118, P26; JONES JM, 1991, ANN INTERN MED, V114, P1064, DOI 10.7326/0003-4819-114-12-1064_1; KELLER TL, 1992, NEUROLOGY, V42, P32, DOI 10.1212/WNL.42.1.32; KOWAL K, 1994, ARTHRITIS RHEUM-US, V37, P1206, DOI 10.1002/art.1780370815; KRAMER N, 1986, AM J MED, V81, P149, DOI 10.1016/0002-9343(86)90200-7; LASTAVICA CC, 1989, NEW ENGL J MED, V320, P133, DOI 10.1056/NEJM198901193200301; LIGHTFOOT RW, 1993, ANN INTERN MED, V119, P503, DOI 10.7326/0003-4819-119-6-199309150-00010; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUGER SW, 1990, ARCH INTERN MED, V150, P761, DOI 10.1001/archinte.150.4.761; MAGNARELLI LA, 1984, J CLIN MICROBIOL, V20, P181, DOI 10.1128/JCM.20.2.181-184.1984; MALAWISTA SE, 1986, ADV INTERNAL MED, V31, P147; MARCUS LC, 1985, ANN INTERN MED, V103, P374, DOI 10.7326/0003-4819-103-3-374; MELCHERS W, 1991, J CLIN MICROBIOL, V29, P2401, DOI 10.1128/JCM.29.11.2401-2406.1991; MILLER GL, 1992, P 5 INT C LYM DIS AR; NADELMAN RB, 1990, AM J MED, V88, P21, DOI 10.1016/0002-9343(90)90122-T; NICHOL G, IN PRESS ANN INTERN; NOCTON JJ, 1994, NEW ENGL J MED, V330, P229, DOI 10.1056/NEJM199401273300401; PACHNER AR, 1992, NEUROLOGY, V42, P2185, DOI 10.1212/WNL.42.11.2185; PACHNER AR, 1989, ARCH NEUROL-CHICAGO, V46, P790, DOI 10.1001/archneur.1989.00520430086023; PACHNER AR, 1985, NEUROLOGY, V35, P47, DOI 10.1212/WNL.35.1.47; RUSSELL H, 1984, J INFECT DIS, V149, P465, DOI 10.1093/infdis/149.3.465; Sackett D, 1991, CLIN EPIDEMIOLOGY BA; SCHULZE TL, 1986, ZBL BAKT-INT J MED M, V263, P65; SCHWARTZ BS, 1989, JAMA-J AM MED ASSOC, V262, P3431, DOI 10.1001/jama.262.24.3431; SNYDMAN DR, 1986, ANN INTERN MED, V104, P798, DOI 10.7326/0003-4819-104-6-798; SOX HC, 1997, MED DECISION MAKING; STEERE AC, 1990, J INFECT DIS, V161, P1203, DOI 10.1093/infdis/161.6.1203; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1986, J INFECT DIS, V154, P295, DOI 10.1093/infdis/154.2.295; STEERE AC, 1977, ANN INTERN MED, V86, P685, DOI 10.7326/0003-4819-86-6-685; STEERE AC, 1983, NEW ENGL J MED, V308, P733, DOI 10.1056/NEJM198303313081301; STEERE AC, 1977, ARTHRITIS RHEUM, V20, P7, DOI 10.1002/art.1780200102; WEINSTEIN A, 1989, NEW YORK STATE J MED, V89, P566; Wharton M, 1990, MMWR Recomm Rep, V39, P1; WOLFE F, 1990, ARTHRITIS RHEUM-US, V33, P160, DOI 10.1002/art.1780330203; WORMSER GP, 1992, JAMA-J AM MED ASSOC, V268, P1311, DOI 10.1001/jama.268.10.1311; ZOSCHKE DC, 1992, POSTGRAD MED, V91, P46; 1992, FED REG         0228, V57; 1995, MMWR MORB MORTAL WKL, V44, P459; 1996, MMWR MORB MORTAL WKL, V45, P481; 1994, MMWR MORB MORTAL WKL, V43, P564	66	174	182	0	12	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	DEC 15	1997	127	12					1109	1123		10.7326/0003-4819-127-12-199712150-00011	http://dx.doi.org/10.7326/0003-4819-127-12-199712150-00011			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YL262	9412316				2022-12-01	WOS:000070936600010
J	Edwards, D; Johnson, NW; Cooper, D; Warnakulasuriya, KAAS				Edwards, D; Johnson, NW; Cooper, D; Warnakulasuriya, KAAS			Management of cancers of the head and neck in the United Kingdom: questionnaire survey of consultants	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Surg England, Dept Dent Sci, London SE5 9RW, England; Univ London Kings Coll, Sch Med & Dent, Sch Dent, Dept Oral Med & Pathol, London SE5 9RW, England; Univ London Kings Coll, Sch Med & Dent, Comp Informat Ctr, Western Educ Ctr, London SE5 9DJ, England	Royal College of Surgeons of England; University of London; King's College London; University of London; King's College London	Edwards, D (corresponding author), Bedfordshire Hlth Author, Charter House, Luton LU1 2PL, Beds, England.		, WARNAKULASURIYA/ABB-3793-2020; Johnson, Newell W/D-8152-2019	Johnson, Newell W/0000-0001-5866-262X; Warnakulasuriya, Saman/0000-0003-2103-0746				Birchall M, 1995, HEAD NECK CANC SERVI; EDWARDS D, 1997, FACE FACE HEAD NECK; *EXP ADV GROUP CAN, 1995, REP EXP ADV GROUP CA; LORE JM, 1987, ARCH OTOLARYNGOL, V113, P1165; RAPIDIS AD, 1980, ANN ROY COLL SURG, V62, P116	5	17	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 13	1997	315	7122					1589	1589		10.1136/bmj.315.7122.1589	http://dx.doi.org/10.1136/bmj.315.7122.1589			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YM040	9437278	Green Published			2022-12-01	WOS:000071021900025
J	Zhao, ZS; Granucci, F; Yeh, L; Schaffer, PA; Cantor, H				Zhao, ZS; Granucci, F; Yeh, L; Schaffer, PA; Cantor, H			Molecular mimicry by herpes simplex virus type 1: autoimmune disease after viral infection	SCIENCE			English	Article							DEPENDENT DIABETES-MELLITUS; STROMAL KERATITIS; TRANSGENIC MODEL; UL6 GENE; MUTANTS; DETERMINANTS; PATHOGENESIS; EXPRESSION; MICE; EYE	Viral infection is sometimes associated with the initiation or exacerbation of autoimmune disease, although the underlying mechanisms remain unclear. One proposed mechanism is that viral determinants that mimic host antigens trigger self-reactive T cell clones to destroy host tissue. An epitope expressed by a coat protein of herpes simplex virus-type 1 (HSV-1) KOS strain has now been shown to be recognized by autoreactive T cells that target corneal antigens in a murine model of autoimmune herpes stromal keratitis. Mutant HSV-1 viruses that lacked this epitope did not induce autoimmune disease. Thus, expression of molecular mimics can influence the development of autoimmune disease after viral infection.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA; Dana Farber Canc Inst, Div Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute	Zhao, ZS (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.		GRANUCCI, Francesca/K-6150-2019	granucci, francesca/0000-0002-7046-4914	NIAID NIH HHS [AI 37562] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKOVA YA, 1993, CURR EYE RES, V12, P1093, DOI 10.3109/02713689309033507; AVERY AC, 1995, NATURE, V376, P431, DOI 10.1038/376431a0; CAI WH, 1987, J VIROL, V61, P714, DOI 10.1128/JVI.61.3.714-721.1987; CAI WZ, 1992, J VIROL, V66, P2904, DOI 10.1128/JVI.66.5.2904-2915.1992; CHALLONER PB, 1995, P NATL ACAD SCI USA, V92, P7440, DOI 10.1073/pnas.92.16.7440; DAHLQUIST G, 1995, DIABETOLOGIA, V38, P1371; FOSTER CS, 1990, INT CONGR SER, V918, P111; FRIEDMAN S, 1987, IMMUNOGENETICS, V26, P193, DOI 10.1007/BF00346512; GOLDIN AL, 1981, J VIROL, V38, P50, DOI 10.1128/JVI.38.1.50-58.1981; HAY J, 1992, CURR TOP MICROBIOL, V179, P1; Hemmer B, 1997, J EXP MED, V185, P1651, DOI 10.1084/jem.185.9.1651; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MERCADAL CM, 1993, J VIROL, V67, P3404, DOI 10.1128/JVI.67.6.3404-3408.1993; MORRISON LA, 1994, J VIROL, V68, P689, DOI 10.1128/JVI.68.2.689-696.1994; NIEMIALTOWSKI MG, 1992, J IMMUNOL, V148, P1864; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; OPREMCAK EM, 1988, INVEST OPHTH VIS SCI, V29, P749; PATEL AH, 1995, VIROLOGY, V206, P465, DOI 10.1016/S0042-6822(95)80062-X; Patel AH, 1996, VIROLOGY, V217, P111, DOI 10.1006/viro.1996.0098; RAIZMAN MB, 1988, CURR EYE RES, V7, P823, DOI 10.3109/02713688809033214; RIDGWAY WM, 1994, CURR OPIN IMMUNOL, V6, P946, DOI 10.1016/0952-7915(94)90018-3; Rouse BT, 1996, ADV VIRUS RES, V47, P353, DOI 10.1016/S0065-3527(08)60739-3; SERCARZ EE, 1993, ANNU REV IMMUNOL, V11, P729, DOI 10.1146/annurev.iy.11.040193.003501; STREILEIN JW, 1992, J NEUROIMMUNOL, V39, P185, DOI 10.1016/0165-5728(92)90253-H; Streilein JW, 1997, IMMUNOL TODAY, V18, P443, DOI 10.1016/S0167-5699(97)01114-6; VENTO S, 1995, LANCET, V346, P608, DOI 10.1016/S0140-6736(95)91438-2; vonHerrath MG, 1996, CURR OPIN IMMUNOL, V8, P878, DOI 10.1016/S0952-7915(96)80019-7; VONHERRATH MG, 1994, IMMUNITY, V1, P231, DOI 10.1016/1074-7613(94)90101-5; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8	32	403	413	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 27	1998	279	5355					1344	1347		10.1126/science.279.5355.1344	http://dx.doi.org/10.1126/science.279.5355.1344			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YZ412	9478893				2022-12-01	WOS:000072251800048
J	Shen, H; Miller, JF; Fan, X; Kolwyck, D; Ahmed, R; Harty, JT				Shen, H; Miller, JF; Fan, X; Kolwyck, D; Ahmed, R; Harty, JT			Compartmentalization of bacterial antigens: Differential effects on priming of CD8 T cells and protective immunity	CELL			English	Article							RECOMBINANT LISTERIA-MONOCYTOGENES; TOXIC LYMPHOCYTE-T; I MHC PRESENTATION; EXOGENOUS ANTIGENS; CHORIOMENINGITIS VIRUS; INTRACELLULAR BACTERIA; MEDIATED-IMMUNITY; EPITOPE; INFECTION; PROTEIN	Bacterial pathogens synthesize numerous proteins that are either secreted or localized within bacterial cells. To address the impact of antigen compartmentalization on T cell immunity, we constructed recombinant Listeria monocytogenes that express a model CD8 T cell epitope as a secreted or nonsecreted fusion protein. Both forms of the antigen, either secreted into the host cell cytoplasm or retained within bacterial cells, efficiently prime CD8 T cell responses. However, epitope-specific CD8 T cells confer protection only against bacteria secreting the antigen but not against the bacteria expressing the nonsecreted form of the same antigen. This dichotomy as a result of antigen compartmentalization suggests that bacterial antigens are presented by multiple MHC class I pathways to prime CD8 T cells, but only the endogenous pathway provides target antigens for CD8 T cell-mediated protective immunity.	Emory Univ, Sch Med, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Dept Microbiol, Iowa City, IA 52242 USA	Emory University; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Iowa	Ahmed, R (corresponding author), Emory Univ, Sch Med, Dept Microbiol & Immunol, Emory Vaccine Ctr, Atlanta, GA 30322 USA.			Harty, John/0000-0001-7266-2802	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI038955, R37AI030048, R01AI030048, R29AI036864] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38955, AI36864, AI30048] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; AHMED R, 1984, J EXP MED, V160, P521, DOI 10.1084/jem.160.2.521; BARRY RA, 1992, INFECT IMMUN, V60, P1625, DOI 10.1128/IAI.60.4.1625-1632.1992; BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BIELECKI J, 1990, NATURE, V345, P175, DOI 10.1038/345175a0; BRUNT LM, 1990, J IMMUNOL, V145, P3540; COSSART P, 1989, MOL BIOL MED, V6, P463; DECHASTELLIER C, 1994, INFECT IMMUN, V62, P543, DOI 10.1128/IAI.62.2.543-553.1994; DEVRIES JE, 1989, IMMUNOL REV, V109, P119; FRANKEL FR, 1995, J IMMUNOL, V155, P4775; Harding CV, 1996, J CLIN IMMUNOL, V16, P90, DOI 10.1007/BF01540955; HARTY JT, 1992, J EXP MED, V175, P1531, DOI 10.1084/jem.175.6.1531; HARTY JT, 1995, IMMUNITY, V3, P109, DOI 10.1016/1074-7613(95)90163-9; HARTY JT, 1995, J IMMUNOL, V154, P4642; Hess J, 1996, P NATL ACAD SCI USA, V93, P1458, DOI 10.1073/pnas.93.4.1458; HURT EC, 1984, EMBO J, V3, P3149, DOI 10.1002/j.1460-2075.1984.tb02272.x; IKONOMIDIS G, 1994, J EXP MED, V180, P2209, DOI 10.1084/jem.180.6.2209; Jensen ER, 1997, IMMUNOL REV, V158, P147, DOI 10.1111/j.1600-065X.1997.tb01001.x; Jondal M, 1996, IMMUNITY, V5, P295, DOI 10.1016/S1074-7613(00)80255-1; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.iy.11.040193.001021; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KOVACSOVICSBANKOWSKI M, 1995, SCIENCE, V267, P243, DOI 10.1126/science.7809629; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; LAU LL, 1994, NATURE, V369, P648, DOI 10.1038/369648a0; LOESSNER MJ, 1995, APPL ENVIRON MICROB, V61, P1150, DOI 10.1128/AEM.61.3.1150-1152.1995; MATLOUBIAN M, 1994, J VIROL, V68, P8056, DOI 10.1128/JVI.68.12.8056-8063.1994; MURALIKRISHNA K, 1998, IN PRES IMMUNITY; NORTH RJ, 1970, J EXP MED, V132, P521, DOI 10.1084/jem.132.3.521; PAMER EG, 1991, NATURE, V353, P852, DOI 10.1038/353852a0; PAN ZK, 1995, NAT MED, V1, P471, DOI 10.1038/nm0595-471; PFEIFER JD, 1993, NATURE, V361, P359, DOI 10.1038/361359a0; PORTNOY DA, 1994, ANN NY ACAD SCI, V730, P15, DOI 10.1111/j.1749-6632.1994.tb44235.x; PORTNOY DA, 1989, J EXP MED, V170, P2141, DOI 10.1084/jem.170.6.2141; Rock KL, 1996, IMMUNOL TODAY, V17, P131, DOI 10.1016/0167-5699(96)80605-0; ROGERS HW, 1993, INFECT IMMUN, V61, P5090, DOI 10.1128/IAI.61.12.5090-5096.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V3; SCHAFER R, 1992, J IMMUNOL, V149, P53; SHEN H, 1995, P NATL ACAD SCI USA, V92, P3987, DOI 10.1073/pnas.92.9.3987; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; Slifka MK, 1996, J VIROL, V70, P2902, DOI 10.1128/JVI.70.5.2902-2910.1996; SMITH GA, 1995, INFECT IMMUN, V63, P4231, DOI 10.1128/IAI.63.11.4231-4237.1995; Smith GA, 1996, J CELL BIOL, V135, P647, DOI 10.1083/jcb.135.3.647; SOLDATI T, 1991, CELL, V66, P277, DOI 10.1016/0092-8674(91)90618-9; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; vanderMost RG, 1996, J IMMUNOL, V157, P5543; Vijh S, 1997, J IMMUNOL, V158, P3366; VILLANUEVA MS, 1995, J IMMUNOL, V155, P5227; WHITTON JL, 1989, J VIROL, V63, P4303, DOI 10.1128/JVI.63.10.4303-4310.1989; WICK MJ, 1995, MOL MICROBIOL, V16, P465, DOI 10.1111/j.1365-2958.1995.tb02411.x; York IA, 1996, ANNU REV IMMUNOL, V14, P369, DOI 10.1146/annurev.immunol.14.1.369	51	180	207	0	8	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 20	1998	92	4					535	545		10.1016/S0092-8674(00)80946-0	http://dx.doi.org/10.1016/S0092-8674(00)80946-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491894	hybrid			2022-12-01	WOS:000072251500013
J	Wei, P; Garber, ME; Fang, SM; Fischer, WH; Jones, KA				Wei, P; Garber, ME; Fang, SM; Fischer, WH; Jones, KA			A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA	CELL			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CARBOXYL-TERMINAL DOMAIN; CELLULAR PROTEIN-KINASE; POLYMERASE-II; ACTIVATING KINASE; TRANSCRIPTION; ELONGATION; TRANSACTIVATION; RECOGNITION; INITIATION	The HIV-1 Tat protein regulates transcription elongation through binding to the viral TAR RNA stem-loop structure. We have isolated a novel 87 kDa cyclin C-related protein (cyclin T) that interacts specifically with the transactivation domain of Tat. Cyclin T is a partner for CDK9, an RNAPII transcription elongation factor. Remarkably, the interaction of Tat with cyclin T strongly enhances the affinity and specificity of the Tat:TAR RNA interaction, and confers a requirement for sequences in the loop of TAR that are not recognized by Tat alone. Moreover, overexpression of human cyclin T rescues Tat activity in nonpermissive rodent cells. We propose that Tat directs cyclin T-CDK9 to RNAPII through cooperative binding to TAR RNA.	Salk Inst Biol Studies, Regulat Biol Lab, La Jolla, CA 92037 USA; Salk Inst Biol Studies, Peptide Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Grad Program Biomed Sci, La Jolla, CA 92093 USA	Salk Institute; Salk Institute; University of California System; University of California San Diego	Jones, KA (corresponding author), Salk Inst Biol Studies, Regulat Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033824] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33824] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALONSO A, 1994, J VIROL, V68, P6505, DOI 10.1128/JVI.68.10.6505-6513.1994; Bellier S, 1997, EMBO J, V16, P6250, DOI 10.1093/emboj/16.20.6250; BOELENS W, 1991, NUCLEIC ACIDS RES, V19, P455, DOI 10.1093/nar/19.3.455; CHURCHER MJ, 1993, J MOL BIOL, V230, P90, DOI 10.1006/jmbi.1993.1128; Cooper KF, 1997, EMBO J, V16, P4665, DOI 10.1093/emboj/16.15.4665; Cujec TP, 1997, MOL CELL BIOL, V17, P1817, DOI 10.1128/MCB.17.4.1817; CULLEN BR, 1993, CELL, V73, P417, DOI 10.1016/0092-8674(93)90126-B; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; FISHER RP, 1995, CELL, V83, P47, DOI 10.1016/0092-8674(95)90233-3; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Furnari BA, 1997, J BIOL CHEM, V272, P12100, DOI 10.1074/jbc.272.18.12100; GAIT MJ, 1993, TRENDS BIOCHEM SCI, V18, P255, DOI 10.1016/0968-0004(93)90176-N; GarciaMartinez LF, 1997, J BIOL CHEM, V272, P6951, DOI 10.1074/jbc.272.11.6951; GHOSH S, 1993, J MOL BIOL, V234, P610, DOI 10.1006/jmbi.1993.1615; HART CE, 1993, J VIROL, V67, P5020, DOI 10.1128/JVI.67.8.5020-5024.1993; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Keen NJ, 1997, EMBO J, V16, P5260, DOI 10.1093/emboj/16.17.5260; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; Lee JM, 1997, J BIOL CHEM, V272, P10990; Li HM, 1996, ONCOGENE, V13, P705; LIAO SM, 1995, NATURE, V374, P193, DOI 10.1038/374193a0; LUO Y, 1993, J VIROL, V67, P3441, DOI 10.1128/JVI.67.6.3441-3445.1993; LUO Y, 1993, J VIROL, V67, P5617, DOI 10.1128/JVI.67.9.5617-5622.1993; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1992, MOL CELL BIOL, V12, P2078, DOI 10.1128/MCB.12.5.2078; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MORAS D, 1995, CURR BIOL, V5, P249, DOI 10.1016/S0960-9822(95)00051-0; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SCHERLY D, 1990, EMBO J, V9, P3675, DOI 10.1002/j.1460-2075.1990.tb07579.x; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; Shilatifard A, 1997, CURR OPIN GENET DEV, V7, P199, DOI 10.1016/S0959-437X(97)80129-3; STEMER D, 1995, MOL CELL BIOL, V15, P5716; TILEY LS, 1992, GENE DEV, V6, P2077, DOI 10.1101/gad.6.11.2077; WATERMAN ML, 1991, GENE DEV, V5, P656, DOI 10.1101/gad.5.4.656; Yang XZ, 1997, P NATL ACAD SCI USA, V94, P12331, DOI 10.1073/pnas.94.23.12331; Yang XZ, 1996, J VIROL, V70, P4576, DOI 10.1128/JVI.70.7.4576-4584.1996; ZHOU QA, 1995, EMBO J, V14, P321, DOI 10.1002/j.1460-2075.1995.tb07006.x; Zhou QA, 1996, SCIENCE, V274, P605, DOI 10.1126/science.274.5287.605; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	48	1019	1044	1	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 20	1998	92	4					451	462		10.1016/S0092-8674(00)80939-3	http://dx.doi.org/10.1016/S0092-8674(00)80939-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YZ409	9491887	Bronze			2022-12-01	WOS:000072251500006
J	Rivera, JM; Martin, T; Rebek, J				Rivera, JM; Martin, T; Rebek, J			Chiral spaces: Dissymmetric capsules through self-assembly	SCIENCE			English	Article							RESOLUTION; MOLECULES	Molecules with self-complementary surfaces interact through weak intermolecular forces to form assemblies, and the assembled states frequently exhibit distinctive properties. Described here are systems in which symmetrical molecules assemble through hydrogen bonding to produce capsules with dissymmetric cavities. The capsules form and dissipate on a time scale that permits their direct observation by nuclear magnetic resonance measurements, and they act as hosts for smaller molecular guests, Molecular recognition of chiral guests, such as naturally occurring terpenes, determines which dissymmetric cavities are preferentially formed in the assembly process.	Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; MIT, Dept Chem, Cambridge, MA 02139 USA	Scripps Research Institute; Scripps Research Institute; Massachusetts Institute of Technology (MIT)	Rebek, J (corresponding author), Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.		Rivera, Jose/B-5657-2008; Martin, Tomas/J-9222-2014	Martin, Tomas/0000-0002-9504-7287				BILYK A, 1995, J CHEM SOC CHEM COMM, P1697, DOI 10.1039/c39950001697; BRIENNE MJ, 1994, TETRAHEDRON LETT, V35, P8157, DOI 10.1016/0040-4039(94)88270-3; CANCEILL J, 1985, J AM CHEM SOC, V107, P6993, DOI 10.1021/ja00310a041; Castellano RK, 1997, J AM CHEM SOC, V119, P12671, DOI 10.1021/ja973132+; CostanteCrassous J, 1997, J AM CHEM SOC, V119, P3818, DOI 10.1021/ja9701164; CRAM DJ, 1991, ANGEW CHEM INT EDIT, V30, P1024, DOI 10.1002/anie.199110241; JUDICE JK, 1991, J AM CHEM SOC, V113, P2790, DOI 10.1021/ja00007a085; Kang JM, 1997, NATURE, V385, P50, DOI 10.1038/385050a0; Lee SB, 1996, TETRAHEDRON LETT, V37, P8501, DOI 10.1016/0040-4039(96)01950-8; MacGillivray LR, 1997, NATURE, V389, P469, DOI 10.1038/38985; MECOZZI S, IN PRESS CHEM EUR J; Meissner R, 1997, J AM CHEM SOC, V119, P77, DOI 10.1021/ja962991f; MEISSNER RS, 1995, SCIENCE, V270, P1485, DOI 10.1126/science.270.5241.1485; Mizutani T, 1996, J AM CHEM SOC, V118, P5318, DOI 10.1021/ja953932p; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; RIVERAORTIZ JM, IN PRESS J AM CHEM S; SanchezQuesada J, 1996, J AM CHEM SOC, V118, P277, DOI 10.1021/ja953243d; Simanek EE, 1997, J ORG CHEM, V62, P2619, DOI 10.1021/jo9615460; TIMMERMAN P, 1994, ANGEW CHEM INT EDIT, V33, P2345, DOI 10.1002/anie.199423451; Tokunaga Y, 1998, J AM CHEM SOC, V120, P66, DOI 10.1021/ja972885t; Warmuth R, 1997, ANGEW CHEM INT EDIT, V36, P1347, DOI 10.1002/anie.199713471; Yoon JY, 1997, J AM CHEM SOC, V119, P11796, DOI 10.1021/ja972719l	23	181	184	1	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 13	1998	279	5353					1021	1023		10.1126/science.279.5353.1021	http://dx.doi.org/10.1126/science.279.5353.1021			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YX100	9461432				2022-12-01	WOS:000072006400044
J	Brooks, PC; Silletti, S; von Schalscha, TL; Friedlander, M; Cheresh, DA				Brooks, PC; Silletti, S; von Schalscha, TL; Friedlander, M; Cheresh, DA			Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity	CELL			English	Article							HUMAN-ENDOTHELIAL CELLS; MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; IV COLLAGENASE; EXTRACELLULAR-MATRIX; ADHESION RECEPTOR; PROGELATINASE-A; ACTIVATION; ALPHA(V)BETA(3); SURFACE	Angiogenesis depends on both cell adhesion and proteolytic mechanisms. In fact, matrix metalloproteinase 2 (MMP-2) and integrin alpha v beta 3 are functionally associated on the surface of angiogenic blood vessels. A fragment of MMP-2, which comprises the C-terminal hemopexin-like domain, termed PEX, prevents this enzyme binding to alpha v beta 3 and blocks cell surface collagenolytic activity. PEX blocks MMP-2 activity on the chick chorioallantoic membrane where it disrupts angiogenesis and tumor growth. Importantly, a naturally occurring form of PEX can be detected in vivo in conjunction with alpha v beta 3 expression in tumors and during developmental retinal neovascularization. Levels of PEX in these vascularized tissues suggest that it interacts with endothelial cell alpha v beta 3 where it serves as a natural inhibitor of MMP-2 activity, thereby regulating the invasive behavior of new blood vessels.	Scripps Res Inst, Dept Immunol & Vasc Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Cheresh, DA (corresponding author), Scripps Res Inst, Dept Immunol & Vasc Biol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R37CA050286, R01CA050286, R01CA045726] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054444] Funding Source: NIH RePORTER; NCI NIH HHS [CA45726, CA50286] Funding Source: Medline; NHLBI NIH HHS [HL54444] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIMES RT, 1994, BIOCHEM J, V200, P729; AnandApte B, 1997, INVEST OPHTH VIS SCI, V38, P817; AUERBACH W, 1994, PHARMACOL THERAPEUT, V63, P265, DOI 10.1016/0163-7258(94)90027-2; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1995, J CLIN INVEST, V96, P1815, DOI 10.1172/JCI118227; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Cao JA, 1996, J BIOL CHEM, V271, P30174, DOI 10.1074/jbc.271.47.30174; CHERESH DA, 1989, CELL, V58, P945, DOI 10.1016/0092-8674(89)90946-X; CHERESH DA, 1987, P NATL ACAD SCI USA, V84, P6471, DOI 10.1073/pnas.84.18.6471; DAMORE PA, 1987, ANNU REV PHYSIOL, V49, P453; DeClerck YA, 1996, ENZYME PROTEIN, V49, P72, DOI 10.1159/000468617; FILARDO EJ, 1995, J CELL BIOL, V130, P441, DOI 10.1083/jcb.130.2.441; Foda HD, 1996, LAB INVEST, V74, P538; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; GALARDY RE, 1994, CANCER RES, V54, P4715; GRANT DS, 1989, CELL, V58, P933, DOI 10.1016/0092-8674(89)90945-8; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HOWARD EW, 1991, J BIOL CHEM, V266, P13064; INGBER DE, 1989, J CELL BIOL, V109, P317, DOI 10.1083/jcb.109.1.317; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MONTGOMERY AMP, 1994, P NATL ACAD SCI USA, V91, P8856, DOI 10.1073/pnas.91.19.8856; MOSES MA, 1990, SCIENCE, V248, P1408, DOI 10.1126/science.1694043; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Senger DR, 1996, AM J PATHOL, V149, P1; SMITH JW, 1990, J BIOL CHEM, V265, P11008; StetlerStevenson WG, 1996, AM J PATHOL, V148, P1345; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; STONE J, 1995, J NEUROSCI, V15, P4738, DOI 10.1523/jneurosci.15-07-04738.1995; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TOLSMA SS, 1993, J CELL BIOL, V122, P497, DOI 10.1083/jcb.122.2.497; VOLPERT OV, 1995, BIOCHEM BIOPH RES CO, V217, P326, DOI 10.1006/bbrc.1995.2780; WARD RV, 1991, BIOCHIM BIOPHYS ACTA, V1079, P242, DOI 10.1016/0167-4838(91)90132-J; ZUCKER S, 1995, J BIOL CHEM, V270, P23730, DOI 10.1074/jbc.270.40.23730	41	515	566	0	13	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 6	1998	92	3					391	400		10.1016/S0092-8674(00)80931-9	http://dx.doi.org/10.1016/S0092-8674(00)80931-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YX283	9476898	Bronze			2022-12-01	WOS:000072024700010
J	Ravelli, ACJ; van der Meulen, JHP; Michels, RPJ; Osmond, C; Barker, DJP; Hales, CN; Bleker, OP				Ravelli, ACJ; van der Meulen, JHP; Michels, RPJ; Osmond, C; Barker, DJP; Hales, CN; Bleker, OP			Glucose tolerance in adults after prenatal exposure to famine	LANCET			English	Article							LOW-PROTEIN-DIET; DEPENDENT DIABETES-MELLITUS; CARDIOVASCULAR RISK-FACTORS; CORONARY HEART-DISEASE; FETAL GROWTH; BIRTH-WEIGHT; THRIFTY PHENOTYPE; INFANT GROWTH; YOUNG MEN; INSULIN	Background Reduced growth in utero is associated with type 2 (non-insulin-dependent) diabetes and impaired glucose tolerance in adult life. There is no direct evidence in human beings that maternal nutrition during gestation affects insulin-glucose metabolism. We investigated glucose tolerance in people born around the time of famine in the Netherlands during 1944-45. Methods We included 702 people born between Nov 1, 1943, and Feb 28, 1947, in Amsterdam, for whom we had detailed prenatal and birth records. We compared glucose and insulin responses to a standard oral glucose load in participants exposed to famine at any stage during gestation (exposed participants) with those who were born in the year before or conceived in the year after the famine (non-ex posed participants). Findings Glucose concentrations were increased 2 h after a standard glucose load among exposed participants (p=0.006), and were highest in men and women exposed during mid and late gestation. Mean 2 h glucose concentration among non-exposed participants was 5.8 mmol/L; concentrations were 0.5 mmol/L (95% Cl 0.1-0.9) higher among participants exposed during late gestation, 0.4 mmol/L (0-0.8) higher among those exposed during mid gestation, and 0.1 mmol/L (-0.4 to 0.6) among those exposed during early gestation. Participants born as thin babies to mothers with low bodyweights had the highest concentrations and concentrations were especially high among people exposed to famine who became obese as adults, Prenatal exposure to famine was related to increased fasting proinsulin (p=0.05) and 2 h insulin concentrations (p=0.04), which suggests an association with insulin resistance. Interpretation Prenatal exposure to famine, especially during late gestation, is linked to decreased glucose tolerance in adults. Poor nutrition in utero may lead to permanent changes in insulin-glucose metabolism, even if the effect on fetal growth is small. This effect of famine on glucose tolerance is especially important in people who become obese.	Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam Zuidoost, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Internal Med, NL-1100 DE Amsterdam Zuidoost, Netherlands; Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton, Hants, England; Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QQ, England; Univ Amsterdam, Acad Med Ctr, Dept Obstet & Gynaecol, NL-1100 DE Amsterdam Zuidoost, Netherlands	University of Amsterdam; University of Amsterdam; University of Southampton; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Amsterdam	van der Meulen, JHP (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, POB 22700, NL-1100 DE Amsterdam Zuidoost, Netherlands.		Ravelli, Anita CJ/ABR-1494-2022	Ravelli, Anita CJ/0000-0002-3447-8286; van der Meulen, Jan/0000-0002-9451-2335; Osmond, Clive/0000-0002-9054-4655				Bakker B., 1997, SOCIALE WETENSCHAPPE, V40, P1; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BENSHLOMO Y, 1991, LANCET, V337, P530, DOI 10.1016/0140-6736(91)91307-G; Burger G., 1948, MALNUTRITION STARVAT; COOK JTE, 1993, BRIT MED J, V306, P302, DOI 10.1136/bmj.306.6873.302; Curhan GC, 1996, CIRCULATION, V94, P3246, DOI 10.1161/01.CIR.94.12.3246; DAHRI S, 1991, DIABETES, V40, P115, DOI 10.2337/diab.40.2.S115; FALL CHD, 1995, BRIT MED J, V310, P428, DOI 10.1136/bmj.310.6977.428; Forrester TE, 1996, BRIT MED J, V312, P156; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HALES CN, 1994, DIABETOLOGIA, V37, pS162, DOI 10.1007/BF00400840; HARDING JE, 1995, REPROD FERT DEVELOP, V7, P539, DOI 10.1071/RD9950539; Hofman PL, 1997, J CLIN ENDOCR METAB, V82, P402, DOI 10.1210/jc.82.2.402; Holemans K, 1996, J SOC GYNECOL INVEST, V3, P71, DOI 10.1016/1071-5576(95)00046-1; IglesiasBarreira V, 1996, ENDOCRINOLOGY, V137, P3797, DOI 10.1210/en.137.9.3797; Kramer MS, 1996, LANCET, V348, P1254, DOI 10.1016/S0140-6736(05)65750-9; Law CM, 1996, DIABETIC MED, V13, pS49; LAW CM, 1995, DIABETIC MED, V12, P24, DOI 10.1111/j.1464-5491.1995.tb02057.x; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; LUMEY LH, 1995, EUR J OBSTET GYN R B, V61, P23, DOI 10.1016/0028-2243(95)02149-M; MCCANCE DR, 1994, BRIT MED J, V308, P942, DOI 10.1136/bmj.308.6934.942; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; RAVELLI GP, 1976, NEW ENGL J MED, V295, P349, DOI 10.1056/NEJM197608122950701; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SNOECK A, 1990, BIOL NEONATE, V57, P107, DOI 10.1159/000243170; Stein Z., 1975, FAMINE HUM DEV DUTCH; SWENNE I, 1987, DIABETES, V36, P454, DOI 10.2337/diabetes.36.4.454; VALDEZ R, 1994, DIABETOLOGIA, V37, P624, DOI 10.1007/BF00403383; Wareham N J, 1995, Diabet Med, V12, P931; Whincup PH, 1997, DIABETOLOGIA, V40, P319, DOI 10.1007/s001250050681; YAJNIK CS, 1995, DIABETIC MED, V12, P330, DOI 10.1111/j.1464-5491.1995.tb00487.x	34	1093	1119	0	82	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON WC1B 3SL, ENGLAND	0140-6736			LANCET	Lancet	JAN 17	1998	351	9097					173	177		10.1016/S0140-6736(97)07244-9	http://dx.doi.org/10.1016/S0140-6736(97)07244-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YT530	9449872				2022-12-01	WOS:000071616300011
J	Kiefer, JR; Mao, C; Braman, JC; Beese, LS				Kiefer, JR; Mao, C; Braman, JC; Beese, LS			Visualizing DNA replication in a catalytically active Bacillus DNA polymerase crystal	NATURE			English	Article							ESCHERICHIA-COLI; KLENOW FRAGMENT; KINETIC MECHANISM; NUCLEIC-ACIDS; FIDELITY; BINDING	DNA polymerases copy DNA templates with remarkably high fidelity, checking for correct base-pair formation both at nucleotide insertion and at subsequent DNA extension steps(1-3). Despite extensive biochemical, genetic and structural studies(2,4), the mechanism by which nucleotides are correctly incorporated is not known, Here we present high-resolution crystal structures of a thermostable bacterial (Bacillus stearothermophiIus) DNA polymerase large fragment(5) with DNA primer templates bound productively at the polymerase active site. The active site retains catalytic activity, allowing direct observation of the products of several rounds of nucleotide incorporation, The polymerase also retains its ability to discriminate between correct and incorrectly paired nucleotides in the crystal, Comparison of the structures of successively translocated complexes allows the structural features for the sequence-independent molecular recognition of correctly formed base pairs to be deduced unambiguously. These include extensive interactions with the first four to five base pairs in the minor groove, location of the terminal base pair in a pocket of excellent steric complementarity favouring correct base-pair formation, and a conformational switch from B-form to underwound A-form DNA at the polymerase active site.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Stratagene, La Jolla, CA 92017 USA	Duke University	Beese, LS (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Box 3711, Durham, NC 27710 USA.		beese, lorena/G-4993-2010	Kiefer, James/0000-0001-6317-0902				Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BRAITHWAITE DK, 1993, NUCLEIC ACIDS RES, V21, P787, DOI 10.1093/nar/21.4.787; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; *COLL COMP PROJ 4, 1994, ACTA CRYSTALLOGR D, V50, P607; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DICKERSON DE, 1997, OXFORD HDB NUCL ACID; ECHOLS H, 1991, ANNU REV BIOCHEM, V60, P477, DOI 10.1146/annurev.biochem.60.1.477; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joyce CM, 1997, P NATL ACAD SCI USA, V94, P1619, DOI 10.1073/pnas.94.5.1619; JOYCE CM, 1995, J BACTERIOL, V177, P6321, DOI 10.1128/jb.177.22.6321-6329.1995; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.biochem.63.1.777; Kiefer JR, 1997, STRUCTURE, V5, P95, DOI 10.1016/S0969-2126(97)00169-X; KUCHTA RD, 1988, BIOCHEMISTRY-US, V27, P6716, DOI 10.1021/bi00418a012; LAVERY R, 1989, J BIOMOL STRUCT DYN, V6, P655, DOI 10.1080/07391102.1989.10507728; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARKINSON G, 1996, ACTA CRYSTALLOGR D, V52, P557; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Saenger W, 2013, PRINCIPLES NUCL ACID; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STEITZ TA, 1993, CURR OPIN STRUC BIOL, V3, P31, DOI 10.1016/0959-440X(93)90198-T; STEITZ TA, 1987, COLD SPRING HARB SYM, V52, P465, DOI 10.1101/SQB.1987.052.01.053; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; WONG I, 1991, BIOCHEMISTRY-US, V30, P526, DOI 10.1021/bi00216a030	30	482	494	0	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 15	1998	391	6664					304	307		10.1038/34693	http://dx.doi.org/10.1038/34693			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YR328	9440698				2022-12-01	WOS:000071484400057
J	Wilson, KS; Noller, HF				Wilson, KS; Noller, HF			Mapping the position of translational elongation factor EF-G in the ribosome by directed hydroxyl radical probing	CELL			English	Article							ESCHERICHIA-COLI RIBOSOME; TRANSFER-RNA; CRYSTAL-STRUCTURE; P-SITE; CROSS-LINKING; BINDING-SITES; FACTOR-TU; 16S RNA; 23S RNA; A-SITE	The interaction of translational elongation factor EF-G with the ribosome in the posttranslocational state has been mapped by directed hydroxyl radical probing. Localized hydroxyl radicals were generated from Fe(II) tethered to 18 different sites on the surface of EF-G bound to the ribosome. Cleavages in ribosomal RNA were mapped, providing proximity relationships between specific sites of EF-G and rRNA elements of the ribosome. Collectively, these data provide a set of constraints by which EF-G can be positioned unambiguously in the ribosome at low resolution. The proximities of different domains of EF-G to well-characterized elements of rRNA have additional implications for the mechanism of protein synthesis.	Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Noller, HF (corresponding author), Univ Calif Santa Cruz, Sinsheimer Labs, Ctr Mol Biol RNA, Santa Cruz, CA 95064 USA.							Abel K, 1996, STRUCTURE, V4, P229, DOI 10.1016/S0969-2126(96)00027-5; Agrawal RK, 1996, SCIENCE, V271, P1000, DOI 10.1126/science.271.5251.1000; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BODLEY JW, 1970, NATURE, V227, P60, DOI 10.1038/227060a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRETSCHER MS, 1968, NATURE, V218, P675, DOI 10.1038/218675a0; BRIGOTTI M, 1989, BIOCHEM J, V257, P723, DOI 10.1042/bj2570723; BRIMACOMBE R, 1988, J MOL BIOL, V199, P115, DOI 10.1016/0022-2836(88)90383-X; CAPEL MS, 1987, SCIENCE, V238, P1403, DOI 10.1126/science.3317832; CZWORKOWSKI J, 1994, EMBO J, V13, P3661, DOI 10.1002/j.1460-2075.1994.tb06675.x; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; EGEBJERG J, 1990, J MOL BIOL, V213, P275, DOI 10.1016/S0022-2836(05)80190-1; EVARSSON A, 1995, J MOL EVOL, V41, P1096; FRANK J, 1991, J CELL BIOL, V115, P597, DOI 10.1083/jcb.115.3.597; GAVRILOVA LP, 1976, J MOL BIOL, V101, P537, DOI 10.1016/0022-2836(76)90243-6; GORDON J, 1969, J BIOL CHEM, V244, P5680; HAUSNER TP, 1987, BIOCHIMIE, V69, P911, DOI 10.1016/0300-9084(87)90225-2; Heilek GM, 1996, SCIENCE, V272, P1659, DOI 10.1126/science.272.5268.1659; HEILEK GM, 1995, P NATL ACAD SCI USA, V92, P1113, DOI 10.1073/pnas.92.4.1113; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; JOHANSON U, 1994, GENE, V143, P55, DOI 10.1016/0378-1119(94)90604-1; Joseph S, 1997, SCIENCE, V278, P1093, DOI 10.1126/science.278.5340.1093; MAASSEN JA, 1981, EUR J BIOCHEM, V115, P279, DOI 10.1111/j.1432-1033.1981.tb05235.x; MITCHELL P, 1992, BIOCHEMISTRY-US, V31, P3004, DOI 10.1021/bi00126a023; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; MOAZED D, 1988, NATURE, V334, P362, DOI 10.1038/334362a0; MOAZED D, 1986, CELL, V47, P985, DOI 10.1016/0092-8674(86)90813-5; Mueller F, 1997, J MOL BIOL, V271, P524, DOI 10.1006/jmbi.1997.1210; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; NOLLER HF, 1989, RIBOSOME STRUCTURE F, P73; OAKES MI, 1989, RIBOSOME STRUCTURE F, P180; PESTKA S, 1969, J BIOL CHEM, V244, P1533; POWERS T, 1993, P NATL ACAD SCI USA, V90, P1364, DOI 10.1073/pnas.90.4.1364; POWERS T, 1995, RNA, V1, P194; PRINCE JB, 1982, P NATL ACAD SCI-BIOL, V79, P5450, DOI 10.1073/pnas.79.18.5450; RANA TM, 1990, J AM CHEM SOC, V112, P2457, DOI 10.1021/ja00162a077; RICHMAN N, 1972, P NATL ACAD SCI USA, V69, P686, DOI 10.1073/pnas.69.3.686; Rodnina MV, 1997, NATURE, V385, P37, DOI 10.1038/385037a0; ROSSET R, 1969, J MOL BIOL, V39, P95, DOI 10.1016/0022-2836(69)90336-2; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; SCHILLINGBARTETZKO S, 1992, J BIOL CHEM, V267, P4703; SERDYUK I, 1992, BIOCHIMIE, V74, P299, DOI 10.1016/0300-9084(92)90107-P; SKOLD SE, 1983, NUCLEIC ACIDS RES, V11, P4923, DOI 10.1093/nar/11.14.4923; SPIRIN AS, 1985, PROG NUCLEIC ACID RE, V32, P75, DOI 10.1016/S0079-6603(08)60346-3; Stark H, 1997, CELL, V88, P19, DOI 10.1016/S0092-8674(00)81854-1; Stark H, 1997, NATURE, V389, P403, DOI 10.1038/38770; STERN S, 1988, METHOD ENZYMOL, V164, P481; STERN S, 1988, J MOL BIOL, V204, P447, DOI 10.1016/0022-2836(88)90588-8; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THOMPSON J, 1982, J BIOL CHEM, V257, P7915; WOWER J, 1989, P NATL ACAD SCI USA, V86, P5232, DOI 10.1073/pnas.86.14.5232	51	180	187	1	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 9	1998	92	1					131	139		10.1016/S0092-8674(00)80905-8	http://dx.doi.org/10.1016/S0092-8674(00)80905-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	YR227	9489706	Bronze			2022-12-01	WOS:000071473700014
J	Brown, DR; Qin, KF; Herms, JW; Madlung, A; Manson, J; Strome, R; Fraser, PE; Kruck, T; vonBohlen, A; SchulzSchaeffer, W; Giese, A; Westaway, D; Kretzschmar, H				Brown, DR; Qin, KF; Herms, JW; Madlung, A; Manson, J; Strome, R; Fraser, PE; Kruck, T; vonBohlen, A; SchulzSchaeffer, W; Giese, A; Westaway, D; Kretzschmar, H			The cellular prion protein binds copper in vivo	NATURE			English	Article							SERUM-ALBUMIN; HIGH-AFFINITY; COMPLEX; REGION; SITE; PRP	The normal cellular form of prion protein (PrPC) is a precursor to the pathogenic protease-resistant forms (PrPSc) believed to cause scrapie, bovine spongiform encephalopathy (BSE) and Creutzfeldt-Jakob disease(1). Its amino terminus contains the octapeptide PHGGGWGQ, which is repeated four times and is among the best-preserved regions of mammalian PrPC. Here we show that the amino-terminal domain of PrPC exhibits five to six sites that bind copper (Cu(II)) presented as a glycine chelate. At neutral pH, binding occurs with positive cooperativity, with binding affinity compatible with estimates for extracellular, labile copper. Two lines of independently derived PrPC gene-ablated (Prnp(0/0)) mice exhibit severe reductions in the copper content of membrane-enriched brain extracts and similar reductions in synaptosomal and endosome-enriched subcellular fractions. Prnp(0/0) mice also have altered cellular phenotypes, including a reduction in the activity of copper/zinc superoxide dismutase and altered electrophysiological responses in the presence of excess copper. These findings indicate that PrPC can exist in a Cu-metalloprotein form in vivo.	UNIV GOTTINGEN,DEPT NEUROPATHOL,D-37075 GOTTINGEN,GERMANY; UNIV TORONTO,CTR RES NEURODEGENERAT DIS,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT LAB MED & PATHOBIOL,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5S 3H2,CANADA; UNIV TORONTO,DEPT PHYSIOL,TORONTO,ON M5S 3H2,CANADA; NEUROPATHOGENESIS UNIT,EDINBURGH EA 3TF,MIDLOTHIAN,SCOTLAND; INST SPEKTROCHEM & ANGEW SPEKTROSKOPIE,D-44013 DORTMUND,GERMANY	University of Gottingen; University of Toronto; University of Toronto; University of Toronto; University of Toronto			Herms, Jochen/D-3518-2011; Brown, David/A-4083-2008; Giese, Armin/F-3271-2010; von Bohlen, Alex/C-2450-2008	Giese, Armin/0000-0002-8238-4102; von Bohlen, Alex/0000-0002-1572-6176				Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Brown DR, 1997, EXP NEUROL, V146, P104, DOI 10.1006/exnr.1997.6505; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; CURZON G, 1960, BIOCHEM J, V74, P279, DOI 10.1042/bj0740279; GIROUX E, 1981, J INORG BIOCHEM, V14, P359, DOI 10.1016/S0162-0134(00)80292-5; GOLDFARB LG, 1991, P NATL ACAD SCI USA, V88, P10926, DOI 10.1073/pnas.88.23.10926; HARTTER DE, 1988, J BIOL CHEM, V263, P799; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V207, P621, DOI 10.1006/bbrc.1995.1233; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; KLOCKENKAMPER R, 1992, ANAL CHEM, V64, pA1115, DOI 10.1021/ac00047a001; KRETZSCHMAR HA, 1986, DNA-J MOLEC CELL BIO, V5, P315, DOI 10.1089/dna.1986.5.315; LAU SJ, 1971, J BIOL CHEM, V246, P5938; Linder M.C., 1991, BIOCH COPPER; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; Martell A.E., 1974, CRITICAL STABILITY C; MASUOKA J, 1993, J BIOL CHEM, V268, P21533; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; NARAHASHI T, 1994, CELL MOL NEUROBIOL, V14, P599, DOI 10.1007/BF02088671; NEUMANN PZ, 1967, J CLIN INVEST, V46, P646, DOI 10.1172/JCI105566; Prusiner SB, 1997, SCIENCE, V278, P245, DOI 10.1126/science.278.5336.245; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; SARKAR B, 1968, CAN J BIOCHEM CELL B, V46, P601, DOI 10.1139/o68-092; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOLDATI T, 1995, METHOD ENZYMOL, V257, P253; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4	27	1106	1136	4	129	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 25	1997	390	6661					684	687		10.1038/37783	http://dx.doi.org/10.1038/37783			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM508	9414160				2022-12-01	WOS:A1997YM50800031
J	McCune, JM				McCune, JM			Animal models of HIV-1 disease	SCIENCE			English	Article							SCID-HU MOUSE; IMMUNODEFICIENCY-VIRUS TYPE-1; HUMAN HEMATOLYMPHOID DIFFERENTIATION; TRANSGENIC MODELS; IN-VIVO; REPLICATION; CELLS		UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,DIV AIDS,SAN FRANCISCO,CA 94110	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco	McCune, JM (corresponding author), UNIV CALIF SAN FRANCISCO,SAN FRANCISCO GEN HOSP,GLADSTONE INST VIROL & IMMUNOL,POB 419100,SAN FRANCISCO,CA 94110, USA.							AKKINA RK, 1994, BLOOD, V84, P1393; BAUM CM, 1992, P NATL ACAD SCI USA, V89, P2804, DOI 10.1073/pnas.89.7.2804; Bonyhadi ML, 1997, J VIROL, V71, P4707, DOI 10.1128/JVI.71.6.4707-4716.1997; JAMIESON BD, 1994, J VIROL, V68, P3478, DOI 10.1128/JVI.68.6.3478-3485.1994; Kitchen SG, 1997, J VIROL, V71, P6928, DOI 10.1128/JVI.71.9.6928-6934.1997; Klotman PE, 1996, CURR TOP MICROBIOL, V206, P197; Levy JA, 1996, J MED PRIMATOL, V25, P163, DOI 10.1111/j.1600-0684.1996.tb00013.x; LEWIS AD, 1995, TRENDS BIOTECHNOL, V13, P142, DOI 10.1016/S0167-7799(00)88925-8; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCCUNE JM, 1992, BONE MARROW TRANSPL, V9, P74; MCCUNE JM, 1990, SEMIN VIROL, V1, P229; MOCARSKI ES, 1993, P NATL ACAD SCI USA, V90, P104, DOI 10.1073/pnas.90.1.104; MOSIER DE, 1988, NATURE, V335, P256, DOI 10.1038/335256a0; Rabin L, 1996, ANTIMICROB AGENTS CH, V40, P755, DOI 10.1128/AAC.40.3.755; RONCAROLO M, 1995, HUMAN HEMATOPOIESIS; SU L, 1995, IMMUNITY, V2, P25, DOI 10.1016/1074-7613(95)90076-4; Su LS, 1997, VIROLOGY, V227, P45, DOI 10.1006/viro.1996.8338; TARYLEHMANN M, 1994, J EXP MED, V180, P1817, DOI 10.1084/jem.180.5.1817; Toggas SM, 1996, CURR TOP MICROBIOL, V206, P223	19	35	39	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 19	1997	278	5346					2141	2142		10.1126/science.278.5346.2141	http://dx.doi.org/10.1126/science.278.5346.2141			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	YM235	9432722				2022-12-01	WOS:A1997YM23500058
J	Giannou, C				Giannou, C			Antipersonnel landmines: facts, fictions, and priorities	BRITISH MEDICAL JOURNAL			English	Article							LAND MINES; MOZAMBIQUE; INJURIES				Giannou, C (corresponding author), RED CROSS,INT COMM,DIV HLTH OPERAT,CAMPAIGN BAN ANTIPERSONNEL MINES,CH-1202 GENEVA,SWITZERLAND.							ANDERSSON N, 1995, BRIT MED J, V311, P718, DOI 10.1136/bmj.311.7007.718; ASCHERIO A, 1995, LANCET, V346, P721, DOI 10.1016/S0140-6736(95)91501-X; COUPLAND R, 1997, ASSISTANCE VICTIMS A; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; *INT COMM RED CROS, 1996, ANT LANDM FRIEND FOE; *INT COMM RED CROS, 1995, WORLDW EP LANDM INJ; Jeffrey SJ, 1996, J ACCID EMERG MED, V13, P343; KAKAR F, 1996, PREHOSPITAL DISASTER, V11, P13; STOVER E, 1994, JAMA-J AM MED ASSOC, V272, P1245	9	18	18	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1453	1454		10.1136/bmj.315.7120.1453	http://dx.doi.org/10.1136/bmj.315.7120.1453			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418100	Green Published			2022-12-01	WOS:A1997YJ67200036
J	Meddings, DR				Meddings, DR			Weapons injuries during and after periods of conflict: retrospective analysis	BRITISH MEDICAL JOURNAL			English	Article								Objective: To assess the relative frequency of weapon injuries during conflict and after periods of conflict in the absence of disarmament. Design: Retrospective analysis of a database of war wounds. Setting: Region with a protracted conflict between rival combatant groups and a subsequent transition to the uncontested military authority of a single power. Subjects: 2332 people who received weapons injuries during the conflict or post-conflict periods and were admitted to hospital within 24 hours of injury. Main outcome measures: Percentage change in mean monthly admission rate by weapon type between conflict and post-conflict periods; annual incidence of injury by weapon type during conflict and post-conflict periods; percentage change in annual incidence by weapon type between conflict and post-conflict periods. Results: Mean monthly admission rates for-injuries from fragmentation munitions decreased by 8% between conflict and post-conflict periods and by 23% for injuries from mines and 32% for gunshot injuries. The decline in admissions for all injuries was 23%. After adjustment for population growth over the study period, declines in annual incidence were 22% for fragmentation munitions injuries, 34% for mine injuries, and 40% for gunshot injuries. The decline in incidence for all injuries was 33%. In-hospital mortality from weapons related injuries increased from 2.5% to 6.1% (P < 0.001) between conflict and post-conflict periods. Conclusions: In this setting, continued availability of weapons is associated with increased mortality and a level of injuries from weapons that is only somewhat reduced from that observed during a period of conflict.			Meddings, DR (corresponding author), INT COMM RED CROSS,19 AVE PAIX,CH-1202 GENEVA,SWITZERLAND.							COUPLAND RM, 1996, MED GLOBAL SURVIVAL, V3, pA1; COUPLAND RM, 1994, RECENT ADV SURG, P121; COX D, 1996, MANAGING ARMS PEACE, P83; EISEMAN B, 1979, J TRAUMA, V19, P848, DOI 10.1097/00005373-197911000-00011; GAMBA V, 1997, SOC SIEGE CRIME VIOL, P1; GAMBA V, 1996, MANAGING ARMS PEACE, pR13; Klare M. T., 1995, LETHAL COMMERCE GLOB; Smith C., 1995, LETHAL COMMERCE GLOB, P61; Williams P., 1997, SOC SIEGE CRIME VIOL; Zawels Estanislao A, 1996, MANAGING ARMS PEACE	10	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 29	1997	315	7120					1417	1420		10.1136/bmj.315.7120.1417	http://dx.doi.org/10.1136/bmj.315.7120.1417			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YJ672	9418089	Green Published			2022-12-01	WOS:A1997YJ67200025
J	Nightingale, SL				Nightingale, SL			FDA Modernization Act of 1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-01	WOS:000071731300008
J	Nightingale, SL				Nightingale, SL			Two new warnings added to labeling for Mibefradil	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									US FDA, Off Hlth Affairs, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Nightingale, SL (corresponding author), US FDA, Off Hlth Affairs, Parklawn Bldg,5600 Fishers Ln, Rockville, MD 20857 USA.								0	9	9	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					346	346		10.1001/jama.279.5.346	http://dx.doi.org/10.1001/jama.279.5.346			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	YU572	9459455				2022-12-01	WOS:000071731300005
J	Schwartz, BS; Stewart, WF; Simon, D; Lipton, RB				Schwartz, BS; Stewart, WF; Simon, D; Lipton, RB			Epidemiology of tension-type headache	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	8th Congress of the International-Headache-Society	JUN 10-14, 1997	AMSTERDAM, NETHERLANDS	Int Headache Soc			PREVALENCE; MIGRAINE; POPULATION; RACE	Context.-Tension-type headache is a highly prevalent condition, Because few population-based studies have been performed, little is known about its epidemiology. Objectives.-To estimate the 1-year period prevalence of episodic tension-type headache (ETTH) and chronic tension-type headache (CTTH) in a population-based study; to describe differences in 1-year period prevalence by sex, age, education, and race; and to describe attack frequency and headache pain intensity, Design.-Telephone survey conducted 1993 to 1994. Setting.-Baltimore County, Maryland. Participants.-A total of 13 345 subjects from the community. Main Outcome Measures.-Percentage of respondents with diagnoses of headache using International Headache Society criteria. Workdays lost and reduced effectiveness at work, home, and school because of headache, based on self-report. Results.-The overall prevalence of ETTH in the past year was 38.3%, Women had a higher 1-year ETTH prevalence than men in all age, race, and education groups, with an overall prevalence ratio of 1.16. Prevalence peaked in the 30- to 39-year-old age group in both men (42.3%) and women (46.9%). Whites had a higher 1-year prevalence than African Americans in men (40.1% vs. 22.8%) and women (46.8% vs 30.9%). Prevalence increased with increasing educational levels in both sexes, reaching a peak in subjects with graduate school educations of 48.5% for men and 48.9% for women. The 1-year period prevalence of CTTH was 2.2%; prevalence was higher in women and declined with increasing education. Of subjects with ETTH, 8.3% reported lost workdays because of their headaches, while 43.6% reported decreased effectiveness at work, home, or school, Subjects with CTTH reported more lost workdays (mean of 27.4 days vs 8.9 days for those reporting lost workdays) and reduced-effectiveness days (mean of 20.4 vs 5.0 days for those reporting reduced effectiveness) compared with subjects with ETTH. Conclusions.-Episodic tension-type headache is a highly prevalent condition with a significant functional impact at work, home, and school. Chronic tension-type headache is much less prevalent than ETTH; despite its greater individual impact, CTTH has a smaller societal impact than ETTH.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Div Occupat & Environm Hlth, Baltimore, MD 21205 USA; Albert Einstein Coll Med, Dept Neurol, New York, NY USA; Albert Einstein Coll Med, Dept Epidemiol, New York, NY USA; Albert Einstein Coll Med, Dept Social Med, New York, NY USA; Innovat Med Res, Towson, MD USA	Johns Hopkins University; Johns Hopkins University; Yeshiva University; Yeshiva University; Yeshiva University	Stewart, WF (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, 615 N Wolfe St, Baltimore, MD 21205 USA.		Lipton, Richard Bruce/AAY-2818-2021; Lipton, Richard B/B-5060-2011					ABUAREFEH I, 1994, BRIT MED J, V309, P765, DOI 10.1136/bmj.309.6957.765; GOBEL H, 1994, CEPHALALGIA, V14, P97, DOI 10.1046/j.1468-2982.1994.1402097.x; MATUJA WBP, 1995, HEADACHE, V35, P273, DOI 10.1111/j.1526-4610.1995.hed3505273.x; MERIKANGAS KR, 1993, CEPHALALGIA, V13, P47, DOI 10.1177/0333102493013S1210; MITSIKOSTAS DD, 1994, HEADACHE, V34, P539, DOI 10.1111/j.1526-4610.1994.hed3409539.x; MONTEIRO JMP, 1994, NEUROEPIDEMIOLOGY, V13, P103; PRYSEPHILLIPS W, 1992, CAN J NEUROL SCI, V19, P333, DOI 10.1017/S0317167100041950; RASMUSSEN BK, 1991, J CLIN EPIDEMIOL, V44, P1147, DOI 10.1016/0895-4356(91)90147-2; SACHS H, 1985, HEADACHE, V25, P190, DOI 10.1111/j.1526-4610.1985.hed2504190.x; Schwartz BS, 1997, J OCCUP ENVIRON MED, V39, P320, DOI 10.1097/00043764-199704000-00009; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; SRIKIATKHACHORN A, 1991, HEADACHE, V31, P677, DOI 10.1111/j.1526-4610.1991.hed3110677.x; STEWART WF, 1989, BIOMED PHARMACOTHER, V43, P711, DOI 10.1016/0753-3322(89)90159-5; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Stewart WF, 1996, NEUROLOGY, V47, P52, DOI 10.1212/WNL.47.1.52; WONG TW, 1995, NEUROEPIDEMIOLOGY, V14, P82, DOI 10.1159/000109782	16	437	453	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 4	1998	279	5					381	383		10.1001/jama.279.5.381	http://dx.doi.org/10.1001/jama.279.5.381			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	YU572	20865353				2022-12-01	WOS:000071731300029
